activity_comment	activity_id	assay_chembl_id	assay_description	assay_type	canonical_smiles	data_validity_comment	molecule_chembl_id	relation	standard_type	standard_units	standard_value	target_chembl_id	target_organism	type	units	value
	2051679	CHEMBL941815	Inhibition of TBK1	B	N#Cc1ncc2nc1OCCCCOc1cc(NCc3cncs3)c(Cl)cc1NC(=O)N2		CHEMBL248757	>	Ki	nM	1525.0	CHEMBL5408	Homo sapiens	Ki	uM	1.525
	2051679	CHEMBL941815	Inhibition of TBK1	B	N#Cc1ncc2nc1OCCCCOc1cc(NCc3cncs3)c(Cl)cc1NC(=O)N2		CHEMBL248757	>	Ki	nM	1525.0	CHEMBL5408	Homo sapiens	Ki	uM	1.525
	2147399	CHEMBL922185	Activity of human TBK1 kinase at 1 uM	B	O=C(O)c1ccc(Nc2ncc3c(n2)-c2ccc(Cl)cc2C(c2c(F)cccc2F)=NC3)cc1		CHEMBL259084	=	Activity	%	100.0	CHEMBL5408	Homo sapiens	Activity	%	100.0
Not Active	2302222	CHEMBL938096	Inhibition of human TBK1 at 10 uM	B	Nc1ncnc2ncn(CC(=O)c3c[nH]c4ccccc34)c12		CHEMBL485246		Inhibition	%		CHEMBL5408	Homo sapiens	INH		
	2489767	CHEMBL1035610	Inhibition of TBK1 at 1 uM	B	COc1cc2ncc(C(N)=O)c(Nc3ccc(F)cc3F)c2cc1OC		CHEMBL479847	=	Inhibition	%	15.0	CHEMBL5408	Homo sapiens	INH	%	15.0
	2721731	CHEMBL1053576	Inhibition of TBK1 at 1 uM	B	C[C@@H](Oc1cc(-c2cnc3ccccn23)sc1C(N)=O)c1ccc(CNC(C)(C)C)cc1OC(F)F		CHEMBL551079	<	Inhibition	%	50.0	CHEMBL5408	Homo sapiens	INH	%	50.0
Antagonist	2894762	CHEMBL1061112	Percentage TBK1 activity remaining in the presence of 0.01uM inhibitor	B	O=C(NCCCNc1nc(Nc2cccc(NC(=O)N3CCCC3)c2)ncc1I)c1cccs1		CHEMBL577784	=	Activity	%	7.0	CHEMBL5408	Homo sapiens	Activity	%	7.0
Antagonist	2894763	CHEMBL1052921	Percentage TBK1 activity remaining in the presence of 0.1uM inhibitor	B	O=C(NCCCNc1nc(Nc2cccc(NC(=O)N3CCCC3)c2)ncc1I)c1cccs1		CHEMBL577784	=	Activity	%	1.0	CHEMBL5408	Homo sapiens	Activity	%	1.0
Antagonist	2894764	CHEMBL1052123	Percentage TBK1 activity remaining in the presence of 10uM inhibitor	B	CC(C)(C(N)=O)C(=O)NCCCNc1nc(Nc2cccc(NC(=O)N3CCCC3)c2)ncc1Br		CHEMBL573108	=	Activity	%	5.0	CHEMBL5408	Homo sapiens	Activity	%	5.0
	2894765	CHEMBL1052123	Percentage TBK1 activity remaining in the presence of 10uM inhibitor	B	Cc1ccc2nc(NCCN)c3ncc(C)n3c2c1		CHEMBL249697	=	Activity	%	93.0	CHEMBL5408	Homo sapiens	Activity	%	93.0
	2894766	CHEMBL1052123	Percentage TBK1 activity remaining in the presence of 10uM inhibitor	B	NC(=O)c1sc(-c2ccsc2)cc1N		CHEMBL193093	=	Activity	%	93.0	CHEMBL5408	Homo sapiens	Activity	%	93.0
	2894767	CHEMBL1052123	Percentage TBK1 activity remaining in the presence of 10uM inhibitor	B	O=C(Nc1cc(Cl)cc2c1[nH]c1cnccc12)c1cccnc1		CHEMBL79004	=	Activity	%	87.0	CHEMBL5408	Homo sapiens	Activity	%	87.0
	2894768	CHEMBL1052123	Percentage TBK1 activity remaining in the presence of 10uM inhibitor	B	O=c1[nH]c2ccccc2n1C1CCN(Cc2ccc(-c3nc4cc5[nH]cnc5cc4nc3-c3ccccc3)cc2)CC1		CHEMBL258844	=	Activity	%	107.0	CHEMBL5408	Homo sapiens	Activity	%	107.0
Antagonist	2894769	CHEMBL1061113	Percentage TBK1 activity remaining in the presence of 1uM inhibitor	B	CC(C)(C(N)=O)C(=O)NCCCNc1nc(Nc2cccc(NC(=O)N3CCCC3)c2)ncc1Br		CHEMBL573108	=	Activity	%	32.0	CHEMBL5408	Homo sapiens	Activity	%	32.0
Antagonist	2894770	CHEMBL1061113	Percentage TBK1 activity remaining in the presence of 1uM inhibitor	B	Cc1[nH]c(/C=C2\C(=O)Nc3ccccc32)c(C)c1CCC(=O)O		CHEMBL274654	=	Activity	%	34.0	CHEMBL5408	Homo sapiens	Activity	%	34.0
Antagonist	2894771	CHEMBL1061113	Percentage TBK1 activity remaining in the presence of 1uM inhibitor	B	c1cc(-c2cnn3cc(-c4ccc(OCCN5CCCCC5)cc4)cnc23)ccn1		CHEMBL478629	=	Activity	%	45.0	CHEMBL5408	Homo sapiens	Activity	%	45.0
	2894772	CHEMBL1061113	Percentage TBK1 activity remaining in the presence of 1uM inhibitor	B	O=c1[nH]c2ccccc2n1C1CCN(Cc2ccc(-c3nc4cc5[nH]cnc5cc4nc3-c3ccccc3)cc2)CC1		CHEMBL258844	=	Activity	%	101.0	CHEMBL5408	Homo sapiens	Activity	%	101.0
	2926261	CHEMBL1056934	Inhibition of TBK1 assessed as remaining enzyme activity at 3 uM relative to DMSO	B	COc1ccccc1-n1c(-c2ccccc2C)cn2c3c(=O)[nH]c(=O)n(C)c3nc12		CHEMBL574236	=	Activity	%	79.0	CHEMBL5408	Homo sapiens	Activity	%	79.0
	2928447	CHEMBL1048228	Inhibition of TBK1 assessed as remaining enzyme activity at 1 uM relative to DMSO	B	COc1ccccc1-n1c(-c2cc(O)ccc2C)cn2c3c(=O)[nH]c(=O)n(C)c3nc12		CHEMBL566515	=	Activity	%	89.0	CHEMBL5408	Homo sapiens	Activity	%	89.0
	2938396	CHEMBL1040490	Inhibition of NAK	B	Cc1cnc(Nc2ccc(F)cc2Cl)nc1-c1c[nH]c(C(=O)N[C@H](CO)c2cccc(Cl)c2)c1		CHEMBL583042	>	Ki	nM	10000.0	CHEMBL5408	Homo sapiens	Ki	uM	10.0
	2938436	CHEMBL1036952	Inhibition of TBK1 at 1 uM	B	Cc1cnc(Nc2ccc(F)cc2Cl)nc1-c1c[nH]c(C(=O)N[C@H](CO)c2cccc(Cl)c2)c1		CHEMBL583042	=	Inhibition	%	3.0	CHEMBL5408	Homo sapiens	INH	%	3.0
	2999767	CHEMBL1045499	Inhibition of TBK1 assessed as residual activity at 10 uM by Cherenkov counting relative to control in presence of 50 uM ATP	B	CC(C)c1onc(-c2ccc(F)cc2)c1-c1ccncc1		CHEMBL220227	=	Activity	%	90.0	CHEMBL5408	Homo sapiens	Activity	%	90.0
	2999845	CHEMBL1045499	Inhibition of TBK1 assessed as residual activity at 10 uM by Cherenkov counting relative to control in presence of 50 uM ATP	B	CC(C)c1noc(-c2ccc(F)cc2)c1-c1ccncc1		CHEMBL375428	=	Activity	%	80.0	CHEMBL5408	Homo sapiens	Activity	%	80.0
	2999920	CHEMBL1041101	Inhibition of TBK1 assessed as residual activity at 0.1 uM by Cherenkov counting relative to control in presence of 50 uM ATP	B	COc1ccc(/C=C/C(=O)Nc2cc(-c3[nH]c(SC)nc3-c3ccc(F)cc3)ccn2)c(OC)c1		CHEMBL569114	=	Activity	%	103.0	CHEMBL5408	Homo sapiens	Activity	%	103.0
	2999996	CHEMBL1041101	Inhibition of TBK1 assessed as residual activity at 0.1 uM by Cherenkov counting relative to control in presence of 50 uM ATP	B	COc1ccc(/C=C/C(=O)Nc2cc(-c3[nH]c([S+](C)[O-])nc3-c3ccc(F)cc3)ccn2)c(OC)c1		CHEMBL572006	=	Activity	%	106.0	CHEMBL5408	Homo sapiens	Activity	%	106.0
	3052494	CHEMBL1072532	Residual activity of TBK1 at 0.1 uM by microplate scintillation counting	B	COc1cc2c(Oc3ccc(-c4nc5ccccc5s4)cc3F)ncnc2cc1OCCCN1CCN(C)CC1		CHEMBL604483	=	Residual activity	%	94.0	CHEMBL5408	Homo sapiens	Residual activity	%	94.0
	3052746	CHEMBL1043825	Residual activity of TBK1 at 1 uM by microplate scintillation counting	B	COc1cc2c(Oc3ccc(-c4nc5ccccc5s4)cc3F)ncnc2cc1OCCCN1CCN(C)CC1		CHEMBL604483	=	Residual activity	%	99.0	CHEMBL5408	Homo sapiens	Residual activity	%	99.0
	3054055	CHEMBL1071984	Residual activity of TBK1 at 10 uM by microplate scintillation counting	B	COc1cc2c(Oc3ccc(-c4nc5ccccc5s4)cc3F)ncnc2cc1OCCCN1CCN(C)CC1		CHEMBL604483	=	Residual activity	%	141.0	CHEMBL5408	Homo sapiens	Residual activity	%	141.0
	3055342	CHEMBL1072532	Residual activity of TBK1 at 0.1 uM by microplate scintillation counting	B	COc1cc2c(Oc3ccc(-c4nc5ccccc5s4)cc3)ncnc2cc1OCCCN1CCN(C)CC1		CHEMBL595143	=	Residual activity	%	79.0	CHEMBL5408	Homo sapiens	Residual activity	%	79.0
	3055594	CHEMBL1043825	Residual activity of TBK1 at 1 uM by microplate scintillation counting	B	COc1cc2c(Oc3ccc(-c4nc5ccccc5s4)cc3)ncnc2cc1OCCCN1CCN(C)CC1		CHEMBL595143	=	Residual activity	%	85.0	CHEMBL5408	Homo sapiens	Residual activity	%	85.0
	3056899	CHEMBL1071984	Residual activity of TBK1 at 10 uM by microplate scintillation counting	B	COc1cc2c(Oc3ccc(-c4nc5ccccc5s4)cc3)ncnc2cc1OCCCN1CCN(C)CC1		CHEMBL595143	=	Residual activity	%	171.0	CHEMBL5408	Homo sapiens	Residual activity	%	171.0
	3057151	CHEMBL1072532	Residual activity of TBK1 at 0.1 uM by microplate scintillation counting	B	COc1cc2c(Oc3ccc(-c4nc5ccccc5s4)cc3)ncnc2cc1OCCCN1CCCC1		CHEMBL595373	=	Residual activity	%	94.0	CHEMBL5408	Homo sapiens	Residual activity	%	94.0
	3058471	CHEMBL1043825	Residual activity of TBK1 at 1 uM by microplate scintillation counting	B	COc1cc2c(Oc3ccc(-c4nc5ccccc5s4)cc3)ncnc2cc1OCCCN1CCCC1		CHEMBL595373	=	Residual activity	%	92.0	CHEMBL5408	Homo sapiens	Residual activity	%	92.0
	3059755	CHEMBL1071984	Residual activity of TBK1 at 10 uM by microplate scintillation counting	B	COc1cc2c(Oc3ccc(-c4nc5ccccc5s4)cc3)ncnc2cc1OCCCN1CCCC1		CHEMBL595373	=	Residual activity	%	143.0	CHEMBL5408	Homo sapiens	Residual activity	%	143.0
Not Active	3133143	CHEMBL1066215	Inhibition of TBK1	B	CN1CCN(c2cc(C(=O)Nc3ccc4c(c3)-c3c(c(C(N)=O)nn3-c3ccc(F)cc3)CC4)c(Cl)cn2)CC1		CHEMBL592893		Inhibition	%		CHEMBL5408	Homo sapiens	INH		
	3214050	CHEMBL1105933	Inhibition of TBK1 at 5 uM	B	O=C(Nc1ccccc1Cl)c1cnc2ccc(C3CCNCC3)cn12.O=C(O)C(=O)O		CHEMBL1077739	=	Inhibition	%	2.0	CHEMBL5408	Homo sapiens	INH	%	2.0
	3224977	CHEMBL1101781	Inhibition of TBK1 at 10 uM	B	Cc1cc(OCc2ccc(F)cc2F)c(Br)c(=O)n1-c1cnc(CO)cn1		CHEMBL1081678	<	Inhibition	%	50.0	CHEMBL5408	Homo sapiens	INH	%	50.0
	3226356	CHEMBL1101781	Inhibition of TBK1 at 10 uM	B	Cc1cc(OCc2ccc(F)cc2F)c(Br)c(=O)n1Cc1ccc(CN(C)C)cc1		CHEMBL1078665	<	Inhibition	%	50.0	CHEMBL5408	Homo sapiens	INH	%	50.0
	3332171	CHEMBL1168123	Inhibition of TBK1 at 1 uM	B	CN1CCN(c2ccc(-c3cnc4c(c3)N(Cc3cc(F)ccc3F)CCN4)cn2)CC1		CHEMBL1165499	<	Inhibition	%	50.0	CHEMBL5408	Homo sapiens	INH	%	50.0
	3333586	CHEMBL1168123	Inhibition of TBK1 at 1 uM	B	CN1CCN(c2ccc(-c3cnc4c(c3)N(Cc3cc(Cl)ccc3C(F)(F)F)CCN4)cn2)CC1		CHEMBL1164180	<	Inhibition	%	50.0	CHEMBL5408	Homo sapiens	INH	%	50.0
	3334991	CHEMBL1168123	Inhibition of TBK1 at 1 uM	B	CN1CCN(c2ccc(-c3cnc4c(c3)N(Cc3cc(Cl)ccc3Cl)CCN4)cn2)CC1		CHEMBL1164181	<	Inhibition	%	50.0	CHEMBL5408	Homo sapiens	INH	%	50.0
	3336411	CHEMBL1168123	Inhibition of TBK1 at 1 uM	B	CN1CCN(c2ccc(-c3cnc4c(c3)N(Cc3c(F)ccc(F)c3Cl)CCN4)cn2)CC1		CHEMBL1164265	<	Inhibition	%	50.0	CHEMBL5408	Homo sapiens	INH	%	50.0
	3341953	CHEMBL1168123	Inhibition of TBK1 at 1 uM	B	FC(F)(F)c1ccc(Cl)cc1CN1CCNc2ncc(-c3ccnc(N4CCNCC4)c3)cc21		CHEMBL1163566	<	Inhibition	%	50.0	CHEMBL5408	Homo sapiens	INH	%	50.0
	3343400	CHEMBL1168123	Inhibition of TBK1 at 1 uM	B	CC(=O)N1CCN(c2cc(-c3cnc4c(c3)N(Cc3cc(Cl)ccc3C(F)(F)F)CCN4)ccn2)CC1		CHEMBL1163565	<	Inhibition	%	50.0	CHEMBL5408	Homo sapiens	INH	%	50.0
	3351777	CHEMBL1175091	Inhibition of TBK1 at 10 uM	B	CCN1CCN(Cc2ccc(NC(=O)c3ccc(C)c(C#Cc4cnc5[nH]ccc5c4)c3)cc2C(F)(F)F)CC1		CHEMBL1170139	=	Inhibition	%	84.0	CHEMBL5408	Homo sapiens	INH	%	84.0
	3358829	CHEMBL1175091	Inhibition of TBK1 at 10 uM	B	CCN1CCN(Cc2ccc(NC(=O)c3ccc(C)c(C#Cc4cccnc4)c3)cc2C(F)(F)F)CC1		CHEMBL1171523	=	Inhibition	%	100.0	CHEMBL5408	Homo sapiens	INH	%	100.0
	3443323	CHEMBL1244306	Inhibition of TBK1 at 1 uM after 60 mins by FRET assay in presence of 10 uM ATP	B	CC(C)n1nc(-c2ccc3ncccc3c2)c2c(N)ncnc21		CHEMBL1233882	=	Inhibition	%	5.0	CHEMBL5408	Homo sapiens	INH	%	5.0
	3443540	CHEMBL1244306	Inhibition of TBK1 at 1 uM after 60 mins by FRET assay in presence of 10 uM ATP	B	CC(C)n1nc(-c2ccc(Br)c(O)c2)c2c(N)ncnc21		CHEMBL1241578	=	Inhibition	%	3.0	CHEMBL5408	Homo sapiens	INH	%	3.0
	3445319	CHEMBL1244306	Inhibition of TBK1 at 1 uM after 60 mins by FRET assay in presence of 10 uM ATP	B	Nc1ncnc2c1c(-c1cnc3[nH]ccc3c1)nn2C1CCCC1		CHEMBL1081312	=	Inhibition	%	2.0	CHEMBL5408	Homo sapiens	INH	%	2.0
	3445536	CHEMBL1244306	Inhibition of TBK1 at 1 uM after 60 mins by FRET assay in presence of 10 uM ATP	B	COc1ccc(-c2nn(C3CCC3)c3ncnc(N)c23)cc1OC		CHEMBL1233881	=	Inhibition	%	3.0	CHEMBL5408	Homo sapiens	INH	%	3.0
	3445753	CHEMBL1244306	Inhibition of TBK1 at 1 uM after 60 mins by FRET assay in presence of 10 uM ATP	B	CC(C)n1nc(-c2cc3cc(O)ccc3[nH]2)c2c(N)ncnc21		CHEMBL1241674	=	Inhibition	%	1.0	CHEMBL5408	Homo sapiens	INH	%	1.0
	3445943	CHEMBL1244306	Inhibition of TBK1 at 1 uM after 60 mins by FRET assay in presence of 10 uM ATP	B	CC(C)n1nc(-c2cccc(O)c2)c2c(N)ncnc21		CHEMBL1230790	=	Inhibition	%	2.0	CHEMBL5408	Homo sapiens	INH	%	2.0
	3446133	CHEMBL1244306	Inhibition of TBK1 at 1 uM after 60 mins by FRET assay in presence of 10 uM ATP	B	Cn1nc(-c2ccc3ccccc3c2)c2c(N)ncnc21		CHEMBL1234815	=	Inhibition	%	7.0	CHEMBL5408	Homo sapiens	INH	%	7.0
	3446208	CHEMBL1244348	Inhibition of TBK1	B	COc1cc(Nc2c(C#N)cnc3cc(OCCCN4CCN(C)CC4)c(OC)cc23)c(Cl)cc1Cl		CHEMBL288441	=	IC50	nM	471.0	CHEMBL5408	Homo sapiens	IC50	nM	471.0
	3448644	CHEMBL1244997	Binding affinity to TBK1	B	COc1cc2c(N3CCN(C(=O)Nc4ccc(OC(C)C)cc4)CC3)ncnc2cc1OCCCN1CCCCC1		CHEMBL124660	>	Kd	nM	10000.0	CHEMBL5408	Homo sapiens	Kd	uM	10.0
	3448801	CHEMBL1244997	Binding affinity to TBK1	B	C[C@]12O[C@H](C[C@]1(O)CO)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)CNC4=O		CHEMBL603469	=	Kd	nM	18.0	CHEMBL5408	Homo sapiens	Kd	nM	18.0
	3449059	CHEMBL1244997	Binding affinity to TBK1	B	CO[C@@H]1[C@H](N(C)C(=O)c2ccccc2)C[C@H]2O[C@]1(C)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)C(=O)NC4		CHEMBL608533	=	Kd	nM	9.3	CHEMBL5408	Homo sapiens	Kd	nM	9.3
	3449359	CHEMBL1244997	Binding affinity to TBK1	B	CCN(CC)CCNC(=O)c1c(C)[nH]c(/C=C2\C(=O)Nc3ccc(F)cc32)c1C		CHEMBL535	=	Kd	nM	120.0	CHEMBL5408	Homo sapiens	Kd	nM	120.0
	3449360	CHEMBL1244997	Binding affinity to TBK1	B	CO[C@@H]1[C@H](N(C)C(=O)c2ccccc2)C[C@H]2O[C@]1(C)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)C(=O)N[C@H]4O		CHEMBL1240703	=	Kd	nM	150.0	CHEMBL5408	Homo sapiens	Kd	nM	150.0
	3449870	CHEMBL1244997	Binding affinity to TBK1	B	CC(C)(C)c1cc(NC(=O)Nc2ccc(-c3cn4c(n3)sc3cc(OCCN5CCOCC5)ccc34)cc2)no1		CHEMBL576982	>	Kd	nM	10000.0	CHEMBL5408	Homo sapiens	Kd	uM	10.0
	3450255	CHEMBL1244997	Binding affinity to TBK1	B	CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3ccc(Cl)c(C(F)(F)F)c3)cc2)ccn1		CHEMBL1336	>	Kd	nM	10000.0	CHEMBL5408	Homo sapiens	Kd	uM	10.0
	3463373	CHEMBL1251706	Inhibition of TBK1 at 1 uM in presence of 100 uM ATP by Select Screen kinase assay relative to untreated control	B	Cc1n[nH]c2ccc(-c3cncc(OC[C@@H](N)Cc4c[nH]c5ccccc45)c3)cc12		CHEMBL379300	=	Inhibition	%	39.0	CHEMBL5408	Homo sapiens	INH	%	39.0
	3463917	CHEMBL1251706	Inhibition of TBK1 at 1 uM in presence of 100 uM ATP by Select Screen kinase assay relative to untreated control	B	COc1ccccc1N1CCN(c2ncnc3[nH]nc(Br)c23)CC1		CHEMBL1254209	=	Inhibition	%	12.0	CHEMBL5408	Homo sapiens	INH	%	12.0
	3464136	CHEMBL1251706	Inhibition of TBK1 at 1 uM in presence of 100 uM ATP by Select Screen kinase assay relative to untreated control	B	O=C(NCCCNc1nc(Nc2cccc(NC(=O)N3CCCC3)c2)ncc1I)c1cccs1		CHEMBL577784	=	Inhibition	%	97.0	CHEMBL5408	Homo sapiens	INH	%	97.0
	5120410	CHEMBL1646666	Inhibition of human TBK1 at 10 uM after 60 mins by TR-FRET assay	B	S=c1[nH]nc(-c2ccncc2)n1-c1ccc2ccccc2c1		CHEMBL1644616	=	Inhibition	%	108.0	CHEMBL5408	Homo sapiens	INH	%	108.0
	5133664	CHEMBL1648749	Inhibition of TBK1 assessed as residual activity at 10 uM	B	CN(C)C/C=C/C(=O)Nc1ccc2c(C#N)cnc(Nc3cccc(Br)c3)c2c1		CHEMBL1641990	=	Activity	%	82.0	CHEMBL5408	Homo sapiens	Activity	%	82.0
	5133759	CHEMBL1648749	Inhibition of TBK1 assessed as residual activity at 10 uM	B	CN(C)CCCC(=O)Nc1ccc2c(C#N)cnc(Nc3cccc(Br)c3)c2c1		CHEMBL1641989	=	Activity	%	99.0	CHEMBL5408	Homo sapiens	Activity	%	99.0
	5133912	CHEMBL1648749	Inhibition of TBK1 assessed as residual activity at 10 uM	B	CN1CCN(CCC(=O)Nc2ccc3c(C#N)cnc(Nc4cccc(Br)c4)c3c2)CC1		CHEMBL1641992	=	Activity	%	87.0	CHEMBL5408	Homo sapiens	Activity	%	87.0
	5190278	CHEMBL1663330	Inhibition of human recombinant TBK1 by radiometric assay	B	O=C(O)c1ccc2c(c1)nc(Nc1cccc(Cl)c1)c1ccncc12		CHEMBL1230165	=	IC50	nM	35.0	CHEMBL5408	Homo sapiens	IC50	nM	35.0
	5191475	CHEMBL1664094	Inhibition of TBK1 at 1 uM	B	COc1cc2nc(-c3cc(F)ccc3O)nc(N[C@@H]3CNC[C@H]3C(C)(C)O)c2cc1OC		CHEMBL1236782	=	Inhibition	%	0.0	CHEMBL5408	Homo sapiens	INH	%	0.0
	5191476	CHEMBL1664094	Inhibition of TBK1 at 1 uM	B	CC(C)(O)[C@@H]1CNC[C@H]1Nc1nc(-c2cc(-c3cc[nH]n3)ccc2O)nc2ccccc12		CHEMBL1650131	=	Inhibition	%	10.0	CHEMBL5408	Homo sapiens	INH	%	10.0
	5243774	CHEMBL1685878	Inhibition of TBK1 at 0.1 uM	B	Cc1ccc2cc(-c3n[nH]c4ccc(NC5CCN(Cc6ccccc6)CC5)cc34)[nH]c2c1		CHEMBL1684543	=	Inhibition	%	53.0	CHEMBL5408	Homo sapiens	INH	%	53.0
	5243882	CHEMBL1686094	Inhibition of TBK1 at 1 uM	B	Cc1ccc2cc(-c3n[nH]c4ccc(NC5CCN(Cc6ccccc6)CC5)cc34)[nH]c2c1		CHEMBL1684543	=	Inhibition	%	9.0	CHEMBL5408	Homo sapiens	INH	%	9.0
	5243995	CHEMBL1685878	Inhibition of TBK1 at 0.1 uM	B	Cc1ccc2cc(-c3n[nH]c4ccc(NC5CCNC5)cc34)[nH]c2c1		CHEMBL1684654	=	Inhibition	%	19.0	CHEMBL5408	Homo sapiens	INH	%	19.0
	5244103	CHEMBL1686094	Inhibition of TBK1 at 1 uM	B	Cc1ccc2cc(-c3n[nH]c4ccc(NC5CCNC5)cc34)[nH]c2c1		CHEMBL1684654	=	Inhibition	%	2.0	CHEMBL5408	Homo sapiens	INH	%	2.0
	5244976	CHEMBL1685878	Inhibition of TBK1 at 0.1 uM	B	O=C(Cc1ccc2cc(-c3n[nH]c4cccnc34)[nH]c2c1)c1ccccc1		CHEMBL1684662	=	Inhibition	%	65.0	CHEMBL5408	Homo sapiens	INH	%	65.0
	5245084	CHEMBL1686094	Inhibition of TBK1 at 1 uM	B	O=C(Cc1ccc2cc(-c3n[nH]c4cccnc34)[nH]c2c1)c1ccccc1		CHEMBL1684662	=	Inhibition	%	16.0	CHEMBL5408	Homo sapiens	INH	%	16.0
	5245235	CHEMBL1685878	Inhibition of TBK1 at 0.1 uM	B	Cc1ccc2cc(-c3n[nH]c4ccc(NS(=O)(=O)c5ncn(C)c5C)cc34)[nH]c2c1		CHEMBL1684525	=	Inhibition	%	108.0	CHEMBL5408	Homo sapiens	INH	%	108.0
	5246065	CHEMBL1686094	Inhibition of TBK1 at 1 uM	B	Cc1ccc2cc(-c3n[nH]c4ccc(NS(=O)(=O)c5ncn(C)c5C)cc34)[nH]c2c1		CHEMBL1684525	=	Inhibition	%	42.0	CHEMBL5408	Homo sapiens	INH	%	42.0
	6161914	CHEMBL1764210	Inhibition of TBK-1	B	NC(=O)c1cc(-c2ccccc2)cc2c(C3CCCNC3)c[nH]c12		CHEMBL1761510	<	IC50	nM	3162.28	CHEMBL5408	Homo sapiens	pIC50		5.5
	6161916	CHEMBL1764210	Inhibition of TBK-1	B	CCCS(=O)(=O)N1CCC(c2c[nH]c3c(C(N)=O)cc(-c4ccccc4)cc23)CC1		CHEMBL1761512	<	IC50	nM	3162.28	CHEMBL5408	Homo sapiens	pIC50		5.5
	6167680	CHEMBL1769221	Inhibition of TBK1	B	CNc1cncc(-c2c[nH]c(=O)c(NC(=O)c3ccc(N4CCC[C@H]4CN4CCCC4)cc3)c2)n1		CHEMBL1765781	>	Ki	nM	1000.0	CHEMBL5408	Homo sapiens	Ki	uM	1.0
	6262756	CHEMBL1798625	Inhibition of TBK1	B	Cc1ccc(C(=O)NCCO)cc1-n1cnc(OCc2ccc(F)cc2F)c(Cl)c1=O		CHEMBL1738710	>	IC50	nM	10000.0	CHEMBL5408	Homo sapiens	IC50	uM	10.0
	6273854	CHEMBL1806272	Inhibition of TBK1 assessed as residual enzyme activity at 10 uM	B	CC(C)c1cnn2c(NCc3ccccc3)cc(N[C@@H](CO)[C@H](O)CO)nc12		CHEMBL1234833	=	Activity	%	87.0	CHEMBL5408	Homo sapiens	Activity	%	87.0
	6341135	CHEMBL1826992	Activity of TBK1 kinase at 1 uM	B	CC(=O)Nc1cn2nc(-c3cnc(Cl)c(NS(=O)(=O)c4ccc(F)cc4)c3)ccc2n1		CHEMBL1822054	=	Activity	%	100.0	CHEMBL5408	Homo sapiens	Activity	%	100.0
	6352283	CHEMBL1826260	Inhibition of TBK1 assessed as residual activity at 10 uM by radioactivity assay in presence of 50 uM ATP	B	Nc1n[nH]c(N)c1/N=N/c1ccc(O)cc1		CHEMBL215205	=	Activity	%	55.0	CHEMBL5408	Homo sapiens	Activity	%	55.0
	7567472	CHEMBL1908769	Binding constant for TBK1 kinase domain	B	COc1cc2c(Oc3ccc4[nH]c(C)cc4c3F)ncnc2cc1OCCCN1CCCC1		CHEMBL491473	>	Kd	nM	10000.0	CHEMBL5408	Homo sapiens	Kd	nM	10000.0
	7567489	CHEMBL1908769	Binding constant for TBK1 kinase domain	B	O=C(NOCC1CC1)c1ccc(F)c(F)c1Nc1ccc(I)cc1Cl		CHEMBL105442	>	Kd	nM	10000.0	CHEMBL5408	Homo sapiens	Kd	nM	10000.0
	7567960	CHEMBL1908769	Binding constant for TBK1 kinase domain	B	CCOc1cc2ncc(C#N)c(Nc3ccc(OCc4ccccn4)c(Cl)c3)c2cc1NC(=O)/C=C/CN(C)C		CHEMBL180022	>	Kd	nM	10000.0	CHEMBL5408	Homo sapiens	Kd	nM	10000.0
	7568428	CHEMBL1908769	Binding constant for TBK1 kinase domain	B	CSc1cccc(Nc2ncc3cc(-c4c(Cl)cccc4Cl)c(=O)n(C)c3n2)c1		CHEMBL386051	>	Kd	nM	10000.0	CHEMBL5408	Homo sapiens	Kd	nM	10000.0
	7568860	CHEMBL1908769	Binding constant for TBK1 kinase domain	B	Cc1[nH]c(/C=C2\C(=O)Nc3ccc(F)cc32)c(C)c1C(=O)NC[C@H](O)CN1CCOCC1		CHEMBL1721885	=	Kd	nM	160.0	CHEMBL5408	Homo sapiens	Kd	nM	160.0
	7569463	CHEMBL1908769	Binding constant for TBK1 kinase domain	B	C[C@@H]1CCN(C(=O)CC#N)C[C@@H]1N(C)c1ncnc2[nH]ccc12		CHEMBL221959	>	Kd	nM	10000.0	CHEMBL5408	Homo sapiens	Kd	nM	10000.0
	7569935	CHEMBL1908769	Binding constant for TBK1 kinase domain	B	Cc1ccc(NC(=O)c2ccc(CN3CCN(C)CC3)cc2)cc1Nc1nccc(-c2cccnc2)n1		CHEMBL941	>	Kd	nM	10000.0	CHEMBL5408	Homo sapiens	Kd	nM	10000.0
	7570398	CHEMBL1908769	Binding constant for TBK1 kinase domain	B	Cc1[nH]c(/C=C2\C(=O)Nc3ccc(S(=O)(=O)Cc4c(Cl)cccc4Cl)cc32)c(C)c1C(=O)N1CCC[C@@H]1CN1CCCC1		CHEMBL450786	=	Kd	nM	970.0	CHEMBL5408	Homo sapiens	Kd	nM	970.0
	7570825	CHEMBL1908769	Binding constant for TBK1 kinase domain	B	CCN(CC)CCNC(=O)c1c(C)[nH]c(/C=C2\C(=O)Nc3ccc(F)cc32)c1C		CHEMBL535	=	Kd	nM	120.0	CHEMBL5408	Homo sapiens	Kd	nM	120.0
	7570979	CHEMBL1908769	Binding constant for TBK1 kinase domain	B	Cn1cnc2c(F)c(Nc3ccc(Br)cc3Cl)c(C(=O)NOCCO)cc21		CHEMBL1614701	>	Kd	nM	10000.0	CHEMBL5408	Homo sapiens	Kd	nM	10000.0
	7571436	CHEMBL1908769	Binding constant for TBK1 kinase domain	B	C[C@@H](Oc1cc(-c2cnn(C3CCNCC3)c2)cnc1N)c1c(Cl)ccc(F)c1Cl		CHEMBL601719	=	Kd	nM	690.0	CHEMBL5408	Homo sapiens	Kd	nM	690.0
	7571912	CHEMBL1908769	Binding constant for TBK1 kinase domain	B	N#CC[C@H](C1CCCC1)n1cc(-c2ncnc3[nH]ccc23)cn1		CHEMBL1789941	=	Kd	nM	1700.0	CHEMBL5408	Homo sapiens	Kd	nM	1700.0
	7572375	CHEMBL1908769	Binding constant for TBK1 kinase domain	B	Oc1cccc(-c2nc(N3CCOCC3)c3oc4ncccc4c3n2)c1		CHEMBL573339	>	Kd	nM	10000.0	CHEMBL5408	Homo sapiens	Kd	nM	10000.0
	7572791	CHEMBL1908769	Binding constant for TBK1 kinase domain	B	COc1cc(N2CCC(N3CCN(C)CC3)CC2)ccc1Nc1ncc(Cl)c(Nc2ccccc2S(=O)(=O)C(C)C)n1		CHEMBL509032	=	Kd	nM	470.0	CHEMBL5408	Homo sapiens	Kd	nM	470.0
	7572960	CHEMBL1908769	Binding constant for TBK1 kinase domain	B	CC[C@@H]1C(=O)N(C)c2cnc(Nc3ccc(C(=O)NC4CCN(C)CC4)cc3OC)nc2N1C1CCCC1		CHEMBL513909	>	Kd	nM	10000.0	CHEMBL5408	Homo sapiens	Kd	nM	10000.0
	7573417	CHEMBL1908769	Binding constant for TBK1 kinase domain	B	Cc1nc(Nc2ncc(C(=O)Nc3c(C)cccc3Cl)s2)cc(N2CCN(CCO)CC2)n1		CHEMBL1421	>	Kd	nM	10000.0	CHEMBL5408	Homo sapiens	Kd	nM	10000.0
	7573893	CHEMBL1908769	Binding constant for TBK1 kinase domain	B	CN(C)CC(=O)N1CCC(c2ccc(NC(=O)c3nc(C#N)c[nH]3)c(C3=CCCCC3)c2)CC1.Cl		CHEMBL1908395	=	Kd	nM	470.0	CHEMBL5408	Homo sapiens	Kd	nM	470.0
	7574362	CHEMBL1908769	Binding constant for TBK1 kinase domain	B	CO[C@@H]1[C@H](N(C)C(=O)c2ccccc2)C[C@H]2O[C@]1(C)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)C(=O)NC4		CHEMBL608533	=	Kd	nM	9.3	CHEMBL5408	Homo sapiens	Kd	nM	9.3
	7574938	CHEMBL1908769	Binding constant for TBK1 kinase domain	B	COC(=O)c1ccc2c(c1)NC(=O)/C2=C(\Nc1ccc(N(C)C(=O)CN2CCN(C)CC2)cc1)c1ccccc1		CHEMBL502835	=	Kd	nM	150.0	CHEMBL5408	Homo sapiens	Kd	nM	150.0
	7575399	CHEMBL1908769	Binding constant for TBK1 kinase domain	B	C#Cc1cccc(Nc2ncnc3cc(OCCOC)c(OCCOC)cc23)c1		CHEMBL553	=	Kd	nM	3100.0	CHEMBL5408	Homo sapiens	Kd	nM	3100.0
	7575870	CHEMBL1908769	Binding constant for TBK1 kinase domain	B	COc1cc(Oc2ccnc3cc(OC)c(OC)cc23)ccc1NC(=O)NC(C)c1nccs1		CHEMBL1908396	>	Kd	nM	10000.0	CHEMBL5408	Homo sapiens	Kd	nM	10000.0
	7576301	CHEMBL1908769	Binding constant for TBK1 kinase domain	B	Nc1nc(N)c2nc(-c3cccc(O)c3)c(-c3cccc(O)c3)nc2n1		CHEMBL230011	>	Kd	nM	10000.0	CHEMBL5408	Homo sapiens	Kd	nM	10000.0
	7576912	CHEMBL1908769	Binding constant for TBK1 kinase domain	B	CN(C)C/C=C/C(=O)Nc1cc2c(Nc3ccc(F)c(Cl)c3)ncnc2cc1O[C@H]1CCOC1		CHEMBL1173655	>	Kd	nM	10000.0	CHEMBL5408	Homo sapiens	Kd	nM	10000.0
	7577371	CHEMBL1908769	Binding constant for TBK1 kinase domain	B	COc1cc2c(Oc3ccc(NC(=O)C4(C(=O)Nc5ccc(F)cc5)CC4)cc3F)ccnc2cc1OCCCN1CCOCC1		CHEMBL1230609	=	Kd	nM	800.0	CHEMBL5408	Homo sapiens	Kd	nM	800.0
	7577877	CHEMBL1908769	Binding constant for TBK1 kinase domain	B	CCCS(=O)(=O)Nc1ccc(F)c(C(=O)c2c[nH]c3ncc(Cl)cc23)c1F		CHEMBL1230020	>	Kd	nM	10000.0	CHEMBL5408	Homo sapiens	Kd	nM	10000.0
	7578282	CHEMBL1908769	Binding constant for TBK1 kinase domain	B	Cc1cnc(Nc2ccc(OCCN3CCCC3)cc2)nc1Nc1cccc(S(=O)(=O)NC(C)(C)C)c1		CHEMBL1287853	=	Kd	nM	92.0	CHEMBL5408	Homo sapiens	Kd	nM	92.0
	7578920	CHEMBL1908769	Binding constant for TBK1 kinase domain	B	Cc1n[nH]c2ccc(-c3cncc(OC[C@@H](N)Cc4ccccc4)c3)cc12		CHEMBL379218	>	Kd	nM	10000.0	CHEMBL5408	Homo sapiens	Kd	nM	10000.0
	7579294	CHEMBL1908769	Binding constant for TBK1 kinase domain	B	Cc1ccc(-n2nc(C(C)(C)C)cc2NC(=O)Nc2ccc(OCCN3CCOCC3)c3ccccc23)cc1		CHEMBL103667	>	Kd	nM	10000.0	CHEMBL5408	Homo sapiens	Kd	nM	10000.0
	7579744	CHEMBL1908769	Binding constant for TBK1 kinase domain	B	CN1CC[C@H](c2c(O)cc(O)c3c(=O)cc(-c4ccccc4Cl)oc23)[C@H](O)C1		CHEMBL428690	=	Kd	nM	470.0	CHEMBL5408	Homo sapiens	Kd	nM	470.0
	7579776	CHEMBL1908769	Binding constant for TBK1 kinase domain	B	O=C(c1ccc(/C=C/c2n[nH]c3ccccc23)cc1)N1CCNCC1		CHEMBL1908397	=	Kd	nM	130.0	CHEMBL5408	Homo sapiens	Kd	nM	130.0
	7580245	CHEMBL1908769	Binding constant for TBK1 kinase domain	B	CC(C)n1nc(-c2cc3cc(O)ccc3[nH]2)c2c(N)ncnc21		CHEMBL1241674	>	Kd	nM	10000.0	CHEMBL5408	Homo sapiens	Kd	nM	10000.0
	7580648	CHEMBL1908769	Binding constant for TBK1 kinase domain	B	COc1cc2c(Nc3ccc(Br)cc3F)ncnc2cc1OCC1CCN(C)CC1		CHEMBL24828	>	Kd	nM	10000.0	CHEMBL5408	Homo sapiens	Kd	nM	10000.0
	7581278	CHEMBL1908769	Binding constant for TBK1 kinase domain	B	Cc1ccc(NC(=O)c2ccc(CN3CCN(C)CC3)cc2)cc1Nc1nc(-c2cccnc2)cs1		CHEMBL1908391	>	Kd	nM	10000.0	CHEMBL5408	Homo sapiens	Kd	nM	10000.0
	7581663	CHEMBL1908769	Binding constant for TBK1 kinase domain	B	Cc1ccc2nc(NCCN)c3ncc(C)n3c2c1		CHEMBL249697	>	Kd	nM	10000.0	CHEMBL5408	Homo sapiens	Kd	nM	10000.0
	7582137	CHEMBL1908769	Binding constant for TBK1 kinase domain	B	CS(=O)(=O)CCNCc1ccc(-c2ccc3ncnc(Nc4ccc(OCc5cccc(F)c5)c(Cl)c4)c3c2)o1		CHEMBL554	>	Kd	nM	10000.0	CHEMBL5408	Homo sapiens	Kd	nM	10000.0
	7582601	CHEMBL1908769	Binding constant for TBK1 kinase domain	B	Clc1ccc(Nc2nnc(Cc3ccncc3)c3ccccc23)cc1		CHEMBL101253	>	Kd	nM	10000.0	CHEMBL5408	Homo sapiens	Kd	nM	10000.0
	7583001	CHEMBL1908769	Binding constant for TBK1 kinase domain	B	Cc1cc(Nc2cc(N3CCN(C)CC3)nc(Sc3ccc(NC(=O)C4CC4)cc3)n2)n[nH]1		CHEMBL572878	=	Kd	nM	490.0	CHEMBL5408	Homo sapiens	Kd	nM	490.0
	7584024	CHEMBL1908769	Binding constant for TBK1 kinase domain	B	OCCn1cc(-c2ccc3c(c2)CC/C3=N\O)c(-c2ccncc2)n1		CHEMBL525191	>	Kd	nM	10000.0	CHEMBL5408	Homo sapiens	Kd	nM	10000.0
	7584495	CHEMBL1908769	Binding constant for TBK1 kinase domain	B	Cn1cc(C2=C(c3cn(C4CCN(Cc5ccccn5)CC4)c4ccccc34)C(=O)NC2=O)c2ccccc21		CHEMBL300138	>	Kd	nM	10000.0	CHEMBL5408	Homo sapiens	Kd	nM	10000.0
	7584957	CHEMBL1908769	Binding constant for TBK1 kinase domain	B	COc1cc(Nc2ncc(F)c(Nc3ccc4c(n3)NC(=O)C(C)(C)O4)n2)cc(OC)c1OC		CHEMBL475251	=	Kd	nM	23.0	CHEMBL5408	Homo sapiens	Kd	nM	23.0
	7585361	CHEMBL1908769	Binding constant for TBK1 kinase domain	B	O=c1ncn2nc(Sc3ccc(F)cc3F)ccc2c1-c1c(Cl)cccc1Cl		CHEMBL119385	>	Kd	nM	10000.0	CHEMBL5408	Homo sapiens	Kd	nM	10000.0
	7585512	CHEMBL1908769	Binding constant for TBK1 kinase domain	B	Cc1ccc(F)c(NC(=O)Nc2ccc(-c3cccc4[nH]nc(N)c34)cc2)c1		CHEMBL223360	>	Kd	nM	10000.0	CHEMBL5408	Homo sapiens	Kd	nM	10000.0
	7585920	CHEMBL1908769	Binding constant for TBK1 kinase domain	B	CC(C)(C)c1cnc(CSc2cnc(NC(=O)C3CCNCC3)s2)o1		CHEMBL296468	>	Kd	nM	10000.0	CHEMBL5408	Homo sapiens	Kd	nM	10000.0
	7586366	CHEMBL1908769	Binding constant for TBK1 kinase domain	B	CS(=O)(=O)N1CCN(Cc2cc3nc(-c4cccc5[nH]ncc45)nc(N4CCOCC4)c3s2)CC1		CHEMBL521851	>	Kd	nM	10000.0	CHEMBL5408	Homo sapiens	Kd	nM	10000.0
	7586837	CHEMBL1908769	Binding constant for TBK1 kinase domain	B	CN(C)C[C@@H]1CCn2cc(c3ccccc32)C2=C(C(=O)NC2=O)c2cn(c3ccccc23)CCO1		CHEMBL91829	=	Kd	nM	970.0	CHEMBL5408	Homo sapiens	Kd	nM	970.0
	7587291	CHEMBL1908769	Binding constant for TBK1 kinase domain	B	COc1ccc(F)c(F)c1C(=O)c1cnc(NC2CCN(S(C)(=O)=O)CC2)nc1N		CHEMBL384304	>	Kd	nM	10000.0	CHEMBL5408	Homo sapiens	Kd	nM	10000.0
	7587473	CHEMBL1908769	Binding constant for TBK1 kinase domain	B	CC(C)(C)c1cc(NC(=O)Nc2ccc(-c3cn4c(n3)sc3cc(OCCN5CCOCC5)ccc34)cc2)no1		CHEMBL576982	>	Kd	nM	10000.0	CHEMBL5408	Homo sapiens	Kd	nM	10000.0
	7587892	CHEMBL1908769	Binding constant for TBK1 kinase domain	B	Cc1cc2c(F)c(Oc3ncnn4cc(OC[C@@H](C)O)c(C)c34)ccc2[nH]1		CHEMBL377300	>	Kd	nM	10000.0	CHEMBL5408	Homo sapiens	Kd	nM	10000.0
	7588345	CHEMBL1908769	Binding constant for TBK1 kinase domain	B	COc1cc2ncnc(Nc3ccc(F)c(Cl)c3)c2cc1OCCCN1CCOCC1		CHEMBL939	>	Kd	nM	10000.0	CHEMBL5408	Homo sapiens	Kd	nM	10000.0
	7588816	CHEMBL1908769	Binding constant for TBK1 kinase domain	B	COc1c(Cl)cc2c([nH]c3cnccc32)c1NC(=O)c1cccnc1C		CHEMBL608154	>	Kd	nM	10000.0	CHEMBL5408	Homo sapiens	Kd	nM	10000.0
	7589267	CHEMBL1908769	Binding constant for TBK1 kinase domain	B	C[S+]([O-])c1ccc(-c2nc(-c3ccc(F)cc3)c(-c3ccncc3)[nH]2)cc1		CHEMBL10	>	Kd	nM	10000.0	CHEMBL5408	Homo sapiens	Kd	nM	10000.0
	7589438	CHEMBL1908769	Binding constant for TBK1 kinase domain	B	CNC(=O)c1ccccc1Sc1ccc2c(/C=C/c3ccccn3)n[nH]c2c1		CHEMBL1289926	>	Kd	nM	10000.0	CHEMBL5408	Homo sapiens	Kd	nM	10000.0
	7589862	CHEMBL1908769	Binding constant for TBK1 kinase domain	B	C[C@]12O[C@H](C[C@]1(O)CO)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)CNC4=O		CHEMBL603469	=	Kd	nM	18.0	CHEMBL5408	Homo sapiens	Kd	nM	18.0
	7590329	CHEMBL1908769	Binding constant for TBK1 kinase domain	B	CNC(=O)c1c(F)cccc1Nc1nc(Nc2cc3c(cc2OC)CCN3C(=O)CN(C)C)nc2[nH]ccc12		CHEMBL464552	>	Kd	nM	10000.0	CHEMBL5408	Homo sapiens	Kd	nM	10000.0
	7590803	CHEMBL1908769	Binding constant for TBK1 kinase domain	B	COc1cc2c(N3CCN(C(=O)Nc4ccc(OC(C)C)cc4)CC3)ncnc2cc1OCCCN1CCCCC1		CHEMBL124660	>	Kd	nM	10000.0	CHEMBL5408	Homo sapiens	Kd	nM	10000.0
	7591411	CHEMBL1908769	Binding constant for TBK1 kinase domain	B	CC1(C)CNc2cc(NC(=O)c3cccnc3NCc3ccncc3)ccc21		CHEMBL572881	>	Kd	nM	10000.0	CHEMBL5408	Homo sapiens	Kd	nM	10000.0
	7591833	CHEMBL1908769	Binding constant for TBK1 kinase domain	B	CN1CCN(c2ccc3nc(-c4c(N)c5c(F)cccc5[nH]c4=O)[nH]c3c2)CC1		CHEMBL522892	=	Kd	nM	130.0	CHEMBL5408	Homo sapiens	Kd	nM	130.0
	7592305	CHEMBL1908769	Binding constant for TBK1 kinase domain	B	C[C@@H](Oc1cc(-n2cnc3ccc(CN4CCN(C)CC4)cc32)sc1C(N)=O)c1ccccc1C(F)(F)F		CHEMBL1908394	>	Kd	nM	10000.0	CHEMBL5408	Homo sapiens	Kd	nM	10000.0
	7592789	CHEMBL1908769	Binding constant for TBK1 kinase domain	B	Cn1cc(-c2ccc3nnc(Sc4ccc5ncccc5c4)n3n2)cn1		CHEMBL1236107	>	Kd	nM	10000.0	CHEMBL5408	Homo sapiens	Kd	nM	10000.0
	7593378	CHEMBL1908769	Binding constant for TBK1 kinase domain	B	CCN1CCN(Cc2ccc(NC(=O)Nc3ccc(Oc4cc(NC)ncn4)cc3)cc2C(F)(F)F)CC1		CHEMBL574738	>	Kd	nM	10000.0	CHEMBL5408	Homo sapiens	Kd	nM	10000.0
	7593813	CHEMBL1908769	Binding constant for TBK1 kinase domain	B	Cn1c(Nc2ccc(C(F)(F)F)cc2)nc2cc(Oc3ccnc(-c4ncc(C(F)(F)F)[nH]4)c3)ccc21		CHEMBL558752	>	Kd	nM	10000.0	CHEMBL5408	Homo sapiens	Kd	nM	10000.0
	7594285	CHEMBL1908769	Binding constant for TBK1 kinase domain	B	CCn1c(-c2nonc2N)nc2c(C#CC(C)(C)O)ncc(OC[C@H]3CCCNC3)c21		CHEMBL494089	>	Kd	nM	10000.0	CHEMBL5408	Homo sapiens	Kd	nM	10000.0
	7594316	CHEMBL1908769	Binding constant for TBK1 kinase domain	B	O=C(O)c1ccc(Nc2ncc3c(n2)-c2ccc(Cl)cc2C(c2c(F)cccc2F)=NC3)cc1		CHEMBL259084	>	Kd	nM	10000.0	CHEMBL5408	Homo sapiens	Kd	nM	10000.0
	7594768	CHEMBL1908769	Binding constant for TBK1 kinase domain	B	COc1cc(Nc2c(C#N)cnc3cc(OCCCN4CCN(C)CC4)c(OC)cc23)c(Cl)cc1Cl		CHEMBL288441	=	Kd	nM	250.0	CHEMBL5408	Homo sapiens	Kd	nM	250.0
	7595346	CHEMBL1908769	Binding constant for TBK1 kinase domain	B	O=C(NC1CCNCC1)c1n[nH]cc1NC(=O)c1c(Cl)cccc1Cl		CHEMBL445813	>	Kd	nM	10000.0	CHEMBL5408	Homo sapiens	Kd	nM	10000.0
	7595790	CHEMBL1908769	Binding constant for TBK1 kinase domain	B	C=CC(=O)Nc1cc2c(Nc3ccc(F)c(Cl)c3)ncnc2cc1OCCCN1CCOCC1		CHEMBL31965	>	Kd	nM	10000.0	CHEMBL5408	Homo sapiens	Kd	nM	10000.0
	7596293	CHEMBL1908769	Binding constant for TBK1 kinase domain	B	Cc1cn(-c2cc(NC(=O)c3ccc(C)c(Nc4nccc(-c5cccnc5)n4)c3)cc(C(F)(F)F)c2)cn1		CHEMBL255863	>	Kd	nM	10000.0	CHEMBL5408	Homo sapiens	Kd	nM	10000.0
	7596740	CHEMBL1908769	Binding constant for TBK1 kinase domain	B	CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3ccc(Cl)c(C(F)(F)F)c3)cc2)ccn1		CHEMBL1336	>	Kd	nM	10000.0	CHEMBL5408	Homo sapiens	Kd	nM	10000.0
	7597318	CHEMBL1908769	Binding constant for TBK1 kinase domain	B	CCN(CCO)CCCOc1ccc2c(Nc3cc(CC(=O)Nc4cccc(F)c4)[nH]n3)ncnc2c1		CHEMBL215152	>	Kd	nM	10000.0	CHEMBL5408	Homo sapiens	Kd	nM	10000.0
	7597802	CHEMBL1908769	Binding constant for TBK1 kinase domain	B	COc1ccc(COc2ccc(Cc3cnc(N)nc3N)cc2OC)cc1		CHEMBL261849	>	Kd	nM	10000.0	CHEMBL5408	Homo sapiens	Kd	nM	10000.0
	7598272	CHEMBL1908769	Binding constant for TBK1 kinase domain	B	Cc1ccc(Nc2nccc(N(C)c3ccc4c(C)n(C)nc4c3)n2)cc1S(N)(=O)=O		CHEMBL477772	>	Kd	nM	10000.0	CHEMBL5408	Homo sapiens	Kd	nM	10000.0
	7598714	CHEMBL1908769	Binding constant for TBK1 kinase domain	B	CN[C@@H]1C[C@H]2O[C@@](C)([C@@H]1OC)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)C(=O)NC4		CHEMBL388978	=	Kd	nM	0.89	CHEMBL5408	Homo sapiens	Kd	nM	0.89
	7931136	CHEMBL1919473	Inhibition of TBK1 relative to control	B	Cc1ccccc1Nc1nc2cc(F)c(N(C)C(=O)/C=C/CN(C)C)cc2n2cncc12		CHEMBL1916891	=	Inhibition	%	-5.0	CHEMBL5408	Homo sapiens	INH	%	-5.0
	7961165	CHEMBL1931564	Inhibition of TBK1	B	CN(C)CCN1CCN(C(=O)c2cc(C(C)(C)C)sc2NC(=O)Nc2cccc(Cl)c2Cl)CCC1=O		CHEMBL1929238	>	IC50	nM	30000.0	CHEMBL5408	Homo sapiens	IC50	uM	30.0
	7961166	CHEMBL1931564	Inhibition of TBK1	B	Cc1ccc(-n2nc(C(C)(C)C)cc2NC(=O)Nc2ccc(OCCN3CCOCC3)c3ccccc23)cc1		CHEMBL103667	>	IC50	nM	30000.0	CHEMBL5408	Homo sapiens	IC50	uM	30.0
	7969803	CHEMBL1930375	Inhibition of TBK1 assessed as residual activity at 10 uM using [33P-ATP] by radiometric filter binding assay	B	Cc1ccc(F)cc1-c1nc2[nH]nc(N)c2c2c1CCCC2		CHEMBL1927262	=	Activity	%	107.0	CHEMBL5408	Homo sapiens	Activity	%	107.0
	8003620	CHEMBL1942760	Inhibition of human TBK1 in HL-60 cells lysate assessed as reduction of labeling of acyl-phosphate ATP probe at 100 nM	B	C[C@H]1COc2c(NCCCn3cccn3)c(F)c(N)c3c(=O)c(C(=O)O)cn1c23		CHEMBL1940980	<	Inhibition	%	35.0	CHEMBL5408	Homo sapiens	INH	%	35.0
	8003621	CHEMBL1942760	Inhibition of human TBK1 in HL-60 cells lysate assessed as reduction of labeling of acyl-phosphate ATP probe at 100 nM	B	C[C@H]1COc2c(NCCCn3cccn3)c(F)c(N)c3c(=O)c(C#N)cn1c23		CHEMBL1940981	<	Inhibition	%	35.0	CHEMBL5408	Homo sapiens	INH	%	35.0
	8003622	CHEMBL1942760	Inhibition of human TBK1 in HL-60 cells lysate assessed as reduction of labeling of acyl-phosphate ATP probe at 100 nM	B	C[C@H]1COc2c(NCCCc3ccccn3)c(F)c(N)c3c(=O)c(C(=O)O)cn1c23		CHEMBL1940987	<	Inhibition	%	35.0	CHEMBL5408	Homo sapiens	INH	%	35.0
	8003623	CHEMBL1942760	Inhibition of human TBK1 in HL-60 cells lysate assessed as reduction of labeling of acyl-phosphate ATP probe at 100 nM	B	C[C@H]1COc2c(NCCCc3ccccn3)c(F)c(N)c3c(=O)c(C#N)cn1c23		CHEMBL1940990	<	Inhibition	%	35.0	CHEMBL5408	Homo sapiens	INH	%	35.0
	8018915	CHEMBL1949067	Inhibition of TBK1 assessed as activity remaining at 10 uM	B	O=c1[nH]c2ncc(-c3ccc(-c4nc[nH]n4)cc3)nc2n1CC1CCOCC1		CHEMBL1945953	=	Activity	%	94.0	CHEMBL5408	Homo sapiens	Activity	%	94.0
	8018916	CHEMBL1949067	Inhibition of TBK1 assessed as activity remaining at 10 uM	B	CC(C)(O)c1ccc(-c2cnc3[nH]c(=O)n(CC4CCCCC4)c3n2)cc1		CHEMBL1945950	=	Activity	%	91.0	CHEMBL5408	Homo sapiens	Activity	%	91.0
	8018917	CHEMBL1949067	Inhibition of TBK1 assessed as activity remaining at 10 uM	B	O=c1[nH]c2ncc(-c3ccc4[nH]cnc4c3)nc2n1CC1CCCCC1		CHEMBL1946262	=	Activity	%	77.0	CHEMBL5408	Homo sapiens	Activity	%	77.0
	8061283	CHEMBL1962004	GSK_PKIS: TBK1 mean inhibition at 0.1 uM [Nanosyn]	B	Cl.NCc1ccc(-c2nc(-c3ccc(Cl)c(O)c3)c(-c3ccncc3)[nH]2)cc1		CHEMBL1909412	=	Inhibition	%	-1.21	CHEMBL5408	Homo sapiens	Inhibition	%	-1.21
	8061460	CHEMBL1962005	GSK_PKIS: TBK1 mean inhibition at 1 uM [Nanosyn]	B	COc1cc(C=NNc2ncnc3c2cnn3Cc2ccccc2)ccc1O		CHEMBL1789962	=	Inhibition	%	3.75	CHEMBL5408	Homo sapiens	Inhibition	%	3.75
	8061791	CHEMBL1962005	GSK_PKIS: TBK1 mean inhibition at 1 uM [Nanosyn]	B	CN1CCC(n2cnc(-c3ccc(F)cc3)c2-c2ccnc(Nc3ccccc3)n2)CC1		CHEMBL318892	=	Inhibition	%	2.8	CHEMBL5408	Homo sapiens	Inhibition	%	2.8
	8061982	CHEMBL1962004	GSK_PKIS: TBK1 mean inhibition at 0.1 uM [Nanosyn]	B	Cn1cc(C=C2C(=O)Nc3cccnc32)c2ccccc21		CHEMBL1516890	=	Inhibition	%	2.42	CHEMBL5408	Homo sapiens	Inhibition	%	2.42
	8062322	CHEMBL1962004	GSK_PKIS: TBK1 mean inhibition at 0.1 uM [Nanosyn]	B	Cn1c(-c2nonc2N)nc2cnccc21		CHEMBL188048	=	Inhibition	%	1.34	CHEMBL5408	Homo sapiens	Inhibition	%	1.34
	8062484	CHEMBL1962005	GSK_PKIS: TBK1 mean inhibition at 1 uM [Nanosyn]	B	CN1CCC(C(=O)Nc2n[nH]c3nc(-c4ccc(O)cc4)c(Br)cc23)CC1		CHEMBL261129	=	Inhibition	%	6.1	CHEMBL5408	Homo sapiens	Inhibition	%	6.1
	8062708	CHEMBL1962004	GSK_PKIS: TBK1 mean inhibition at 0.1 uM [Nanosyn]	B	O=C1Nc2ccccc2/C1=C/Nc1ccc(-n2cncn2)cc1		CHEMBL1794056	=	Inhibition	%	6.41	CHEMBL5408	Homo sapiens	Inhibition	%	6.41
	8062806	CHEMBL1962005	GSK_PKIS: TBK1 mean inhibition at 1 uM [Nanosyn]	B	CCn1c(-c2nonc2N)nc2ccncc21		CHEMBL185710	=	Inhibition	%	1.82	CHEMBL5408	Homo sapiens	Inhibition	%	1.82
	8063162	CHEMBL1962005	GSK_PKIS: TBK1 mean inhibition at 1 uM [Nanosyn]	B	Cl.NCc1ccc(-c2nc(-c3ccc(Cl)c(O)c3)c(-c3ccncc3)[nH]2)cc1		CHEMBL1909412	=	Inhibition	%	1.76	CHEMBL5408	Homo sapiens	Inhibition	%	1.76
	8063329	CHEMBL1962004	GSK_PKIS: TBK1 mean inhibition at 0.1 uM [Nanosyn]	B	COc1ccc(-c2nn3ncccc3c2-c2ccnc(Nc3ccc(Cl)c(C(F)(F)F)c3)n2)cc1		CHEMBL188794	=	Inhibition	%	0.22	CHEMBL5408	Homo sapiens	Inhibition	%	0.22
	8063553	CHEMBL1962005	GSK_PKIS: TBK1 mean inhibition at 1 uM [Nanosyn]	B	COc1ccc(-c2nn3ncccc3c2-c2ccnc(Nc3ccc(Cl)c(C(F)(F)F)c3)n2)cc1		CHEMBL188794	=	Inhibition	%	2.16	CHEMBL5408	Homo sapiens	Inhibition	%	2.16
	8063661	CHEMBL1962004	GSK_PKIS: TBK1 mean inhibition at 0.1 uM [Nanosyn]	B	Cl.NC(=O)c1ccc(-c2nc(-c3ccccn3)c(-c3ccc4c(c3)OCO4)[nH]2)cc1		CHEMBL1909378	=	Inhibition	%	2.24	CHEMBL5408	Homo sapiens	Inhibition	%	2.24
	8063843	CHEMBL1962005	GSK_PKIS: TBK1 mean inhibition at 1 uM [Nanosyn]	B	Cn1cc(C=C2C(=O)Nc3cccnc32)c2ccccc21		CHEMBL1516890	=	Inhibition	%	10.17	CHEMBL5408	Homo sapiens	Inhibition	%	10.17
	8064067	CHEMBL1962004	GSK_PKIS: TBK1 mean inhibition at 0.1 uM [Nanosyn]	B	FC(F)(F)c1cccc(-c2nn3ncccc3c2-c2ccnc(Nc3ccc4c(c3)OCCO4)n2)c1		CHEMBL362155	=	Inhibition	%	0.3	CHEMBL5408	Homo sapiens	Inhibition	%	0.3
	8064182	CHEMBL1962005	GSK_PKIS: TBK1 mean inhibition at 1 uM [Nanosyn]	B	Cn1c(-c2nonc2N)nc2cnccc21		CHEMBL188048	=	Inhibition	%	7.42	CHEMBL5408	Homo sapiens	Inhibition	%	7.42
	8064392	CHEMBL1962004	GSK_PKIS: TBK1 mean inhibition at 0.1 uM [Nanosyn]	B	CN(C)C(=O)O[C@@H]1CN[C@@H](C#Cc2cc3ncnc(Nc4ccc(OCc5cccc(F)c5)c(Cl)c4)c3s2)C1		CHEMBL466412	=	Inhibition	%	4.03	CHEMBL5408	Homo sapiens	Inhibition	%	4.03
	8064616	CHEMBL1962005	GSK_PKIS: TBK1 mean inhibition at 1 uM [Nanosyn]	B	CN(C)C(=O)O[C@@H]1CN[C@@H](C#Cc2cc3ncnc(Nc4ccc(OCc5cccc(F)c5)c(Cl)c4)c3s2)C1		CHEMBL466412	=	Inhibition	%	2.9	CHEMBL5408	Homo sapiens	Inhibition	%	2.9
	8064754	CHEMBL1962004	GSK_PKIS: TBK1 mean inhibition at 0.1 uM [Nanosyn]	B	COc1ccc(Nc2ncc(-c3ccccc3)o2)cc1OC.Cl		CHEMBL1794060	=	Inhibition	%	-0.12	CHEMBL5408	Homo sapiens	Inhibition	%	-0.12
	8065144	CHEMBL1962004	GSK_PKIS: TBK1 mean inhibition at 0.1 uM [Nanosyn]	B	COc1ccc(-c2ccc3c(NC(=O)C4CC4)n[nH]c3n2)cc1		CHEMBL408732	=	Inhibition	%	2.33	CHEMBL5408	Homo sapiens	Inhibition	%	2.33
	8065260	CHEMBL1962005	GSK_PKIS: TBK1 mean inhibition at 1 uM [Nanosyn]	B	Cl.NC(=O)c1ccc(-c2nc(-c3ccccn3)c(-c3ccc4c(c3)OCO4)[nH]2)cc1		CHEMBL1909378	=	Inhibition	%	2.25	CHEMBL5408	Homo sapiens	Inhibition	%	2.25
	8065659	CHEMBL1962005	GSK_PKIS: TBK1 mean inhibition at 1 uM [Nanosyn]	B	FC(F)(F)c1cccc(-c2nn3ncccc3c2-c2ccnc(Nc3ccc4c(c3)OCCO4)n2)c1		CHEMBL362155	=	Inhibition	%	2.28	CHEMBL5408	Homo sapiens	Inhibition	%	2.28
	8065774	CHEMBL1962004	GSK_PKIS: TBK1 mean inhibition at 0.1 uM [Nanosyn]	B	CCn1c(-c2nonc2N)nc2cnc(Oc3cccc(NC(=O)c4ccc(N(C)C)cc4)c3)cc21		CHEMBL220465	=	Inhibition	%	0.53	CHEMBL5408	Homo sapiens	Inhibition	%	0.53
	8065998	CHEMBL1962005	GSK_PKIS: TBK1 mean inhibition at 1 uM [Nanosyn]	B	CCn1c(-c2nonc2N)nc2cnc(Oc3cccc(NC(=O)c4ccc(N(C)C)cc4)c3)cc21		CHEMBL220465	=	Inhibition	%	6.31	CHEMBL5408	Homo sapiens	Inhibition	%	6.31
	8066208	CHEMBL1962004	GSK_PKIS: TBK1 mean inhibition at 0.1 uM [Nanosyn]	B	CCc1nccc2c1nc(-c1nonc1N)n2CC		CHEMBL365072	=	Inhibition	%	1.12	CHEMBL5408	Homo sapiens	Inhibition	%	1.12
	8066344	CHEMBL1962005	GSK_PKIS: TBK1 mean inhibition at 1 uM [Nanosyn]	B	COc1ccc(Nc2ncc(-c3ccccc3)o2)cc1OC.Cl		CHEMBL1794060	=	Inhibition	%	10.67	CHEMBL5408	Homo sapiens	Inhibition	%	10.67
	8066568	CHEMBL1962004	GSK_PKIS: TBK1 mean inhibition at 0.1 uM [Nanosyn]	B	COc1cc(Nc2nccc(-c3cnn4ncccc34)n2)cc(OC)c1		CHEMBL359999	=	Inhibition	%	3.49	CHEMBL5408	Homo sapiens	Inhibition	%	3.49
	8066734	CHEMBL1962005	GSK_PKIS: TBK1 mean inhibition at 1 uM [Nanosyn]	B	COc1ccc(-c2ccc3c(NC(=O)C4CC4)n[nH]c3n2)cc1		CHEMBL408732	=	Inhibition	%	0.62	CHEMBL5408	Homo sapiens	Inhibition	%	0.62
	8066858	CHEMBL1962004	GSK_PKIS: TBK1 mean inhibition at 0.1 uM [Nanosyn]	B	COC(=O)Nc1nc2cc(Oc3ccc(NC(=O)Nc4cccc(Br)c4)cc3)ccc2[nH]1.Cl		CHEMBL1909370	=	Inhibition	%	-1.34	CHEMBL5408	Homo sapiens	Inhibition	%	-1.34
	8067082	CHEMBL1962005	GSK_PKIS: TBK1 mean inhibition at 1 uM [Nanosyn]	B	COC(=O)Nc1nc2cc(Oc3ccc(NC(=O)Nc4cccc(Br)c4)cc3)ccc2[nH]1.Cl		CHEMBL1909370	=	Inhibition	%	3.82	CHEMBL5408	Homo sapiens	Inhibition	%	3.82
	8067257	CHEMBL1962004	GSK_PKIS: TBK1 mean inhibition at 0.1 uM [Nanosyn]	B	COC(=O)Nc1nc2ccc(S(=O)(=O)c3ccc(NC(=O)Nc4cc(C(F)(F)F)ccc4F)cc3)cc2[nH]1.Cl		CHEMBL1909367	=	Inhibition	%	2.66	CHEMBL5408	Homo sapiens	Inhibition	%	2.66
	8067602	CHEMBL1962004	GSK_PKIS: TBK1 mean inhibition at 0.1 uM [Nanosyn]	B	Fc1ccc(-c2nn3ccccc3c2-c2ccncc2)cc1		CHEMBL485745	=	Inhibition	%	2.66	CHEMBL5408	Homo sapiens	Inhibition	%	2.66
	8067812	CHEMBL1962005	GSK_PKIS: TBK1 mean inhibition at 1 uM [Nanosyn]	B	CCc1nccc2c1nc(-c1nonc1N)n2CC		CHEMBL365072	=	Inhibition	%	6.1	CHEMBL5408	Homo sapiens	Inhibition	%	6.1
	8068171	CHEMBL1962005	GSK_PKIS: TBK1 mean inhibition at 1 uM [Nanosyn]	B	COc1cc(Nc2nccc(-c3cnn4ncccc34)n2)cc(OC)c1		CHEMBL359999	=	Inhibition	%	33.25	CHEMBL5408	Homo sapiens	Inhibition	%	33.25
	8068335	CHEMBL1962004	GSK_PKIS: TBK1 mean inhibition at 0.1 uM [Nanosyn]	B	Cl.N#Cc1cccc(Nc2ncc(-c3ccccc3)o2)c1		CHEMBL1794061	=	Inhibition	%	1.05	CHEMBL5408	Homo sapiens	Inhibition	%	1.05
	8068684	CHEMBL1962004	GSK_PKIS: TBK1 mean inhibition at 0.1 uM [Nanosyn]	B	N#Cc1c(NC(=O)c2ccc(F)cc2)sc2c1CCCC2		CHEMBL397570	=	Inhibition	%	0.78	CHEMBL5408	Homo sapiens	Inhibition	%	0.78
	8068858	CHEMBL1962005	GSK_PKIS: TBK1 mean inhibition at 1 uM [Nanosyn]	B	COC(=O)Nc1nc2ccc(S(=O)(=O)c3ccc(NC(=O)Nc4cc(C(F)(F)F)ccc4F)cc3)cc2[nH]1.Cl		CHEMBL1909367	=	Inhibition	%	3.98	CHEMBL5408	Homo sapiens	Inhibition	%	3.98
	8069207	CHEMBL1962005	GSK_PKIS: TBK1 mean inhibition at 1 uM [Nanosyn]	B	Fc1ccc(-c2nn3ccccc3c2-c2ccncc2)cc1		CHEMBL485745	=	Inhibition	%	0.18	CHEMBL5408	Homo sapiens	Inhibition	%	0.18
	8069502	CHEMBL1962004	GSK_PKIS: TBK1 mean inhibition at 0.1 uM [Nanosyn]	B	CN1CCN(c2ccc(Nc3nccc(-c4cnn5ncccc45)n3)cc2C(F)(F)F)CC1		CHEMBL468963	=	Inhibition	%	10.76	CHEMBL5408	Homo sapiens	Inhibition	%	10.76
	8069663	CHEMBL1962005	GSK_PKIS: TBK1 mean inhibition at 1 uM [Nanosyn]	B	Cl.N#Cc1cccc(Nc2ncc(-c3ccccc3)o2)c1		CHEMBL1794061	=	Inhibition	%	3.86	CHEMBL5408	Homo sapiens	Inhibition	%	3.86
	8069887	CHEMBL1962004	GSK_PKIS: TBK1 mean inhibition at 0.1 uM [Nanosyn]	B	Cc1cc(Cl)cc2c1NC(=O)C2=NNc1ccc(S(N)(=O)=O)cc1		CHEMBL1909397	=	Inhibition	%	1.17	CHEMBL5408	Homo sapiens	Inhibition	%	1.17
	8070013	CHEMBL1962005	GSK_PKIS: TBK1 mean inhibition at 1 uM [Nanosyn]	B	N#Cc1c(NC(=O)c2ccc(F)cc2)sc2c1CCCC2		CHEMBL397570	=	Inhibition	%	0.54	CHEMBL5408	Homo sapiens	Inhibition	%	0.54
	8070185	CHEMBL1962004	GSK_PKIS: TBK1 mean inhibition at 0.1 uM [Nanosyn]	B	COc1ccc2cc(-c3c(-c4ccncc4)nc(-c4ccc([S+](C)[O-])cc4)n3C)ccc2c1		CHEMBL399410	=	Inhibition	%	-2.09	CHEMBL5408	Homo sapiens	Inhibition	%	-2.09
	8070409	CHEMBL1962005	GSK_PKIS: TBK1 mean inhibition at 1 uM [Nanosyn]	B	COc1ccc2cc(-c3c(-c4ccncc4)nc(-c4ccc([S+](C)[O-])cc4)n3C)ccc2c1		CHEMBL399410	=	Inhibition	%	3.63	CHEMBL5408	Homo sapiens	Inhibition	%	3.63
	8070534	CHEMBL1962004	GSK_PKIS: TBK1 mean inhibition at 0.1 uM [Nanosyn]	B	CC(C)c1ccc(-c2cc(-c3c[nH]nc3-c3ccccn3)ccn2)cc1		CHEMBL206544	=	Inhibition	%	0.97	CHEMBL5408	Homo sapiens	Inhibition	%	0.97
	8070832	CHEMBL1962005	GSK_PKIS: TBK1 mean inhibition at 1 uM [Nanosyn]	B	CN1CCN(c2ccc(Nc3nccc(-c4cnn5ncccc45)n3)cc2C(F)(F)F)CC1		CHEMBL468963	=	Inhibition	%	57.28	CHEMBL5408	Homo sapiens	Inhibition	%	57.28
	8071213	CHEMBL1962005	GSK_PKIS: TBK1 mean inhibition at 1 uM [Nanosyn]	B	Cc1cc(Cl)cc2c1NC(=O)C2=NNc1ccc(S(N)(=O)=O)cc1		CHEMBL1909397	=	Inhibition	%	1.59	CHEMBL5408	Homo sapiens	Inhibition	%	1.59
	8071339	CHEMBL1962004	GSK_PKIS: TBK1 mean inhibition at 0.1 uM [Nanosyn]	B	Cc1cccc(-c2n[nH]cc2-c2ccc3ncccc3n2)n1		CHEMBL185238	=	Inhibition	%	-2.48	CHEMBL5408	Homo sapiens	Inhibition	%	-2.48
	8071736	CHEMBL1962004	GSK_PKIS: TBK1 mean inhibition at 0.1 uM [Nanosyn]	B	O=C(Nc1n[nH]c2nc(-c3ccco3)c(Br)cc12)C1CC1		CHEMBL408564	=	Inhibition	%	6.52	CHEMBL5408	Homo sapiens	Inhibition	%	6.52
	8071861	CHEMBL1962005	GSK_PKIS: TBK1 mean inhibition at 1 uM [Nanosyn]	B	CC(C)c1ccc(-c2cc(-c3c[nH]nc3-c3ccccn3)ccn2)cc1		CHEMBL206544	=	Inhibition	%	-0.11	CHEMBL5408	Homo sapiens	Inhibition	%	-0.11
	8072085	CHEMBL1962004	GSK_PKIS: TBK1 mean inhibition at 0.1 uM [Nanosyn]	B	COC(=O)Nc1nc2ccc(Oc3ccc(NC(=O)Nc4cc(C(F)(F)F)ccc4F)cc3)cc2s1.Cl		CHEMBL1909369	=	Inhibition	%	-0.35	CHEMBL5408	Homo sapiens	Inhibition	%	-0.35
	8072175	CHEMBL1962004	GSK_PKIS: TBK1 mean inhibition at 0.1 uM [Nanosyn]	B	COC(=O)Nc1nc2cc(Oc3cccc(NC(=O)Nc4cc(C(F)(F)F)ccc4F)c3)ccc2[nH]1.Cl	Outside typical range	CHEMBL1909366	=	Inhibition	%	-12.96	CHEMBL5408	Homo sapiens	Inhibition	%	-12.96
	8072556	CHEMBL1962004	GSK_PKIS: TBK1 mean inhibition at 0.1 uM [Nanosyn]	B	COC(=O)Nc1nc2cc(Oc3ccc(NC(=O)Nc4ccccc4)cc3)ccc2[nH]1.Cl		CHEMBL1909371	=	Inhibition	%	-0.2	CHEMBL5408	Homo sapiens	Inhibition	%	-0.2
	8072681	CHEMBL1962005	GSK_PKIS: TBK1 mean inhibition at 1 uM [Nanosyn]	B	Cc1cccc(-c2n[nH]cc2-c2ccc3ncccc3n2)n1		CHEMBL185238	=	Inhibition	%	-2.11	CHEMBL5408	Homo sapiens	Inhibition	%	-2.11
	8072905	CHEMBL1962004	GSK_PKIS: TBK1 mean inhibition at 0.1 uM [Nanosyn]	B	COc1cc2ncn(-c3cc(OCc4ccccc4C(F)(F)F)c(C(=O)N(C)C)s3)c2cc1OC		CHEMBL482326	=	Inhibition	%	2.13	CHEMBL5408	Homo sapiens	Inhibition	%	2.13
	8073072	CHEMBL1962005	GSK_PKIS: TBK1 mean inhibition at 1 uM [Nanosyn]	B	O=C(Nc1n[nH]c2nc(-c3ccco3)c(Br)cc12)C1CC1		CHEMBL408564	=	Inhibition	%	4.8	CHEMBL5408	Homo sapiens	Inhibition	%	4.8
	8073421	CHEMBL1962005	GSK_PKIS: TBK1 mean inhibition at 1 uM [Nanosyn]	B	COC(=O)Nc1nc2ccc(Oc3ccc(NC(=O)Nc4cc(C(F)(F)F)ccc4F)cc3)cc2s1.Cl		CHEMBL1909369	=	Inhibition	%	-0.01	CHEMBL5408	Homo sapiens	Inhibition	%	-0.01
	8073540	CHEMBL1962004	GSK_PKIS: TBK1 mean inhibition at 0.1 uM [Nanosyn]	B	Cc1ccc2c(c1)/C(=N/Nc1ccc(S(N)(=O)=O)cc1)C(=O)N2		CHEMBL271843	=	Inhibition	%	-2.1	CHEMBL5408	Homo sapiens	Inhibition	%	-2.1
	8073773	CHEMBL1962005	GSK_PKIS: TBK1 mean inhibition at 1 uM [Nanosyn]	B	COC(=O)Nc1nc2cc(Oc3cccc(NC(=O)Nc4cc(C(F)(F)F)ccc4F)c3)ccc2[nH]1.Cl		CHEMBL1909366	=	Inhibition	%	4.23	CHEMBL5408	Homo sapiens	Inhibition	%	4.23
	8073997	CHEMBL1962004	GSK_PKIS: TBK1 mean inhibition at 0.1 uM [Nanosyn]	B	CCn1c(-c2nonc2N)nc2c(C#CC(C)(C)O)nc(CN3CCCC3)cc21		CHEMBL1096290	=	Inhibition	%	1.77	CHEMBL5408	Homo sapiens	Inhibition	%	1.77
	8074149	CHEMBL1962005	GSK_PKIS: TBK1 mean inhibition at 1 uM [Nanosyn]	B	COC(=O)Nc1nc2cc(Oc3ccc(NC(=O)Nc4ccccc4)cc3)ccc2[nH]1.Cl		CHEMBL1909371	=	Inhibition	%	2.25	CHEMBL5408	Homo sapiens	Inhibition	%	2.25
	8074503	CHEMBL1962005	GSK_PKIS: TBK1 mean inhibition at 1 uM [Nanosyn]	B	COc1cc2ncn(-c3cc(OCc4ccccc4C(F)(F)F)c(C(=O)N(C)C)s3)c2cc1OC		CHEMBL482326	=	Inhibition	%	0.81	CHEMBL5408	Homo sapiens	Inhibition	%	0.81
	8074660	CHEMBL1962004	GSK_PKIS: TBK1 mean inhibition at 0.1 uM [Nanosyn]	B	NC(=O)Cc1ccccc1Oc1nccc(-c2c(-c3ccc(F)cc3)ncn2C2CCNCC2)n1		CHEMBL1785002	=	Inhibition	%	5.2	CHEMBL5408	Homo sapiens	Inhibition	%	5.2
	8075011	CHEMBL1962004	GSK_PKIS: TBK1 mean inhibition at 0.1 uM [Nanosyn]	B	COc1cc(N2CCN(C(C)C)CC2)ccc1Nc1nc(Nc2cccc3ncccc23)c2cc[nH]c2n1		CHEMBL458438	=	Inhibition	%	-0.11	CHEMBL5408	Homo sapiens	Inhibition	%	-0.11
	8075122	CHEMBL1962005	GSK_PKIS: TBK1 mean inhibition at 1 uM [Nanosyn]	B	Cc1ccc2c(c1)/C(=N/Nc1ccc(S(N)(=O)=O)cc1)C(=O)N2		CHEMBL271843	=	Inhibition	%	6.6	CHEMBL5408	Homo sapiens	Inhibition	%	6.6
	8075346	CHEMBL1962004	GSK_PKIS: TBK1 mean inhibition at 0.1 uM [Nanosyn]	B	Fc1ccc(-c2ncn(CCCN3CCOCC3)c2-c2ccncc2)cc1		CHEMBL14112	=	Inhibition	%	1.21	CHEMBL5408	Homo sapiens	Inhibition	%	1.21
	8075583	CHEMBL1962005	GSK_PKIS: TBK1 mean inhibition at 1 uM [Nanosyn]	B	CCn1c(-c2nonc2N)nc2c(C#CC(C)(C)O)nc(CN3CCCC3)cc21		CHEMBL1096290	=	Inhibition	%	9.67	CHEMBL5408	Homo sapiens	Inhibition	%	9.67
	8075724	CHEMBL1962004	GSK_PKIS: TBK1 mean inhibition at 0.1 uM [Nanosyn]	B	O=C1NC(=O)C(c2cccc(Cl)c2)=C1Nc1ccc(Cl)c(C(=O)O)c1		CHEMBL156987	=	Inhibition	%	2.24	CHEMBL5408	Homo sapiens	Inhibition	%	2.24
	8076090	CHEMBL1962004	GSK_PKIS: TBK1 mean inhibition at 0.1 uM [Nanosyn]	B	COc1ccc2ncn(-c3cc(O[C@H](C)c4ccccc4C(F)(F)F)c(C(N)=O)s3)c2c1		CHEMBL522709	=	Inhibition	%	1.28	CHEMBL5408	Homo sapiens	Inhibition	%	1.28
	8076238	CHEMBL1962005	GSK_PKIS: TBK1 mean inhibition at 1 uM [Nanosyn]	B	NC(=O)Cc1ccccc1Oc1nccc(-c2c(-c3ccc(F)cc3)ncn2C2CCNCC2)n1		CHEMBL1785002	=	Inhibition	%	4.55	CHEMBL5408	Homo sapiens	Inhibition	%	4.55
	8076462	CHEMBL1962004	GSK_PKIS: TBK1 mean inhibition at 0.1 uM [Nanosyn]	B	COc1cc2ncn(-c3cc(OCCc4ccccc4)c(C(N)=O)s3)c2cc1OC		CHEMBL473629	=	Inhibition	%	0.96	CHEMBL5408	Homo sapiens	Inhibition	%	0.96
	8076596	CHEMBL1962005	GSK_PKIS: TBK1 mean inhibition at 1 uM [Nanosyn]	B	COc1cc(N2CCN(C(C)C)CC2)ccc1Nc1nc(Nc2cccc3ncccc23)c2cc[nH]c2n1		CHEMBL458438	=	Inhibition	%	0.59	CHEMBL5408	Homo sapiens	Inhibition	%	0.59
	8076922	CHEMBL1962005	GSK_PKIS: TBK1 mean inhibition at 1 uM [Nanosyn]	B	Fc1ccc(-c2ncn(CCCN3CCOCC3)c2-c2ccncc2)cc1		CHEMBL14112	=	Inhibition	%	0.48	CHEMBL5408	Homo sapiens	Inhibition	%	0.48
	8077169	CHEMBL1962004	GSK_PKIS: TBK1 mean inhibition at 0.1 uM [Nanosyn]	B	CCn1c(-c2nonc2N)nc2c(C#CC(C)(C)O)nc(O[C@@H](CN)c3ccccc3)cc21.O=C(O)C(F)(F)F		CHEMBL1909349	=	Inhibition	%	20.86	CHEMBL5408	Homo sapiens	Inhibition	%	20.86
	8077297	CHEMBL1962005	GSK_PKIS: TBK1 mean inhibition at 1 uM [Nanosyn]	B	O=C1NC(=O)C(c2cccc(Cl)c2)=C1Nc1ccc(Cl)c(C(=O)O)c1		CHEMBL156987	=	Inhibition	%	5.8	CHEMBL5408	Homo sapiens	Inhibition	%	5.8
	8077521	CHEMBL1962004	GSK_PKIS: TBK1 mean inhibition at 0.1 uM [Nanosyn]	B	Cc1nnc(-c2ccc(C)c(-c3ccc(C(=O)Nc4cccc(C#N)c4)cc3)c2)o1		CHEMBL270164	=	Inhibition	%	5.08	CHEMBL5408	Homo sapiens	Inhibition	%	5.08
	8077672	CHEMBL1962005	GSK_PKIS: TBK1 mean inhibition at 1 uM [Nanosyn]	B	COc1ccc2ncn(-c3cc(O[C@H](C)c4ccccc4C(F)(F)F)c(C(N)=O)s3)c2c1		CHEMBL522709	=	Inhibition	%	-0.87	CHEMBL5408	Homo sapiens	Inhibition	%	-0.87
	8078039	CHEMBL1962005	GSK_PKIS: TBK1 mean inhibition at 1 uM [Nanosyn]	B	COc1cc2ncn(-c3cc(OCCc4ccccc4)c(C(N)=O)s3)c2cc1OC		CHEMBL473629	=	Inhibition	%	22.3	CHEMBL5408	Homo sapiens	Inhibition	%	22.3
	8078178	CHEMBL1962004	GSK_PKIS: TBK1 mean inhibition at 0.1 uM [Nanosyn]	B	NS(=O)(=O)c1ccc(Nc2cc(-c3ccc(O)c(F)c3)n[nH]2)cc1		CHEMBL103115	=	Inhibition	%	-1.0	CHEMBL5408	Homo sapiens	Inhibition	%	-1.0
	8078504	CHEMBL1962004	GSK_PKIS: TBK1 mean inhibition at 0.1 uM [Nanosyn]	B	Cl.ON=C1CCc2cc(-c3nc(C4CCNCC4)[nH]c3-c3ccncc3)ccc21		CHEMBL1794071	=	Inhibition	%	0.4	CHEMBL5408	Homo sapiens	Inhibition	%	0.4
	8078754	CHEMBL1962005	GSK_PKIS: TBK1 mean inhibition at 1 uM [Nanosyn]	B	CCn1c(-c2nonc2N)nc2c(C#CC(C)(C)O)nc(O[C@@H](CN)c3ccccc3)cc21.O=C(O)C(F)(F)F		CHEMBL1909349	=	Inhibition	%	67.96	CHEMBL5408	Homo sapiens	Inhibition	%	67.96
	8079094	CHEMBL1962005	GSK_PKIS: TBK1 mean inhibition at 1 uM [Nanosyn]	B	Cc1nnc(-c2ccc(C)c(-c3ccc(C(=O)Nc4cccc(C#N)c4)cc3)c2)o1		CHEMBL270164	=	Inhibition	%	5.0	CHEMBL5408	Homo sapiens	Inhibition	%	5.0
	8079252	CHEMBL1962004	GSK_PKIS: TBK1 mean inhibition at 0.1 uM [Nanosyn]	B	C[C@@H](Oc1cc(-n2cnc3ccc(OC[C@@H](O)CO)cc32)sc1C(N)=O)c1ccccc1Cl		CHEMBL1794067	=	Inhibition	%	0.21	CHEMBL5408	Homo sapiens	Inhibition	%	0.21
	8079618	CHEMBL1962004	GSK_PKIS: TBK1 mean inhibition at 0.1 uM [Nanosyn]	B	Cl.[O-][S+]1CCN(Cc2ccc(-c3ccc4ncnc(Nc5ccc(OCc6ccccc6)c(F)c5)c4c3)o2)CC1		CHEMBL1909391	=	Inhibition	%	1.1	CHEMBL5408	Homo sapiens	Inhibition	%	1.1
	8079757	CHEMBL1962005	GSK_PKIS: TBK1 mean inhibition at 1 uM [Nanosyn]	B	NS(=O)(=O)c1ccc(Nc2cc(-c3ccc(O)c(F)c3)n[nH]2)cc1		CHEMBL103115	=	Inhibition	%	7.59	CHEMBL5408	Homo sapiens	Inhibition	%	7.59
	8079981	CHEMBL1962004	GSK_PKIS: TBK1 mean inhibition at 0.1 uM [Nanosyn]	B	CCCN1CCC(c2ccc(Nc3nc(Nc4cc(F)ccc4C(N)=O)c4cc[nH]c4n3)c(OC)c2)CC1		CHEMBL476259	=	Inhibition	%	0.75	CHEMBL5408	Homo sapiens	Inhibition	%	0.75
	8080086	CHEMBL1962005	GSK_PKIS: TBK1 mean inhibition at 1 uM [Nanosyn]	B	Cl.ON=C1CCc2cc(-c3nc(C4CCNCC4)[nH]c3-c3ccncc3)ccc21		CHEMBL1794071	=	Inhibition	%	1.68	CHEMBL5408	Homo sapiens	Inhibition	%	1.68
	8080338	CHEMBL1962004	GSK_PKIS: TBK1 mean inhibition at 0.1 uM [Nanosyn]	B	CC(C)COC(=O)c1ccc2c(c1)/C(=C/Nc1ccc(S(N)(=O)=O)cc1)C(=O)N2		CHEMBL269883	=	Inhibition	%	38.11	CHEMBL5408	Homo sapiens	Inhibition	%	38.11
	8080677	CHEMBL1962004	GSK_PKIS: TBK1 mean inhibition at 0.1 uM [Nanosyn]	B	COc1ccc2ncnc(Nc3ccc(OCc4ccccc4)cc3)c2c1.Cl		CHEMBL1909411	=	Inhibition	%	1.67	CHEMBL5408	Homo sapiens	Inhibition	%	1.67
	8080841	CHEMBL1962005	GSK_PKIS: TBK1 mean inhibition at 1 uM [Nanosyn]	B	C[C@@H](Oc1cc(-n2cnc3ccc(OC[C@@H](O)CO)cc32)sc1C(N)=O)c1ccccc1Cl		CHEMBL1794067	=	Inhibition	%	-0.29	CHEMBL5408	Homo sapiens	Inhibition	%	-0.29
	8081065	CHEMBL1962004	GSK_PKIS: TBK1 mean inhibition at 0.1 uM [Nanosyn]	B	Cl.Nc1nccc(-c2c(-c3ccc(F)cc3)ncn2C2CCNCC2)n1		CHEMBL1909407	=	Inhibition	%	-1.45	CHEMBL5408	Homo sapiens	Inhibition	%	-1.45
	8081200	CHEMBL1962005	GSK_PKIS: TBK1 mean inhibition at 1 uM [Nanosyn]	B	Cl.[O-][S+]1CCN(Cc2ccc(-c3ccc4ncnc(Nc5ccc(OCc6ccccc6)c(F)c5)c4c3)o2)CC1		CHEMBL1909391	=	Inhibition	%	2.87	CHEMBL5408	Homo sapiens	Inhibition	%	2.87
	8081568	CHEMBL1962005	GSK_PKIS: TBK1 mean inhibition at 1 uM [Nanosyn]	B	CCCN1CCC(c2ccc(Nc3nc(Nc4cc(F)ccc4C(N)=O)c4cc[nH]c4n3)c(OC)c2)CC1		CHEMBL476259	=	Inhibition	%	10.22	CHEMBL5408	Homo sapiens	Inhibition	%	10.22
	8081671	CHEMBL1962004	GSK_PKIS: TBK1 mean inhibition at 0.1 uM [Nanosyn]	B	O=C1NC(=O)C(c2cccc(Cl)c2)=C1Nc1ccc(O)c(Cl)c1		CHEMBL160333	=	Inhibition	%	3.62	CHEMBL5408	Homo sapiens	Inhibition	%	3.62
	8081895	CHEMBL1962005	GSK_PKIS: TBK1 mean inhibition at 1 uM [Nanosyn]	B	O=C1NC(=O)C(c2cccc(Cl)c2)=C1Nc1ccc(O)c(Cl)c1		CHEMBL160333	=	Inhibition	%	23.89	CHEMBL5408	Homo sapiens	Inhibition	%	23.89
	8081923	CHEMBL1962005	GSK_PKIS: TBK1 mean inhibition at 1 uM [Nanosyn]	B	CC(C)COC(=O)c1ccc2c(c1)/C(=C/Nc1ccc(S(N)(=O)=O)cc1)C(=O)N2		CHEMBL269883	=	Inhibition	%	82.9	CHEMBL5408	Homo sapiens	Inhibition	%	82.9
	8082147	CHEMBL1962004	GSK_PKIS: TBK1 mean inhibition at 0.1 uM [Nanosyn]	B	Nc1nonc1-c1nc2cnccc2n1C1CCCCC1		CHEMBL189231	=	Inhibition	%	3.95	CHEMBL5408	Homo sapiens	Inhibition	%	3.95
	8082260	CHEMBL1962005	GSK_PKIS: TBK1 mean inhibition at 1 uM [Nanosyn]	B	COc1ccc2ncnc(Nc3ccc(OCc4ccccc4)cc3)c2c1.Cl		CHEMBL1909411	=	Inhibition	%	1.27	CHEMBL5408	Homo sapiens	Inhibition	%	1.27
	8082657	CHEMBL1962005	GSK_PKIS: TBK1 mean inhibition at 1 uM [Nanosyn]	B	Cl.Nc1nccc(-c2c(-c3ccc(F)cc3)ncn2C2CCNCC2)n1		CHEMBL1909407	=	Inhibition	%	-0.8	CHEMBL5408	Homo sapiens	Inhibition	%	-0.8
	8082780	CHEMBL1962004	GSK_PKIS: TBK1 mean inhibition at 0.1 uM [Nanosyn]	B	Cc1ccc(C(=O)NC2CCC2)cc1-c1ccc(C(=O)NCC2CC2)cc1		CHEMBL517507	=	Inhibition	%	1.61	CHEMBL5408	Homo sapiens	Inhibition	%	1.61
	8083160	CHEMBL1962004	GSK_PKIS: TBK1 mean inhibition at 0.1 uM [Nanosyn]	B	NS(=O)(=O)c1ccc(N/N=C2\C(=O)Nc3ccc(C(=O)NCCCn4ccnc4)cc32)cc1		CHEMBL272026	=	Inhibition	%	3.93	CHEMBL5408	Homo sapiens	Inhibition	%	3.93
	8083483	CHEMBL1962004	GSK_PKIS: TBK1 mean inhibition at 0.1 uM [Nanosyn]	B	CS(=O)(=O)Nc1cccc(-c2ccc3c(NC(=O)C4CC4)n[nH]c3c2)c1		CHEMBL103080	=	Inhibition	%	-0.1	CHEMBL5408	Homo sapiens	Inhibition	%	-0.1
	8083737	CHEMBL1962005	GSK_PKIS: TBK1 mean inhibition at 1 uM [Nanosyn]	B	Nc1nonc1-c1nc2cnccc2n1C1CCCCC1		CHEMBL189231	=	Inhibition	%	24.77	CHEMBL5408	Homo sapiens	Inhibition	%	24.77
	8083847	CHEMBL1962004	GSK_PKIS: TBK1 mean inhibition at 0.1 uM [Nanosyn]	B	CN1CCC(n2cnc(-c3ccc(F)cc3)c2-c2ccnc(N)n2)CC1		CHEMBL95207	=	Inhibition	%	-1.27	CHEMBL5408	Homo sapiens	Inhibition	%	-1.27
	8084071	CHEMBL1962005	GSK_PKIS: TBK1 mean inhibition at 1 uM [Nanosyn]	B	CN1CCC(n2cnc(-c3ccc(F)cc3)c2-c2ccnc(N)n2)CC1		CHEMBL95207	=	Inhibition	%	3.54	CHEMBL5408	Homo sapiens	Inhibition	%	3.54
	8084256	CHEMBL1962004	GSK_PKIS: TBK1 mean inhibition at 0.1 uM [Nanosyn]	B	NS(=O)(=O)c1ccc(N/N=C2\C(=O)Nc3ccc4ncccc4c32)cc1		CHEMBL409892	=	Inhibition	%	7.16	CHEMBL5408	Homo sapiens	Inhibition	%	7.16
	8084374	CHEMBL1962005	GSK_PKIS: TBK1 mean inhibition at 1 uM [Nanosyn]	B	Cc1ccc(C(=O)NC2CCC2)cc1-c1ccc(C(=O)NCC2CC2)cc1		CHEMBL517507	=	Inhibition	%	2.24	CHEMBL5408	Homo sapiens	Inhibition	%	2.24
	8084598	CHEMBL1962004	GSK_PKIS: TBK1 mean inhibition at 0.1 uM [Nanosyn]	B	CN(C)c1cc2c(Nc3ccc4c(cnn4Cc4ccccc4)c3)ncnc2cn1		CHEMBL30432	=	Inhibition	%	1.07	CHEMBL5408	Homo sapiens	Inhibition	%	1.07
	8084759	CHEMBL1962005	GSK_PKIS: TBK1 mean inhibition at 1 uM [Nanosyn]	B	NS(=O)(=O)c1ccc(N/N=C2\C(=O)Nc3ccc(C(=O)NCCCn4ccnc4)cc32)cc1		CHEMBL272026	=	Inhibition	%	30.41	CHEMBL5408	Homo sapiens	Inhibition	%	30.41
	8085081	CHEMBL1962005	GSK_PKIS: TBK1 mean inhibition at 1 uM [Nanosyn]	B	CS(=O)(=O)Nc1cccc(-c2ccc3c(NC(=O)C4CC4)n[nH]c3c2)c1		CHEMBL103080	=	Inhibition	%	3.56	CHEMBL5408	Homo sapiens	Inhibition	%	3.56
	8085337	CHEMBL1962004	GSK_PKIS: TBK1 mean inhibition at 0.1 uM [Nanosyn]	B	COc1cc(C=NNc2ncnc3c2cnn3Cc2ccccc2)ccc1O		CHEMBL1789962	=	Inhibition	%	0.04	CHEMBL5408	Homo sapiens	Inhibition	%	0.04
	8085669	CHEMBL1962004	GSK_PKIS: TBK1 mean inhibition at 0.1 uM [Nanosyn]	B	CN1CCC(n2cnc(-c3ccc(F)cc3)c2-c2ccnc(Nc3ccccc3)n2)CC1		CHEMBL318892	=	Inhibition	%	0.4	CHEMBL5408	Homo sapiens	Inhibition	%	0.4
	8085858	CHEMBL1962005	GSK_PKIS: TBK1 mean inhibition at 1 uM [Nanosyn]	B	NS(=O)(=O)c1ccc(N/N=C2\C(=O)Nc3ccc4ncccc4c32)cc1		CHEMBL409892	=	Inhibition	%	50.38	CHEMBL5408	Homo sapiens	Inhibition	%	50.38
	8086197	CHEMBL1962005	GSK_PKIS: TBK1 mean inhibition at 1 uM [Nanosyn]	B	CN(C)c1cc2c(Nc3ccc4c(cnn4Cc4ccccc4)c3)ncnc2cn1		CHEMBL30432	=	Inhibition	%	3.14	CHEMBL5408	Homo sapiens	Inhibition	%	3.14
	8086359	CHEMBL1962004	GSK_PKIS: TBK1 mean inhibition at 0.1 uM [Nanosyn]	B	CN1CCC(C(=O)Nc2n[nH]c3nc(-c4ccc(O)cc4)c(Br)cc23)CC1		CHEMBL261129	=	Inhibition	%	4.48	CHEMBL5408	Homo sapiens	Inhibition	%	4.48
	8086682	CHEMBL1962004	GSK_PKIS: TBK1 mean inhibition at 0.1 uM [Nanosyn]	B	CCn1c(-c2nonc2N)nc2ccncc21		CHEMBL185710	=	Inhibition	%	2.23	CHEMBL5408	Homo sapiens	Inhibition	%	2.23
	8086893	CHEMBL1962004	GSK_PKIS: TBK1 mean inhibition at 0.1 uM [Nanosyn]	B	CNC(=O)c1cncc(/C=C/c2c(Cl)cccc2Cl)c1		CHEMBL263796	=	Inhibition	%	2.82	CHEMBL5408	Homo sapiens	Inhibition	%	2.82
	8087117	CHEMBL1962005	GSK_PKIS: TBK1 mean inhibition at 1 uM [Nanosyn]	B	CNC(=O)c1cncc(/C=C/c2c(Cl)cccc2Cl)c1		CHEMBL263796	=	Inhibition	%	4.76	CHEMBL5408	Homo sapiens	Inhibition	%	4.76
	8087275	CHEMBL1962004	GSK_PKIS: TBK1 mean inhibition at 0.1 uM [Nanosyn]	B	CCC(=O)Nc1ccc(C)c(-c2ccc(C(=O)NCC3CC3)cc2)c1		CHEMBL517666	=	Inhibition	%	2.36	CHEMBL5408	Homo sapiens	Inhibition	%	2.36
	8087613	CHEMBL1962004	GSK_PKIS: TBK1 mean inhibition at 0.1 uM [Nanosyn]	B	COc1ccccc1Nc1ncc(-c2ccccc2)o1.Cl		CHEMBL1794062	=	Inhibition	%	1.18	CHEMBL5408	Homo sapiens	Inhibition	%	1.18
	8087751	CHEMBL1962005	GSK_PKIS: TBK1 mean inhibition at 1 uM [Nanosyn]	B	CN1CCN(Cc2ccc(-c3cc4ncnc(Nc5ccc(OCc6cccc(F)c6)c(Cl)c5)c4s3)o2)CC1		CHEMBL475761	=	Inhibition	%	2.76	CHEMBL5408	Homo sapiens	Inhibition	%	2.76
	8088117	CHEMBL1962005	GSK_PKIS: TBK1 mean inhibition at 1 uM [Nanosyn]	B	CCn1c(-c2nonc2N)nc2cncc(C(=O)N3CCNCC3)c21.Cl		CHEMBL1909376	=	Inhibition	%	5.51	CHEMBL5408	Homo sapiens	Inhibition	%	5.51
	8088265	CHEMBL1962004	GSK_PKIS: TBK1 mean inhibition at 0.1 uM [Nanosyn]	B	CS(=O)(=O)Nc1ccc(-c2cc(-c3ccccc3)cc(C(N)=O)c2N)cc1		CHEMBL230597	=	Inhibition	%	1.82	CHEMBL5408	Homo sapiens	Inhibition	%	1.82
	8088489	CHEMBL1962005	GSK_PKIS: TBK1 mean inhibition at 1 uM [Nanosyn]	B	CS(=O)(=O)Nc1ccc(-c2cc(-c3ccccc3)cc(C(N)=O)c2N)cc1		CHEMBL230597	=	Inhibition	%	2.08	CHEMBL5408	Homo sapiens	Inhibition	%	2.08
	8088617	CHEMBL1962004	GSK_PKIS: TBK1 mean inhibition at 0.1 uM [Nanosyn]	B	COc1cc2ncn(-c3cc(O[C@@H](C)c4ccccc4Cl)c(C(N)=O)s3)c2cc1OC		CHEMBL521806	=	Inhibition	%	4.39	CHEMBL5408	Homo sapiens	Inhibition	%	4.39
	8088934	CHEMBL1962005	GSK_PKIS: TBK1 mean inhibition at 1 uM [Nanosyn]	B	CCn1c(-c2nonc2N)nc2ccccc21		CHEMBL365286	=	Inhibition	%	3.36	CHEMBL5408	Homo sapiens	Inhibition	%	3.36
	8089062	CHEMBL1962004	GSK_PKIS: TBK1 mean inhibition at 0.1 uM [Nanosyn]	B	CCCN1CCC(Oc2cc(Nc3nc(Nc4cccc(F)c4C(N)=O)c4cc[nH]c4n3)c(OC)cc2Cl)CC1		CHEMBL517171	=	Inhibition	%	-0.35	CHEMBL5408	Homo sapiens	Inhibition	%	-0.35
	8089286	CHEMBL1962005	GSK_PKIS: TBK1 mean inhibition at 1 uM [Nanosyn]	B	CCCN1CCC(Oc2cc(Nc3nc(Nc4cccc(F)c4C(N)=O)c4cc[nH]c4n3)c(OC)cc2Cl)CC1		CHEMBL517171	=	Inhibition	%	2.35	CHEMBL5408	Homo sapiens	Inhibition	%	2.35
	8089434	CHEMBL1962004	GSK_PKIS: TBK1 mean inhibition at 0.1 uM [Nanosyn]	B	CC(C)=Cc1cccc2c1/C(=N/Nc1ccc(S(N)(=O)=O)cc1)C(=O)N2		CHEMBL270544	=	Inhibition	%	3.78	CHEMBL5408	Homo sapiens	Inhibition	%	3.78
	8089778	CHEMBL1962004	GSK_PKIS: TBK1 mean inhibition at 0.1 uM [Nanosyn]	B	CCS(=O)(=O)c1ccc(OC)c(Nc2ncc(-c3ccccc3Cl)o2)c1		CHEMBL179453	=	Inhibition	%	1.3	CHEMBL5408	Homo sapiens	Inhibition	%	1.3
	8089958	CHEMBL1962005	GSK_PKIS: TBK1 mean inhibition at 1 uM [Nanosyn]	B	Nc1nccc(-c2c(-c3ccc(F)cc3)nn3cc(C(F)(F)F)ccc23)n1		CHEMBL1909402	=	Inhibition	%	-0.2	CHEMBL5408	Homo sapiens	Inhibition	%	-0.2
	8090347	CHEMBL1962005	GSK_PKIS: TBK1 mean inhibition at 1 uM [Nanosyn]	B	COc1cc2c(cc1Nc1nc(Nc3cccc(F)c3C(N)=O)c3cc[nH]c3n1)N(C(=O)CN1CCN(C(C)C)CC1)CC2		CHEMBL505915	=	Inhibition	%	3.05	CHEMBL5408	Homo sapiens	Inhibition	%	3.05
	8090514	CHEMBL1962004	GSK_PKIS: TBK1 mean inhibition at 0.1 uM [Nanosyn]	B	Cc1nc(-c2ccccc2)n2nc(NCCCN3CCOCC3)ncc12		CHEMBL486124	=	Inhibition	%	1.18	CHEMBL5408	Homo sapiens	Inhibition	%	1.18
	8090877	CHEMBL1962004	GSK_PKIS: TBK1 mean inhibition at 0.1 uM [Nanosyn]	B	CN(c1ccc(NC(=O)Nc2ccc(OC(F)(F)F)cc2)cc1)c1ccnc(Nc2cccc(S(N)(=O)=O)c2)n1		CHEMBL188381	=	Inhibition	%	0.04	CHEMBL5408	Homo sapiens	Inhibition	%	0.04
	8091082	CHEMBL1962004	GSK_PKIS: TBK1 mean inhibition at 0.1 uM [Nanosyn]	B	CS(=O)(=O)CCNCc1ccc(-c2ccc3ncnc(Nc4ccc(OCc5ccccc5)cc4)c3c2)o1.Cl		CHEMBL1909385	=	Inhibition	%	3.64	CHEMBL5408	Homo sapiens	Inhibition	%	3.64
	8091443	CHEMBL1962004	GSK_PKIS: TBK1 mean inhibition at 0.1 uM [Nanosyn]	B	CCCN1CCC=C(c2ccc(Nc3nc(Nc4ccccc4C(N)=O)c4cc[nH]c4n3)c(C)c2)C1		CHEMBL513897	=	Inhibition	%	3.95	CHEMBL5408	Homo sapiens	Inhibition	%	3.95
	8091598	CHEMBL1962005	GSK_PKIS: TBK1 mean inhibition at 1 uM [Nanosyn]	B	CCC(=O)Nc1ccc(C)c(-c2ccc(C(=O)NCC3CC3)cc2)c1		CHEMBL517666	=	Inhibition	%	2.69	CHEMBL5408	Homo sapiens	Inhibition	%	2.69
	8091938	CHEMBL1962005	GSK_PKIS: TBK1 mean inhibition at 1 uM [Nanosyn]	B	COc1ccccc1Nc1ncc(-c2ccccc2)o1.Cl		CHEMBL1794062	=	Inhibition	%	2.91	CHEMBL5408	Homo sapiens	Inhibition	%	2.91
	8092075	CHEMBL1962004	GSK_PKIS: TBK1 mean inhibition at 0.1 uM [Nanosyn]	B	Fc1ccc(-c2ncn(C3CCNCC3)c2-c2ccnc(Oc3ccccc3)n2)cc1		CHEMBL275798	=	Inhibition	%	0.83	CHEMBL5408	Homo sapiens	Inhibition	%	0.83
	8092299	CHEMBL1962005	GSK_PKIS: TBK1 mean inhibition at 1 uM [Nanosyn]	B	Fc1ccc(-c2ncn(C3CCNCC3)c2-c2ccnc(Oc3ccccc3)n2)cc1		CHEMBL275798	=	Inhibition	%	2.78	CHEMBL5408	Homo sapiens	Inhibition	%	2.78
	8092450	CHEMBL1962004	GSK_PKIS: TBK1 mean inhibition at 0.1 uM [Nanosyn]	B	CS(=O)(=O)CCNCc1cc(-c2cc3c(Nc4ccc(OCc5cccc(F)c5)c(Cl)c4)ncnc3s2)cs1		CHEMBL475599	=	Inhibition	%	5.03	CHEMBL5408	Homo sapiens	Inhibition	%	5.03
	8092822	CHEMBL1962004	GSK_PKIS: TBK1 mean inhibition at 0.1 uM [Nanosyn]	B	Fc1cccc(COc2ccc(Nc3ncnc4sc(-c5cccs5)cc34)cc2Cl)c1		CHEMBL506414	=	Inhibition	%	0.83	CHEMBL5408	Homo sapiens	Inhibition	%	0.83
	8092951	CHEMBL1962005	GSK_PKIS: TBK1 mean inhibition at 1 uM [Nanosyn]	B	COc1cc2ncn(-c3cc(O[C@@H](C)c4ccccc4Cl)c(C(N)=O)s3)c2cc1OC		CHEMBL521806	=	Inhibition	%	26.97	CHEMBL5408	Homo sapiens	Inhibition	%	26.97
	8093263	CHEMBL1962004	GSK_PKIS: TBK1 mean inhibition at 0.1 uM [Nanosyn]	B	O=C(O)/C=C/C(=O)O.OCCCNc1nccc(-c2c(-c3ccc(F)cc3)nn3cc(C(F)(F)F)ccc23)n1		CHEMBL1909403	=	Inhibition	%	2.49	CHEMBL5408	Homo sapiens	Inhibition	%	2.49
	8093627	CHEMBL1962004	GSK_PKIS: TBK1 mean inhibition at 0.1 uM [Nanosyn]	B	CCn1c(-c2nonc2N)nc2c(C#CC(C)(C)O)nc(OC[C@@H](N)c3ccccc3)cc21		CHEMBL1096626	=	Inhibition	%	0.4	CHEMBL5408	Homo sapiens	Inhibition	%	0.4
	8093766	CHEMBL1962005	GSK_PKIS: TBK1 mean inhibition at 1 uM [Nanosyn]	B	CC(C)=Cc1cccc2c1/C(=N/Nc1ccc(S(N)(=O)=O)cc1)C(=O)N2		CHEMBL270544	=	Inhibition	%	26.33	CHEMBL5408	Homo sapiens	Inhibition	%	26.33
	8094110	CHEMBL1962005	GSK_PKIS: TBK1 mean inhibition at 1 uM [Nanosyn]	B	CCS(=O)(=O)c1ccc(OC)c(Nc2ncc(-c3ccccc3Cl)o2)c1		CHEMBL179453	=	Inhibition	%	7.68	CHEMBL5408	Homo sapiens	Inhibition	%	7.68
	8094290	CHEMBL1962004	GSK_PKIS: TBK1 mean inhibition at 0.1 uM [Nanosyn]	B	Cc1cc(-c2ccco2)cc(C)c1/C=C/c1cncc(-c2nn[nH]n2)c1.Cl		CHEMBL1909353	=	Inhibition	%	0.36	CHEMBL5408	Homo sapiens	Inhibition	%	0.36
	8094514	CHEMBL1962005	GSK_PKIS: TBK1 mean inhibition at 1 uM [Nanosyn]	B	Cc1cc(-c2ccco2)cc(C)c1/C=C/c1cncc(-c2nn[nH]n2)c1.Cl		CHEMBL1909353	=	Inhibition	%	2.37	CHEMBL5408	Homo sapiens	Inhibition	%	2.37
	8094689	CHEMBL1962004	GSK_PKIS: TBK1 mean inhibition at 0.1 uM [Nanosyn]	B	COc1cc(N2CCN(C(C)C)CC2)ccc1Nc1nc(Nc2ccc(F)cc2C(N)=O)c2cc[nH]c2n1		CHEMBL458865	=	Inhibition	%	3.02	CHEMBL5408	Homo sapiens	Inhibition	%	3.02
	8094845	CHEMBL1962005	GSK_PKIS: TBK1 mean inhibition at 1 uM [Nanosyn]	B	Cc1nc(-c2ccccc2)n2nc(NCCCN3CCOCC3)ncc12		CHEMBL486124	=	Inhibition	%	6.52	CHEMBL5408	Homo sapiens	Inhibition	%	6.52
	8095209	CHEMBL1962005	GSK_PKIS: TBK1 mean inhibition at 1 uM [Nanosyn]	B	CN(c1ccc(NC(=O)Nc2ccc(OC(F)(F)F)cc2)cc1)c1ccnc(Nc2cccc(S(N)(=O)=O)c2)n1		CHEMBL188381	=	Inhibition	%	9.01	CHEMBL5408	Homo sapiens	Inhibition	%	9.01
	8095412	CHEMBL1962005	GSK_PKIS: TBK1 mean inhibition at 1 uM [Nanosyn]	B	CS(=O)(=O)CCNCc1ccc(-c2ccc3ncnc(Nc4ccc(OCc5ccccc5)cc4)c3c2)o1.Cl		CHEMBL1909385	=	Inhibition	%	3.03	CHEMBL5408	Homo sapiens	Inhibition	%	3.03
	8095777	CHEMBL1962005	GSK_PKIS: TBK1 mean inhibition at 1 uM [Nanosyn]	B	CCCN1CCC=C(c2ccc(Nc3nc(Nc4ccccc4C(N)=O)c4cc[nH]c4n3)c(C)c2)C1		CHEMBL513897	=	Inhibition	%	9.03	CHEMBL5408	Homo sapiens	Inhibition	%	9.03
	8095925	CHEMBL1962004	GSK_PKIS: TBK1 mean inhibition at 0.1 uM [Nanosyn]	B	COc1cc2ncnc(Nc3ccc4c(cnn4Cc4ccccc4)c3)c2cc1OC.Cl		CHEMBL1909380	=	Inhibition	%	0.22	CHEMBL5408	Homo sapiens	Inhibition	%	0.22
	8096149	CHEMBL1962005	GSK_PKIS: TBK1 mean inhibition at 1 uM [Nanosyn]	B	COc1cc2ncnc(Nc3ccc4c(cnn4Cc4ccccc4)c3)c2cc1OC.Cl		CHEMBL1909380	=	Inhibition	%	1.45	CHEMBL5408	Homo sapiens	Inhibition	%	1.45
	8096266	CHEMBL1962004	GSK_PKIS: TBK1 mean inhibition at 0.1 uM [Nanosyn]	B	Fc1ccc(-c2ncn(C3CCNCC3)c2-c2ccnc(Oc3cccc(C(F)(F)F)c3)n2)cc1		CHEMBL275666	=	Inhibition	%	4.6	CHEMBL5408	Homo sapiens	Inhibition	%	4.6
	8096629	CHEMBL1962004	GSK_PKIS: TBK1 mean inhibition at 0.1 uM [Nanosyn]	B	Cl.[O-][S+]1CCN(Cc2ccc(-c3ccc4ncnc(Nc5ccc(OCc6ccccc6)c(Cl)c5)c4c3)o2)CC1		CHEMBL1909393	=	Inhibition	%	0.91	CHEMBL5408	Homo sapiens	Inhibition	%	0.91
	8096785	CHEMBL1962005	GSK_PKIS: TBK1 mean inhibition at 1 uM [Nanosyn]	B	CS(=O)(=O)CCNCc1cc(-c2cc3c(Nc4ccc(OCc5cccc(F)c5)c(Cl)c4)ncnc3s2)cs1		CHEMBL475599	=	Inhibition	%	4.88	CHEMBL5408	Homo sapiens	Inhibition	%	4.88
	8097156	CHEMBL1962005	GSK_PKIS: TBK1 mean inhibition at 1 uM [Nanosyn]	B	Fc1cccc(COc2ccc(Nc3ncnc4sc(-c5cccs5)cc34)cc2Cl)c1		CHEMBL506414	=	Inhibition	%	2.3	CHEMBL5408	Homo sapiens	Inhibition	%	2.3
	8097463	CHEMBL1962005	GSK_PKIS: TBK1 mean inhibition at 1 uM [Nanosyn]	B	O=C(O)/C=C/C(=O)O.OCCCNc1nccc(-c2c(-c3ccc(F)cc3)nn3cc(C(F)(F)F)ccc23)n1		CHEMBL1909403	=	Inhibition	%	5.25	CHEMBL5408	Homo sapiens	Inhibition	%	5.25
	8097837	CHEMBL1962005	GSK_PKIS: TBK1 mean inhibition at 1 uM [Nanosyn]	B	CCn1c(-c2nonc2N)nc2c(C#CC(C)(C)O)nc(OC[C@@H](N)c3ccccc3)cc21		CHEMBL1096626	=	Inhibition	%	3.45	CHEMBL5408	Homo sapiens	Inhibition	%	3.45
	8097970	CHEMBL1962004	GSK_PKIS: TBK1 mean inhibition at 0.1 uM [Nanosyn]	B	COC(=O)Nc1nc2cc(Oc3ccc(NC(=O)Nc4cccc(C(=O)O)c4)cc3)ccc2[nH]1.Cl		CHEMBL1909373	=	Inhibition	%	0.81	CHEMBL5408	Homo sapiens	Inhibition	%	0.81
	8098194	CHEMBL1962005	GSK_PKIS: TBK1 mean inhibition at 1 uM [Nanosyn]	B	COC(=O)Nc1nc2cc(Oc3ccc(NC(=O)Nc4cccc(C(=O)O)c4)cc3)ccc2[nH]1.Cl		CHEMBL1909373	=	Inhibition	%	2.42	CHEMBL5408	Homo sapiens	Inhibition	%	2.42
	8098314	CHEMBL1962004	GSK_PKIS: TBK1 mean inhibition at 0.1 uM [Nanosyn]	B	COc1cccc(COc2cc(-n3cnc4ccccc43)sc2C(N)=O)c1		CHEMBL516248	=	Inhibition	%	-1.18	CHEMBL5408	Homo sapiens	Inhibition	%	-1.18
	8098718	CHEMBL1962004	GSK_PKIS: TBK1 mean inhibition at 0.1 uM [Nanosyn]	B	c1ccc(COc2ccc(Nc3ncnc4ccc(-c5ccco5)cc34)cc2)cc1		CHEMBL215993	=	Inhibition	%	-0.27	CHEMBL5408	Homo sapiens	Inhibition	%	-0.27
	8098903	CHEMBL1962005	GSK_PKIS: TBK1 mean inhibition at 1 uM [Nanosyn]	B	COc1cc(N2CCN(C(C)C)CC2)ccc1Nc1nc(Nc2ccc(F)cc2C(N)=O)c2cc[nH]c2n1		CHEMBL458865	=	Inhibition	%	6.76	CHEMBL5408	Homo sapiens	Inhibition	%	6.76
	8099047	CHEMBL1962004	GSK_PKIS: TBK1 mean inhibition at 0.1 uM [Nanosyn]	B	CS(=O)(=O)CCNCc1coc(-c2ccc3ncnc(Nc4ccc(OCc5ccccc5)cc4)c3c2)c1.Cl		CHEMBL1909386	=	Inhibition	%	2.64	CHEMBL5408	Homo sapiens	Inhibition	%	2.64
	8099271	CHEMBL1962005	GSK_PKIS: TBK1 mean inhibition at 1 uM [Nanosyn]	B	CS(=O)(=O)CCNCc1coc(-c2ccc3ncnc(Nc4ccc(OCc5ccccc5)cc4)c3c2)c1.Cl		CHEMBL1909386	=	Inhibition	%	2.44	CHEMBL5408	Homo sapiens	Inhibition	%	2.44
	8099413	CHEMBL1962004	GSK_PKIS: TBK1 mean inhibition at 0.1 uM [Nanosyn]	B	COc1cc2ncn(-c3cc(OCc4ccccc4C(F)(F)F)c(C(C)=O)s3)c2cc1OC		CHEMBL471789	=	Inhibition	%	2.89	CHEMBL5408	Homo sapiens	Inhibition	%	2.89
	8099607	CHEMBL1962004	GSK_PKIS: TBK1 mean inhibition at 0.1 uM [Nanosyn]	B	N#Cc1ccc2c(-c3ccnc(NC4CC4)n3)c(-c3ccc(F)cc3)nn2c1		CHEMBL1885746	=	Inhibition	%	1.15	CHEMBL5408	Homo sapiens	Inhibition	%	1.15
	8099831	CHEMBL1962005	GSK_PKIS: TBK1 mean inhibition at 1 uM [Nanosyn]	B	N#Cc1ccc2c(-c3ccnc(NC4CC4)n3)c(-c3ccc(F)cc3)nn2c1		CHEMBL1885746	=	Inhibition	%	0.07	CHEMBL5408	Homo sapiens	Inhibition	%	0.07
	8099978	CHEMBL1962004	GSK_PKIS: TBK1 mean inhibition at 0.1 uM [Nanosyn]	B	COc1cccc(-n2ncc3c(N/N=C/c4ccc(C)cc4)ncnc32)c1		CHEMBL303687	=	Inhibition	%	2.64	CHEMBL5408	Homo sapiens	Inhibition	%	2.64
	8100348	CHEMBL1962004	GSK_PKIS: TBK1 mean inhibition at 0.1 uM [Nanosyn]	B	NS(=O)(=O)c1ccc(N/N=C2\C(=O)Nc3ccc(-c4cnco4)cc32)cc1		CHEMBL269827	=	Inhibition	%	7.17	CHEMBL5408	Homo sapiens	Inhibition	%	7.17
	8100464	CHEMBL1962005	GSK_PKIS: TBK1 mean inhibition at 1 uM [Nanosyn]	B	Fc1ccc(-c2ncn(C3CCNCC3)c2-c2ccnc(Oc3cccc(C(F)(F)F)c3)n2)cc1		CHEMBL275666	=	Inhibition	%	3.82	CHEMBL5408	Homo sapiens	Inhibition	%	3.82
	8100688	CHEMBL1962004	GSK_PKIS: TBK1 mean inhibition at 0.1 uM [Nanosyn]	B	N#Cc1ccc(Oc2nccc(-c3c(-c4ccc(F)cc4)ncn3C3CCNCC3)n2)cc1		CHEMBL13972	=	Inhibition	%	1.69	CHEMBL5408	Homo sapiens	Inhibition	%	1.69
	8100828	CHEMBL1962005	GSK_PKIS: TBK1 mean inhibition at 1 uM [Nanosyn]	B	Cl.[O-][S+]1CCN(Cc2ccc(-c3ccc4ncnc(Nc5ccc(OCc6ccccc6)c(Cl)c5)c4c3)o2)CC1		CHEMBL1909393	=	Inhibition	%	2.35	CHEMBL5408	Homo sapiens	Inhibition	%	2.35
	8100988	CHEMBL1962004	GSK_PKIS: TBK1 mean inhibition at 0.1 uM [Nanosyn]	B	COc1ccc(-c2ccncc2)cc1C(N)=O		CHEMBL231013	=	Inhibition	%	2.55	CHEMBL5408	Homo sapiens	Inhibition	%	2.55
	8101212	CHEMBL1962005	GSK_PKIS: TBK1 mean inhibition at 1 uM [Nanosyn]	B	COc1ccc(-c2ccncc2)cc1C(N)=O		CHEMBL231013	=	Inhibition	%	2.44	CHEMBL5408	Homo sapiens	Inhibition	%	2.44
	8101354	CHEMBL1962004	GSK_PKIS: TBK1 mean inhibition at 0.1 uM [Nanosyn]	B	COc1cc(Nc2ncc(-c3ccccc3)o2)cc(OC)c1OC		CHEMBL443563	=	Inhibition	%	2.26	CHEMBL5408	Homo sapiens	Inhibition	%	2.26
	8101539	CHEMBL1962004	GSK_PKIS: TBK1 mean inhibition at 0.1 uM [Nanosyn]	B	COc1ccc2ncn(-c3cc(O[C@H](C)c4ccccc4Cl)c(C(N)=O)s3)c2c1		CHEMBL493326	=	Inhibition	%	2.41	CHEMBL5408	Homo sapiens	Inhibition	%	2.41
	8101763	CHEMBL1962005	GSK_PKIS: TBK1 mean inhibition at 1 uM [Nanosyn]	B	COc1ccc2ncn(-c3cc(O[C@H](C)c4ccccc4Cl)c(C(N)=O)s3)c2c1		CHEMBL493326	=	Inhibition	%	3.86	CHEMBL5408	Homo sapiens	Inhibition	%	3.86
	8101792	CHEMBL1962004	GSK_PKIS: TBK1 mean inhibition at 0.1 uM [Nanosyn]	B	COc1cccc(-c2c[nH]c3c(N/N=C/c4ccncc4)ncnc23)c1		CHEMBL206010	=	Inhibition	%	3.26	CHEMBL5408	Homo sapiens	Inhibition	%	3.26
	8102016	CHEMBL1962005	GSK_PKIS: TBK1 mean inhibition at 1 uM [Nanosyn]	B	COc1cccc(-c2c[nH]c3c(N/N=C/c4ccncc4)ncnc23)c1		CHEMBL206010	=	Inhibition	%	34.58	CHEMBL5408	Homo sapiens	Inhibition	%	34.58
	8102171	CHEMBL1962004	GSK_PKIS: TBK1 mean inhibition at 0.1 uM [Nanosyn]	B	NC(=O)c1cccc(Nc2nccc(Nc3cccc4[nH]ncc34)n2)c1		CHEMBL251549	=	Inhibition	%	0.88	CHEMBL5408	Homo sapiens	Inhibition	%	0.88
	8102526	CHEMBL1962004	GSK_PKIS: TBK1 mean inhibition at 0.1 uM [Nanosyn]	B	CCN(CC)S(=O)(=O)c1ccc(OC)c(Nc2ncc(-c3ccccc3)o2)c1		CHEMBL275473	=	Inhibition	%	1.32	CHEMBL5408	Homo sapiens	Inhibition	%	1.32
	8102646	CHEMBL1962005	GSK_PKIS: TBK1 mean inhibition at 1 uM [Nanosyn]	B	COc1cccc(COc2cc(-n3cnc4ccccc43)sc2C(N)=O)c1		CHEMBL516248	=	Inhibition	%	1.53	CHEMBL5408	Homo sapiens	Inhibition	%	1.53
	8102870	CHEMBL1962004	GSK_PKIS: TBK1 mean inhibition at 0.1 uM [Nanosyn]	B	CCn1cc(-c2ccnc3[nH]ccc23)c(-c2cccc(NC(=O)Nc3ccc(OCc4ccccc4)cc3)c2)n1		CHEMBL505187	=	Inhibition	%	-0.45	CHEMBL5408	Homo sapiens	Inhibition	%	-0.45
	8103048	CHEMBL1962005	GSK_PKIS: TBK1 mean inhibition at 1 uM [Nanosyn]	B	c1ccc(COc2ccc(Nc3ncnc4ccc(-c5ccco5)cc34)cc2)cc1		CHEMBL215993	=	Inhibition	%	0.67	CHEMBL5408	Homo sapiens	Inhibition	%	0.67
	8103244	CHEMBL1962004	GSK_PKIS: TBK1 mean inhibition at 0.1 uM [Nanosyn]	B	CCn1c(-c2nonc2N)nc2c(C#CC(C)(C)O)nc(OC[C@H](N)c3ccccc3)cc21		CHEMBL1096634	=	Inhibition	%	3.75	CHEMBL5408	Homo sapiens	Inhibition	%	3.75
	8103606	CHEMBL1962004	GSK_PKIS: TBK1 mean inhibition at 0.1 uM [Nanosyn]	B	Cl.NC(=O)c1cccc(Nc2nccc(Nc3cccc(F)c3)n2)c1		CHEMBL1909382	=	Inhibition	%	1.55	CHEMBL5408	Homo sapiens	Inhibition	%	1.55
	8103756	CHEMBL1962005	GSK_PKIS: TBK1 mean inhibition at 1 uM [Nanosyn]	B	COc1cc2ncn(-c3cc(OCc4ccccc4C(F)(F)F)c(C(C)=O)s3)c2cc1OC		CHEMBL471789	=	Inhibition	%	2.12	CHEMBL5408	Homo sapiens	Inhibition	%	2.12
	8104165	CHEMBL1962004	GSK_PKIS: TBK1 mean inhibition at 0.1 uM [Nanosyn]	B	COC(=O)Nc1nc2ccc(Oc3ccc(NC(=O)Nc4cccc(Cl)c4)cc3)cc2[nH]1.Cl		CHEMBL1909364	=	Inhibition	%	1.34	CHEMBL5408	Homo sapiens	Inhibition	%	1.34
	8104313	CHEMBL1962005	GSK_PKIS: TBK1 mean inhibition at 1 uM [Nanosyn]	B	COc1cccc(-n2ncc3c(N/N=C/c4ccc(C)cc4)ncnc32)c1		CHEMBL303687	=	Inhibition	%	5.4	CHEMBL5408	Homo sapiens	Inhibition	%	5.4
	8104683	CHEMBL1962005	GSK_PKIS: TBK1 mean inhibition at 1 uM [Nanosyn]	B	NS(=O)(=O)c1ccc(N/N=C2\C(=O)Nc3ccc(-c4cnco4)cc32)cc1		CHEMBL269827	=	Inhibition	%	38.36	CHEMBL5408	Homo sapiens	Inhibition	%	38.36
	8105021	CHEMBL1962005	GSK_PKIS: TBK1 mean inhibition at 1 uM [Nanosyn]	B	N#Cc1ccc(Oc2nccc(-c3c(-c4ccc(F)cc4)ncn3C3CCNCC3)n2)cc1		CHEMBL13972	=	Inhibition	%	3.03	CHEMBL5408	Homo sapiens	Inhibition	%	3.03
	8105161	CHEMBL1962004	GSK_PKIS: TBK1 mean inhibition at 0.1 uM [Nanosyn]	B	Fc1ccc(-c2ncn(C3CCNCC3)c2-c2ccnc(Oc3ccc(Cl)cc3)n2)cc1		CHEMBL275168	=	Inhibition	%	-0.4	CHEMBL5408	Homo sapiens	Inhibition	%	-0.4
	8105551	CHEMBL1962004	GSK_PKIS: TBK1 mean inhibition at 0.1 uM [Nanosyn]	B	C[C@@H](Oc1cc(-n2cnc3ccc(OC4CCN(C)CC4)cc32)sc1C(N)=O)c1ccccc1Cl		CHEMBL1794070	=	Inhibition	%	4.61	CHEMBL5408	Homo sapiens	Inhibition	%	4.61
	8105689	CHEMBL1962005	GSK_PKIS: TBK1 mean inhibition at 1 uM [Nanosyn]	B	COc1cc(Nc2ncc(-c3ccccc3)o2)cc(OC)c1OC		CHEMBL443563	=	Inhibition	%	13.74	CHEMBL5408	Homo sapiens	Inhibition	%	13.74
	8105969	CHEMBL1962004	GSK_PKIS: TBK1 mean inhibition at 0.1 uM [Nanosyn]	B	CC(=O)Nc1cccc(C#Cc2cncnc2Nc2ccc(OCc3cccc(F)c3)c(Cl)c2)c1		CHEMBL205798	=	Inhibition	%	1.95	CHEMBL5408	Homo sapiens	Inhibition	%	1.95
	8106358	CHEMBL1962004	GSK_PKIS: TBK1 mean inhibition at 0.1 uM [Nanosyn]	B	CN(C)CCCNc1nccc(-c2c(-c3ccc(F)cc3)nn3cc(C(F)(F)F)ccc23)n1.CS(=O)(=O)O		CHEMBL1909405	=	Inhibition	%	0.75	CHEMBL5408	Homo sapiens	Inhibition	%	0.75
	8106514	CHEMBL1962005	GSK_PKIS: TBK1 mean inhibition at 1 uM [Nanosyn]	B	NC(=O)c1cccc(Nc2nccc(Nc3cccc4[nH]ncc34)n2)c1		CHEMBL251549	=	Inhibition	%	26.14	CHEMBL5408	Homo sapiens	Inhibition	%	26.14
	8106867	CHEMBL1962005	GSK_PKIS: TBK1 mean inhibition at 1 uM [Nanosyn]	B	CCN(CC)S(=O)(=O)c1ccc(OC)c(Nc2ncc(-c3ccccc3)o2)c1		CHEMBL275473	=	Inhibition	%	4.22	CHEMBL5408	Homo sapiens	Inhibition	%	4.22
	8107212	CHEMBL1962005	GSK_PKIS: TBK1 mean inhibition at 1 uM [Nanosyn]	B	CCn1cc(-c2ccnc3[nH]ccc23)c(-c2cccc(NC(=O)Nc3ccc(OCc4ccccc4)cc3)c2)n1		CHEMBL505187	=	Inhibition	%	-0.26	CHEMBL5408	Homo sapiens	Inhibition	%	-0.26
	8107384	CHEMBL1962004	GSK_PKIS: TBK1 mean inhibition at 0.1 uM [Nanosyn]	B	NC(=O)c1sc(-n2cnc3cc(C(F)(F)F)ccc32)cc1OCc1ccccc1Br		CHEMBL480371	=	Inhibition	%	0.98	CHEMBL5408	Homo sapiens	Inhibition	%	0.98
	8107585	CHEMBL1962005	GSK_PKIS: TBK1 mean inhibition at 1 uM [Nanosyn]	B	CCn1c(-c2nonc2N)nc2c(C#CC(C)(C)O)nc(OC[C@H](N)c3ccccc3)cc21		CHEMBL1096634	=	Inhibition	%	6.85	CHEMBL5408	Homo sapiens	Inhibition	%	6.85
	8107809	CHEMBL1962004	GSK_PKIS: TBK1 mean inhibition at 0.1 uM [Nanosyn]	B	Cc1cccc(Nc2ncc(-c3ccccc3)o2)c1		CHEMBL192417	=	Inhibition	%	2.6	CHEMBL5408	Homo sapiens	Inhibition	%	2.6
	8107944	CHEMBL1962005	GSK_PKIS: TBK1 mean inhibition at 1 uM [Nanosyn]	B	Cl.NC(=O)c1cccc(Nc2nccc(Nc3cccc(F)c3)n2)c1		CHEMBL1909382	=	Inhibition	%	6.93	CHEMBL5408	Homo sapiens	Inhibition	%	6.93
	8108102	CHEMBL1962004	GSK_PKIS: TBK1 mean inhibition at 0.1 uM [Nanosyn]	B	CNC(=O)c1sc(-n2cnc3cc(OC)c(OC)cc32)cc1OCc1ccccc1C(F)(F)F		CHEMBL518968	=	Inhibition	%	1.68	CHEMBL5408	Homo sapiens	Inhibition	%	1.68
	8108326	CHEMBL1962005	GSK_PKIS: TBK1 mean inhibition at 1 uM [Nanosyn]	B	CNC(=O)c1sc(-n2cnc3cc(OC)c(OC)cc32)cc1OCc1ccccc1C(F)(F)F		CHEMBL518968	=	Inhibition	%	4.39	CHEMBL5408	Homo sapiens	Inhibition	%	4.39
	8108501	CHEMBL1962005	GSK_PKIS: TBK1 mean inhibition at 1 uM [Nanosyn]	B	COC(=O)Nc1nc2ccc(Oc3ccc(NC(=O)Nc4cccc(Cl)c4)cc3)cc2[nH]1.Cl		CHEMBL1909364	=	Inhibition	%	-2.2	CHEMBL5408	Homo sapiens	Inhibition	%	-2.2
	8108648	CHEMBL1962004	GSK_PKIS: TBK1 mean inhibition at 0.1 uM [Nanosyn]	B	C[C@@H](Oc1cc(-n2cnc3ccc(OCC4CCN(C)CC4)cc32)sc1C(N)=O)c1ccccc1Cl		CHEMBL1794069	=	Inhibition	%	4.93	CHEMBL5408	Homo sapiens	Inhibition	%	4.93
	8108872	CHEMBL1962005	GSK_PKIS: TBK1 mean inhibition at 1 uM [Nanosyn]	B	C[C@@H](Oc1cc(-n2cnc3ccc(OCC4CCN(C)CC4)cc32)sc1C(N)=O)c1ccccc1Cl		CHEMBL1794069	=	Inhibition	%	6.08	CHEMBL5408	Homo sapiens	Inhibition	%	6.08
	8109014	CHEMBL1962004	GSK_PKIS: TBK1 mean inhibition at 0.1 uM [Nanosyn]	B	O=S(=O)(CCOCc1ccc(-c2ccc3ncnc(Nc4ccc(OCc5cccc(F)c5)c(Cl)c4)c3c2)o1)c1ccccc1		CHEMBL212250	=	Inhibition	%	0.12	CHEMBL5408	Homo sapiens	Inhibition	%	0.12
	8109352	CHEMBL1962004	GSK_PKIS: TBK1 mean inhibition at 0.1 uM [Nanosyn]	B	Cc1cccc(Oc2nccc(-c3c(-c4ccc(F)cc4)ncn3C3CCNCC3)n2)c1C.O=C(O)C(F)(F)F		CHEMBL1909400	=	Inhibition	%	1.51	CHEMBL5408	Homo sapiens	Inhibition	%	1.51
	8109482	CHEMBL1962005	GSK_PKIS: TBK1 mean inhibition at 1 uM [Nanosyn]	B	Fc1ccc(-c2ncn(C3CCNCC3)c2-c2ccnc(Oc3ccc(Cl)cc3)n2)cc1		CHEMBL275168	=	Inhibition	%	1.95	CHEMBL5408	Homo sapiens	Inhibition	%	1.95
	8109706	CHEMBL1962004	GSK_PKIS: TBK1 mean inhibition at 0.1 uM [Nanosyn]	B	NC(=O)CCc1ccccc1Oc1nccc(-c2c(-c3ccc(F)cc3)ncn2C2CCNCC2)n1		CHEMBL1785003	=	Inhibition	%	2.53	CHEMBL5408	Homo sapiens	Inhibition	%	2.53
	8109877	CHEMBL1962005	GSK_PKIS: TBK1 mean inhibition at 1 uM [Nanosyn]	B	C[C@@H](Oc1cc(-n2cnc3ccc(OC4CCN(C)CC4)cc32)sc1C(N)=O)c1ccccc1Cl		CHEMBL1794070	=	Inhibition	%	4.33	CHEMBL5408	Homo sapiens	Inhibition	%	4.33
	8110009	CHEMBL1962004	GSK_PKIS: TBK1 mean inhibition at 0.1 uM [Nanosyn]	B	COc1cc(Nc2ncc(-c3ccccc3)o2)cc(OC)c1		CHEMBL176553	=	Inhibition	%	2.71	CHEMBL5408	Homo sapiens	Inhibition	%	2.71
	8110233	CHEMBL1962005	GSK_PKIS: TBK1 mean inhibition at 1 uM [Nanosyn]	B	COc1cc(Nc2ncc(-c3ccccc3)o2)cc(OC)c1		CHEMBL176553	=	Inhibition	%	4.2	CHEMBL5408	Homo sapiens	Inhibition	%	4.2
	8110288	CHEMBL1962005	GSK_PKIS: TBK1 mean inhibition at 1 uM [Nanosyn]	B	CC(=O)Nc1cccc(C#Cc2cncnc2Nc2ccc(OCc3cccc(F)c3)c(Cl)c2)c1		CHEMBL205798	=	Inhibition	%	3.45	CHEMBL5408	Homo sapiens	Inhibition	%	3.45
	8110512	CHEMBL1962004	GSK_PKIS: TBK1 mean inhibition at 0.1 uM [Nanosyn]	B	Cc1ccc(C(=O)NC2CCCCC2)cc1-c1ccc(C(=O)NCC2CC2)cc1		CHEMBL477978	=	Inhibition	%	1.75	CHEMBL5408	Homo sapiens	Inhibition	%	1.75
	8110678	CHEMBL1962005	GSK_PKIS: TBK1 mean inhibition at 1 uM [Nanosyn]	B	CN(C)CCCNc1nccc(-c2c(-c3ccc(F)cc3)nn3cc(C(F)(F)F)ccc23)n1.CS(=O)(=O)O		CHEMBL1909405	=	Inhibition	%	4.86	CHEMBL5408	Homo sapiens	Inhibition	%	4.86
	8110836	CHEMBL1962004	GSK_PKIS: TBK1 mean inhibition at 0.1 uM [Nanosyn]	B	CCn1c(-c2nonc2N)nc2c(C#CCN)ncc(OCCCN)c21.O=C(O)C(F)(F)F		CHEMBL1794064	=	Inhibition	%	-0.18	CHEMBL5408	Homo sapiens	Inhibition	%	-0.18
	8111060	CHEMBL1962005	GSK_PKIS: TBK1 mean inhibition at 1 uM [Nanosyn]	B	CCn1c(-c2nonc2N)nc2c(C#CCN)ncc(OCCCN)c21.O=C(O)C(F)(F)F		CHEMBL1794064	=	Inhibition	%	4.32	CHEMBL5408	Homo sapiens	Inhibition	%	4.32
	8111183	CHEMBL1962004	GSK_PKIS: TBK1 mean inhibition at 0.1 uM [Nanosyn]	B	CCc1cccc(NC(=O)Nc2ccc(Oc3ccc4nc(NC(=O)OC)[nH]c4c3)cc2)c1		CHEMBL243907	=	Inhibition	%	0.31	CHEMBL5408	Homo sapiens	Inhibition	%	0.31
	8111534	CHEMBL1962004	GSK_PKIS: TBK1 mean inhibition at 0.1 uM [Nanosyn]	B	CCn1c(-c2nonc2N)nc2c(C#CC(C)(C)O)ncc(OC[C@@H]3CCCN3)c21.O=C(O)C(F)(F)F		CHEMBL1909375	=	Inhibition	%	5.1	CHEMBL5408	Homo sapiens	Inhibition	%	5.1
	8111700	CHEMBL1962005	GSK_PKIS: TBK1 mean inhibition at 1 uM [Nanosyn]	B	NC(=O)c1sc(-n2cnc3cc(C(F)(F)F)ccc32)cc1OCc1ccccc1Br		CHEMBL480371	=	Inhibition	%	1.3	CHEMBL5408	Homo sapiens	Inhibition	%	1.3
	8112129	CHEMBL1962005	GSK_PKIS: TBK1 mean inhibition at 1 uM [Nanosyn]	B	Cc1cccc(Nc2ncc(-c3ccccc3)o2)c1		CHEMBL192417	=	Inhibition	%	7.09	CHEMBL5408	Homo sapiens	Inhibition	%	7.09
	8112266	CHEMBL1962004	GSK_PKIS: TBK1 mean inhibition at 0.1 uM [Nanosyn]	B	COc1cccc(-n2nc(C)c3c(N/N=C(\C)c4ccncc4)ncnc32)c1		CHEMBL442363	=	Inhibition	%	-0.16	CHEMBL5408	Homo sapiens	Inhibition	%	-0.16
	8112658	CHEMBL1962004	GSK_PKIS: TBK1 mean inhibition at 0.1 uM [Nanosyn]	B	Nc1ncc(-c2cccc(S(N)(=O)=O)c2)c2scc(-c3ccc(F)c(Cl)c3)c12		CHEMBL241517	=	Inhibition	%	3.75	CHEMBL5408	Homo sapiens	Inhibition	%	3.75
	8112830	CHEMBL1962004	GSK_PKIS: TBK1 mean inhibition at 0.1 uM [Nanosyn]	B	CS(=O)(=O)CCNCc1ccoc1-c1ccc2ncnc(Nc3ccc(OCc4ccccc4)cc3)c2c1.Cl		CHEMBL1909388	=	Inhibition	%	0.39	CHEMBL5408	Homo sapiens	Inhibition	%	0.39
	8113206	CHEMBL1962004	GSK_PKIS: TBK1 mean inhibition at 0.1 uM [Nanosyn]	B	CCn1c(-c2nonc2N)nc2c(C#CC(C)(C)O)nc(OCCNC)cc21.Cl		CHEMBL1909350	=	Inhibition	%	3.53	CHEMBL5408	Homo sapiens	Inhibition	%	3.53
	8113342	CHEMBL1962005	GSK_PKIS: TBK1 mean inhibition at 1 uM [Nanosyn]	B	O=S(=O)(CCOCc1ccc(-c2ccc3ncnc(Nc4ccc(OCc5cccc(F)c5)c(Cl)c4)c3c2)o1)c1ccccc1		CHEMBL212250	=	Inhibition	%	2.8	CHEMBL5408	Homo sapiens	Inhibition	%	2.8
	8113690	CHEMBL1962005	GSK_PKIS: TBK1 mean inhibition at 1 uM [Nanosyn]	B	Cc1cccc(Oc2nccc(-c3c(-c4ccc(F)cc4)ncn3C3CCNCC3)n2)c1C.O=C(O)C(F)(F)F		CHEMBL1909400	=	Inhibition	%	2.0	CHEMBL5408	Homo sapiens	Inhibition	%	2.0
	8114030	CHEMBL1962005	GSK_PKIS: TBK1 mean inhibition at 1 uM [Nanosyn]	B	NC(=O)CCc1ccccc1Oc1nccc(-c2c(-c3ccc(F)cc3)ncn2C2CCNCC2)n1		CHEMBL1785003	=	Inhibition	%	2.87	CHEMBL5408	Homo sapiens	Inhibition	%	2.87
	8114206	CHEMBL1962004	GSK_PKIS: TBK1 mean inhibition at 0.1 uM [Nanosyn]	B	CS(=O)(=O)CCNCc1ccc(-c2ccc3ncnc(Nc4ccc(OCc5cccc(C(F)(F)F)c5)cc4)c3c2)o1.Cl		CHEMBL1909387	=	Inhibition	%	3.15	CHEMBL5408	Homo sapiens	Inhibition	%	3.15
	8114562	CHEMBL1962004	GSK_PKIS: TBK1 mean inhibition at 0.1 uM [Nanosyn]	B	Fc1cccc(COc2ccc(Nc3ncnc4sc(-c5ccco5)cc34)cc2Cl)c1		CHEMBL514938	=	Inhibition	%	0.55	CHEMBL5408	Homo sapiens	Inhibition	%	0.55
	8114838	CHEMBL1962005	GSK_PKIS: TBK1 mean inhibition at 1 uM [Nanosyn]	B	Cc1ccc(C(=O)NC2CCCCC2)cc1-c1ccc(C(=O)NCC2CC2)cc1		CHEMBL477978	=	Inhibition	%	3.86	CHEMBL5408	Homo sapiens	Inhibition	%	3.86
	8115004	CHEMBL1962004	GSK_PKIS: TBK1 mean inhibition at 0.1 uM [Nanosyn]	B	Cl.Nc1ncnc2occ(-c3ccc(NC(=O)Nc4cc(C(F)(F)F)ccc4F)cc3)c12		CHEMBL588025	=	Inhibition	%	0.47	CHEMBL5408	Homo sapiens	Inhibition	%	0.47
	8115393	CHEMBL1962004	GSK_PKIS: TBK1 mean inhibition at 0.1 uM [Nanosyn]	B	CC(=O)Nc1cccc(C#Cc2cncnc2Nc2ccc(OCc3cccc(F)c3)c(Cl)c2)n1		CHEMBL205765	=	Inhibition	%	1.99	CHEMBL5408	Homo sapiens	Inhibition	%	1.99
	8115513	CHEMBL1962005	GSK_PKIS: TBK1 mean inhibition at 1 uM [Nanosyn]	B	CCc1cccc(NC(=O)Nc2ccc(Oc3ccc4nc(NC(=O)OC)[nH]c4c3)cc2)c1		CHEMBL243907	=	Inhibition	%	0.79	CHEMBL5408	Homo sapiens	Inhibition	%	0.79
	8115737	CHEMBL1962004	GSK_PKIS: TBK1 mean inhibition at 0.1 uM [Nanosyn]	B	CS(=O)(=O)CCNCc1nc(-c2ccc3ncnc(Nc4ccc(F)c(Cl)c4)c3c2)cs1.Cl		CHEMBL1909355	=	Inhibition	%	1.85	CHEMBL5408	Homo sapiens	Inhibition	%	1.85
	8115870	CHEMBL1962005	GSK_PKIS: TBK1 mean inhibition at 1 uM [Nanosyn]	B	CCn1c(-c2nonc2N)nc2c(C#CC(C)(C)O)ncc(OC[C@@H]3CCCN3)c21.O=C(O)C(F)(F)F		CHEMBL1909375	=	Inhibition	%	41.18	CHEMBL5408	Homo sapiens	Inhibition	%	41.18
	8116029	CHEMBL1962004	GSK_PKIS: TBK1 mean inhibition at 0.1 uM [Nanosyn]	B	CC(C)(CO)CNC(=O)c1ccc2c(c1)/C(=N/Nc1ccc(S(N)(=O)=O)cc1)C(=O)N2		CHEMBL410072	=	Inhibition	%	21.69	CHEMBL5408	Homo sapiens	Inhibition	%	21.69
	8116253	CHEMBL1962005	GSK_PKIS: TBK1 mean inhibition at 1 uM [Nanosyn]	B	CC(C)(CO)CNC(=O)c1ccc2c(c1)/C(=N/Nc1ccc(S(N)(=O)=O)cc1)C(=O)N2		CHEMBL410072	=	Inhibition	%	63.35	CHEMBL5408	Homo sapiens	Inhibition	%	63.35
	8116456	CHEMBL1962004	GSK_PKIS: TBK1 mean inhibition at 0.1 uM [Nanosyn]	B	CCn1c(-c2nonc2N)nc2c(C#CC(C)(C)O)ncc(OC3CCNCC3)c21.O=C(O)C(F)(F)F		CHEMBL1794066	=	Inhibition	%	12.23	CHEMBL5408	Homo sapiens	Inhibition	%	12.23
	8116590	CHEMBL1962005	GSK_PKIS: TBK1 mean inhibition at 1 uM [Nanosyn]	B	COc1cccc(-n2nc(C)c3c(N/N=C(\C)c4ccncc4)ncnc32)c1		CHEMBL442363	=	Inhibition	%	-1.57	CHEMBL5408	Homo sapiens	Inhibition	%	-1.57
	8116814	CHEMBL1962004	GSK_PKIS: TBK1 mean inhibition at 0.1 uM [Nanosyn]	B	CC(C)c1ccc2c(c1)NC(=O)/C2=N/Nc1ccc(S(N)(=O)=O)cc1		CHEMBL271594	=	Inhibition	%	-1.0	CHEMBL5408	Homo sapiens	Inhibition	%	-1.0
	8116986	CHEMBL1962005	GSK_PKIS: TBK1 mean inhibition at 1 uM [Nanosyn]	B	Nc1ncc(-c2cccc(S(N)(=O)=O)c2)c2scc(-c3ccc(F)c(Cl)c3)c12		CHEMBL241517	=	Inhibition	%	3.47	CHEMBL5408	Homo sapiens	Inhibition	%	3.47
	8117157	CHEMBL1962005	GSK_PKIS: TBK1 mean inhibition at 1 uM [Nanosyn]	B	CS(=O)(=O)CCNCc1ccoc1-c1ccc2ncnc(Nc3ccc(OCc4ccccc4)cc3)c2c1.Cl		CHEMBL1909388	=	Inhibition	%	-2.25	CHEMBL5408	Homo sapiens	Inhibition	%	-2.25
	8117381	CHEMBL1962004	GSK_PKIS: TBK1 mean inhibition at 0.1 uM [Nanosyn]	B	Cl.NS(=O)(=O)c1ccc(N/N=C2\C(=O)Nc3cccc(CCc4ccncc4)c32)cc1		CHEMBL1909399	=	Inhibition	%	1.99	CHEMBL5408	Homo sapiens	Inhibition	%	1.99
	8117539	CHEMBL1962005	GSK_PKIS: TBK1 mean inhibition at 1 uM [Nanosyn]	B	CCn1c(-c2nonc2N)nc2c(C#CC(C)(C)O)nc(OCCNC)cc21.Cl		CHEMBL1909350	=	Inhibition	%	8.57	CHEMBL5408	Homo sapiens	Inhibition	%	8.57
	8117669	CHEMBL1962004	GSK_PKIS: TBK1 mean inhibition at 0.1 uM [Nanosyn]	B	CS(=O)(=O)CCNCc1ccc(-c2ccc3ncnc(Nc4ccc(OCc5ccccc5)c(Cl)c4)c3c2)o1.Cl		CHEMBL529066	=	Inhibition	%	0.47	CHEMBL5408	Homo sapiens	Inhibition	%	0.47
	8117893	CHEMBL1962005	GSK_PKIS: TBK1 mean inhibition at 1 uM [Nanosyn]	B	CS(=O)(=O)CCNCc1ccc(-c2ccc3ncnc(Nc4ccc(OCc5ccccc5)c(Cl)c4)c3c2)o1.Cl		CHEMBL529066	=	Inhibition	%	2.91	CHEMBL5408	Homo sapiens	Inhibition	%	2.91
	8118031	CHEMBL1962004	GSK_PKIS: TBK1 mean inhibition at 0.1 uM [Nanosyn]	B	Fc1ccc(-c2ncn(C3CCNCC3)c2-c2ccnc(Oc3ccc(F)c(F)c3)n2)cc1		CHEMBL1785004	=	Inhibition	%	2.13	CHEMBL5408	Homo sapiens	Inhibition	%	2.13
	8118371	CHEMBL1962004	GSK_PKIS: TBK1 mean inhibition at 0.1 uM [Nanosyn]	B	COc1c(C(N)=O)cc(-c2ccc(Cl)cc2)cc1-c1ccc(S(N)(=O)=O)cc1		CHEMBL268885	=	Inhibition	%	4.69	CHEMBL5408	Homo sapiens	Inhibition	%	4.69
	8118543	CHEMBL1962005	GSK_PKIS: TBK1 mean inhibition at 1 uM [Nanosyn]	B	CS(=O)(=O)CCNCc1ccc(-c2ccc3ncnc(Nc4ccc(OCc5cccc(C(F)(F)F)c5)cc4)c3c2)o1.Cl		CHEMBL1909387	=	Inhibition	%	6.44	CHEMBL5408	Homo sapiens	Inhibition	%	6.44
	8118903	CHEMBL1962005	GSK_PKIS: TBK1 mean inhibition at 1 uM [Nanosyn]	B	Fc1cccc(COc2ccc(Nc3ncnc4sc(-c5ccco5)cc34)cc2Cl)c1		CHEMBL514938	=	Inhibition	%	2.89	CHEMBL5408	Homo sapiens	Inhibition	%	2.89
	8119174	CHEMBL1962004	GSK_PKIS: TBK1 mean inhibition at 0.1 uM [Nanosyn]	B	COc1cc(C)c(NC(=O)CN(C)C)cc1Nc1nc(Nc2cccc(F)c2C(N)=O)c2cc[nH]c2n1		CHEMBL511765	=	Inhibition	%	1.95	CHEMBL5408	Homo sapiens	Inhibition	%	1.95
	8119333	CHEMBL1962005	GSK_PKIS: TBK1 mean inhibition at 1 uM [Nanosyn]	B	Cl.Nc1ncnc2occ(-c3ccc(NC(=O)Nc4cc(C(F)(F)F)ccc4F)cc3)c12		CHEMBL588025	=	Inhibition	%	6.12	CHEMBL5408	Homo sapiens	Inhibition	%	6.12
	8119557	CHEMBL1962004	GSK_PKIS: TBK1 mean inhibition at 0.1 uM [Nanosyn]	B	COc1cc(C=NNc2ncnc3c2cnn3-c2ccccc2)ccc1O		CHEMBL1789961	=	Inhibition	%	3.55	CHEMBL5408	Homo sapiens	Inhibition	%	3.55
	8119724	CHEMBL1962005	GSK_PKIS: TBK1 mean inhibition at 1 uM [Nanosyn]	B	CC(=O)Nc1cccc(C#Cc2cncnc2Nc2ccc(OCc3cccc(F)c3)c(Cl)c2)n1		CHEMBL205765	=	Inhibition	%	-0.27	CHEMBL5408	Homo sapiens	Inhibition	%	-0.27
	8120067	CHEMBL1962005	GSK_PKIS: TBK1 mean inhibition at 1 uM [Nanosyn]	B	CS(=O)(=O)CCNCc1nc(-c2ccc3ncnc(Nc4ccc(F)c(Cl)c4)c3c2)cs1.Cl		CHEMBL1909355	=	Inhibition	%	2.28	CHEMBL5408	Homo sapiens	Inhibition	%	2.28
	8120206	CHEMBL1962004	GSK_PKIS: TBK1 mean inhibition at 0.1 uM [Nanosyn]	B	Cc1ccc2c(-c3ccnc(Nc4ccc5c(c4)OCCO5)n3)c(-c3ccc(C(F)(F)F)cc3)nn2n1		CHEMBL188247	=	Inhibition	%	0.84	CHEMBL5408	Homo sapiens	Inhibition	%	0.84
	8120590	CHEMBL1962004	GSK_PKIS: TBK1 mean inhibition at 0.1 uM [Nanosyn]	B	Cl.O=C(O[C@H]1CN[C@H](C#Cc2cc3ncnc(Nc4ccc5c(cnn5Cc5ccccc5)c4)c3s2)C1)N1CCOCC1		CHEMBL1909408	=	Inhibition	%	-0.69	CHEMBL5408	Homo sapiens	Inhibition	%	-0.69
	8120791	CHEMBL1962005	GSK_PKIS: TBK1 mean inhibition at 1 uM [Nanosyn]	B	CCn1c(-c2nonc2N)nc2c(C#CC(C)(C)O)ncc(OC3CCNCC3)c21.O=C(O)C(F)(F)F		CHEMBL1794066	=	Inhibition	%	45.91	CHEMBL5408	Homo sapiens	Inhibition	%	45.91
	8121143	CHEMBL1962005	GSK_PKIS: TBK1 mean inhibition at 1 uM [Nanosyn]	B	CC(C)c1ccc2c(c1)NC(=O)/C2=N/Nc1ccc(S(N)(=O)=O)cc1		CHEMBL271594	=	Inhibition	%	-0.26	CHEMBL5408	Homo sapiens	Inhibition	%	-0.26
	8121315	CHEMBL1962004	GSK_PKIS: TBK1 mean inhibition at 0.1 uM [Nanosyn]	B	O=C(O)C(F)(F)F.O=C(O[C@H]1CN[C@H](C#Cc2cc3ncnc(Nc4ccc(Cc5ccccc5)cc4)c3s2)C1)N1CCOCC1		CHEMBL1909409	=	Inhibition	%	-0.27	CHEMBL5408	Homo sapiens	Inhibition	%	-0.27
	8121706	CHEMBL1962005	GSK_PKIS: TBK1 mean inhibition at 1 uM [Nanosyn]	B	Cl.NS(=O)(=O)c1ccc(N/N=C2\C(=O)Nc3cccc(CCc4ccncc4)c32)cc1		CHEMBL1909399	=	Inhibition	%	4.17	CHEMBL5408	Homo sapiens	Inhibition	%	4.17
	8121869	CHEMBL1962004	GSK_PKIS: TBK1 mean inhibition at 0.1 uM [Nanosyn]	B	NC(=O)c1sc(-n2cnc3ccccc32)cc1OCc1ccccc1Br		CHEMBL518953	=	Inhibition	%	0.38	CHEMBL5408	Homo sapiens	Inhibition	%	0.38
	8122214	CHEMBL1962004	GSK_PKIS: TBK1 mean inhibition at 0.1 uM [Nanosyn]	B	Nc1ncnc2occ(-c3ccc(NC(=O)Nc4cc(C(F)(F)F)ccc4F)cc3)c12		CHEMBL247228	=	Inhibition	%	0.44	CHEMBL5408	Homo sapiens	Inhibition	%	0.44
	8122352	CHEMBL1962005	GSK_PKIS: TBK1 mean inhibition at 1 uM [Nanosyn]	B	Fc1ccc(-c2ncn(C3CCNCC3)c2-c2ccnc(Oc3ccc(F)c(F)c3)n2)cc1		CHEMBL1785004	=	Inhibition	%	5.03	CHEMBL5408	Homo sapiens	Inhibition	%	5.03
	8122576	CHEMBL1962004	GSK_PKIS: TBK1 mean inhibition at 0.1 uM [Nanosyn]	B	NS(=O)(=O)c1ccc(N/C=C2\C(=O)Nc3ccc4ncsc4c32)cc1		CHEMBL271595	=	Inhibition	%	10.73	CHEMBL5408	Homo sapiens	Inhibition	%	10.73
	8122696	CHEMBL1962005	GSK_PKIS: TBK1 mean inhibition at 1 uM [Nanosyn]	B	COc1c(C(N)=O)cc(-c2ccc(Cl)cc2)cc1-c1ccc(S(N)(=O)=O)cc1		CHEMBL268885	=	Inhibition	%	3.5	CHEMBL5408	Homo sapiens	Inhibition	%	3.5
	8122863	CHEMBL1962004	GSK_PKIS: TBK1 mean inhibition at 0.1 uM [Nanosyn]	B	Fc1ccc(-c2ncn(C3CCNCC3)c2-c2ccnc(Oc3cccc(F)c3)n2)cc1		CHEMBL14014	=	Inhibition	%	3.75	CHEMBL5408	Homo sapiens	Inhibition	%	3.75
	8123087	CHEMBL1962005	GSK_PKIS: TBK1 mean inhibition at 1 uM [Nanosyn]	B	Fc1ccc(-c2ncn(C3CCNCC3)c2-c2ccnc(Oc3cccc(F)c3)n2)cc1		CHEMBL14014	=	Inhibition	%	6.05	CHEMBL5408	Homo sapiens	Inhibition	%	6.05
	8123229	CHEMBL1962004	GSK_PKIS: TBK1 mean inhibition at 0.1 uM [Nanosyn]	B	COc1cc2ncn(-c3cc(OCc4ccccc4C(F)(F)F)c(C(N)=O)s3)c2cc1OC		CHEMBL514499	=	Inhibition	%	3.59	CHEMBL5408	Homo sapiens	Inhibition	%	3.59
	8123507	CHEMBL1962005	GSK_PKIS: TBK1 mean inhibition at 1 uM [Nanosyn]	B	COc1cc(C)c(NC(=O)CN(C)C)cc1Nc1nc(Nc2cccc(F)c2C(N)=O)c2cc[nH]c2n1		CHEMBL511765	=	Inhibition	%	25.51	CHEMBL5408	Homo sapiens	Inhibition	%	25.51
	8123881	CHEMBL1962005	GSK_PKIS: TBK1 mean inhibition at 1 uM [Nanosyn]	B	COc1cc(C=NNc2ncnc3c2cnn3-c2ccccc2)ccc1O		CHEMBL1789961	=	Inhibition	%	21.49	CHEMBL5408	Homo sapiens	Inhibition	%	21.49
	8124048	CHEMBL1962004	GSK_PKIS: TBK1 mean inhibition at 0.1 uM [Nanosyn]	B	COc1cccc(-n2cnc3c(N/N=C/c4ccncc4)ncnc32)c1		CHEMBL204934	=	Inhibition	%	0.99	CHEMBL5408	Homo sapiens	Inhibition	%	0.99
	8124391	CHEMBL1962004	GSK_PKIS: TBK1 mean inhibition at 0.1 uM [Nanosyn]	B	COc1cccc(Nc2nccc(-c3cnn4ncccc34)n2)c1		CHEMBL187081	=	Inhibition	%	4.06	CHEMBL5408	Homo sapiens	Inhibition	%	4.06
	8124530	CHEMBL1962005	GSK_PKIS: TBK1 mean inhibition at 1 uM [Nanosyn]	B	Cc1ccc2c(-c3ccnc(Nc4ccc5c(c4)OCCO5)n3)c(-c3ccc(C(F)(F)F)cc3)nn2n1		CHEMBL188247	=	Inhibition	%	4.69	CHEMBL5408	Homo sapiens	Inhibition	%	4.69
	8124754	CHEMBL1962004	GSK_PKIS: TBK1 mean inhibition at 0.1 uM [Nanosyn]	B	O=C1NC(=O)C(c2cccc([N+](=O)[O-])c2)=C1Nc1cc(Cl)c(O)c(Cl)c1		CHEMBL352222	=	Inhibition	%	7.31	CHEMBL5408	Homo sapiens	Inhibition	%	7.31
	8124919	CHEMBL1962005	GSK_PKIS: TBK1 mean inhibition at 1 uM [Nanosyn]	B	Cl.O=C(O[C@H]1CN[C@H](C#Cc2cc3ncnc(Nc4ccc5c(cnn5Cc5ccccc5)c4)c3s2)C1)N1CCOCC1		CHEMBL1909408	=	Inhibition	%	1.41	CHEMBL5408	Homo sapiens	Inhibition	%	1.41
	8125120	CHEMBL1962004	GSK_PKIS: TBK1 mean inhibition at 0.1 uM [Nanosyn]	B	CCc1ccc(Oc2nccc(-c3c(-c4ccc(F)cc4)ncn3C3CCNCC3)n2)cc1		CHEMBL428877	=	Inhibition	%	4.53	CHEMBL5408	Homo sapiens	Inhibition	%	4.53
	8125474	CHEMBL1962004	GSK_PKIS: TBK1 mean inhibition at 0.1 uM [Nanosyn]	B	O=C(Nc1n[nH]c2nnc(-c3cccnc3)cc12)C1CC1.O=C(O)C(F)(F)F		CHEMBL1909343	=	Inhibition	%	0.25	CHEMBL5408	Homo sapiens	Inhibition	%	0.25
	8125642	CHEMBL1962005	GSK_PKIS: TBK1 mean inhibition at 1 uM [Nanosyn]	B	O=C(O)C(F)(F)F.O=C(O[C@H]1CN[C@H](C#Cc2cc3ncnc(Nc4ccc(Cc5ccccc5)cc4)c3s2)C1)N1CCOCC1		CHEMBL1909409	=	Inhibition	%	1.65	CHEMBL5408	Homo sapiens	Inhibition	%	1.65
	8125866	CHEMBL1962004	GSK_PKIS: TBK1 mean inhibition at 0.1 uM [Nanosyn]	B	FC(F)(F)CNc1nccc(-c2cnn3ncccc23)n1		CHEMBL446024	=	Inhibition	%	1.42	CHEMBL5408	Homo sapiens	Inhibition	%	1.42
	8126030	CHEMBL1962004	GSK_PKIS: TBK1 mean inhibition at 0.1 uM [Nanosyn]	B	CCN1CCC(C(=O)Nc2n[nH]c3nnc(-c4cccc(F)c4F)cc23)CC1.Cl		CHEMBL1909345	=	Inhibition	%	0.48	CHEMBL5408	Homo sapiens	Inhibition	%	0.48
	8126194	CHEMBL1962005	GSK_PKIS: TBK1 mean inhibition at 1 uM [Nanosyn]	B	NC(=O)c1sc(-n2cnc3ccccc32)cc1OCc1ccccc1Br		CHEMBL518953	=	Inhibition	%	2.68	CHEMBL5408	Homo sapiens	Inhibition	%	2.68
	8126533	CHEMBL1962005	GSK_PKIS: TBK1 mean inhibition at 1 uM [Nanosyn]	B	Nc1ncnc2occ(-c3ccc(NC(=O)Nc4cc(C(F)(F)F)ccc4F)cc3)c12		CHEMBL247228	=	Inhibition	%	3.01	CHEMBL5408	Homo sapiens	Inhibition	%	3.01
	8126893	CHEMBL1962005	GSK_PKIS: TBK1 mean inhibition at 1 uM [Nanosyn]	B	NS(=O)(=O)c1ccc(N/C=C2\C(=O)Nc3ccc4ncsc4c32)cc1		CHEMBL271595	=	Inhibition	%	46.7	CHEMBL5408	Homo sapiens	Inhibition	%	46.7
	8127015	CHEMBL1962004	GSK_PKIS: TBK1 mean inhibition at 0.1 uM [Nanosyn]	B	Fc1ccc(-c2ncn(C3CCNCC3)c2-c2ccnc(Oc3ccc(Oc4ccccc4)cc3)n2)cc1		CHEMBL13868	=	Inhibition	%	2.66	CHEMBL5408	Homo sapiens	Inhibition	%	2.66
	8127406	CHEMBL1962004	GSK_PKIS: TBK1 mean inhibition at 0.1 uM [Nanosyn]	B	CCS(=O)(=O)c1ccc(OC)c(Nc2ncc(-c3cccc(F)c3)o2)c1		CHEMBL179465	=	Inhibition	%	5.98	CHEMBL5408	Homo sapiens	Inhibition	%	5.98
	8127548	CHEMBL1962005	GSK_PKIS: TBK1 mean inhibition at 1 uM [Nanosyn]	B	COc1cc2ncn(-c3cc(OCc4ccccc4C(F)(F)F)c(C(N)=O)s3)c2cc1OC		CHEMBL514499	=	Inhibition	%	13.58	CHEMBL5408	Homo sapiens	Inhibition	%	13.58
	8127772	CHEMBL1962004	GSK_PKIS: TBK1 mean inhibition at 0.1 uM [Nanosyn]	B	Nc1ncnc2occ(-c3ccc(NC(=O)Nc4cccc(C(F)(F)F)c4)cc3)c12		CHEMBL273564	=	Inhibition	%	3.95	CHEMBL5408	Homo sapiens	Inhibition	%	3.95
	8127836	CHEMBL1962004	GSK_PKIS: TBK1 mean inhibition at 0.1 uM [Nanosyn]	B	COc1cc(Nc2ncc3c(C)nc(-c4cccc(Oc5ccccc5)c4)n3n2)cc(OC)c1OC		CHEMBL519881	=	Inhibition	%	4.47	CHEMBL5408	Homo sapiens	Inhibition	%	4.47
	8128060	CHEMBL1962005	GSK_PKIS: TBK1 mean inhibition at 1 uM [Nanosyn]	B	COc1cc(Nc2ncc3c(C)nc(-c4cccc(Oc5ccccc5)c4)n3n2)cc(OC)c1OC		CHEMBL519881	=	Inhibition	%	28.81	CHEMBL5408	Homo sapiens	Inhibition	%	28.81
	8128212	CHEMBL1962004	GSK_PKIS: TBK1 mean inhibition at 0.1 uM [Nanosyn]	B	Cc1cc(O)cc(C)c1/C=C/c1cncc(C(=O)N(C)C)c1		CHEMBL220244	=	Inhibition	%	1.36	CHEMBL5408	Homo sapiens	Inhibition	%	1.36
	8128379	CHEMBL1962005	GSK_PKIS: TBK1 mean inhibition at 1 uM [Nanosyn]	B	COc1cccc(-n2cnc3c(N/N=C/c4ccncc4)ncnc32)c1		CHEMBL204934	=	Inhibition	%	2.56	CHEMBL5408	Homo sapiens	Inhibition	%	2.56
	8128603	CHEMBL1962004	GSK_PKIS: TBK1 mean inhibition at 0.1 uM [Nanosyn]	B	CNC(=O)c1cncc(/C=C/c2ccccc2Cl)c1		CHEMBL218970	=	Inhibition	%	0.45	CHEMBL5408	Homo sapiens	Inhibition	%	0.45
	8128722	CHEMBL1962005	GSK_PKIS: TBK1 mean inhibition at 1 uM [Nanosyn]	B	COc1cccc(Nc2nccc(-c3cnn4ncccc34)n2)c1		CHEMBL187081	=	Inhibition	%	22.9	CHEMBL5408	Homo sapiens	Inhibition	%	22.9
	8129083	CHEMBL1962005	GSK_PKIS: TBK1 mean inhibition at 1 uM [Nanosyn]	B	O=C1NC(=O)C(c2cccc([N+](=O)[O-])c2)=C1Nc1cc(Cl)c(O)c(Cl)c1		CHEMBL352222	=	Inhibition	%	47.44	CHEMBL5408	Homo sapiens	Inhibition	%	47.44
	8129254	CHEMBL1962004	GSK_PKIS: TBK1 mean inhibition at 0.1 uM [Nanosyn]	B	CN(C)CCOc1ccc(-c2cc(-c3ccc4c(c3)CCC4=NO)c(-c3ccncc3)o2)cc1.Cl		CHEMBL1794072	=	Inhibition	%	-2.4	CHEMBL5408	Homo sapiens	Inhibition	%	-2.4
	8129443	CHEMBL1962005	GSK_PKIS: TBK1 mean inhibition at 1 uM [Nanosyn]	B	CCc1ccc(Oc2nccc(-c3c(-c4ccc(F)cc4)ncn3C3CCNCC3)n2)cc1		CHEMBL428877	=	Inhibition	%	4.95	CHEMBL5408	Homo sapiens	Inhibition	%	4.95
	8129667	CHEMBL1962004	GSK_PKIS: TBK1 mean inhibition at 0.1 uM [Nanosyn]	B	CN1CCN(C(=O)c2ccc(NC(=O)Nc3ccc(N(C)c4ccnc(Nc5ccc(CS(C)(=O)=O)cc5)n4)cc3)cc2)CC1.Cl		CHEMBL1909360	=	Inhibition	%	2.62	CHEMBL5408	Homo sapiens	Inhibition	%	2.62
	8129806	CHEMBL1962005	GSK_PKIS: TBK1 mean inhibition at 1 uM [Nanosyn]	B	O=C(Nc1n[nH]c2nnc(-c3cccnc3)cc12)C1CC1.O=C(O)C(F)(F)F		CHEMBL1909343	=	Inhibition	%	1.3	CHEMBL5408	Homo sapiens	Inhibition	%	1.3
	8130191	CHEMBL1962005	GSK_PKIS: TBK1 mean inhibition at 1 uM [Nanosyn]	B	FC(F)(F)CNc1nccc(-c2cnn3ncccc23)n1		CHEMBL446024	=	Inhibition	%	0.21	CHEMBL5408	Homo sapiens	Inhibition	%	0.21
	8130363	CHEMBL1962005	GSK_PKIS: TBK1 mean inhibition at 1 uM [Nanosyn]	B	CCN1CCC(C(=O)Nc2n[nH]c3nnc(-c4cccc(F)c4F)cc23)CC1.Cl		CHEMBL1909345	=	Inhibition	%	0.85	CHEMBL5408	Homo sapiens	Inhibition	%	0.85
	8130523	CHEMBL1962004	GSK_PKIS: TBK1 mean inhibition at 0.1 uM [Nanosyn]	B	CCN(CC)Cc1ccc(Nc2nccc(-c3cnn4ncccc34)n2)cc1		CHEMBL1882194	=	Inhibition	%	5.04	CHEMBL5408	Homo sapiens	Inhibition	%	5.04
	8130747	CHEMBL1962005	GSK_PKIS: TBK1 mean inhibition at 1 uM [Nanosyn]	B	CCN(CC)Cc1ccc(Nc2nccc(-c3cnn4ncccc34)n2)cc1		CHEMBL1882194	=	Inhibition	%	12.29	CHEMBL5408	Homo sapiens	Inhibition	%	12.29
	8130863	CHEMBL1962004	GSK_PKIS: TBK1 mean inhibition at 0.1 uM [Nanosyn]	B	CS(=O)(=O)c1ccc(Oc2nccc(-c3c(-c4ccc(F)cc4)ncn3C3CCNCC3)n2)cc1		CHEMBL418348	=	Inhibition	%	0.81	CHEMBL5408	Homo sapiens	Inhibition	%	0.81
	8131226	CHEMBL1962004	GSK_PKIS: TBK1 mean inhibition at 0.1 uM [Nanosyn]	B	COc1ccccc1Oc1nccc(-c2c(-c3ccc(F)cc3)ncn2C2CCNCC2)n1		CHEMBL417804	=	Inhibition	%	3.06	CHEMBL5408	Homo sapiens	Inhibition	%	3.06
	8131346	CHEMBL1962005	GSK_PKIS: TBK1 mean inhibition at 1 uM [Nanosyn]	B	Fc1ccc(-c2ncn(C3CCNCC3)c2-c2ccnc(Oc3ccc(Oc4ccccc4)cc3)n2)cc1		CHEMBL13868	=	Inhibition	%	2.57	CHEMBL5408	Homo sapiens	Inhibition	%	2.57
	8131570	CHEMBL1962004	GSK_PKIS: TBK1 mean inhibition at 0.1 uM [Nanosyn]	B	Fc1ccc(Oc2nccc(-c3c(-c4ccc(F)cc4)ncn3C3CCNCC3)n2)cc1		CHEMBL269450	=	Inhibition	%	5.6	CHEMBL5408	Homo sapiens	Inhibition	%	5.6
	8131737	CHEMBL1962005	GSK_PKIS: TBK1 mean inhibition at 1 uM [Nanosyn]	B	CCS(=O)(=O)c1ccc(OC)c(Nc2ncc(-c3cccc(F)c3)o2)c1		CHEMBL179465	=	Inhibition	%	11.5	CHEMBL5408	Homo sapiens	Inhibition	%	11.5
	8132102	CHEMBL1962005	GSK_PKIS: TBK1 mean inhibition at 1 uM [Nanosyn]	B	Nc1ncnc2occ(-c3ccc(NC(=O)Nc4cccc(C(F)(F)F)c4)cc3)c12		CHEMBL273564	=	Inhibition	%	4.59	CHEMBL5408	Homo sapiens	Inhibition	%	4.59
	8132388	CHEMBL1962004	GSK_PKIS: TBK1 mean inhibition at 0.1 uM [Nanosyn]	B	COc1cc(C)c(N(C)C(=O)CN(C)C)cc1Nc1nc(Nc2cccc(F)c2C(N)=O)c2cc[nH]c2n1		CHEMBL467581	=	Inhibition	%	1.26	CHEMBL5408	Homo sapiens	Inhibition	%	1.26
	8132535	CHEMBL1962005	GSK_PKIS: TBK1 mean inhibition at 1 uM [Nanosyn]	B	Cc1cc(O)cc(C)c1/C=C/c1cncc(C(=O)N(C)C)c1		CHEMBL220244	=	Inhibition	%	4.11	CHEMBL5408	Homo sapiens	Inhibition	%	4.11
	8132927	CHEMBL1962005	GSK_PKIS: TBK1 mean inhibition at 1 uM [Nanosyn]	B	CNC(=O)c1cncc(/C=C/c2ccccc2Cl)c1		CHEMBL218970	=	Inhibition	%	4.1	CHEMBL5408	Homo sapiens	Inhibition	%	4.1
	8133048	CHEMBL1962004	GSK_PKIS: TBK1 mean inhibition at 0.1 uM [Nanosyn]	B	Clc1ccc(CNc2nccc(-c3cnn4ncccc34)n2)cc1		CHEMBL513330	=	Inhibition	%	0.1	CHEMBL5408	Homo sapiens	Inhibition	%	0.1
	8133410	CHEMBL1962004	GSK_PKIS: TBK1 mean inhibition at 0.1 uM [Nanosyn]	B	CCN1CCC(CC(=O)Nc2n[nH]c3nnc(-c4cccc(F)c4F)cc23)CC1.O=C(O)C(O)C(O)C(=O)O		CHEMBL2062289	=	Inhibition	%	1.12	CHEMBL5408	Homo sapiens	Inhibition	%	1.12
	8133582	CHEMBL1962005	GSK_PKIS: TBK1 mean inhibition at 1 uM [Nanosyn]	B	CN(C)CCOc1ccc(-c2cc(-c3ccc4c(c3)CCC4=NO)c(-c3ccncc3)o2)cc1.Cl		CHEMBL1794072	=	Inhibition	%	-0.95	CHEMBL5408	Homo sapiens	Inhibition	%	-0.95
	8133986	CHEMBL1962005	GSK_PKIS: TBK1 mean inhibition at 1 uM [Nanosyn]	B	CN1CCN(C(=O)c2ccc(NC(=O)Nc3ccc(N(C)c4ccnc(Nc5ccc(CS(C)(=O)=O)cc5)n4)cc3)cc2)CC1.Cl		CHEMBL1909360	=	Inhibition	%	12.56	CHEMBL5408	Homo sapiens	Inhibition	%	12.56
	8134134	CHEMBL1962004	GSK_PKIS: TBK1 mean inhibition at 0.1 uM [Nanosyn]	B	COc1ccc(-c2cc3c(N)ncnc3o2)cc1		CHEMBL373073	=	Inhibition	%	0.41	CHEMBL5408	Homo sapiens	Inhibition	%	0.41
	8134518	CHEMBL1962004	GSK_PKIS: TBK1 mean inhibition at 0.1 uM [Nanosyn]	B	Cc1ccc(NC(=O)c2ccoc2)cc1-c1ccc(C(=O)NCC2CC2)cc1		CHEMBL477583	=	Inhibition	%	0.28	CHEMBL5408	Homo sapiens	Inhibition	%	0.28
	8134702	CHEMBL1962004	GSK_PKIS: TBK1 mean inhibition at 0.1 uM [Nanosyn]	B	CS(=O)(=O)Nc1ccc(N/C=C2\C(=O)Nc3ccccc32)cc1		CHEMBL1794058	=	Inhibition	%	0.52	CHEMBL5408	Homo sapiens	Inhibition	%	0.52
	8135086	CHEMBL1962004	GSK_PKIS: TBK1 mean inhibition at 0.1 uM [Nanosyn]	B	Cc1cc(-c2ccccn2)cc(C)c1/C=C/c1cncc(-c2nn[nH]n2)c1.Cl		CHEMBL1909354	=	Inhibition	%	3.59	CHEMBL5408	Homo sapiens	Inhibition	%	3.59
	8135201	CHEMBL1962005	GSK_PKIS: TBK1 mean inhibition at 1 uM [Nanosyn]	B	CS(=O)(=O)c1ccc(Oc2nccc(-c3c(-c4ccc(F)cc4)ncn3C3CCNCC3)n2)cc1		CHEMBL418348	=	Inhibition	%	0.82	CHEMBL5408	Homo sapiens	Inhibition	%	0.82
	8135425	CHEMBL1962004	GSK_PKIS: TBK1 mean inhibition at 0.1 uM [Nanosyn]	B	CS(=O)(=O)CCNCc1ccc(-c2ccc3ncnc(Nc4ccc(OCc5ccccc5)c(C(F)(F)F)c4)c3c2)o1.Cl		CHEMBL1909389	=	Inhibition	%	0.23	CHEMBL5408	Homo sapiens	Inhibition	%	0.23
	8135566	CHEMBL1962005	GSK_PKIS: TBK1 mean inhibition at 1 uM [Nanosyn]	B	COc1ccccc1Oc1nccc(-c2c(-c3ccc(F)cc3)ncn2C2CCNCC2)n1		CHEMBL417804	=	Inhibition	%	5.91	CHEMBL5408	Homo sapiens	Inhibition	%	5.91
	8135911	CHEMBL1962005	GSK_PKIS: TBK1 mean inhibition at 1 uM [Nanosyn]	B	Fc1ccc(Oc2nccc(-c3c(-c4ccc(F)cc4)ncn3C3CCNCC3)n2)cc1		CHEMBL269450	=	Inhibition	%	4.08	CHEMBL5408	Homo sapiens	Inhibition	%	4.08
	8136079	CHEMBL1962004	GSK_PKIS: TBK1 mean inhibition at 0.1 uM [Nanosyn]	B	COc1cccc(/C=N/Nc2ncnc3c2cnn3-c2cccc(OC)c2)c1		CHEMBL305477	=	Inhibition	%	3.28	CHEMBL5408	Homo sapiens	Inhibition	%	3.28
	8136447	CHEMBL1962004	GSK_PKIS: TBK1 mean inhibition at 0.1 uM [Nanosyn]	B	Fc1ccc(-c2ncn(C3CCNCC3)c2-c2ccnc(Oc3ccc4c(c3)OCO4)n2)cc1		CHEMBL273611	=	Inhibition	%	2.29	CHEMBL5408	Homo sapiens	Inhibition	%	2.29
	8136737	CHEMBL1962005	GSK_PKIS: TBK1 mean inhibition at 1 uM [Nanosyn]	B	COc1cc(C)c(N(C)C(=O)CN(C)C)cc1Nc1nc(Nc2cccc(F)c2C(N)=O)c2cc[nH]c2n1		CHEMBL467581	=	Inhibition	%	3.23	CHEMBL5408	Homo sapiens	Inhibition	%	3.23
	8136872	CHEMBL1962004	GSK_PKIS: TBK1 mean inhibition at 0.1 uM [Nanosyn]	B	CC1=C(C(=O)Nc2ccc3[nH]ncc3c2)C(c2ccc(Cl)c(Cl)c2)CC(=O)N1		CHEMBL374453	=	Inhibition	%	-0.19	CHEMBL5408	Homo sapiens	Inhibition	%	-0.19
	8137096	CHEMBL1962005	GSK_PKIS: TBK1 mean inhibition at 1 uM [Nanosyn]	B	CC1=C(C(=O)Nc2ccc3[nH]ncc3c2)C(c2ccc(Cl)c(Cl)c2)CC(=O)N1		CHEMBL374453	=	Inhibition	%	0.46	CHEMBL5408	Homo sapiens	Inhibition	%	0.46
	8137259	CHEMBL1962004	GSK_PKIS: TBK1 mean inhibition at 0.1 uM [Nanosyn]	B	CCCNc1cccc(-n2ncc3c(N/N=C/c4ccncc4)ncnc32)c1		CHEMBL67241	=	Inhibition	%	2.22	CHEMBL5408	Homo sapiens	Inhibition	%	2.22
	8137379	CHEMBL1962005	GSK_PKIS: TBK1 mean inhibition at 1 uM [Nanosyn]	B	Clc1ccc(CNc2nccc(-c3cnn4ncccc34)n2)cc1		CHEMBL513330	=	Inhibition	%	2.91	CHEMBL5408	Homo sapiens	Inhibition	%	2.91
	8137603	CHEMBL1962004	GSK_PKIS: TBK1 mean inhibition at 0.1 uM [Nanosyn]	B	CNC(=O)c1cncc(/C=C/c2c(C)cccc2C)c1		CHEMBL218859	=	Inhibition	%	0.21	CHEMBL5408	Homo sapiens	Inhibition	%	0.21
	8137751	CHEMBL1962005	GSK_PKIS: TBK1 mean inhibition at 1 uM [Nanosyn]	B	CCN1CCC(CC(=O)Nc2n[nH]c3nnc(-c4cccc(F)c4F)cc23)CC1.O=C(O)C(O)C(O)C(=O)O		CHEMBL2062289	=	Inhibition	%	4.19	CHEMBL5408	Homo sapiens	Inhibition	%	4.19
	8137917	CHEMBL1962004	GSK_PKIS: TBK1 mean inhibition at 0.1 uM [Nanosyn]	B	N#Cc1c(NC(=O)c2ccccc2F)sc2c1CCCC2		CHEMBL234838	=	Inhibition	%	-1.61	CHEMBL5408	Homo sapiens	Inhibition	%	-1.61
	8138141	CHEMBL1962005	GSK_PKIS: TBK1 mean inhibition at 1 uM [Nanosyn]	B	N#Cc1c(NC(=O)c2ccccc2F)sc2c1CCCC2		CHEMBL234838	=	Inhibition	%	-0.25	CHEMBL5408	Homo sapiens	Inhibition	%	-0.25
	8138320	CHEMBL1962004	GSK_PKIS: TBK1 mean inhibition at 0.1 uM [Nanosyn]	B	CS(=O)(=O)CCNCc1nc(-c2ccc3ncnc(Nc4ccc(OCc5cccc(C(F)(F)F)c5)cc4)c3c2)cs1.Cl		CHEMBL1909356	=	Inhibition	%	2.22	CHEMBL5408	Homo sapiens	Inhibition	%	2.22
	8138468	CHEMBL1962005	GSK_PKIS: TBK1 mean inhibition at 1 uM [Nanosyn]	B	COc1ccc(-c2cc3c(N)ncnc3o2)cc1		CHEMBL373073	=	Inhibition	%	1.62	CHEMBL5408	Homo sapiens	Inhibition	%	1.62
	8138692	CHEMBL1962004	GSK_PKIS: TBK1 mean inhibition at 0.1 uM [Nanosyn]	B	Cc1ccc(C(=O)NC(C)C)cc1-c1ccc(C(=O)NCC2CC2)cc1		CHEMBL477979	=	Inhibition	%	-1.37	CHEMBL5408	Homo sapiens	Inhibition	%	-1.37
	8138850	CHEMBL1962005	GSK_PKIS: TBK1 mean inhibition at 1 uM [Nanosyn]	B	Cc1ccc(NC(=O)c2ccoc2)cc1-c1ccc(C(=O)NCC2CC2)cc1		CHEMBL477583	=	Inhibition	%	0.72	CHEMBL5408	Homo sapiens	Inhibition	%	0.72
	8139035	CHEMBL1962005	GSK_PKIS: TBK1 mean inhibition at 1 uM [Nanosyn]	B	CS(=O)(=O)Nc1ccc(N/C=C2\C(=O)Nc3ccccc32)cc1		CHEMBL1794058	=	Inhibition	%	14.23	CHEMBL5408	Homo sapiens	Inhibition	%	14.23
	8139259	CHEMBL1962004	GSK_PKIS: TBK1 mean inhibition at 0.1 uM [Nanosyn]	B	O=C1Nc2ccc(I)cc2C1=Cc1cc(Br)c(O)c(Br)c1		CHEMBL1880739	=	Inhibition	%	3.66	CHEMBL5408	Homo sapiens	Inhibition	%	3.66
	8139418	CHEMBL1962005	GSK_PKIS: TBK1 mean inhibition at 1 uM [Nanosyn]	B	Cc1cc(-c2ccccn2)cc(C)c1/C=C/c1cncc(-c2nn[nH]n2)c1.Cl		CHEMBL1909354	=	Inhibition	%	2.21	CHEMBL5408	Homo sapiens	Inhibition	%	2.21
	8139756	CHEMBL1962005	GSK_PKIS: TBK1 mean inhibition at 1 uM [Nanosyn]	B	CS(=O)(=O)CCNCc1ccc(-c2ccc3ncnc(Nc4ccc(OCc5ccccc5)c(C(F)(F)F)c4)c3c2)o1.Cl		CHEMBL1909389	=	Inhibition	%	1.05	CHEMBL5408	Homo sapiens	Inhibition	%	1.05
	8139897	CHEMBL1962004	GSK_PKIS: TBK1 mean inhibition at 0.1 uM [Nanosyn]	B	O=C(O)C(F)(F)F.[O-][S+]1CCN(Cc2ccc(-c3ccc4ncnc(Nc5ccc(OCc6cccc(F)c6)c(Cl)c5)c4c3)o2)CC1		CHEMBL1909390	=	Inhibition	%	5.39	CHEMBL5408	Homo sapiens	Inhibition	%	5.39
	8140244	CHEMBL1962004	GSK_PKIS: TBK1 mean inhibition at 0.1 uM [Nanosyn]	B	O=C([O-])c1ccc(Oc2nccc(-c3c(-c4ccc(F)cc4)ncn3C3CCNCC3)n2)cc1.[Li+]		CHEMBL1909401	=	Inhibition	%	4.78	CHEMBL5408	Homo sapiens	Inhibition	%	4.78
	8140403	CHEMBL1962005	GSK_PKIS: TBK1 mean inhibition at 1 uM [Nanosyn]	B	COc1cccc(/C=N/Nc2ncnc3c2cnn3-c2cccc(OC)c2)c1		CHEMBL305477	=	Inhibition	%	1.31	CHEMBL5408	Homo sapiens	Inhibition	%	1.31
	8140627	CHEMBL1962004	GSK_PKIS: TBK1 mean inhibition at 0.1 uM [Nanosyn]	B	CNC(=O)c1cc(-c2ccc(F)cc2)cc(-c2ccc(S(=O)(=O)N3CCCC3)cc2)c1N		CHEMBL230592	=	Inhibition	%	0.38	CHEMBL5408	Homo sapiens	Inhibition	%	0.38
	8140770	CHEMBL1962005	GSK_PKIS: TBK1 mean inhibition at 1 uM [Nanosyn]	B	Fc1ccc(-c2ncn(C3CCNCC3)c2-c2ccnc(Oc3ccc4c(c3)OCO4)n2)cc1		CHEMBL273611	=	Inhibition	%	4.07	CHEMBL5408	Homo sapiens	Inhibition	%	4.07
	8141072	CHEMBL1962004	GSK_PKIS: TBK1 mean inhibition at 0.1 uM [Nanosyn]	B	COc1cc2c(cc1Nc1nc(N3CCc4ccccc43)c3cc[nH]c3n1)N(C(=O)CN(C)C)CC2		CHEMBL458415	=	Inhibition	%	0.22	CHEMBL5408	Homo sapiens	Inhibition	%	0.22
	8141426	CHEMBL1962004	GSK_PKIS: TBK1 mean inhibition at 0.1 uM [Nanosyn]	B	O=C(Nc1n[nH]c2nc(-c3ccco3)ccc12)C1CC1		CHEMBL101804	=	Inhibition	%	1.19	CHEMBL5408	Homo sapiens	Inhibition	%	1.19
	8141586	CHEMBL1962005	GSK_PKIS: TBK1 mean inhibition at 1 uM [Nanosyn]	B	CCCNc1cccc(-n2ncc3c(N/N=C/c4ccncc4)ncnc32)c1		CHEMBL67241	=	Inhibition	%	20.19	CHEMBL5408	Homo sapiens	Inhibition	%	20.19
	8141929	CHEMBL1962005	GSK_PKIS: TBK1 mean inhibition at 1 uM [Nanosyn]	B	CNC(=O)c1cncc(/C=C/c2c(C)cccc2C)c1		CHEMBL218859	=	Inhibition	%	0.94	CHEMBL5408	Homo sapiens	Inhibition	%	0.94
	8142090	CHEMBL1962004	GSK_PKIS: TBK1 mean inhibition at 0.1 uM [Nanosyn]	B	COc1ccc(-c2nn3ncccc3c2-c2ccnc(Nc3ccc4c(c3)OCCO4)n2)cc1		CHEMBL188257	=	Inhibition	%	-0.73	CHEMBL5408	Homo sapiens	Inhibition	%	-0.73
	8142482	CHEMBL1962004	GSK_PKIS: TBK1 mean inhibition at 0.1 uM [Nanosyn]	B	C[C@@H](Oc1cc(-n2cnc3ccc(OCC4CCN(C)CC4)cc32)sc1C(N)=O)c1ccccc1C(F)(F)F		CHEMBL1794068	=	Inhibition	%	-2.73	CHEMBL5408	Homo sapiens	Inhibition	%	-2.73
	8142658	CHEMBL1962005	GSK_PKIS: TBK1 mean inhibition at 1 uM [Nanosyn]	B	CS(=O)(=O)CCNCc1nc(-c2ccc3ncnc(Nc4ccc(OCc5cccc(C(F)(F)F)c5)cc4)c3c2)cs1.Cl		CHEMBL1909356	=	Inhibition	%	0.57	CHEMBL5408	Homo sapiens	Inhibition	%	0.57
	8143031	CHEMBL1962005	GSK_PKIS: TBK1 mean inhibition at 1 uM [Nanosyn]	B	Cc1ccc(C(=O)NC(C)C)cc1-c1ccc(C(=O)NCC2CC2)cc1		CHEMBL477979	=	Inhibition	%	-1.07	CHEMBL5408	Homo sapiens	Inhibition	%	-1.07
	8143186	CHEMBL1962004	GSK_PKIS: TBK1 mean inhibition at 0.1 uM [Nanosyn]	B	Nc1ccc(C#Cc2cncnc2Nc2ccc(OCc3cccc(F)c3)c(Cl)c2)cc1		CHEMBL205966	=	Inhibition	%	2.5	CHEMBL5408	Homo sapiens	Inhibition	%	2.5
	8143597	CHEMBL1962005	GSK_PKIS: TBK1 mean inhibition at 1 uM [Nanosyn]	B	O=C1Nc2ccc(I)cc2C1=Cc1cc(Br)c(O)c(Br)c1		CHEMBL1880739	=	Inhibition	%	2.5	CHEMBL5408	Homo sapiens	Inhibition	%	2.5
	8143756	CHEMBL1962004	GSK_PKIS: TBK1 mean inhibition at 0.1 uM [Nanosyn]	B	Cc1ccc2c(-c3ccnc(Nc4cccc(C(F)(F)F)c4)n3)c(-c3ccccc3)nn2n1		CHEMBL434729	=	Inhibition	%	3.23	CHEMBL5408	Homo sapiens	Inhibition	%	3.23
	8144094	CHEMBL1962004	GSK_PKIS: TBK1 mean inhibition at 0.1 uM [Nanosyn]	B	CS(=O)(=O)CCNCc1ccc(-c2ccc3ncnc(Nc4ccc(OCc5ccccc5)c(Br)c4)c3c2)o1.Cl		CHEMBL1909392	=	Inhibition	%	1.02	CHEMBL5408	Homo sapiens	Inhibition	%	1.02
	8144233	CHEMBL1962005	GSK_PKIS: TBK1 mean inhibition at 1 uM [Nanosyn]	B	O=C(O)C(F)(F)F.[O-][S+]1CCN(Cc2ccc(-c3ccc4ncnc(Nc5ccc(OCc6cccc(F)c6)c(Cl)c5)c4c3)o2)CC1		CHEMBL1909390	=	Inhibition	%	5.41	CHEMBL5408	Homo sapiens	Inhibition	%	5.41
	8144457	CHEMBL1962004	GSK_PKIS: TBK1 mean inhibition at 0.1 uM [Nanosyn]	B	CC(C)(C)c1ccc(Oc2nccc(-c3c(-c4ccc(F)cc4)ncn3C3CCNCC3)n2)cc1		CHEMBL275200	=	Inhibition	%	1.92	CHEMBL5408	Homo sapiens	Inhibition	%	1.92
	8144587	CHEMBL1962005	GSK_PKIS: TBK1 mean inhibition at 1 uM [Nanosyn]	B	O=C([O-])c1ccc(Oc2nccc(-c3c(-c4ccc(F)cc4)ncn3C3CCNCC3)n2)cc1.[Li+]		CHEMBL1909401	=	Inhibition	%	4.39	CHEMBL5408	Homo sapiens	Inhibition	%	4.39
	8144964	CHEMBL1962005	GSK_PKIS: TBK1 mean inhibition at 1 uM [Nanosyn]	B	CNC(=O)c1cc(-c2ccc(F)cc2)cc(-c2ccc(S(=O)(=O)N3CCCC3)cc2)c1N		CHEMBL230592	=	Inhibition	%	1.13	CHEMBL5408	Homo sapiens	Inhibition	%	1.13
	8145101	CHEMBL1962004	GSK_PKIS: TBK1 mean inhibition at 0.1 uM [Nanosyn]	B	Cl.O=S(=O)(CCNCc1ccc(-c2ccc3ncnc(Nc4ccc(OCc5cccc(F)c5)c(Cl)c4)c3c2)o1)c1ccccc1		CHEMBL1909395	=	Inhibition	%	4.82	CHEMBL5408	Homo sapiens	Inhibition	%	4.82
	8145414	CHEMBL1962005	GSK_PKIS: TBK1 mean inhibition at 1 uM [Nanosyn]	B	COc1cc2c(cc1Nc1nc(N3CCc4ccccc43)c3cc[nH]c3n1)N(C(=O)CN(C)C)CC2		CHEMBL458415	=	Inhibition	%	5.19	CHEMBL5408	Homo sapiens	Inhibition	%	5.19
	8145762	CHEMBL1962005	GSK_PKIS: TBK1 mean inhibition at 1 uM [Nanosyn]	B	O=C(Nc1n[nH]c2nc(-c3ccco3)ccc12)C1CC1		CHEMBL101804	=	Inhibition	%	2.8	CHEMBL5408	Homo sapiens	Inhibition	%	2.8
	8145923	CHEMBL1962004	GSK_PKIS: TBK1 mean inhibition at 0.1 uM [Nanosyn]	B	CN(c1ccc(NC(=O)Nc2c(Cl)cccc2Cl)cc1)c1ccnc(Nc2cccc(CS(C)(=O)=O)c2)n1		CHEMBL189353	=	Inhibition	%	3.74	CHEMBL5408	Homo sapiens	Inhibition	%	3.74
	8146267	CHEMBL1962004	GSK_PKIS: TBK1 mean inhibition at 0.1 uM [Nanosyn]	B	COC(=O)Nc1nc2ccc(Sc3ccc(NC(=O)Nc4cc(C(F)(F)F)ccc4F)cc3)cc2[nH]1.O=S(=O)(O)O		CHEMBL1909365	=	Inhibition	%	-0.64	CHEMBL5408	Homo sapiens	Inhibition	%	-0.64
	8146427	CHEMBL1962005	GSK_PKIS: TBK1 mean inhibition at 1 uM [Nanosyn]	B	COc1ccc(-c2nn3ncccc3c2-c2ccnc(Nc3ccc4c(c3)OCCO4)n2)cc1		CHEMBL188257	=	Inhibition	%	1.43	CHEMBL5408	Homo sapiens	Inhibition	%	1.43
	8146651	CHEMBL1962004	GSK_PKIS: TBK1 mean inhibition at 0.1 uM [Nanosyn]	B	COc1cc2c(cc1Nc1nc(Nc3ccsc3C(N)=O)c3cc[nH]c3n1)N(C(=O)CN(C)C)CCC2		CHEMBL456252	=	Inhibition	%	9.46	CHEMBL5408	Homo sapiens	Inhibition	%	9.46
	8146818	CHEMBL1962005	GSK_PKIS: TBK1 mean inhibition at 1 uM [Nanosyn]	B	C[C@@H](Oc1cc(-n2cnc3ccc(OCC4CCN(C)CC4)cc32)sc1C(N)=O)c1ccccc1C(F)(F)F		CHEMBL1794068	=	Inhibition	%	-1.33	CHEMBL5408	Homo sapiens	Inhibition	%	-1.33
	8146987	CHEMBL1962004	GSK_PKIS: TBK1 mean inhibition at 0.1 uM [Nanosyn]	B	CN1CCC(C(=O)Nc2n[nH]c3nc(-c4ccc(O)cc4)c(Br)cc23)CC1.O=C(O)/C=C\C(=O)O		CHEMBL1909347	=	Inhibition	%	3.27	CHEMBL5408	Homo sapiens	Inhibition	%	3.27
	8147211	CHEMBL1962005	GSK_PKIS: TBK1 mean inhibition at 1 uM [Nanosyn]	B	CN1CCC(C(=O)Nc2n[nH]c3nc(-c4ccc(O)cc4)c(Br)cc23)CC1.O=C(O)/C=C\C(=O)O		CHEMBL1909347	=	Inhibition	%	2.08	CHEMBL5408	Homo sapiens	Inhibition	%	2.08
	8147353	CHEMBL1962004	GSK_PKIS: TBK1 mean inhibition at 0.1 uM [Nanosyn]	B	FC(F)(F)c1cccc(Nc2nccc(-c3cnn4nc(-c5ccccc5)ccc34)n2)c1		CHEMBL189415	=	Inhibition	%	-0.2	CHEMBL5408	Homo sapiens	Inhibition	%	-0.2
	8147506	CHEMBL1962005	GSK_PKIS: TBK1 mean inhibition at 1 uM [Nanosyn]	B	Nc1ccc(C#Cc2cncnc2Nc2ccc(OCc3cccc(F)c3)c(Cl)c2)cc1		CHEMBL205966	=	Inhibition	%	3.55	CHEMBL5408	Homo sapiens	Inhibition	%	3.55
	8147730	CHEMBL1962004	GSK_PKIS: TBK1 mean inhibition at 0.1 uM [Nanosyn]	B	COc1ccc(-c2nn3ncccc3c2-c2ccnc(Nc3cccc(C(F)(F)F)c3)n2)cc1		CHEMBL186213	=	Inhibition	%	0.76	CHEMBL5408	Homo sapiens	Inhibition	%	0.76
	8147917	CHEMBL1962004	GSK_PKIS: TBK1 mean inhibition at 0.1 uM [Nanosyn]	B	COC(=O)c1ccc2c(c1)C(=Cc1cc(Br)c(O)c(Br)c1)C(=O)N2		CHEMBL1794052	=	Inhibition	%	1.23	CHEMBL5408	Homo sapiens	Inhibition	%	1.23
	8148075	CHEMBL1962005	GSK_PKIS: TBK1 mean inhibition at 1 uM [Nanosyn]	B	Cc1ccc2c(-c3ccnc(Nc4cccc(C(F)(F)F)c4)n3)c(-c3ccccc3)nn2n1		CHEMBL434729	=	Inhibition	%	4.86	CHEMBL5408	Homo sapiens	Inhibition	%	4.86
	8148299	CHEMBL1962004	GSK_PKIS: TBK1 mean inhibition at 0.1 uM [Nanosyn]	B	c1ccc(Nc2ncc(-c3ccccc3)o2)cc1		CHEMBL318728	=	Inhibition	%	5.72	CHEMBL5408	Homo sapiens	Inhibition	%	5.72
	8148413	CHEMBL1962005	GSK_PKIS: TBK1 mean inhibition at 1 uM [Nanosyn]	B	CS(=O)(=O)CCNCc1ccc(-c2ccc3ncnc(Nc4ccc(OCc5ccccc5)c(Br)c4)c3c2)o1.Cl		CHEMBL1909392	=	Inhibition	%	1.05	CHEMBL5408	Homo sapiens	Inhibition	%	1.05
	8148776	CHEMBL1962005	GSK_PKIS: TBK1 mean inhibition at 1 uM [Nanosyn]	B	CC(C)(C)c1ccc(Oc2nccc(-c3c(-c4ccc(F)cc4)ncn3C3CCNCC3)n2)cc1		CHEMBL275200	=	Inhibition	%	4.71	CHEMBL5408	Homo sapiens	Inhibition	%	4.71
	8148914	CHEMBL1962004	GSK_PKIS: TBK1 mean inhibition at 0.1 uM [Nanosyn]	B	NC(=O)c1ccc(Oc2nccc(-c3c(-c4ccc(F)cc4)ncn3C3CCNCC3)n2)cc1		CHEMBL275724	=	Inhibition	%	3.9	CHEMBL5408	Homo sapiens	Inhibition	%	3.9
	8149138	CHEMBL1962005	GSK_PKIS: TBK1 mean inhibition at 1 uM [Nanosyn]	B	NC(=O)c1ccc(Oc2nccc(-c3c(-c4ccc(F)cc4)ncn3C3CCNCC3)n2)cc1		CHEMBL275724	=	Inhibition	%	4.3	CHEMBL5408	Homo sapiens	Inhibition	%	4.3
	8149297	CHEMBL1962004	GSK_PKIS: TBK1 mean inhibition at 0.1 uM [Nanosyn]	B	CS(=O)(=O)CCN(CC#N)Cc1ccc(-c2ccc3ncnc(Nc4ccc(OCc5cccc(F)c5)c(Cl)c4)c3c2)o1		CHEMBL384407	=	Inhibition	%	0.72	CHEMBL5408	Homo sapiens	Inhibition	%	0.72
	8149431	CHEMBL1962005	GSK_PKIS: TBK1 mean inhibition at 1 uM [Nanosyn]	B	Cl.O=S(=O)(CCNCc1ccc(-c2ccc3ncnc(Nc4ccc(OCc5cccc(F)c5)c(Cl)c4)c3c2)o1)c1ccccc1		CHEMBL1909395	=	Inhibition	%	5.89	CHEMBL5408	Homo sapiens	Inhibition	%	5.89
	8149655	CHEMBL1962004	GSK_PKIS: TBK1 mean inhibition at 0.1 uM [Nanosyn]	B	CCn1c(-c2nonc2N)nc2cncc(C(=O)NCCNC)c21		CHEMBL506153	=	Inhibition	%	4.08	CHEMBL5408	Homo sapiens	Inhibition	%	4.08
	8149753	CHEMBL1962004	GSK_PKIS: TBK1 mean inhibition at 0.1 uM [Nanosyn]	B	CNC(=O)Oc1cc(C)c(/C=C/c2cncc(C(=O)NC)c2)c(C)c1		CHEMBL218932	=	Inhibition	%	2.75	CHEMBL5408	Homo sapiens	Inhibition	%	2.75
	8149977	CHEMBL1962005	GSK_PKIS: TBK1 mean inhibition at 1 uM [Nanosyn]	B	CNC(=O)Oc1cc(C)c(/C=C/c2cncc(C(=O)NC)c2)c(C)c1		CHEMBL218932	=	Inhibition	%	3.73	CHEMBL5408	Homo sapiens	Inhibition	%	3.73
	8150102	CHEMBL1962004	GSK_PKIS: TBK1 mean inhibition at 0.1 uM [Nanosyn]	B	Cl.O=C(Nc1ccc(Oc2ccc3[nH]c(NC(=O)c4ccco4)nc3c2)cc1)Nc1cc(C(F)(F)F)ccc1F		CHEMBL1909368	=	Inhibition	%	0.65	CHEMBL5408	Homo sapiens	Inhibition	%	0.65
	8150262	CHEMBL1962005	GSK_PKIS: TBK1 mean inhibition at 1 uM [Nanosyn]	B	CN(c1ccc(NC(=O)Nc2c(Cl)cccc2Cl)cc1)c1ccnc(Nc2cccc(CS(C)(=O)=O)c2)n1		CHEMBL189353	=	Inhibition	%	8.89	CHEMBL5408	Homo sapiens	Inhibition	%	8.89
	8150486	CHEMBL1962004	GSK_PKIS: TBK1 mean inhibition at 0.1 uM [Nanosyn]	B	CNC(=O)c1cccc(C#Cc2cncnc2Nc2ccc(OCc3cccc(F)c3)c(Cl)c2)c1		CHEMBL207410	=	Inhibition	%	-0.71	CHEMBL5408	Homo sapiens	Inhibition	%	-0.71
	8150606	CHEMBL1962005	GSK_PKIS: TBK1 mean inhibition at 1 uM [Nanosyn]	B	COC(=O)Nc1nc2ccc(Sc3ccc(NC(=O)Nc4cc(C(F)(F)F)ccc4F)cc3)cc2[nH]1.O=S(=O)(O)O		CHEMBL1909365	=	Inhibition	%	2.38	CHEMBL5408	Homo sapiens	Inhibition	%	2.38
	8150995	CHEMBL1962005	GSK_PKIS: TBK1 mean inhibition at 1 uM [Nanosyn]	B	COc1cc2c(cc1Nc1nc(Nc3ccsc3C(N)=O)c3cc[nH]c3n1)N(C(=O)CN(C)C)CCC2		CHEMBL456252	=	Inhibition	%	25.01	CHEMBL5408	Homo sapiens	Inhibition	%	25.01
	8151158	CHEMBL1962004	GSK_PKIS: TBK1 mean inhibition at 0.1 uM [Nanosyn]	B	Cc1ccc(C(=O)NC2CC2)cc1-c1ccc2[nH]ncc2c1		CHEMBL495902	=	Inhibition	%	-3.58	CHEMBL5408	Homo sapiens	Inhibition	%	-3.58
	8151559	CHEMBL1962004	GSK_PKIS: TBK1 mean inhibition at 0.1 uM [Nanosyn]	B	CCc1nn2ncccc2c1-c1ccnc(NC2CC2)n1		CHEMBL524057	=	Inhibition	%	2.11	CHEMBL5408	Homo sapiens	Inhibition	%	2.11
	8151697	CHEMBL1962005	GSK_PKIS: TBK1 mean inhibition at 1 uM [Nanosyn]	B	FC(F)(F)c1cccc(Nc2nccc(-c3cnn4nc(-c5ccccc5)ccc34)n2)c1		CHEMBL189415	=	Inhibition	%	4.35	CHEMBL5408	Homo sapiens	Inhibition	%	4.35
	8152075	CHEMBL1962005	GSK_PKIS: TBK1 mean inhibition at 1 uM [Nanosyn]	B	COc1ccc(-c2nn3ncccc3c2-c2ccnc(Nc3cccc(C(F)(F)F)c3)n2)cc1		CHEMBL186213	=	Inhibition	%	1.7	CHEMBL5408	Homo sapiens	Inhibition	%	1.7
	8152263	CHEMBL1962005	GSK_PKIS: TBK1 mean inhibition at 1 uM [Nanosyn]	B	COC(=O)c1ccc2c(c1)C(=Cc1cc(Br)c(O)c(Br)c1)C(=O)N2		CHEMBL1794052	=	Inhibition	%	6.58	CHEMBL5408	Homo sapiens	Inhibition	%	6.58
	8152645	CHEMBL1962005	GSK_PKIS: TBK1 mean inhibition at 1 uM [Nanosyn]	B	c1ccc(Nc2ncc(-c3ccccc3)o2)cc1		CHEMBL318728	=	Inhibition	%	5.74	CHEMBL5408	Homo sapiens	Inhibition	%	5.74
	8152759	CHEMBL1962004	GSK_PKIS: TBK1 mean inhibition at 0.1 uM [Nanosyn]	B	CCS(=O)(=O)c1ccc(OC)c(Nc2nccc(N(C)c3ccc4c(C)n[nH]c4c3)n2)c1.Cl		CHEMBL1909358	=	Inhibition	%	2.62	CHEMBL5408	Homo sapiens	Inhibition	%	2.62
	8152983	CHEMBL1962005	GSK_PKIS: TBK1 mean inhibition at 1 uM [Nanosyn]	B	CCS(=O)(=O)c1ccc(OC)c(Nc2nccc(N(C)c3ccc4c(C)n[nH]c4c3)n2)c1.Cl		CHEMBL1909358	=	Inhibition	%	4.2	CHEMBL5408	Homo sapiens	Inhibition	%	4.2
	8153122	CHEMBL1962004	GSK_PKIS: TBK1 mean inhibition at 0.1 uM [Nanosyn]	B	CN1CCN(Cc2ccc(-c3cc4ncnc(Nc5ccc(OCc6cccc(F)c6)c(Cl)c5)c4s3)o2)CC1		CHEMBL475761	=	Inhibition	%	1.51	CHEMBL5408	Homo sapiens	Inhibition	%	1.51
	8153483	CHEMBL1962004	GSK_PKIS: TBK1 mean inhibition at 0.1 uM [Nanosyn]	B	CCn1c(-c2nonc2N)nc2cncc(C(=O)N3CCNCC3)c21.Cl		CHEMBL1909376	=	Inhibition	%	6.79	CHEMBL5408	Homo sapiens	Inhibition	%	6.79
	8153640	CHEMBL1962005	GSK_PKIS: TBK1 mean inhibition at 1 uM [Nanosyn]	B	CS(=O)(=O)CCN(CC#N)Cc1ccc(-c2ccc3ncnc(Nc4ccc(OCc5cccc(F)c5)c(Cl)c4)c3c2)o1		CHEMBL384407	=	Inhibition	%	1.61	CHEMBL5408	Homo sapiens	Inhibition	%	1.61
	8153997	CHEMBL1962005	GSK_PKIS: TBK1 mean inhibition at 1 uM [Nanosyn]	B	CCn1c(-c2nonc2N)nc2cncc(C(=O)NCCNC)c21		CHEMBL506153	=	Inhibition	%	9.32	CHEMBL5408	Homo sapiens	Inhibition	%	9.32
	8154318	CHEMBL1962004	GSK_PKIS: TBK1 mean inhibition at 0.1 uM [Nanosyn]	B	CCn1c(-c2nonc2N)nc2ccccc21		CHEMBL365286	=	Inhibition	%	3.25	CHEMBL5408	Homo sapiens	Inhibition	%	3.25
	8154444	CHEMBL1962005	GSK_PKIS: TBK1 mean inhibition at 1 uM [Nanosyn]	B	Cl.O=C(Nc1ccc(Oc2ccc3[nH]c(NC(=O)c4ccco4)nc3c2)cc1)Nc1cc(C(F)(F)F)ccc1F		CHEMBL1909368	=	Inhibition	%	0.97	CHEMBL5408	Homo sapiens	Inhibition	%	0.97
	8154827	CHEMBL1962005	GSK_PKIS: TBK1 mean inhibition at 1 uM [Nanosyn]	B	CNC(=O)c1cccc(C#Cc2cncnc2Nc2ccc(OCc3cccc(F)c3)c(Cl)c2)c1		CHEMBL207410	=	Inhibition	%	0.61	CHEMBL5408	Homo sapiens	Inhibition	%	0.61
	8154947	CHEMBL1962004	GSK_PKIS: TBK1 mean inhibition at 0.1 uM [Nanosyn]	B	Cc1ccc(NC(=O)c2ccnc(N3CCOCC3)c2)cc1-c1ccc(C(=O)NCC2CC2)cc1		CHEMBL476351	=	Inhibition	%	1.33	CHEMBL5408	Homo sapiens	Inhibition	%	1.33
	8155171	CHEMBL1962005	GSK_PKIS: TBK1 mean inhibition at 1 uM [Nanosyn]	B	Cc1ccc(NC(=O)c2ccnc(N3CCOCC3)c2)cc1-c1ccc(C(=O)NCC2CC2)cc1		CHEMBL476351	=	Inhibition	%	1.13	CHEMBL5408	Homo sapiens	Inhibition	%	1.13
	8155347	CHEMBL1962004	GSK_PKIS: TBK1 mean inhibition at 0.1 uM [Nanosyn]	B	Nc1nccc(-c2c(-c3ccc(F)cc3)nn3cc(C(F)(F)F)ccc23)n1		CHEMBL1909402	=	Inhibition	%	-2.75	CHEMBL5408	Homo sapiens	Inhibition	%	-2.75
	8155508	CHEMBL1962005	GSK_PKIS: TBK1 mean inhibition at 1 uM [Nanosyn]	B	Cc1ccc(C(=O)NC2CC2)cc1-c1ccc2[nH]ncc2c1		CHEMBL495902	=	Inhibition	%	-1.07	CHEMBL5408	Homo sapiens	Inhibition	%	-1.07
	8155732	CHEMBL1962004	GSK_PKIS: TBK1 mean inhibition at 0.1 uM [Nanosyn]	B	COc1cc2c(cc1Nc1nc(Nc3cccc(F)c3C(N)=O)c3cc[nH]c3n1)N(C(=O)CN1CCN(C(C)C)CC1)CC2		CHEMBL505915	=	Inhibition	%	2.33	CHEMBL5408	Homo sapiens	Inhibition	%	2.33
	8155910	CHEMBL1962005	GSK_PKIS: TBK1 mean inhibition at 1 uM [Nanosyn]	B	CCc1nn2ncccc2c1-c1ccnc(NC2CC2)n1		CHEMBL524057	=	Inhibition	%	3.02	CHEMBL5408	Homo sapiens	Inhibition	%	3.02
	8156048	CHEMBL1962004	GSK_PKIS: TBK1 mean inhibition at 0.1 uM [Nanosyn]	B	CCOc1ccc2c(-c3ccnc(Nc4cccc(C(F)(F)F)c4)n3)cnn2n1		CHEMBL183993	=	Inhibition	%	2.13	CHEMBL5408	Homo sapiens	Inhibition	%	2.13
	8156272	CHEMBL1962005	GSK_PKIS: TBK1 mean inhibition at 1 uM [Nanosyn]	B	CCOc1ccc2c(-c3ccnc(Nc4cccc(C(F)(F)F)c4)n3)cnn2n1		CHEMBL183993	=	Inhibition	%	13.14	CHEMBL5408	Homo sapiens	Inhibition	%	13.14
	8156484	CHEMBL1962004	GSK_PKIS: TBK1 mean inhibition at 0.1 uM [Nanosyn]	B	Cc1ccc(-c2cc3c(NC(=O)C4CC4)ncnc3o2)cc1		CHEMBL182283	=	Inhibition	%	3.64	CHEMBL5408	Homo sapiens	Inhibition	%	3.64
	8156634	CHEMBL1962005	GSK_PKIS: TBK1 mean inhibition at 1 uM [Nanosyn]	B	CCS(=O)(=O)c1ccc(OC)c(Nc2ncc(-c3cccc(C(C)=O)c3)o2)c1		CHEMBL191705	=	Inhibition	%	5.54	CHEMBL5408	Homo sapiens	Inhibition	%	5.54
	8157001	CHEMBL1962005	GSK_PKIS: TBK1 mean inhibition at 1 uM [Nanosyn]	B	NS(=O)(=O)c1ccc(Nc2ncc(-c3ccccc3)o2)cc1		CHEMBL194062	=	Inhibition	%	8.12	CHEMBL5408	Homo sapiens	Inhibition	%	8.12
	8157345	CHEMBL1962005	GSK_PKIS: TBK1 mean inhibition at 1 uM [Nanosyn]	B	CC1=C(C(=O)Nc2ccc3[nH]nc(C)c3c2)C(c2ccc(C(F)(F)F)cc2)CC(=O)N1		CHEMBL218720	=	Inhibition	%	3.52	CHEMBL5408	Homo sapiens	Inhibition	%	3.52
	8157486	CHEMBL1962004	GSK_PKIS: TBK1 mean inhibition at 0.1 uM [Nanosyn]	B	COc1cc(Nc2ncc3c(C)nc(-c4cccc(C(F)(F)F)c4)n3n2)cc(OC)c1OC		CHEMBL520037	=	Inhibition	%	1.64	CHEMBL5408	Homo sapiens	Inhibition	%	1.64
	8157840	CHEMBL1962004	GSK_PKIS: TBK1 mean inhibition at 0.1 uM [Nanosyn]	B	COc1ccccc1C1=C(Nc2ccccc2)C(=O)NC1=O		CHEMBL156263	=	Inhibition	%	2.56	CHEMBL5408	Homo sapiens	Inhibition	%	2.56
	8158001	CHEMBL1962005	GSK_PKIS: TBK1 mean inhibition at 1 uM [Nanosyn]	B	COc1ccc(COc2ccc(Cc3cnc(N)nc3N)cc2OC)cc1		CHEMBL261849	=	Inhibition	%	2.86	CHEMBL5408	Homo sapiens	Inhibition	%	2.86
	8158225	CHEMBL1962004	GSK_PKIS: TBK1 mean inhibition at 0.1 uM [Nanosyn]	B	CN1CCN(CCCNc2nc3ccc(Oc4ccc(NC(=O)Nc5cc(C(F)(F)F)ccc5F)cc4)cc3[nH]2)CC1.Cl		CHEMBL1909372	=	Inhibition	%	1.88	CHEMBL5408	Homo sapiens	Inhibition	%	1.88
	8158251	CHEMBL1962005	GSK_PKIS: TBK1 mean inhibition at 1 uM [Nanosyn]	B	COc1ccc2cc(-c3c(-c4ccncc4)nc(-c4ccc(S(C)(=O)=O)cc4C)n3C)ccc2c1		CHEMBL237571	=	Inhibition	%	5.22	CHEMBL5408	Homo sapiens	Inhibition	%	5.22
	8158475	CHEMBL1962004	GSK_PKIS: TBK1 mean inhibition at 0.1 uM [Nanosyn]	B	CCn1c(-c2nonc2N)nc2cncc(C(=O)N3CC[C@H](N)C3)c21.Cl		CHEMBL1909384	=	Inhibition	%	3.11	CHEMBL5408	Homo sapiens	Inhibition	%	3.11
	8158633	CHEMBL1962005	GSK_PKIS: TBK1 mean inhibition at 1 uM [Nanosyn]	B	Cc1ccc(NC(=O)c2ccnc(N3CCCC3)c2)cc1-c1ccc(C(=O)NCC2CC2)cc1		CHEMBL477182	=	Inhibition	%	8.32	CHEMBL5408	Homo sapiens	Inhibition	%	8.32
	8158802	CHEMBL1962004	GSK_PKIS: TBK1 mean inhibition at 0.1 uM [Nanosyn]	B	O=C(Nc1n[nH]c2cc(-c3cc(F)ccc3F)ccc12)C1CC1		CHEMBL261440	=	Inhibition	%	3.98	CHEMBL5408	Homo sapiens	Inhibition	%	3.98
	8159026	CHEMBL1962005	GSK_PKIS: TBK1 mean inhibition at 1 uM [Nanosyn]	B	O=C(Nc1n[nH]c2cc(-c3cc(F)ccc3F)ccc12)C1CC1		CHEMBL261440	=	Inhibition	%	5.44	CHEMBL5408	Homo sapiens	Inhibition	%	5.44
	8159161	CHEMBL1962004	GSK_PKIS: TBK1 mean inhibition at 0.1 uM [Nanosyn]	B	O=C(O[C@H]1CN[C@H](C#Cc2cc3ncnc(Nc4ccc(OCc5cccc(F)c5)c(Cl)c4)c3s2)C1)N1CCOCC1		CHEMBL507329	=	Inhibition	%	1.96	CHEMBL5408	Homo sapiens	Inhibition	%	1.96
	8159505	CHEMBL1962004	GSK_PKIS: TBK1 mean inhibition at 0.1 uM [Nanosyn]	B	Fc1ccc(-c2c(-c3ccncc3)nc3n2CCS3)cc1		CHEMBL266707	=	Inhibition	%	0.11	CHEMBL5408	Homo sapiens	Inhibition	%	0.11
	8159636	CHEMBL1962005	GSK_PKIS: TBK1 mean inhibition at 1 uM [Nanosyn]	B	NS(=O)(=O)c1ccc(Nc2cc(-c3cccc(O)c3)n[nH]2)cc1		CHEMBL103104	=	Inhibition	%	6.87	CHEMBL5408	Homo sapiens	Inhibition	%	6.87
	8159860	CHEMBL1962004	GSK_PKIS: TBK1 mean inhibition at 0.1 uM [Nanosyn]	B	CCCN1CCCC(c2ccc(Nc3nc(Nc4cc(F)ccc4C(N)=O)c4cc[nH]c4n3)c(OC)c2)C1		CHEMBL477069	=	Inhibition	%	4.22	CHEMBL5408	Homo sapiens	Inhibition	%	4.22
	8160001	CHEMBL1962005	GSK_PKIS: TBK1 mean inhibition at 1 uM [Nanosyn]	B	Cl.c1ccc(-c2nc3n(c2-c2ccc4c(c2)OCO4)CCC3)nc1		CHEMBL1909377	=	Inhibition	%	2.71	CHEMBL5408	Homo sapiens	Inhibition	%	2.71
	8160362	CHEMBL1962005	GSK_PKIS: TBK1 mean inhibition at 1 uM [Nanosyn]	B	N#Cc1c(NC(=O)CN2CCOCC2)sc2c1CCCC2.O=C(O)C(=O)O		CHEMBL1909342	=	Inhibition	%	4.24	CHEMBL5408	Homo sapiens	Inhibition	%	4.24
	8160512	CHEMBL1962004	GSK_PKIS: TBK1 mean inhibition at 0.1 uM [Nanosyn]	B	Nc1nccc(-c2c(-c3ccc(F)cc3)ncn2C2CCC(O)CC2)n1		CHEMBL1888586	=	Inhibition	%	5.52	CHEMBL5408	Homo sapiens	Inhibition	%	5.52
	8160806	CHEMBL1962005	GSK_PKIS: TBK1 mean inhibition at 1 uM [Nanosyn]	B	Cc1ccc(-c2cc3c(NC(=O)C4CC4)ncnc3o2)cc1		CHEMBL182283	=	Inhibition	%	10.11	CHEMBL5408	Homo sapiens	Inhibition	%	10.11
	8160956	CHEMBL1962004	GSK_PKIS: TBK1 mean inhibition at 0.1 uM [Nanosyn]	B	CN(c1ccc(NC(=O)NCCN2CCOCC2)cc1)c1ccnc(Nc2ccc(CS(C)(=O)=O)cc2)n1.Cl		CHEMBL1909361	=	Inhibition	%	1.55	CHEMBL5408	Homo sapiens	Inhibition	%	1.55
	8161180	CHEMBL1962005	GSK_PKIS: TBK1 mean inhibition at 1 uM [Nanosyn]	B	CN(c1ccc(NC(=O)NCCN2CCOCC2)cc1)c1ccnc(Nc2ccc(CS(C)(=O)=O)cc2)n1.Cl		CHEMBL1909361	=	Inhibition	%	4.49	CHEMBL5408	Homo sapiens	Inhibition	%	4.49
	8161323	CHEMBL1962004	GSK_PKIS: TBK1 mean inhibition at 0.1 uM [Nanosyn]	B	c1cnn2ncc(-c3ccnc(Nc4ccc5c(c4)OCCO5)n3)c2c1		CHEMBL361894	=	Inhibition	%	3.41	CHEMBL5408	Homo sapiens	Inhibition	%	3.41
	8161672	CHEMBL1962004	GSK_PKIS: TBK1 mean inhibition at 0.1 uM [Nanosyn]	B	O=C1NC(=O)C(c2ccccc2Cl)=C1Nc1cccc(O)c1		CHEMBL160937	=	Inhibition	%	2.04	CHEMBL5408	Homo sapiens	Inhibition	%	2.04
	8161810	CHEMBL1962005	GSK_PKIS: TBK1 mean inhibition at 1 uM [Nanosyn]	B	COc1cc(Nc2ncc3c(C)nc(-c4cccc(C(F)(F)F)c4)n3n2)cc(OC)c1OC		CHEMBL520037	=	Inhibition	%	25.51	CHEMBL5408	Homo sapiens	Inhibition	%	25.51
	8162034	CHEMBL1962004	GSK_PKIS: TBK1 mean inhibition at 0.1 uM [Nanosyn]	B	Cl.NS(=O)(=O)c1cccc(Nc2cc(-c3ccc(F)cc3)n[nH]2)c1		CHEMBL1909351	=	Inhibition	%	2.64	CHEMBL5408	Homo sapiens	Inhibition	%	2.64
	8162164	CHEMBL1962005	GSK_PKIS: TBK1 mean inhibition at 1 uM [Nanosyn]	B	COc1ccccc1C1=C(Nc2ccccc2)C(=O)NC1=O		CHEMBL156263	=	Inhibition	%	7.18	CHEMBL5408	Homo sapiens	Inhibition	%	7.18
	8162548	CHEMBL1962005	GSK_PKIS: TBK1 mean inhibition at 1 uM [Nanosyn]	B	CN1CCN(CCCNc2nc3ccc(Oc4ccc(NC(=O)Nc5cc(C(F)(F)F)ccc5F)cc4)cc3[nH]2)CC1.Cl		CHEMBL1909372	=	Inhibition	%	3.78	CHEMBL5408	Homo sapiens	Inhibition	%	3.78
	8162801	CHEMBL1962005	GSK_PKIS: TBK1 mean inhibition at 1 uM [Nanosyn]	B	CCn1c(-c2nonc2N)nc2cncc(C(=O)N3CC[C@H](N)C3)c21.Cl		CHEMBL1909384	=	Inhibition	%	19.71	CHEMBL5408	Homo sapiens	Inhibition	%	19.71
	8162949	CHEMBL1962004	GSK_PKIS: TBK1 mean inhibition at 0.1 uM [Nanosyn]	B	NS(=O)(=O)c1ccc(NC=C2C(=O)Nc3ccc4ncsc4c32)cc1		CHEMBL1794055	=	Inhibition	%	13.39	CHEMBL5408	Homo sapiens	Inhibition	%	13.39
	8163342	CHEMBL1962004	GSK_PKIS: TBK1 mean inhibition at 0.1 uM [Nanosyn]	B	N#Cc1c(NC(=O)c2cccc3ccccc23)sc2c1CCCC2		CHEMBL233001	=	Inhibition	%	0.12	CHEMBL5408	Homo sapiens	Inhibition	%	0.12
	8163476	CHEMBL1962005	GSK_PKIS: TBK1 mean inhibition at 1 uM [Nanosyn]	B	O=C(O[C@H]1CN[C@H](C#Cc2cc3ncnc(Nc4ccc(OCc5cccc(F)c5)c(Cl)c4)c3s2)C1)N1CCOCC1		CHEMBL507329	=	Inhibition	%	2.81	CHEMBL5408	Homo sapiens	Inhibition	%	2.81
	8163823	CHEMBL1962005	GSK_PKIS: TBK1 mean inhibition at 1 uM [Nanosyn]	B	Fc1ccc(-c2c(-c3ccncc3)nc3n2CCS3)cc1		CHEMBL266707	=	Inhibition	%	2.15	CHEMBL5408	Homo sapiens	Inhibition	%	2.15
	8164181	CHEMBL1962005	GSK_PKIS: TBK1 mean inhibition at 1 uM [Nanosyn]	B	CCCN1CCCC(c2ccc(Nc3nc(Nc4cc(F)ccc4C(N)=O)c4cc[nH]c4n3)c(OC)c2)C1		CHEMBL477069	=	Inhibition	%	11.5	CHEMBL5408	Homo sapiens	Inhibition	%	11.5
	8164321	CHEMBL1962004	GSK_PKIS: TBK1 mean inhibition at 0.1 uM [Nanosyn]	B	CC1(C)CC(n2cnc(-c3ccc(F)cc3)c2-c2ccnc(N)n2)CC(C)(C)N1		CHEMBL95502	=	Inhibition	%	0.42	CHEMBL5408	Homo sapiens	Inhibition	%	0.42
	8164700	CHEMBL1962004	GSK_PKIS: TBK1 mean inhibition at 0.1 uM [Nanosyn]	B	N#Cc1cccc(Nc2nccc(-c3cnn4ncccc34)n2)c1		CHEMBL495696	=	Inhibition	%	1.58	CHEMBL5408	Homo sapiens	Inhibition	%	1.58
	8164844	CHEMBL1962005	GSK_PKIS: TBK1 mean inhibition at 1 uM [Nanosyn]	B	Nc1nccc(-c2c(-c3ccc(F)cc3)ncn2C2CCC(O)CC2)n1		CHEMBL1888586	=	Inhibition	%	1.41	CHEMBL5408	Homo sapiens	Inhibition	%	1.41
	8165138	CHEMBL1962004	GSK_PKIS: TBK1 mean inhibition at 0.1 uM [Nanosyn]	B	CNC(=O)c1ncccc1Nc1nc(Nc2cc3c(cc2OC)CCCN3C(=O)CN(C)C)nc2[nH]ccc12		CHEMBL1895450	=	Inhibition	%	5.66	CHEMBL5408	Homo sapiens	Inhibition	%	5.66
	8165503	CHEMBL1962004	GSK_PKIS: TBK1 mean inhibition at 0.1 uM [Nanosyn]	B	O=C1NC(=O)C(c2ccccc2Cl)=C1Nc1cc(Cl)c(O)c(Cl)c1		CHEMBL157258	=	Inhibition	%	0.38	CHEMBL5408	Homo sapiens	Inhibition	%	0.38
	8165646	CHEMBL1962005	GSK_PKIS: TBK1 mean inhibition at 1 uM [Nanosyn]	B	c1cnn2ncc(-c3ccnc(Nc4ccc5c(c4)OCCO5)n3)c2c1		CHEMBL361894	=	Inhibition	%	23.85	CHEMBL5408	Homo sapiens	Inhibition	%	23.85
	8165870	CHEMBL1962004	GSK_PKIS: TBK1 mean inhibition at 0.1 uM [Nanosyn]	B	Nc1ncnc2occ(-c3ccc(NC(=O)Nc4cc(C(F)(F)F)cc(C(F)(F)F)c4)cc3)c12		CHEMBL396107	=	Inhibition	%	-0.65	CHEMBL5408	Homo sapiens	Inhibition	%	-0.65
	8165996	CHEMBL1962005	GSK_PKIS: TBK1 mean inhibition at 1 uM [Nanosyn]	B	O=C1NC(=O)C(c2ccccc2Cl)=C1Nc1cccc(O)c1		CHEMBL160937	=	Inhibition	%	6.91	CHEMBL5408	Homo sapiens	Inhibition	%	6.91
	8166358	CHEMBL1962005	GSK_PKIS: TBK1 mean inhibition at 1 uM [Nanosyn]	B	Cl.NS(=O)(=O)c1cccc(Nc2cc(-c3ccc(F)cc3)n[nH]2)c1		CHEMBL1909351	=	Inhibition	%	15.18	CHEMBL5408	Homo sapiens	Inhibition	%	15.18
	8166488	CHEMBL1962004	GSK_PKIS: TBK1 mean inhibition at 0.1 uM [Nanosyn]	B	Cl.Oc1cccc(-c2nc(-c3ccccc3)[nH]c2-c2ccncc2)c1		CHEMBL1909413	=	Inhibition	%	1.64	CHEMBL5408	Homo sapiens	Inhibition	%	1.64
	8166813	CHEMBL1962005	GSK_PKIS: TBK1 mean inhibition at 1 uM [Nanosyn]	B	COc1cc(Nc2nccc(Nc3ccc4c(C)n[nH]c4c3)n2)cc(OC)c1OC		CHEMBL479079	=	Inhibition	%	26.33	CHEMBL5408	Homo sapiens	Inhibition	%	26.33
	8167125	CHEMBL1962004	GSK_PKIS: TBK1 mean inhibition at 0.1 uM [Nanosyn]	B	CCn1c(-c2nonc2N)nc2cnc(Oc3cccc(NC(=O)c4ccc(OCCN5CCOCC5)cc4)c3)cc21.Cl		CHEMBL1909363	=	Inhibition	%	0.71	CHEMBL5408	Homo sapiens	Inhibition	%	0.71
	8167266	CHEMBL1962005	GSK_PKIS: TBK1 mean inhibition at 1 uM [Nanosyn]	B	NS(=O)(=O)c1ccc(NC=C2C(=O)Nc3ccc4ncsc4c32)cc1		CHEMBL1794055	=	Inhibition	%	65.58	CHEMBL5408	Homo sapiens	Inhibition	%	65.58
	8167490	CHEMBL1962004	GSK_PKIS: TBK1 mean inhibition at 0.1 uM [Nanosyn]	B	COc1cc2c(cc1Nc1nc(Nc3ccsc3C(N)=O)c3cc[nH]c3n1)N(C(=O)CN(C)C)CCC2(C)C		CHEMBL463931	=	Inhibition	%	11.33	CHEMBL5408	Homo sapiens	Inhibition	%	11.33
	8167654	CHEMBL1962005	GSK_PKIS: TBK1 mean inhibition at 1 uM [Nanosyn]	B	N#Cc1c(NC(=O)c2cccc3ccccc23)sc2c1CCCC2		CHEMBL233001	=	Inhibition	%	6.64	CHEMBL5408	Homo sapiens	Inhibition	%	6.64
	8167787	CHEMBL1962004	GSK_PKIS: TBK1 mean inhibition at 0.1 uM [Nanosyn]	B	CCn1c(-c2nonc2N)nc2ccc(F)cc21		CHEMBL426800	=	Inhibition	%	5.18	CHEMBL5408	Homo sapiens	Inhibition	%	5.18
	8168011	CHEMBL1962005	GSK_PKIS: TBK1 mean inhibition at 1 uM [Nanosyn]	B	CCn1c(-c2nonc2N)nc2ccc(F)cc21		CHEMBL426800	=	Inhibition	%	4.44	CHEMBL5408	Homo sapiens	Inhibition	%	4.44
	8168135	CHEMBL1962004	GSK_PKIS: TBK1 mean inhibition at 0.1 uM [Nanosyn]	B	CC1=C(C(=O)Nc2ccc3[nH]ncc3c2)C(c2ccc(F)cc2)NC(=O)N1		CHEMBL384073	=	Inhibition	%	2.82	CHEMBL5408	Homo sapiens	Inhibition	%	2.82
	8168500	CHEMBL1962004	GSK_PKIS: TBK1 mean inhibition at 0.1 uM [Nanosyn]	B	NC(=O)c1ccc2c(-c3ccnc(NCCCO)n3)c(-c3ccc(F)cc3)nn2c1		CHEMBL1909404	=	Inhibition	%	4.13	CHEMBL5408	Homo sapiens	Inhibition	%	4.13
	8168636	CHEMBL1962005	GSK_PKIS: TBK1 mean inhibition at 1 uM [Nanosyn]	B	CC1(C)CC(n2cnc(-c3ccc(F)cc3)c2-c2ccnc(N)n2)CC(C)(C)N1		CHEMBL95502	=	Inhibition	%	0.35	CHEMBL5408	Homo sapiens	Inhibition	%	0.35
	8168860	CHEMBL1962004	GSK_PKIS: TBK1 mean inhibition at 0.1 uM [Nanosyn]	B	NS(=O)(=O)c1cccc(-c2ccc3c(NC(=O)C4CC4)n[nH]c3c2)c1		CHEMBL407113	=	Inhibition	%	0.24	CHEMBL5408	Homo sapiens	Inhibition	%	0.24
	8169024	CHEMBL1962005	GSK_PKIS: TBK1 mean inhibition at 1 uM [Nanosyn]	B	N#Cc1cccc(Nc2nccc(-c3cnn4ncccc34)n2)c1		CHEMBL495696	=	Inhibition	%	22.05	CHEMBL5408	Homo sapiens	Inhibition	%	22.05
	8169166	CHEMBL1962004	GSK_PKIS: TBK1 mean inhibition at 0.1 uM [Nanosyn]	B	CS(=O)(=O)Nc1ccc(-c2ccc3c(NC(=O)C4CC4)n[nH]c3c2)cc1		CHEMBL102936	=	Inhibition	%	0.86	CHEMBL5408	Homo sapiens	Inhibition	%	0.86
	8169390	CHEMBL1962005	GSK_PKIS: TBK1 mean inhibition at 1 uM [Nanosyn]	B	CS(=O)(=O)Nc1ccc(-c2ccc3c(NC(=O)C4CC4)n[nH]c3c2)cc1		CHEMBL102936	=	Inhibition	%	7.65	CHEMBL5408	Homo sapiens	Inhibition	%	7.65
	8169470	CHEMBL1962005	GSK_PKIS: TBK1 mean inhibition at 1 uM [Nanosyn]	B	CNC(=O)c1ncccc1Nc1nc(Nc2cc3c(cc2OC)CCCN3C(=O)CN(C)C)nc2[nH]ccc12		CHEMBL1895450	=	Inhibition	%	26.15	CHEMBL5408	Homo sapiens	Inhibition	%	26.15
	8169694	CHEMBL1962004	GSK_PKIS: TBK1 mean inhibition at 0.1 uM [Nanosyn]	B	NS(=O)(=O)c1ccc(N/N=C2\C(=O)Nc3ccc(C(=O)NCCc4c[nH]cn4)cc32)cc1		CHEMBL272028	=	Inhibition	%	3.67	CHEMBL5408	Homo sapiens	Inhibition	%	3.67
	8169828	CHEMBL1962005	GSK_PKIS: TBK1 mean inhibition at 1 uM [Nanosyn]	B	O=C1NC(=O)C(c2ccccc2Cl)=C1Nc1cc(Cl)c(O)c(Cl)c1		CHEMBL157258	=	Inhibition	%	6.6	CHEMBL5408	Homo sapiens	Inhibition	%	6.6
	8170197	CHEMBL1962005	GSK_PKIS: TBK1 mean inhibition at 1 uM [Nanosyn]	B	Nc1ncnc2occ(-c3ccc(NC(=O)Nc4cc(C(F)(F)F)cc(C(F)(F)F)c4)cc3)c12		CHEMBL396107	=	Inhibition	%	3.1	CHEMBL5408	Homo sapiens	Inhibition	%	3.1
	8170322	CHEMBL1962004	GSK_PKIS: TBK1 mean inhibition at 0.1 uM [Nanosyn]	B	Cc1cccc2c1NC(=O)/C2=N\Nc1ccc(S(N)(=O)=O)cc1		CHEMBL1909398	=	Inhibition	%	2.84	CHEMBL5408	Homo sapiens	Inhibition	%	2.84
	8170686	CHEMBL1962004	GSK_PKIS: TBK1 mean inhibition at 0.1 uM [Nanosyn]	B	CCn1c(-c2nonc2N)nc2c(C#CC(C)(C)O)ncc(OCC3CCNCC3)c21.O=C(O)C(F)(F)F		CHEMBL1794065	=	Inhibition	%	5.26	CHEMBL5408	Homo sapiens	Inhibition	%	5.26
	8170821	CHEMBL1962005	GSK_PKIS: TBK1 mean inhibition at 1 uM [Nanosyn]	B	Cl.Oc1cccc(-c2nc(-c3ccccc3)[nH]c2-c2ccncc2)c1		CHEMBL1909413	=	Inhibition	%	2.77	CHEMBL5408	Homo sapiens	Inhibition	%	2.77
	8171045	CHEMBL1962004	GSK_PKIS: TBK1 mean inhibition at 0.1 uM [Nanosyn]	B	CC(C)c1ccc(Nc2nccc(-c3cnn4ncccc34)n2)cc1		CHEMBL359963	=	Inhibition	%	1.14	CHEMBL5408	Homo sapiens	Inhibition	%	1.14
	8171242	CHEMBL1962004	GSK_PKIS: TBK1 mean inhibition at 0.1 uM [Nanosyn]	B	COc1cc(Nc2nccc(Nc3ccc4c(C)n[nH]c4c3)n2)cc(OC)c1OC		CHEMBL479079	=	Inhibition	%	4.57	CHEMBL5408	Homo sapiens	Inhibition	%	4.57
	8171459	CHEMBL1962005	GSK_PKIS: TBK1 mean inhibition at 1 uM [Nanosyn]	B	CCn1c(-c2nonc2N)nc2cnc(Oc3cccc(NC(=O)c4ccc(OCCN5CCOCC5)cc4)c3)cc21.Cl		CHEMBL1909363	=	Inhibition	%	7.42	CHEMBL5408	Homo sapiens	Inhibition	%	7.42
	8171824	CHEMBL1962005	GSK_PKIS: TBK1 mean inhibition at 1 uM [Nanosyn]	B	COc1cc2c(cc1Nc1nc(Nc3ccsc3C(N)=O)c3cc[nH]c3n1)N(C(=O)CN(C)C)CCC2(C)C		CHEMBL463931	=	Inhibition	%	50.71	CHEMBL5408	Homo sapiens	Inhibition	%	50.71
	8171977	CHEMBL1962004	GSK_PKIS: TBK1 mean inhibition at 0.1 uM [Nanosyn]	B	COc1cccc(-n2ncc3c(N/N=C/c4cccc(F)c4)ncnc32)c1		CHEMBL69757	=	Inhibition	%	1.92	CHEMBL5408	Homo sapiens	Inhibition	%	1.92
	8172333	CHEMBL1962004	GSK_PKIS: TBK1 mean inhibition at 0.1 uM [Nanosyn]	B	O=C1Nc2ccccc2/C1=C/Nc1ccc2[nH]c(=O)[nH]c2c1		CHEMBL1794057	=	Inhibition	%	8.2	CHEMBL5408	Homo sapiens	Inhibition	%	8.2
	8172461	CHEMBL1962005	GSK_PKIS: TBK1 mean inhibition at 1 uM [Nanosyn]	B	CC1=C(C(=O)Nc2ccc3[nH]ncc3c2)C(c2ccc(F)cc2)NC(=O)N1		CHEMBL384073	=	Inhibition	%	3.11	CHEMBL5408	Homo sapiens	Inhibition	%	3.11
	8172685	CHEMBL1962004	GSK_PKIS: TBK1 mean inhibition at 0.1 uM [Nanosyn]	B	c1ccc(-c2n[nH]cc2-c2ccnc(-c3ccc(OCCn4ccnc4)cc3)c2)nc1		CHEMBL208437	=	Inhibition	%	0.6	CHEMBL5408	Homo sapiens	Inhibition	%	0.6
	8172827	CHEMBL1962005	GSK_PKIS: TBK1 mean inhibition at 1 uM [Nanosyn]	B	NC(=O)c1ccc2c(-c3ccnc(NCCCO)n3)c(-c3ccc(F)cc3)nn2c1		CHEMBL1909404	=	Inhibition	%	4.69	CHEMBL5408	Homo sapiens	Inhibition	%	4.69
	8173187	CHEMBL1962005	GSK_PKIS: TBK1 mean inhibition at 1 uM [Nanosyn]	B	NS(=O)(=O)c1cccc(-c2ccc3c(NC(=O)C4CC4)n[nH]c3c2)c1		CHEMBL407113	=	Inhibition	%	0.44	CHEMBL5408	Homo sapiens	Inhibition	%	0.44
	8173352	CHEMBL1962004	GSK_PKIS: TBK1 mean inhibition at 0.1 uM [Nanosyn]	B	COc1cccc(-n2ncc3c(N/N=C/c4ccncc4)ncnc32)c1		CHEMBL306865	=	Inhibition	%	3.12	CHEMBL5408	Homo sapiens	Inhibition	%	3.12
	8173717	CHEMBL1962004	GSK_PKIS: TBK1 mean inhibition at 0.1 uM [Nanosyn]	B	Cl.O=C1Nc2ccc(-c3cccnc3)cc2C1=Cc1cc(Br)c(O)c(Br)c1		CHEMBL1794050	=	Inhibition	%	3.66	CHEMBL5408	Homo sapiens	Inhibition	%	3.66
	8174028	CHEMBL1962005	GSK_PKIS: TBK1 mean inhibition at 1 uM [Nanosyn]	B	NS(=O)(=O)c1ccc(N/N=C2\C(=O)Nc3ccc(C(=O)NCCc4c[nH]cn4)cc32)cc1		CHEMBL272028	=	Inhibition	%	26.79	CHEMBL5408	Homo sapiens	Inhibition	%	26.79
	8174160	CHEMBL1962004	GSK_PKIS: TBK1 mean inhibition at 0.1 uM [Nanosyn]	B	COC(=O)c1cncc(/C=C/c2c(C)cc(O)cc2C)c1		CHEMBL220243	=	Inhibition	%	1.26	CHEMBL5408	Homo sapiens	Inhibition	%	1.26
	8174532	CHEMBL1962004	GSK_PKIS: TBK1 mean inhibition at 0.1 uM [Nanosyn]	B	O=C(NCC1CC1)c1ccc(-c2cccc(C(=O)NC3CC3)c2)cc1		CHEMBL479038	=	Inhibition	%	2.28	CHEMBL5408	Homo sapiens	Inhibition	%	2.28
	8174654	CHEMBL1962005	GSK_PKIS: TBK1 mean inhibition at 1 uM [Nanosyn]	B	Cc1cccc2c1NC(=O)/C2=N\Nc1ccc(S(N)(=O)=O)cc1		CHEMBL1909398	=	Inhibition	%	3.42	CHEMBL5408	Homo sapiens	Inhibition	%	3.42
	8174878	CHEMBL1962004	GSK_PKIS: TBK1 mean inhibition at 0.1 uM [Nanosyn]	B	CCNC(=O)O[C@H]1CN[C@H](C#Cc2cc3ncnc(Nc4ccc(OCc5cccc(F)c5)c(Cl)c4)c3s2)C1		CHEMBL512076	=	Inhibition	%	1.48	CHEMBL5408	Homo sapiens	Inhibition	%	1.48
	8175021	CHEMBL1962005	GSK_PKIS: TBK1 mean inhibition at 1 uM [Nanosyn]	B	CCn1c(-c2nonc2N)nc2c(C#CC(C)(C)O)ncc(OCC3CCNCC3)c21.O=C(O)C(F)(F)F		CHEMBL1794065	=	Inhibition	%	44.66	CHEMBL5408	Homo sapiens	Inhibition	%	44.66
	8175381	CHEMBL1962005	GSK_PKIS: TBK1 mean inhibition at 1 uM [Nanosyn]	B	CC(C)c1ccc(Nc2nccc(-c3cnn4ncccc34)n2)cc1		CHEMBL359963	=	Inhibition	%	13.88	CHEMBL5408	Homo sapiens	Inhibition	%	13.88
	8175637	CHEMBL1962005	GSK_PKIS: TBK1 mean inhibition at 1 uM [Nanosyn]	B	O=C1Nc2ccccc2/C1=C/Nc1ccc(-n2cncn2)cc1		CHEMBL1794056	=	Inhibition	%	17.26	CHEMBL5408	Homo sapiens	Inhibition	%	17.26
	8175800	CHEMBL1962004	GSK_PKIS: TBK1 mean inhibition at 0.1 uM [Nanosyn]	B	Cc1nn(C)c2cc(N(C)c3ccnc(Nc4cccc(S(N)(=O)=O)c4)n3)ccc12.Cl		CHEMBL1794073	=	Inhibition	%	2.88	CHEMBL5408	Homo sapiens	Inhibition	%	2.88
	8176177	CHEMBL1962004	GSK_PKIS: TBK1 mean inhibition at 0.1 uM [Nanosyn]	B	NCc1ccc(-n2c(-c3nonc3N)nc3cnccc32)cc1		CHEMBL188268	=	Inhibition	%	4.35	CHEMBL5408	Homo sapiens	Inhibition	%	4.35
	8176326	CHEMBL1962005	GSK_PKIS: TBK1 mean inhibition at 1 uM [Nanosyn]	B	COc1cccc(-n2ncc3c(N/N=C/c4cccc(F)c4)ncnc32)c1		CHEMBL69757	=	Inhibition	%	5.66	CHEMBL5408	Homo sapiens	Inhibition	%	5.66
	8176550	CHEMBL1962004	GSK_PKIS: TBK1 mean inhibition at 0.1 uM [Nanosyn]	B	CN(C)c1ccc2c(c1)/C(=C/Nc1ccc(S(N)(=O)=O)cc1)C(=O)N2		CHEMBL272414	=	Inhibition	%	6.65	CHEMBL5408	Homo sapiens	Inhibition	%	6.65
	8176682	CHEMBL1962005	GSK_PKIS: TBK1 mean inhibition at 1 uM [Nanosyn]	B	O=C1Nc2ccccc2/C1=C/Nc1ccc2[nH]c(=O)[nH]c2c1		CHEMBL1794057	=	Inhibition	%	21.19	CHEMBL5408	Homo sapiens	Inhibition	%	21.19
	8177036	CHEMBL1962005	GSK_PKIS: TBK1 mean inhibition at 1 uM [Nanosyn]	B	c1ccc(-c2n[nH]cc2-c2ccnc(-c3ccc(OCCn4ccnc4)cc3)c2)nc1		CHEMBL208437	=	Inhibition	%	0.29	CHEMBL5408	Homo sapiens	Inhibition	%	0.29
	8177178	CHEMBL1962004	GSK_PKIS: TBK1 mean inhibition at 0.1 uM [Nanosyn]	B	Cc1cc(O)cc(C)c1/C=C/c1cncc(-c2nn[nH]n2)c1.Cl		CHEMBL1909352	=	Inhibition	%	1.57	CHEMBL5408	Homo sapiens	Inhibition	%	1.57
	8177540	CHEMBL1962004	GSK_PKIS: TBK1 mean inhibition at 0.1 uM [Nanosyn]	B	COc1ccc2[nH]c3c4[nH]c5ccc(OC)cc5c4c4c(c3c2c1)C(=O)NC4=O		CHEMBL1956068	=	Inhibition	%	10.86	CHEMBL5408	Homo sapiens	Inhibition	%	10.86
	8177704	CHEMBL1962005	GSK_PKIS: TBK1 mean inhibition at 1 uM [Nanosyn]	B	COc1cccc(-n2ncc3c(N/N=C/c4ccncc4)ncnc32)c1		CHEMBL306865	=	Inhibition	%	13.1	CHEMBL5408	Homo sapiens	Inhibition	%	13.1
	8177928	CHEMBL1962004	GSK_PKIS: TBK1 mean inhibition at 0.1 uM [Nanosyn]	B	Nc1nc(-c2ccc(F)cc2)c(-c2ccc3ncccc3n2)s1		CHEMBL361237	=	Inhibition	%	3.41	CHEMBL5408	Homo sapiens	Inhibition	%	3.41
	8178068	CHEMBL1962005	GSK_PKIS: TBK1 mean inhibition at 1 uM [Nanosyn]	B	Cl.O=C1Nc2ccc(-c3cccnc3)cc2C1=Cc1cc(Br)c(O)c(Br)c1		CHEMBL1794050	=	Inhibition	%	7.51	CHEMBL5408	Homo sapiens	Inhibition	%	7.51
	8178380	CHEMBL1962004	GSK_PKIS: TBK1 mean inhibition at 0.1 uM [Nanosyn]	B	CN(C)C(=O)O[C@H]1CN[C@H](C#Cc2cc3ncnc(Nc4ccc(OCc5cccc(F)c5)c(Cl)c4)c3s2)C1		CHEMBL517123	=	Inhibition	%	-0.37	CHEMBL5408	Homo sapiens	Inhibition	%	-0.37
	8178507	CHEMBL1962005	GSK_PKIS: TBK1 mean inhibition at 1 uM [Nanosyn]	B	COC(=O)c1cncc(/C=C/c2c(C)cc(O)cc2C)c1		CHEMBL220243	=	Inhibition	%	3.98	CHEMBL5408	Homo sapiens	Inhibition	%	3.98
	8178731	CHEMBL1962004	GSK_PKIS: TBK1 mean inhibition at 0.1 uM [Nanosyn]	B	COc1cccc(-n2ncc3c(N/N=C/c4ccc(F)cc4)ncnc32)c1		CHEMBL65884	=	Inhibition	%	2.42	CHEMBL5408	Homo sapiens	Inhibition	%	2.42
	8178880	CHEMBL1962005	GSK_PKIS: TBK1 mean inhibition at 1 uM [Nanosyn]	B	O=C(NCC1CC1)c1ccc(-c2cccc(C(=O)NC3CC3)c2)cc1		CHEMBL479038	=	Inhibition	%	0.69	CHEMBL5408	Homo sapiens	Inhibition	%	0.69
	8179227	CHEMBL1962005	GSK_PKIS: TBK1 mean inhibition at 1 uM [Nanosyn]	B	CCNC(=O)O[C@H]1CN[C@H](C#Cc2cc3ncnc(Nc4ccc(OCc5cccc(F)c5)c(Cl)c4)c3s2)C1		CHEMBL512076	=	Inhibition	%	3.67	CHEMBL5408	Homo sapiens	Inhibition	%	3.67
	8179371	CHEMBL1962004	GSK_PKIS: TBK1 mean inhibition at 0.1 uM [Nanosyn]	B	NS(=O)(=O)c1ccc(N/N=C2\C(=O)Nc3ccc(C(=O)NCc4ccncc4)cc32)cc1		CHEMBL272165	=	Inhibition	%	3.83	CHEMBL5408	Homo sapiens	Inhibition	%	3.83
	8179732	CHEMBL1962004	GSK_PKIS: TBK1 mean inhibition at 0.1 uM [Nanosyn]	B	CCCN(CCS(C)(=O)=O)Cc1ccc(-c2ccc3ncnc(Nc4ccc(OCc5cccc(F)c5)c(Cl)c4)c3c2)o1.Cl		CHEMBL1909394	=	Inhibition	%	2.46	CHEMBL5408	Homo sapiens	Inhibition	%	2.46
	8179989	CHEMBL1962004	GSK_PKIS: TBK1 mean inhibition at 0.1 uM [Nanosyn]	B	CN1CCC(C(=O)Nc2n[nH]c3nnc(-c4ccccc4)cc23)CC1.Cl		CHEMBL1909344	=	Inhibition	%	2.09	CHEMBL5408	Homo sapiens	Inhibition	%	2.09
	8180143	CHEMBL1962005	GSK_PKIS: TBK1 mean inhibition at 1 uM [Nanosyn]	B	Cc1nn(C)c2cc(N(C)c3ccnc(Nc4cccc(S(N)(=O)=O)c4)n3)ccc12.Cl		CHEMBL1794073	=	Inhibition	%	10.3	CHEMBL5408	Homo sapiens	Inhibition	%	10.3
	8180367	CHEMBL1962004	GSK_PKIS: TBK1 mean inhibition at 0.1 uM [Nanosyn]	B	Cl.Fc1cccc(COc2ccc(Nc3ncnc4cc(-c5ccc[nH]5)sc34)cc2Cl)c1		CHEMBL1909415	=	Inhibition	%	2.35	CHEMBL5408	Homo sapiens	Inhibition	%	2.35
	8180523	CHEMBL1962005	GSK_PKIS: TBK1 mean inhibition at 1 uM [Nanosyn]	B	NCc1ccc(-n2c(-c3nonc3N)nc3cnccc32)cc1		CHEMBL188268	=	Inhibition	%	11.6	CHEMBL5408	Homo sapiens	Inhibition	%	11.6
	8180895	CHEMBL1962005	GSK_PKIS: TBK1 mean inhibition at 1 uM [Nanosyn]	B	CN(C)c1ccc2c(c1)/C(=C/Nc1ccc(S(N)(=O)=O)cc1)C(=O)N2		CHEMBL272414	=	Inhibition	%	49.74	CHEMBL5408	Homo sapiens	Inhibition	%	49.74
	8181028	CHEMBL1962004	GSK_PKIS: TBK1 mean inhibition at 0.1 uM [Nanosyn]	B	Cc1ccc(O)cc1Nc1ccnc2ccc(S(C)(=O)=O)cc12		CHEMBL237347	=	Inhibition	%	2.4	CHEMBL5408	Homo sapiens	Inhibition	%	2.4
	8181383	CHEMBL1962004	GSK_PKIS: TBK1 mean inhibition at 0.1 uM [Nanosyn]	B	C/C(Nc1ccc(S(N)(=O)=O)cc1)=C1/C(=O)Nc2ccccc21		CHEMBL405042	=	Inhibition	%	0.77	CHEMBL5408	Homo sapiens	Inhibition	%	0.77
	8181523	CHEMBL1962005	GSK_PKIS: TBK1 mean inhibition at 1 uM [Nanosyn]	B	Cc1cc(O)cc(C)c1/C=C/c1cncc(-c2nn[nH]n2)c1.Cl		CHEMBL1909352	=	Inhibition	%	5.41	CHEMBL5408	Homo sapiens	Inhibition	%	5.41
	8181747	CHEMBL1962004	GSK_PKIS: TBK1 mean inhibition at 0.1 uM [Nanosyn]	B	O=C(Nc1n[nH]c2cc(-c3ccccc3)ccc12)C1CC1		CHEMBL405021	=	Inhibition	%	1.84	CHEMBL5408	Homo sapiens	Inhibition	%	1.84
	8181886	CHEMBL1962005	GSK_PKIS: TBK1 mean inhibition at 1 uM [Nanosyn]	B	COc1ccc2[nH]c3c4[nH]c5ccc(OC)cc5c4c4c(c3c2c1)C(=O)NC4=O		CHEMBL1956068	=	Inhibition	%	53.91	CHEMBL5408	Homo sapiens	Inhibition	%	53.91
	8182273	CHEMBL1962005	GSK_PKIS: TBK1 mean inhibition at 1 uM [Nanosyn]	B	Nc1nc(-c2ccc(F)cc2)c(-c2ccc3ncccc3n2)s1		CHEMBL361237	=	Inhibition	%	6.6	CHEMBL5408	Homo sapiens	Inhibition	%	6.6
	8182413	CHEMBL1962004	GSK_PKIS: TBK1 mean inhibition at 0.1 uM [Nanosyn]	B	Fc1ccc(Nc2nccc(-c3c(-c4ccc(C(F)(F)F)cc4)nn4ncccc34)n2)cc1F		CHEMBL188784	=	Inhibition	%	-0.07	CHEMBL5408	Homo sapiens	Inhibition	%	-0.07
	8182729	CHEMBL1962005	GSK_PKIS: TBK1 mean inhibition at 1 uM [Nanosyn]	B	CN(C)C(=O)O[C@H]1CN[C@H](C#Cc2cc3ncnc(Nc4ccc(OCc5cccc(F)c5)c(Cl)c4)c3s2)C1		CHEMBL517123	=	Inhibition	%	4.42	CHEMBL5408	Homo sapiens	Inhibition	%	4.42
	8183075	CHEMBL1962005	GSK_PKIS: TBK1 mean inhibition at 1 uM [Nanosyn]	B	COc1cccc(-n2ncc3c(N/N=C/c4ccc(F)cc4)ncnc32)c1		CHEMBL65884	=	Inhibition	%	6.85	CHEMBL5408	Homo sapiens	Inhibition	%	6.85
	8183224	CHEMBL1962004	GSK_PKIS: TBK1 mean inhibition at 0.1 uM [Nanosyn]	B	CCS(=O)(=O)c1ccc(OC)c(Nc2ncc(-c3cccc(OC)c3)o2)c1		CHEMBL179311	=	Inhibition	%	0.69	CHEMBL5408	Homo sapiens	Inhibition	%	0.69
	8183577	CHEMBL1962004	GSK_PKIS: TBK1 mean inhibition at 0.1 uM [Nanosyn]	B	FC(F)(F)c1ccc(-c2nn3ncccc3c2-c2ccnc(Nc3ccc4c(c3)OCCO4)n2)cc1		CHEMBL185939	=	Inhibition	%	5.62	CHEMBL5408	Homo sapiens	Inhibition	%	5.62
	8183719	CHEMBL1962005	GSK_PKIS: TBK1 mean inhibition at 1 uM [Nanosyn]	B	NS(=O)(=O)c1ccc(N/N=C2\C(=O)Nc3ccc(C(=O)NCc4ccncc4)cc32)cc1		CHEMBL272165	=	Inhibition	%	43.96	CHEMBL5408	Homo sapiens	Inhibition	%	43.96
	8183943	CHEMBL1962004	GSK_PKIS: TBK1 mean inhibition at 0.1 uM [Nanosyn]	B	NS(=O)(=O)c1ccc(N/N=C2\C(=O)Nc3ccc(Cl)cc32)cc1		CHEMBL270054	=	Inhibition	%	2.27	CHEMBL5408	Homo sapiens	Inhibition	%	2.27
	8184079	CHEMBL1962005	GSK_PKIS: TBK1 mean inhibition at 1 uM [Nanosyn]	B	CCCN(CCS(C)(=O)=O)Cc1ccc(-c2ccc3ncnc(Nc4ccc(OCc5cccc(F)c5)c(Cl)c4)c3c2)o1.Cl		CHEMBL1909394	=	Inhibition	%	5.16	CHEMBL5408	Homo sapiens	Inhibition	%	5.16
	8184345	CHEMBL1962005	GSK_PKIS: TBK1 mean inhibition at 1 uM [Nanosyn]	B	CN1CCC(C(=O)Nc2n[nH]c3nnc(-c4ccccc4)cc23)CC1.Cl		CHEMBL1909344	=	Inhibition	%	3.05	CHEMBL5408	Homo sapiens	Inhibition	%	3.05
	8184716	CHEMBL1962005	GSK_PKIS: TBK1 mean inhibition at 1 uM [Nanosyn]	B	Cl.Fc1cccc(COc2ccc(Nc3ncnc4cc(-c5ccc[nH]5)sc34)cc2Cl)c1		CHEMBL1909415	=	Inhibition	%	3.65	CHEMBL5408	Homo sapiens	Inhibition	%	3.65
	8184873	CHEMBL1962004	GSK_PKIS: TBK1 mean inhibition at 0.1 uM [Nanosyn]	B	Fc1ccc(-c2nn3ncccc3c2-c2ccnc(Nc3ccc4c(c3)OCCO4)n2)cc1		CHEMBL365297	=	Inhibition	%	5.89	CHEMBL5408	Homo sapiens	Inhibition	%	5.89
	8185246	CHEMBL1962004	GSK_PKIS: TBK1 mean inhibition at 0.1 uM [Nanosyn]	B	CC(=O)NCc1cccc(C#Cc2cncnc2Nc2ccc(OCc3cccc(F)c3)c(Cl)c2)c1		CHEMBL207247	=	Inhibition	%	-0.27	CHEMBL5408	Homo sapiens	Inhibition	%	-0.27
	8185377	CHEMBL1962005	GSK_PKIS: TBK1 mean inhibition at 1 uM [Nanosyn]	B	Cc1ccc(O)cc1Nc1ccnc2ccc(S(C)(=O)=O)cc12		CHEMBL237347	=	Inhibition	%	9.14	CHEMBL5408	Homo sapiens	Inhibition	%	9.14
	8185601	CHEMBL1962004	GSK_PKIS: TBK1 mean inhibition at 0.1 uM [Nanosyn]	B	C#Cc1cccc(Nc2ncnc3ccc(OCCCCNCCS(C)(=O)=O)cc23)c1		CHEMBL517907	=	Inhibition	%	1.72	CHEMBL5408	Homo sapiens	Inhibition	%	1.72
	8185732	CHEMBL1962005	GSK_PKIS: TBK1 mean inhibition at 1 uM [Nanosyn]	B	C/C(Nc1ccc(S(N)(=O)=O)cc1)=C1/C(=O)Nc2ccccc21		CHEMBL405042	=	Inhibition	%	4.75	CHEMBL5408	Homo sapiens	Inhibition	%	4.75
	8186095	CHEMBL1962005	GSK_PKIS: TBK1 mean inhibition at 1 uM [Nanosyn]	B	O=C(Nc1n[nH]c2cc(-c3ccccc3)ccc12)C1CC1		CHEMBL405021	=	Inhibition	%	8.06	CHEMBL5408	Homo sapiens	Inhibition	%	8.06
	8186236	CHEMBL1962004	GSK_PKIS: TBK1 mean inhibition at 0.1 uM [Nanosyn]	B	COc1ccc(-c2nn3ncccc3c2-c2ccnc(Nc3ccc(F)c(F)c3)n2)cc1		CHEMBL427159	=	Inhibition	%	-2.71	CHEMBL5408	Homo sapiens	Inhibition	%	-2.71
	8186460	CHEMBL1962005	GSK_PKIS: TBK1 mean inhibition at 1 uM [Nanosyn]	B	COc1ccc(-c2nn3ncccc3c2-c2ccnc(Nc3ccc(F)c(F)c3)n2)cc1		CHEMBL427159	=	Inhibition	%	5.55	CHEMBL5408	Homo sapiens	Inhibition	%	5.55
	8186624	CHEMBL1962004	GSK_PKIS: TBK1 mean inhibition at 0.1 uM [Nanosyn]	B	COc1ccc(C2=C(N3CCc4ccccc43)C(=O)NC2=O)cc1		CHEMBL347580	=	Inhibition	%	0.88	CHEMBL5408	Homo sapiens	Inhibition	%	0.88
	8186763	CHEMBL1962005	GSK_PKIS: TBK1 mean inhibition at 1 uM [Nanosyn]	B	Fc1ccc(Nc2nccc(-c3c(-c4ccc(C(F)(F)F)cc4)nn4ncccc34)n2)cc1F		CHEMBL188784	=	Inhibition	%	5.12	CHEMBL5408	Homo sapiens	Inhibition	%	5.12
	8186987	CHEMBL1962004	GSK_PKIS: TBK1 mean inhibition at 0.1 uM [Nanosyn]	B	CN(C)CCNC(=O)Nc1ccc(N(C)c2ccnc(Nc3ccc(CS(C)(=O)=O)cc3)n2)cc1.Cl		CHEMBL1909362	=	Inhibition	%	2.12	CHEMBL5408	Homo sapiens	Inhibition	%	2.12
	8187085	CHEMBL1962004	GSK_PKIS: TBK1 mean inhibition at 0.1 uM [Nanosyn]	B	Cc1cc(O)cc(C)c1/C=C/c1cncc(C(N)=O)c1		CHEMBL218088	=	Inhibition	%	2.21	CHEMBL5408	Homo sapiens	Inhibition	%	2.21
	8187433	CHEMBL1962004	GSK_PKIS: TBK1 mean inhibition at 0.1 uM [Nanosyn]	B	COc1ccc2c(-c3ccnc(Nc4cccc(OC(F)(F)F)c4)n3)cnn2n1		CHEMBL365248	=	Inhibition	%	7.22	CHEMBL5408	Homo sapiens	Inhibition	%	7.22
	8187581	CHEMBL1962005	GSK_PKIS: TBK1 mean inhibition at 1 uM [Nanosyn]	B	CCS(=O)(=O)c1ccc(OC)c(Nc2ncc(-c3cccc(OC)c3)o2)c1		CHEMBL179311	=	Inhibition	%	9.22	CHEMBL5408	Homo sapiens	Inhibition	%	9.22
	8187805	CHEMBL1962004	GSK_PKIS: TBK1 mean inhibition at 0.1 uM [Nanosyn]	B	CCc1cccc(CC)c1/C=C/c1cncc(C(=O)NC)c1		CHEMBL385426	=	Inhibition	%	0.14	CHEMBL5408	Homo sapiens	Inhibition	%	0.14
	8187934	CHEMBL1962005	GSK_PKIS: TBK1 mean inhibition at 1 uM [Nanosyn]	B	FC(F)(F)c1ccc(-c2nn3ncccc3c2-c2ccnc(Nc3ccc4c(c3)OCCO4)n2)cc1		CHEMBL185939	=	Inhibition	%	4.67	CHEMBL5408	Homo sapiens	Inhibition	%	4.67
	8188301	CHEMBL1962005	GSK_PKIS: TBK1 mean inhibition at 1 uM [Nanosyn]	B	NS(=O)(=O)c1ccc(N/N=C2\C(=O)Nc3ccc(Cl)cc32)cc1		CHEMBL270054	=	Inhibition	%	9.93	CHEMBL5408	Homo sapiens	Inhibition	%	9.93
	8188436	CHEMBL1962004	GSK_PKIS: TBK1 mean inhibition at 0.1 uM [Nanosyn]	B	COc1cccc(-n2ncc3c(N/N=C/c4ccc(S(C)(=O)=O)cc4)ncnc32)c1		CHEMBL66292	=	Inhibition	%	8.06	CHEMBL5408	Homo sapiens	Inhibition	%	8.06
	8188660	CHEMBL1962005	GSK_PKIS: TBK1 mean inhibition at 1 uM [Nanosyn]	B	COc1cccc(-n2ncc3c(N/N=C/c4ccc(S(C)(=O)=O)cc4)ncnc32)c1		CHEMBL66292	=	Inhibition	%	7.99	CHEMBL5408	Homo sapiens	Inhibition	%	7.99
	8188710	CHEMBL1962004	GSK_PKIS: TBK1 mean inhibition at 0.1 uM [Nanosyn]	B	CN1CCN(Cc2ccc(-c3cc4ncnc(Nc5ccc(OCc6cccc(F)c6)c(Cl)c5)c4s3)o2)CC1		CHEMBL475761	=	Inhibition	%	5.0	CHEMBL5408	Homo sapiens	Inhibition	%	5.0
	8188934	CHEMBL1962005	GSK_PKIS: TBK1 mean inhibition at 1 uM [Nanosyn]	B	CN1CCN(Cc2ccc(-c3cc4ncnc(Nc5ccc(OCc6cccc(F)c6)c(Cl)c5)c4s3)o2)CC1		CHEMBL475761	=	Inhibition	%	4.14	CHEMBL5408	Homo sapiens	Inhibition	%	4.14
	8189082	CHEMBL1962004	GSK_PKIS: TBK1 mean inhibition at 0.1 uM [Nanosyn]	B	COc1cc(/C=N/Nc2ncnc3c2cnn3C(C)C)ccc1O		CHEMBL63728	=	Inhibition	%	2.37	CHEMBL5408	Homo sapiens	Inhibition	%	2.37
	8189238	CHEMBL1962005	GSK_PKIS: TBK1 mean inhibition at 1 uM [Nanosyn]	B	Fc1ccc(-c2nn3ncccc3c2-c2ccnc(Nc3ccc4c(c3)OCCO4)n2)cc1		CHEMBL365297	=	Inhibition	%	4.55	CHEMBL5408	Homo sapiens	Inhibition	%	4.55
	8189462	CHEMBL1962004	GSK_PKIS: TBK1 mean inhibition at 0.1 uM [Nanosyn]	B	NS(=O)(=O)c1cccc(N/C=C2\C(=O)Nc3ccccc32)c1		CHEMBL1794059	=	Inhibition	%	3.79	CHEMBL5408	Homo sapiens	Inhibition	%	3.79
	8189611	CHEMBL1962005	GSK_PKIS: TBK1 mean inhibition at 1 uM [Nanosyn]	B	CC(=O)NCc1cccc(C#Cc2cncnc2Nc2ccc(OCc3cccc(F)c3)c(Cl)c2)c1		CHEMBL207247	=	Inhibition	%	4.8	CHEMBL5408	Homo sapiens	Inhibition	%	4.8
	8189967	CHEMBL1962005	GSK_PKIS: TBK1 mean inhibition at 1 uM [Nanosyn]	B	C#Cc1cccc(Nc2ncnc3ccc(OCCCCNCCS(C)(=O)=O)cc23)c1		CHEMBL517907	=	Inhibition	%	8.32	CHEMBL5408	Homo sapiens	Inhibition	%	8.32
	8190099	CHEMBL1962004	GSK_PKIS: TBK1 mean inhibition at 0.1 uM [Nanosyn]	B	COc1ccccc1-c1cc(/C=C2\C(=O)Nc3ncc(Br)cc32)cc(Br)c1O		CHEMBL176857	=	Inhibition	%	0.53	CHEMBL5408	Homo sapiens	Inhibition	%	0.53
	8190323	CHEMBL1962005	GSK_PKIS: TBK1 mean inhibition at 1 uM [Nanosyn]	B	COc1ccccc1-c1cc(/C=C2\C(=O)Nc3ncc(Br)cc32)cc(Br)c1O		CHEMBL176857	=	Inhibition	%	6.07	CHEMBL5408	Homo sapiens	Inhibition	%	6.07
	8190463	CHEMBL1962004	GSK_PKIS: TBK1 mean inhibition at 0.1 uM [Nanosyn]	B	NC(=O)c1cc(-c2ccncc2)cc(-c2ccccc2)c1N		CHEMBL230911	=	Inhibition	%	3.5	CHEMBL5408	Homo sapiens	Inhibition	%	3.5
	8190824	CHEMBL1962004	GSK_PKIS: TBK1 mean inhibition at 0.1 uM [Nanosyn]	B	CN1CCC(n2cnc(-c3ccc(F)cc3)c2-c2ccnc(NCCO)n2)CC1		CHEMBL330422	=	Inhibition	%	-0.04	CHEMBL5408	Homo sapiens	Inhibition	%	-0.04
	8190988	CHEMBL1962005	GSK_PKIS: TBK1 mean inhibition at 1 uM [Nanosyn]	B	COc1ccc(C2=C(N3CCc4ccccc43)C(=O)NC2=O)cc1		CHEMBL347580	=	Inhibition	%	7.18	CHEMBL5408	Homo sapiens	Inhibition	%	7.18
	8191350	CHEMBL1962005	GSK_PKIS: TBK1 mean inhibition at 1 uM [Nanosyn]	B	CN(C)CCNC(=O)Nc1ccc(N(C)c2ccnc(Nc3ccc(CS(C)(=O)=O)cc3)n2)cc1.Cl		CHEMBL1909362	=	Inhibition	%	5.74	CHEMBL5408	Homo sapiens	Inhibition	%	5.74
	8191446	CHEMBL1962005	GSK_PKIS: TBK1 mean inhibition at 1 uM [Nanosyn]	B	Cc1cc(O)cc(C)c1/C=C/c1cncc(C(N)=O)c1		CHEMBL218088	=	Inhibition	%	1.71	CHEMBL5408	Homo sapiens	Inhibition	%	1.71
	8191670	CHEMBL1962004	GSK_PKIS: TBK1 mean inhibition at 0.1 uM [Nanosyn]	B	CC1=C(C(=O)Nc2ccc3[nH]ncc3c2)C(c2ccc(F)cc2)N=C(c2ccc(C(F)(F)F)nc2)N1		CHEMBL485598	=	Inhibition	%	-0.16	CHEMBL5408	Homo sapiens	Inhibition	%	-0.16
	8191792	CHEMBL1962005	GSK_PKIS: TBK1 mean inhibition at 1 uM [Nanosyn]	B	COc1ccc2c(-c3ccnc(Nc4cccc(OC(F)(F)F)c4)n3)cnn2n1		CHEMBL365248	=	Inhibition	%	31.55	CHEMBL5408	Homo sapiens	Inhibition	%	31.55
	8192165	CHEMBL1962005	GSK_PKIS: TBK1 mean inhibition at 1 uM [Nanosyn]	B	CCc1cccc(CC)c1/C=C/c1cncc(C(=O)NC)c1		CHEMBL385426	=	Inhibition	%	1.52	CHEMBL5408	Homo sapiens	Inhibition	%	1.52
	8192294	CHEMBL1962004	GSK_PKIS: TBK1 mean inhibition at 0.1 uM [Nanosyn]	B	COc1ccc(CNC(=O)c2ccc(-c3cc(-c4nnc(C)o4)ccc3C)cc2)cc1		CHEMBL269985	=	Inhibition	%	2.25	CHEMBL5408	Homo sapiens	Inhibition	%	2.25
	8192518	CHEMBL1962005	GSK_PKIS: TBK1 mean inhibition at 1 uM [Nanosyn]	B	COc1ccc(CNC(=O)c2ccc(-c3cc(-c4nnc(C)o4)ccc3C)cc2)cc1		CHEMBL269985	=	Inhibition	%	4.66	CHEMBL5408	Homo sapiens	Inhibition	%	4.66
	8192662	CHEMBL1962004	GSK_PKIS: TBK1 mean inhibition at 0.1 uM [Nanosyn]	B	CNC(=O)c1cncc(/C=C/c2ccccc2C)c1		CHEMBL218969	=	Inhibition	%	2.9	CHEMBL5408	Homo sapiens	Inhibition	%	2.9
	8193022	CHEMBL1962004	GSK_PKIS: TBK1 mean inhibition at 0.1 uM [Nanosyn]	B	CCOc1ccc2c(-c3ccnc(Nc4cc(OC)cc(C(F)(F)F)c4)n3)cnn2n1		CHEMBL188426	=	Inhibition	%	-0.57	CHEMBL5408	Homo sapiens	Inhibition	%	-0.57
	8193294	CHEMBL1962004	GSK_PKIS: TBK1 mean inhibition at 0.1 uM [Nanosyn]	B	NC(=O)c1cc(-c2ccc(F)cc2)cc(-c2ccncc2)c1N		CHEMBL231623	=	Inhibition	%	3.66	CHEMBL5408	Homo sapiens	Inhibition	%	3.66
	8193439	CHEMBL1962005	GSK_PKIS: TBK1 mean inhibition at 1 uM [Nanosyn]	B	COc1cc(/C=N/Nc2ncnc3c2cnn3C(C)C)ccc1O		CHEMBL63728	=	Inhibition	%	6.12	CHEMBL5408	Homo sapiens	Inhibition	%	6.12
	8193820	CHEMBL1962005	GSK_PKIS: TBK1 mean inhibition at 1 uM [Nanosyn]	B	NS(=O)(=O)c1cccc(N/C=C2\C(=O)Nc3ccccc32)c1		CHEMBL1794059	=	Inhibition	%	14.44	CHEMBL5408	Homo sapiens	Inhibition	%	14.44
	8193969	CHEMBL1962004	GSK_PKIS: TBK1 mean inhibition at 0.1 uM [Nanosyn]	B	CCn1c(-c2nonc2N)nc2c(N3CCCC3)nccc21		CHEMBL187985	=	Inhibition	%	-0.24	CHEMBL5408	Homo sapiens	Inhibition	%	-0.24
	8194324	CHEMBL1962004	GSK_PKIS: TBK1 mean inhibition at 0.1 uM [Nanosyn]	B	COc1cc2ncnc(Nc3ccc(C)c(O)c3)c2cc1OC.Cl		CHEMBL1909357	=	Inhibition	%	1.88	CHEMBL5408	Homo sapiens	Inhibition	%	1.88
	8194679	CHEMBL1962004	GSK_PKIS: TBK1 mean inhibition at 0.1 uM [Nanosyn]	B	O=C1NC(=O)C(N2CCc3ccccc32)=C1c1ccc(Cl)cc1		CHEMBL156524	=	Inhibition	%	3.01	CHEMBL5408	Homo sapiens	Inhibition	%	3.01
	8194822	CHEMBL1962005	GSK_PKIS: TBK1 mean inhibition at 1 uM [Nanosyn]	B	NC(=O)c1cc(-c2ccncc2)cc(-c2ccccc2)c1N		CHEMBL230911	=	Inhibition	%	9.27	CHEMBL5408	Homo sapiens	Inhibition	%	9.27
	8195179	CHEMBL1962005	GSK_PKIS: TBK1 mean inhibition at 1 uM [Nanosyn]	B	CN1CCC(n2cnc(-c3ccc(F)cc3)c2-c2ccnc(NCCO)n2)CC1		CHEMBL330422	=	Inhibition	%	7.57	CHEMBL5408	Homo sapiens	Inhibition	%	7.57
	8195343	CHEMBL1962004	GSK_PKIS: TBK1 mean inhibition at 0.1 uM [Nanosyn]	B	O=C1Nc2ccc(C(=O)c3ccco3)cc2C1=Cc1cc(Cl)c(O)c(Cl)c1		CHEMBL1789963	=	Inhibition	%	4.59	CHEMBL5408	Homo sapiens	Inhibition	%	4.59
	8195706	CHEMBL1962004	GSK_PKIS: TBK1 mean inhibition at 0.1 uM [Nanosyn]	B	OCc1ccc(-c2nc(-c3ccccn3)c(-c3ccc4c(c3)OCO4)[nH]2)cc1		CHEMBL267228	=	Inhibition	%	2.36	CHEMBL5408	Homo sapiens	Inhibition	%	2.36
	8196028	CHEMBL1962005	GSK_PKIS: TBK1 mean inhibition at 1 uM [Nanosyn]	B	CC1=C(C(=O)Nc2ccc3[nH]ncc3c2)C(c2ccc(F)cc2)N=C(c2ccc(C(F)(F)F)nc2)N1		CHEMBL485598	=	Inhibition	%	2.03	CHEMBL5408	Homo sapiens	Inhibition	%	2.03
	8196145	CHEMBL1962004	GSK_PKIS: TBK1 mean inhibition at 0.1 uM [Nanosyn]	B	Cl.c1ccc(Cc2nc3ccc(Nc4ncnc5ccccc45)cc3[nH]2)cc1		CHEMBL1909379	=	Inhibition	%	3.57	CHEMBL5408	Homo sapiens	Inhibition	%	3.57
	8196369	CHEMBL1962005	GSK_PKIS: TBK1 mean inhibition at 1 uM [Nanosyn]	B	Cl.c1ccc(Cc2nc3ccc(Nc4ncnc5ccccc45)cc3[nH]2)cc1		CHEMBL1909379	=	Inhibition	%	5.54	CHEMBL5408	Homo sapiens	Inhibition	%	5.54
	8196519	CHEMBL1962004	GSK_PKIS: TBK1 mean inhibition at 0.1 uM [Nanosyn]	B	Cc1ccc2c(-c3ccnc(Nc4ccccc4)n3)c(-c3ccc(F)cc3)nn2n1		CHEMBL189459	=	Inhibition	%	1.85	CHEMBL5408	Homo sapiens	Inhibition	%	1.85
	8196871	CHEMBL1962004	GSK_PKIS: TBK1 mean inhibition at 0.1 uM [Nanosyn]	B	COc1cc2ncn(-c3cc(OCc4cccs4)c(C(N)=O)s3)c2cc1OC		CHEMBL480382	=	Inhibition	%	3.06	CHEMBL5408	Homo sapiens	Inhibition	%	3.06
	8197012	CHEMBL1962005	GSK_PKIS: TBK1 mean inhibition at 1 uM [Nanosyn]	B	CNC(=O)c1cncc(/C=C/c2ccccc2C)c1		CHEMBL218969	=	Inhibition	%	6.39	CHEMBL5408	Homo sapiens	Inhibition	%	6.39
	8197373	CHEMBL1962005	GSK_PKIS: TBK1 mean inhibition at 1 uM [Nanosyn]	B	CCOc1ccc2c(-c3ccnc(Nc4cc(OC)cc(C(F)(F)F)c4)n3)cnn2n1		CHEMBL188426	=	Inhibition	%	37.01	CHEMBL5408	Homo sapiens	Inhibition	%	37.01
	8197648	CHEMBL1962005	GSK_PKIS: TBK1 mean inhibition at 1 uM [Nanosyn]	B	NC(=O)c1cc(-c2ccc(F)cc2)cc(-c2ccncc2)c1N		CHEMBL231623	=	Inhibition	%	2.04	CHEMBL5408	Homo sapiens	Inhibition	%	2.04
	8197788	CHEMBL1962004	GSK_PKIS: TBK1 mean inhibition at 0.1 uM [Nanosyn]	B	COc1cc2ncn(-c3cc(OCc4ccccc4Cl)c(C(N)=O)s3)c2cc1OC		CHEMBL514162	=	Inhibition	%	3.64	CHEMBL5408	Homo sapiens	Inhibition	%	3.64
	8198012	CHEMBL1962005	GSK_PKIS: TBK1 mean inhibition at 1 uM [Nanosyn]	B	COc1cc2ncn(-c3cc(OCc4ccccc4Cl)c(C(N)=O)s3)c2cc1OC		CHEMBL514162	=	Inhibition	%	28.66	CHEMBL5408	Homo sapiens	Inhibition	%	28.66
	8198169	CHEMBL1962004	GSK_PKIS: TBK1 mean inhibition at 0.1 uM [Nanosyn]	B	Cl.Fc1ccc(-c2nc3n(c2-c2ccncc2)CCS3)cc1		CHEMBL1909406	=	Inhibition	%	2.27	CHEMBL5408	Homo sapiens	Inhibition	%	2.27
	8198307	CHEMBL1962005	GSK_PKIS: TBK1 mean inhibition at 1 uM [Nanosyn]	B	CCn1c(-c2nonc2N)nc2c(N3CCCC3)nccc21		CHEMBL187985	=	Inhibition	%	2.54	CHEMBL5408	Homo sapiens	Inhibition	%	2.54
	8198531	CHEMBL1962004	GSK_PKIS: TBK1 mean inhibition at 0.1 uM [Nanosyn]	B	Fc1ccc(-c2cc(-c3c[nH]nc3-c3ccccn3)ccn2)cc1		CHEMBL381948	=	Inhibition	%	0.43	CHEMBL5408	Homo sapiens	Inhibition	%	0.43
	8198661	CHEMBL1962005	GSK_PKIS: TBK1 mean inhibition at 1 uM [Nanosyn]	B	COc1cc2ncnc(Nc3ccc(C)c(O)c3)c2cc1OC.Cl		CHEMBL1909357	=	Inhibition	%	5.95	CHEMBL5408	Homo sapiens	Inhibition	%	5.95
	8199016	CHEMBL1962005	GSK_PKIS: TBK1 mean inhibition at 1 uM [Nanosyn]	B	O=C1NC(=O)C(N2CCc3ccccc32)=C1c1ccc(Cl)cc1		CHEMBL156524	=	Inhibition	%	5.62	CHEMBL5408	Homo sapiens	Inhibition	%	5.62
	8199164	CHEMBL1962004	GSK_PKIS: TBK1 mean inhibition at 0.1 uM [Nanosyn]	B	CN(C)c1cc2c(Nc3ccc4nc(Cc5ccccc5)[nH]c4c3)ncnc2cn1		CHEMBL531804	=	Inhibition	%	2.69	CHEMBL5408	Homo sapiens	Inhibition	%	2.69
	8199388	CHEMBL1962005	GSK_PKIS: TBK1 mean inhibition at 1 uM [Nanosyn]	B	CN(C)c1cc2c(Nc3ccc4nc(Cc5ccccc5)[nH]c4c3)ncnc2cn1		CHEMBL531804	=	Inhibition	%	4.24	CHEMBL5408	Homo sapiens	Inhibition	%	4.24
	8199522	CHEMBL1962004	GSK_PKIS: TBK1 mean inhibition at 0.1 uM [Nanosyn]	B	Fc1cccc(COc2ccc(Nc3ncncc3C#Cc3ccccc3)cc2Cl)c1		CHEMBL379093	=	Inhibition	%	5.15	CHEMBL5408	Homo sapiens	Inhibition	%	5.15
	8199685	CHEMBL1962005	GSK_PKIS: TBK1 mean inhibition at 1 uM [Nanosyn]	B	O=C1Nc2ccc(C(=O)c3ccco3)cc2C1=Cc1cc(Cl)c(O)c(Cl)c1		CHEMBL1789963	=	Inhibition	%	40.66	CHEMBL5408	Homo sapiens	Inhibition	%	40.66
	8199909	CHEMBL1962004	GSK_PKIS: TBK1 mean inhibition at 0.1 uM [Nanosyn]	B	Cc1cc(O)cc(C)c1/C=C/c1cncc(C(=O)OC(C)(C)C)c1		CHEMBL374060	=	Inhibition	%	2.04	CHEMBL5408	Homo sapiens	Inhibition	%	2.04
	8200047	CHEMBL1962005	GSK_PKIS: TBK1 mean inhibition at 1 uM [Nanosyn]	B	OCc1ccc(-c2nc(-c3ccccn3)c(-c3ccc4c(c3)OCO4)[nH]2)cc1		CHEMBL267228	=	Inhibition	%	4.95	CHEMBL5408	Homo sapiens	Inhibition	%	4.95
	8200375	CHEMBL1962004	GSK_PKIS: TBK1 mean inhibition at 0.1 uM [Nanosyn]	B	Clc1ccc(-c2nn3ncccc3c2-c2ccnc(Nc3ccccc3)n2)cc1		CHEMBL189148	=	Inhibition	%	1.29	CHEMBL5408	Homo sapiens	Inhibition	%	1.29
	8200714	CHEMBL1962004	GSK_PKIS: TBK1 mean inhibition at 0.1 uM [Nanosyn]	B	COc1cc(/C=N/Nc2ncnc3[nH]ncc23)ccc1O		CHEMBL66004	=	Inhibition	%	4.18	CHEMBL5408	Homo sapiens	Inhibition	%	4.18
	8200864	CHEMBL1962005	GSK_PKIS: TBK1 mean inhibition at 1 uM [Nanosyn]	B	Cc1ccc2c(-c3ccnc(Nc4ccccc4)n3)c(-c3ccc(F)cc3)nn2n1		CHEMBL189459	=	Inhibition	%	2.79	CHEMBL5408	Homo sapiens	Inhibition	%	2.79
	8201218	CHEMBL1962005	GSK_PKIS: TBK1 mean inhibition at 1 uM [Nanosyn]	B	COc1cc2ncn(-c3cc(OCc4cccs4)c(C(N)=O)s3)c2cc1OC		CHEMBL480382	=	Inhibition	%	16.69	CHEMBL5408	Homo sapiens	Inhibition	%	16.69
	8201353	CHEMBL1962004	GSK_PKIS: TBK1 mean inhibition at 0.1 uM [Nanosyn]	B	NS(=O)(=O)c1ccc(-c2cc3ccncc3cc2OCc2ccccc2)cc1		CHEMBL483748	=	Inhibition	%	5.88	CHEMBL5408	Homo sapiens	Inhibition	%	5.88
	8201577	CHEMBL1962005	GSK_PKIS: TBK1 mean inhibition at 1 uM [Nanosyn]	B	NS(=O)(=O)c1ccc(-c2cc3ccncc3cc2OCc2ccccc2)cc1		CHEMBL483748	=	Inhibition	%	2.74	CHEMBL5408	Homo sapiens	Inhibition	%	2.74
	8201710	CHEMBL1962004	GSK_PKIS: TBK1 mean inhibition at 0.1 uM [Nanosyn]	B	COc1ccc2cc(-c3c(-c4ccncc4)nc(-c4ccc([S+](C)[O-])cc4C)n3C)ccc2c1		CHEMBL237570	=	Inhibition	%	0.16	CHEMBL5408	Homo sapiens	Inhibition	%	0.16
	8201989	CHEMBL1962004	GSK_PKIS: TBK1 mean inhibition at 0.1 uM [Nanosyn]	B	CS(=O)(=O)CCNCc1ccc(-c2ccc3ncnc(Nc4ccc(OCc5cccc(F)c5)c(C(F)(F)F)c4)c3c2)o1		CHEMBL215814	=	Inhibition	%	1.68	CHEMBL5408	Homo sapiens	Inhibition	%	1.68
	8202353	CHEMBL1962004	GSK_PKIS: TBK1 mean inhibition at 0.1 uM [Nanosyn]	B	Cl.Nc1nc(-c2ccc3c(c2)C(=Cc2cc(Br)c(O)c(Br)c2)C(=O)N3)cs1		CHEMBL1794053	=	Inhibition	%	0.67	CHEMBL5408	Homo sapiens	Inhibition	%	0.67
	8202520	CHEMBL1962005	GSK_PKIS: TBK1 mean inhibition at 1 uM [Nanosyn]	B	Cl.Fc1ccc(-c2nc3n(c2-c2ccncc2)CCS3)cc1		CHEMBL1909406	=	Inhibition	%	2.87	CHEMBL5408	Homo sapiens	Inhibition	%	2.87
	8202869	CHEMBL1962005	GSK_PKIS: TBK1 mean inhibition at 1 uM [Nanosyn]	B	Fc1ccc(-c2cc(-c3c[nH]nc3-c3ccccn3)ccn2)cc1		CHEMBL381948	=	Inhibition	%	3.03	CHEMBL5408	Homo sapiens	Inhibition	%	3.03
	8202999	CHEMBL1962004	GSK_PKIS: TBK1 mean inhibition at 0.1 uM [Nanosyn]	B	O=C1NC(=O)C(c2ccccc2)=C1Nc1ccccc1		CHEMBL346551	=	Inhibition	%	2.92	CHEMBL5408	Homo sapiens	Inhibition	%	2.92
	8203223	CHEMBL1962005	GSK_PKIS: TBK1 mean inhibition at 1 uM [Nanosyn]	B	O=C1NC(=O)C(c2ccccc2)=C1Nc1ccccc1		CHEMBL346551	=	Inhibition	%	7.59	CHEMBL5408	Homo sapiens	Inhibition	%	7.59
	8203354	CHEMBL1962004	GSK_PKIS: TBK1 mean inhibition at 0.1 uM [Nanosyn]	B	Cc1c2ccc(N(C)c3ccnc(Nc4cccc(S(N)(=O)=O)c4)n3)cc2nn1C.Cl		CHEMBL1909359	=	Inhibition	%	4.99	CHEMBL5408	Homo sapiens	Inhibition	%	4.99
	8203724	CHEMBL1962004	GSK_PKIS: TBK1 mean inhibition at 0.1 uM [Nanosyn]	B	c1cnn2ncc(-c3ccnc(NCCCN4CCOCC4)n3)c2c1		CHEMBL524901	=	Inhibition	%	0.82	CHEMBL5408	Homo sapiens	Inhibition	%	0.82
	8203858	CHEMBL1962005	GSK_PKIS: TBK1 mean inhibition at 1 uM [Nanosyn]	B	Fc1cccc(COc2ccc(Nc3ncncc3C#Cc3ccccc3)cc2Cl)c1		CHEMBL379093	=	Inhibition	%	6.39	CHEMBL5408	Homo sapiens	Inhibition	%	6.39
	8204248	CHEMBL1962005	GSK_PKIS: TBK1 mean inhibition at 1 uM [Nanosyn]	B	Cc1cc(O)cc(C)c1/C=C/c1cncc(C(=O)OC(C)(C)C)c1		CHEMBL374060	=	Inhibition	%	2.33	CHEMBL5408	Homo sapiens	Inhibition	%	2.33
	8204385	CHEMBL1962004	GSK_PKIS: TBK1 mean inhibition at 0.1 uM [Nanosyn]	B	Cc1ccc(O)cc1Nc1ccnc2cc(-c3ccccn3)ccc12.Cl		CHEMBL581096	=	Inhibition	%	2.89	CHEMBL5408	Homo sapiens	Inhibition	%	2.89
	8204609	CHEMBL1962005	GSK_PKIS: TBK1 mean inhibition at 1 uM [Nanosyn]	B	Cc1ccc(O)cc1Nc1ccnc2cc(-c3ccccn3)ccc12.Cl		CHEMBL581096	=	Inhibition	%	6.68	CHEMBL5408	Homo sapiens	Inhibition	%	6.68
	8204714	CHEMBL1962005	GSK_PKIS: TBK1 mean inhibition at 1 uM [Nanosyn]	B	Clc1ccc(-c2nn3ncccc3c2-c2ccnc(Nc3ccccc3)n2)cc1		CHEMBL189148	=	Inhibition	%	2.57	CHEMBL5408	Homo sapiens	Inhibition	%	2.57
	8205053	CHEMBL1962005	GSK_PKIS: TBK1 mean inhibition at 1 uM [Nanosyn]	B	COc1cc(/C=N/Nc2ncnc3[nH]ncc23)ccc1O		CHEMBL66004	=	Inhibition	%	21.15	CHEMBL5408	Homo sapiens	Inhibition	%	21.15
	8205202	CHEMBL1962004	GSK_PKIS: TBK1 mean inhibition at 0.1 uM [Nanosyn]	B	c1cc(-c2cnn3nc(N4CCOCC4)ccc23)nc(NC2CC2)n1		CHEMBL495771	=	Inhibition	%	3.02	CHEMBL5408	Homo sapiens	Inhibition	%	3.02
	8205426	CHEMBL1962005	GSK_PKIS: TBK1 mean inhibition at 1 uM [Nanosyn]	B	c1cc(-c2cnn3nc(N4CCOCC4)ccc23)nc(NC2CC2)n1		CHEMBL495771	=	Inhibition	%	6.36	CHEMBL5408	Homo sapiens	Inhibition	%	6.36
	8205562	CHEMBL1962004	GSK_PKIS: TBK1 mean inhibition at 0.1 uM [Nanosyn]	B	CCOc1nccc2c1nc(-c1nonc1N)n2CC		CHEMBL188240	=	Inhibition	%	1.76	CHEMBL5408	Homo sapiens	Inhibition	%	1.76
	8205925	CHEMBL1962004	GSK_PKIS: TBK1 mean inhibition at 0.1 uM [Nanosyn]	B	Cc1ccc(NC(=O)CC2CC2)cc1-c1ccc(C(=O)NCC2CC2)cc1		CHEMBL516908	=	Inhibition	%	2.81	CHEMBL5408	Homo sapiens	Inhibition	%	2.81
	8206057	CHEMBL1962005	GSK_PKIS: TBK1 mean inhibition at 1 uM [Nanosyn]	B	COc1ccc2cc(-c3c(-c4ccncc4)nc(-c4ccc([S+](C)[O-])cc4C)n3C)ccc2c1		CHEMBL237570	=	Inhibition	%	1.97	CHEMBL5408	Homo sapiens	Inhibition	%	1.97
	8206333	CHEMBL1962005	GSK_PKIS: TBK1 mean inhibition at 1 uM [Nanosyn]	B	CS(=O)(=O)CCNCc1ccc(-c2ccc3ncnc(Nc4ccc(OCc5cccc(F)c5)c(C(F)(F)F)c4)c3c2)o1		CHEMBL215814	=	Inhibition	%	4.04	CHEMBL5408	Homo sapiens	Inhibition	%	4.04
	8206700	CHEMBL1962005	GSK_PKIS: TBK1 mean inhibition at 1 uM [Nanosyn]	B	Cl.Nc1nc(-c2ccc3c(c2)C(=Cc2cc(Br)c(O)c(Br)c2)C(=O)N3)cs1		CHEMBL1794053	=	Inhibition	%	0.36	CHEMBL5408	Homo sapiens	Inhibition	%	0.36
	8206880	CHEMBL1962004	GSK_PKIS: TBK1 mean inhibition at 0.1 uM [Nanosyn]	B	CN(C)CCCn1c(-c2nonc2N)nc2cnccc21		CHEMBL191105	=	Inhibition	%	1.24	CHEMBL5408	Homo sapiens	Inhibition	%	1.24
	8207230	CHEMBL1962004	GSK_PKIS: TBK1 mean inhibition at 0.1 uM [Nanosyn]	B	Nc1nc(-c2cccc(Cl)c2)c(-c2ccc3ncccc3n2)s1		CHEMBL365663	=	Inhibition	%	3.03	CHEMBL5408	Homo sapiens	Inhibition	%	3.03
	8207584	CHEMBL1962004	GSK_PKIS: TBK1 mean inhibition at 0.1 uM [Nanosyn]	B	O=C(Nc1n[nH]c2nc(-c3ccc(O)cc3)c(Br)cc12)C1CC1		CHEMBL260417	=	Inhibition	%	4.12	CHEMBL5408	Homo sapiens	Inhibition	%	4.12
	8207716	CHEMBL1962005	GSK_PKIS: TBK1 mean inhibition at 1 uM [Nanosyn]	B	Cc1c2ccc(N(C)c3ccnc(Nc4cccc(S(N)(=O)=O)c4)n3)cc2nn1C.Cl		CHEMBL1909359	=	Inhibition	%	8.43	CHEMBL5408	Homo sapiens	Inhibition	%	8.43
	8208085	CHEMBL1962005	GSK_PKIS: TBK1 mean inhibition at 1 uM [Nanosyn]	B	c1cnn2ncc(-c3ccnc(NCCCN4CCOCC4)n3)c2c1		CHEMBL524901	=	Inhibition	%	1.95	CHEMBL5408	Homo sapiens	Inhibition	%	1.95
	8208217	CHEMBL1962004	GSK_PKIS: TBK1 mean inhibition at 0.1 uM [Nanosyn]	B	COc1ccc(-c2cc(-c3c[nH]nc3-c3ccccn3)ccn2)cc1		CHEMBL202891	=	Inhibition	%	4.48	CHEMBL5408	Homo sapiens	Inhibition	%	4.48
	8208441	CHEMBL1962005	GSK_PKIS: TBK1 mean inhibition at 1 uM [Nanosyn]	B	COc1ccc(-c2cc(-c3c[nH]nc3-c3ccccn3)ccn2)cc1		CHEMBL202891	=	Inhibition	%	6.38	CHEMBL5408	Homo sapiens	Inhibition	%	6.38
	8208607	CHEMBL1962004	GSK_PKIS: TBK1 mean inhibition at 0.1 uM [Nanosyn]	B	CC1=C(C(=O)Nc2ccc3[nH]ncc3c2)C(c2ccc3ccccc3c2)CC(=O)N1		CHEMBL441702	=	Inhibition	%	-1.92	CHEMBL5408	Homo sapiens	Inhibition	%	-1.92
	8208964	CHEMBL1962004	GSK_PKIS: TBK1 mean inhibition at 0.1 uM [Nanosyn]	B	Nc1nonc1-c1nc2cnccc2n1C1CC1		CHEMBL185962	=	Inhibition	%	7.96	CHEMBL5408	Homo sapiens	Inhibition	%	7.96
	8209069	CHEMBL1962004	GSK_PKIS: TBK1 mean inhibition at 0.1 uM [Nanosyn]	B	CCS(=O)(=O)c1ccc(OC)c(Nc2ncc(-c3cccc(-c4ccccc4F)c3)o2)c1		CHEMBL372474	=	Inhibition	%	0.72	CHEMBL5408	Homo sapiens	Inhibition	%	0.72
	8209293	CHEMBL1962005	GSK_PKIS: TBK1 mean inhibition at 1 uM [Nanosyn]	B	CCS(=O)(=O)c1ccc(OC)c(Nc2ncc(-c3cccc(-c4ccccc4F)c3)o2)c1		CHEMBL372474	=	Inhibition	%	5.42	CHEMBL5408	Homo sapiens	Inhibition	%	5.42
	8209409	CHEMBL1962004	GSK_PKIS: TBK1 mean inhibition at 0.1 uM [Nanosyn]	B	Nc1nc(-c2ccccn2)c(-c2ccc3ncccc3n2)s1		CHEMBL181361	=	Inhibition	%	2.8	CHEMBL5408	Homo sapiens	Inhibition	%	2.8
	8209783	CHEMBL1962004	GSK_PKIS: TBK1 mean inhibition at 0.1 uM [Nanosyn]	B	NS(=O)(=O)c1ccc(-c2ccc3c(NC(=O)C4CC4)n[nH]c3c2)cc1		CHEMBL103098	=	Inhibition	%	5.3	CHEMBL5408	Homo sapiens	Inhibition	%	5.3
	8209919	CHEMBL1962005	GSK_PKIS: TBK1 mean inhibition at 1 uM [Nanosyn]	B	CCOc1nccc2c1nc(-c1nonc1N)n2CC		CHEMBL188240	=	Inhibition	%	6.01	CHEMBL5408	Homo sapiens	Inhibition	%	6.01
	8210284	CHEMBL1962005	GSK_PKIS: TBK1 mean inhibition at 1 uM [Nanosyn]	B	Cc1ccc(NC(=O)CC2CC2)cc1-c1ccc(C(=O)NCC2CC2)cc1		CHEMBL516908	=	Inhibition	%	5.71	CHEMBL5408	Homo sapiens	Inhibition	%	5.71
	8210420	CHEMBL1962004	GSK_PKIS: TBK1 mean inhibition at 0.1 uM [Nanosyn]	B	CCN1CCC(CC(=O)Nc2n[nH]c3nc(-c4cccs4)c(Br)cc23)CC1.O=C(O)C(O)C(O)C(=O)O		CHEMBL2062290	=	Inhibition	%	-0.25	CHEMBL5408	Homo sapiens	Inhibition	%	-0.25
	8210644	CHEMBL1962005	GSK_PKIS: TBK1 mean inhibition at 1 uM [Nanosyn]	B	CCN1CCC(CC(=O)Nc2n[nH]c3nc(-c4cccs4)c(Br)cc23)CC1.O=C(O)C(O)C(O)C(=O)O		CHEMBL2062290	=	Inhibition	%	1.1	CHEMBL5408	Homo sapiens	Inhibition	%	1.1
	8210679	CHEMBL1962004	GSK_PKIS: TBK1 mean inhibition at 0.1 uM [Nanosyn]	B	Cc1nnc(-c2ccc(C)c(-c3ccc(C(=O)NCc4ccc(Cl)cc4)cc3)c2)o1		CHEMBL402108	=	Inhibition	%	1.16	CHEMBL5408	Homo sapiens	Inhibition	%	1.16
	8210903	CHEMBL1962005	GSK_PKIS: TBK1 mean inhibition at 1 uM [Nanosyn]	B	Cc1nnc(-c2ccc(C)c(-c3ccc(C(=O)NCc4ccc(Cl)cc4)cc3)c2)o1		CHEMBL402108	=	Inhibition	%	3.88	CHEMBL5408	Homo sapiens	Inhibition	%	3.88
	8211047	CHEMBL1962004	GSK_PKIS: TBK1 mean inhibition at 0.1 uM [Nanosyn]	B	COC(=O)c1sc(-n2cnc3cc(OC)c(OC)cc32)cc1OCc1ccccc1C(F)(F)F		CHEMBL473420	=	Inhibition	%	3.44	CHEMBL5408	Homo sapiens	Inhibition	%	3.44
	8211217	CHEMBL1962005	GSK_PKIS: TBK1 mean inhibition at 1 uM [Nanosyn]	B	CN(C)CCCn1c(-c2nonc2N)nc2cnccc21		CHEMBL191105	=	Inhibition	%	6.08	CHEMBL5408	Homo sapiens	Inhibition	%	6.08
	8211441	CHEMBL1962004	GSK_PKIS: TBK1 mean inhibition at 0.1 uM [Nanosyn]	B	O=C(O)C(F)(F)F.O=C(O[C@H]1CN[C@H](C#Cc2cc3ncnc(Nc4ccc5c(ccn5Cc5cc(F)ccc5F)c4)c3s2)C1)N1CCOCC1		CHEMBL1909410	=	Inhibition	%	2.75	CHEMBL5408	Homo sapiens	Inhibition	%	2.75
	8211564	CHEMBL1962005	GSK_PKIS: TBK1 mean inhibition at 1 uM [Nanosyn]	B	Nc1nc(-c2cccc(Cl)c2)c(-c2ccc3ncccc3n2)s1		CHEMBL365663	=	Inhibition	%	4.37	CHEMBL5408	Homo sapiens	Inhibition	%	4.37
	8211917	CHEMBL1962005	GSK_PKIS: TBK1 mean inhibition at 1 uM [Nanosyn]	B	O=C(Nc1n[nH]c2nc(-c3ccc(O)cc3)c(Br)cc12)C1CC1		CHEMBL260417	=	Inhibition	%	22.56	CHEMBL5408	Homo sapiens	Inhibition	%	22.56
	8212049	CHEMBL1962004	GSK_PKIS: TBK1 mean inhibition at 0.1 uM [Nanosyn]	B	NS(=O)(=O)c1cccc(-c2cc3ccncc3cc2OCc2ccccc2)c1		CHEMBL483747	=	Inhibition	%	2.28	CHEMBL5408	Homo sapiens	Inhibition	%	2.28
	8212273	CHEMBL1962005	GSK_PKIS: TBK1 mean inhibition at 1 uM [Nanosyn]	B	NS(=O)(=O)c1cccc(-c2cc3ccncc3cc2OCc2ccccc2)c1		CHEMBL483747	=	Inhibition	%	6.61	CHEMBL5408	Homo sapiens	Inhibition	%	6.61
	8212414	CHEMBL1962004	GSK_PKIS: TBK1 mean inhibition at 0.1 uM [Nanosyn]	B	O=C(Nc1n[nH]c2cc(-c3ccc(F)cc3)ccc12)C1CC1		CHEMBL419903	=	Inhibition	%	2.6	CHEMBL5408	Homo sapiens	Inhibition	%	2.6
	8212771	CHEMBL1962004	GSK_PKIS: TBK1 mean inhibition at 0.1 uM [Nanosyn]	B	Cc1nnc(-c2cccc(-c3ccc(C(=O)NCC4CC4)cc3)c2)o1		CHEMBL257113	=	Inhibition	%	2.51	CHEMBL5408	Homo sapiens	Inhibition	%	2.51
	8212941	CHEMBL1962005	GSK_PKIS: TBK1 mean inhibition at 1 uM [Nanosyn]	B	CC1=C(C(=O)Nc2ccc3[nH]ncc3c2)C(c2ccc3ccccc3c2)CC(=O)N1		CHEMBL441702	=	Inhibition	%	4.09	CHEMBL5408	Homo sapiens	Inhibition	%	4.09
	8213294	CHEMBL1962005	GSK_PKIS: TBK1 mean inhibition at 1 uM [Nanosyn]	B	Nc1nonc1-c1nc2cnccc2n1C1CC1		CHEMBL185962	=	Inhibition	%	15.35	CHEMBL5408	Homo sapiens	Inhibition	%	15.35
	8213622	CHEMBL1962004	GSK_PKIS: TBK1 mean inhibition at 0.1 uM [Nanosyn]	B	O=C1NC(=O)C(c2ccc(Cl)cc2)=C1Nc1ccc(Cl)c(C(=O)O)c1		CHEMBL160876	=	Inhibition	%	-0.72	CHEMBL5408	Homo sapiens	Inhibition	%	-0.72
	8213735	CHEMBL1962005	GSK_PKIS: TBK1 mean inhibition at 1 uM [Nanosyn]	B	Nc1nc(-c2ccccn2)c(-c2ccc3ncccc3n2)s1		CHEMBL181361	=	Inhibition	%	5.59	CHEMBL5408	Homo sapiens	Inhibition	%	5.59
	8214106	CHEMBL1962005	GSK_PKIS: TBK1 mean inhibition at 1 uM [Nanosyn]	B	NS(=O)(=O)c1ccc(-c2ccc3c(NC(=O)C4CC4)n[nH]c3c2)cc1		CHEMBL103098	=	Inhibition	%	3.1	CHEMBL5408	Homo sapiens	Inhibition	%	3.1
	8214243	CHEMBL1962004	GSK_PKIS: TBK1 mean inhibition at 0.1 uM [Nanosyn]	B	COc1cc2ncn(-c3cc(O[C@H](C)c4ccccc4Cl)c(C(N)=O)s3)c2cc1OC		CHEMBL222419	=	Inhibition	%	3.11	CHEMBL5408	Homo sapiens	Inhibition	%	3.11
	8214467	CHEMBL1962005	GSK_PKIS: TBK1 mean inhibition at 1 uM [Nanosyn]	B	COc1cc2ncn(-c3cc(O[C@H](C)c4ccccc4Cl)c(C(N)=O)s3)c2cc1OC		CHEMBL222419	=	Inhibition	%	6.39	CHEMBL5408	Homo sapiens	Inhibition	%	6.39
	8214601	CHEMBL1962004	GSK_PKIS: TBK1 mean inhibition at 0.1 uM [Nanosyn]	B	Cc1ccc(Nc2ccnc(Nc3cccc(C(N)=O)c3)n2)cc1O.Cl		CHEMBL1909381	=	Inhibition	%	2.74	CHEMBL5408	Homo sapiens	Inhibition	%	2.74
	8214977	CHEMBL1962004	GSK_PKIS: TBK1 mean inhibition at 0.1 uM [Nanosyn]	B	c1ccc(-c2n[nH]cc2-c2ccnc(-c3ccc(OCCN4CCOCC4)cc3)c2)nc1		CHEMBL205158	=	Inhibition	%	1.5	CHEMBL5408	Homo sapiens	Inhibition	%	1.5
	8215228	CHEMBL1962004	GSK_PKIS: TBK1 mean inhibition at 0.1 uM [Nanosyn]	B	Nc1nccc(-c2c(-c3ccc(F)cc3)ncn2CCCN2CCOCC2)n1		CHEMBL274863	=	Inhibition	%	0.96	CHEMBL5408	Homo sapiens	Inhibition	%	0.96
	8215381	CHEMBL1962005	GSK_PKIS: TBK1 mean inhibition at 1 uM [Nanosyn]	B	COC(=O)c1sc(-n2cnc3cc(OC)c(OC)cc32)cc1OCc1ccccc1C(F)(F)F		CHEMBL473420	=	Inhibition	%	28.64	CHEMBL5408	Homo sapiens	Inhibition	%	28.64
	8215769	CHEMBL1962005	GSK_PKIS: TBK1 mean inhibition at 1 uM [Nanosyn]	B	O=C(O)C(F)(F)F.O=C(O[C@H]1CN[C@H](C#Cc2cc3ncnc(Nc4ccc5c(ccn5Cc5cc(F)ccc5F)c4)c3s2)C1)N1CCOCC1		CHEMBL1909410	=	Inhibition	%	2.11	CHEMBL5408	Homo sapiens	Inhibition	%	2.11
	8215888	CHEMBL1962004	GSK_PKIS: TBK1 mean inhibition at 0.1 uM [Nanosyn]	B	COc1cc(N2CCN(C(C)C)CC2)ccc1Nc1nc(Nc2ccc(F)cc2C(=O)NC[C@@H](O)CO)c2cc[nH]c2n1		CHEMBL450071	=	Inhibition	%	1.74	CHEMBL5408	Homo sapiens	Inhibition	%	1.74
	8216112	CHEMBL1962005	GSK_PKIS: TBK1 mean inhibition at 1 uM [Nanosyn]	B	COc1cc(N2CCN(C(C)C)CC2)ccc1Nc1nc(Nc2ccc(F)cc2C(=O)NC[C@@H](O)CO)c2cc[nH]c2n1		CHEMBL450071	=	Inhibition	%	4.23	CHEMBL5408	Homo sapiens	Inhibition	%	4.23
	8216231	CHEMBL1962004	GSK_PKIS: TBK1 mean inhibition at 0.1 uM [Nanosyn]	B	NC(=O)c1sc(-n2cnc3ccc(C(F)(F)F)cc32)cc1OCc1ccccc1Br		CHEMBL481510	=	Inhibition	%	0.45	CHEMBL5408	Homo sapiens	Inhibition	%	0.45
	8216591	CHEMBL1962004	GSK_PKIS: TBK1 mean inhibition at 0.1 uM [Nanosyn]	B	O=C1Nc2ccccc2/C1=C1\CCc2cc(O)ccc21		CHEMBL175321	=	Inhibition	%	1.68	CHEMBL5408	Homo sapiens	Inhibition	%	1.68
	8216729	CHEMBL1962005	GSK_PKIS: TBK1 mean inhibition at 1 uM [Nanosyn]	B	O=C(Nc1n[nH]c2cc(-c3ccc(F)cc3)ccc12)C1CC1		CHEMBL419903	=	Inhibition	%	5.39	CHEMBL5408	Homo sapiens	Inhibition	%	5.39
	8216953	CHEMBL1962004	GSK_PKIS: TBK1 mean inhibition at 0.1 uM [Nanosyn]	B	Nc1nonc1-c1nc2cnccc2n1C1CC1		CHEMBL185962	=	Inhibition	%	1.98	CHEMBL5408	Homo sapiens	Inhibition	%	1.98
	8217087	CHEMBL1962005	GSK_PKIS: TBK1 mean inhibition at 1 uM [Nanosyn]	B	Cc1nnc(-c2cccc(-c3ccc(C(=O)NCC4CC4)cc3)c2)o1		CHEMBL257113	=	Inhibition	%	6.92	CHEMBL5408	Homo sapiens	Inhibition	%	6.92
	8217261	CHEMBL1962004	GSK_PKIS: TBK1 mean inhibition at 0.1 uM [Nanosyn]	B	Cl.c1ccc(Oc2ccc(Nc3ncc(-c4ccccc4)o3)cc2)cc1		CHEMBL1909341	=	Inhibition	%	3.15	CHEMBL5408	Homo sapiens	Inhibition	%	3.15
	8217485	CHEMBL1962005	GSK_PKIS: TBK1 mean inhibition at 1 uM [Nanosyn]	B	Cl.c1ccc(Oc2ccc(Nc3ncc(-c4ccccc4)o3)cc2)cc1		CHEMBL1909341	=	Inhibition	%	2.41	CHEMBL5408	Homo sapiens	Inhibition	%	2.41
	8217616	CHEMBL1962004	GSK_PKIS: TBK1 mean inhibition at 0.1 uM [Nanosyn]	B	COc1cc2ncn(-c3cc(OCc4ccccc4S(C)(=O)=O)c(C#N)s3)c2cc1OC		CHEMBL373751	=	Inhibition	%	64.94	CHEMBL5408	Homo sapiens	Inhibition	%	64.94
	8217941	CHEMBL1962005	GSK_PKIS: TBK1 mean inhibition at 1 uM [Nanosyn]	B	O=C1NC(=O)C(c2ccc(Cl)cc2)=C1Nc1ccc(Cl)c(C(=O)O)c1		CHEMBL160876	=	Inhibition	%	0.78	CHEMBL5408	Homo sapiens	Inhibition	%	0.78
	8218056	CHEMBL1962004	GSK_PKIS: TBK1 mean inhibition at 0.1 uM [Nanosyn]	B	CN(C)CCOc1ccc(-c2nc(-c3ccncc3)c(-c3ccc4c(c3)CC/C4=N\O)[nH]2)cc1.Cl.O		CHEMBL1909414	=	Inhibition	%	1.69	CHEMBL5408	Homo sapiens	Inhibition	%	1.69
	8218280	CHEMBL1962005	GSK_PKIS: TBK1 mean inhibition at 1 uM [Nanosyn]	B	CN(C)CCOc1ccc(-c2nc(-c3ccncc3)c(-c3ccc4c(c3)CC/C4=N\O)[nH]2)cc1.Cl.O		CHEMBL1909414	=	Inhibition	%	3.98	CHEMBL5408	Homo sapiens	Inhibition	%	3.98
	8218407	CHEMBL1962004	GSK_PKIS: TBK1 mean inhibition at 0.1 uM [Nanosyn]	B	COc1cccc(-n2ncc3c(N/N=C/c4ccc(C(=O)NCCN(C)C)cc4)ncnc32)c1.Cl		CHEMBL1909383	=	Inhibition	%	2.76	CHEMBL5408	Homo sapiens	Inhibition	%	2.76
	8218774	CHEMBL1962004	GSK_PKIS: TBK1 mean inhibition at 0.1 uM [Nanosyn]	B	COc1ccc(-c2oc3ncnc(N)c3c2-c2ccc(NC(=O)Nc3cc(C(F)(F)F)ccc3F)cc2)cc1.Cl		CHEMBL1909396	=	Inhibition	%	1.47	CHEMBL5408	Homo sapiens	Inhibition	%	1.47
	8218905	CHEMBL1962005	GSK_PKIS: TBK1 mean inhibition at 1 uM [Nanosyn]	B	Cc1ccc(Nc2ccnc(Nc3cccc(C(N)=O)c3)n2)cc1O.Cl		CHEMBL1909381	=	Inhibition	%	19.65	CHEMBL5408	Homo sapiens	Inhibition	%	19.65
	8219129	CHEMBL1962004	GSK_PKIS: TBK1 mean inhibition at 0.1 uM [Nanosyn]	B	Cl.O=C(Nc1ccc(Oc2ccc3[nH]c(NC(=O)c4ccccc4)nc3c2)cc1)Nc1cc(C(F)(F)F)ccc1F		CHEMBL1909374	=	Inhibition	%	0.91	CHEMBL5408	Homo sapiens	Inhibition	%	0.91
	8219289	CHEMBL1962005	GSK_PKIS: TBK1 mean inhibition at 1 uM [Nanosyn]	B	c1ccc(-c2n[nH]cc2-c2ccnc(-c3ccc(OCCN4CCOCC4)cc3)c2)nc1		CHEMBL205158	=	Inhibition	%	1.95	CHEMBL5408	Homo sapiens	Inhibition	%	1.95
	8219539	CHEMBL1962005	GSK_PKIS: TBK1 mean inhibition at 1 uM [Nanosyn]	B	Nc1nccc(-c2c(-c3ccc(F)cc3)ncn2CCCN2CCOCC2)n1		CHEMBL274863	=	Inhibition	%	4.85	CHEMBL5408	Homo sapiens	Inhibition	%	4.85
	8219700	CHEMBL1962004	GSK_PKIS: TBK1 mean inhibition at 0.1 uM [Nanosyn]	B	COc1ccc(-c2coc3ncnc(N)c23)cc1		CHEMBL196022	=	Inhibition	%	-0.45	CHEMBL5408	Homo sapiens	Inhibition	%	-0.45
	8219924	CHEMBL1962005	GSK_PKIS: TBK1 mean inhibition at 1 uM [Nanosyn]	B	COc1ccc(-c2coc3ncnc(N)c23)cc1		CHEMBL196022	=	Inhibition	%	7.65	CHEMBL5408	Homo sapiens	Inhibition	%	7.65
	8220093	CHEMBL1962004	GSK_PKIS: TBK1 mean inhibition at 0.1 uM [Nanosyn]	B	N#Cc1c(NC(=O)c2ccc(F)c3ccccc23)sc2c1CCCC2		CHEMBL233002	=	Inhibition	%	2.42	CHEMBL5408	Homo sapiens	Inhibition	%	2.42
	8220446	CHEMBL1962004	GSK_PKIS: TBK1 mean inhibition at 0.1 uM [Nanosyn]	B	N#Cc1c(NC(=O)c2cccc3ccccc23)sc2c1CCCN2C(=O)C1CC1		CHEMBL232601	=	Inhibition	%	2.04	CHEMBL5408	Homo sapiens	Inhibition	%	2.04
	8220560	CHEMBL1962005	GSK_PKIS: TBK1 mean inhibition at 1 uM [Nanosyn]	B	NC(=O)c1sc(-n2cnc3ccc(C(F)(F)F)cc32)cc1OCc1ccccc1Br		CHEMBL481510	=	Inhibition	%	2.04	CHEMBL5408	Homo sapiens	Inhibition	%	2.04
	8220784	CHEMBL1962004	GSK_PKIS: TBK1 mean inhibition at 0.1 uM [Nanosyn]	B	CC1=C(C(=O)Nc2cc(Cl)c3[nH]ncc3c2)C(c2ccc(C(F)(F)F)cc2)CC(=O)N1		CHEMBL427058	=	Inhibition	%	2.77	CHEMBL5408	Homo sapiens	Inhibition	%	2.77
	8220922	CHEMBL1962005	GSK_PKIS: TBK1 mean inhibition at 1 uM [Nanosyn]	B	O=C1Nc2ccccc2/C1=C1\CCc2cc(O)ccc21		CHEMBL175321	=	Inhibition	%	12.96	CHEMBL5408	Homo sapiens	Inhibition	%	12.96
	8221282	CHEMBL1962005	GSK_PKIS: TBK1 mean inhibition at 1 uM [Nanosyn]	B	Nc1nonc1-c1nc2cnccc2n1C1CC1		CHEMBL185962	=	Inhibition	%	9.0	CHEMBL5408	Homo sapiens	Inhibition	%	9.0
	8221415	CHEMBL1962004	GSK_PKIS: TBK1 mean inhibition at 0.1 uM [Nanosyn]	B	COc1cc(N2CCN(C(C)C)CC2)ccc1Nc1nc(Nc2cccc(F)c2C(=O)O)c2cc[nH]c2n1		CHEMBL514261	=	Inhibition	%	4.45	CHEMBL5408	Homo sapiens	Inhibition	%	4.45
	8221804	CHEMBL1962004	GSK_PKIS: TBK1 mean inhibition at 0.1 uM [Nanosyn]	B	Cl.Nc1nccc(-c2c(-c3ccc(F)cc3)ncn2C2CCNCC2)n1		CHEMBL1909407	=	Inhibition	%	-0.58	CHEMBL5408	Homo sapiens	Inhibition	%	-0.58
	8221935	CHEMBL1962005	GSK_PKIS: TBK1 mean inhibition at 1 uM [Nanosyn]	B	COc1cc2ncn(-c3cc(OCc4ccccc4S(C)(=O)=O)c(C#N)s3)c2cc1OC		CHEMBL373751	=	Inhibition	%	82.95	CHEMBL5408	Homo sapiens	Inhibition	%	82.95
	8222257	CHEMBL1962004	GSK_PKIS: TBK1 mean inhibition at 0.1 uM [Nanosyn]	B	CCS(=O)(=O)c1ccc(OC)c(Nc2ncc(-c3cccc(C(C)=O)c3)o2)c1		CHEMBL191705	=	Inhibition	%	0.54	CHEMBL5408	Homo sapiens	Inhibition	%	0.54
	8222615	CHEMBL1962004	GSK_PKIS: TBK1 mean inhibition at 0.1 uM [Nanosyn]	B	NS(=O)(=O)c1ccc(Nc2ncc(-c3ccccc3)o2)cc1		CHEMBL194062	=	Inhibition	%	3.13	CHEMBL5408	Homo sapiens	Inhibition	%	3.13
	8222733	CHEMBL1962005	GSK_PKIS: TBK1 mean inhibition at 1 uM [Nanosyn]	B	COc1cccc(-n2ncc3c(N/N=C/c4ccc(C(=O)NCCN(C)C)cc4)ncnc32)c1.Cl		CHEMBL1909383	=	Inhibition	%	11.18	CHEMBL5408	Homo sapiens	Inhibition	%	11.18
	8222957	CHEMBL1962004	GSK_PKIS: TBK1 mean inhibition at 0.1 uM [Nanosyn]	B	CC1=C(C(=O)Nc2ccc3[nH]nc(C)c3c2)C(c2ccc(C(F)(F)F)cc2)CC(=O)N1		CHEMBL218720	=	Inhibition	%	-1.52	CHEMBL5408	Homo sapiens	Inhibition	%	-1.52
	8223101	CHEMBL1962005	GSK_PKIS: TBK1 mean inhibition at 1 uM [Nanosyn]	B	COc1ccc(-c2oc3ncnc(N)c3c2-c2ccc(NC(=O)Nc3cc(C(F)(F)F)ccc3F)cc2)cc1.Cl		CHEMBL1909396	=	Inhibition	%	3.95	CHEMBL5408	Homo sapiens	Inhibition	%	3.95
	8223454	CHEMBL1962005	GSK_PKIS: TBK1 mean inhibition at 1 uM [Nanosyn]	B	Cl.O=C(Nc1ccc(Oc2ccc3[nH]c(NC(=O)c4ccccc4)nc3c2)cc1)Nc1cc(C(F)(F)F)ccc1F		CHEMBL1909374	=	Inhibition	%	4.56	CHEMBL5408	Homo sapiens	Inhibition	%	4.56
	8223615	CHEMBL1962004	GSK_PKIS: TBK1 mean inhibition at 0.1 uM [Nanosyn]	B	COc1ccc(COc2ccc(Cc3cnc(N)nc3N)cc2OC)cc1		CHEMBL261849	=	Inhibition	%	2.12	CHEMBL5408	Homo sapiens	Inhibition	%	2.12
	8223865	CHEMBL1962004	GSK_PKIS: TBK1 mean inhibition at 0.1 uM [Nanosyn]	B	COc1ccc2cc(-c3c(-c4ccncc4)nc(-c4ccc(S(C)(=O)=O)cc4C)n3C)ccc2c1		CHEMBL237571	=	Inhibition	%	2.5	CHEMBL5408	Homo sapiens	Inhibition	%	2.5
	8224251	CHEMBL1962004	GSK_PKIS: TBK1 mean inhibition at 0.1 uM [Nanosyn]	B	Cc1ccc(NC(=O)c2ccnc(N3CCCC3)c2)cc1-c1ccc(C(=O)NCC2CC2)cc1		CHEMBL477182	=	Inhibition	%	6.98	CHEMBL5408	Homo sapiens	Inhibition	%	6.98
	8224421	CHEMBL1962005	GSK_PKIS: TBK1 mean inhibition at 1 uM [Nanosyn]	B	N#Cc1c(NC(=O)c2ccc(F)c3ccccc23)sc2c1CCCC2		CHEMBL233002	=	Inhibition	%	3.89	CHEMBL5408	Homo sapiens	Inhibition	%	3.89
	8224780	CHEMBL1962005	GSK_PKIS: TBK1 mean inhibition at 1 uM [Nanosyn]	B	N#Cc1c(NC(=O)c2cccc3ccccc23)sc2c1CCCN2C(=O)C1CC1		CHEMBL232601	=	Inhibition	%	5.06	CHEMBL5408	Homo sapiens	Inhibition	%	5.06
	8225118	CHEMBL1962005	GSK_PKIS: TBK1 mean inhibition at 1 uM [Nanosyn]	B	CC1=C(C(=O)Nc2cc(Cl)c3[nH]ncc3c2)C(c2ccc(C(F)(F)F)cc2)CC(=O)N1		CHEMBL427058	=	Inhibition	%	3.48	CHEMBL5408	Homo sapiens	Inhibition	%	3.48
	8225252	CHEMBL1962004	GSK_PKIS: TBK1 mean inhibition at 0.1 uM [Nanosyn]	B	NS(=O)(=O)c1ccc(Nc2cc(-c3cccc(O)c3)n[nH]2)cc1		CHEMBL103104	=	Inhibition	%	4.83	CHEMBL5408	Homo sapiens	Inhibition	%	4.83
	8225614	CHEMBL1962004	GSK_PKIS: TBK1 mean inhibition at 0.1 uM [Nanosyn]	B	Cl.c1ccc(-c2nc3n(c2-c2ccc4c(c2)OCO4)CCC3)nc1		CHEMBL1909377	=	Inhibition	%	1.0	CHEMBL5408	Homo sapiens	Inhibition	%	1.0
	8225749	CHEMBL1962005	GSK_PKIS: TBK1 mean inhibition at 1 uM [Nanosyn]	B	COc1cc(N2CCN(C(C)C)CC2)ccc1Nc1nc(Nc2cccc(F)c2C(=O)O)c2cc[nH]c2n1		CHEMBL514261	=	Inhibition	%	6.19	CHEMBL5408	Homo sapiens	Inhibition	%	6.19
	8225973	CHEMBL1962004	GSK_PKIS: TBK1 mean inhibition at 0.1 uM [Nanosyn]	B	N#Cc1c(NC(=O)CN2CCOCC2)sc2c1CCCC2.O=C(O)C(=O)O		CHEMBL1909342	=	Inhibition	%	1.76	CHEMBL5408	Homo sapiens	Inhibition	%	1.76
	8226131	CHEMBL1962005	GSK_PKIS: TBK1 mean inhibition at 1 uM [Nanosyn]	B	Cl.Nc1nccc(-c2c(-c3ccc(F)cc3)ncn2C2CCNCC2)n1		CHEMBL1909407	=	Inhibition	%	3.12	CHEMBL5408	Homo sapiens	Inhibition	%	3.12
	8226256	CHEMBL1962004	GSK_PKIS: TBK1 mean inhibition at 0.1 uM [Nanosyn]	B	Nc1nccc(C#Cc2cncnc2Nc2ccc(OCc3cccc(F)c3)c(Cl)c2)n1		CHEMBL381604	=	Inhibition	%	4.36	CHEMBL5408	Homo sapiens	Inhibition	%	4.36
	8226480	CHEMBL1962005	GSK_PKIS: TBK1 mean inhibition at 1 uM [Nanosyn]	B	Nc1nccc(C#Cc2cncnc2Nc2ccc(OCc3cccc(F)c3)c(Cl)c2)n1		CHEMBL381604	=	Inhibition	%	9.39	CHEMBL5408	Homo sapiens	Inhibition	%	9.39
inactive	9512014	CHEMBL1963698	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: TBK1	F	CC(C)(C)c1cc(NC(=O)Nc2cccc3ccccc23)n(-c2cccc(C(=O)NCCOCCO)c2)n1		CHEMBL1978271	<	Ki	nM	3162.28	CHEMBL5408	Homo sapiens	pKi		5.5
inactive	9512015	CHEMBL1963698	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: TBK1	F	Cc1ccc(F)c(NC(=O)Nc2ccc(-c3ccc(OCCCn4cccc4)c4[nH]nc(N)c34)cc2)c1		CHEMBL2007266	<	Ki	nM	3162.28	CHEMBL5408	Homo sapiens	pKi		5.5
inactive	9512016	CHEMBL1963698	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: TBK1	F	COc1cc2c(Nc3ccc(NC(=O)c4ccccc4)cc3)ncnc2cc1OCCCN1CCOCC1		CHEMBL202721	<	Ki	nM	3162.28	CHEMBL5408	Homo sapiens	pKi		5.5
inactive	9512017	CHEMBL1963698	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: TBK1	F	CC(=O)c1cccc(-c2cnc3[nH]ccc3c2)c1		CHEMBL2000568	<	Ki	nM	3162.28	CHEMBL5408	Homo sapiens	pKi		5.5
inactive	9512018	CHEMBL1963698	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: TBK1	F	O=C(CCC(=O)Nc1cc(C(F)(F)F)ccc1Cl)NN=Cc1c[nH]c2ccccc12		CHEMBL1994308	<	Ki	nM	3162.28	CHEMBL5408	Homo sapiens	pKi		5.5
inactive	9512019	CHEMBL1963698	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: TBK1	F	O=c1ncn2nc(Sc3ccc(F)cc3F)ccc2c1-c1c(Cl)cccc1Cl		CHEMBL119385	<	Ki	nM	3162.28	CHEMBL5408	Homo sapiens	pKi		5.5
inactive	9512020	CHEMBL1963698	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: TBK1	F	CC(Oc1cc(-c2cnn(C3CCNCC3)c2)cnc1N)c1c(Cl)ccc(F)c1Cl		CHEMBL1825138	<	Ki	nM	3162.28	CHEMBL5408	Homo sapiens	pKi		5.5
active	9512021	CHEMBL1963698	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: TBK1	F	CN(c1ncccc1CNc1nc(Nc2ccc3c(c2)CC(=O)N3)ncc1C(F)(F)F)S(C)(=O)=O		CHEMBL1084546	=	Ki	nM	1995.26	CHEMBL5408	Homo sapiens	pKi		5.7
inactive	9512022	CHEMBL1963698	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: TBK1	F	CCN1CCN(c2ccc(Nc3ncc(C#N)c(Nc4ccc5[nH]ncc5c4)n3)cc2)CC1		CHEMBL1973516	<	Ki	nM	3162.28	CHEMBL5408	Homo sapiens	pKi		5.5
inactive	9512023	CHEMBL1963698	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: TBK1	F	Cc1cccc(Nc2nc(NC3CCCCC3N)cnc2C(N)=O)c1		CHEMBL1974328	<	Ki	nM	2511.89	CHEMBL5408	Homo sapiens	pKi		5.6
active	9512024	CHEMBL1963698	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: TBK1	F	COc1cc(N2CCC(N3CCN(C)CC3)CC2)ccc1Nc1ncc(Cl)c(Nc2ccccc2S(=O)(=O)C(C)C)n1		CHEMBL509032	=	Ki	nM	630.96	CHEMBL5408	Homo sapiens	pKi		6.2
active	9512025	CHEMBL1963698	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: TBK1	F	NC(COc1cncc(-c2ccc3c(c2)C(=Cc2ccc[nH]2)C(=O)N3)c1)Cc1ccccc1		CHEMBL1980407	=	Ki	nM	7.943	CHEMBL5408	Homo sapiens	pKi		8.1
inactive	9512026	CHEMBL1963698	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: TBK1	F	CN(C)CCCN(C)C(=O)c1cccc(-n2nc(C(C)(C)C)cc2NC(=O)Nc2cccc3ccccc23)c1		CHEMBL1964948	<	Ki	nM	3162.28	CHEMBL5408	Homo sapiens	pKi		5.5
inactive	9512027	CHEMBL1963698	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: TBK1	F	Cc1cnc(Nc2nc(NC(C)C)ncc2Br)s1		CHEMBL1973013	<	Ki	nM	3162.28	CHEMBL5408	Homo sapiens	pKi		5.5
inactive	9512028	CHEMBL1963698	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: TBK1	F	O=c1[nH][nH]c2cccc(-c3ccccc3)c12		CHEMBL1989834	<	Ki	nM	25118.86	CHEMBL5408	Homo sapiens	pKi		4.6
inactive	9512029	CHEMBL1963698	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: TBK1	F	O=S(=O)(c1cccc2cnccc12)N1CCCNCC1		CHEMBL38380	<	Ki	nM	3162.28	CHEMBL5408	Homo sapiens	pKi		5.5
inactive	9512030	CHEMBL1963698	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: TBK1	F	CCCc1ccc2nccc(NC(=O)Nc3cccc(C(F)(F)F)n3)c2c1		CHEMBL1987430	<	Ki	nM	3162.28	CHEMBL5408	Homo sapiens	pKi		5.5
inactive	9512031	CHEMBL1963698	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: TBK1	F	O=C(Nc1cc(-c2c[nH]c3ncccc23)cc(Cl)n1)c1ccccc1		CHEMBL1993413	<	Ki	nM	3162.28	CHEMBL5408	Homo sapiens	pKi		5.5
inactive	9512032	CHEMBL1963698	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: TBK1	F	NC(Cc1c[nH]c2ccccc12)C(=O)Nc1cncc(C=Cc2ccncc2)c1		CHEMBL1983945	<	Ki	nM	3162.28	CHEMBL5408	Homo sapiens	pKi		5.5
active	9512033	CHEMBL1963698	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: TBK1	F	COc1ccc(-n2ccc3cnc(Nc4cc(OC)c(OC)c(OC)c4)nc32)cc1		CHEMBL1975927	=	Ki	nM	316.23	CHEMBL5408	Homo sapiens	pKi		6.5
active	9512034	CHEMBL1963698	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: TBK1	F	OC1CCC(Nc2nc(Cl)cc(-c3c[nH]c4ncccc34)n2)CC1		CHEMBL1986943	=	Ki	nM	1000.0	CHEMBL5408	Homo sapiens	pKi		6.0
inactive	9512035	CHEMBL1963698	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: TBK1	F	O=C1NC(=S)SC1=C1C(=O)Nc2ccc(Br)cc21		CHEMBL2001920	<	Ki	nM	1584.89	CHEMBL5408	Homo sapiens	pKi		5.8
active	9512036	CHEMBL1963698	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: TBK1	F	CC(Nc1cncc(-n2cnc3ccc(C#N)cc32)n1)c1ccccc1F		CHEMBL1977138	=	Ki	nM	2511.89	CHEMBL5408	Homo sapiens	pKi		5.6
inactive	9512037	CHEMBL1963698	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: TBK1	F	CS(=O)(=O)N(Cc1ccc2[nH]c(=O)c3cccn3c2c1)C1CC1		CHEMBL1978448	<	Ki	nM	3162.28	CHEMBL5408	Homo sapiens	pKi		5.5
active	9512038	CHEMBL1963698	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: TBK1	F	O=C1Nc2cc(-c3ccc(O)cc3)ccc2C1=Cc1ccc[nH]1		CHEMBL1980329	=	Ki	nM	1258.93	CHEMBL5408	Homo sapiens	pKi		5.9
active	9512039	CHEMBL1963698	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: TBK1	F	O=C(Nc1cccc(C2Nc3ccc4ccccc4c3C3C=CCC32)c1)c1ccc(F)cc1		CHEMBL1992042	=	Ki	nM	3162.28	CHEMBL5408	Homo sapiens	pKi		5.5
inactive	9512040	CHEMBL1963698	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: TBK1	F	O=C(O)C1CN(Cc2ccc(OCc3cccc(C(F)(F)F)c3)cc2Cl)C1		CHEMBL1986265	<	Ki	nM	3162.28	CHEMBL5408	Homo sapiens	pKi		5.5
inactive	9512041	CHEMBL1963698	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: TBK1	F	O=C(NCc1ccccc1)Nc1ncc([N+](=O)[O-])s1		CHEMBL1964644	<	Ki	nM	1584.89	CHEMBL5408	Homo sapiens	pKi		5.8
active	9512042	CHEMBL1963698	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: TBK1	F	CN1c2ccc(N)cc2C(c2ccccc2)c2cc(N)ccc21		CHEMBL1991734	=	Ki	nM	316.23	CHEMBL5408	Homo sapiens	pKi		6.5
active	9512043	CHEMBL1963698	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: TBK1	F	CC(C)(C)c1nc2c3ccc(F)cc3c3c(=O)[nH]ccc3c2[nH]1		CHEMBL21156	=	Ki	nM	199.53	CHEMBL5408	Homo sapiens	pKi		6.7
inactive	9512044	CHEMBL1963698	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: TBK1	F	COc1cccc(C(C)NC(=O)c2ccc(-c3ccncc3)s2)c1		CHEMBL1994724	<	Ki	nM	3162.28	CHEMBL5408	Homo sapiens	pKi		5.5
active	9512045	CHEMBL1963698	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: TBK1	F	COc1cc(-c2csc3c(C=CC(=O)NCCN(C)C)cnc(N)c23)ccc1NC(=O)c1cc2ccccc2n1C		CHEMBL1989267	=	Ki	nM	2511.89	CHEMBL5408	Homo sapiens	pKi		5.6
inactive	9512046	CHEMBL1963698	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: TBK1	F	COc1cc2c(N3CCN(C(=O)Nc4ccc(OC(C)C)cc4)CC3)ncnc2cc1OCCCN1CCCCC1		CHEMBL124660	<	Ki	nM	3162.28	CHEMBL5408	Homo sapiens	pKi		5.5
inactive	9512047	CHEMBL1963698	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: TBK1	F	O=C1NCc2c1cccc2-c1cccs1		CHEMBL1991782	<	Ki	nM	63095.73	CHEMBL5408	Homo sapiens	pKi		4.2
inactive	9512048	CHEMBL1963698	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: TBK1	F	Cc1ccc(F)c(NC(=O)Nc2ccc(-c3cccc4[nH]nc(N)c34)cc2)c1		CHEMBL223360	<	Ki	nM	3162.28	CHEMBL5408	Homo sapiens	pKi		5.5
active	9512049	CHEMBL1963698	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: TBK1	F	CCCCN(CCC#N)C(=O)c1ccc2nc(-c3n[nH]c4ccccc34)[nH]c2c1		CHEMBL1983348	=	Ki	nM	316.23	CHEMBL5408	Homo sapiens	pKi		6.5
inactive	9512050	CHEMBL1963698	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: TBK1	F	CCN(CC)CCNC(=O)c1cccc(-n2nc(C(C)(C)C)cc2NC(=O)Nc2cccc3ccccc23)c1		CHEMBL1970290	<	Ki	nM	3162.28	CHEMBL5408	Homo sapiens	pKi		5.5
active	9512051	CHEMBL1963698	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: TBK1	F	C=CCn1c(=O)c2cnc(Nc3ccc(N4CCN(C)CC4)cc3)nc2n1-c1cccc(C(C)(C)O)n1		CHEMBL1976040	=	Ki	nM	1000.0	CHEMBL5408	Homo sapiens	pKi		6.0
inactive	9512052	CHEMBL1963698	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: TBK1	F	Cc1nc(Nc2ncc(C(=O)Nc3c(C)cccc3Cl)s2)cc(N2CCN(CCO)CC2)n1		CHEMBL1421	<	Ki	nM	3162.28	CHEMBL5408	Homo sapiens	pKi		5.5
inactive	9512053	CHEMBL1963698	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: TBK1	F	C#Cc1cn(C2CCCC2)c2ncnc(N)c12		CHEMBL1993877	<	Ki	nM	3162.28	CHEMBL5408	Homo sapiens	pKi		5.5
inactive	9512054	CHEMBL1963698	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: TBK1	F	Cc1nccn2c(-c3ccnc(NCC(C)(C)O)n3)c(-c3ccc(F)cc3F)nc12		CHEMBL1996500	<	Ki	nM	3162.28	CHEMBL5408	Homo sapiens	pKi		5.5
inactive	9512055	CHEMBL1963698	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: TBK1	F	O=C(Nc1cccc(Cl)c1)Nc1nc(CCNc2ncnc3ccsc23)cs1		CHEMBL1986177	<	Ki	nM	3162.28	CHEMBL5408	Homo sapiens	pKi		5.5
inactive	9512056	CHEMBL1963698	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: TBK1	F	Cc1cccc(NC(=O)Nc2ccc(-c3csc4c(-c5cnn(CC(C)O)c5)cnc(N)c34)cc2)c1		CHEMBL1989708	<	Ki	nM	3162.28	CHEMBL5408	Homo sapiens	pKi		5.5
inactive	9512057	CHEMBL1963698	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: TBK1	F	CCc1c(-c2ccc(C(C)(C)O)cc2)[nH]c2nccnc12		CHEMBL1976420	<	Ki	nM	3162.28	CHEMBL5408	Homo sapiens	pKi		5.5
inactive	9512058	CHEMBL1963698	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: TBK1	F	O=C(Nc1cccc(C(F)(F)F)n1)Nc1ccnc2cc(Cl)ccc12		CHEMBL1981744	<	Ki	nM	3162.28	CHEMBL5408	Homo sapiens	pKi		5.5
inactive	9512059	CHEMBL1963698	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: TBK1	F	Cc1ccnc(Nc2cc(C)nc(-c3ccccc3)n2)c1		CHEMBL1985367	<	Ki	nM	3162.28	CHEMBL5408	Homo sapiens	pKi		5.5
inactive	9512060	CHEMBL1963698	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: TBK1	F	Cn1c(=O)n(-c2ccc(C(C)(C)C#N)cc2)c2c3cc(-c4cnc5ccccc5c4)ccc3ncc21		CHEMBL1879463	<	Ki	nM	3162.28	CHEMBL5408	Homo sapiens	pKi		5.5
inactive	9512061	CHEMBL1963698	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: TBK1	F	O=C1NC(=O)C(c2c[nH]c3ccccc23)=C1c1nc(N2CCNCC2)nc2ccccc12		CHEMBL1996510	<	Ki	nM	3162.28	CHEMBL5408	Homo sapiens	pKi		5.5
active	9512062	CHEMBL1963698	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: TBK1	F	O=c1nc(-c2cc3c(Oc4ccc(I)cc4)cncc3s2)[nH]o1		CHEMBL497151	=	Ki	nM	1258.93	CHEMBL5408	Homo sapiens	pKi		5.9
active	9512063	CHEMBL1963698	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: TBK1	F	Cc1ccccc1-c1c(-c2ccc3[nH]nc(N)c3c2)nnn1Cc1ccccc1		CHEMBL2000029	=	Ki	nM	316.23	CHEMBL5408	Homo sapiens	pKi		6.5
inactive	9512064	CHEMBL1963698	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: TBK1	F	Brc1ccc2c(c1)-c1[nH]ncc1C2		CHEMBL1995172	<	Ki	nM	3162.28	CHEMBL5408	Homo sapiens	pKi		5.5
inactive	9512065	CHEMBL1963698	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: TBK1	F	Cn1cc(-c2cccc(NC(=O)c3ccc(C(C)(C)C)cc3)c2CO)cc(Nc2ccc(C(=O)N3CCOCC3)cn2)c1=O		CHEMBL2001584	<	Ki	nM	3162.28	CHEMBL5408	Homo sapiens	pKi		5.5
inactive	9512066	CHEMBL1963698	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: TBK1	F	COc1cc(N2CCN(C)CC2)ccc1C(=O)Nc1n[nH]c2ccc(Cc3cc(F)cc(F)c3)cc12		CHEMBL1973961	<	Ki	nM	3162.28	CHEMBL5408	Homo sapiens	pKi		5.5
active	9512067	CHEMBL1963698	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: TBK1	F	CCN1CCN(c2ccc(Nc3ncc(Cl)c(Nc4ccc5[nH]ncc5c4)n3)cc2)CC1		CHEMBL1967998	=	Ki	nM	316.23	CHEMBL5408	Homo sapiens	pKi		6.5
inactive	9512068	CHEMBL1963698	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: TBK1	F	Cn1cc(-c2cc3nc(Br)cnc3[nH]2)c2cc(C#N)ccc21		CHEMBL1978562	<	Ki	nM	3162.28	CHEMBL5408	Homo sapiens	pKi		5.5
inactive	9512069	CHEMBL1963698	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: TBK1	F	CC(C)(C)c1cc(NC(=O)Nc2cccc3ccccc23)n(-c2cccc(C(=O)NCCCCO)c2)n1		CHEMBL1994977	<	Ki	nM	3162.28	CHEMBL5408	Homo sapiens	pKi		5.5
inactive	9512070	CHEMBL1963698	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: TBK1	F	Oc1ccc2nc(-c3ccc(Sc4ccc(-c5nc6ccc(O)cc6[nH]5)cc4)cc3)[nH]c2c1		CHEMBL2001149	<	Ki	nM	3162.28	CHEMBL5408	Homo sapiens	pKi		5.5
active	9512071	CHEMBL1963698	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: TBK1	F	O=C(O)c1csc2c1NCCNC2=O		CHEMBL1974875	=	Ki	nM	79432.82	CHEMBL5408	Homo sapiens	pKi		4.1
active	9512072	CHEMBL1963698	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: TBK1	F	COc1ccc2c(c1)c(-c1cc3nc(Br)cnc3[nH]1)cn2C		CHEMBL2005478	=	Ki	nM	3162.28	CHEMBL5408	Homo sapiens	pKi		5.5
active	9512073	CHEMBL1963698	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: TBK1	F	COc1cccc(OC)c1CNc1nc(NC2CCCCC2)nc2ccc(Cl)cc12		CHEMBL1996646	=	Ki	nM	3162.28	CHEMBL5408	Homo sapiens	pKi		5.5
inactive	9512074	CHEMBL1963698	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: TBK1	F	CN(CCN)C(=O)c1cccc(-n2nc(C(C)(C)C)cc2NC(=O)Nc2cccc3ccccc23)c1		CHEMBL1979773	<	Ki	nM	3162.28	CHEMBL5408	Homo sapiens	pKi		5.5
active	9512075	CHEMBL1963698	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: TBK1	F	Cc1ccnc2[nH]c3cc(C(C)C)ccc3c(=O)c12		CHEMBL1989471	=	Ki	nM	1258.93	CHEMBL5408	Homo sapiens	pKi		5.9
inactive	9512076	CHEMBL1963698	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: TBK1	F	O=C1Nc2ccccc2Nc2nnc(I)cc21		CHEMBL1977346	<	Ki	nM	1584.89	CHEMBL5408	Homo sapiens	pKi		5.8
inactive	9512077	CHEMBL1963698	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: TBK1	F	N#CCC(C1CCCC1)n1cc(-c2ncnc3[nH]ccc23)cn1		CHEMBL2002099	<	Ki	nM	3162.28	CHEMBL5408	Homo sapiens	pKi		5.5
inactive	9512078	CHEMBL1963698	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: TBK1	F	COc1cc(-c2ccc3c(c2)Nc2ccc(C(=O)NCCCN(C)C)cc2NC3=O)ccc1O		CHEMBL1996702	<	Ki	nM	3162.28	CHEMBL5408	Homo sapiens	pKi		5.5
inactive	9512079	CHEMBL1963698	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: TBK1	F	Cc1cc(Nc2cc(N3CCN(C)CC3)nc(Sc3ccc(NC(=O)C4CC4)cc3)n2)n[nH]1		CHEMBL572878	<	Ki	nM	1995.26	CHEMBL5408	Homo sapiens	pKi		5.7
inactive	9512080	CHEMBL1963698	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: TBK1	F	O=C(Nc1ccc(-c2ccc(=O)[nH]n2)cc1)Nc1cccc(C(F)(F)F)c1		CHEMBL2007124	<	Ki	nM	3162.28	CHEMBL5408	Homo sapiens	pKi		5.5
inactive	9512081	CHEMBL1963698	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: TBK1	F	NC(=O)c1cc2c(-c3ccc(Br)cc3)cncc2s1		CHEMBL1978195	<	Ki	nM	3162.28	CHEMBL5408	Homo sapiens	pKi		5.5
inactive	9512082	CHEMBL1963698	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: TBK1	F	C#Cc1cccc(Nc2ncnc3cc(OCCOC)c(OCCOC)cc23)c1		CHEMBL553	<	Ki	nM	3162.28	CHEMBL5408	Homo sapiens	pKi		5.5
inactive	9512083	CHEMBL1963698	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: TBK1	F	Clc1cc(-c2c[nH]c3ncccc23)nc(NC2CCCCC2)n1		CHEMBL2006439	<	Ki	nM	3162.28	CHEMBL5408	Homo sapiens	pKi		5.5
active	9512084	CHEMBL1963698	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: TBK1	F	N#Cc1ccc2c(c1)C(c1ccc3c(n1)CCCC3O)C(=O)N2		CHEMBL1985681	=	Ki	nM	794.33	CHEMBL5408	Homo sapiens	pKi		6.1
active	9512085	CHEMBL1963698	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: TBK1	F	COc1cc(Nc2ncc(F)c(Nc3ccc4c(n3)NC(=O)C(C)(C)O4)n2)cc(OC)c1OC		CHEMBL475251	=	Ki	nM	100.0	CHEMBL5408	Homo sapiens	pKi		7.0
inactive	9512086	CHEMBL1963698	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: TBK1	F	N#CCC(C1CCCC1)n1cc(-c2ncnc3[nH]ccc23)cn1		CHEMBL2002099	<	Ki	nM	3162.28	CHEMBL5408	Homo sapiens	pKi		5.5
inactive	9512087	CHEMBL1963698	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: TBK1	F	OC1CCC(Nc2cc(Cl)nc(-c3c[nH]c4ncccc34)n2)CC1		CHEMBL1991674	<	Ki	nM	3162.28	CHEMBL5408	Homo sapiens	pKi		5.5
active	9512088	CHEMBL1963698	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: TBK1	F	NC(=O)c1ccc(-c2c[nH]c3nccc(Cl)c23)cc1		CHEMBL1982711	=	Ki	nM	794.33	CHEMBL5408	Homo sapiens	pKi		6.1
active	9512089	CHEMBL1963698	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: TBK1	F	Nc1ncnc2c1N=C(c1ccccc1)CCN2		CHEMBL262623	=	Ki	nM	39810.72	CHEMBL5408	Homo sapiens	pKi		4.4
inactive	9512090	CHEMBL1963698	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: TBK1	F	CC(C)COc1nccn2c(-c3ccnc(NCC(C)(C)CO)n3)c(-c3ccc(F)cc3)nc12		CHEMBL1984842	<	Ki	nM	3162.28	CHEMBL5408	Homo sapiens	pKi		5.5
active	9512091	CHEMBL1963698	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: TBK1	F	CCc1nc(Nc2ccc(N3CCOCC3)c(Cl)c2)nc2[nH]ccc12		CHEMBL2004118	=	Ki	nM	501.19	CHEMBL5408	Homo sapiens	pKi		6.3
inactive	9512092	CHEMBL1963698	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: TBK1	F	CCN1CCN(c2ccc(Nc3ncc(C#N)c(Nc4ccc5[nH]ncc5c4)n3)cc2)CC1		CHEMBL1973516	<	Ki	nM	3162.28	CHEMBL5408	Homo sapiens	pKi		5.5
inactive	9512093	CHEMBL1963698	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: TBK1	F	N#Cc1ccc2nc(N)n(-c3nc4c(s3)CCCC4)c2c1		CHEMBL1996345	<	Ki	nM	3162.28	CHEMBL5408	Homo sapiens	pKi		5.5
inactive	9512094	CHEMBL1963698	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: TBK1	F	COCOc1cccc(OCOC)c1-c1ccc(NS(C)(=O)=O)cc1C(=O)OC		CHEMBL2004025	<	Ki	nM	3162.28	CHEMBL5408	Homo sapiens	pKi		5.5
inactive	9512095	CHEMBL1963698	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: TBK1	F	Cc1ccc(-c2cc3c(NCCN)ccc(C(N)=O)c3[nH]2)cc1		CHEMBL1996048	<	Ki	nM	3162.28	CHEMBL5408	Homo sapiens	pKi		5.5
inactive	9512096	CHEMBL1963698	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: TBK1	F	O=C1Cc2c([nH]c3ccc([N+](=O)[O-])cc23)-c2ccccc2N1		CHEMBL50894	<	Ki	nM	3162.28	CHEMBL5408	Homo sapiens	pKi		5.5
inactive	9512097	CHEMBL1963698	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: TBK1	F	CC(C)(C)Nc1ncnc2[nH]cc(-c3ccccc3)c12		CHEMBL1995211	<	Ki	nM	3162.28	CHEMBL5408	Homo sapiens	pKi		5.5
inactive	9512098	CHEMBL1963698	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: TBK1	F	Cc1cc(=O)[nH]nc1-c1ccc(NC(=O)Nc2cc(C(F)(F)F)ccc2F)cc1		CHEMBL1965033	<	Ki	nM	3162.28	CHEMBL5408	Homo sapiens	pKi		5.5
inactive	9512099	CHEMBL1963698	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: TBK1	F	COc1cc2c(cc1Nc1nc(Nc3cccc(F)c3C(N)=O)c3cc[nH]c3n1)N(C(=O)CN(C)C)CC2		CHEMBL461876	<	Ki	nM	3162.28	CHEMBL5408	Homo sapiens	pKi		5.5
inactive	9512100	CHEMBL1963698	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: TBK1	F	COc1cc2c(Oc3ccc4[nH]c(C)cc4c3F)ncnc2cc1OCCCN1CCCC1		CHEMBL491473	<	Ki	nM	3162.28	CHEMBL5408	Homo sapiens	pKi		5.5
inactive	9512101	CHEMBL1963698	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: TBK1	F	NC(=O)c1ccc(NC2CCCCC2N)nc1Nc1cccc(Cl)c1		CHEMBL1982753	<	Ki	nM	3162.28	CHEMBL5408	Homo sapiens	pKi		5.5
inactive	9512102	CHEMBL1963698	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: TBK1	F	COc1cccc(CNC(=O)c2ccc(-c3ccncc3)cc2)c1		CHEMBL2006299	<	Ki	nM	3162.28	CHEMBL5408	Homo sapiens	pKi		5.5
active	9512103	CHEMBL1963698	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: TBK1	F	Oc1cc(O)cc(C=Cc2ccc(O)c(O)c2)c1		CHEMBL1972346	=	Ki	nM	630.96	CHEMBL5408	Homo sapiens	pKi		6.2
active	9512104	CHEMBL1963698	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: TBK1	F	COc1ccc(C2=NNc3cccc4c(OC)ccc2c34)cc1OC		CHEMBL1997335	=	Ki	nM	630.96	CHEMBL5408	Homo sapiens	pKi		6.2
inactive	9512105	CHEMBL1963698	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: TBK1	F	Cc1ccc(-c2cc3nc(Br)cnc3[nH]2)cc1		CHEMBL1965169	<	Ki	nM	3162.28	CHEMBL5408	Homo sapiens	pKi		5.5
inactive	9512106	CHEMBL1963698	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: TBK1	F	Nc1ncnc2c1c(-c1cnc3[nH]ccc3c1)nn2C1CCCC1		CHEMBL1081312	<	Ki	nM	3162.28	CHEMBL5408	Homo sapiens	pKi		5.5
inactive	9512107	CHEMBL1963698	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: TBK1	F	COc1ccc(NC(=O)Nc2ccc(-c3csc4c(-c5cnn(CC(O)CO)c5)cnc(N)c34)cc2)cc1		CHEMBL1965170	<	Ki	nM	3162.28	CHEMBL5408	Homo sapiens	pKi		5.5
inactive	9512108	CHEMBL1963698	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: TBK1	F	COc1nccn2c(-c3ccnc(NCC(C)(C)CO)n3)c(-c3ccc(F)cc3)nc12		CHEMBL2005792	<	Ki	nM	3162.28	CHEMBL5408	Homo sapiens	pKi		5.5
active	9512109	CHEMBL1963698	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: TBK1	F	COc1c(-c2nc3ccccc3[nH]2)c(O)cc2oc(C)cc(=O)c12		CHEMBL1972355	=	Ki	nM	1584.89	CHEMBL5408	Homo sapiens	pKi		5.8
inactive	9512110	CHEMBL1963698	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: TBK1	F	Cc1cc(=O)[nH]nc1-c1ccc(NC(=O)Nc2cc(C(F)(F)F)ccc2F)c(Cl)c1		CHEMBL1997892	<	Ki	nM	3162.28	CHEMBL5408	Homo sapiens	pKi		5.5
active	9516020	CHEMBL1963698	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: TBK1	F	CC(C)(O)c1cn(-c2ccc3[nH]ncc3c2)nn1		CHEMBL2001641	=	Ki	nM	79432.82	CHEMBL5408	Homo sapiens	pKi		4.1
inactive	9516021	CHEMBL1963698	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: TBK1	F	Cc1ccc(-c2cc(-c3cc(Br)ccc3O)[nH]c(=O)c2C#N)s1		CHEMBL1997193	<	Ki	nM	3162.28	CHEMBL5408	Homo sapiens	pKi		5.5
inactive	9516022	CHEMBL1963698	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: TBK1	F	CC(C)(C)c1cc(NC(=O)C(=O)c2cccc3ccccc23)n(-c2cccc(OCC(=O)O)c2)n1		CHEMBL1964902	<	Ki	nM	3162.28	CHEMBL5408	Homo sapiens	pKi		5.5
inactive	9516023	CHEMBL1963698	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: TBK1	F	Oc1cnc2ccc(-c3ccncc3)cc2c1		CHEMBL1973868	<	Ki	nM	3162.28	CHEMBL5408	Homo sapiens	pKi		5.5
inactive	9516024	CHEMBL1963698	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: TBK1	F	CCCCC#Cc1ccc(CN2CC(C(=O)O)C2)cc1		CHEMBL1972462	<	Ki	nM	3162.28	CHEMBL5408	Homo sapiens	pKi		5.5
inactive	9516025	CHEMBL1963698	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: TBK1	F	COc1cc2ncnc(Nc3ccc(F)c(Cl)c3)c2cc1OCCCN1CCOCC1		CHEMBL939	<	Ki	nM	3162.28	CHEMBL5408	Homo sapiens	pKi		5.5
inactive	9516026	CHEMBL1963698	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: TBK1	F	COc1cc2c(Nc3ccc(Br)cc3F)ncnc2cc1OCC1CCN(C)CC1		CHEMBL24828	<	Ki	nM	3162.28	CHEMBL5408	Homo sapiens	pKi		5.5
active	9516027	CHEMBL1963698	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: TBK1	F	CC(Oc1cc(-c2cnn(C3CCNCC3)c2)cnc1N)c1c(Cl)ccc(F)c1Cl		CHEMBL1825138	=	Ki	nM	1995.26	CHEMBL5408	Homo sapiens	pKi		5.7
active	9516028	CHEMBL1963698	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: TBK1	F	CCNc1nc(C)c(-c2ccnc(Nc3ccc(N4CCN(C(C)=O)CC4)cc3)n2)s1		CHEMBL1983715	=	Ki	nM	100.0	CHEMBL5408	Homo sapiens	pKi		7.0
inactive	9516029	CHEMBL1963698	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: TBK1	F	O=C1NCc2c(Br)cccc21		CHEMBL1984500	<	Ki	nM	63095.73	CHEMBL5408	Homo sapiens	pKi		4.2
inactive	9516030	CHEMBL1963698	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: TBK1	F	Cc1ccc(Nc2nccc(N(C)c3ccc4c(C)n(C)nc4c3)n2)cc1S(N)(=O)=O		CHEMBL477772	<	Ki	nM	3162.28	CHEMBL5408	Homo sapiens	pKi		5.5
inactive	9516031	CHEMBL1963698	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: TBK1	F	CC(N)C1CCC(C(=O)Nc2ccnc3[nH]ccc23)CC1		CHEMBL2002992	<	Ki	nM	3162.28	CHEMBL5408	Homo sapiens	pKi		5.5
inactive	9516032	CHEMBL1963698	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: TBK1	F	N#Cc1cnc(NC(=O)Nc2ccc3cc(C(=O)O)ccc3c2)cn1		CHEMBL560813	<	Ki	nM	1584.89	CHEMBL5408	Homo sapiens	pKi		5.8
inactive	9516033	CHEMBL1963698	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: TBK1	F	CCCCNC(=O)c1cn(C(CC)CC)c(=O)c2cc(OC)c(OC)cc12		CHEMBL1982700	<	Ki	nM	3162.28	CHEMBL5408	Homo sapiens	pKi		5.5
inactive	9516034	CHEMBL1963698	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: TBK1	F	C[S+]([O-])c1ccc(-c2nc(-c3ccc(F)cc3)c(-c3ccncc3)[nH]2)cc1		CHEMBL10	<	Ki	nM	3162.28	CHEMBL5408	Homo sapiens	pKi		5.5
active	9516035	CHEMBL1963698	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: TBK1	F	CC(C)Cc1nc(Nc2ccc(N3CCOCC3)c(Cl)c2)nc2[nH]ccc12		CHEMBL1980763	=	Ki	nM	3162.28	CHEMBL5408	Homo sapiens	pKi		5.5
inactive	9516036	CHEMBL1963698	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: TBK1	F	CC(C)(C)c1cc(NC(=O)C(=O)c2cccc3ccccc23)n(-c2ccc(OCC(N)=O)cc2)n1		CHEMBL1977634	<	Ki	nM	3162.28	CHEMBL5408	Homo sapiens	pKi		5.5
active	9516037	CHEMBL1963698	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: TBK1	F	CC(=O)c1ccccc1-c1ncnc2[nH]ccc12		CHEMBL1977931	=	Ki	nM	63095.73	CHEMBL5408	Homo sapiens	pKi		4.2
inactive	9516038	CHEMBL1963698	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: TBK1	F	Clc1ccc(Nc2nnc(Cc3ccncc3)c3ccccc23)cc1		CHEMBL101253	<	Ki	nM	3162.28	CHEMBL5408	Homo sapiens	pKi		5.5
inactive	9516039	CHEMBL1963698	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: TBK1	F	CCCCNc1nc(N)c(C(=O)c2ccccc2)s1		CHEMBL2007479	<	Ki	nM	3162.28	CHEMBL5408	Homo sapiens	pKi		5.5
inactive	9516040	CHEMBL1963698	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: TBK1	F	c1ccc(-c2c[nH]c3ncnc(N4CCCCC4)c23)cc1		CHEMBL1998953	<	Ki	nM	3162.28	CHEMBL5408	Homo sapiens	pKi		5.5
inactive	9516041	CHEMBL1963698	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: TBK1	F	CCCOc1cccc(C(C)NC(=O)c2ccc(-c3ccncc3F)cc2)c1		CHEMBL1971606	<	Ki	nM	3162.28	CHEMBL5408	Homo sapiens	pKi		5.5
inactive	9516042	CHEMBL1963698	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: TBK1	F	Nc1ccc(-c2cncc(OCC(N)Cc3c[nH]c4ccccc34)c2)cc1C(=O)c1ccccc1		CHEMBL1972125	<	Ki	nM	1584.89	CHEMBL5408	Homo sapiens	pKi		5.8
inactive	9516043	CHEMBL1963698	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: TBK1	F	Cc1ccc(NC(=O)c2ccc(CN3CCN(C)CC3)cc2)cc1Nc1nccc(-c2cccnc2)n1		CHEMBL941	<	Ki	nM	3162.28	CHEMBL5408	Homo sapiens	pKi		5.5
inactive	9516044	CHEMBL1963698	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: TBK1	F	Nc1ncc(-c2cnn(CCO)c2)c2scc(-c3ccc(NC(=O)Nc4ccc(OC(F)F)cc4)cc3)c12		CHEMBL1972220	<	Ki	nM	3162.28	CHEMBL5408	Homo sapiens	pKi		5.5
inactive	9516045	CHEMBL1963698	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: TBK1	F	O=C(Nc1cccc(C(F)(F)F)n1)Nc1ccnc2cc(OC(F)F)ccc12		CHEMBL1981215	<	Ki	nM	3162.28	CHEMBL5408	Homo sapiens	pKi		5.5
active	9516046	CHEMBL1963698	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: TBK1	F	Fc1cccc(CNc2ncnc3[nH]cnc23)c1		CHEMBL2003785	=	Ki	nM	63095.73	CHEMBL5408	Homo sapiens	pKi		4.2
active	9516047	CHEMBL1963698	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: TBK1	F	NC1CCC(Nc2nc(Cl)cc(-c3c[nH]c4ncccc34)n2)CC1		CHEMBL1973720	=	Ki	nM	1995.26	CHEMBL5408	Homo sapiens	pKi		5.7
inactive	9516048	CHEMBL1963698	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: TBK1	F	O=C(Nc1cccc(Cl)c1)Nc1ncc(CCN=c2[nH]cnc3ccsc23)s1		CHEMBL482767	<	Ki	nM	3162.28	CHEMBL5408	Homo sapiens	pKi		5.5
inactive	9516049	CHEMBL1963698	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: TBK1	F	CCN(CC)CCCNC(=O)c1cnc(N)c2c(-c3ccc(NC(=O)Nc4cccc(C)c4)cc3)csc12		CHEMBL1999414	<	Ki	nM	3162.28	CHEMBL5408	Homo sapiens	pKi		5.5
inactive	9516050	CHEMBL1963698	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: TBK1	F	O=C(Nc1cnccn1)Nc1ccnc2c(F)cc(F)cc12		CHEMBL1967336	<	Ki	nM	3162.28	CHEMBL5408	Homo sapiens	pKi		5.5
inactive	9516051	CHEMBL1963698	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: TBK1	F	O=C1Nc2cc(CCOc3ccc(N4CCOCC4)cc3)ccc2Nc2cc(-c3cn(Cc4cc(F)c(F)c(F)c4)c4cnccc34)ccc21		CHEMBL2001923	<	Ki	nM	3162.28	CHEMBL5408	Homo sapiens	pKi		5.5
inactive	9516052	CHEMBL1963698	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: TBK1	F	CCOc1ccccc1-c1cccc(-c2n[nH]c3nc(O)cc(C)c23)c1		CHEMBL1983070	<	Ki	nM	3162.28	CHEMBL5408	Homo sapiens	pKi		5.5
inactive	9516053	CHEMBL1963698	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: TBK1	F	COc1cccc(C(C)NC(=O)c2cnc(-c3ccncc3)nc2)c1		CHEMBL2003514	<	Ki	nM	3162.28	CHEMBL5408	Homo sapiens	pKi		5.5
inactive	9516054	CHEMBL1963698	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: TBK1	F	OCCn1cc(-c2cnc3nnn(Cc4ccc5ncccc5c4)c3n2)cn1		CHEMBL2001019	<	Ki	nM	3162.28	CHEMBL5408	Homo sapiens	pKi		5.5
inactive	9516055	CHEMBL1963698	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: TBK1	F	N#Cc1ccc(-c2ccncc2)cc1NCc1ccccc1		CHEMBL1967992	<	Ki	nM	3162.28	CHEMBL5408	Homo sapiens	pKi		5.5
inactive	9516056	CHEMBL1963698	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: TBK1	F	CCN1CCN(Cc2ccc(NC(=O)Nc3ccc(Oc4cc(NC)ncn4)cc3)cc2C(F)(F)F)CC1		CHEMBL574738	<	Ki	nM	3162.28	CHEMBL5408	Homo sapiens	pKi		5.5
inactive	9516057	CHEMBL1963698	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: TBK1	F	CN1CCN(c2ccc(Nc3nc(N)c(C(=O)c4c(Cl)cccc4Cl)s3)cc2)CC1		CHEMBL1989043	<	Ki	nM	3162.28	CHEMBL5408	Homo sapiens	pKi		5.5
inactive	9516058	CHEMBL1963698	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: TBK1	F	CC(C)(C)c1cnc(CSc2cnc(NC(=O)C3CCNCC3)s2)o1		CHEMBL296468	<	Ki	nM	3162.28	CHEMBL5408	Homo sapiens	pKi		5.5
inactive	9516059	CHEMBL1963698	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: TBK1	F	CCCCC(=O)Nc1cc(-c2c[nH]c3ncccc23)cc(Cl)n1		CHEMBL2006450	<	Ki	nM	3162.28	CHEMBL5408	Homo sapiens	pKi		5.5
active	9516060	CHEMBL1963698	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: TBK1	F	NCC(O)C(O)Cn1cc(I)c2c(N)ncnc21		CHEMBL1975534	=	Ki	nM	1258.93	CHEMBL5408	Homo sapiens	pKi		5.9
inactive	9516061	CHEMBL1963698	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: TBK1	F	O=C(Nc1cccc(C(F)(F)F)n1)Nc1ccnc2c(F)ccc(F)c12		CHEMBL2001987	<	Ki	nM	3162.28	CHEMBL5408	Homo sapiens	pKi		5.5
inactive	9516062	CHEMBL1963698	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: TBK1	F	CCc1c(-c2ccc(C(C)=O)cc2)[nH]c2nccnc12		CHEMBL1994555	<	Ki	nM	3162.28	CHEMBL5408	Homo sapiens	pKi		5.5
inactive	9516063	CHEMBL1963698	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: TBK1	F	CN1CCN(c2ccc(-c3cnc4c(c3)N(Cc3cc(Cl)ccc3C(F)(F)F)CCN4)cn2)CC1		CHEMBL1164180	<	Ki	nM	3162.28	CHEMBL5408	Homo sapiens	pKi		5.5
inactive	9516064	CHEMBL1963698	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: TBK1	F	CCN(CCCOc1ccc2c(Nc3cc(CC(=O)Nc4cccc(F)c4)[nH]n3)ncnc2c1)CCOP(=O)(O)O		CHEMBL415049	<	Ki	nM	3162.28	CHEMBL5408	Homo sapiens	pKi		5.5
inactive	9516065	CHEMBL1963698	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: TBK1	F	COc1cccc(C(C)NC(=O)c2ccc(-c3ccncc3)cc2)c1		CHEMBL1975121	<	Ki	nM	3162.28	CHEMBL5408	Homo sapiens	pKi		5.5
inactive	9516066	CHEMBL1963698	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: TBK1	F	Cc1ccc(F)c(NC(=O)Nc2ccc(-c3coc4c(C#CCN5CCOCC5)cnc(N)c34)cc2)c1		CHEMBL1983640	<	Ki	nM	3162.28	CHEMBL5408	Homo sapiens	pKi		5.5
inactive	9516067	CHEMBL1963698	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: TBK1	F	CCOC(=O)c1nc2c(=O)[nH]c3cc([N+](=O)[O-])c(NC(C)=O)cc3n2c1C		CHEMBL1997611	<	Ki	nM	3162.28	CHEMBL5408	Homo sapiens	pKi		5.5
inactive	9516068	CHEMBL1963698	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: TBK1	F	Cc1c[nH]c2nccc(Oc3c(F)cc(Nc4cc(Cl)nc(N)n4)cc3F)c12		CHEMBL1971943	<	Ki	nM	3162.28	CHEMBL5408	Homo sapiens	pKi		5.5
inactive	9516069	CHEMBL1963698	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: TBK1	F	Brc1ccc2cnc(Nc3ccncn3)cc2c1		CHEMBL1984686	<	Ki	nM	3162.28	CHEMBL5408	Homo sapiens	pKi		5.5
inactive	9516070	CHEMBL1963698	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: TBK1	F	CS(=O)(=O)CCNCc1ccc(-c2ccc3ncnc(Nc4ccc(OCc5cccc(F)c5)c(Cl)c4)c3c2)o1		CHEMBL554	<	Ki	nM	3162.28	CHEMBL5408	Homo sapiens	pKi		5.5
inactive	9516071	CHEMBL1963698	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: TBK1	F	O=S(=O)(Nc1ccc2c(c1)C(=NO)c1ccccc1-2)c1cccc(Br)c1		CHEMBL1973793	<	Ki	nM	3162.28	CHEMBL5408	Homo sapiens	pKi		5.5
inactive	9516072	CHEMBL1963698	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: TBK1	F	CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3ccc(Cl)c(C(F)(F)F)c3)cc2)ccn1		CHEMBL1336	<	Ki	nM	3162.28	CHEMBL5408	Homo sapiens	pKi		5.5
active	9516073	CHEMBL1963698	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: TBK1	F	Cc1cc(Nc2ncc(F)c(NC3C4C=CC(C4)C3C(N)=O)n2)ccc1N1CCN(C)CC1		CHEMBL1967878	=	Ki	nM	79.43	CHEMBL5408	Homo sapiens	pKi		7.1
inactive	9516074	CHEMBL1963698	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: TBK1	F	CCC1CC(NS(=O)(=O)C2CC2)CC1c1ncc2cnc3[nH]ccc3n12		CHEMBL1992073	<	Ki	nM	3162.28	CHEMBL5408	Homo sapiens	pKi		5.5
inactive	9516075	CHEMBL1963698	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: TBK1	F	NCC(NC(=O)c1ccc(-c2ccncc2)cc1)c1ccccc1		CHEMBL1990254	<	Ki	nM	3162.28	CHEMBL5408	Homo sapiens	pKi		5.5
inactive	9516076	CHEMBL1963698	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: TBK1	F	O=C(NC(CCO)c1ccccc1)c1ccc(-c2ccncc2)cc1		CHEMBL1986143	<	Ki	nM	3162.28	CHEMBL5408	Homo sapiens	pKi		5.5
inactive	9516077	CHEMBL1963698	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: TBK1	F	CCCNC(=O)c1ccc(Nc2nc(NCC(F)(F)F)c3sccc3n2)cc1		CHEMBL2007559	<	Ki	nM	3162.28	CHEMBL5408	Homo sapiens	pKi		5.5
active	9516078	CHEMBL1963698	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: TBK1	F	O=C(Cc1ccc(-c2cccnc2)cc1)Nc1ccc(SC(F)F)cc1		CHEMBL1992581	=	Ki	nM	199.53	CHEMBL5408	Homo sapiens	pKi		6.7
inactive	9516079	CHEMBL1963698	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: TBK1	F	COc1ccc(NC(=O)Nc2ccc(-c3csc4c(-c5cnn(CC(C)(C)O)c5)cnc(N)c34)cc2)cc1		CHEMBL2004290	<	Ki	nM	3162.28	CHEMBL5408	Homo sapiens	pKi		5.5
active	9516080	CHEMBL1963698	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: TBK1	F	O=c1[nH]c2cc(Br)cnc2[nH]1		CHEMBL1975921	=	Ki	nM	79432.82	CHEMBL5408	Homo sapiens	pKi		4.1
inactive	9516081	CHEMBL1963698	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: TBK1	F	Brc1cnc2[nH]cc(-c3ccccc3)c2c1		CHEMBL1992634	<	Ki	nM	1584.89	CHEMBL5408	Homo sapiens	pKi		5.8
inactive	9516082	CHEMBL1963698	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: TBK1	F	CC(CCC(=O)O)(c1ccc(O)c(N)c1)c1ccc(O)c(N)c1		CHEMBL1975923	<	Ki	nM	1584.89	CHEMBL5408	Homo sapiens	pKi		5.8
inactive	9516083	CHEMBL1963698	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: TBK1	F	CC(=O)OCCn1nc(-c2cccc(Br)c2)c2c(C(F)(F)F)cc(=O)[nH]c21		CHEMBL1984847	<	Ki	nM	3162.28	CHEMBL5408	Homo sapiens	pKi		5.5
inactive	9516084	CHEMBL1963698	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: TBK1	F	Cc1cc(Nc2nc(Cl)cc(NCc3ccccc3)n2)n[nH]1		CHEMBL2005449	<	Ki	nM	3162.28	CHEMBL5408	Homo sapiens	pKi		5.5
inactive	9516085	CHEMBL1963698	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: TBK1	F	O=C(Cc1ccc(OC(F)(F)F)cc1)N1CCC2(CC1)NCCc1c2[nH]c2ccccc12		CHEMBL1996576	<	Ki	nM	3162.28	CHEMBL5408	Homo sapiens	pKi		5.5
inactive	9516086	CHEMBL1963698	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: TBK1	F	Cc1nccn2c(-c3ccnc(NCC(C)(C)CO)n3)c(-c3ccc(F)cc3F)nc12		CHEMBL1991678	<	Ki	nM	3162.28	CHEMBL5408	Homo sapiens	pKi		5.5
inactive	9516087	CHEMBL1963698	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: TBK1	F	O=C(O)C1CN(Cc2ccc(OCc3ccccc3)cc2Cl)C1		CHEMBL1987998	<	Ki	nM	3162.28	CHEMBL5408	Homo sapiens	pKi		5.5
active	9516088	CHEMBL1963698	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: TBK1	F	NC(=O)c1cc2ccncc2s1		CHEMBL1971534	=	Ki	nM	79432.82	CHEMBL5408	Homo sapiens	pKi		4.1
inactive	9516089	CHEMBL1963698	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: TBK1	F	Cn1c(NCC(N)Cc2ccccc2)nc(-c2ccncc2)c(-c2ccc3ccccc3c2)c1=O		CHEMBL1990496	<	Ki	nM	3162.28	CHEMBL5408	Homo sapiens	pKi		5.5
active	9516090	CHEMBL1963698	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: TBK1	F	O=C(O)c1ccccc1Nc1ccnc(Nc2ccc([N+](=O)[O-])cc2)n1		CHEMBL242865	=	Ki	nM	398.11	CHEMBL5408	Homo sapiens	pKi		6.4
inactive	9516091	CHEMBL1963698	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: TBK1	F	NC(=O)c1c(OCc2c(F)cc(Br)cc2F)nsc1NC(=O)NCCCCN1CCCC1		CHEMBL253969	<	Ki	nM	3162.28	CHEMBL5408	Homo sapiens	pKi		5.5
inactive	9516092	CHEMBL1963698	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: TBK1	F	COc1cc2ncc3c(N)nc4c(C)c(N)ccc4c3c2cc1OC		CHEMBL235157	<	Ki	nM	3162.28	CHEMBL5408	Homo sapiens	pKi		5.5
active	9516093	CHEMBL1963698	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: TBK1	F	CN(C)CC(=O)NC(COc1cncc(-c2ccc3cnccc3c2)c1)Cc1c[nH]c2ccccc12		CHEMBL1991725	=	Ki	nM	79.43	CHEMBL5408	Homo sapiens	pKi		7.1
inactive	9516094	CHEMBL1963698	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: TBK1	F	CC(=O)c1c(C)c2cnc(Nc3ccc(N4CCNCC4)cn3)nc2n(C2CCCC2)c1=O		CHEMBL189963	<	Ki	nM	3162.28	CHEMBL5408	Homo sapiens	pKi		5.5
inactive	9516095	CHEMBL1963698	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: TBK1	F	COc1cccc(CNC(=O)c2cnc(-c3ccncc3)nc2)c1		CHEMBL2004159	<	Ki	nM	3162.28	CHEMBL5408	Homo sapiens	pKi		5.5
inactive	9516096	CHEMBL1963698	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: TBK1	F	N#CC1=C(c2ccccc2)CC(c2ccc(Cl)cc2)C(C(=O)c2ccccc2)C1=O		CHEMBL1978371	<	Ki	nM	3162.28	CHEMBL5408	Homo sapiens	pKi		5.5
inactive	9516097	CHEMBL1963698	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: TBK1	F	NC(=O)c1ccc(-c2nc(-c3ccccn3)c(-c3ccc4c(c3)OCO4)[nH]2)cc1		CHEMBL440084	<	Ki	nM	3162.28	CHEMBL5408	Homo sapiens	pKi		5.5
inactive	9516098	CHEMBL1963698	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: TBK1	F	[2H]C([2H])([2H])Oc1cccc(C(C)NC(=O)c2sc(-c3ccncc3)nc2C)c1		CHEMBL1998110	<	Ki	nM	3162.28	CHEMBL5408	Homo sapiens	pKi		5.5
active	9516099	CHEMBL1963698	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: TBK1	F	Cc1cccc(NC(=O)Nc2ccc(-c3csc4c(C#CCCCCCCCCN)cnc(N)c34)cc2)c1		CHEMBL1978166	=	Ki	nM	1584.89	CHEMBL5408	Homo sapiens	pKi		5.8
active	9516100	CHEMBL1963698	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: TBK1	F	COc1cc(-c2ccc3c(c2)Nc2ccc(C(=O)NCc4cccc(F)c4)cc2NC3=O)ccc1O		CHEMBL2000832	=	Ki	nM	630.96	CHEMBL5408	Homo sapiens	pKi		6.2
inactive	9516101	CHEMBL1963698	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: TBK1	F	Cc1cc(O)nc2[nH]nc(-c3cccc(-c4ccc(Cl)cc4)c3)c12		CHEMBL1990590	<	Ki	nM	3162.28	CHEMBL5408	Homo sapiens	pKi		5.5
inactive	9516102	CHEMBL1963698	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: TBK1	F	Cc1nn(C)c2c1c(=O)c1cc(Cl)ccc1n2OCC(C)C		CHEMBL1977814	<	Ki	nM	3162.28	CHEMBL5408	Homo sapiens	pKi		5.5
active	9516103	CHEMBL1963698	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: TBK1	F	OCc1cc(-c2ccc3[nH]ncc3c2)on1		CHEMBL1974617	=	Ki	nM	50118.72	CHEMBL5408	Homo sapiens	pKi		4.3
inactive	9516104	CHEMBL1963698	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: TBK1	F	O=C1Nc2ccccc2C1=Cc1ccc[nH]1		CHEMBL1996176	<	Ki	nM	3162.28	CHEMBL5408	Homo sapiens	pKi		5.5
inactive	9516105	CHEMBL1963698	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: TBK1	F	NC(=O)c1cc(-c2ccnc(N)n2)[nH]c1-c1ccc(Cl)cc1Cl		CHEMBL1965660	<	Ki	nM	3162.28	CHEMBL5408	Homo sapiens	pKi		5.5
active	9516106	CHEMBL1963698	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: TBK1	F	COc1cc(Nc2ncnc(N3CCCc4cc(C)ccc43)n2)cc(OC)c1OC		CHEMBL1992125	=	Ki	nM	3162.28	CHEMBL5408	Homo sapiens	pKi		5.5
inactive	9516107	CHEMBL1963698	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: TBK1	F	CC1CCN(C(=O)CC#N)CC1c1ncc2cnc3[nH]ccc3n12		CHEMBL1966175	<	Ki	nM	3162.28	CHEMBL5408	Homo sapiens	pKi		5.5
inactive	9516108	CHEMBL1963698	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: TBK1	F	Cc1nc2c(sc3c(Br)ccc(Cl)c32)c(=O)o1		CHEMBL1974702	<	Ki	nM	1584.89	CHEMBL5408	Homo sapiens	pKi		5.8
inactive	9516109	CHEMBL1963698	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: TBK1	F	Cc1nccn2c(-c3ccnc(NCC4(O)CC4)n3)c(-c3ccc(F)cc3F)nc12		CHEMBL1965589	<	Ki	nM	1584.89	CHEMBL5408	Homo sapiens	pKi		5.8
inactive	9516110	CHEMBL1963698	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: TBK1	F	CC#Cc1ccc2nccc(NC(=O)Nc3cccc(C(F)(F)F)n3)c2c1		CHEMBL2007375	<	Ki	nM	3162.28	CHEMBL5408	Homo sapiens	pKi		5.5
active	9516111	CHEMBL1963698	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: TBK1	F	CC(C)(C)c1ccc2nc(-c3n[nH]c4ccccc34)[nH]c2c1		CHEMBL1970104	=	Ki	nM	158.49	CHEMBL5408	Homo sapiens	pKi		6.8
inactive	9516112	CHEMBL1963698	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: TBK1	F	O=C1NC(=O)c2c1c(-c1ccccc1Cl)cc1[nH]c3ccc(O)cc3c21		CHEMBL379975	<	Ki	nM	3162.28	CHEMBL5408	Homo sapiens	pKi		5.5
inactive	9516113	CHEMBL1963698	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: TBK1	F	Nc1n[nH]c2c(OCCCn3cccc3)ccc(-c3ccc(NC(=O)Nc4cccc(Cl)c4)cc3)c12		CHEMBL1965387	<	Ki	nM	3162.28	CHEMBL5408	Homo sapiens	pKi		5.5
active	9516114	CHEMBL1963698	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: TBK1	F	CNC1CC2OC(C)(C1OC)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)C(=O)NC4		CHEMBL1980995	=	Ki	nM	1.259	CHEMBL5408	Homo sapiens	pKi		8.9
active	9516115	CHEMBL1963698	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: TBK1	F	Cc1cc(-c2ncnc3[nH]ccc23)ccc1F		CHEMBL1997041	=	Ki	nM	50118.72	CHEMBL5408	Homo sapiens	pKi		4.3
inactive	9516116	CHEMBL1963698	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: TBK1	F	COc1cc(-c2ccc3c(c2)Nc2c(O)cccc2NC3=O)ccc1O		CHEMBL550418	<	Ki	nM	3162.28	CHEMBL5408	Homo sapiens	pKi		5.5
inactive	9516117	CHEMBL1963698	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: TBK1	F	CC(=O)N1CCN(C2CCC(n3nc(-c4ccc(NC(=O)c5cc6ccccc6n5C)cc4)c4c(N)ncnc43)CC2)CC1		CHEMBL1972584	<	Ki	nM	1584.89	CHEMBL5408	Homo sapiens	pKi		5.8
inactive	9516118	CHEMBL1963698	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: TBK1	F	N#Cc1ccc2[nH]c(O)c(-c3ccc(CN4CCOCC4)cn3)c2c1		CHEMBL1969664	<	Ki	nM	3162.28	CHEMBL5408	Homo sapiens	pKi		5.5
inactive	9516119	CHEMBL1963698	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: TBK1	F	N#Cc1ccc(-c2n[nH]c3c2Cc2ccc(OCCCCN4CCOCC4)cc2-3)cn1		CHEMBL398951	<	Ki	nM	3162.28	CHEMBL5408	Homo sapiens	pKi		5.5
inactive	9516120	CHEMBL1963698	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: TBK1	F	CCOc1ccc(C=C2SC(=N)NC2=O)c(O)c1		CHEMBL1971289	<	Ki	nM	3162.28	CHEMBL5408	Homo sapiens	pKi		5.5
active	9516121	CHEMBL1963698	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: TBK1	F	CNC(=O)c1ccccc1Sc1ccc2c(C=Cc3ccccn3)n[nH]c2c1		CHEMBL1988437	=	Ki	nM	1584.89	CHEMBL5408	Homo sapiens	pKi		5.8
inactive	9516122	CHEMBL1963698	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: TBK1	F	CCCC(=O)Nc1n[nH]c2ccc(-c3cccc(F)c3F)cc12		CHEMBL1985406	<	Ki	nM	1584.89	CHEMBL5408	Homo sapiens	pKi		5.8
active	9516123	CHEMBL1963698	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: TBK1	F	O=C(Cc1cccs1)Nc1nc2ccccc2s1		CHEMBL1421720	=	Ki	nM	2511.89	CHEMBL5408	Homo sapiens	pKi		5.6
inactive	9516124	CHEMBL1963698	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: TBK1	F	COc1ccc2c(c1)c(-c1cc3nccnc3[nH]1)cn2C		CHEMBL1233887	<	Ki	nM	3162.28	CHEMBL5408	Homo sapiens	pKi		5.5
active	9516125	CHEMBL1963698	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: TBK1	F	Nc1ncnc2c1C(=O)NCCN2		CHEMBL1992607	=	Ki	nM	50118.72	CHEMBL5408	Homo sapiens	pKi		4.3
inactive	9516126	CHEMBL1963698	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: TBK1	F	CCN(CC)CCCNC(=O)c1cnc(N)c2c(-c3ccc(NC(=O)Nc4cccc(F)c4)cc3)csc12		CHEMBL1996649	<	Ki	nM	3162.28	CHEMBL5408	Homo sapiens	pKi		5.5
inactive	9516127	CHEMBL1963698	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: TBK1	F	CCc1ccc2c(NC(=O)Nc3cccc(C(F)(F)F)n3)ccnc2c1		CHEMBL1986756	<	Ki	nM	3162.28	CHEMBL5408	Homo sapiens	pKi		5.5
inactive	9516128	CHEMBL1963698	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: TBK1	F	COc1cc(Nc2ncc3c(n2)-c2ccc(Cl)cc2C(c2c(F)cccc2OC)=NC3)ccc1C(=O)O		CHEMBL483158	<	Ki	nM	3162.28	CHEMBL5408	Homo sapiens	pKi		5.5
active	9516129	CHEMBL1963698	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: TBK1	F	O=c1[nH]cnc2c(Cl)cccc12		CHEMBL1949855	=	Ki	nM	79432.82	CHEMBL5408	Homo sapiens	pKi		4.1
inactive	9516130	CHEMBL1963698	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: TBK1	F	CCN(CC)CCNC(=O)c1c(C)[nH]c(C=C2C(=O)Nc3ccc(F)cc32)c1C		CHEMBL1990885	<	Ki	nM	3162.28	CHEMBL5408	Homo sapiens	pKi		5.5
inactive	9516131	CHEMBL1963698	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: TBK1	F	Cc1cc(OCc2ccc(Cl)c(Cl)c2)ccc1CN1CC(C(=O)O)C1		CHEMBL1990223	<	Ki	nM	3162.28	CHEMBL5408	Homo sapiens	pKi		5.5
inactive	9516132	CHEMBL1963698	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: TBK1	F	Nc1c(-c2ccc(NC(=O)Nc3cccc(C(F)(F)F)c3)cc2)ccc2nccnc12		CHEMBL2004438	<	Ki	nM	3162.28	CHEMBL5408	Homo sapiens	pKi		5.5
inactive	9516133	CHEMBL1963698	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: TBK1	F	CC(C)(c1cc(Br)c(O)c(I)c1)c1cc(Br)c(O)c(I)c1		CHEMBL1964382	<	Ki	nM	3162.28	CHEMBL5408	Homo sapiens	pKi		5.5
inactive	9516134	CHEMBL1963698	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: TBK1	F	CN(C)CC(O)COc1ccc(Nc2nccc(Nc3cc(Cl)ccc3Cl)n2)cc1		CHEMBL101311	<	Ki	nM	3162.28	CHEMBL5408	Homo sapiens	pKi		5.5
inactive	9516135	CHEMBL1963698	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: TBK1	F	Nc1nc(Nc2ccc(S(N)(=O)=O)cc2)nn1C(=O)c1c(F)cccc1F		CHEMBL191003	<	Ki	nM	3162.28	CHEMBL5408	Homo sapiens	pKi		5.5
active	9516136	CHEMBL1963698	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: TBK1	F	NC(=O)c1ccc2nc(-c3ccc([N+](=O)[O-])o3)cn2c1		CHEMBL1973359	=	Ki	nM	501.19	CHEMBL5408	Homo sapiens	pKi		6.3
active	9516137	CHEMBL1963698	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: TBK1	F	Cc1cc(=O)n2ccc(CN(C)C)c(O)c2n1		CHEMBL1988581	=	Ki	nM	125.89	CHEMBL5408	Homo sapiens	pKi		6.9
inactive	9516138	CHEMBL1963698	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: TBK1	F	COc1cc(-c2ccc3c(c2)Nc2ccc(C(=O)NCCNC(C)=O)cc2NC3=O)ccc1O		CHEMBL1975500	<	Ki	nM	1584.89	CHEMBL5408	Homo sapiens	pKi		5.8
inactive	9516139	CHEMBL1963698	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: TBK1	F	CC(C)(C)c1cc(NC(=O)C(=O)c2cccc3ccccc23)n(-c2ccc(OCC(=O)O)cc2)n1		CHEMBL2005699	<	Ki	nM	3162.28	CHEMBL5408	Homo sapiens	pKi		5.5
active	9516140	CHEMBL1963698	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: TBK1	F	CCN(C(C)=O)c1ccc(Nc2nc(NC3CC3)c3nc[nH]c3n2)cc1		CHEMBL2006564	=	Ki	nM	79.43	CHEMBL5408	Homo sapiens	pKi		7.1
active	9516141	CHEMBL1963698	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: TBK1	F	OC1CCC(Nc2nc(Cl)cc(-c3c[nH]c4ncccc34)n2)CC1		CHEMBL1986943	=	Ki	nM	1000.0	CHEMBL5408	Homo sapiens	pKi		6.0
active	9516142	CHEMBL1963698	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: TBK1	F	CN1CCN(c2ccc(Nc3ncc(Cl)c(Nc4ccc5[nH]ncc5c4)n3)cc2)CC1		CHEMBL1979690	=	Ki	nM	100.0	CHEMBL5408	Homo sapiens	pKi		7.0
inactive	9516143	CHEMBL1963698	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: TBK1	F	CC1CCN(C(=O)CC#N)CC1N(C)c1ncnc2[nH]ccc12		CHEMBL234085	<	Ki	nM	3162.28	CHEMBL5408	Homo sapiens	pKi		5.5
inactive	9516144	CHEMBL1963698	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: TBK1	F	Cn1cc(-c2cc3nc(Br)cnc3[nH]2)c2ccccc21		CHEMBL1978167	<	Ki	nM	3162.28	CHEMBL5408	Homo sapiens	pKi		5.5
active	9516145	CHEMBL1963698	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: TBK1	F	CN1CCC(c2c(O)cc(O)c3c(=O)cc(-c4ccccc4Cl)oc23)C(O)C1		CHEMBL422897	=	Ki	nM	3162.28	CHEMBL5408	Homo sapiens	pKi		5.5
inactive	9516146	CHEMBL1963698	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: TBK1	F	CN1CCN(c2ccc3nc(-c4c(N)c5c(F)cccc5[nH]c4=O)[nH]c3c2)CC1		CHEMBL522892	<	Ki	nM	1000.0	CHEMBL5408	Homo sapiens	pKi		6.0
inactive	9516147	CHEMBL1963698	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: TBK1	F	O=C1NCCc2[nH]c(-c3ccncc3)cc21		CHEMBL225519	<	Ki	nM	3162.28	CHEMBL5408	Homo sapiens	pKi		5.5
inactive	9516148	CHEMBL1963698	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: TBK1	F	Nc1ncnc2c1c(-c1ccc(Oc3ccc(CO)cc3)cc1)cn2C1CCOC1		CHEMBL1976376	<	Ki	nM	3162.28	CHEMBL5408	Homo sapiens	pKi		5.5
active	9516149	CHEMBL1963698	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: TBK1	F	O=C(NN=Cc1cc(Br)c(O)c(Br)c1)Nc1ccccc1		CHEMBL1983575	=	Ki	nM	794.33	CHEMBL5408	Homo sapiens	pKi		6.1
inactive	9516150	CHEMBL1963698	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: TBK1	F	N#Cc1cccc(NC(=O)Nc2ccnc3cc(C(F)(F)F)ccc23)n1		CHEMBL1968868	<	Ki	nM	3162.28	CHEMBL5408	Homo sapiens	pKi		5.5
inactive	9516151	CHEMBL1963698	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: TBK1	F	COC(C(=O)N1Cc2[nH]nc(NC(=O)c3ccc(N4CCN(C)CC4)cc3)c2C1)c1ccccc1		CHEMBL1981047	<	Ki	nM	3162.28	CHEMBL5408	Homo sapiens	pKi		5.5
inactive	9516152	CHEMBL1963698	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: TBK1	F	CCCC(=O)Nc1cc(-c2c[nH]c3ncccc23)cc(Cl)n1		CHEMBL1998470	<	Ki	nM	3162.28	CHEMBL5408	Homo sapiens	pKi		5.5
inactive	9516153	CHEMBL1963698	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: TBK1	F	O=C(Nc1ccc([N+](=O)[O-])cc1)N1CCc2[nH]c3c(Cl)cc(Cl)cc3c2C1		CHEMBL1976196	<	Ki	nM	3162.28	CHEMBL5408	Homo sapiens	pKi		5.5
inactive	9516154	CHEMBL1963698	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: TBK1	F	COc1ccccc1CNC(=N)Nc1nccc(-c2cccs2)n1		CHEMBL1997197	<	Ki	nM	3162.28	CHEMBL5408	Homo sapiens	pKi		5.5
inactive	9516155	CHEMBL1963698	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: TBK1	F	COc1ccccc1-c1ccnc(Nc2cccc(S(C)(=O)=O)c2)n1		CHEMBL1975903	<	Ki	nM	3162.28	CHEMBL5408	Homo sapiens	pKi		5.5
active	9516156	CHEMBL1963698	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: TBK1	F	O=C1Cc2cc(-c3ccccc3)cnc2N1		CHEMBL1983630	=	Ki	nM	79432.82	CHEMBL5408	Homo sapiens	pKi		4.1
active	9516157	CHEMBL1963698	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: TBK1	F	Cc1nc(N)sc1-c1ccnc(Nc2ccc(N3CCOCC3)cc2)n1		CHEMBL482967	=	Ki	nM	63.1	CHEMBL5408	Homo sapiens	pKi		7.2
inactive	9516158	CHEMBL1963698	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: TBK1	F	N#Cc1ccc2nc(N)n(-c3nccs3)c2c1		CHEMBL1988805	<	Ki	nM	3162.28	CHEMBL5408	Homo sapiens	pKi		5.5
active	9516159	CHEMBL1963698	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: TBK1	F	CNC(=O)c1ccccc1Nc1nc(Nc2ccc(N3CCOCC3)cc2OC)ncc1Cl		CHEMBL458997	=	Ki	nM	1258.93	CHEMBL5408	Homo sapiens	pKi		5.9
inactive	9516160	CHEMBL1963698	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: TBK1	F	O=C(Nc1ccc(-c2ccc3cn[nH]c3c2)cc1)Nc1cccc(F)c1		CHEMBL1969942	<	Ki	nM	3162.28	CHEMBL5408	Homo sapiens	pKi		5.5
active	9516161	CHEMBL1963698	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: TBK1	F	NC(=O)c1cc2c(-c3ccc(F)cc3)cncc2s1		CHEMBL1974310	=	Ki	nM	1258.93	CHEMBL5408	Homo sapiens	pKi		5.9
inactive	9516162	CHEMBL1963698	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: TBK1	F	COc1cccc(C(C)NC(=O)c2sc(-c3ccncc3)nc2C)c1		CHEMBL1978567	<	Ki	nM	3162.28	CHEMBL5408	Homo sapiens	pKi		5.5
inactive	9516163	CHEMBL1963698	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: TBK1	F	CC(Oc1cc(-c2cnn(C3CCNCC3)c2)cnc1N)c1c(Cl)ccc(F)c1Cl		CHEMBL1825138	<	Ki	nM	1584.89	CHEMBL5408	Homo sapiens	pKi		5.8
inactive	9516164	CHEMBL1963698	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: TBK1	F	O=C1Nc2ccccc2C1=Cc1ccc[nH]1		CHEMBL1996176	<	Ki	nM	3162.28	CHEMBL5408	Homo sapiens	pKi		5.5
active	9516165	CHEMBL1963698	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: TBK1	F	Nc1cc(=O)[nH]n1-c1ccccn1		CHEMBL1995765	=	Ki	nM	7943.28	CHEMBL5408	Homo sapiens	pKi		5.1
inactive	9516166	CHEMBL1963698	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: TBK1	F	O=C(NNC(=S)Nc1ccc(F)cc1)C(O)(c1ccccc1)c1ccccc1		CHEMBL1975138	<	Ki	nM	1584.89	CHEMBL5408	Homo sapiens	pKi		5.8
inactive	9516167	CHEMBL1963698	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: TBK1	F	CCCNC(=O)c1ccc(Nc2nc(CCC(F)(F)F)c3cc[nH]c3n2)cc1		CHEMBL1984760	<	Ki	nM	3162.28	CHEMBL5408	Homo sapiens	pKi		5.5
inactive	9516168	CHEMBL1963698	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: TBK1	F	Clc1cc(NC2CCCCC2)nc(-c2c[nH]c3ncccc23)n1		CHEMBL1997846	<	Ki	nM	3162.28	CHEMBL5408	Homo sapiens	pKi		5.5
inactive	9516169	CHEMBL1963698	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: TBK1	F	CCOc1nc(C(=O)NCc2ccc(S(C)(=O)=O)cc2)cc(N)c1C#N		CHEMBL424872	<	Ki	nM	3162.28	CHEMBL5408	Homo sapiens	pKi		5.5
inactive	9516170	CHEMBL1963698	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: TBK1	F	Cc1ccc(-n2nc(C(C)(C)C)cc2NC(=O)Nc2ccc(OCCN3CCOCC3)c3ccccc23)cc1		CHEMBL103667	<	Ki	nM	3162.28	CHEMBL5408	Homo sapiens	pKi		5.5
active	9516171	CHEMBL1963698	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: TBK1	F	CN(C)CC1CCn2cc(c3ccccc32)C2=C(C(=O)NC2=O)c2cn(c3ccccc23)CCO1		CHEMBL360847	=	Ki	nM	501.19	CHEMBL5408	Homo sapiens	pKi		6.3
active	9516172	CHEMBL1963698	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: TBK1	F	O=C(Nc1n[nH]c2ccc(-c3cn(Cc4ccccc4)nn3)cc12)c1cc(F)ccc1F		CHEMBL1995811	=	Ki	nM	794.33	CHEMBL5408	Homo sapiens	pKi		6.1
inactive	9516173	CHEMBL1963698	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: TBK1	F	CCN(CC)CCOc1ccc(Nc2ncc3cc(-c4c(Cl)cccc4Cl)c(=O)n(C)c3n2)cc1		CHEMBL49120	<	Ki	nM	3162.28	CHEMBL5408	Homo sapiens	pKi		5.5
active	9516174	CHEMBL1963698	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: TBK1	F	CC(=O)NCC(=O)N1C2CCC1c1cc(Nc3ncc(C(F)(F)F)c(NC4CCC4)n3)ccc12		CHEMBL1983111	=	Ki	nM	12.59	CHEMBL5408	Homo sapiens	pKi		7.9
inactive	9516175	CHEMBL1963698	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: TBK1	F	CCC(=O)Nc1ccc(C(=O)N2CCNCC2)c(O)c1		CHEMBL1988141	<	Ki	nM	3162.28	CHEMBL5408	Homo sapiens	pKi		5.5
inactive	9516176	CHEMBL1963698	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: TBK1	F	Cc1ccc(Nc2nc3ccc([N+](=O)[O-])cc3[nH]2)nc1		CHEMBL1992937	<	Ki	nM	3162.28	CHEMBL5408	Homo sapiens	pKi		5.5
inactive	9516177	CHEMBL1963698	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: TBK1	F	Nc1c(-c2ccc(NC(=O)Nc3cccc(C(F)(F)F)c3)cc2)cnc2c(-c3ccc4c(c3)OCO4)cnn12		CHEMBL1977134	<	Ki	nM	3162.28	CHEMBL5408	Homo sapiens	pKi		5.5
inactive	9516178	CHEMBL1963698	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: TBK1	F	COCC#Cc1cccc2c1Cc1c(-c3cccs3)n[nH]c1-2		CHEMBL1985206	<	Ki	nM	3162.28	CHEMBL5408	Homo sapiens	pKi		5.5
inactive	9516179	CHEMBL1963698	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: TBK1	F	O=C(O)c1ccc(Nc2ncc3c(n2)-c2ccc(Cl)cc2C(c2c(F)cccc2F)=NC3)cc1		CHEMBL259084	<	Ki	nM	3162.28	CHEMBL5408	Homo sapiens	pKi		5.5
active	9516180	CHEMBL1963698	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: TBK1	F	COc1ccc(C(=O)Nc2n[nH]c3ccc(-c4cn(Cc5ccccc5)nn4)cc23)cc1OC		CHEMBL1991078	=	Ki	nM	25.12	CHEMBL5408	Homo sapiens	pKi		7.6
inactive	9516181	CHEMBL1963698	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: TBK1	F	O=C(Cc1ccccc1)Nc1cccc(-c2nc3sccn3c2-c2ccnc(Nc3ccc(N4CCOCC4)cc3)n2)c1		CHEMBL1090356	<	Ki	nM	1584.89	CHEMBL5408	Homo sapiens	pKi		5.8
active	9516182	CHEMBL1963698	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: TBK1	F	C=CCc1cccc2c(=NO)cc(-c3ccccc3)oc12		CHEMBL1977749	=	Ki	nM	2511.89	CHEMBL5408	Homo sapiens	pKi		5.6
active	9516183	CHEMBL1963698	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: TBK1	F	O=c1[nH][nH]c2ccc(Br)cc12		CHEMBL2001613	=	Ki	nM	31622.78	CHEMBL5408	Homo sapiens	pKi		4.5
inactive	9516184	CHEMBL1963698	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: TBK1	F	COc1ccc(COc2ccc(Cc3cnc(N)nc3N)cc2OC)cc1		CHEMBL261849	<	Ki	nM	3162.28	CHEMBL5408	Homo sapiens	pKi		5.5
active	9516185	CHEMBL1963698	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: TBK1	F	Cc1cc(Nc2cc(N3CCN(C)CC3)nc(C=Cc3ccccc3)n2)n[nH]1		CHEMBL1983923	=	Ki	nM	158.49	CHEMBL5408	Homo sapiens	pKi		6.8
inactive	9516186	CHEMBL1963698	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: TBK1	F	CN1CCN(c2nc(C3=C(c4c[nH]c5ccccc45)C(=O)NC3=O)c3ccccc3n2)CC1		CHEMBL565612	<	Ki	nM	3162.28	CHEMBL5408	Homo sapiens	pKi		5.5
inactive	9516187	CHEMBL1963698	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: TBK1	F	NC(=O)c1cc2c(-c3ccc(Nc4nc5ccccc5o4)cc3)cnc(N)c2s1		CHEMBL1993904	<	Ki	nM	3162.28	CHEMBL5408	Homo sapiens	pKi		5.5
inactive	9516188	CHEMBL1963698	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: TBK1	F	COc1ccc2[nH]cc(C=C3C(=O)Nc4ccccc43)c2c1		CHEMBL1997275	<	Ki	nM	3162.28	CHEMBL5408	Homo sapiens	pKi		5.5
inactive	9516189	CHEMBL1963698	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: TBK1	F	CCOC(=O)C1=c2sc(=Cc3ccco3)c(=O)n2C(N)=C(C#N)C1c1ccco1		CHEMBL1999112	<	Ki	nM	1584.89	CHEMBL5408	Homo sapiens	pKi		5.8
inactive	9516190	CHEMBL1963698	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: TBK1	F	O=C(Nc1cccc(C(F)(F)F)n1)Nc1ccnc2ccc(Cl)cc12		CHEMBL1967513	<	Ki	nM	3162.28	CHEMBL5408	Homo sapiens	pKi		5.5
inactive	9516191	CHEMBL1963698	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: TBK1	F	Cc1cc(O)nc2[nH]nc(-c3cccc(-c4ccc(C#N)cc4)c3)c12		CHEMBL2000724	<	Ki	nM	3162.28	CHEMBL5408	Homo sapiens	pKi		5.5
inactive	9516192	CHEMBL1963698	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: TBK1	F	COc1ccc2c(NC(=O)Nc3cccc(C(F)(F)F)n3)ccnc2c1		CHEMBL1982660	<	Ki	nM	3162.28	CHEMBL5408	Homo sapiens	pKi		5.5
inactive	9516193	CHEMBL1963698	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: TBK1	F	CN(Cc1cc(Cl)c(O)c2ncccc12)C1CCCCC1		CHEMBL1982413	<	Ki	nM	3162.28	CHEMBL5408	Homo sapiens	pKi		5.5
active	9516194	CHEMBL1963698	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: TBK1	F	Cc1cc(=O)[nH]c2[nH]n(-c3ccccc3)c(=O)c12		CHEMBL1985042	=	Ki	nM	50118.72	CHEMBL5408	Homo sapiens	pKi		4.3
inactive	9516195	CHEMBL1963698	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: TBK1	F	O=C(NCCc1cccs1)N1CC=C(c2c[nH]c3ncccc23)CC1		CHEMBL1987535	<	Ki	nM	3162.28	CHEMBL5408	Homo sapiens	pKi		5.5
inactive	9516196	CHEMBL1963698	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: TBK1	F	O=C(Nc1cccc(F)c1)Nc1cccc(-c2ccc3cn[nH]c3c2)c1		CHEMBL1983393	<	Ki	nM	3162.28	CHEMBL5408	Homo sapiens	pKi		5.5
inactive	9516197	CHEMBL1963698	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: TBK1	F	O=C(Nc1cccc(C(F)(F)F)n1)Nc1ccnc2cc(F)c(F)cc12		CHEMBL1981792	<	Ki	nM	3162.28	CHEMBL5408	Homo sapiens	pKi		5.5
inactive	9516198	CHEMBL1963698	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: TBK1	F	Clc1cc(Nc2nc(NC3CC3)c3sccc3n2)ccc1N1CCOCC1		CHEMBL2002586	<	Ki	nM	3162.28	CHEMBL5408	Homo sapiens	pKi		5.5
inactive	9516199	CHEMBL1963698	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: TBK1	F	CCc1cnn2c(NCc3ccc[n+]([O-])c3)cc(N3CCCCC3CCO)nc12		CHEMBL2006674	<	Ki	nM	3162.28	CHEMBL5408	Homo sapiens	pKi		5.5
inactive	9516200	CHEMBL1963698	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: TBK1	F	NC(COc1cncc(-c2ccc3cnccc3c2)c1)Cc1c[nH]c2ccccc12		CHEMBL1981133	<	Ki	nM	3162.28	CHEMBL5408	Homo sapiens	pKi		5.5
inactive	9516201	CHEMBL1963698	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: TBK1	F	O=C(Nc1cnccn1)Nc1cccc2c(O)cccc12		CHEMBL1992371	<	Ki	nM	3162.28	CHEMBL5408	Homo sapiens	pKi		5.5
inactive	9516202	CHEMBL1963698	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: TBK1	F	CN(C)c1ccc(Nc2cc(-c3csc(Br)c3)[nH]n2)cc1		CHEMBL1984236	<	Ki	nM	3162.28	CHEMBL5408	Homo sapiens	pKi		5.5
inactive	9516203	CHEMBL1963698	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: TBK1	F	CC(C)Oc1cc(Nc2nc(NC(C)c3ccc(F)cn3)ncc2Cl)n[nH]1		CHEMBL2007421	<	Ki	nM	3162.28	CHEMBL5408	Homo sapiens	pKi		5.5
inactive	9516204	CHEMBL1963698	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: TBK1	F	Cc1c(NC(=O)c2ccc(C(C)(C)C)cc2)cccc1-c1cc(Nc2ccc(C(=O)N3CCOCC3)cn2)c(=O)n(C)c1		CHEMBL1973138	<	Ki	nM	3162.28	CHEMBL5408	Homo sapiens	pKi		5.5
inactive	9516205	CHEMBL1963698	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: TBK1	F	O=C(Nc1cnccn1)Nc1ccnc2ccc(N3CC4COCC4C3)cc12		CHEMBL2002599	<	Ki	nM	3162.28	CHEMBL5408	Homo sapiens	pKi		5.5
active	9516206	CHEMBL1963698	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: TBK1	F	CN1CCN(c2ccc(C(=O)Nc3n[nH]c4ccc(Cc5cc(F)cc(F)c5)cc34)c(NC3CCOCC3)c2)CC1		CHEMBL1983268	=	Ki	nM	2511.89	CHEMBL5408	Homo sapiens	pKi		5.6
active	9516207	CHEMBL1963698	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: TBK1	F	CN(C)C1CCC(Nc2nc(Cl)cc(-c3c[nH]c4ncccc34)n2)CC1		CHEMBL1969151	=	Ki	nM	1995.26	CHEMBL5408	Homo sapiens	pKi		5.7
active	9516208	CHEMBL1963698	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: TBK1	F	Cc1n[nH]c2ccc(-c3cccnc3)cc12		CHEMBL1967252	=	Ki	nM	39810.72	CHEMBL5408	Homo sapiens	pKi		4.4
active	9516209	CHEMBL1963698	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: TBK1	F	Cn1cc(-c2cc3nc(Br)cnc3[nH]2)c2cc(F)ccc21		CHEMBL1993335	=	Ki	nM	1000.0	CHEMBL5408	Homo sapiens	pKi		6.0
inactive	9516210	CHEMBL1963698	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: TBK1	F	Nc1nc(Cl)cc(-c2c[nH]c3ncccc23)n1		CHEMBL2007574	<	Ki	nM	3162.28	CHEMBL5408	Homo sapiens	pKi		5.5
inactive	9516211	CHEMBL1963698	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: TBK1	F	CC(C)NC1=NNC(=O)C1=Cc1cc2ccccc2[nH]1		CHEMBL1988692	<	Ki	nM	3162.28	CHEMBL5408	Homo sapiens	pKi		5.5
inactive	9516212	CHEMBL1963698	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: TBK1	F	CCN(CCN)C(=O)c1cccc(-n2nc(C(C)(C)C)cc2NC(=O)Nc2cccc3ccccc23)c1		CHEMBL2004637	<	Ki	nM	3162.28	CHEMBL5408	Homo sapiens	pKi		5.5
inactive	9516213	CHEMBL1963698	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: TBK1	F	CC(C)C(C)Nc1ncc(Cl)c(Nc2nccs2)n1		CHEMBL1993374	<	Ki	nM	3162.28	CHEMBL5408	Homo sapiens	pKi		5.5
inactive	9516214	CHEMBL1963698	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: TBK1	F	CC(C)N(CCCN)C(=O)c1cccc(-n2nc(C(C)(C)C)cc2NC(=O)Nc2cccc3ccccc23)c1		CHEMBL1994318	<	Ki	nM	3162.28	CHEMBL5408	Homo sapiens	pKi		5.5
inactive	9516215	CHEMBL1963698	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: TBK1	F	COc1ccc(C=C2SC(=Nc3ccccc3)NC2=O)cc1O		CHEMBL2000354	<	Ki	nM	1584.89	CHEMBL5408	Homo sapiens	pKi		5.8
inactive	9516216	CHEMBL1963698	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: TBK1	F	CC(C)(C)c1cc(NC(=O)C(=O)c2cccc3ccccc23)n(-c2cccc(OCC(=O)NCCO)c2)n1		CHEMBL1998680	<	Ki	nM	3162.28	CHEMBL5408	Homo sapiens	pKi		5.5
inactive	9516217	CHEMBL1963698	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: TBK1	F	NCCCn1cc(-c2cc(-c3cc4ccccc4s3)c3[nH]ncc3c2)c2nc(N)ncc21		CHEMBL592030	<	Ki	nM	1584.89	CHEMBL5408	Homo sapiens	pKi		5.8
inactive	9516218	CHEMBL1963698	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: TBK1	F	CC(C)(C)c1cc(NC(=O)Nc2cccc3ccccc23)n(-c2cccc(C(=O)NCCCCC(=O)O)c2)n1		CHEMBL1999506	<	Ki	nM	3162.28	CHEMBL5408	Homo sapiens	pKi		5.5
inactive	9516219	CHEMBL1963698	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: TBK1	F	CC(N)C1CCC(C(=O)Nc2ccncc2)CC1		CHEMBL1994526	<	Ki	nM	3162.28	CHEMBL5408	Homo sapiens	pKi		5.5
inactive	9516220	CHEMBL1963698	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: TBK1	F	CC(C)OC1=NNC(=O)C1=Cc1c[nH]c2ccccc12		CHEMBL1989029	<	Ki	nM	1584.89	CHEMBL5408	Homo sapiens	pKi		5.8
active	9516221	CHEMBL1963698	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: TBK1	F	CCCNC(=O)c1ccc(Nc2nc(CC)c3cc[nH]c3n2)cc1		CHEMBL1997007	=	Ki	nM	2511.89	CHEMBL5408	Homo sapiens	pKi		5.6
inactive	9516222	CHEMBL1963698	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: TBK1	F	CCOC(=O)c1c(C)n(-c2ccc(I)cc2)c2c1cc(O)c1ccccc12		CHEMBL1970352	<	Ki	nM	3162.28	CHEMBL5408	Homo sapiens	pKi		5.5
inactive	9516223	CHEMBL1963698	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: TBK1	F	O=C(Nc1nc2c(O)cccc2s1)Nc1ccccc1-c1ccccc1		CHEMBL2002690	<	Ki	nM	3162.28	CHEMBL5408	Homo sapiens	pKi		5.5
inactive	9516224	CHEMBL1963698	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: TBK1	F	CN(C)c1ccc(-c2cc(-c3ccc([N+](=O)[O-])cc3)nc(NS(=O)(=O)c3ccc(N)cc3)n2)cc1		CHEMBL1980167	<	Ki	nM	3162.28	CHEMBL5408	Homo sapiens	pKi		5.5
inactive	9516225	CHEMBL1963698	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: TBK1	F	CCOc1nc(C(=O)NCc2ccccc2S(N)(=O)=O)cc(N)c1C#N		CHEMBL377408	<	Ki	nM	3162.28	CHEMBL5408	Homo sapiens	pKi		5.5
inactive	9516226	CHEMBL1963698	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: TBK1	F	Oc1ccc(-c2nc(-c3ccc(F)cc3)c(-c3ccncc3)[nH]2)cc1		CHEMBL278041	<	Ki	nM	3162.28	CHEMBL5408	Homo sapiens	pKi		5.5
inactive	9516227	CHEMBL1963698	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: TBK1	F	CCN(CCO)CCCOc1ccc2c(Nc3cc(CC(=O)Nc4cccc(F)c4)[nH]n3)ncnc2c1		CHEMBL215152	<	Ki	nM	3162.28	CHEMBL5408	Homo sapiens	pKi		5.5
active	9516228	CHEMBL1963698	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: TBK1	F	CCCNC(=O)c1ccc(Nc2nc(NCC(F)(F)F)c3cc[nH]c3n2)cc1		CHEMBL2006765	=	Ki	nM	501.19	CHEMBL5408	Homo sapiens	pKi		6.3
inactive	9516229	CHEMBL1963698	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: TBK1	F	O=C1Nc2ccccc2C1=Cc1c[nH]c2ccccc12		CHEMBL1986590	<	Ki	nM	3162.28	CHEMBL5408	Homo sapiens	pKi		5.5
inactive	9516230	CHEMBL1963698	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: TBK1	F	CCn1c(-c2nonc2N)nc2cncc(C(=O)N3CCC(N)C3)c21		CHEMBL1870106	<	Ki	nM	3162.28	CHEMBL5408	Homo sapiens	pKi		5.5
inactive	9516231	CHEMBL1963698	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: TBK1	F	CC(C)(C)n1nc(-c2ccc(Cl)cc2)c2c(N)ncnc21		CHEMBL406845	<	Ki	nM	3162.28	CHEMBL5408	Homo sapiens	pKi		5.5
inactive	9516232	CHEMBL1963698	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: TBK1	F	NCc1cc(Nc2ncnc(-c3ccccc3)n2)ccc1O		CHEMBL1980246	<	Ki	nM	3162.28	CHEMBL5408	Homo sapiens	pKi		5.5
active	9516233	CHEMBL1963698	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: TBK1	F	CC(C)(C)c1ccc2nc(-c3n[nH]c4ccccc34)[nH]c2c1		CHEMBL1970104	=	Ki	nM	158.49	CHEMBL5408	Homo sapiens	pKi		6.8
active	9516234	CHEMBL1963698	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: TBK1	F	O=C(Nc1nc2ccccc2s1)c1cccc2c1CN(c1nc(C(=O)O)c(-c3ccc(CO)cc3)s1)CC2		CHEMBL1983980	=	Ki	nM	3162.28	CHEMBL5408	Homo sapiens	pKi		5.5
active	9516235	CHEMBL1963698	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: TBK1	F	CNc1nc(C)c(-c2ccnc(Nc3ccc(N4CCNCC4)cc3)n2)s1		CHEMBL1999484	=	Ki	nM	158.49	CHEMBL5408	Homo sapiens	pKi		6.8
inactive	9516236	CHEMBL1963698	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: TBK1	F	Nc1ncc(-c2cnn(CCO)c2)c2scc(-c3ccc(NC(=O)Nc4cccc(F)c4)cc3)c12		CHEMBL1980297	<	Ki	nM	3162.28	CHEMBL5408	Homo sapiens	pKi		5.5
inactive	9516237	CHEMBL1963698	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: TBK1	F	Cc1ccc(C)c(NC(=O)c2cc(-c3ccco3)nc3ccccc23)c1		CHEMBL1984296	<	Ki	nM	3162.28	CHEMBL5408	Homo sapiens	pKi		5.5
inactive	9516238	CHEMBL1963698	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: TBK1	F	Cc1ccc(NCc2ccc(-c3ccc(F)cc3)nc2)cc1		CHEMBL1986899	<	Ki	nM	3162.28	CHEMBL5408	Homo sapiens	pKi		5.5
inactive	9516239	CHEMBL1963698	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: TBK1	F	COc1cc(-c2ccc3c(c2)NC(=O)c2ccc(-c4ccccc4NS(C)(=O)=O)cc2N3)cc(OC)c1OC		CHEMBL1984038	<	Ki	nM	3162.28	CHEMBL5408	Homo sapiens	pKi		5.5
active	9516240	CHEMBL1963698	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: TBK1	F	CNS(=O)(=O)c1ccccc1Nc1nc(Nc2cc(OC)c(OC)c(OC)c2)ncc1Cl		CHEMBL1993661	=	Ki	nM	39.81	CHEMBL5408	Homo sapiens	pKi		7.4
inactive	9516241	CHEMBL1963698	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: TBK1	F	CCCC(=O)Nc1cccc(-c2nc(Nc3ccc4[nH]ncc4c3)c3cc(OCCN4CCCC4)ccc3n2)c1		CHEMBL1968705	<	Ki	nM	3162.28	CHEMBL5408	Homo sapiens	pKi		5.5
inactive	9516242	CHEMBL1963698	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: TBK1	F	O=C(Nc1cc(-c2c[nH]c3ncccc23)cc(Cl)n1)c1c(F)cccc1F		CHEMBL1991410	<	Ki	nM	3162.28	CHEMBL5408	Homo sapiens	pKi		5.5
inactive	9516243	CHEMBL1963698	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: TBK1	F	CNCC#Cc1cnc(N)c2c(-c3ccc(NC(=O)Nc4cccc(C)c4)cc3)csc12		CHEMBL1964441	<	Ki	nM	3162.28	CHEMBL5408	Homo sapiens	pKi		5.5
inactive	9516244	CHEMBL1963698	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: TBK1	F	COc1cc2c(cc1F)C(c1ccccc1Cl)=Nc1c(n[nH]c1C)N2		CHEMBL1980391	<	Ki	nM	2511.89	CHEMBL5408	Homo sapiens	pKi		5.6
inactive	9516245	CHEMBL1963698	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: TBK1	F	ON=C(c1nc2ccccc2[nH]1)c1nc2ccccc2[nH]1		CHEMBL546797	<	Ki	nM	3162.28	CHEMBL5408	Homo sapiens	pKi		5.5
	10832564	CHEMBL2007667	GSK_PKIS: TBK1 % inhibition at 1 uM [UNC Frye lab]	B	CC(C)c1ccc(Nc2nccc(-c3cnn4ncccc34)n2)cc1		CHEMBL359963	=	Inhibition	%	18.0	CHEMBL5408	Homo sapiens	Inhibition	%	18.0
	10832565	CHEMBL2007667	GSK_PKIS: TBK1 % inhibition at 1 uM [UNC Frye lab]	B	O=C(NCC1CC1)c1ccc(-c2cccc(C(=O)NC3CC3)c2)cc1		CHEMBL479038	=	Inhibition	%	2.0	CHEMBL5408	Homo sapiens	Inhibition	%	2.0
	10832566	CHEMBL2007667	GSK_PKIS: TBK1 % inhibition at 1 uM [UNC Frye lab]	B	COc1ccc(-c2cc3c(N)ncnc3o2)cc1		CHEMBL373073	=	Inhibition	%	1.0	CHEMBL5408	Homo sapiens	Inhibition	%	1.0
	10832567	CHEMBL2007667	GSK_PKIS: TBK1 % inhibition at 1 uM [UNC Frye lab]	B	COc1cc(/C=N/Nc2ncnc3[nH]ncc23)ccc1O		CHEMBL66004	=	Inhibition	%	31.0	CHEMBL5408	Homo sapiens	Inhibition	%	31.0
	10832568	CHEMBL2007667	GSK_PKIS: TBK1 % inhibition at 1 uM [UNC Frye lab]	B	Nc1nonc1-c1nc2cnccc2n1C1CCCCC1		CHEMBL189231	=	Inhibition	%	36.0	CHEMBL5408	Homo sapiens	Inhibition	%	36.0
	10832569	CHEMBL2007667	GSK_PKIS: TBK1 % inhibition at 1 uM [UNC Frye lab]	B	Cl.NS(=O)(=O)c1cccc(Nc2cc(-c3ccc(F)cc3)n[nH]2)c1		CHEMBL1909351	=	Inhibition	%	23.0	CHEMBL5408	Homo sapiens	Inhibition	%	23.0
	10832570	CHEMBL2007667	GSK_PKIS: TBK1 % inhibition at 1 uM [UNC Frye lab]	B	CN1CCC(C(=O)Nc2n[nH]c3nc(-c4ccc(O)cc4)c(Br)cc23)CC1		CHEMBL261129	=	Inhibition	%	1.0	CHEMBL5408	Homo sapiens	Inhibition	%	1.0
	10832571	CHEMBL2007667	GSK_PKIS: TBK1 % inhibition at 1 uM [UNC Frye lab]	B	CC1(C)CC(n2cnc(-c3ccc(F)cc3)c2-c2ccnc(N)n2)CC(C)(C)N1		CHEMBL95502	=	Inhibition	%	-5.0	CHEMBL5408	Homo sapiens	Inhibition	%	-5.0
	10832572	CHEMBL2007667	GSK_PKIS: TBK1 % inhibition at 1 uM [UNC Frye lab]	B	COC(=O)c1cncc(/C=C/c2c(C)cc(O)cc2C)c1		CHEMBL220243	=	Inhibition	%	-1.0	CHEMBL5408	Homo sapiens	Inhibition	%	-1.0
	10832573	CHEMBL2007667	GSK_PKIS: TBK1 % inhibition at 1 uM [UNC Frye lab]	B	COc1ccc(-c2cc(-c3c[nH]nc3-c3ccccn3)ccn2)cc1		CHEMBL202891	=	Inhibition	%	-4.0	CHEMBL5408	Homo sapiens	Inhibition	%	-4.0
	10832574	CHEMBL2007667	GSK_PKIS: TBK1 % inhibition at 1 uM [UNC Frye lab]	B	NS(=O)(=O)c1ccc(Nc2cc(-c3cccc(O)c3)n[nH]2)cc1		CHEMBL103104	=	Inhibition	%	-4.0	CHEMBL5408	Homo sapiens	Inhibition	%	-4.0
	10832575	CHEMBL2007667	GSK_PKIS: TBK1 % inhibition at 1 uM [UNC Frye lab]	B	NS(=O)(=O)c1ccc(-c2ccc3c(NC(=O)C4CC4)n[nH]c3c2)cc1		CHEMBL103098	=	Inhibition	%	-3.0	CHEMBL5408	Homo sapiens	Inhibition	%	-3.0
	10832576	CHEMBL2007667	GSK_PKIS: TBK1 % inhibition at 1 uM [UNC Frye lab]	B	CC1=C(C(=O)Nc2ccc3[nH]nc(C)c3c2)C(c2ccc(C(F)(F)F)cc2)CC(=O)N1		CHEMBL218720	=	Inhibition	%	-5.0	CHEMBL5408	Homo sapiens	Inhibition	%	-5.0
	10832577	CHEMBL2007667	GSK_PKIS: TBK1 % inhibition at 1 uM [UNC Frye lab]	B	Fc1ccc(-c2ncn(C3CCNCC3)c2-c2ccnc(Oc3cccc(F)c3)n2)cc1		CHEMBL14014	=	Inhibition	%	-2.0	CHEMBL5408	Homo sapiens	Inhibition	%	-2.0
	10832578	CHEMBL2007667	GSK_PKIS: TBK1 % inhibition at 1 uM [UNC Frye lab]	B	Cl.c1ccc(Oc2ccc(Nc3ncc(-c4ccccc4)o3)cc2)cc1		CHEMBL1909341	=	Inhibition	%	-5.0	CHEMBL5408	Homo sapiens	Inhibition	%	-5.0
	10832579	CHEMBL2007667	GSK_PKIS: TBK1 % inhibition at 1 uM [UNC Frye lab]	B	CN1CCC(C(=O)Nc2n[nH]c3nc(-c4ccc(O)cc4)c(Br)cc23)CC1.O=C(O)/C=C\C(=O)O		CHEMBL1909347	=	Inhibition	%	2.0	CHEMBL5408	Homo sapiens	Inhibition	%	2.0
	10832580	CHEMBL2007667	GSK_PKIS: TBK1 % inhibition at 1 uM [UNC Frye lab]	B	COc1ccccc1Oc1nccc(-c2c(-c3ccc(F)cc3)ncn2C2CCNCC2)n1		CHEMBL417804	=	Inhibition	%	3.0	CHEMBL5408	Homo sapiens	Inhibition	%	3.0
	10832581	CHEMBL2007667	GSK_PKIS: TBK1 % inhibition at 1 uM [UNC Frye lab]	B	Cl.Nc1ncnc2occ(-c3ccc(NC(=O)Nc4cc(C(F)(F)F)ccc4F)cc3)c12		CHEMBL588025	=	Inhibition	%	-1.0	CHEMBL5408	Homo sapiens	Inhibition	%	-1.0
	10832582	CHEMBL2007667	GSK_PKIS: TBK1 % inhibition at 1 uM [UNC Frye lab]	B	COC(=O)c1ccc2c(c1)C(=Cc1cc(Br)c(O)c(Br)c1)C(=O)N2		CHEMBL1794052	=	Inhibition	%	36.0	CHEMBL5408	Homo sapiens	Inhibition	%	36.0
	10832583	CHEMBL2007667	GSK_PKIS: TBK1 % inhibition at 1 uM [UNC Frye lab]	B	CN(C)CCOc1ccc(-c2nc(-c3ccncc3)c(-c3ccc4c(c3)CC/C4=N\O)[nH]2)cc1.Cl.O		CHEMBL1909414	=	Inhibition	%	-3.0	CHEMBL5408	Homo sapiens	Inhibition	%	-3.0
	10832584	CHEMBL2007667	GSK_PKIS: TBK1 % inhibition at 1 uM [UNC Frye lab]	B	COc1cccc(-c2c[nH]c3c(N/N=C/c4ccncc4)ncnc23)c1		CHEMBL206010	=	Inhibition	%	74.0	CHEMBL5408	Homo sapiens	Inhibition	%	74.0
	10832585	CHEMBL2007667	GSK_PKIS: TBK1 % inhibition at 1 uM [UNC Frye lab]	B	COc1ccc(Nc2ncc(-c3ccccc3)o2)cc1OC.Cl		CHEMBL1794060	=	Inhibition	%	8.0	CHEMBL5408	Homo sapiens	Inhibition	%	8.0
	10832586	CHEMBL2007667	GSK_PKIS: TBK1 % inhibition at 1 uM [UNC Frye lab]	B	NS(=O)(=O)c1ccc(-c2cc3ccncc3cc2OCc2ccccc2)cc1		CHEMBL483748	=	Inhibition	%	-1.0	CHEMBL5408	Homo sapiens	Inhibition	%	-1.0
	10832587	CHEMBL2007667	GSK_PKIS: TBK1 % inhibition at 1 uM [UNC Frye lab]	B	O=S(=O)(CCOCc1ccc(-c2ccc3ncnc(Nc4ccc(OCc5cccc(F)c5)c(Cl)c4)c3c2)o1)c1ccccc1		CHEMBL212250	=	Inhibition	%	-2.0	CHEMBL5408	Homo sapiens	Inhibition	%	-2.0
	10832588	CHEMBL2007667	GSK_PKIS: TBK1 % inhibition at 1 uM [UNC Frye lab]	B	CCS(=O)(=O)c1ccc(OC)c(Nc2ncc(-c3cccc(-c4ccccc4F)c3)o2)c1		CHEMBL372474	=	Inhibition	%	13.0	CHEMBL5408	Homo sapiens	Inhibition	%	13.0
	10832589	CHEMBL2007667	GSK_PKIS: TBK1 % inhibition at 1 uM [UNC Frye lab]	B	Fc1ccc(-c2c(-c3ccncc3)nc3n2CCS3)cc1		CHEMBL266707	=	Inhibition	%	2.0	CHEMBL5408	Homo sapiens	Inhibition	%	2.0
	10832590	CHEMBL2007667	GSK_PKIS: TBK1 % inhibition at 1 uM [UNC Frye lab]	B	Nc1nc(-c2cccc(Cl)c2)c(-c2ccc3ncccc3n2)s1		CHEMBL365663	=	Inhibition	%	5.0	CHEMBL5408	Homo sapiens	Inhibition	%	5.0
	10832591	CHEMBL2007667	GSK_PKIS: TBK1 % inhibition at 1 uM [UNC Frye lab]	B	CN(C)CCOc1ccc(-c2cc(-c3ccc4c(c3)CCC4=NO)c(-c3ccncc3)o2)cc1.Cl		CHEMBL1794072	=	Inhibition	%	5.0	CHEMBL5408	Homo sapiens	Inhibition	%	5.0
	10832592	CHEMBL2007667	GSK_PKIS: TBK1 % inhibition at 1 uM [UNC Frye lab]	B	CCOc1nccc2c1nc(-c1nonc1N)n2CC		CHEMBL188240	=	Inhibition	%	-2.0	CHEMBL5408	Homo sapiens	Inhibition	%	-2.0
	10832593	CHEMBL2007667	GSK_PKIS: TBK1 % inhibition at 1 uM [UNC Frye lab]	B	COc1ccc2cc(-c3c(-c4ccncc4)nc(-c4ccc(S(C)(=O)=O)cc4C)n3C)ccc2c1		CHEMBL237571	=	Inhibition	%	-4.0	CHEMBL5408	Homo sapiens	Inhibition	%	-4.0
	10832594	CHEMBL2007667	GSK_PKIS: TBK1 % inhibition at 1 uM [UNC Frye lab]	B	COc1ccc(CNC(=O)c2ccc(-c3cc(-c4nnc(C)o4)ccc3C)cc2)cc1		CHEMBL269985	=	Inhibition	%	-6.0	CHEMBL5408	Homo sapiens	Inhibition	%	-6.0
	10832595	CHEMBL2007667	GSK_PKIS: TBK1 % inhibition at 1 uM [UNC Frye lab]	B	Cc1ccc2c(c1)/C(=N/Nc1ccc(S(N)(=O)=O)cc1)C(=O)N2		CHEMBL271843	=	Inhibition	%	-2.0	CHEMBL5408	Homo sapiens	Inhibition	%	-2.0
	10832596	CHEMBL2007667	GSK_PKIS: TBK1 % inhibition at 1 uM [UNC Frye lab]	B	CCN(CC)S(=O)(=O)c1ccc(OC)c(Nc2ncc(-c3ccccc3)o2)c1		CHEMBL275473	=	Inhibition	%	-2.0	CHEMBL5408	Homo sapiens	Inhibition	%	-2.0
	10832597	CHEMBL2007667	GSK_PKIS: TBK1 % inhibition at 1 uM [UNC Frye lab]	B	O=C1NC(=O)C(N2CCc3ccccc32)=C1c1ccc(Cl)cc1		CHEMBL156524	=	Inhibition	%	1.0	CHEMBL5408	Homo sapiens	Inhibition	%	1.0
	10832598	CHEMBL2007667	GSK_PKIS: TBK1 % inhibition at 1 uM [UNC Frye lab]	B	N#Cc1cccc(Nc2nccc(-c3cnn4ncccc34)n2)c1		CHEMBL495696	=	Inhibition	%	37.0	CHEMBL5408	Homo sapiens	Inhibition	%	37.0
	10832599	CHEMBL2007667	GSK_PKIS: TBK1 % inhibition at 1 uM [UNC Frye lab]	B	O=C1NC(=O)C(c2cccc([N+](=O)[O-])c2)=C1Nc1cc(Cl)c(O)c(Cl)c1		CHEMBL352222	=	Inhibition	%	91.0	CHEMBL5408	Homo sapiens	Inhibition	%	91.0
	10832600	CHEMBL2007667	GSK_PKIS: TBK1 % inhibition at 1 uM [UNC Frye lab]	B	C/C(Nc1ccc(S(N)(=O)=O)cc1)=C1/C(=O)Nc2ccccc21		CHEMBL405042	=	Inhibition	%	11.0	CHEMBL5408	Homo sapiens	Inhibition	%	11.0
	10832601	CHEMBL2007667	GSK_PKIS: TBK1 % inhibition at 1 uM [UNC Frye lab]	B	Cc1ccc2c(-c3ccnc(Nc4ccc5c(c4)OCCO5)n3)c(-c3ccc(C(F)(F)F)cc3)nn2n1		CHEMBL188247	=	Inhibition	%	-5.0	CHEMBL5408	Homo sapiens	Inhibition	%	-5.0
	10832602	CHEMBL2007667	GSK_PKIS: TBK1 % inhibition at 1 uM [UNC Frye lab]	B	COC(=O)Nc1nc2ccc(Sc3ccc(NC(=O)Nc4cc(C(F)(F)F)ccc4F)cc3)cc2[nH]1.O=S(=O)(O)O		CHEMBL1909365	=	Inhibition	%	-3.0	CHEMBL5408	Homo sapiens	Inhibition	%	-3.0
	10832603	CHEMBL2007667	GSK_PKIS: TBK1 % inhibition at 1 uM [UNC Frye lab]	B	Fc1ccc(Oc2nccc(-c3c(-c4ccc(F)cc4)ncn3C3CCNCC3)n2)cc1		CHEMBL269450	=	Inhibition	%	2.0	CHEMBL5408	Homo sapiens	Inhibition	%	2.0
	10832604	CHEMBL2007667	GSK_PKIS: TBK1 % inhibition at 1 uM [UNC Frye lab]	B	CCn1c(-c2nonc2N)nc2cncc(C(=O)NCCNC)c21		CHEMBL506153	=	Inhibition	%	17.0	CHEMBL5408	Homo sapiens	Inhibition	%	17.0
	10832605	CHEMBL2007667	GSK_PKIS: TBK1 % inhibition at 1 uM [UNC Frye lab]	B	CCS(=O)(=O)c1ccc(OC)c(Nc2ncc(-c3cccc(C(C)=O)c3)o2)c1		CHEMBL191705	=	Inhibition	%	7.0	CHEMBL5408	Homo sapiens	Inhibition	%	7.0
	10832606	CHEMBL2007667	GSK_PKIS: TBK1 % inhibition at 1 uM [UNC Frye lab]	B	COc1cc(C)c(NC(=O)CN(C)C)cc1Nc1nc(Nc2cccc(F)c2C(N)=O)c2cc[nH]c2n1		CHEMBL511765	=	Inhibition	%	30.0	CHEMBL5408	Homo sapiens	Inhibition	%	30.0
	10832607	CHEMBL2007667	GSK_PKIS: TBK1 % inhibition at 1 uM [UNC Frye lab]	B	Nc1ccc(C#Cc2cncnc2Nc2ccc(OCc3cccc(F)c3)c(Cl)c2)cc1		CHEMBL205966	=	Inhibition	%	1.0	CHEMBL5408	Homo sapiens	Inhibition	%	1.0
	10832608	CHEMBL2007667	GSK_PKIS: TBK1 % inhibition at 1 uM [UNC Frye lab]	B	Cl.O=S(=O)(CCNCc1ccc(-c2ccc3ncnc(Nc4ccc(OCc5cccc(F)c5)c(Cl)c4)c3c2)o1)c1ccccc1		CHEMBL1909395	=	Inhibition	%	12.0	CHEMBL5408	Homo sapiens	Inhibition	%	12.0
	10832609	CHEMBL2007667	GSK_PKIS: TBK1 % inhibition at 1 uM [UNC Frye lab]	B	COc1cc(C)c(N(C)C(=O)CN(C)C)cc1Nc1nc(Nc2cccc(F)c2C(N)=O)c2cc[nH]c2n1		CHEMBL467581	=	Inhibition	%	-4.0	CHEMBL5408	Homo sapiens	Inhibition	%	-4.0
	10832610	CHEMBL2007667	GSK_PKIS: TBK1 % inhibition at 1 uM [UNC Frye lab]	B	Fc1ccc(-c2ncn(C3CCNCC3)c2-c2ccnc(Oc3ccccc3)n2)cc1		CHEMBL275798	=	Inhibition	%	0.0	CHEMBL5408	Homo sapiens	Inhibition	%	0.0
	10832611	CHEMBL2007667	GSK_PKIS: TBK1 % inhibition at 1 uM [UNC Frye lab]	B	CCn1c(-c2nonc2N)nc2cncc(C(=O)NCCNC)c21		CHEMBL506153	=	Inhibition	%	13.0	CHEMBL5408	Homo sapiens	Inhibition	%	13.0
	10832612	CHEMBL2007667	GSK_PKIS: TBK1 % inhibition at 1 uM [UNC Frye lab]	B	CCn1c(-c2nonc2N)nc2cncc(C(=O)N3CCNCC3)c21.Cl		CHEMBL1909376	=	Inhibition	%	3.0	CHEMBL5408	Homo sapiens	Inhibition	%	3.0
	10832613	CHEMBL2007667	GSK_PKIS: TBK1 % inhibition at 1 uM [UNC Frye lab]	B	COc1cccc(-n2ncc3c(N/N=C/c4ccc(S(C)(=O)=O)cc4)ncnc32)c1		CHEMBL66292	=	Inhibition	%	20.0	CHEMBL5408	Homo sapiens	Inhibition	%	20.0
	10832614	CHEMBL2007667	GSK_PKIS: TBK1 % inhibition at 1 uM [UNC Frye lab]	B	COc1cccc(-n2ncc3c(N/N=C/c4ccncc4)ncnc32)c1		CHEMBL306865	=	Inhibition	%	13.0	CHEMBL5408	Homo sapiens	Inhibition	%	13.0
	10832615	CHEMBL2007667	GSK_PKIS: TBK1 % inhibition at 1 uM [UNC Frye lab]	B	CN1CCC(n2cnc(-c3ccc(F)cc3)c2-c2ccnc(Nc3ccccc3)n2)CC1		CHEMBL318892	=	Inhibition	%	0.0	CHEMBL5408	Homo sapiens	Inhibition	%	0.0
	10832616	CHEMBL2007667	GSK_PKIS: TBK1 % inhibition at 1 uM [UNC Frye lab]	B	Cl.NC(=O)c1ccc(-c2nc(-c3ccccn3)c(-c3ccc4c(c3)OCO4)[nH]2)cc1		CHEMBL1909378	=	Inhibition	%	0.0	CHEMBL5408	Homo sapiens	Inhibition	%	0.0
	10832617	CHEMBL2007667	GSK_PKIS: TBK1 % inhibition at 1 uM [UNC Frye lab]	B	CN(C)c1cc2c(Nc3ccc4nc(Cc5ccccc5)[nH]c4c3)ncnc2cn1		CHEMBL531804	=	Inhibition	%	2.0	CHEMBL5408	Homo sapiens	Inhibition	%	2.0
	10832618	CHEMBL2007667	GSK_PKIS: TBK1 % inhibition at 1 uM [UNC Frye lab]	B	CCOc1ccc2c(-c3ccnc(Nc4cccc(C(F)(F)F)c4)n3)cnn2n1		CHEMBL183993	=	Inhibition	%	55.0	CHEMBL5408	Homo sapiens	Inhibition	%	55.0
	10832619	CHEMBL2007667	GSK_PKIS: TBK1 % inhibition at 1 uM [UNC Frye lab]	B	CCn1c(-c2nonc2N)nc2c(C#CC(C)(C)O)nc(OC[C@@H](N)c3ccccc3)cc21		CHEMBL1096626	=	Inhibition	%	6.0	CHEMBL5408	Homo sapiens	Inhibition	%	6.0
	10832620	CHEMBL2007667	GSK_PKIS: TBK1 % inhibition at 1 uM [UNC Frye lab]	B	CCn1c(-c2nonc2N)nc2c(C#CC(C)(C)O)nc(O[C@@H](CN)c3ccccc3)cc21.O=C(O)C(F)(F)F		CHEMBL1909349	=	Inhibition	%	85.0	CHEMBL5408	Homo sapiens	Inhibition	%	85.0
	10832621	CHEMBL2007667	GSK_PKIS: TBK1 % inhibition at 1 uM [UNC Frye lab]	B	COc1ccc(-c2nn3ncccc3c2-c2ccnc(Nc3ccc4c(c3)OCCO4)n2)cc1		CHEMBL188257	=	Inhibition	%	1.0	CHEMBL5408	Homo sapiens	Inhibition	%	1.0
	10832622	CHEMBL2007667	GSK_PKIS: TBK1 % inhibition at 1 uM [UNC Frye lab]	B	Cc1ccc(C(=O)NC(C)C)cc1-c1ccc(C(=O)NCC2CC2)cc1		CHEMBL477979	=	Inhibition	%	-1.0	CHEMBL5408	Homo sapiens	Inhibition	%	-1.0
	10832623	CHEMBL2007667	GSK_PKIS: TBK1 % inhibition at 1 uM [UNC Frye lab]	B	FC(F)(F)c1cccc(Nc2nccc(-c3cnn4nc(-c5ccccc5)ccc34)n2)c1		CHEMBL189415	=	Inhibition	%	17.0	CHEMBL5408	Homo sapiens	Inhibition	%	17.0
	10832624	CHEMBL2007667	GSK_PKIS: TBK1 % inhibition at 1 uM [UNC Frye lab]	B	Nc1nccc(C#Cc2cncnc2Nc2ccc(OCc3cccc(F)c3)c(Cl)c2)n1		CHEMBL381604	=	Inhibition	%	18.0	CHEMBL5408	Homo sapiens	Inhibition	%	18.0
	10832625	CHEMBL2007667	GSK_PKIS: TBK1 % inhibition at 1 uM [UNC Frye lab]	B	Cc1ccc(O)cc1Nc1ccnc2ccc(S(C)(=O)=O)cc12		CHEMBL237347	=	Inhibition	%	1.0	CHEMBL5408	Homo sapiens	Inhibition	%	1.0
	10832626	CHEMBL2007667	GSK_PKIS: TBK1 % inhibition at 1 uM [UNC Frye lab]	B	CS(=O)(=O)Nc1ccc(-c2cc(-c3ccccc3)cc(C(N)=O)c2N)cc1		CHEMBL230597	=	Inhibition	%	-2.0	CHEMBL5408	Homo sapiens	Inhibition	%	-2.0
	10832627	CHEMBL2007667	GSK_PKIS: TBK1 % inhibition at 1 uM [UNC Frye lab]	B	Cc1cc(-c2ccco2)cc(C)c1/C=C/c1cncc(-c2nn[nH]n2)c1.Cl		CHEMBL1909353	=	Inhibition	%	5.0	CHEMBL5408	Homo sapiens	Inhibition	%	5.0
	10832628	CHEMBL2007667	GSK_PKIS: TBK1 % inhibition at 1 uM [UNC Frye lab]	B	N#Cc1c(NC(=O)c2ccc(F)c3ccccc23)sc2c1CCCC2		CHEMBL233002	=	Inhibition	%	1.0	CHEMBL5408	Homo sapiens	Inhibition	%	1.0
	10832629	CHEMBL2007667	GSK_PKIS: TBK1 % inhibition at 1 uM [UNC Frye lab]	B	NS(=O)(=O)c1cccc(-c2ccc3c(NC(=O)C4CC4)n[nH]c3c2)c1		CHEMBL407113	=	Inhibition	%	2.0	CHEMBL5408	Homo sapiens	Inhibition	%	2.0
	10832630	CHEMBL2007667	GSK_PKIS: TBK1 % inhibition at 1 uM [UNC Frye lab]	B	CCN1CCC(CC(=O)Nc2n[nH]c3nc(-c4cccs4)c(Br)cc23)CC1.O=C(O)C(O)C(O)C(=O)O		CHEMBL2062290	=	Inhibition	%	8.0	CHEMBL5408	Homo sapiens	Inhibition	%	8.0
	10832631	CHEMBL2007667	GSK_PKIS: TBK1 % inhibition at 1 uM [UNC Frye lab]	B	Cc1ccc2c(-c3ccnc(Nc4ccccc4)n3)c(-c3ccc(F)cc3)nn2n1		CHEMBL189459	=	Inhibition	%	-1.0	CHEMBL5408	Homo sapiens	Inhibition	%	-1.0
	10832632	CHEMBL2007667	GSK_PKIS: TBK1 % inhibition at 1 uM [UNC Frye lab]	B	Fc1cccc(COc2ccc(Nc3ncncc3C#Cc3ccccc3)cc2Cl)c1		CHEMBL379093	=	Inhibition	%	-6.0	CHEMBL5408	Homo sapiens	Inhibition	%	-6.0
	10832633	CHEMBL2007667	GSK_PKIS: TBK1 % inhibition at 1 uM [UNC Frye lab]	B	CCn1c(-c2nonc2N)nc2ccccc21		CHEMBL365286	=	Inhibition	%	-2.0	CHEMBL5408	Homo sapiens	Inhibition	%	-2.0
	10832634	CHEMBL2007667	GSK_PKIS: TBK1 % inhibition at 1 uM [UNC Frye lab]	B	O=C1NC(=O)C(c2cccc(Cl)c2)=C1Nc1ccc(O)c(Cl)c1		CHEMBL160333	=	Inhibition	%	58.0	CHEMBL5408	Homo sapiens	Inhibition	%	58.0
	10832635	CHEMBL2007667	GSK_PKIS: TBK1 % inhibition at 1 uM [UNC Frye lab]	B	Fc1ccc(-c2nn3ccccc3c2-c2ccncc2)cc1		CHEMBL485745	=	Inhibition	%	-4.0	CHEMBL5408	Homo sapiens	Inhibition	%	-4.0
	10832636	CHEMBL2007667	GSK_PKIS: TBK1 % inhibition at 1 uM [UNC Frye lab]	B	Cl.NS(=O)(=O)c1ccc(N/N=C2\C(=O)Nc3cccc(CCc4ccncc4)c32)cc1		CHEMBL1909399	=	Inhibition	%	29.0	CHEMBL5408	Homo sapiens	Inhibition	%	29.0
	10832637	CHEMBL2007667	GSK_PKIS: TBK1 % inhibition at 1 uM [UNC Frye lab]	B	CCN1CCC(C(=O)Nc2n[nH]c3nnc(-c4cccc(F)c4F)cc23)CC1.Cl		CHEMBL1909345	=	Inhibition	%	-3.0	CHEMBL5408	Homo sapiens	Inhibition	%	-3.0
	10832638	CHEMBL2007667	GSK_PKIS: TBK1 % inhibition at 1 uM [UNC Frye lab]	B	CC(=O)NCc1cccc(C#Cc2cncnc2Nc2ccc(OCc3cccc(F)c3)c(Cl)c2)c1		CHEMBL207247	=	Inhibition	%	-6.0	CHEMBL5408	Homo sapiens	Inhibition	%	-6.0
	10832639	CHEMBL2007667	GSK_PKIS: TBK1 % inhibition at 1 uM [UNC Frye lab]	B	CNC(=O)c1cncc(/C=C/c2ccccc2Cl)c1		CHEMBL218970	=	Inhibition	%	2.0	CHEMBL5408	Homo sapiens	Inhibition	%	2.0
	10832640	CHEMBL2007667	GSK_PKIS: TBK1 % inhibition at 1 uM [UNC Frye lab]	B	CNC(=O)c1cccc(C#Cc2cncnc2Nc2ccc(OCc3cccc(F)c3)c(Cl)c2)c1		CHEMBL207410	=	Inhibition	%	6.0	CHEMBL5408	Homo sapiens	Inhibition	%	6.0
	10832641	CHEMBL2007667	GSK_PKIS: TBK1 % inhibition at 1 uM [UNC Frye lab]	B	O=C1NC(=O)C(c2ccccc2Cl)=C1Nc1cccc(O)c1		CHEMBL160937	=	Inhibition	%	9.0	CHEMBL5408	Homo sapiens	Inhibition	%	9.0
	10832642	CHEMBL2007667	GSK_PKIS: TBK1 % inhibition at 1 uM [UNC Frye lab]	B	COc1cc(Nc2nccc(-c3cnn4ncccc34)n2)cc(OC)c1		CHEMBL359999	=	Inhibition	%	38.0	CHEMBL5408	Homo sapiens	Inhibition	%	38.0
	10832643	CHEMBL2007667	GSK_PKIS: TBK1 % inhibition at 1 uM [UNC Frye lab]	B	NS(=O)(=O)c1ccc(N/N=C2\C(=O)Nc3ccc(C(=O)NCCc4c[nH]cn4)cc32)cc1		CHEMBL272028	=	Inhibition	%	32.0	CHEMBL5408	Homo sapiens	Inhibition	%	32.0
	10832644	CHEMBL2007667	GSK_PKIS: TBK1 % inhibition at 1 uM [UNC Frye lab]	B	CCC(=O)Nc1ccc(C)c(-c2ccc(C(=O)NCC3CC3)cc2)c1		CHEMBL517666	=	Inhibition	%	1.0	CHEMBL5408	Homo sapiens	Inhibition	%	1.0
	10832645	CHEMBL2007667	GSK_PKIS: TBK1 % inhibition at 1 uM [UNC Frye lab]	B	Cl.O=C(O[C@H]1CN[C@H](C#Cc2cc3ncnc(Nc4ccc5c(cnn5Cc5ccccc5)c4)c3s2)C1)N1CCOCC1		CHEMBL1909408	=	Inhibition	%	26.0	CHEMBL5408	Homo sapiens	Inhibition	%	26.0
	10832646	CHEMBL2007667	GSK_PKIS: TBK1 % inhibition at 1 uM [UNC Frye lab]	B	CC(C)c1ccc(-c2cc(-c3c[nH]nc3-c3ccccn3)ccn2)cc1		CHEMBL206544	=	Inhibition	%	-5.0	CHEMBL5408	Homo sapiens	Inhibition	%	-5.0
	10832647	CHEMBL2007667	GSK_PKIS: TBK1 % inhibition at 1 uM [UNC Frye lab]	B	Cc1cc(O)cc(C)c1/C=C/c1cncc(-c2nn[nH]n2)c1.Cl		CHEMBL1909352	=	Inhibition	%	3.0	CHEMBL5408	Homo sapiens	Inhibition	%	3.0
	10832648	CHEMBL2007667	GSK_PKIS: TBK1 % inhibition at 1 uM [UNC Frye lab]	B	Cc1ccc(Nc2ccnc(Nc3cccc(C(N)=O)c3)n2)cc1O.Cl		CHEMBL1909381	=	Inhibition	%	27.0	CHEMBL5408	Homo sapiens	Inhibition	%	27.0
	10832649	CHEMBL2007667	GSK_PKIS: TBK1 % inhibition at 1 uM [UNC Frye lab]	B	C[C@@H](Oc1cc(-n2cnc3ccc(OCC4CCN(C)CC4)cc32)sc1C(N)=O)c1ccccc1C(F)(F)F		CHEMBL1794068	=	Inhibition	%	11.0	CHEMBL5408	Homo sapiens	Inhibition	%	11.0
	10832650	CHEMBL2007667	GSK_PKIS: TBK1 % inhibition at 1 uM [UNC Frye lab]	B	Cc1nnc(-c2cccc(-c3ccc(C(=O)NCC4CC4)cc3)c2)o1		CHEMBL257113	=	Inhibition	%	-1.0	CHEMBL5408	Homo sapiens	Inhibition	%	-1.0
	10832651	CHEMBL2007667	GSK_PKIS: TBK1 % inhibition at 1 uM [UNC Frye lab]	B	COc1cccc(/C=N/Nc2ncnc3c2cnn3-c2cccc(OC)c2)c1		CHEMBL305477	=	Inhibition	%	2.0	CHEMBL5408	Homo sapiens	Inhibition	%	2.0
	10832652	CHEMBL2007667	GSK_PKIS: TBK1 % inhibition at 1 uM [UNC Frye lab]	B	Cl.Fc1ccc(-c2nc3n(c2-c2ccncc2)CCS3)cc1		CHEMBL1909406	=	Inhibition	%	-4.0	CHEMBL5408	Homo sapiens	Inhibition	%	-4.0
	10832653	CHEMBL2007667	GSK_PKIS: TBK1 % inhibition at 1 uM [UNC Frye lab]	B	CC(=O)Nc1cccc(C#Cc2cncnc2Nc2ccc(OCc3cccc(F)c3)c(Cl)c2)c1		CHEMBL205798	=	Inhibition	%	-6.0	CHEMBL5408	Homo sapiens	Inhibition	%	-6.0
	10832654	CHEMBL2007667	GSK_PKIS: TBK1 % inhibition at 1 uM [UNC Frye lab]	B	FC(F)(F)CNc1nccc(-c2cnn3ncccc23)n1		CHEMBL446024	=	Inhibition	%	-2.0	CHEMBL5408	Homo sapiens	Inhibition	%	-2.0
	10832655	CHEMBL2007667	GSK_PKIS: TBK1 % inhibition at 1 uM [UNC Frye lab]	B	NS(=O)(=O)c1ccc(N/N=C2\C(=O)Nc3ccc4ncccc4c32)cc1		CHEMBL409892	=	Inhibition	%	76.0	CHEMBL5408	Homo sapiens	Inhibition	%	76.0
	10832656	CHEMBL2007667	GSK_PKIS: TBK1 % inhibition at 1 uM [UNC Frye lab]	B	CC1=C(C(=O)Nc2ccc3[nH]ncc3c2)C(c2ccc(F)cc2)N=C(c2ccc(C(F)(F)F)nc2)N1		CHEMBL485598	=	Inhibition	%	1.0	CHEMBL5408	Homo sapiens	Inhibition	%	1.0
	10832657	CHEMBL2007667	GSK_PKIS: TBK1 % inhibition at 1 uM [UNC Frye lab]	B	CN(c1ccc(NC(=O)Nc2c(Cl)cccc2Cl)cc1)c1ccnc(Nc2cccc(CS(C)(=O)=O)c2)n1		CHEMBL189353	=	Inhibition	%	19.0	CHEMBL5408	Homo sapiens	Inhibition	%	19.0
	10832658	CHEMBL2007667	GSK_PKIS: TBK1 % inhibition at 1 uM [UNC Frye lab]	B	COc1ccc(CNC(=O)c2ccc(-c3cc(-c4nnc(C)o4)ccc3C)cc2)cc1		CHEMBL269985	=	Inhibition	%	-5.0	CHEMBL5408	Homo sapiens	Inhibition	%	-5.0
	10832659	CHEMBL2007667	GSK_PKIS: TBK1 % inhibition at 1 uM [UNC Frye lab]	B	CCn1c(-c2nonc2N)nc2c(C#CC(C)(C)O)ncc(OC[C@@H]3CCCN3)c21.O=C(O)C(F)(F)F		CHEMBL1909375	=	Inhibition	%	65.0	CHEMBL5408	Homo sapiens	Inhibition	%	65.0
	10832660	CHEMBL2007667	GSK_PKIS: TBK1 % inhibition at 1 uM [UNC Frye lab]	B	Cl.Nc1nccc(-c2c(-c3ccc(F)cc3)ncn2C2CCNCC2)n1		CHEMBL1909407	=	Inhibition	%	-3.0	CHEMBL5408	Homo sapiens	Inhibition	%	-3.0
	10832661	CHEMBL2007667	GSK_PKIS: TBK1 % inhibition at 1 uM [UNC Frye lab]	B	CCn1c(-c2nonc2N)nc2cnc(Oc3cccc(NC(=O)c4ccc(OCCN5CCOCC5)cc4)c3)cc21.Cl		CHEMBL1909363	=	Inhibition	%	12.0	CHEMBL5408	Homo sapiens	Inhibition	%	12.0
	10832662	CHEMBL2007667	GSK_PKIS: TBK1 % inhibition at 1 uM [UNC Frye lab]	B	O=C1NC(=O)C(c2cccc([N+](=O)[O-])c2)=C1Nc1cc(Cl)c(O)c(Cl)c1		CHEMBL352222	=	Inhibition	%	90.0	CHEMBL5408	Homo sapiens	Inhibition	%	90.0
	10832663	CHEMBL2007667	GSK_PKIS: TBK1 % inhibition at 1 uM [UNC Frye lab]	B	Cc1ccc(O)cc1Nc1ccnc2cc(-c3ccccn3)ccc12.Cl		CHEMBL581096	=	Inhibition	%	2.0	CHEMBL5408	Homo sapiens	Inhibition	%	2.0
	10832664	CHEMBL2007667	GSK_PKIS: TBK1 % inhibition at 1 uM [UNC Frye lab]	B	COc1cc2c(cc1Nc1nc(Nc3cccc(F)c3C(N)=O)c3cc[nH]c3n1)N(C(=O)CN1CCN(C(C)C)CC1)CC2		CHEMBL505915	=	Inhibition	%	-2.0	CHEMBL5408	Homo sapiens	Inhibition	%	-2.0
	10832665	CHEMBL2007667	GSK_PKIS: TBK1 % inhibition at 1 uM [UNC Frye lab]	B	Cc1ccc2c(-c3ccnc(Nc4ccc5c(c4)OCCO5)n3)c(-c3ccc(C(F)(F)F)cc3)nn2n1		CHEMBL188247	=	Inhibition	%	1.0	CHEMBL5408	Homo sapiens	Inhibition	%	1.0
	10832666	CHEMBL2007667	GSK_PKIS: TBK1 % inhibition at 1 uM [UNC Frye lab]	B	Cc1c2ccc(N(C)c3ccnc(Nc4cccc(S(N)(=O)=O)c4)n3)cc2nn1C.Cl		CHEMBL1909359	=	Inhibition	%	1.0	CHEMBL5408	Homo sapiens	Inhibition	%	1.0
	10832667	CHEMBL2007667	GSK_PKIS: TBK1 % inhibition at 1 uM [UNC Frye lab]	B	COc1cc(N2CCN(C(C)C)CC2)ccc1Nc1nc(Nc2ccc(F)cc2C(N)=O)c2cc[nH]c2n1		CHEMBL458865	=	Inhibition	%	16.0	CHEMBL5408	Homo sapiens	Inhibition	%	16.0
	10832668	CHEMBL2007667	GSK_PKIS: TBK1 % inhibition at 1 uM [UNC Frye lab]	B	FC(F)(F)c1cccc(-c2nn3ncccc3c2-c2ccnc(Nc3ccc4c(c3)OCCO4)n2)c1		CHEMBL362155	=	Inhibition	%	3.0	CHEMBL5408	Homo sapiens	Inhibition	%	3.0
	10832669	CHEMBL2007667	GSK_PKIS: TBK1 % inhibition at 1 uM [UNC Frye lab]	B	CNC(=O)c1cc(-c2ccc(F)cc2)cc(-c2ccc(S(=O)(=O)N3CCCC3)cc2)c1N		CHEMBL230592	=	Inhibition	%	4.0	CHEMBL5408	Homo sapiens	Inhibition	%	4.0
	10832670	CHEMBL2007667	GSK_PKIS: TBK1 % inhibition at 1 uM [UNC Frye lab]	B	COc1ccc(-c2oc3ncnc(N)c3c2-c2ccc(NC(=O)Nc3cc(C(F)(F)F)ccc3F)cc2)cc1.Cl		CHEMBL1909396	=	Inhibition	%	-3.0	CHEMBL5408	Homo sapiens	Inhibition	%	-3.0
	10832671	CHEMBL2007667	GSK_PKIS: TBK1 % inhibition at 1 uM [UNC Frye lab]	B	Cl.ON=C1CCc2cc(-c3nc(C4CCNCC4)[nH]c3-c3ccncc3)ccc21		CHEMBL1794071	=	Inhibition	%	1.0	CHEMBL5408	Homo sapiens	Inhibition	%	1.0
	10832672	CHEMBL2007667	GSK_PKIS: TBK1 % inhibition at 1 uM [UNC Frye lab]	B	CCn1c(-c2nonc2N)nc2c(C#CC(C)(C)O)nc(OC[C@H](N)c3ccccc3)cc21		CHEMBL1096634	=	Inhibition	%	8.0	CHEMBL5408	Homo sapiens	Inhibition	%	8.0
	10832673	CHEMBL2007667	GSK_PKIS: TBK1 % inhibition at 1 uM [UNC Frye lab]	B	NS(=O)(=O)c1cccc(N/C=C2\C(=O)Nc3ccccc32)c1		CHEMBL1794059	=	Inhibition	%	31.0	CHEMBL5408	Homo sapiens	Inhibition	%	31.0
	10832674	CHEMBL2007667	GSK_PKIS: TBK1 % inhibition at 1 uM [UNC Frye lab]	B	Fc1ccc(-c2ncn(CCCN3CCOCC3)c2-c2ccncc2)cc1		CHEMBL14112	=	Inhibition	%	-1.0	CHEMBL5408	Homo sapiens	Inhibition	%	-1.0
	10832675	CHEMBL2007667	GSK_PKIS: TBK1 % inhibition at 1 uM [UNC Frye lab]	B	Cc1ccc(O)cc1Nc1ccnc2ccc(S(C)(=O)=O)cc12		CHEMBL237347	=	Inhibition	%	-2.0	CHEMBL5408	Homo sapiens	Inhibition	%	-2.0
	10832676	CHEMBL2007667	GSK_PKIS: TBK1 % inhibition at 1 uM [UNC Frye lab]	B	O=C1Nc2ccc(C(=O)c3ccco3)cc2C1=Cc1cc(Cl)c(O)c(Cl)c1		CHEMBL1789963	=	Inhibition	%	86.0	CHEMBL5408	Homo sapiens	Inhibition	%	86.0
	10832677	CHEMBL2007667	GSK_PKIS: TBK1 % inhibition at 1 uM [UNC Frye lab]	B	CS(=O)(=O)Nc1ccc(-c2cc(-c3ccccc3)cc(C(N)=O)c2N)cc1		CHEMBL230597	=	Inhibition	%	-4.0	CHEMBL5408	Homo sapiens	Inhibition	%	-4.0
	10832678	CHEMBL2007667	GSK_PKIS: TBK1 % inhibition at 1 uM [UNC Frye lab]	B	COc1ccc(-c2coc3ncnc(N)c23)cc1		CHEMBL196022	=	Inhibition	%	-7.0	CHEMBL5408	Homo sapiens	Inhibition	%	-7.0
	10832679	CHEMBL2007667	GSK_PKIS: TBK1 % inhibition at 1 uM [UNC Frye lab]	B	COc1cc(C=NNc2ncnc3c2cnn3Cc2ccccc2)ccc1O		CHEMBL1789962	=	Inhibition	%	9.0	CHEMBL5408	Homo sapiens	Inhibition	%	9.0
	10832680	CHEMBL2007667	GSK_PKIS: TBK1 % inhibition at 1 uM [UNC Frye lab]	B	Fc1cccc(COc2ccc(Nc3ncnc4sc(-c5cccs5)cc34)cc2Cl)c1		CHEMBL506414	=	Inhibition	%	-3.0	CHEMBL5408	Homo sapiens	Inhibition	%	-3.0
	10832681	CHEMBL2007667	GSK_PKIS: TBK1 % inhibition at 1 uM [UNC Frye lab]	B	c1ccc(COc2ccc(Nc3ncnc4ccc(-c5ccco5)cc34)cc2)cc1		CHEMBL215993	=	Inhibition	%	-3.0	CHEMBL5408	Homo sapiens	Inhibition	%	-3.0
	10832682	CHEMBL2007667	GSK_PKIS: TBK1 % inhibition at 1 uM [UNC Frye lab]	B	Cc1cccc(-c2n[nH]cc2-c2ccc3ncccc3n2)n1		CHEMBL185238	=	Inhibition	%	-10.0	CHEMBL5408	Homo sapiens	Inhibition	%	-10.0
	10832683	CHEMBL2007667	GSK_PKIS: TBK1 % inhibition at 1 uM [UNC Frye lab]	B	CCn1c(-c2nonc2N)nc2c(C#CC(C)(C)O)ncc(OC3CCNCC3)c21.O=C(O)C(F)(F)F		CHEMBL1794066	=	Inhibition	%	55.0	CHEMBL5408	Homo sapiens	Inhibition	%	55.0
	10832684	CHEMBL2007667	GSK_PKIS: TBK1 % inhibition at 1 uM [UNC Frye lab]	B	C#Cc1cccc(Nc2ncnc3ccc(OCCCCNCCS(C)(=O)=O)cc23)c1		CHEMBL517907	=	Inhibition	%	-4.0	CHEMBL5408	Homo sapiens	Inhibition	%	-4.0
	10832685	CHEMBL2007667	GSK_PKIS: TBK1 % inhibition at 1 uM [UNC Frye lab]	B	O=C1NC(=O)C(c2cccc(Cl)c2)=C1Nc1ccc(O)c(Cl)c1		CHEMBL160333	=	Inhibition	%	55.0	CHEMBL5408	Homo sapiens	Inhibition	%	55.0
	10832686	CHEMBL2007667	GSK_PKIS: TBK1 % inhibition at 1 uM [UNC Frye lab]	B	COc1cccc(-n2ncc3c(N/N=C/c4cccc(F)c4)ncnc32)c1		CHEMBL69757	=	Inhibition	%	6.0	CHEMBL5408	Homo sapiens	Inhibition	%	6.0
	10832687	CHEMBL2007667	GSK_PKIS: TBK1 % inhibition at 1 uM [UNC Frye lab]	B	CCCN1CCCC(c2ccc(Nc3nc(Nc4cc(F)ccc4C(N)=O)c4cc[nH]c4n3)c(OC)c2)C1		CHEMBL477069	=	Inhibition	%	9.0	CHEMBL5408	Homo sapiens	Inhibition	%	9.0
	10832688	CHEMBL2007667	GSK_PKIS: TBK1 % inhibition at 1 uM [UNC Frye lab]	B	CCS(=O)(=O)c1ccc(OC)c(Nc2ncc(-c3ccccc3Cl)o2)c1		CHEMBL179453	=	Inhibition	%	2.0	CHEMBL5408	Homo sapiens	Inhibition	%	2.0
	10832689	CHEMBL2007667	GSK_PKIS: TBK1 % inhibition at 1 uM [UNC Frye lab]	B	Cc1ccc2c(-c3ccnc(Nc4cccc(C(F)(F)F)c4)n3)c(-c3ccccc3)nn2n1		CHEMBL434729	=	Inhibition	%	-1.0	CHEMBL5408	Homo sapiens	Inhibition	%	-1.0
	10832690	CHEMBL2007667	GSK_PKIS: TBK1 % inhibition at 1 uM [UNC Frye lab]	B	COc1ccc(-c2nn3ncccc3c2-c2ccnc(Nc3ccc(Cl)c(C(F)(F)F)c3)n2)cc1		CHEMBL188794	=	Inhibition	%	-6.0	CHEMBL5408	Homo sapiens	Inhibition	%	-6.0
	10832691	CHEMBL2007667	GSK_PKIS: TBK1 % inhibition at 1 uM [UNC Frye lab]	B	CN(C)c1ccc2c(c1)/C(=C/Nc1ccc(S(N)(=O)=O)cc1)C(=O)N2		CHEMBL272414	=	Inhibition	%	76.0	CHEMBL5408	Homo sapiens	Inhibition	%	76.0
	10832692	CHEMBL2007667	GSK_PKIS: TBK1 % inhibition at 1 uM [UNC Frye lab]	B	Cl.Nc1nccc(-c2c(-c3ccc(F)cc3)ncn2C2CCNCC2)n1		CHEMBL1909407	=	Inhibition	%	0.0	CHEMBL5408	Homo sapiens	Inhibition	%	0.0
	10832693	CHEMBL2007667	GSK_PKIS: TBK1 % inhibition at 1 uM [UNC Frye lab]	B	CC1=C(C(=O)Nc2cc(Cl)c3[nH]ncc3c2)C(c2ccc(C(F)(F)F)cc2)CC(=O)N1		CHEMBL427058	=	Inhibition	%	-2.0	CHEMBL5408	Homo sapiens	Inhibition	%	-2.0
	10832694	CHEMBL2007667	GSK_PKIS: TBK1 % inhibition at 1 uM [UNC Frye lab]	B	O=C(O)C(F)(F)F.O=C(O[C@H]1CN[C@H](C#Cc2cc3ncnc(Nc4ccc(Cc5ccccc5)cc4)c3s2)C1)N1CCOCC1		CHEMBL1909409	=	Inhibition	%	14.0	CHEMBL5408	Homo sapiens	Inhibition	%	14.0
	10832695	CHEMBL2007667	GSK_PKIS: TBK1 % inhibition at 1 uM [UNC Frye lab]	B	CN(C)C(=O)O[C@H]1CN[C@H](C#Cc2cc3ncnc(Nc4ccc(OCc5cccc(F)c5)c(Cl)c4)c3s2)C1		CHEMBL517123	=	Inhibition	%	7.0	CHEMBL5408	Homo sapiens	Inhibition	%	7.0
	10832696	CHEMBL2007667	GSK_PKIS: TBK1 % inhibition at 1 uM [UNC Frye lab]	B	Cc1nnc(-c2ccc(C)c(-c3ccc(C(=O)NCc4ccc(Cl)cc4)cc3)c2)o1		CHEMBL402108	=	Inhibition	%	3.0	CHEMBL5408	Homo sapiens	Inhibition	%	3.0
	10832697	CHEMBL2007667	GSK_PKIS: TBK1 % inhibition at 1 uM [UNC Frye lab]	B	CCNC(=O)O[C@H]1CN[C@H](C#Cc2cc3ncnc(Nc4ccc(OCc5cccc(F)c5)c(Cl)c4)c3s2)C1		CHEMBL512076	=	Inhibition	%	0.0	CHEMBL5408	Homo sapiens	Inhibition	%	0.0
	10832698	CHEMBL2007667	GSK_PKIS: TBK1 % inhibition at 1 uM [UNC Frye lab]	B	N#Cc1c(NC(=O)c2cccc3ccccc23)sc2c1CCCN2C(=O)C1CC1		CHEMBL232601	=	Inhibition	%	-6.0	CHEMBL5408	Homo sapiens	Inhibition	%	-6.0
	10832699	CHEMBL2007667	GSK_PKIS: TBK1 % inhibition at 1 uM [UNC Frye lab]	B	FC(F)(F)CNc1nccc(-c2cnn3ncccc23)n1		CHEMBL446024	=	Inhibition	%	-4.0	CHEMBL5408	Homo sapiens	Inhibition	%	-4.0
	10832700	CHEMBL2007667	GSK_PKIS: TBK1 % inhibition at 1 uM [UNC Frye lab]	B	COC(=O)Nc1nc2ccc(Oc3ccc(NC(=O)Nc4cc(C(F)(F)F)ccc4F)cc3)cc2s1.Cl		CHEMBL1909369	=	Inhibition	%	-5.0	CHEMBL5408	Homo sapiens	Inhibition	%	-5.0
	10832701	CHEMBL2007667	GSK_PKIS: TBK1 % inhibition at 1 uM [UNC Frye lab]	B	O=C(Nc1n[nH]c2nc(-c3ccco3)c(Br)cc12)C1CC1		CHEMBL408564	=	Inhibition	%	18.0	CHEMBL5408	Homo sapiens	Inhibition	%	18.0
	10832702	CHEMBL2007667	GSK_PKIS: TBK1 % inhibition at 1 uM [UNC Frye lab]	B	Nc1nonc1-c1nc2cnccc2n1C1CC1		CHEMBL185962	=	Inhibition	%	8.0	CHEMBL5408	Homo sapiens	Inhibition	%	8.0
	10832703	CHEMBL2007667	GSK_PKIS: TBK1 % inhibition at 1 uM [UNC Frye lab]	B	CCc1cccc(NC(=O)Nc2ccc(Oc3ccc4nc(NC(=O)OC)[nH]c4c3)cc2)c1		CHEMBL243907	=	Inhibition	%	-3.0	CHEMBL5408	Homo sapiens	Inhibition	%	-3.0
	10832704	CHEMBL2007667	GSK_PKIS: TBK1 % inhibition at 1 uM [UNC Frye lab]	B	COC(=O)Nc1nc2cc(Oc3cccc(NC(=O)Nc4cc(C(F)(F)F)ccc4F)c3)ccc2[nH]1.Cl		CHEMBL1909366	=	Inhibition	%	-2.0	CHEMBL5408	Homo sapiens	Inhibition	%	-2.0
	10832705	CHEMBL2007667	GSK_PKIS: TBK1 % inhibition at 1 uM [UNC Frye lab]	B	NS(=O)(=O)c1ccc(Nc2cc(-c3ccc(O)c(F)c3)n[nH]2)cc1		CHEMBL103115	=	Inhibition	%	16.0	CHEMBL5408	Homo sapiens	Inhibition	%	16.0
	10832706	CHEMBL2007667	GSK_PKIS: TBK1 % inhibition at 1 uM [UNC Frye lab]	B	Cc1ccc(NC(=O)c2ccoc2)cc1-c1ccc(C(=O)NCC2CC2)cc1		CHEMBL477583	=	Inhibition	%	1.0	CHEMBL5408	Homo sapiens	Inhibition	%	1.0
	10832707	CHEMBL2007667	GSK_PKIS: TBK1 % inhibition at 1 uM [UNC Frye lab]	B	CS(=O)(=O)CCN(CC#N)Cc1ccc(-c2ccc3ncnc(Nc4ccc(OCc5cccc(F)c5)c(Cl)c4)c3c2)o1		CHEMBL384407	=	Inhibition	%	11.0	CHEMBL5408	Homo sapiens	Inhibition	%	11.0
	10832708	CHEMBL2007667	GSK_PKIS: TBK1 % inhibition at 1 uM [UNC Frye lab]	B	O=C(O)C(F)(F)F.[O-][S+]1CCN(Cc2ccc(-c3ccc4ncnc(Nc5ccc(OCc6cccc(F)c6)c(Cl)c5)c4c3)o2)CC1		CHEMBL1909390	=	Inhibition	%	7.0	CHEMBL5408	Homo sapiens	Inhibition	%	7.0
	10832709	CHEMBL2007667	GSK_PKIS: TBK1 % inhibition at 1 uM [UNC Frye lab]	B	COc1cc2ncn(-c3cc(OCc4ccccc4Cl)c(C(N)=O)s3)c2cc1OC		CHEMBL514162	=	Inhibition	%	56.0	CHEMBL5408	Homo sapiens	Inhibition	%	56.0
	10832710	CHEMBL2007667	GSK_PKIS: TBK1 % inhibition at 1 uM [UNC Frye lab]	B	C[C@@H](Oc1cc(-n2cnc3ccc(OC4CCN(C)CC4)cc32)sc1C(N)=O)c1ccccc1Cl		CHEMBL1794070	=	Inhibition	%	7.0	CHEMBL5408	Homo sapiens	Inhibition	%	7.0
	10832711	CHEMBL2007667	GSK_PKIS: TBK1 % inhibition at 1 uM [UNC Frye lab]	B	Cc1cccc(Nc2ncc(-c3ccccc3)o2)c1		CHEMBL192417	=	Inhibition	%	1.0	CHEMBL5408	Homo sapiens	Inhibition	%	1.0
	10832712	CHEMBL2007667	GSK_PKIS: TBK1 % inhibition at 1 uM [UNC Frye lab]	B	NC(=O)c1sc(-n2cnc3ccccc32)cc1OCc1ccccc1Br		CHEMBL518953	=	Inhibition	%	0.0	CHEMBL5408	Homo sapiens	Inhibition	%	0.0
	10832713	CHEMBL2007667	GSK_PKIS: TBK1 % inhibition at 1 uM [UNC Frye lab]	B	COc1cc(Nc2ncc(-c3ccccc3)o2)cc(OC)c1OC		CHEMBL443563	=	Inhibition	%	35.0	CHEMBL5408	Homo sapiens	Inhibition	%	35.0
	10832714	CHEMBL2007667	GSK_PKIS: TBK1 % inhibition at 1 uM [UNC Frye lab]	B	Nc1ccc(C#Cc2cncnc2Nc2ccc(OCc3cccc(F)c3)c(Cl)c2)cc1		CHEMBL205966	=	Inhibition	%	2.0	CHEMBL5408	Homo sapiens	Inhibition	%	2.0
	10832715	CHEMBL2007667	GSK_PKIS: TBK1 % inhibition at 1 uM [UNC Frye lab]	B	COc1cc2c(cc1Nc1nc(N3CCc4ccccc43)c3cc[nH]c3n1)N(C(=O)CN(C)C)CC2		CHEMBL458415	=	Inhibition	%	24.0	CHEMBL5408	Homo sapiens	Inhibition	%	24.0
	10832716	CHEMBL2007667	GSK_PKIS: TBK1 % inhibition at 1 uM [UNC Frye lab]	B	O=C(NCC1CC1)c1ccc(-c2cccc(C(=O)NC3CC3)c2)cc1		CHEMBL479038	=	Inhibition	%	1.0	CHEMBL5408	Homo sapiens	Inhibition	%	1.0
	10832717	CHEMBL2007667	GSK_PKIS: TBK1 % inhibition at 1 uM [UNC Frye lab]	B	CCN1CCC(CC(=O)Nc2n[nH]c3nnc(-c4cccc(F)c4F)cc23)CC1.O=C(O)C(O)C(O)C(=O)O		CHEMBL2062289	=	Inhibition	%	0.0	CHEMBL5408	Homo sapiens	Inhibition	%	0.0
	10832718	CHEMBL2007667	GSK_PKIS: TBK1 % inhibition at 1 uM [UNC Frye lab]	B	O=C1Nc2ccccc2/C1=C/Nc1ccc2[nH]c(=O)[nH]c2c1		CHEMBL1794057	=	Inhibition	%	30.0	CHEMBL5408	Homo sapiens	Inhibition	%	30.0
	10832719	CHEMBL2007667	GSK_PKIS: TBK1 % inhibition at 1 uM [UNC Frye lab]	B	CCCN(CCS(C)(=O)=O)Cc1ccc(-c2ccc3ncnc(Nc4ccc(OCc5cccc(F)c5)c(Cl)c4)c3c2)o1.Cl		CHEMBL1909394	=	Inhibition	%	7.0	CHEMBL5408	Homo sapiens	Inhibition	%	7.0
	10832720	CHEMBL2007667	GSK_PKIS: TBK1 % inhibition at 1 uM [UNC Frye lab]	B	CCCN1CCC(c2ccc(Nc3nc(Nc4cc(F)ccc4C(N)=O)c4cc[nH]c4n3)c(OC)c2)CC1		CHEMBL476259	=	Inhibition	%	13.0	CHEMBL5408	Homo sapiens	Inhibition	%	13.0
	10832721	CHEMBL2007667	GSK_PKIS: TBK1 % inhibition at 1 uM [UNC Frye lab]	B	Nc1nc(-c2ccc(F)cc2)c(-c2ccc3ncccc3n2)s1		CHEMBL361237	=	Inhibition	%	4.0	CHEMBL5408	Homo sapiens	Inhibition	%	4.0
	10832722	CHEMBL2007667	GSK_PKIS: TBK1 % inhibition at 1 uM [UNC Frye lab]	B	O=C1Nc2ccc(C(=O)c3ccco3)cc2C1=Cc1cc(Cl)c(O)c(Cl)c1		CHEMBL1789963	=	Inhibition	%	87.0	CHEMBL5408	Homo sapiens	Inhibition	%	87.0
	10832723	CHEMBL2007667	GSK_PKIS: TBK1 % inhibition at 1 uM [UNC Frye lab]	B	CNC(=O)Oc1cc(C)c(/C=C/c2cncc(C(=O)NC)c2)c(C)c1		CHEMBL218932	=	Inhibition	%	-1.0	CHEMBL5408	Homo sapiens	Inhibition	%	-1.0
	10832724	CHEMBL2007667	GSK_PKIS: TBK1 % inhibition at 1 uM [UNC Frye lab]	B	Cl.NS(=O)(=O)c1cccc(Nc2cc(-c3ccc(F)cc3)n[nH]2)c1		CHEMBL1909351	=	Inhibition	%	21.0	CHEMBL5408	Homo sapiens	Inhibition	%	21.0
	10832725	CHEMBL2007667	GSK_PKIS: TBK1 % inhibition at 1 uM [UNC Frye lab]	B	COC(=O)c1cncc(/C=C/c2c(C)cc(O)cc2C)c1		CHEMBL220243	=	Inhibition	%	2.0	CHEMBL5408	Homo sapiens	Inhibition	%	2.0
	10832726	CHEMBL2007667	GSK_PKIS: TBK1 % inhibition at 1 uM [UNC Frye lab]	B	COc1ccc(-c2cc(-c3c[nH]nc3-c3ccccn3)ccn2)cc1		CHEMBL202891	=	Inhibition	%	-2.0	CHEMBL5408	Homo sapiens	Inhibition	%	-2.0
	10832727	CHEMBL2007667	GSK_PKIS: TBK1 % inhibition at 1 uM [UNC Frye lab]	B	COC(=O)c1sc(-n2cnc3cc(OC)c(OC)cc32)cc1OCc1ccccc1C(F)(F)F		CHEMBL473420	=	Inhibition	%	37.0	CHEMBL5408	Homo sapiens	Inhibition	%	37.0
	10832728	CHEMBL2007667	GSK_PKIS: TBK1 % inhibition at 1 uM [UNC Frye lab]	B	COc1ccc(-c2coc3ncnc(N)c23)cc1		CHEMBL196022	=	Inhibition	%	-5.0	CHEMBL5408	Homo sapiens	Inhibition	%	-5.0
	10832729	CHEMBL2007667	GSK_PKIS: TBK1 % inhibition at 1 uM [UNC Frye lab]	B	CN1CCC(C(=O)Nc2n[nH]c3nnc(-c4ccccc4)cc23)CC1.Cl		CHEMBL1909344	=	Inhibition	%	-3.0	CHEMBL5408	Homo sapiens	Inhibition	%	-3.0
	10832730	CHEMBL2007667	GSK_PKIS: TBK1 % inhibition at 1 uM [UNC Frye lab]	B	Fc1cccc(COc2ccc(Nc3ncnc4sc(-c5cccs5)cc34)cc2Cl)c1		CHEMBL506414	=	Inhibition	%	-2.0	CHEMBL5408	Homo sapiens	Inhibition	%	-2.0
	10832731	CHEMBL2007667	GSK_PKIS: TBK1 % inhibition at 1 uM [UNC Frye lab]	B	COc1cccc(-n2ncc3c(N/N=C/c4ccc(C(=O)NCCN(C)C)cc4)ncnc32)c1.Cl		CHEMBL1909383	=	Inhibition	%	28.0	CHEMBL5408	Homo sapiens	Inhibition	%	28.0
	10832732	CHEMBL2007667	GSK_PKIS: TBK1 % inhibition at 1 uM [UNC Frye lab]	B	c1ccc(COc2ccc(Nc3ncnc4ccc(-c5ccco5)cc34)cc2)cc1		CHEMBL215993	=	Inhibition	%	-2.0	CHEMBL5408	Homo sapiens	Inhibition	%	-2.0
	10832733	CHEMBL2007667	GSK_PKIS: TBK1 % inhibition at 1 uM [UNC Frye lab]	B	CCn1c(-c2nonc2N)nc2ccncc21		CHEMBL185710	=	Inhibition	%	-4.0	CHEMBL5408	Homo sapiens	Inhibition	%	-4.0
	10832734	CHEMBL2007667	GSK_PKIS: TBK1 % inhibition at 1 uM [UNC Frye lab]	B	Nc1nc(-c2ccccn2)c(-c2ccc3ncccc3n2)s1		CHEMBL181361	=	Inhibition	%	3.0	CHEMBL5408	Homo sapiens	Inhibition	%	3.0
	10832735	CHEMBL2007667	GSK_PKIS: TBK1 % inhibition at 1 uM [UNC Frye lab]	B	Cc1cc(-c2ccccn2)cc(C)c1/C=C/c1cncc(-c2nn[nH]n2)c1.Cl		CHEMBL1909354	=	Inhibition	%	-2.0	CHEMBL5408	Homo sapiens	Inhibition	%	-2.0
	10832736	CHEMBL2007667	GSK_PKIS: TBK1 % inhibition at 1 uM [UNC Frye lab]	B	Cc1cc(O)cc(C)c1/C=C/c1cncc(C(=O)OC(C)(C)C)c1		CHEMBL374060	=	Inhibition	%	0.0	CHEMBL5408	Homo sapiens	Inhibition	%	0.0
	10832737	CHEMBL2007667	GSK_PKIS: TBK1 % inhibition at 1 uM [UNC Frye lab]	B	Fc1ccc(-c2ncn(C3CCNCC3)c2-c2ccnc(Oc3ccc4c(c3)OCO4)n2)cc1		CHEMBL273611	=	Inhibition	%	-3.0	CHEMBL5408	Homo sapiens	Inhibition	%	-3.0
	10832738	CHEMBL2007667	GSK_PKIS: TBK1 % inhibition at 1 uM [UNC Frye lab]	B	c1ccc(Nc2ncc(-c3ccccc3)o2)cc1		CHEMBL318728	=	Inhibition	%	2.0	CHEMBL5408	Homo sapiens	Inhibition	%	2.0
	10832739	CHEMBL2007667	GSK_PKIS: TBK1 % inhibition at 1 uM [UNC Frye lab]	B	NS(=O)(=O)c1ccc(N/C=C2\C(=O)Nc3ccc4ncsc4c32)cc1		CHEMBL271595	=	Inhibition	%	85.0	CHEMBL5408	Homo sapiens	Inhibition	%	85.0
	10832740	CHEMBL2007667	GSK_PKIS: TBK1 % inhibition at 1 uM [UNC Frye lab]	B	CC(=O)Nc1cccc(C#Cc2cncnc2Nc2ccc(OCc3cccc(F)c3)c(Cl)c2)n1		CHEMBL205765	=	Inhibition	%	3.0	CHEMBL5408	Homo sapiens	Inhibition	%	3.0
	10832741	CHEMBL2007667	GSK_PKIS: TBK1 % inhibition at 1 uM [UNC Frye lab]	B	Cl.[O-][S+]1CCN(Cc2ccc(-c3ccc4ncnc(Nc5ccc(OCc6ccccc6)c(Cl)c5)c4c3)o2)CC1		CHEMBL1909393	=	Inhibition	%	-4.0	CHEMBL5408	Homo sapiens	Inhibition	%	-4.0
	10832742	CHEMBL2007667	GSK_PKIS: TBK1 % inhibition at 1 uM [UNC Frye lab]	B	NC(=O)c1ccc2c(-c3ccnc(NCCCO)n3)c(-c3ccc(F)cc3)nn2c1		CHEMBL1909404	=	Inhibition	%	3.0	CHEMBL5408	Homo sapiens	Inhibition	%	3.0
	10832743	CHEMBL2007667	GSK_PKIS: TBK1 % inhibition at 1 uM [UNC Frye lab]	B	Cc1cc(Cl)cc2c1NC(=O)C2=NNc1ccc(S(N)(=O)=O)cc1		CHEMBL1909397	=	Inhibition	%	29.0	CHEMBL5408	Homo sapiens	Inhibition	%	29.0
	10832744	CHEMBL2007667	GSK_PKIS: TBK1 % inhibition at 1 uM [UNC Frye lab]	B	CS(=O)(=O)CCNCc1ccc(-c2ccc3ncnc(Nc4ccc(OCc5cccc(F)c5)c(C(F)(F)F)c4)c3c2)o1		CHEMBL215814	=	Inhibition	%	3.0	CHEMBL5408	Homo sapiens	Inhibition	%	3.0
	10832745	CHEMBL2007667	GSK_PKIS: TBK1 % inhibition at 1 uM [UNC Frye lab]	B	CC1=C(C(=O)Nc2cc(Cl)c3[nH]ncc3c2)C(c2ccc(C(F)(F)F)cc2)CC(=O)N1		CHEMBL427058	=	Inhibition	%	0.0	CHEMBL5408	Homo sapiens	Inhibition	%	0.0
	10832746	CHEMBL2007667	GSK_PKIS: TBK1 % inhibition at 1 uM [UNC Frye lab]	B	COc1cc2ncnc(Nc3ccc4c(cnn4Cc4ccccc4)c3)c2cc1OC.Cl		CHEMBL1909380	=	Inhibition	%	5.0	CHEMBL5408	Homo sapiens	Inhibition	%	5.0
	10832747	CHEMBL2007667	GSK_PKIS: TBK1 % inhibition at 1 uM [UNC Frye lab]	B	CN1CCN(CCCNc2nc3ccc(Oc4ccc(NC(=O)Nc5cc(C(F)(F)F)ccc5F)cc4)cc3[nH]2)CC1.Cl		CHEMBL1909372	=	Inhibition	%	0.0	CHEMBL5408	Homo sapiens	Inhibition	%	0.0
	10832748	CHEMBL2007667	GSK_PKIS: TBK1 % inhibition at 1 uM [UNC Frye lab]	B	O=C1NC(=O)C(c2cccc(Cl)c2)=C1Nc1ccc(Cl)c(C(=O)O)c1		CHEMBL156987	=	Inhibition	%	19.0	CHEMBL5408	Homo sapiens	Inhibition	%	19.0
	10832749	CHEMBL2007667	GSK_PKIS: TBK1 % inhibition at 1 uM [UNC Frye lab]	B	COc1cc(N2CCN(C(C)C)CC2)ccc1Nc1nc(Nc2ccc(F)cc2C(=O)NC[C@@H](O)CO)c2cc[nH]c2n1		CHEMBL450071	=	Inhibition	%	-1.0	CHEMBL5408	Homo sapiens	Inhibition	%	-1.0
	10832750	CHEMBL2007667	GSK_PKIS: TBK1 % inhibition at 1 uM [UNC Frye lab]	B	N#Cc1c(NC(=O)c2cccc3ccccc23)sc2c1CCCN2C(=O)C1CC1		CHEMBL232601	=	Inhibition	%	-5.0	CHEMBL5408	Homo sapiens	Inhibition	%	-5.0
	10832751	CHEMBL2007667	GSK_PKIS: TBK1 % inhibition at 1 uM [UNC Frye lab]	B	O=C(Nc1n[nH]c2cc(-c3ccccc3)ccc12)C1CC1		CHEMBL405021	=	Inhibition	%	2.0	CHEMBL5408	Homo sapiens	Inhibition	%	2.0
	10832752	CHEMBL2007667	GSK_PKIS: TBK1 % inhibition at 1 uM [UNC Frye lab]	B	O=C1NC(=O)C(c2ccc(Cl)cc2)=C1Nc1ccc(Cl)c(C(=O)O)c1		CHEMBL160876	=	Inhibition	%	-2.0	CHEMBL5408	Homo sapiens	Inhibition	%	-2.0
	10832753	CHEMBL2007667	GSK_PKIS: TBK1 % inhibition at 1 uM [UNC Frye lab]	B	COc1cc2ncn(-c3cc(OCc4cccs4)c(C(N)=O)s3)c2cc1OC		CHEMBL480382	=	Inhibition	%	35.0	CHEMBL5408	Homo sapiens	Inhibition	%	35.0
	10832754	CHEMBL2007667	GSK_PKIS: TBK1 % inhibition at 1 uM [UNC Frye lab]	B	O=C(Nc1n[nH]c2nc(-c3ccco3)c(Br)cc12)C1CC1		CHEMBL408564	=	Inhibition	%	25.0	CHEMBL5408	Homo sapiens	Inhibition	%	25.0
	10832755	CHEMBL2007667	GSK_PKIS: TBK1 % inhibition at 1 uM [UNC Frye lab]	B	N#Cc1cccc(Nc2nccc(-c3cnn4ncccc34)n2)c1		CHEMBL495696	=	Inhibition	%	39.0	CHEMBL5408	Homo sapiens	Inhibition	%	39.0
	10832756	CHEMBL2007667	GSK_PKIS: TBK1 % inhibition at 1 uM [UNC Frye lab]	B	CN(C)CCCn1c(-c2nonc2N)nc2cnccc21		CHEMBL191105	=	Inhibition	%	1.0	CHEMBL5408	Homo sapiens	Inhibition	%	1.0
	10832757	CHEMBL2007667	GSK_PKIS: TBK1 % inhibition at 1 uM [UNC Frye lab]	B	COc1ccccc1-c1cc(/C=C2\C(=O)Nc3ncc(Br)cc32)cc(Br)c1O		CHEMBL176857	=	Inhibition	%	15.0	CHEMBL5408	Homo sapiens	Inhibition	%	15.0
	10832758	CHEMBL2007667	GSK_PKIS: TBK1 % inhibition at 1 uM [UNC Frye lab]	B	Nc1ncnc2occ(-c3ccc(NC(=O)Nc4cc(C(F)(F)F)cc(C(F)(F)F)c4)cc3)c12		CHEMBL396107	=	Inhibition	%	-3.0	CHEMBL5408	Homo sapiens	Inhibition	%	-3.0
	10832759	CHEMBL2007667	GSK_PKIS: TBK1 % inhibition at 1 uM [UNC Frye lab]	B	CN1CCC(n2cnc(-c3ccc(F)cc3)c2-c2ccnc(Nc3ccccc3)n2)CC1		CHEMBL318892	=	Inhibition	%	-2.0	CHEMBL5408	Homo sapiens	Inhibition	%	-2.0
	10832760	CHEMBL2007667	GSK_PKIS: TBK1 % inhibition at 1 uM [UNC Frye lab]	B	Cl.NC(=O)c1ccc(-c2nc(-c3ccccn3)c(-c3ccc4c(c3)OCO4)[nH]2)cc1		CHEMBL1909378	=	Inhibition	%	5.0	CHEMBL5408	Homo sapiens	Inhibition	%	5.0
	10832761	CHEMBL2007667	GSK_PKIS: TBK1 % inhibition at 1 uM [UNC Frye lab]	B	COc1c(C(N)=O)cc(-c2ccc(Cl)cc2)cc1-c1ccc(S(N)(=O)=O)cc1		CHEMBL268885	=	Inhibition	%	0.0	CHEMBL5408	Homo sapiens	Inhibition	%	0.0
	10832762	CHEMBL2007667	GSK_PKIS: TBK1 % inhibition at 1 uM [UNC Frye lab]	B	NS(=O)(=O)c1ccc(N/N=C2\C(=O)Nc3ccc(C(=O)NCCCn4ccnc4)cc32)cc1		CHEMBL272026	=	Inhibition	%	42.0	CHEMBL5408	Homo sapiens	Inhibition	%	42.0
	10832763	CHEMBL2007667	GSK_PKIS: TBK1 % inhibition at 1 uM [UNC Frye lab]	B	COC(=O)Nc1nc2ccc(S(=O)(=O)c3ccc(NC(=O)Nc4cc(C(F)(F)F)ccc4F)cc3)cc2[nH]1.Cl		CHEMBL1909367	=	Inhibition	%	0.0	CHEMBL5408	Homo sapiens	Inhibition	%	0.0
	10832764	CHEMBL2007667	GSK_PKIS: TBK1 % inhibition at 1 uM [UNC Frye lab]	B	O=C1NC(=O)C(c2ccccc2Cl)=C1Nc1cc(Cl)c(O)c(Cl)c1		CHEMBL157258	=	Inhibition	%	21.0	CHEMBL5408	Homo sapiens	Inhibition	%	21.0
	10832765	CHEMBL2007667	GSK_PKIS: TBK1 % inhibition at 1 uM [UNC Frye lab]	B	COC(=O)Nc1nc2cc(Oc3ccc(NC(=O)Nc4cccc(Br)c4)cc3)ccc2[nH]1.Cl		CHEMBL1909370	=	Inhibition	%	0.0	CHEMBL5408	Homo sapiens	Inhibition	%	0.0
	10832766	CHEMBL2007667	GSK_PKIS: TBK1 % inhibition at 1 uM [UNC Frye lab]	B	CCn1c(-c2nonc2N)nc2ccc(F)cc21		CHEMBL426800	=	Inhibition	%	2.0	CHEMBL5408	Homo sapiens	Inhibition	%	2.0
	10832767	CHEMBL2007667	GSK_PKIS: TBK1 % inhibition at 1 uM [UNC Frye lab]	B	Nc1nccc(C#Cc2cncnc2Nc2ccc(OCc3cccc(F)c3)c(Cl)c2)n1		CHEMBL381604	=	Inhibition	%	9.0	CHEMBL5408	Homo sapiens	Inhibition	%	9.0
	10832768	CHEMBL2007667	GSK_PKIS: TBK1 % inhibition at 1 uM [UNC Frye lab]	B	CS(=O)(=O)CCNCc1ccc(-c2ccc3ncnc(Nc4ccc(OCc5ccccc5)c(C(F)(F)F)c4)c3c2)o1.Cl		CHEMBL1909389	=	Inhibition	%	-3.0	CHEMBL5408	Homo sapiens	Inhibition	%	-3.0
	10832769	CHEMBL2007667	GSK_PKIS: TBK1 % inhibition at 1 uM [UNC Frye lab]	B	NS(=O)(=O)c1cccc(-c2ccc3c(NC(=O)C4CC4)n[nH]c3c2)c1		CHEMBL407113	=	Inhibition	%	1.0	CHEMBL5408	Homo sapiens	Inhibition	%	1.0
	10832770	CHEMBL2007667	GSK_PKIS: TBK1 % inhibition at 1 uM [UNC Frye lab]	B	COc1cc2ncn(-c3cc(OCc4ccccc4S(C)(=O)=O)c(C#N)s3)c2cc1OC		CHEMBL373751	=	Inhibition	%	103.0	CHEMBL5408	Homo sapiens	Inhibition	%	103.0
	10832771	CHEMBL2007667	GSK_PKIS: TBK1 % inhibition at 1 uM [UNC Frye lab]	B	COc1cc(Nc2ncc3c(C)nc(-c4cccc(C(F)(F)F)c4)n3n2)cc(OC)c1OC		CHEMBL520037	=	Inhibition	%	53.0	CHEMBL5408	Homo sapiens	Inhibition	%	53.0
	10832772	CHEMBL2007667	GSK_PKIS: TBK1 % inhibition at 1 uM [UNC Frye lab]	B	CCn1c(-c2nonc2N)nc2ccncc21		CHEMBL185710	=	Inhibition	%	-5.0	CHEMBL5408	Homo sapiens	Inhibition	%	-5.0
	10832773	CHEMBL2007667	GSK_PKIS: TBK1 % inhibition at 1 uM [UNC Frye lab]	B	Cc1cc(O)cc(C)c1/C=C/c1cncc(C(=O)OC(C)(C)C)c1		CHEMBL374060	=	Inhibition	%	-2.0	CHEMBL5408	Homo sapiens	Inhibition	%	-2.0
	10832774	CHEMBL2007667	GSK_PKIS: TBK1 % inhibition at 1 uM [UNC Frye lab]	B	NC(=O)c1sc(-n2cnc3cc(C(F)(F)F)ccc32)cc1OCc1ccccc1Br		CHEMBL480371	=	Inhibition	%	3.0	CHEMBL5408	Homo sapiens	Inhibition	%	3.0
	10832775	CHEMBL2007667	GSK_PKIS: TBK1 % inhibition at 1 uM [UNC Frye lab]	B	CC(C)(CO)CNC(=O)c1ccc2c(c1)/C(=N/Nc1ccc(S(N)(=O)=O)cc1)C(=O)N2		CHEMBL410072	=	Inhibition	%	87.0	CHEMBL5408	Homo sapiens	Inhibition	%	87.0
	10832776	CHEMBL2007667	GSK_PKIS: TBK1 % inhibition at 1 uM [UNC Frye lab]	B	Cn1c(-c2nonc2N)nc2cnccc21		CHEMBL188048	=	Inhibition	%	-4.0	CHEMBL5408	Homo sapiens	Inhibition	%	-4.0
	10832777	CHEMBL2007667	GSK_PKIS: TBK1 % inhibition at 1 uM [UNC Frye lab]	B	O=C1Nc2ccc(I)cc2C1=Cc1cc(Br)c(O)c(Br)c1		CHEMBL1880739	=	Inhibition	%	3.0	CHEMBL5408	Homo sapiens	Inhibition	%	3.0
	10832778	CHEMBL2007667	GSK_PKIS: TBK1 % inhibition at 1 uM [UNC Frye lab]	B	Fc1ccc(-c2ncn(C3CCNCC3)c2-c2ccnc(Oc3ccc(Cl)cc3)n2)cc1		CHEMBL275168	=	Inhibition	%	3.0	CHEMBL5408	Homo sapiens	Inhibition	%	3.0
	10832779	CHEMBL2007667	GSK_PKIS: TBK1 % inhibition at 1 uM [UNC Frye lab]	B	Cl.O=C(O[C@H]1CN[C@H](C#Cc2cc3ncnc(Nc4ccc5c(cnn5Cc5ccccc5)c4)c3s2)C1)N1CCOCC1		CHEMBL1909408	=	Inhibition	%	31.0	CHEMBL5408	Homo sapiens	Inhibition	%	31.0
	10832780	CHEMBL2007667	GSK_PKIS: TBK1 % inhibition at 1 uM [UNC Frye lab]	B	CC(C)c1ccc(-c2cc(-c3c[nH]nc3-c3ccccn3)ccn2)cc1		CHEMBL206544	=	Inhibition	%	-7.0	CHEMBL5408	Homo sapiens	Inhibition	%	-7.0
	10832781	CHEMBL2007667	GSK_PKIS: TBK1 % inhibition at 1 uM [UNC Frye lab]	B	Cl.O=C1Nc2ccc(-c3cccnc3)cc2C1=Cc1cc(Br)c(O)c(Br)c1		CHEMBL1794050	=	Inhibition	%	40.0	CHEMBL5408	Homo sapiens	Inhibition	%	40.0
	10832782	CHEMBL2007667	GSK_PKIS: TBK1 % inhibition at 1 uM [UNC Frye lab]	B	COc1cc(C=NNc2ncnc3c2cnn3-c2ccccc2)ccc1O		CHEMBL1789961	=	Inhibition	%	38.0	CHEMBL5408	Homo sapiens	Inhibition	%	38.0
	10832783	CHEMBL2007667	GSK_PKIS: TBK1 % inhibition at 1 uM [UNC Frye lab]	B	Cc1cc(O)cc(C)c1/C=C/c1cncc(C(=O)N(C)C)c1		CHEMBL220244	=	Inhibition	%	1.0	CHEMBL5408	Homo sapiens	Inhibition	%	1.0
	10832784	CHEMBL2007667	GSK_PKIS: TBK1 % inhibition at 1 uM [UNC Frye lab]	B	Cc1ccc(C(=O)NC2CC2)cc1-c1ccc2[nH]ncc2c1		CHEMBL495902	=	Inhibition	%	0.0	CHEMBL5408	Homo sapiens	Inhibition	%	0.0
	10832785	CHEMBL2007667	GSK_PKIS: TBK1 % inhibition at 1 uM [UNC Frye lab]	B	c1cnn2ncc(-c3ccnc(Nc4ccc5c(c4)OCCO5)n3)c2c1		CHEMBL361894	=	Inhibition	%	29.0	CHEMBL5408	Homo sapiens	Inhibition	%	29.0
	10832786	CHEMBL2007667	GSK_PKIS: TBK1 % inhibition at 1 uM [UNC Frye lab]	B	COc1cccc(/C=N/Nc2ncnc3c2cnn3-c2cccc(OC)c2)c1		CHEMBL305477	=	Inhibition	%	1.0	CHEMBL5408	Homo sapiens	Inhibition	%	1.0
	10832787	CHEMBL2007667	GSK_PKIS: TBK1 % inhibition at 1 uM [UNC Frye lab]	B	Cc1nnc(-c2ccc(C)c(-c3ccc(C(=O)Nc4cccc(C#N)c4)cc3)c2)o1		CHEMBL270164	=	Inhibition	%	-2.0	CHEMBL5408	Homo sapiens	Inhibition	%	-2.0
	10832788	CHEMBL2007667	GSK_PKIS: TBK1 % inhibition at 1 uM [UNC Frye lab]	B	CC1=C(C(=O)Nc2ccc3[nH]ncc3c2)C(c2ccc(F)cc2)N=C(c2ccc(C(F)(F)F)nc2)N1		CHEMBL485598	=	Inhibition	%	-1.0	CHEMBL5408	Homo sapiens	Inhibition	%	-1.0
	10832789	CHEMBL2007667	GSK_PKIS: TBK1 % inhibition at 1 uM [UNC Frye lab]	B	CN(c1ccc(NC(=O)Nc2c(Cl)cccc2Cl)cc1)c1ccnc(Nc2cccc(CS(C)(=O)=O)c2)n1		CHEMBL189353	=	Inhibition	%	17.0	CHEMBL5408	Homo sapiens	Inhibition	%	17.0
	10832790	CHEMBL2007667	GSK_PKIS: TBK1 % inhibition at 1 uM [UNC Frye lab]	B	Cl.NC(=O)c1cccc(Nc2nccc(Nc3cccc(F)c3)n2)c1		CHEMBL1909382	=	Inhibition	%	6.0	CHEMBL5408	Homo sapiens	Inhibition	%	6.0
	10832791	CHEMBL2007667	GSK_PKIS: TBK1 % inhibition at 1 uM [UNC Frye lab]	B	COc1cc(N2CCN(C(C)C)CC2)ccc1Nc1nc(Nc2cccc(F)c2C(=O)O)c2cc[nH]c2n1		CHEMBL514261	=	Inhibition	%	-3.0	CHEMBL5408	Homo sapiens	Inhibition	%	-3.0
	10832792	CHEMBL2007667	GSK_PKIS: TBK1 % inhibition at 1 uM [UNC Frye lab]	B	Cl.Nc1nccc(-c2c(-c3ccc(F)cc3)ncn2C2CCNCC2)n1		CHEMBL1909407	=	Inhibition	%	-4.0	CHEMBL5408	Homo sapiens	Inhibition	%	-4.0
	10832793	CHEMBL2007667	GSK_PKIS: TBK1 % inhibition at 1 uM [UNC Frye lab]	B	O=C(Nc1n[nH]c2nnc(-c3cccnc3)cc12)C1CC1.O=C(O)C(F)(F)F		CHEMBL1909343	=	Inhibition	%	5.0	CHEMBL5408	Homo sapiens	Inhibition	%	5.0
	10832794	CHEMBL2007667	GSK_PKIS: TBK1 % inhibition at 1 uM [UNC Frye lab]	B	c1ccc(-c2n[nH]cc2-c2ccnc(-c3ccc(OCCn4ccnc4)cc3)c2)nc1		CHEMBL208437	=	Inhibition	%	-4.0	CHEMBL5408	Homo sapiens	Inhibition	%	-4.0
	10832795	CHEMBL2007667	GSK_PKIS: TBK1 % inhibition at 1 uM [UNC Frye lab]	B	NC(=O)c1sc(-n2cnc3ccccc32)cc1OCc1ccccc1Br		CHEMBL518953	=	Inhibition	%	3.0	CHEMBL5408	Homo sapiens	Inhibition	%	3.0
	10832796	CHEMBL2007667	GSK_PKIS: TBK1 % inhibition at 1 uM [UNC Frye lab]	B	CS(=O)(=O)CCNCc1ccoc1-c1ccc2ncnc(Nc3ccc(OCc4ccccc4)cc3)c2c1.Cl		CHEMBL1909388	=	Inhibition	%	5.0	CHEMBL5408	Homo sapiens	Inhibition	%	5.0
	10832797	CHEMBL2007667	GSK_PKIS: TBK1 % inhibition at 1 uM [UNC Frye lab]	B	CCS(=O)(=O)c1ccc(OC)c(Nc2ncc(-c3cccc(F)c3)o2)c1		CHEMBL179465	=	Inhibition	%	8.0	CHEMBL5408	Homo sapiens	Inhibition	%	8.0
	10832798	CHEMBL2007667	GSK_PKIS: TBK1 % inhibition at 1 uM [UNC Frye lab]	B	COc1ccc2ncn(-c3cc(O[C@H](C)c4ccccc4Cl)c(C(N)=O)s3)c2c1		CHEMBL493326	=	Inhibition	%	0.0	CHEMBL5408	Homo sapiens	Inhibition	%	0.0
	10832799	CHEMBL2007667	GSK_PKIS: TBK1 % inhibition at 1 uM [UNC Frye lab]	B	CS(=O)(=O)CCNCc1coc(-c2ccc3ncnc(Nc4ccc(OCc5ccccc5)cc4)c3c2)c1.Cl		CHEMBL1909386	=	Inhibition	%	-1.0	CHEMBL5408	Homo sapiens	Inhibition	%	-1.0
	10832800	CHEMBL2007667	GSK_PKIS: TBK1 % inhibition at 1 uM [UNC Frye lab]	B	Cl.O=C(Nc1ccc(Oc2ccc3[nH]c(NC(=O)c4ccco4)nc3c2)cc1)Nc1cc(C(F)(F)F)ccc1F		CHEMBL1909368	=	Inhibition	%	0.0	CHEMBL5408	Homo sapiens	Inhibition	%	0.0
	10832801	CHEMBL2007667	GSK_PKIS: TBK1 % inhibition at 1 uM [UNC Frye lab]	B	Fc1ccc(-c2ncn(C3CCNCC3)c2-c2ccnc(Oc3ccc(F)c(F)c3)n2)cc1		CHEMBL1785004	=	Inhibition	%	2.0	CHEMBL5408	Homo sapiens	Inhibition	%	2.0
	10832802	CHEMBL2007667	GSK_PKIS: TBK1 % inhibition at 1 uM [UNC Frye lab]	B	COc1cccc(Nc2nccc(-c3cnn4ncccc34)n2)c1		CHEMBL187081	=	Inhibition	%	24.0	CHEMBL5408	Homo sapiens	Inhibition	%	24.0
	10832803	CHEMBL2007667	GSK_PKIS: TBK1 % inhibition at 1 uM [UNC Frye lab]	B	NS(=O)(=O)c1cccc(-c2cc3ccncc3cc2OCc2ccccc2)c1		CHEMBL483747	=	Inhibition	%	-7.0	CHEMBL5408	Homo sapiens	Inhibition	%	-7.0
	10832804	CHEMBL2007667	GSK_PKIS: TBK1 % inhibition at 1 uM [UNC Frye lab]	B	CCS(=O)(=O)c1ccc(OC)c(Nc2ncc(-c3cccc(OC)c3)o2)c1		CHEMBL179311	=	Inhibition	%	11.0	CHEMBL5408	Homo sapiens	Inhibition	%	11.0
	10832805	CHEMBL2007667	GSK_PKIS: TBK1 % inhibition at 1 uM [UNC Frye lab]	B	FC(F)(F)c1cccc(-c2nn3ncccc3c2-c2ccnc(Nc3ccc4c(c3)OCCO4)n2)c1		CHEMBL362155	=	Inhibition	%	1.0	CHEMBL5408	Homo sapiens	Inhibition	%	1.0
	10832806	CHEMBL2007667	GSK_PKIS: TBK1 % inhibition at 1 uM [UNC Frye lab]	B	COc1c(C(N)=O)cc(-c2ccc(Cl)cc2)cc1-c1ccc(S(N)(=O)=O)cc1		CHEMBL268885	=	Inhibition	%	1.0	CHEMBL5408	Homo sapiens	Inhibition	%	1.0
	10832807	CHEMBL2007667	GSK_PKIS: TBK1 % inhibition at 1 uM [UNC Frye lab]	B	COc1ccc(-c2oc3ncnc(N)c3c2-c2ccc(NC(=O)Nc3cc(C(F)(F)F)ccc3F)cc2)cc1.Cl		CHEMBL1909396	=	Inhibition	%	-1.0	CHEMBL5408	Homo sapiens	Inhibition	%	-1.0
	10832808	CHEMBL2007667	GSK_PKIS: TBK1 % inhibition at 1 uM [UNC Frye lab]	B	CN(c1ccc(NC(=O)NCCN2CCOCC2)cc1)c1ccnc(Nc2ccc(CS(C)(=O)=O)cc2)n1.Cl		CHEMBL1909361	=	Inhibition	%	3.0	CHEMBL5408	Homo sapiens	Inhibition	%	3.0
	10832809	CHEMBL2007667	GSK_PKIS: TBK1 % inhibition at 1 uM [UNC Frye lab]	B	COc1ccc(-c2cc3c(N)ncnc3o2)cc1		CHEMBL373073	=	Inhibition	%	2.0	CHEMBL5408	Homo sapiens	Inhibition	%	2.0
	10832810	CHEMBL2007667	GSK_PKIS: TBK1 % inhibition at 1 uM [UNC Frye lab]	B	CC(C)(C)c1ccc(Oc2nccc(-c3c(-c4ccc(F)cc4)ncn3C3CCNCC3)n2)cc1		CHEMBL275200	=	Inhibition	%	1.0	CHEMBL5408	Homo sapiens	Inhibition	%	1.0
	10832811	CHEMBL2007667	GSK_PKIS: TBK1 % inhibition at 1 uM [UNC Frye lab]	B	Cl.c1ccc(Cc2nc3ccc(Nc4ncnc5ccccc45)cc3[nH]2)cc1		CHEMBL1909379	=	Inhibition	%	-5.0	CHEMBL5408	Homo sapiens	Inhibition	%	-5.0
	10832812	CHEMBL2007667	GSK_PKIS: TBK1 % inhibition at 1 uM [UNC Frye lab]	B	Cc1ccc(NC(=O)c2ccnc(N3CCOCC3)c2)cc1-c1ccc(C(=O)NCC2CC2)cc1		CHEMBL476351	=	Inhibition	%	-4.0	CHEMBL5408	Homo sapiens	Inhibition	%	-4.0
	10832813	CHEMBL2007667	GSK_PKIS: TBK1 % inhibition at 1 uM [UNC Frye lab]	B	COc1cc2ncnc(Nc3ccc(C)c(O)c3)c2cc1OC.Cl		CHEMBL1909357	=	Inhibition	%	3.0	CHEMBL5408	Homo sapiens	Inhibition	%	3.0
	10832814	CHEMBL2007667	GSK_PKIS: TBK1 % inhibition at 1 uM [UNC Frye lab]	B	O=C([O-])c1ccc(Oc2nccc(-c3c(-c4ccc(F)cc4)ncn3C3CCNCC3)n2)cc1.[Li+]		CHEMBL1909401	=	Inhibition	%	-5.0	CHEMBL5408	Homo sapiens	Inhibition	%	-5.0
	10832815	CHEMBL2007667	GSK_PKIS: TBK1 % inhibition at 1 uM [UNC Frye lab]	B	COc1cccc(-n2ncc3c(N/N=C/c4cccc(F)c4)ncnc32)c1		CHEMBL69757	=	Inhibition	%	5.0	CHEMBL5408	Homo sapiens	Inhibition	%	5.0
	10832816	CHEMBL2007667	GSK_PKIS: TBK1 % inhibition at 1 uM [UNC Frye lab]	B	CNC(=O)c1sc(-n2cnc3cc(OC)c(OC)cc32)cc1OCc1ccccc1C(F)(F)F		CHEMBL518968	=	Inhibition	%	3.0	CHEMBL5408	Homo sapiens	Inhibition	%	3.0
	10832817	CHEMBL2007667	GSK_PKIS: TBK1 % inhibition at 1 uM [UNC Frye lab]	B	Nc1ncc(-c2cccc(S(N)(=O)=O)c2)c2scc(-c3ccc(F)c(Cl)c3)c12		CHEMBL241517	=	Inhibition	%	0.0	CHEMBL5408	Homo sapiens	Inhibition	%	0.0
	10832818	CHEMBL2007667	GSK_PKIS: TBK1 % inhibition at 1 uM [UNC Frye lab]	B	CCCN1CCCC(c2ccc(Nc3nc(Nc4cc(F)ccc4C(N)=O)c4cc[nH]c4n3)c(OC)c2)C1		CHEMBL477069	=	Inhibition	%	11.0	CHEMBL5408	Homo sapiens	Inhibition	%	11.0
	10832819	CHEMBL2007667	GSK_PKIS: TBK1 % inhibition at 1 uM [UNC Frye lab]	B	Cc1ccc2c(-c3ccnc(Nc4cccc(C(F)(F)F)c4)n3)c(-c3ccccc3)nn2n1		CHEMBL434729	=	Inhibition	%	1.0	CHEMBL5408	Homo sapiens	Inhibition	%	1.0
	10832820	CHEMBL2007667	GSK_PKIS: TBK1 % inhibition at 1 uM [UNC Frye lab]	B	CN(C)c1ccc2c(c1)/C(=C/Nc1ccc(S(N)(=O)=O)cc1)C(=O)N2		CHEMBL272414	=	Inhibition	%	74.0	CHEMBL5408	Homo sapiens	Inhibition	%	74.0
	10832821	CHEMBL2007667	GSK_PKIS: TBK1 % inhibition at 1 uM [UNC Frye lab]	B	C[C@@H](Oc1cc(-n2cnc3ccc(OC[C@@H](O)CO)cc32)sc1C(N)=O)c1ccccc1Cl		CHEMBL1794067	=	Inhibition	%	4.0	CHEMBL5408	Homo sapiens	Inhibition	%	4.0
	10832822	CHEMBL2007667	GSK_PKIS: TBK1 % inhibition at 1 uM [UNC Frye lab]	B	CN1CCC(C(=O)Nc2n[nH]c3nc(-c4ccc(O)cc4)c(Br)cc23)CC1.O=C(O)/C=C\C(=O)O		CHEMBL1909347	=	Inhibition	%	3.0	CHEMBL5408	Homo sapiens	Inhibition	%	3.0
	10832823	CHEMBL2007667	GSK_PKIS: TBK1 % inhibition at 1 uM [UNC Frye lab]	B	Cl.Nc1ncnc2occ(-c3ccc(NC(=O)Nc4cc(C(F)(F)F)ccc4F)cc3)c12		CHEMBL588025	=	Inhibition	%	2.0	CHEMBL5408	Homo sapiens	Inhibition	%	2.0
	10832824	CHEMBL2007667	GSK_PKIS: TBK1 % inhibition at 1 uM [UNC Frye lab]	B	COc1cccc(-c2c[nH]c3c(N/N=C/c4ccncc4)ncnc23)c1		CHEMBL206010	=	Inhibition	%	76.0	CHEMBL5408	Homo sapiens	Inhibition	%	76.0
	10832825	CHEMBL2007667	GSK_PKIS: TBK1 % inhibition at 1 uM [UNC Frye lab]	B	Cl.O=C(Nc1ccc(Oc2ccc3[nH]c(NC(=O)c4ccccc4)nc3c2)cc1)Nc1cc(C(F)(F)F)ccc1F		CHEMBL1909374	=	Inhibition	%	6.0	CHEMBL5408	Homo sapiens	Inhibition	%	6.0
	10832826	CHEMBL2007667	GSK_PKIS: TBK1 % inhibition at 1 uM [UNC Frye lab]	B	Fc1ccc(-c2c(-c3ccncc3)nc3n2CCS3)cc1		CHEMBL266707	=	Inhibition	%	3.0	CHEMBL5408	Homo sapiens	Inhibition	%	3.0
	10832827	CHEMBL2007667	GSK_PKIS: TBK1 % inhibition at 1 uM [UNC Frye lab]	B	Cc1cc(O)cc(C)c1/C=C/c1cncc(C(=O)N(C)C)c1		CHEMBL220244	=	Inhibition	%	6.0	CHEMBL5408	Homo sapiens	Inhibition	%	6.0
	10832828	CHEMBL2007667	GSK_PKIS: TBK1 % inhibition at 1 uM [UNC Frye lab]	B	Nc1nc(-c2cccc(Cl)c2)c(-c2ccc3ncccc3n2)s1		CHEMBL365663	=	Inhibition	%	7.0	CHEMBL5408	Homo sapiens	Inhibition	%	7.0
	10832829	CHEMBL2007667	GSK_PKIS: TBK1 % inhibition at 1 uM [UNC Frye lab]	B	NS(=O)(=O)c1ccc(Nc2ncc(-c3ccccc3)o2)cc1		CHEMBL194062	=	Inhibition	%	10.0	CHEMBL5408	Homo sapiens	Inhibition	%	10.0
	10832830	CHEMBL2007667	GSK_PKIS: TBK1 % inhibition at 1 uM [UNC Frye lab]	B	O=C(O)C(F)(F)F.O=C(O[C@H]1CN[C@H](C#Cc2cc3ncnc(Nc4ccc(Cc5ccccc5)cc4)c3s2)C1)N1CCOCC1		CHEMBL1909409	=	Inhibition	%	20.0	CHEMBL5408	Homo sapiens	Inhibition	%	20.0
	10832831	CHEMBL2007667	GSK_PKIS: TBK1 % inhibition at 1 uM [UNC Frye lab]	B	CC(C)=Cc1cccc2c1/C(=N/Nc1ccc(S(N)(=O)=O)cc1)C(=O)N2		CHEMBL270544	=	Inhibition	%	46.0	CHEMBL5408	Homo sapiens	Inhibition	%	46.0
	10832832	CHEMBL2007667	GSK_PKIS: TBK1 % inhibition at 1 uM [UNC Frye lab]	B	CCCN1CCC=C(c2ccc(Nc3nc(Nc4ccccc4C(N)=O)c4cc[nH]c4n3)c(C)c2)C1		CHEMBL513897	=	Inhibition	%	28.0	CHEMBL5408	Homo sapiens	Inhibition	%	28.0
	10832833	CHEMBL2007667	GSK_PKIS: TBK1 % inhibition at 1 uM [UNC Frye lab]	B	Cl.Fc1cccc(COc2ccc(Nc3ncnc4cc(-c5ccc[nH]5)sc34)cc2Cl)c1		CHEMBL1909415	=	Inhibition	%	0.0	CHEMBL5408	Homo sapiens	Inhibition	%	0.0
	10832834	CHEMBL2007667	GSK_PKIS: TBK1 % inhibition at 1 uM [UNC Frye lab]	B	COc1cc2ncn(-c3cc(O[C@H](C)c4ccccc4Cl)c(C(N)=O)s3)c2cc1OC		CHEMBL222419	=	Inhibition	%	2.0	CHEMBL5408	Homo sapiens	Inhibition	%	2.0
	10832835	CHEMBL2007667	GSK_PKIS: TBK1 % inhibition at 1 uM [UNC Frye lab]	B	CS(=O)(=O)CCNCc1nc(-c2ccc3ncnc(Nc4ccc(F)c(Cl)c4)c3c2)cs1.Cl		CHEMBL1909355	=	Inhibition	%	1.0	CHEMBL5408	Homo sapiens	Inhibition	%	1.0
	10832836	CHEMBL2007667	GSK_PKIS: TBK1 % inhibition at 1 uM [UNC Frye lab]	B	O=C(O[C@H]1CN[C@H](C#Cc2cc3ncnc(Nc4ccc(OCc5cccc(F)c5)c(Cl)c4)c3s2)C1)N1CCOCC1		CHEMBL507329	=	Inhibition	%	1.0	CHEMBL5408	Homo sapiens	Inhibition	%	1.0
	10832837	CHEMBL2007667	GSK_PKIS: TBK1 % inhibition at 1 uM [UNC Frye lab]	B	COc1ccc(-c2nn3ncccc3c2-c2ccnc(Nc3ccc4c(c3)OCCO4)n2)cc1		CHEMBL188257	=	Inhibition	%	0.0	CHEMBL5408	Homo sapiens	Inhibition	%	0.0
	10832838	CHEMBL2007667	GSK_PKIS: TBK1 % inhibition at 1 uM [UNC Frye lab]	B	FC(F)(F)c1cccc(Nc2nccc(-c3cnn4nc(-c5ccccc5)ccc34)n2)c1		CHEMBL189415	=	Inhibition	%	7.0	CHEMBL5408	Homo sapiens	Inhibition	%	7.0
	10832839	CHEMBL2007667	GSK_PKIS: TBK1 % inhibition at 1 uM [UNC Frye lab]	B	CCCN1CCC(c2ccc(Nc3nc(Nc4cc(F)ccc4C(N)=O)c4cc[nH]c4n3)c(OC)c2)CC1		CHEMBL476259	=	Inhibition	%	7.0	CHEMBL5408	Homo sapiens	Inhibition	%	7.0
	10832840	CHEMBL2007667	GSK_PKIS: TBK1 % inhibition at 1 uM [UNC Frye lab]	B	COc1ccc(-c2nn3ncccc3c2-c2ccnc(Nc3cccc(C(F)(F)F)c3)n2)cc1		CHEMBL186213	=	Inhibition	%	-2.0	CHEMBL5408	Homo sapiens	Inhibition	%	-2.0
	10832841	CHEMBL2007667	GSK_PKIS: TBK1 % inhibition at 1 uM [UNC Frye lab]	B	Cl.c1ccc(Cc2nc3ccc(Nc4ncnc5ccccc45)cc3[nH]2)cc1		CHEMBL1909379	=	Inhibition	%	-7.0	CHEMBL5408	Homo sapiens	Inhibition	%	-7.0
	10832842	CHEMBL2007667	GSK_PKIS: TBK1 % inhibition at 1 uM [UNC Frye lab]	B	c1ccc(-c2n[nH]cc2-c2ccnc(-c3ccc(OCCN4CCOCC4)cc3)c2)nc1		CHEMBL205158	=	Inhibition	%	-2.0	CHEMBL5408	Homo sapiens	Inhibition	%	-2.0
	10832843	CHEMBL2007667	GSK_PKIS: TBK1 % inhibition at 1 uM [UNC Frye lab]	B	Cl.Nc1nc(-c2ccc3c(c2)C(=Cc2cc(Br)c(O)c(Br)c2)C(=O)N3)cs1		CHEMBL1794053	=	Inhibition	%	7.0	CHEMBL5408	Homo sapiens	Inhibition	%	7.0
	10832844	CHEMBL2007667	GSK_PKIS: TBK1 % inhibition at 1 uM [UNC Frye lab]	B	CCN(CC)Cc1ccc(Nc2nccc(-c3cnn4ncccc34)n2)cc1		CHEMBL1882194	=	Inhibition	%	10.0	CHEMBL5408	Homo sapiens	Inhibition	%	10.0
	10832845	CHEMBL2007667	GSK_PKIS: TBK1 % inhibition at 1 uM [UNC Frye lab]	B	Cc1cc(-c2ccco2)cc(C)c1/C=C/c1cncc(-c2nn[nH]n2)c1.Cl		CHEMBL1909353	=	Inhibition	%	3.0	CHEMBL5408	Homo sapiens	Inhibition	%	3.0
	10832846	CHEMBL2007667	GSK_PKIS: TBK1 % inhibition at 1 uM [UNC Frye lab]	B	O=C(Nc1n[nH]c2cc(-c3cc(F)ccc3F)ccc12)C1CC1		CHEMBL261440	=	Inhibition	%	-4.0	CHEMBL5408	Homo sapiens	Inhibition	%	-4.0
	10832847	CHEMBL2007667	GSK_PKIS: TBK1 % inhibition at 1 uM [UNC Frye lab]	B	CC1=C(C(=O)Nc2ccc3[nH]ncc3c2)C(c2ccc3ccccc3c2)CC(=O)N1		CHEMBL441702	=	Inhibition	%	-2.0	CHEMBL5408	Homo sapiens	Inhibition	%	-2.0
	10832848	CHEMBL2007667	GSK_PKIS: TBK1 % inhibition at 1 uM [UNC Frye lab]	B	COc1cccc(-n2ncc3c(N/N=C/c4ccc(C(=O)NCCN(C)C)cc4)ncnc32)c1.Cl		CHEMBL1909383	=	Inhibition	%	31.0	CHEMBL5408	Homo sapiens	Inhibition	%	31.0
	10832849	CHEMBL2007667	GSK_PKIS: TBK1 % inhibition at 1 uM [UNC Frye lab]	B	Fc1cccc(COc2ccc(Nc3ncncc3C#Cc3ccccc3)cc2Cl)c1		CHEMBL379093	=	Inhibition	%	-7.0	CHEMBL5408	Homo sapiens	Inhibition	%	-7.0
	10832850	CHEMBL2007667	GSK_PKIS: TBK1 % inhibition at 1 uM [UNC Frye lab]	B	CS(=O)(=O)CCNCc1ccc(-c2ccc3ncnc(Nc4ccc(OCc5cccc(C(F)(F)F)c5)cc4)c3c2)o1.Cl		CHEMBL1909387	=	Inhibition	%	-3.0	CHEMBL5408	Homo sapiens	Inhibition	%	-3.0
	10832851	CHEMBL2007667	GSK_PKIS: TBK1 % inhibition at 1 uM [UNC Frye lab]	B	Cl.N#Cc1cccc(Nc2ncc(-c3ccccc3)o2)c1		CHEMBL1794061	=	Inhibition	%	4.0	CHEMBL5408	Homo sapiens	Inhibition	%	4.0
	10832852	CHEMBL2007667	GSK_PKIS: TBK1 % inhibition at 1 uM [UNC Frye lab]	B	Fc1ccc(-c2cc(-c3c[nH]nc3-c3ccccn3)ccn2)cc1		CHEMBL381948	=	Inhibition	%	-4.0	CHEMBL5408	Homo sapiens	Inhibition	%	-4.0
	10832853	CHEMBL2007667	GSK_PKIS: TBK1 % inhibition at 1 uM [UNC Frye lab]	B	COc1ccc2ncn(-c3cc(O[C@H](C)c4ccccc4C(F)(F)F)c(C(N)=O)s3)c2c1		CHEMBL522709	=	Inhibition	%	-8.0	CHEMBL5408	Homo sapiens	Inhibition	%	-8.0
	10832854	CHEMBL2007667	GSK_PKIS: TBK1 % inhibition at 1 uM [UNC Frye lab]	B	CCn1c(-c2nonc2N)nc2c(C#CC(C)(C)O)ncc(OCC3CCNCC3)c21.O=C(O)C(F)(F)F		CHEMBL1794065	=	Inhibition	%	55.0	CHEMBL5408	Homo sapiens	Inhibition	%	55.0
	10832855	CHEMBL2007667	GSK_PKIS: TBK1 % inhibition at 1 uM [UNC Frye lab]	B	CC(=O)Nc1cccc(C#Cc2cncnc2Nc2ccc(OCc3cccc(F)c3)c(Cl)c2)n1		CHEMBL205765	=	Inhibition	%	0.0	CHEMBL5408	Homo sapiens	Inhibition	%	0.0
	10832856	CHEMBL2007667	GSK_PKIS: TBK1 % inhibition at 1 uM [UNC Frye lab]	B	Cl.NS(=O)(=O)c1ccc(N/N=C2\C(=O)Nc3cccc(CCc4ccncc4)c32)cc1		CHEMBL1909399	=	Inhibition	%	25.0	CHEMBL5408	Homo sapiens	Inhibition	%	25.0
	10832857	CHEMBL2007667	GSK_PKIS: TBK1 % inhibition at 1 uM [UNC Frye lab]	B	CCn1c(-c2nonc2N)nc2c(N3CCCC3)nccc21		CHEMBL187985	=	Inhibition	%	-8.0	CHEMBL5408	Homo sapiens	Inhibition	%	-8.0
	10832858	CHEMBL2007667	GSK_PKIS: TBK1 % inhibition at 1 uM [UNC Frye lab]	B	CNC(=O)c1cncc(/C=C/c2ccccc2Cl)c1		CHEMBL218970	=	Inhibition	%	1.0	CHEMBL5408	Homo sapiens	Inhibition	%	1.0
	10832859	CHEMBL2007667	GSK_PKIS: TBK1 % inhibition at 1 uM [UNC Frye lab]	B	CNC(=O)c1cccc(C#Cc2cncnc2Nc2ccc(OCc3cccc(F)c3)c(Cl)c2)c1		CHEMBL207410	=	Inhibition	%	3.0	CHEMBL5408	Homo sapiens	Inhibition	%	3.0
	10832860	CHEMBL2007667	GSK_PKIS: TBK1 % inhibition at 1 uM [UNC Frye lab]	B	NC(=O)c1sc(-n2cnc3ccc(C(F)(F)F)cc32)cc1OCc1ccccc1Br		CHEMBL481510	=	Inhibition	%	21.0	CHEMBL5408	Homo sapiens	Inhibition	%	21.0
	10832861	CHEMBL2007667	GSK_PKIS: TBK1 % inhibition at 1 uM [UNC Frye lab]	B	O=C1NC(=O)C(c2ccccc2Cl)=C1Nc1cccc(O)c1		CHEMBL160937	=	Inhibition	%	7.0	CHEMBL5408	Homo sapiens	Inhibition	%	7.0
	10832862	CHEMBL2007667	GSK_PKIS: TBK1 % inhibition at 1 uM [UNC Frye lab]	B	CCn1cc(-c2ccnc3[nH]ccc23)c(-c2cccc(NC(=O)Nc3ccc(OCc4ccccc4)cc3)c2)n1		CHEMBL505187	=	Inhibition	%	-4.0	CHEMBL5408	Homo sapiens	Inhibition	%	-4.0
	10832863	CHEMBL2007667	GSK_PKIS: TBK1 % inhibition at 1 uM [UNC Frye lab]	B	CCC(=O)Nc1ccc(C)c(-c2ccc(C(=O)NCC3CC3)cc2)c1		CHEMBL517666	=	Inhibition	%	-2.0	CHEMBL5408	Homo sapiens	Inhibition	%	-2.0
	10832864	CHEMBL2007667	GSK_PKIS: TBK1 % inhibition at 1 uM [UNC Frye lab]	B	COC(=O)Nc1nc2cc(Oc3ccc(NC(=O)Nc4ccccc4)cc3)ccc2[nH]1.Cl		CHEMBL1909371	=	Inhibition	%	8.0	CHEMBL5408	Homo sapiens	Inhibition	%	8.0
	10832865	CHEMBL2007667	GSK_PKIS: TBK1 % inhibition at 1 uM [UNC Frye lab]	B	COc1cc2ncnc(Nc3ccc4c(cnn4Cc4ccccc4)c3)c2cc1OC.Cl		CHEMBL1909380	=	Inhibition	%	2.0	CHEMBL5408	Homo sapiens	Inhibition	%	2.0
	10832866	CHEMBL2007667	GSK_PKIS: TBK1 % inhibition at 1 uM [UNC Frye lab]	B	C[C@@H](Oc1cc(-n2cnc3ccc(OCC4CCN(C)CC4)cc32)sc1C(N)=O)c1ccccc1C(F)(F)F		CHEMBL1794068	=	Inhibition	%	4.0	CHEMBL5408	Homo sapiens	Inhibition	%	4.0
	10832867	CHEMBL2007667	GSK_PKIS: TBK1 % inhibition at 1 uM [UNC Frye lab]	B	Cc1ccc(NC(=O)CC2CC2)cc1-c1ccc(C(=O)NCC2CC2)cc1		CHEMBL516908	=	Inhibition	%	-1.0	CHEMBL5408	Homo sapiens	Inhibition	%	-1.0
	10832868	CHEMBL2007667	GSK_PKIS: TBK1 % inhibition at 1 uM [UNC Frye lab]	B	CN(C)CCNC(=O)Nc1ccc(N(C)c2ccnc(Nc3ccc(CS(C)(=O)=O)cc3)n2)cc1.Cl		CHEMBL1909362	=	Inhibition	%	-2.0	CHEMBL5408	Homo sapiens	Inhibition	%	-2.0
	10832869	CHEMBL2007667	GSK_PKIS: TBK1 % inhibition at 1 uM [UNC Frye lab]	B	OCc1ccc(-c2nc(-c3ccccn3)c(-c3ccc4c(c3)OCO4)[nH]2)cc1		CHEMBL267228	=	Inhibition	%	-6.0	CHEMBL5408	Homo sapiens	Inhibition	%	-6.0
	10832870	CHEMBL2007667	GSK_PKIS: TBK1 % inhibition at 1 uM [UNC Frye lab]	B	COc1cc(N2CCN(C(C)C)CC2)ccc1Nc1nc(Nc2ccc(F)cc2C(=O)NC[C@@H](O)CO)c2cc[nH]c2n1		CHEMBL450071	=	Inhibition	%	-3.0	CHEMBL5408	Homo sapiens	Inhibition	%	-3.0
	10832871	CHEMBL2007667	GSK_PKIS: TBK1 % inhibition at 1 uM [UNC Frye lab]	B	CC(=O)Nc1cccc(C#Cc2cncnc2Nc2ccc(OCc3cccc(F)c3)c(Cl)c2)c1		CHEMBL205798	=	Inhibition	%	-7.0	CHEMBL5408	Homo sapiens	Inhibition	%	-7.0
	10832872	CHEMBL2007667	GSK_PKIS: TBK1 % inhibition at 1 uM [UNC Frye lab]	B	Nc1nccc(-c2c(-c3ccc(F)cc3)ncn2CCCN2CCOCC2)n1		CHEMBL274863	=	Inhibition	%	0.0	CHEMBL5408	Homo sapiens	Inhibition	%	0.0
	10832873	CHEMBL2007667	GSK_PKIS: TBK1 % inhibition at 1 uM [UNC Frye lab]	B	COc1cc(N2CCN(C(C)C)CC2)ccc1Nc1nc(Nc2cccc3ncccc23)c2cc[nH]c2n1		CHEMBL458438	=	Inhibition	%	7.0	CHEMBL5408	Homo sapiens	Inhibition	%	7.0
	10832874	CHEMBL2007667	GSK_PKIS: TBK1 % inhibition at 1 uM [UNC Frye lab]	B	Nc1ncnc2occ(-c3ccc(NC(=O)Nc4cccc(C(F)(F)F)c4)cc3)c12		CHEMBL273564	=	Inhibition	%	0.0	CHEMBL5408	Homo sapiens	Inhibition	%	0.0
	10832875	CHEMBL2007667	GSK_PKIS: TBK1 % inhibition at 1 uM [UNC Frye lab]	B	Cc1cccc(Nc2ncc(-c3ccccc3)o2)c1		CHEMBL192417	=	Inhibition	%	4.0	CHEMBL5408	Homo sapiens	Inhibition	%	4.0
	10832876	CHEMBL2007667	GSK_PKIS: TBK1 % inhibition at 1 uM [UNC Frye lab]	B	COc1cc2ncn(-c3cc(OCc4ccccc4C(F)(F)F)c(C(N)=O)s3)c2cc1OC		CHEMBL514499	=	Inhibition	%	12.0	CHEMBL5408	Homo sapiens	Inhibition	%	12.0
	10832877	CHEMBL2007667	GSK_PKIS: TBK1 % inhibition at 1 uM [UNC Frye lab]	B	Cl.O=C(Nc1ccc(Oc2ccc3[nH]c(NC(=O)c4ccco4)nc3c2)cc1)Nc1cc(C(F)(F)F)ccc1F		CHEMBL1909368	=	Inhibition	%	2.0	CHEMBL5408	Homo sapiens	Inhibition	%	2.0
	10832878	CHEMBL2007667	GSK_PKIS: TBK1 % inhibition at 1 uM [UNC Frye lab]	B	NC(=O)CCc1ccccc1Oc1nccc(-c2c(-c3ccc(F)cc3)ncn2C2CCNCC2)n1		CHEMBL1785003	=	Inhibition	%	4.0	CHEMBL5408	Homo sapiens	Inhibition	%	4.0
	10832879	CHEMBL2007667	GSK_PKIS: TBK1 % inhibition at 1 uM [UNC Frye lab]	B	CNC(=O)c1ncccc1Nc1nc(Nc2cc3c(cc2OC)CCCN3C(=O)CN(C)C)nc2[nH]ccc12		CHEMBL1895450	=	Inhibition	%	8.0	CHEMBL5408	Homo sapiens	Inhibition	%	8.0
	10832880	CHEMBL2007667	GSK_PKIS: TBK1 % inhibition at 1 uM [UNC Frye lab]	B	Fc1ccc(-c2ncn(C3CCNCC3)c2-c2ccnc(Oc3cccc(C(F)(F)F)c3)n2)cc1		CHEMBL275666	=	Inhibition	%	2.0	CHEMBL5408	Homo sapiens	Inhibition	%	2.0
	10832881	CHEMBL2007667	GSK_PKIS: TBK1 % inhibition at 1 uM [UNC Frye lab]	B	COc1cccc(-n2ncc3c(N/N=C/c4ccncc4)ncnc32)c1		CHEMBL306865	=	Inhibition	%	14.0	CHEMBL5408	Homo sapiens	Inhibition	%	14.0
	10832882	CHEMBL2007667	GSK_PKIS: TBK1 % inhibition at 1 uM [UNC Frye lab]	B	Nc1ncnc2occ(-c3ccc(NC(=O)Nc4cc(C(F)(F)F)ccc4F)cc3)c12		CHEMBL247228	=	Inhibition	%	-1.0	CHEMBL5408	Homo sapiens	Inhibition	%	-1.0
	10832883	CHEMBL2007667	GSK_PKIS: TBK1 % inhibition at 1 uM [UNC Frye lab]	B	COc1cc2ncn(-c3cc(OCc4ccccc4Cl)c(C(N)=O)s3)c2cc1OC		CHEMBL514162	=	Inhibition	%	50.0	CHEMBL5408	Homo sapiens	Inhibition	%	50.0
	10832884	CHEMBL2007667	GSK_PKIS: TBK1 % inhibition at 1 uM [UNC Frye lab]	B	CCS(=O)(=O)c1ccc(OC)c(Nc2ncc(-c3cccc(F)c3)o2)c1		CHEMBL179465	=	Inhibition	%	7.0	CHEMBL5408	Homo sapiens	Inhibition	%	7.0
	10832885	CHEMBL2007667	GSK_PKIS: TBK1 % inhibition at 1 uM [UNC Frye lab]	B	Cl.O=S(=O)(CCNCc1ccc(-c2ccc3ncnc(Nc4ccc(OCc5cccc(F)c5)c(Cl)c4)c3c2)o1)c1ccccc1		CHEMBL1909395	=	Inhibition	%	18.0	CHEMBL5408	Homo sapiens	Inhibition	%	18.0
	10832886	CHEMBL2007667	GSK_PKIS: TBK1 % inhibition at 1 uM [UNC Frye lab]	B	COc1ccc2ncn(-c3cc(O[C@H](C)c4ccccc4Cl)c(C(N)=O)s3)c2c1		CHEMBL493326	=	Inhibition	%	-4.0	CHEMBL5408	Homo sapiens	Inhibition	%	-4.0
	10832887	CHEMBL2007667	GSK_PKIS: TBK1 % inhibition at 1 uM [UNC Frye lab]	B	CS(=O)(=O)CCNCc1ccc(-c2ccc3ncnc(Nc4ccc(OCc5ccccc5)c(Cl)c4)c3c2)o1.Cl		CHEMBL529066	=	Inhibition	%	-2.0	CHEMBL5408	Homo sapiens	Inhibition	%	-2.0
	10832888	CHEMBL2007667	GSK_PKIS: TBK1 % inhibition at 1 uM [UNC Frye lab]	B	CNC(=O)c1ncccc1Nc1nc(Nc2cc3c(cc2OC)CCCN3C(=O)CN(C)C)nc2[nH]ccc12		CHEMBL1895450	=	Inhibition	%	12.0	CHEMBL5408	Homo sapiens	Inhibition	%	12.0
	10832889	CHEMBL2007667	GSK_PKIS: TBK1 % inhibition at 1 uM [UNC Frye lab]	B	Fc1ccc(-c2ncn(C3CCNCC3)c2-c2ccnc(Oc3cccc(C(F)(F)F)c3)n2)cc1		CHEMBL275666	=	Inhibition	%	0.0	CHEMBL5408	Homo sapiens	Inhibition	%	0.0
	10832890	CHEMBL2007667	GSK_PKIS: TBK1 % inhibition at 1 uM [UNC Frye lab]	B	CC(C)c1ccc(Nc2nccc(-c3cnn4ncccc34)n2)cc1		CHEMBL359963	=	Inhibition	%	19.0	CHEMBL5408	Homo sapiens	Inhibition	%	19.0
	10832891	CHEMBL2007667	GSK_PKIS: TBK1 % inhibition at 1 uM [UNC Frye lab]	B	CN1CCC(n2cnc(-c3ccc(F)cc3)c2-c2ccnc(N)n2)CC1		CHEMBL95207	=	Inhibition	%	0.0	CHEMBL5408	Homo sapiens	Inhibition	%	0.0
	10832892	CHEMBL2007667	GSK_PKIS: TBK1 % inhibition at 1 uM [UNC Frye lab]	B	N#Cc1ccc(Oc2nccc(-c3c(-c4ccc(F)cc4)ncn3C3CCNCC3)n2)cc1		CHEMBL13972	=	Inhibition	%	8.0	CHEMBL5408	Homo sapiens	Inhibition	%	8.0
	10832893	CHEMBL2007667	GSK_PKIS: TBK1 % inhibition at 1 uM [UNC Frye lab]	B	Fc1ccc(-c2ncn(C3CCNCC3)c2-c2ccnc(Oc3ccc(Oc4ccccc4)cc3)n2)cc1		CHEMBL13868	=	Inhibition	%	3.0	CHEMBL5408	Homo sapiens	Inhibition	%	3.0
	10832894	CHEMBL2007667	GSK_PKIS: TBK1 % inhibition at 1 uM [UNC Frye lab]	B	CCCN1CCC(Oc2cc(Nc3nc(Nc4cccc(F)c4C(N)=O)c4cc[nH]c4n3)c(OC)cc2Cl)CC1		CHEMBL517171	=	Inhibition	%	0.0	CHEMBL5408	Homo sapiens	Inhibition	%	0.0
	10832895	CHEMBL2007667	GSK_PKIS: TBK1 % inhibition at 1 uM [UNC Frye lab]	B	COc1ccc(-c2nn3ncccc3c2-c2ccnc(Nc3cccc(C(F)(F)F)c3)n2)cc1		CHEMBL186213	=	Inhibition	%	0.0	CHEMBL5408	Homo sapiens	Inhibition	%	0.0
	10832896	CHEMBL2007667	GSK_PKIS: TBK1 % inhibition at 1 uM [UNC Frye lab]	B	NS(=O)(=O)c1cccc(N/C=C2\C(=O)Nc3ccccc32)c1		CHEMBL1794059	=	Inhibition	%	38.0	CHEMBL5408	Homo sapiens	Inhibition	%	38.0
	10832897	CHEMBL2007667	GSK_PKIS: TBK1 % inhibition at 1 uM [UNC Frye lab]	B	O=C(O)C(F)(F)F.O=C(O[C@H]1CN[C@H](C#Cc2cc3ncnc(Nc4ccc5c(ccn5Cc5cc(F)ccc5F)c4)c3s2)C1)N1CCOCC1		CHEMBL1909410	=	Inhibition	%	11.0	CHEMBL5408	Homo sapiens	Inhibition	%	11.0
	10832898	CHEMBL2007667	GSK_PKIS: TBK1 % inhibition at 1 uM [UNC Frye lab]	B	Cl.Oc1cccc(-c2nc(-c3ccccc3)[nH]c2-c2ccncc2)c1		CHEMBL1909413	=	Inhibition	%	-1.0	CHEMBL5408	Homo sapiens	Inhibition	%	-1.0
	10832899	CHEMBL2007667	GSK_PKIS: TBK1 % inhibition at 1 uM [UNC Frye lab]	B	COc1cc(/C=N/Nc2ncnc3[nH]ncc23)ccc1O		CHEMBL66004	=	Inhibition	%	33.0	CHEMBL5408	Homo sapiens	Inhibition	%	33.0
	10832900	CHEMBL2007667	GSK_PKIS: TBK1 % inhibition at 1 uM [UNC Frye lab]	B	Cc1ccc(-c2cc3c(NC(=O)C4CC4)ncnc3o2)cc1		CHEMBL182283	=	Inhibition	%	-2.0	CHEMBL5408	Homo sapiens	Inhibition	%	-2.0
	10832901	CHEMBL2007667	GSK_PKIS: TBK1 % inhibition at 1 uM [UNC Frye lab]	B	CCOc1ccc2c(-c3ccnc(Nc4cc(OC)cc(C(F)(F)F)c4)n3)cnn2n1		CHEMBL188426	=	Inhibition	%	51.0	CHEMBL5408	Homo sapiens	Inhibition	%	51.0
	10832902	CHEMBL2007667	GSK_PKIS: TBK1 % inhibition at 1 uM [UNC Frye lab]	B	COc1cc(Nc2ncc3c(C)nc(-c4cccc(C(F)(F)F)c4)n3n2)cc(OC)c1OC		CHEMBL520037	=	Inhibition	%	45.0	CHEMBL5408	Homo sapiens	Inhibition	%	45.0
	10832903	CHEMBL2007667	GSK_PKIS: TBK1 % inhibition at 1 uM [UNC Frye lab]	B	CC(C)COC(=O)c1ccc2c(c1)/C(=C/Nc1ccc(S(N)(=O)=O)cc1)C(=O)N2		CHEMBL269883	=	Inhibition	%	93.0	CHEMBL5408	Homo sapiens	Inhibition	%	93.0
	10832904	CHEMBL2007667	GSK_PKIS: TBK1 % inhibition at 1 uM [UNC Frye lab]	B	Cl.c1ccc(-c2nc3n(c2-c2ccc4c(c2)OCO4)CCC3)nc1		CHEMBL1909377	=	Inhibition	%	5.0	CHEMBL5408	Homo sapiens	Inhibition	%	5.0
	10832905	CHEMBL2007667	GSK_PKIS: TBK1 % inhibition at 1 uM [UNC Frye lab]	B	CC1=C(C(=O)Nc2ccc3[nH]ncc3c2)C(c2ccc3ccccc3c2)CC(=O)N1		CHEMBL441702	=	Inhibition	%	-5.0	CHEMBL5408	Homo sapiens	Inhibition	%	-5.0
	10832906	CHEMBL2007667	GSK_PKIS: TBK1 % inhibition at 1 uM [UNC Frye lab]	B	CN1CCN(C(=O)c2ccc(NC(=O)Nc3ccc(N(C)c4ccnc(Nc5ccc(CS(C)(=O)=O)cc5)n4)cc3)cc2)CC1.Cl		CHEMBL1909360	=	Inhibition	%	14.0	CHEMBL5408	Homo sapiens	Inhibition	%	14.0
	10832907	CHEMBL2007667	GSK_PKIS: TBK1 % inhibition at 1 uM [UNC Frye lab]	B	NC(=O)c1ccc(Oc2nccc(-c3c(-c4ccc(F)cc4)ncn3C3CCNCC3)n2)cc1		CHEMBL275724	=	Inhibition	%	5.0	CHEMBL5408	Homo sapiens	Inhibition	%	5.0
	10832908	CHEMBL2007667	GSK_PKIS: TBK1 % inhibition at 1 uM [UNC Frye lab]	B	CCn1c(-c2nonc2N)nc2cnc(Oc3cccc(NC(=O)c4ccc(N(C)C)cc4)c3)cc21		CHEMBL220465	=	Inhibition	%	4.0	CHEMBL5408	Homo sapiens	Inhibition	%	4.0
	10832909	CHEMBL2007667	GSK_PKIS: TBK1 % inhibition at 1 uM [UNC Frye lab]	B	Cl.c1ccc(Oc2ccc(Nc3ncc(-c4ccccc4)o3)cc2)cc1		CHEMBL1909341	=	Inhibition	%	-4.0	CHEMBL5408	Homo sapiens	Inhibition	%	-4.0
	10832910	CHEMBL2007667	GSK_PKIS: TBK1 % inhibition at 1 uM [UNC Frye lab]	B	O=C(O)/C=C/C(=O)O.OCCCNc1nccc(-c2c(-c3ccc(F)cc3)nn3cc(C(F)(F)F)ccc23)n1		CHEMBL1909403	=	Inhibition	%	-2.0	CHEMBL5408	Homo sapiens	Inhibition	%	-2.0
	10832911	CHEMBL2007667	GSK_PKIS: TBK1 % inhibition at 1 uM [UNC Frye lab]	B	COc1cccc(COc2cc(-n3cnc4ccccc43)sc2C(N)=O)c1		CHEMBL516248	=	Inhibition	%	2.0	CHEMBL5408	Homo sapiens	Inhibition	%	2.0
	10832912	CHEMBL2007667	GSK_PKIS: TBK1 % inhibition at 1 uM [UNC Frye lab]	B	CCn1cc(-c2ccnc3[nH]ccc23)c(-c2cccc(NC(=O)Nc3ccc(OCc4ccccc4)cc3)c2)n1		CHEMBL505187	=	Inhibition	%	-1.0	CHEMBL5408	Homo sapiens	Inhibition	%	-1.0
	10832913	CHEMBL2007667	GSK_PKIS: TBK1 % inhibition at 1 uM [UNC Frye lab]	B	CCS(=O)(=O)c1ccc(OC)c(Nc2nccc(N(C)c3ccc4c(C)n[nH]c4c3)n2)c1.Cl		CHEMBL1909358	=	Inhibition	%	1.0	CHEMBL5408	Homo sapiens	Inhibition	%	1.0
	10832914	CHEMBL2007667	GSK_PKIS: TBK1 % inhibition at 1 uM [UNC Frye lab]	B	CN(C)C(=O)O[C@H]1CN[C@H](C#Cc2cc3ncnc(Nc4ccc(OCc5cccc(F)c5)c(Cl)c4)c3s2)C1		CHEMBL517123	=	Inhibition	%	8.0	CHEMBL5408	Homo sapiens	Inhibition	%	8.0
	10832915	CHEMBL2007667	GSK_PKIS: TBK1 % inhibition at 1 uM [UNC Frye lab]	B	COc1ccccc1Nc1ncc(-c2ccccc2)o1.Cl		CHEMBL1794062	=	Inhibition	%	10.0	CHEMBL5408	Homo sapiens	Inhibition	%	10.0
	10832916	CHEMBL2007667	GSK_PKIS: TBK1 % inhibition at 1 uM [UNC Frye lab]	B	Fc1ccc(Nc2nccc(-c3c(-c4ccc(C(F)(F)F)cc4)nn4ncccc34)n2)cc1F		CHEMBL188784	=	Inhibition	%	-5.0	CHEMBL5408	Homo sapiens	Inhibition	%	-5.0
	10832917	CHEMBL2007667	GSK_PKIS: TBK1 % inhibition at 1 uM [UNC Frye lab]	B	OCc1ccc(-c2nc(-c3ccccn3)c(-c3ccc4c(c3)OCO4)[nH]2)cc1		CHEMBL267228	=	Inhibition	%	-5.0	CHEMBL5408	Homo sapiens	Inhibition	%	-5.0
	10832918	CHEMBL2007667	GSK_PKIS: TBK1 % inhibition at 1 uM [UNC Frye lab]	B	c1cnn2ncc(-c3ccnc(NCCCN4CCOCC4)n3)c2c1		CHEMBL524901	=	Inhibition	%	-2.0	CHEMBL5408	Homo sapiens	Inhibition	%	-2.0
	10832919	CHEMBL2007667	GSK_PKIS: TBK1 % inhibition at 1 uM [UNC Frye lab]	B	Cl.NC(=O)c1cccc(Nc2nccc(Nc3cccc(F)c3)n2)c1		CHEMBL1909382	=	Inhibition	%	11.0	CHEMBL5408	Homo sapiens	Inhibition	%	11.0
	10832920	CHEMBL2007667	GSK_PKIS: TBK1 % inhibition at 1 uM [UNC Frye lab]	B	O=C(Nc1n[nH]c2nc(-c3ccco3)ccc12)C1CC1		CHEMBL101804	=	Inhibition	%	4.0	CHEMBL5408	Homo sapiens	Inhibition	%	4.0
	10832921	CHEMBL2007667	GSK_PKIS: TBK1 % inhibition at 1 uM [UNC Frye lab]	B	N#Cc1c(NC(=O)CN2CCOCC2)sc2c1CCCC2.O=C(O)C(=O)O		CHEMBL1909342	=	Inhibition	%	-6.0	CHEMBL5408	Homo sapiens	Inhibition	%	-6.0
	10832922	CHEMBL2007667	GSK_PKIS: TBK1 % inhibition at 1 uM [UNC Frye lab]	B	O=C(Nc1n[nH]c2nnc(-c3cccnc3)cc12)C1CC1.O=C(O)C(F)(F)F		CHEMBL1909343	=	Inhibition	%	3.0	CHEMBL5408	Homo sapiens	Inhibition	%	3.0
	10832923	CHEMBL2007667	GSK_PKIS: TBK1 % inhibition at 1 uM [UNC Frye lab]	B	CCn1c(-c2nonc2N)nc2c(C#CC(C)(C)O)nc(CN3CCCC3)cc21		CHEMBL1096290	=	Inhibition	%	24.0	CHEMBL5408	Homo sapiens	Inhibition	%	24.0
	10832924	CHEMBL2007667	GSK_PKIS: TBK1 % inhibition at 1 uM [UNC Frye lab]	B	Cc1ccc(C(=O)NC2CCCCC2)cc1-c1ccc(C(=O)NCC2CC2)cc1		CHEMBL477978	=	Inhibition	%	-2.0	CHEMBL5408	Homo sapiens	Inhibition	%	-2.0
	10832925	CHEMBL2007667	GSK_PKIS: TBK1 % inhibition at 1 uM [UNC Frye lab]	B	Fc1ccc(-c2nn3ncccc3c2-c2ccnc(Nc3ccc4c(c3)OCCO4)n2)cc1		CHEMBL365297	=	Inhibition	%	4.0	CHEMBL5408	Homo sapiens	Inhibition	%	4.0
	10832926	CHEMBL2007667	GSK_PKIS: TBK1 % inhibition at 1 uM [UNC Frye lab]	B	COc1cccc(-n2nc(C)c3c(N/N=C(\C)c4ccncc4)ncnc32)c1		CHEMBL442363	=	Inhibition	%	4.0	CHEMBL5408	Homo sapiens	Inhibition	%	4.0
	10832927	CHEMBL2007667	GSK_PKIS: TBK1 % inhibition at 1 uM [UNC Frye lab]	B	COc1ccc2ncnc(Nc3ccc(OCc4ccccc4)cc3)c2c1.Cl		CHEMBL1909411	=	Inhibition	%	1.0	CHEMBL5408	Homo sapiens	Inhibition	%	1.0
	10832928	CHEMBL2007667	GSK_PKIS: TBK1 % inhibition at 1 uM [UNC Frye lab]	B	NCc1ccc(-n2c(-c3nonc3N)nc3cnccc32)cc1		CHEMBL188268	=	Inhibition	%	6.0	CHEMBL5408	Homo sapiens	Inhibition	%	6.0
	10832929	CHEMBL2007667	GSK_PKIS: TBK1 % inhibition at 1 uM [UNC Frye lab]	B	CN(C)c1cc2c(Nc3ccc4nc(Cc5ccccc5)[nH]c4c3)ncnc2cn1		CHEMBL531804	=	Inhibition	%	6.0	CHEMBL5408	Homo sapiens	Inhibition	%	6.0
	10832930	CHEMBL2007667	GSK_PKIS: TBK1 % inhibition at 1 uM [UNC Frye lab]	B	CCOc1ccc2c(-c3ccnc(Nc4cccc(C(F)(F)F)c4)n3)cnn2n1		CHEMBL183993	=	Inhibition	%	52.0	CHEMBL5408	Homo sapiens	Inhibition	%	52.0
	10832931	CHEMBL2007667	GSK_PKIS: TBK1 % inhibition at 1 uM [UNC Frye lab]	B	Cc1ccc(C(=O)NC(C)C)cc1-c1ccc(C(=O)NCC2CC2)cc1		CHEMBL477979	=	Inhibition	%	-2.0	CHEMBL5408	Homo sapiens	Inhibition	%	-2.0
	10832932	CHEMBL2007667	GSK_PKIS: TBK1 % inhibition at 1 uM [UNC Frye lab]	B	COc1ccc(-c2ccncc2)cc1C(N)=O		CHEMBL231013	=	Inhibition	%	4.0	CHEMBL5408	Homo sapiens	Inhibition	%	4.0
	10832933	CHEMBL2007667	GSK_PKIS: TBK1 % inhibition at 1 uM [UNC Frye lab]	B	Cc1ccc(-c2cc3c(NC(=O)C4CC4)ncnc3o2)cc1		CHEMBL182283	=	Inhibition	%	-3.0	CHEMBL5408	Homo sapiens	Inhibition	%	-3.0
	10832934	CHEMBL2007667	GSK_PKIS: TBK1 % inhibition at 1 uM [UNC Frye lab]	B	CCOc1ccc2c(-c3ccnc(Nc4cc(OC)cc(C(F)(F)F)c4)n3)cnn2n1		CHEMBL188426	=	Inhibition	%	43.0	CHEMBL5408	Homo sapiens	Inhibition	%	43.0
	10832935	CHEMBL2007667	GSK_PKIS: TBK1 % inhibition at 1 uM [UNC Frye lab]	B	Cc1ccc(NC(=O)c2ccnc(N3CCOCC3)c2)cc1-c1ccc(C(=O)NCC2CC2)cc1		CHEMBL476351	=	Inhibition	%	-6.0	CHEMBL5408	Homo sapiens	Inhibition	%	-6.0
	10832936	CHEMBL2007667	GSK_PKIS: TBK1 % inhibition at 1 uM [UNC Frye lab]	B	COc1ccc(C2=C(N3CCc4ccccc43)C(=O)NC2=O)cc1		CHEMBL347580	=	Inhibition	%	0.0	CHEMBL5408	Homo sapiens	Inhibition	%	0.0
	10832937	CHEMBL2007667	GSK_PKIS: TBK1 % inhibition at 1 uM [UNC Frye lab]	B	COc1cc2ncnc(Nc3ccc(C)c(O)c3)c2cc1OC.Cl		CHEMBL1909357	=	Inhibition	%	1.0	CHEMBL5408	Homo sapiens	Inhibition	%	1.0
	10832938	CHEMBL2007667	GSK_PKIS: TBK1 % inhibition at 1 uM [UNC Frye lab]	B	CS(=O)(=O)Nc1cccc(-c2ccc3c(NC(=O)C4CC4)n[nH]c3c2)c1		CHEMBL103080	=	Inhibition	%	3.0	CHEMBL5408	Homo sapiens	Inhibition	%	3.0
	10832939	CHEMBL2007667	GSK_PKIS: TBK1 % inhibition at 1 uM [UNC Frye lab]	B	CN(C)c1cc2c(Nc3ccc4c(cnn4Cc4ccccc4)c3)ncnc2cn1		CHEMBL30432	=	Inhibition	%	2.0	CHEMBL5408	Homo sapiens	Inhibition	%	2.0
	10832940	CHEMBL2007667	GSK_PKIS: TBK1 % inhibition at 1 uM [UNC Frye lab]	B	Cc1cc(-c2ccccn2)cc(C)c1/C=C/c1cncc(-c2nn[nH]n2)c1.Cl		CHEMBL1909354	=	Inhibition	%	-5.0	CHEMBL5408	Homo sapiens	Inhibition	%	-5.0
	10832941	CHEMBL2007667	GSK_PKIS: TBK1 % inhibition at 1 uM [UNC Frye lab]	B	Fc1ccc(-c2ncn(C3CCNCC3)c2-c2ccnc(Oc3ccc4c(c3)OCO4)n2)cc1		CHEMBL273611	=	Inhibition	%	-5.0	CHEMBL5408	Homo sapiens	Inhibition	%	-5.0
	10832942	CHEMBL2007667	GSK_PKIS: TBK1 % inhibition at 1 uM [UNC Frye lab]	B	Cl.[O-][S+]1CCN(Cc2ccc(-c3ccc4ncnc(Nc5ccc(OCc6ccccc6)c(F)c5)c4c3)o2)CC1		CHEMBL1909391	=	Inhibition	%	5.0	CHEMBL5408	Homo sapiens	Inhibition	%	5.0
	10832943	CHEMBL2007667	GSK_PKIS: TBK1 % inhibition at 1 uM [UNC Frye lab]	B	c1ccc(Nc2ncc(-c3ccccc3)o2)cc1		CHEMBL318728	=	Inhibition	%	1.0	CHEMBL5408	Homo sapiens	Inhibition	%	1.0
	10832944	CHEMBL2007667	GSK_PKIS: TBK1 % inhibition at 1 uM [UNC Frye lab]	B	O=C(Nc1n[nH]c2nc(-c3ccc(O)cc3)c(Br)cc12)C1CC1		CHEMBL260417	=	Inhibition	%	37.0	CHEMBL5408	Homo sapiens	Inhibition	%	37.0
	10832945	CHEMBL2007667	GSK_PKIS: TBK1 % inhibition at 1 uM [UNC Frye lab]	B	CCn1c(-c2nonc2N)nc2cnc(Oc3cccc(NC(=O)c4ccc(N(C)C)cc4)c3)cc21		CHEMBL220465	=	Inhibition	%	1.0	CHEMBL5408	Homo sapiens	Inhibition	%	1.0
	10832946	CHEMBL2007667	GSK_PKIS: TBK1 % inhibition at 1 uM [UNC Frye lab]	B	NS(=O)(=O)c1ccc(N/N=C2\C(=O)Nc3ccc(-c4cnco4)cc32)cc1		CHEMBL269827	=	Inhibition	%	61.0	CHEMBL5408	Homo sapiens	Inhibition	%	61.0
	10832947	CHEMBL2007667	GSK_PKIS: TBK1 % inhibition at 1 uM [UNC Frye lab]	B	CS(=O)(=O)CCNCc1nc(-c2ccc3ncnc(Nc4ccc(OCc5cccc(C(F)(F)F)c5)cc4)c3c2)cs1.Cl		CHEMBL1909356	=	Inhibition	%	-2.0	CHEMBL5408	Homo sapiens	Inhibition	%	-2.0
	10832948	CHEMBL2007667	GSK_PKIS: TBK1 % inhibition at 1 uM [UNC Frye lab]	B	Cl.NCc1ccc(-c2nc(-c3ccc(Cl)c(O)c3)c(-c3ccncc3)[nH]2)cc1		CHEMBL1909412	=	Inhibition	%	14.0	CHEMBL5408	Homo sapiens	Inhibition	%	14.0
	10832949	CHEMBL2007667	GSK_PKIS: TBK1 % inhibition at 1 uM [UNC Frye lab]	B	NS(=O)(=O)c1ccc(Nc2ncc(-c3ccccc3)o2)cc1		CHEMBL194062	=	Inhibition	%	5.0	CHEMBL5408	Homo sapiens	Inhibition	%	5.0
	10832950	CHEMBL2007667	GSK_PKIS: TBK1 % inhibition at 1 uM [UNC Frye lab]	B	CNC(=O)c1cncc(/C=C/c2ccccc2C)c1		CHEMBL218969	=	Inhibition	%	2.0	CHEMBL5408	Homo sapiens	Inhibition	%	2.0
	10832951	CHEMBL2007667	GSK_PKIS: TBK1 % inhibition at 1 uM [UNC Frye lab]	B	CC(C)=Cc1cccc2c1/C(=N/Nc1ccc(S(N)(=O)=O)cc1)C(=O)N2		CHEMBL270544	=	Inhibition	%	45.0	CHEMBL5408	Homo sapiens	Inhibition	%	45.0
	10832952	CHEMBL2007667	GSK_PKIS: TBK1 % inhibition at 1 uM [UNC Frye lab]	B	Cl.Fc1ccc(-c2nc3n(c2-c2ccncc2)CCS3)cc1		CHEMBL1909406	=	Inhibition	%	3.0	CHEMBL5408	Homo sapiens	Inhibition	%	3.0
	10832953	CHEMBL2007667	GSK_PKIS: TBK1 % inhibition at 1 uM [UNC Frye lab]	B	c1cnn2ncc(-c3ccnc(NCCCN4CCOCC4)n3)c2c1		CHEMBL524901	=	Inhibition	%	-4.0	CHEMBL5408	Homo sapiens	Inhibition	%	-4.0
	10832954	CHEMBL2007667	GSK_PKIS: TBK1 % inhibition at 1 uM [UNC Frye lab]	B	O=C1NC(=O)C(c2ccc(Cl)cc2)=C1Nc1ccc(Cl)c(C(=O)O)c1		CHEMBL160876	=	Inhibition	%	-4.0	CHEMBL5408	Homo sapiens	Inhibition	%	-4.0
	10832955	CHEMBL2007667	GSK_PKIS: TBK1 % inhibition at 1 uM [UNC Frye lab]	B	O=C(Nc1n[nH]c2nc(-c3ccco3)ccc12)C1CC1		CHEMBL101804	=	Inhibition	%	3.0	CHEMBL5408	Homo sapiens	Inhibition	%	3.0
	10832956	CHEMBL2007667	GSK_PKIS: TBK1 % inhibition at 1 uM [UNC Frye lab]	B	CCn1c(-c2nonc2N)nc2c(C#CC(C)(C)O)ncc(OC[C@@H]3CCCN3)c21.O=C(O)C(F)(F)F		CHEMBL1909375	=	Inhibition	%	66.0	CHEMBL5408	Homo sapiens	Inhibition	%	66.0
	10832957	CHEMBL2007667	GSK_PKIS: TBK1 % inhibition at 1 uM [UNC Frye lab]	B	Cc1nn(C)c2cc(N(C)c3ccnc(Nc4cccc(S(N)(=O)=O)c4)n3)ccc12.Cl		CHEMBL1794073	=	Inhibition	%	1.0	CHEMBL5408	Homo sapiens	Inhibition	%	1.0
	10832958	CHEMBL2007667	GSK_PKIS: TBK1 % inhibition at 1 uM [UNC Frye lab]	B	Cn1cc(C=C2C(=O)Nc3cccnc32)c2ccccc21		CHEMBL1516890	=	Inhibition	%	17.0	CHEMBL5408	Homo sapiens	Inhibition	%	17.0
	10832959	CHEMBL2007667	GSK_PKIS: TBK1 % inhibition at 1 uM [UNC Frye lab]	B	COc1ccc2cc(-c3c(-c4ccncc4)nc(-c4ccc([S+](C)[O-])cc4)n3C)ccc2c1		CHEMBL399410	=	Inhibition	%	-3.0	CHEMBL5408	Homo sapiens	Inhibition	%	-3.0
	10832960	CHEMBL2007667	GSK_PKIS: TBK1 % inhibition at 1 uM [UNC Frye lab]	B	COc1cccc(-n2nc(C)c3c(N/N=C(\C)c4ccncc4)ncnc32)c1		CHEMBL442363	=	Inhibition	%	2.0	CHEMBL5408	Homo sapiens	Inhibition	%	2.0
	10832961	CHEMBL2007667	GSK_PKIS: TBK1 % inhibition at 1 uM [UNC Frye lab]	B	COc1cc2c(cc1Nc1nc(Nc3cccc(F)c3C(N)=O)c3cc[nH]c3n1)N(C(=O)CN1CCN(C(C)C)CC1)CC2		CHEMBL505915	=	Inhibition	%	-6.0	CHEMBL5408	Homo sapiens	Inhibition	%	-6.0
	10832962	CHEMBL2007667	GSK_PKIS: TBK1 % inhibition at 1 uM [UNC Frye lab]	B	Nc1ncnc2occ(-c3ccc(NC(=O)Nc4cc(C(F)(F)F)ccc4F)cc3)c12		CHEMBL247228	=	Inhibition	%	1.0	CHEMBL5408	Homo sapiens	Inhibition	%	1.0
	10832963	CHEMBL2007667	GSK_PKIS: TBK1 % inhibition at 1 uM [UNC Frye lab]	B	CS(=O)(=O)CCNCc1ccc(-c2ccc3ncnc(Nc4ccc(OCc5ccccc5)c(Br)c4)c3c2)o1.Cl		CHEMBL1909392	=	Inhibition	%	0.0	CHEMBL5408	Homo sapiens	Inhibition	%	0.0
	10832964	CHEMBL2007667	GSK_PKIS: TBK1 % inhibition at 1 uM [UNC Frye lab]	B	COc1cc2c(cc1Nc1nc(N3CCc4ccccc43)c3cc[nH]c3n1)N(C(=O)CN(C)C)CC2		CHEMBL458415	=	Inhibition	%	28.0	CHEMBL5408	Homo sapiens	Inhibition	%	28.0
	10832965	CHEMBL2007667	GSK_PKIS: TBK1 % inhibition at 1 uM [UNC Frye lab]	B	NS(=O)(=O)c1cccc(-c2cc3ccncc3cc2OCc2ccccc2)c1		CHEMBL483747	=	Inhibition	%	-1.0	CHEMBL5408	Homo sapiens	Inhibition	%	-1.0
	10832966	CHEMBL2007667	GSK_PKIS: TBK1 % inhibition at 1 uM [UNC Frye lab]	B	COc1cc2c(cc1Nc1nc(Nc3ccsc3C(N)=O)c3cc[nH]c3n1)N(C(=O)CN(C)C)CCC2(C)C		CHEMBL463931	=	Inhibition	%	57.0	CHEMBL5408	Homo sapiens	Inhibition	%	57.0
	10832967	CHEMBL2007667	GSK_PKIS: TBK1 % inhibition at 1 uM [UNC Frye lab]	B	C[C@@H](Oc1cc(-n2cnc3ccc(OCC4CCN(C)CC4)cc32)sc1C(N)=O)c1ccccc1Cl		CHEMBL1794069	=	Inhibition	%	6.0	CHEMBL5408	Homo sapiens	Inhibition	%	6.0
	10832968	CHEMBL2007667	GSK_PKIS: TBK1 % inhibition at 1 uM [UNC Frye lab]	B	COc1cc2ncn(-c3cc(OCCc4ccccc4)c(C(N)=O)s3)c2cc1OC		CHEMBL473629	=	Inhibition	%	65.0	CHEMBL5408	Homo sapiens	Inhibition	%	65.0
	10832969	CHEMBL2007667	GSK_PKIS: TBK1 % inhibition at 1 uM [UNC Frye lab]	B	N#Cc1c(NC(=O)c2cccc3ccccc23)sc2c1CCCC2		CHEMBL233001	=	Inhibition	%	-4.0	CHEMBL5408	Homo sapiens	Inhibition	%	-4.0
	10832970	CHEMBL2007667	GSK_PKIS: TBK1 % inhibition at 1 uM [UNC Frye lab]	B	COc1cc(C)c(N(C)C(=O)CN(C)C)cc1Nc1nc(Nc2cccc(F)c2C(N)=O)c2cc[nH]c2n1		CHEMBL467581	=	Inhibition	%	-3.0	CHEMBL5408	Homo sapiens	Inhibition	%	-3.0
	10832971	CHEMBL2007667	GSK_PKIS: TBK1 % inhibition at 1 uM [UNC Frye lab]	B	O=C(O[C@H]1CN[C@H](C#Cc2cc3ncnc(Nc4ccc(OCc5cccc(F)c5)c(Cl)c4)c3s2)C1)N1CCOCC1		CHEMBL507329	=	Inhibition	%	3.0	CHEMBL5408	Homo sapiens	Inhibition	%	3.0
	10832972	CHEMBL2007667	GSK_PKIS: TBK1 % inhibition at 1 uM [UNC Frye lab]	B	CCn1c(-c2nonc2N)nc2ccc(F)cc21		CHEMBL426800	=	Inhibition	%	1.0	CHEMBL5408	Homo sapiens	Inhibition	%	1.0
	10832973	CHEMBL2007667	GSK_PKIS: TBK1 % inhibition at 1 uM [UNC Frye lab]	B	CCN(CC)Cc1ccc(Nc2nccc(-c3cnn4ncccc34)n2)cc1		CHEMBL1882194	=	Inhibition	%	14.0	CHEMBL5408	Homo sapiens	Inhibition	%	14.0
	10832974	CHEMBL2007667	GSK_PKIS: TBK1 % inhibition at 1 uM [UNC Frye lab]	B	CN1CCC(C(=O)Nc2n[nH]c3nc(-c4ccc(O)cc4)c(Br)cc23)CC1		CHEMBL261129	=	Inhibition	%	5.0	CHEMBL5408	Homo sapiens	Inhibition	%	5.0
	10832975	CHEMBL2007667	GSK_PKIS: TBK1 % inhibition at 1 uM [UNC Frye lab]	B	CC1(C)CC(n2cnc(-c3ccc(F)cc3)c2-c2ccnc(N)n2)CC(C)(C)N1		CHEMBL95502	=	Inhibition	%	-3.0	CHEMBL5408	Homo sapiens	Inhibition	%	-3.0
	10832976	CHEMBL2007667	GSK_PKIS: TBK1 % inhibition at 1 uM [UNC Frye lab]	B	CN(C)c1cc2c(Nc3ccc4c(cnn4Cc4ccccc4)c3)ncnc2cn1		CHEMBL30432	=	Inhibition	%	-3.0	CHEMBL5408	Homo sapiens	Inhibition	%	-3.0
	10832977	CHEMBL2007667	GSK_PKIS: TBK1 % inhibition at 1 uM [UNC Frye lab]	B	CN1CCC(n2cnc(-c3ccc(F)cc3)c2-c2ccnc(NCCO)n2)CC1		CHEMBL330422	=	Inhibition	%	-6.0	CHEMBL5408	Homo sapiens	Inhibition	%	-6.0
	10832978	CHEMBL2007667	GSK_PKIS: TBK1 % inhibition at 1 uM [UNC Frye lab]	B	Cc1cccc(-c2n[nH]cc2-c2ccc3ncccc3n2)n1		CHEMBL185238	=	Inhibition	%	-6.0	CHEMBL5408	Homo sapiens	Inhibition	%	-6.0
	10832979	CHEMBL2007667	GSK_PKIS: TBK1 % inhibition at 1 uM [UNC Frye lab]	B	CCn1c(-c2nonc2N)nc2c(C#CC(C)(C)O)ncc(OC3CCNCC3)c21.O=C(O)C(F)(F)F		CHEMBL1794066	=	Inhibition	%	57.0	CHEMBL5408	Homo sapiens	Inhibition	%	57.0
	10832980	CHEMBL2007667	GSK_PKIS: TBK1 % inhibition at 1 uM [UNC Frye lab]	B	C#Cc1cccc(Nc2ncnc3ccc(OCCCCNCCS(C)(=O)=O)cc23)c1		CHEMBL517907	=	Inhibition	%	0.0	CHEMBL5408	Homo sapiens	Inhibition	%	0.0
	10832981	CHEMBL2007667	GSK_PKIS: TBK1 % inhibition at 1 uM [UNC Frye lab]	B	Cc1ccc(C(=O)NC2CCC2)cc1-c1ccc(C(=O)NCC2CC2)cc1		CHEMBL517507	=	Inhibition	%	-4.0	CHEMBL5408	Homo sapiens	Inhibition	%	-4.0
	10832982	CHEMBL2007667	GSK_PKIS: TBK1 % inhibition at 1 uM [UNC Frye lab]	B	CC1=C(C(=O)Nc2ccc3[nH]nc(C)c3c2)C(c2ccc(C(F)(F)F)cc2)CC(=O)N1		CHEMBL218720	=	Inhibition	%	-3.0	CHEMBL5408	Homo sapiens	Inhibition	%	-3.0
	10832983	CHEMBL2007667	GSK_PKIS: TBK1 % inhibition at 1 uM [UNC Frye lab]	B	Fc1ccc(-c2cc(-c3c[nH]nc3-c3ccccn3)ccn2)cc1		CHEMBL381948	=	Inhibition	%	-3.0	CHEMBL5408	Homo sapiens	Inhibition	%	-3.0
	10832984	CHEMBL2007667	GSK_PKIS: TBK1 % inhibition at 1 uM [UNC Frye lab]	B	CN1CCN(Cc2ccc(-c3cc4ncnc(Nc5ccc(OCc6cccc(F)c6)c(Cl)c5)c4s3)o2)CC1		CHEMBL475761	=	Inhibition	%	7.0	CHEMBL5408	Homo sapiens	Inhibition	%	7.0
	10832985	CHEMBL2007667	GSK_PKIS: TBK1 % inhibition at 1 uM [UNC Frye lab]	B	O=C1NC(=O)C(c2ccccc2)=C1Nc1ccccc1		CHEMBL346551	=	Inhibition	%	3.0	CHEMBL5408	Homo sapiens	Inhibition	%	3.0
	10832986	CHEMBL2007667	GSK_PKIS: TBK1 % inhibition at 1 uM [UNC Frye lab]	B	CN(C)C(=O)O[C@@H]1CN[C@@H](C#Cc2cc3ncnc(Nc4ccc(OCc5cccc(F)c5)c(Cl)c4)c3s2)C1		CHEMBL466412	=	Inhibition	%	12.0	CHEMBL5408	Homo sapiens	Inhibition	%	12.0
	10832987	CHEMBL2007667	GSK_PKIS: TBK1 % inhibition at 1 uM [UNC Frye lab]	B	NS(=O)(=O)c1ccc(N/N=C2\C(=O)Nc3ccc(-c4cnco4)cc32)cc1		CHEMBL269827	=	Inhibition	%	57.0	CHEMBL5408	Homo sapiens	Inhibition	%	57.0
	10832988	CHEMBL2007667	GSK_PKIS: TBK1 % inhibition at 1 uM [UNC Frye lab]	B	NC(=O)c1sc(-n2cnc3ccc(C(F)(F)F)cc32)cc1OCc1ccccc1Br		CHEMBL481510	=	Inhibition	%	4.0	CHEMBL5408	Homo sapiens	Inhibition	%	4.0
	10832989	CHEMBL2007667	GSK_PKIS: TBK1 % inhibition at 1 uM [UNC Frye lab]	B	Cc1cccc2c1NC(=O)/C2=N\Nc1ccc(S(N)(=O)=O)cc1		CHEMBL1909398	=	Inhibition	%	3.0	CHEMBL5408	Homo sapiens	Inhibition	%	3.0
	10832990	CHEMBL2007667	GSK_PKIS: TBK1 % inhibition at 1 uM [UNC Frye lab]	B	COc1cccc(-n2cnc3c(N/N=C/c4ccncc4)ncnc32)c1		CHEMBL204934	=	Inhibition	%	4.0	CHEMBL5408	Homo sapiens	Inhibition	%	4.0
	10832991	CHEMBL2007667	GSK_PKIS: TBK1 % inhibition at 1 uM [UNC Frye lab]	B	Cl.NCc1ccc(-c2nc(-c3ccc(Cl)c(O)c3)c(-c3ccncc3)[nH]2)cc1		CHEMBL1909412	=	Inhibition	%	16.0	CHEMBL5408	Homo sapiens	Inhibition	%	16.0
	10832992	CHEMBL2007667	GSK_PKIS: TBK1 % inhibition at 1 uM [UNC Frye lab]	B	Cl.O=C1Nc2ccc(-c3cccnc3)cc2C1=Cc1cc(Br)c(O)c(Br)c1		CHEMBL1794050	=	Inhibition	%	43.0	CHEMBL5408	Homo sapiens	Inhibition	%	43.0
	10832993	CHEMBL2007667	GSK_PKIS: TBK1 % inhibition at 1 uM [UNC Frye lab]	B	CC1=C(C(=O)Nc2ccc3[nH]ncc3c2)C(c2ccc(Cl)c(Cl)c2)CC(=O)N1		CHEMBL374453	=	Inhibition	%	3.0	CHEMBL5408	Homo sapiens	Inhibition	%	3.0
	10832994	CHEMBL2007667	GSK_PKIS: TBK1 % inhibition at 1 uM [UNC Frye lab]	B	NS(=O)(=O)c1ccc(NC=C2C(=O)Nc3ccc4ncsc4c32)cc1		CHEMBL1794055	=	Inhibition	%	89.0	CHEMBL5408	Homo sapiens	Inhibition	%	89.0
	10832995	CHEMBL2007667	GSK_PKIS: TBK1 % inhibition at 1 uM [UNC Frye lab]	B	CNC(=O)c1cncc(/C=C/c2ccccc2C)c1		CHEMBL218969	=	Inhibition	%	5.0	CHEMBL5408	Homo sapiens	Inhibition	%	5.0
	10832996	CHEMBL2007667	GSK_PKIS: TBK1 % inhibition at 1 uM [UNC Frye lab]	B	CCNC(=O)O[C@H]1CN[C@H](C#Cc2cc3ncnc(Nc4ccc(OCc5cccc(F)c5)c(Cl)c4)c3s2)C1		CHEMBL512076	=	Inhibition	%	3.0	CHEMBL5408	Homo sapiens	Inhibition	%	3.0
	10832997	CHEMBL2007667	GSK_PKIS: TBK1 % inhibition at 1 uM [UNC Frye lab]	B	O=C(Nc1n[nH]c2cc(-c3ccc(F)cc3)ccc12)C1CC1		CHEMBL419903	=	Inhibition	%	2.0	CHEMBL5408	Homo sapiens	Inhibition	%	2.0
	10832998	CHEMBL2007667	GSK_PKIS: TBK1 % inhibition at 1 uM [UNC Frye lab]	B	CN1CCN(c2ccc(Nc3nccc(-c4cnn5ncccc45)n3)cc2C(F)(F)F)CC1		CHEMBL468963	=	Inhibition	%	76.0	CHEMBL5408	Homo sapiens	Inhibition	%	76.0
	10832999	CHEMBL2007667	GSK_PKIS: TBK1 % inhibition at 1 uM [UNC Frye lab]	B	Cc1ccc2c(c1)/C(=N/Nc1ccc(S(N)(=O)=O)cc1)C(=O)N2		CHEMBL271843	=	Inhibition	%	3.0	CHEMBL5408	Homo sapiens	Inhibition	%	3.0
	10833000	CHEMBL2007667	GSK_PKIS: TBK1 % inhibition at 1 uM [UNC Frye lab]	B	CCc1cccc(NC(=O)Nc2ccc(Oc3ccc4nc(NC(=O)OC)[nH]c4c3)cc2)c1		CHEMBL243907	=	Inhibition	%	-1.0	CHEMBL5408	Homo sapiens	Inhibition	%	-1.0
	10833001	CHEMBL2007667	GSK_PKIS: TBK1 % inhibition at 1 uM [UNC Frye lab]	B	c1ccc(-c2n[nH]cc2-c2ccnc(-c3ccc(OCCn4ccnc4)cc3)c2)nc1		CHEMBL208437	=	Inhibition	%	-3.0	CHEMBL5408	Homo sapiens	Inhibition	%	-3.0
	10833002	CHEMBL2007667	GSK_PKIS: TBK1 % inhibition at 1 uM [UNC Frye lab]	B	COc1cc(N2CCN(C(C)C)CC2)ccc1Nc1nc(Nc2cccc3ncccc23)c2cc[nH]c2n1		CHEMBL458438	=	Inhibition	%	2.0	CHEMBL5408	Homo sapiens	Inhibition	%	2.0
	10833003	CHEMBL2007667	GSK_PKIS: TBK1 % inhibition at 1 uM [UNC Frye lab]	B	COc1cccc(-n2ncc3c(N/N=C/c4ccc(F)cc4)ncnc32)c1		CHEMBL65884	=	Inhibition	%	5.0	CHEMBL5408	Homo sapiens	Inhibition	%	5.0
	10833004	CHEMBL2007667	GSK_PKIS: TBK1 % inhibition at 1 uM [UNC Frye lab]	B	Clc1ccc(CNc2nccc(-c3cnn4ncccc34)n2)cc1		CHEMBL513330	=	Inhibition	%	-1.0	CHEMBL5408	Homo sapiens	Inhibition	%	-1.0
	10833005	CHEMBL2007667	GSK_PKIS: TBK1 % inhibition at 1 uM [UNC Frye lab]	B	CCn1c(-c2nonc2N)nc2c(C#CC(C)(C)O)nc(OC[C@@H](N)c3ccccc3)cc21		CHEMBL1096626	=	Inhibition	%	7.0	CHEMBL5408	Homo sapiens	Inhibition	%	7.0
	10833006	CHEMBL2007667	GSK_PKIS: TBK1 % inhibition at 1 uM [UNC Frye lab]	B	O=C1Nc2ccccc2/C1=C/Nc1ccc2[nH]c(=O)[nH]c2c1		CHEMBL1794057	=	Inhibition	%	27.0	CHEMBL5408	Homo sapiens	Inhibition	%	27.0
	10833007	CHEMBL2007667	GSK_PKIS: TBK1 % inhibition at 1 uM [UNC Frye lab]	B	COc1cc(Nc2ncc3c(C)nc(-c4cccc(Oc5ccccc5)c4)n3n2)cc(OC)c1OC		CHEMBL519881	=	Inhibition	%	75.0	CHEMBL5408	Homo sapiens	Inhibition	%	75.0
	10833008	CHEMBL2007667	GSK_PKIS: TBK1 % inhibition at 1 uM [UNC Frye lab]	B	O=C(O)C(F)(F)F.O=C(O[C@H]1CN[C@H](C#Cc2cc3ncnc(Nc4ccc5c(ccn5Cc5cc(F)ccc5F)c4)c3s2)C1)N1CCOCC1		CHEMBL1909410	=	Inhibition	%	9.0	CHEMBL5408	Homo sapiens	Inhibition	%	9.0
	10833009	CHEMBL2007667	GSK_PKIS: TBK1 % inhibition at 1 uM [UNC Frye lab]	B	c1cc(-c2cnn3nc(N4CCOCC4)ccc23)nc(NC2CC2)n1		CHEMBL495771	=	Inhibition	%	5.0	CHEMBL5408	Homo sapiens	Inhibition	%	5.0
	10833010	CHEMBL2007667	GSK_PKIS: TBK1 % inhibition at 1 uM [UNC Frye lab]	B	N#Cc1c(NC(=O)c2ccc(F)c3ccccc23)sc2c1CCCC2		CHEMBL233002	=	Inhibition	%	6.0	CHEMBL5408	Homo sapiens	Inhibition	%	6.0
	10833011	CHEMBL2007667	GSK_PKIS: TBK1 % inhibition at 1 uM [UNC Frye lab]	B	CC(C)COC(=O)c1ccc2c(c1)/C(=C/Nc1ccc(S(N)(=O)=O)cc1)C(=O)N2		CHEMBL269883	=	Inhibition	%	98.0	CHEMBL5408	Homo sapiens	Inhibition	%	98.0
	10833012	CHEMBL2007667	GSK_PKIS: TBK1 % inhibition at 1 uM [UNC Frye lab]	B	Cc1ccc2c(-c3ccnc(Nc4ccccc4)n3)c(-c3ccc(F)cc3)nn2n1		CHEMBL189459	=	Inhibition	%	-3.0	CHEMBL5408	Homo sapiens	Inhibition	%	-3.0
	10833013	CHEMBL2007667	GSK_PKIS: TBK1 % inhibition at 1 uM [UNC Frye lab]	B	Nc1nccc(-c2c(-c3ccc(F)cc3)nn3cc(C(F)(F)F)ccc23)n1		CHEMBL1909402	=	Inhibition	%	-3.0	CHEMBL5408	Homo sapiens	Inhibition	%	-3.0
	10833014	CHEMBL2007667	GSK_PKIS: TBK1 % inhibition at 1 uM [UNC Frye lab]	B	COc1cc2ncn(-c3cc(OCc4ccccc4C(F)(F)F)c(C(C)=O)s3)c2cc1OC		CHEMBL471789	=	Inhibition	%	-3.0	CHEMBL5408	Homo sapiens	Inhibition	%	-3.0
	10833015	CHEMBL2007667	GSK_PKIS: TBK1 % inhibition at 1 uM [UNC Frye lab]	B	CCn1c(-c2nonc2N)nc2c(C#CCN)ncc(OCCCN)c21.O=C(O)C(F)(F)F		CHEMBL1794064	=	Inhibition	%	1.0	CHEMBL5408	Homo sapiens	Inhibition	%	1.0
	10833016	CHEMBL2007667	GSK_PKIS: TBK1 % inhibition at 1 uM [UNC Frye lab]	B	CCc1ccc(Oc2nccc(-c3c(-c4ccc(F)cc4)ncn3C3CCNCC3)n2)cc1		CHEMBL428877	=	Inhibition	%	-6.0	CHEMBL5408	Homo sapiens	Inhibition	%	-6.0
	10833017	CHEMBL2007667	GSK_PKIS: TBK1 % inhibition at 1 uM [UNC Frye lab]	B	O=C1Nc2ccccc2/C1=C/Nc1ccc(-n2cncn2)cc1		CHEMBL1794056	=	Inhibition	%	23.0	CHEMBL5408	Homo sapiens	Inhibition	%	23.0
	10833018	CHEMBL2007667	GSK_PKIS: TBK1 % inhibition at 1 uM [UNC Frye lab]	B	CNC(=O)c1sc(-n2cnc3cc(OC)c(OC)cc32)cc1OCc1ccccc1C(F)(F)F		CHEMBL518968	=	Inhibition	%	2.0	CHEMBL5408	Homo sapiens	Inhibition	%	2.0
	10833019	CHEMBL2007667	GSK_PKIS: TBK1 % inhibition at 1 uM [UNC Frye lab]	B	COc1ccc(-c2ccc3c(NC(=O)C4CC4)n[nH]c3n2)cc1		CHEMBL408732	=	Inhibition	%	4.0	CHEMBL5408	Homo sapiens	Inhibition	%	4.0
	10833020	CHEMBL2007667	GSK_PKIS: TBK1 % inhibition at 1 uM [UNC Frye lab]	B	Fc1ccc(-c2nn3ccccc3c2-c2ccncc2)cc1		CHEMBL485745	=	Inhibition	%	-8.0	CHEMBL5408	Homo sapiens	Inhibition	%	-8.0
	10833021	CHEMBL2007667	GSK_PKIS: TBK1 % inhibition at 1 uM [UNC Frye lab]	B	CN1CCN(Cc2ccc(-c3cc4ncnc(Nc5ccc(OCc6cccc(F)c6)c(Cl)c5)c4s3)o2)CC1		CHEMBL475761	=	Inhibition	%	3.0	CHEMBL5408	Homo sapiens	Inhibition	%	3.0
	10833022	CHEMBL2007667	GSK_PKIS: TBK1 % inhibition at 1 uM [UNC Frye lab]	B	CN(C)C(=O)O[C@@H]1CN[C@@H](C#Cc2cc3ncnc(Nc4ccc(OCc5cccc(F)c5)c(Cl)c4)c3s2)C1		CHEMBL466412	=	Inhibition	%	7.0	CHEMBL5408	Homo sapiens	Inhibition	%	7.0
	10833023	CHEMBL2007667	GSK_PKIS: TBK1 % inhibition at 1 uM [UNC Frye lab]	B	C[C@@H](Oc1cc(-n2cnc3ccc(OC[C@@H](O)CO)cc32)sc1C(N)=O)c1ccccc1Cl		CHEMBL1794067	=	Inhibition	%	1.0	CHEMBL5408	Homo sapiens	Inhibition	%	1.0
	10833024	CHEMBL2007667	GSK_PKIS: TBK1 % inhibition at 1 uM [UNC Frye lab]	B	NC(=O)c1ccc2c(-c3ccnc(NCCCO)n3)c(-c3ccc(F)cc3)nn2c1		CHEMBL1909404	=	Inhibition	%	1.0	CHEMBL5408	Homo sapiens	Inhibition	%	1.0
	10833025	CHEMBL2007667	GSK_PKIS: TBK1 % inhibition at 1 uM [UNC Frye lab]	B	COc1cc(Nc2nccc(-c3cnn4ncccc34)n2)cc(OC)c1		CHEMBL359999	=	Inhibition	%	33.0	CHEMBL5408	Homo sapiens	Inhibition	%	33.0
	10833026	CHEMBL2007667	GSK_PKIS: TBK1 % inhibition at 1 uM [UNC Frye lab]	B	COc1cccc(COc2cc(-n3cnc4ccccc43)sc2C(N)=O)c1		CHEMBL516248	=	Inhibition	%	0.0	CHEMBL5408	Homo sapiens	Inhibition	%	0.0
	10833027	CHEMBL2007667	GSK_PKIS: TBK1 % inhibition at 1 uM [UNC Frye lab]	B	Cc1ccc(NC(=O)c2ccnc(N3CCCC3)c2)cc1-c1ccc(C(=O)NCC2CC2)cc1		CHEMBL477182	=	Inhibition	%	33.0	CHEMBL5408	Homo sapiens	Inhibition	%	33.0
	10833028	CHEMBL2007667	GSK_PKIS: TBK1 % inhibition at 1 uM [UNC Frye lab]	B	Cl.O=C(Nc1ccc(Oc2ccc3[nH]c(NC(=O)c4ccccc4)nc3c2)cc1)Nc1cc(C(F)(F)F)ccc1F		CHEMBL1909374	=	Inhibition	%	3.0	CHEMBL5408	Homo sapiens	Inhibition	%	3.0
	10833029	CHEMBL2007667	GSK_PKIS: TBK1 % inhibition at 1 uM [UNC Frye lab]	B	COc1ccccc1Nc1ncc(-c2ccccc2)o1.Cl		CHEMBL1794062	=	Inhibition	%	5.0	CHEMBL5408	Homo sapiens	Inhibition	%	5.0
	10833030	CHEMBL2007667	GSK_PKIS: TBK1 % inhibition at 1 uM [UNC Frye lab]	B	CS(=O)(=O)Nc1ccc(-c2ccc3c(NC(=O)C4CC4)n[nH]c3c2)cc1		CHEMBL102936	=	Inhibition	%	3.0	CHEMBL5408	Homo sapiens	Inhibition	%	3.0
	10833031	CHEMBL2007667	GSK_PKIS: TBK1 % inhibition at 1 uM [UNC Frye lab]	B	Cc1nnc(-c2cccc(-c3ccc(C(=O)NCC4CC4)cc3)c2)o1		CHEMBL257113	=	Inhibition	%	-2.0	CHEMBL5408	Homo sapiens	Inhibition	%	-2.0
	10833032	CHEMBL2007667	GSK_PKIS: TBK1 % inhibition at 1 uM [UNC Frye lab]	B	O=C(Nc1n[nH]c2cc(-c3ccc(F)cc3)ccc12)C1CC1		CHEMBL419903	=	Inhibition	%	4.0	CHEMBL5408	Homo sapiens	Inhibition	%	4.0
	10833033	CHEMBL2007667	GSK_PKIS: TBK1 % inhibition at 1 uM [UNC Frye lab]	B	CCn1c(-c2nonc2N)nc2cncc(C(=O)N3CC[C@H](N)C3)c21.Cl		CHEMBL1909384	=	Inhibition	%	32.0	CHEMBL5408	Homo sapiens	Inhibition	%	32.0
	10833034	CHEMBL2007667	GSK_PKIS: TBK1 % inhibition at 1 uM [UNC Frye lab]	B	NS(=O)(=O)c1ccc(N/N=C2\C(=O)Nc3ccc4ncccc4c32)cc1		CHEMBL409892	=	Inhibition	%	77.0	CHEMBL5408	Homo sapiens	Inhibition	%	77.0
	10833035	CHEMBL2007667	GSK_PKIS: TBK1 % inhibition at 1 uM [UNC Frye lab]	B	COc1cc2ncn(-c3cc(O[C@H](C)c4ccccc4Cl)c(C(N)=O)s3)c2cc1OC		CHEMBL222419	=	Inhibition	%	0.0	CHEMBL5408	Homo sapiens	Inhibition	%	0.0
	10833036	CHEMBL2007667	GSK_PKIS: TBK1 % inhibition at 1 uM [UNC Frye lab]	B	CCn1c(-c2nonc2N)nc2c(C#CC(C)(C)O)nc(CN3CCCC3)cc21		CHEMBL1096290	=	Inhibition	%	20.0	CHEMBL5408	Homo sapiens	Inhibition	%	20.0
	10833037	CHEMBL2007667	GSK_PKIS: TBK1 % inhibition at 1 uM [UNC Frye lab]	B	Cc1ccc(C(=O)NC2CCCCC2)cc1-c1ccc(C(=O)NCC2CC2)cc1		CHEMBL477978	=	Inhibition	%	-3.0	CHEMBL5408	Homo sapiens	Inhibition	%	-3.0
	10833038	CHEMBL2007667	GSK_PKIS: TBK1 % inhibition at 1 uM [UNC Frye lab]	B	CC(C)c1ccc2c(c1)NC(=O)/C2=N/Nc1ccc(S(N)(=O)=O)cc1		CHEMBL271594	=	Inhibition	%	-5.0	CHEMBL5408	Homo sapiens	Inhibition	%	-5.0
	10833039	CHEMBL2007667	GSK_PKIS: TBK1 % inhibition at 1 uM [UNC Frye lab]	B	COc1ccccc1-c1cc(/C=C2\C(=O)Nc3ncc(Br)cc32)cc(Br)c1O		CHEMBL176857	=	Inhibition	%	7.0	CHEMBL5408	Homo sapiens	Inhibition	%	7.0
	10833040	CHEMBL2007667	GSK_PKIS: TBK1 % inhibition at 1 uM [UNC Frye lab]	B	Cc1ccc(O)cc1Nc1ccnc2cc(-c3ccccn3)ccc12.Cl		CHEMBL581096	=	Inhibition	%	1.0	CHEMBL5408	Homo sapiens	Inhibition	%	1.0
	10833041	CHEMBL2007667	GSK_PKIS: TBK1 % inhibition at 1 uM [UNC Frye lab]	B	Fc1ccc(-c2ncn(C3CCNCC3)c2-c2ccnc(Oc3ccccc3)n2)cc1		CHEMBL275798	=	Inhibition	%	3.0	CHEMBL5408	Homo sapiens	Inhibition	%	3.0
	10833042	CHEMBL2007667	GSK_PKIS: TBK1 % inhibition at 1 uM [UNC Frye lab]	B	CCn1c(-c2nonc2N)nc2cncc(C(=O)N3CCNCC3)c21.Cl		CHEMBL1909376	=	Inhibition	%	0.0	CHEMBL5408	Homo sapiens	Inhibition	%	0.0
	10833043	CHEMBL2007667	GSK_PKIS: TBK1 % inhibition at 1 uM [UNC Frye lab]	B	COc1cc2c(cc1Nc1nc(Nc3ccsc3C(N)=O)c3cc[nH]c3n1)N(C(=O)CN(C)C)CCC2(C)C		CHEMBL463931	=	Inhibition	%	54.0	CHEMBL5408	Homo sapiens	Inhibition	%	54.0
	10833044	CHEMBL2007667	GSK_PKIS: TBK1 % inhibition at 1 uM [UNC Frye lab]	B	COc1cc(Nc2ncc(-c3ccccc3)o2)cc(OC)c1OC		CHEMBL443563	=	Inhibition	%	27.0	CHEMBL5408	Homo sapiens	Inhibition	%	27.0
	10833045	CHEMBL2007667	GSK_PKIS: TBK1 % inhibition at 1 uM [UNC Frye lab]	B	COc1cc2ncn(-c3cc(OCCc4ccccc4)c(C(N)=O)s3)c2cc1OC		CHEMBL473629	=	Inhibition	%	61.0	CHEMBL5408	Homo sapiens	Inhibition	%	61.0
	10833046	CHEMBL2007667	GSK_PKIS: TBK1 % inhibition at 1 uM [UNC Frye lab]	B	COc1cccc(Nc2nccc(-c3cnn4ncccc34)n2)c1		CHEMBL187081	=	Inhibition	%	31.0	CHEMBL5408	Homo sapiens	Inhibition	%	31.0
	10833047	CHEMBL2007667	GSK_PKIS: TBK1 % inhibition at 1 uM [UNC Frye lab]	B	COc1cc2c(cc1Nc1nc(Nc3ccsc3C(N)=O)c3cc[nH]c3n1)N(C(=O)CN(C)C)CCC2		CHEMBL456252	=	Inhibition	%	23.0	CHEMBL5408	Homo sapiens	Inhibition	%	23.0
	10833048	CHEMBL2007667	GSK_PKIS: TBK1 % inhibition at 1 uM [UNC Frye lab]	B	Fc1cccc(COc2ccc(Nc3ncnc4sc(-c5ccco5)cc34)cc2Cl)c1		CHEMBL514938	=	Inhibition	%	41.0	CHEMBL5408	Homo sapiens	Inhibition	%	41.0
	10833049	CHEMBL2007667	GSK_PKIS: TBK1 % inhibition at 1 uM [UNC Frye lab]	B	COc1cccc(-n2ncc3c(N/N=C/c4ccc(C)cc4)ncnc32)c1		CHEMBL303687	=	Inhibition	%	1.0	CHEMBL5408	Homo sapiens	Inhibition	%	1.0
	10833050	CHEMBL2007667	GSK_PKIS: TBK1 % inhibition at 1 uM [UNC Frye lab]	B	COc1cc2c(cc1Nc1nc(Nc3ccsc3C(N)=O)c3cc[nH]c3n1)N(C(=O)CN(C)C)CCC2		CHEMBL456252	=	Inhibition	%	19.0	CHEMBL5408	Homo sapiens	Inhibition	%	19.0
	10833051	CHEMBL2007667	GSK_PKIS: TBK1 % inhibition at 1 uM [UNC Frye lab]	B	Fc1cccc(COc2ccc(Nc3ncnc4sc(-c5ccco5)cc34)cc2Cl)c1		CHEMBL514938	=	Inhibition	%	42.0	CHEMBL5408	Homo sapiens	Inhibition	%	42.0
	10833052	CHEMBL2007667	GSK_PKIS: TBK1 % inhibition at 1 uM [UNC Frye lab]	B	COc1cc(N2CCN(C(C)C)CC2)ccc1Nc1nc(Nc2ccc(F)cc2C(N)=O)c2cc[nH]c2n1		CHEMBL458865	=	Inhibition	%	10.0	CHEMBL5408	Homo sapiens	Inhibition	%	10.0
	10833053	CHEMBL2007667	GSK_PKIS: TBK1 % inhibition at 1 uM [UNC Frye lab]	B	CCn1c(-c2nonc2N)nc2c(C#CC(C)(C)O)nc(OCCNC)cc21.Cl		CHEMBL1909350	=	Inhibition	%	23.0	CHEMBL5408	Homo sapiens	Inhibition	%	23.0
	10833054	CHEMBL2007667	GSK_PKIS: TBK1 % inhibition at 1 uM [UNC Frye lab]	B	CNC(=O)c1cc(-c2ccc(F)cc2)cc(-c2ccc(S(=O)(=O)N3CCCC3)cc2)c1N		CHEMBL230592	=	Inhibition	%	2.0	CHEMBL5408	Homo sapiens	Inhibition	%	2.0
	10833055	CHEMBL2007667	GSK_PKIS: TBK1 % inhibition at 1 uM [UNC Frye lab]	B	CNC(=O)c1cncc(/C=C/c2c(C)cccc2C)c1		CHEMBL218859	=	Inhibition	%	3.0	CHEMBL5408	Homo sapiens	Inhibition	%	3.0
	10833056	CHEMBL2007667	GSK_PKIS: TBK1 % inhibition at 1 uM [UNC Frye lab]	B	CN(c1ccc(NC(=O)Nc2ccc(OC(F)(F)F)cc2)cc1)c1ccnc(Nc2cccc(S(N)(=O)=O)c2)n1		CHEMBL188381	=	Inhibition	%	18.0	CHEMBL5408	Homo sapiens	Inhibition	%	18.0
	10833057	CHEMBL2007667	GSK_PKIS: TBK1 % inhibition at 1 uM [UNC Frye lab]	B	NS(=O)(=O)c1ccc(N/N=C2\C(=O)Nc3ccc(C(=O)NCCCn4ccnc4)cc32)cc1		CHEMBL272026	=	Inhibition	%	41.0	CHEMBL5408	Homo sapiens	Inhibition	%	41.0
	10833058	CHEMBL2007667	GSK_PKIS: TBK1 % inhibition at 1 uM [UNC Frye lab]	B	CCc1cccc(CC)c1/C=C/c1cncc(C(=O)NC)c1		CHEMBL385426	=	Inhibition	%	0.0	CHEMBL5408	Homo sapiens	Inhibition	%	0.0
	10833059	CHEMBL2007667	GSK_PKIS: TBK1 % inhibition at 1 uM [UNC Frye lab]	B	N#Cc1ccc2c(-c3ccnc(NC4CC4)n3)c(-c3ccc(F)cc3)nn2c1		CHEMBL1885746	=	Inhibition	%	-1.0	CHEMBL5408	Homo sapiens	Inhibition	%	-1.0
	10833060	CHEMBL2007667	GSK_PKIS: TBK1 % inhibition at 1 uM [UNC Frye lab]	B	COC(=O)Nc1nc2cc(Oc3ccc(NC(=O)Nc4cccc(Br)c4)cc3)ccc2[nH]1.Cl		CHEMBL1909370	=	Inhibition	%	2.0	CHEMBL5408	Homo sapiens	Inhibition	%	2.0
	10833061	CHEMBL2007667	GSK_PKIS: TBK1 % inhibition at 1 uM [UNC Frye lab]	B	N#Cc1c(NC(=O)c2ccc(F)cc2)sc2c1CCCC2		CHEMBL397570	=	Inhibition	%	-4.0	CHEMBL5408	Homo sapiens	Inhibition	%	-4.0
	10833062	CHEMBL2007667	GSK_PKIS: TBK1 % inhibition at 1 uM [UNC Frye lab]	B	COc1cc(Nc2ncc3c(C)nc(-c4cccc(Oc5ccccc5)c4)n3n2)cc(OC)c1OC		CHEMBL519881	=	Inhibition	%	71.0	CHEMBL5408	Homo sapiens	Inhibition	%	71.0
	10833063	CHEMBL2007667	GSK_PKIS: TBK1 % inhibition at 1 uM [UNC Frye lab]	B	COc1ccc(-c2ccncc2)cc1C(N)=O		CHEMBL231013	=	Inhibition	%	3.0	CHEMBL5408	Homo sapiens	Inhibition	%	3.0
	10833064	CHEMBL2007667	GSK_PKIS: TBK1 % inhibition at 1 uM [UNC Frye lab]	B	c1ccc(-c2n[nH]cc2-c2ccnc(-c3ccc(OCCN4CCOCC4)cc3)c2)nc1		CHEMBL205158	=	Inhibition	%	-1.0	CHEMBL5408	Homo sapiens	Inhibition	%	-1.0
	10833065	CHEMBL2007667	GSK_PKIS: TBK1 % inhibition at 1 uM [UNC Frye lab]	B	Cl.Nc1nc(-c2ccc3c(c2)C(=Cc2cc(Br)c(O)c(Br)c2)C(=O)N3)cs1		CHEMBL1794053	=	Inhibition	%	5.0	CHEMBL5408	Homo sapiens	Inhibition	%	5.0
	10833066	CHEMBL2007667	GSK_PKIS: TBK1 % inhibition at 1 uM [UNC Frye lab]	B	Nc1nonc1-c1nc2cnccc2n1C1CCCCC1		CHEMBL189231	=	Inhibition	%	37.0	CHEMBL5408	Homo sapiens	Inhibition	%	37.0
	10833067	CHEMBL2007667	GSK_PKIS: TBK1 % inhibition at 1 uM [UNC Frye lab]	B	c1cc(-c2cnn3nc(N4CCOCC4)ccc23)nc(NC2CC2)n1		CHEMBL495771	=	Inhibition	%	6.0	CHEMBL5408	Homo sapiens	Inhibition	%	6.0
	10833068	CHEMBL2007667	GSK_PKIS: TBK1 % inhibition at 1 uM [UNC Frye lab]	B	CS(=O)(=O)CCNCc1ccc(-c2ccc3ncnc(Nc4ccc(OCc5ccccc5)c(C(F)(F)F)c4)c3c2)o1.Cl		CHEMBL1909389	=	Inhibition	%	-1.0	CHEMBL5408	Homo sapiens	Inhibition	%	-1.0
	10833069	CHEMBL2007667	GSK_PKIS: TBK1 % inhibition at 1 uM [UNC Frye lab]	B	COc1ccc2cc(-c3c(-c4ccncc4)nc(-c4ccc([S+](C)[O-])cc4C)n3C)ccc2c1		CHEMBL237570	=	Inhibition	%	-2.0	CHEMBL5408	Homo sapiens	Inhibition	%	-2.0
	10833070	CHEMBL2007667	GSK_PKIS: TBK1 % inhibition at 1 uM [UNC Frye lab]	B	COc1ccc(C2=C(N3CCc4ccccc43)C(=O)NC2=O)cc1		CHEMBL347580	=	Inhibition	%	3.0	CHEMBL5408	Homo sapiens	Inhibition	%	3.0
	10833071	CHEMBL2007667	GSK_PKIS: TBK1 % inhibition at 1 uM [UNC Frye lab]	B	CS(=O)(=O)CCNCc1ccc(-c2ccc3ncnc(Nc4ccc(OCc5ccccc5)cc4)c3c2)o1.Cl		CHEMBL1909385	=	Inhibition	%	-1.0	CHEMBL5408	Homo sapiens	Inhibition	%	-1.0
	10833072	CHEMBL2007667	GSK_PKIS: TBK1 % inhibition at 1 uM [UNC Frye lab]	B	Nc1nccc(-c2c(-c3ccc(F)cc3)nn3cc(C(F)(F)F)ccc23)n1		CHEMBL1909402	=	Inhibition	%	1.0	CHEMBL5408	Homo sapiens	Inhibition	%	1.0
	10833073	CHEMBL2007667	GSK_PKIS: TBK1 % inhibition at 1 uM [UNC Frye lab]	B	COc1ccc(-c2nn3ncccc3c2-c2ccnc(Nc3ccc(F)c(F)c3)n2)cc1		CHEMBL427159	=	Inhibition	%	-6.0	CHEMBL5408	Homo sapiens	Inhibition	%	-6.0
	10833074	CHEMBL2007667	GSK_PKIS: TBK1 % inhibition at 1 uM [UNC Frye lab]	B	NS(=O)(=O)c1ccc(Nc2cc(-c3cccc(O)c3)n[nH]2)cc1		CHEMBL103104	=	Inhibition	%	-2.0	CHEMBL5408	Homo sapiens	Inhibition	%	-2.0
	10833075	CHEMBL2007667	GSK_PKIS: TBK1 % inhibition at 1 uM [UNC Frye lab]	B	CS(=O)(=O)CCNCc1ccc(-c2ccc3ncnc(Nc4ccc(OCc5cccc(C(F)(F)F)c5)cc4)c3c2)o1.Cl		CHEMBL1909387	=	Inhibition	%	-1.0	CHEMBL5408	Homo sapiens	Inhibition	%	-1.0
	10833076	CHEMBL2007667	GSK_PKIS: TBK1 % inhibition at 1 uM [UNC Frye lab]	B	Cl.[O-][S+]1CCN(Cc2ccc(-c3ccc4ncnc(Nc5ccc(OCc6ccccc6)c(F)c5)c4c3)o2)CC1		CHEMBL1909391	=	Inhibition	%	2.0	CHEMBL5408	Homo sapiens	Inhibition	%	2.0
	10833077	CHEMBL2007667	GSK_PKIS: TBK1 % inhibition at 1 uM [UNC Frye lab]	B	COc1ccc2c(-c3ccnc(Nc4cccc(OC(F)(F)F)c4)n3)cnn2n1		CHEMBL365248	=	Inhibition	%	49.0	CHEMBL5408	Homo sapiens	Inhibition	%	49.0
	10833078	CHEMBL2007667	GSK_PKIS: TBK1 % inhibition at 1 uM [UNC Frye lab]	B	NC(=O)c1sc(-n2cnc3cc(C(F)(F)F)ccc32)cc1OCc1ccccc1Br		CHEMBL480371	=	Inhibition	%	6.0	CHEMBL5408	Homo sapiens	Inhibition	%	6.0
	10833079	CHEMBL2007667	GSK_PKIS: TBK1 % inhibition at 1 uM [UNC Frye lab]	B	CC(C)(CO)CNC(=O)c1ccc2c(c1)/C(=N/Nc1ccc(S(N)(=O)=O)cc1)C(=O)N2		CHEMBL410072	=	Inhibition	%	88.0	CHEMBL5408	Homo sapiens	Inhibition	%	88.0
	10833080	CHEMBL2007667	GSK_PKIS: TBK1 % inhibition at 1 uM [UNC Frye lab]	B	CS(=O)(=O)Nc1ccc(N/C=C2\C(=O)Nc3ccccc32)cc1		CHEMBL1794058	=	Inhibition	%	29.0	CHEMBL5408	Homo sapiens	Inhibition	%	29.0
	10833081	CHEMBL2007667	GSK_PKIS: TBK1 % inhibition at 1 uM [UNC Frye lab]	B	Cn1c(-c2nonc2N)nc2cnccc21		CHEMBL188048	=	Inhibition	%	-2.0	CHEMBL5408	Homo sapiens	Inhibition	%	-2.0
	10833082	CHEMBL2007667	GSK_PKIS: TBK1 % inhibition at 1 uM [UNC Frye lab]	B	CCn1c(-c2nonc2N)nc2c(C#CC(C)(C)O)ncc(OCC3CCNCC3)c21.O=C(O)C(F)(F)F		CHEMBL1794065	=	Inhibition	%	59.0	CHEMBL5408	Homo sapiens	Inhibition	%	59.0
	10833083	CHEMBL2007667	GSK_PKIS: TBK1 % inhibition at 1 uM [UNC Frye lab]	B	NS(=O)(=O)c1ccc(N/N=C2\C(=O)Nc3ccc(Cl)cc32)cc1		CHEMBL270054	=	Inhibition	%	5.0	CHEMBL5408	Homo sapiens	Inhibition	%	5.0
	10833084	CHEMBL2007667	GSK_PKIS: TBK1 % inhibition at 1 uM [UNC Frye lab]	B	COc1ccccc1Oc1nccc(-c2c(-c3ccc(F)cc3)ncn2C2CCNCC2)n1		CHEMBL417804	=	Inhibition	%	5.0	CHEMBL5408	Homo sapiens	Inhibition	%	5.0
	10833085	CHEMBL2007667	GSK_PKIS: TBK1 % inhibition at 1 uM [UNC Frye lab]	B	CNC(=O)c1cncc(/C=C/c2c(Cl)cccc2Cl)c1		CHEMBL263796	=	Inhibition	%	0.0	CHEMBL5408	Homo sapiens	Inhibition	%	0.0
	10833086	CHEMBL2007667	GSK_PKIS: TBK1 % inhibition at 1 uM [UNC Frye lab]	B	CN(C)CCOc1ccc(-c2nc(-c3ccncc3)c(-c3ccc4c(c3)CC/C4=N\O)[nH]2)cc1.Cl.O		CHEMBL1909414	=	Inhibition	%	-1.0	CHEMBL5408	Homo sapiens	Inhibition	%	-1.0
	10833087	CHEMBL2007667	GSK_PKIS: TBK1 % inhibition at 1 uM [UNC Frye lab]	B	Cc1ccc(NC(=O)c2ccnc(N3CCCC3)c2)cc1-c1ccc(C(=O)NCC2CC2)cc1		CHEMBL477182	=	Inhibition	%	39.0	CHEMBL5408	Homo sapiens	Inhibition	%	39.0
	10833088	CHEMBL2007667	GSK_PKIS: TBK1 % inhibition at 1 uM [UNC Frye lab]	B	Fc1ccc(-c2ncn(C3CCNCC3)c2-c2ccnc(Oc3ccc(Cl)cc3)n2)cc1		CHEMBL275168	=	Inhibition	%	4.0	CHEMBL5408	Homo sapiens	Inhibition	%	4.0
	10833089	CHEMBL2007667	GSK_PKIS: TBK1 % inhibition at 1 uM [UNC Frye lab]	B	Cl.Nc1nccc(-c2c(-c3ccc(F)cc3)ncn2C2CCNCC2)n1		CHEMBL1909407	=	Inhibition	%	2.0	CHEMBL5408	Homo sapiens	Inhibition	%	2.0
	10833090	CHEMBL2007667	GSK_PKIS: TBK1 % inhibition at 1 uM [UNC Frye lab]	B	Cc1cc(O)cc(C)c1/C=C/c1cncc(C(N)=O)c1		CHEMBL218088	=	Inhibition	%	-3.0	CHEMBL5408	Homo sapiens	Inhibition	%	-3.0
	10833091	CHEMBL2007667	GSK_PKIS: TBK1 % inhibition at 1 uM [UNC Frye lab]	B	Nc1nccc(-c2c(-c3ccc(F)cc3)ncn2C2CCC(O)CC2)n1		CHEMBL1888586	=	Inhibition	%	0.0	CHEMBL5408	Homo sapiens	Inhibition	%	0.0
	10833092	CHEMBL2007667	GSK_PKIS: TBK1 % inhibition at 1 uM [UNC Frye lab]	B	CS(=O)(=O)Nc1ccc(-c2ccc3c(NC(=O)C4CC4)n[nH]c3c2)cc1		CHEMBL102936	=	Inhibition	%	5.0	CHEMBL5408	Homo sapiens	Inhibition	%	5.0
	10833093	CHEMBL2007667	GSK_PKIS: TBK1 % inhibition at 1 uM [UNC Frye lab]	B	COc1cc(Nc2nccc(Nc3ccc4c(C)n[nH]c4c3)n2)cc(OC)c1OC		CHEMBL479079	=	Inhibition	%	33.0	CHEMBL5408	Homo sapiens	Inhibition	%	33.0
	10833094	CHEMBL2007667	GSK_PKIS: TBK1 % inhibition at 1 uM [UNC Frye lab]	B	COC(=O)Nc1nc2ccc(Oc3ccc(NC(=O)Nc4cc(C(F)(F)F)ccc4F)cc3)cc2s1.Cl		CHEMBL1909369	=	Inhibition	%	-3.0	CHEMBL5408	Homo sapiens	Inhibition	%	-3.0
	10833095	CHEMBL2007667	GSK_PKIS: TBK1 % inhibition at 1 uM [UNC Frye lab]	B	CCN(CC)S(=O)(=O)c1ccc(OC)c(Nc2ncc(-c3ccccc3)o2)c1		CHEMBL275473	=	Inhibition	%	2.0	CHEMBL5408	Homo sapiens	Inhibition	%	2.0
	10833096	CHEMBL2007667	GSK_PKIS: TBK1 % inhibition at 1 uM [UNC Frye lab]	B	Cn1cc(C=C2C(=O)Nc3cccnc32)c2ccccc21		CHEMBL1516890	=	Inhibition	%	18.0	CHEMBL5408	Homo sapiens	Inhibition	%	18.0
	10833097	CHEMBL2007667	GSK_PKIS: TBK1 % inhibition at 1 uM [UNC Frye lab]	B	Clc1ccc(-c2nn3ncccc3c2-c2ccnc(Nc3ccccc3)n2)cc1		CHEMBL189148	=	Inhibition	%	-2.0	CHEMBL5408	Homo sapiens	Inhibition	%	-2.0
	10833098	CHEMBL2007667	GSK_PKIS: TBK1 % inhibition at 1 uM [UNC Frye lab]	B	COc1ccccc1C1=C(Nc2ccccc2)C(=O)NC1=O		CHEMBL156263	=	Inhibition	%	5.0	CHEMBL5408	Homo sapiens	Inhibition	%	5.0
	10833099	CHEMBL2007667	GSK_PKIS: TBK1 % inhibition at 1 uM [UNC Frye lab]	B	CC(C)c1ccc2c(c1)NC(=O)/C2=N/Nc1ccc(S(N)(=O)=O)cc1		CHEMBL271594	=	Inhibition	%	-1.0	CHEMBL5408	Homo sapiens	Inhibition	%	-1.0
	10833100	CHEMBL2007667	GSK_PKIS: TBK1 % inhibition at 1 uM [UNC Frye lab]	B	NS(=O)(=O)c1ccc(Nc2cc(-c3ccc(O)c(F)c3)n[nH]2)cc1		CHEMBL103115	=	Inhibition	%	17.0	CHEMBL5408	Homo sapiens	Inhibition	%	17.0
	10833101	CHEMBL2007667	GSK_PKIS: TBK1 % inhibition at 1 uM [UNC Frye lab]	B	COc1cc(/C=N/Nc2ncnc3c2cnn3C(C)C)ccc1O		CHEMBL63728	=	Inhibition	%	9.0	CHEMBL5408	Homo sapiens	Inhibition	%	9.0
	10833102	CHEMBL2007667	GSK_PKIS: TBK1 % inhibition at 1 uM [UNC Frye lab]	B	CCc1cccc(CC)c1/C=C/c1cncc(C(=O)NC)c1		CHEMBL385426	=	Inhibition	%	-2.0	CHEMBL5408	Homo sapiens	Inhibition	%	-2.0
	10833103	CHEMBL2007667	GSK_PKIS: TBK1 % inhibition at 1 uM [UNC Frye lab]	B	N#Cc1ccc(Oc2nccc(-c3c(-c4ccc(F)cc4)ncn3C3CCNCC3)n2)cc1		CHEMBL13972	=	Inhibition	%	3.0	CHEMBL5408	Homo sapiens	Inhibition	%	3.0
	10833104	CHEMBL2007667	GSK_PKIS: TBK1 % inhibition at 1 uM [UNC Frye lab]	B	CN(c1ccc(NC(=O)NCCN2CCOCC2)cc1)c1ccnc(Nc2ccc(CS(C)(=O)=O)cc2)n1.Cl		CHEMBL1909361	=	Inhibition	%	2.0	CHEMBL5408	Homo sapiens	Inhibition	%	2.0
	10833105	CHEMBL2007667	GSK_PKIS: TBK1 % inhibition at 1 uM [UNC Frye lab]	B	CCCN(CCS(C)(=O)=O)Cc1ccc(-c2ccc3ncnc(Nc4ccc(OCc5cccc(F)c5)c(Cl)c4)c3c2)o1.Cl		CHEMBL1909394	=	Inhibition	%	10.0	CHEMBL5408	Homo sapiens	Inhibition	%	10.0
	10833106	CHEMBL2007667	GSK_PKIS: TBK1 % inhibition at 1 uM [UNC Frye lab]	B	CCCN1CCC(Oc2cc(Nc3nc(Nc4cccc(F)c4C(N)=O)c4cc[nH]c4n3)c(OC)cc2Cl)CC1		CHEMBL517171	=	Inhibition	%	-3.0	CHEMBL5408	Homo sapiens	Inhibition	%	-3.0
	10833107	CHEMBL2007667	GSK_PKIS: TBK1 % inhibition at 1 uM [UNC Frye lab]	B	CC(C)(C)c1ccc(Oc2nccc(-c3c(-c4ccc(F)cc4)ncn3C3CCNCC3)n2)cc1		CHEMBL275200	=	Inhibition	%	0.0	CHEMBL5408	Homo sapiens	Inhibition	%	0.0
	10833108	CHEMBL2007667	GSK_PKIS: TBK1 % inhibition at 1 uM [UNC Frye lab]	B	COc1ccc2cc(-c3c(-c4ccncc4)nc(-c4ccc([S+](C)[O-])cc4C)n3C)ccc2c1		CHEMBL237570	=	Inhibition	%	-3.0	CHEMBL5408	Homo sapiens	Inhibition	%	-3.0
	10833109	CHEMBL2007667	GSK_PKIS: TBK1 % inhibition at 1 uM [UNC Frye lab]	B	COC(=O)Nc1nc2ccc(Oc3ccc(NC(=O)Nc4cccc(Cl)c4)cc3)cc2[nH]1.Cl		CHEMBL1909364	=	Inhibition	%	0.0	CHEMBL5408	Homo sapiens	Inhibition	%	0.0
	10833110	CHEMBL2007667	GSK_PKIS: TBK1 % inhibition at 1 uM [UNC Frye lab]	B	CN1CCC(C(=O)Nc2n[nH]c3nnc(-c4ccccc4)cc23)CC1.Cl		CHEMBL1909344	=	Inhibition	%	-7.0	CHEMBL5408	Homo sapiens	Inhibition	%	-7.0
	10833111	CHEMBL2007667	GSK_PKIS: TBK1 % inhibition at 1 uM [UNC Frye lab]	B	CN1CCC(n2cnc(-c3ccc(F)cc3)c2-c2ccnc(NCCO)n2)CC1		CHEMBL330422	=	Inhibition	%	-9.0	CHEMBL5408	Homo sapiens	Inhibition	%	-9.0
	10833112	CHEMBL2007667	GSK_PKIS: TBK1 % inhibition at 1 uM [UNC Frye lab]	B	CCn1c(-c2nonc2N)nc2ccccc21		CHEMBL365286	=	Inhibition	%	-3.0	CHEMBL5408	Homo sapiens	Inhibition	%	-3.0
	10833113	CHEMBL2007667	GSK_PKIS: TBK1 % inhibition at 1 uM [UNC Frye lab]	B	Cc1ccc(C(=O)NC2CCC2)cc1-c1ccc(C(=O)NCC2CC2)cc1		CHEMBL517507	=	Inhibition	%	-6.0	CHEMBL5408	Homo sapiens	Inhibition	%	-6.0
	10833114	CHEMBL2007667	GSK_PKIS: TBK1 % inhibition at 1 uM [UNC Frye lab]	B	CN1CCN(C(=O)c2ccc(NC(=O)Nc3ccc(N(C)c4ccnc(Nc5ccc(CS(C)(=O)=O)cc5)n4)cc3)cc2)CC1.Cl		CHEMBL1909360	=	Inhibition	%	13.0	CHEMBL5408	Homo sapiens	Inhibition	%	13.0
	10833115	CHEMBL2007667	GSK_PKIS: TBK1 % inhibition at 1 uM [UNC Frye lab]	B	NS(=O)(=O)c1ccc(N/C=C2\C(=O)Nc3ccc4ncsc4c32)cc1		CHEMBL271595	=	Inhibition	%	86.0	CHEMBL5408	Homo sapiens	Inhibition	%	86.0
	10833116	CHEMBL2007667	GSK_PKIS: TBK1 % inhibition at 1 uM [UNC Frye lab]	B	NC(=O)c1ccc(Oc2nccc(-c3c(-c4ccc(F)cc4)ncn3C3CCNCC3)n2)cc1		CHEMBL275724	=	Inhibition	%	4.0	CHEMBL5408	Homo sapiens	Inhibition	%	4.0
	10833117	CHEMBL2007667	GSK_PKIS: TBK1 % inhibition at 1 uM [UNC Frye lab]	B	CS(=O)(=O)Nc1ccc(N/C=C2\C(=O)Nc3ccccc32)cc1		CHEMBL1794058	=	Inhibition	%	20.0	CHEMBL5408	Homo sapiens	Inhibition	%	20.0
	10833118	CHEMBL2007667	GSK_PKIS: TBK1 % inhibition at 1 uM [UNC Frye lab]	B	O=C(O)/C=C/C(=O)O.OCCCNc1nccc(-c2c(-c3ccc(F)cc3)nn3cc(C(F)(F)F)ccc23)n1		CHEMBL1909403	=	Inhibition	%	-5.0	CHEMBL5408	Homo sapiens	Inhibition	%	-5.0
	10833119	CHEMBL2007667	GSK_PKIS: TBK1 % inhibition at 1 uM [UNC Frye lab]	B	Cc1cc(Cl)cc2c1NC(=O)C2=NNc1ccc(S(N)(=O)=O)cc1		CHEMBL1909397	=	Inhibition	%	26.0	CHEMBL5408	Homo sapiens	Inhibition	%	26.0
	10833120	CHEMBL2007667	GSK_PKIS: TBK1 % inhibition at 1 uM [UNC Frye lab]	B	Cc1cccc2c1NC(=O)/C2=N\Nc1ccc(S(N)(=O)=O)cc1		CHEMBL1909398	=	Inhibition	%	0.0	CHEMBL5408	Homo sapiens	Inhibition	%	0.0
	10833121	CHEMBL2007667	GSK_PKIS: TBK1 % inhibition at 1 uM [UNC Frye lab]	B	NS(=O)(=O)c1ccc(N/N=C2\C(=O)Nc3ccc(C(=O)NCCc4c[nH]cn4)cc32)cc1		CHEMBL272028	=	Inhibition	%	29.0	CHEMBL5408	Homo sapiens	Inhibition	%	29.0
	10833122	CHEMBL2007667	GSK_PKIS: TBK1 % inhibition at 1 uM [UNC Frye lab]	B	COc1cccc(-n2cnc3c(N/N=C/c4ccncc4)ncnc32)c1		CHEMBL204934	=	Inhibition	%	-1.0	CHEMBL5408	Homo sapiens	Inhibition	%	-1.0
	10833123	CHEMBL2007667	GSK_PKIS: TBK1 % inhibition at 1 uM [UNC Frye lab]	B	CS(=O)(=O)CCNCc1ccc(-c2ccc3ncnc(Nc4ccc(OCc5cccc(F)c5)c(C(F)(F)F)c4)c3c2)o1		CHEMBL215814	=	Inhibition	%	1.0	CHEMBL5408	Homo sapiens	Inhibition	%	1.0
	10833124	CHEMBL2007667	GSK_PKIS: TBK1 % inhibition at 1 uM [UNC Frye lab]	B	CCc1nccc2c1nc(-c1nonc1N)n2CC		CHEMBL365072	=	Inhibition	%	-2.0	CHEMBL5408	Homo sapiens	Inhibition	%	-2.0
	10833125	CHEMBL2007667	GSK_PKIS: TBK1 % inhibition at 1 uM [UNC Frye lab]	B	CC1=C(C(=O)Nc2ccc3[nH]ncc3c2)C(c2ccc(Cl)c(Cl)c2)CC(=O)N1		CHEMBL374453	=	Inhibition	%	2.0	CHEMBL5408	Homo sapiens	Inhibition	%	2.0
	10833126	CHEMBL2007667	GSK_PKIS: TBK1 % inhibition at 1 uM [UNC Frye lab]	B	NS(=O)(=O)c1ccc(NC=C2C(=O)Nc3ccc4ncsc4c32)cc1		CHEMBL1794055	=	Inhibition	%	88.0	CHEMBL5408	Homo sapiens	Inhibition	%	88.0
	10833127	CHEMBL2007667	GSK_PKIS: TBK1 % inhibition at 1 uM [UNC Frye lab]	B	CCCNc1cccc(-n2ncc3c(N/N=C/c4ccncc4)ncnc32)c1		CHEMBL67241	=	Inhibition	%	18.0	CHEMBL5408	Homo sapiens	Inhibition	%	18.0
	10833128	CHEMBL2007667	GSK_PKIS: TBK1 % inhibition at 1 uM [UNC Frye lab]	B	N#Cc1c(NC(=O)c2ccccc2F)sc2c1CCCC2		CHEMBL234838	=	Inhibition	%	0.0	CHEMBL5408	Homo sapiens	Inhibition	%	0.0
	10833129	CHEMBL2007667	GSK_PKIS: TBK1 % inhibition at 1 uM [UNC Frye lab]	B	COc1cc(Nc2nccc(Nc3ccc4c(C)n[nH]c4c3)n2)cc(OC)c1OC		CHEMBL479079	=	Inhibition	%	30.0	CHEMBL5408	Homo sapiens	Inhibition	%	30.0
	10833130	CHEMBL2007667	GSK_PKIS: TBK1 % inhibition at 1 uM [UNC Frye lab]	B	NC(=O)c1cc(-c2ccncc2)cc(-c2ccccc2)c1N		CHEMBL230911	=	Inhibition	%	10.0	CHEMBL5408	Homo sapiens	Inhibition	%	10.0
	10833131	CHEMBL2007667	GSK_PKIS: TBK1 % inhibition at 1 uM [UNC Frye lab]	B	O=C1NC(=O)C(c2cccc(Cl)c2)=C1Nc1ccc(Cl)c(C(=O)O)c1		CHEMBL156987	=	Inhibition	%	18.0	CHEMBL5408	Homo sapiens	Inhibition	%	18.0
	10833132	CHEMBL2007667	GSK_PKIS: TBK1 % inhibition at 1 uM [UNC Frye lab]	B	COc1cc2ncn(-c3cc(OCc4cccs4)c(C(N)=O)s3)c2cc1OC		CHEMBL480382	=	Inhibition	%	33.0	CHEMBL5408	Homo sapiens	Inhibition	%	33.0
	10833133	CHEMBL2007667	GSK_PKIS: TBK1 % inhibition at 1 uM [UNC Frye lab]	B	Cl.Fc1cccc(COc2ccc(Nc3ncnc4cc(-c5ccc[nH]5)sc34)cc2Cl)c1		CHEMBL1909415	=	Inhibition	%	-4.0	CHEMBL5408	Homo sapiens	Inhibition	%	-4.0
	10833134	CHEMBL2007667	GSK_PKIS: TBK1 % inhibition at 1 uM [UNC Frye lab]	B	Clc1ccc(-c2nn3ncccc3c2-c2ccnc(Nc3ccccc3)n2)cc1		CHEMBL189148	=	Inhibition	%	-3.0	CHEMBL5408	Homo sapiens	Inhibition	%	-3.0
	10833135	CHEMBL2007667	GSK_PKIS: TBK1 % inhibition at 1 uM [UNC Frye lab]	B	CS(=O)(=O)CCNCc1cc(-c2cc3c(Nc4ccc(OCc5cccc(F)c5)c(Cl)c4)ncnc3s2)cs1		CHEMBL475599	=	Inhibition	%	0.0	CHEMBL5408	Homo sapiens	Inhibition	%	0.0
	10833136	CHEMBL2007667	GSK_PKIS: TBK1 % inhibition at 1 uM [UNC Frye lab]	B	Nc1ncnc2occ(-c3ccc(NC(=O)Nc4cc(C(F)(F)F)cc(C(F)(F)F)c4)cc3)c12		CHEMBL396107	=	Inhibition	%	-6.0	CHEMBL5408	Homo sapiens	Inhibition	%	-6.0
	10833137	CHEMBL2007667	GSK_PKIS: TBK1 % inhibition at 1 uM [UNC Frye lab]	B	NC(=O)c1cccc(Nc2nccc(Nc3cccc4[nH]ncc34)n2)c1		CHEMBL251549	=	Inhibition	%	45.0	CHEMBL5408	Homo sapiens	Inhibition	%	45.0
	10833138	CHEMBL2007667	GSK_PKIS: TBK1 % inhibition at 1 uM [UNC Frye lab]	B	C[C@@H](Oc1cc(-n2cnc3ccc(OC4CCN(C)CC4)cc32)sc1C(N)=O)c1ccccc1Cl		CHEMBL1794070	=	Inhibition	%	3.0	CHEMBL5408	Homo sapiens	Inhibition	%	3.0
	10833139	CHEMBL2007667	GSK_PKIS: TBK1 % inhibition at 1 uM [UNC Frye lab]	B	COc1cccc(-n2ncc3c(N/N=C/c4ccc(S(C)(=O)=O)cc4)ncnc32)c1		CHEMBL66292	=	Inhibition	%	30.0	CHEMBL5408	Homo sapiens	Inhibition	%	30.0
	10833140	CHEMBL2007667	GSK_PKIS: TBK1 % inhibition at 1 uM [UNC Frye lab]	B	CS(=O)(=O)CCNCc1ccc(-c2ccc3ncnc(Nc4ccc(OCc5ccccc5)c(Cl)c4)c3c2)o1.Cl		CHEMBL529066	=	Inhibition	%	0.0	CHEMBL5408	Homo sapiens	Inhibition	%	0.0
	10833141	CHEMBL2007667	GSK_PKIS: TBK1 % inhibition at 1 uM [UNC Frye lab]	B	Nc1ncnc2occ(-c3ccc(NC(=O)Nc4cccc(C(F)(F)F)c4)cc3)c12		CHEMBL273564	=	Inhibition	%	-1.0	CHEMBL5408	Homo sapiens	Inhibition	%	-1.0
	10833142	CHEMBL2007667	GSK_PKIS: TBK1 % inhibition at 1 uM [UNC Frye lab]	B	CS(=O)(=O)CCN(CC#N)Cc1ccc(-c2ccc3ncnc(Nc4ccc(OCc5cccc(F)c5)c(Cl)c4)c3c2)o1		CHEMBL384407	=	Inhibition	%	12.0	CHEMBL5408	Homo sapiens	Inhibition	%	12.0
	10833143	CHEMBL2007667	GSK_PKIS: TBK1 % inhibition at 1 uM [UNC Frye lab]	B	COc1cc(C)c(NC(=O)CN(C)C)cc1Nc1nc(Nc2cccc(F)c2C(N)=O)c2cc[nH]c2n1		CHEMBL511765	=	Inhibition	%	32.0	CHEMBL5408	Homo sapiens	Inhibition	%	32.0
	10833144	CHEMBL2007667	GSK_PKIS: TBK1 % inhibition at 1 uM [UNC Frye lab]	B	NC(=O)c1cc(-c2ccc(F)cc2)cc(-c2ccncc2)c1N		CHEMBL231623	=	Inhibition	%	16.0	CHEMBL5408	Homo sapiens	Inhibition	%	16.0
	10833145	CHEMBL2007667	GSK_PKIS: TBK1 % inhibition at 1 uM [UNC Frye lab]	B	CS(=O)(=O)CCNCc1nc(-c2ccc3ncnc(Nc4ccc(F)c(Cl)c4)c3c2)cs1.Cl		CHEMBL1909355	=	Inhibition	%	-2.0	CHEMBL5408	Homo sapiens	Inhibition	%	-2.0
	10833146	CHEMBL2007667	GSK_PKIS: TBK1 % inhibition at 1 uM [UNC Frye lab]	B	COc1cc(/C=N/Nc2ncnc3c2cnn3C(C)C)ccc1O		CHEMBL63728	=	Inhibition	%	8.0	CHEMBL5408	Homo sapiens	Inhibition	%	8.0
	10833147	CHEMBL2007667	GSK_PKIS: TBK1 % inhibition at 1 uM [UNC Frye lab]	B	COc1cccc(-n2ncc3c(N/N=C/c4ccc(F)cc4)ncnc32)c1		CHEMBL65884	=	Inhibition	%	11.0	CHEMBL5408	Homo sapiens	Inhibition	%	11.0
	10833148	CHEMBL2007667	GSK_PKIS: TBK1 % inhibition at 1 uM [UNC Frye lab]	B	O=C1NC(=O)C(c2ccccc2Cl)=C1Nc1cc(Cl)c(O)c(Cl)c1		CHEMBL157258	=	Inhibition	%	19.0	CHEMBL5408	Homo sapiens	Inhibition	%	19.0
	10833149	CHEMBL2007667	GSK_PKIS: TBK1 % inhibition at 1 uM [UNC Frye lab]	B	CCn1c(-c2nonc2N)nc2c(C#CC(C)(C)O)nc(OC[C@H](N)c3ccccc3)cc21		CHEMBL1096634	=	Inhibition	%	11.0	CHEMBL5408	Homo sapiens	Inhibition	%	11.0
	10833150	CHEMBL2007667	GSK_PKIS: TBK1 % inhibition at 1 uM [UNC Frye lab]	B	COc1cc2ncn(-c3cc(OCc4ccccc4C(F)(F)F)c(C(C)=O)s3)c2cc1OC		CHEMBL471789	=	Inhibition	%	-2.0	CHEMBL5408	Homo sapiens	Inhibition	%	-2.0
	10833151	CHEMBL2007667	GSK_PKIS: TBK1 % inhibition at 1 uM [UNC Frye lab]	B	CCn1c(-c2nonc2N)nc2c(C#CCN)ncc(OCCCN)c21.O=C(O)C(F)(F)F		CHEMBL1794064	=	Inhibition	%	4.0	CHEMBL5408	Homo sapiens	Inhibition	%	4.0
	10833152	CHEMBL2007667	GSK_PKIS: TBK1 % inhibition at 1 uM [UNC Frye lab]	B	COc1cc(C=NNc2ncnc3c2cnn3Cc2ccccc2)ccc1O		CHEMBL1789962	=	Inhibition	%	14.0	CHEMBL5408	Homo sapiens	Inhibition	%	14.0
	10833153	CHEMBL2007667	GSK_PKIS: TBK1 % inhibition at 1 uM [UNC Frye lab]	B	CS(=O)(=O)Nc1cccc(-c2ccc3c(NC(=O)C4CC4)n[nH]c3c2)c1		CHEMBL103080	=	Inhibition	%	5.0	CHEMBL5408	Homo sapiens	Inhibition	%	5.0
	10833154	CHEMBL2007667	GSK_PKIS: TBK1 % inhibition at 1 uM [UNC Frye lab]	B	O=C1Nc2ccccc2/C1=C/Nc1ccc(-n2cncn2)cc1		CHEMBL1794056	=	Inhibition	%	27.0	CHEMBL5408	Homo sapiens	Inhibition	%	27.0
	10833155	CHEMBL2007667	GSK_PKIS: TBK1 % inhibition at 1 uM [UNC Frye lab]	B	NS(=O)(=O)c1ccc(N/N=C2\C(=O)Nc3ccc(C(=O)NCc4ccncc4)cc32)cc1		CHEMBL272165	=	Inhibition	%	59.0	CHEMBL5408	Homo sapiens	Inhibition	%	59.0
	10833156	CHEMBL2007667	GSK_PKIS: TBK1 % inhibition at 1 uM [UNC Frye lab]	B	O=C(Nc1n[nH]c2nc(-c3ccc(O)cc3)c(Br)cc12)C1CC1		CHEMBL260417	=	Inhibition	%	33.0	CHEMBL5408	Homo sapiens	Inhibition	%	33.0
	10833157	CHEMBL2007667	GSK_PKIS: TBK1 % inhibition at 1 uM [UNC Frye lab]	B	CCS(=O)(=O)c1ccc(OC)c(Nc2ncc(-c3ccccc3Cl)o2)c1		CHEMBL179453	=	Inhibition	%	6.0	CHEMBL5408	Homo sapiens	Inhibition	%	6.0
	10833158	CHEMBL2007667	GSK_PKIS: TBK1 % inhibition at 1 uM [UNC Frye lab]	B	COc1ccc(-c2nn3ncccc3c2-c2ccnc(Nc3ccc(Cl)c(C(F)(F)F)c3)n2)cc1		CHEMBL188794	=	Inhibition	%	-3.0	CHEMBL5408	Homo sapiens	Inhibition	%	-3.0
	10833159	CHEMBL2007667	GSK_PKIS: TBK1 % inhibition at 1 uM [UNC Frye lab]	B	CCc1nccc2c1nc(-c1nonc1N)n2CC		CHEMBL365072	=	Inhibition	%	1.0	CHEMBL5408	Homo sapiens	Inhibition	%	1.0
	10833160	CHEMBL2007667	GSK_PKIS: TBK1 % inhibition at 1 uM [UNC Frye lab]	B	COc1ccc(Nc2ncc(-c3ccccc3)o2)cc1OC.Cl		CHEMBL1794060	=	Inhibition	%	20.0	CHEMBL5408	Homo sapiens	Inhibition	%	20.0
	10833161	CHEMBL2007667	GSK_PKIS: TBK1 % inhibition at 1 uM [UNC Frye lab]	B	COc1ccc(COc2ccc(Cc3cnc(N)nc3N)cc2OC)cc1		CHEMBL261849	=	Inhibition	%	-3.0	CHEMBL5408	Homo sapiens	Inhibition	%	-3.0
	10833162	CHEMBL2007667	GSK_PKIS: TBK1 % inhibition at 1 uM [UNC Frye lab]	B	CCc1nn2ncccc2c1-c1ccnc(NC2CC2)n1		CHEMBL524057	=	Inhibition	%	0.0	CHEMBL5408	Homo sapiens	Inhibition	%	0.0
	10833163	CHEMBL2007667	GSK_PKIS: TBK1 % inhibition at 1 uM [UNC Frye lab]	B	O=S(=O)(CCOCc1ccc(-c2ccc3ncnc(Nc4ccc(OCc5cccc(F)c5)c(Cl)c4)c3c2)o1)c1ccccc1		CHEMBL212250	=	Inhibition	%	1.0	CHEMBL5408	Homo sapiens	Inhibition	%	1.0
	10833164	CHEMBL2007667	GSK_PKIS: TBK1 % inhibition at 1 uM [UNC Frye lab]	B	COc1cc(C=NNc2ncnc3c2cnn3-c2ccccc2)ccc1O		CHEMBL1789961	=	Inhibition	%	42.0	CHEMBL5408	Homo sapiens	Inhibition	%	42.0
	10833165	CHEMBL2007667	GSK_PKIS: TBK1 % inhibition at 1 uM [UNC Frye lab]	B	Cc1ccc(C(=O)NC2CC2)cc1-c1ccc2[nH]ncc2c1		CHEMBL495902	=	Inhibition	%	2.0	CHEMBL5408	Homo sapiens	Inhibition	%	2.0
	10833166	CHEMBL2007667	GSK_PKIS: TBK1 % inhibition at 1 uM [UNC Frye lab]	B	Cc1nnc(-c2ccc(C)c(-c3ccc(C(=O)NCc4ccc(Cl)cc4)cc3)c2)o1		CHEMBL402108	=	Inhibition	%	4.0	CHEMBL5408	Homo sapiens	Inhibition	%	4.0
	10833167	CHEMBL2007667	GSK_PKIS: TBK1 % inhibition at 1 uM [UNC Frye lab]	B	N#Cc1c(NC(=O)c2ccccc2F)sc2c1CCCC2		CHEMBL234838	=	Inhibition	%	2.0	CHEMBL5408	Homo sapiens	Inhibition	%	2.0
	10833168	CHEMBL2007667	GSK_PKIS: TBK1 % inhibition at 1 uM [UNC Frye lab]	B	NC(=O)c1cc(-c2ccncc2)cc(-c2ccccc2)c1N		CHEMBL230911	=	Inhibition	%	13.0	CHEMBL5408	Homo sapiens	Inhibition	%	13.0
	10833169	CHEMBL2007667	GSK_PKIS: TBK1 % inhibition at 1 uM [UNC Frye lab]	B	Cc1ccc(NC(=O)CC2CC2)cc1-c1ccc(C(=O)NCC2CC2)cc1		CHEMBL516908	=	Inhibition	%	1.0	CHEMBL5408	Homo sapiens	Inhibition	%	1.0
	10833170	CHEMBL2007667	GSK_PKIS: TBK1 % inhibition at 1 uM [UNC Frye lab]	B	COC(=O)Nc1nc2cc(Oc3ccc(NC(=O)Nc4cccc(C(=O)O)c4)cc3)ccc2[nH]1.Cl		CHEMBL1909373	=	Inhibition	%	-5.0	CHEMBL5408	Homo sapiens	Inhibition	%	-5.0
	10833171	CHEMBL2007667	GSK_PKIS: TBK1 % inhibition at 1 uM [UNC Frye lab]	B	CCn1c(-c2nonc2N)nc2cncc(C(=O)N3CC[C@H](N)C3)c21.Cl		CHEMBL1909384	=	Inhibition	%	36.0	CHEMBL5408	Homo sapiens	Inhibition	%	36.0
	10833172	CHEMBL2007667	GSK_PKIS: TBK1 % inhibition at 1 uM [UNC Frye lab]	B	CN(C)CCNC(=O)Nc1ccc(N(C)c2ccnc(Nc3ccc(CS(C)(=O)=O)cc3)n2)cc1.Cl		CHEMBL1909362	=	Inhibition	%	-4.0	CHEMBL5408	Homo sapiens	Inhibition	%	-4.0
	10833173	CHEMBL2007667	GSK_PKIS: TBK1 % inhibition at 1 uM [UNC Frye lab]	B	COc1ccc2cc(-c3c(-c4ccncc4)nc(-c4ccc(S(C)(=O)=O)cc4C)n3C)ccc2c1		CHEMBL237571	=	Inhibition	%	-1.0	CHEMBL5408	Homo sapiens	Inhibition	%	-1.0
	10833174	CHEMBL2007667	GSK_PKIS: TBK1 % inhibition at 1 uM [UNC Frye lab]	B	FC(F)(F)c1ccc(-c2nn3ncccc3c2-c2ccnc(Nc3ccc4c(c3)OCCO4)n2)cc1		CHEMBL185939	=	Inhibition	%	-5.0	CHEMBL5408	Homo sapiens	Inhibition	%	-5.0
	10833175	CHEMBL2007667	GSK_PKIS: TBK1 % inhibition at 1 uM [UNC Frye lab]	B	Cc1nn(C)c2cc(N(C)c3ccnc(Nc4cccc(S(N)(=O)=O)c4)n3)ccc12.Cl		CHEMBL1794073	=	Inhibition	%	5.0	CHEMBL5408	Homo sapiens	Inhibition	%	5.0
	10833176	CHEMBL2007667	GSK_PKIS: TBK1 % inhibition at 1 uM [UNC Frye lab]	B	CN1CCC(n2cnc(-c3ccc(F)cc3)c2-c2ccnc(N)n2)CC1		CHEMBL95207	=	Inhibition	%	2.0	CHEMBL5408	Homo sapiens	Inhibition	%	2.0
	10833177	CHEMBL2007667	GSK_PKIS: TBK1 % inhibition at 1 uM [UNC Frye lab]	B	CCn1c(-c2nonc2N)nc2c(C#CC(C)(C)O)nc(OCCNC)cc21.Cl		CHEMBL1909350	=	Inhibition	%	19.0	CHEMBL5408	Homo sapiens	Inhibition	%	19.0
	10833178	CHEMBL2007667	GSK_PKIS: TBK1 % inhibition at 1 uM [UNC Frye lab]	B	CCS(=O)(=O)c1ccc(OC)c(Nc2ncc(-c3cccc(OC)c3)o2)c1		CHEMBL179311	=	Inhibition	%	8.0	CHEMBL5408	Homo sapiens	Inhibition	%	8.0
	10833179	CHEMBL2007667	GSK_PKIS: TBK1 % inhibition at 1 uM [UNC Frye lab]	B	CNC(=O)c1cncc(/C=C/c2c(C)cccc2C)c1		CHEMBL218859	=	Inhibition	%	-1.0	CHEMBL5408	Homo sapiens	Inhibition	%	-1.0
	10833180	CHEMBL2007667	GSK_PKIS: TBK1 % inhibition at 1 uM [UNC Frye lab]	B	CCn1c(-c2nonc2N)nc2c(C#CC(C)(C)O)nc(O[C@@H](CN)c3ccccc3)cc21.O=C(O)C(F)(F)F		CHEMBL1909349	=	Inhibition	%	87.0	CHEMBL5408	Homo sapiens	Inhibition	%	87.0
	10833181	CHEMBL2007667	GSK_PKIS: TBK1 % inhibition at 1 uM [UNC Frye lab]	B	Fc1ccc(-c2ncn(C3CCNCC3)c2-c2ccnc(Oc3ccc(Oc4ccccc4)cc3)n2)cc1		CHEMBL13868	=	Inhibition	%	2.0	CHEMBL5408	Homo sapiens	Inhibition	%	2.0
	10833182	CHEMBL2007667	GSK_PKIS: TBK1 % inhibition at 1 uM [UNC Frye lab]	B	N#Cc1c(NC(=O)c2ccc(F)cc2)sc2c1CCCC2		CHEMBL397570	=	Inhibition	%	-6.0	CHEMBL5408	Homo sapiens	Inhibition	%	-6.0
	10833183	CHEMBL2007667	GSK_PKIS: TBK1 % inhibition at 1 uM [UNC Frye lab]	B	Nc1nc(-c2ccc(F)cc2)c(-c2ccc3ncccc3n2)s1		CHEMBL361237	=	Inhibition	%	1.0	CHEMBL5408	Homo sapiens	Inhibition	%	1.0
	10833184	CHEMBL2007667	GSK_PKIS: TBK1 % inhibition at 1 uM [UNC Frye lab]	B	COc1ccc2[nH]c3c4[nH]c5ccc(OC)cc5c4c4c(c3c2c1)C(=O)NC4=O		CHEMBL1956068	=	Inhibition	%	55.0	CHEMBL5408	Homo sapiens	Inhibition	%	55.0
	10833185	CHEMBL2007667	GSK_PKIS: TBK1 % inhibition at 1 uM [UNC Frye lab]	B	CCN1CCC(CC(=O)Nc2n[nH]c3nc(-c4cccs4)c(Br)cc23)CC1.O=C(O)C(O)C(O)C(=O)O		CHEMBL2062290	=	Inhibition	%	6.0	CHEMBL5408	Homo sapiens	Inhibition	%	6.0
	10833186	CHEMBL2007667	GSK_PKIS: TBK1 % inhibition at 1 uM [UNC Frye lab]	B	CS(=O)(=O)CCNCc1ccc(-c2ccc3ncnc(Nc4ccc(OCc5ccccc5)cc4)c3c2)o1.Cl		CHEMBL1909385	=	Inhibition	%	-2.0	CHEMBL5408	Homo sapiens	Inhibition	%	-2.0
	10833187	CHEMBL2007667	GSK_PKIS: TBK1 % inhibition at 1 uM [UNC Frye lab]	B	CS(=O)(=O)c1ccc(Oc2nccc(-c3c(-c4ccc(F)cc4)ncn3C3CCNCC3)n2)cc1		CHEMBL418348	=	Inhibition	%	3.0	CHEMBL5408	Homo sapiens	Inhibition	%	3.0
	10833188	CHEMBL2007667	GSK_PKIS: TBK1 % inhibition at 1 uM [UNC Frye lab]	B	Cc1cccc(Oc2nccc(-c3c(-c4ccc(F)cc4)ncn3C3CCNCC3)n2)c1C.O=C(O)C(F)(F)F		CHEMBL1909400	=	Inhibition	%	2.0	CHEMBL5408	Homo sapiens	Inhibition	%	2.0
	10833189	CHEMBL2007667	GSK_PKIS: TBK1 % inhibition at 1 uM [UNC Frye lab]	B	COC(=O)c1sc(-n2cnc3cc(OC)c(OC)cc32)cc1OCc1ccccc1C(F)(F)F		CHEMBL473420	=	Inhibition	%	39.0	CHEMBL5408	Homo sapiens	Inhibition	%	39.0
	10833190	CHEMBL2007667	GSK_PKIS: TBK1 % inhibition at 1 uM [UNC Frye lab]	B	O=C([O-])c1ccc(Oc2nccc(-c3c(-c4ccc(F)cc4)ncn3C3CCNCC3)n2)cc1.[Li+]		CHEMBL1909401	=	Inhibition	%	-6.0	CHEMBL5408	Homo sapiens	Inhibition	%	-6.0
	10833191	CHEMBL2007667	GSK_PKIS: TBK1 % inhibition at 1 uM [UNC Frye lab]	B	COc1ccc(-c2nn3ncccc3c2-c2ccnc(Nc3ccc(F)c(F)c3)n2)cc1		CHEMBL427159	=	Inhibition	%	-9.0	CHEMBL5408	Homo sapiens	Inhibition	%	-9.0
	10833192	CHEMBL2007667	GSK_PKIS: TBK1 % inhibition at 1 uM [UNC Frye lab]	B	Nc1nc(-c2ccccn2)c(-c2ccc3ncccc3n2)s1		CHEMBL181361	=	Inhibition	%	0.0	CHEMBL5408	Homo sapiens	Inhibition	%	0.0
	10833193	CHEMBL2007667	GSK_PKIS: TBK1 % inhibition at 1 uM [UNC Frye lab]	B	O=C1Nc2ccccc2/C1=C1\CCc2cc(O)ccc21		CHEMBL175321	=	Inhibition	%	25.0	CHEMBL5408	Homo sapiens	Inhibition	%	25.0
	10833194	CHEMBL2007667	GSK_PKIS: TBK1 % inhibition at 1 uM [UNC Frye lab]	B	NS(=O)(=O)c1ccc(N/N=C2\C(=O)Nc3ccc(C(=O)NCc4ccncc4)cc32)cc1		CHEMBL272165	=	Inhibition	%	60.0	CHEMBL5408	Homo sapiens	Inhibition	%	60.0
	10833195	CHEMBL2007667	GSK_PKIS: TBK1 % inhibition at 1 uM [UNC Frye lab]	B	COc1cc2ncn(-c3cc(OCc4ccccc4C(F)(F)F)c(C(=O)N(C)C)s3)c2cc1OC		CHEMBL482326	=	Inhibition	%	-1.0	CHEMBL5408	Homo sapiens	Inhibition	%	-1.0
	10833196	CHEMBL2007667	GSK_PKIS: TBK1 % inhibition at 1 uM [UNC Frye lab]	B	Cl.[O-][S+]1CCN(Cc2ccc(-c3ccc4ncnc(Nc5ccc(OCc6ccccc6)c(Cl)c5)c4c3)o2)CC1		CHEMBL1909393	=	Inhibition	%	-6.0	CHEMBL5408	Homo sapiens	Inhibition	%	-6.0
	10833197	CHEMBL2007667	GSK_PKIS: TBK1 % inhibition at 1 uM [UNC Frye lab]	B	CCN1CCC(C(=O)Nc2n[nH]c3nnc(-c4cccc(F)c4F)cc23)CC1.Cl		CHEMBL1909345	=	Inhibition	%	-6.0	CHEMBL5408	Homo sapiens	Inhibition	%	-6.0
	10833198	CHEMBL2007667	GSK_PKIS: TBK1 % inhibition at 1 uM [UNC Frye lab]	B	CC(=O)NCc1cccc(C#Cc2cncnc2Nc2ccc(OCc3cccc(F)c3)c(Cl)c2)c1		CHEMBL207247	=	Inhibition	%	-7.0	CHEMBL5408	Homo sapiens	Inhibition	%	-7.0
	10833199	CHEMBL2007667	GSK_PKIS: TBK1 % inhibition at 1 uM [UNC Frye lab]	B	NS(=O)(=O)c1ccc(N/N=C2\C(=O)Nc3ccc(Cl)cc32)cc1		CHEMBL270054	=	Inhibition	%	4.0	CHEMBL5408	Homo sapiens	Inhibition	%	4.0
	10833200	CHEMBL2007667	GSK_PKIS: TBK1 % inhibition at 1 uM [UNC Frye lab]	B	CNC(=O)c1cncc(/C=C/c2c(Cl)cccc2Cl)c1		CHEMBL263796	=	Inhibition	%	-1.0	CHEMBL5408	Homo sapiens	Inhibition	%	-1.0
	10833201	CHEMBL2007667	GSK_PKIS: TBK1 % inhibition at 1 uM [UNC Frye lab]	B	Cc1nc(-c2ccccc2)n2nc(NCCCN3CCOCC3)ncc12		CHEMBL486124	=	Inhibition	%	5.0	CHEMBL5408	Homo sapiens	Inhibition	%	5.0
	10833202	CHEMBL2007667	GSK_PKIS: TBK1 % inhibition at 1 uM [UNC Frye lab]	B	CN(C)CCCNc1nccc(-c2c(-c3ccc(F)cc3)nn3cc(C(F)(F)F)ccc23)n1.CS(=O)(=O)O		CHEMBL1909405	=	Inhibition	%	-1.0	CHEMBL5408	Homo sapiens	Inhibition	%	-1.0
	10833203	CHEMBL2007667	GSK_PKIS: TBK1 % inhibition at 1 uM [UNC Frye lab]	B	COc1ccc(COc2ccc(Cc3cnc(N)nc3N)cc2OC)cc1		CHEMBL261849	=	Inhibition	%	-2.0	CHEMBL5408	Homo sapiens	Inhibition	%	-2.0
	10833204	CHEMBL2007667	GSK_PKIS: TBK1 % inhibition at 1 uM [UNC Frye lab]	B	Cc1cc(O)cc(C)c1/C=C/c1cncc(C(N)=O)c1		CHEMBL218088	=	Inhibition	%	-6.0	CHEMBL5408	Homo sapiens	Inhibition	%	-6.0
	10833205	CHEMBL2007667	GSK_PKIS: TBK1 % inhibition at 1 uM [UNC Frye lab]	B	CCc1nn2ncccc2c1-c1ccnc(NC2CC2)n1		CHEMBL524057	=	Inhibition	%	-2.0	CHEMBL5408	Homo sapiens	Inhibition	%	-2.0
	10833206	CHEMBL2007667	GSK_PKIS: TBK1 % inhibition at 1 uM [UNC Frye lab]	B	Nc1nccc(-c2c(-c3ccc(F)cc3)ncn2C2CCC(O)CC2)n1		CHEMBL1888586	=	Inhibition	%	-2.0	CHEMBL5408	Homo sapiens	Inhibition	%	-2.0
	10833207	CHEMBL2007667	GSK_PKIS: TBK1 % inhibition at 1 uM [UNC Frye lab]	B	CCCN1CCC=C(c2ccc(Nc3nc(Nc4ccccc4C(N)=O)c4cc[nH]c4n3)c(C)c2)C1		CHEMBL513897	=	Inhibition	%	24.0	CHEMBL5408	Homo sapiens	Inhibition	%	24.0
	10833208	CHEMBL2007667	GSK_PKIS: TBK1 % inhibition at 1 uM [UNC Frye lab]	B	COC(=O)Nc1nc2cc(Oc3ccc(NC(=O)Nc4cccc(C(=O)O)c4)cc3)ccc2[nH]1.Cl		CHEMBL1909373	=	Inhibition	%	-2.0	CHEMBL5408	Homo sapiens	Inhibition	%	-2.0
	10833209	CHEMBL2007667	GSK_PKIS: TBK1 % inhibition at 1 uM [UNC Frye lab]	B	CN1CCN(c2ccc(Nc3nccc(-c4cnn5ncccc45)n3)cc2C(F)(F)F)CC1		CHEMBL468963	=	Inhibition	%	77.0	CHEMBL5408	Homo sapiens	Inhibition	%	77.0
	10833210	CHEMBL2007667	GSK_PKIS: TBK1 % inhibition at 1 uM [UNC Frye lab]	B	O=C(Nc1n[nH]c2cc(-c3ccccc3)ccc12)C1CC1		CHEMBL405021	=	Inhibition	%	0.0	CHEMBL5408	Homo sapiens	Inhibition	%	0.0
	10833211	CHEMBL2007667	GSK_PKIS: TBK1 % inhibition at 1 uM [UNC Frye lab]	B	COc1cc(Nc2ncc(-c3ccccc3)o2)cc(OC)c1		CHEMBL176553	=	Inhibition	%	0.0	CHEMBL5408	Homo sapiens	Inhibition	%	0.0
	10833212	CHEMBL2007667	GSK_PKIS: TBK1 % inhibition at 1 uM [UNC Frye lab]	B	CC1=C(C(=O)Nc2ccc3[nH]ncc3c2)C(c2ccc(F)cc2)NC(=O)N1		CHEMBL384073	=	Inhibition	%	-2.0	CHEMBL5408	Homo sapiens	Inhibition	%	-2.0
	10833213	CHEMBL2007667	GSK_PKIS: TBK1 % inhibition at 1 uM [UNC Frye lab]	B	FC(F)(F)c1ccc(-c2nn3ncccc3c2-c2ccnc(Nc3ccc4c(c3)OCCO4)n2)cc1		CHEMBL185939	=	Inhibition	%	-7.0	CHEMBL5408	Homo sapiens	Inhibition	%	-7.0
	10833214	CHEMBL2007667	GSK_PKIS: TBK1 % inhibition at 1 uM [UNC Frye lab]	B	Fc1ccc(-c2nn3ncccc3c2-c2ccnc(Nc3ccc4c(c3)OCCO4)n2)cc1		CHEMBL365297	=	Inhibition	%	-2.0	CHEMBL5408	Homo sapiens	Inhibition	%	-2.0
	10833215	CHEMBL2007667	GSK_PKIS: TBK1 % inhibition at 1 uM [UNC Frye lab]	B	CN(C)CCCn1c(-c2nonc2N)nc2cnccc21		CHEMBL191105	=	Inhibition	%	0.0	CHEMBL5408	Homo sapiens	Inhibition	%	0.0
	10833216	CHEMBL2007667	GSK_PKIS: TBK1 % inhibition at 1 uM [UNC Frye lab]	B	COc1ccc2ncnc(Nc3ccc(OCc4ccccc4)cc3)c2c1.Cl		CHEMBL1909411	=	Inhibition	%	-2.0	CHEMBL5408	Homo sapiens	Inhibition	%	-2.0
	10833217	CHEMBL2007667	GSK_PKIS: TBK1 % inhibition at 1 uM [UNC Frye lab]	B	NCc1ccc(-n2c(-c3nonc3N)nc3cnccc32)cc1		CHEMBL188268	=	Inhibition	%	5.0	CHEMBL5408	Homo sapiens	Inhibition	%	5.0
	10833218	CHEMBL2007667	GSK_PKIS: TBK1 % inhibition at 1 uM [UNC Frye lab]	B	C[C@@H](Oc1cc(-n2cnc3ccc(OCC4CCN(C)CC4)cc32)sc1C(N)=O)c1ccccc1Cl		CHEMBL1794069	=	Inhibition	%	8.0	CHEMBL5408	Homo sapiens	Inhibition	%	8.0
	10833219	CHEMBL2007667	GSK_PKIS: TBK1 % inhibition at 1 uM [UNC Frye lab]	B	N#Cc1c(NC(=O)c2cccc3ccccc23)sc2c1CCCC2		CHEMBL233001	=	Inhibition	%	-3.0	CHEMBL5408	Homo sapiens	Inhibition	%	-3.0
	10833220	CHEMBL2007667	GSK_PKIS: TBK1 % inhibition at 1 uM [UNC Frye lab]	B	Fc1ccc(-c2ncn(C3CCNCC3)c2-c2ccnc(Oc3ccc(F)c(F)c3)n2)cc1		CHEMBL1785004	=	Inhibition	%	0.0	CHEMBL5408	Homo sapiens	Inhibition	%	0.0
	10833221	CHEMBL2007667	GSK_PKIS: TBK1 % inhibition at 1 uM [UNC Frye lab]	B	COc1cc2ncn(-c3cc(O[C@@H](C)c4ccccc4Cl)c(C(N)=O)s3)c2cc1OC		CHEMBL521806	=	Inhibition	%	54.0	CHEMBL5408	Homo sapiens	Inhibition	%	54.0
	10833222	CHEMBL2007667	GSK_PKIS: TBK1 % inhibition at 1 uM [UNC Frye lab]	B	NC(=O)c1cc(-c2ccc(F)cc2)cc(-c2ccncc2)c1N		CHEMBL231623	=	Inhibition	%	21.0	CHEMBL5408	Homo sapiens	Inhibition	%	21.0
	10833223	CHEMBL2007667	GSK_PKIS: TBK1 % inhibition at 1 uM [UNC Frye lab]	B	NC(=O)Cc1ccccc1Oc1nccc(-c2c(-c3ccc(F)cc3)ncn2C2CCNCC2)n1		CHEMBL1785002	=	Inhibition	%	-1.0	CHEMBL5408	Homo sapiens	Inhibition	%	-1.0
	10833224	CHEMBL2007667	GSK_PKIS: TBK1 % inhibition at 1 uM [UNC Frye lab]	B	Fc1ccc(Oc2nccc(-c3c(-c4ccc(F)cc4)ncn3C3CCNCC3)n2)cc1		CHEMBL269450	=	Inhibition	%	4.0	CHEMBL5408	Homo sapiens	Inhibition	%	4.0
	10833225	CHEMBL2007667	GSK_PKIS: TBK1 % inhibition at 1 uM [UNC Frye lab]	B	NC(=O)c1cccc(Nc2nccc(Nc3cccc4[nH]ncc34)n2)c1		CHEMBL251549	=	Inhibition	%	44.0	CHEMBL5408	Homo sapiens	Inhibition	%	44.0
	10833226	CHEMBL2007667	GSK_PKIS: TBK1 % inhibition at 1 uM [UNC Frye lab]	B	CS(=O)(=O)CCNCc1ccoc1-c1ccc2ncnc(Nc3ccc(OCc4ccccc4)cc3)c2c1.Cl		CHEMBL1909388	=	Inhibition	%	2.0	CHEMBL5408	Homo sapiens	Inhibition	%	2.0
	10833227	CHEMBL2007667	GSK_PKIS: TBK1 % inhibition at 1 uM [UNC Frye lab]	B	CCS(=O)(=O)c1ccc(OC)c(Nc2ncc(-c3cccc(C(C)=O)c3)o2)c1		CHEMBL191705	=	Inhibition	%	5.0	CHEMBL5408	Homo sapiens	Inhibition	%	5.0
	10833228	CHEMBL2007667	GSK_PKIS: TBK1 % inhibition at 1 uM [UNC Frye lab]	B	CS(=O)(=O)CCNCc1ccc(-c2ccc3ncnc(Nc4ccc(OCc5ccccc5)c(Br)c4)c3c2)o1.Cl		CHEMBL1909392	=	Inhibition	%	1.0	CHEMBL5408	Homo sapiens	Inhibition	%	1.0
	10833229	CHEMBL2007667	GSK_PKIS: TBK1 % inhibition at 1 uM [UNC Frye lab]	B	O=C(O)C(F)(F)F.[O-][S+]1CCN(Cc2ccc(-c3ccc4ncnc(Nc5ccc(OCc6cccc(F)c6)c(Cl)c5)c4c3)o2)CC1		CHEMBL1909390	=	Inhibition	%	0.0	CHEMBL5408	Homo sapiens	Inhibition	%	0.0
	10833230	CHEMBL2007667	GSK_PKIS: TBK1 % inhibition at 1 uM [UNC Frye lab]	B	COc1cc2ncn(-c3cc(O[C@@H](C)c4ccccc4Cl)c(C(N)=O)s3)c2cc1OC		CHEMBL521806	=	Inhibition	%	57.0	CHEMBL5408	Homo sapiens	Inhibition	%	57.0
	10833231	CHEMBL2007667	GSK_PKIS: TBK1 % inhibition at 1 uM [UNC Frye lab]	B	COc1cccc(-n2ncc3c(N/N=C/c4ccc(C)cc4)ncnc32)c1		CHEMBL303687	=	Inhibition	%	2.0	CHEMBL5408	Homo sapiens	Inhibition	%	2.0
	10833232	CHEMBL2007667	GSK_PKIS: TBK1 % inhibition at 1 uM [UNC Frye lab]	B	NC(=O)Cc1ccccc1Oc1nccc(-c2c(-c3ccc(F)cc3)ncn2C2CCNCC2)n1		CHEMBL1785002	=	Inhibition	%	-2.0	CHEMBL5408	Homo sapiens	Inhibition	%	-2.0
	10833233	CHEMBL2007667	GSK_PKIS: TBK1 % inhibition at 1 uM [UNC Frye lab]	B	Cc1c2ccc(N(C)c3ccnc(Nc4cccc(S(N)(=O)=O)c4)n3)cc2nn1C.Cl		CHEMBL1909359	=	Inhibition	%	2.0	CHEMBL5408	Homo sapiens	Inhibition	%	2.0
	10833234	CHEMBL2007667	GSK_PKIS: TBK1 % inhibition at 1 uM [UNC Frye lab]	B	Clc1ccc(CNc2nccc(-c3cnn4ncccc34)n2)cc1		CHEMBL513330	=	Inhibition	%	0.0	CHEMBL5408	Homo sapiens	Inhibition	%	0.0
	10833235	CHEMBL2007667	GSK_PKIS: TBK1 % inhibition at 1 uM [UNC Frye lab]	B	O=C(Nc1n[nH]c2cc(-c3cc(F)ccc3F)ccc12)C1CC1		CHEMBL261440	=	Inhibition	%	-2.0	CHEMBL5408	Homo sapiens	Inhibition	%	-2.0
	10833236	CHEMBL2007667	GSK_PKIS: TBK1 % inhibition at 1 uM [UNC Frye lab]	B	COc1ccc2[nH]c3c4[nH]c5ccc(OC)cc5c4c4c(c3c2c1)C(=O)NC4=O		CHEMBL1956068	=	Inhibition	%	56.0	CHEMBL5408	Homo sapiens	Inhibition	%	56.0
	10833237	CHEMBL2007667	GSK_PKIS: TBK1 % inhibition at 1 uM [UNC Frye lab]	B	COc1cc2ncn(-c3cc(OCc4ccccc4S(C)(=O)=O)c(C#N)s3)c2cc1OC		CHEMBL373751	=	Inhibition	%	101.0	CHEMBL5408	Homo sapiens	Inhibition	%	101.0
	10833238	CHEMBL2007667	GSK_PKIS: TBK1 % inhibition at 1 uM [UNC Frye lab]	B	CS(=O)(=O)c1ccc(Oc2nccc(-c3c(-c4ccc(F)cc4)ncn3C3CCNCC3)n2)cc1		CHEMBL418348	=	Inhibition	%	5.0	CHEMBL5408	Homo sapiens	Inhibition	%	5.0
	10833239	CHEMBL2007667	GSK_PKIS: TBK1 % inhibition at 1 uM [UNC Frye lab]	B	Cc1cccc(Oc2nccc(-c3c(-c4ccc(F)cc4)ncn3C3CCNCC3)n2)c1C.O=C(O)C(F)(F)F		CHEMBL1909400	=	Inhibition	%	4.0	CHEMBL5408	Homo sapiens	Inhibition	%	4.0
	10833240	CHEMBL2007667	GSK_PKIS: TBK1 % inhibition at 1 uM [UNC Frye lab]	B	COC(=O)Nc1nc2ccc(Oc3ccc(NC(=O)Nc4cccc(Cl)c4)cc3)cc2[nH]1.Cl		CHEMBL1909364	=	Inhibition	%	2.0	CHEMBL5408	Homo sapiens	Inhibition	%	2.0
	10833241	CHEMBL2007667	GSK_PKIS: TBK1 % inhibition at 1 uM [UNC Frye lab]	B	CCc1ccc(Oc2nccc(-c3c(-c4ccc(F)cc4)ncn3C3CCNCC3)n2)cc1		CHEMBL428877	=	Inhibition	%	-3.0	CHEMBL5408	Homo sapiens	Inhibition	%	-3.0
	10833242	CHEMBL2007667	GSK_PKIS: TBK1 % inhibition at 1 uM [UNC Frye lab]	B	O=C1Nc2ccccc2/C1=C1\CCc2cc(O)ccc21		CHEMBL175321	=	Inhibition	%	30.0	CHEMBL5408	Homo sapiens	Inhibition	%	30.0
	10833243	CHEMBL2007667	GSK_PKIS: TBK1 % inhibition at 1 uM [UNC Frye lab]	B	NS(=O)(=O)c1ccc(-c2ccc3c(NC(=O)C4CC4)n[nH]c3c2)cc1		CHEMBL103098	=	Inhibition	%	0.0	CHEMBL5408	Homo sapiens	Inhibition	%	0.0
	10833244	CHEMBL2007667	GSK_PKIS: TBK1 % inhibition at 1 uM [UNC Frye lab]	B	COc1ccc(-c2ccc3c(NC(=O)C4CC4)n[nH]c3n2)cc1		CHEMBL408732	=	Inhibition	%	5.0	CHEMBL5408	Homo sapiens	Inhibition	%	5.0
	10833245	CHEMBL2007667	GSK_PKIS: TBK1 % inhibition at 1 uM [UNC Frye lab]	B	COc1cc2ncn(-c3cc(OCc4ccccc4C(F)(F)F)c(C(=O)N(C)C)s3)c2cc1OC		CHEMBL482326	=	Inhibition	%	0.0	CHEMBL5408	Homo sapiens	Inhibition	%	0.0
	10833246	CHEMBL2007667	GSK_PKIS: TBK1 % inhibition at 1 uM [UNC Frye lab]	B	COc1ccc2ncn(-c3cc(O[C@H](C)c4ccccc4C(F)(F)F)c(C(N)=O)s3)c2c1		CHEMBL522709	=	Inhibition	%	-6.0	CHEMBL5408	Homo sapiens	Inhibition	%	-6.0
	10833247	CHEMBL2007667	GSK_PKIS: TBK1 % inhibition at 1 uM [UNC Frye lab]	B	CCn1c(-c2nonc2N)nc2c(N3CCCC3)nccc21		CHEMBL187985	=	Inhibition	%	-4.0	CHEMBL5408	Homo sapiens	Inhibition	%	-4.0
	10833248	CHEMBL2007667	GSK_PKIS: TBK1 % inhibition at 1 uM [UNC Frye lab]	B	CS(=O)(=O)CCNCc1nc(-c2ccc3ncnc(Nc4ccc(OCc5cccc(C(F)(F)F)c5)cc4)c3c2)cs1.Cl		CHEMBL1909356	=	Inhibition	%	1.0	CHEMBL5408	Homo sapiens	Inhibition	%	1.0
	10833249	CHEMBL2007667	GSK_PKIS: TBK1 % inhibition at 1 uM [UNC Frye lab]	B	Cc1nc(-c2ccccc2)n2nc(NCCCN3CCOCC3)ncc12		CHEMBL486124	=	Inhibition	%	8.0	CHEMBL5408	Homo sapiens	Inhibition	%	8.0
	10833250	CHEMBL2007667	GSK_PKIS: TBK1 % inhibition at 1 uM [UNC Frye lab]	B	CN(C)CCCNc1nccc(-c2c(-c3ccc(F)cc3)nn3cc(C(F)(F)F)ccc23)n1.CS(=O)(=O)O		CHEMBL1909405	=	Inhibition	%	2.0	CHEMBL5408	Homo sapiens	Inhibition	%	2.0
	10833251	CHEMBL2007667	GSK_PKIS: TBK1 % inhibition at 1 uM [UNC Frye lab]	B	NS(=O)(=O)c1ccc(-c2cc3ccncc3cc2OCc2ccccc2)cc1		CHEMBL483748	=	Inhibition	%	0.0	CHEMBL5408	Homo sapiens	Inhibition	%	0.0
	10833252	CHEMBL2007667	GSK_PKIS: TBK1 % inhibition at 1 uM [UNC Frye lab]	B	c1cnn2ncc(-c3ccnc(Nc4ccc5c(c4)OCCO5)n3)c2c1		CHEMBL361894	=	Inhibition	%	33.0	CHEMBL5408	Homo sapiens	Inhibition	%	33.0
	10833253	CHEMBL2007667	GSK_PKIS: TBK1 % inhibition at 1 uM [UNC Frye lab]	B	CN(C)CCOc1ccc(-c2cc(-c3ccc4c(c3)CCC4=NO)c(-c3ccncc3)o2)cc1.Cl		CHEMBL1794072	=	Inhibition	%	6.0	CHEMBL5408	Homo sapiens	Inhibition	%	6.0
	10833254	CHEMBL2007667	GSK_PKIS: TBK1 % inhibition at 1 uM [UNC Frye lab]	B	CCOc1nccc2c1nc(-c1nonc1N)n2CC		CHEMBL188240	=	Inhibition	%	0.0	CHEMBL5408	Homo sapiens	Inhibition	%	0.0
	10833255	CHEMBL2007667	GSK_PKIS: TBK1 % inhibition at 1 uM [UNC Frye lab]	B	COc1cc(Nc2ncc(-c3ccccc3)o2)cc(OC)c1		CHEMBL176553	=	Inhibition	%	3.0	CHEMBL5408	Homo sapiens	Inhibition	%	3.0
	10833256	CHEMBL2007667	GSK_PKIS: TBK1 % inhibition at 1 uM [UNC Frye lab]	B	Nc1nccc(-c2c(-c3ccc(F)cc3)ncn2CCCN2CCOCC2)n1		CHEMBL274863	=	Inhibition	%	1.0	CHEMBL5408	Homo sapiens	Inhibition	%	1.0
	10833257	CHEMBL2007667	GSK_PKIS: TBK1 % inhibition at 1 uM [UNC Frye lab]	B	CC1=C(C(=O)Nc2ccc3[nH]ncc3c2)C(c2ccc(F)cc2)NC(=O)N1		CHEMBL384073	=	Inhibition	%	0.0	CHEMBL5408	Homo sapiens	Inhibition	%	0.0
	10833258	CHEMBL2007667	GSK_PKIS: TBK1 % inhibition at 1 uM [UNC Frye lab]	B	COc1cc(N2CCN(C(C)C)CC2)ccc1Nc1nc(Nc2cccc(F)c2C(=O)O)c2cc[nH]c2n1		CHEMBL514261	=	Inhibition	%	0.0	CHEMBL5408	Homo sapiens	Inhibition	%	0.0
	10833259	CHEMBL2007667	GSK_PKIS: TBK1 % inhibition at 1 uM [UNC Frye lab]	B	COc1ccc2cc(-c3c(-c4ccncc4)nc(-c4ccc([S+](C)[O-])cc4)n3C)ccc2c1		CHEMBL399410	=	Inhibition	%	0.0	CHEMBL5408	Homo sapiens	Inhibition	%	0.0
	10833260	CHEMBL2007667	GSK_PKIS: TBK1 % inhibition at 1 uM [UNC Frye lab]	B	C/C(Nc1ccc(S(N)(=O)=O)cc1)=C1/C(=O)Nc2ccccc21		CHEMBL405042	=	Inhibition	%	14.0	CHEMBL5408	Homo sapiens	Inhibition	%	14.0
	10833261	CHEMBL2007667	GSK_PKIS: TBK1 % inhibition at 1 uM [UNC Frye lab]	B	Cc1ccc(NC(=O)c2ccoc2)cc1-c1ccc(C(=O)NCC2CC2)cc1		CHEMBL477583	=	Inhibition	%	2.0	CHEMBL5408	Homo sapiens	Inhibition	%	2.0
	10834080	CHEMBL2013355	Inhibition of recombinant TBK1 using 5FAM-AhxKRRAL(ps)VASLPGL as substrate by microfluidic mobility shift assay	B	CNc1c(Br)cnc2[nH]c(-c3ccc(OCCN4CCCCC4)cc3)nc12		CHEMBL2011895	=	IC50	nM	151.0	CHEMBL5408	Homo sapiens	IC50	uM	0.151
	10834081	CHEMBL2013355	Inhibition of recombinant TBK1 using 5FAM-AhxKRRAL(ps)VASLPGL as substrate by microfluidic mobility shift assay	B	Brc1cnc2[nH]c(-c3ccc(OCCN4CCCCC4)cc3)nc2c1NC1CCCC1		CHEMBL2011896	=	IC50	nM	1220.0	CHEMBL5408	Homo sapiens	IC50	uM	1.22
	10834082	CHEMBL2013355	Inhibition of recombinant TBK1 using 5FAM-AhxKRRAL(ps)VASLPGL as substrate by microfluidic mobility shift assay	B	CN(C)CCCNc1c(Br)cnc2[nH]c(-c3ccc(OCCN4CCCCC4)cc3)nc12		CHEMBL2011897	=	IC50	nM	2290.0	CHEMBL5408	Homo sapiens	IC50	uM	2.29
	10834083	CHEMBL2013355	Inhibition of recombinant TBK1 using 5FAM-AhxKRRAL(ps)VASLPGL as substrate by microfluidic mobility shift assay	B	CN(C)CCNc1c(Br)cnc2[nH]c(-c3ccc(OCCN4CCCCC4)cc3)nc12		CHEMBL2011898	=	IC50	nM	10300.0	CHEMBL5408	Homo sapiens	IC50	uM	10.3
	10834084	CHEMBL2013355	Inhibition of recombinant TBK1 using 5FAM-AhxKRRAL(ps)VASLPGL as substrate by microfluidic mobility shift assay	B	Brc1cnc2[nH]c(-c3ccc(OCCN4CCCCC4)cc3)nc2c1NCC1CCNCC1		CHEMBL2011899	=	IC50	nM	105.0	CHEMBL5408	Homo sapiens	IC50	uM	0.105
	10834085	CHEMBL2013355	Inhibition of recombinant TBK1 using 5FAM-AhxKRRAL(ps)VASLPGL as substrate by microfluidic mobility shift assay	B	Brc1cnc2[nH]c(-c3ccc(OCCN4CCCCC4)cc3)nc2c1NCCC1CCNCC1		CHEMBL2011900	=	IC50	nM	468.0	CHEMBL5408	Homo sapiens	IC50	uM	0.468
	10834086	CHEMBL2013355	Inhibition of recombinant TBK1 using 5FAM-AhxKRRAL(ps)VASLPGL as substrate by microfluidic mobility shift assay	B	CNc1c(C#N)cnc2[nH]c(-c3ccc(OCCN4CCCCC4)cc3)nc12		CHEMBL2011901	=	IC50	nM	426.0	CHEMBL5408	Homo sapiens	IC50	uM	0.426
	10834087	CHEMBL2013355	Inhibition of recombinant TBK1 using 5FAM-AhxKRRAL(ps)VASLPGL as substrate by microfluidic mobility shift assay	B	Clc1c(Br)cnc2[nH]c(-c3ccc(OCCN4CCCCC4)cc3)nc12		CHEMBL2011902	=	IC50	nM	2740.0	CHEMBL5408	Homo sapiens	IC50	uM	2.74
	10834088	CHEMBL2013355	Inhibition of recombinant TBK1 using 5FAM-AhxKRRAL(ps)VASLPGL as substrate by microfluidic mobility shift assay	B	CNc1c(Br)cnc2[nH]c(-c3ccc(OC)cc3)nc12		CHEMBL2011903	=	IC50	nM	335.0	CHEMBL5408	Homo sapiens	IC50	uM	0.335
	10834089	CHEMBL2013355	Inhibition of recombinant TBK1 using 5FAM-AhxKRRAL(ps)VASLPGL as substrate by microfluidic mobility shift assay	B	CCOc1ccc(-c2nc3c(NC)c(Br)cnc3[nH]2)cc1		CHEMBL2011904	=	IC50	nM	231.0	CHEMBL5408	Homo sapiens	IC50	uM	0.231
	10834090	CHEMBL2013355	Inhibition of recombinant TBK1 using 5FAM-AhxKRRAL(ps)VASLPGL as substrate by microfluidic mobility shift assay	B	CNc1c(Br)cnc2[nH]c(-c3ccc(OC(C)C)cc3)nc12		CHEMBL2011905	=	IC50	nM	1410.0	CHEMBL5408	Homo sapiens	IC50	uM	1.41
	10834091	CHEMBL2013355	Inhibition of recombinant TBK1 using 5FAM-AhxKRRAL(ps)VASLPGL as substrate by microfluidic mobility shift assay	B	CNc1c(Br)cnc2[nH]c(-c3ccc(O)cc3)nc12		CHEMBL2011906	=	IC50	nM	201.0	CHEMBL5408	Homo sapiens	IC50	uM	0.201
	10834092	CHEMBL2013355	Inhibition of recombinant TBK1 using 5FAM-AhxKRRAL(ps)VASLPGL as substrate by microfluidic mobility shift assay	B	CNc1c(Br)cnc2[nH]c(-c3ccc(C(=O)O)cc3)nc12		CHEMBL2011907	=	IC50	nM	257.0	CHEMBL5408	Homo sapiens	IC50	uM	0.257
	10834093	CHEMBL2013355	Inhibition of recombinant TBK1 using 5FAM-AhxKRRAL(ps)VASLPGL as substrate by microfluidic mobility shift assay	B	CNc1c(Br)cnc2[nH]c(-c3ccc(S(C)(=O)=O)cc3)nc12		CHEMBL2011908	=	IC50	nM	229.0	CHEMBL5408	Homo sapiens	IC50	uM	0.229
	10834094	CHEMBL2013355	Inhibition of recombinant TBK1 using 5FAM-AhxKRRAL(ps)VASLPGL as substrate by microfluidic mobility shift assay	B	CNc1c(Br)cnc2[nH]c(-c3cccc(S(C)(=O)=O)c3)nc12		CHEMBL2011909	=	IC50	nM	9550.0	CHEMBL5408	Homo sapiens	IC50	uM	9.55
	10834095	CHEMBL2013355	Inhibition of recombinant TBK1 using 5FAM-AhxKRRAL(ps)VASLPGL as substrate by microfluidic mobility shift assay	B	CNc1c(Br)cnc2[nH]c(-c3cccc(N)c3)nc12		CHEMBL2011910	=	IC50	nM	65.0	CHEMBL5408	Homo sapiens	IC50	uM	0.065
	10834096	CHEMBL2013355	Inhibition of recombinant TBK1 using 5FAM-AhxKRRAL(ps)VASLPGL as substrate by microfluidic mobility shift assay	B	CNc1c(Br)cnc2[nH]c(-c3ccc(N)cc3)nc12		CHEMBL2011911	=	IC50	nM	111.0	CHEMBL5408	Homo sapiens	IC50	uM	0.111
	10834097	CHEMBL2013355	Inhibition of recombinant TBK1 using 5FAM-AhxKRRAL(ps)VASLPGL as substrate by microfluidic mobility shift assay	B	CNc1c(Br)cnc2[nH]c(-c3ccnc(N)c3)nc12		CHEMBL2011912	=	IC50	nM	93.0	CHEMBL5408	Homo sapiens	IC50	uM	0.093
	10834098	CHEMBL2013355	Inhibition of recombinant TBK1 using 5FAM-AhxKRRAL(ps)VASLPGL as substrate by microfluidic mobility shift assay	B	CNc1c(Br)cnc2[nH]c(-c3ccc(OC)c(OC)c3)nc12		CHEMBL2011913	=	IC50	nM	345.0	CHEMBL5408	Homo sapiens	IC50	uM	0.345
	10834099	CHEMBL2013355	Inhibition of recombinant TBK1 using 5FAM-AhxKRRAL(ps)VASLPGL as substrate by microfluidic mobility shift assay	B	CNc1c(Br)cnc2[nH]c(-c3ccc(N4CCCC4)cc3)nc12		CHEMBL2011914	=	IC50	nM	388.0	CHEMBL5408	Homo sapiens	IC50	uM	0.388
	10834100	CHEMBL2013355	Inhibition of recombinant TBK1 using 5FAM-AhxKRRAL(ps)VASLPGL as substrate by microfluidic mobility shift assay	B	CNc1c(Br)cnc2[nH]c(-c3ccc(N4CCOCC4)cc3)nc12		CHEMBL2011915	=	IC50	nM	213.0	CHEMBL5408	Homo sapiens	IC50	uM	0.213
	10834101	CHEMBL2013355	Inhibition of recombinant TBK1 using 5FAM-AhxKRRAL(ps)VASLPGL as substrate by microfluidic mobility shift assay	B	CNc1c(Br)cnc2[nH]c(-c3ccc(OCCCN4CCOCC4)cc3)nc12		CHEMBL2011916	=	IC50	nM	233.0	CHEMBL5408	Homo sapiens	IC50	uM	0.233
	10834102	CHEMBL2013355	Inhibition of recombinant TBK1 using 5FAM-AhxKRRAL(ps)VASLPGL as substrate by microfluidic mobility shift assay	B	CNc1c(Br)cnc2[nH]c(-c3ccc(OCCN4CCOCC4)cc3)nc12		CHEMBL2011917	=	IC50	nM	178.0	CHEMBL5408	Homo sapiens	IC50	uM	0.178
	10834103	CHEMBL2013355	Inhibition of recombinant TBK1 using 5FAM-AhxKRRAL(ps)VASLPGL as substrate by microfluidic mobility shift assay	B	CNc1c(Br)cnc2[nH]c(-c3ccc(OCCN4CCN(C)CC4)cc3)nc12		CHEMBL2011918	=	IC50	nM	106.0	CHEMBL5408	Homo sapiens	IC50	uM	0.106
	10834104	CHEMBL2013355	Inhibition of recombinant TBK1 using 5FAM-AhxKRRAL(ps)VASLPGL as substrate by microfluidic mobility shift assay	B	CNc1c(Br)cnc2[nH]c(-c3ccc(C(=O)NCCN4CCN(C)CC4)cc3)nc12		CHEMBL2011919	=	IC50	nM	196.0	CHEMBL5408	Homo sapiens	IC50	uM	0.196
	10834105	CHEMBL2013355	Inhibition of recombinant TBK1 using 5FAM-AhxKRRAL(ps)VASLPGL as substrate by microfluidic mobility shift assay	B	CNc1c(Br)cnc2[nH]c(-c3cnn(C4CCN(C)CC4)c3)nc12		CHEMBL2011920	=	IC50	nM	192.0	CHEMBL5408	Homo sapiens	IC50	uM	0.192
	10834106	CHEMBL2013355	Inhibition of recombinant TBK1 using 5FAM-AhxKRRAL(ps)VASLPGL as substrate by microfluidic mobility shift assay	B	CNc1c(Br)cnc2[nH]c(-c3ccc4[nH]ncc4c3)nc12		CHEMBL2011921	=	IC50	nM	288.0	CHEMBL5408	Homo sapiens	IC50	uM	0.288
	10834107	CHEMBL2013355	Inhibition of recombinant TBK1 using 5FAM-AhxKRRAL(ps)VASLPGL as substrate by microfluidic mobility shift assay	B	CNc1c(Br)cnc2[nH]c(-c3cnn(C)c3)nc12		CHEMBL2011922	=	IC50	nM	1520.0	CHEMBL5408	Homo sapiens	IC50	uM	1.52
	10834108	CHEMBL2013355	Inhibition of recombinant TBK1 using 5FAM-AhxKRRAL(ps)VASLPGL as substrate by microfluidic mobility shift assay	B	CNc1c(C(N)=O)cnc2[nH]c(-c3ccc(OCCN4CCOCC4)cc3)nc12		CHEMBL2011923	=	IC50	nM	162.0	CHEMBL5408	Homo sapiens	IC50	uM	0.162
	10834109	CHEMBL2013355	Inhibition of recombinant TBK1 using 5FAM-AhxKRRAL(ps)VASLPGL as substrate by microfluidic mobility shift assay	B	CNc1c(Cl)cnc2[nH]c(-c3ccc(OCCN4CCOCC4)cc3)nc12		CHEMBL2011924	=	IC50	nM	383.0	CHEMBL5408	Homo sapiens	IC50	uM	0.383
	10834110	CHEMBL2013355	Inhibition of recombinant TBK1 using 5FAM-AhxKRRAL(ps)VASLPGL as substrate by microfluidic mobility shift assay	B	CNc1ccnc2[nH]c(-c3ccc(OCCN4CCOCC4)cc3)nc12		CHEMBL2011925	=	IC50	nM	12000.0	CHEMBL5408	Homo sapiens	IC50	uM	12.0
	10834111	CHEMBL2013355	Inhibition of recombinant TBK1 using 5FAM-AhxKRRAL(ps)VASLPGL as substrate by microfluidic mobility shift assay	B	COc1ccc(-c2nc3c(NCC4CCNCC4)c(Br)cnc3[nH]2)cc1		CHEMBL2011926	=	IC50	nM	57.0	CHEMBL5408	Homo sapiens	IC50	uM	0.057
	10834112	CHEMBL2013355	Inhibition of recombinant TBK1 using 5FAM-AhxKRRAL(ps)VASLPGL as substrate by microfluidic mobility shift assay	B	COc1ccc(-c2nc3c(OCC4CCNCC4)c(Br)cnc3[nH]2)cc1		CHEMBL2011927	=	IC50	nM	39.0	CHEMBL5408	Homo sapiens	IC50	uM	0.039
	10834113	CHEMBL2013355	Inhibition of recombinant TBK1 using 5FAM-AhxKRRAL(ps)VASLPGL as substrate by microfluidic mobility shift assay	B	COc1ccc(-c2nc3c(NCCCNC(C)=O)c(Br)cnc3[nH]2)cc1		CHEMBL2011928	=	IC50	nM	70.0	CHEMBL5408	Homo sapiens	IC50	uM	0.07
	10834114	CHEMBL2013355	Inhibition of recombinant TBK1 using 5FAM-AhxKRRAL(ps)VASLPGL as substrate by microfluidic mobility shift assay	B	COc1ccc(-c2nc3c(NCCCNC(=O)C(C)C)c(Br)cnc3[nH]2)cc1		CHEMBL2011929	=	IC50	nM	10.0	CHEMBL5408	Homo sapiens	IC50	uM	0.01
	10834115	CHEMBL2013355	Inhibition of recombinant TBK1 using 5FAM-AhxKRRAL(ps)VASLPGL as substrate by microfluidic mobility shift assay	B	COc1ccc(-c2nc3c(NCCCNC(=O)C(C)(C)C)c(Br)cnc3[nH]2)cc1		CHEMBL2011930	=	IC50	nM	7.0	CHEMBL5408	Homo sapiens	IC50	uM	0.007
	10834116	CHEMBL2013355	Inhibition of recombinant TBK1 using 5FAM-AhxKRRAL(ps)VASLPGL as substrate by microfluidic mobility shift assay	B	COc1ccc(-c2nc3c(NCCCNC(=O)C4CC4)c(Br)cnc3[nH]2)cc1		CHEMBL2011931	=	IC50	nM	18.0	CHEMBL5408	Homo sapiens	IC50	uM	0.018
	10834117	CHEMBL2013355	Inhibition of recombinant TBK1 using 5FAM-AhxKRRAL(ps)VASLPGL as substrate by microfluidic mobility shift assay	B	COc1ccc(-c2nc3c(NCCCNC(=O)C4(CN)CC4)c(Br)cnc3[nH]2)cc1		CHEMBL2011932	=	IC50	nM	4.0	CHEMBL5408	Homo sapiens	IC50	uM	0.004
	10834118	CHEMBL2013355	Inhibition of recombinant TBK1 using 5FAM-AhxKRRAL(ps)VASLPGL as substrate by microfluidic mobility shift assay	B	COc1ccc(-c2nc3c(NCCCNC(=O)C4CCC4)c(Br)cnc3[nH]2)cc1		CHEMBL2011933	=	IC50	nM	4.0	CHEMBL5408	Homo sapiens	IC50	uM	0.004
	10834119	CHEMBL2013355	Inhibition of recombinant TBK1 using 5FAM-AhxKRRAL(ps)VASLPGL as substrate by microfluidic mobility shift assay	B	COc1ccc(-c2nc3c(NCCCN(C)C(=O)C4CCC4)c(Br)cnc3[nH]2)cc1		CHEMBL2011934	=	IC50	nM	5.0	CHEMBL5408	Homo sapiens	IC50	uM	0.005
	10834120	CHEMBL2013355	Inhibition of recombinant TBK1 using 5FAM-AhxKRRAL(ps)VASLPGL as substrate by microfluidic mobility shift assay	B	COc1ccc(-c2nc3c(NCCCNC(=O)C4CC(O)C4)c(Br)cnc3[nH]2)cc1		CHEMBL2011935	=	IC50	nM	8.0	CHEMBL5408	Homo sapiens	IC50	uM	0.008
	10834121	CHEMBL2013355	Inhibition of recombinant TBK1 using 5FAM-AhxKRRAL(ps)VASLPGL as substrate by microfluidic mobility shift assay	B	COc1ccc(-c2nc3c(NCCCNC(=O)C4CCCC4)c(Br)cnc3[nH]2)cc1		CHEMBL2011936	=	IC50	nM	10.0	CHEMBL5408	Homo sapiens	IC50	uM	0.01
	10834122	CHEMBL2013355	Inhibition of recombinant TBK1 using 5FAM-AhxKRRAL(ps)VASLPGL as substrate by microfluidic mobility shift assay	B	COc1ccc(-c2nc3c(NCCCNC(=O)c4ccccc4)c(Br)cnc3[nH]2)cc1		CHEMBL2011937	=	IC50	nM	106.0	CHEMBL5408	Homo sapiens	IC50	uM	0.106
	10834123	CHEMBL2013355	Inhibition of recombinant TBK1 using 5FAM-AhxKRRAL(ps)VASLPGL as substrate by microfluidic mobility shift assay	B	COc1ccc(-c2nc3c(NCCCNC(=O)c4cccnc4)c(Br)cnc3[nH]2)cc1		CHEMBL2011938	=	IC50	nM	59.0	CHEMBL5408	Homo sapiens	IC50	uM	0.059
	10834124	CHEMBL2013355	Inhibition of recombinant TBK1 using 5FAM-AhxKRRAL(ps)VASLPGL as substrate by microfluidic mobility shift assay	B	COc1ccc(-c2nc3c(NCCCNC(=O)c4cccs4)c(Br)cnc3[nH]2)cc1		CHEMBL2011939	=	IC50	nM	46.0	CHEMBL5408	Homo sapiens	IC50	uM	0.046
	10834125	CHEMBL2013355	Inhibition of recombinant TBK1 using 5FAM-AhxKRRAL(ps)VASLPGL as substrate by microfluidic mobility shift assay	B	Nc1cccc(-c2nc3c(NCCCNC(=O)C4CCC4)c(Br)cnc3[nH]2)c1		CHEMBL2011940	=	IC50	nM	3.0	CHEMBL5408	Homo sapiens	IC50	uM	0.003
	10834126	CHEMBL2013355	Inhibition of recombinant TBK1 using 5FAM-AhxKRRAL(ps)VASLPGL as substrate by microfluidic mobility shift assay	B	O=C(NCCCNc1c(Br)cnc2[nH]c(-c3ccc(OCCN4CCCCC4)cc3)nc12)C1CCC1		CHEMBL2011941	=	IC50	nM	4.0	CHEMBL5408	Homo sapiens	IC50	uM	0.004
	10834127	CHEMBL2013355	Inhibition of recombinant TBK1 using 5FAM-AhxKRRAL(ps)VASLPGL as substrate by microfluidic mobility shift assay	B	NC(=O)c1cnc2[nH]c(-c3ccc(OCCN4CCCCC4)cc3)nc2c1NCCCNC(=O)C1CCC1		CHEMBL2011942	=	IC50	nM	4.0	CHEMBL5408	Homo sapiens	IC50	uM	0.004
	10834128	CHEMBL2013355	Inhibition of recombinant TBK1 using 5FAM-AhxKRRAL(ps)VASLPGL as substrate by microfluidic mobility shift assay	B	COc1ccc(-c2nc3c(NCCCNC(=O)C4CCCC4)c(C(N)=O)cnc3[nH]2)cc1		CHEMBL2011943	=	IC50	nM	9.0	CHEMBL5408	Homo sapiens	IC50	uM	0.009
	10834129	CHEMBL2013355	Inhibition of recombinant TBK1 using 5FAM-AhxKRRAL(ps)VASLPGL as substrate by microfluidic mobility shift assay	B	COc1ccccc1-c1nc2c(NCC(O)CNC(=O)C3CCC3)c(Br)cnc2[nH]1		CHEMBL2011944	=	IC50	nM	32.0	CHEMBL5408	Homo sapiens	IC50	uM	0.032
	10834130	CHEMBL2013355	Inhibition of recombinant TBK1 using 5FAM-AhxKRRAL(ps)VASLPGL as substrate by microfluidic mobility shift assay	B	COc1ccc(F)cc1-c1nc2c(NCCCNC(=O)C3CCC3)c(Br)cnc2[nH]1		CHEMBL2011945	=	IC50	nM	40.0	CHEMBL5408	Homo sapiens	IC50	uM	0.04
	10834131	CHEMBL2013355	Inhibition of recombinant TBK1 using 5FAM-AhxKRRAL(ps)VASLPGL as substrate by microfluidic mobility shift assay	B	COc1cc(F)ccc1-c1nc2c(NCCCNC(=O)C3CCC3)c(Br)cnc2[nH]1		CHEMBL2010815	=	IC50	nM	38.0	CHEMBL5408	Homo sapiens	IC50	uM	0.038
	10834184	CHEMBL2013353	Inhibition of TBK1-mediated NFkappaB activation expressed in ds-RNA activated HEK293 cells coexpressing TLR3 after 4.5 hrs by luciferase reporter gene assay	B	COc1ccc(-c2nc3c(NCC4CCNCC4)c(Br)cnc3[nH]2)cc1		CHEMBL2011926	=	EC50	nM	111.0	CHEMBL5408	Homo sapiens	EC50	uM	0.111
	10834185	CHEMBL2013353	Inhibition of TBK1-mediated NFkappaB activation expressed in ds-RNA activated HEK293 cells coexpressing TLR3 after 4.5 hrs by luciferase reporter gene assay	B	COc1ccc(-c2nc3c(OCC4CCNCC4)c(Br)cnc3[nH]2)cc1		CHEMBL2011927	=	EC50	nM	76.0	CHEMBL5408	Homo sapiens	EC50	uM	0.076
	10834186	CHEMBL2013353	Inhibition of TBK1-mediated NFkappaB activation expressed in ds-RNA activated HEK293 cells coexpressing TLR3 after 4.5 hrs by luciferase reporter gene assay	B	COc1ccc(-c2nc3c(NCCCNC(C)=O)c(Br)cnc3[nH]2)cc1		CHEMBL2011928	=	EC50	nM	73.0	CHEMBL5408	Homo sapiens	EC50	uM	0.073
	10834187	CHEMBL2013353	Inhibition of TBK1-mediated NFkappaB activation expressed in ds-RNA activated HEK293 cells coexpressing TLR3 after 4.5 hrs by luciferase reporter gene assay	B	COc1ccc(-c2nc3c(NCCCNC(=O)C(C)C)c(Br)cnc3[nH]2)cc1		CHEMBL2011929	=	EC50	nM	14.0	CHEMBL5408	Homo sapiens	EC50	uM	0.014
	10834188	CHEMBL2013353	Inhibition of TBK1-mediated NFkappaB activation expressed in ds-RNA activated HEK293 cells coexpressing TLR3 after 4.5 hrs by luciferase reporter gene assay	B	COc1ccc(-c2nc3c(NCCCNC(=O)C(C)(C)C)c(Br)cnc3[nH]2)cc1		CHEMBL2011930	=	EC50	nM	11.0	CHEMBL5408	Homo sapiens	EC50	uM	0.011
	10834189	CHEMBL2013353	Inhibition of TBK1-mediated NFkappaB activation expressed in ds-RNA activated HEK293 cells coexpressing TLR3 after 4.5 hrs by luciferase reporter gene assay	B	COc1ccc(-c2nc3c(NCCCNC(=O)C4CC4)c(Br)cnc3[nH]2)cc1		CHEMBL2011931	=	EC50	nM	25.0	CHEMBL5408	Homo sapiens	EC50	uM	0.025
	10834190	CHEMBL2013353	Inhibition of TBK1-mediated NFkappaB activation expressed in ds-RNA activated HEK293 cells coexpressing TLR3 after 4.5 hrs by luciferase reporter gene assay	B	COc1ccc(-c2nc3c(NCCCNC(=O)C4(CN)CC4)c(Br)cnc3[nH]2)cc1		CHEMBL2011932	=	EC50	nM	20.0	CHEMBL5408	Homo sapiens	EC50	uM	0.02
	10834191	CHEMBL2013353	Inhibition of TBK1-mediated NFkappaB activation expressed in ds-RNA activated HEK293 cells coexpressing TLR3 after 4.5 hrs by luciferase reporter gene assay	B	COc1ccc(-c2nc3c(NCCCNC(=O)C4CCC4)c(Br)cnc3[nH]2)cc1		CHEMBL2011933	=	EC50	nM	6.0	CHEMBL5408	Homo sapiens	EC50	uM	0.006
	10834715	CHEMBL2013353	Inhibition of TBK1-mediated NFkappaB activation expressed in ds-RNA activated HEK293 cells coexpressing TLR3 after 4.5 hrs by luciferase reporter gene assay	B	COc1ccc(-c2nc3c(NCCCN(C)C(=O)C4CCC4)c(Br)cnc3[nH]2)cc1		CHEMBL2011934	=	EC50	nM	6.0	CHEMBL5408	Homo sapiens	EC50	uM	0.006
	10834716	CHEMBL2013353	Inhibition of TBK1-mediated NFkappaB activation expressed in ds-RNA activated HEK293 cells coexpressing TLR3 after 4.5 hrs by luciferase reporter gene assay	B	COc1ccc(-c2nc3c(NCCCNC(=O)C4CC(O)C4)c(Br)cnc3[nH]2)cc1		CHEMBL2011935	=	EC50	nM	40.0	CHEMBL5408	Homo sapiens	EC50	uM	0.04
	10834717	CHEMBL2013353	Inhibition of TBK1-mediated NFkappaB activation expressed in ds-RNA activated HEK293 cells coexpressing TLR3 after 4.5 hrs by luciferase reporter gene assay	B	COc1ccc(-c2nc3c(NCCCNC(=O)C4CCCC4)c(Br)cnc3[nH]2)cc1		CHEMBL2011936	=	EC50	nM	8.0	CHEMBL5408	Homo sapiens	EC50	uM	0.008
	10834718	CHEMBL2013353	Inhibition of TBK1-mediated NFkappaB activation expressed in ds-RNA activated HEK293 cells coexpressing TLR3 after 4.5 hrs by luciferase reporter gene assay	B	COc1ccc(-c2nc3c(NCCCNC(=O)c4ccccc4)c(Br)cnc3[nH]2)cc1		CHEMBL2011937	=	EC50	nM	84.0	CHEMBL5408	Homo sapiens	EC50	uM	0.084
	10834719	CHEMBL2013353	Inhibition of TBK1-mediated NFkappaB activation expressed in ds-RNA activated HEK293 cells coexpressing TLR3 after 4.5 hrs by luciferase reporter gene assay	B	COc1ccc(-c2nc3c(NCCCNC(=O)c4cccnc4)c(Br)cnc3[nH]2)cc1		CHEMBL2011938	=	EC50	nM	87.0	CHEMBL5408	Homo sapiens	EC50	uM	0.087
	10834720	CHEMBL2013353	Inhibition of TBK1-mediated NFkappaB activation expressed in ds-RNA activated HEK293 cells coexpressing TLR3 after 4.5 hrs by luciferase reporter gene assay	B	COc1ccc(-c2nc3c(NCCCNC(=O)c4cccs4)c(Br)cnc3[nH]2)cc1		CHEMBL2011939	=	EC50	nM	26.0	CHEMBL5408	Homo sapiens	EC50	uM	0.026
	10834721	CHEMBL2013353	Inhibition of TBK1-mediated NFkappaB activation expressed in ds-RNA activated HEK293 cells coexpressing TLR3 after 4.5 hrs by luciferase reporter gene assay	B	Nc1cccc(-c2nc3c(NCCCNC(=O)C4CCC4)c(Br)cnc3[nH]2)c1		CHEMBL2011940	=	EC50	nM	4.0	CHEMBL5408	Homo sapiens	EC50	uM	0.004
	10834722	CHEMBL2013353	Inhibition of TBK1-mediated NFkappaB activation expressed in ds-RNA activated HEK293 cells coexpressing TLR3 after 4.5 hrs by luciferase reporter gene assay	B	O=C(NCCCNc1c(Br)cnc2[nH]c(-c3ccc(OCCN4CCCCC4)cc3)nc12)C1CCC1		CHEMBL2011941	=	EC50	nM	12.0	CHEMBL5408	Homo sapiens	EC50	uM	0.012
	10834723	CHEMBL2013353	Inhibition of TBK1-mediated NFkappaB activation expressed in ds-RNA activated HEK293 cells coexpressing TLR3 after 4.5 hrs by luciferase reporter gene assay	B	NC(=O)c1cnc2[nH]c(-c3ccc(OCCN4CCCCC4)cc3)nc2c1NCCCNC(=O)C1CCC1		CHEMBL2011942	=	EC50	nM	1460.0	CHEMBL5408	Homo sapiens	EC50	uM	1.46
	10834724	CHEMBL2013353	Inhibition of TBK1-mediated NFkappaB activation expressed in ds-RNA activated HEK293 cells coexpressing TLR3 after 4.5 hrs by luciferase reporter gene assay	B	COc1ccc(-c2nc3c(NCCCNC(=O)C4CCCC4)c(C(N)=O)cnc3[nH]2)cc1		CHEMBL2011943	=	EC50	nM	139.0	CHEMBL5408	Homo sapiens	EC50	uM	0.139
	10834725	CHEMBL2013353	Inhibition of TBK1-mediated NFkappaB activation expressed in ds-RNA activated HEK293 cells coexpressing TLR3 after 4.5 hrs by luciferase reporter gene assay	B	COc1ccccc1-c1nc2c(NCC(O)CNC(=O)C3CCC3)c(Br)cnc2[nH]1		CHEMBL2011944	=	EC50	nM	35.0	CHEMBL5408	Homo sapiens	EC50	uM	0.035
	10834726	CHEMBL2013353	Inhibition of TBK1-mediated NFkappaB activation expressed in ds-RNA activated HEK293 cells coexpressing TLR3 after 4.5 hrs by luciferase reporter gene assay	B	COc1ccc(F)cc1-c1nc2c(NCCCNC(=O)C3CCC3)c(Br)cnc2[nH]1		CHEMBL2011945	=	EC50	nM	17.0	CHEMBL5408	Homo sapiens	EC50	uM	0.017
	10834727	CHEMBL2013353	Inhibition of TBK1-mediated NFkappaB activation expressed in ds-RNA activated HEK293 cells coexpressing TLR3 after 4.5 hrs by luciferase reporter gene assay	B	COc1cc(F)ccc1-c1nc2c(NCCCNC(=O)C3CCC3)c(Br)cnc2[nH]1		CHEMBL2010815	=	EC50	nM	34.0	CHEMBL5408	Homo sapiens	EC50	uM	0.034
	10839492	CHEMBL2015523	Inhibition of TBK1 at 10 uM	B	COc1ccc2c3ccnc(C(F)(F)F)c3n(CCCCN)c2c1		CHEMBL2012574	=	Inhibition	%	4.0	CHEMBL5408	Homo sapiens	INH	%	4.0
	10839584	CHEMBL2015817	Inhibition of TBK1 assessed as residual activity at 10 uM relative to control	B	COc1cc(N2CCC(N3CCN(C)CC3)CC2)ccc1Nc1ncc(Cl)c(Nc2ccccc2S(=O)(=O)C(C)C)n1		CHEMBL509032	=	Activity	%	71.0	CHEMBL5408	Homo sapiens	Activity	%	71.0
	10840431	CHEMBL2014708	Inhibition of TBK1 assessed as residual activity at 1 uM relative to control	B	COc1cc(N2CCC(N3CCN(C)CC3)CC2)ccc1Nc1ncc(Cl)c(Nc2ccccc2S(=O)(=O)C(C)C)n1		CHEMBL509032	=	Activity	%	93.0	CHEMBL5408	Homo sapiens	Activity	%	93.0
	12047360	CHEMBL2157713	Inhibition of TBK1 at 1 uM	B	CC(C)(O)C1CCN(Cc2ccc3nc(-c4c(F)ccc5[nH]ccc45)nc(N4CCOCC4)c3n2)CC1		CHEMBL2152768	=	Inhibition	%	3.6	CHEMBL5408	Homo sapiens	INH	%	3.6
	12170726	CHEMBL2214634	Inhibition of TBK1 assessed as residual activity at 1 uM	B	O=C(Nc1cccnc1)c1cc(-c2ccnc(F)c2)ccc1OCc1ccccc1		CHEMBL2204495	=	Activity	%	97.0	CHEMBL5408	Homo sapiens	Activity	%	97.0
	12170857	CHEMBL2212724	Inhibition of TBK1 assessed as residual activity at 10 uM	B	O=C(Nc1cccnc1)c1cc(-c2ccnc(F)c2)ccc1OCc1ccccc1		CHEMBL2204495	=	Activity	%	88.0	CHEMBL5408	Homo sapiens	Activity	%	88.0
	12172186	CHEMBL2209264	Inhibition of TBK1 assessed as residual activity at 10 uM relative to control	B	O=C(Nc1cccnc1)c1cc(-c2ccnc(F)c2)ccc1OCc1ccccc1		CHEMBL2204495	=	Activity	%	68.0	CHEMBL5408	Homo sapiens	Activity	%	68.0
	12183804	CHEMBL2214457	Inhibition of TBK1	B	CC(C)(C)NS(=O)(=O)c1cncc(-c2ccn3nc(N)nc3c2)c1		CHEMBL2205766	<	IC50	nM	10000.0	CHEMBL5408	Homo sapiens	pIC50		5.0
	12190932	CHEMBL2213811	Inhibition of TBK1 by radiometry	B	CC(C)N1CCC(n2cc(Nc3ncc(C4CC4)c(NCCCNC(=O)C4CCC4)n3)cn2)CC1		CHEMBL2207216	=	IC50	nM	7.0	CHEMBL5408	Homo sapiens	IC50	nM	7.0
	12190933	CHEMBL2213811	Inhibition of TBK1 by radiometry	B	O=C(NCCCNc1nc(Nc2cnn(CCN3CCOCC3)c2)ncc1C1CC1)C1CCC1		CHEMBL2207215	=	IC50	nM	9.0	CHEMBL5408	Homo sapiens	IC50	nM	9.0
	12190934	CHEMBL2213811	Inhibition of TBK1 by radiometry	B	O=C(NCCCNc1nc(Nc2cnn(C3CCOCC3)c2)ncc1C1CC1)C1CCC1		CHEMBL2207214	=	IC50	nM	2.0	CHEMBL5408	Homo sapiens	IC50	nM	2.0
	12190935	CHEMBL2213811	Inhibition of TBK1 by radiometry	B	O=C(NCCCNc1nc(Nc2cnn(C3CCCC3)c2)ncc1C1CC1)C1CCC1		CHEMBL2207213	=	IC50	nM	4.0	CHEMBL5408	Homo sapiens	IC50	nM	4.0
	12190936	CHEMBL2213811	Inhibition of TBK1 by radiometry	B	O=C(NCCCNc1nc(Nc2cnn(C3CCC3)c2)ncc1C1CC1)C1CCC1		CHEMBL2207212	=	IC50	nM	2.0	CHEMBL5408	Homo sapiens	IC50	nM	2.0
	12190937	CHEMBL2213811	Inhibition of TBK1 by radiometry	B	O=C(NCCCNc1nc(Nc2cnn(C3CC3)c2)ncc1C1CC1)C1CCC1		CHEMBL2207211	=	IC50	nM	10.0	CHEMBL5408	Homo sapiens	IC50	nM	10.0
	12190938	CHEMBL2213811	Inhibition of TBK1 by radiometry	B	CCn1cc(Nc2ncc(C3CC3)c(NCCCNC(=O)C3CCC3)n2)cn1		CHEMBL2207210	=	IC50	nM	7.0	CHEMBL5408	Homo sapiens	IC50	nM	7.0
	12190939	CHEMBL2213811	Inhibition of TBK1 by radiometry	B	CC(C)n1cc(Nc2ncc(C3CC3)c(NCCCNC(=O)C3CCC3)n2)cn1		CHEMBL2207209	=	IC50	nM	4.0	CHEMBL5408	Homo sapiens	IC50	nM	4.0
	12190940	CHEMBL2213811	Inhibition of TBK1 by radiometry	B	Cn1cc(Nc2ncc(C3CC3)c(NCCCNC(=O)C3CCC3)n2)cn1		CHEMBL2207208	=	IC50	nM	8.0	CHEMBL5408	Homo sapiens	IC50	nM	8.0
	12190941	CHEMBL2213811	Inhibition of TBK1 by radiometry	B	Cn1ccc(Nc2ncc(C3CC3)c(NCCCNC(=O)C3CCC3)n2)n1		CHEMBL2207207	>	IC50	nM	1000.0	CHEMBL5408	Homo sapiens	IC50	nM	1000.0
	12190942	CHEMBL2213811	Inhibition of TBK1 by radiometry	B	Cc1nn(C)c2cc(Nc3ncc(C4CC4)c(NCCCNC(=O)C4CCC4)n3)ccc12		CHEMBL2207206	=	IC50	nM	7.0	CHEMBL5408	Homo sapiens	IC50	nM	7.0
	12190943	CHEMBL2213811	Inhibition of TBK1 by radiometry	B	Cn1ncc2cc(Nc3ncc(C4CC4)c(NCCCNC(=O)C4CCC4)n3)ccc21		CHEMBL2207205	=	IC50	nM	16.0	CHEMBL5408	Homo sapiens	IC50	nM	16.0
	12190944	CHEMBL2213811	Inhibition of TBK1 by radiometry	B	O=C(NCCCNc1nc(Nc2ccc3c(c2)CN(C2CC2)CC3)ncc1C1CC1)C1CCC1		CHEMBL2207204	=	IC50	nM	7.0	CHEMBL5408	Homo sapiens	IC50	nM	7.0
	12190945	CHEMBL2213811	Inhibition of TBK1 by radiometry	B	O=C(NCCCNc1nc(Nc2cncnc2)ncc1C1CC1)C1CCC1		CHEMBL2207203	=	IC50	nM	3200.0	CHEMBL5408	Homo sapiens	IC50	nM	3200.0
	12190946	CHEMBL2213811	Inhibition of TBK1 by radiometry	B	O=C(NCCCNc1nc(Nc2ccc(CN3CCCCC3)nc2)ncc1C1CC1)C1CCC1		CHEMBL2207202	=	IC50	nM	9.0	CHEMBL5408	Homo sapiens	IC50	nM	9.0
	12190947	CHEMBL2213811	Inhibition of TBK1 by radiometry	B	O=C(NCCCNc1nc(Nc2ccc(N3CCOCC3)nc2)ncc1C1CC1)C1CCC1		CHEMBL2207201	=	IC50	nM	15.0	CHEMBL5408	Homo sapiens	IC50	nM	15.0
	12190948	CHEMBL2213811	Inhibition of TBK1 by radiometry	B	O=C(NCCCNc1nc(Nc2cccnc2)ncc1C1CC1)C1CCC1		CHEMBL2207200	=	IC50	nM	13.0	CHEMBL5408	Homo sapiens	IC50	nM	13.0
	12190949	CHEMBL2213811	Inhibition of TBK1 by radiometry	B	O=C(NCCCNc1nc(Nc2ccc(-n3cncn3)cc2)ncc1C1CC1)C1CCC1		CHEMBL2207199	=	IC50	nM	3.0	CHEMBL5408	Homo sapiens	IC50	nM	3.0
	12190950	CHEMBL2213811	Inhibition of TBK1 by radiometry	B	O=C(NCCCNc1nc(Nc2ccc(N3CCOCC3)cc2)ncc1C1CC1)C1CCC1		CHEMBL2207198	=	IC50	nM	6.0	CHEMBL5408	Homo sapiens	IC50	nM	6.0
	12190951	CHEMBL2213811	Inhibition of TBK1 by radiometry	B	CN1CCC(c2ccc(Nc3ncc(C4CC4)c(NCCCNC(=O)C4CCC4)n3)cc2)CC1		CHEMBL2207197	=	IC50	nM	8.0	CHEMBL5408	Homo sapiens	IC50	nM	8.0
	12190952	CHEMBL2213811	Inhibition of TBK1 by radiometry	B	CN(C)Cc1ccc(Nc2ncc(C3CC3)c(NCCCNC(=O)C3CCC3)n2)cc1		CHEMBL2207196	=	IC50	nM	6.0	CHEMBL5408	Homo sapiens	IC50	nM	6.0
	12190953	CHEMBL2213811	Inhibition of TBK1 by radiometry	B	CN1CCN(C(=O)c2ccc(Nc3ncc(C4CC4)c(NCCCNC(=O)C4CCC4)n3)cc2)CC1		CHEMBL2207195	=	IC50	nM	2.0	CHEMBL5408	Homo sapiens	IC50	nM	2.0
	12190954	CHEMBL2213811	Inhibition of TBK1 by radiometry	B	O=C(NCCCNc1nc(Nc2cccc(Cn3cncn3)c2)ncc1C1CC1)C1CCC1		CHEMBL2207194	=	IC50	nM	3.0	CHEMBL5408	Homo sapiens	IC50	nM	3.0
	12190955	CHEMBL2213811	Inhibition of TBK1 by radiometry	B	O=C(NCCCNc1nc(Nc2cccc(N3CCOCC3)c2)ncc1C1CC1)C1CCC1		CHEMBL2207193	=	IC50	nM	28.0	CHEMBL5408	Homo sapiens	IC50	nM	28.0
	12190956	CHEMBL2213811	Inhibition of TBK1 by radiometry	B	O=C(NCCCNc1nc(Nc2cccc(-c3cnco3)c2)ncc1C1CC1)C1CCC1		CHEMBL2207192	=	IC50	nM	11.0	CHEMBL5408	Homo sapiens	IC50	nM	11.0
	12190957	CHEMBL2213811	Inhibition of TBK1 by radiometry	B	O=C(NCCCNc1nc(NC2CCCCC2)ncc1C1CC1)c1cccs1		CHEMBL2207191	>	IC50	nM	10000.0	CHEMBL5408	Homo sapiens	IC50	nM	10000.0
	12190958	CHEMBL2213811	Inhibition of TBK1 by radiometry	B	O=C(NCCCNc1nc(NCc2ccc(F)cc2)ncc1C1CC1)c1cccs1		CHEMBL2207190	>	IC50	nM	10000.0	CHEMBL5408	Homo sapiens	IC50	nM	10000.0
	12190959	CHEMBL2213811	Inhibition of TBK1 by radiometry	B	O=C(NCCCNc1nc(Nc2ccccc2F)ncc1C1CC1)c1cccs1		CHEMBL2207189	=	IC50	nM	820.0	CHEMBL5408	Homo sapiens	IC50	nM	820.0
	12190960	CHEMBL2213811	Inhibition of TBK1 by radiometry	B	O=C(NCCCNc1nc(Nc2cccc(F)c2)ncc1C1CC1)c1cccs1		CHEMBL2207188	=	IC50	nM	110.0	CHEMBL5408	Homo sapiens	IC50	nM	110.0
	12190961	CHEMBL2213811	Inhibition of TBK1 by radiometry	B	O=C(NCCCNc1nc(Nc2cccc(F)c2)ncc1C1CC1)C1CCC1		CHEMBL2207187	=	IC50	nM	8.0	CHEMBL5408	Homo sapiens	IC50	nM	8.0
	12190962	CHEMBL2213811	Inhibition of TBK1 by radiometry	B	O=C(NCCCNc1nc(Nc2cccc(F)c2)ncc1CC1CC1)C1CCC1		CHEMBL2207186	>	IC50	nM	1000.0	CHEMBL5408	Homo sapiens	IC50	nM	1000.0
	12190963	CHEMBL2213811	Inhibition of TBK1 by radiometry	B	CC(C)c1cnc(Nc2cccc(F)c2)nc1NCCCNC(=O)C1CCC1		CHEMBL2207185	>	IC50	nM	1000.0	CHEMBL5408	Homo sapiens	IC50	nM	1000.0
	12190964	CHEMBL2213811	Inhibition of TBK1 by radiometry	B	CCc1cnc(Nc2cccc(F)c2)nc1NCCCNC(=O)C1CCC1		CHEMBL2207184	=	IC50	nM	63.0	CHEMBL5408	Homo sapiens	IC50	nM	63.0
	12190965	CHEMBL2213811	Inhibition of TBK1 by radiometry	B	CC(=O)N1CCC(C(=O)NCCCNc2nc(Nc3cccc(F)c3)ncc2Br)CC1		CHEMBL2207183	=	IC50	nM	430.0	CHEMBL5408	Homo sapiens	IC50	nM	430.0
	12190966	CHEMBL2213811	Inhibition of TBK1 by radiometry	B	CN1CCC(C(=O)NCCCNc2nc(Nc3cccc(F)c3)ncc2Br)CC1		CHEMBL2207182	=	IC50	nM	4300.0	CHEMBL5408	Homo sapiens	IC50	nM	4300.0
	12190967	CHEMBL2213811	Inhibition of TBK1 by radiometry	B	O=C(NCCCNc1nc(Nc2cccc(F)c2)ncc1Br)C1CCC1		CHEMBL2207181	=	IC50	nM	2.0	CHEMBL5408	Homo sapiens	IC50	nM	2.0
	12190968	CHEMBL2213811	Inhibition of TBK1 by radiometry	B	O=C(NCCCNc1nc(Nc2cccc(F)c2)ncc1Br)C1CCCC1		CHEMBL2207180	=	IC50	nM	8.0	CHEMBL5408	Homo sapiens	IC50	nM	8.0
	12190969	CHEMBL2213811	Inhibition of TBK1 by radiometry	B	O=C(CCc1ccccc1)NCCCNc1nc(Nc2cccc(F)c2)ncc1Br		CHEMBL2207179	=	IC50	nM	560.0	CHEMBL5408	Homo sapiens	IC50	nM	560.0
	12190970	CHEMBL2213811	Inhibition of TBK1 by radiometry	B	O=C(NCCCNc1nc(Nc2cccc(F)c2)ncc1Br)c1cnccn1		CHEMBL2207178	=	IC50	nM	22.0	CHEMBL5408	Homo sapiens	IC50	nM	22.0
	12190971	CHEMBL2213811	Inhibition of TBK1 by radiometry	B	O=C(NCCCNc1nc(Nc2cccc(F)c2)ncc1Br)c1cccc(N2CCOCC2)c1		CHEMBL2207221	=	IC50	nM	3600.0	CHEMBL5408	Homo sapiens	IC50	nM	3600.0
	12190972	CHEMBL2213811	Inhibition of TBK1 by radiometry	B	O=C(NCCCNc1nc(Nc2cccc(F)c2)ncc1Br)c1ccc(C(F)(F)F)cc1		CHEMBL2207220	=	IC50	nM	450.0	CHEMBL5408	Homo sapiens	IC50	nM	450.0
	12190973	CHEMBL2213811	Inhibition of TBK1 by radiometry	B	COCCC(=O)NCCCNc1nc(Nc2cccc(F)c2)ncc1Br		CHEMBL2207219	=	IC50	nM	60.0	CHEMBL5408	Homo sapiens	IC50	nM	60.0
	12190974	CHEMBL2213811	Inhibition of TBK1 by radiometry	B	O=C(NCCCNc1nc(Nc2cccc(F)c2)ncc1Br)c1cccs1		CHEMBL2207218	=	IC50	nM	9.0	CHEMBL5408	Homo sapiens	IC50	nM	9.0
	12190975	CHEMBL2213811	Inhibition of TBK1 by radiometry	B	O=C(NCCCNc1nc(Nc2cccc(NC(=O)N3CCCC3)c2)ncc1Br)c1cccs1		CHEMBL2207217	=	IC50	nM	6.0	CHEMBL5408	Homo sapiens	IC50	nM	6.0
	12276528	CHEMBL2219205	Millipore: Percentage of residual kinase activity of TBK1 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	CC(C)(C)c1cc(C=C(C#N)C#N)cc(Br)c1O		CHEMBL2218926	=	Residual Activity	%	103.0	CHEMBL5408	Homo sapiens	Residual Activity	%	103.0
	12276529	CHEMBL2219205	Millipore: Percentage of residual kinase activity of TBK1 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	O=C1NC(=O)C(c2c[nH]c3ccccc23)=C1c1c[nH]c2ccccc12		CHEMBL266487	=	Residual Activity	%	70.0	CHEMBL5408	Homo sapiens	Residual Activity	%	70.0
	12276530	CHEMBL2219205	Millipore: Percentage of residual kinase activity of TBK1 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	O=C(Nc1cccc(Nc2cc(Nc3cccc(C(F)(F)F)c3)ncn2)c1)C1CC1		CHEMBL387187	=	Residual Activity	%	89.0	CHEMBL5408	Homo sapiens	Residual Activity	%	89.0
	12276531	CHEMBL2219205	Millipore: Percentage of residual kinase activity of TBK1 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	COc1ccc(Cl)cc1NC(=O)Nc1cc(C)nc2ccccc12		CHEMBL439259	=	Residual Activity	%	78.0	CHEMBL5408	Homo sapiens	Residual Activity	%	78.0
	12276532	CHEMBL2219205	Millipore: Percentage of residual kinase activity of TBK1 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	CNc1cc2c(Nc3cccc(Br)c3)ncnc2cn1		CHEMBL53753	=	Residual Activity	%	79.0	CHEMBL5408	Homo sapiens	Residual Activity	%	79.0
	12276533	CHEMBL2219205	Millipore: Percentage of residual kinase activity of TBK1 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	Nc1ncnc2c1cnn2-c1ccccc1		CHEMBL65063	=	Residual Activity	%	82.0	CHEMBL5408	Homo sapiens	Residual Activity	%	82.0
	12276534	CHEMBL2219205	Millipore: Percentage of residual kinase activity of TBK1 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	Cn1cc(/C=C2\C(=O)Nc3ccc(S(N)(=O)=O)cc32)c2ccccc21		CHEMBL104279	=	Residual Activity	%	8.0	CHEMBL5408	Homo sapiens	Residual Activity	%	8.0
	12276535	CHEMBL2219205	Millipore: Percentage of residual kinase activity of TBK1 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	COc1cc2ncnc(Nc3cccc(Cl)c3)c2cc1OC		CHEMBL7917	=	Residual Activity	%	98.0	CHEMBL5408	Homo sapiens	Residual Activity	%	98.0
	12276536	CHEMBL2219205	Millipore: Percentage of residual kinase activity of TBK1 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	Cc1nc2cc3nc(-c4cccs4)cnc3cc2n1C		CHEMBL2218927	=	Residual Activity	%	105.0	CHEMBL5408	Homo sapiens	Residual Activity	%	105.0
	12276537	CHEMBL2219205	Millipore: Percentage of residual kinase activity of TBK1 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	Cn1cnc2cc3c(Nc4cccc(Br)c4)ncnc3cc21		CHEMBL174426	=	Residual Activity	%	83.0	CHEMBL5408	Homo sapiens	Residual Activity	%	83.0
	12276538	CHEMBL2219205	Millipore: Percentage of residual kinase activity of TBK1 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	CC#CC(=O)Nc1cc2c(Nc3ccc(F)c(Cl)c3)ncnc2cn1		CHEMBL203644	=	Residual Activity	%	78.0	CHEMBL5408	Homo sapiens	Residual Activity	%	78.0
	12276539	CHEMBL2219205	Millipore: Percentage of residual kinase activity of TBK1 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	O=C(Nc1nc2ccccc2n1CCN1CCOCC1)c1cccc([N+](=O)[O-])c1		CHEMBL379787	=	Residual Activity	%	73.0	CHEMBL5408	Homo sapiens	Residual Activity	%	73.0
	12276540	CHEMBL2219205	Millipore: Percentage of residual kinase activity of TBK1 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	CCC(=O)Nc1ccc2ncnc(Nc3cccc(Br)c3)c2c1		CHEMBL188762	=	Residual Activity	%	69.0	CHEMBL5408	Homo sapiens	Residual Activity	%	69.0
	12276541	CHEMBL2219205	Millipore: Percentage of residual kinase activity of TBK1 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	CC(C)(C)n1nc(Cc2cccc3ccccc23)c2c(N)ncnc21		CHEMBL573578	=	Residual Activity	%	78.0	CHEMBL5408	Homo sapiens	Residual Activity	%	78.0
	12276542	CHEMBL2219205	Millipore: Percentage of residual kinase activity of TBK1 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	NCCNc1ncc(C(N)=O)c(Nc2cccc(C(F)(F)F)c2)n1		CHEMBL471901	=	Residual Activity	%	79.0	CHEMBL5408	Homo sapiens	Residual Activity	%	79.0
	12276543	CHEMBL2219205	Millipore: Percentage of residual kinase activity of TBK1 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	CCOC(=O)c1c(C)[nH]c(/C=C2\C(=O)Nc3ccccc32)c1C		CHEMBL86943	=	Residual Activity	%	92.0	CHEMBL5408	Homo sapiens	Residual Activity	%	92.0
	12276544	CHEMBL2219205	Millipore: Percentage of residual kinase activity of TBK1 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	CC[n+]1c(/C=C/N(C)c2ccccc2)n(-c2ccccc2)c2ccc(-c3nc4ccccc4s3)cc21		CHEMBL1186409	=	Residual Activity	%	104.0	CHEMBL5408	Homo sapiens	Residual Activity	%	104.0
	12276545	CHEMBL2219205	Millipore: Percentage of residual kinase activity of TBK1 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	COc1ccc2c(c[n+](C)c3c4cc5c(cc4ccc23)OCO5)c1OC		CHEMBL13045	=	Residual Activity	%	81.0	CHEMBL5408	Homo sapiens	Residual Activity	%	81.0
	12276546	CHEMBL2219205	Millipore: Percentage of residual kinase activity of TBK1 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	COc1ccc(C(=O)Nc2sc3c(c2C(N)=O)CCCC3)cc1OC		CHEMBL210833	=	Residual Activity	%	72.0	CHEMBL5408	Homo sapiens	Residual Activity	%	72.0
	12276547	CHEMBL2219205	Millipore: Percentage of residual kinase activity of TBK1 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	CC(C)(C)c1nc2c3ccc(F)cc3c3c(=O)[nH]ccc3c2[nH]1		CHEMBL21156	=	Residual Activity	%	15.0	CHEMBL5408	Homo sapiens	Residual Activity	%	15.0
	12276548	CHEMBL2219205	Millipore: Percentage of residual kinase activity of TBK1 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	CCCC(=O)Oc1ccc2[nH]c(C(=O)c3cc4ccccc4[nH]3)cc2c1		CHEMBL266325	=	Residual Activity	%	63.0	CHEMBL5408	Homo sapiens	Residual Activity	%	63.0
	12276549	CHEMBL2219205	Millipore: Percentage of residual kinase activity of TBK1 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	O=C1NC(=O)c2cc(Nc3ccc(F)cc3)c(Nc3ccc(F)cc3)cc21		CHEMBL7939	=	Residual Activity	%	69.0	CHEMBL5408	Homo sapiens	Residual Activity	%	69.0
	12276550	CHEMBL2219205	Millipore: Percentage of residual kinase activity of TBK1 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	O=[N+]([O-])/C=C/c1ccc2c(c1)OCO2		CHEMBL596380	=	Residual Activity	%	87.0	CHEMBL5408	Homo sapiens	Residual Activity	%	87.0
	12276551	CHEMBL2219205	Millipore: Percentage of residual kinase activity of TBK1 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	O=C(Nc1ccc(Cl)cc1)c1ccccc1NCc1ccncc1		CHEMBL101683	=	Residual Activity	%	103.0	CHEMBL5408	Homo sapiens	Residual Activity	%	103.0
	12276552	CHEMBL2219205	Millipore: Percentage of residual kinase activity of TBK1 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	CN1N=C(N)c2cn([C@@H]3O[C@H](CO)[C@@H](O)[C@H]3O)c3ncnc1c23		CHEMBL331237	=	Residual Activity	%	99.0	CHEMBL5408	Homo sapiens	Residual Activity	%	99.0
	12276553	CHEMBL2219205	Millipore: Percentage of residual kinase activity of TBK1 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	CCOc1cc2ncnc(Nc3cccc(Br)c3)c2cc1OCC		CHEMBL35820	=	Residual Activity	%	70.0	CHEMBL5408	Homo sapiens	Residual Activity	%	70.0
	12276554	CHEMBL2219205	Millipore: Percentage of residual kinase activity of TBK1 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	O=C(c1cc2cc(O)ccc2[nH]1)c1cc2cc(O)ccc2[nH]1		CHEMBL377193	=	Residual Activity	%	16.0	CHEMBL5408	Homo sapiens	Residual Activity	%	16.0
	12276555	CHEMBL2219205	Millipore: Percentage of residual kinase activity of TBK1 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	COc1cc2ncnc(Nc3ccc(O)c(Br)c3)c2cc1OC		CHEMBL473773	=	Residual Activity	%	41.0	CHEMBL5408	Homo sapiens	Residual Activity	%	41.0
	12276556	CHEMBL2219205	Millipore: Percentage of residual kinase activity of TBK1 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	COc1cc2ncnc(N3CCN(C(=O)Nc4ccc(Oc5ccccc5)cc4)CC3)c2cc1OC		CHEMBL102346	=	Residual Activity	%	57.0	CHEMBL5408	Homo sapiens	Residual Activity	%	57.0
	12276557	CHEMBL2219205	Millipore: Percentage of residual kinase activity of TBK1 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	O=C1NC(=O)C(c2cn(CCCn3ccnc3)c3ccccc23)=C1Nc1ccccc1		CHEMBL366266	=	Residual Activity	%	22.0	CHEMBL5408	Homo sapiens	Residual Activity	%	22.0
	12276558	CHEMBL2219205	Millipore: Percentage of residual kinase activity of TBK1 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	c1ccc(-c2n[nH]cc2-c2ccnc3ccccc23)nc1		CHEMBL261454	=	Residual Activity	%	71.0	CHEMBL5408	Homo sapiens	Residual Activity	%	71.0
	12276559	CHEMBL2219205	Millipore: Percentage of residual kinase activity of TBK1 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	COc1cc2nccc(Oc3ccc(NC(=O)Nc4cc(C)on4)c(Cl)c3)c2cc1OC		CHEMBL1289494	=	Residual Activity	%	82.0	CHEMBL5408	Homo sapiens	Residual Activity	%	82.0
	12276560	CHEMBL2219205	Millipore: Percentage of residual kinase activity of TBK1 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	O=c1[nH]c2ccccc2n1C1CCN(Cc2ccc(-c3nc4cc5[nH]cnc5cc4nc3-c3ccccc3)cc2)CC1		CHEMBL258844	=	Residual Activity	%	82.0	CHEMBL5408	Homo sapiens	Residual Activity	%	82.0
	12276561	CHEMBL2219205	Millipore: Percentage of residual kinase activity of TBK1 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	O=c1cc(N2CCOCC2)oc2c1ccc1ccccc12		CHEMBL104468	=	Residual Activity	%	77.0	CHEMBL5408	Homo sapiens	Residual Activity	%	77.0
	12276562	CHEMBL2219205	Millipore: Percentage of residual kinase activity of TBK1 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	COc1ccc(COc2ccc(Cc3cnc(N)nc3N)cc2OC)cc1		CHEMBL261849	=	Residual Activity	%	61.0	CHEMBL5408	Homo sapiens	Residual Activity	%	61.0
	12276563	CHEMBL2219205	Millipore: Percentage of residual kinase activity of TBK1 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	CC(C)N(CCC(=O)c1ccc2ccccc2c1)Cc1ccccc1		CHEMBL596674	=	Residual Activity	%	52.0	CHEMBL5408	Homo sapiens	Residual Activity	%	52.0
	12276564	CHEMBL2219205	Millipore: Percentage of residual kinase activity of TBK1 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	COc1cc2c(cc1OC)-c1n[nH]c(Nc3cccc(F)c3)c1C2		CHEMBL120077	=	Residual Activity	%	52.0	CHEMBL5408	Homo sapiens	Residual Activity	%	52.0
	12276565	CHEMBL2219205	Millipore: Percentage of residual kinase activity of TBK1 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	CO[C@H]1C[C@@H]2CC[C@@H](C)[C@@](O)(O2)C(=O)C(=O)N2CCCC[C@H]2C(=O)O[C@H]([C@H](C)C[C@@H]2CC[C@@H](O)[C@H](OC)C2)CC(=O)[C@H](C)/C=C(\C)[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)/C=C/C=C/C=C/1C		CHEMBL413	=	Residual Activity	%	63.0	CHEMBL5408	Homo sapiens	Residual Activity	%	63.0
	12276566	CHEMBL2219205	Millipore: Percentage of residual kinase activity of TBK1 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	Cc1cccc(-c2[nH]c(C(C)(C)C)nc2-c2ccc3c(c2)OCO3)n1		CHEMBL226838	=	Residual Activity	%	73.0	CHEMBL5408	Homo sapiens	Residual Activity	%	73.0
	12276567	CHEMBL2219205	Millipore: Percentage of residual kinase activity of TBK1 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	O=C1Nc2ccc(Br)cc2/C1=C\c1cc2c([nH]1)CCCC2		CHEMBL2218925	=	Residual Activity	%	59.0	CHEMBL5408	Homo sapiens	Residual Activity	%	59.0
	12276568	CHEMBL2219205	Millipore: Percentage of residual kinase activity of TBK1 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	CCN(CC)CCCCN1c2ccccc2Oc2ccc(Cl)cc21		CHEMBL1398474	=	Residual Activity	%	91.0	CHEMBL5408	Homo sapiens	Residual Activity	%	91.0
	12276569	CHEMBL2219205	Millipore: Percentage of residual kinase activity of TBK1 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	CC(=O)c1ccc(N2CCOCC2)cc1O		CHEMBL1317546	=	Residual Activity	%	74.0	CHEMBL5408	Homo sapiens	Residual Activity	%	74.0
	12276570	CHEMBL2219205	Millipore: Percentage of residual kinase activity of TBK1 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	Cn1c2ccccc2c2c3c(c4c5ccccc5n(CCC#N)c4c21)CNC3=O		CHEMBL302449	=	Residual Activity	%	11.0	CHEMBL5408	Homo sapiens	Residual Activity	%	11.0
	12276571	CHEMBL2219205	Millipore: Percentage of residual kinase activity of TBK1 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	O=C1Nc2ccc(-c3cccnc3)cc2/C1=C\c1ccc[nH]1		CHEMBL2218929	=	Residual Activity	%	1.0	CHEMBL5408	Homo sapiens	Residual Activity	%	1.0
	12276572	CHEMBL2219205	Millipore: Percentage of residual kinase activity of TBK1 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	COc1cc2nccc(Oc3ccc(NC(=S)NC(=O)c4ccccc4C)cc3)c2cc1OC		CHEMBL2218930	=	Residual Activity	%	57.0	CHEMBL5408	Homo sapiens	Residual Activity	%	57.0
	12276573	CHEMBL2219205	Millipore: Percentage of residual kinase activity of TBK1 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	c1ccc2c(-c3ccncc3)c[nH]c2c1		CHEMBL380071	=	Residual Activity	%	65.0	CHEMBL5408	Homo sapiens	Residual Activity	%	65.0
	12276574	CHEMBL2219205	Millipore: Percentage of residual kinase activity of TBK1 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	COc1ccc(C=C(C#N)C#N)cc1		CHEMBL77456	=	Residual Activity	%	84.0	CHEMBL5408	Homo sapiens	Residual Activity	%	84.0
	12276575	CHEMBL2219205	Millipore: Percentage of residual kinase activity of TBK1 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	Cc1cc(C)c(/C=C2\C(=O)Nc3ccccc32)[nH]1		CHEMBL276711	=	Residual Activity	%	70.0	CHEMBL5408	Homo sapiens	Residual Activity	%	70.0
	12276576	CHEMBL2219205	Millipore: Percentage of residual kinase activity of TBK1 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	O=C1c2ccccc2-c2nc3nnnn3nc21		CHEMBL599894	=	Residual Activity	%	97.0	CHEMBL5408	Homo sapiens	Residual Activity	%	97.0
	12276577	CHEMBL2219205	Millipore: Percentage of residual kinase activity of TBK1 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	Oc1cccc(-c2nc(N3CCOCC3)c3oc4ncccc4c3n2)c1		CHEMBL573339	=	Residual Activity	%	82.0	CHEMBL5408	Homo sapiens	Residual Activity	%	82.0
	12276578	CHEMBL2219205	Millipore: Percentage of residual kinase activity of TBK1 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	COc1ccc2c(c1)c(C1=C(c3c[nH]c4ccccc34)C(=O)NC1=O)cn2CCCN(C)C		CHEMBL261491	=	Residual Activity	%	59.0	CHEMBL5408	Homo sapiens	Residual Activity	%	59.0
	12276579	CHEMBL2219205	Millipore: Percentage of residual kinase activity of TBK1 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	Nc1ncnc2c1c(-c1ccc(Oc3ccccc3)cc1)cn2C1CCCC1		CHEMBL47940	=	Residual Activity	%	61.0	CHEMBL5408	Homo sapiens	Residual Activity	%	61.0
	12276580	CHEMBL2219205	Millipore: Percentage of residual kinase activity of TBK1 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	O=C1Nc2ccc3ncsc3c2/C1=C/c1c[nH]cn1		CHEMBL235641	=	Residual Activity	%	7.0	CHEMBL5408	Homo sapiens	Residual Activity	%	7.0
	12276581	CHEMBL2219205	Millipore: Percentage of residual kinase activity of TBK1 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	Cc1cncc2cccc(S(=O)(=O)N3CCCN(C(=O)CN)C[C@H]3C)c12		CHEMBL2218931	=	Residual Activity	%	68.0	CHEMBL5408	Homo sapiens	Residual Activity	%	68.0
	12276582	CHEMBL2219205	Millipore: Percentage of residual kinase activity of TBK1 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	N#C/C(=C\c1ccc(O)c(O)c1)C(=O)NCc1ccccc1		CHEMBL56543	=	Residual Activity	%	82.0	CHEMBL5408	Homo sapiens	Residual Activity	%	82.0
	12276583	CHEMBL2219205	Millipore: Percentage of residual kinase activity of TBK1 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	COc1ccc(-c2cnc3c(-c4ccsc4)cnn3c2)cc1		CHEMBL92461	=	Residual Activity	%	97.0	CHEMBL5408	Homo sapiens	Residual Activity	%	97.0
	12276584	CHEMBL2219205	Millipore: Percentage of residual kinase activity of TBK1 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	COc1cc2ncnc(Nc3ccc(NC(=O)c4ccccc4)cc3)c2cc1OC		CHEMBL382590	=	Residual Activity	%	96.0	CHEMBL5408	Homo sapiens	Residual Activity	%	96.0
	12276585	CHEMBL2219205	Millipore: Percentage of residual kinase activity of TBK1 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	O=c1c2ccccc2[nH]c(=S)n1CCN1CCC(=C(c2ccc(F)cc2)c2ccc(F)cc2)CC1		CHEMBL261131	=	Residual Activity	%	91.0	CHEMBL5408	Homo sapiens	Residual Activity	%	91.0
	12276586	CHEMBL2219205	Millipore: Percentage of residual kinase activity of TBK1 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	c1ccc(-c2n[nH]c3c2oc2ccccc23)cc1		CHEMBL406375	=	Residual Activity	%	67.0	CHEMBL5408	Homo sapiens	Residual Activity	%	67.0
	12276587	CHEMBL2219205	Millipore: Percentage of residual kinase activity of TBK1 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	O=c1cc(N2CCOCC2)oc2c(-c3ccccc3)cccc12		CHEMBL98350	=	Residual Activity	%	68.0	CHEMBL5408	Homo sapiens	Residual Activity	%	68.0
	12276588	CHEMBL2219205	Millipore: Percentage of residual kinase activity of TBK1 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	O=C1Nc2ccc(Cl)cc2/C1=C/c1cc(Cl)c(O)c(Cl)c1		CHEMBL2218932	=	Residual Activity	%	59.0	CHEMBL5408	Homo sapiens	Residual Activity	%	59.0
	12276589	CHEMBL2219205	Millipore: Percentage of residual kinase activity of TBK1 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	CO[C@@H]1[C@H](N(C)C(=O)c2ccccc2)C[C@H]2O[C@]1(C)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)C(=O)NC4		CHEMBL608533	=	Residual Activity	%	2.0	CHEMBL5408	Homo sapiens	Residual Activity	%	2.0
	12276590	CHEMBL2219205	Millipore: Percentage of residual kinase activity of TBK1 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	N#CC(C#N)=C(N)/C(C#N)=C/c1ccc(O)cc1		CHEMBL76589	=	Residual Activity	%	82.0	CHEMBL5408	Homo sapiens	Residual Activity	%	82.0
	12276591	CHEMBL2219205	Millipore: Percentage of residual kinase activity of TBK1 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	O=C(c1ccccc1)c1ccc(N2CCOCC2)cc1O		CHEMBL478980	=	Residual Activity	%	91.0	CHEMBL5408	Homo sapiens	Residual Activity	%	91.0
	12276592	CHEMBL2219205	Millipore: Percentage of residual kinase activity of TBK1 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	NC(=O)c1cccc(-c2cc(Nc3ccc(OC(F)(F)F)cc3)ncn2)c1		CHEMBL483847	=	Residual Activity	%	98.0	CHEMBL5408	Homo sapiens	Residual Activity	%	98.0
	12276593	CHEMBL2219205	Millipore: Percentage of residual kinase activity of TBK1 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	CN(C)c1ccc(/C=C2\C(=O)Nc3ccccc32)cc1		CHEMBL328710	=	Residual Activity	%	81.0	CHEMBL5408	Homo sapiens	Residual Activity	%	81.0
	12276594	CHEMBL2219205	Millipore: Percentage of residual kinase activity of TBK1 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	CO[C@H]1/C=C/C=C(\C)C(=O)NC2=CC(=O)C=C(C2=O)[C@H](OC)[C@@H](C)C[C@H](OC)[C@H](OC)[C@@H](C)/C=C(\C)[C@@H]1OC(N)=O		CHEMBL479533	=	Residual Activity	%	77.0	CHEMBL5408	Homo sapiens	Residual Activity	%	77.0
	12276595	CHEMBL2219205	Millipore: Percentage of residual kinase activity of TBK1 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	O=c1cc(N2CCNCC2)oc2c(-c3ccccc3)cccc12		CHEMBL1363184	=	Residual Activity	%	72.0	CHEMBL5408	Homo sapiens	Residual Activity	%	72.0
	12276596	CHEMBL2219205	Millipore: Percentage of residual kinase activity of TBK1 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	O=C1NC(=O)/C(=C\c2ccc3nccnc3c2)S1		CHEMBL2218934	=	Residual Activity	%	56.0	CHEMBL5408	Homo sapiens	Residual Activity	%	56.0
	12276597	CHEMBL2219205	Millipore: Percentage of residual kinase activity of TBK1 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	COc1cc2ncnc(Nc3ccc(Oc4ccccc4)cc3)c2cc1OC		CHEMBL97771	=	Residual Activity	%	72.0	CHEMBL5408	Homo sapiens	Residual Activity	%	72.0
	12276598	CHEMBL2219205	Millipore: Percentage of residual kinase activity of TBK1 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	Cc1cc2ncc(-c3ccccc3)nc2cc1C		CHEMBL7724	=	Residual Activity	%	86.0	CHEMBL5408	Homo sapiens	Residual Activity	%	86.0
	12276599	CHEMBL2219205	Millipore: Percentage of residual kinase activity of TBK1 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	O=C(Nc1cccc(Nc2nccc(Nc3cccc(C(F)(F)F)c3)n2)c1)C1CC1		CHEMBL383899	=	Residual Activity	%	78.0	CHEMBL5408	Homo sapiens	Residual Activity	%	78.0
	12276600	CHEMBL2219205	Millipore: Percentage of residual kinase activity of TBK1 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	CN(C)CCCn1cc(C2=C(c3c[nH]c4ccccc34)C(=O)NC2=O)c2ccccc21		CHEMBL7463	=	Residual Activity	%	80.0	CHEMBL5408	Homo sapiens	Residual Activity	%	80.0
	12276601	CHEMBL2219205	Millipore: Percentage of residual kinase activity of TBK1 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	COc1cc2ncnc(Nc3ccc(OCc4ccccc4)cc3)c2cc1OC		CHEMBL563845	=	Residual Activity	%	92.0	CHEMBL5408	Homo sapiens	Residual Activity	%	92.0
	12276602	CHEMBL2219205	Millipore: Percentage of residual kinase activity of TBK1 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	c1ccc(-c2cnc(Nc3ccc(OCCN4CCCC4)cc3)s2)cc1		CHEMBL2218935	=	Residual Activity	%	70.0	CHEMBL5408	Homo sapiens	Residual Activity	%	70.0
	12276603	CHEMBL2219205	Millipore: Percentage of residual kinase activity of TBK1 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	CC1=C(C(=O)N2CCN(C)CC2)C(C)=C(/C=C2\C(=O)Nc3ccc(S(=O)(=O)N(C)c4cccc(Cl)c4)cc32)C1		CHEMBL2218936	=	Residual Activity	%	60.0	CHEMBL5408	Homo sapiens	Residual Activity	%	60.0
	12276604	CHEMBL2219205	Millipore: Percentage of residual kinase activity of TBK1 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	O=C1NC(=O)/C(=C/c2ccc3c(c2)OC(F)(F)O3)S1		CHEMBL1231533	=	Residual Activity	%	80.0	CHEMBL5408	Homo sapiens	Residual Activity	%	80.0
	12276605	CHEMBL2219205	Millipore: Percentage of residual kinase activity of TBK1 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	CCN(CC)CCNC(=O)c1c(C)[nH]c(/C=C2\C(=O)Nc3ccc(Cl)cc32)c1C		CHEMBL13485	=	Residual Activity	%	15.0	CHEMBL5408	Homo sapiens	Residual Activity	%	15.0
	12276606	CHEMBL2219205	Millipore: Percentage of residual kinase activity of TBK1 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	COc1cc2ncc(-c3ccccc3)nc2cc1OC		CHEMBL71191	=	Residual Activity	%	91.0	CHEMBL5408	Homo sapiens	Residual Activity	%	91.0
	12276607	CHEMBL2219205	Millipore: Percentage of residual kinase activity of TBK1 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	CN[C@@H]1C[C@H]2O[C@@](C)([C@@H]1OC)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)C(=O)NC4		CHEMBL388978	=	Residual Activity	%	2.0	CHEMBL5408	Homo sapiens	Residual Activity	%	2.0
	12276608	CHEMBL2219205	Millipore: Percentage of residual kinase activity of TBK1 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	CN([C@@H](Cc1ccc(OS(=O)(=O)c2cccc3cnccc23)cc1)C(=O)N1CCN(c2ccccc2)CC1)S(=O)(=O)c1cccc2cnccc12		CHEMBL28324	=	Residual Activity	%	107.0	CHEMBL5408	Homo sapiens	Residual Activity	%	107.0
	12276609	CHEMBL2219205	Millipore: Percentage of residual kinase activity of TBK1 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	Nc1nc(Nc2ccc(S(N)(=O)=O)cc2)nn1C(=O)c1c(F)cccc1F		CHEMBL191003	=	Residual Activity	%	72.0	CHEMBL5408	Homo sapiens	Residual Activity	%	72.0
	12276610	CHEMBL2219205	Millipore: Percentage of residual kinase activity of TBK1 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	O=C1NC(=O)c2c1c1c3ccccc3[nH]c1c1[nH]c3cc(Br)ccc3c21		CHEMBL64758	=	Residual Activity	%	75.0	CHEMBL5408	Homo sapiens	Residual Activity	%	75.0
	12276611	CHEMBL2219205	Millipore: Percentage of residual kinase activity of TBK1 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	C[C@@H](N)[C@H]1CC[C@H](C(=O)Nc2ccncc2)CC1		CHEMBL559147	=	Residual Activity	%	107.0	CHEMBL5408	Homo sapiens	Residual Activity	%	107.0
	12276612	CHEMBL2219205	Millipore: Percentage of residual kinase activity of TBK1 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	CN(C)S(=O)(=O)c1ccc2c(c1)/C(=C/c1cc3c([nH]1)CCCC3)C(=O)N2		CHEMBL605003	=	Residual Activity	%	74.0	CHEMBL5408	Homo sapiens	Residual Activity	%	74.0
	12276613	CHEMBL2219205	Millipore: Percentage of residual kinase activity of TBK1 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	O=C(CCCc1ccc(-c2ccccc2F)cc1)Nc1ccc(O)cc1		CHEMBL235658	=	Residual Activity	%	90.0	CHEMBL5408	Homo sapiens	Residual Activity	%	90.0
	12276614	CHEMBL2219205	Millipore: Percentage of residual kinase activity of TBK1 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	CSc1nc(-c2ccc(F)cc2)c(-c2ccnc(NC(C)c3ccccc3)c2)[nH]1		CHEMBL111364	=	Residual Activity	%	102.0	CHEMBL5408	Homo sapiens	Residual Activity	%	102.0
	12276615	CHEMBL2219205	Millipore: Percentage of residual kinase activity of TBK1 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	C[S+]([O-])c1ccc(-c2nc(-c3ccc(F)cc3)c(-c3ccncc3)[nH]2)cc1		CHEMBL10	=	Residual Activity	%	124.0	CHEMBL5408	Homo sapiens	Residual Activity	%	124.0
	12276616	CHEMBL2219205	Millipore: Percentage of residual kinase activity of TBK1 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	O=c1cc(-c2cccc3c2Sc2ccccc2S3)oc(N2CCOCC2)c1		CHEMBL222102	=	Residual Activity	%	99.0	CHEMBL5408	Homo sapiens	Residual Activity	%	99.0
	12276617	CHEMBL2219205	Millipore: Percentage of residual kinase activity of TBK1 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	O=Nc1c(-c2c(O)[nH]c3ccccc23)[nH]c2ccccc12		CHEMBL126077	=	Residual Activity	%	9.0	CHEMBL5408	Homo sapiens	Residual Activity	%	9.0
	12276618	CHEMBL2219205	Millipore: Percentage of residual kinase activity of TBK1 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	COc1ccc(OC)c2c(=S)c3ccccc3[nH]c12		CHEMBL1331734	=	Residual Activity	%	82.0	CHEMBL5408	Homo sapiens	Residual Activity	%	82.0
	12276619	CHEMBL2219205	Millipore: Percentage of residual kinase activity of TBK1 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	Nc1n[nH]c2nnc(-c3c(-c4ccccc4)nn4ccccc34)cc12		CHEMBL259551	=	Residual Activity	%	75.0	CHEMBL5408	Homo sapiens	Residual Activity	%	75.0
	12276620	CHEMBL2219205	Millipore: Percentage of residual kinase activity of TBK1 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	Cc1cc(Nc2nc(-c3ccccc3)nc3ccccc23)n[nH]1		CHEMBL359482	=	Residual Activity	%	19.0	CHEMBL5408	Homo sapiens	Residual Activity	%	19.0
	12276621	CHEMBL2219205	Millipore: Percentage of residual kinase activity of TBK1 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	CCOc1nc(NC(=O)Cc2cc(OC)ccc2OC)cc(N)c1C#N		CHEMBL210618	=	Residual Activity	%	79.0	CHEMBL5408	Homo sapiens	Residual Activity	%	79.0
	12276622	CHEMBL2219205	Millipore: Percentage of residual kinase activity of TBK1 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	Oc1c(-c2ccc(F)cc2)c(-c2ccncc2)nn1-c1ccc(Cl)cc1		CHEMBL91730	=	Residual Activity	%	106.0	CHEMBL5408	Homo sapiens	Residual Activity	%	106.0
	12276623	CHEMBL2219205	Millipore: Percentage of residual kinase activity of TBK1 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	O=S(=O)(c1cccc2cnccc12)N1CCCNCC1		CHEMBL38380	=	Residual Activity	%	115.0	CHEMBL5408	Homo sapiens	Residual Activity	%	115.0
	12276624	CHEMBL2219205	Millipore: Percentage of residual kinase activity of TBK1 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	O=C(NC(NC(=S)Nc1ccc(F)c([N+](=O)[O-])c1)C(Cl)(Cl)Cl)C(c1ccccc1)c1ccccc1		CHEMBL1221601	=	Residual Activity	%	96.0	CHEMBL5408	Homo sapiens	Residual Activity	%	96.0
	12276625	CHEMBL2219205	Millipore: Percentage of residual kinase activity of TBK1 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	Cc1ccc(S(=O)(=O)/C=C/C#N)cc1		CHEMBL403183	=	Residual Activity	%	87.0	CHEMBL5408	Homo sapiens	Residual Activity	%	87.0
	12276626	CHEMBL2219205	Millipore: Percentage of residual kinase activity of TBK1 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	Cc1ccc(NC2=CC(=O)c3sc(C)nc3C2=O)cc1		CHEMBL290904	=	Residual Activity	%	77.0	CHEMBL5408	Homo sapiens	Residual Activity	%	77.0
	12276627	CHEMBL2219205	Millipore: Percentage of residual kinase activity of TBK1 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	Oc1n[nH]c2nnc(-c3c(-c4ccccc4)nn4ccccc34)cc12		CHEMBL2218938	=	Residual Activity	%	67.0	CHEMBL5408	Homo sapiens	Residual Activity	%	67.0
	12276628	CHEMBL2219205	Millipore: Percentage of residual kinase activity of TBK1 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	O=C1NC(=O)c2c1c1c3ccccc3[nH]c1n1cncc21		CHEMBL413188	=	Residual Activity	%	53.0	CHEMBL5408	Homo sapiens	Residual Activity	%	53.0
	12276629	CHEMBL2219205	Millipore: Percentage of residual kinase activity of TBK1 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	COC(=O)[C@@]1(O)C[C@H]2O[C@]1(C)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)C(=O)NC4		CHEMBL281948	=	Residual Activity	%	-1.0	CHEMBL5408	Homo sapiens	Residual Activity	%	-1.0
	12276630	CHEMBL2219205	Millipore: Percentage of residual kinase activity of TBK1 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	COc1cccc(-c2cc(=O)c3ccccc3o2)c1N		CHEMBL35482	=	Residual Activity	%	97.0	CHEMBL5408	Homo sapiens	Residual Activity	%	97.0
	12276631	CHEMBL2219205	Millipore: Percentage of residual kinase activity of TBK1 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	O=C1NC(=O)c2c1c1c3ccccc3n3c1c1c2c2ccccc2n1C1CCC3O1		CHEMBL304428	=	Residual Activity	%	54.0	CHEMBL5408	Homo sapiens	Residual Activity	%	54.0
	12276632	CHEMBL2219205	Millipore: Percentage of residual kinase activity of TBK1 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	O=C1Cc2c([nH]c3ccc([N+](=O)[O-])cc23)-c2ccccc2N1		CHEMBL50894	=	Residual Activity	%	51.0	CHEMBL5408	Homo sapiens	Residual Activity	%	51.0
	12276633	CHEMBL2219205	Millipore: Percentage of residual kinase activity of TBK1 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	CC(C)n1cnc2c(NCc3ccccc3)nc(NCCCO)nc21		CHEMBL83980	=	Residual Activity	%	79.0	CHEMBL5408	Homo sapiens	Residual Activity	%	79.0
	12276634	CHEMBL2219205	Millipore: Percentage of residual kinase activity of TBK1 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	CCN1/C(=C/C(C)=O)Sc2ccc(OC)cc21		CHEMBL408982	=	Residual Activity	%	70.0	CHEMBL5408	Homo sapiens	Residual Activity	%	70.0
	12276635	CHEMBL2219205	Millipore: Percentage of residual kinase activity of TBK1 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	O=C1c2ccccc2-[n+]2ccc3c([nH]c4ccccc43)c21		CHEMBL602937	=	Residual Activity	%	58.0	CHEMBL5408	Homo sapiens	Residual Activity	%	58.0
	12276636	CHEMBL2219205	Millipore: Percentage of residual kinase activity of TBK1 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	COc1cc(OC)c(/C=C2\C(=O)Nc3ccccc32)c(OC)c1		CHEMBL404941	=	Residual Activity	%	61.0	CHEMBL5408	Homo sapiens	Residual Activity	%	61.0
	12276637	CHEMBL2219205	Millipore: Percentage of residual kinase activity of TBK1 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	O=C1Cc2c([nH]c3ccc(Br)cc23)-c2ccccc2N1		CHEMBL296586	=	Residual Activity	%	53.0	CHEMBL5408	Homo sapiens	Residual Activity	%	53.0
	12276638	CHEMBL2219205	Millipore: Percentage of residual kinase activity of TBK1 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	O=[N+]([O-])c1ccc(-c2nc(-c3ccc(F)cc3)c(-c3ccncc3)[nH]2)cc1		CHEMBL17331	=	Residual Activity	%	87.0	CHEMBL5408	Homo sapiens	Residual Activity	%	87.0
	12276639	CHEMBL2219205	Millipore: Percentage of residual kinase activity of TBK1 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	Cc1nc(-c2ccccc2)c(-c2ccncc2)o1		CHEMBL36450	=	Residual Activity	%	102.0	CHEMBL5408	Homo sapiens	Residual Activity	%	102.0
	12276640	CHEMBL2219205	Millipore: Percentage of residual kinase activity of TBK1 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	N#CCCc1ccc2c(c1)-c1[nH]c3ccc([N+](=O)[O-])cc3c1CC(=O)N2		CHEMBL260138	=	Residual Activity	%	38.0	CHEMBL5408	Homo sapiens	Residual Activity	%	38.0
	12276641	CHEMBL2219205	Millipore: Percentage of residual kinase activity of TBK1 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	O=C1Nc2ccccc2/C1=C\c1c(Cl)[nH]c2ccccc12		CHEMBL261425	=	Residual Activity	%	72.0	CHEMBL5408	Homo sapiens	Residual Activity	%	72.0
	12276642	CHEMBL2219205	Millipore: Percentage of residual kinase activity of TBK1 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	NC(=O)c1ccc2[nH]c(-c3ccc(Oc4ccc(Cl)cc4)cc3)nc2c1		CHEMBL179583	=	Residual Activity	%	67.0	CHEMBL5408	Homo sapiens	Residual Activity	%	67.0
	12276643	CHEMBL2219205	Millipore: Percentage of residual kinase activity of TBK1 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	Cn1sc(=O)n(Cc2ccccc2)c1=O		CHEMBL284861	=	Residual Activity	%	61.0	CHEMBL5408	Homo sapiens	Residual Activity	%	61.0
	12276644	CHEMBL2219205	Millipore: Percentage of residual kinase activity of TBK1 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	NC(=O)Nc1sc(-c2ccc(F)cc2)cc1C(N)=O		CHEMBL257167	=	Residual Activity	%	35.0	CHEMBL5408	Homo sapiens	Residual Activity	%	35.0
	12276645	CHEMBL2219205	Millipore: Percentage of residual kinase activity of TBK1 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	COc1ccc(S(=O)(=O)N(CCO)c2ccccc2CN(C)C/C=C/c2ccc(Cl)cc2)cc1		CHEMBL155333	=	Residual Activity	%	73.0	CHEMBL5408	Homo sapiens	Residual Activity	%	73.0
	12276646	CHEMBL2219205	Millipore: Percentage of residual kinase activity of TBK1 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	Nc1nccc(-c2c(-c3ccc(F)cc3)ncn2C2CCNCC2)n1		CHEMBL274064	=	Residual Activity	%	88.0	CHEMBL5408	Homo sapiens	Residual Activity	%	88.0
	12276647	CHEMBL2219205	Millipore: Percentage of residual kinase activity of TBK1 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	Fc1ccc(-c2nc3n(c2-c2ccncc2)CCS3)cc1		CHEMBL313417	=	Residual Activity	%	106.0	CHEMBL5408	Homo sapiens	Residual Activity	%	106.0
	12276648	CHEMBL2219205	Millipore: Percentage of residual kinase activity of TBK1 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	CCCCc1c(-c2ccc(O)cc2)[nH]c2nccnc12		CHEMBL75680	=	Residual Activity	%	70.0	CHEMBL5408	Homo sapiens	Residual Activity	%	70.0
	12276649	CHEMBL2219205	Millipore: Percentage of residual kinase activity of TBK1 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	CCn1cnc2c(Nc3cccc(Cl)c3)nc(N[C@@H]3CCCC[C@@H]3N)nc21		CHEMBL367625	=	Residual Activity	%	68.0	CHEMBL5408	Homo sapiens	Residual Activity	%	68.0
	12276650	CHEMBL2219205	Millipore: Percentage of residual kinase activity of TBK1 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	CC(C)n1cnc2/c(=N/c3cccc(Cl)c3)nc(NCCO)[nH]c21		CHEMBL311228	=	Residual Activity	%	57.0	CHEMBL5408	Homo sapiens	Residual Activity	%	57.0
	12276651	CHEMBL2219205	Millipore: Percentage of residual kinase activity of TBK1 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	Ic1cccc(CSc2nnc(-c3ccncc3)o2)c1		CHEMBL288064	=	Residual Activity	%	15.0	CHEMBL5408	Homo sapiens	Residual Activity	%	15.0
	12276652	CHEMBL2219205	Millipore: Percentage of residual kinase activity of TBK1 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	O=C1Nc2ccccc2/C1=C1/Nc2ccccc2/C1=N\OCCC(O)CO		CHEMBL1802727	=	Residual Activity	%	9.0	CHEMBL5408	Homo sapiens	Residual Activity	%	9.0
	12276653	CHEMBL2219205	Millipore: Percentage of residual kinase activity of TBK1 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	N#C/C(=C(/N)SC1C=CC=CC1)c1cccc(C(O)c2ccncc2)c1		CHEMBL2218939	=	Residual Activity	%	77.0	CHEMBL5408	Homo sapiens	Residual Activity	%	77.0
	12276654	CHEMBL2219205	Millipore: Percentage of residual kinase activity of TBK1 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	CC(C)[C@H](CO)Nc1nc(Nc2cccc(Cl)c2)c2ncn(C(C)C)c2n1		CHEMBL23327	=	Residual Activity	%	90.0	CHEMBL5408	Homo sapiens	Residual Activity	%	90.0
	12276655	CHEMBL2219205	Millipore: Percentage of residual kinase activity of TBK1 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	Oc1ccc(Nc2nc(-c3ccc(Cl)cc3)cs2)cc1		CHEMBL1076555	=	Residual Activity	%	114.0	CHEMBL5408	Homo sapiens	Residual Activity	%	114.0
	12276656	CHEMBL2219205	Millipore: Percentage of residual kinase activity of TBK1 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	CCCCc1c(-c2ccc(OC)cc2)[nH]c2nccnc12		CHEMBL306498	=	Residual Activity	%	61.0	CHEMBL5408	Homo sapiens	Residual Activity	%	61.0
	12276657	CHEMBL2219205	Millipore: Percentage of residual kinase activity of TBK1 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	Nc1nc(Nc2ccc(S(N)(=O)=O)cc2)nn1C(=S)Nc1c(F)cccc1F		CHEMBL261720	=	Residual Activity	%	-1.0	CHEMBL5408	Homo sapiens	Residual Activity	%	-1.0
	12276658	CHEMBL2219205	Millipore: Percentage of residual kinase activity of TBK1 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	COc1ccc(CNc2nc(N(CCO)CCO)nc3c2ncn3C(C)C)cc1		CHEMBL80713	=	Residual Activity	%	69.0	CHEMBL5408	Homo sapiens	Residual Activity	%	69.0
	12276659	CHEMBL2219205	Millipore: Percentage of residual kinase activity of TBK1 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	COc1ccc(CNC(=O)Nc2ncc([N+](=O)[O-])s2)cc1		CHEMBL259850	=	Residual Activity	%	59.0	CHEMBL5408	Homo sapiens	Residual Activity	%	59.0
	12276660	CHEMBL2219205	Millipore: Percentage of residual kinase activity of TBK1 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	Oc1c2ccccc2c2c3c(cccc13)N=N2		CHEMBL1725279	=	Residual Activity	%	35.0	CHEMBL5408	Homo sapiens	Residual Activity	%	35.0
	12276661	CHEMBL2219205	Millipore: Percentage of residual kinase activity of TBK1 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	O=C1C(Cl)=C(N2C(=O)CCC2=O)C(=O)c2ccccc21		CHEMBL404939	=	Residual Activity	%	68.0	CHEMBL5408	Homo sapiens	Residual Activity	%	68.0
	12276662	CHEMBL2219205	Millipore: Percentage of residual kinase activity of TBK1 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	Nc1cccc(-c2cc3c(Oc4cccc(O)c4)ncnc3[nH]2)c1		CHEMBL405759	=	Residual Activity	%	70.0	CHEMBL5408	Homo sapiens	Residual Activity	%	70.0
	12276663	CHEMBL2219205	Millipore: Percentage of residual kinase activity of TBK1 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	CC(C)[C@H](CO)Nc1nc(Nc2cc(N)cc(Cl)c2)c2ncn(C(C)C)c2n1		CHEMBL286721	=	Residual Activity	%	97.0	CHEMBL5408	Homo sapiens	Residual Activity	%	97.0
	12276664	CHEMBL2219205	Millipore: Percentage of residual kinase activity of TBK1 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	Nc1n[nH]c2nc3ccccc3nc12		CHEMBL259389	=	Residual Activity	%	78.0	CHEMBL5408	Homo sapiens	Residual Activity	%	78.0
	12276665	CHEMBL2219205	Millipore: Percentage of residual kinase activity of TBK1 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	CCN(CC)C(=O)c1ccc(Nc2nc(OCC3CCCCC3)c3nc[nH]c3n2)cc1		CHEMBL1802728	=	Residual Activity	%	15.0	CHEMBL5408	Homo sapiens	Residual Activity	%	15.0
	12276666	CHEMBL2219205	Millipore: Percentage of residual kinase activity of TBK1 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	O=C1Nc2cc(Br)ccc2/C1=C1/Nc2ccccc2/C1=N\O		CHEMBL409450	=	Residual Activity	%	8.0	CHEMBL5408	Homo sapiens	Residual Activity	%	8.0
	12276667	CHEMBL2219205	Millipore: Percentage of residual kinase activity of TBK1 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	Cn1nc2c3c(cccc31)C(=O)c1ccccc1-2		CHEMBL1802485	=	Residual Activity	%	67.0	CHEMBL5408	Homo sapiens	Residual Activity	%	67.0
	12276668	CHEMBL2219205	Millipore: Percentage of residual kinase activity of TBK1 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	N#C/C(=C(\N)Sc1ccc(N)cc1)c1ccccc1C(F)(F)F		CHEMBL2218940	=	Residual Activity	%	31.0	CHEMBL5408	Homo sapiens	Residual Activity	%	31.0
	12276669	CHEMBL2219205	Millipore: Percentage of residual kinase activity of TBK1 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	O=S(=O)(NCCNC/C=C/c1ccc(Br)cc1)c1cccc2cnccc12		CHEMBL104264	=	Residual Activity	%	85.0	CHEMBL5408	Homo sapiens	Residual Activity	%	85.0
	12276670	CHEMBL2219205	Millipore: Percentage of residual kinase activity of TBK1 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	O=C(O)c1ccc2c3c1cccc3c(=O)n1c3ccccc3nc21		CHEMBL1182777	=	Residual Activity	%	19.0	CHEMBL5408	Homo sapiens	Residual Activity	%	19.0
	12276671	CHEMBL2219205	Millipore: Percentage of residual kinase activity of TBK1 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	c1cc(-c2cnn3cc(-c4ccc(OCCN5CCCCC5)cc4)cnc23)ccn1		CHEMBL478629	=	Residual Activity	%	64.0	CHEMBL5408	Homo sapiens	Residual Activity	%	64.0
	12276672	CHEMBL2219205	Millipore: Percentage of residual kinase activity of TBK1 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	NC(=O)c1ccc(-c2nc(-c3ccc4c(c3)OCCO4)c(-c3ccccn3)[nH]2)cc1		CHEMBL410456	=	Residual Activity	%	83.0	CHEMBL5408	Homo sapiens	Residual Activity	%	83.0
	12276673	CHEMBL2219205	Millipore: Percentage of residual kinase activity of TBK1 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	CC(C)c1nn(-c2c(Cl)cccc2Cl)c2nc(Cc3ccc(OCCO)cc3)[nH]c(=O)c12		CHEMBL258721	=	Residual Activity	%	82.0	CHEMBL5408	Homo sapiens	Residual Activity	%	82.0
	12276674	CHEMBL2219205	Millipore: Percentage of residual kinase activity of TBK1 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	CC(=O)O/N=C1C(=C2\C(=O)Nc3cc(Br)ccc32)\Nc2ccccc2\1		CHEMBL2218941	=	Residual Activity	%	57.0	CHEMBL5408	Homo sapiens	Residual Activity	%	57.0
	12276675	CHEMBL2219205	Millipore: Percentage of residual kinase activity of TBK1 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	N#C/C(=C1/Nc2ccccc2S1)c1ccnc(NCCc2cccnc2)n1		CHEMBL191384	=	Residual Activity	%	71.0	CHEMBL5408	Homo sapiens	Residual Activity	%	71.0
	12276676	CHEMBL2219205	Millipore: Percentage of residual kinase activity of TBK1 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	Nc1ncnc2[nH]nc(Nc3ccc(F)cc3)c12		CHEMBL1240885	=	Residual Activity	%	77.0	CHEMBL5408	Homo sapiens	Residual Activity	%	77.0
	12276677	CHEMBL2219205	Millipore: Percentage of residual kinase activity of TBK1 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	CCc1nc(-c2ccc(OC)cc2)[nH]c1-c1ccncc1		CHEMBL278724	=	Residual Activity	%	108.0	CHEMBL5408	Homo sapiens	Residual Activity	%	108.0
	12276678	CHEMBL2219205	Millipore: Percentage of residual kinase activity of TBK1 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	COc1ccc2c(c1)/C(=C/c1cnc[nH]1)C(=O)N2		CHEMBL258805	=	Residual Activity	%	82.0	CHEMBL5408	Homo sapiens	Residual Activity	%	82.0
	12276679	CHEMBL2219205	Millipore: Percentage of residual kinase activity of TBK1 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	O=C(O)/C=C/c1cc(Br)c(Br)c(Br)c1Br		CHEMBL270724	=	Residual Activity	%	69.0	CHEMBL5408	Homo sapiens	Residual Activity	%	69.0
	12276680	CHEMBL2219205	Millipore: Percentage of residual kinase activity of TBK1 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	N/C(=N\[N+](=O)[O-])N/N=C\c1ccc(-c2cccc([N+](=O)[O-])c2)o1		CHEMBL221271	=	Residual Activity	%	94.0	CHEMBL5408	Homo sapiens	Residual Activity	%	94.0
	12276681	CHEMBL2219205	Millipore: Percentage of residual kinase activity of TBK1 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	O=C1NC(=O)C(c2cn(CCCO)c3ncccc23)=C1c1cnccn1		CHEMBL272629	=	Residual Activity	%	92.0	CHEMBL5408	Homo sapiens	Residual Activity	%	92.0
	12276682	CHEMBL2219205	Millipore: Percentage of residual kinase activity of TBK1 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	N#Cc1c(NC(=O)c2cccc3ccccc23)sc2c1CCCC2		CHEMBL233001	=	Residual Activity	%	67.0	CHEMBL5408	Homo sapiens	Residual Activity	%	67.0
	12276683	CHEMBL2219205	Millipore: Percentage of residual kinase activity of TBK1 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	Nc1ccc2ncnc(NCCc3ccc(Oc4ccccc4)cc3)c2c1		CHEMBL522502	=	Residual Activity	%	94.0	CHEMBL5408	Homo sapiens	Residual Activity	%	94.0
	12276684	CHEMBL2219205	Millipore: Percentage of residual kinase activity of TBK1 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	Oc1ccc(-c2nc(-c3ccc(F)cc3)c(-c3ccncc3)[nH]2)cc1		CHEMBL278041	=	Residual Activity	%	110.0	CHEMBL5408	Homo sapiens	Residual Activity	%	110.0
	12276685	CHEMBL2219205	Millipore: Percentage of residual kinase activity of TBK1 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	N#Cc1cnc2cnc(NCc3cccnc3)cc2c1Nc1ccc(F)c(Cl)c1		CHEMBL200381	=	Residual Activity	%	5.0	CHEMBL5408	Homo sapiens	Residual Activity	%	5.0
	12276686	CHEMBL2219206	Millipore: Percentage of residual kinase activity of TBK1 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	CC(C)(C)c1cc(C=C(C#N)C#N)cc(Br)c1O		CHEMBL2218926	=	Residual Activity	%	94.0	CHEMBL5408	Homo sapiens	Residual Activity	%	94.0
	12276687	CHEMBL2219206	Millipore: Percentage of residual kinase activity of TBK1 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	O=C1NC(=O)C(c2c[nH]c3ccccc23)=C1c1c[nH]c2ccccc12		CHEMBL266487	=	Residual Activity	%	14.0	CHEMBL5408	Homo sapiens	Residual Activity	%	14.0
	12276688	CHEMBL2219206	Millipore: Percentage of residual kinase activity of TBK1 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	O=C(Nc1cccc(Nc2cc(Nc3cccc(C(F)(F)F)c3)ncn2)c1)C1CC1		CHEMBL387187	=	Residual Activity	%	61.0	CHEMBL5408	Homo sapiens	Residual Activity	%	61.0
	12276689	CHEMBL2219206	Millipore: Percentage of residual kinase activity of TBK1 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	COc1ccc(Cl)cc1NC(=O)Nc1cc(C)nc2ccccc12		CHEMBL439259	=	Residual Activity	%	69.0	CHEMBL5408	Homo sapiens	Residual Activity	%	69.0
	12276690	CHEMBL2219206	Millipore: Percentage of residual kinase activity of TBK1 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	CNc1cc2c(Nc3cccc(Br)c3)ncnc2cn1		CHEMBL53753	=	Residual Activity	%	64.0	CHEMBL5408	Homo sapiens	Residual Activity	%	64.0
	12276691	CHEMBL2219206	Millipore: Percentage of residual kinase activity of TBK1 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	Nc1ncnc2c1cnn2-c1ccccc1		CHEMBL65063	=	Residual Activity	%	81.0	CHEMBL5408	Homo sapiens	Residual Activity	%	81.0
	12276692	CHEMBL2219206	Millipore: Percentage of residual kinase activity of TBK1 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	Cn1cc(/C=C2\C(=O)Nc3ccc(S(N)(=O)=O)cc32)c2ccccc21		CHEMBL104279	=	Residual Activity	%	10.0	CHEMBL5408	Homo sapiens	Residual Activity	%	10.0
	12276693	CHEMBL2219206	Millipore: Percentage of residual kinase activity of TBK1 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	COc1cc2ncnc(Nc3cccc(Cl)c3)c2cc1OC		CHEMBL7917	=	Residual Activity	%	59.0	CHEMBL5408	Homo sapiens	Residual Activity	%	59.0
	12276694	CHEMBL2219206	Millipore: Percentage of residual kinase activity of TBK1 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	Cc1nc2cc3nc(-c4cccs4)cnc3cc2n1C		CHEMBL2218927	=	Residual Activity	%	87.0	CHEMBL5408	Homo sapiens	Residual Activity	%	87.0
	12276695	CHEMBL2219206	Millipore: Percentage of residual kinase activity of TBK1 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	Cn1cnc2cc3c(Nc4cccc(Br)c4)ncnc3cc21		CHEMBL174426	=	Residual Activity	%	63.0	CHEMBL5408	Homo sapiens	Residual Activity	%	63.0
	12276696	CHEMBL2219206	Millipore: Percentage of residual kinase activity of TBK1 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	CC#CC(=O)Nc1cc2c(Nc3ccc(F)c(Cl)c3)ncnc2cn1		CHEMBL203644	=	Residual Activity	%	72.0	CHEMBL5408	Homo sapiens	Residual Activity	%	72.0
	12276697	CHEMBL2219206	Millipore: Percentage of residual kinase activity of TBK1 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	O=C(Nc1nc2ccccc2n1CCN1CCOCC1)c1cccc([N+](=O)[O-])c1		CHEMBL379787	=	Residual Activity	%	60.0	CHEMBL5408	Homo sapiens	Residual Activity	%	60.0
	12276698	CHEMBL2219206	Millipore: Percentage of residual kinase activity of TBK1 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	CCC(=O)Nc1ccc2ncnc(Nc3cccc(Br)c3)c2c1		CHEMBL188762	=	Residual Activity	%	68.0	CHEMBL5408	Homo sapiens	Residual Activity	%	68.0
	12276699	CHEMBL2219206	Millipore: Percentage of residual kinase activity of TBK1 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	CC(C)(C)n1nc(Cc2cccc3ccccc23)c2c(N)ncnc21		CHEMBL573578	=	Residual Activity	%	67.0	CHEMBL5408	Homo sapiens	Residual Activity	%	67.0
	12276700	CHEMBL2219206	Millipore: Percentage of residual kinase activity of TBK1 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	NCCNc1ncc(C(N)=O)c(Nc2cccc(C(F)(F)F)c2)n1		CHEMBL471901	=	Residual Activity	%	54.0	CHEMBL5408	Homo sapiens	Residual Activity	%	54.0
	12276701	CHEMBL2219206	Millipore: Percentage of residual kinase activity of TBK1 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	CCOC(=O)c1c(C)[nH]c(/C=C2\C(=O)Nc3ccccc32)c1C		CHEMBL86943	=	Residual Activity	%	85.0	CHEMBL5408	Homo sapiens	Residual Activity	%	85.0
	12276702	CHEMBL2219206	Millipore: Percentage of residual kinase activity of TBK1 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	CC[n+]1c(/C=C/N(C)c2ccccc2)n(-c2ccccc2)c2ccc(-c3nc4ccccc4s3)cc21		CHEMBL1186409	=	Residual Activity	%	68.0	CHEMBL5408	Homo sapiens	Residual Activity	%	68.0
	12276703	CHEMBL2219206	Millipore: Percentage of residual kinase activity of TBK1 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	COc1ccc2c(c[n+](C)c3c4cc5c(cc4ccc23)OCO5)c1OC		CHEMBL13045	=	Residual Activity	%	65.0	CHEMBL5408	Homo sapiens	Residual Activity	%	65.0
	12276704	CHEMBL2219206	Millipore: Percentage of residual kinase activity of TBK1 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	COc1ccc(C(=O)Nc2sc3c(c2C(N)=O)CCCC3)cc1OC		CHEMBL210833	=	Residual Activity	%	71.0	CHEMBL5408	Homo sapiens	Residual Activity	%	71.0
	12276705	CHEMBL2219206	Millipore: Percentage of residual kinase activity of TBK1 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	CC(C)(C)c1nc2c3ccc(F)cc3c3c(=O)[nH]ccc3c2[nH]1		CHEMBL21156	=	Residual Activity	%	3.0	CHEMBL5408	Homo sapiens	Residual Activity	%	3.0
	12276706	CHEMBL2219206	Millipore: Percentage of residual kinase activity of TBK1 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	CCCC(=O)Oc1ccc2[nH]c(C(=O)c3cc4ccccc4[nH]3)cc2c1		CHEMBL266325	=	Residual Activity	%	59.0	CHEMBL5408	Homo sapiens	Residual Activity	%	59.0
	12276707	CHEMBL2219206	Millipore: Percentage of residual kinase activity of TBK1 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	O=C1NC(=O)c2cc(Nc3ccc(F)cc3)c(Nc3ccc(F)cc3)cc21		CHEMBL7939	=	Residual Activity	%	54.0	CHEMBL5408	Homo sapiens	Residual Activity	%	54.0
	12276708	CHEMBL2219206	Millipore: Percentage of residual kinase activity of TBK1 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	O=[N+]([O-])/C=C/c1ccc2c(c1)OCO2		CHEMBL596380	=	Residual Activity	%	81.0	CHEMBL5408	Homo sapiens	Residual Activity	%	81.0
	12276709	CHEMBL2219206	Millipore: Percentage of residual kinase activity of TBK1 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	O=C(Nc1ccc(Cl)cc1)c1ccccc1NCc1ccncc1		CHEMBL101683	=	Residual Activity	%	90.0	CHEMBL5408	Homo sapiens	Residual Activity	%	90.0
	12276710	CHEMBL2219206	Millipore: Percentage of residual kinase activity of TBK1 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	CN1N=C(N)c2cn([C@@H]3O[C@H](CO)[C@@H](O)[C@H]3O)c3ncnc1c23		CHEMBL331237	=	Residual Activity	%	92.0	CHEMBL5408	Homo sapiens	Residual Activity	%	92.0
	12276711	CHEMBL2219206	Millipore: Percentage of residual kinase activity of TBK1 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	CCOc1cc2ncnc(Nc3cccc(Br)c3)c2cc1OCC		CHEMBL35820	=	Residual Activity	%	33.0	CHEMBL5408	Homo sapiens	Residual Activity	%	33.0
	12276712	CHEMBL2219206	Millipore: Percentage of residual kinase activity of TBK1 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	O=C(c1cc2cc(O)ccc2[nH]1)c1cc2cc(O)ccc2[nH]1		CHEMBL377193	=	Residual Activity	%	2.0	CHEMBL5408	Homo sapiens	Residual Activity	%	2.0
	12276713	CHEMBL2219206	Millipore: Percentage of residual kinase activity of TBK1 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	COc1cc2ncnc(Nc3ccc(O)c(Br)c3)c2cc1OC		CHEMBL473773	=	Residual Activity	%	15.0	CHEMBL5408	Homo sapiens	Residual Activity	%	15.0
	12276714	CHEMBL2219206	Millipore: Percentage of residual kinase activity of TBK1 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	COc1cc2ncnc(N3CCN(C(=O)Nc4ccc(Oc5ccccc5)cc4)CC3)c2cc1OC		CHEMBL102346	=	Residual Activity	%	53.0	CHEMBL5408	Homo sapiens	Residual Activity	%	53.0
	12276715	CHEMBL2219206	Millipore: Percentage of residual kinase activity of TBK1 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	O=C1NC(=O)C(c2cn(CCCn3ccnc3)c3ccccc23)=C1Nc1ccccc1		CHEMBL366266	=	Residual Activity	%	9.0	CHEMBL5408	Homo sapiens	Residual Activity	%	9.0
	12276716	CHEMBL2219206	Millipore: Percentage of residual kinase activity of TBK1 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	c1ccc(-c2n[nH]cc2-c2ccnc3ccccc23)nc1		CHEMBL261454	=	Residual Activity	%	66.0	CHEMBL5408	Homo sapiens	Residual Activity	%	66.0
	12276717	CHEMBL2219206	Millipore: Percentage of residual kinase activity of TBK1 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	COc1cc2nccc(Oc3ccc(NC(=O)Nc4cc(C)on4)c(Cl)c3)c2cc1OC		CHEMBL1289494	=	Residual Activity	%	68.0	CHEMBL5408	Homo sapiens	Residual Activity	%	68.0
	12276718	CHEMBL2219206	Millipore: Percentage of residual kinase activity of TBK1 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	O=c1[nH]c2ccccc2n1C1CCN(Cc2ccc(-c3nc4cc5[nH]cnc5cc4nc3-c3ccccc3)cc2)CC1		CHEMBL258844	=	Residual Activity	%	68.0	CHEMBL5408	Homo sapiens	Residual Activity	%	68.0
	12276719	CHEMBL2219206	Millipore: Percentage of residual kinase activity of TBK1 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	O=c1cc(N2CCOCC2)oc2c1ccc1ccccc12		CHEMBL104468	=	Residual Activity	%	71.0	CHEMBL5408	Homo sapiens	Residual Activity	%	71.0
	12276720	CHEMBL2219206	Millipore: Percentage of residual kinase activity of TBK1 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	COc1ccc(COc2ccc(Cc3cnc(N)nc3N)cc2OC)cc1		CHEMBL261849	=	Residual Activity	%	58.0	CHEMBL5408	Homo sapiens	Residual Activity	%	58.0
	12276721	CHEMBL2219206	Millipore: Percentage of residual kinase activity of TBK1 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	CC(C)N(CCC(=O)c1ccc2ccccc2c1)Cc1ccccc1		CHEMBL596674	=	Residual Activity	%	51.0	CHEMBL5408	Homo sapiens	Residual Activity	%	51.0
	12276722	CHEMBL2219206	Millipore: Percentage of residual kinase activity of TBK1 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	COc1cc2c(cc1OC)-c1n[nH]c(Nc3cccc(F)c3)c1C2		CHEMBL120077	=	Residual Activity	%	43.0	CHEMBL5408	Homo sapiens	Residual Activity	%	43.0
	12276723	CHEMBL2219206	Millipore: Percentage of residual kinase activity of TBK1 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	CO[C@H]1C[C@@H]2CC[C@@H](C)[C@@](O)(O2)C(=O)C(=O)N2CCCC[C@H]2C(=O)O[C@H]([C@H](C)C[C@@H]2CC[C@@H](O)[C@H](OC)C2)CC(=O)[C@H](C)/C=C(\C)[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)/C=C/C=C/C=C/1C		CHEMBL413	=	Residual Activity	%	55.0	CHEMBL5408	Homo sapiens	Residual Activity	%	55.0
	12276724	CHEMBL2219206	Millipore: Percentage of residual kinase activity of TBK1 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	Cc1cccc(-c2[nH]c(C(C)(C)C)nc2-c2ccc3c(c2)OCO3)n1		CHEMBL226838	=	Residual Activity	%	72.0	CHEMBL5408	Homo sapiens	Residual Activity	%	72.0
	12276725	CHEMBL2219206	Millipore: Percentage of residual kinase activity of TBK1 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	O=C1Nc2ccc(Br)cc2/C1=C\c1cc2c([nH]1)CCCC2		CHEMBL2218925	=	Residual Activity	%	65.0	CHEMBL5408	Homo sapiens	Residual Activity	%	65.0
	12276726	CHEMBL2219206	Millipore: Percentage of residual kinase activity of TBK1 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	CCN(CC)CCCCN1c2ccccc2Oc2ccc(Cl)cc21		CHEMBL1398474	=	Residual Activity	%	82.0	CHEMBL5408	Homo sapiens	Residual Activity	%	82.0
	12276727	CHEMBL2219206	Millipore: Percentage of residual kinase activity of TBK1 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	CC(=O)c1ccc(N2CCOCC2)cc1O		CHEMBL1317546	=	Residual Activity	%	70.0	CHEMBL5408	Homo sapiens	Residual Activity	%	70.0
	12276728	CHEMBL2219206	Millipore: Percentage of residual kinase activity of TBK1 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	Cn1c2ccccc2c2c3c(c4c5ccccc5n(CCC#N)c4c21)CNC3=O		CHEMBL302449	=	Residual Activity	%	9.0	CHEMBL5408	Homo sapiens	Residual Activity	%	9.0
	12276729	CHEMBL2219206	Millipore: Percentage of residual kinase activity of TBK1 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	O=C1Nc2ccc(-c3cccnc3)cc2/C1=C\c1ccc[nH]1		CHEMBL2218929	=	Residual Activity	%	0.0	CHEMBL5408	Homo sapiens	Residual Activity	%	0.0
	12276730	CHEMBL2219206	Millipore: Percentage of residual kinase activity of TBK1 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	COc1cc2nccc(Oc3ccc(NC(=S)NC(=O)c4ccccc4C)cc3)c2cc1OC		CHEMBL2218930	=	Residual Activity	%	48.0	CHEMBL5408	Homo sapiens	Residual Activity	%	48.0
	12276731	CHEMBL2219206	Millipore: Percentage of residual kinase activity of TBK1 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	c1ccc2c(-c3ccncc3)c[nH]c2c1		CHEMBL380071	=	Residual Activity	%	51.0	CHEMBL5408	Homo sapiens	Residual Activity	%	51.0
	12276732	CHEMBL2219206	Millipore: Percentage of residual kinase activity of TBK1 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	COc1ccc(C=C(C#N)C#N)cc1		CHEMBL77456	=	Residual Activity	%	73.0	CHEMBL5408	Homo sapiens	Residual Activity	%	73.0
	12276733	CHEMBL2219206	Millipore: Percentage of residual kinase activity of TBK1 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	Cc1cc(C)c(/C=C2\C(=O)Nc3ccccc32)[nH]1		CHEMBL276711	=	Residual Activity	%	52.0	CHEMBL5408	Homo sapiens	Residual Activity	%	52.0
	12276734	CHEMBL2219206	Millipore: Percentage of residual kinase activity of TBK1 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	O=C1c2ccccc2-c2nc3nnnn3nc21		CHEMBL599894	=	Residual Activity	%	83.0	CHEMBL5408	Homo sapiens	Residual Activity	%	83.0
	12276735	CHEMBL2219206	Millipore: Percentage of residual kinase activity of TBK1 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	Oc1cccc(-c2nc(N3CCOCC3)c3oc4ncccc4c3n2)c1		CHEMBL573339	=	Residual Activity	%	67.0	CHEMBL5408	Homo sapiens	Residual Activity	%	67.0
	12276736	CHEMBL2219206	Millipore: Percentage of residual kinase activity of TBK1 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	COc1ccc2c(c1)c(C1=C(c3c[nH]c4ccccc34)C(=O)NC1=O)cn2CCCN(C)C		CHEMBL261491	=	Residual Activity	%	24.0	CHEMBL5408	Homo sapiens	Residual Activity	%	24.0
	12278378	CHEMBL2219206	Millipore: Percentage of residual kinase activity of TBK1 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	Nc1ncnc2c1c(-c1ccc(Oc3ccccc3)cc1)cn2C1CCCC1		CHEMBL47940	=	Residual Activity	%	54.0	CHEMBL5408	Homo sapiens	Residual Activity	%	54.0
	12278379	CHEMBL2219206	Millipore: Percentage of residual kinase activity of TBK1 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	O=C1Nc2ccc3ncsc3c2/C1=C/c1c[nH]cn1		CHEMBL235641	=	Residual Activity	%	0.0	CHEMBL5408	Homo sapiens	Residual Activity	%	0.0
	12278380	CHEMBL2219206	Millipore: Percentage of residual kinase activity of TBK1 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	Cc1cncc2cccc(S(=O)(=O)N3CCCN(C(=O)CN)C[C@H]3C)c12		CHEMBL2218931	=	Residual Activity	%	55.0	CHEMBL5408	Homo sapiens	Residual Activity	%	55.0
	12278381	CHEMBL2219206	Millipore: Percentage of residual kinase activity of TBK1 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	N#C/C(=C\c1ccc(O)c(O)c1)C(=O)NCc1ccccc1		CHEMBL56543	=	Residual Activity	%	65.0	CHEMBL5408	Homo sapiens	Residual Activity	%	65.0
	12278382	CHEMBL2219206	Millipore: Percentage of residual kinase activity of TBK1 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	COc1ccc(-c2cnc3c(-c4ccsc4)cnn3c2)cc1		CHEMBL92461	=	Residual Activity	%	85.0	CHEMBL5408	Homo sapiens	Residual Activity	%	85.0
	12278383	CHEMBL2219206	Millipore: Percentage of residual kinase activity of TBK1 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	COc1cc2ncnc(Nc3ccc(NC(=O)c4ccccc4)cc3)c2cc1OC		CHEMBL382590	=	Residual Activity	%	75.0	CHEMBL5408	Homo sapiens	Residual Activity	%	75.0
	12278384	CHEMBL2219206	Millipore: Percentage of residual kinase activity of TBK1 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	O=c1c2ccccc2[nH]c(=S)n1CCN1CCC(=C(c2ccc(F)cc2)c2ccc(F)cc2)CC1		CHEMBL261131	=	Residual Activity	%	68.0	CHEMBL5408	Homo sapiens	Residual Activity	%	68.0
	12278385	CHEMBL2219206	Millipore: Percentage of residual kinase activity of TBK1 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	c1ccc(-c2n[nH]c3c2oc2ccccc23)cc1		CHEMBL406375	=	Residual Activity	%	55.0	CHEMBL5408	Homo sapiens	Residual Activity	%	55.0
	12278386	CHEMBL2219206	Millipore: Percentage of residual kinase activity of TBK1 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	O=c1cc(N2CCOCC2)oc2c(-c3ccccc3)cccc12		CHEMBL98350	=	Residual Activity	%	55.0	CHEMBL5408	Homo sapiens	Residual Activity	%	55.0
	12278387	CHEMBL2219206	Millipore: Percentage of residual kinase activity of TBK1 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	O=C1Nc2ccc(Cl)cc2/C1=C/c1cc(Cl)c(O)c(Cl)c1		CHEMBL2218932	=	Residual Activity	%	38.0	CHEMBL5408	Homo sapiens	Residual Activity	%	38.0
	12278388	CHEMBL2219206	Millipore: Percentage of residual kinase activity of TBK1 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	CO[C@@H]1[C@H](N(C)C(=O)c2ccccc2)C[C@H]2O[C@]1(C)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)C(=O)NC4		CHEMBL608533	=	Residual Activity	%	1.0	CHEMBL5408	Homo sapiens	Residual Activity	%	1.0
	12278389	CHEMBL2219206	Millipore: Percentage of residual kinase activity of TBK1 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	N#CC(C#N)=C(N)/C(C#N)=C/c1ccc(O)cc1		CHEMBL76589	=	Residual Activity	%	72.0	CHEMBL5408	Homo sapiens	Residual Activity	%	72.0
	12278390	CHEMBL2219206	Millipore: Percentage of residual kinase activity of TBK1 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	O=C(c1ccccc1)c1ccc(N2CCOCC2)cc1O		CHEMBL478980	=	Residual Activity	%	77.0	CHEMBL5408	Homo sapiens	Residual Activity	%	77.0
	12278391	CHEMBL2219206	Millipore: Percentage of residual kinase activity of TBK1 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	NC(=O)c1cccc(-c2cc(Nc3ccc(OC(F)(F)F)cc3)ncn2)c1		CHEMBL483847	=	Residual Activity	%	79.0	CHEMBL5408	Homo sapiens	Residual Activity	%	79.0
	12278392	CHEMBL2219206	Millipore: Percentage of residual kinase activity of TBK1 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	CN(C)c1ccc(/C=C2\C(=O)Nc3ccccc32)cc1		CHEMBL328710	=	Residual Activity	%	45.0	CHEMBL5408	Homo sapiens	Residual Activity	%	45.0
	12278393	CHEMBL2219206	Millipore: Percentage of residual kinase activity of TBK1 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	CO[C@H]1/C=C/C=C(\C)C(=O)NC2=CC(=O)C=C(C2=O)[C@H](OC)[C@@H](C)C[C@H](OC)[C@H](OC)[C@@H](C)/C=C(\C)[C@@H]1OC(N)=O		CHEMBL479533	=	Residual Activity	%	69.0	CHEMBL5408	Homo sapiens	Residual Activity	%	69.0
	12278394	CHEMBL2219206	Millipore: Percentage of residual kinase activity of TBK1 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	O=c1cc(N2CCNCC2)oc2c(-c3ccccc3)cccc12		CHEMBL1363184	=	Residual Activity	%	54.0	CHEMBL5408	Homo sapiens	Residual Activity	%	54.0
	12278395	CHEMBL2219206	Millipore: Percentage of residual kinase activity of TBK1 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	O=C1NC(=O)/C(=C\c2ccc3nccnc3c2)S1		CHEMBL2218934	=	Residual Activity	%	27.0	CHEMBL5408	Homo sapiens	Residual Activity	%	27.0
	12278396	CHEMBL2219206	Millipore: Percentage of residual kinase activity of TBK1 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	COc1cc2ncnc(Nc3ccc(Oc4ccccc4)cc3)c2cc1OC		CHEMBL97771	=	Residual Activity	%	57.0	CHEMBL5408	Homo sapiens	Residual Activity	%	57.0
	12278397	CHEMBL2219206	Millipore: Percentage of residual kinase activity of TBK1 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	Cc1cc2ncc(-c3ccccc3)nc2cc1C		CHEMBL7724	=	Residual Activity	%	73.0	CHEMBL5408	Homo sapiens	Residual Activity	%	73.0
	12278398	CHEMBL2219206	Millipore: Percentage of residual kinase activity of TBK1 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	O=C(Nc1cccc(Nc2nccc(Nc3cccc(C(F)(F)F)c3)n2)c1)C1CC1		CHEMBL383899	=	Residual Activity	%	32.0	CHEMBL5408	Homo sapiens	Residual Activity	%	32.0
	12278399	CHEMBL2219206	Millipore: Percentage of residual kinase activity of TBK1 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	CN(C)CCCn1cc(C2=C(c3c[nH]c4ccccc34)C(=O)NC2=O)c2ccccc21		CHEMBL7463	=	Residual Activity	%	22.0	CHEMBL5408	Homo sapiens	Residual Activity	%	22.0
	12278400	CHEMBL2219206	Millipore: Percentage of residual kinase activity of TBK1 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	COc1cc2ncnc(Nc3ccc(OCc4ccccc4)cc3)c2cc1OC		CHEMBL563845	=	Residual Activity	%	71.0	CHEMBL5408	Homo sapiens	Residual Activity	%	71.0
	12278401	CHEMBL2219206	Millipore: Percentage of residual kinase activity of TBK1 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	c1ccc(-c2cnc(Nc3ccc(OCCN4CCCC4)cc3)s2)cc1		CHEMBL2218935	=	Residual Activity	%	23.0	CHEMBL5408	Homo sapiens	Residual Activity	%	23.0
	12278402	CHEMBL2219206	Millipore: Percentage of residual kinase activity of TBK1 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	CC1=C(C(=O)N2CCN(C)CC2)C(C)=C(/C=C2\C(=O)Nc3ccc(S(=O)(=O)N(C)c4cccc(Cl)c4)cc32)C1		CHEMBL2218936	=	Residual Activity	%	20.0	CHEMBL5408	Homo sapiens	Residual Activity	%	20.0
	12278403	CHEMBL2219206	Millipore: Percentage of residual kinase activity of TBK1 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	O=C1NC(=O)/C(=C/c2ccc3c(c2)OC(F)(F)O3)S1		CHEMBL1231533	=	Residual Activity	%	67.0	CHEMBL5408	Homo sapiens	Residual Activity	%	67.0
	12278404	CHEMBL2219206	Millipore: Percentage of residual kinase activity of TBK1 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	CCN(CC)CCNC(=O)c1c(C)[nH]c(/C=C2\C(=O)Nc3ccc(Cl)cc32)c1C		CHEMBL13485	=	Residual Activity	%	1.0	CHEMBL5408	Homo sapiens	Residual Activity	%	1.0
	12278405	CHEMBL2219206	Millipore: Percentage of residual kinase activity of TBK1 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	COc1cc2ncc(-c3ccccc3)nc2cc1OC		CHEMBL71191	=	Residual Activity	%	76.0	CHEMBL5408	Homo sapiens	Residual Activity	%	76.0
	12278406	CHEMBL2219206	Millipore: Percentage of residual kinase activity of TBK1 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	CN[C@@H]1C[C@H]2O[C@@](C)([C@@H]1OC)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)C(=O)NC4		CHEMBL388978	=	Residual Activity	%	0.0	CHEMBL5408	Homo sapiens	Residual Activity	%	0.0
	12278407	CHEMBL2219206	Millipore: Percentage of residual kinase activity of TBK1 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	CN([C@@H](Cc1ccc(OS(=O)(=O)c2cccc3cnccc23)cc1)C(=O)N1CCN(c2ccccc2)CC1)S(=O)(=O)c1cccc2cnccc12		CHEMBL28324	=	Residual Activity	%	95.0	CHEMBL5408	Homo sapiens	Residual Activity	%	95.0
	12278408	CHEMBL2219206	Millipore: Percentage of residual kinase activity of TBK1 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	Nc1nc(Nc2ccc(S(N)(=O)=O)cc2)nn1C(=O)c1c(F)cccc1F		CHEMBL191003	=	Residual Activity	%	19.0	CHEMBL5408	Homo sapiens	Residual Activity	%	19.0
	12278409	CHEMBL2219206	Millipore: Percentage of residual kinase activity of TBK1 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	O=C1NC(=O)c2c1c1c3ccccc3[nH]c1c1[nH]c3cc(Br)ccc3c21		CHEMBL64758	=	Residual Activity	%	54.0	CHEMBL5408	Homo sapiens	Residual Activity	%	54.0
	12278410	CHEMBL2219206	Millipore: Percentage of residual kinase activity of TBK1 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	C[C@@H](N)[C@H]1CC[C@H](C(=O)Nc2ccncc2)CC1		CHEMBL559147	=	Residual Activity	%	99.0	CHEMBL5408	Homo sapiens	Residual Activity	%	99.0
	12278411	CHEMBL2219206	Millipore: Percentage of residual kinase activity of TBK1 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	CN(C)S(=O)(=O)c1ccc2c(c1)/C(=C/c1cc3c([nH]1)CCCC3)C(=O)N2		CHEMBL605003	=	Residual Activity	%	60.0	CHEMBL5408	Homo sapiens	Residual Activity	%	60.0
	12278412	CHEMBL2219206	Millipore: Percentage of residual kinase activity of TBK1 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	O=C(CCCc1ccc(-c2ccccc2F)cc1)Nc1ccc(O)cc1		CHEMBL235658	=	Residual Activity	%	73.0	CHEMBL5408	Homo sapiens	Residual Activity	%	73.0
	12278413	CHEMBL2219206	Millipore: Percentage of residual kinase activity of TBK1 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	CSc1nc(-c2ccc(F)cc2)c(-c2ccnc(NC(C)c3ccccc3)c2)[nH]1		CHEMBL111364	=	Residual Activity	%	77.0	CHEMBL5408	Homo sapiens	Residual Activity	%	77.0
	12278414	CHEMBL2219206	Millipore: Percentage of residual kinase activity of TBK1 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	C[S+]([O-])c1ccc(-c2nc(-c3ccc(F)cc3)c(-c3ccncc3)[nH]2)cc1		CHEMBL10	=	Residual Activity	%	111.0	CHEMBL5408	Homo sapiens	Residual Activity	%	111.0
	12278415	CHEMBL2219206	Millipore: Percentage of residual kinase activity of TBK1 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	O=c1cc(-c2cccc3c2Sc2ccccc2S3)oc(N2CCOCC2)c1		CHEMBL222102	=	Residual Activity	%	80.0	CHEMBL5408	Homo sapiens	Residual Activity	%	80.0
	12278416	CHEMBL2219206	Millipore: Percentage of residual kinase activity of TBK1 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	O=Nc1c(-c2c(O)[nH]c3ccccc23)[nH]c2ccccc12		CHEMBL126077	=	Residual Activity	%	1.0	CHEMBL5408	Homo sapiens	Residual Activity	%	1.0
	12278417	CHEMBL2219206	Millipore: Percentage of residual kinase activity of TBK1 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	COc1ccc(OC)c2c(=S)c3ccccc3[nH]c12		CHEMBL1331734	=	Residual Activity	%	67.0	CHEMBL5408	Homo sapiens	Residual Activity	%	67.0
	12278418	CHEMBL2219206	Millipore: Percentage of residual kinase activity of TBK1 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	Nc1n[nH]c2nnc(-c3c(-c4ccccc4)nn4ccccc34)cc12		CHEMBL259551	=	Residual Activity	%	67.0	CHEMBL5408	Homo sapiens	Residual Activity	%	67.0
	12278419	CHEMBL2219206	Millipore: Percentage of residual kinase activity of TBK1 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	Cc1cc(Nc2nc(-c3ccccc3)nc3ccccc23)n[nH]1		CHEMBL359482	=	Residual Activity	%	0.0	CHEMBL5408	Homo sapiens	Residual Activity	%	0.0
	12278420	CHEMBL2219206	Millipore: Percentage of residual kinase activity of TBK1 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	CCOc1nc(NC(=O)Cc2cc(OC)ccc2OC)cc(N)c1C#N		CHEMBL210618	=	Residual Activity	%	68.0	CHEMBL5408	Homo sapiens	Residual Activity	%	68.0
	12278421	CHEMBL2219206	Millipore: Percentage of residual kinase activity of TBK1 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	Oc1c(-c2ccc(F)cc2)c(-c2ccncc2)nn1-c1ccc(Cl)cc1		CHEMBL91730	=	Residual Activity	%	97.0	CHEMBL5408	Homo sapiens	Residual Activity	%	97.0
	12278422	CHEMBL2219206	Millipore: Percentage of residual kinase activity of TBK1 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	O=S(=O)(c1cccc2cnccc12)N1CCCNCC1		CHEMBL38380	=	Residual Activity	%	97.0	CHEMBL5408	Homo sapiens	Residual Activity	%	97.0
	12278423	CHEMBL2219206	Millipore: Percentage of residual kinase activity of TBK1 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	O=C(NC(NC(=S)Nc1ccc(F)c([N+](=O)[O-])c1)C(Cl)(Cl)Cl)C(c1ccccc1)c1ccccc1		CHEMBL1221601	=	Residual Activity	%	74.0	CHEMBL5408	Homo sapiens	Residual Activity	%	74.0
	12278424	CHEMBL2219206	Millipore: Percentage of residual kinase activity of TBK1 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	Cc1ccc(S(=O)(=O)/C=C/C#N)cc1		CHEMBL403183	=	Residual Activity	%	81.0	CHEMBL5408	Homo sapiens	Residual Activity	%	81.0
	12278425	CHEMBL2219206	Millipore: Percentage of residual kinase activity of TBK1 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	Cc1ccc(NC2=CC(=O)c3sc(C)nc3C2=O)cc1		CHEMBL290904	=	Residual Activity	%	74.0	CHEMBL5408	Homo sapiens	Residual Activity	%	74.0
	12278426	CHEMBL2219206	Millipore: Percentage of residual kinase activity of TBK1 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	Oc1n[nH]c2nnc(-c3c(-c4ccccc4)nn4ccccc34)cc12		CHEMBL2218938	=	Residual Activity	%	60.0	CHEMBL5408	Homo sapiens	Residual Activity	%	60.0
	12278427	CHEMBL2219206	Millipore: Percentage of residual kinase activity of TBK1 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	O=C1NC(=O)c2c1c1c3ccccc3[nH]c1n1cncc21		CHEMBL413188	=	Residual Activity	%	35.0	CHEMBL5408	Homo sapiens	Residual Activity	%	35.0
	12278428	CHEMBL2219206	Millipore: Percentage of residual kinase activity of TBK1 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	COC(=O)[C@@]1(O)C[C@H]2O[C@]1(C)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)C(=O)NC4		CHEMBL281948	=	Residual Activity	%	3.0	CHEMBL5408	Homo sapiens	Residual Activity	%	3.0
	12278429	CHEMBL2219206	Millipore: Percentage of residual kinase activity of TBK1 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	COc1cccc(-c2cc(=O)c3ccccc3o2)c1N		CHEMBL35482	=	Residual Activity	%	95.0	CHEMBL5408	Homo sapiens	Residual Activity	%	95.0
	12278430	CHEMBL2219206	Millipore: Percentage of residual kinase activity of TBK1 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	O=C1NC(=O)c2c1c1c3ccccc3n3c1c1c2c2ccccc2n1C1CCC3O1		CHEMBL304428	=	Residual Activity	%	62.0	CHEMBL5408	Homo sapiens	Residual Activity	%	62.0
	12278431	CHEMBL2219206	Millipore: Percentage of residual kinase activity of TBK1 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	O=C1Cc2c([nH]c3ccc([N+](=O)[O-])cc23)-c2ccccc2N1		CHEMBL50894	=	Residual Activity	%	37.0	CHEMBL5408	Homo sapiens	Residual Activity	%	37.0
	12278432	CHEMBL2219206	Millipore: Percentage of residual kinase activity of TBK1 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	CC(C)n1cnc2c(NCc3ccccc3)nc(NCCCO)nc21		CHEMBL83980	=	Residual Activity	%	66.0	CHEMBL5408	Homo sapiens	Residual Activity	%	66.0
	12278433	CHEMBL2219206	Millipore: Percentage of residual kinase activity of TBK1 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	CCN1/C(=C/C(C)=O)Sc2ccc(OC)cc21		CHEMBL408982	=	Residual Activity	%	51.0	CHEMBL5408	Homo sapiens	Residual Activity	%	51.0
	12278434	CHEMBL2219206	Millipore: Percentage of residual kinase activity of TBK1 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	O=C1c2ccccc2-[n+]2ccc3c([nH]c4ccccc43)c21		CHEMBL602937	=	Residual Activity	%	53.0	CHEMBL5408	Homo sapiens	Residual Activity	%	53.0
	12278435	CHEMBL2219206	Millipore: Percentage of residual kinase activity of TBK1 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	COc1cc(OC)c(/C=C2\C(=O)Nc3ccccc32)c(OC)c1		CHEMBL404941	=	Residual Activity	%	56.0	CHEMBL5408	Homo sapiens	Residual Activity	%	56.0
	12278436	CHEMBL2219206	Millipore: Percentage of residual kinase activity of TBK1 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	O=C1Cc2c([nH]c3ccc(Br)cc23)-c2ccccc2N1		CHEMBL296586	=	Residual Activity	%	31.0	CHEMBL5408	Homo sapiens	Residual Activity	%	31.0
	12278437	CHEMBL2219206	Millipore: Percentage of residual kinase activity of TBK1 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	O=[N+]([O-])c1ccc(-c2nc(-c3ccc(F)cc3)c(-c3ccncc3)[nH]2)cc1		CHEMBL17331	=	Residual Activity	%	76.0	CHEMBL5408	Homo sapiens	Residual Activity	%	76.0
	12278438	CHEMBL2219206	Millipore: Percentage of residual kinase activity of TBK1 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	Cc1nc(-c2ccccc2)c(-c2ccncc2)o1		CHEMBL36450	=	Residual Activity	%	88.0	CHEMBL5408	Homo sapiens	Residual Activity	%	88.0
	12278439	CHEMBL2219206	Millipore: Percentage of residual kinase activity of TBK1 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	N#CCCc1ccc2c(c1)-c1[nH]c3ccc([N+](=O)[O-])cc3c1CC(=O)N2		CHEMBL260138	=	Residual Activity	%	13.0	CHEMBL5408	Homo sapiens	Residual Activity	%	13.0
	12278440	CHEMBL2219206	Millipore: Percentage of residual kinase activity of TBK1 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	O=C1Nc2ccccc2/C1=C\c1c(Cl)[nH]c2ccccc12		CHEMBL261425	=	Residual Activity	%	43.0	CHEMBL5408	Homo sapiens	Residual Activity	%	43.0
	12278441	CHEMBL2219206	Millipore: Percentage of residual kinase activity of TBK1 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	NC(=O)c1ccc2[nH]c(-c3ccc(Oc4ccc(Cl)cc4)cc3)nc2c1		CHEMBL179583	=	Residual Activity	%	60.0	CHEMBL5408	Homo sapiens	Residual Activity	%	60.0
	12278442	CHEMBL2219206	Millipore: Percentage of residual kinase activity of TBK1 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	Cn1sc(=O)n(Cc2ccccc2)c1=O		CHEMBL284861	=	Residual Activity	%	55.0	CHEMBL5408	Homo sapiens	Residual Activity	%	55.0
	12278443	CHEMBL2219206	Millipore: Percentage of residual kinase activity of TBK1 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	NC(=O)Nc1sc(-c2ccc(F)cc2)cc1C(N)=O		CHEMBL257167	=	Residual Activity	%	6.0	CHEMBL5408	Homo sapiens	Residual Activity	%	6.0
	12278444	CHEMBL2219206	Millipore: Percentage of residual kinase activity of TBK1 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	COc1ccc(S(=O)(=O)N(CCO)c2ccccc2CN(C)C/C=C/c2ccc(Cl)cc2)cc1		CHEMBL155333	=	Residual Activity	%	56.0	CHEMBL5408	Homo sapiens	Residual Activity	%	56.0
	12278445	CHEMBL2219206	Millipore: Percentage of residual kinase activity of TBK1 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	Nc1nccc(-c2c(-c3ccc(F)cc3)ncn2C2CCNCC2)n1		CHEMBL274064	=	Residual Activity	%	69.0	CHEMBL5408	Homo sapiens	Residual Activity	%	69.0
	12278446	CHEMBL2219206	Millipore: Percentage of residual kinase activity of TBK1 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	Fc1ccc(-c2nc3n(c2-c2ccncc2)CCS3)cc1		CHEMBL313417	=	Residual Activity	%	89.0	CHEMBL5408	Homo sapiens	Residual Activity	%	89.0
	12278447	CHEMBL2219206	Millipore: Percentage of residual kinase activity of TBK1 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	CCCCc1c(-c2ccc(O)cc2)[nH]c2nccnc12		CHEMBL75680	=	Residual Activity	%	35.0	CHEMBL5408	Homo sapiens	Residual Activity	%	35.0
	12278448	CHEMBL2219206	Millipore: Percentage of residual kinase activity of TBK1 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	CCn1cnc2c(Nc3cccc(Cl)c3)nc(N[C@@H]3CCCC[C@@H]3N)nc21		CHEMBL367625	=	Residual Activity	%	45.0	CHEMBL5408	Homo sapiens	Residual Activity	%	45.0
	12278449	CHEMBL2219206	Millipore: Percentage of residual kinase activity of TBK1 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	CC(C)n1cnc2/c(=N/c3cccc(Cl)c3)nc(NCCO)[nH]c21		CHEMBL311228	=	Residual Activity	%	33.0	CHEMBL5408	Homo sapiens	Residual Activity	%	33.0
	12278450	CHEMBL2219206	Millipore: Percentage of residual kinase activity of TBK1 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	Ic1cccc(CSc2nnc(-c3ccncc3)o2)c1		CHEMBL288064	=	Residual Activity	%	6.0	CHEMBL5408	Homo sapiens	Residual Activity	%	6.0
	12278451	CHEMBL2219206	Millipore: Percentage of residual kinase activity of TBK1 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	O=C1Nc2ccccc2/C1=C1/Nc2ccccc2/C1=N\OCCC(O)CO		CHEMBL1802727	=	Residual Activity	%	1.0	CHEMBL5408	Homo sapiens	Residual Activity	%	1.0
	12278452	CHEMBL2219206	Millipore: Percentage of residual kinase activity of TBK1 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	N#C/C(=C(/N)SC1C=CC=CC1)c1cccc(C(O)c2ccncc2)c1		CHEMBL2218939	=	Residual Activity	%	62.0	CHEMBL5408	Homo sapiens	Residual Activity	%	62.0
	12278453	CHEMBL2219206	Millipore: Percentage of residual kinase activity of TBK1 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	CC(C)[C@H](CO)Nc1nc(Nc2cccc(Cl)c2)c2ncn(C(C)C)c2n1		CHEMBL23327	=	Residual Activity	%	66.0	CHEMBL5408	Homo sapiens	Residual Activity	%	66.0
	12278454	CHEMBL2219206	Millipore: Percentage of residual kinase activity of TBK1 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	Oc1ccc(Nc2nc(-c3ccc(Cl)cc3)cs2)cc1		CHEMBL1076555	=	Residual Activity	%	80.0	CHEMBL5408	Homo sapiens	Residual Activity	%	80.0
	12278455	CHEMBL2219206	Millipore: Percentage of residual kinase activity of TBK1 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	CCCCc1c(-c2ccc(OC)cc2)[nH]c2nccnc12		CHEMBL306498	=	Residual Activity	%	59.0	CHEMBL5408	Homo sapiens	Residual Activity	%	59.0
	12278456	CHEMBL2219206	Millipore: Percentage of residual kinase activity of TBK1 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	Nc1nc(Nc2ccc(S(N)(=O)=O)cc2)nn1C(=S)Nc1c(F)cccc1F		CHEMBL261720	=	Residual Activity	%	-2.0	CHEMBL5408	Homo sapiens	Residual Activity	%	-2.0
	12278457	CHEMBL2219206	Millipore: Percentage of residual kinase activity of TBK1 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	COc1ccc(CNc2nc(N(CCO)CCO)nc3c2ncn3C(C)C)cc1		CHEMBL80713	=	Residual Activity	%	55.0	CHEMBL5408	Homo sapiens	Residual Activity	%	55.0
	12278458	CHEMBL2219206	Millipore: Percentage of residual kinase activity of TBK1 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	COc1ccc(CNC(=O)Nc2ncc([N+](=O)[O-])s2)cc1		CHEMBL259850	=	Residual Activity	%	59.0	CHEMBL5408	Homo sapiens	Residual Activity	%	59.0
	12278459	CHEMBL2219206	Millipore: Percentage of residual kinase activity of TBK1 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	Oc1c2ccccc2c2c3c(cccc13)N=N2		CHEMBL1725279	=	Residual Activity	%	11.0	CHEMBL5408	Homo sapiens	Residual Activity	%	11.0
	12278460	CHEMBL2219206	Millipore: Percentage of residual kinase activity of TBK1 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	O=C1C(Cl)=C(N2C(=O)CCC2=O)C(=O)c2ccccc21		CHEMBL404939	=	Residual Activity	%	60.0	CHEMBL5408	Homo sapiens	Residual Activity	%	60.0
	12278461	CHEMBL2219206	Millipore: Percentage of residual kinase activity of TBK1 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	Nc1cccc(-c2cc3c(Oc4cccc(O)c4)ncnc3[nH]2)c1		CHEMBL405759	=	Residual Activity	%	19.0	CHEMBL5408	Homo sapiens	Residual Activity	%	19.0
	12278462	CHEMBL2219206	Millipore: Percentage of residual kinase activity of TBK1 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	CC(C)[C@H](CO)Nc1nc(Nc2cc(N)cc(Cl)c2)c2ncn(C(C)C)c2n1		CHEMBL286721	=	Residual Activity	%	43.0	CHEMBL5408	Homo sapiens	Residual Activity	%	43.0
	12278463	CHEMBL2219206	Millipore: Percentage of residual kinase activity of TBK1 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	Nc1n[nH]c2nc3ccccc3nc12		CHEMBL259389	=	Residual Activity	%	63.0	CHEMBL5408	Homo sapiens	Residual Activity	%	63.0
	12278464	CHEMBL2219206	Millipore: Percentage of residual kinase activity of TBK1 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	CCN(CC)C(=O)c1ccc(Nc2nc(OCC3CCCCC3)c3nc[nH]c3n2)cc1		CHEMBL1802728	=	Residual Activity	%	2.0	CHEMBL5408	Homo sapiens	Residual Activity	%	2.0
	12278465	CHEMBL2219206	Millipore: Percentage of residual kinase activity of TBK1 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	O=C1Nc2cc(Br)ccc2/C1=C1/Nc2ccccc2/C1=N\O		CHEMBL409450	=	Residual Activity	%	15.0	CHEMBL5408	Homo sapiens	Residual Activity	%	15.0
	12278466	CHEMBL2219206	Millipore: Percentage of residual kinase activity of TBK1 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	Cn1nc2c3c(cccc31)C(=O)c1ccccc1-2		CHEMBL1802485	=	Residual Activity	%	55.0	CHEMBL5408	Homo sapiens	Residual Activity	%	55.0
	12278467	CHEMBL2219206	Millipore: Percentage of residual kinase activity of TBK1 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	N#C/C(=C(\N)Sc1ccc(N)cc1)c1ccccc1C(F)(F)F		CHEMBL2218940	=	Residual Activity	%	16.0	CHEMBL5408	Homo sapiens	Residual Activity	%	16.0
	12278468	CHEMBL2219206	Millipore: Percentage of residual kinase activity of TBK1 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	O=S(=O)(NCCNC/C=C/c1ccc(Br)cc1)c1cccc2cnccc12		CHEMBL104264	=	Residual Activity	%	66.0	CHEMBL5408	Homo sapiens	Residual Activity	%	66.0
	12278469	CHEMBL2219206	Millipore: Percentage of residual kinase activity of TBK1 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	O=C(O)c1ccc2c3c1cccc3c(=O)n1c3ccccc3nc21		CHEMBL1182777	=	Residual Activity	%	4.0	CHEMBL5408	Homo sapiens	Residual Activity	%	4.0
	12278470	CHEMBL2219206	Millipore: Percentage of residual kinase activity of TBK1 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	c1cc(-c2cnn3cc(-c4ccc(OCCN5CCCCC5)cc4)cnc23)ccn1		CHEMBL478629	=	Residual Activity	%	13.0	CHEMBL5408	Homo sapiens	Residual Activity	%	13.0
	12278471	CHEMBL2219206	Millipore: Percentage of residual kinase activity of TBK1 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	NC(=O)c1ccc(-c2nc(-c3ccc4c(c3)OCCO4)c(-c3ccccn3)[nH]2)cc1		CHEMBL410456	=	Residual Activity	%	72.0	CHEMBL5408	Homo sapiens	Residual Activity	%	72.0
	12278472	CHEMBL2219206	Millipore: Percentage of residual kinase activity of TBK1 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	CC(C)c1nn(-c2c(Cl)cccc2Cl)c2nc(Cc3ccc(OCCO)cc3)[nH]c(=O)c12		CHEMBL258721	=	Residual Activity	%	63.0	CHEMBL5408	Homo sapiens	Residual Activity	%	63.0
	12278473	CHEMBL2219206	Millipore: Percentage of residual kinase activity of TBK1 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	CC(=O)O/N=C1C(=C2\C(=O)Nc3cc(Br)ccc32)\Nc2ccccc2\1		CHEMBL2218941	=	Residual Activity	%	14.0	CHEMBL5408	Homo sapiens	Residual Activity	%	14.0
	12278474	CHEMBL2219206	Millipore: Percentage of residual kinase activity of TBK1 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	N#C/C(=C1/Nc2ccccc2S1)c1ccnc(NCCc2cccnc2)n1		CHEMBL191384	=	Residual Activity	%	40.0	CHEMBL5408	Homo sapiens	Residual Activity	%	40.0
	12278475	CHEMBL2219206	Millipore: Percentage of residual kinase activity of TBK1 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	Nc1ncnc2[nH]nc(Nc3ccc(F)cc3)c12		CHEMBL1240885	=	Residual Activity	%	58.0	CHEMBL5408	Homo sapiens	Residual Activity	%	58.0
	12278476	CHEMBL2219206	Millipore: Percentage of residual kinase activity of TBK1 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	CCc1nc(-c2ccc(OC)cc2)[nH]c1-c1ccncc1		CHEMBL278724	=	Residual Activity	%	84.0	CHEMBL5408	Homo sapiens	Residual Activity	%	84.0
	12278477	CHEMBL2219206	Millipore: Percentage of residual kinase activity of TBK1 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	COc1ccc2c(c1)/C(=C/c1cnc[nH]1)C(=O)N2		CHEMBL258805	=	Residual Activity	%	15.0	CHEMBL5408	Homo sapiens	Residual Activity	%	15.0
	12278478	CHEMBL2219206	Millipore: Percentage of residual kinase activity of TBK1 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	O=C(O)/C=C/c1cc(Br)c(Br)c(Br)c1Br		CHEMBL270724	=	Residual Activity	%	58.0	CHEMBL5408	Homo sapiens	Residual Activity	%	58.0
	12278479	CHEMBL2219206	Millipore: Percentage of residual kinase activity of TBK1 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	N/C(=N\[N+](=O)[O-])N/N=C\c1ccc(-c2cccc([N+](=O)[O-])c2)o1		CHEMBL221271	=	Residual Activity	%	72.0	CHEMBL5408	Homo sapiens	Residual Activity	%	72.0
	12278480	CHEMBL2219206	Millipore: Percentage of residual kinase activity of TBK1 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	O=C1NC(=O)C(c2cn(CCCO)c3ncccc23)=C1c1cnccn1		CHEMBL272629	=	Residual Activity	%	67.0	CHEMBL5408	Homo sapiens	Residual Activity	%	67.0
	12278481	CHEMBL2219206	Millipore: Percentage of residual kinase activity of TBK1 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	N#Cc1c(NC(=O)c2cccc3ccccc23)sc2c1CCCC2		CHEMBL233001	=	Residual Activity	%	73.0	CHEMBL5408	Homo sapiens	Residual Activity	%	73.0
	12278482	CHEMBL2219206	Millipore: Percentage of residual kinase activity of TBK1 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	Nc1ccc2ncnc(NCCc3ccc(Oc4ccccc4)cc3)c2c1		CHEMBL522502	=	Residual Activity	%	62.0	CHEMBL5408	Homo sapiens	Residual Activity	%	62.0
	12278483	CHEMBL2219206	Millipore: Percentage of residual kinase activity of TBK1 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	Oc1ccc(-c2nc(-c3ccc(F)cc3)c(-c3ccncc3)[nH]2)cc1		CHEMBL278041	=	Residual Activity	%	85.0	CHEMBL5408	Homo sapiens	Residual Activity	%	85.0
	12278484	CHEMBL2219206	Millipore: Percentage of residual kinase activity of TBK1 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	N#Cc1cnc2cnc(NCc3cccnc3)cc2c1Nc1ccc(F)c(Cl)c1		CHEMBL200381	=	Residual Activity	%	2.0	CHEMBL5408	Homo sapiens	Residual Activity	%	2.0
	12672881	CHEMBL2341142	Inhibition of recombinant TBK1 (unknown origin) assessed as residual activity using [gamma-33P]ATP as substrate at 1 uM	B	CC[C@@H](CO)Nc1nc(NC(=N)N)c2ncn(C(C)C)c2n1		CHEMBL2336379	=	Activity	%	90.0	CHEMBL5408	Homo sapiens	Activity	%	90.0
	12672882	CHEMBL2341142	Inhibition of recombinant TBK1 (unknown origin) assessed as residual activity using [gamma-33P]ATP as substrate at 1 uM	B	CC[C@H](CO)Nc1nc(NC(=N)N)c2ncn(C(C)C)c2n1		CHEMBL2336377	=	Activity	%	92.0	CHEMBL5408	Homo sapiens	Activity	%	92.0
	12693161	CHEMBL2345764	Inhibition of TBK1 (unknown origin)	B	Cc1c(C(=O)N2CCOc3ccc(-c4ccc(N)nc4)cc3C2)ccc(S(C)(=O)=O)c1F		CHEMBL2333365	>	IC50	nM	10000.0	CHEMBL5408	Homo sapiens	IC50	nM	10000.0
	12727643	CHEMBL2351106	Inhibition of TBK1 (unknown origin) assessed as remaining activity at 10 uM relative to control	B	O=c1[nH]c2ncc(-c3ccc(-c4nc[nH]n4)cc3)nc2n1CCC1CCOCC1		CHEMBL2348865	=	Activity	%	92.0	CHEMBL5408	Homo sapiens	Activity	%	92.0
	12728928	CHEMBL2352827	Inhibition of TBK1 (unknown origin) assessed as remaining activity at 1 uM relative to control	B	CC(C)(O)c1ccc(-c2cnc3c(n2)N(CC2CCOCC2)CC(=O)N3)cn1		CHEMBL2348862	=	Activity	%	102.0	CHEMBL5408	Homo sapiens	Activity	%	102.0
	12729813	CHEMBL2352145	Inhibition of TBK1 (unknown origin) using [gamma-33P]ATP assessed as residual activity at 3 uM	B	CCc1ccc(-c2ccc3c(c2)-c2[nH]ncc2S(=O)(=O)N3C)cc1		CHEMBL2333445	=	Activity	%	71.0	CHEMBL5408	Homo sapiens	Activity	%	71.0
	12730071	CHEMBL2351106	Inhibition of TBK1 (unknown origin) assessed as remaining activity at 10 uM relative to control	B	CC(C)(O)c1ccc(-c2cnc3c(n2)N(CC2CCOCC2)CC(=O)N3)cn1		CHEMBL2348862	=	Activity	%	104.0	CHEMBL5408	Homo sapiens	Activity	%	104.0
	13374325	CHEMBL2405489	Inhibition of TBK1 (unknown origin) at 10 uM relative to control	B	CC[C@@H]1C(=O)N(C)c2cnc(-n3ccnc3-c3ccc(F)cc3)nc2N1c1ccn(C)n1		CHEMBL2402081	=	Inhibition	%	4.0	CHEMBL5408	Homo sapiens	INH	%	4.0
	13465456	CHEMBL2434206	Inhibition of human TBK1 assessed as residual activity at 1 uM relative to control	B	CCCC(=O)Nc1n[nH]c2ncc(-c3cccnc3)cc12		CHEMBL407002	=	Activity	%	91.0	CHEMBL5408	Homo sapiens	Activity	%	91.0
	13465482	CHEMBL2434377	Inhibition of human TBK1 assessed as residual activity at 10 uM relative to control	B	CCCC(=O)Nc1n[nH]c2ncc(-c3cccnc3)cc12		CHEMBL407002	=	Activity	%	70.0	CHEMBL5408	Homo sapiens	Activity	%	70.0
	13466457	CHEMBL2434206	Inhibition of human TBK1 assessed as residual activity at 1 uM relative to control	B	CC(=O)Nc1nccc(-c2c(-c3ccccc3)noc2C)n1		CHEMBL2430324	=	Activity	%	106.21	CHEMBL5408	Homo sapiens	Activity	%	106.21
	13466484	CHEMBL2434377	Inhibition of human TBK1 assessed as residual activity at 10 uM relative to control	B	CC(=O)Nc1nccc(-c2c(-c3ccccc3)noc2C)n1		CHEMBL2430324	=	Activity	%	104.56	CHEMBL5408	Homo sapiens	Activity	%	104.56
	13466511	CHEMBL2434206	Inhibition of human TBK1 assessed as residual activity at 1 uM relative to control	B	CC(=O)Nc1cccc(-c2cnc3[nH]nc(C)c3c2)c1		CHEMBL2430323	=	Activity	%	88.9	CHEMBL5408	Homo sapiens	Activity	%	88.9
	13466538	CHEMBL2434377	Inhibition of human TBK1 assessed as residual activity at 10 uM relative to control	B	CC(=O)Nc1cccc(-c2cnc3[nH]nc(C)c3c2)c1		CHEMBL2430323	=	Activity	%	48.24	CHEMBL5408	Homo sapiens	Activity	%	48.24
Not Active	13508510	CHEMBL2447621	Inhibition of TBK1 (unknown origin) at 30 uM	B	O=C(Nc1ccc2c(c1)B(O)OC2)c1c(C(F)(F)F)ccc(Cl)c1F		CHEMBL2441375		Inhibition	%		CHEMBL5408	Homo sapiens	INH		
	13871732	CHEMBL3100768	Inhibition of human TBK1 assessed as residual activity at 1 uM relative to control	B	O=C1Nc2ncccc2/C1=C1/Nc2ncccc2C1=O		CHEMBL3099673	=	Activity	%	120.0	CHEMBL5408	Homo sapiens	Activity	%	120.0
	13953189	CHEMBL3132510	Inhibition of TBK1 in HEK293 cells after 4.5 hrs by ISRE-luciferase reporter gene assay in presence of poly I:C	B	COc1ccc(-c2nc3cc(-c4csc(C(=O)O)c4)cnc3[nH]2)cc1		CHEMBL3125741	>	IC50	nM	30000.0	CHEMBL5408	Homo sapiens	IC50	uM	30.0
	13953190	CHEMBL3132510	Inhibition of TBK1 in HEK293 cells after 4.5 hrs by ISRE-luciferase reporter gene assay in presence of poly I:C	B	COc1ccc(-c2nc3cc(-c4cc(C(=O)O)co4)cnc3[nH]2)cc1		CHEMBL3125740	>	IC50	nM	30000.0	CHEMBL5408	Homo sapiens	IC50	uM	30.0
	13953191	CHEMBL3132510	Inhibition of TBK1 in HEK293 cells after 4.5 hrs by ISRE-luciferase reporter gene assay in presence of poly I:C	B	COc1ccc(-c2nc3cc(-c4cc(C(=O)O)cs4)cnc3[nH]2)cc1		CHEMBL3125739	>	IC50	nM	30000.0	CHEMBL5408	Homo sapiens	IC50	uM	30.0
	13953192	CHEMBL3132510	Inhibition of TBK1 in HEK293 cells after 4.5 hrs by ISRE-luciferase reporter gene assay in presence of poly I:C	B	COc1ccc(-c2nc3cc(-c4ccc(C(=O)O)s4)cnc3[nH]2)cc1		CHEMBL3125738	>	IC50	nM	30000.0	CHEMBL5408	Homo sapiens	IC50	uM	30.0
	13953202	CHEMBL3132514	Inhibition of recombinant full-length TBK1 (unknown origin) using CK1tide as substrate by microfluidic mobility shift assay	B	COc1ccc(-c2nc3cc(-c4csc(C#N)c4)cnc3[nH]2)cc1		CHEMBL3125742	>	IC50	nM	30000.0	CHEMBL5408	Homo sapiens	IC50	uM	30.0
	13953203	CHEMBL3132510	Inhibition of TBK1 in HEK293 cells after 4.5 hrs by ISRE-luciferase reporter gene assay in presence of poly I:C	B	COc1ccc(-c2nc3c(OCCCNC(=O)C4CCCC4)c(-c4csc(C(=O)O)c4)cnc3[nH]2)cc1		CHEMBL3125724	>	IC50	nM	3000.0	CHEMBL5408	Homo sapiens	IC50	uM	3.0
	13954597	CHEMBL3132510	Inhibition of TBK1 in HEK293 cells after 4.5 hrs by ISRE-luciferase reporter gene assay in presence of poly I:C	B	COc1ccc(-c2nc3c(NCCCNC(=O)C4CCCC4)c(-c4nc(C(=O)O)cs4)cnc3[nH]2)cc1		CHEMBL3125722	=	IC50	nM	2170.0	CHEMBL5408	Homo sapiens	IC50	uM	2.17
	13954598	CHEMBL3132515	Inhibition of human TBK1 assessed as residual activity at 1 uM relative to control	B	COc1ccc(-c2nc3cc(-c4csc(C(=O)NCC(C)(C)C)c4)cnc3[nH]2)cc1		CHEMBL3125726	=	Activity	%	2.0	CHEMBL5408	Homo sapiens	Activity	%	2.0
	13954599	CHEMBL3132515	Inhibition of human TBK1 assessed as residual activity at 1 uM relative to control	B	COc1ccc(-c2nc3cc(-c4csc(C(=O)NCCC(C)C)c4)cnc3[nH]2)cc1		CHEMBL3125728	=	Activity	%	2.0	CHEMBL5408	Homo sapiens	Activity	%	2.0
	13954600	CHEMBL3132514	Inhibition of recombinant full-length TBK1 (unknown origin) using CK1tide as substrate by microfluidic mobility shift assay	B	CNc1c(-c2ccc(C(=O)O)cc2)cnc2[nH]c(-c3ccc(OC)cc3)nc12		CHEMBL3125736	=	IC50	nM	1800.0	CHEMBL5408	Homo sapiens	IC50	uM	1.8
	13954606	CHEMBL3132514	Inhibition of recombinant full-length TBK1 (unknown origin) using CK1tide as substrate by microfluidic mobility shift assay	B	COc1ccc(-c2nc3cc(-c4cc(C(=O)O)co4)cnc3[nH]2)cc1		CHEMBL3125740	=	IC50	nM	1050.0	CHEMBL5408	Homo sapiens	IC50	uM	1.05
	13954608	CHEMBL3132514	Inhibition of recombinant full-length TBK1 (unknown origin) using CK1tide as substrate by microfluidic mobility shift assay	B	CNc1c(-c2ccc(C(=O)O)s2)cnc2[nH]c(-c3ccc(OC)cc3)nc12		CHEMBL3125737	=	IC50	nM	1040.0	CHEMBL5408	Homo sapiens	IC50	uM	1.04
	13954616	CHEMBL3132514	Inhibition of recombinant full-length TBK1 (unknown origin) using CK1tide as substrate by microfluidic mobility shift assay	B	O=C(O)c1ccc(-c2cnc3[nH]c(-c4ccc(OCCN5CCCCC5)cc4)nc3c2)cc1		CHEMBL3125735	=	IC50	nM	859.0	CHEMBL5408	Homo sapiens	IC50	uM	0.859
	13954617	CHEMBL3132514	Inhibition of recombinant full-length TBK1 (unknown origin) using CK1tide as substrate by microfluidic mobility shift assay	B	COc1ccc(-c2nc3c(OCCCNC(=O)C4CCCC4)c(Br)cnc3[nH]2)cc1		CHEMBL3125725	=	IC50	nM	759.0	CHEMBL5408	Homo sapiens	IC50	uM	0.759
	13954622	CHEMBL3132514	Inhibition of recombinant full-length TBK1 (unknown origin) using CK1tide as substrate by microfluidic mobility shift assay	B	COc1ccc(-c2nc3c(OCCCNC(=O)C4CCCC4)c(-c4csc(C(=O)O)c4)cnc3[nH]2)cc1		CHEMBL3125724	=	IC50	nM	460.0	CHEMBL5408	Homo sapiens	IC50	uM	0.46
	13954628	CHEMBL3132514	Inhibition of recombinant full-length TBK1 (unknown origin) using CK1tide as substrate by microfluidic mobility shift assay	B	COc1ccc(-c2nc3c(NCCCNC(=O)C4CCCC4)c(-c4nc(C(=O)NCC(C)C)cs4)cnc3[nH]2)cc1		CHEMBL3125720	=	IC50	nM	388.0	CHEMBL5408	Homo sapiens	IC50	uM	0.388
	13954635	CHEMBL3132514	Inhibition of recombinant full-length TBK1 (unknown origin) using CK1tide as substrate by microfluidic mobility shift assay	B	COc1ccc(-c2nc3cc(-c4ccc(C(=O)O)s4)cnc3[nH]2)cc1		CHEMBL3125738	=	IC50	nM	256.0	CHEMBL5408	Homo sapiens	IC50	uM	0.256
	13954639	CHEMBL3132510	Inhibition of TBK1 in HEK293 cells after 4.5 hrs by ISRE-luciferase reporter gene assay in presence of poly I:C	B	COc1ccc(-c2nc3c(NCCCNC(=O)C4CCCC4)c(C(N)=S)cnc3[nH]2)cc1		CHEMBL3125723	=	IC50	nM	165.0	CHEMBL5408	Homo sapiens	IC50	uM	0.165
	13954645	CHEMBL3132514	Inhibition of recombinant full-length TBK1 (unknown origin) using CK1tide as substrate by microfluidic mobility shift assay	B	COc1ccc(-c2nc3cc(-c4csc(C(=O)NCCC(C)C)c4)cnc3[nH]2)cc1		CHEMBL3125728	=	IC50	nM	143.0	CHEMBL5408	Homo sapiens	IC50	uM	0.143
	13954646	CHEMBL3132514	Inhibition of recombinant full-length TBK1 (unknown origin) using CK1tide as substrate by microfluidic mobility shift assay	B	COc1ccc(-c2nc3cc(-c4cc(C(=O)O)cs4)cnc3[nH]2)cc1		CHEMBL3125739	=	IC50	nM	129.0	CHEMBL5408	Homo sapiens	IC50	uM	0.129
	13954647	CHEMBL3132510	Inhibition of TBK1 in HEK293 cells after 4.5 hrs by ISRE-luciferase reporter gene assay in presence of poly I:C	B	COc1ccc(-c2nc3c(NCCCNC(=O)C4CCCC4)c(-c4nc(C(=O)NCC(C)C)cs4)cnc3[nH]2)cc1		CHEMBL3125720	=	IC50	nM	128.0	CHEMBL5408	Homo sapiens	IC50	uM	0.128
	13954652	CHEMBL3132514	Inhibition of recombinant full-length TBK1 (unknown origin) using CK1tide as substrate by microfluidic mobility shift assay	B	COc1cc2ncn(-c3cc(OCc4ccccc4S(C)(=O)=O)c(C#N)s3)c2cc1OC		CHEMBL373751	=	IC50	nM	93.0	CHEMBL5408	Homo sapiens	IC50	uM	0.093
	13954654	CHEMBL3132514	Inhibition of recombinant full-length TBK1 (unknown origin) using CK1tide as substrate by microfluidic mobility shift assay	B	COc1ccc(-c2nc3cc(-c4csc(C(=O)NCC(C)(C)C)c4)cnc3[nH]2)cc1		CHEMBL3125726	=	IC50	nM	84.0	CHEMBL5408	Homo sapiens	IC50	uM	0.084
	13954655	CHEMBL3132510	Inhibition of TBK1 in HEK293 cells after 4.5 hrs by ISRE-luciferase reporter gene assay in presence of poly I:C	B	COc1ccc(-c2nc3cc(-c4csc(C(=O)NCCC(C)C)c4)cnc3[nH]2)cc1		CHEMBL3125728	=	IC50	nM	78.0	CHEMBL5408	Homo sapiens	IC50	uM	0.078
	13954656	CHEMBL3132514	Inhibition of recombinant full-length TBK1 (unknown origin) using CK1tide as substrate by microfluidic mobility shift assay	B	COc1ccc(-c2nc3cc(-c4csc(C(=O)NCC(C)C)c4)cnc3[nH]2)cc1		CHEMBL3125727	=	IC50	nM	77.0	CHEMBL5408	Homo sapiens	IC50	uM	0.077
	13954659	CHEMBL3132510	Inhibition of TBK1 in HEK293 cells after 4.5 hrs by ISRE-luciferase reporter gene assay in presence of poly I:C	B	COc1cc2ncn(-c3cc(OCc4ccccc4S(C)(=O)=O)c(C#N)s3)c2cc1OC		CHEMBL373751	=	IC50	nM	72.0	CHEMBL5408	Homo sapiens	IC50	uM	0.072
	13954660	CHEMBL3132514	Inhibition of recombinant full-length TBK1 (unknown origin) using CK1tide as substrate by microfluidic mobility shift assay	B	COc1ccc(-c2nc3cc(-c4csc(C(=O)O)c4)cnc3[nH]2)cc1		CHEMBL3125741	=	IC50	nM	49.0	CHEMBL5408	Homo sapiens	IC50	uM	0.049
	13954662	CHEMBL3132514	Inhibition of recombinant full-length TBK1 (unknown origin) using CK1tide as substrate by microfluidic mobility shift assay	B	COc1ccc(-c2nc3c(NCCCNC(=O)C4CCCC4)c(C(N)=S)cnc3[nH]2)cc1		CHEMBL3125723	=	IC50	nM	46.0	CHEMBL5408	Homo sapiens	IC50	uM	0.046
	13954667	CHEMBL3132514	Inhibition of recombinant full-length TBK1 (unknown origin) using CK1tide as substrate by microfluidic mobility shift assay	B	COc1ccc(-c2nc3c(NCCCNC(=O)C4CCCC4)c(-c4nc(C(=O)O)cs4)cnc3[nH]2)cc1		CHEMBL3125722	=	IC50	nM	36.0	CHEMBL5408	Homo sapiens	IC50	uM	0.036
	13954669	CHEMBL3132510	Inhibition of TBK1 in HEK293 cells after 4.5 hrs by ISRE-luciferase reporter gene assay in presence of poly I:C	B	COc1ccc(-c2nc3cc(-c4csc(C(=O)NCC(C)(C)C)c4)cnc3[nH]2)cc1		CHEMBL3125726	=	IC50	nM	30.0	CHEMBL5408	Homo sapiens	IC50	uM	0.03
	13954671	CHEMBL3132514	Inhibition of recombinant full-length TBK1 (unknown origin) using CK1tide as substrate by microfluidic mobility shift assay	B	COc1ccc(-c2nc3cc(-c4csc(C(N)=O)c4)cnc3[nH]2)cc1		CHEMBL3125732	=	IC50	nM	30.0	CHEMBL5408	Homo sapiens	IC50	uM	0.03
	13954675	CHEMBL3132514	Inhibition of recombinant full-length TBK1 (unknown origin) using CK1tide as substrate by microfluidic mobility shift assay	B	COc1ccc(-c2nc3c(NCCCNC(=O)C4CCCC4)c(Br)cnc3[nH]2)cc1		CHEMBL2011936	=	IC50	nM	10.0	CHEMBL5408	Homo sapiens	IC50	uM	0.01
	13954677	CHEMBL3132514	Inhibition of recombinant full-length TBK1 (unknown origin) using CK1tide as substrate by microfluidic mobility shift assay	B	COc1ccc(-c2nc3c(NCCCNC(=O)C4CCCC4)c(-c4nc(C(N)=O)cs4)cnc3[nH]2)cc1		CHEMBL3125721	=	IC50	nM	9.0	CHEMBL5408	Homo sapiens	IC50	uM	0.009
	13954678	CHEMBL3132510	Inhibition of TBK1 in HEK293 cells after 4.5 hrs by ISRE-luciferase reporter gene assay in presence of poly I:C	B	COc1ccc(-c2nc3c(NCCCNC(=O)C4CCCC4)c(-c4nc(C(N)=O)cs4)cnc3[nH]2)cc1		CHEMBL3125721	=	IC50	nM	7.0	CHEMBL5408	Homo sapiens	IC50	uM	0.007
	13954679	CHEMBL3132514	Inhibition of recombinant full-length TBK1 (unknown origin) using CK1tide as substrate by microfluidic mobility shift assay	B	COc1ccc(-c2nc3c(NCCCNC(=O)C4CCC4)c(Br)cnc3[nH]2)cc1		CHEMBL2011933	=	IC50	nM	4.0	CHEMBL5408	Homo sapiens	IC50	uM	0.004
	13954824	CHEMBL3132510	Inhibition of TBK1 in HEK293 cells after 4.5 hrs by ISRE-luciferase reporter gene assay in presence of poly I:C	B	COc1ccc(-c2nc3cc(-c4csc(C(C)=O)c4)cnc3[nH]2)cc1		CHEMBL3125734	=	IC50	nM	1780.0	CHEMBL5408	Homo sapiens	IC50	uM	1.78
	13954828	CHEMBL3132515	Inhibition of human TBK1 assessed as residual activity at 1 uM relative to control	B	COc1ccc(-c2nc3cc(-c4csc(C(=O)NCC(C)C)c4)cnc3[nH]2)cc1		CHEMBL3125727	=	Activity	%	1.0	CHEMBL5408	Homo sapiens	Activity	%	1.0
	13954830	CHEMBL3132514	Inhibition of recombinant full-length TBK1 (unknown origin) using CK1tide as substrate by microfluidic mobility shift assay	B	CCC(C)CNC(=O)c1cc(-c2cnc3[nH]c(-c4ccc(OC)cc4)nc3c2)cs1		CHEMBL3125729	=	IC50	nM	219.0	CHEMBL5408	Homo sapiens	IC50	uM	0.219
	13954831	CHEMBL3132510	Inhibition of TBK1 in HEK293 cells after 4.5 hrs by ISRE-luciferase reporter gene assay in presence of poly I:C	B	COc1ccc(-c2nc3cc(-c4csc(C(N)=O)c4)cnc3[nH]2)cc1		CHEMBL3125732	=	IC50	nM	268.0	CHEMBL5408	Homo sapiens	IC50	uM	0.268
	13954834	CHEMBL3132510	Inhibition of TBK1 in HEK293 cells after 4.5 hrs by ISRE-luciferase reporter gene assay in presence of poly I:C	B	COc1ccc(-c2nc3cc(-c4csc(C(=O)NCC(C)(C)CO)c4)cnc3[nH]2)cc1		CHEMBL3125730	=	IC50	nM	136.0	CHEMBL5408	Homo sapiens	IC50	uM	0.136
	13954835	CHEMBL3132510	Inhibition of TBK1 in HEK293 cells after 4.5 hrs by ISRE-luciferase reporter gene assay in presence of poly I:C	B	COCCNC(=O)c1cc(-c2cnc3[nH]c(-c4ccc(OC)cc4)nc3c2)cs1		CHEMBL3125731	=	IC50	nM	170.0	CHEMBL5408	Homo sapiens	IC50	uM	0.17
	13954836	CHEMBL3132514	Inhibition of recombinant full-length TBK1 (unknown origin) using CK1tide as substrate by microfluidic mobility shift assay	B	CNC(=O)c1cc(-c2cnc3[nH]c(-c4ccc(OC)cc4)nc3c2)cs1		CHEMBL3125733	=	IC50	nM	203.0	CHEMBL5408	Homo sapiens	IC50	uM	0.203
	13954837	CHEMBL3132514	Inhibition of recombinant full-length TBK1 (unknown origin) using CK1tide as substrate by microfluidic mobility shift assay	B	COc1ccc(-c2nc3cc(-c4csc(C(C)=O)c4)cnc3[nH]2)cc1		CHEMBL3125734	=	IC50	nM	650.0	CHEMBL5408	Homo sapiens	IC50	uM	0.65
	13954838	CHEMBL3132510	Inhibition of TBK1 in HEK293 cells after 4.5 hrs by ISRE-luciferase reporter gene assay in presence of poly I:C	B	CNC(=O)c1cc(-c2cnc3[nH]c(-c4ccc(OC)cc4)nc3c2)cs1		CHEMBL3125733	=	IC50	nM	851.0	CHEMBL5408	Homo sapiens	IC50	uM	0.851
	13954839	CHEMBL3132510	Inhibition of TBK1 in HEK293 cells after 4.5 hrs by ISRE-luciferase reporter gene assay in presence of poly I:C	B	CCC(C)CNC(=O)c1cc(-c2cnc3[nH]c(-c4ccc(OC)cc4)nc3c2)cs1		CHEMBL3125729	=	IC50	nM	89.0	CHEMBL5408	Homo sapiens	IC50	uM	0.089
	13954840	CHEMBL3132514	Inhibition of recombinant full-length TBK1 (unknown origin) using CK1tide as substrate by microfluidic mobility shift assay	B	COCCNC(=O)c1cc(-c2cnc3[nH]c(-c4ccc(OC)cc4)nc3c2)cs1		CHEMBL3125731	=	IC50	nM	98.0	CHEMBL5408	Homo sapiens	IC50	uM	0.098
	13954841	CHEMBL3132514	Inhibition of recombinant full-length TBK1 (unknown origin) using CK1tide as substrate by microfluidic mobility shift assay	B	COc1ccc(-c2nc3cc(-c4csc(C(=O)NCC(C)(C)CO)c4)cnc3[nH]2)cc1		CHEMBL3125730	=	IC50	nM	100.0	CHEMBL5408	Homo sapiens	IC50	uM	0.1
	13954843	CHEMBL3132510	Inhibition of TBK1 in HEK293 cells after 4.5 hrs by ISRE-luciferase reporter gene assay in presence of poly I:C	B	COc1ccc(-c2nc3c(NCCCNC(=O)C4CCC4)c(Br)cnc3[nH]2)cc1		CHEMBL2011933	=	IC50	nM	6.0	CHEMBL5408	Homo sapiens	IC50	uM	0.006
	13954844	CHEMBL3132510	Inhibition of TBK1 in HEK293 cells after 4.5 hrs by ISRE-luciferase reporter gene assay in presence of poly I:C	B	COc1ccc(-c2nc3c(NCCCNC(=O)C4CCCC4)c(Br)cnc3[nH]2)cc1		CHEMBL2011936	=	IC50	nM	8.0	CHEMBL5408	Homo sapiens	IC50	uM	0.008
	13954845	CHEMBL3132510	Inhibition of TBK1 in HEK293 cells after 4.5 hrs by ISRE-luciferase reporter gene assay in presence of poly I:C	B	COc1ccc(-c2nc3cc(-c4csc(C(=O)NCC(C)C)c4)cnc3[nH]2)cc1		CHEMBL3125727	=	IC50	nM	37.0	CHEMBL5408	Homo sapiens	IC50	uM	0.037
	14545804	CHEMBL3224474	Inhibition of TBK1 (unknown origin) assessed as residual activity at 1 uM	B	CS(=O)(=O)O.O=C(NCc1cccc(O)c1)Nc1nc(-c2ccncc2)cs1		CHEMBL3218297	=	Activity	%	100.8	CHEMBL5408	Homo sapiens	Activity	%	100.8
	14545828	CHEMBL3224498	Inhibition of TBK1 (unknown origin)	B	CS(=O)(=O)O.O=C(NCc1cccc(O)c1)Nc1nc(-c2ccncc2)cs1		CHEMBL3218297	<	IC50	nM	1.0	CHEMBL5408	Homo sapiens	IC50	nM	1.0
	14585341	CHEMBL3240758	Inhibition of human TBK1 assessed as enzyme activity at 1 uM relative to control	B	CCCS(=O)(=O)Nc1cccc(Nc2ccc3ncn(C)c(=O)c3c2)c1C#N		CHEMBL3236464	=	Activity	%	98.0	CHEMBL5408	Homo sapiens	Activity	%	98.0
	14648128	CHEMBL3267021	Inhibition of human TBK1 at 1 uM relative to control	B	CC(C)CCNc1ccc(-c2cnc3ccc(NC4CCN(C)CC4)nn23)cn1		CHEMBL2380687	<	Inhibition	%	50.0	CHEMBL5408	Homo sapiens	INH	%	50.0
	14648129	CHEMBL3267021	Inhibition of human TBK1 at 1 uM relative to control	B	N[C@H]1CC[C@H](Nc2ccc3ncc(-c4cnc(Nc5ncccc5F)nc4)n3n2)CC1		CHEMBL3264059	<	Inhibition	%	50.0	CHEMBL5408	Homo sapiens	INH	%	50.0
	14664338	CHEMBL3271272	Inhibition of TBK1 (unknown origin) at 1 uM relative to control	B	CCOC(=O)c1sc(-c2ccncc2)nc1O		CHEMBL3261228	=	Inhibition	%	100.0	CHEMBL5408	Homo sapiens	INH	%	100.0
	14664339	CHEMBL3271272	Inhibition of TBK1 (unknown origin) at 1 uM relative to control	B	NC(=O)c1sc(-c2ccnc(N)n2)nc1-c1ccc(Cl)cc1Cl		CHEMBL3261514	=	Inhibition	%	85.0	CHEMBL5408	Homo sapiens	INH	%	85.0
	14664340	CHEMBL3271272	Inhibition of TBK1 (unknown origin) at 1 uM relative to control	B	COc1ccc(-c2nc(-c3ccnc(N)n3)sc2C(N)=O)c(Cl)c1		CHEMBL3261517	=	Inhibition	%	100.0	CHEMBL5408	Homo sapiens	INH	%	100.0
Not Active	14999362	CHEMBL3368453	Inhibition of human TBK1 at 10 uM relative to control	B	CC(C)(C)C1=NN(c2ccc(Cl)cc2)C(c2ccc(O)cc2)C1		CHEMBL3323314		Inhibition	%		CHEMBL5408	Homo sapiens	INH		
	15018702	CHEMBL3369202	Inhibition of TBK1 (unknown origin) at 100 nM	B	O=C(N[C@H](CO)c1ccc(Cl)c(F)c1)N1CCc2cnc(NC3CCOCC3)nc2C1		CHEMBL3298678	=	Inhibition	%	6.0	CHEMBL5408	Homo sapiens	INH	%	6.0
	15072423	CHEMBL3388070	Inhibition of TBK1 (unknown origin) assessed as remaining enzyme activity at 10 uM by radioactive [33P]-ATP filter binding assay	B	Cc1ccc(-c2cc(C(=O)Nc3ccnc(Cl)c3)nn2-c2ccc3ccccc3n2)cc1		CHEMBL3338802	=	Activity	%	93.0	CHEMBL5408	Homo sapiens	Activity	%	93.0
	15112147	CHEMBL3388159	Inhibition of TBK1 (unknown origin)	B	COc1ccc(-c2cccc3nc(NC(=O)C4CC4)nn23)cc1		CHEMBL3360318	>	IC50	nM	4000.0	CHEMBL5408	Homo sapiens	IC50	nM	4000.0
	15250016	CHEMBL3428991	Inhibition of human TBK1 using KRRRAL[pS]VASLPGL peptide substrate at 1 uM by 33P Hotspot assay	B	CN1CCN(c2ccc(Nc3ncc(Cl)c(NC[C@H]4CCCO4)n3)cc2)CC1		CHEMBL3426891	=	Inhibition	%	71.8	CHEMBL5408	Homo sapiens	INH	%	71.8
	15251841	CHEMBL3428240	Inhibition of TBK1 (unknown origin) assessed as remaining activity at 100 uM by radioactive filter binding assay in presence of [33P]-ATP relative to control	B	O=C(O)[C@H]1CSC(c2nc3ccc(O)cc3s2)=N1		CHEMBL443738	=	Activity	%	64.0	CHEMBL5408	Homo sapiens	Activity	%	64.0
	15251956	CHEMBL3428240	Inhibition of TBK1 (unknown origin) assessed as remaining activity at 100 uM by radioactive filter binding assay in presence of [33P]-ATP relative to control	B	O=C(O)[C@@H]1CSC(c2nc3ccc(O)cc3s2)=N1		CHEMBL3427170	=	Activity	%	99.0	CHEMBL5408	Homo sapiens	Activity	%	99.0
	15252058	CHEMBL3428240	Inhibition of TBK1 (unknown origin) assessed as remaining activity at 100 uM by radioactive filter binding assay in presence of [33P]-ATP relative to control	B	COC(=O)[C@H]1CSC(c2nc3ccc(O)cc3s2)=N1		CHEMBL3427171	=	Activity	%	89.0	CHEMBL5408	Homo sapiens	Activity	%	89.0
	15252703	CHEMBL3428240	Inhibition of TBK1 (unknown origin) assessed as remaining activity at 100 uM by radioactive filter binding assay in presence of [33P]-ATP relative to control	B	COC(=O)[C@@H]1CSC(c2nc3ccc(O)cc3s2)=N1		CHEMBL3427172	=	Activity	%	87.0	CHEMBL5408	Homo sapiens	Activity	%	87.0
	15252805	CHEMBL3428240	Inhibition of TBK1 (unknown origin) assessed as remaining activity at 100 uM by radioactive filter binding assay in presence of [33P]-ATP relative to control	B	COc1ccc2nc(C3=N[C@@H](C(=O)O)CS3)sc2c1		CHEMBL3427173	=	Activity	%	90.0	CHEMBL5408	Homo sapiens	Activity	%	90.0
	15252907	CHEMBL3428240	Inhibition of TBK1 (unknown origin) assessed as remaining activity at 100 uM by radioactive filter binding assay in presence of [33P]-ATP relative to control	B	COc1ccc2nc(C3=N[C@H](C(=O)O)CS3)sc2c1		CHEMBL3427174	=	Activity	%	98.0	CHEMBL5408	Homo sapiens	Activity	%	98.0
	15253581	CHEMBL3428240	Inhibition of TBK1 (unknown origin) assessed as remaining activity at 100 uM by radioactive filter binding assay in presence of [33P]-ATP relative to control	B	COC(=O)[C@H]1CSC(c2nc3ccc(OC)cc3s2)=N1		CHEMBL3427175	=	Activity	%	76.0	CHEMBL5408	Homo sapiens	Activity	%	76.0
	15253683	CHEMBL3428240	Inhibition of TBK1 (unknown origin) assessed as remaining activity at 100 uM by radioactive filter binding assay in presence of [33P]-ATP relative to control	B	COC(=O)[C@@H]1CSC(c2nc3ccc(OC)cc3s2)=N1		CHEMBL3427176	=	Activity	%	84.0	CHEMBL5408	Homo sapiens	Activity	%	84.0
	15253785	CHEMBL3428240	Inhibition of TBK1 (unknown origin) assessed as remaining activity at 100 uM by radioactive filter binding assay in presence of [33P]-ATP relative to control	B	COc1ccc2nc(C3=N[C@@H](C(=O)O)C(C)(C)S3)sc2c1		CHEMBL3427177	=	Activity	%	66.0	CHEMBL5408	Homo sapiens	Activity	%	66.0
	15253802	CHEMBL3429892	Inhibition of human TBK1	B	CCn1nc(C#Cc2cc(C(=O)Nc3ccc(CN4CCN(C)CC4)c(C(F)(F)F)c3)ccc2C)c2c(N)ncnc21		CHEMBL3426225	>	IC50	nM	10000.0	CHEMBL5408	Homo sapiens	IC50	uM	10.0
	15254451	CHEMBL3428240	Inhibition of TBK1 (unknown origin) assessed as remaining activity at 100 uM by radioactive filter binding assay in presence of [33P]-ATP relative to control	B	COc1ccc2nc(C3=N[C@H](C(=O)O)C(C)(C)S3)sc2c1		CHEMBL3427178	=	Activity	%	60.0	CHEMBL5408	Homo sapiens	Activity	%	60.0
	15254553	CHEMBL3428240	Inhibition of TBK1 (unknown origin) assessed as remaining activity at 100 uM by radioactive filter binding assay in presence of [33P]-ATP relative to control	B	CC1(C)SC(c2nc3ccc(O)cc3s2)=N[C@H]1C(=O)O		CHEMBL3427179	=	Activity	%	98.0	CHEMBL5408	Homo sapiens	Activity	%	98.0
	15254655	CHEMBL3428240	Inhibition of TBK1 (unknown origin) assessed as remaining activity at 100 uM by radioactive filter binding assay in presence of [33P]-ATP relative to control	B	CC1(C)SC(c2nc3ccc(O)cc3s2)=N[C@@H]1C(=O)O		CHEMBL3427180	=	Activity	%	78.0	CHEMBL5408	Homo sapiens	Activity	%	78.0
	15255346	CHEMBL3428240	Inhibition of TBK1 (unknown origin) assessed as remaining activity at 100 uM by radioactive filter binding assay in presence of [33P]-ATP relative to control	B	O=C(O)[C@H]1CSC(c2ccc3cc(O)ccc3n2)=N1		CHEMBL3427181	=	Activity	%	67.0	CHEMBL5408	Homo sapiens	Activity	%	67.0
	15255448	CHEMBL3428240	Inhibition of TBK1 (unknown origin) assessed as remaining activity at 100 uM by radioactive filter binding assay in presence of [33P]-ATP relative to control	B	O=C(O)[C@@H]1CSC(c2ccc3cc(O)ccc3n2)=N1		CHEMBL3427182	=	Activity	%	65.0	CHEMBL5408	Homo sapiens	Activity	%	65.0
	15256180	CHEMBL3428240	Inhibition of TBK1 (unknown origin) assessed as remaining activity at 100 uM by radioactive filter binding assay in presence of [33P]-ATP relative to control	B	O=C(O)[C@H]1CSC(c2ccc3cccc(O)c3n2)=N1		CHEMBL3427183	=	Activity	%	82.0	CHEMBL5408	Homo sapiens	Activity	%	82.0
	15256282	CHEMBL3428240	Inhibition of TBK1 (unknown origin) assessed as remaining activity at 100 uM by radioactive filter binding assay in presence of [33P]-ATP relative to control	B	O=C(O)[C@@H]1CSC(c2ccc3cccc(O)c3n2)=N1		CHEMBL3427184	=	Activity	%	53.0	CHEMBL5408	Homo sapiens	Activity	%	53.0
	15686146	CHEMBL3606970	Inhibition of TBK1 (unknown origin) at 250 nM by radioactive filter-binding assay	B	c1ccc2c(Nc3cc(C4CCC4)[nH]n3)nc(Nc3ccc4[nH]cnc4c3)nc2c1		CHEMBL3605055	>=	Inhibition	%	80.0	CHEMBL5408	Homo sapiens	INH	%	80.0
	15686167	CHEMBL3606877	Inhibition of TBK1 (unknown origin) at 2 uM by radioactive filter-binding assay	B	NCCCNc1nc(Nc2cccc(NC(=O)N3CCCC3)c2)ncc1I		CHEMBL3605056	>=	Inhibition	%	80.0	CHEMBL5408	Homo sapiens	INH	%	80.0
	15756793	CHEMBL3631493	Inhibition of TBK1 (unknown origin) at 10 uM after 120 mins P33 radiolabeled kinase activity assay	B	CC(C)(C)c1cc(NC(=O)Nc2ccc(Oc3ccncc3)cc2)no1		CHEMBL166031	=	Inhibition	%	4.25	CHEMBL5408	Homo sapiens	INH	%	4.25
	15757930	CHEMBL3631493	Inhibition of TBK1 (unknown origin) at 10 uM after 120 mins P33 radiolabeled kinase activity assay	B	CS(=O)(=O)c1cccc(Nc2nccc(-c3sc(N4CCOCC4)nc3-c3cccc(NS(=O)(=O)c4c(F)cccc4F)c3)n2)c1		CHEMBL3628627	=	Inhibition	%	55.43	CHEMBL5408	Homo sapiens	INH	%	55.43
	15758909	CHEMBL3631493	Inhibition of TBK1 (unknown origin) at 10 uM after 120 mins P33 radiolabeled kinase activity assay	B	COCCNC(=O)c1ccc2c(c1)nc(-c1cnc(-c3ccc(Cl)cc3)[nH]1)n2CCOC		CHEMBL3628628	=	Inhibition	%	5.84	CHEMBL5408	Homo sapiens	INH	%	5.84
286073	16258430	CHEMBL3707833	Time-Resolved Fluorescence-based Lanthascreen Assay: Inhibitions studies were performed using a time-resolved fluorescence-based Lanthascreen assay. Phosphorylation of a fluorescein-labelled substrate peptide is measured using terbium-labeled phosphospecific antibodies. Terbium is excited at 340 nm and the FRET energy transfer to fluorescein is measured at 495 and 520 nm. The emission ratio between 520 and 495 is a measure of the level of phosphorylation of the substrate by the kinase.Kinase inhibition assays (10 Î¼L) were performed at 20Â° C. in 384-well plate format. Compound IC50 values were determined at the apparent Km for ATP (20 Î¼M) based on a radiometric assay (Invitrogen) using 8 or 10 point curves in duplicate. The final reaction conditions contained 400 nM fluorescein-IkBÎ± substrate (DRHDSGLDSMKDE), 20 Î¼M ATP, 2 nM or 8 nM IKKÎµ or TBK1 kinase respectively, and 3% DMSO in kinase assay buffer consisting of 50 mM HEPES (pH 7.5), 10 mM MgCl, 1 mM EGTA, 0.01% Brij-35.	B	CN(C)c1ccc(Nc2nccc(-c3ccc(N4CCCC4)c(C#N)c3)n2)cn1		CHEMBL3650702	<	IC50	nM	30.0	CHEMBL5408	Homo sapiens	IC50	nM	30.0
286113	16261351	CHEMBL3707833	Time-Resolved Fluorescence-based Lanthascreen Assay: Inhibitions studies were performed using a time-resolved fluorescence-based Lanthascreen assay. Phosphorylation of a fluorescein-labelled substrate peptide is measured using terbium-labeled phosphospecific antibodies. Terbium is excited at 340 nm and the FRET energy transfer to fluorescein is measured at 495 and 520 nm. The emission ratio between 520 and 495 is a measure of the level of phosphorylation of the substrate by the kinase.Kinase inhibition assays (10 Î¼L) were performed at 20Â° C. in 384-well plate format. Compound IC50 values were determined at the apparent Km for ATP (20 Î¼M) based on a radiometric assay (Invitrogen) using 8 or 10 point curves in duplicate. The final reaction conditions contained 400 nM fluorescein-IkBÎ± substrate (DRHDSGLDSMKDE), 20 Î¼M ATP, 2 nM or 8 nM IKKÎµ or TBK1 kinase respectively, and 3% DMSO in kinase assay buffer consisting of 50 mM HEPES (pH 7.5), 10 mM MgCl, 1 mM EGTA, 0.01% Brij-35.	B	CC(=O)Nc1ccc(Nc2nccc(-c3ccc(N4CC[C@@H](O)C4)c(C#N)c3)n2)cn1		CHEMBL3650748	<	IC50	nM	30.0	CHEMBL5408	Homo sapiens	IC50	nM	30.0
286064	16262681	CHEMBL3707833	Time-Resolved Fluorescence-based Lanthascreen Assay: Inhibitions studies were performed using a time-resolved fluorescence-based Lanthascreen assay. Phosphorylation of a fluorescein-labelled substrate peptide is measured using terbium-labeled phosphospecific antibodies. Terbium is excited at 340 nm and the FRET energy transfer to fluorescein is measured at 495 and 520 nm. The emission ratio between 520 and 495 is a measure of the level of phosphorylation of the substrate by the kinase.Kinase inhibition assays (10 Î¼L) were performed at 20Â° C. in 384-well plate format. Compound IC50 values were determined at the apparent Km for ATP (20 Î¼M) based on a radiometric assay (Invitrogen) using 8 or 10 point curves in duplicate. The final reaction conditions contained 400 nM fluorescein-IkBÎ± substrate (DRHDSGLDSMKDE), 20 Î¼M ATP, 2 nM or 8 nM IKKÎµ or TBK1 kinase respectively, and 3% DMSO in kinase assay buffer consisting of 50 mM HEPES (pH 7.5), 10 mM MgCl, 1 mM EGTA, 0.01% Brij-35.	B	CC(=O)Nc1cccc(Nc2nccc(-c3ccc(N4CCCC4)c(C#N)c3)n2)c1		CHEMBL3650690	<	IC50	nM	30.0	CHEMBL5408	Homo sapiens	IC50	nM	30.0
286069	16263903	CHEMBL3707833	Time-Resolved Fluorescence-based Lanthascreen Assay: Inhibitions studies were performed using a time-resolved fluorescence-based Lanthascreen assay. Phosphorylation of a fluorescein-labelled substrate peptide is measured using terbium-labeled phosphospecific antibodies. Terbium is excited at 340 nm and the FRET energy transfer to fluorescein is measured at 495 and 520 nm. The emission ratio between 520 and 495 is a measure of the level of phosphorylation of the substrate by the kinase.Kinase inhibition assays (10 Î¼L) were performed at 20Â° C. in 384-well plate format. Compound IC50 values were determined at the apparent Km for ATP (20 Î¼M) based on a radiometric assay (Invitrogen) using 8 or 10 point curves in duplicate. The final reaction conditions contained 400 nM fluorescein-IkBÎ± substrate (DRHDSGLDSMKDE), 20 Î¼M ATP, 2 nM or 8 nM IKKÎµ or TBK1 kinase respectively, and 3% DMSO in kinase assay buffer consisting of 50 mM HEPES (pH 7.5), 10 mM MgCl, 1 mM EGTA, 0.01% Brij-35.	B	CC(=O)Nc1ccc(Nc2nccc(-c3ccc(N4CCCC4)c(C#N)c3)n2)cn1		CHEMBL3650698	<	IC50	nM	30.0	CHEMBL5408	Homo sapiens	IC50	nM	30.0
286077	16264075	CHEMBL3707833	Time-Resolved Fluorescence-based Lanthascreen Assay: Inhibitions studies were performed using a time-resolved fluorescence-based Lanthascreen assay. Phosphorylation of a fluorescein-labelled substrate peptide is measured using terbium-labeled phosphospecific antibodies. Terbium is excited at 340 nm and the FRET energy transfer to fluorescein is measured at 495 and 520 nm. The emission ratio between 520 and 495 is a measure of the level of phosphorylation of the substrate by the kinase.Kinase inhibition assays (10 Î¼L) were performed at 20Â° C. in 384-well plate format. Compound IC50 values were determined at the apparent Km for ATP (20 Î¼M) based on a radiometric assay (Invitrogen) using 8 or 10 point curves in duplicate. The final reaction conditions contained 400 nM fluorescein-IkBÎ± substrate (DRHDSGLDSMKDE), 20 Î¼M ATP, 2 nM or 8 nM IKKÎµ or TBK1 kinase respectively, and 3% DMSO in kinase assay buffer consisting of 50 mM HEPES (pH 7.5), 10 mM MgCl, 1 mM EGTA, 0.01% Brij-35.	B	COc1ccc(Nc2nccc(-c3ccc(N4CCCC4)c(C#N)c3)n2)cn1		CHEMBL3650706	<	IC50	nM	30.0	CHEMBL5408	Homo sapiens	IC50	nM	30.0
286108	16266299	CHEMBL3707833	Time-Resolved Fluorescence-based Lanthascreen Assay: Inhibitions studies were performed using a time-resolved fluorescence-based Lanthascreen assay. Phosphorylation of a fluorescein-labelled substrate peptide is measured using terbium-labeled phosphospecific antibodies. Terbium is excited at 340 nm and the FRET energy transfer to fluorescein is measured at 495 and 520 nm. The emission ratio between 520 and 495 is a measure of the level of phosphorylation of the substrate by the kinase.Kinase inhibition assays (10 Î¼L) were performed at 20Â° C. in 384-well plate format. Compound IC50 values were determined at the apparent Km for ATP (20 Î¼M) based on a radiometric assay (Invitrogen) using 8 or 10 point curves in duplicate. The final reaction conditions contained 400 nM fluorescein-IkBÎ± substrate (DRHDSGLDSMKDE), 20 Î¼M ATP, 2 nM or 8 nM IKKÎµ or TBK1 kinase respectively, and 3% DMSO in kinase assay buffer consisting of 50 mM HEPES (pH 7.5), 10 mM MgCl, 1 mM EGTA, 0.01% Brij-35.	B	CNC(=O)C1CCN(c2ccc(-c3ccnc(Nc4ccc(NC(C)=O)nc4)n3)cc2C#N)CC1		CHEMBL3650743	<	IC50	nM	300.0	CHEMBL5408	Homo sapiens	IC50	nM	300.0
286092	16267468	CHEMBL3707833	Time-Resolved Fluorescence-based Lanthascreen Assay: Inhibitions studies were performed using a time-resolved fluorescence-based Lanthascreen assay. Phosphorylation of a fluorescein-labelled substrate peptide is measured using terbium-labeled phosphospecific antibodies. Terbium is excited at 340 nm and the FRET energy transfer to fluorescein is measured at 495 and 520 nm. The emission ratio between 520 and 495 is a measure of the level of phosphorylation of the substrate by the kinase.Kinase inhibition assays (10 Î¼L) were performed at 20Â° C. in 384-well plate format. Compound IC50 values were determined at the apparent Km for ATP (20 Î¼M) based on a radiometric assay (Invitrogen) using 8 or 10 point curves in duplicate. The final reaction conditions contained 400 nM fluorescein-IkBÎ± substrate (DRHDSGLDSMKDE), 20 Î¼M ATP, 2 nM or 8 nM IKKÎµ or TBK1 kinase respectively, and 3% DMSO in kinase assay buffer consisting of 50 mM HEPES (pH 7.5), 10 mM MgCl, 1 mM EGTA, 0.01% Brij-35.	B	CN(C)CCNC(=O)c1cccc(Nc2nccc(-c3ccc(N4CCCC4)c(C#N)c3)n2)c1		CHEMBL3650727	<	IC50	nM	30.0	CHEMBL5408	Homo sapiens	IC50	nM	30.0
286089	16268326	CHEMBL3707833	Time-Resolved Fluorescence-based Lanthascreen Assay: Inhibitions studies were performed using a time-resolved fluorescence-based Lanthascreen assay. Phosphorylation of a fluorescein-labelled substrate peptide is measured using terbium-labeled phosphospecific antibodies. Terbium is excited at 340 nm and the FRET energy transfer to fluorescein is measured at 495 and 520 nm. The emission ratio between 520 and 495 is a measure of the level of phosphorylation of the substrate by the kinase.Kinase inhibition assays (10 Î¼L) were performed at 20Â° C. in 384-well plate format. Compound IC50 values were determined at the apparent Km for ATP (20 Î¼M) based on a radiometric assay (Invitrogen) using 8 or 10 point curves in duplicate. The final reaction conditions contained 400 nM fluorescein-IkBÎ± substrate (DRHDSGLDSMKDE), 20 Î¼M ATP, 2 nM or 8 nM IKKÎµ or TBK1 kinase respectively, and 3% DMSO in kinase assay buffer consisting of 50 mM HEPES (pH 7.5), 10 mM MgCl, 1 mM EGTA, 0.01% Brij-35.	B	N#Cc1cc(-c2ccnc(Nc3cccc(C(=O)O)c3)n2)ccc1N1CCCC1		CHEMBL3650724	<	IC50	nM	30.0	CHEMBL5408	Homo sapiens	IC50	nM	30.0
286109	16268585	CHEMBL3707833	Time-Resolved Fluorescence-based Lanthascreen Assay: Inhibitions studies were performed using a time-resolved fluorescence-based Lanthascreen assay. Phosphorylation of a fluorescein-labelled substrate peptide is measured using terbium-labeled phosphospecific antibodies. Terbium is excited at 340 nm and the FRET energy transfer to fluorescein is measured at 495 and 520 nm. The emission ratio between 520 and 495 is a measure of the level of phosphorylation of the substrate by the kinase.Kinase inhibition assays (10 Î¼L) were performed at 20Â° C. in 384-well plate format. Compound IC50 values were determined at the apparent Km for ATP (20 Î¼M) based on a radiometric assay (Invitrogen) using 8 or 10 point curves in duplicate. The final reaction conditions contained 400 nM fluorescein-IkBÎ± substrate (DRHDSGLDSMKDE), 20 Î¼M ATP, 2 nM or 8 nM IKKÎµ or TBK1 kinase respectively, and 3% DMSO in kinase assay buffer consisting of 50 mM HEPES (pH 7.5), 10 mM MgCl, 1 mM EGTA, 0.01% Brij-35.	B	CN(C)CCNc1ccc(Nc2nccc(-c3ccc(N4CC[C@H](F)C4)c(C#N)c3)n2)cn1		CHEMBL3650744	<	IC50	nM	30.0	CHEMBL5408	Homo sapiens	IC50	nM	30.0
286088	16271657	CHEMBL3707833	Time-Resolved Fluorescence-based Lanthascreen Assay: Inhibitions studies were performed using a time-resolved fluorescence-based Lanthascreen assay. Phosphorylation of a fluorescein-labelled substrate peptide is measured using terbium-labeled phosphospecific antibodies. Terbium is excited at 340 nm and the FRET energy transfer to fluorescein is measured at 495 and 520 nm. The emission ratio between 520 and 495 is a measure of the level of phosphorylation of the substrate by the kinase.Kinase inhibition assays (10 Î¼L) were performed at 20Â° C. in 384-well plate format. Compound IC50 values were determined at the apparent Km for ATP (20 Î¼M) based on a radiometric assay (Invitrogen) using 8 or 10 point curves in duplicate. The final reaction conditions contained 400 nM fluorescein-IkBÎ± substrate (DRHDSGLDSMKDE), 20 Î¼M ATP, 2 nM or 8 nM IKKÎµ or TBK1 kinase respectively, and 3% DMSO in kinase assay buffer consisting of 50 mM HEPES (pH 7.5), 10 mM MgCl, 1 mM EGTA, 0.01% Brij-35.	B	Cn1nc(C(N)=O)cc1Nc1nccc(-c2ccc(N3CCCC3)c(C#N)c2)n1		CHEMBL3650723	<	IC50	nM	300.0	CHEMBL5408	Homo sapiens	IC50	nM	300.0
286075	16274637	CHEMBL3707833	Time-Resolved Fluorescence-based Lanthascreen Assay: Inhibitions studies were performed using a time-resolved fluorescence-based Lanthascreen assay. Phosphorylation of a fluorescein-labelled substrate peptide is measured using terbium-labeled phosphospecific antibodies. Terbium is excited at 340 nm and the FRET energy transfer to fluorescein is measured at 495 and 520 nm. The emission ratio between 520 and 495 is a measure of the level of phosphorylation of the substrate by the kinase.Kinase inhibition assays (10 Î¼L) were performed at 20Â° C. in 384-well plate format. Compound IC50 values were determined at the apparent Km for ATP (20 Î¼M) based on a radiometric assay (Invitrogen) using 8 or 10 point curves in duplicate. The final reaction conditions contained 400 nM fluorescein-IkBÎ± substrate (DRHDSGLDSMKDE), 20 Î¼M ATP, 2 nM or 8 nM IKKÎµ or TBK1 kinase respectively, and 3% DMSO in kinase assay buffer consisting of 50 mM HEPES (pH 7.5), 10 mM MgCl, 1 mM EGTA, 0.01% Brij-35.	B	Cn1cc(Nc2nccc(-c3ccc(N4CCCC4)c(C#N)c3)n2)cn1		CHEMBL3650704	<	IC50	nM	30.0	CHEMBL5408	Homo sapiens	IC50	nM	30.0
286096	16274987	CHEMBL3707833	Time-Resolved Fluorescence-based Lanthascreen Assay: Inhibitions studies were performed using a time-resolved fluorescence-based Lanthascreen assay. Phosphorylation of a fluorescein-labelled substrate peptide is measured using terbium-labeled phosphospecific antibodies. Terbium is excited at 340 nm and the FRET energy transfer to fluorescein is measured at 495 and 520 nm. The emission ratio between 520 and 495 is a measure of the level of phosphorylation of the substrate by the kinase.Kinase inhibition assays (10 Î¼L) were performed at 20Â° C. in 384-well plate format. Compound IC50 values were determined at the apparent Km for ATP (20 Î¼M) based on a radiometric assay (Invitrogen) using 8 or 10 point curves in duplicate. The final reaction conditions contained 400 nM fluorescein-IkBÎ± substrate (DRHDSGLDSMKDE), 20 Î¼M ATP, 2 nM or 8 nM IKKÎµ or TBK1 kinase respectively, and 3% DMSO in kinase assay buffer consisting of 50 mM HEPES (pH 7.5), 10 mM MgCl, 1 mM EGTA, 0.01% Brij-35.	B	CN(C)CC(=O)Nc1ccc(Nc2nccc(-c3ccc(N4CCCC4)c(C#N)c3)n2)cn1		CHEMBL3650731	<	IC50	nM	30.0	CHEMBL5408	Homo sapiens	IC50	nM	30.0
198638	16275409	CHEMBL3706335	Flashplate Assay: 1 nM IKKe, 800 nM biotinylated IkBalpha(19-42) peptide (Biotin-C6-C6-GLKKERLLDDRHDSGLDSMKDEE) and 10 Î¼M ATP (spiked with 0.3 uCi of 33P-ATP/well) are incubated at 30 C. for 2 hours in a total volume of 50 ul (10 mM MOPS, 10 mM Mg acetate, 0.1 mM EGTA, 1 mM dithiothreitol, 0.02% of Brij35, 0.1% of BSA, 0.1% of BioStab, pH 7.5) with or without test compound. The reaction is stopped using 25 ul of 200 mM EDTA. After 30 min at room temperature, the liquid is removed, and each well is washed three times with 100 Î¼l of 0.9% sodium chloride solution. Non-specific reaction is determined in the presence of 3 uM MSC2119074 (BX-795). The radioactivity is measured using a Topcount (PerkinElmer).	B	N#Cc1cc(-c2ccnc(Nc3cncc(-c4cccnc4)c3)c2)ccc1OC1CCOCC1		CHEMBL3687187	=	IC50	nM	260.0	CHEMBL5408	Homo sapiens	IC50	nM	260.0
286103	16276488	CHEMBL3707833	Time-Resolved Fluorescence-based Lanthascreen Assay: Inhibitions studies were performed using a time-resolved fluorescence-based Lanthascreen assay. Phosphorylation of a fluorescein-labelled substrate peptide is measured using terbium-labeled phosphospecific antibodies. Terbium is excited at 340 nm and the FRET energy transfer to fluorescein is measured at 495 and 520 nm. The emission ratio between 520 and 495 is a measure of the level of phosphorylation of the substrate by the kinase.Kinase inhibition assays (10 Î¼L) were performed at 20Â° C. in 384-well plate format. Compound IC50 values were determined at the apparent Km for ATP (20 Î¼M) based on a radiometric assay (Invitrogen) using 8 or 10 point curves in duplicate. The final reaction conditions contained 400 nM fluorescein-IkBÎ± substrate (DRHDSGLDSMKDE), 20 Î¼M ATP, 2 nM or 8 nM IKKÎµ or TBK1 kinase respectively, and 3% DMSO in kinase assay buffer consisting of 50 mM HEPES (pH 7.5), 10 mM MgCl, 1 mM EGTA, 0.01% Brij-35.	B	C[C@H]1CCCN1c1ccc(-c2ccnc(Nc3ccc(NCCN(C)C)nc3)n2)cc1C#N		CHEMBL3650738	<	IC50	nM	30.0	CHEMBL5408	Homo sapiens	IC50	nM	30.0
286084	16276884	CHEMBL3707833	Time-Resolved Fluorescence-based Lanthascreen Assay: Inhibitions studies were performed using a time-resolved fluorescence-based Lanthascreen assay. Phosphorylation of a fluorescein-labelled substrate peptide is measured using terbium-labeled phosphospecific antibodies. Terbium is excited at 340 nm and the FRET energy transfer to fluorescein is measured at 495 and 520 nm. The emission ratio between 520 and 495 is a measure of the level of phosphorylation of the substrate by the kinase.Kinase inhibition assays (10 Î¼L) were performed at 20Â° C. in 384-well plate format. Compound IC50 values were determined at the apparent Km for ATP (20 Î¼M) based on a radiometric assay (Invitrogen) using 8 or 10 point curves in duplicate. The final reaction conditions contained 400 nM fluorescein-IkBÎ± substrate (DRHDSGLDSMKDE), 20 Î¼M ATP, 2 nM or 8 nM IKKÎµ or TBK1 kinase respectively, and 3% DMSO in kinase assay buffer consisting of 50 mM HEPES (pH 7.5), 10 mM MgCl, 1 mM EGTA, 0.01% Brij-35.	B	CN(C)CCN(C)c1ccc(Nc2nccc(-c3ccc(N4CCCC4)c(C#N)c3)n2)cn1		CHEMBL3650717	<	IC50	nM	30.0	CHEMBL5408	Homo sapiens	IC50	nM	30.0
286114	16280697	CHEMBL3707833	Time-Resolved Fluorescence-based Lanthascreen Assay: Inhibitions studies were performed using a time-resolved fluorescence-based Lanthascreen assay. Phosphorylation of a fluorescein-labelled substrate peptide is measured using terbium-labeled phosphospecific antibodies. Terbium is excited at 340 nm and the FRET energy transfer to fluorescein is measured at 495 and 520 nm. The emission ratio between 520 and 495 is a measure of the level of phosphorylation of the substrate by the kinase.Kinase inhibition assays (10 Î¼L) were performed at 20Â° C. in 384-well plate format. Compound IC50 values were determined at the apparent Km for ATP (20 Î¼M) based on a radiometric assay (Invitrogen) using 8 or 10 point curves in duplicate. The final reaction conditions contained 400 nM fluorescein-IkBÎ± substrate (DRHDSGLDSMKDE), 20 Î¼M ATP, 2 nM or 8 nM IKKÎµ or TBK1 kinase respectively, and 3% DMSO in kinase assay buffer consisting of 50 mM HEPES (pH 7.5), 10 mM MgCl, 1 mM EGTA, 0.01% Brij-35.	B	Cn1cc(Nc2nccc(-c3ccc(N4CC[C@H](O)C4)c(C#N)c3)n2)cn1		CHEMBL3650749	<	IC50	nM	30.0	CHEMBL5408	Homo sapiens	IC50	nM	30.0
286119	16283083	CHEMBL3707833	Time-Resolved Fluorescence-based Lanthascreen Assay: Inhibitions studies were performed using a time-resolved fluorescence-based Lanthascreen assay. Phosphorylation of a fluorescein-labelled substrate peptide is measured using terbium-labeled phosphospecific antibodies. Terbium is excited at 340 nm and the FRET energy transfer to fluorescein is measured at 495 and 520 nm. The emission ratio between 520 and 495 is a measure of the level of phosphorylation of the substrate by the kinase.Kinase inhibition assays (10 Î¼L) were performed at 20Â° C. in 384-well plate format. Compound IC50 values were determined at the apparent Km for ATP (20 Î¼M) based on a radiometric assay (Invitrogen) using 8 or 10 point curves in duplicate. The final reaction conditions contained 400 nM fluorescein-IkBÎ± substrate (DRHDSGLDSMKDE), 20 Î¼M ATP, 2 nM or 8 nM IKKÎµ or TBK1 kinase respectively, and 3% DMSO in kinase assay buffer consisting of 50 mM HEPES (pH 7.5), 10 mM MgCl, 1 mM EGTA, 0.01% Brij-35.	B	CN1CCC(Nc2ccc(Nc3nccc(-c4ccc(N5CC[C@H](O)C5)c(C#N)c4)n3)cn2)CC1		CHEMBL3650754	<	IC50	nM	30.0	CHEMBL5408	Homo sapiens	IC50	nM	30.0
286080	16285801	CHEMBL3707833	Time-Resolved Fluorescence-based Lanthascreen Assay: Inhibitions studies were performed using a time-resolved fluorescence-based Lanthascreen assay. Phosphorylation of a fluorescein-labelled substrate peptide is measured using terbium-labeled phosphospecific antibodies. Terbium is excited at 340 nm and the FRET energy transfer to fluorescein is measured at 495 and 520 nm. The emission ratio between 520 and 495 is a measure of the level of phosphorylation of the substrate by the kinase.Kinase inhibition assays (10 Î¼L) were performed at 20Â° C. in 384-well plate format. Compound IC50 values were determined at the apparent Km for ATP (20 Î¼M) based on a radiometric assay (Invitrogen) using 8 or 10 point curves in duplicate. The final reaction conditions contained 400 nM fluorescein-IkBÎ± substrate (DRHDSGLDSMKDE), 20 Î¼M ATP, 2 nM or 8 nM IKKÎµ or TBK1 kinase respectively, and 3% DMSO in kinase assay buffer consisting of 50 mM HEPES (pH 7.5), 10 mM MgCl, 1 mM EGTA, 0.01% Brij-35.	B	Cc1cc(Nc2nccc(-c3ccc(N4CCCC4)c(C#N)c3)n2)on1		CHEMBL3650710	<	IC50	nM	300.0	CHEMBL5408	Homo sapiens	IC50	nM	300.0
286070	16287363	CHEMBL3707833	Time-Resolved Fluorescence-based Lanthascreen Assay: Inhibitions studies were performed using a time-resolved fluorescence-based Lanthascreen assay. Phosphorylation of a fluorescein-labelled substrate peptide is measured using terbium-labeled phosphospecific antibodies. Terbium is excited at 340 nm and the FRET energy transfer to fluorescein is measured at 495 and 520 nm. The emission ratio between 520 and 495 is a measure of the level of phosphorylation of the substrate by the kinase.Kinase inhibition assays (10 Î¼L) were performed at 20Â° C. in 384-well plate format. Compound IC50 values were determined at the apparent Km for ATP (20 Î¼M) based on a radiometric assay (Invitrogen) using 8 or 10 point curves in duplicate. The final reaction conditions contained 400 nM fluorescein-IkBÎ± substrate (DRHDSGLDSMKDE), 20 Î¼M ATP, 2 nM or 8 nM IKKÎµ or TBK1 kinase respectively, and 3% DMSO in kinase assay buffer consisting of 50 mM HEPES (pH 7.5), 10 mM MgCl, 1 mM EGTA, 0.01% Brij-35.	B	N#Cc1cc(-c2ccnc(Nc3ccc(N4CCOCC4)nc3)n2)ccc1N1CCCC1		CHEMBL3639495	<	IC50	nM	30.0	CHEMBL5408	Homo sapiens	IC50	nM	30.0
286071	16290124	CHEMBL3707833	Time-Resolved Fluorescence-based Lanthascreen Assay: Inhibitions studies were performed using a time-resolved fluorescence-based Lanthascreen assay. Phosphorylation of a fluorescein-labelled substrate peptide is measured using terbium-labeled phosphospecific antibodies. Terbium is excited at 340 nm and the FRET energy transfer to fluorescein is measured at 495 and 520 nm. The emission ratio between 520 and 495 is a measure of the level of phosphorylation of the substrate by the kinase.Kinase inhibition assays (10 Î¼L) were performed at 20Â° C. in 384-well plate format. Compound IC50 values were determined at the apparent Km for ATP (20 Î¼M) based on a radiometric assay (Invitrogen) using 8 or 10 point curves in duplicate. The final reaction conditions contained 400 nM fluorescein-IkBÎ± substrate (DRHDSGLDSMKDE), 20 Î¼M ATP, 2 nM or 8 nM IKKÎµ or TBK1 kinase respectively, and 3% DMSO in kinase assay buffer consisting of 50 mM HEPES (pH 7.5), 10 mM MgCl, 1 mM EGTA, 0.01% Brij-35.	B	N#Cc1cc(-c2ccnc(Nc3ccc4c(c3)NC(=O)CC4)n2)ccc1N1CCCC1		CHEMBL3650699	<	IC50	nM	30.0	CHEMBL5408	Homo sapiens	IC50	nM	30.0
286078	16292985	CHEMBL3707833	Time-Resolved Fluorescence-based Lanthascreen Assay: Inhibitions studies were performed using a time-resolved fluorescence-based Lanthascreen assay. Phosphorylation of a fluorescein-labelled substrate peptide is measured using terbium-labeled phosphospecific antibodies. Terbium is excited at 340 nm and the FRET energy transfer to fluorescein is measured at 495 and 520 nm. The emission ratio between 520 and 495 is a measure of the level of phosphorylation of the substrate by the kinase.Kinase inhibition assays (10 Î¼L) were performed at 20Â° C. in 384-well plate format. Compound IC50 values were determined at the apparent Km for ATP (20 Î¼M) based on a radiometric assay (Invitrogen) using 8 or 10 point curves in duplicate. The final reaction conditions contained 400 nM fluorescein-IkBÎ± substrate (DRHDSGLDSMKDE), 20 Î¼M ATP, 2 nM or 8 nM IKKÎµ or TBK1 kinase respectively, and 3% DMSO in kinase assay buffer consisting of 50 mM HEPES (pH 7.5), 10 mM MgCl, 1 mM EGTA, 0.01% Brij-35.	B	N#Cc1cc(-c2ccnc(Nc3ccn(CC(N)=O)n3)n2)ccc1N1CCCC1		CHEMBL3650707	<	IC50	nM	300.0	CHEMBL5408	Homo sapiens	IC50	nM	300.0
286095	16295203	CHEMBL3707833	Time-Resolved Fluorescence-based Lanthascreen Assay: Inhibitions studies were performed using a time-resolved fluorescence-based Lanthascreen assay. Phosphorylation of a fluorescein-labelled substrate peptide is measured using terbium-labeled phosphospecific antibodies. Terbium is excited at 340 nm and the FRET energy transfer to fluorescein is measured at 495 and 520 nm. The emission ratio between 520 and 495 is a measure of the level of phosphorylation of the substrate by the kinase.Kinase inhibition assays (10 Î¼L) were performed at 20Â° C. in 384-well plate format. Compound IC50 values were determined at the apparent Km for ATP (20 Î¼M) based on a radiometric assay (Invitrogen) using 8 or 10 point curves in duplicate. The final reaction conditions contained 400 nM fluorescein-IkBÎ± substrate (DRHDSGLDSMKDE), 20 Î¼M ATP, 2 nM or 8 nM IKKÎµ or TBK1 kinase respectively, and 3% DMSO in kinase assay buffer consisting of 50 mM HEPES (pH 7.5), 10 mM MgCl, 1 mM EGTA, 0.01% Brij-35.	B	CC(=O)Nc1ccc(Nc2nccc(-c3ccc(N4CC[C@H](O)C4)c(C#N)c3)n2)cn1		CHEMBL3650730	<	IC50	nM	30.0	CHEMBL5408	Homo sapiens	IC50	nM	30.0
286115	16296812	CHEMBL3707833	Time-Resolved Fluorescence-based Lanthascreen Assay: Inhibitions studies were performed using a time-resolved fluorescence-based Lanthascreen assay. Phosphorylation of a fluorescein-labelled substrate peptide is measured using terbium-labeled phosphospecific antibodies. Terbium is excited at 340 nm and the FRET energy transfer to fluorescein is measured at 495 and 520 nm. The emission ratio between 520 and 495 is a measure of the level of phosphorylation of the substrate by the kinase.Kinase inhibition assays (10 Î¼L) were performed at 20Â° C. in 384-well plate format. Compound IC50 values were determined at the apparent Km for ATP (20 Î¼M) based on a radiometric assay (Invitrogen) using 8 or 10 point curves in duplicate. The final reaction conditions contained 400 nM fluorescein-IkBÎ± substrate (DRHDSGLDSMKDE), 20 Î¼M ATP, 2 nM or 8 nM IKKÎµ or TBK1 kinase respectively, and 3% DMSO in kinase assay buffer consisting of 50 mM HEPES (pH 7.5), 10 mM MgCl, 1 mM EGTA, 0.01% Brij-35.	B	Cn1cc(Nc2nccc(-c3ccc(N4CCC(C(N)=O)CC4)c(C#N)c3)n2)cn1		CHEMBL3650750	<	IC50	nM	300.0	CHEMBL5408	Homo sapiens	IC50	nM	300.0
286105	16296838	CHEMBL3707833	Time-Resolved Fluorescence-based Lanthascreen Assay: Inhibitions studies were performed using a time-resolved fluorescence-based Lanthascreen assay. Phosphorylation of a fluorescein-labelled substrate peptide is measured using terbium-labeled phosphospecific antibodies. Terbium is excited at 340 nm and the FRET energy transfer to fluorescein is measured at 495 and 520 nm. The emission ratio between 520 and 495 is a measure of the level of phosphorylation of the substrate by the kinase.Kinase inhibition assays (10 Î¼L) were performed at 20Â° C. in 384-well plate format. Compound IC50 values were determined at the apparent Km for ATP (20 Î¼M) based on a radiometric assay (Invitrogen) using 8 or 10 point curves in duplicate. The final reaction conditions contained 400 nM fluorescein-IkBÎ± substrate (DRHDSGLDSMKDE), 20 Î¼M ATP, 2 nM or 8 nM IKKÎµ or TBK1 kinase respectively, and 3% DMSO in kinase assay buffer consisting of 50 mM HEPES (pH 7.5), 10 mM MgCl, 1 mM EGTA, 0.01% Brij-35.	B	CN(C)CCNc1ccc(Nc2nccc(-c3ccc(N4CCC(O)CC4)c(C#N)c3)n2)cn1		CHEMBL3650740	<	IC50	nM	300.0	CHEMBL5408	Homo sapiens	IC50	nM	300.0
286107	16297330	CHEMBL3707833	Time-Resolved Fluorescence-based Lanthascreen Assay: Inhibitions studies were performed using a time-resolved fluorescence-based Lanthascreen assay. Phosphorylation of a fluorescein-labelled substrate peptide is measured using terbium-labeled phosphospecific antibodies. Terbium is excited at 340 nm and the FRET energy transfer to fluorescein is measured at 495 and 520 nm. The emission ratio between 520 and 495 is a measure of the level of phosphorylation of the substrate by the kinase.Kinase inhibition assays (10 Î¼L) were performed at 20Â° C. in 384-well plate format. Compound IC50 values were determined at the apparent Km for ATP (20 Î¼M) based on a radiometric assay (Invitrogen) using 8 or 10 point curves in duplicate. The final reaction conditions contained 400 nM fluorescein-IkBÎ± substrate (DRHDSGLDSMKDE), 20 Î¼M ATP, 2 nM or 8 nM IKKÎµ or TBK1 kinase respectively, and 3% DMSO in kinase assay buffer consisting of 50 mM HEPES (pH 7.5), 10 mM MgCl, 1 mM EGTA, 0.01% Brij-35.	B	CNC(=O)[C@H]1CCCN1c1ccc(-c2ccnc(Nc3ccc(NC(C)=O)nc3)n2)cc1C#N		CHEMBL3650742	<	IC50	nM	9000.0	CHEMBL5408	Homo sapiens	IC50	nM	9000.0
286110	16297861	CHEMBL3707833	Time-Resolved Fluorescence-based Lanthascreen Assay: Inhibitions studies were performed using a time-resolved fluorescence-based Lanthascreen assay. Phosphorylation of a fluorescein-labelled substrate peptide is measured using terbium-labeled phosphospecific antibodies. Terbium is excited at 340 nm and the FRET energy transfer to fluorescein is measured at 495 and 520 nm. The emission ratio between 520 and 495 is a measure of the level of phosphorylation of the substrate by the kinase.Kinase inhibition assays (10 Î¼L) were performed at 20Â° C. in 384-well plate format. Compound IC50 values were determined at the apparent Km for ATP (20 Î¼M) based on a radiometric assay (Invitrogen) using 8 or 10 point curves in duplicate. The final reaction conditions contained 400 nM fluorescein-IkBÎ± substrate (DRHDSGLDSMKDE), 20 Î¼M ATP, 2 nM or 8 nM IKKÎµ or TBK1 kinase respectively, and 3% DMSO in kinase assay buffer consisting of 50 mM HEPES (pH 7.5), 10 mM MgCl, 1 mM EGTA, 0.01% Brij-35.	B	CC(=O)Nc1ccc(Nc2nccc(-c3ccc(N4CCC[C@H]4C(N)=O)c(C#N)c3)n2)cn1		CHEMBL3650745	<	IC50	nM	300.0	CHEMBL5408	Homo sapiens	IC50	nM	300.0
286104	16298023	CHEMBL3707833	Time-Resolved Fluorescence-based Lanthascreen Assay: Inhibitions studies were performed using a time-resolved fluorescence-based Lanthascreen assay. Phosphorylation of a fluorescein-labelled substrate peptide is measured using terbium-labeled phosphospecific antibodies. Terbium is excited at 340 nm and the FRET energy transfer to fluorescein is measured at 495 and 520 nm. The emission ratio between 520 and 495 is a measure of the level of phosphorylation of the substrate by the kinase.Kinase inhibition assays (10 Î¼L) were performed at 20Â° C. in 384-well plate format. Compound IC50 values were determined at the apparent Km for ATP (20 Î¼M) based on a radiometric assay (Invitrogen) using 8 or 10 point curves in duplicate. The final reaction conditions contained 400 nM fluorescein-IkBÎ± substrate (DRHDSGLDSMKDE), 20 Î¼M ATP, 2 nM or 8 nM IKKÎµ or TBK1 kinase respectively, and 3% DMSO in kinase assay buffer consisting of 50 mM HEPES (pH 7.5), 10 mM MgCl, 1 mM EGTA, 0.01% Brij-35.	B	CN(C)CCNc1ccc(Nc2nccc(-c3ccc(N4CCC(C(N)=O)CC4)c(C#N)c3)n2)cn1		CHEMBL3650739	<	IC50	nM	300.0	CHEMBL5408	Homo sapiens	IC50	nM	300.0
286072	16303403	CHEMBL3707833	Time-Resolved Fluorescence-based Lanthascreen Assay: Inhibitions studies were performed using a time-resolved fluorescence-based Lanthascreen assay. Phosphorylation of a fluorescein-labelled substrate peptide is measured using terbium-labeled phosphospecific antibodies. Terbium is excited at 340 nm and the FRET energy transfer to fluorescein is measured at 495 and 520 nm. The emission ratio between 520 and 495 is a measure of the level of phosphorylation of the substrate by the kinase.Kinase inhibition assays (10 Î¼L) were performed at 20Â° C. in 384-well plate format. Compound IC50 values were determined at the apparent Km for ATP (20 Î¼M) based on a radiometric assay (Invitrogen) using 8 or 10 point curves in duplicate. The final reaction conditions contained 400 nM fluorescein-IkBÎ± substrate (DRHDSGLDSMKDE), 20 Î¼M ATP, 2 nM or 8 nM IKKÎµ or TBK1 kinase respectively, and 3% DMSO in kinase assay buffer consisting of 50 mM HEPES (pH 7.5), 10 mM MgCl, 1 mM EGTA, 0.01% Brij-35.	B	CN1CCN(c2ccc(Nc3nccc(-c4ccc(N5CCCC5)c(C#N)c4)n3)cn2)CC1		CHEMBL3650701	<	IC50	nM	30.0	CHEMBL5408	Homo sapiens	IC50	nM	30.0
286076	16303691	CHEMBL3707833	Time-Resolved Fluorescence-based Lanthascreen Assay: Inhibitions studies were performed using a time-resolved fluorescence-based Lanthascreen assay. Phosphorylation of a fluorescein-labelled substrate peptide is measured using terbium-labeled phosphospecific antibodies. Terbium is excited at 340 nm and the FRET energy transfer to fluorescein is measured at 495 and 520 nm. The emission ratio between 520 and 495 is a measure of the level of phosphorylation of the substrate by the kinase.Kinase inhibition assays (10 Î¼L) were performed at 20Â° C. in 384-well plate format. Compound IC50 values were determined at the apparent Km for ATP (20 Î¼M) based on a radiometric assay (Invitrogen) using 8 or 10 point curves in duplicate. The final reaction conditions contained 400 nM fluorescein-IkBÎ± substrate (DRHDSGLDSMKDE), 20 Î¼M ATP, 2 nM or 8 nM IKKÎµ or TBK1 kinase respectively, and 3% DMSO in kinase assay buffer consisting of 50 mM HEPES (pH 7.5), 10 mM MgCl, 1 mM EGTA, 0.01% Brij-35.	B	Cn1cnc(Nc2nccc(-c3ccc(N4CCCC4)c(C#N)c3)n2)c1		CHEMBL3650705	<	IC50	nM	300.0	CHEMBL5408	Homo sapiens	IC50	nM	300.0
286100	16306202	CHEMBL3707833	Time-Resolved Fluorescence-based Lanthascreen Assay: Inhibitions studies were performed using a time-resolved fluorescence-based Lanthascreen assay. Phosphorylation of a fluorescein-labelled substrate peptide is measured using terbium-labeled phosphospecific antibodies. Terbium is excited at 340 nm and the FRET energy transfer to fluorescein is measured at 495 and 520 nm. The emission ratio between 520 and 495 is a measure of the level of phosphorylation of the substrate by the kinase.Kinase inhibition assays (10 Î¼L) were performed at 20Â° C. in 384-well plate format. Compound IC50 values were determined at the apparent Km for ATP (20 Î¼M) based on a radiometric assay (Invitrogen) using 8 or 10 point curves in duplicate. The final reaction conditions contained 400 nM fluorescein-IkBÎ± substrate (DRHDSGLDSMKDE), 20 Î¼M ATP, 2 nM or 8 nM IKKÎµ or TBK1 kinase respectively, and 3% DMSO in kinase assay buffer consisting of 50 mM HEPES (pH 7.5), 10 mM MgCl, 1 mM EGTA, 0.01% Brij-35.	B	CN1CCN(c2ccc(Nc3nccc(-c4ccc(N5CC[C@H](O)C5)c(C#N)c4)n3)cn2)CC1		CHEMBL3650735	<	IC50	nM	30.0	CHEMBL5408	Homo sapiens	IC50	nM	30.0
286097	16308757	CHEMBL3707833	Time-Resolved Fluorescence-based Lanthascreen Assay: Inhibitions studies were performed using a time-resolved fluorescence-based Lanthascreen assay. Phosphorylation of a fluorescein-labelled substrate peptide is measured using terbium-labeled phosphospecific antibodies. Terbium is excited at 340 nm and the FRET energy transfer to fluorescein is measured at 495 and 520 nm. The emission ratio between 520 and 495 is a measure of the level of phosphorylation of the substrate by the kinase.Kinase inhibition assays (10 Î¼L) were performed at 20Â° C. in 384-well plate format. Compound IC50 values were determined at the apparent Km for ATP (20 Î¼M) based on a radiometric assay (Invitrogen) using 8 or 10 point curves in duplicate. The final reaction conditions contained 400 nM fluorescein-IkBÎ± substrate (DRHDSGLDSMKDE), 20 Î¼M ATP, 2 nM or 8 nM IKKÎµ or TBK1 kinase respectively, and 3% DMSO in kinase assay buffer consisting of 50 mM HEPES (pH 7.5), 10 mM MgCl, 1 mM EGTA, 0.01% Brij-35.	B	CC(=O)Nc1ccc(Nc2nccc(-c3ccc(N4CCC[C@@H]4C(N)=O)c(C#N)c3)n2)cn1		CHEMBL3650732	<	IC50	nM	300.0	CHEMBL5408	Homo sapiens	IC50	nM	300.0
286087	16308867	CHEMBL3707833	Time-Resolved Fluorescence-based Lanthascreen Assay: Inhibitions studies were performed using a time-resolved fluorescence-based Lanthascreen assay. Phosphorylation of a fluorescein-labelled substrate peptide is measured using terbium-labeled phosphospecific antibodies. Terbium is excited at 340 nm and the FRET energy transfer to fluorescein is measured at 495 and 520 nm. The emission ratio between 520 and 495 is a measure of the level of phosphorylation of the substrate by the kinase.Kinase inhibition assays (10 Î¼L) were performed at 20Â° C. in 384-well plate format. Compound IC50 values were determined at the apparent Km for ATP (20 Î¼M) based on a radiometric assay (Invitrogen) using 8 or 10 point curves in duplicate. The final reaction conditions contained 400 nM fluorescein-IkBÎ± substrate (DRHDSGLDSMKDE), 20 Î¼M ATP, 2 nM or 8 nM IKKÎµ or TBK1 kinase respectively, and 3% DMSO in kinase assay buffer consisting of 50 mM HEPES (pH 7.5), 10 mM MgCl, 1 mM EGTA, 0.01% Brij-35.	B	Cn1nc(Nc2nccc(-c3ccc(N4CCCC4)c(C#N)c3)n2)cc1C(N)=O		CHEMBL3650722	<	IC50	nM	3000.0	CHEMBL5408	Homo sapiens	IC50	nM	3000.0
286086	16314379	CHEMBL3707833	Time-Resolved Fluorescence-based Lanthascreen Assay: Inhibitions studies were performed using a time-resolved fluorescence-based Lanthascreen assay. Phosphorylation of a fluorescein-labelled substrate peptide is measured using terbium-labeled phosphospecific antibodies. Terbium is excited at 340 nm and the FRET energy transfer to fluorescein is measured at 495 and 520 nm. The emission ratio between 520 and 495 is a measure of the level of phosphorylation of the substrate by the kinase.Kinase inhibition assays (10 Î¼L) were performed at 20Â° C. in 384-well plate format. Compound IC50 values were determined at the apparent Km for ATP (20 Î¼M) based on a radiometric assay (Invitrogen) using 8 or 10 point curves in duplicate. The final reaction conditions contained 400 nM fluorescein-IkBÎ± substrate (DRHDSGLDSMKDE), 20 Î¼M ATP, 2 nM or 8 nM IKKÎµ or TBK1 kinase respectively, and 3% DMSO in kinase assay buffer consisting of 50 mM HEPES (pH 7.5), 10 mM MgCl, 1 mM EGTA, 0.01% Brij-35.	B	CN(C)CCOc1ccc(Nc2nccc(-c3ccc(N4CCCC4)c(C#N)c3)n2)cn1		CHEMBL3650719	<	IC50	nM	30.0	CHEMBL5408	Homo sapiens	IC50	nM	30.0
286082	16315244	CHEMBL3707833	Time-Resolved Fluorescence-based Lanthascreen Assay: Inhibitions studies were performed using a time-resolved fluorescence-based Lanthascreen assay. Phosphorylation of a fluorescein-labelled substrate peptide is measured using terbium-labeled phosphospecific antibodies. Terbium is excited at 340 nm and the FRET energy transfer to fluorescein is measured at 495 and 520 nm. The emission ratio between 520 and 495 is a measure of the level of phosphorylation of the substrate by the kinase.Kinase inhibition assays (10 Î¼L) were performed at 20Â° C. in 384-well plate format. Compound IC50 values were determined at the apparent Km for ATP (20 Î¼M) based on a radiometric assay (Invitrogen) using 8 or 10 point curves in duplicate. The final reaction conditions contained 400 nM fluorescein-IkBÎ± substrate (DRHDSGLDSMKDE), 20 Î¼M ATP, 2 nM or 8 nM IKKÎµ or TBK1 kinase respectively, and 3% DMSO in kinase assay buffer consisting of 50 mM HEPES (pH 7.5), 10 mM MgCl, 1 mM EGTA, 0.01% Brij-35.	B	Cn1ccc(Nc2nccc(-c3ccc(N4CCCC4)c(C#N)c3)n2)n1		CHEMBL3650712	<	IC50	nM	300.0	CHEMBL5408	Homo sapiens	IC50	nM	300.0
286090	16316652	CHEMBL3707833	Time-Resolved Fluorescence-based Lanthascreen Assay: Inhibitions studies were performed using a time-resolved fluorescence-based Lanthascreen assay. Phosphorylation of a fluorescein-labelled substrate peptide is measured using terbium-labeled phosphospecific antibodies. Terbium is excited at 340 nm and the FRET energy transfer to fluorescein is measured at 495 and 520 nm. The emission ratio between 520 and 495 is a measure of the level of phosphorylation of the substrate by the kinase.Kinase inhibition assays (10 Î¼L) were performed at 20Â° C. in 384-well plate format. Compound IC50 values were determined at the apparent Km for ATP (20 Î¼M) based on a radiometric assay (Invitrogen) using 8 or 10 point curves in duplicate. The final reaction conditions contained 400 nM fluorescein-IkBÎ± substrate (DRHDSGLDSMKDE), 20 Î¼M ATP, 2 nM or 8 nM IKKÎµ or TBK1 kinase respectively, and 3% DMSO in kinase assay buffer consisting of 50 mM HEPES (pH 7.5), 10 mM MgCl, 1 mM EGTA, 0.01% Brij-35.	B	CN1CCN(C(=O)c2cccc(Nc3nccc(-c4ccc(N5CCCC5)c(C#N)c4)n3)c2)CC1		CHEMBL3650725	<	IC50	nM	30.0	CHEMBL5408	Homo sapiens	IC50	nM	30.0
286101	16317284	CHEMBL3707833	Time-Resolved Fluorescence-based Lanthascreen Assay: Inhibitions studies were performed using a time-resolved fluorescence-based Lanthascreen assay. Phosphorylation of a fluorescein-labelled substrate peptide is measured using terbium-labeled phosphospecific antibodies. Terbium is excited at 340 nm and the FRET energy transfer to fluorescein is measured at 495 and 520 nm. The emission ratio between 520 and 495 is a measure of the level of phosphorylation of the substrate by the kinase.Kinase inhibition assays (10 Î¼L) were performed at 20Â° C. in 384-well plate format. Compound IC50 values were determined at the apparent Km for ATP (20 Î¼M) based on a radiometric assay (Invitrogen) using 8 or 10 point curves in duplicate. The final reaction conditions contained 400 nM fluorescein-IkBÎ± substrate (DRHDSGLDSMKDE), 20 Î¼M ATP, 2 nM or 8 nM IKKÎµ or TBK1 kinase respectively, and 3% DMSO in kinase assay buffer consisting of 50 mM HEPES (pH 7.5), 10 mM MgCl, 1 mM EGTA, 0.01% Brij-35.	B	CN1CCN(c2ccc(Nc3nccc(-c4ccc(N5CCC[C@@H]5C(N)=O)c(C#N)c4)n3)cn2)CC1		CHEMBL3650736	<	IC50	nM	30.0	CHEMBL5408	Homo sapiens	IC50	nM	30.0
286085	16318603	CHEMBL3707833	Time-Resolved Fluorescence-based Lanthascreen Assay: Inhibitions studies were performed using a time-resolved fluorescence-based Lanthascreen assay. Phosphorylation of a fluorescein-labelled substrate peptide is measured using terbium-labeled phosphospecific antibodies. Terbium is excited at 340 nm and the FRET energy transfer to fluorescein is measured at 495 and 520 nm. The emission ratio between 520 and 495 is a measure of the level of phosphorylation of the substrate by the kinase.Kinase inhibition assays (10 Î¼L) were performed at 20Â° C. in 384-well plate format. Compound IC50 values were determined at the apparent Km for ATP (20 Î¼M) based on a radiometric assay (Invitrogen) using 8 or 10 point curves in duplicate. The final reaction conditions contained 400 nM fluorescein-IkBÎ± substrate (DRHDSGLDSMKDE), 20 Î¼M ATP, 2 nM or 8 nM IKKÎµ or TBK1 kinase respectively, and 3% DMSO in kinase assay buffer consisting of 50 mM HEPES (pH 7.5), 10 mM MgCl, 1 mM EGTA, 0.01% Brij-35.	B	CC(=O)N(C)c1ccc(Nc2nccc(-c3ccc(N4CCCC4)c(C#N)c3)n2)cc1		CHEMBL3650718	<	IC50	nM	30.0	CHEMBL5408	Homo sapiens	IC50	nM	30.0
286079	16318661	CHEMBL3707833	Time-Resolved Fluorescence-based Lanthascreen Assay: Inhibitions studies were performed using a time-resolved fluorescence-based Lanthascreen assay. Phosphorylation of a fluorescein-labelled substrate peptide is measured using terbium-labeled phosphospecific antibodies. Terbium is excited at 340 nm and the FRET energy transfer to fluorescein is measured at 495 and 520 nm. The emission ratio between 520 and 495 is a measure of the level of phosphorylation of the substrate by the kinase.Kinase inhibition assays (10 Î¼L) were performed at 20Â° C. in 384-well plate format. Compound IC50 values were determined at the apparent Km for ATP (20 Î¼M) based on a radiometric assay (Invitrogen) using 8 or 10 point curves in duplicate. The final reaction conditions contained 400 nM fluorescein-IkBÎ± substrate (DRHDSGLDSMKDE), 20 Î¼M ATP, 2 nM or 8 nM IKKÎµ or TBK1 kinase respectively, and 3% DMSO in kinase assay buffer consisting of 50 mM HEPES (pH 7.5), 10 mM MgCl, 1 mM EGTA, 0.01% Brij-35.	B	Cn1cncc1Nc1nccc(-c2ccc(N3CCCC3)c(C#N)c2)n1		CHEMBL3650708	<	IC50	nM	300.0	CHEMBL5408	Homo sapiens	IC50	nM	300.0
286120	16323120	CHEMBL3707833	Time-Resolved Fluorescence-based Lanthascreen Assay: Inhibitions studies were performed using a time-resolved fluorescence-based Lanthascreen assay. Phosphorylation of a fluorescein-labelled substrate peptide is measured using terbium-labeled phosphospecific antibodies. Terbium is excited at 340 nm and the FRET energy transfer to fluorescein is measured at 495 and 520 nm. The emission ratio between 520 and 495 is a measure of the level of phosphorylation of the substrate by the kinase.Kinase inhibition assays (10 Î¼L) were performed at 20Â° C. in 384-well plate format. Compound IC50 values were determined at the apparent Km for ATP (20 Î¼M) based on a radiometric assay (Invitrogen) using 8 or 10 point curves in duplicate. The final reaction conditions contained 400 nM fluorescein-IkBÎ± substrate (DRHDSGLDSMKDE), 20 Î¼M ATP, 2 nM or 8 nM IKKÎµ or TBK1 kinase respectively, and 3% DMSO in kinase assay buffer consisting of 50 mM HEPES (pH 7.5), 10 mM MgCl, 1 mM EGTA, 0.01% Brij-35.	B	CN1CCC(Nc2ccc(Nc3nccc(-c4ccc(N5CCC(F)(F)C5)c(C#N)c4)n3)cn2)CC1		CHEMBL3650755	<	IC50	nM	30.0	CHEMBL5408	Homo sapiens	IC50	nM	30.0
286081	16323166	CHEMBL3707833	Time-Resolved Fluorescence-based Lanthascreen Assay: Inhibitions studies were performed using a time-resolved fluorescence-based Lanthascreen assay. Phosphorylation of a fluorescein-labelled substrate peptide is measured using terbium-labeled phosphospecific antibodies. Terbium is excited at 340 nm and the FRET energy transfer to fluorescein is measured at 495 and 520 nm. The emission ratio between 520 and 495 is a measure of the level of phosphorylation of the substrate by the kinase.Kinase inhibition assays (10 Î¼L) were performed at 20Â° C. in 384-well plate format. Compound IC50 values were determined at the apparent Km for ATP (20 Î¼M) based on a radiometric assay (Invitrogen) using 8 or 10 point curves in duplicate. The final reaction conditions contained 400 nM fluorescein-IkBÎ± substrate (DRHDSGLDSMKDE), 20 Î¼M ATP, 2 nM or 8 nM IKKÎµ or TBK1 kinase respectively, and 3% DMSO in kinase assay buffer consisting of 50 mM HEPES (pH 7.5), 10 mM MgCl, 1 mM EGTA, 0.01% Brij-35.	B	Cn1nccc1Nc1nccc(-c2ccc(N3CCCC3)c(C#N)c2)n1		CHEMBL3650711	<	IC50	nM	30.0	CHEMBL5408	Homo sapiens	IC50	nM	30.0
286116	16325412	CHEMBL3707833	Time-Resolved Fluorescence-based Lanthascreen Assay: Inhibitions studies were performed using a time-resolved fluorescence-based Lanthascreen assay. Phosphorylation of a fluorescein-labelled substrate peptide is measured using terbium-labeled phosphospecific antibodies. Terbium is excited at 340 nm and the FRET energy transfer to fluorescein is measured at 495 and 520 nm. The emission ratio between 520 and 495 is a measure of the level of phosphorylation of the substrate by the kinase.Kinase inhibition assays (10 Î¼L) were performed at 20Â° C. in 384-well plate format. Compound IC50 values were determined at the apparent Km for ATP (20 Î¼M) based on a radiometric assay (Invitrogen) using 8 or 10 point curves in duplicate. The final reaction conditions contained 400 nM fluorescein-IkBÎ± substrate (DRHDSGLDSMKDE), 20 Î¼M ATP, 2 nM or 8 nM IKKÎµ or TBK1 kinase respectively, and 3% DMSO in kinase assay buffer consisting of 50 mM HEPES (pH 7.5), 10 mM MgCl, 1 mM EGTA, 0.01% Brij-35.	B	CO[C@H]1CCN(c2ccc(-c3ccnc(Nc4ccc(NC(C)=O)nc4)n3)cc2C#N)C1		CHEMBL3650751	<	IC50	nM	30.0	CHEMBL5408	Homo sapiens	IC50	nM	30.0
286083	16328282	CHEMBL3707833	Time-Resolved Fluorescence-based Lanthascreen Assay: Inhibitions studies were performed using a time-resolved fluorescence-based Lanthascreen assay. Phosphorylation of a fluorescein-labelled substrate peptide is measured using terbium-labeled phosphospecific antibodies. Terbium is excited at 340 nm and the FRET energy transfer to fluorescein is measured at 495 and 520 nm. The emission ratio between 520 and 495 is a measure of the level of phosphorylation of the substrate by the kinase.Kinase inhibition assays (10 Î¼L) were performed at 20Â° C. in 384-well plate format. Compound IC50 values were determined at the apparent Km for ATP (20 Î¼M) based on a radiometric assay (Invitrogen) using 8 or 10 point curves in duplicate. The final reaction conditions contained 400 nM fluorescein-IkBÎ± substrate (DRHDSGLDSMKDE), 20 Î¼M ATP, 2 nM or 8 nM IKKÎµ or TBK1 kinase respectively, and 3% DMSO in kinase assay buffer consisting of 50 mM HEPES (pH 7.5), 10 mM MgCl, 1 mM EGTA, 0.01% Brij-35.	B	CN(C)CCNc1ccc(Nc2nccc(-c3ccc(N4CCCC4)c(C#N)c3)n2)cn1		CHEMBL3650716	<	IC50	nM	30.0	CHEMBL5408	Homo sapiens	IC50	nM	30.0
286093	16329896	CHEMBL3707833	Time-Resolved Fluorescence-based Lanthascreen Assay: Inhibitions studies were performed using a time-resolved fluorescence-based Lanthascreen assay. Phosphorylation of a fluorescein-labelled substrate peptide is measured using terbium-labeled phosphospecific antibodies. Terbium is excited at 340 nm and the FRET energy transfer to fluorescein is measured at 495 and 520 nm. The emission ratio between 520 and 495 is a measure of the level of phosphorylation of the substrate by the kinase.Kinase inhibition assays (10 Î¼L) were performed at 20Â° C. in 384-well plate format. Compound IC50 values were determined at the apparent Km for ATP (20 Î¼M) based on a radiometric assay (Invitrogen) using 8 or 10 point curves in duplicate. The final reaction conditions contained 400 nM fluorescein-IkBÎ± substrate (DRHDSGLDSMKDE), 20 Î¼M ATP, 2 nM or 8 nM IKKÎµ or TBK1 kinase respectively, and 3% DMSO in kinase assay buffer consisting of 50 mM HEPES (pH 7.5), 10 mM MgCl, 1 mM EGTA, 0.01% Brij-35.	B	CC(=O)Nc1ccc(Nc2nccc(-c3ccc(N4CCOCC4)c(C#N)c3)n2)cn1		CHEMBL3650728	<	IC50	nM	30.0	CHEMBL5408	Homo sapiens	IC50	nM	30.0
286111	16330643	CHEMBL3707833	Time-Resolved Fluorescence-based Lanthascreen Assay: Inhibitions studies were performed using a time-resolved fluorescence-based Lanthascreen assay. Phosphorylation of a fluorescein-labelled substrate peptide is measured using terbium-labeled phosphospecific antibodies. Terbium is excited at 340 nm and the FRET energy transfer to fluorescein is measured at 495 and 520 nm. The emission ratio between 520 and 495 is a measure of the level of phosphorylation of the substrate by the kinase.Kinase inhibition assays (10 Î¼L) were performed at 20Â° C. in 384-well plate format. Compound IC50 values were determined at the apparent Km for ATP (20 Î¼M) based on a radiometric assay (Invitrogen) using 8 or 10 point curves in duplicate. The final reaction conditions contained 400 nM fluorescein-IkBÎ± substrate (DRHDSGLDSMKDE), 20 Î¼M ATP, 2 nM or 8 nM IKKÎµ or TBK1 kinase respectively, and 3% DMSO in kinase assay buffer consisting of 50 mM HEPES (pH 7.5), 10 mM MgCl, 1 mM EGTA, 0.01% Brij-35.	B	COC[C@H]1CCCN1c1ccc(-c2ccnc(Nc3ccc(NC(C)=O)nc3)n2)cc1C#N		CHEMBL3650746	<	IC50	nM	30.0	CHEMBL5408	Homo sapiens	IC50	nM	30.0
286106	16331712	CHEMBL3707833	Time-Resolved Fluorescence-based Lanthascreen Assay: Inhibitions studies were performed using a time-resolved fluorescence-based Lanthascreen assay. Phosphorylation of a fluorescein-labelled substrate peptide is measured using terbium-labeled phosphospecific antibodies. Terbium is excited at 340 nm and the FRET energy transfer to fluorescein is measured at 495 and 520 nm. The emission ratio between 520 and 495 is a measure of the level of phosphorylation of the substrate by the kinase.Kinase inhibition assays (10 Î¼L) were performed at 20Â° C. in 384-well plate format. Compound IC50 values were determined at the apparent Km for ATP (20 Î¼M) based on a radiometric assay (Invitrogen) using 8 or 10 point curves in duplicate. The final reaction conditions contained 400 nM fluorescein-IkBÎ± substrate (DRHDSGLDSMKDE), 20 Î¼M ATP, 2 nM or 8 nM IKKÎµ or TBK1 kinase respectively, and 3% DMSO in kinase assay buffer consisting of 50 mM HEPES (pH 7.5), 10 mM MgCl, 1 mM EGTA, 0.01% Brij-35.	B	CC(=O)Nc1ccc(Nc2nccc(-c3ccc(N4CC(O)C4)c(C#N)c3)n2)cn1		CHEMBL3650741	<	IC50	nM	30.0	CHEMBL5408	Homo sapiens	IC50	nM	30.0
286074	16331920	CHEMBL3707833	Time-Resolved Fluorescence-based Lanthascreen Assay: Inhibitions studies were performed using a time-resolved fluorescence-based Lanthascreen assay. Phosphorylation of a fluorescein-labelled substrate peptide is measured using terbium-labeled phosphospecific antibodies. Terbium is excited at 340 nm and the FRET energy transfer to fluorescein is measured at 495 and 520 nm. The emission ratio between 520 and 495 is a measure of the level of phosphorylation of the substrate by the kinase.Kinase inhibition assays (10 Î¼L) were performed at 20Â° C. in 384-well plate format. Compound IC50 values were determined at the apparent Km for ATP (20 Î¼M) based on a radiometric assay (Invitrogen) using 8 or 10 point curves in duplicate. The final reaction conditions contained 400 nM fluorescein-IkBÎ± substrate (DRHDSGLDSMKDE), 20 Î¼M ATP, 2 nM or 8 nM IKKÎµ or TBK1 kinase respectively, and 3% DMSO in kinase assay buffer consisting of 50 mM HEPES (pH 7.5), 10 mM MgCl, 1 mM EGTA, 0.01% Brij-35.	B	Cc1cc(C(N)=O)ccc1Nc1nccc(-c2ccc(N3CCCC3)c(C#N)c2)n1		CHEMBL3650703	<	IC50	nM	300.0	CHEMBL5408	Homo sapiens	IC50	nM	300.0
286068	16332535	CHEMBL3707833	Time-Resolved Fluorescence-based Lanthascreen Assay: Inhibitions studies were performed using a time-resolved fluorescence-based Lanthascreen assay. Phosphorylation of a fluorescein-labelled substrate peptide is measured using terbium-labeled phosphospecific antibodies. Terbium is excited at 340 nm and the FRET energy transfer to fluorescein is measured at 495 and 520 nm. The emission ratio between 520 and 495 is a measure of the level of phosphorylation of the substrate by the kinase.Kinase inhibition assays (10 Î¼L) were performed at 20Â° C. in 384-well plate format. Compound IC50 values were determined at the apparent Km for ATP (20 Î¼M) based on a radiometric assay (Invitrogen) using 8 or 10 point curves in duplicate. The final reaction conditions contained 400 nM fluorescein-IkBÎ± substrate (DRHDSGLDSMKDE), 20 Î¼M ATP, 2 nM or 8 nM IKKÎµ or TBK1 kinase respectively, and 3% DMSO in kinase assay buffer consisting of 50 mM HEPES (pH 7.5), 10 mM MgCl, 1 mM EGTA, 0.01% Brij-35.	B	N#Cc1cc(-c2ccnc(Nc3ccc4c(c3)CC(=O)N4)n2)ccc1N1CCCC1		CHEMBL3650697	<	IC50	nM	30.0	CHEMBL5408	Homo sapiens	IC50	nM	30.0
286066	16333915	CHEMBL3707833	Time-Resolved Fluorescence-based Lanthascreen Assay: Inhibitions studies were performed using a time-resolved fluorescence-based Lanthascreen assay. Phosphorylation of a fluorescein-labelled substrate peptide is measured using terbium-labeled phosphospecific antibodies. Terbium is excited at 340 nm and the FRET energy transfer to fluorescein is measured at 495 and 520 nm. The emission ratio between 520 and 495 is a measure of the level of phosphorylation of the substrate by the kinase.Kinase inhibition assays (10 Î¼L) were performed at 20Â° C. in 384-well plate format. Compound IC50 values were determined at the apparent Km for ATP (20 Î¼M) based on a radiometric assay (Invitrogen) using 8 or 10 point curves in duplicate. The final reaction conditions contained 400 nM fluorescein-IkBÎ± substrate (DRHDSGLDSMKDE), 20 Î¼M ATP, 2 nM or 8 nM IKKÎµ or TBK1 kinase respectively, and 3% DMSO in kinase assay buffer consisting of 50 mM HEPES (pH 7.5), 10 mM MgCl, 1 mM EGTA, 0.01% Brij-35.	B	CC(=O)Nc1ccc(Nc2nccc(-c3ccc(N4CCCC4)c(C#N)c3)n2)cc1		CHEMBL3650692	<	IC50	nM	30.0	CHEMBL5408	Homo sapiens	IC50	nM	30.0
286117	16334296	CHEMBL3707833	Time-Resolved Fluorescence-based Lanthascreen Assay: Inhibitions studies were performed using a time-resolved fluorescence-based Lanthascreen assay. Phosphorylation of a fluorescein-labelled substrate peptide is measured using terbium-labeled phosphospecific antibodies. Terbium is excited at 340 nm and the FRET energy transfer to fluorescein is measured at 495 and 520 nm. The emission ratio between 520 and 495 is a measure of the level of phosphorylation of the substrate by the kinase.Kinase inhibition assays (10 Î¼L) were performed at 20Â° C. in 384-well plate format. Compound IC50 values were determined at the apparent Km for ATP (20 Î¼M) based on a radiometric assay (Invitrogen) using 8 or 10 point curves in duplicate. The final reaction conditions contained 400 nM fluorescein-IkBÎ± substrate (DRHDSGLDSMKDE), 20 Î¼M ATP, 2 nM or 8 nM IKKÎµ or TBK1 kinase respectively, and 3% DMSO in kinase assay buffer consisting of 50 mM HEPES (pH 7.5), 10 mM MgCl, 1 mM EGTA, 0.01% Brij-35.	B	CN1CCC(Nc2ccc(Nc3nccc(-c4ccc(N5CC[C@@H](F)C5)c(C#N)c4)n3)cn2)CC1		CHEMBL3650752	<	IC50	nM	30.0	CHEMBL5408	Homo sapiens	IC50	nM	30.0
286112	16338246	CHEMBL3707833	Time-Resolved Fluorescence-based Lanthascreen Assay: Inhibitions studies were performed using a time-resolved fluorescence-based Lanthascreen assay. Phosphorylation of a fluorescein-labelled substrate peptide is measured using terbium-labeled phosphospecific antibodies. Terbium is excited at 340 nm and the FRET energy transfer to fluorescein is measured at 495 and 520 nm. The emission ratio between 520 and 495 is a measure of the level of phosphorylation of the substrate by the kinase.Kinase inhibition assays (10 Î¼L) were performed at 20Â° C. in 384-well plate format. Compound IC50 values were determined at the apparent Km for ATP (20 Î¼M) based on a radiometric assay (Invitrogen) using 8 or 10 point curves in duplicate. The final reaction conditions contained 400 nM fluorescein-IkBÎ± substrate (DRHDSGLDSMKDE), 20 Î¼M ATP, 2 nM or 8 nM IKKÎµ or TBK1 kinase respectively, and 3% DMSO in kinase assay buffer consisting of 50 mM HEPES (pH 7.5), 10 mM MgCl, 1 mM EGTA, 0.01% Brij-35.	B	CN(C)CCNc1ccc(Nc2nccc(-c3ccc(N4CCC[C@@H]4C(N)=O)c(C#N)c3)n2)cn1		CHEMBL3650747	<	IC50	nM	300.0	CHEMBL5408	Homo sapiens	IC50	nM	300.0
286118	16338959	CHEMBL3707833	Time-Resolved Fluorescence-based Lanthascreen Assay: Inhibitions studies were performed using a time-resolved fluorescence-based Lanthascreen assay. Phosphorylation of a fluorescein-labelled substrate peptide is measured using terbium-labeled phosphospecific antibodies. Terbium is excited at 340 nm and the FRET energy transfer to fluorescein is measured at 495 and 520 nm. The emission ratio between 520 and 495 is a measure of the level of phosphorylation of the substrate by the kinase.Kinase inhibition assays (10 Î¼L) were performed at 20Â° C. in 384-well plate format. Compound IC50 values were determined at the apparent Km for ATP (20 Î¼M) based on a radiometric assay (Invitrogen) using 8 or 10 point curves in duplicate. The final reaction conditions contained 400 nM fluorescein-IkBÎ± substrate (DRHDSGLDSMKDE), 20 Î¼M ATP, 2 nM or 8 nM IKKÎµ or TBK1 kinase respectively, and 3% DMSO in kinase assay buffer consisting of 50 mM HEPES (pH 7.5), 10 mM MgCl, 1 mM EGTA, 0.01% Brij-35.	B	CN1CCC(Nc2ccc(Nc3nccc(-c4ccc(N5CC[C@H](F)C5)c(C#N)c4)n3)cn2)CC1		CHEMBL3650753	<	IC50	nM	30.0	CHEMBL5408	Homo sapiens	IC50	nM	30.0
286067	16339259	CHEMBL3707833	Time-Resolved Fluorescence-based Lanthascreen Assay: Inhibitions studies were performed using a time-resolved fluorescence-based Lanthascreen assay. Phosphorylation of a fluorescein-labelled substrate peptide is measured using terbium-labeled phosphospecific antibodies. Terbium is excited at 340 nm and the FRET energy transfer to fluorescein is measured at 495 and 520 nm. The emission ratio between 520 and 495 is a measure of the level of phosphorylation of the substrate by the kinase.Kinase inhibition assays (10 Î¼L) were performed at 20Â° C. in 384-well plate format. Compound IC50 values were determined at the apparent Km for ATP (20 Î¼M) based on a radiometric assay (Invitrogen) using 8 or 10 point curves in duplicate. The final reaction conditions contained 400 nM fluorescein-IkBÎ± substrate (DRHDSGLDSMKDE), 20 Î¼M ATP, 2 nM or 8 nM IKKÎµ or TBK1 kinase respectively, and 3% DMSO in kinase assay buffer consisting of 50 mM HEPES (pH 7.5), 10 mM MgCl, 1 mM EGTA, 0.01% Brij-35.	B	CS(=O)(=O)c1cccc(Nc2nccc(-c3ccc(N4CCCC4)c(C#N)c3)n2)c1		CHEMBL3650693	<	IC50	nM	30.0	CHEMBL5408	Homo sapiens	IC50	nM	30.0
286091	16339472	CHEMBL3707833	Time-Resolved Fluorescence-based Lanthascreen Assay: Inhibitions studies were performed using a time-resolved fluorescence-based Lanthascreen assay. Phosphorylation of a fluorescein-labelled substrate peptide is measured using terbium-labeled phosphospecific antibodies. Terbium is excited at 340 nm and the FRET energy transfer to fluorescein is measured at 495 and 520 nm. The emission ratio between 520 and 495 is a measure of the level of phosphorylation of the substrate by the kinase.Kinase inhibition assays (10 Î¼L) were performed at 20Â° C. in 384-well plate format. Compound IC50 values were determined at the apparent Km for ATP (20 Î¼M) based on a radiometric assay (Invitrogen) using 8 or 10 point curves in duplicate. The final reaction conditions contained 400 nM fluorescein-IkBÎ± substrate (DRHDSGLDSMKDE), 20 Î¼M ATP, 2 nM or 8 nM IKKÎµ or TBK1 kinase respectively, and 3% DMSO in kinase assay buffer consisting of 50 mM HEPES (pH 7.5), 10 mM MgCl, 1 mM EGTA, 0.01% Brij-35.	B	CN1CCC(NC(=O)c2cccc(Nc3nccc(-c4ccc(N5CCCC5)c(C#N)c4)n3)c2)CC1		CHEMBL3650726	<	IC50	nM	30.0	CHEMBL5408	Homo sapiens	IC50	nM	30.0
286065	16342516	CHEMBL3707833	Time-Resolved Fluorescence-based Lanthascreen Assay: Inhibitions studies were performed using a time-resolved fluorescence-based Lanthascreen assay. Phosphorylation of a fluorescein-labelled substrate peptide is measured using terbium-labeled phosphospecific antibodies. Terbium is excited at 340 nm and the FRET energy transfer to fluorescein is measured at 495 and 520 nm. The emission ratio between 520 and 495 is a measure of the level of phosphorylation of the substrate by the kinase.Kinase inhibition assays (10 Î¼L) were performed at 20Â° C. in 384-well plate format. Compound IC50 values were determined at the apparent Km for ATP (20 Î¼M) based on a radiometric assay (Invitrogen) using 8 or 10 point curves in duplicate. The final reaction conditions contained 400 nM fluorescein-IkBÎ± substrate (DRHDSGLDSMKDE), 20 Î¼M ATP, 2 nM or 8 nM IKKÎµ or TBK1 kinase respectively, and 3% DMSO in kinase assay buffer consisting of 50 mM HEPES (pH 7.5), 10 mM MgCl, 1 mM EGTA, 0.01% Brij-35.	B	N#Cc1cc(-c2ccnc(Nc3ccc(C(N)=O)cc3)n2)ccc1N1CCCC1		CHEMBL3650691	<	IC50	nM	30.0	CHEMBL5408	Homo sapiens	IC50	nM	30.0
286094	16345222	CHEMBL3707833	Time-Resolved Fluorescence-based Lanthascreen Assay: Inhibitions studies were performed using a time-resolved fluorescence-based Lanthascreen assay. Phosphorylation of a fluorescein-labelled substrate peptide is measured using terbium-labeled phosphospecific antibodies. Terbium is excited at 340 nm and the FRET energy transfer to fluorescein is measured at 495 and 520 nm. The emission ratio between 520 and 495 is a measure of the level of phosphorylation of the substrate by the kinase.Kinase inhibition assays (10 Î¼L) were performed at 20Â° C. in 384-well plate format. Compound IC50 values were determined at the apparent Km for ATP (20 Î¼M) based on a radiometric assay (Invitrogen) using 8 or 10 point curves in duplicate. The final reaction conditions contained 400 nM fluorescein-IkBÎ± substrate (DRHDSGLDSMKDE), 20 Î¼M ATP, 2 nM or 8 nM IKKÎµ or TBK1 kinase respectively, and 3% DMSO in kinase assay buffer consisting of 50 mM HEPES (pH 7.5), 10 mM MgCl, 1 mM EGTA, 0.01% Brij-35.	B	CC(=O)Nc1ccc(Nc2nccc(-c3ccc(N4CCN(C)CC4)c(C#N)c3)n2)cn1		CHEMBL3650729	<	IC50	nM	300.0	CHEMBL5408	Homo sapiens	IC50	nM	300.0
286099	16349964	CHEMBL3707833	Time-Resolved Fluorescence-based Lanthascreen Assay: Inhibitions studies were performed using a time-resolved fluorescence-based Lanthascreen assay. Phosphorylation of a fluorescein-labelled substrate peptide is measured using terbium-labeled phosphospecific antibodies. Terbium is excited at 340 nm and the FRET energy transfer to fluorescein is measured at 495 and 520 nm. The emission ratio between 520 and 495 is a measure of the level of phosphorylation of the substrate by the kinase.Kinase inhibition assays (10 Î¼L) were performed at 20Â° C. in 384-well plate format. Compound IC50 values were determined at the apparent Km for ATP (20 Î¼M) based on a radiometric assay (Invitrogen) using 8 or 10 point curves in duplicate. The final reaction conditions contained 400 nM fluorescein-IkBÎ± substrate (DRHDSGLDSMKDE), 20 Î¼M ATP, 2 nM or 8 nM IKKÎµ or TBK1 kinase respectively, and 3% DMSO in kinase assay buffer consisting of 50 mM HEPES (pH 7.5), 10 mM MgCl, 1 mM EGTA, 0.01% Brij-35.	B	Cn1nccc1Nc1nccc(-c2ccc(N3CCC[C@@H]3C(N)=O)c(C#N)c2)n1		CHEMBL3650734	<	IC50	nM	3000.0	CHEMBL5408	Homo sapiens	IC50	nM	3000.0
286102	16350934	CHEMBL3707833	Time-Resolved Fluorescence-based Lanthascreen Assay: Inhibitions studies were performed using a time-resolved fluorescence-based Lanthascreen assay. Phosphorylation of a fluorescein-labelled substrate peptide is measured using terbium-labeled phosphospecific antibodies. Terbium is excited at 340 nm and the FRET energy transfer to fluorescein is measured at 495 and 520 nm. The emission ratio between 520 and 495 is a measure of the level of phosphorylation of the substrate by the kinase.Kinase inhibition assays (10 Î¼L) were performed at 20Â° C. in 384-well plate format. Compound IC50 values were determined at the apparent Km for ATP (20 Î¼M) based on a radiometric assay (Invitrogen) using 8 or 10 point curves in duplicate. The final reaction conditions contained 400 nM fluorescein-IkBÎ± substrate (DRHDSGLDSMKDE), 20 Î¼M ATP, 2 nM or 8 nM IKKÎµ or TBK1 kinase respectively, and 3% DMSO in kinase assay buffer consisting of 50 mM HEPES (pH 7.5), 10 mM MgCl, 1 mM EGTA, 0.01% Brij-35.	B	CN(C)CCNc1ccc(Nc2nccc(-c3ccc(N4CC[C@H](O)C4)c(C#N)c3)n2)cn1		CHEMBL3650737	<	IC50	nM	30.0	CHEMBL5408	Homo sapiens	IC50	nM	30.0
286098	16351926	CHEMBL3707833	Time-Resolved Fluorescence-based Lanthascreen Assay: Inhibitions studies were performed using a time-resolved fluorescence-based Lanthascreen assay. Phosphorylation of a fluorescein-labelled substrate peptide is measured using terbium-labeled phosphospecific antibodies. Terbium is excited at 340 nm and the FRET energy transfer to fluorescein is measured at 495 and 520 nm. The emission ratio between 520 and 495 is a measure of the level of phosphorylation of the substrate by the kinase.Kinase inhibition assays (10 Î¼L) were performed at 20Â° C. in 384-well plate format. Compound IC50 values were determined at the apparent Km for ATP (20 Î¼M) based on a radiometric assay (Invitrogen) using 8 or 10 point curves in duplicate. The final reaction conditions contained 400 nM fluorescein-IkBÎ± substrate (DRHDSGLDSMKDE), 20 Î¼M ATP, 2 nM or 8 nM IKKÎµ or TBK1 kinase respectively, and 3% DMSO in kinase assay buffer consisting of 50 mM HEPES (pH 7.5), 10 mM MgCl, 1 mM EGTA, 0.01% Brij-35.	B	Cn1nccc1Nc1nccc(-c2ccc(N3CC[C@H](O)C3)c(C#N)c2)n1		CHEMBL3650733	<	IC50	nM	300.0	CHEMBL5408	Homo sapiens	IC50	nM	300.0
	16425354	CHEMBL3751238	Inhibition of TBK1 (unknown origin) at 1 uM	B	Cc1c(-c2cc(Nc3cc4n(n3)CCN(C)C4)c(=O)[nH]n2)ccc(F)c1NC(=O)c1cc2ccccc2s1		CHEMBL3746293	=	Inhibition	%	7.5	CHEMBL5408	Homo sapiens	INH	%	7.5
	16432025	CHEMBL3750179	Inhibition of human TBK1 using [KRRRAL[pS]VASLPGL] as substrate	B	Cn1c(=O)c(S(=O)(=O)c2ccc(F)cc2F)cc2cnc(Nc3ccc4[nH]ccc4c3)nc21		CHEMBL3745885	>	IC50	nM	10000.0	CHEMBL5408	Homo sapiens	IC50	uM	10.0
	16451625	CHEMBL3761206	Inhibition of TBK1 (unknown origin) at 100 nM	B	CC1(C)OCc2c(Nc3n[nH]c4ccccc34)nc(-c3cn[nH]c3)nc21		CHEMBL3758502	=	Inhibition	%	7.9	CHEMBL5408	Homo sapiens	INH	%	7.9
	16451755	CHEMBL3761206	Inhibition of TBK1 (unknown origin) at 100 nM	B	CC1(C)OCc2c(Nc3n[nH]c4c(Cl)cccc34)nc(-c3cn[nH]c3)nc21		CHEMBL3758602	=	Inhibition	%	9.4	CHEMBL5408	Homo sapiens	INH	%	9.4
	16474711	CHEMBL3767331	Inhibition of TBK1 (unknown origin) at 10 uM	B	CN1CCN(CCCOc2ccc(N3C(=O)/C(=C/c4ccc(Oc5ccc(F)cc5)cc4)SC3=S)cc2)CC1		CHEMBL3765499	=	Inhibition	%	0.0	CHEMBL5408	Homo sapiens	INH	%	0.0
	16495240	CHEMBL3778883	Inhibition of N-terminal His6-tagged recombinant human TBK1 expressed in baculovirus infected insect Sf9 cells assessed as remaining activity at 1 uM relative to control	B	Cn1cc(-c2ccc(Cc3n[nH]c4ccc(C(=O)N5CC[C@@H](O)C5)cc34)cc2)cn1		CHEMBL3775317	=	Activity	%	22.0	CHEMBL5408	Homo sapiens	Activity	%	22.0
	16496159	CHEMBL3778883	Inhibition of N-terminal His6-tagged recombinant human TBK1 expressed in baculovirus infected insect Sf9 cells assessed as remaining activity at 1 uM relative to control	B	Cn1cc(-c2ccc(Cc3n[nH]c4ccc(C(=O)N5CCOCC5)cc34)cc2)cn1		CHEMBL3774885	=	Activity	%	-7.0	CHEMBL5408	Homo sapiens	Activity	%	-7.0
Not Active	16497481	CHEMBL3776622	Inhibition of human TBK1 (1 to 729 residues) at 1 uM by radioactive [33P]-ATP filter binding assay	B	O=c1[nH]cnc2c(-n3cc(CCN4CCC(c5cccc(Cl)c5)CC4)cn3)nccc12		CHEMBL3774537		Inhibition	%		CHEMBL5408	Homo sapiens	INH		
	16507190	CHEMBL3778986	Inhibition of recombinant TBK1 (unknown origin) assessed as residual activity at 1 uM relative to control	B	CC(O)CNc1nc(NCc2ccc(-c3ccccn3)cc2)c2[nH]nc(C(C)C)c2n1		CHEMBL3774632	=	Activity	%	92.0	CHEMBL5408	Homo sapiens	Activity	%	92.0
	16508949	CHEMBL3778883	Inhibition of N-terminal His6-tagged recombinant human TBK1 expressed in baculovirus infected insect Sf9 cells assessed as remaining activity at 1 uM relative to control	B	CNC(=O)c1ccc2[nH]nc(Cc3ccc4c(cnn4C)c3)c2c1		CHEMBL3775576	=	Activity	%	-4.0	CHEMBL5408	Homo sapiens	Activity	%	-4.0
	16579277	CHEMBL3802474	Inhibition of full length wild type human TBK1 expressed in mammalian system assessed as enzyme activity at 1 uM relative to control	B	CN(C)S(=O)(=O)Nc1ccc(F)c(Nc2ncccc2-c2ncnc3[nH]cnc23)c1F		CHEMBL3798256	=	Activity	%	100.0	CHEMBL5408	Homo sapiens	Activity	%	100.0
	16612744	CHEMBL3815742	Inhibition of human TBK1 (1 to 729 residues) assessed as enzyme activity at 1 uM using 33P ATP by radioactive filter binding assay	B	Nc1nccc(-c2c[nH]c3ncccc23)n1		CHEMBL405665	=	Activity	%	-17.0	CHEMBL5408	Homo sapiens	Activity	%	-17.0
	16612745	CHEMBL3815742	Inhibition of human TBK1 (1 to 729 residues) assessed as enzyme activity at 1 uM using 33P ATP by radioactive filter binding assay	B	CCCCc1cc(-c2c[nH]c3ncccc23)nc(N)n1		CHEMBL3814340	=	Activity	%	-37.0	CHEMBL5408	Homo sapiens	Activity	%	-37.0
	16612746	CHEMBL3815742	Inhibition of human TBK1 (1 to 729 residues) assessed as enzyme activity at 1 uM using 33P ATP by radioactive filter binding assay	B	CCc1cc(-c2c[nH]c3ncc(-c4cnn(C5CCNCC5)c4)cc23)nc(N)n1		CHEMBL3814140	=	Activity	%	-65.0	CHEMBL5408	Homo sapiens	Activity	%	-65.0
	16612747	CHEMBL3815742	Inhibition of human TBK1 (1 to 729 residues) assessed as enzyme activity at 1 uM using 33P ATP by radioactive filter binding assay	B	CCCCc1cc(-c2c[nH]c3ncc(-c4cnn(C5CCNCC5)c4)cc23)nc(N)n1		CHEMBL3815046	=	Activity	%	-93.0	CHEMBL5408	Homo sapiens	Activity	%	-93.0
	16614645	CHEMBL3816861	Inhibition of human TBK1 at 1 uM using [KRRRAL[pS]VASLPGL] as substrate	B	CNS(=O)(=O)c1ccc(N(C)C)c(Nc2ncnc3cc(OC)c(OC)cc23)c1		CHEMBL3815093	=	Inhibition	%	-1.0	CHEMBL5408	Homo sapiens	INH	%	-1.0
	16618665	CHEMBL3816416	Inhibition of full length recombinant human GST-tagged TBK1 expressed in insect cells at 1 uM relative to control	B	CC1(C)OCCn2c1nc1c(N3CCOCC3)nc(-c3cnc(N)nc3)nc12		CHEMBL3813842	<	Inhibition	%	50.0	CHEMBL5408	Homo sapiens	INH	%	50.0
	16628485	CHEMBL3820297	Inhibition of human recombinant full-length TBK1 expressed in insect Sf21 cells at 1 uM using AKPKGNKDYHLQTCCGSLAYRRR as substrate	B	O=C(Nc1cc(Nc2c(Cl)cnc3c2OCO3)ccn1)C1CC1		CHEMBL3818173	<	Inhibition	%	80.0	CHEMBL5408	Homo sapiens	INH	%	80.0
	16654117	CHEMBL3829297	Inhibition of human TBK1 (1 to 729 residues) assessed as remaining enzyme activity at 50 uM after 30 mins by 33P-ATP filter-binding assay	B	Cc1cc(=O)c2c(O)cc(O)c([C@H]3CCN(C)C[C@H]3O)c2o1		CHEMBL1077604	=	Activity	%	55.0	CHEMBL5408	Homo sapiens	Activity	%	55.0
	16837472	CHEMBL3876132	Inhibition of human recombinant full length GST-tagged TBK1 expressed in insect expression system	B	CC1(C)C(=O)N([C@H]2CCc3c(O)cccc32)c2nc(Nc3ccccc3)ncc21		CHEMBL3884319	=	IC50	nM	10000.0	CHEMBL5408	Homo sapiens	IC50	nM	10000.0
280334	17662679	CHEMBL3706282	Flashplate Assay: The kinase assay is performed as 384-well flashplate assay (for example for Topcount measurement).0.6 nM TANK binding kinase (TBK1), 800 nM biotinylated MELK-derived peptide (Biotin-Ah-Ah-AKPKGNKDYHLQTCCGSLAYRRR) and 10 uM ATP (spiked with 0.25 uCi of 33P-ATP/well) are incubated at 30 C. for 120 min in a total volume of 50 ul (10 mM MOPS, 10 mM Mg acetate, 0.1 mM EGTA, 1 mM DTT, 0.02% of Brij35, 0.1% of BSA, pH 7.5) with or without test compound. The reaction is stopped with 25 ul of 200 mM EDTA. After 30 min at room temperature, the liquid is removed, and each well is washed three times with 100 ul of 0.9% sodium chloride solution. Non-specific reaction is measured in the presence of 100 nM staurosporine. The radioactivity is measured in a Topcount (PerkinElmer).	B	CN1CCC(n2cc(Nc3cc(-c4ccc(OC5CCOCC5)c(C#N)c4)ccn3)cn2)CC1		CHEMBL3687148	=	IC50	nM	83.0	CHEMBL5408	Homo sapiens	IC50	nM	83.0
280335	17662680	CHEMBL3706282	Flashplate Assay: The kinase assay is performed as 384-well flashplate assay (for example for Topcount measurement).0.6 nM TANK binding kinase (TBK1), 800 nM biotinylated MELK-derived peptide (Biotin-Ah-Ah-AKPKGNKDYHLQTCCGSLAYRRR) and 10 uM ATP (spiked with 0.25 uCi of 33P-ATP/well) are incubated at 30 C. for 120 min in a total volume of 50 ul (10 mM MOPS, 10 mM Mg acetate, 0.1 mM EGTA, 1 mM DTT, 0.02% of Brij35, 0.1% of BSA, pH 7.5) with or without test compound. The reaction is stopped with 25 ul of 200 mM EDTA. After 30 min at room temperature, the liquid is removed, and each well is washed three times with 100 ul of 0.9% sodium chloride solution. Non-specific reaction is measured in the presence of 100 nM staurosporine. The radioactivity is measured in a Topcount (PerkinElmer).	B	Cc1cc(Nc2cc(-c3ccc(OC4CCOCC4)c(C#N)c3)ccn2)no1		CHEMBL3687149	=	IC50	nM	34.0	CHEMBL5408	Homo sapiens	IC50	nM	34.0
280336	17662681	CHEMBL3706282	Flashplate Assay: The kinase assay is performed as 384-well flashplate assay (for example for Topcount measurement).0.6 nM TANK binding kinase (TBK1), 800 nM biotinylated MELK-derived peptide (Biotin-Ah-Ah-AKPKGNKDYHLQTCCGSLAYRRR) and 10 uM ATP (spiked with 0.25 uCi of 33P-ATP/well) are incubated at 30 C. for 120 min in a total volume of 50 ul (10 mM MOPS, 10 mM Mg acetate, 0.1 mM EGTA, 1 mM DTT, 0.02% of Brij35, 0.1% of BSA, pH 7.5) with or without test compound. The reaction is stopped with 25 ul of 200 mM EDTA. After 30 min at room temperature, the liquid is removed, and each well is washed three times with 100 ul of 0.9% sodium chloride solution. Non-specific reaction is measured in the presence of 100 nM staurosporine. The radioactivity is measured in a Topcount (PerkinElmer).	B	Cn1ccc(Nc2cc(-c3ccc(OC4CCOCC4)c(C#N)c3)ccn2)n1		CHEMBL3687150	=	IC50	nM	97.0	CHEMBL5408	Homo sapiens	IC50	nM	97.0
280337	17662682	CHEMBL3706282	Flashplate Assay: The kinase assay is performed as 384-well flashplate assay (for example for Topcount measurement).0.6 nM TANK binding kinase (TBK1), 800 nM biotinylated MELK-derived peptide (Biotin-Ah-Ah-AKPKGNKDYHLQTCCGSLAYRRR) and 10 uM ATP (spiked with 0.25 uCi of 33P-ATP/well) are incubated at 30 C. for 120 min in a total volume of 50 ul (10 mM MOPS, 10 mM Mg acetate, 0.1 mM EGTA, 1 mM DTT, 0.02% of Brij35, 0.1% of BSA, pH 7.5) with or without test compound. The reaction is stopped with 25 ul of 200 mM EDTA. After 30 min at room temperature, the liquid is removed, and each well is washed three times with 100 ul of 0.9% sodium chloride solution. Non-specific reaction is measured in the presence of 100 nM staurosporine. The radioactivity is measured in a Topcount (PerkinElmer).	B	N#Cc1cc(-c2ccnc(Nc3ccc(N4CCOCC4)cn3)c2)ccc1OC1CCOCC1		CHEMBL3687151	=	IC50	nM	8.0	CHEMBL5408	Homo sapiens	IC50	nM	8.0
280338	17662683	CHEMBL3706282	Flashplate Assay: The kinase assay is performed as 384-well flashplate assay (for example for Topcount measurement).0.6 nM TANK binding kinase (TBK1), 800 nM biotinylated MELK-derived peptide (Biotin-Ah-Ah-AKPKGNKDYHLQTCCGSLAYRRR) and 10 uM ATP (spiked with 0.25 uCi of 33P-ATP/well) are incubated at 30 C. for 120 min in a total volume of 50 ul (10 mM MOPS, 10 mM Mg acetate, 0.1 mM EGTA, 1 mM DTT, 0.02% of Brij35, 0.1% of BSA, pH 7.5) with or without test compound. The reaction is stopped with 25 ul of 200 mM EDTA. After 30 min at room temperature, the liquid is removed, and each well is washed three times with 100 ul of 0.9% sodium chloride solution. Non-specific reaction is measured in the presence of 100 nM staurosporine. The radioactivity is measured in a Topcount (PerkinElmer).	B	N#Cc1cc(-c2ccnc(Nc3ccc(-c4cn[nH]c4)cn3)c2)ccc1OC1CCOCC1		CHEMBL3687152	=	IC50	nM	120.0	CHEMBL5408	Homo sapiens	IC50	nM	120.0
280339	17662684	CHEMBL3706282	Flashplate Assay: The kinase assay is performed as 384-well flashplate assay (for example for Topcount measurement).0.6 nM TANK binding kinase (TBK1), 800 nM biotinylated MELK-derived peptide (Biotin-Ah-Ah-AKPKGNKDYHLQTCCGSLAYRRR) and 10 uM ATP (spiked with 0.25 uCi of 33P-ATP/well) are incubated at 30 C. for 120 min in a total volume of 50 ul (10 mM MOPS, 10 mM Mg acetate, 0.1 mM EGTA, 1 mM DTT, 0.02% of Brij35, 0.1% of BSA, pH 7.5) with or without test compound. The reaction is stopped with 25 ul of 200 mM EDTA. After 30 min at room temperature, the liquid is removed, and each well is washed three times with 100 ul of 0.9% sodium chloride solution. Non-specific reaction is measured in the presence of 100 nM staurosporine. The radioactivity is measured in a Topcount (PerkinElmer).	B	CC(C)(C)c1cc(Nc2cc(-c3ccc(OC4CCOCC4)c(C#N)c3)ccn2)n[nH]1		CHEMBL3687153	=	IC50	nM	21.0	CHEMBL5408	Homo sapiens	IC50	nM	21.0
280340	17662685	CHEMBL3706282	Flashplate Assay: The kinase assay is performed as 384-well flashplate assay (for example for Topcount measurement).0.6 nM TANK binding kinase (TBK1), 800 nM biotinylated MELK-derived peptide (Biotin-Ah-Ah-AKPKGNKDYHLQTCCGSLAYRRR) and 10 uM ATP (spiked with 0.25 uCi of 33P-ATP/well) are incubated at 30 C. for 120 min in a total volume of 50 ul (10 mM MOPS, 10 mM Mg acetate, 0.1 mM EGTA, 1 mM DTT, 0.02% of Brij35, 0.1% of BSA, pH 7.5) with or without test compound. The reaction is stopped with 25 ul of 200 mM EDTA. After 30 min at room temperature, the liquid is removed, and each well is washed three times with 100 ul of 0.9% sodium chloride solution. Non-specific reaction is measured in the presence of 100 nM staurosporine. The radioactivity is measured in a Topcount (PerkinElmer).	B	N#Cc1ccc(Nc2cc(-c3ccc(OC4CCOCC4)c(C#N)c3)ccn2)nc1		CHEMBL3687154	=	IC50	nM	250.0	CHEMBL5408	Homo sapiens	IC50	nM	250.0
280341	17662686	CHEMBL3706282	Flashplate Assay: The kinase assay is performed as 384-well flashplate assay (for example for Topcount measurement).0.6 nM TANK binding kinase (TBK1), 800 nM biotinylated MELK-derived peptide (Biotin-Ah-Ah-AKPKGNKDYHLQTCCGSLAYRRR) and 10 uM ATP (spiked with 0.25 uCi of 33P-ATP/well) are incubated at 30 C. for 120 min in a total volume of 50 ul (10 mM MOPS, 10 mM Mg acetate, 0.1 mM EGTA, 1 mM DTT, 0.02% of Brij35, 0.1% of BSA, pH 7.5) with or without test compound. The reaction is stopped with 25 ul of 200 mM EDTA. After 30 min at room temperature, the liquid is removed, and each well is washed three times with 100 ul of 0.9% sodium chloride solution. Non-specific reaction is measured in the presence of 100 nM staurosporine. The radioactivity is measured in a Topcount (PerkinElmer).	B	N#Cc1cc(-c2ccnc(Nc3cc(C4CC4)n[nH]3)c2)ccc1OC1CCOCC1		CHEMBL3687155	=	IC50	nM	30.0	CHEMBL5408	Homo sapiens	IC50	nM	30.0
280342	17662687	CHEMBL3706282	Flashplate Assay: The kinase assay is performed as 384-well flashplate assay (for example for Topcount measurement).0.6 nM TANK binding kinase (TBK1), 800 nM biotinylated MELK-derived peptide (Biotin-Ah-Ah-AKPKGNKDYHLQTCCGSLAYRRR) and 10 uM ATP (spiked with 0.25 uCi of 33P-ATP/well) are incubated at 30 C. for 120 min in a total volume of 50 ul (10 mM MOPS, 10 mM Mg acetate, 0.1 mM EGTA, 1 mM DTT, 0.02% of Brij35, 0.1% of BSA, pH 7.5) with or without test compound. The reaction is stopped with 25 ul of 200 mM EDTA. After 30 min at room temperature, the liquid is removed, and each well is washed three times with 100 ul of 0.9% sodium chloride solution. Non-specific reaction is measured in the presence of 100 nM staurosporine. The radioactivity is measured in a Topcount (PerkinElmer).	B	N#Cc1cc(-c2ccnc(Nc3ccc(C(F)(F)F)cn3)c2)ccc1OC1CCOCC1		CHEMBL3687156	=	IC50	nM	310.0	CHEMBL5408	Homo sapiens	IC50	nM	310.0
280343	17662688	CHEMBL3706282	Flashplate Assay: The kinase assay is performed as 384-well flashplate assay (for example for Topcount measurement).0.6 nM TANK binding kinase (TBK1), 800 nM biotinylated MELK-derived peptide (Biotin-Ah-Ah-AKPKGNKDYHLQTCCGSLAYRRR) and 10 uM ATP (spiked with 0.25 uCi of 33P-ATP/well) are incubated at 30 C. for 120 min in a total volume of 50 ul (10 mM MOPS, 10 mM Mg acetate, 0.1 mM EGTA, 1 mM DTT, 0.02% of Brij35, 0.1% of BSA, pH 7.5) with or without test compound. The reaction is stopped with 25 ul of 200 mM EDTA. After 30 min at room temperature, the liquid is removed, and each well is washed three times with 100 ul of 0.9% sodium chloride solution. Non-specific reaction is measured in the presence of 100 nM staurosporine. The radioactivity is measured in a Topcount (PerkinElmer).	B	N#Cc1cc(-c2ccnc(Nc3ncccn3)c2)ccc1OC1CCOCC1		CHEMBL3687157	=	IC50	nM	670.0	CHEMBL5408	Homo sapiens	IC50	nM	670.0
280344	17662689	CHEMBL3706282	Flashplate Assay: The kinase assay is performed as 384-well flashplate assay (for example for Topcount measurement).0.6 nM TANK binding kinase (TBK1), 800 nM biotinylated MELK-derived peptide (Biotin-Ah-Ah-AKPKGNKDYHLQTCCGSLAYRRR) and 10 uM ATP (spiked with 0.25 uCi of 33P-ATP/well) are incubated at 30 C. for 120 min in a total volume of 50 ul (10 mM MOPS, 10 mM Mg acetate, 0.1 mM EGTA, 1 mM DTT, 0.02% of Brij35, 0.1% of BSA, pH 7.5) with or without test compound. The reaction is stopped with 25 ul of 200 mM EDTA. After 30 min at room temperature, the liquid is removed, and each well is washed three times with 100 ul of 0.9% sodium chloride solution. Non-specific reaction is measured in the presence of 100 nM staurosporine. The radioactivity is measured in a Topcount (PerkinElmer).	B	N#Cc1cc(-c2ccnc(Nc3ccc(CO)cn3)c2)ccc1OC1CCOCC1		CHEMBL3687158	=	IC50	nM	14.0	CHEMBL5408	Homo sapiens	IC50	nM	14.0
280345	17662690	CHEMBL3706282	Flashplate Assay: The kinase assay is performed as 384-well flashplate assay (for example for Topcount measurement).0.6 nM TANK binding kinase (TBK1), 800 nM biotinylated MELK-derived peptide (Biotin-Ah-Ah-AKPKGNKDYHLQTCCGSLAYRRR) and 10 uM ATP (spiked with 0.25 uCi of 33P-ATP/well) are incubated at 30 C. for 120 min in a total volume of 50 ul (10 mM MOPS, 10 mM Mg acetate, 0.1 mM EGTA, 1 mM DTT, 0.02% of Brij35, 0.1% of BSA, pH 7.5) with or without test compound. The reaction is stopped with 25 ul of 200 mM EDTA. After 30 min at room temperature, the liquid is removed, and each well is washed three times with 100 ul of 0.9% sodium chloride solution. Non-specific reaction is measured in the presence of 100 nM staurosporine. The radioactivity is measured in a Topcount (PerkinElmer).	B	N#Cc1cc(-c2ccnc(Nc3cnn(C4CCNCC4)c3)c2)ccc1OC1CCOCC1		CHEMBL3687159	=	IC50	nM	71.0	CHEMBL5408	Homo sapiens	IC50	nM	71.0
280346	17662691	CHEMBL3706282	Flashplate Assay: The kinase assay is performed as 384-well flashplate assay (for example for Topcount measurement).0.6 nM TANK binding kinase (TBK1), 800 nM biotinylated MELK-derived peptide (Biotin-Ah-Ah-AKPKGNKDYHLQTCCGSLAYRRR) and 10 uM ATP (spiked with 0.25 uCi of 33P-ATP/well) are incubated at 30 C. for 120 min in a total volume of 50 ul (10 mM MOPS, 10 mM Mg acetate, 0.1 mM EGTA, 1 mM DTT, 0.02% of Brij35, 0.1% of BSA, pH 7.5) with or without test compound. The reaction is stopped with 25 ul of 200 mM EDTA. After 30 min at room temperature, the liquid is removed, and each well is washed three times with 100 ul of 0.9% sodium chloride solution. Non-specific reaction is measured in the presence of 100 nM staurosporine. The radioactivity is measured in a Topcount (PerkinElmer).	B	N#Cc1cc(-c2ccnc(Nc3cc(CO)ccn3)c2)ccc1OC1CCOCC1		CHEMBL3687160	=	IC50	nM	8.0	CHEMBL5408	Homo sapiens	IC50	nM	8.0
280347	17662692	CHEMBL3706282	Flashplate Assay: The kinase assay is performed as 384-well flashplate assay (for example for Topcount measurement).0.6 nM TANK binding kinase (TBK1), 800 nM biotinylated MELK-derived peptide (Biotin-Ah-Ah-AKPKGNKDYHLQTCCGSLAYRRR) and 10 uM ATP (spiked with 0.25 uCi of 33P-ATP/well) are incubated at 30 C. for 120 min in a total volume of 50 ul (10 mM MOPS, 10 mM Mg acetate, 0.1 mM EGTA, 1 mM DTT, 0.02% of Brij35, 0.1% of BSA, pH 7.5) with or without test compound. The reaction is stopped with 25 ul of 200 mM EDTA. After 30 min at room temperature, the liquid is removed, and each well is washed three times with 100 ul of 0.9% sodium chloride solution. Non-specific reaction is measured in the presence of 100 nM staurosporine. The radioactivity is measured in a Topcount (PerkinElmer).	B	N#Cc1cc(-c2ccnc(Nc3ccc4oc(C(N)=O)cc4c3)c2)ccc1OC1CCOCC1		CHEMBL3687161	=	IC50	nM	1900.0	CHEMBL5408	Homo sapiens	IC50	nM	1900.0
280348	17662693	CHEMBL3706282	Flashplate Assay: The kinase assay is performed as 384-well flashplate assay (for example for Topcount measurement).0.6 nM TANK binding kinase (TBK1), 800 nM biotinylated MELK-derived peptide (Biotin-Ah-Ah-AKPKGNKDYHLQTCCGSLAYRRR) and 10 uM ATP (spiked with 0.25 uCi of 33P-ATP/well) are incubated at 30 C. for 120 min in a total volume of 50 ul (10 mM MOPS, 10 mM Mg acetate, 0.1 mM EGTA, 1 mM DTT, 0.02% of Brij35, 0.1% of BSA, pH 7.5) with or without test compound. The reaction is stopped with 25 ul of 200 mM EDTA. After 30 min at room temperature, the liquid is removed, and each well is washed three times with 100 ul of 0.9% sodium chloride solution. Non-specific reaction is measured in the presence of 100 nM staurosporine. The radioactivity is measured in a Topcount (PerkinElmer).	B	N#Cc1cc(-c2ccnc(Nc3cnn(CC(F)F)c3)c2)ccc1OC1CCOCC1		CHEMBL3687162	=	IC50	nM	55.0	CHEMBL5408	Homo sapiens	IC50	nM	55.0
280349	17662694	CHEMBL3706282	Flashplate Assay: The kinase assay is performed as 384-well flashplate assay (for example for Topcount measurement).0.6 nM TANK binding kinase (TBK1), 800 nM biotinylated MELK-derived peptide (Biotin-Ah-Ah-AKPKGNKDYHLQTCCGSLAYRRR) and 10 uM ATP (spiked with 0.25 uCi of 33P-ATP/well) are incubated at 30 C. for 120 min in a total volume of 50 ul (10 mM MOPS, 10 mM Mg acetate, 0.1 mM EGTA, 1 mM DTT, 0.02% of Brij35, 0.1% of BSA, pH 7.5) with or without test compound. The reaction is stopped with 25 ul of 200 mM EDTA. After 30 min at room temperature, the liquid is removed, and each well is washed three times with 100 ul of 0.9% sodium chloride solution. Non-specific reaction is measured in the presence of 100 nM staurosporine. The radioactivity is measured in a Topcount (PerkinElmer).	B	N#Cc1cc(-c2ccnc(Nc3cnn(CCC4CCNCC4)c3)c2)ccc1OC1CCOCC1		CHEMBL3687163	=	IC50	nM	70.0	CHEMBL5408	Homo sapiens	IC50	nM	70.0
280350	17662695	CHEMBL3706282	Flashplate Assay: The kinase assay is performed as 384-well flashplate assay (for example for Topcount measurement).0.6 nM TANK binding kinase (TBK1), 800 nM biotinylated MELK-derived peptide (Biotin-Ah-Ah-AKPKGNKDYHLQTCCGSLAYRRR) and 10 uM ATP (spiked with 0.25 uCi of 33P-ATP/well) are incubated at 30 C. for 120 min in a total volume of 50 ul (10 mM MOPS, 10 mM Mg acetate, 0.1 mM EGTA, 1 mM DTT, 0.02% of Brij35, 0.1% of BSA, pH 7.5) with or without test compound. The reaction is stopped with 25 ul of 200 mM EDTA. After 30 min at room temperature, the liquid is removed, and each well is washed three times with 100 ul of 0.9% sodium chloride solution. Non-specific reaction is measured in the presence of 100 nM staurosporine. The radioactivity is measured in a Topcount (PerkinElmer).	B	N#Cc1cc(-c2ccnc(Nc3cnn(CCN4CCOCC4)c3)c2)ccc1OC1CCOCC1		CHEMBL3687164	=	IC50	nM	100.0	CHEMBL5408	Homo sapiens	IC50	nM	100.0
280351	17662696	CHEMBL3706282	Flashplate Assay: The kinase assay is performed as 384-well flashplate assay (for example for Topcount measurement).0.6 nM TANK binding kinase (TBK1), 800 nM biotinylated MELK-derived peptide (Biotin-Ah-Ah-AKPKGNKDYHLQTCCGSLAYRRR) and 10 uM ATP (spiked with 0.25 uCi of 33P-ATP/well) are incubated at 30 C. for 120 min in a total volume of 50 ul (10 mM MOPS, 10 mM Mg acetate, 0.1 mM EGTA, 1 mM DTT, 0.02% of Brij35, 0.1% of BSA, pH 7.5) with or without test compound. The reaction is stopped with 25 ul of 200 mM EDTA. After 30 min at room temperature, the liquid is removed, and each well is washed three times with 100 ul of 0.9% sodium chloride solution. Non-specific reaction is measured in the presence of 100 nM staurosporine. The radioactivity is measured in a Topcount (PerkinElmer).	B	COCCCn1cc(Nc2cc(-c3ccc(OC4CCOCC4)c(C#N)c3)ccn2)cn1		CHEMBL3687165	=	IC50	nM	120.0	CHEMBL5408	Homo sapiens	IC50	nM	120.0
280352	17662697	CHEMBL3706282	Flashplate Assay: The kinase assay is performed as 384-well flashplate assay (for example for Topcount measurement).0.6 nM TANK binding kinase (TBK1), 800 nM biotinylated MELK-derived peptide (Biotin-Ah-Ah-AKPKGNKDYHLQTCCGSLAYRRR) and 10 uM ATP (spiked with 0.25 uCi of 33P-ATP/well) are incubated at 30 C. for 120 min in a total volume of 50 ul (10 mM MOPS, 10 mM Mg acetate, 0.1 mM EGTA, 1 mM DTT, 0.02% of Brij35, 0.1% of BSA, pH 7.5) with or without test compound. The reaction is stopped with 25 ul of 200 mM EDTA. After 30 min at room temperature, the liquid is removed, and each well is washed three times with 100 ul of 0.9% sodium chloride solution. Non-specific reaction is measured in the presence of 100 nM staurosporine. The radioactivity is measured in a Topcount (PerkinElmer).	B	N#Cc1cc(-c2ccnc(Nc3cnn(CC4CC4C#N)c3)c2)ccc1OC1CCOCC1		CHEMBL3687166	=	IC50	nM	110.0	CHEMBL5408	Homo sapiens	IC50	nM	110.0
280353	17662698	CHEMBL3706282	Flashplate Assay: The kinase assay is performed as 384-well flashplate assay (for example for Topcount measurement).0.6 nM TANK binding kinase (TBK1), 800 nM biotinylated MELK-derived peptide (Biotin-Ah-Ah-AKPKGNKDYHLQTCCGSLAYRRR) and 10 uM ATP (spiked with 0.25 uCi of 33P-ATP/well) are incubated at 30 C. for 120 min in a total volume of 50 ul (10 mM MOPS, 10 mM Mg acetate, 0.1 mM EGTA, 1 mM DTT, 0.02% of Brij35, 0.1% of BSA, pH 7.5) with or without test compound. The reaction is stopped with 25 ul of 200 mM EDTA. After 30 min at room temperature, the liquid is removed, and each well is washed three times with 100 ul of 0.9% sodium chloride solution. Non-specific reaction is measured in the presence of 100 nM staurosporine. The radioactivity is measured in a Topcount (PerkinElmer).	B	N#Cc1cc(-c2ccnc(Nc3cnn(C4CNC4)c3)c2)ccc1OC1CCOCC1		CHEMBL3687167	=	IC50	nM	290.0	CHEMBL5408	Homo sapiens	IC50	nM	290.0
280354	17662699	CHEMBL3706282	Flashplate Assay: The kinase assay is performed as 384-well flashplate assay (for example for Topcount measurement).0.6 nM TANK binding kinase (TBK1), 800 nM biotinylated MELK-derived peptide (Biotin-Ah-Ah-AKPKGNKDYHLQTCCGSLAYRRR) and 10 uM ATP (spiked with 0.25 uCi of 33P-ATP/well) are incubated at 30 C. for 120 min in a total volume of 50 ul (10 mM MOPS, 10 mM Mg acetate, 0.1 mM EGTA, 1 mM DTT, 0.02% of Brij35, 0.1% of BSA, pH 7.5) with or without test compound. The reaction is stopped with 25 ul of 200 mM EDTA. After 30 min at room temperature, the liquid is removed, and each well is washed three times with 100 ul of 0.9% sodium chloride solution. Non-specific reaction is measured in the presence of 100 nM staurosporine. The radioactivity is measured in a Topcount (PerkinElmer).	B	N#Cc1cc(-c2ccnc(Nc3cnn(C[C@H]4C[C@@H]4CO)c3)c2)ccc1OC1CCOCC1		CHEMBL3687168	=	IC50	nM	18.0	CHEMBL5408	Homo sapiens	IC50	nM	18.0
280355	17662700	CHEMBL3706282	Flashplate Assay: The kinase assay is performed as 384-well flashplate assay (for example for Topcount measurement).0.6 nM TANK binding kinase (TBK1), 800 nM biotinylated MELK-derived peptide (Biotin-Ah-Ah-AKPKGNKDYHLQTCCGSLAYRRR) and 10 uM ATP (spiked with 0.25 uCi of 33P-ATP/well) are incubated at 30 C. for 120 min in a total volume of 50 ul (10 mM MOPS, 10 mM Mg acetate, 0.1 mM EGTA, 1 mM DTT, 0.02% of Brij35, 0.1% of BSA, pH 7.5) with or without test compound. The reaction is stopped with 25 ul of 200 mM EDTA. After 30 min at room temperature, the liquid is removed, and each well is washed three times with 100 ul of 0.9% sodium chloride solution. Non-specific reaction is measured in the presence of 100 nM staurosporine. The radioactivity is measured in a Topcount (PerkinElmer).	B	N#Cc1cc(-c2ccnc(Nc3cnn(CC4CCOC4)c3)c2)ccc1OC1CCOCC1		CHEMBL3687169	=	IC50	nM	85.0	CHEMBL5408	Homo sapiens	IC50	nM	85.0
280356	17662701	CHEMBL3706282	Flashplate Assay: The kinase assay is performed as 384-well flashplate assay (for example for Topcount measurement).0.6 nM TANK binding kinase (TBK1), 800 nM biotinylated MELK-derived peptide (Biotin-Ah-Ah-AKPKGNKDYHLQTCCGSLAYRRR) and 10 uM ATP (spiked with 0.25 uCi of 33P-ATP/well) are incubated at 30 C. for 120 min in a total volume of 50 ul (10 mM MOPS, 10 mM Mg acetate, 0.1 mM EGTA, 1 mM DTT, 0.02% of Brij35, 0.1% of BSA, pH 7.5) with or without test compound. The reaction is stopped with 25 ul of 200 mM EDTA. After 30 min at room temperature, the liquid is removed, and each well is washed three times with 100 ul of 0.9% sodium chloride solution. Non-specific reaction is measured in the presence of 100 nM staurosporine. The radioactivity is measured in a Topcount (PerkinElmer).	B	N#Cc1cc(-c2ccnc(Nc3cnn(C4CCNC4)c3)c2)ccc1OC1CCOCC1		CHEMBL3687170	=	IC50	nM	280.0	CHEMBL5408	Homo sapiens	IC50	nM	280.0
280357	17662702	CHEMBL3706282	Flashplate Assay: The kinase assay is performed as 384-well flashplate assay (for example for Topcount measurement).0.6 nM TANK binding kinase (TBK1), 800 nM biotinylated MELK-derived peptide (Biotin-Ah-Ah-AKPKGNKDYHLQTCCGSLAYRRR) and 10 uM ATP (spiked with 0.25 uCi of 33P-ATP/well) are incubated at 30 C. for 120 min in a total volume of 50 ul (10 mM MOPS, 10 mM Mg acetate, 0.1 mM EGTA, 1 mM DTT, 0.02% of Brij35, 0.1% of BSA, pH 7.5) with or without test compound. The reaction is stopped with 25 ul of 200 mM EDTA. After 30 min at room temperature, the liquid is removed, and each well is washed three times with 100 ul of 0.9% sodium chloride solution. Non-specific reaction is measured in the presence of 100 nM staurosporine. The radioactivity is measured in a Topcount (PerkinElmer).	B	N#Cc1cc(-c2ccnc(Nc3cnn(CCC4CCN(C(=O)CO)CC4)c3)c2)ccc1OC1CCOCC1		CHEMBL3687171	=	IC50	nM	120.0	CHEMBL5408	Homo sapiens	IC50	nM	120.0
280358	17662703	CHEMBL3706282	Flashplate Assay: The kinase assay is performed as 384-well flashplate assay (for example for Topcount measurement).0.6 nM TANK binding kinase (TBK1), 800 nM biotinylated MELK-derived peptide (Biotin-Ah-Ah-AKPKGNKDYHLQTCCGSLAYRRR) and 10 uM ATP (spiked with 0.25 uCi of 33P-ATP/well) are incubated at 30 C. for 120 min in a total volume of 50 ul (10 mM MOPS, 10 mM Mg acetate, 0.1 mM EGTA, 1 mM DTT, 0.02% of Brij35, 0.1% of BSA, pH 7.5) with or without test compound. The reaction is stopped with 25 ul of 200 mM EDTA. After 30 min at room temperature, the liquid is removed, and each well is washed three times with 100 ul of 0.9% sodium chloride solution. Non-specific reaction is measured in the presence of 100 nM staurosporine. The radioactivity is measured in a Topcount (PerkinElmer).	B	N#Cc1cc(-c2ccnc(Nc3cnn(CCC4CCN(C(=O)CN)CC4)c3)c2)ccc1OC1CCOCC1		CHEMBL3687172	=	IC50	nM	42.0	CHEMBL5408	Homo sapiens	IC50	nM	42.0
280359	17662704	CHEMBL3706282	Flashplate Assay: The kinase assay is performed as 384-well flashplate assay (for example for Topcount measurement).0.6 nM TANK binding kinase (TBK1), 800 nM biotinylated MELK-derived peptide (Biotin-Ah-Ah-AKPKGNKDYHLQTCCGSLAYRRR) and 10 uM ATP (spiked with 0.25 uCi of 33P-ATP/well) are incubated at 30 C. for 120 min in a total volume of 50 ul (10 mM MOPS, 10 mM Mg acetate, 0.1 mM EGTA, 1 mM DTT, 0.02% of Brij35, 0.1% of BSA, pH 7.5) with or without test compound. The reaction is stopped with 25 ul of 200 mM EDTA. After 30 min at room temperature, the liquid is removed, and each well is washed three times with 100 ul of 0.9% sodium chloride solution. Non-specific reaction is measured in the presence of 100 nM staurosporine. The radioactivity is measured in a Topcount (PerkinElmer).	B	CC(C)(C)c1cc(Nc2cc(-c3ccc(OC4CCOCC4)c(C#N)c3)ccn2)on1		CHEMBL3687173	=	IC50	nM	860.0	CHEMBL5408	Homo sapiens	IC50	nM	860.0
280360	17662705	CHEMBL3706282	Flashplate Assay: The kinase assay is performed as 384-well flashplate assay (for example for Topcount measurement).0.6 nM TANK binding kinase (TBK1), 800 nM biotinylated MELK-derived peptide (Biotin-Ah-Ah-AKPKGNKDYHLQTCCGSLAYRRR) and 10 uM ATP (spiked with 0.25 uCi of 33P-ATP/well) are incubated at 30 C. for 120 min in a total volume of 50 ul (10 mM MOPS, 10 mM Mg acetate, 0.1 mM EGTA, 1 mM DTT, 0.02% of Brij35, 0.1% of BSA, pH 7.5) with or without test compound. The reaction is stopped with 25 ul of 200 mM EDTA. After 30 min at room temperature, the liquid is removed, and each well is washed three times with 100 ul of 0.9% sodium chloride solution. Non-specific reaction is measured in the presence of 100 nM staurosporine. The radioactivity is measured in a Topcount (PerkinElmer).	B	Cn1ccc(Nc2nccc(-c3ccc(OC4CCOCC4)c(C#N)c3)n2)n1		CHEMBL3687174	=	IC50	nM	130.0	CHEMBL5408	Homo sapiens	IC50	nM	130.0
280361	17662706	CHEMBL3706282	Flashplate Assay: The kinase assay is performed as 384-well flashplate assay (for example for Topcount measurement).0.6 nM TANK binding kinase (TBK1), 800 nM biotinylated MELK-derived peptide (Biotin-Ah-Ah-AKPKGNKDYHLQTCCGSLAYRRR) and 10 uM ATP (spiked with 0.25 uCi of 33P-ATP/well) are incubated at 30 C. for 120 min in a total volume of 50 ul (10 mM MOPS, 10 mM Mg acetate, 0.1 mM EGTA, 1 mM DTT, 0.02% of Brij35, 0.1% of BSA, pH 7.5) with or without test compound. The reaction is stopped with 25 ul of 200 mM EDTA. After 30 min at room temperature, the liquid is removed, and each well is washed three times with 100 ul of 0.9% sodium chloride solution. Non-specific reaction is measured in the presence of 100 nM staurosporine. The radioactivity is measured in a Topcount (PerkinElmer).	B	N#Cc1cc(-c2ccnc(Nc3cn[nH]c3)n2)ccc1OC1CCOCC1		CHEMBL3687175	=	IC50	nM	6.0	CHEMBL5408	Homo sapiens	IC50	nM	6.0
280362	17662707	CHEMBL3706282	Flashplate Assay: The kinase assay is performed as 384-well flashplate assay (for example for Topcount measurement).0.6 nM TANK binding kinase (TBK1), 800 nM biotinylated MELK-derived peptide (Biotin-Ah-Ah-AKPKGNKDYHLQTCCGSLAYRRR) and 10 uM ATP (spiked with 0.25 uCi of 33P-ATP/well) are incubated at 30 C. for 120 min in a total volume of 50 ul (10 mM MOPS, 10 mM Mg acetate, 0.1 mM EGTA, 1 mM DTT, 0.02% of Brij35, 0.1% of BSA, pH 7.5) with or without test compound. The reaction is stopped with 25 ul of 200 mM EDTA. After 30 min at room temperature, the liquid is removed, and each well is washed three times with 100 ul of 0.9% sodium chloride solution. Non-specific reaction is measured in the presence of 100 nM staurosporine. The radioactivity is measured in a Topcount (PerkinElmer).	B	COCCn1cc(Nc2nccc(-c3ccc(OC4CCOCC4)c(C#N)c3)n2)cn1		CHEMBL3687176	=	IC50	nM	6.0	CHEMBL5408	Homo sapiens	IC50	nM	6.0
280364	17662709	CHEMBL3706282	Flashplate Assay: The kinase assay is performed as 384-well flashplate assay (for example for Topcount measurement).0.6 nM TANK binding kinase (TBK1), 800 nM biotinylated MELK-derived peptide (Biotin-Ah-Ah-AKPKGNKDYHLQTCCGSLAYRRR) and 10 uM ATP (spiked with 0.25 uCi of 33P-ATP/well) are incubated at 30 C. for 120 min in a total volume of 50 ul (10 mM MOPS, 10 mM Mg acetate, 0.1 mM EGTA, 1 mM DTT, 0.02% of Brij35, 0.1% of BSA, pH 7.5) with or without test compound. The reaction is stopped with 25 ul of 200 mM EDTA. After 30 min at room temperature, the liquid is removed, and each well is washed three times with 100 ul of 0.9% sodium chloride solution. Non-specific reaction is measured in the presence of 100 nM staurosporine. The radioactivity is measured in a Topcount (PerkinElmer).	B	N#Cc1cc(-c2ccnc(Nc3ccc(C(N)=O)cn3)c2)ccc1OC1CCOCC1		CHEMBL3687178	=	IC50	nM	32.0	CHEMBL5408	Homo sapiens	IC50	nM	32.0
280365	17662710	CHEMBL3706282	Flashplate Assay: The kinase assay is performed as 384-well flashplate assay (for example for Topcount measurement).0.6 nM TANK binding kinase (TBK1), 800 nM biotinylated MELK-derived peptide (Biotin-Ah-Ah-AKPKGNKDYHLQTCCGSLAYRRR) and 10 uM ATP (spiked with 0.25 uCi of 33P-ATP/well) are incubated at 30 C. for 120 min in a total volume of 50 ul (10 mM MOPS, 10 mM Mg acetate, 0.1 mM EGTA, 1 mM DTT, 0.02% of Brij35, 0.1% of BSA, pH 7.5) with or without test compound. The reaction is stopped with 25 ul of 200 mM EDTA. After 30 min at room temperature, the liquid is removed, and each well is washed three times with 100 ul of 0.9% sodium chloride solution. Non-specific reaction is measured in the presence of 100 nM staurosporine. The radioactivity is measured in a Topcount (PerkinElmer).	B	N#Cc1cc(-c2ccnc(Nc3cnn(CCn4cccn4)c3)c2)ccc1OC1CCOCC1		CHEMBL3687179	=	IC50	nM	460.0	CHEMBL5408	Homo sapiens	IC50	nM	460.0
280366	17662711	CHEMBL3706282	Flashplate Assay: The kinase assay is performed as 384-well flashplate assay (for example for Topcount measurement).0.6 nM TANK binding kinase (TBK1), 800 nM biotinylated MELK-derived peptide (Biotin-Ah-Ah-AKPKGNKDYHLQTCCGSLAYRRR) and 10 uM ATP (spiked with 0.25 uCi of 33P-ATP/well) are incubated at 30 C. for 120 min in a total volume of 50 ul (10 mM MOPS, 10 mM Mg acetate, 0.1 mM EGTA, 1 mM DTT, 0.02% of Brij35, 0.1% of BSA, pH 7.5) with or without test compound. The reaction is stopped with 25 ul of 200 mM EDTA. After 30 min at room temperature, the liquid is removed, and each well is washed three times with 100 ul of 0.9% sodium chloride solution. Non-specific reaction is measured in the presence of 100 nM staurosporine. The radioactivity is measured in a Topcount (PerkinElmer).	B	N#Cc1cc(-c2ccnc(Nc3cnn(CCN4CCOCC4)c3)n2)ccc1OC1CCOCC1		CHEMBL3687180	=	IC50	nM	16.0	CHEMBL5408	Homo sapiens	IC50	nM	16.0
280367	17662712	CHEMBL3706282	Flashplate Assay: The kinase assay is performed as 384-well flashplate assay (for example for Topcount measurement).0.6 nM TANK binding kinase (TBK1), 800 nM biotinylated MELK-derived peptide (Biotin-Ah-Ah-AKPKGNKDYHLQTCCGSLAYRRR) and 10 uM ATP (spiked with 0.25 uCi of 33P-ATP/well) are incubated at 30 C. for 120 min in a total volume of 50 ul (10 mM MOPS, 10 mM Mg acetate, 0.1 mM EGTA, 1 mM DTT, 0.02% of Brij35, 0.1% of BSA, pH 7.5) with or without test compound. The reaction is stopped with 25 ul of 200 mM EDTA. After 30 min at room temperature, the liquid is removed, and each well is washed three times with 100 ul of 0.9% sodium chloride solution. Non-specific reaction is measured in the presence of 100 nM staurosporine. The radioactivity is measured in a Topcount (PerkinElmer).	B	N#Cc1cc(-c2ccnc(Nc3cnn(C4CCNC4)c3)n2)ccc1OC1CCOCC1		CHEMBL3687181	=	IC50	nM	7.0	CHEMBL5408	Homo sapiens	IC50	nM	7.0
280368	17662713	CHEMBL3706282	Flashplate Assay: The kinase assay is performed as 384-well flashplate assay (for example for Topcount measurement).0.6 nM TANK binding kinase (TBK1), 800 nM biotinylated MELK-derived peptide (Biotin-Ah-Ah-AKPKGNKDYHLQTCCGSLAYRRR) and 10 uM ATP (spiked with 0.25 uCi of 33P-ATP/well) are incubated at 30 C. for 120 min in a total volume of 50 ul (10 mM MOPS, 10 mM Mg acetate, 0.1 mM EGTA, 1 mM DTT, 0.02% of Brij35, 0.1% of BSA, pH 7.5) with or without test compound. The reaction is stopped with 25 ul of 200 mM EDTA. After 30 min at room temperature, the liquid is removed, and each well is washed three times with 100 ul of 0.9% sodium chloride solution. Non-specific reaction is measured in the presence of 100 nM staurosporine. The radioactivity is measured in a Topcount (PerkinElmer).	B	N#Cc1cc(-c2ccnc(Nc3cnn(CC4CCOC4)c3)n2)ccc1OC1CCOCC1		CHEMBL3687182	=	IC50	nM	12.0	CHEMBL5408	Homo sapiens	IC50	nM	12.0
280369	17662714	CHEMBL3706282	Flashplate Assay: The kinase assay is performed as 384-well flashplate assay (for example for Topcount measurement).0.6 nM TANK binding kinase (TBK1), 800 nM biotinylated MELK-derived peptide (Biotin-Ah-Ah-AKPKGNKDYHLQTCCGSLAYRRR) and 10 uM ATP (spiked with 0.25 uCi of 33P-ATP/well) are incubated at 30 C. for 120 min in a total volume of 50 ul (10 mM MOPS, 10 mM Mg acetate, 0.1 mM EGTA, 1 mM DTT, 0.02% of Brij35, 0.1% of BSA, pH 7.5) with or without test compound. The reaction is stopped with 25 ul of 200 mM EDTA. After 30 min at room temperature, the liquid is removed, and each well is washed three times with 100 ul of 0.9% sodium chloride solution. Non-specific reaction is measured in the presence of 100 nM staurosporine. The radioactivity is measured in a Topcount (PerkinElmer).	B	N#Cc1cc(-c2ccnc(Nc3ccc4oc(C(N)=O)cc4c3)n2)ccc1OC1CCOCC1		CHEMBL3687183	=	IC50	nM	10.0	CHEMBL5408	Homo sapiens	IC50	nM	10.0
280370	17662715	CHEMBL3706282	Flashplate Assay: The kinase assay is performed as 384-well flashplate assay (for example for Topcount measurement).0.6 nM TANK binding kinase (TBK1), 800 nM biotinylated MELK-derived peptide (Biotin-Ah-Ah-AKPKGNKDYHLQTCCGSLAYRRR) and 10 uM ATP (spiked with 0.25 uCi of 33P-ATP/well) are incubated at 30 C. for 120 min in a total volume of 50 ul (10 mM MOPS, 10 mM Mg acetate, 0.1 mM EGTA, 1 mM DTT, 0.02% of Brij35, 0.1% of BSA, pH 7.5) with or without test compound. The reaction is stopped with 25 ul of 200 mM EDTA. After 30 min at room temperature, the liquid is removed, and each well is washed three times with 100 ul of 0.9% sodium chloride solution. Non-specific reaction is measured in the presence of 100 nM staurosporine. The radioactivity is measured in a Topcount (PerkinElmer).	B	N#Cc1cc(-c2ccnc(Nc3cnn(CCn4cccn4)c3)n2)ccc1OC1CCOCC1		CHEMBL3687184	=	IC50	nM	70.0	CHEMBL5408	Homo sapiens	IC50	nM	70.0
280371	17662716	CHEMBL3706282	Flashplate Assay: The kinase assay is performed as 384-well flashplate assay (for example for Topcount measurement).0.6 nM TANK binding kinase (TBK1), 800 nM biotinylated MELK-derived peptide (Biotin-Ah-Ah-AKPKGNKDYHLQTCCGSLAYRRR) and 10 uM ATP (spiked with 0.25 uCi of 33P-ATP/well) are incubated at 30 C. for 120 min in a total volume of 50 ul (10 mM MOPS, 10 mM Mg acetate, 0.1 mM EGTA, 1 mM DTT, 0.02% of Brij35, 0.1% of BSA, pH 7.5) with or without test compound. The reaction is stopped with 25 ul of 200 mM EDTA. After 30 min at room temperature, the liquid is removed, and each well is washed three times with 100 ul of 0.9% sodium chloride solution. Non-specific reaction is measured in the presence of 100 nM staurosporine. The radioactivity is measured in a Topcount (PerkinElmer).	B	N#Cc1cc(-c2ccnc(Nc3cnn(CC(F)F)c3)n2)ccc1OC1CCOCC1		CHEMBL3687185	=	IC50	nM	5.0	CHEMBL5408	Homo sapiens	IC50	nM	5.0
280372	17662717	CHEMBL3706282	Flashplate Assay: The kinase assay is performed as 384-well flashplate assay (for example for Topcount measurement).0.6 nM TANK binding kinase (TBK1), 800 nM biotinylated MELK-derived peptide (Biotin-Ah-Ah-AKPKGNKDYHLQTCCGSLAYRRR) and 10 uM ATP (spiked with 0.25 uCi of 33P-ATP/well) are incubated at 30 C. for 120 min in a total volume of 50 ul (10 mM MOPS, 10 mM Mg acetate, 0.1 mM EGTA, 1 mM DTT, 0.02% of Brij35, 0.1% of BSA, pH 7.5) with or without test compound. The reaction is stopped with 25 ul of 200 mM EDTA. After 30 min at room temperature, the liquid is removed, and each well is washed three times with 100 ul of 0.9% sodium chloride solution. Non-specific reaction is measured in the presence of 100 nM staurosporine. The radioactivity is measured in a Topcount (PerkinElmer).	B	N#Cc1cc(-c2ccnc(Nc3cnn(CCC4CCNCC4)c3)n2)ccc1OC1CCOCC1		CHEMBL3687186	=	IC50	nM	2.0	CHEMBL5408	Homo sapiens	IC50	nM	2.0
280373	17662718	CHEMBL3706282	Flashplate Assay: The kinase assay is performed as 384-well flashplate assay (for example for Topcount measurement).0.6 nM TANK binding kinase (TBK1), 800 nM biotinylated MELK-derived peptide (Biotin-Ah-Ah-AKPKGNKDYHLQTCCGSLAYRRR) and 10 uM ATP (spiked with 0.25 uCi of 33P-ATP/well) are incubated at 30 C. for 120 min in a total volume of 50 ul (10 mM MOPS, 10 mM Mg acetate, 0.1 mM EGTA, 1 mM DTT, 0.02% of Brij35, 0.1% of BSA, pH 7.5) with or without test compound. The reaction is stopped with 25 ul of 200 mM EDTA. After 30 min at room temperature, the liquid is removed, and each well is washed three times with 100 ul of 0.9% sodium chloride solution. Non-specific reaction is measured in the presence of 100 nM staurosporine. The radioactivity is measured in a Topcount (PerkinElmer).	B	N#Cc1cc(-c2ccnc(Nc3cnn(C4CCNCC4)c3)n2)ccc1OC1CCOCC1		CHEMBL3682420	=	IC50	nM	6.0	CHEMBL5408	Homo sapiens	IC50	nM	6.0
280374	17662719	CHEMBL3706282	Flashplate Assay: The kinase assay is performed as 384-well flashplate assay (for example for Topcount measurement).0.6 nM TANK binding kinase (TBK1), 800 nM biotinylated MELK-derived peptide (Biotin-Ah-Ah-AKPKGNKDYHLQTCCGSLAYRRR) and 10 uM ATP (spiked with 0.25 uCi of 33P-ATP/well) are incubated at 30 C. for 120 min in a total volume of 50 ul (10 mM MOPS, 10 mM Mg acetate, 0.1 mM EGTA, 1 mM DTT, 0.02% of Brij35, 0.1% of BSA, pH 7.5) with or without test compound. The reaction is stopped with 25 ul of 200 mM EDTA. After 30 min at room temperature, the liquid is removed, and each well is washed three times with 100 ul of 0.9% sodium chloride solution. Non-specific reaction is measured in the presence of 100 nM staurosporine. The radioactivity is measured in a Topcount (PerkinElmer).	B	N#Cc1cc(-c2ccnc(Nc3cc(C(=O)O)ccn3)c2)ccc1OC1CCOCC1		CHEMBL3682421	=	IC50	nM	170.0	CHEMBL5408	Homo sapiens	IC50	nM	170.0
280375	17662720	CHEMBL3706282	Flashplate Assay: The kinase assay is performed as 384-well flashplate assay (for example for Topcount measurement).0.6 nM TANK binding kinase (TBK1), 800 nM biotinylated MELK-derived peptide (Biotin-Ah-Ah-AKPKGNKDYHLQTCCGSLAYRRR) and 10 uM ATP (spiked with 0.25 uCi of 33P-ATP/well) are incubated at 30 C. for 120 min in a total volume of 50 ul (10 mM MOPS, 10 mM Mg acetate, 0.1 mM EGTA, 1 mM DTT, 0.02% of Brij35, 0.1% of BSA, pH 7.5) with or without test compound. The reaction is stopped with 25 ul of 200 mM EDTA. After 30 min at room temperature, the liquid is removed, and each well is washed three times with 100 ul of 0.9% sodium chloride solution. Non-specific reaction is measured in the presence of 100 nM staurosporine. The radioactivity is measured in a Topcount (PerkinElmer).	B	N#Cc1cc(-c2ccnc(Nc3ncc(C4CCNCC4)cn3)c2)ccc1OC1CCOCC1		CHEMBL3682422	=	IC50	nM	100.0	CHEMBL5408	Homo sapiens	IC50	nM	100.0
280376	17662721	CHEMBL3706282	Flashplate Assay: The kinase assay is performed as 384-well flashplate assay (for example for Topcount measurement).0.6 nM TANK binding kinase (TBK1), 800 nM biotinylated MELK-derived peptide (Biotin-Ah-Ah-AKPKGNKDYHLQTCCGSLAYRRR) and 10 uM ATP (spiked with 0.25 uCi of 33P-ATP/well) are incubated at 30 C. for 120 min in a total volume of 50 ul (10 mM MOPS, 10 mM Mg acetate, 0.1 mM EGTA, 1 mM DTT, 0.02% of Brij35, 0.1% of BSA, pH 7.5) with or without test compound. The reaction is stopped with 25 ul of 200 mM EDTA. After 30 min at room temperature, the liquid is removed, and each well is washed three times with 100 ul of 0.9% sodium chloride solution. Non-specific reaction is measured in the presence of 100 nM staurosporine. The radioactivity is measured in a Topcount (PerkinElmer).	B	N#Cc1cc(-c2ccnc(Nc3cnn(C[C@H]4C[C@@H]4CO)c3)n2)ccc1OC1CCOCC1		CHEMBL3682423	=	IC50	nM	6.0	CHEMBL5408	Homo sapiens	IC50	nM	6.0
280377	17662722	CHEMBL3706282	Flashplate Assay: The kinase assay is performed as 384-well flashplate assay (for example for Topcount measurement).0.6 nM TANK binding kinase (TBK1), 800 nM biotinylated MELK-derived peptide (Biotin-Ah-Ah-AKPKGNKDYHLQTCCGSLAYRRR) and 10 uM ATP (spiked with 0.25 uCi of 33P-ATP/well) are incubated at 30 C. for 120 min in a total volume of 50 ul (10 mM MOPS, 10 mM Mg acetate, 0.1 mM EGTA, 1 mM DTT, 0.02% of Brij35, 0.1% of BSA, pH 7.5) with or without test compound. The reaction is stopped with 25 ul of 200 mM EDTA. After 30 min at room temperature, the liquid is removed, and each well is washed three times with 100 ul of 0.9% sodium chloride solution. Non-specific reaction is measured in the presence of 100 nM staurosporine. The radioactivity is measured in a Topcount (PerkinElmer).	B	Cn1nc(Nc2nccc(-c3ccc(OC4CCOCC4)c(C#N)c3)n2)ccc1=O		CHEMBL3682424	=	IC50	nM	160.0	CHEMBL5408	Homo sapiens	IC50	nM	160.0
280378	17662723	CHEMBL3706282	Flashplate Assay: The kinase assay is performed as 384-well flashplate assay (for example for Topcount measurement).0.6 nM TANK binding kinase (TBK1), 800 nM biotinylated MELK-derived peptide (Biotin-Ah-Ah-AKPKGNKDYHLQTCCGSLAYRRR) and 10 uM ATP (spiked with 0.25 uCi of 33P-ATP/well) are incubated at 30 C. for 120 min in a total volume of 50 ul (10 mM MOPS, 10 mM Mg acetate, 0.1 mM EGTA, 1 mM DTT, 0.02% of Brij35, 0.1% of BSA, pH 7.5) with or without test compound. The reaction is stopped with 25 ul of 200 mM EDTA. After 30 min at room temperature, the liquid is removed, and each well is washed three times with 100 ul of 0.9% sodium chloride solution. Non-specific reaction is measured in the presence of 100 nM staurosporine. The radioactivity is measured in a Topcount (PerkinElmer).	B	N#Cc1cc(-c2ccnc(Nc3ccc(=O)[nH]n3)n2)ccc1OC1CCOCC1		CHEMBL3682425	=	IC50	nM	1600.0	CHEMBL5408	Homo sapiens	IC50	nM	1600.0
280379	17662724	CHEMBL3706282	Flashplate Assay: The kinase assay is performed as 384-well flashplate assay (for example for Topcount measurement).0.6 nM TANK binding kinase (TBK1), 800 nM biotinylated MELK-derived peptide (Biotin-Ah-Ah-AKPKGNKDYHLQTCCGSLAYRRR) and 10 uM ATP (spiked with 0.25 uCi of 33P-ATP/well) are incubated at 30 C. for 120 min in a total volume of 50 ul (10 mM MOPS, 10 mM Mg acetate, 0.1 mM EGTA, 1 mM DTT, 0.02% of Brij35, 0.1% of BSA, pH 7.5) with or without test compound. The reaction is stopped with 25 ul of 200 mM EDTA. After 30 min at room temperature, the liquid is removed, and each well is washed three times with 100 ul of 0.9% sodium chloride solution. Non-specific reaction is measured in the presence of 100 nM staurosporine. The radioactivity is measured in a Topcount (PerkinElmer).	B	N#Cc1cc(-c2ccnc(Nc3cc(CO)ccn3)n2)ccc1OC1CCOCC1		CHEMBL3682426	=	IC50	nM	180.0	CHEMBL5408	Homo sapiens	IC50	nM	180.0
280380	17662725	CHEMBL3706282	Flashplate Assay: The kinase assay is performed as 384-well flashplate assay (for example for Topcount measurement).0.6 nM TANK binding kinase (TBK1), 800 nM biotinylated MELK-derived peptide (Biotin-Ah-Ah-AKPKGNKDYHLQTCCGSLAYRRR) and 10 uM ATP (spiked with 0.25 uCi of 33P-ATP/well) are incubated at 30 C. for 120 min in a total volume of 50 ul (10 mM MOPS, 10 mM Mg acetate, 0.1 mM EGTA, 1 mM DTT, 0.02% of Brij35, 0.1% of BSA, pH 7.5) with or without test compound. The reaction is stopped with 25 ul of 200 mM EDTA. After 30 min at room temperature, the liquid is removed, and each well is washed three times with 100 ul of 0.9% sodium chloride solution. Non-specific reaction is measured in the presence of 100 nM staurosporine. The radioactivity is measured in a Topcount (PerkinElmer).	B	N#Cc1cc(-c2ccnc(Nc3ccc(C4CCNCC4)nn3)c2)ccc1OC1CCOCC1		CHEMBL3682427	=	IC50	nM	21.0	CHEMBL5408	Homo sapiens	IC50	nM	21.0
280381	17662726	CHEMBL3706282	Flashplate Assay: The kinase assay is performed as 384-well flashplate assay (for example for Topcount measurement).0.6 nM TANK binding kinase (TBK1), 800 nM biotinylated MELK-derived peptide (Biotin-Ah-Ah-AKPKGNKDYHLQTCCGSLAYRRR) and 10 uM ATP (spiked with 0.25 uCi of 33P-ATP/well) are incubated at 30 C. for 120 min in a total volume of 50 ul (10 mM MOPS, 10 mM Mg acetate, 0.1 mM EGTA, 1 mM DTT, 0.02% of Brij35, 0.1% of BSA, pH 7.5) with or without test compound. The reaction is stopped with 25 ul of 200 mM EDTA. After 30 min at room temperature, the liquid is removed, and each well is washed three times with 100 ul of 0.9% sodium chloride solution. Non-specific reaction is measured in the presence of 100 nM staurosporine. The radioactivity is measured in a Topcount (PerkinElmer).	B	N#Cc1cc(-c2ccnc(Nc3cnc(C4CCNCC4)cn3)c2)ccc1OC1CCOCC1		CHEMBL3682428	=	IC50	nM	10.0	CHEMBL5408	Homo sapiens	IC50	nM	10.0
280382	17662727	CHEMBL3706282	Flashplate Assay: The kinase assay is performed as 384-well flashplate assay (for example for Topcount measurement).0.6 nM TANK binding kinase (TBK1), 800 nM biotinylated MELK-derived peptide (Biotin-Ah-Ah-AKPKGNKDYHLQTCCGSLAYRRR) and 10 uM ATP (spiked with 0.25 uCi of 33P-ATP/well) are incubated at 30 C. for 120 min in a total volume of 50 ul (10 mM MOPS, 10 mM Mg acetate, 0.1 mM EGTA, 1 mM DTT, 0.02% of Brij35, 0.1% of BSA, pH 7.5) with or without test compound. The reaction is stopped with 25 ul of 200 mM EDTA. After 30 min at room temperature, the liquid is removed, and each well is washed three times with 100 ul of 0.9% sodium chloride solution. Non-specific reaction is measured in the presence of 100 nM staurosporine. The radioactivity is measured in a Topcount (PerkinElmer).	B	N#Cc1cc(-c2ccnc(Nc3cnn([C@H]4CC[C@@H](O)CC4)c3)n2)ccc1OC1CCOCC1		CHEMBL3682429	=	IC50	nM	8.0	CHEMBL5408	Homo sapiens	IC50	nM	8.0
280383	17662728	CHEMBL3706282	Flashplate Assay: The kinase assay is performed as 384-well flashplate assay (for example for Topcount measurement).0.6 nM TANK binding kinase (TBK1), 800 nM biotinylated MELK-derived peptide (Biotin-Ah-Ah-AKPKGNKDYHLQTCCGSLAYRRR) and 10 uM ATP (spiked with 0.25 uCi of 33P-ATP/well) are incubated at 30 C. for 120 min in a total volume of 50 ul (10 mM MOPS, 10 mM Mg acetate, 0.1 mM EGTA, 1 mM DTT, 0.02% of Brij35, 0.1% of BSA, pH 7.5) with or without test compound. The reaction is stopped with 25 ul of 200 mM EDTA. After 30 min at room temperature, the liquid is removed, and each well is washed three times with 100 ul of 0.9% sodium chloride solution. Non-specific reaction is measured in the presence of 100 nM staurosporine. The radioactivity is measured in a Topcount (PerkinElmer).	B	N#Cc1cc(-c2ccnc(Nc3cc(C4CCNCC4)ccn3)c2)ccc1OC1CCOCC1		CHEMBL3682430	=	IC50	nM	2.0	CHEMBL5408	Homo sapiens	IC50	nM	2.0
280384	17662729	CHEMBL3706282	Flashplate Assay: The kinase assay is performed as 384-well flashplate assay (for example for Topcount measurement).0.6 nM TANK binding kinase (TBK1), 800 nM biotinylated MELK-derived peptide (Biotin-Ah-Ah-AKPKGNKDYHLQTCCGSLAYRRR) and 10 uM ATP (spiked with 0.25 uCi of 33P-ATP/well) are incubated at 30 C. for 120 min in a total volume of 50 ul (10 mM MOPS, 10 mM Mg acetate, 0.1 mM EGTA, 1 mM DTT, 0.02% of Brij35, 0.1% of BSA, pH 7.5) with or without test compound. The reaction is stopped with 25 ul of 200 mM EDTA. After 30 min at room temperature, the liquid is removed, and each well is washed three times with 100 ul of 0.9% sodium chloride solution. Non-specific reaction is measured in the presence of 100 nM staurosporine. The radioactivity is measured in a Topcount (PerkinElmer).	B	N#Cc1cc(-c2ccnc(Nc3cnn(CCO)c3)n2)ccc1OC1CCOCC1		CHEMBL3682431	=	IC50	nM	3.0	CHEMBL5408	Homo sapiens	IC50	nM	3.0
280385	17662730	CHEMBL3706282	Flashplate Assay: The kinase assay is performed as 384-well flashplate assay (for example for Topcount measurement).0.6 nM TANK binding kinase (TBK1), 800 nM biotinylated MELK-derived peptide (Biotin-Ah-Ah-AKPKGNKDYHLQTCCGSLAYRRR) and 10 uM ATP (spiked with 0.25 uCi of 33P-ATP/well) are incubated at 30 C. for 120 min in a total volume of 50 ul (10 mM MOPS, 10 mM Mg acetate, 0.1 mM EGTA, 1 mM DTT, 0.02% of Brij35, 0.1% of BSA, pH 7.5) with or without test compound. The reaction is stopped with 25 ul of 200 mM EDTA. After 30 min at room temperature, the liquid is removed, and each well is washed three times with 100 ul of 0.9% sodium chloride solution. Non-specific reaction is measured in the presence of 100 nM staurosporine. The radioactivity is measured in a Topcount (PerkinElmer).	B	COc1nc(Nc2nccc(-c3ccc(OC4CCOCC4)c(C#N)c3)n2)ccc1C1=CCNCC1		CHEMBL3682432	=	IC50	nM	27.0	CHEMBL5408	Homo sapiens	IC50	nM	27.0
280386	17662731	CHEMBL3706282	Flashplate Assay: The kinase assay is performed as 384-well flashplate assay (for example for Topcount measurement).0.6 nM TANK binding kinase (TBK1), 800 nM biotinylated MELK-derived peptide (Biotin-Ah-Ah-AKPKGNKDYHLQTCCGSLAYRRR) and 10 uM ATP (spiked with 0.25 uCi of 33P-ATP/well) are incubated at 30 C. for 120 min in a total volume of 50 ul (10 mM MOPS, 10 mM Mg acetate, 0.1 mM EGTA, 1 mM DTT, 0.02% of Brij35, 0.1% of BSA, pH 7.5) with or without test compound. The reaction is stopped with 25 ul of 200 mM EDTA. After 30 min at room temperature, the liquid is removed, and each well is washed three times with 100 ul of 0.9% sodium chloride solution. Non-specific reaction is measured in the presence of 100 nM staurosporine. The radioactivity is measured in a Topcount (PerkinElmer).	B	N#Cc1cc(-c2ccnc(Nc3cc(CN)ccn3)c2)ccc1OC1CCOCC1		CHEMBL3682433	=	IC50	nM	30.0	CHEMBL5408	Homo sapiens	IC50	nM	30.0
280387	17662732	CHEMBL3706282	Flashplate Assay: The kinase assay is performed as 384-well flashplate assay (for example for Topcount measurement).0.6 nM TANK binding kinase (TBK1), 800 nM biotinylated MELK-derived peptide (Biotin-Ah-Ah-AKPKGNKDYHLQTCCGSLAYRRR) and 10 uM ATP (spiked with 0.25 uCi of 33P-ATP/well) are incubated at 30 C. for 120 min in a total volume of 50 ul (10 mM MOPS, 10 mM Mg acetate, 0.1 mM EGTA, 1 mM DTT, 0.02% of Brij35, 0.1% of BSA, pH 7.5) with or without test compound. The reaction is stopped with 25 ul of 200 mM EDTA. After 30 min at room temperature, the liquid is removed, and each well is washed three times with 100 ul of 0.9% sodium chloride solution. Non-specific reaction is measured in the presence of 100 nM staurosporine. The radioactivity is measured in a Topcount (PerkinElmer).	B	CN1CCC(c2ccnc(Nc3cc(-c4ccc(OC5CCOCC5)c(C#N)c4)ccn3)c2)CC1		CHEMBL3682434	=	IC50	nM	5.0	CHEMBL5408	Homo sapiens	IC50	nM	5.0
280388	17662733	CHEMBL3706282	Flashplate Assay: The kinase assay is performed as 384-well flashplate assay (for example for Topcount measurement).0.6 nM TANK binding kinase (TBK1), 800 nM biotinylated MELK-derived peptide (Biotin-Ah-Ah-AKPKGNKDYHLQTCCGSLAYRRR) and 10 uM ATP (spiked with 0.25 uCi of 33P-ATP/well) are incubated at 30 C. for 120 min in a total volume of 50 ul (10 mM MOPS, 10 mM Mg acetate, 0.1 mM EGTA, 1 mM DTT, 0.02% of Brij35, 0.1% of BSA, pH 7.5) with or without test compound. The reaction is stopped with 25 ul of 200 mM EDTA. After 30 min at room temperature, the liquid is removed, and each well is washed three times with 100 ul of 0.9% sodium chloride solution. Non-specific reaction is measured in the presence of 100 nM staurosporine. The radioactivity is measured in a Topcount (PerkinElmer).	B	N#Cc1cc(-c2ccnc(Nc3cnn(CCO)c3)c2)ccc1OC1CCOCC1		CHEMBL3682435	=	IC50	nM	120.0	CHEMBL5408	Homo sapiens	IC50	nM	120.0
280389	17662734	CHEMBL3706282	Flashplate Assay: The kinase assay is performed as 384-well flashplate assay (for example for Topcount measurement).0.6 nM TANK binding kinase (TBK1), 800 nM biotinylated MELK-derived peptide (Biotin-Ah-Ah-AKPKGNKDYHLQTCCGSLAYRRR) and 10 uM ATP (spiked with 0.25 uCi of 33P-ATP/well) are incubated at 30 C. for 120 min in a total volume of 50 ul (10 mM MOPS, 10 mM Mg acetate, 0.1 mM EGTA, 1 mM DTT, 0.02% of Brij35, 0.1% of BSA, pH 7.5) with or without test compound. The reaction is stopped with 25 ul of 200 mM EDTA. After 30 min at room temperature, the liquid is removed, and each well is washed three times with 100 ul of 0.9% sodium chloride solution. Non-specific reaction is measured in the presence of 100 nM staurosporine. The radioactivity is measured in a Topcount (PerkinElmer).	B	Cc1cc(Nc2nccc(-c3ccc(OC4CCOCC4)c(C#N)c3)n2)no1		CHEMBL3687110	=	IC50	nM	230.0	CHEMBL5408	Homo sapiens	IC50	nM	230.0
280390	17662735	CHEMBL3706282	Flashplate Assay: The kinase assay is performed as 384-well flashplate assay (for example for Topcount measurement).0.6 nM TANK binding kinase (TBK1), 800 nM biotinylated MELK-derived peptide (Biotin-Ah-Ah-AKPKGNKDYHLQTCCGSLAYRRR) and 10 uM ATP (spiked with 0.25 uCi of 33P-ATP/well) are incubated at 30 C. for 120 min in a total volume of 50 ul (10 mM MOPS, 10 mM Mg acetate, 0.1 mM EGTA, 1 mM DTT, 0.02% of Brij35, 0.1% of BSA, pH 7.5) with or without test compound. The reaction is stopped with 25 ul of 200 mM EDTA. After 30 min at room temperature, the liquid is removed, and each well is washed three times with 100 ul of 0.9% sodium chloride solution. Non-specific reaction is measured in the presence of 100 nM staurosporine. The radioactivity is measured in a Topcount (PerkinElmer).	B	CN(C)Cc1ccnc(Nc2cc(-c3ccc(OC4CCOCC4)c(C#N)c3)ccn2)c1		CHEMBL3687111	=	IC50	nM	14.0	CHEMBL5408	Homo sapiens	IC50	nM	14.0
280391	17662736	CHEMBL3706282	Flashplate Assay: The kinase assay is performed as 384-well flashplate assay (for example for Topcount measurement).0.6 nM TANK binding kinase (TBK1), 800 nM biotinylated MELK-derived peptide (Biotin-Ah-Ah-AKPKGNKDYHLQTCCGSLAYRRR) and 10 uM ATP (spiked with 0.25 uCi of 33P-ATP/well) are incubated at 30 C. for 120 min in a total volume of 50 ul (10 mM MOPS, 10 mM Mg acetate, 0.1 mM EGTA, 1 mM DTT, 0.02% of Brij35, 0.1% of BSA, pH 7.5) with or without test compound. The reaction is stopped with 25 ul of 200 mM EDTA. After 30 min at room temperature, the liquid is removed, and each well is washed three times with 100 ul of 0.9% sodium chloride solution. Non-specific reaction is measured in the presence of 100 nM staurosporine. The radioactivity is measured in a Topcount (PerkinElmer).	B	N#Cc1cc(-c2ccnc(Nc3cc(N4CCOCC4)ccn3)c2)ccc1OC1CCOCC1		CHEMBL3687112	=	IC50	nM	230.0	CHEMBL5408	Homo sapiens	IC50	nM	230.0
280392	17662737	CHEMBL3706282	Flashplate Assay: The kinase assay is performed as 384-well flashplate assay (for example for Topcount measurement).0.6 nM TANK binding kinase (TBK1), 800 nM biotinylated MELK-derived peptide (Biotin-Ah-Ah-AKPKGNKDYHLQTCCGSLAYRRR) and 10 uM ATP (spiked with 0.25 uCi of 33P-ATP/well) are incubated at 30 C. for 120 min in a total volume of 50 ul (10 mM MOPS, 10 mM Mg acetate, 0.1 mM EGTA, 1 mM DTT, 0.02% of Brij35, 0.1% of BSA, pH 7.5) with or without test compound. The reaction is stopped with 25 ul of 200 mM EDTA. After 30 min at room temperature, the liquid is removed, and each well is washed three times with 100 ul of 0.9% sodium chloride solution. Non-specific reaction is measured in the presence of 100 nM staurosporine. The radioactivity is measured in a Topcount (PerkinElmer).	B	N#Cc1cc(-c2ccnc(Nc3cnn(CCN4CCCC4)c3)n2)ccc1OC1CCOCC1		CHEMBL3687113	=	IC50	nM	60.0	CHEMBL5408	Homo sapiens	IC50	nM	60.0
280393	17662738	CHEMBL3706282	Flashplate Assay: The kinase assay is performed as 384-well flashplate assay (for example for Topcount measurement).0.6 nM TANK binding kinase (TBK1), 800 nM biotinylated MELK-derived peptide (Biotin-Ah-Ah-AKPKGNKDYHLQTCCGSLAYRRR) and 10 uM ATP (spiked with 0.25 uCi of 33P-ATP/well) are incubated at 30 C. for 120 min in a total volume of 50 ul (10 mM MOPS, 10 mM Mg acetate, 0.1 mM EGTA, 1 mM DTT, 0.02% of Brij35, 0.1% of BSA, pH 7.5) with or without test compound. The reaction is stopped with 25 ul of 200 mM EDTA. After 30 min at room temperature, the liquid is removed, and each well is washed three times with 100 ul of 0.9% sodium chloride solution. Non-specific reaction is measured in the presence of 100 nM staurosporine. The radioactivity is measured in a Topcount (PerkinElmer).	B	CN1CCN(c2ccnc(Nc3cc(-c4ccc(OC5CCOCC5)c(C#N)c4)ccn3)c2)CC1		CHEMBL3687114	=	IC50	nM	350.0	CHEMBL5408	Homo sapiens	IC50	nM	350.0
280394	17662739	CHEMBL3706282	Flashplate Assay: The kinase assay is performed as 384-well flashplate assay (for example for Topcount measurement).0.6 nM TANK binding kinase (TBK1), 800 nM biotinylated MELK-derived peptide (Biotin-Ah-Ah-AKPKGNKDYHLQTCCGSLAYRRR) and 10 uM ATP (spiked with 0.25 uCi of 33P-ATP/well) are incubated at 30 C. for 120 min in a total volume of 50 ul (10 mM MOPS, 10 mM Mg acetate, 0.1 mM EGTA, 1 mM DTT, 0.02% of Brij35, 0.1% of BSA, pH 7.5) with or without test compound. The reaction is stopped with 25 ul of 200 mM EDTA. After 30 min at room temperature, the liquid is removed, and each well is washed three times with 100 ul of 0.9% sodium chloride solution. Non-specific reaction is measured in the presence of 100 nM staurosporine. The radioactivity is measured in a Topcount (PerkinElmer).	B	N#Cc1cc(-c2ccnc(Nc3cncc(N4CCOCC4)n3)c2)ccc1OC1CCOCC1		CHEMBL3687115	=	IC50	nM	330.0	CHEMBL5408	Homo sapiens	IC50	nM	330.0
280395	17662740	CHEMBL3706282	Flashplate Assay: The kinase assay is performed as 384-well flashplate assay (for example for Topcount measurement).0.6 nM TANK binding kinase (TBK1), 800 nM biotinylated MELK-derived peptide (Biotin-Ah-Ah-AKPKGNKDYHLQTCCGSLAYRRR) and 10 uM ATP (spiked with 0.25 uCi of 33P-ATP/well) are incubated at 30 C. for 120 min in a total volume of 50 ul (10 mM MOPS, 10 mM Mg acetate, 0.1 mM EGTA, 1 mM DTT, 0.02% of Brij35, 0.1% of BSA, pH 7.5) with or without test compound. The reaction is stopped with 25 ul of 200 mM EDTA. After 30 min at room temperature, the liquid is removed, and each well is washed three times with 100 ul of 0.9% sodium chloride solution. Non-specific reaction is measured in the presence of 100 nM staurosporine. The radioactivity is measured in a Topcount (PerkinElmer).	B	N#Cc1cc(-c2ccnc(Nc3cc(C4=CCCCO4)ccn3)c2)ccc1OC1CCOCC1		CHEMBL3687116	=	IC50	nM	290.0	CHEMBL5408	Homo sapiens	IC50	nM	290.0
280396	17662741	CHEMBL3706282	Flashplate Assay: The kinase assay is performed as 384-well flashplate assay (for example for Topcount measurement).0.6 nM TANK binding kinase (TBK1), 800 nM biotinylated MELK-derived peptide (Biotin-Ah-Ah-AKPKGNKDYHLQTCCGSLAYRRR) and 10 uM ATP (spiked with 0.25 uCi of 33P-ATP/well) are incubated at 30 C. for 120 min in a total volume of 50 ul (10 mM MOPS, 10 mM Mg acetate, 0.1 mM EGTA, 1 mM DTT, 0.02% of Brij35, 0.1% of BSA, pH 7.5) with or without test compound. The reaction is stopped with 25 ul of 200 mM EDTA. After 30 min at room temperature, the liquid is removed, and each well is washed three times with 100 ul of 0.9% sodium chloride solution. Non-specific reaction is measured in the presence of 100 nM staurosporine. The radioactivity is measured in a Topcount (PerkinElmer).	B	N#Cc1cc(-c2ccnc(Nc3nc(C4CC4)cs3)n2)ccc1OC1CCOCC1		CHEMBL3687117	=	IC50	nM	300.0	CHEMBL5408	Homo sapiens	IC50	nM	300.0
280397	17662742	CHEMBL3706282	Flashplate Assay: The kinase assay is performed as 384-well flashplate assay (for example for Topcount measurement).0.6 nM TANK binding kinase (TBK1), 800 nM biotinylated MELK-derived peptide (Biotin-Ah-Ah-AKPKGNKDYHLQTCCGSLAYRRR) and 10 uM ATP (spiked with 0.25 uCi of 33P-ATP/well) are incubated at 30 C. for 120 min in a total volume of 50 ul (10 mM MOPS, 10 mM Mg acetate, 0.1 mM EGTA, 1 mM DTT, 0.02% of Brij35, 0.1% of BSA, pH 7.5) with or without test compound. The reaction is stopped with 25 ul of 200 mM EDTA. After 30 min at room temperature, the liquid is removed, and each well is washed three times with 100 ul of 0.9% sodium chloride solution. Non-specific reaction is measured in the presence of 100 nM staurosporine. The radioactivity is measured in a Topcount (PerkinElmer).	B	N#Cc1cc(-c2ccnc(Nc3ccc(CN4CC5(COC5)C4)cn3)c2)ccc1OC1CCOCC1		CHEMBL3687118	=	IC50	nM	41.0	CHEMBL5408	Homo sapiens	IC50	nM	41.0
280398	17662743	CHEMBL3706282	Flashplate Assay: The kinase assay is performed as 384-well flashplate assay (for example for Topcount measurement).0.6 nM TANK binding kinase (TBK1), 800 nM biotinylated MELK-derived peptide (Biotin-Ah-Ah-AKPKGNKDYHLQTCCGSLAYRRR) and 10 uM ATP (spiked with 0.25 uCi of 33P-ATP/well) are incubated at 30 C. for 120 min in a total volume of 50 ul (10 mM MOPS, 10 mM Mg acetate, 0.1 mM EGTA, 1 mM DTT, 0.02% of Brij35, 0.1% of BSA, pH 7.5) with or without test compound. The reaction is stopped with 25 ul of 200 mM EDTA. After 30 min at room temperature, the liquid is removed, and each well is washed three times with 100 ul of 0.9% sodium chloride solution. Non-specific reaction is measured in the presence of 100 nM staurosporine. The radioactivity is measured in a Topcount (PerkinElmer).	B	N#Cc1cc(-c2ccnc(Nc3nccc(C4CCNCC4)n3)c2)ccc1OC1CCOCC1		CHEMBL3687119	=	IC50	nM	140.0	CHEMBL5408	Homo sapiens	IC50	nM	140.0
280399	17662744	CHEMBL3706282	Flashplate Assay: The kinase assay is performed as 384-well flashplate assay (for example for Topcount measurement).0.6 nM TANK binding kinase (TBK1), 800 nM biotinylated MELK-derived peptide (Biotin-Ah-Ah-AKPKGNKDYHLQTCCGSLAYRRR) and 10 uM ATP (spiked with 0.25 uCi of 33P-ATP/well) are incubated at 30 C. for 120 min in a total volume of 50 ul (10 mM MOPS, 10 mM Mg acetate, 0.1 mM EGTA, 1 mM DTT, 0.02% of Brij35, 0.1% of BSA, pH 7.5) with or without test compound. The reaction is stopped with 25 ul of 200 mM EDTA. After 30 min at room temperature, the liquid is removed, and each well is washed three times with 100 ul of 0.9% sodium chloride solution. Non-specific reaction is measured in the presence of 100 nM staurosporine. The radioactivity is measured in a Topcount (PerkinElmer).	B	N#Cc1cc(-c2ccnc(Nc3ccc(N4CCOCC4)nn3)c2)ccc1OC1CCOCC1		CHEMBL3687120	=	IC50	nM	88.0	CHEMBL5408	Homo sapiens	IC50	nM	88.0
280400	17662745	CHEMBL3706282	Flashplate Assay: The kinase assay is performed as 384-well flashplate assay (for example for Topcount measurement).0.6 nM TANK binding kinase (TBK1), 800 nM biotinylated MELK-derived peptide (Biotin-Ah-Ah-AKPKGNKDYHLQTCCGSLAYRRR) and 10 uM ATP (spiked with 0.25 uCi of 33P-ATP/well) are incubated at 30 C. for 120 min in a total volume of 50 ul (10 mM MOPS, 10 mM Mg acetate, 0.1 mM EGTA, 1 mM DTT, 0.02% of Brij35, 0.1% of BSA, pH 7.5) with or without test compound. The reaction is stopped with 25 ul of 200 mM EDTA. After 30 min at room temperature, the liquid is removed, and each well is washed three times with 100 ul of 0.9% sodium chloride solution. Non-specific reaction is measured in the presence of 100 nM staurosporine. The radioactivity is measured in a Topcount (PerkinElmer).	B	N#Cc1cc(-c2ccnc(Nc3cccc(C4CCNCC4)n3)c2)ccc1OC1CCOCC1		CHEMBL3687121	=	IC50	nM	32.0	CHEMBL5408	Homo sapiens	IC50	nM	32.0
280401	17662746	CHEMBL3706282	Flashplate Assay: The kinase assay is performed as 384-well flashplate assay (for example for Topcount measurement).0.6 nM TANK binding kinase (TBK1), 800 nM biotinylated MELK-derived peptide (Biotin-Ah-Ah-AKPKGNKDYHLQTCCGSLAYRRR) and 10 uM ATP (spiked with 0.25 uCi of 33P-ATP/well) are incubated at 30 C. for 120 min in a total volume of 50 ul (10 mM MOPS, 10 mM Mg acetate, 0.1 mM EGTA, 1 mM DTT, 0.02% of Brij35, 0.1% of BSA, pH 7.5) with or without test compound. The reaction is stopped with 25 ul of 200 mM EDTA. After 30 min at room temperature, the liquid is removed, and each well is washed three times with 100 ul of 0.9% sodium chloride solution. Non-specific reaction is measured in the presence of 100 nM staurosporine. The radioactivity is measured in a Topcount (PerkinElmer).	B	N#Cc1cc(-c2ccnc(Nc3cncc(C4=CCCCO4)n3)c2)ccc1OC1CCOCC1		CHEMBL3687122	=	IC50	nM	850.0	CHEMBL5408	Homo sapiens	IC50	nM	850.0
280402	17662747	CHEMBL3706282	Flashplate Assay: The kinase assay is performed as 384-well flashplate assay (for example for Topcount measurement).0.6 nM TANK binding kinase (TBK1), 800 nM biotinylated MELK-derived peptide (Biotin-Ah-Ah-AKPKGNKDYHLQTCCGSLAYRRR) and 10 uM ATP (spiked with 0.25 uCi of 33P-ATP/well) are incubated at 30 C. for 120 min in a total volume of 50 ul (10 mM MOPS, 10 mM Mg acetate, 0.1 mM EGTA, 1 mM DTT, 0.02% of Brij35, 0.1% of BSA, pH 7.5) with or without test compound. The reaction is stopped with 25 ul of 200 mM EDTA. After 30 min at room temperature, the liquid is removed, and each well is washed three times with 100 ul of 0.9% sodium chloride solution. Non-specific reaction is measured in the presence of 100 nM staurosporine. The radioactivity is measured in a Topcount (PerkinElmer).	B	Cc1coc(Nc2nccc(-c3ccc(OC4CCOCC4)c(C#N)c3)n2)n1		CHEMBL3687123	=	IC50	nM	550.0	CHEMBL5408	Homo sapiens	IC50	nM	550.0
280403	17662748	CHEMBL3706282	Flashplate Assay: The kinase assay is performed as 384-well flashplate assay (for example for Topcount measurement).0.6 nM TANK binding kinase (TBK1), 800 nM biotinylated MELK-derived peptide (Biotin-Ah-Ah-AKPKGNKDYHLQTCCGSLAYRRR) and 10 uM ATP (spiked with 0.25 uCi of 33P-ATP/well) are incubated at 30 C. for 120 min in a total volume of 50 ul (10 mM MOPS, 10 mM Mg acetate, 0.1 mM EGTA, 1 mM DTT, 0.02% of Brij35, 0.1% of BSA, pH 7.5) with or without test compound. The reaction is stopped with 25 ul of 200 mM EDTA. After 30 min at room temperature, the liquid is removed, and each well is washed three times with 100 ul of 0.9% sodium chloride solution. Non-specific reaction is measured in the presence of 100 nM staurosporine. The radioactivity is measured in a Topcount (PerkinElmer).	B	N#Cc1cc(-c2ccnc(Nc3cnn(CCO)c3)n2)ccc1OCC1CCC1		CHEMBL3687124	=	IC50	nM	14.0	CHEMBL5408	Homo sapiens	IC50	nM	14.0
280404	17662749	CHEMBL3706282	Flashplate Assay: The kinase assay is performed as 384-well flashplate assay (for example for Topcount measurement).0.6 nM TANK binding kinase (TBK1), 800 nM biotinylated MELK-derived peptide (Biotin-Ah-Ah-AKPKGNKDYHLQTCCGSLAYRRR) and 10 uM ATP (spiked with 0.25 uCi of 33P-ATP/well) are incubated at 30 C. for 120 min in a total volume of 50 ul (10 mM MOPS, 10 mM Mg acetate, 0.1 mM EGTA, 1 mM DTT, 0.02% of Brij35, 0.1% of BSA, pH 7.5) with or without test compound. The reaction is stopped with 25 ul of 200 mM EDTA. After 30 min at room temperature, the liquid is removed, and each well is washed three times with 100 ul of 0.9% sodium chloride solution. Non-specific reaction is measured in the presence of 100 nM staurosporine. The radioactivity is measured in a Topcount (PerkinElmer).	B	N#Cc1cc(-c2ccnc(Nc3cnn(C[C@H]4C[C@@H]4CO)c3)n2)ccc1OCC1CCC1		CHEMBL3687125	=	IC50	nM	10.0	CHEMBL5408	Homo sapiens	IC50	nM	10.0
280405	17662750	CHEMBL3706282	Flashplate Assay: The kinase assay is performed as 384-well flashplate assay (for example for Topcount measurement).0.6 nM TANK binding kinase (TBK1), 800 nM biotinylated MELK-derived peptide (Biotin-Ah-Ah-AKPKGNKDYHLQTCCGSLAYRRR) and 10 uM ATP (spiked with 0.25 uCi of 33P-ATP/well) are incubated at 30 C. for 120 min in a total volume of 50 ul (10 mM MOPS, 10 mM Mg acetate, 0.1 mM EGTA, 1 mM DTT, 0.02% of Brij35, 0.1% of BSA, pH 7.5) with or without test compound. The reaction is stopped with 25 ul of 200 mM EDTA. After 30 min at room temperature, the liquid is removed, and each well is washed three times with 100 ul of 0.9% sodium chloride solution. Non-specific reaction is measured in the presence of 100 nM staurosporine. The radioactivity is measured in a Topcount (PerkinElmer).	B	N#Cc1cc(-c2ccnc(Nc3cncc(C4CCNCC4)n3)c2)ccc1OC1CCOCC1		CHEMBL3687126	=	IC50	nM	24.0	CHEMBL5408	Homo sapiens	IC50	nM	24.0
280406	17662751	CHEMBL3706282	Flashplate Assay: The kinase assay is performed as 384-well flashplate assay (for example for Topcount measurement).0.6 nM TANK binding kinase (TBK1), 800 nM biotinylated MELK-derived peptide (Biotin-Ah-Ah-AKPKGNKDYHLQTCCGSLAYRRR) and 10 uM ATP (spiked with 0.25 uCi of 33P-ATP/well) are incubated at 30 C. for 120 min in a total volume of 50 ul (10 mM MOPS, 10 mM Mg acetate, 0.1 mM EGTA, 1 mM DTT, 0.02% of Brij35, 0.1% of BSA, pH 7.5) with or without test compound. The reaction is stopped with 25 ul of 200 mM EDTA. After 30 min at room temperature, the liquid is removed, and each well is washed three times with 100 ul of 0.9% sodium chloride solution. Non-specific reaction is measured in the presence of 100 nM staurosporine. The radioactivity is measured in a Topcount (PerkinElmer).	B	N#Cc1cc(-c2ccnc(Nc3cnn([C@H]4CC[C@@H](O)CC4)c3)n2)ccc1OCC1CCC1		CHEMBL3687127	=	IC50	nM	11.0	CHEMBL5408	Homo sapiens	IC50	nM	11.0
280407	17662752	CHEMBL3706282	Flashplate Assay: The kinase assay is performed as 384-well flashplate assay (for example for Topcount measurement).0.6 nM TANK binding kinase (TBK1), 800 nM biotinylated MELK-derived peptide (Biotin-Ah-Ah-AKPKGNKDYHLQTCCGSLAYRRR) and 10 uM ATP (spiked with 0.25 uCi of 33P-ATP/well) are incubated at 30 C. for 120 min in a total volume of 50 ul (10 mM MOPS, 10 mM Mg acetate, 0.1 mM EGTA, 1 mM DTT, 0.02% of Brij35, 0.1% of BSA, pH 7.5) with or without test compound. The reaction is stopped with 25 ul of 200 mM EDTA. After 30 min at room temperature, the liquid is removed, and each well is washed three times with 100 ul of 0.9% sodium chloride solution. Non-specific reaction is measured in the presence of 100 nM staurosporine. The radioactivity is measured in a Topcount (PerkinElmer).	B	N#Cc1cc(-c2ccnc(Nc3cnc(C4CCOCC4)cn3)c2)ccc1OC1CCOCC1		CHEMBL3687128	=	IC50	nM	5.0	CHEMBL5408	Homo sapiens	IC50	nM	5.0
280408	17662753	CHEMBL3706282	Flashplate Assay: The kinase assay is performed as 384-well flashplate assay (for example for Topcount measurement).0.6 nM TANK binding kinase (TBK1), 800 nM biotinylated MELK-derived peptide (Biotin-Ah-Ah-AKPKGNKDYHLQTCCGSLAYRRR) and 10 uM ATP (spiked with 0.25 uCi of 33P-ATP/well) are incubated at 30 C. for 120 min in a total volume of 50 ul (10 mM MOPS, 10 mM Mg acetate, 0.1 mM EGTA, 1 mM DTT, 0.02% of Brij35, 0.1% of BSA, pH 7.5) with or without test compound. The reaction is stopped with 25 ul of 200 mM EDTA. After 30 min at room temperature, the liquid is removed, and each well is washed three times with 100 ul of 0.9% sodium chloride solution. Non-specific reaction is measured in the presence of 100 nM staurosporine. The radioactivity is measured in a Topcount (PerkinElmer).	B	N#Cc1cc(-c2ccnc(Nc3cnc(CO)cn3)c2)ccc1OC1CCOCC1		CHEMBL3687129	=	IC50	nM	6.0	CHEMBL5408	Homo sapiens	IC50	nM	6.0
280409	17662754	CHEMBL3706282	Flashplate Assay: The kinase assay is performed as 384-well flashplate assay (for example for Topcount measurement).0.6 nM TANK binding kinase (TBK1), 800 nM biotinylated MELK-derived peptide (Biotin-Ah-Ah-AKPKGNKDYHLQTCCGSLAYRRR) and 10 uM ATP (spiked with 0.25 uCi of 33P-ATP/well) are incubated at 30 C. for 120 min in a total volume of 50 ul (10 mM MOPS, 10 mM Mg acetate, 0.1 mM EGTA, 1 mM DTT, 0.02% of Brij35, 0.1% of BSA, pH 7.5) with or without test compound. The reaction is stopped with 25 ul of 200 mM EDTA. After 30 min at room temperature, the liquid is removed, and each well is washed three times with 100 ul of 0.9% sodium chloride solution. Non-specific reaction is measured in the presence of 100 nM staurosporine. The radioactivity is measured in a Topcount (PerkinElmer).	B	N#Cc1cc(-c2ccnc(Nc3ccc(C4CCOCC4)nn3)c2)ccc1OC1CCOCC1		CHEMBL3687130	=	IC50	nM	14.0	CHEMBL5408	Homo sapiens	IC50	nM	14.0
280410	17662755	CHEMBL3706282	Flashplate Assay: The kinase assay is performed as 384-well flashplate assay (for example for Topcount measurement).0.6 nM TANK binding kinase (TBK1), 800 nM biotinylated MELK-derived peptide (Biotin-Ah-Ah-AKPKGNKDYHLQTCCGSLAYRRR) and 10 uM ATP (spiked with 0.25 uCi of 33P-ATP/well) are incubated at 30 C. for 120 min in a total volume of 50 ul (10 mM MOPS, 10 mM Mg acetate, 0.1 mM EGTA, 1 mM DTT, 0.02% of Brij35, 0.1% of BSA, pH 7.5) with or without test compound. The reaction is stopped with 25 ul of 200 mM EDTA. After 30 min at room temperature, the liquid is removed, and each well is washed three times with 100 ul of 0.9% sodium chloride solution. Non-specific reaction is measured in the presence of 100 nM staurosporine. The radioactivity is measured in a Topcount (PerkinElmer).	B	N#Cc1cc(-c2ccnc(Nc3cnn([C@H]4CC[C@H](O)CC4)c3)n2)ccc1OC1CCOCC1		CHEMBL3639859	=	IC50	nM	3.0	CHEMBL5408	Homo sapiens	IC50	nM	3.0
280411	17662756	CHEMBL3706282	Flashplate Assay: The kinase assay is performed as 384-well flashplate assay (for example for Topcount measurement).0.6 nM TANK binding kinase (TBK1), 800 nM biotinylated MELK-derived peptide (Biotin-Ah-Ah-AKPKGNKDYHLQTCCGSLAYRRR) and 10 uM ATP (spiked with 0.25 uCi of 33P-ATP/well) are incubated at 30 C. for 120 min in a total volume of 50 ul (10 mM MOPS, 10 mM Mg acetate, 0.1 mM EGTA, 1 mM DTT, 0.02% of Brij35, 0.1% of BSA, pH 7.5) with or without test compound. The reaction is stopped with 25 ul of 200 mM EDTA. After 30 min at room temperature, the liquid is removed, and each well is washed three times with 100 ul of 0.9% sodium chloride solution. Non-specific reaction is measured in the presence of 100 nM staurosporine. The radioactivity is measured in a Topcount (PerkinElmer).	B	N#Cc1cc(-c2ccnc(Nc3nccnc3CO)c2)ccc1OC1CCOCC1		CHEMBL3687131	=	IC50	nM	350.0	CHEMBL5408	Homo sapiens	IC50	nM	350.0
280412	17662757	CHEMBL3706282	Flashplate Assay: The kinase assay is performed as 384-well flashplate assay (for example for Topcount measurement).0.6 nM TANK binding kinase (TBK1), 800 nM biotinylated MELK-derived peptide (Biotin-Ah-Ah-AKPKGNKDYHLQTCCGSLAYRRR) and 10 uM ATP (spiked with 0.25 uCi of 33P-ATP/well) are incubated at 30 C. for 120 min in a total volume of 50 ul (10 mM MOPS, 10 mM Mg acetate, 0.1 mM EGTA, 1 mM DTT, 0.02% of Brij35, 0.1% of BSA, pH 7.5) with or without test compound. The reaction is stopped with 25 ul of 200 mM EDTA. After 30 min at room temperature, the liquid is removed, and each well is washed three times with 100 ul of 0.9% sodium chloride solution. Non-specific reaction is measured in the presence of 100 nM staurosporine. The radioactivity is measured in a Topcount (PerkinElmer).	B	COCCn1cc(Nc2nccc(-c3ccc(OCC4CCC4)c(C#N)c3)n2)cn1		CHEMBL3687132	=	IC50	nM	7.0	CHEMBL5408	Homo sapiens	IC50	nM	7.0
280413	17662758	CHEMBL3706282	Flashplate Assay: The kinase assay is performed as 384-well flashplate assay (for example for Topcount measurement).0.6 nM TANK binding kinase (TBK1), 800 nM biotinylated MELK-derived peptide (Biotin-Ah-Ah-AKPKGNKDYHLQTCCGSLAYRRR) and 10 uM ATP (spiked with 0.25 uCi of 33P-ATP/well) are incubated at 30 C. for 120 min in a total volume of 50 ul (10 mM MOPS, 10 mM Mg acetate, 0.1 mM EGTA, 1 mM DTT, 0.02% of Brij35, 0.1% of BSA, pH 7.5) with or without test compound. The reaction is stopped with 25 ul of 200 mM EDTA. After 30 min at room temperature, the liquid is removed, and each well is washed three times with 100 ul of 0.9% sodium chloride solution. Non-specific reaction is measured in the presence of 100 nM staurosporine. The radioactivity is measured in a Topcount (PerkinElmer).	B	N#Cc1cc(-c2ccnc(Nc3cn[nH]c3)c2)ccc1OCC1CC1		CHEMBL3687134	=	IC50	nM	460.0	CHEMBL5408	Homo sapiens	IC50	nM	460.0
280414	17662759	CHEMBL3706282	Flashplate Assay: The kinase assay is performed as 384-well flashplate assay (for example for Topcount measurement).0.6 nM TANK binding kinase (TBK1), 800 nM biotinylated MELK-derived peptide (Biotin-Ah-Ah-AKPKGNKDYHLQTCCGSLAYRRR) and 10 uM ATP (spiked with 0.25 uCi of 33P-ATP/well) are incubated at 30 C. for 120 min in a total volume of 50 ul (10 mM MOPS, 10 mM Mg acetate, 0.1 mM EGTA, 1 mM DTT, 0.02% of Brij35, 0.1% of BSA, pH 7.5) with or without test compound. The reaction is stopped with 25 ul of 200 mM EDTA. After 30 min at room temperature, the liquid is removed, and each well is washed three times with 100 ul of 0.9% sodium chloride solution. Non-specific reaction is measured in the presence of 100 nM staurosporine. The radioactivity is measured in a Topcount (PerkinElmer).	B	COCCn1cc(Nc2cc(-c3ccc(OCC4CC4)c(C#N)c3)ccn2)cn1		CHEMBL3687135	=	IC50	nM	220.0	CHEMBL5408	Homo sapiens	IC50	nM	220.0
280415	17662760	CHEMBL3706282	Flashplate Assay: The kinase assay is performed as 384-well flashplate assay (for example for Topcount measurement).0.6 nM TANK binding kinase (TBK1), 800 nM biotinylated MELK-derived peptide (Biotin-Ah-Ah-AKPKGNKDYHLQTCCGSLAYRRR) and 10 uM ATP (spiked with 0.25 uCi of 33P-ATP/well) are incubated at 30 C. for 120 min in a total volume of 50 ul (10 mM MOPS, 10 mM Mg acetate, 0.1 mM EGTA, 1 mM DTT, 0.02% of Brij35, 0.1% of BSA, pH 7.5) with or without test compound. The reaction is stopped with 25 ul of 200 mM EDTA. After 30 min at room temperature, the liquid is removed, and each well is washed three times with 100 ul of 0.9% sodium chloride solution. Non-specific reaction is measured in the presence of 100 nM staurosporine. The radioactivity is measured in a Topcount (PerkinElmer).	B	N#Cc1cc(-c2ccnc(Nc3ccc(CO)cn3)c2)ccc1OCC1CC1		CHEMBL3687136	=	IC50	nM	41.0	CHEMBL5408	Homo sapiens	IC50	nM	41.0
280416	17662761	CHEMBL3706282	Flashplate Assay: The kinase assay is performed as 384-well flashplate assay (for example for Topcount measurement).0.6 nM TANK binding kinase (TBK1), 800 nM biotinylated MELK-derived peptide (Biotin-Ah-Ah-AKPKGNKDYHLQTCCGSLAYRRR) and 10 uM ATP (spiked with 0.25 uCi of 33P-ATP/well) are incubated at 30 C. for 120 min in a total volume of 50 ul (10 mM MOPS, 10 mM Mg acetate, 0.1 mM EGTA, 1 mM DTT, 0.02% of Brij35, 0.1% of BSA, pH 7.5) with or without test compound. The reaction is stopped with 25 ul of 200 mM EDTA. After 30 min at room temperature, the liquid is removed, and each well is washed three times with 100 ul of 0.9% sodium chloride solution. Non-specific reaction is measured in the presence of 100 nM staurosporine. The radioactivity is measured in a Topcount (PerkinElmer).	B	[C-]#[N+]c1cc(-c2ccnc(Nc3ccn(C4CCNCC4)n3)c2)ccc1OCC1CC1		CHEMBL3687137	=	IC50	nM	50.0	CHEMBL5408	Homo sapiens	IC50	nM	50.0
280417	17662762	CHEMBL3706282	Flashplate Assay: The kinase assay is performed as 384-well flashplate assay (for example for Topcount measurement).0.6 nM TANK binding kinase (TBK1), 800 nM biotinylated MELK-derived peptide (Biotin-Ah-Ah-AKPKGNKDYHLQTCCGSLAYRRR) and 10 uM ATP (spiked with 0.25 uCi of 33P-ATP/well) are incubated at 30 C. for 120 min in a total volume of 50 ul (10 mM MOPS, 10 mM Mg acetate, 0.1 mM EGTA, 1 mM DTT, 0.02% of Brij35, 0.1% of BSA, pH 7.5) with or without test compound. The reaction is stopped with 25 ul of 200 mM EDTA. After 30 min at room temperature, the liquid is removed, and each well is washed three times with 100 ul of 0.9% sodium chloride solution. Non-specific reaction is measured in the presence of 100 nM staurosporine. The radioactivity is measured in a Topcount (PerkinElmer).	B	N#Cc1cc(-c2ccnc(Nc3ccc(N4CCOCC4)cn3)c2)ccc1OCC1CC1		CHEMBL3687138	=	IC50	nM	23.0	CHEMBL5408	Homo sapiens	IC50	nM	23.0
280418	17662763	CHEMBL3706282	Flashplate Assay: The kinase assay is performed as 384-well flashplate assay (for example for Topcount measurement).0.6 nM TANK binding kinase (TBK1), 800 nM biotinylated MELK-derived peptide (Biotin-Ah-Ah-AKPKGNKDYHLQTCCGSLAYRRR) and 10 uM ATP (spiked with 0.25 uCi of 33P-ATP/well) are incubated at 30 C. for 120 min in a total volume of 50 ul (10 mM MOPS, 10 mM Mg acetate, 0.1 mM EGTA, 1 mM DTT, 0.02% of Brij35, 0.1% of BSA, pH 7.5) with or without test compound. The reaction is stopped with 25 ul of 200 mM EDTA. After 30 min at room temperature, the liquid is removed, and each well is washed three times with 100 ul of 0.9% sodium chloride solution. Non-specific reaction is measured in the presence of 100 nM staurosporine. The radioactivity is measured in a Topcount (PerkinElmer).	B	N#Cc1cc(-c2ccnc(Nc3cn[nH]c3)c2)ccc1OCC1CCC1		CHEMBL3687139	=	IC50	nM	380.0	CHEMBL5408	Homo sapiens	IC50	nM	380.0
280419	17662764	CHEMBL3706282	Flashplate Assay: The kinase assay is performed as 384-well flashplate assay (for example for Topcount measurement).0.6 nM TANK binding kinase (TBK1), 800 nM biotinylated MELK-derived peptide (Biotin-Ah-Ah-AKPKGNKDYHLQTCCGSLAYRRR) and 10 uM ATP (spiked with 0.25 uCi of 33P-ATP/well) are incubated at 30 C. for 120 min in a total volume of 50 ul (10 mM MOPS, 10 mM Mg acetate, 0.1 mM EGTA, 1 mM DTT, 0.02% of Brij35, 0.1% of BSA, pH 7.5) with or without test compound. The reaction is stopped with 25 ul of 200 mM EDTA. After 30 min at room temperature, the liquid is removed, and each well is washed three times with 100 ul of 0.9% sodium chloride solution. Non-specific reaction is measured in the presence of 100 nM staurosporine. The radioactivity is measured in a Topcount (PerkinElmer).	B	COCCn1cc(Nc2cc(-c3ccc(OCC4CCC4)c(C#N)c3)ccn2)cn1		CHEMBL3687140	=	IC50	nM	490.0	CHEMBL5408	Homo sapiens	IC50	nM	490.0
280420	17662765	CHEMBL3706282	Flashplate Assay: The kinase assay is performed as 384-well flashplate assay (for example for Topcount measurement).0.6 nM TANK binding kinase (TBK1), 800 nM biotinylated MELK-derived peptide (Biotin-Ah-Ah-AKPKGNKDYHLQTCCGSLAYRRR) and 10 uM ATP (spiked with 0.25 uCi of 33P-ATP/well) are incubated at 30 C. for 120 min in a total volume of 50 ul (10 mM MOPS, 10 mM Mg acetate, 0.1 mM EGTA, 1 mM DTT, 0.02% of Brij35, 0.1% of BSA, pH 7.5) with or without test compound. The reaction is stopped with 25 ul of 200 mM EDTA. After 30 min at room temperature, the liquid is removed, and each well is washed three times with 100 ul of 0.9% sodium chloride solution. Non-specific reaction is measured in the presence of 100 nM staurosporine. The radioactivity is measured in a Topcount (PerkinElmer).	B	N#Cc1cc(-c2ccnc(Nc3ccc(CO)cn3)c2)ccc1OCC1CCC1		CHEMBL3687141	=	IC50	nM	89.0	CHEMBL5408	Homo sapiens	IC50	nM	89.0
280421	17662766	CHEMBL3706282	Flashplate Assay: The kinase assay is performed as 384-well flashplate assay (for example for Topcount measurement).0.6 nM TANK binding kinase (TBK1), 800 nM biotinylated MELK-derived peptide (Biotin-Ah-Ah-AKPKGNKDYHLQTCCGSLAYRRR) and 10 uM ATP (spiked with 0.25 uCi of 33P-ATP/well) are incubated at 30 C. for 120 min in a total volume of 50 ul (10 mM MOPS, 10 mM Mg acetate, 0.1 mM EGTA, 1 mM DTT, 0.02% of Brij35, 0.1% of BSA, pH 7.5) with or without test compound. The reaction is stopped with 25 ul of 200 mM EDTA. After 30 min at room temperature, the liquid is removed, and each well is washed three times with 100 ul of 0.9% sodium chloride solution. Non-specific reaction is measured in the presence of 100 nM staurosporine. The radioactivity is measured in a Topcount (PerkinElmer).	B	[C-]#[N+]c1cc(-c2ccnc(Nc3ccn(C4CCNCC4)n3)c2)ccc1OCC1CCC1		CHEMBL3687142	=	IC50	nM	65.0	CHEMBL5408	Homo sapiens	IC50	nM	65.0
280422	17662767	CHEMBL3706282	Flashplate Assay: The kinase assay is performed as 384-well flashplate assay (for example for Topcount measurement).0.6 nM TANK binding kinase (TBK1), 800 nM biotinylated MELK-derived peptide (Biotin-Ah-Ah-AKPKGNKDYHLQTCCGSLAYRRR) and 10 uM ATP (spiked with 0.25 uCi of 33P-ATP/well) are incubated at 30 C. for 120 min in a total volume of 50 ul (10 mM MOPS, 10 mM Mg acetate, 0.1 mM EGTA, 1 mM DTT, 0.02% of Brij35, 0.1% of BSA, pH 7.5) with or without test compound. The reaction is stopped with 25 ul of 200 mM EDTA. After 30 min at room temperature, the liquid is removed, and each well is washed three times with 100 ul of 0.9% sodium chloride solution. Non-specific reaction is measured in the presence of 100 nM staurosporine. The radioactivity is measured in a Topcount (PerkinElmer).	B	N#Cc1cc(-c2ccnc(Nc3ccc(N4CCOCC4)cn3)c2)ccc1CCC1CCC1		CHEMBL3687143	=	IC50	nM	54.0	CHEMBL5408	Homo sapiens	IC50	nM	54.0
280423	17662768	CHEMBL3706282	Flashplate Assay: The kinase assay is performed as 384-well flashplate assay (for example for Topcount measurement).0.6 nM TANK binding kinase (TBK1), 800 nM biotinylated MELK-derived peptide (Biotin-Ah-Ah-AKPKGNKDYHLQTCCGSLAYRRR) and 10 uM ATP (spiked with 0.25 uCi of 33P-ATP/well) are incubated at 30 C. for 120 min in a total volume of 50 ul (10 mM MOPS, 10 mM Mg acetate, 0.1 mM EGTA, 1 mM DTT, 0.02% of Brij35, 0.1% of BSA, pH 7.5) with or without test compound. The reaction is stopped with 25 ul of 200 mM EDTA. After 30 min at room temperature, the liquid is removed, and each well is washed three times with 100 ul of 0.9% sodium chloride solution. Non-specific reaction is measured in the presence of 100 nM staurosporine. The radioactivity is measured in a Topcount (PerkinElmer).	B	[C-]#[N+]c1cc(-c2ccnc(Nc3cnn(CCOC)c3)c2)ccc1OCC1CCN(C(C)=O)CC1		CHEMBL3687144	=	IC50	nM	5500.0	CHEMBL5408	Homo sapiens	IC50	nM	5500.0
280424	17662769	CHEMBL3706282	Flashplate Assay: The kinase assay is performed as 384-well flashplate assay (for example for Topcount measurement).0.6 nM TANK binding kinase (TBK1), 800 nM biotinylated MELK-derived peptide (Biotin-Ah-Ah-AKPKGNKDYHLQTCCGSLAYRRR) and 10 uM ATP (spiked with 0.25 uCi of 33P-ATP/well) are incubated at 30 C. for 120 min in a total volume of 50 ul (10 mM MOPS, 10 mM Mg acetate, 0.1 mM EGTA, 1 mM DTT, 0.02% of Brij35, 0.1% of BSA, pH 7.5) with or without test compound. The reaction is stopped with 25 ul of 200 mM EDTA. After 30 min at room temperature, the liquid is removed, and each well is washed three times with 100 ul of 0.9% sodium chloride solution. Non-specific reaction is measured in the presence of 100 nM staurosporine. The radioactivity is measured in a Topcount (PerkinElmer).	B	[C-]#[N+]c1cc(-c2ccnc(Nc3ccc(CO)cn3)c2)ccc1OCC1CCN(C(C)=O)CC1		CHEMBL3687145	=	IC50	nM	1500.0	CHEMBL5408	Homo sapiens	IC50	nM	1500.0
280425	17662770	CHEMBL3706282	Flashplate Assay: The kinase assay is performed as 384-well flashplate assay (for example for Topcount measurement).0.6 nM TANK binding kinase (TBK1), 800 nM biotinylated MELK-derived peptide (Biotin-Ah-Ah-AKPKGNKDYHLQTCCGSLAYRRR) and 10 uM ATP (spiked with 0.25 uCi of 33P-ATP/well) are incubated at 30 C. for 120 min in a total volume of 50 ul (10 mM MOPS, 10 mM Mg acetate, 0.1 mM EGTA, 1 mM DTT, 0.02% of Brij35, 0.1% of BSA, pH 7.5) with or without test compound. The reaction is stopped with 25 ul of 200 mM EDTA. After 30 min at room temperature, the liquid is removed, and each well is washed three times with 100 ul of 0.9% sodium chloride solution. Non-specific reaction is measured in the presence of 100 nM staurosporine. The radioactivity is measured in a Topcount (PerkinElmer).	B	[C-]#[N+]c1cc(-c2ccnc(Nc3cnn(C4CCNCC4)c3)c2)ccc1OCC1CCN(C(C)=O)CC1		CHEMBL3687146	=	IC50	nM	6600.0	CHEMBL5408	Homo sapiens	IC50	nM	6600.0
280426	17662771	CHEMBL3706282	Flashplate Assay: The kinase assay is performed as 384-well flashplate assay (for example for Topcount measurement).0.6 nM TANK binding kinase (TBK1), 800 nM biotinylated MELK-derived peptide (Biotin-Ah-Ah-AKPKGNKDYHLQTCCGSLAYRRR) and 10 uM ATP (spiked with 0.25 uCi of 33P-ATP/well) are incubated at 30 C. for 120 min in a total volume of 50 ul (10 mM MOPS, 10 mM Mg acetate, 0.1 mM EGTA, 1 mM DTT, 0.02% of Brij35, 0.1% of BSA, pH 7.5) with or without test compound. The reaction is stopped with 25 ul of 200 mM EDTA. After 30 min at room temperature, the liquid is removed, and each well is washed three times with 100 ul of 0.9% sodium chloride solution. Non-specific reaction is measured in the presence of 100 nM staurosporine. The radioactivity is measured in a Topcount (PerkinElmer).	B	[C-]#[N+]c1cc(-c2ccnc(Nc3ccc(N4CCOCC4)cn3)c2)ccc1OCC1CCN(C(C)=O)CC1		CHEMBL3687147	=	IC50	nM	810.0	CHEMBL5408	Homo sapiens	IC50	nM	810.0
280427	17662772	CHEMBL3706282	Flashplate Assay: The kinase assay is performed as 384-well flashplate assay (for example for Topcount measurement).0.6 nM TANK binding kinase (TBK1), 800 nM biotinylated MELK-derived peptide (Biotin-Ah-Ah-AKPKGNKDYHLQTCCGSLAYRRR) and 10 uM ATP (spiked with 0.25 uCi of 33P-ATP/well) are incubated at 30 C. for 120 min in a total volume of 50 ul (10 mM MOPS, 10 mM Mg acetate, 0.1 mM EGTA, 1 mM DTT, 0.02% of Brij35, 0.1% of BSA, pH 7.5) with or without test compound. The reaction is stopped with 25 ul of 200 mM EDTA. After 30 min at room temperature, the liquid is removed, and each well is washed three times with 100 ul of 0.9% sodium chloride solution. Non-specific reaction is measured in the presence of 100 nM staurosporine. The radioactivity is measured in a Topcount (PerkinElmer).	B	N#Cc1cc(-c2ccnc(Nc3ccc(CN4CCOCC4)cn3)c2)ccc1OC1CCOCC1		CHEMBL3687133	=	IC50	nM	24.0	CHEMBL5408	Homo sapiens	IC50	nM	24.0
363251	17738626	CHEMBL3887915	TBK1 Enzyme Assay: The kinase assay is performed as 384-well Flashplate assay assay (for e.g. Topcount measurement. 0.6 nM TANK binding kinase (TBK1), 800 nM biotinylated MELK-derived peptide (Biotin-Ah-Ah-AKPKGNKDYHLQTCCGSLAYRRR) SEQ ID NO: 2 and 10 μM ATP (spiked with 0.25 μCi 33P-ATP/well) are incubated in a total volume of 50 μl (10 mM MOPS, 10 mM Mg-acetat, 0.1 mM EGTA, 1 mM DTT, 0.02% Brij35, 0.1% BSA, pH 7.5) with or without test compound for 120 Min at 30° C. The reaction is stopped with 25 μl 200 mM EDTA. After 30 Min at room temperature the liquid is removed and each well washed thrice with 100 μl 0.9% sodium chloride solution. Nonspecific reaction is determined in presence of 100 nM Staurosporine. Radioactivity is measured in a Topcount (PerkinElmer).	B	CN1CCN(Cc2ccc(C(=O)Nc3sc(-c4ccncc4)nc3C(N)=O)cc2)CC1		CHEMBL3906947	=	IC50	nM	300.0	CHEMBL5408	Homo sapiens	IC50	nM	300.0
363252	17738627	CHEMBL3887915	TBK1 Enzyme Assay: The kinase assay is performed as 384-well Flashplate assay assay (for e.g. Topcount measurement. 0.6 nM TANK binding kinase (TBK1), 800 nM biotinylated MELK-derived peptide (Biotin-Ah-Ah-AKPKGNKDYHLQTCCGSLAYRRR) SEQ ID NO: 2 and 10 μM ATP (spiked with 0.25 μCi 33P-ATP/well) are incubated in a total volume of 50 μl (10 mM MOPS, 10 mM Mg-acetat, 0.1 mM EGTA, 1 mM DTT, 0.02% Brij35, 0.1% BSA, pH 7.5) with or without test compound for 120 Min at 30° C. The reaction is stopped with 25 μl 200 mM EDTA. After 30 Min at room temperature the liquid is removed and each well washed thrice with 100 μl 0.9% sodium chloride solution. Nonspecific reaction is determined in presence of 100 nM Staurosporine. Radioactivity is measured in a Topcount (PerkinElmer).	B	CN1CCN(Cc2ccc(C(=O)Nc3sc(-c4ccnc(Cl)c4)nc3C(N)=O)cc2)CC1		CHEMBL3963569	=	IC50	nM	1400.0	CHEMBL5408	Homo sapiens	IC50	nM	1400.0
363253	17738628	CHEMBL3887915	TBK1 Enzyme Assay: The kinase assay is performed as 384-well Flashplate assay assay (for e.g. Topcount measurement. 0.6 nM TANK binding kinase (TBK1), 800 nM biotinylated MELK-derived peptide (Biotin-Ah-Ah-AKPKGNKDYHLQTCCGSLAYRRR) SEQ ID NO: 2 and 10 μM ATP (spiked with 0.25 μCi 33P-ATP/well) are incubated in a total volume of 50 μl (10 mM MOPS, 10 mM Mg-acetat, 0.1 mM EGTA, 1 mM DTT, 0.02% Brij35, 0.1% BSA, pH 7.5) with or without test compound for 120 Min at 30° C. The reaction is stopped with 25 μl 200 mM EDTA. After 30 Min at room temperature the liquid is removed and each well washed thrice with 100 μl 0.9% sodium chloride solution. Nonspecific reaction is determined in presence of 100 nM Staurosporine. Radioactivity is measured in a Topcount (PerkinElmer).	B	CN1CCN(Cc2ccc(C(=O)Nc3sc(-c4ccnc(F)c4)nc3C(N)=O)cc2)CC1		CHEMBL3926136	=	IC50	nM	630.0	CHEMBL5408	Homo sapiens	IC50	nM	630.0
363254	17738629	CHEMBL3887915	TBK1 Enzyme Assay: The kinase assay is performed as 384-well Flashplate assay assay (for e.g. Topcount measurement. 0.6 nM TANK binding kinase (TBK1), 800 nM biotinylated MELK-derived peptide (Biotin-Ah-Ah-AKPKGNKDYHLQTCCGSLAYRRR) SEQ ID NO: 2 and 10 μM ATP (spiked with 0.25 μCi 33P-ATP/well) are incubated in a total volume of 50 μl (10 mM MOPS, 10 mM Mg-acetat, 0.1 mM EGTA, 1 mM DTT, 0.02% Brij35, 0.1% BSA, pH 7.5) with or without test compound for 120 Min at 30° C. The reaction is stopped with 25 μl 200 mM EDTA. After 30 Min at room temperature the liquid is removed and each well washed thrice with 100 μl 0.9% sodium chloride solution. Nonspecific reaction is determined in presence of 100 nM Staurosporine. Radioactivity is measured in a Topcount (PerkinElmer).	B	Cc1cc(-c2nc(C(N)=O)c(NC(=O)c3ccc(CN4CCN(C)CC4)cc3)s2)ccn1		CHEMBL3896866	=	IC50	nM	410.0	CHEMBL5408	Homo sapiens	IC50	nM	410.0
363255	17738630	CHEMBL3887915	TBK1 Enzyme Assay: The kinase assay is performed as 384-well Flashplate assay assay (for e.g. Topcount measurement. 0.6 nM TANK binding kinase (TBK1), 800 nM biotinylated MELK-derived peptide (Biotin-Ah-Ah-AKPKGNKDYHLQTCCGSLAYRRR) SEQ ID NO: 2 and 10 μM ATP (spiked with 0.25 μCi 33P-ATP/well) are incubated in a total volume of 50 μl (10 mM MOPS, 10 mM Mg-acetat, 0.1 mM EGTA, 1 mM DTT, 0.02% Brij35, 0.1% BSA, pH 7.5) with or without test compound for 120 Min at 30° C. The reaction is stopped with 25 μl 200 mM EDTA. After 30 Min at room temperature the liquid is removed and each well washed thrice with 100 μl 0.9% sodium chloride solution. Nonspecific reaction is determined in presence of 100 nM Staurosporine. Radioactivity is measured in a Topcount (PerkinElmer).	B	CN1CCN(Cc2ccc(C(=O)Nc3sc(-c4ccnc(C(F)(F)F)c4)nc3C(N)=O)cc2)CC1		CHEMBL3921400	=	IC50	nM	6300.0	CHEMBL5408	Homo sapiens	IC50	nM	6300.0
363256	17738631	CHEMBL3887915	TBK1 Enzyme Assay: The kinase assay is performed as 384-well Flashplate assay assay (for e.g. Topcount measurement. 0.6 nM TANK binding kinase (TBK1), 800 nM biotinylated MELK-derived peptide (Biotin-Ah-Ah-AKPKGNKDYHLQTCCGSLAYRRR) SEQ ID NO: 2 and 10 μM ATP (spiked with 0.25 μCi 33P-ATP/well) are incubated in a total volume of 50 μl (10 mM MOPS, 10 mM Mg-acetat, 0.1 mM EGTA, 1 mM DTT, 0.02% Brij35, 0.1% BSA, pH 7.5) with or without test compound for 120 Min at 30° C. The reaction is stopped with 25 μl 200 mM EDTA. After 30 Min at room temperature the liquid is removed and each well washed thrice with 100 μl 0.9% sodium chloride solution. Nonspecific reaction is determined in presence of 100 nM Staurosporine. Radioactivity is measured in a Topcount (PerkinElmer).	B	CN1CCN(Cc2ccc(C(=O)Nc3sc(-c4ccnc(C#N)c4)nc3C(N)=O)cc2)CC1		CHEMBL3956191	=	IC50	nM	2000.0	CHEMBL5408	Homo sapiens	IC50	nM	2000.0
363257	17738632	CHEMBL3887915	TBK1 Enzyme Assay: The kinase assay is performed as 384-well Flashplate assay assay (for e.g. Topcount measurement. 0.6 nM TANK binding kinase (TBK1), 800 nM biotinylated MELK-derived peptide (Biotin-Ah-Ah-AKPKGNKDYHLQTCCGSLAYRRR) SEQ ID NO: 2 and 10 μM ATP (spiked with 0.25 μCi 33P-ATP/well) are incubated in a total volume of 50 μl (10 mM MOPS, 10 mM Mg-acetat, 0.1 mM EGTA, 1 mM DTT, 0.02% Brij35, 0.1% BSA, pH 7.5) with or without test compound for 120 Min at 30° C. The reaction is stopped with 25 μl 200 mM EDTA. After 30 Min at room temperature the liquid is removed and each well washed thrice with 100 μl 0.9% sodium chloride solution. Nonspecific reaction is determined in presence of 100 nM Staurosporine. Radioactivity is measured in a Topcount (PerkinElmer).	B	CN1CCN(Cc2ccc(Nc3sc(-c4ccncc4)nc3C(N)=O)cc2)CC1		CHEMBL3968131	=	IC50	nM	1700.0	CHEMBL5408	Homo sapiens	IC50	nM	1700.0
363258	17738633	CHEMBL3887915	TBK1 Enzyme Assay: The kinase assay is performed as 384-well Flashplate assay assay (for e.g. Topcount measurement. 0.6 nM TANK binding kinase (TBK1), 800 nM biotinylated MELK-derived peptide (Biotin-Ah-Ah-AKPKGNKDYHLQTCCGSLAYRRR) SEQ ID NO: 2 and 10 μM ATP (spiked with 0.25 μCi 33P-ATP/well) are incubated in a total volume of 50 μl (10 mM MOPS, 10 mM Mg-acetat, 0.1 mM EGTA, 1 mM DTT, 0.02% Brij35, 0.1% BSA, pH 7.5) with or without test compound for 120 Min at 30° C. The reaction is stopped with 25 μl 200 mM EDTA. After 30 Min at room temperature the liquid is removed and each well washed thrice with 100 μl 0.9% sodium chloride solution. Nonspecific reaction is determined in presence of 100 nM Staurosporine. Radioactivity is measured in a Topcount (PerkinElmer).	B	CN1CCN(Cc2ccc(C(=O)Nc3sc(-c4ccncc4C(F)(F)F)nc3C(N)=O)cc2)CC1		CHEMBL3901254	=	IC50	nM	1400.0	CHEMBL5408	Homo sapiens	IC50	nM	1400.0
363259	17738634	CHEMBL3887915	TBK1 Enzyme Assay: The kinase assay is performed as 384-well Flashplate assay assay (for e.g. Topcount measurement. 0.6 nM TANK binding kinase (TBK1), 800 nM biotinylated MELK-derived peptide (Biotin-Ah-Ah-AKPKGNKDYHLQTCCGSLAYRRR) SEQ ID NO: 2 and 10 μM ATP (spiked with 0.25 μCi 33P-ATP/well) are incubated in a total volume of 50 μl (10 mM MOPS, 10 mM Mg-acetat, 0.1 mM EGTA, 1 mM DTT, 0.02% Brij35, 0.1% BSA, pH 7.5) with or without test compound for 120 Min at 30° C. The reaction is stopped with 25 μl 200 mM EDTA. After 30 Min at room temperature the liquid is removed and each well washed thrice with 100 μl 0.9% sodium chloride solution. Nonspecific reaction is determined in presence of 100 nM Staurosporine. Radioactivity is measured in a Topcount (PerkinElmer).	B	CN1CCN(Cc2ccc(C(=O)Nc3sc(-c4ccncc4Br)nc3C(N)=O)cc2)CC1		CHEMBL3913460	=	IC50	nM	310.0	CHEMBL5408	Homo sapiens	IC50	nM	310.0
363260	17738635	CHEMBL3887915	TBK1 Enzyme Assay: The kinase assay is performed as 384-well Flashplate assay assay (for e.g. Topcount measurement. 0.6 nM TANK binding kinase (TBK1), 800 nM biotinylated MELK-derived peptide (Biotin-Ah-Ah-AKPKGNKDYHLQTCCGSLAYRRR) SEQ ID NO: 2 and 10 μM ATP (spiked with 0.25 μCi 33P-ATP/well) are incubated in a total volume of 50 μl (10 mM MOPS, 10 mM Mg-acetat, 0.1 mM EGTA, 1 mM DTT, 0.02% Brij35, 0.1% BSA, pH 7.5) with or without test compound for 120 Min at 30° C. The reaction is stopped with 25 μl 200 mM EDTA. After 30 Min at room temperature the liquid is removed and each well washed thrice with 100 μl 0.9% sodium chloride solution. Nonspecific reaction is determined in presence of 100 nM Staurosporine. Radioactivity is measured in a Topcount (PerkinElmer).	B	CN1CCN(Cc2ccc(C(=O)Nc3sc(-c4ccncc4F)nc3C(N)=O)cc2)CC1		CHEMBL3944901	=	IC50	nM	370.0	CHEMBL5408	Homo sapiens	IC50	nM	370.0
363261	17738636	CHEMBL3887915	TBK1 Enzyme Assay: The kinase assay is performed as 384-well Flashplate assay assay (for e.g. Topcount measurement. 0.6 nM TANK binding kinase (TBK1), 800 nM biotinylated MELK-derived peptide (Biotin-Ah-Ah-AKPKGNKDYHLQTCCGSLAYRRR) SEQ ID NO: 2 and 10 μM ATP (spiked with 0.25 μCi 33P-ATP/well) are incubated in a total volume of 50 μl (10 mM MOPS, 10 mM Mg-acetat, 0.1 mM EGTA, 1 mM DTT, 0.02% Brij35, 0.1% BSA, pH 7.5) with or without test compound for 120 Min at 30° C. The reaction is stopped with 25 μl 200 mM EDTA. After 30 Min at room temperature the liquid is removed and each well washed thrice with 100 μl 0.9% sodium chloride solution. Nonspecific reaction is determined in presence of 100 nM Staurosporine. Radioactivity is measured in a Topcount (PerkinElmer).	B	CN1CCN(Cc2ccc(C(=O)Nc3sc(-c4ccncc4Cl)nc3C(N)=O)cc2)CC1		CHEMBL3922448	=	IC50	nM	640.0	CHEMBL5408	Homo sapiens	IC50	nM	640.0
363262	17738637	CHEMBL3887915	TBK1 Enzyme Assay: The kinase assay is performed as 384-well Flashplate assay assay (for e.g. Topcount measurement. 0.6 nM TANK binding kinase (TBK1), 800 nM biotinylated MELK-derived peptide (Biotin-Ah-Ah-AKPKGNKDYHLQTCCGSLAYRRR) SEQ ID NO: 2 and 10 μM ATP (spiked with 0.25 μCi 33P-ATP/well) are incubated in a total volume of 50 μl (10 mM MOPS, 10 mM Mg-acetat, 0.1 mM EGTA, 1 mM DTT, 0.02% Brij35, 0.1% BSA, pH 7.5) with or without test compound for 120 Min at 30° C. The reaction is stopped with 25 μl 200 mM EDTA. After 30 Min at room temperature the liquid is removed and each well washed thrice with 100 μl 0.9% sodium chloride solution. Nonspecific reaction is determined in presence of 100 nM Staurosporine. Radioactivity is measured in a Topcount (PerkinElmer).	B	COc1cnccc1-c1nc(C(N)=O)c(NC(=O)c2ccc(CN3CCN(C)CC3)cc2)s1		CHEMBL3950168	=	IC50	nM	46.0	CHEMBL5408	Homo sapiens	IC50	nM	46.0
363263	17738638	CHEMBL3887915	TBK1 Enzyme Assay: The kinase assay is performed as 384-well Flashplate assay assay (for e.g. Topcount measurement. 0.6 nM TANK binding kinase (TBK1), 800 nM biotinylated MELK-derived peptide (Biotin-Ah-Ah-AKPKGNKDYHLQTCCGSLAYRRR) SEQ ID NO: 2 and 10 μM ATP (spiked with 0.25 μCi 33P-ATP/well) are incubated in a total volume of 50 μl (10 mM MOPS, 10 mM Mg-acetat, 0.1 mM EGTA, 1 mM DTT, 0.02% Brij35, 0.1% BSA, pH 7.5) with or without test compound for 120 Min at 30° C. The reaction is stopped with 25 μl 200 mM EDTA. After 30 Min at room temperature the liquid is removed and each well washed thrice with 100 μl 0.9% sodium chloride solution. Nonspecific reaction is determined in presence of 100 nM Staurosporine. Radioactivity is measured in a Topcount (PerkinElmer).	B	Cc1cnccc1-c1nc(C(N)=O)c(NC(=O)c2ccc(CN3CCN(C)CC3)cc2)s1		CHEMBL3934866	=	IC50	nM	350.0	CHEMBL5408	Homo sapiens	IC50	nM	350.0
363264	17738639	CHEMBL3887915	TBK1 Enzyme Assay: The kinase assay is performed as 384-well Flashplate assay assay (for e.g. Topcount measurement. 0.6 nM TANK binding kinase (TBK1), 800 nM biotinylated MELK-derived peptide (Biotin-Ah-Ah-AKPKGNKDYHLQTCCGSLAYRRR) SEQ ID NO: 2 and 10 μM ATP (spiked with 0.25 μCi 33P-ATP/well) are incubated in a total volume of 50 μl (10 mM MOPS, 10 mM Mg-acetat, 0.1 mM EGTA, 1 mM DTT, 0.02% Brij35, 0.1% BSA, pH 7.5) with or without test compound for 120 Min at 30° C. The reaction is stopped with 25 μl 200 mM EDTA. After 30 Min at room temperature the liquid is removed and each well washed thrice with 100 μl 0.9% sodium chloride solution. Nonspecific reaction is determined in presence of 100 nM Staurosporine. Radioactivity is measured in a Topcount (PerkinElmer).	B	NC(=O)c1nc(-c2ccncc2)sc1NC(=O)c1ccc(CC2CCN(C(N)=O)CC2)cc1		CHEMBL3958876	=	IC50	nM	94.0	CHEMBL5408	Homo sapiens	IC50	nM	94.0
363265	17738640	CHEMBL3887915	TBK1 Enzyme Assay: The kinase assay is performed as 384-well Flashplate assay assay (for e.g. Topcount measurement. 0.6 nM TANK binding kinase (TBK1), 800 nM biotinylated MELK-derived peptide (Biotin-Ah-Ah-AKPKGNKDYHLQTCCGSLAYRRR) SEQ ID NO: 2 and 10 μM ATP (spiked with 0.25 μCi 33P-ATP/well) are incubated in a total volume of 50 μl (10 mM MOPS, 10 mM Mg-acetat, 0.1 mM EGTA, 1 mM DTT, 0.02% Brij35, 0.1% BSA, pH 7.5) with or without test compound for 120 Min at 30° C. The reaction is stopped with 25 μl 200 mM EDTA. After 30 Min at room temperature the liquid is removed and each well washed thrice with 100 μl 0.9% sodium chloride solution. Nonspecific reaction is determined in presence of 100 nM Staurosporine. Radioactivity is measured in a Topcount (PerkinElmer).	B	NC(=O)c1nc(-c2ccncc2)sc1NC(=O)c1ccc(CN2CCNCC2)cc1		CHEMBL3923270	=	IC50	nM	95.0	CHEMBL5408	Homo sapiens	IC50	nM	95.0
363266	17738641	CHEMBL3887915	TBK1 Enzyme Assay: The kinase assay is performed as 384-well Flashplate assay assay (for e.g. Topcount measurement. 0.6 nM TANK binding kinase (TBK1), 800 nM biotinylated MELK-derived peptide (Biotin-Ah-Ah-AKPKGNKDYHLQTCCGSLAYRRR) SEQ ID NO: 2 and 10 μM ATP (spiked with 0.25 μCi 33P-ATP/well) are incubated in a total volume of 50 μl (10 mM MOPS, 10 mM Mg-acetat, 0.1 mM EGTA, 1 mM DTT, 0.02% Brij35, 0.1% BSA, pH 7.5) with or without test compound for 120 Min at 30° C. The reaction is stopped with 25 μl 200 mM EDTA. After 30 Min at room temperature the liquid is removed and each well washed thrice with 100 μl 0.9% sodium chloride solution. Nonspecific reaction is determined in presence of 100 nM Staurosporine. Radioactivity is measured in a Topcount (PerkinElmer).	B	CN(C)C(=O)CCCCc1ccc(C(=O)Nc2sc(-c3ccncc3)nc2C(N)=O)cc1		CHEMBL3896126	=	IC50	nM	99.0	CHEMBL5408	Homo sapiens	IC50	nM	99.0
363267	17738642	CHEMBL3887915	TBK1 Enzyme Assay: The kinase assay is performed as 384-well Flashplate assay assay (for e.g. Topcount measurement. 0.6 nM TANK binding kinase (TBK1), 800 nM biotinylated MELK-derived peptide (Biotin-Ah-Ah-AKPKGNKDYHLQTCCGSLAYRRR) SEQ ID NO: 2 and 10 μM ATP (spiked with 0.25 μCi 33P-ATP/well) are incubated in a total volume of 50 μl (10 mM MOPS, 10 mM Mg-acetat, 0.1 mM EGTA, 1 mM DTT, 0.02% Brij35, 0.1% BSA, pH 7.5) with or without test compound for 120 Min at 30° C. The reaction is stopped with 25 μl 200 mM EDTA. After 30 Min at room temperature the liquid is removed and each well washed thrice with 100 μl 0.9% sodium chloride solution. Nonspecific reaction is determined in presence of 100 nM Staurosporine. Radioactivity is measured in a Topcount (PerkinElmer).	B	CN1CCC(Cc2ccc(C(=O)Nc3sc(-c4ccncc4)nc3C(N)=O)cc2)CC1		CHEMBL3943590	=	IC50	nM	100.0	CHEMBL5408	Homo sapiens	IC50	nM	100.0
363268	17738643	CHEMBL3887915	TBK1 Enzyme Assay: The kinase assay is performed as 384-well Flashplate assay assay (for e.g. Topcount measurement. 0.6 nM TANK binding kinase (TBK1), 800 nM biotinylated MELK-derived peptide (Biotin-Ah-Ah-AKPKGNKDYHLQTCCGSLAYRRR) SEQ ID NO: 2 and 10 μM ATP (spiked with 0.25 μCi 33P-ATP/well) are incubated in a total volume of 50 μl (10 mM MOPS, 10 mM Mg-acetat, 0.1 mM EGTA, 1 mM DTT, 0.02% Brij35, 0.1% BSA, pH 7.5) with or without test compound for 120 Min at 30° C. The reaction is stopped with 25 μl 200 mM EDTA. After 30 Min at room temperature the liquid is removed and each well washed thrice with 100 μl 0.9% sodium chloride solution. Nonspecific reaction is determined in presence of 100 nM Staurosporine. Radioactivity is measured in a Topcount (PerkinElmer).	B	CC(=O)N1CCN(Cc2ccc(C(=O)Nc3sc(-c4ccncc4)nc3C(N)=O)cc2)CC1		CHEMBL3973084	=	IC50	nM	140.0	CHEMBL5408	Homo sapiens	IC50	nM	140.0
363269	17738644	CHEMBL3887915	TBK1 Enzyme Assay: The kinase assay is performed as 384-well Flashplate assay assay (for e.g. Topcount measurement. 0.6 nM TANK binding kinase (TBK1), 800 nM biotinylated MELK-derived peptide (Biotin-Ah-Ah-AKPKGNKDYHLQTCCGSLAYRRR) SEQ ID NO: 2 and 10 μM ATP (spiked with 0.25 μCi 33P-ATP/well) are incubated in a total volume of 50 μl (10 mM MOPS, 10 mM Mg-acetat, 0.1 mM EGTA, 1 mM DTT, 0.02% Brij35, 0.1% BSA, pH 7.5) with or without test compound for 120 Min at 30° C. The reaction is stopped with 25 μl 200 mM EDTA. After 30 Min at room temperature the liquid is removed and each well washed thrice with 100 μl 0.9% sodium chloride solution. Nonspecific reaction is determined in presence of 100 nM Staurosporine. Radioactivity is measured in a Topcount (PerkinElmer).	B	NC(=O)c1nc(-c2ccncc2)sc1NC(=O)c1ccc(CCCCCC(=O)O)cc1		CHEMBL3955705	=	IC50	nM	160.0	CHEMBL5408	Homo sapiens	IC50	nM	160.0
363270	17738645	CHEMBL3887915	TBK1 Enzyme Assay: The kinase assay is performed as 384-well Flashplate assay assay (for e.g. Topcount measurement. 0.6 nM TANK binding kinase (TBK1), 800 nM biotinylated MELK-derived peptide (Biotin-Ah-Ah-AKPKGNKDYHLQTCCGSLAYRRR) SEQ ID NO: 2 and 10 μM ATP (spiked with 0.25 μCi 33P-ATP/well) are incubated in a total volume of 50 μl (10 mM MOPS, 10 mM Mg-acetat, 0.1 mM EGTA, 1 mM DTT, 0.02% Brij35, 0.1% BSA, pH 7.5) with or without test compound for 120 Min at 30° C. The reaction is stopped with 25 μl 200 mM EDTA. After 30 Min at room temperature the liquid is removed and each well washed thrice with 100 μl 0.9% sodium chloride solution. Nonspecific reaction is determined in presence of 100 nM Staurosporine. Radioactivity is measured in a Topcount (PerkinElmer).	B	NC(=O)c1nc(-c2ccncc2)sc1NC(=O)c1ccc(CC2CCNCC2)cc1		CHEMBL3981105	=	IC50	nM	190.0	CHEMBL5408	Homo sapiens	IC50	nM	190.0
363271	17738646	CHEMBL3887915	TBK1 Enzyme Assay: The kinase assay is performed as 384-well Flashplate assay assay (for e.g. Topcount measurement. 0.6 nM TANK binding kinase (TBK1), 800 nM biotinylated MELK-derived peptide (Biotin-Ah-Ah-AKPKGNKDYHLQTCCGSLAYRRR) SEQ ID NO: 2 and 10 μM ATP (spiked with 0.25 μCi 33P-ATP/well) are incubated in a total volume of 50 μl (10 mM MOPS, 10 mM Mg-acetat, 0.1 mM EGTA, 1 mM DTT, 0.02% Brij35, 0.1% BSA, pH 7.5) with or without test compound for 120 Min at 30° C. The reaction is stopped with 25 μl 200 mM EDTA. After 30 Min at room temperature the liquid is removed and each well washed thrice with 100 μl 0.9% sodium chloride solution. Nonspecific reaction is determined in presence of 100 nM Staurosporine. Radioactivity is measured in a Topcount (PerkinElmer).	B	CC(=O)N1CCC(Cc2ccc(C(=O)Nc3sc(-c4ccncc4)nc3C(N)=O)cc2)CC1		CHEMBL3929152	=	IC50	nM	200.0	CHEMBL5408	Homo sapiens	IC50	nM	200.0
363272	17738647	CHEMBL3887915	TBK1 Enzyme Assay: The kinase assay is performed as 384-well Flashplate assay assay (for e.g. Topcount measurement. 0.6 nM TANK binding kinase (TBK1), 800 nM biotinylated MELK-derived peptide (Biotin-Ah-Ah-AKPKGNKDYHLQTCCGSLAYRRR) SEQ ID NO: 2 and 10 μM ATP (spiked with 0.25 μCi 33P-ATP/well) are incubated in a total volume of 50 μl (10 mM MOPS, 10 mM Mg-acetat, 0.1 mM EGTA, 1 mM DTT, 0.02% Brij35, 0.1% BSA, pH 7.5) with or without test compound for 120 Min at 30° C. The reaction is stopped with 25 μl 200 mM EDTA. After 30 Min at room temperature the liquid is removed and each well washed thrice with 100 μl 0.9% sodium chloride solution. Nonspecific reaction is determined in presence of 100 nM Staurosporine. Radioactivity is measured in a Topcount (PerkinElmer).	B	CN(C)CCNCc1ccc(C(=O)Nc2sc(-c3ccncc3)nc2C(N)=O)cc1		CHEMBL3956700	=	IC50	nM	210.0	CHEMBL5408	Homo sapiens	IC50	nM	210.0
363273	17738648	CHEMBL3887915	TBK1 Enzyme Assay: The kinase assay is performed as 384-well Flashplate assay assay (for e.g. Topcount measurement. 0.6 nM TANK binding kinase (TBK1), 800 nM biotinylated MELK-derived peptide (Biotin-Ah-Ah-AKPKGNKDYHLQTCCGSLAYRRR) SEQ ID NO: 2 and 10 μM ATP (spiked with 0.25 μCi 33P-ATP/well) are incubated in a total volume of 50 μl (10 mM MOPS, 10 mM Mg-acetat, 0.1 mM EGTA, 1 mM DTT, 0.02% Brij35, 0.1% BSA, pH 7.5) with or without test compound for 120 Min at 30° C. The reaction is stopped with 25 μl 200 mM EDTA. After 30 Min at room temperature the liquid is removed and each well washed thrice with 100 μl 0.9% sodium chloride solution. Nonspecific reaction is determined in presence of 100 nM Staurosporine. Radioactivity is measured in a Topcount (PerkinElmer).	B	CNC(=O)CCCCc1ccc(C(=O)Nc2sc(-c3ccncc3)nc2C(N)=O)cc1		CHEMBL3983696	=	IC50	nM	240.0	CHEMBL5408	Homo sapiens	IC50	nM	240.0
363274	17738649	CHEMBL3887915	TBK1 Enzyme Assay: The kinase assay is performed as 384-well Flashplate assay assay (for e.g. Topcount measurement. 0.6 nM TANK binding kinase (TBK1), 800 nM biotinylated MELK-derived peptide (Biotin-Ah-Ah-AKPKGNKDYHLQTCCGSLAYRRR) SEQ ID NO: 2 and 10 μM ATP (spiked with 0.25 μCi 33P-ATP/well) are incubated in a total volume of 50 μl (10 mM MOPS, 10 mM Mg-acetat, 0.1 mM EGTA, 1 mM DTT, 0.02% Brij35, 0.1% BSA, pH 7.5) with or without test compound for 120 Min at 30° C. The reaction is stopped with 25 μl 200 mM EDTA. After 30 Min at room temperature the liquid is removed and each well washed thrice with 100 μl 0.9% sodium chloride solution. Nonspecific reaction is determined in presence of 100 nM Staurosporine. Radioactivity is measured in a Topcount (PerkinElmer).	B	COCCNCc1ccc(C(=O)Nc2sc(-c3ccncc3)nc2C(N)=O)cc1		CHEMBL3951517	=	IC50	nM	260.0	CHEMBL5408	Homo sapiens	IC50	nM	260.0
363275	17738650	CHEMBL3887915	TBK1 Enzyme Assay: The kinase assay is performed as 384-well Flashplate assay assay (for e.g. Topcount measurement. 0.6 nM TANK binding kinase (TBK1), 800 nM biotinylated MELK-derived peptide (Biotin-Ah-Ah-AKPKGNKDYHLQTCCGSLAYRRR) SEQ ID NO: 2 and 10 μM ATP (spiked with 0.25 μCi 33P-ATP/well) are incubated in a total volume of 50 μl (10 mM MOPS, 10 mM Mg-acetat, 0.1 mM EGTA, 1 mM DTT, 0.02% Brij35, 0.1% BSA, pH 7.5) with or without test compound for 120 Min at 30° C. The reaction is stopped with 25 μl 200 mM EDTA. After 30 Min at room temperature the liquid is removed and each well washed thrice with 100 μl 0.9% sodium chloride solution. Nonspecific reaction is determined in presence of 100 nM Staurosporine. Radioactivity is measured in a Topcount (PerkinElmer).	B	CN1CCN(C(=O)c2ccc(C(=O)Nc3sc(-c4ccncc4)nc3C(N)=O)cc2)CC1		CHEMBL3951104	=	IC50	nM	310.0	CHEMBL5408	Homo sapiens	IC50	nM	310.0
363276	17738651	CHEMBL3887915	TBK1 Enzyme Assay: The kinase assay is performed as 384-well Flashplate assay assay (for e.g. Topcount measurement. 0.6 nM TANK binding kinase (TBK1), 800 nM biotinylated MELK-derived peptide (Biotin-Ah-Ah-AKPKGNKDYHLQTCCGSLAYRRR) SEQ ID NO: 2 and 10 μM ATP (spiked with 0.25 μCi 33P-ATP/well) are incubated in a total volume of 50 μl (10 mM MOPS, 10 mM Mg-acetat, 0.1 mM EGTA, 1 mM DTT, 0.02% Brij35, 0.1% BSA, pH 7.5) with or without test compound for 120 Min at 30° C. The reaction is stopped with 25 μl 200 mM EDTA. After 30 Min at room temperature the liquid is removed and each well washed thrice with 100 μl 0.9% sodium chloride solution. Nonspecific reaction is determined in presence of 100 nM Staurosporine. Radioactivity is measured in a Topcount (PerkinElmer).	B	CN(C)C(=O)CCCCCc1ccc(C(=O)Nc2sc(-c3ccncc3)nc2C(N)=O)cc1		CHEMBL3980051	=	IC50	nM	580.0	CHEMBL5408	Homo sapiens	IC50	nM	580.0
363277	17738652	CHEMBL3887915	TBK1 Enzyme Assay: The kinase assay is performed as 384-well Flashplate assay assay (for e.g. Topcount measurement. 0.6 nM TANK binding kinase (TBK1), 800 nM biotinylated MELK-derived peptide (Biotin-Ah-Ah-AKPKGNKDYHLQTCCGSLAYRRR) SEQ ID NO: 2 and 10 μM ATP (spiked with 0.25 μCi 33P-ATP/well) are incubated in a total volume of 50 μl (10 mM MOPS, 10 mM Mg-acetat, 0.1 mM EGTA, 1 mM DTT, 0.02% Brij35, 0.1% BSA, pH 7.5) with or without test compound for 120 Min at 30° C. The reaction is stopped with 25 μl 200 mM EDTA. After 30 Min at room temperature the liquid is removed and each well washed thrice with 100 μl 0.9% sodium chloride solution. Nonspecific reaction is determined in presence of 100 nM Staurosporine. Radioactivity is measured in a Topcount (PerkinElmer).	B	NC(=O)c1nc(-c2ccncc2)sc1NC(=O)c1ccc(CN2CCOCC2)cc1		CHEMBL3946038	=	IC50	nM	645.0	CHEMBL5408	Homo sapiens	IC50	nM	645.0
363278	17738653	CHEMBL3887915	TBK1 Enzyme Assay: The kinase assay is performed as 384-well Flashplate assay assay (for e.g. Topcount measurement. 0.6 nM TANK binding kinase (TBK1), 800 nM biotinylated MELK-derived peptide (Biotin-Ah-Ah-AKPKGNKDYHLQTCCGSLAYRRR) SEQ ID NO: 2 and 10 μM ATP (spiked with 0.25 μCi 33P-ATP/well) are incubated in a total volume of 50 μl (10 mM MOPS, 10 mM Mg-acetat, 0.1 mM EGTA, 1 mM DTT, 0.02% Brij35, 0.1% BSA, pH 7.5) with or without test compound for 120 Min at 30° C. The reaction is stopped with 25 μl 200 mM EDTA. After 30 Min at room temperature the liquid is removed and each well washed thrice with 100 μl 0.9% sodium chloride solution. Nonspecific reaction is determined in presence of 100 nM Staurosporine. Radioactivity is measured in a Topcount (PerkinElmer).	B	CN1CCN(Cc2ccc(C(=O)Nc3sc(-c4ccncc4)nc3C(N)=O)cc2)CC1		CHEMBL3906947	=	IC50	nM	710.0	CHEMBL5408	Homo sapiens	IC50	nM	710.0
363279	17738654	CHEMBL3887915	TBK1 Enzyme Assay: The kinase assay is performed as 384-well Flashplate assay assay (for e.g. Topcount measurement. 0.6 nM TANK binding kinase (TBK1), 800 nM biotinylated MELK-derived peptide (Biotin-Ah-Ah-AKPKGNKDYHLQTCCGSLAYRRR) SEQ ID NO: 2 and 10 μM ATP (spiked with 0.25 μCi 33P-ATP/well) are incubated in a total volume of 50 μl (10 mM MOPS, 10 mM Mg-acetat, 0.1 mM EGTA, 1 mM DTT, 0.02% Brij35, 0.1% BSA, pH 7.5) with or without test compound for 120 Min at 30° C. The reaction is stopped with 25 μl 200 mM EDTA. After 30 Min at room temperature the liquid is removed and each well washed thrice with 100 μl 0.9% sodium chloride solution. Nonspecific reaction is determined in presence of 100 nM Staurosporine. Radioactivity is measured in a Topcount (PerkinElmer).	B	NC(=O)c1nc(-c2ccncc2)sc1NC(=O)c1ccc(CN2CCCC2)cc1		CHEMBL3967014	=	IC50	nM	1160.0	CHEMBL5408	Homo sapiens	IC50	nM	1160.0
363280	17738655	CHEMBL3887915	TBK1 Enzyme Assay: The kinase assay is performed as 384-well Flashplate assay assay (for e.g. Topcount measurement. 0.6 nM TANK binding kinase (TBK1), 800 nM biotinylated MELK-derived peptide (Biotin-Ah-Ah-AKPKGNKDYHLQTCCGSLAYRRR) SEQ ID NO: 2 and 10 μM ATP (spiked with 0.25 μCi 33P-ATP/well) are incubated in a total volume of 50 μl (10 mM MOPS, 10 mM Mg-acetat, 0.1 mM EGTA, 1 mM DTT, 0.02% Brij35, 0.1% BSA, pH 7.5) with or without test compound for 120 Min at 30° C. The reaction is stopped with 25 μl 200 mM EDTA. After 30 Min at room temperature the liquid is removed and each well washed thrice with 100 μl 0.9% sodium chloride solution. Nonspecific reaction is determined in presence of 100 nM Staurosporine. Radioactivity is measured in a Topcount (PerkinElmer).	B	CC(C)(C)OC(=O)N1CCN(c2ccc(C(=O)Nc3sc(-c4ccncc4)nc3C(N)=O)cn2)CC1		CHEMBL3937277	=	IC50	nM	1200.0	CHEMBL5408	Homo sapiens	IC50	nM	1200.0
363281	17738656	CHEMBL3887915	TBK1 Enzyme Assay: The kinase assay is performed as 384-well Flashplate assay assay (for e.g. Topcount measurement. 0.6 nM TANK binding kinase (TBK1), 800 nM biotinylated MELK-derived peptide (Biotin-Ah-Ah-AKPKGNKDYHLQTCCGSLAYRRR) SEQ ID NO: 2 and 10 μM ATP (spiked with 0.25 μCi 33P-ATP/well) are incubated in a total volume of 50 μl (10 mM MOPS, 10 mM Mg-acetat, 0.1 mM EGTA, 1 mM DTT, 0.02% Brij35, 0.1% BSA, pH 7.5) with or without test compound for 120 Min at 30° C. The reaction is stopped with 25 μl 200 mM EDTA. After 30 Min at room temperature the liquid is removed and each well washed thrice with 100 μl 0.9% sodium chloride solution. Nonspecific reaction is determined in presence of 100 nM Staurosporine. Radioactivity is measured in a Topcount (PerkinElmer).	B	CN(C)Cc1ccc(C(=O)Nc2sc(-c3ccncc3)nc2C(N)=O)cc1		CHEMBL3960048	=	IC50	nM	1250.0	CHEMBL5408	Homo sapiens	IC50	nM	1250.0
363282	17738657	CHEMBL3887915	TBK1 Enzyme Assay: The kinase assay is performed as 384-well Flashplate assay assay (for e.g. Topcount measurement. 0.6 nM TANK binding kinase (TBK1), 800 nM biotinylated MELK-derived peptide (Biotin-Ah-Ah-AKPKGNKDYHLQTCCGSLAYRRR) SEQ ID NO: 2 and 10 μM ATP (spiked with 0.25 μCi 33P-ATP/well) are incubated in a total volume of 50 μl (10 mM MOPS, 10 mM Mg-acetat, 0.1 mM EGTA, 1 mM DTT, 0.02% Brij35, 0.1% BSA, pH 7.5) with or without test compound for 120 Min at 30° C. The reaction is stopped with 25 μl 200 mM EDTA. After 30 Min at room temperature the liquid is removed and each well washed thrice with 100 μl 0.9% sodium chloride solution. Nonspecific reaction is determined in presence of 100 nM Staurosporine. Radioactivity is measured in a Topcount (PerkinElmer).	B	COc1ccc(C(=O)Nc2sc(-c3ccncc3)nc2C(N)=O)cc1OC		CHEMBL3936038	=	IC50	nM	1500.0	CHEMBL5408	Homo sapiens	IC50	nM	1500.0
363283	17738658	CHEMBL3887915	TBK1 Enzyme Assay: The kinase assay is performed as 384-well Flashplate assay assay (for e.g. Topcount measurement. 0.6 nM TANK binding kinase (TBK1), 800 nM biotinylated MELK-derived peptide (Biotin-Ah-Ah-AKPKGNKDYHLQTCCGSLAYRRR) SEQ ID NO: 2 and 10 μM ATP (spiked with 0.25 μCi 33P-ATP/well) are incubated in a total volume of 50 μl (10 mM MOPS, 10 mM Mg-acetat, 0.1 mM EGTA, 1 mM DTT, 0.02% Brij35, 0.1% BSA, pH 7.5) with or without test compound for 120 Min at 30° C. The reaction is stopped with 25 μl 200 mM EDTA. After 30 Min at room temperature the liquid is removed and each well washed thrice with 100 μl 0.9% sodium chloride solution. Nonspecific reaction is determined in presence of 100 nM Staurosporine. Radioactivity is measured in a Topcount (PerkinElmer).	B	NC(=O)c1nc(-c2ccncc2)sc1NC(=O)c1cn[nH]c1		CHEMBL3964075	=	IC50	nM	2700.0	CHEMBL5408	Homo sapiens	IC50	nM	2700.0
363284	17738659	CHEMBL3887915	TBK1 Enzyme Assay: The kinase assay is performed as 384-well Flashplate assay assay (for e.g. Topcount measurement. 0.6 nM TANK binding kinase (TBK1), 800 nM biotinylated MELK-derived peptide (Biotin-Ah-Ah-AKPKGNKDYHLQTCCGSLAYRRR) SEQ ID NO: 2 and 10 μM ATP (spiked with 0.25 μCi 33P-ATP/well) are incubated in a total volume of 50 μl (10 mM MOPS, 10 mM Mg-acetat, 0.1 mM EGTA, 1 mM DTT, 0.02% Brij35, 0.1% BSA, pH 7.5) with or without test compound for 120 Min at 30° C. The reaction is stopped with 25 μl 200 mM EDTA. After 30 Min at room temperature the liquid is removed and each well washed thrice with 100 μl 0.9% sodium chloride solution. Nonspecific reaction is determined in presence of 100 nM Staurosporine. Radioactivity is measured in a Topcount (PerkinElmer).	B	NC(=O)c1nc(-c2ccncc2)sc1NC(=O)c1ccc(N2CCOCC2)nc1		CHEMBL3923590	=	IC50	nM	7300.0	CHEMBL5408	Homo sapiens	IC50	nM	7300.0
363285	17738660	CHEMBL3887915	TBK1 Enzyme Assay: The kinase assay is performed as 384-well Flashplate assay assay (for e.g. Topcount measurement. 0.6 nM TANK binding kinase (TBK1), 800 nM biotinylated MELK-derived peptide (Biotin-Ah-Ah-AKPKGNKDYHLQTCCGSLAYRRR) SEQ ID NO: 2 and 10 μM ATP (spiked with 0.25 μCi 33P-ATP/well) are incubated in a total volume of 50 μl (10 mM MOPS, 10 mM Mg-acetat, 0.1 mM EGTA, 1 mM DTT, 0.02% Brij35, 0.1% BSA, pH 7.5) with or without test compound for 120 Min at 30° C. The reaction is stopped with 25 μl 200 mM EDTA. After 30 Min at room temperature the liquid is removed and each well washed thrice with 100 μl 0.9% sodium chloride solution. Nonspecific reaction is determined in presence of 100 nM Staurosporine. Radioactivity is measured in a Topcount (PerkinElmer).	B	NC(=O)c1nc(-c2ccncc2)sc1NC(=O)c1cnn(CC2CCNCC2)c1		CHEMBL3890128	=	IC50	nM	7900.0	CHEMBL5408	Homo sapiens	IC50	nM	7900.0
363286	17738661	CHEMBL3887915	TBK1 Enzyme Assay: The kinase assay is performed as 384-well Flashplate assay assay (for e.g. Topcount measurement. 0.6 nM TANK binding kinase (TBK1), 800 nM biotinylated MELK-derived peptide (Biotin-Ah-Ah-AKPKGNKDYHLQTCCGSLAYRRR) SEQ ID NO: 2 and 10 μM ATP (spiked with 0.25 μCi 33P-ATP/well) are incubated in a total volume of 50 μl (10 mM MOPS, 10 mM Mg-acetat, 0.1 mM EGTA, 1 mM DTT, 0.02% Brij35, 0.1% BSA, pH 7.5) with or without test compound for 120 Min at 30° C. The reaction is stopped with 25 μl 200 mM EDTA. After 30 Min at room temperature the liquid is removed and each well washed thrice with 100 μl 0.9% sodium chloride solution. Nonspecific reaction is determined in presence of 100 nM Staurosporine. Radioactivity is measured in a Topcount (PerkinElmer).	B	CN1CCN(Cc2ccc(C(=O)Nc3sc(-c4ccncc4)nc3C#N)cc2)CC1		CHEMBL3896182	=	IC50	nM	8200.0	CHEMBL5408	Homo sapiens	IC50	nM	8200.0
363287	17738662	CHEMBL3887915	TBK1 Enzyme Assay: The kinase assay is performed as 384-well Flashplate assay assay (for e.g. Topcount measurement. 0.6 nM TANK binding kinase (TBK1), 800 nM biotinylated MELK-derived peptide (Biotin-Ah-Ah-AKPKGNKDYHLQTCCGSLAYRRR) SEQ ID NO: 2 and 10 μM ATP (spiked with 0.25 μCi 33P-ATP/well) are incubated in a total volume of 50 μl (10 mM MOPS, 10 mM Mg-acetat, 0.1 mM EGTA, 1 mM DTT, 0.02% Brij35, 0.1% BSA, pH 7.5) with or without test compound for 120 Min at 30° C. The reaction is stopped with 25 μl 200 mM EDTA. After 30 Min at room temperature the liquid is removed and each well washed thrice with 100 μl 0.9% sodium chloride solution. Nonspecific reaction is determined in presence of 100 nM Staurosporine. Radioactivity is measured in a Topcount (PerkinElmer).	B	Cc1ccc(C(=O)Nc2sc(-c3ccncc3)nc2C(N)=O)cc1		CHEMBL3956718	=	IC50	nM	10000.0	CHEMBL5408	Homo sapiens	IC50	nM	10000.0
363288	17738663	CHEMBL3887915	TBK1 Enzyme Assay: The kinase assay is performed as 384-well Flashplate assay assay (for e.g. Topcount measurement. 0.6 nM TANK binding kinase (TBK1), 800 nM biotinylated MELK-derived peptide (Biotin-Ah-Ah-AKPKGNKDYHLQTCCGSLAYRRR) SEQ ID NO: 2 and 10 μM ATP (spiked with 0.25 μCi 33P-ATP/well) are incubated in a total volume of 50 μl (10 mM MOPS, 10 mM Mg-acetat, 0.1 mM EGTA, 1 mM DTT, 0.02% Brij35, 0.1% BSA, pH 7.5) with or without test compound for 120 Min at 30° C. The reaction is stopped with 25 μl 200 mM EDTA. After 30 Min at room temperature the liquid is removed and each well washed thrice with 100 μl 0.9% sodium chloride solution. Nonspecific reaction is determined in presence of 100 nM Staurosporine. Radioactivity is measured in a Topcount (PerkinElmer).	B	NC(=O)c1nc(-c2ccncc2)sc1NC(=O)c1ccccc1		CHEMBL3947554	=	IC50	nM	3600.0	CHEMBL5408	Homo sapiens	IC50	nM	3600.0
363289	17738664	CHEMBL3887915	TBK1 Enzyme Assay: The kinase assay is performed as 384-well Flashplate assay assay (for e.g. Topcount measurement. 0.6 nM TANK binding kinase (TBK1), 800 nM biotinylated MELK-derived peptide (Biotin-Ah-Ah-AKPKGNKDYHLQTCCGSLAYRRR) SEQ ID NO: 2 and 10 μM ATP (spiked with 0.25 μCi 33P-ATP/well) are incubated in a total volume of 50 μl (10 mM MOPS, 10 mM Mg-acetat, 0.1 mM EGTA, 1 mM DTT, 0.02% Brij35, 0.1% BSA, pH 7.5) with or without test compound for 120 Min at 30° C. The reaction is stopped with 25 μl 200 mM EDTA. After 30 Min at room temperature the liquid is removed and each well washed thrice with 100 μl 0.9% sodium chloride solution. Nonspecific reaction is determined in presence of 100 nM Staurosporine. Radioactivity is measured in a Topcount (PerkinElmer).	B	CN(C)c1ccc(C(=O)Nc2sc(-c3ccncc3)nc2C(N)=O)cc1		CHEMBL3919767	=	IC50	nM	1800.0	CHEMBL5408	Homo sapiens	IC50	nM	1800.0
363290	17738665	CHEMBL3887915	TBK1 Enzyme Assay: The kinase assay is performed as 384-well Flashplate assay assay (for e.g. Topcount measurement. 0.6 nM TANK binding kinase (TBK1), 800 nM biotinylated MELK-derived peptide (Biotin-Ah-Ah-AKPKGNKDYHLQTCCGSLAYRRR) SEQ ID NO: 2 and 10 μM ATP (spiked with 0.25 μCi 33P-ATP/well) are incubated in a total volume of 50 μl (10 mM MOPS, 10 mM Mg-acetat, 0.1 mM EGTA, 1 mM DTT, 0.02% Brij35, 0.1% BSA, pH 7.5) with or without test compound for 120 Min at 30° C. The reaction is stopped with 25 μl 200 mM EDTA. After 30 Min at room temperature the liquid is removed and each well washed thrice with 100 μl 0.9% sodium chloride solution. Nonspecific reaction is determined in presence of 100 nM Staurosporine. Radioactivity is measured in a Topcount (PerkinElmer).	B	NC(=O)c1nc(-c2ccncc2)sc1NC(=O)c1ccc(N)cc1		CHEMBL3956252	=	IC50	nM	110.0	CHEMBL5408	Homo sapiens	IC50	nM	110.0
363291	17738666	CHEMBL3887915	TBK1 Enzyme Assay: The kinase assay is performed as 384-well Flashplate assay assay (for e.g. Topcount measurement. 0.6 nM TANK binding kinase (TBK1), 800 nM biotinylated MELK-derived peptide (Biotin-Ah-Ah-AKPKGNKDYHLQTCCGSLAYRRR) SEQ ID NO: 2 and 10 μM ATP (spiked with 0.25 μCi 33P-ATP/well) are incubated in a total volume of 50 μl (10 mM MOPS, 10 mM Mg-acetat, 0.1 mM EGTA, 1 mM DTT, 0.02% Brij35, 0.1% BSA, pH 7.5) with or without test compound for 120 Min at 30° C. The reaction is stopped with 25 μl 200 mM EDTA. After 30 Min at room temperature the liquid is removed and each well washed thrice with 100 μl 0.9% sodium chloride solution. Nonspecific reaction is determined in presence of 100 nM Staurosporine. Radioactivity is measured in a Topcount (PerkinElmer).	B	Cn1cccc1C(=O)Nc1sc(-c2ccncc2)nc1C(N)=O		CHEMBL3925224	=	IC50	nM	400.0	CHEMBL5408	Homo sapiens	IC50	nM	400.0
363292	17738667	CHEMBL3887915	TBK1 Enzyme Assay: The kinase assay is performed as 384-well Flashplate assay assay (for e.g. Topcount measurement. 0.6 nM TANK binding kinase (TBK1), 800 nM biotinylated MELK-derived peptide (Biotin-Ah-Ah-AKPKGNKDYHLQTCCGSLAYRRR) SEQ ID NO: 2 and 10 μM ATP (spiked with 0.25 μCi 33P-ATP/well) are incubated in a total volume of 50 μl (10 mM MOPS, 10 mM Mg-acetat, 0.1 mM EGTA, 1 mM DTT, 0.02% Brij35, 0.1% BSA, pH 7.5) with or without test compound for 120 Min at 30° C. The reaction is stopped with 25 μl 200 mM EDTA. After 30 Min at room temperature the liquid is removed and each well washed thrice with 100 μl 0.9% sodium chloride solution. Nonspecific reaction is determined in presence of 100 nM Staurosporine. Radioactivity is measured in a Topcount (PerkinElmer).	B	NC(=O)c1nc(-c2ccncc2)sc1NC(=O)c1ccco1		CHEMBL3935343	=	IC50	nM	3700.0	CHEMBL5408	Homo sapiens	IC50	nM	3700.0
363293	17738668	CHEMBL3887915	TBK1 Enzyme Assay: The kinase assay is performed as 384-well Flashplate assay assay (for e.g. Topcount measurement. 0.6 nM TANK binding kinase (TBK1), 800 nM biotinylated MELK-derived peptide (Biotin-Ah-Ah-AKPKGNKDYHLQTCCGSLAYRRR) SEQ ID NO: 2 and 10 μM ATP (spiked with 0.25 μCi 33P-ATP/well) are incubated in a total volume of 50 μl (10 mM MOPS, 10 mM Mg-acetat, 0.1 mM EGTA, 1 mM DTT, 0.02% Brij35, 0.1% BSA, pH 7.5) with or without test compound for 120 Min at 30° C. The reaction is stopped with 25 μl 200 mM EDTA. After 30 Min at room temperature the liquid is removed and each well washed thrice with 100 μl 0.9% sodium chloride solution. Nonspecific reaction is determined in presence of 100 nM Staurosporine. Radioactivity is measured in a Topcount (PerkinElmer).	B	NC(=O)c1nc(-c2ccncc2)sc1NC(=O)c1ccc[nH]1		CHEMBL3934112	=	IC50	nM	120.0	CHEMBL5408	Homo sapiens	IC50	nM	120.0
363294	17738669	CHEMBL3887915	TBK1 Enzyme Assay: The kinase assay is performed as 384-well Flashplate assay assay (for e.g. Topcount measurement. 0.6 nM TANK binding kinase (TBK1), 800 nM biotinylated MELK-derived peptide (Biotin-Ah-Ah-AKPKGNKDYHLQTCCGSLAYRRR) SEQ ID NO: 2 and 10 μM ATP (spiked with 0.25 μCi 33P-ATP/well) are incubated in a total volume of 50 μl (10 mM MOPS, 10 mM Mg-acetat, 0.1 mM EGTA, 1 mM DTT, 0.02% Brij35, 0.1% BSA, pH 7.5) with or without test compound for 120 Min at 30° C. The reaction is stopped with 25 μl 200 mM EDTA. After 30 Min at room temperature the liquid is removed and each well washed thrice with 100 μl 0.9% sodium chloride solution. Nonspecific reaction is determined in presence of 100 nM Staurosporine. Radioactivity is measured in a Topcount (PerkinElmer).	B	NC(=O)c1nc(-c2ccncc2)sc1NC(=O)c1cccs1		CHEMBL3972661	=	IC50	nM	2000.0	CHEMBL5408	Homo sapiens	IC50	nM	2000.0
363295	17738670	CHEMBL3887915	TBK1 Enzyme Assay: The kinase assay is performed as 384-well Flashplate assay assay (for e.g. Topcount measurement. 0.6 nM TANK binding kinase (TBK1), 800 nM biotinylated MELK-derived peptide (Biotin-Ah-Ah-AKPKGNKDYHLQTCCGSLAYRRR) SEQ ID NO: 2 and 10 μM ATP (spiked with 0.25 μCi 33P-ATP/well) are incubated in a total volume of 50 μl (10 mM MOPS, 10 mM Mg-acetat, 0.1 mM EGTA, 1 mM DTT, 0.02% Brij35, 0.1% BSA, pH 7.5) with or without test compound for 120 Min at 30° C. The reaction is stopped with 25 μl 200 mM EDTA. After 30 Min at room temperature the liquid is removed and each well washed thrice with 100 μl 0.9% sodium chloride solution. Nonspecific reaction is determined in presence of 100 nM Staurosporine. Radioactivity is measured in a Topcount (PerkinElmer).	B	NC(=O)c1nc(-c2ccncc2)sc1NC(=O)c1cc[nH]n1		CHEMBL3946536	=	IC50	nM	2700.0	CHEMBL5408	Homo sapiens	IC50	nM	2700.0
363296	17738671	CHEMBL3887915	TBK1 Enzyme Assay: The kinase assay is performed as 384-well Flashplate assay assay (for e.g. Topcount measurement. 0.6 nM TANK binding kinase (TBK1), 800 nM biotinylated MELK-derived peptide (Biotin-Ah-Ah-AKPKGNKDYHLQTCCGSLAYRRR) SEQ ID NO: 2 and 10 μM ATP (spiked with 0.25 μCi 33P-ATP/well) are incubated in a total volume of 50 μl (10 mM MOPS, 10 mM Mg-acetat, 0.1 mM EGTA, 1 mM DTT, 0.02% Brij35, 0.1% BSA, pH 7.5) with or without test compound for 120 Min at 30° C. The reaction is stopped with 25 μl 200 mM EDTA. After 30 Min at room temperature the liquid is removed and each well washed thrice with 100 μl 0.9% sodium chloride solution. Nonspecific reaction is determined in presence of 100 nM Staurosporine. Radioactivity is measured in a Topcount (PerkinElmer).	B	NC(=O)c1nc(-c2ccncc2)sc1NC(=O)c1ccoc1		CHEMBL3968170	=	IC50	nM	4600.0	CHEMBL5408	Homo sapiens	IC50	nM	4600.0
363297	17738672	CHEMBL3887915	TBK1 Enzyme Assay: The kinase assay is performed as 384-well Flashplate assay assay (for e.g. Topcount measurement. 0.6 nM TANK binding kinase (TBK1), 800 nM biotinylated MELK-derived peptide (Biotin-Ah-Ah-AKPKGNKDYHLQTCCGSLAYRRR) SEQ ID NO: 2 and 10 μM ATP (spiked with 0.25 μCi 33P-ATP/well) are incubated in a total volume of 50 μl (10 mM MOPS, 10 mM Mg-acetat, 0.1 mM EGTA, 1 mM DTT, 0.02% Brij35, 0.1% BSA, pH 7.5) with or without test compound for 120 Min at 30° C. The reaction is stopped with 25 μl 200 mM EDTA. After 30 Min at room temperature the liquid is removed and each well washed thrice with 100 μl 0.9% sodium chloride solution. Nonspecific reaction is determined in presence of 100 nM Staurosporine. Radioactivity is measured in a Topcount (PerkinElmer).	B	NC(=O)c1nc(-c2ccncc2)sc1NC(=O)c1ccsc1		CHEMBL3955236	=	IC50	nM	200.0	CHEMBL5408	Homo sapiens	IC50	nM	200.0
370531	17745315	CHEMBL3888070	TBK1 : The kinase assay is performed as 384-well Flashplate assay assay (for e.g. Topcount measurement. 0.6 nM TANK binding kinase (TBK1), 800 nM biotinylated MELK-derived peptide (Biotin-Ah-Ah-AKPKGNKDYHLQTCCGSLAYRRR) SEQ ID NO: 2 and 10 uM ATP (spiked with 0.25 uCi 33P-ATP/well) are incubated in a total volume of 50 ul (10 mM MOPS, 10 mM Mg-acetat, 0.1 mM EGTA, 1 mM DTT, 0.02% Brij35, 0.1% BSA, pH 7.5) with or without test compound for 120 Min at 30° C. The reaction is stopped with 25 ul 200 mM EDTA. After 30 Min at room temperature the liquid is removed and each well washed thrice with 100 ul 0.9% sodium chloride solution.	B	Nc1ncc(-c2ccc(CN3CCCCC3)s2)cc1C(=O)Nc1ccncc1		CHEMBL3961973	=	IC50	nM	390.0	CHEMBL5408	Homo sapiens	IC50	nM	390.0
370532	17745316	CHEMBL3888070	TBK1 : The kinase assay is performed as 384-well Flashplate assay assay (for e.g. Topcount measurement. 0.6 nM TANK binding kinase (TBK1), 800 nM biotinylated MELK-derived peptide (Biotin-Ah-Ah-AKPKGNKDYHLQTCCGSLAYRRR) SEQ ID NO: 2 and 10 uM ATP (spiked with 0.25 uCi 33P-ATP/well) are incubated in a total volume of 50 ul (10 mM MOPS, 10 mM Mg-acetat, 0.1 mM EGTA, 1 mM DTT, 0.02% Brij35, 0.1% BSA, pH 7.5) with or without test compound for 120 Min at 30° C. The reaction is stopped with 25 ul 200 mM EDTA. After 30 Min at room temperature the liquid is removed and each well washed thrice with 100 ul 0.9% sodium chloride solution.	B	Nc1ncc(-c2ccc(CN3CCCC3)s2)cc1C(=O)Nc1ccncc1		CHEMBL3924260	=	IC50	nM	130.0	CHEMBL5408	Homo sapiens	IC50	nM	130.0
370533	17745317	CHEMBL3888070	TBK1 : The kinase assay is performed as 384-well Flashplate assay assay (for e.g. Topcount measurement. 0.6 nM TANK binding kinase (TBK1), 800 nM biotinylated MELK-derived peptide (Biotin-Ah-Ah-AKPKGNKDYHLQTCCGSLAYRRR) SEQ ID NO: 2 and 10 uM ATP (spiked with 0.25 uCi 33P-ATP/well) are incubated in a total volume of 50 ul (10 mM MOPS, 10 mM Mg-acetat, 0.1 mM EGTA, 1 mM DTT, 0.02% Brij35, 0.1% BSA, pH 7.5) with or without test compound for 120 Min at 30° C. The reaction is stopped with 25 ul 200 mM EDTA. After 30 Min at room temperature the liquid is removed and each well washed thrice with 100 ul 0.9% sodium chloride solution.	B	Cc1ccc(-c2cnc(N)c(C(=O)Nc3ccncc3)c2)s1		CHEMBL3900950	=	IC50	nM	120.0	CHEMBL5408	Homo sapiens	IC50	nM	120.0
370534	17745318	CHEMBL3888070	TBK1 : The kinase assay is performed as 384-well Flashplate assay assay (for e.g. Topcount measurement. 0.6 nM TANK binding kinase (TBK1), 800 nM biotinylated MELK-derived peptide (Biotin-Ah-Ah-AKPKGNKDYHLQTCCGSLAYRRR) SEQ ID NO: 2 and 10 uM ATP (spiked with 0.25 uCi 33P-ATP/well) are incubated in a total volume of 50 ul (10 mM MOPS, 10 mM Mg-acetat, 0.1 mM EGTA, 1 mM DTT, 0.02% Brij35, 0.1% BSA, pH 7.5) with or without test compound for 120 Min at 30° C. The reaction is stopped with 25 ul 200 mM EDTA. After 30 Min at room temperature the liquid is removed and each well washed thrice with 100 ul 0.9% sodium chloride solution.	B	Nc1ncc(-c2cccc(-n3cccn3)c2)cc1C(=O)Nc1ccncc1		CHEMBL3928914	=	IC50	nM	400.0	CHEMBL5408	Homo sapiens	IC50	nM	400.0
370535	17745319	CHEMBL3888070	TBK1 : The kinase assay is performed as 384-well Flashplate assay assay (for e.g. Topcount measurement. 0.6 nM TANK binding kinase (TBK1), 800 nM biotinylated MELK-derived peptide (Biotin-Ah-Ah-AKPKGNKDYHLQTCCGSLAYRRR) SEQ ID NO: 2 and 10 uM ATP (spiked with 0.25 uCi 33P-ATP/well) are incubated in a total volume of 50 ul (10 mM MOPS, 10 mM Mg-acetat, 0.1 mM EGTA, 1 mM DTT, 0.02% Brij35, 0.1% BSA, pH 7.5) with or without test compound for 120 Min at 30° C. The reaction is stopped with 25 ul 200 mM EDTA. After 30 Min at room temperature the liquid is removed and each well washed thrice with 100 ul 0.9% sodium chloride solution.	B	Nc1ncc(-c2ccc(-n3cccn3)cc2)cc1C(=O)Nc1ccncc1		CHEMBL3906387	=	IC50	nM	120.0	CHEMBL5408	Homo sapiens	IC50	nM	120.0
370536	17745320	CHEMBL3888070	TBK1 : The kinase assay is performed as 384-well Flashplate assay assay (for e.g. Topcount measurement. 0.6 nM TANK binding kinase (TBK1), 800 nM biotinylated MELK-derived peptide (Biotin-Ah-Ah-AKPKGNKDYHLQTCCGSLAYRRR) SEQ ID NO: 2 and 10 uM ATP (spiked with 0.25 uCi 33P-ATP/well) are incubated in a total volume of 50 ul (10 mM MOPS, 10 mM Mg-acetat, 0.1 mM EGTA, 1 mM DTT, 0.02% Brij35, 0.1% BSA, pH 7.5) with or without test compound for 120 Min at 30° C. The reaction is stopped with 25 ul 200 mM EDTA. After 30 Min at room temperature the liquid is removed and each well washed thrice with 100 ul 0.9% sodium chloride solution.	B	COCCn1cc(-c2cnc(N)c(C(=O)Nc3ccncc3)c2)cn1		CHEMBL3937942	=	IC50	nM	67.0	CHEMBL5408	Homo sapiens	IC50	nM	67.0
370537	17745321	CHEMBL3888070	TBK1 : The kinase assay is performed as 384-well Flashplate assay assay (for e.g. Topcount measurement. 0.6 nM TANK binding kinase (TBK1), 800 nM biotinylated MELK-derived peptide (Biotin-Ah-Ah-AKPKGNKDYHLQTCCGSLAYRRR) SEQ ID NO: 2 and 10 uM ATP (spiked with 0.25 uCi 33P-ATP/well) are incubated in a total volume of 50 ul (10 mM MOPS, 10 mM Mg-acetat, 0.1 mM EGTA, 1 mM DTT, 0.02% Brij35, 0.1% BSA, pH 7.5) with or without test compound for 120 Min at 30° C. The reaction is stopped with 25 ul 200 mM EDTA. After 30 Min at room temperature the liquid is removed and each well washed thrice with 100 ul 0.9% sodium chloride solution.	B	Nc1ncc(-c2ccc(S(N)(=O)=O)cc2)cc1C(=O)Nc1ccncc1		CHEMBL3915353	=	IC50	nM	150.0	CHEMBL5408	Homo sapiens	IC50	nM	150.0
370538	17745322	CHEMBL3888070	TBK1 : The kinase assay is performed as 384-well Flashplate assay assay (for e.g. Topcount measurement. 0.6 nM TANK binding kinase (TBK1), 800 nM biotinylated MELK-derived peptide (Biotin-Ah-Ah-AKPKGNKDYHLQTCCGSLAYRRR) SEQ ID NO: 2 and 10 uM ATP (spiked with 0.25 uCi 33P-ATP/well) are incubated in a total volume of 50 ul (10 mM MOPS, 10 mM Mg-acetat, 0.1 mM EGTA, 1 mM DTT, 0.02% Brij35, 0.1% BSA, pH 7.5) with or without test compound for 120 Min at 30° C. The reaction is stopped with 25 ul 200 mM EDTA. After 30 Min at room temperature the liquid is removed and each well washed thrice with 100 ul 0.9% sodium chloride solution.	B	Cc1cc(NC(=O)c2cc(-c3ccc(CN4CCOCC4)s3)cnc2N)ccn1		CHEMBL3943325	=	IC50	nM	78.0	CHEMBL5408	Homo sapiens	IC50	nM	78.0
370539	17745323	CHEMBL3888070	TBK1 : The kinase assay is performed as 384-well Flashplate assay assay (for e.g. Topcount measurement. 0.6 nM TANK binding kinase (TBK1), 800 nM biotinylated MELK-derived peptide (Biotin-Ah-Ah-AKPKGNKDYHLQTCCGSLAYRRR) SEQ ID NO: 2 and 10 uM ATP (spiked with 0.25 uCi 33P-ATP/well) are incubated in a total volume of 50 ul (10 mM MOPS, 10 mM Mg-acetat, 0.1 mM EGTA, 1 mM DTT, 0.02% Brij35, 0.1% BSA, pH 7.5) with or without test compound for 120 Min at 30° C. The reaction is stopped with 25 ul 200 mM EDTA. After 30 Min at room temperature the liquid is removed and each well washed thrice with 100 ul 0.9% sodium chloride solution.	B	CCOc1cc(NC(=O)c2cc(-c3ccc(CN4CCOCC4)s3)cnc2N)ccn1		CHEMBL3899705	=	IC50	nM	430.0	CHEMBL5408	Homo sapiens	IC50	nM	430.0
370540	17745324	CHEMBL3888070	TBK1 : The kinase assay is performed as 384-well Flashplate assay assay (for e.g. Topcount measurement. 0.6 nM TANK binding kinase (TBK1), 800 nM biotinylated MELK-derived peptide (Biotin-Ah-Ah-AKPKGNKDYHLQTCCGSLAYRRR) SEQ ID NO: 2 and 10 uM ATP (spiked with 0.25 uCi 33P-ATP/well) are incubated in a total volume of 50 ul (10 mM MOPS, 10 mM Mg-acetat, 0.1 mM EGTA, 1 mM DTT, 0.02% Brij35, 0.1% BSA, pH 7.5) with or without test compound for 120 Min at 30° C. The reaction is stopped with 25 ul 200 mM EDTA. After 30 Min at room temperature the liquid is removed and each well washed thrice with 100 ul 0.9% sodium chloride solution.	B	Nc1ncc(-c2ccc(CN3CCOCC3)s2)nc1C(=O)Nc1ccncc1		CHEMBL3924214	=	IC50	nM	1000.0	CHEMBL5408	Homo sapiens	IC50	nM	1000.0
370541	17745325	CHEMBL3888070	TBK1 : The kinase assay is performed as 384-well Flashplate assay assay (for e.g. Topcount measurement. 0.6 nM TANK binding kinase (TBK1), 800 nM biotinylated MELK-derived peptide (Biotin-Ah-Ah-AKPKGNKDYHLQTCCGSLAYRRR) SEQ ID NO: 2 and 10 uM ATP (spiked with 0.25 uCi 33P-ATP/well) are incubated in a total volume of 50 ul (10 mM MOPS, 10 mM Mg-acetat, 0.1 mM EGTA, 1 mM DTT, 0.02% Brij35, 0.1% BSA, pH 7.5) with or without test compound for 120 Min at 30° C. The reaction is stopped with 25 ul 200 mM EDTA. After 30 Min at room temperature the liquid is removed and each well washed thrice with 100 ul 0.9% sodium chloride solution.	B	Nc1ncc(-c2ccc(N3CCNCC3)nc2)cc1C(=O)Nc1ccncc1		CHEMBL3936692	=	IC50	nM	770.0	CHEMBL5408	Homo sapiens	IC50	nM	770.0
370542	17745326	CHEMBL3888070	TBK1 : The kinase assay is performed as 384-well Flashplate assay assay (for e.g. Topcount measurement. 0.6 nM TANK binding kinase (TBK1), 800 nM biotinylated MELK-derived peptide (Biotin-Ah-Ah-AKPKGNKDYHLQTCCGSLAYRRR) SEQ ID NO: 2 and 10 uM ATP (spiked with 0.25 uCi 33P-ATP/well) are incubated in a total volume of 50 ul (10 mM MOPS, 10 mM Mg-acetat, 0.1 mM EGTA, 1 mM DTT, 0.02% Brij35, 0.1% BSA, pH 7.5) with or without test compound for 120 Min at 30° C. The reaction is stopped with 25 ul 200 mM EDTA. After 30 Min at room temperature the liquid is removed and each well washed thrice with 100 ul 0.9% sodium chloride solution.	B	Nc1ncc(-c2cnn(CC3OCCO3)c2)nc1C(=O)Nc1ccncc1		CHEMBL3974895	=	IC50	nM	8300.0	CHEMBL5408	Homo sapiens	IC50	nM	8300.0
370543	17745327	CHEMBL3888070	TBK1 : The kinase assay is performed as 384-well Flashplate assay assay (for e.g. Topcount measurement. 0.6 nM TANK binding kinase (TBK1), 800 nM biotinylated MELK-derived peptide (Biotin-Ah-Ah-AKPKGNKDYHLQTCCGSLAYRRR) SEQ ID NO: 2 and 10 uM ATP (spiked with 0.25 uCi 33P-ATP/well) are incubated in a total volume of 50 ul (10 mM MOPS, 10 mM Mg-acetat, 0.1 mM EGTA, 1 mM DTT, 0.02% Brij35, 0.1% BSA, pH 7.5) with or without test compound for 120 Min at 30° C. The reaction is stopped with 25 ul 200 mM EDTA. After 30 Min at room temperature the liquid is removed and each well washed thrice with 100 ul 0.9% sodium chloride solution.	B	Nc1ncc(-c2ccc(CN3CCCCC3)s2)nc1C(=O)Nc1ccncc1		CHEMBL3919706	=	IC50	nM	4000.0	CHEMBL5408	Homo sapiens	IC50	nM	4000.0
370544	17745328	CHEMBL3888070	TBK1 : The kinase assay is performed as 384-well Flashplate assay assay (for e.g. Topcount measurement. 0.6 nM TANK binding kinase (TBK1), 800 nM biotinylated MELK-derived peptide (Biotin-Ah-Ah-AKPKGNKDYHLQTCCGSLAYRRR) SEQ ID NO: 2 and 10 uM ATP (spiked with 0.25 uCi 33P-ATP/well) are incubated in a total volume of 50 ul (10 mM MOPS, 10 mM Mg-acetat, 0.1 mM EGTA, 1 mM DTT, 0.02% Brij35, 0.1% BSA, pH 7.5) with or without test compound for 120 Min at 30° C. The reaction is stopped with 25 ul 200 mM EDTA. After 30 Min at room temperature the liquid is removed and each well washed thrice with 100 ul 0.9% sodium chloride solution.	B	Nc1ncc(-c2ccc(CN3CCCC3)s2)nc1C(=O)Nc1ccncc1		CHEMBL3891661	=	IC50	nM	4200.0	CHEMBL5408	Homo sapiens	IC50	nM	4200.0
370545	17745329	CHEMBL3888070	TBK1 : The kinase assay is performed as 384-well Flashplate assay assay (for e.g. Topcount measurement. 0.6 nM TANK binding kinase (TBK1), 800 nM biotinylated MELK-derived peptide (Biotin-Ah-Ah-AKPKGNKDYHLQTCCGSLAYRRR) SEQ ID NO: 2 and 10 uM ATP (spiked with 0.25 uCi 33P-ATP/well) are incubated in a total volume of 50 ul (10 mM MOPS, 10 mM Mg-acetat, 0.1 mM EGTA, 1 mM DTT, 0.02% Brij35, 0.1% BSA, pH 7.5) with or without test compound for 120 Min at 30° C. The reaction is stopped with 25 ul 200 mM EDTA. After 30 Min at room temperature the liquid is removed and each well washed thrice with 100 ul 0.9% sodium chloride solution.	B	Cc1cc(NC(=O)c2cc(-c3csc(CN4CCOCC4)c3)cnc2N)ccn1		CHEMBL3914197	=	IC50	nM	670.0	CHEMBL5408	Homo sapiens	IC50	nM	670.0
370546	17745330	CHEMBL3888070	TBK1 : The kinase assay is performed as 384-well Flashplate assay assay (for e.g. Topcount measurement. 0.6 nM TANK binding kinase (TBK1), 800 nM biotinylated MELK-derived peptide (Biotin-Ah-Ah-AKPKGNKDYHLQTCCGSLAYRRR) SEQ ID NO: 2 and 10 uM ATP (spiked with 0.25 uCi 33P-ATP/well) are incubated in a total volume of 50 ul (10 mM MOPS, 10 mM Mg-acetat, 0.1 mM EGTA, 1 mM DTT, 0.02% Brij35, 0.1% BSA, pH 7.5) with or without test compound for 120 Min at 30° C. The reaction is stopped with 25 ul 200 mM EDTA. After 30 Min at room temperature the liquid is removed and each well washed thrice with 100 ul 0.9% sodium chloride solution.	B	Nc1ncc(-c2ccc(CN3CCOCC3)s2)cc1C(=O)Nc1ccnnc1		CHEMBL3980829	=	IC50	nM	240.0	CHEMBL5408	Homo sapiens	IC50	nM	240.0
370547	17745331	CHEMBL3888070	TBK1 : The kinase assay is performed as 384-well Flashplate assay assay (for e.g. Topcount measurement. 0.6 nM TANK binding kinase (TBK1), 800 nM biotinylated MELK-derived peptide (Biotin-Ah-Ah-AKPKGNKDYHLQTCCGSLAYRRR) SEQ ID NO: 2 and 10 uM ATP (spiked with 0.25 uCi 33P-ATP/well) are incubated in a total volume of 50 ul (10 mM MOPS, 10 mM Mg-acetat, 0.1 mM EGTA, 1 mM DTT, 0.02% Brij35, 0.1% BSA, pH 7.5) with or without test compound for 120 Min at 30° C. The reaction is stopped with 25 ul 200 mM EDTA. After 30 Min at room temperature the liquid is removed and each well washed thrice with 100 ul 0.9% sodium chloride solution.	B	Cc1cc(NC(=O)c2cc(-c3cnn(Cc4ccccc4)c3)cnc2N)ccn1		CHEMBL3975991	=	IC50	nM	330.0	CHEMBL5408	Homo sapiens	IC50	nM	330.0
370548	17745332	CHEMBL3888070	TBK1 : The kinase assay is performed as 384-well Flashplate assay assay (for e.g. Topcount measurement. 0.6 nM TANK binding kinase (TBK1), 800 nM biotinylated MELK-derived peptide (Biotin-Ah-Ah-AKPKGNKDYHLQTCCGSLAYRRR) SEQ ID NO: 2 and 10 uM ATP (spiked with 0.25 uCi 33P-ATP/well) are incubated in a total volume of 50 ul (10 mM MOPS, 10 mM Mg-acetat, 0.1 mM EGTA, 1 mM DTT, 0.02% Brij35, 0.1% BSA, pH 7.5) with or without test compound for 120 Min at 30° C. The reaction is stopped with 25 ul 200 mM EDTA. After 30 Min at room temperature the liquid is removed and each well washed thrice with 100 ul 0.9% sodium chloride solution.	B	Nc1ncc(-c2cccc(-n3cccn3)c2)cc1C(=O)Nc1ccnnc1		CHEMBL3936393	=	IC50	nM	790.0	CHEMBL5408	Homo sapiens	IC50	nM	790.0
370549	17745333	CHEMBL3888070	TBK1 : The kinase assay is performed as 384-well Flashplate assay assay (for e.g. Topcount measurement. 0.6 nM TANK binding kinase (TBK1), 800 nM biotinylated MELK-derived peptide (Biotin-Ah-Ah-AKPKGNKDYHLQTCCGSLAYRRR) SEQ ID NO: 2 and 10 uM ATP (spiked with 0.25 uCi 33P-ATP/well) are incubated in a total volume of 50 ul (10 mM MOPS, 10 mM Mg-acetat, 0.1 mM EGTA, 1 mM DTT, 0.02% Brij35, 0.1% BSA, pH 7.5) with or without test compound for 120 Min at 30° C. The reaction is stopped with 25 ul 200 mM EDTA. After 30 Min at room temperature the liquid is removed and each well washed thrice with 100 ul 0.9% sodium chloride solution.	B	Cc1cnccc1NC(=O)c1cc(-c2ccc(-n3cccn3)cc2)cnc1N		CHEMBL3911981	=	IC50	nM	1000.0	CHEMBL5408	Homo sapiens	IC50	nM	1000.0
370550	17745334	CHEMBL3888070	TBK1 : The kinase assay is performed as 384-well Flashplate assay assay (for e.g. Topcount measurement. 0.6 nM TANK binding kinase (TBK1), 800 nM biotinylated MELK-derived peptide (Biotin-Ah-Ah-AKPKGNKDYHLQTCCGSLAYRRR) SEQ ID NO: 2 and 10 uM ATP (spiked with 0.25 uCi 33P-ATP/well) are incubated in a total volume of 50 ul (10 mM MOPS, 10 mM Mg-acetat, 0.1 mM EGTA, 1 mM DTT, 0.02% Brij35, 0.1% BSA, pH 7.5) with or without test compound for 120 Min at 30° C. The reaction is stopped with 25 ul 200 mM EDTA. After 30 Min at room temperature the liquid is removed and each well washed thrice with 100 ul 0.9% sodium chloride solution.	B	COCCn1cc(-c2cnc(N)c(C(=O)Nc3ccnc(C)c3)c2)cn1		CHEMBL3953248	=	IC50	nM	1200.0	CHEMBL5408	Homo sapiens	IC50	nM	1200.0
370551	17745335	CHEMBL3888070	TBK1 : The kinase assay is performed as 384-well Flashplate assay assay (for e.g. Topcount measurement. 0.6 nM TANK binding kinase (TBK1), 800 nM biotinylated MELK-derived peptide (Biotin-Ah-Ah-AKPKGNKDYHLQTCCGSLAYRRR) SEQ ID NO: 2 and 10 uM ATP (spiked with 0.25 uCi 33P-ATP/well) are incubated in a total volume of 50 ul (10 mM MOPS, 10 mM Mg-acetat, 0.1 mM EGTA, 1 mM DTT, 0.02% Brij35, 0.1% BSA, pH 7.5) with or without test compound for 120 Min at 30° C. The reaction is stopped with 25 ul 200 mM EDTA. After 30 Min at room temperature the liquid is removed and each well washed thrice with 100 ul 0.9% sodium chloride solution.	B	Cc1cnccc1NC(=O)c1cc(-c2ccc(CN3CCOCC3)s2)cnc1N		CHEMBL3892127	=	IC50	nM	260.0	CHEMBL5408	Homo sapiens	IC50	nM	260.0
370552	17745336	CHEMBL3888070	TBK1 : The kinase assay is performed as 384-well Flashplate assay assay (for e.g. Topcount measurement. 0.6 nM TANK binding kinase (TBK1), 800 nM biotinylated MELK-derived peptide (Biotin-Ah-Ah-AKPKGNKDYHLQTCCGSLAYRRR) SEQ ID NO: 2 and 10 uM ATP (spiked with 0.25 uCi 33P-ATP/well) are incubated in a total volume of 50 ul (10 mM MOPS, 10 mM Mg-acetat, 0.1 mM EGTA, 1 mM DTT, 0.02% Brij35, 0.1% BSA, pH 7.5) with or without test compound for 120 Min at 30° C. The reaction is stopped with 25 ul 200 mM EDTA. After 30 Min at room temperature the liquid is removed and each well washed thrice with 100 ul 0.9% sodium chloride solution.	B	COCCn1cc(-c2cnc(N)c(C(=O)Nc3ccncc3C)c2)cn1		CHEMBL3952415	=	IC50	nM	690.0	CHEMBL5408	Homo sapiens	IC50	nM	690.0
370553	17745337	CHEMBL3888070	TBK1 : The kinase assay is performed as 384-well Flashplate assay assay (for e.g. Topcount measurement. 0.6 nM TANK binding kinase (TBK1), 800 nM biotinylated MELK-derived peptide (Biotin-Ah-Ah-AKPKGNKDYHLQTCCGSLAYRRR) SEQ ID NO: 2 and 10 uM ATP (spiked with 0.25 uCi 33P-ATP/well) are incubated in a total volume of 50 ul (10 mM MOPS, 10 mM Mg-acetat, 0.1 mM EGTA, 1 mM DTT, 0.02% Brij35, 0.1% BSA, pH 7.5) with or without test compound for 120 Min at 30° C. The reaction is stopped with 25 ul 200 mM EDTA. After 30 Min at room temperature the liquid is removed and each well washed thrice with 100 ul 0.9% sodium chloride solution.	B	Cc1ccc(-c2cccc(-c3cnc(N)c(C(=O)Nc4ccncc4)c3)c2)cc1		CHEMBL3981212	=	IC50	nM	7400.0	CHEMBL5408	Homo sapiens	IC50	nM	7400.0
370554	17745338	CHEMBL3888070	TBK1 : The kinase assay is performed as 384-well Flashplate assay assay (for e.g. Topcount measurement. 0.6 nM TANK binding kinase (TBK1), 800 nM biotinylated MELK-derived peptide (Biotin-Ah-Ah-AKPKGNKDYHLQTCCGSLAYRRR) SEQ ID NO: 2 and 10 uM ATP (spiked with 0.25 uCi 33P-ATP/well) are incubated in a total volume of 50 ul (10 mM MOPS, 10 mM Mg-acetat, 0.1 mM EGTA, 1 mM DTT, 0.02% Brij35, 0.1% BSA, pH 7.5) with or without test compound for 120 Min at 30° C. The reaction is stopped with 25 ul 200 mM EDTA. After 30 Min at room temperature the liquid is removed and each well washed thrice with 100 ul 0.9% sodium chloride solution.	B	COCCn1cc(-c2cnc(N)c(C(=O)Nc3ccnnc3)c2)cn1		CHEMBL3915602	=	IC50	nM	1200.0	CHEMBL5408	Homo sapiens	IC50	nM	1200.0
370555	17745339	CHEMBL3888070	TBK1 : The kinase assay is performed as 384-well Flashplate assay assay (for e.g. Topcount measurement. 0.6 nM TANK binding kinase (TBK1), 800 nM biotinylated MELK-derived peptide (Biotin-Ah-Ah-AKPKGNKDYHLQTCCGSLAYRRR) SEQ ID NO: 2 and 10 uM ATP (spiked with 0.25 uCi 33P-ATP/well) are incubated in a total volume of 50 ul (10 mM MOPS, 10 mM Mg-acetat, 0.1 mM EGTA, 1 mM DTT, 0.02% Brij35, 0.1% BSA, pH 7.5) with or without test compound for 120 Min at 30° C. The reaction is stopped with 25 ul 200 mM EDTA. After 30 Min at room temperature the liquid is removed and each well washed thrice with 100 ul 0.9% sodium chloride solution.	B	NC(=O)Cn1cc(-c2cnc(N)c(C(=O)Nc3ccncc3)c2)cn1		CHEMBL3976366	=	IC50	nM	360.0	CHEMBL5408	Homo sapiens	IC50	nM	360.0
370556	17745340	CHEMBL3888070	TBK1 : The kinase assay is performed as 384-well Flashplate assay assay (for e.g. Topcount measurement. 0.6 nM TANK binding kinase (TBK1), 800 nM biotinylated MELK-derived peptide (Biotin-Ah-Ah-AKPKGNKDYHLQTCCGSLAYRRR) SEQ ID NO: 2 and 10 uM ATP (spiked with 0.25 uCi 33P-ATP/well) are incubated in a total volume of 50 ul (10 mM MOPS, 10 mM Mg-acetat, 0.1 mM EGTA, 1 mM DTT, 0.02% Brij35, 0.1% BSA, pH 7.5) with or without test compound for 120 Min at 30° C. The reaction is stopped with 25 ul 200 mM EDTA. After 30 Min at room temperature the liquid is removed and each well washed thrice with 100 ul 0.9% sodium chloride solution.	B	Cc1cc(NC(=O)c2cc(-c3ccc(CN4CCOCC4)s3)cnc2N)cc(C)n1		CHEMBL3910247	=	IC50	nM	8200.0	CHEMBL5408	Homo sapiens	IC50	nM	8200.0
370557	17745341	CHEMBL3888070	TBK1 : The kinase assay is performed as 384-well Flashplate assay assay (for e.g. Topcount measurement. 0.6 nM TANK binding kinase (TBK1), 800 nM biotinylated MELK-derived peptide (Biotin-Ah-Ah-AKPKGNKDYHLQTCCGSLAYRRR) SEQ ID NO: 2 and 10 uM ATP (spiked with 0.25 uCi 33P-ATP/well) are incubated in a total volume of 50 ul (10 mM MOPS, 10 mM Mg-acetat, 0.1 mM EGTA, 1 mM DTT, 0.02% Brij35, 0.1% BSA, pH 7.5) with or without test compound for 120 Min at 30° C. The reaction is stopped with 25 ul 200 mM EDTA. After 30 Min at room temperature the liquid is removed and each well washed thrice with 100 ul 0.9% sodium chloride solution.	B	Nc1ncc(-c2ccc(CN3CCOCC3)s2)cc1C(=O)Nc1ccncn1		CHEMBL3938167	=	IC50	nM	810.0	CHEMBL5408	Homo sapiens	IC50	nM	810.0
370558	17745342	CHEMBL3888070	TBK1 : The kinase assay is performed as 384-well Flashplate assay assay (for e.g. Topcount measurement. 0.6 nM TANK binding kinase (TBK1), 800 nM biotinylated MELK-derived peptide (Biotin-Ah-Ah-AKPKGNKDYHLQTCCGSLAYRRR) SEQ ID NO: 2 and 10 uM ATP (spiked with 0.25 uCi 33P-ATP/well) are incubated in a total volume of 50 ul (10 mM MOPS, 10 mM Mg-acetat, 0.1 mM EGTA, 1 mM DTT, 0.02% Brij35, 0.1% BSA, pH 7.5) with or without test compound for 120 Min at 30° C. The reaction is stopped with 25 ul 200 mM EDTA. After 30 Min at room temperature the liquid is removed and each well washed thrice with 100 ul 0.9% sodium chloride solution.	B	COCCn1cc(-c2cnc(N)c(C(=O)Nc3ccnc4ccoc34)c2)cn1		CHEMBL3901173	=	IC50	nM	1200.0	CHEMBL5408	Homo sapiens	IC50	nM	1200.0
370559	17745343	CHEMBL3888070	TBK1 : The kinase assay is performed as 384-well Flashplate assay assay (for e.g. Topcount measurement. 0.6 nM TANK binding kinase (TBK1), 800 nM biotinylated MELK-derived peptide (Biotin-Ah-Ah-AKPKGNKDYHLQTCCGSLAYRRR) SEQ ID NO: 2 and 10 uM ATP (spiked with 0.25 uCi 33P-ATP/well) are incubated in a total volume of 50 ul (10 mM MOPS, 10 mM Mg-acetat, 0.1 mM EGTA, 1 mM DTT, 0.02% Brij35, 0.1% BSA, pH 7.5) with or without test compound for 120 Min at 30° C. The reaction is stopped with 25 ul 200 mM EDTA. After 30 Min at room temperature the liquid is removed and each well washed thrice with 100 ul 0.9% sodium chloride solution.	B	Nc1ncc(-c2ccc(CN3CCOCC3)s2)cc1C(=O)Nc1ccnc2ccoc12		CHEMBL3925708	=	IC50	nM	890.0	CHEMBL5408	Homo sapiens	IC50	nM	890.0
370560	17745344	CHEMBL3888070	TBK1 : The kinase assay is performed as 384-well Flashplate assay assay (for e.g. Topcount measurement. 0.6 nM TANK binding kinase (TBK1), 800 nM biotinylated MELK-derived peptide (Biotin-Ah-Ah-AKPKGNKDYHLQTCCGSLAYRRR) SEQ ID NO: 2 and 10 uM ATP (spiked with 0.25 uCi 33P-ATP/well) are incubated in a total volume of 50 ul (10 mM MOPS, 10 mM Mg-acetat, 0.1 mM EGTA, 1 mM DTT, 0.02% Brij35, 0.1% BSA, pH 7.5) with or without test compound for 120 Min at 30° C. The reaction is stopped with 25 ul 200 mM EDTA. After 30 Min at room temperature the liquid is removed and each well washed thrice with 100 ul 0.9% sodium chloride solution.	B	COC(=O)c1ccc(-c2cnc(N)c(C(=O)Nc3ccncc3)c2)cc1		CHEMBL3967420	=	IC50	nM	1600.0	CHEMBL5408	Homo sapiens	IC50	nM	1600.0
370561	17745345	CHEMBL3888070	TBK1 : The kinase assay is performed as 384-well Flashplate assay assay (for e.g. Topcount measurement. 0.6 nM TANK binding kinase (TBK1), 800 nM biotinylated MELK-derived peptide (Biotin-Ah-Ah-AKPKGNKDYHLQTCCGSLAYRRR) SEQ ID NO: 2 and 10 uM ATP (spiked with 0.25 uCi 33P-ATP/well) are incubated in a total volume of 50 ul (10 mM MOPS, 10 mM Mg-acetat, 0.1 mM EGTA, 1 mM DTT, 0.02% Brij35, 0.1% BSA, pH 7.5) with or without test compound for 120 Min at 30° C. The reaction is stopped with 25 ul 200 mM EDTA. After 30 Min at room temperature the liquid is removed and each well washed thrice with 100 ul 0.9% sodium chloride solution.	B	Nc1ncc(-c2ccc(C(=O)O)cc2)cc1C(=O)Nc1ccncc1		CHEMBL3937785	=	IC50	nM	400.0	CHEMBL5408	Homo sapiens	IC50	nM	400.0
370562	17745346	CHEMBL3888070	TBK1 : The kinase assay is performed as 384-well Flashplate assay assay (for e.g. Topcount measurement. 0.6 nM TANK binding kinase (TBK1), 800 nM biotinylated MELK-derived peptide (Biotin-Ah-Ah-AKPKGNKDYHLQTCCGSLAYRRR) SEQ ID NO: 2 and 10 uM ATP (spiked with 0.25 uCi 33P-ATP/well) are incubated in a total volume of 50 ul (10 mM MOPS, 10 mM Mg-acetat, 0.1 mM EGTA, 1 mM DTT, 0.02% Brij35, 0.1% BSA, pH 7.5) with or without test compound for 120 Min at 30° C. The reaction is stopped with 25 ul 200 mM EDTA. After 30 Min at room temperature the liquid is removed and each well washed thrice with 100 ul 0.9% sodium chloride solution.	B	Nc1ncc(-c2ccc(CCC(=O)O)cc2)cc1C(=O)Nc1ccncc1		CHEMBL3975928	=	IC50	nM	250.0	CHEMBL5408	Homo sapiens	IC50	nM	250.0
370563	17745347	CHEMBL3888070	TBK1 : The kinase assay is performed as 384-well Flashplate assay assay (for e.g. Topcount measurement. 0.6 nM TANK binding kinase (TBK1), 800 nM biotinylated MELK-derived peptide (Biotin-Ah-Ah-AKPKGNKDYHLQTCCGSLAYRRR) SEQ ID NO: 2 and 10 uM ATP (spiked with 0.25 uCi 33P-ATP/well) are incubated in a total volume of 50 ul (10 mM MOPS, 10 mM Mg-acetat, 0.1 mM EGTA, 1 mM DTT, 0.02% Brij35, 0.1% BSA, pH 7.5) with or without test compound for 120 Min at 30° C. The reaction is stopped with 25 ul 200 mM EDTA. After 30 Min at room temperature the liquid is removed and each well washed thrice with 100 ul 0.9% sodium chloride solution.	B	Nc1ncc(-c2ccc(CN3CCOCC3)s2)cc1C(=O)Nc1ccncc1Cl		CHEMBL3950028	=	IC50	nM	250.0	CHEMBL5408	Homo sapiens	IC50	nM	250.0
370564	17745348	CHEMBL3888070	TBK1 : The kinase assay is performed as 384-well Flashplate assay assay (for e.g. Topcount measurement. 0.6 nM TANK binding kinase (TBK1), 800 nM biotinylated MELK-derived peptide (Biotin-Ah-Ah-AKPKGNKDYHLQTCCGSLAYRRR) SEQ ID NO: 2 and 10 uM ATP (spiked with 0.25 uCi 33P-ATP/well) are incubated in a total volume of 50 ul (10 mM MOPS, 10 mM Mg-acetat, 0.1 mM EGTA, 1 mM DTT, 0.02% Brij35, 0.1% BSA, pH 7.5) with or without test compound for 120 Min at 30° C. The reaction is stopped with 25 ul 200 mM EDTA. After 30 Min at room temperature the liquid is removed and each well washed thrice with 100 ul 0.9% sodium chloride solution.	B	Nc1ncc(-c2cn[nH]c2)cc1C(=O)Nc1ccncc1		CHEMBL3923200	=	IC50	nM	280.0	CHEMBL5408	Homo sapiens	IC50	nM	280.0
370565	17745349	CHEMBL3888070	TBK1 : The kinase assay is performed as 384-well Flashplate assay assay (for e.g. Topcount measurement. 0.6 nM TANK binding kinase (TBK1), 800 nM biotinylated MELK-derived peptide (Biotin-Ah-Ah-AKPKGNKDYHLQTCCGSLAYRRR) SEQ ID NO: 2 and 10 uM ATP (spiked with 0.25 uCi 33P-ATP/well) are incubated in a total volume of 50 ul (10 mM MOPS, 10 mM Mg-acetat, 0.1 mM EGTA, 1 mM DTT, 0.02% Brij35, 0.1% BSA, pH 7.5) with or without test compound for 120 Min at 30° C. The reaction is stopped with 25 ul 200 mM EDTA. After 30 Min at room temperature the liquid is removed and each well washed thrice with 100 ul 0.9% sodium chloride solution.	B	COC(=O)c1cnccc1NC(=O)c1cc(-c2ccc(CN3CCOCC3)s2)cnc1N		CHEMBL3895236	=	IC50	nM	450.0	CHEMBL5408	Homo sapiens	IC50	nM	450.0
370566	17745350	CHEMBL3888070	TBK1 : The kinase assay is performed as 384-well Flashplate assay assay (for e.g. Topcount measurement. 0.6 nM TANK binding kinase (TBK1), 800 nM biotinylated MELK-derived peptide (Biotin-Ah-Ah-AKPKGNKDYHLQTCCGSLAYRRR) SEQ ID NO: 2 and 10 uM ATP (spiked with 0.25 uCi 33P-ATP/well) are incubated in a total volume of 50 ul (10 mM MOPS, 10 mM Mg-acetat, 0.1 mM EGTA, 1 mM DTT, 0.02% Brij35, 0.1% BSA, pH 7.5) with or without test compound for 120 Min at 30° C. The reaction is stopped with 25 ul 200 mM EDTA. After 30 Min at room temperature the liquid is removed and each well washed thrice with 100 ul 0.9% sodium chloride solution.	B	CC(=O)Nc1cc(NC(=O)c2cc(-c3ccc(CN4CCOCC4)s3)cnc2N)ccn1		CHEMBL3959788	=	IC50	nM	190.0	CHEMBL5408	Homo sapiens	IC50	nM	190.0
370567	17745351	CHEMBL3888070	TBK1 : The kinase assay is performed as 384-well Flashplate assay assay (for e.g. Topcount measurement. 0.6 nM TANK binding kinase (TBK1), 800 nM biotinylated MELK-derived peptide (Biotin-Ah-Ah-AKPKGNKDYHLQTCCGSLAYRRR) SEQ ID NO: 2 and 10 uM ATP (spiked with 0.25 uCi 33P-ATP/well) are incubated in a total volume of 50 ul (10 mM MOPS, 10 mM Mg-acetat, 0.1 mM EGTA, 1 mM DTT, 0.02% Brij35, 0.1% BSA, pH 7.5) with or without test compound for 120 Min at 30° C. The reaction is stopped with 25 ul 200 mM EDTA. After 30 Min at room temperature the liquid is removed and each well washed thrice with 100 ul 0.9% sodium chloride solution.	B	Nc1ncc(-c2cccc(C(=O)O)c2)cc1C(=O)Nc1ccncc1		CHEMBL3900659	=	IC50	nM	1100.0	CHEMBL5408	Homo sapiens	IC50	nM	1100.0
370568	17745352	CHEMBL3888070	TBK1 : The kinase assay is performed as 384-well Flashplate assay assay (for e.g. Topcount measurement. 0.6 nM TANK binding kinase (TBK1), 800 nM biotinylated MELK-derived peptide (Biotin-Ah-Ah-AKPKGNKDYHLQTCCGSLAYRRR) SEQ ID NO: 2 and 10 uM ATP (spiked with 0.25 uCi 33P-ATP/well) are incubated in a total volume of 50 ul (10 mM MOPS, 10 mM Mg-acetat, 0.1 mM EGTA, 1 mM DTT, 0.02% Brij35, 0.1% BSA, pH 7.5) with or without test compound for 120 Min at 30° C. The reaction is stopped with 25 ul 200 mM EDTA. After 30 Min at room temperature the liquid is removed and each well washed thrice with 100 ul 0.9% sodium chloride solution.	B	COCCn1cc(-c2cnc(N)c(C(=O)Nc3ccncc3Cl)c2)cn1		CHEMBL3901749	=	IC50	nM	740.0	CHEMBL5408	Homo sapiens	IC50	nM	740.0
370569	17745353	CHEMBL3888070	TBK1 : The kinase assay is performed as 384-well Flashplate assay assay (for e.g. Topcount measurement. 0.6 nM TANK binding kinase (TBK1), 800 nM biotinylated MELK-derived peptide (Biotin-Ah-Ah-AKPKGNKDYHLQTCCGSLAYRRR) SEQ ID NO: 2 and 10 uM ATP (spiked with 0.25 uCi 33P-ATP/well) are incubated in a total volume of 50 ul (10 mM MOPS, 10 mM Mg-acetat, 0.1 mM EGTA, 1 mM DTT, 0.02% Brij35, 0.1% BSA, pH 7.5) with or without test compound for 120 Min at 30° C. The reaction is stopped with 25 ul 200 mM EDTA. After 30 Min at room temperature the liquid is removed and each well washed thrice with 100 ul 0.9% sodium chloride solution.	B	COc1ccc(NC(=O)c2cc(-c3ccc(CN4CCOCC4)s3)cnc2N)cc1		CHEMBL3972829	=	IC50	nM	910.0	CHEMBL5408	Homo sapiens	IC50	nM	910.0
370570	17745354	CHEMBL3888070	TBK1 : The kinase assay is performed as 384-well Flashplate assay assay (for e.g. Topcount measurement. 0.6 nM TANK binding kinase (TBK1), 800 nM biotinylated MELK-derived peptide (Biotin-Ah-Ah-AKPKGNKDYHLQTCCGSLAYRRR) SEQ ID NO: 2 and 10 uM ATP (spiked with 0.25 uCi 33P-ATP/well) are incubated in a total volume of 50 ul (10 mM MOPS, 10 mM Mg-acetat, 0.1 mM EGTA, 1 mM DTT, 0.02% Brij35, 0.1% BSA, pH 7.5) with or without test compound for 120 Min at 30° C. The reaction is stopped with 25 ul 200 mM EDTA. After 30 Min at room temperature the liquid is removed and each well washed thrice with 100 ul 0.9% sodium chloride solution.	B	Nc1ncc(-c2cnn(CCO)c2)cc1C(=O)Nc1ccncc1		CHEMBL3897770	=	IC50	nM	670.0	CHEMBL5408	Homo sapiens	IC50	nM	670.0
370571	17745355	CHEMBL3888070	TBK1 : The kinase assay is performed as 384-well Flashplate assay assay (for e.g. Topcount measurement. 0.6 nM TANK binding kinase (TBK1), 800 nM biotinylated MELK-derived peptide (Biotin-Ah-Ah-AKPKGNKDYHLQTCCGSLAYRRR) SEQ ID NO: 2 and 10 uM ATP (spiked with 0.25 uCi 33P-ATP/well) are incubated in a total volume of 50 ul (10 mM MOPS, 10 mM Mg-acetat, 0.1 mM EGTA, 1 mM DTT, 0.02% Brij35, 0.1% BSA, pH 7.5) with or without test compound for 120 Min at 30° C. The reaction is stopped with 25 ul 200 mM EDTA. After 30 Min at room temperature the liquid is removed and each well washed thrice with 100 ul 0.9% sodium chloride solution.	B	Nc1ncc(-c2csc(CN3CCOCC3)c2)cc1C(=O)Nc1ccncc1		CHEMBL3922312	=	IC50	nM	140.0	CHEMBL5408	Homo sapiens	IC50	nM	140.0
370572	17745356	CHEMBL3888070	TBK1 : The kinase assay is performed as 384-well Flashplate assay assay (for e.g. Topcount measurement. 0.6 nM TANK binding kinase (TBK1), 800 nM biotinylated MELK-derived peptide (Biotin-Ah-Ah-AKPKGNKDYHLQTCCGSLAYRRR) SEQ ID NO: 2 and 10 uM ATP (spiked with 0.25 uCi 33P-ATP/well) are incubated in a total volume of 50 ul (10 mM MOPS, 10 mM Mg-acetat, 0.1 mM EGTA, 1 mM DTT, 0.02% Brij35, 0.1% BSA, pH 7.5) with or without test compound for 120 Min at 30° C. The reaction is stopped with 25 ul 200 mM EDTA. After 30 Min at room temperature the liquid is removed and each well washed thrice with 100 ul 0.9% sodium chloride solution.	B	CC(=O)c1c[nH]c(-c2cnc(N)c(C(=O)Nc3ccncc3)c2)c1		CHEMBL3970040	=	IC50	nM	240.0	CHEMBL5408	Homo sapiens	IC50	nM	240.0
370573	17745357	CHEMBL3888070	TBK1 : The kinase assay is performed as 384-well Flashplate assay assay (for e.g. Topcount measurement. 0.6 nM TANK binding kinase (TBK1), 800 nM biotinylated MELK-derived peptide (Biotin-Ah-Ah-AKPKGNKDYHLQTCCGSLAYRRR) SEQ ID NO: 2 and 10 uM ATP (spiked with 0.25 uCi 33P-ATP/well) are incubated in a total volume of 50 ul (10 mM MOPS, 10 mM Mg-acetat, 0.1 mM EGTA, 1 mM DTT, 0.02% Brij35, 0.1% BSA, pH 7.5) with or without test compound for 120 Min at 30° C. The reaction is stopped with 25 ul 200 mM EDTA. After 30 Min at room temperature the liquid is removed and each well washed thrice with 100 ul 0.9% sodium chloride solution.	B	Nc1ncc(-c2ccoc2)cc1C(=O)Nc1ccncc1		CHEMBL3898836	=	IC50	nM	610.0	CHEMBL5408	Homo sapiens	IC50	nM	610.0
370574	17745358	CHEMBL3888070	TBK1 : The kinase assay is performed as 384-well Flashplate assay assay (for e.g. Topcount measurement. 0.6 nM TANK binding kinase (TBK1), 800 nM biotinylated MELK-derived peptide (Biotin-Ah-Ah-AKPKGNKDYHLQTCCGSLAYRRR) SEQ ID NO: 2 and 10 uM ATP (spiked with 0.25 uCi 33P-ATP/well) are incubated in a total volume of 50 ul (10 mM MOPS, 10 mM Mg-acetat, 0.1 mM EGTA, 1 mM DTT, 0.02% Brij35, 0.1% BSA, pH 7.5) with or without test compound for 120 Min at 30° C. The reaction is stopped with 25 ul 200 mM EDTA. After 30 Min at room temperature the liquid is removed and each well washed thrice with 100 ul 0.9% sodium chloride solution.	B	Nc1ncc(-c2cnn(Cc3ccccc3)c2)cc1C(=O)Nc1ccncc1		CHEMBL3975183	=	IC50	nM	120.0	CHEMBL5408	Homo sapiens	IC50	nM	120.0
370575	17745359	CHEMBL3888070	TBK1 : The kinase assay is performed as 384-well Flashplate assay assay (for e.g. Topcount measurement. 0.6 nM TANK binding kinase (TBK1), 800 nM biotinylated MELK-derived peptide (Biotin-Ah-Ah-AKPKGNKDYHLQTCCGSLAYRRR) SEQ ID NO: 2 and 10 uM ATP (spiked with 0.25 uCi 33P-ATP/well) are incubated in a total volume of 50 ul (10 mM MOPS, 10 mM Mg-acetat, 0.1 mM EGTA, 1 mM DTT, 0.02% Brij35, 0.1% BSA, pH 7.5) with or without test compound for 120 Min at 30° C. The reaction is stopped with 25 ul 200 mM EDTA. After 30 Min at room temperature the liquid is removed and each well washed thrice with 100 ul 0.9% sodium chloride solution.	B	Cn1ccc(-c2cnc(N)c(C(=O)Nc3ccncc3)c2)n1		CHEMBL3902251	=	IC50	nM	330.0	CHEMBL5408	Homo sapiens	IC50	nM	330.0
370576	17745360	CHEMBL3888070	TBK1 : The kinase assay is performed as 384-well Flashplate assay assay (for e.g. Topcount measurement. 0.6 nM TANK binding kinase (TBK1), 800 nM biotinylated MELK-derived peptide (Biotin-Ah-Ah-AKPKGNKDYHLQTCCGSLAYRRR) SEQ ID NO: 2 and 10 uM ATP (spiked with 0.25 uCi 33P-ATP/well) are incubated in a total volume of 50 ul (10 mM MOPS, 10 mM Mg-acetat, 0.1 mM EGTA, 1 mM DTT, 0.02% Brij35, 0.1% BSA, pH 7.5) with or without test compound for 120 Min at 30° C. The reaction is stopped with 25 ul 200 mM EDTA. After 30 Min at room temperature the liquid is removed and each well washed thrice with 100 ul 0.9% sodium chloride solution.	B	Nc1ncc(-c2ccsc2)cc1C(=O)Nc1ccncc1		CHEMBL3964958	=	IC50	nM	410.0	CHEMBL5408	Homo sapiens	IC50	nM	410.0
370577	17745361	CHEMBL3888070	TBK1 : The kinase assay is performed as 384-well Flashplate assay assay (for e.g. Topcount measurement. 0.6 nM TANK binding kinase (TBK1), 800 nM biotinylated MELK-derived peptide (Biotin-Ah-Ah-AKPKGNKDYHLQTCCGSLAYRRR) SEQ ID NO: 2 and 10 uM ATP (spiked with 0.25 uCi 33P-ATP/well) are incubated in a total volume of 50 ul (10 mM MOPS, 10 mM Mg-acetat, 0.1 mM EGTA, 1 mM DTT, 0.02% Brij35, 0.1% BSA, pH 7.5) with or without test compound for 120 Min at 30° C. The reaction is stopped with 25 ul 200 mM EDTA. After 30 Min at room temperature the liquid is removed and each well washed thrice with 100 ul 0.9% sodium chloride solution.	B	Cn1cccc1-c1cnc(N)c(C(=O)Nc2ccncc2)c1		CHEMBL3894537	=	IC50	nM	320.0	CHEMBL5408	Homo sapiens	IC50	nM	320.0
370578	17745362	CHEMBL3888070	TBK1 : The kinase assay is performed as 384-well Flashplate assay assay (for e.g. Topcount measurement. 0.6 nM TANK binding kinase (TBK1), 800 nM biotinylated MELK-derived peptide (Biotin-Ah-Ah-AKPKGNKDYHLQTCCGSLAYRRR) SEQ ID NO: 2 and 10 uM ATP (spiked with 0.25 uCi 33P-ATP/well) are incubated in a total volume of 50 ul (10 mM MOPS, 10 mM Mg-acetat, 0.1 mM EGTA, 1 mM DTT, 0.02% Brij35, 0.1% BSA, pH 7.5) with or without test compound for 120 Min at 30° C. The reaction is stopped with 25 ul 200 mM EDTA. After 30 Min at room temperature the liquid is removed and each well washed thrice with 100 ul 0.9% sodium chloride solution.	B	Nc1ncc(-c2cnn(CCN3CCOCC3)c2)cc1C(=O)Nc1ccncc1		CHEMBL3939553	=	IC50	nM	740.0	CHEMBL5408	Homo sapiens	IC50	nM	740.0
370579	17745363	CHEMBL3888070	TBK1 : The kinase assay is performed as 384-well Flashplate assay assay (for e.g. Topcount measurement. 0.6 nM TANK binding kinase (TBK1), 800 nM biotinylated MELK-derived peptide (Biotin-Ah-Ah-AKPKGNKDYHLQTCCGSLAYRRR) SEQ ID NO: 2 and 10 uM ATP (spiked with 0.25 uCi 33P-ATP/well) are incubated in a total volume of 50 ul (10 mM MOPS, 10 mM Mg-acetat, 0.1 mM EGTA, 1 mM DTT, 0.02% Brij35, 0.1% BSA, pH 7.5) with or without test compound for 120 Min at 30° C. The reaction is stopped with 25 ul 200 mM EDTA. After 30 Min at room temperature the liquid is removed and each well washed thrice with 100 ul 0.9% sodium chloride solution.	B	Nc1ncc(-c2cc3ccccc3s2)cc1C(=O)Nc1ccncc1		CHEMBL3958551	=	IC50	nM	630.0	CHEMBL5408	Homo sapiens	IC50	nM	630.0
370580	17745364	CHEMBL3888070	TBK1 : The kinase assay is performed as 384-well Flashplate assay assay (for e.g. Topcount measurement. 0.6 nM TANK binding kinase (TBK1), 800 nM biotinylated MELK-derived peptide (Biotin-Ah-Ah-AKPKGNKDYHLQTCCGSLAYRRR) SEQ ID NO: 2 and 10 uM ATP (spiked with 0.25 uCi 33P-ATP/well) are incubated in a total volume of 50 ul (10 mM MOPS, 10 mM Mg-acetat, 0.1 mM EGTA, 1 mM DTT, 0.02% Brij35, 0.1% BSA, pH 7.5) with or without test compound for 120 Min at 30° C. The reaction is stopped with 25 ul 200 mM EDTA. After 30 Min at room temperature the liquid is removed and each well washed thrice with 100 ul 0.9% sodium chloride solution.	B	CC(=O)c1ccc(-c2cnc(N)c(C(=O)Nc3ccncc3)c2)s1		CHEMBL3943921	=	IC50	nM	160.0	CHEMBL5408	Homo sapiens	IC50	nM	160.0
370581	17745365	CHEMBL3888070	TBK1 : The kinase assay is performed as 384-well Flashplate assay assay (for e.g. Topcount measurement. 0.6 nM TANK binding kinase (TBK1), 800 nM biotinylated MELK-derived peptide (Biotin-Ah-Ah-AKPKGNKDYHLQTCCGSLAYRRR) SEQ ID NO: 2 and 10 uM ATP (spiked with 0.25 uCi 33P-ATP/well) are incubated in a total volume of 50 ul (10 mM MOPS, 10 mM Mg-acetat, 0.1 mM EGTA, 1 mM DTT, 0.02% Brij35, 0.1% BSA, pH 7.5) with or without test compound for 120 Min at 30° C. The reaction is stopped with 25 ul 200 mM EDTA. After 30 Min at room temperature the liquid is removed and each well washed thrice with 100 ul 0.9% sodium chloride solution.	B	Nc1ncc(-c2ccc(CN3CCOCC3)s2)cc1C(=O)Nc1ccncc1		CHEMBL3982817	=	IC50	nM	88.0	CHEMBL5408	Homo sapiens	IC50	nM	88.0
370582	17745366	CHEMBL3888070	TBK1 : The kinase assay is performed as 384-well Flashplate assay assay (for e.g. Topcount measurement. 0.6 nM TANK binding kinase (TBK1), 800 nM biotinylated MELK-derived peptide (Biotin-Ah-Ah-AKPKGNKDYHLQTCCGSLAYRRR) SEQ ID NO: 2 and 10 uM ATP (spiked with 0.25 uCi 33P-ATP/well) are incubated in a total volume of 50 ul (10 mM MOPS, 10 mM Mg-acetat, 0.1 mM EGTA, 1 mM DTT, 0.02% Brij35, 0.1% BSA, pH 7.5) with or without test compound for 120 Min at 30° C. The reaction is stopped with 25 ul 200 mM EDTA. After 30 Min at room temperature the liquid is removed and each well washed thrice with 100 ul 0.9% sodium chloride solution.	B	Nc1ncc(-c2cc3ccccc3[nH]2)cc1C(=O)Nc1ccncc1		CHEMBL3925987	=	IC50	nM	390.0	CHEMBL5408	Homo sapiens	IC50	nM	390.0
370583	17745367	CHEMBL3888070	TBK1 : The kinase assay is performed as 384-well Flashplate assay assay (for e.g. Topcount measurement. 0.6 nM TANK binding kinase (TBK1), 800 nM biotinylated MELK-derived peptide (Biotin-Ah-Ah-AKPKGNKDYHLQTCCGSLAYRRR) SEQ ID NO: 2 and 10 uM ATP (spiked with 0.25 uCi 33P-ATP/well) are incubated in a total volume of 50 ul (10 mM MOPS, 10 mM Mg-acetat, 0.1 mM EGTA, 1 mM DTT, 0.02% Brij35, 0.1% BSA, pH 7.5) with or without test compound for 120 Min at 30° C. The reaction is stopped with 25 ul 200 mM EDTA. After 30 Min at room temperature the liquid is removed and each well washed thrice with 100 ul 0.9% sodium chloride solution.	B	Nc1ncc(-c2c[nH]c3ccccc23)cc1C(=O)Nc1ccncc1		CHEMBL3931286	=	IC50	nM	510.0	CHEMBL5408	Homo sapiens	IC50	nM	510.0
370584	17745368	CHEMBL3888070	TBK1 : The kinase assay is performed as 384-well Flashplate assay assay (for e.g. Topcount measurement. 0.6 nM TANK binding kinase (TBK1), 800 nM biotinylated MELK-derived peptide (Biotin-Ah-Ah-AKPKGNKDYHLQTCCGSLAYRRR) SEQ ID NO: 2 and 10 uM ATP (spiked with 0.25 uCi 33P-ATP/well) are incubated in a total volume of 50 ul (10 mM MOPS, 10 mM Mg-acetat, 0.1 mM EGTA, 1 mM DTT, 0.02% Brij35, 0.1% BSA, pH 7.5) with or without test compound for 120 Min at 30° C. The reaction is stopped with 25 ul 200 mM EDTA. After 30 Min at room temperature the liquid is removed and each well washed thrice with 100 ul 0.9% sodium chloride solution.	B	Nc1ncc(-c2ccc[nH]2)cc1C(=O)Nc1ccncc1		CHEMBL3945410	=	IC50	nM	410.0	CHEMBL5408	Homo sapiens	IC50	nM	410.0
370585	17745369	CHEMBL3888070	TBK1 : The kinase assay is performed as 384-well Flashplate assay assay (for e.g. Topcount measurement. 0.6 nM TANK binding kinase (TBK1), 800 nM biotinylated MELK-derived peptide (Biotin-Ah-Ah-AKPKGNKDYHLQTCCGSLAYRRR) SEQ ID NO: 2 and 10 uM ATP (spiked with 0.25 uCi 33P-ATP/well) are incubated in a total volume of 50 ul (10 mM MOPS, 10 mM Mg-acetat, 0.1 mM EGTA, 1 mM DTT, 0.02% Brij35, 0.1% BSA, pH 7.5) with or without test compound for 120 Min at 30° C. The reaction is stopped with 25 ul 200 mM EDTA. After 30 Min at room temperature the liquid is removed and each well washed thrice with 100 ul 0.9% sodium chloride solution.	B	Nc1ncc(-c2cnc3ccccn23)cc1C(=O)Nc1ccncc1		CHEMBL3976903	=	IC50	nM	370.0	CHEMBL5408	Homo sapiens	IC50	nM	370.0
370586	17745370	CHEMBL3888070	TBK1 : The kinase assay is performed as 384-well Flashplate assay assay (for e.g. Topcount measurement. 0.6 nM TANK binding kinase (TBK1), 800 nM biotinylated MELK-derived peptide (Biotin-Ah-Ah-AKPKGNKDYHLQTCCGSLAYRRR) SEQ ID NO: 2 and 10 uM ATP (spiked with 0.25 uCi 33P-ATP/well) are incubated in a total volume of 50 ul (10 mM MOPS, 10 mM Mg-acetat, 0.1 mM EGTA, 1 mM DTT, 0.02% Brij35, 0.1% BSA, pH 7.5) with or without test compound for 120 Min at 30° C. The reaction is stopped with 25 ul 200 mM EDTA. After 30 Min at room temperature the liquid is removed and each well washed thrice with 100 ul 0.9% sodium chloride solution.	B	Nc1ncc(-c2cc[nH]c2)cc1C(=O)Nc1ccncc1		CHEMBL3899325	=	IC50	nM	150.0	CHEMBL5408	Homo sapiens	IC50	nM	150.0
370587	17745371	CHEMBL3888070	TBK1 : The kinase assay is performed as 384-well Flashplate assay assay (for e.g. Topcount measurement. 0.6 nM TANK binding kinase (TBK1), 800 nM biotinylated MELK-derived peptide (Biotin-Ah-Ah-AKPKGNKDYHLQTCCGSLAYRRR) SEQ ID NO: 2 and 10 uM ATP (spiked with 0.25 uCi 33P-ATP/well) are incubated in a total volume of 50 ul (10 mM MOPS, 10 mM Mg-acetat, 0.1 mM EGTA, 1 mM DTT, 0.02% Brij35, 0.1% BSA, pH 7.5) with or without test compound for 120 Min at 30° C. The reaction is stopped with 25 ul 200 mM EDTA. After 30 Min at room temperature the liquid is removed and each well washed thrice with 100 ul 0.9% sodium chloride solution.	B	Nc1ncc(-c2coc3ccccc23)cc1C(=O)Nc1ccncc1		CHEMBL3953224	=	IC50	nM	230.0	CHEMBL5408	Homo sapiens	IC50	nM	230.0
370588	17745372	CHEMBL3888070	TBK1 : The kinase assay is performed as 384-well Flashplate assay assay (for e.g. Topcount measurement. 0.6 nM TANK binding kinase (TBK1), 800 nM biotinylated MELK-derived peptide (Biotin-Ah-Ah-AKPKGNKDYHLQTCCGSLAYRRR) SEQ ID NO: 2 and 10 uM ATP (spiked with 0.25 uCi 33P-ATP/well) are incubated in a total volume of 50 ul (10 mM MOPS, 10 mM Mg-acetat, 0.1 mM EGTA, 1 mM DTT, 0.02% Brij35, 0.1% BSA, pH 7.5) with or without test compound for 120 Min at 30° C. The reaction is stopped with 25 ul 200 mM EDTA. After 30 Min at room temperature the liquid is removed and each well washed thrice with 100 ul 0.9% sodium chloride solution.	B	Cn1cc(-c2cnc(N)c(C(=O)Nc3ccncc3)c2)cn1		CHEMBL3925601	=	IC50	nM	160.0	CHEMBL5408	Homo sapiens	IC50	nM	160.0
370640	17745424	CHEMBL3888072	TBK1 Cell Assay: Assay Overview: MDA-MB-468 cells are detached with HyQ-Tase, counted, and seeded into a 384-well clear bottom TC-surface plate at density of 10,000 cells per well in a total volume of 35 ul complete medium. Alternatively cells are directly seeded from frozen vials. Cells are pre-treated with inhibitor compounds for 1 h prior to Poly(I:C) stimulation. After 2 h of incubation with Poly(I:C), cells are fixed in (para)formaldehyde (PFA) and permeabilized with methanol (MeOH). The cells are then blocked and incubated with an anti-pIRF3 antibody at 4oC overnight. The primary antibody is washed off, an AlexaFluor488-conjugated secondary is added, cells are counterstained with propidium iodide followed by image acquisition on IMX Ultra high content reader.	B	Nc1ncc(-c2ccc(CN3CCCCC3)s2)cc1C(=O)Nc1ccncc1		CHEMBL3961973	=	IC50	nM	1100.0	CHEMBL5408	Homo sapiens	IC50	nM	1100.0
370641	17745425	CHEMBL3888072	TBK1 Cell Assay: Assay Overview: MDA-MB-468 cells are detached with HyQ-Tase, counted, and seeded into a 384-well clear bottom TC-surface plate at density of 10,000 cells per well in a total volume of 35 ul complete medium. Alternatively cells are directly seeded from frozen vials. Cells are pre-treated with inhibitor compounds for 1 h prior to Poly(I:C) stimulation. After 2 h of incubation with Poly(I:C), cells are fixed in (para)formaldehyde (PFA) and permeabilized with methanol (MeOH). The cells are then blocked and incubated with an anti-pIRF3 antibody at 4oC overnight. The primary antibody is washed off, an AlexaFluor488-conjugated secondary is added, cells are counterstained with propidium iodide followed by image acquisition on IMX Ultra high content reader.	B	Nc1ncc(-c2cccc(-n3cccn3)c2)cc1C(=O)Nc1ccncc1		CHEMBL3928914	=	IC50	nM	4500.0	CHEMBL5408	Homo sapiens	IC50	nM	4500.0
370642	17745426	CHEMBL3888072	TBK1 Cell Assay: Assay Overview: MDA-MB-468 cells are detached with HyQ-Tase, counted, and seeded into a 384-well clear bottom TC-surface plate at density of 10,000 cells per well in a total volume of 35 ul complete medium. Alternatively cells are directly seeded from frozen vials. Cells are pre-treated with inhibitor compounds for 1 h prior to Poly(I:C) stimulation. After 2 h of incubation with Poly(I:C), cells are fixed in (para)formaldehyde (PFA) and permeabilized with methanol (MeOH). The cells are then blocked and incubated with an anti-pIRF3 antibody at 4oC overnight. The primary antibody is washed off, an AlexaFluor488-conjugated secondary is added, cells are counterstained with propidium iodide followed by image acquisition on IMX Ultra high content reader.	B	Nc1ncc(-c2ccc(-n3cccn3)cc2)cc1C(=O)Nc1ccncc1		CHEMBL3906387	=	IC50	nM	10000.0	CHEMBL5408	Homo sapiens	IC50	nM	10000.0
370643	17745427	CHEMBL3888072	TBK1 Cell Assay: Assay Overview: MDA-MB-468 cells are detached with HyQ-Tase, counted, and seeded into a 384-well clear bottom TC-surface plate at density of 10,000 cells per well in a total volume of 35 ul complete medium. Alternatively cells are directly seeded from frozen vials. Cells are pre-treated with inhibitor compounds for 1 h prior to Poly(I:C) stimulation. After 2 h of incubation with Poly(I:C), cells are fixed in (para)formaldehyde (PFA) and permeabilized with methanol (MeOH). The cells are then blocked and incubated with an anti-pIRF3 antibody at 4oC overnight. The primary antibody is washed off, an AlexaFluor488-conjugated secondary is added, cells are counterstained with propidium iodide followed by image acquisition on IMX Ultra high content reader.	B	COCCn1cc(-c2cnc(N)c(C(=O)Nc3ccncc3)c2)cn1		CHEMBL3937942	=	IC50	nM	7800.0	CHEMBL5408	Homo sapiens	IC50	nM	7800.0
370644	17745428	CHEMBL3888072	TBK1 Cell Assay: Assay Overview: MDA-MB-468 cells are detached with HyQ-Tase, counted, and seeded into a 384-well clear bottom TC-surface plate at density of 10,000 cells per well in a total volume of 35 ul complete medium. Alternatively cells are directly seeded from frozen vials. Cells are pre-treated with inhibitor compounds for 1 h prior to Poly(I:C) stimulation. After 2 h of incubation with Poly(I:C), cells are fixed in (para)formaldehyde (PFA) and permeabilized with methanol (MeOH). The cells are then blocked and incubated with an anti-pIRF3 antibody at 4oC overnight. The primary antibody is washed off, an AlexaFluor488-conjugated secondary is added, cells are counterstained with propidium iodide followed by image acquisition on IMX Ultra high content reader.	B	Cc1cc(NC(=O)c2cc(-c3ccc(CN4CCOCC4)s3)cnc2N)ccn1		CHEMBL3943325	=	IC50	nM	3100.0	CHEMBL5408	Homo sapiens	IC50	nM	3100.0
370645	17745429	CHEMBL3888072	TBK1 Cell Assay: Assay Overview: MDA-MB-468 cells are detached with HyQ-Tase, counted, and seeded into a 384-well clear bottom TC-surface plate at density of 10,000 cells per well in a total volume of 35 ul complete medium. Alternatively cells are directly seeded from frozen vials. Cells are pre-treated with inhibitor compounds for 1 h prior to Poly(I:C) stimulation. After 2 h of incubation with Poly(I:C), cells are fixed in (para)formaldehyde (PFA) and permeabilized with methanol (MeOH). The cells are then blocked and incubated with an anti-pIRF3 antibody at 4oC overnight. The primary antibody is washed off, an AlexaFluor488-conjugated secondary is added, cells are counterstained with propidium iodide followed by image acquisition on IMX Ultra high content reader.	B	CCOc1cc(NC(=O)c2cc(-c3ccc(CN4CCOCC4)s3)cnc2N)ccn1		CHEMBL3899705	=	IC50	nM	3000.0	CHEMBL5408	Homo sapiens	IC50	nM	3000.0
370646	17745430	CHEMBL3888072	TBK1 Cell Assay: Assay Overview: MDA-MB-468 cells are detached with HyQ-Tase, counted, and seeded into a 384-well clear bottom TC-surface plate at density of 10,000 cells per well in a total volume of 35 ul complete medium. Alternatively cells are directly seeded from frozen vials. Cells are pre-treated with inhibitor compounds for 1 h prior to Poly(I:C) stimulation. After 2 h of incubation with Poly(I:C), cells are fixed in (para)formaldehyde (PFA) and permeabilized with methanol (MeOH). The cells are then blocked and incubated with an anti-pIRF3 antibody at 4oC overnight. The primary antibody is washed off, an AlexaFluor488-conjugated secondary is added, cells are counterstained with propidium iodide followed by image acquisition on IMX Ultra high content reader.	B	Nc1ncc(-c2ccc(N3CCNCC3)nc2)cc1C(=O)Nc1ccncc1		CHEMBL3936692	=	IC50	nM	9800.0	CHEMBL5408	Homo sapiens	IC50	nM	9800.0
370647	17745431	CHEMBL3888072	TBK1 Cell Assay: Assay Overview: MDA-MB-468 cells are detached with HyQ-Tase, counted, and seeded into a 384-well clear bottom TC-surface plate at density of 10,000 cells per well in a total volume of 35 ul complete medium. Alternatively cells are directly seeded from frozen vials. Cells are pre-treated with inhibitor compounds for 1 h prior to Poly(I:C) stimulation. After 2 h of incubation with Poly(I:C), cells are fixed in (para)formaldehyde (PFA) and permeabilized with methanol (MeOH). The cells are then blocked and incubated with an anti-pIRF3 antibody at 4oC overnight. The primary antibody is washed off, an AlexaFluor488-conjugated secondary is added, cells are counterstained with propidium iodide followed by image acquisition on IMX Ultra high content reader.	B	Nc1ncc(-c2ccc(CN3CCOCC3)s2)cc1C(=O)Nc1ccnnc1		CHEMBL3980829	=	IC50	nM	9300.0	CHEMBL5408	Homo sapiens	IC50	nM	9300.0
370648	17745432	CHEMBL3888072	TBK1 Cell Assay: Assay Overview: MDA-MB-468 cells are detached with HyQ-Tase, counted, and seeded into a 384-well clear bottom TC-surface plate at density of 10,000 cells per well in a total volume of 35 ul complete medium. Alternatively cells are directly seeded from frozen vials. Cells are pre-treated with inhibitor compounds for 1 h prior to Poly(I:C) stimulation. After 2 h of incubation with Poly(I:C), cells are fixed in (para)formaldehyde (PFA) and permeabilized with methanol (MeOH). The cells are then blocked and incubated with an anti-pIRF3 antibody at 4oC overnight. The primary antibody is washed off, an AlexaFluor488-conjugated secondary is added, cells are counterstained with propidium iodide followed by image acquisition on IMX Ultra high content reader.	B	Cc1cc(NC(=O)c2cc(-c3cnn(Cc4ccccc4)c3)cnc2N)ccn1		CHEMBL3975991	=	IC50	nM	8100.0	CHEMBL5408	Homo sapiens	IC50	nM	8100.0
370649	17745433	CHEMBL3888072	TBK1 Cell Assay: Assay Overview: MDA-MB-468 cells are detached with HyQ-Tase, counted, and seeded into a 384-well clear bottom TC-surface plate at density of 10,000 cells per well in a total volume of 35 ul complete medium. Alternatively cells are directly seeded from frozen vials. Cells are pre-treated with inhibitor compounds for 1 h prior to Poly(I:C) stimulation. After 2 h of incubation with Poly(I:C), cells are fixed in (para)formaldehyde (PFA) and permeabilized with methanol (MeOH). The cells are then blocked and incubated with an anti-pIRF3 antibody at 4oC overnight. The primary antibody is washed off, an AlexaFluor488-conjugated secondary is added, cells are counterstained with propidium iodide followed by image acquisition on IMX Ultra high content reader.	B	Cc1cnccc1NC(=O)c1cc(-c2ccc(CN3CCOCC3)s2)cnc1N		CHEMBL3892127	=	IC50	nM	7000.0	CHEMBL5408	Homo sapiens	IC50	nM	7000.0
429012	17790680	CHEMBL3889017	Time-Resolved Fluorescence-based Lanthascreen Assay: Kinase inhibition assays (10 μL) were performed at 20° C. in 384-well plate format. Compound IC50 values were determined at the apparent Km for ATP (20 μM) based on a radiometric assay (Invitrogen) using 8 or 10 point curves in duplicate. The final reaction conditions contained 400 nM fluorescein-IkBα substrate (DRHDSGLDSMKDE), 20 μM ATP, 2 nM or 8 nM IKKε or TBK1 kinase respectively, and 3% DMSO in kinase assay buffer consisting of 50 mM HEPES (pH 7.5), 10 mM MgCl, 1 mM EGTA, 0.01% Brij-35.Compound dilutions were prepared from 10 mM DMSO stocks by dilution into DMSO. Compound dilution series were further diluted in kinase assay buffer to give a 12% DMSO stock, the final concentration in the assay being 3% DMSO.The kinase phosphorylation assay was initiated by the addition of the kinase and the reaction was allowed to proceed for 1 h or 2.5 h for IKKε and TBK-1 kinase respectively.	B	CN1CCC(NC(=O)c2cccc(Nc3nccc(-c4cnc(N5CC[C@H](F)C5)c(C#N)c4)n3)c2)CC1		CHEMBL3931115	<	IC50	nM	30.0	CHEMBL5408	Homo sapiens	IC50	nM	30.0
429013	17790681	CHEMBL3889017	Time-Resolved Fluorescence-based Lanthascreen Assay: Kinase inhibition assays (10 μL) were performed at 20° C. in 384-well plate format. Compound IC50 values were determined at the apparent Km for ATP (20 μM) based on a radiometric assay (Invitrogen) using 8 or 10 point curves in duplicate. The final reaction conditions contained 400 nM fluorescein-IkBα substrate (DRHDSGLDSMKDE), 20 μM ATP, 2 nM or 8 nM IKKε or TBK1 kinase respectively, and 3% DMSO in kinase assay buffer consisting of 50 mM HEPES (pH 7.5), 10 mM MgCl, 1 mM EGTA, 0.01% Brij-35.Compound dilutions were prepared from 10 mM DMSO stocks by dilution into DMSO. Compound dilution series were further diluted in kinase assay buffer to give a 12% DMSO stock, the final concentration in the assay being 3% DMSO.The kinase phosphorylation assay was initiated by the addition of the kinase and the reaction was allowed to proceed for 1 h or 2.5 h for IKKε and TBK-1 kinase respectively.	B	N#Cc1cc(-c2ccnc(Nc3cccc(C(N)=O)c3)n2)cnc1N1CCCC1		CHEMBL3927043	<	IC50	nM	30.0	CHEMBL5408	Homo sapiens	IC50	nM	30.0
429014	17790682	CHEMBL3889017	Time-Resolved Fluorescence-based Lanthascreen Assay: Kinase inhibition assays (10 μL) were performed at 20° C. in 384-well plate format. Compound IC50 values were determined at the apparent Km for ATP (20 μM) based on a radiometric assay (Invitrogen) using 8 or 10 point curves in duplicate. The final reaction conditions contained 400 nM fluorescein-IkBα substrate (DRHDSGLDSMKDE), 20 μM ATP, 2 nM or 8 nM IKKε or TBK1 kinase respectively, and 3% DMSO in kinase assay buffer consisting of 50 mM HEPES (pH 7.5), 10 mM MgCl, 1 mM EGTA, 0.01% Brij-35.Compound dilutions were prepared from 10 mM DMSO stocks by dilution into DMSO. Compound dilution series were further diluted in kinase assay buffer to give a 12% DMSO stock, the final concentration in the assay being 3% DMSO.The kinase phosphorylation assay was initiated by the addition of the kinase and the reaction was allowed to proceed for 1 h or 2.5 h for IKKε and TBK-1 kinase respectively.	B	CN1CCN(c2ccc(Nc3nccc(-c4cnc(N5CCCC5)c(C#N)c4)n3)cn2)CC1		CHEMBL3930440	<	IC50	nM	15.0	CHEMBL5408	Homo sapiens	IC50	nM	15.0
429015	17790683	CHEMBL3889017	Time-Resolved Fluorescence-based Lanthascreen Assay: Kinase inhibition assays (10 μL) were performed at 20° C. in 384-well plate format. Compound IC50 values were determined at the apparent Km for ATP (20 μM) based on a radiometric assay (Invitrogen) using 8 or 10 point curves in duplicate. The final reaction conditions contained 400 nM fluorescein-IkBα substrate (DRHDSGLDSMKDE), 20 μM ATP, 2 nM or 8 nM IKKε or TBK1 kinase respectively, and 3% DMSO in kinase assay buffer consisting of 50 mM HEPES (pH 7.5), 10 mM MgCl, 1 mM EGTA, 0.01% Brij-35.Compound dilutions were prepared from 10 mM DMSO stocks by dilution into DMSO. Compound dilution series were further diluted in kinase assay buffer to give a 12% DMSO stock, the final concentration in the assay being 3% DMSO.The kinase phosphorylation assay was initiated by the addition of the kinase and the reaction was allowed to proceed for 1 h or 2.5 h for IKKε and TBK-1 kinase respectively.	B	N#Cc1cc(-c2ccnc(Nc3cccc(C(=O)N4CCNCC4)c3)n2)cnc1N1CC[C@H](F)C1		CHEMBL3921622	<	IC50	nM	30.0	CHEMBL5408	Homo sapiens	IC50	nM	30.0
429016	17790684	CHEMBL3889017	Time-Resolved Fluorescence-based Lanthascreen Assay: Kinase inhibition assays (10 μL) were performed at 20° C. in 384-well plate format. Compound IC50 values were determined at the apparent Km for ATP (20 μM) based on a radiometric assay (Invitrogen) using 8 or 10 point curves in duplicate. The final reaction conditions contained 400 nM fluorescein-IkBα substrate (DRHDSGLDSMKDE), 20 μM ATP, 2 nM or 8 nM IKKε or TBK1 kinase respectively, and 3% DMSO in kinase assay buffer consisting of 50 mM HEPES (pH 7.5), 10 mM MgCl, 1 mM EGTA, 0.01% Brij-35.Compound dilutions were prepared from 10 mM DMSO stocks by dilution into DMSO. Compound dilution series were further diluted in kinase assay buffer to give a 12% DMSO stock, the final concentration in the assay being 3% DMSO.The kinase phosphorylation assay was initiated by the addition of the kinase and the reaction was allowed to proceed for 1 h or 2.5 h for IKKε and TBK-1 kinase respectively.	B	N#Cc1cc(-c2ccnc(Nc3ccc(N4CCOCC4)cc3)n2)cnc1N1CCCC1		CHEMBL3963738	<	IC50	nM	15.0	CHEMBL5408	Homo sapiens	IC50	nM	15.0
429017	17790685	CHEMBL3889017	Time-Resolved Fluorescence-based Lanthascreen Assay: Kinase inhibition assays (10 μL) were performed at 20° C. in 384-well plate format. Compound IC50 values were determined at the apparent Km for ATP (20 μM) based on a radiometric assay (Invitrogen) using 8 or 10 point curves in duplicate. The final reaction conditions contained 400 nM fluorescein-IkBα substrate (DRHDSGLDSMKDE), 20 μM ATP, 2 nM or 8 nM IKKε or TBK1 kinase respectively, and 3% DMSO in kinase assay buffer consisting of 50 mM HEPES (pH 7.5), 10 mM MgCl, 1 mM EGTA, 0.01% Brij-35.Compound dilutions were prepared from 10 mM DMSO stocks by dilution into DMSO. Compound dilution series were further diluted in kinase assay buffer to give a 12% DMSO stock, the final concentration in the assay being 3% DMSO.The kinase phosphorylation assay was initiated by the addition of the kinase and the reaction was allowed to proceed for 1 h or 2.5 h for IKKε and TBK-1 kinase respectively.	B	CN1CCN(C(=O)c2cccc(Nc3nccc(-c4cnc(N5CC[C@H](F)C5)c(C#N)c4)n3)c2)CC1		CHEMBL3920382	<	IC50	nM	30.0	CHEMBL5408	Homo sapiens	IC50	nM	30.0
429018	17790686	CHEMBL3889017	Time-Resolved Fluorescence-based Lanthascreen Assay: Kinase inhibition assays (10 μL) were performed at 20° C. in 384-well plate format. Compound IC50 values were determined at the apparent Km for ATP (20 μM) based on a radiometric assay (Invitrogen) using 8 or 10 point curves in duplicate. The final reaction conditions contained 400 nM fluorescein-IkBα substrate (DRHDSGLDSMKDE), 20 μM ATP, 2 nM or 8 nM IKKε or TBK1 kinase respectively, and 3% DMSO in kinase assay buffer consisting of 50 mM HEPES (pH 7.5), 10 mM MgCl, 1 mM EGTA, 0.01% Brij-35.Compound dilutions were prepared from 10 mM DMSO stocks by dilution into DMSO. Compound dilution series were further diluted in kinase assay buffer to give a 12% DMSO stock, the final concentration in the assay being 3% DMSO.The kinase phosphorylation assay was initiated by the addition of the kinase and the reaction was allowed to proceed for 1 h or 2.5 h for IKKε and TBK-1 kinase respectively.	B	Cn1cc(Nc2nccc(-c3cnc(N4CC[C@H](F)C4)c(C#N)c3)n2)cn1		CHEMBL3944797	<	IC50	nM	30.0	CHEMBL5408	Homo sapiens	IC50	nM	30.0
429019	17790687	CHEMBL3889017	Time-Resolved Fluorescence-based Lanthascreen Assay: Kinase inhibition assays (10 μL) were performed at 20° C. in 384-well plate format. Compound IC50 values were determined at the apparent Km for ATP (20 μM) based on a radiometric assay (Invitrogen) using 8 or 10 point curves in duplicate. The final reaction conditions contained 400 nM fluorescein-IkBα substrate (DRHDSGLDSMKDE), 20 μM ATP, 2 nM or 8 nM IKKε or TBK1 kinase respectively, and 3% DMSO in kinase assay buffer consisting of 50 mM HEPES (pH 7.5), 10 mM MgCl, 1 mM EGTA, 0.01% Brij-35.Compound dilutions were prepared from 10 mM DMSO stocks by dilution into DMSO. Compound dilution series were further diluted in kinase assay buffer to give a 12% DMSO stock, the final concentration in the assay being 3% DMSO.The kinase phosphorylation assay was initiated by the addition of the kinase and the reaction was allowed to proceed for 1 h or 2.5 h for IKKε and TBK-1 kinase respectively.	B	CC(=O)Nc1ccc(Nc2nccc(-c3cnc(N4CC[C@H](F)C4)c(C#N)c3)n2)cn1		CHEMBL3907890	<	IC50	nM	30.0	CHEMBL5408	Homo sapiens	IC50	nM	30.0
429020	17790688	CHEMBL3889017	Time-Resolved Fluorescence-based Lanthascreen Assay: Kinase inhibition assays (10 μL) were performed at 20° C. in 384-well plate format. Compound IC50 values were determined at the apparent Km for ATP (20 μM) based on a radiometric assay (Invitrogen) using 8 or 10 point curves in duplicate. The final reaction conditions contained 400 nM fluorescein-IkBα substrate (DRHDSGLDSMKDE), 20 μM ATP, 2 nM or 8 nM IKKε or TBK1 kinase respectively, and 3% DMSO in kinase assay buffer consisting of 50 mM HEPES (pH 7.5), 10 mM MgCl, 1 mM EGTA, 0.01% Brij-35.Compound dilutions were prepared from 10 mM DMSO stocks by dilution into DMSO. Compound dilution series were further diluted in kinase assay buffer to give a 12% DMSO stock, the final concentration in the assay being 3% DMSO.The kinase phosphorylation assay was initiated by the addition of the kinase and the reaction was allowed to proceed for 1 h or 2.5 h for IKKε and TBK-1 kinase respectively.	B	CN1CCC(Nc2ccc(Nc3nccc(-c4cnc(N5CC[C@H](F)C5)c(C#N)c4)n3)cn2)CC1		CHEMBL3935860	<	IC50	nM	30.0	CHEMBL5408	Homo sapiens	IC50	nM	30.0
429021	17790689	CHEMBL3889017	Time-Resolved Fluorescence-based Lanthascreen Assay: Kinase inhibition assays (10 μL) were performed at 20° C. in 384-well plate format. Compound IC50 values were determined at the apparent Km for ATP (20 μM) based on a radiometric assay (Invitrogen) using 8 or 10 point curves in duplicate. The final reaction conditions contained 400 nM fluorescein-IkBα substrate (DRHDSGLDSMKDE), 20 μM ATP, 2 nM or 8 nM IKKε or TBK1 kinase respectively, and 3% DMSO in kinase assay buffer consisting of 50 mM HEPES (pH 7.5), 10 mM MgCl, 1 mM EGTA, 0.01% Brij-35.Compound dilutions were prepared from 10 mM DMSO stocks by dilution into DMSO. Compound dilution series were further diluted in kinase assay buffer to give a 12% DMSO stock, the final concentration in the assay being 3% DMSO.The kinase phosphorylation assay was initiated by the addition of the kinase and the reaction was allowed to proceed for 1 h or 2.5 h for IKKε and TBK-1 kinase respectively.	B	N#Cc1cc(-c2ccnc(Nc3ccc(NC4CCNCC4)nc3)n2)cnc1N1CC[C@H](F)C1		CHEMBL3891126	<	IC50	nM	30.0	CHEMBL5408	Homo sapiens	IC50	nM	30.0
429022	17790690	CHEMBL3889017	Time-Resolved Fluorescence-based Lanthascreen Assay: Kinase inhibition assays (10 μL) were performed at 20° C. in 384-well plate format. Compound IC50 values were determined at the apparent Km for ATP (20 μM) based on a radiometric assay (Invitrogen) using 8 or 10 point curves in duplicate. The final reaction conditions contained 400 nM fluorescein-IkBα substrate (DRHDSGLDSMKDE), 20 μM ATP, 2 nM or 8 nM IKKε or TBK1 kinase respectively, and 3% DMSO in kinase assay buffer consisting of 50 mM HEPES (pH 7.5), 10 mM MgCl, 1 mM EGTA, 0.01% Brij-35.Compound dilutions were prepared from 10 mM DMSO stocks by dilution into DMSO. Compound dilution series were further diluted in kinase assay buffer to give a 12% DMSO stock, the final concentration in the assay being 3% DMSO.The kinase phosphorylation assay was initiated by the addition of the kinase and the reaction was allowed to proceed for 1 h or 2.5 h for IKKε and TBK-1 kinase respectively.	B	N#Cc1cc(-c2ccnc(Nc3cccc(C(=O)NC4CCNCC4)c3)n2)cnc1N1CC[C@H](F)C1		CHEMBL3922677	<	IC50	nM	30.0	CHEMBL5408	Homo sapiens	IC50	nM	30.0
429023	17790691	CHEMBL3889017	Time-Resolved Fluorescence-based Lanthascreen Assay: Kinase inhibition assays (10 μL) were performed at 20° C. in 384-well plate format. Compound IC50 values were determined at the apparent Km for ATP (20 μM) based on a radiometric assay (Invitrogen) using 8 or 10 point curves in duplicate. The final reaction conditions contained 400 nM fluorescein-IkBα substrate (DRHDSGLDSMKDE), 20 μM ATP, 2 nM or 8 nM IKKε or TBK1 kinase respectively, and 3% DMSO in kinase assay buffer consisting of 50 mM HEPES (pH 7.5), 10 mM MgCl, 1 mM EGTA, 0.01% Brij-35.Compound dilutions were prepared from 10 mM DMSO stocks by dilution into DMSO. Compound dilution series were further diluted in kinase assay buffer to give a 12% DMSO stock, the final concentration in the assay being 3% DMSO.The kinase phosphorylation assay was initiated by the addition of the kinase and the reaction was allowed to proceed for 1 h or 2.5 h for IKKε and TBK-1 kinase respectively.	B	CN1CCC(NC(=O)c2cccc(Nc3nccc(-c4cnc(N5CC[C@H](O)C5)c(C#N)c4)n3)c2)CC1		CHEMBL3967101	<	IC50	nM	100.0	CHEMBL5408	Homo sapiens	IC50	nM	100.0
429024	17790692	CHEMBL3889017	Time-Resolved Fluorescence-based Lanthascreen Assay: Kinase inhibition assays (10 μL) were performed at 20° C. in 384-well plate format. Compound IC50 values were determined at the apparent Km for ATP (20 μM) based on a radiometric assay (Invitrogen) using 8 or 10 point curves in duplicate. The final reaction conditions contained 400 nM fluorescein-IkBα substrate (DRHDSGLDSMKDE), 20 μM ATP, 2 nM or 8 nM IKKε or TBK1 kinase respectively, and 3% DMSO in kinase assay buffer consisting of 50 mM HEPES (pH 7.5), 10 mM MgCl, 1 mM EGTA, 0.01% Brij-35.Compound dilutions were prepared from 10 mM DMSO stocks by dilution into DMSO. Compound dilution series were further diluted in kinase assay buffer to give a 12% DMSO stock, the final concentration in the assay being 3% DMSO.The kinase phosphorylation assay was initiated by the addition of the kinase and the reaction was allowed to proceed for 1 h or 2.5 h for IKKε and TBK-1 kinase respectively.	B	CN1CCC(Nc2ccc(Nc3nccc(-c4cnc(N5CC[C@H](O)C5)c(C#N)c4)n3)cn2)CC1		CHEMBL3940936	<	IC50	nM	100.0	CHEMBL5408	Homo sapiens	IC50	nM	100.0
429025	17790693	CHEMBL3889017	Time-Resolved Fluorescence-based Lanthascreen Assay: Kinase inhibition assays (10 μL) were performed at 20° C. in 384-well plate format. Compound IC50 values were determined at the apparent Km for ATP (20 μM) based on a radiometric assay (Invitrogen) using 8 or 10 point curves in duplicate. The final reaction conditions contained 400 nM fluorescein-IkBα substrate (DRHDSGLDSMKDE), 20 μM ATP, 2 nM or 8 nM IKKε or TBK1 kinase respectively, and 3% DMSO in kinase assay buffer consisting of 50 mM HEPES (pH 7.5), 10 mM MgCl, 1 mM EGTA, 0.01% Brij-35.Compound dilutions were prepared from 10 mM DMSO stocks by dilution into DMSO. Compound dilution series were further diluted in kinase assay buffer to give a 12% DMSO stock, the final concentration in the assay being 3% DMSO.The kinase phosphorylation assay was initiated by the addition of the kinase and the reaction was allowed to proceed for 1 h or 2.5 h for IKKε and TBK-1 kinase respectively.	B	CN1CCC(NC(=O)c2cccc(Nc3nccc(-c4cnc(N5CCC(F)(F)C5)c(C#N)c4)n3)c2)CC1		CHEMBL3955989	<	IC50	nM	100.0	CHEMBL5408	Homo sapiens	IC50	nM	100.0
429026	17790694	CHEMBL3889017	Time-Resolved Fluorescence-based Lanthascreen Assay: Kinase inhibition assays (10 μL) were performed at 20° C. in 384-well plate format. Compound IC50 values were determined at the apparent Km for ATP (20 μM) based on a radiometric assay (Invitrogen) using 8 or 10 point curves in duplicate. The final reaction conditions contained 400 nM fluorescein-IkBα substrate (DRHDSGLDSMKDE), 20 μM ATP, 2 nM or 8 nM IKKε or TBK1 kinase respectively, and 3% DMSO in kinase assay buffer consisting of 50 mM HEPES (pH 7.5), 10 mM MgCl, 1 mM EGTA, 0.01% Brij-35.Compound dilutions were prepared from 10 mM DMSO stocks by dilution into DMSO. Compound dilution series were further diluted in kinase assay buffer to give a 12% DMSO stock, the final concentration in the assay being 3% DMSO.The kinase phosphorylation assay was initiated by the addition of the kinase and the reaction was allowed to proceed for 1 h or 2.5 h for IKKε and TBK-1 kinase respectively.	B	CN1CCC(Nc2ccc(Nc3nccc(-c4cnc(N5CCC(F)(F)C5)c(C#N)c4)n3)cn2)CC1		CHEMBL3928378	<	IC50	nM	30.0	CHEMBL5408	Homo sapiens	IC50	nM	30.0
429027	17790695	CHEMBL3889017	Time-Resolved Fluorescence-based Lanthascreen Assay: Kinase inhibition assays (10 μL) were performed at 20° C. in 384-well plate format. Compound IC50 values were determined at the apparent Km for ATP (20 μM) based on a radiometric assay (Invitrogen) using 8 or 10 point curves in duplicate. The final reaction conditions contained 400 nM fluorescein-IkBα substrate (DRHDSGLDSMKDE), 20 μM ATP, 2 nM or 8 nM IKKε or TBK1 kinase respectively, and 3% DMSO in kinase assay buffer consisting of 50 mM HEPES (pH 7.5), 10 mM MgCl, 1 mM EGTA, 0.01% Brij-35.Compound dilutions were prepared from 10 mM DMSO stocks by dilution into DMSO. Compound dilution series were further diluted in kinase assay buffer to give a 12% DMSO stock, the final concentration in the assay being 3% DMSO.The kinase phosphorylation assay was initiated by the addition of the kinase and the reaction was allowed to proceed for 1 h or 2.5 h for IKKε and TBK-1 kinase respectively.	B	Cn1cc(Nc2nccc(-c3cnc(N4CC[C@H](O)C4)c(C#N)c3)n2)cn1		CHEMBL3950694	<	IC50	nM	100.0	CHEMBL5408	Homo sapiens	IC50	nM	100.0
429028	17790696	CHEMBL3889017	Time-Resolved Fluorescence-based Lanthascreen Assay: Kinase inhibition assays (10 μL) were performed at 20° C. in 384-well plate format. Compound IC50 values were determined at the apparent Km for ATP (20 μM) based on a radiometric assay (Invitrogen) using 8 or 10 point curves in duplicate. The final reaction conditions contained 400 nM fluorescein-IkBα substrate (DRHDSGLDSMKDE), 20 μM ATP, 2 nM or 8 nM IKKε or TBK1 kinase respectively, and 3% DMSO in kinase assay buffer consisting of 50 mM HEPES (pH 7.5), 10 mM MgCl, 1 mM EGTA, 0.01% Brij-35.Compound dilutions were prepared from 10 mM DMSO stocks by dilution into DMSO. Compound dilution series were further diluted in kinase assay buffer to give a 12% DMSO stock, the final concentration in the assay being 3% DMSO.The kinase phosphorylation assay was initiated by the addition of the kinase and the reaction was allowed to proceed for 1 h or 2.5 h for IKKε and TBK-1 kinase respectively.	B	N#Cc1cc(-c2ccnc(Nc3ccc(NC(=O)CN4CCOCC4)nc3)n2)cnc1N1CC[C@H](F)C1		CHEMBL3919474	<	IC50	nM	30.0	CHEMBL5408	Homo sapiens	IC50	nM	30.0
429029	17790697	CHEMBL3889017	Time-Resolved Fluorescence-based Lanthascreen Assay: Kinase inhibition assays (10 μL) were performed at 20° C. in 384-well plate format. Compound IC50 values were determined at the apparent Km for ATP (20 μM) based on a radiometric assay (Invitrogen) using 8 or 10 point curves in duplicate. The final reaction conditions contained 400 nM fluorescein-IkBα substrate (DRHDSGLDSMKDE), 20 μM ATP, 2 nM or 8 nM IKKε or TBK1 kinase respectively, and 3% DMSO in kinase assay buffer consisting of 50 mM HEPES (pH 7.5), 10 mM MgCl, 1 mM EGTA, 0.01% Brij-35.Compound dilutions were prepared from 10 mM DMSO stocks by dilution into DMSO. Compound dilution series were further diluted in kinase assay buffer to give a 12% DMSO stock, the final concentration in the assay being 3% DMSO.The kinase phosphorylation assay was initiated by the addition of the kinase and the reaction was allowed to proceed for 1 h or 2.5 h for IKKε and TBK-1 kinase respectively.	B	CC(C(=O)Nc1ccc(Nc2nccc(-c3cnc(N4CC[C@H](F)C4)c(C#N)c3)n2)cn1)N(C)C		CHEMBL3941967	<	IC50	nM	100.0	CHEMBL5408	Homo sapiens	IC50	nM	100.0
429030	17790698	CHEMBL3889017	Time-Resolved Fluorescence-based Lanthascreen Assay: Kinase inhibition assays (10 μL) were performed at 20° C. in 384-well plate format. Compound IC50 values were determined at the apparent Km for ATP (20 μM) based on a radiometric assay (Invitrogen) using 8 or 10 point curves in duplicate. The final reaction conditions contained 400 nM fluorescein-IkBα substrate (DRHDSGLDSMKDE), 20 μM ATP, 2 nM or 8 nM IKKε or TBK1 kinase respectively, and 3% DMSO in kinase assay buffer consisting of 50 mM HEPES (pH 7.5), 10 mM MgCl, 1 mM EGTA, 0.01% Brij-35.Compound dilutions were prepared from 10 mM DMSO stocks by dilution into DMSO. Compound dilution series were further diluted in kinase assay buffer to give a 12% DMSO stock, the final concentration in the assay being 3% DMSO.The kinase phosphorylation assay was initiated by the addition of the kinase and the reaction was allowed to proceed for 1 h or 2.5 h for IKKε and TBK-1 kinase respectively.	B	N#Cc1cc(-c2ccnc(Nc3ccc(NC(=O)C4CC4)nc3)n2)cnc1N1CC[C@H](F)C1		CHEMBL3913990	<	IC50	nM	100.0	CHEMBL5408	Homo sapiens	IC50	nM	100.0
429031	17790699	CHEMBL3889017	Time-Resolved Fluorescence-based Lanthascreen Assay: Kinase inhibition assays (10 μL) were performed at 20° C. in 384-well plate format. Compound IC50 values were determined at the apparent Km for ATP (20 μM) based on a radiometric assay (Invitrogen) using 8 or 10 point curves in duplicate. The final reaction conditions contained 400 nM fluorescein-IkBα substrate (DRHDSGLDSMKDE), 20 μM ATP, 2 nM or 8 nM IKKε or TBK1 kinase respectively, and 3% DMSO in kinase assay buffer consisting of 50 mM HEPES (pH 7.5), 10 mM MgCl, 1 mM EGTA, 0.01% Brij-35.Compound dilutions were prepared from 10 mM DMSO stocks by dilution into DMSO. Compound dilution series were further diluted in kinase assay buffer to give a 12% DMSO stock, the final concentration in the assay being 3% DMSO.The kinase phosphorylation assay was initiated by the addition of the kinase and the reaction was allowed to proceed for 1 h or 2.5 h for IKKε and TBK-1 kinase respectively.	B	N#Cc1cc(-c2ccnc(Nc3cnc(N4CCOCC4)nc3)n2)cnc1N1CC[C@H](F)C1		CHEMBL3929435	<	IC50	nM	100.0	CHEMBL5408	Homo sapiens	IC50	nM	100.0
429032	17790700	CHEMBL3889017	Time-Resolved Fluorescence-based Lanthascreen Assay: Kinase inhibition assays (10 μL) were performed at 20° C. in 384-well plate format. Compound IC50 values were determined at the apparent Km for ATP (20 μM) based on a radiometric assay (Invitrogen) using 8 or 10 point curves in duplicate. The final reaction conditions contained 400 nM fluorescein-IkBα substrate (DRHDSGLDSMKDE), 20 μM ATP, 2 nM or 8 nM IKKε or TBK1 kinase respectively, and 3% DMSO in kinase assay buffer consisting of 50 mM HEPES (pH 7.5), 10 mM MgCl, 1 mM EGTA, 0.01% Brij-35.Compound dilutions were prepared from 10 mM DMSO stocks by dilution into DMSO. Compound dilution series were further diluted in kinase assay buffer to give a 12% DMSO stock, the final concentration in the assay being 3% DMSO.The kinase phosphorylation assay was initiated by the addition of the kinase and the reaction was allowed to proceed for 1 h or 2.5 h for IKKε and TBK-1 kinase respectively.	B	COCCN(C)CC(=O)Nc1ccc(Nc2nccc(-c3cnc(N4CC[C@H](F)C4)c(C#N)c3)n2)cn1		CHEMBL3904988	<	IC50	nM	30.0	CHEMBL5408	Homo sapiens	IC50	nM	30.0
429033	17790701	CHEMBL3889017	Time-Resolved Fluorescence-based Lanthascreen Assay: Kinase inhibition assays (10 μL) were performed at 20° C. in 384-well plate format. Compound IC50 values were determined at the apparent Km for ATP (20 μM) based on a radiometric assay (Invitrogen) using 8 or 10 point curves in duplicate. The final reaction conditions contained 400 nM fluorescein-IkBα substrate (DRHDSGLDSMKDE), 20 μM ATP, 2 nM or 8 nM IKKε or TBK1 kinase respectively, and 3% DMSO in kinase assay buffer consisting of 50 mM HEPES (pH 7.5), 10 mM MgCl, 1 mM EGTA, 0.01% Brij-35.Compound dilutions were prepared from 10 mM DMSO stocks by dilution into DMSO. Compound dilution series were further diluted in kinase assay buffer to give a 12% DMSO stock, the final concentration in the assay being 3% DMSO.The kinase phosphorylation assay was initiated by the addition of the kinase and the reaction was allowed to proceed for 1 h or 2.5 h for IKKε and TBK-1 kinase respectively.	B	CC(C)(O)CNc1ccc(Nc2nccc(-c3cnc(N4CC[C@H](F)C4)c(C#N)c3)n2)cn1		CHEMBL3980518	<	IC50	nM	30.0	CHEMBL5408	Homo sapiens	IC50	nM	30.0
429034	17790702	CHEMBL3889017	Time-Resolved Fluorescence-based Lanthascreen Assay: Kinase inhibition assays (10 μL) were performed at 20° C. in 384-well plate format. Compound IC50 values were determined at the apparent Km for ATP (20 μM) based on a radiometric assay (Invitrogen) using 8 or 10 point curves in duplicate. The final reaction conditions contained 400 nM fluorescein-IkBα substrate (DRHDSGLDSMKDE), 20 μM ATP, 2 nM or 8 nM IKKε or TBK1 kinase respectively, and 3% DMSO in kinase assay buffer consisting of 50 mM HEPES (pH 7.5), 10 mM MgCl, 1 mM EGTA, 0.01% Brij-35.Compound dilutions were prepared from 10 mM DMSO stocks by dilution into DMSO. Compound dilution series were further diluted in kinase assay buffer to give a 12% DMSO stock, the final concentration in the assay being 3% DMSO.The kinase phosphorylation assay was initiated by the addition of the kinase and the reaction was allowed to proceed for 1 h or 2.5 h for IKKε and TBK-1 kinase respectively.	B	CC(C)N1CCN(CC(=O)Nc2ccc(Nc3nccc(-c4cnc(N5CC[C@H](F)C5)c(C#N)c4)n3)cn2)CC1		CHEMBL3910408	<	IC50	nM	30.0	CHEMBL5408	Homo sapiens	IC50	nM	30.0
429035	17790703	CHEMBL3889017	Time-Resolved Fluorescence-based Lanthascreen Assay: Kinase inhibition assays (10 μL) were performed at 20° C. in 384-well plate format. Compound IC50 values were determined at the apparent Km for ATP (20 μM) based on a radiometric assay (Invitrogen) using 8 or 10 point curves in duplicate. The final reaction conditions contained 400 nM fluorescein-IkBα substrate (DRHDSGLDSMKDE), 20 μM ATP, 2 nM or 8 nM IKKε or TBK1 kinase respectively, and 3% DMSO in kinase assay buffer consisting of 50 mM HEPES (pH 7.5), 10 mM MgCl, 1 mM EGTA, 0.01% Brij-35.Compound dilutions were prepared from 10 mM DMSO stocks by dilution into DMSO. Compound dilution series were further diluted in kinase assay buffer to give a 12% DMSO stock, the final concentration in the assay being 3% DMSO.The kinase phosphorylation assay was initiated by the addition of the kinase and the reaction was allowed to proceed for 1 h or 2.5 h for IKKε and TBK-1 kinase respectively.	B	CN1CCN(c2ccc(Nc3nccc(-c4cnc(N5CC[C@H](F)C5)c(C#N)c4)n3)cn2)CC1		CHEMBL3985538	<	IC50	nM	15.0	CHEMBL5408	Homo sapiens	IC50	nM	15.0
429036	17790704	CHEMBL3889017	Time-Resolved Fluorescence-based Lanthascreen Assay: Kinase inhibition assays (10 μL) were performed at 20° C. in 384-well plate format. Compound IC50 values were determined at the apparent Km for ATP (20 μM) based on a radiometric assay (Invitrogen) using 8 or 10 point curves in duplicate. The final reaction conditions contained 400 nM fluorescein-IkBα substrate (DRHDSGLDSMKDE), 20 μM ATP, 2 nM or 8 nM IKKε or TBK1 kinase respectively, and 3% DMSO in kinase assay buffer consisting of 50 mM HEPES (pH 7.5), 10 mM MgCl, 1 mM EGTA, 0.01% Brij-35.Compound dilutions were prepared from 10 mM DMSO stocks by dilution into DMSO. Compound dilution series were further diluted in kinase assay buffer to give a 12% DMSO stock, the final concentration in the assay being 3% DMSO.The kinase phosphorylation assay was initiated by the addition of the kinase and the reaction was allowed to proceed for 1 h or 2.5 h for IKKε and TBK-1 kinase respectively.	B	N#Cc1cc(-c2ccnc(Nc3ccc(N4CCNCC4)nc3)n2)cnc1N1CC[C@H](F)C1		CHEMBL3919338	<	IC50	nM	30.0	CHEMBL5408	Homo sapiens	IC50	nM	30.0
429037	17790705	CHEMBL3889017	Time-Resolved Fluorescence-based Lanthascreen Assay: Kinase inhibition assays (10 μL) were performed at 20° C. in 384-well plate format. Compound IC50 values were determined at the apparent Km for ATP (20 μM) based on a radiometric assay (Invitrogen) using 8 or 10 point curves in duplicate. The final reaction conditions contained 400 nM fluorescein-IkBα substrate (DRHDSGLDSMKDE), 20 μM ATP, 2 nM or 8 nM IKKε or TBK1 kinase respectively, and 3% DMSO in kinase assay buffer consisting of 50 mM HEPES (pH 7.5), 10 mM MgCl, 1 mM EGTA, 0.01% Brij-35.Compound dilutions were prepared from 10 mM DMSO stocks by dilution into DMSO. Compound dilution series were further diluted in kinase assay buffer to give a 12% DMSO stock, the final concentration in the assay being 3% DMSO.The kinase phosphorylation assay was initiated by the addition of the kinase and the reaction was allowed to proceed for 1 h or 2.5 h for IKKε and TBK-1 kinase respectively.	B	C[C@@H]1CN(c2ccc(Nc3nccc(-c4cnc(N5CC[C@H](O)C5)c(C#N)c4)n3)cn2)CCN1		CHEMBL4110039	<	IC50	nM	30.0	CHEMBL5408	Homo sapiens	IC50	nM	30.0
429038	17790706	CHEMBL3889017	Time-Resolved Fluorescence-based Lanthascreen Assay: Kinase inhibition assays (10 μL) were performed at 20° C. in 384-well plate format. Compound IC50 values were determined at the apparent Km for ATP (20 μM) based on a radiometric assay (Invitrogen) using 8 or 10 point curves in duplicate. The final reaction conditions contained 400 nM fluorescein-IkBα substrate (DRHDSGLDSMKDE), 20 μM ATP, 2 nM or 8 nM IKKε or TBK1 kinase respectively, and 3% DMSO in kinase assay buffer consisting of 50 mM HEPES (pH 7.5), 10 mM MgCl, 1 mM EGTA, 0.01% Brij-35.Compound dilutions were prepared from 10 mM DMSO stocks by dilution into DMSO. Compound dilution series were further diluted in kinase assay buffer to give a 12% DMSO stock, the final concentration in the assay being 3% DMSO.The kinase phosphorylation assay was initiated by the addition of the kinase and the reaction was allowed to proceed for 1 h or 2.5 h for IKKε and TBK-1 kinase respectively.	B	N#Cc1cc(-c2ccnc(Nc3ccc(NC(=O)CO)nc3)n2)cnc1N1CC[C@H](F)C1		CHEMBL3924783	<	IC50	nM	30.0	CHEMBL5408	Homo sapiens	IC50	nM	30.0
429039	17790707	CHEMBL3889017	Time-Resolved Fluorescence-based Lanthascreen Assay: Kinase inhibition assays (10 μL) were performed at 20° C. in 384-well plate format. Compound IC50 values were determined at the apparent Km for ATP (20 μM) based on a radiometric assay (Invitrogen) using 8 or 10 point curves in duplicate. The final reaction conditions contained 400 nM fluorescein-IkBα substrate (DRHDSGLDSMKDE), 20 μM ATP, 2 nM or 8 nM IKKε or TBK1 kinase respectively, and 3% DMSO in kinase assay buffer consisting of 50 mM HEPES (pH 7.5), 10 mM MgCl, 1 mM EGTA, 0.01% Brij-35.Compound dilutions were prepared from 10 mM DMSO stocks by dilution into DMSO. Compound dilution series were further diluted in kinase assay buffer to give a 12% DMSO stock, the final concentration in the assay being 3% DMSO.The kinase phosphorylation assay was initiated by the addition of the kinase and the reaction was allowed to proceed for 1 h or 2.5 h for IKKε and TBK-1 kinase respectively.	B	CN1CCC(NC(=O)c2ccc(Nc3ncc(F)c(-c4cnc(N5CC[C@H](F)C5)c(C#N)c4)n3)cc2)CC1		CHEMBL3909307	<	IC50	nM	15.0	CHEMBL5408	Homo sapiens	IC50	nM	15.0
429040	17790708	CHEMBL3889017	Time-Resolved Fluorescence-based Lanthascreen Assay: Kinase inhibition assays (10 μL) were performed at 20° C. in 384-well plate format. Compound IC50 values were determined at the apparent Km for ATP (20 μM) based on a radiometric assay (Invitrogen) using 8 or 10 point curves in duplicate. The final reaction conditions contained 400 nM fluorescein-IkBα substrate (DRHDSGLDSMKDE), 20 μM ATP, 2 nM or 8 nM IKKε or TBK1 kinase respectively, and 3% DMSO in kinase assay buffer consisting of 50 mM HEPES (pH 7.5), 10 mM MgCl, 1 mM EGTA, 0.01% Brij-35.Compound dilutions were prepared from 10 mM DMSO stocks by dilution into DMSO. Compound dilution series were further diluted in kinase assay buffer to give a 12% DMSO stock, the final concentration in the assay being 3% DMSO.The kinase phosphorylation assay was initiated by the addition of the kinase and the reaction was allowed to proceed for 1 h or 2.5 h for IKKε and TBK-1 kinase respectively.	B	N#Cc1cc(-c2ccnc(Nc3ccc(NC(=O)CN4CCC(O)CC4)nc3)n2)cnc1N1CC[C@H](F)C1		CHEMBL3959400	<	IC50	nM	30.0	CHEMBL5408	Homo sapiens	IC50	nM	30.0
429041	17790709	CHEMBL3889017	Time-Resolved Fluorescence-based Lanthascreen Assay: Kinase inhibition assays (10 μL) were performed at 20° C. in 384-well plate format. Compound IC50 values were determined at the apparent Km for ATP (20 μM) based on a radiometric assay (Invitrogen) using 8 or 10 point curves in duplicate. The final reaction conditions contained 400 nM fluorescein-IkBα substrate (DRHDSGLDSMKDE), 20 μM ATP, 2 nM or 8 nM IKKε or TBK1 kinase respectively, and 3% DMSO in kinase assay buffer consisting of 50 mM HEPES (pH 7.5), 10 mM MgCl, 1 mM EGTA, 0.01% Brij-35.Compound dilutions were prepared from 10 mM DMSO stocks by dilution into DMSO. Compound dilution series were further diluted in kinase assay buffer to give a 12% DMSO stock, the final concentration in the assay being 3% DMSO.The kinase phosphorylation assay was initiated by the addition of the kinase and the reaction was allowed to proceed for 1 h or 2.5 h for IKKε and TBK-1 kinase respectively.	B	N#Cc1cc(-c2ccnc(Nc3ccc(CN4CCOCC4)cc3)n2)cnc1N1CC[C@H](F)C1		CHEMBL3915872	<	IC50	nM	15.0	CHEMBL5408	Homo sapiens	IC50	nM	15.0
429042	17790710	CHEMBL3889017	Time-Resolved Fluorescence-based Lanthascreen Assay: Kinase inhibition assays (10 μL) were performed at 20° C. in 384-well plate format. Compound IC50 values were determined at the apparent Km for ATP (20 μM) based on a radiometric assay (Invitrogen) using 8 or 10 point curves in duplicate. The final reaction conditions contained 400 nM fluorescein-IkBα substrate (DRHDSGLDSMKDE), 20 μM ATP, 2 nM or 8 nM IKKε or TBK1 kinase respectively, and 3% DMSO in kinase assay buffer consisting of 50 mM HEPES (pH 7.5), 10 mM MgCl, 1 mM EGTA, 0.01% Brij-35.Compound dilutions were prepared from 10 mM DMSO stocks by dilution into DMSO. Compound dilution series were further diluted in kinase assay buffer to give a 12% DMSO stock, the final concentration in the assay being 3% DMSO.The kinase phosphorylation assay was initiated by the addition of the kinase and the reaction was allowed to proceed for 1 h or 2.5 h for IKKε and TBK-1 kinase respectively.	B	N#Cc1cc(-c2ccnc(Nc3ccc(NC(=O)CN4CCNCC4)nc3)n2)cnc1N1CC[C@H](F)C1		CHEMBL3943824	<	IC50	nM	30.0	CHEMBL5408	Homo sapiens	IC50	nM	30.0
429043	17790711	CHEMBL3889017	Time-Resolved Fluorescence-based Lanthascreen Assay: Kinase inhibition assays (10 μL) were performed at 20° C. in 384-well plate format. Compound IC50 values were determined at the apparent Km for ATP (20 μM) based on a radiometric assay (Invitrogen) using 8 or 10 point curves in duplicate. The final reaction conditions contained 400 nM fluorescein-IkBα substrate (DRHDSGLDSMKDE), 20 μM ATP, 2 nM or 8 nM IKKε or TBK1 kinase respectively, and 3% DMSO in kinase assay buffer consisting of 50 mM HEPES (pH 7.5), 10 mM MgCl, 1 mM EGTA, 0.01% Brij-35.Compound dilutions were prepared from 10 mM DMSO stocks by dilution into DMSO. Compound dilution series were further diluted in kinase assay buffer to give a 12% DMSO stock, the final concentration in the assay being 3% DMSO.The kinase phosphorylation assay was initiated by the addition of the kinase and the reaction was allowed to proceed for 1 h or 2.5 h for IKKε and TBK-1 kinase respectively.	B	CC(C(=O)Nc1ccc(Nc2nccc(-c3cnc(N4CC[C@H](F)C4)c(C#N)c3)n2)cn1)N1CCOCC1		CHEMBL3938197	<	IC50	nM	30.0	CHEMBL5408	Homo sapiens	IC50	nM	30.0
429044	17790712	CHEMBL3889017	Time-Resolved Fluorescence-based Lanthascreen Assay: Kinase inhibition assays (10 μL) were performed at 20° C. in 384-well plate format. Compound IC50 values were determined at the apparent Km for ATP (20 μM) based on a radiometric assay (Invitrogen) using 8 or 10 point curves in duplicate. The final reaction conditions contained 400 nM fluorescein-IkBα substrate (DRHDSGLDSMKDE), 20 μM ATP, 2 nM or 8 nM IKKε or TBK1 kinase respectively, and 3% DMSO in kinase assay buffer consisting of 50 mM HEPES (pH 7.5), 10 mM MgCl, 1 mM EGTA, 0.01% Brij-35.Compound dilutions were prepared from 10 mM DMSO stocks by dilution into DMSO. Compound dilution series were further diluted in kinase assay buffer to give a 12% DMSO stock, the final concentration in the assay being 3% DMSO.The kinase phosphorylation assay was initiated by the addition of the kinase and the reaction was allowed to proceed for 1 h or 2.5 h for IKKε and TBK-1 kinase respectively.	B	N#Cc1cc(-c2ccnc(Nc3cnn(C4CCOCC4)c3)n2)cnc1N1CC[C@H](F)C1		CHEMBL3910276	<	IC50	nM	15.0	CHEMBL5408	Homo sapiens	IC50	nM	15.0
429045	17790713	CHEMBL3889017	Time-Resolved Fluorescence-based Lanthascreen Assay: Kinase inhibition assays (10 μL) were performed at 20° C. in 384-well plate format. Compound IC50 values were determined at the apparent Km for ATP (20 μM) based on a radiometric assay (Invitrogen) using 8 or 10 point curves in duplicate. The final reaction conditions contained 400 nM fluorescein-IkBα substrate (DRHDSGLDSMKDE), 20 μM ATP, 2 nM or 8 nM IKKε or TBK1 kinase respectively, and 3% DMSO in kinase assay buffer consisting of 50 mM HEPES (pH 7.5), 10 mM MgCl, 1 mM EGTA, 0.01% Brij-35.Compound dilutions were prepared from 10 mM DMSO stocks by dilution into DMSO. Compound dilution series were further diluted in kinase assay buffer to give a 12% DMSO stock, the final concentration in the assay being 3% DMSO.The kinase phosphorylation assay was initiated by the addition of the kinase and the reaction was allowed to proceed for 1 h or 2.5 h for IKKε and TBK-1 kinase respectively.	B	N#Cc1cc(-c2ccnc(Nc3ccnc(NC(=O)CN4CCOCC4)c3)n2)cnc1N1CC[C@H](F)C1		CHEMBL3957230	<	IC50	nM	30.0	CHEMBL5408	Homo sapiens	IC50	nM	30.0
429046	17790714	CHEMBL3889017	Time-Resolved Fluorescence-based Lanthascreen Assay: Kinase inhibition assays (10 μL) were performed at 20° C. in 384-well plate format. Compound IC50 values were determined at the apparent Km for ATP (20 μM) based on a radiometric assay (Invitrogen) using 8 or 10 point curves in duplicate. The final reaction conditions contained 400 nM fluorescein-IkBα substrate (DRHDSGLDSMKDE), 20 μM ATP, 2 nM or 8 nM IKKε or TBK1 kinase respectively, and 3% DMSO in kinase assay buffer consisting of 50 mM HEPES (pH 7.5), 10 mM MgCl, 1 mM EGTA, 0.01% Brij-35.Compound dilutions were prepared from 10 mM DMSO stocks by dilution into DMSO. Compound dilution series were further diluted in kinase assay buffer to give a 12% DMSO stock, the final concentration in the assay being 3% DMSO.The kinase phosphorylation assay was initiated by the addition of the kinase and the reaction was allowed to proceed for 1 h or 2.5 h for IKKε and TBK-1 kinase respectively.	B	N#Cc1cc(-c2ccnc(Nc3ccc(NC(=O)CC4CC[C@H](O)C4)nc3)n2)cnc1N1CC[C@H](F)C1		CHEMBL3950524	<	IC50	nM	100.0	CHEMBL5408	Homo sapiens	IC50	nM	100.0
429047	17790715	CHEMBL3889017	Time-Resolved Fluorescence-based Lanthascreen Assay: Kinase inhibition assays (10 μL) were performed at 20° C. in 384-well plate format. Compound IC50 values were determined at the apparent Km for ATP (20 μM) based on a radiometric assay (Invitrogen) using 8 or 10 point curves in duplicate. The final reaction conditions contained 400 nM fluorescein-IkBα substrate (DRHDSGLDSMKDE), 20 μM ATP, 2 nM or 8 nM IKKε or TBK1 kinase respectively, and 3% DMSO in kinase assay buffer consisting of 50 mM HEPES (pH 7.5), 10 mM MgCl, 1 mM EGTA, 0.01% Brij-35.Compound dilutions were prepared from 10 mM DMSO stocks by dilution into DMSO. Compound dilution series were further diluted in kinase assay buffer to give a 12% DMSO stock, the final concentration in the assay being 3% DMSO.The kinase phosphorylation assay was initiated by the addition of the kinase and the reaction was allowed to proceed for 1 h or 2.5 h for IKKε and TBK-1 kinase respectively.	B	N#Cc1cc(-c2ccnc(Nc3ccnc(N4CCOCC4)c3)n2)cnc1N1CC[C@H](F)C1		CHEMBL3923747	<	IC50	nM	15.0	CHEMBL5408	Homo sapiens	IC50	nM	15.0
429048	17790716	CHEMBL3889017	Time-Resolved Fluorescence-based Lanthascreen Assay: Kinase inhibition assays (10 μL) were performed at 20° C. in 384-well plate format. Compound IC50 values were determined at the apparent Km for ATP (20 μM) based on a radiometric assay (Invitrogen) using 8 or 10 point curves in duplicate. The final reaction conditions contained 400 nM fluorescein-IkBα substrate (DRHDSGLDSMKDE), 20 μM ATP, 2 nM or 8 nM IKKε or TBK1 kinase respectively, and 3% DMSO in kinase assay buffer consisting of 50 mM HEPES (pH 7.5), 10 mM MgCl, 1 mM EGTA, 0.01% Brij-35.Compound dilutions were prepared from 10 mM DMSO stocks by dilution into DMSO. Compound dilution series were further diluted in kinase assay buffer to give a 12% DMSO stock, the final concentration in the assay being 3% DMSO.The kinase phosphorylation assay was initiated by the addition of the kinase and the reaction was allowed to proceed for 1 h or 2.5 h for IKKε and TBK-1 kinase respectively.	B	CC(C)(N)C(=O)Nc1ccc(Nc2nccc(-c3cnc(N4CC[C@H](F)C4)c(C#N)c3)n2)cn1		CHEMBL3895745	<	IC50	nM	100.0	CHEMBL5408	Homo sapiens	IC50	nM	100.0
429049	17790717	CHEMBL3889017	Time-Resolved Fluorescence-based Lanthascreen Assay: Kinase inhibition assays (10 μL) were performed at 20° C. in 384-well plate format. Compound IC50 values were determined at the apparent Km for ATP (20 μM) based on a radiometric assay (Invitrogen) using 8 or 10 point curves in duplicate. The final reaction conditions contained 400 nM fluorescein-IkBα substrate (DRHDSGLDSMKDE), 20 μM ATP, 2 nM or 8 nM IKKε or TBK1 kinase respectively, and 3% DMSO in kinase assay buffer consisting of 50 mM HEPES (pH 7.5), 10 mM MgCl, 1 mM EGTA, 0.01% Brij-35.Compound dilutions were prepared from 10 mM DMSO stocks by dilution into DMSO. Compound dilution series were further diluted in kinase assay buffer to give a 12% DMSO stock, the final concentration in the assay being 3% DMSO.The kinase phosphorylation assay was initiated by the addition of the kinase and the reaction was allowed to proceed for 1 h or 2.5 h for IKKε and TBK-1 kinase respectively.	B	N#Cc1cc(-c2ccnc(Nc3cn[nH]c3)n2)cnc1N1CC[C@H](F)C1		CHEMBL3932700	<	IC50	nM	15.0	CHEMBL5408	Homo sapiens	IC50	nM	15.0
429050	17790718	CHEMBL3889017	Time-Resolved Fluorescence-based Lanthascreen Assay: Kinase inhibition assays (10 μL) were performed at 20° C. in 384-well plate format. Compound IC50 values were determined at the apparent Km for ATP (20 μM) based on a radiometric assay (Invitrogen) using 8 or 10 point curves in duplicate. The final reaction conditions contained 400 nM fluorescein-IkBα substrate (DRHDSGLDSMKDE), 20 μM ATP, 2 nM or 8 nM IKKε or TBK1 kinase respectively, and 3% DMSO in kinase assay buffer consisting of 50 mM HEPES (pH 7.5), 10 mM MgCl, 1 mM EGTA, 0.01% Brij-35.Compound dilutions were prepared from 10 mM DMSO stocks by dilution into DMSO. Compound dilution series were further diluted in kinase assay buffer to give a 12% DMSO stock, the final concentration in the assay being 3% DMSO.The kinase phosphorylation assay was initiated by the addition of the kinase and the reaction was allowed to proceed for 1 h or 2.5 h for IKKε and TBK-1 kinase respectively.	B	N#Cc1cc(-c2ccnc(Nc3ccn[nH]3)n2)cnc1N1CC[C@H](F)C1		CHEMBL3901208	<	IC50	nM	1000.0	CHEMBL5408	Homo sapiens	IC50	nM	1000.0
429051	17790719	CHEMBL3889017	Time-Resolved Fluorescence-based Lanthascreen Assay: Kinase inhibition assays (10 μL) were performed at 20° C. in 384-well plate format. Compound IC50 values were determined at the apparent Km for ATP (20 μM) based on a radiometric assay (Invitrogen) using 8 or 10 point curves in duplicate. The final reaction conditions contained 400 nM fluorescein-IkBα substrate (DRHDSGLDSMKDE), 20 μM ATP, 2 nM or 8 nM IKKε or TBK1 kinase respectively, and 3% DMSO in kinase assay buffer consisting of 50 mM HEPES (pH 7.5), 10 mM MgCl, 1 mM EGTA, 0.01% Brij-35.Compound dilutions were prepared from 10 mM DMSO stocks by dilution into DMSO. Compound dilution series were further diluted in kinase assay buffer to give a 12% DMSO stock, the final concentration in the assay being 3% DMSO.The kinase phosphorylation assay was initiated by the addition of the kinase and the reaction was allowed to proceed for 1 h or 2.5 h for IKKε and TBK-1 kinase respectively.	B	N#Cc1cc(-c2ccnc(Nc3ccc(NC(=O)C4CCCN4)nc3)n2)cnc1N1CC[C@H](F)C1		CHEMBL3904619	<	IC50	nM	100.0	CHEMBL5408	Homo sapiens	IC50	nM	100.0
429052	17790720	CHEMBL3889017	Time-Resolved Fluorescence-based Lanthascreen Assay: Kinase inhibition assays (10 μL) were performed at 20° C. in 384-well plate format. Compound IC50 values were determined at the apparent Km for ATP (20 μM) based on a radiometric assay (Invitrogen) using 8 or 10 point curves in duplicate. The final reaction conditions contained 400 nM fluorescein-IkBα substrate (DRHDSGLDSMKDE), 20 μM ATP, 2 nM or 8 nM IKKε or TBK1 kinase respectively, and 3% DMSO in kinase assay buffer consisting of 50 mM HEPES (pH 7.5), 10 mM MgCl, 1 mM EGTA, 0.01% Brij-35.Compound dilutions were prepared from 10 mM DMSO stocks by dilution into DMSO. Compound dilution series were further diluted in kinase assay buffer to give a 12% DMSO stock, the final concentration in the assay being 3% DMSO.The kinase phosphorylation assay was initiated by the addition of the kinase and the reaction was allowed to proceed for 1 h or 2.5 h for IKKε and TBK-1 kinase respectively.	B	N#Cc1cc(-c2ccnc(Nc3ccc(NC(=O)CN4CCCC4)nc3)n2)cnc1N1CC[C@H](F)C1		CHEMBL3975437	<	IC50	nM	30.0	CHEMBL5408	Homo sapiens	IC50	nM	30.0
429053	17790721	CHEMBL3889017	Time-Resolved Fluorescence-based Lanthascreen Assay: Kinase inhibition assays (10 μL) were performed at 20° C. in 384-well plate format. Compound IC50 values were determined at the apparent Km for ATP (20 μM) based on a radiometric assay (Invitrogen) using 8 or 10 point curves in duplicate. The final reaction conditions contained 400 nM fluorescein-IkBα substrate (DRHDSGLDSMKDE), 20 μM ATP, 2 nM or 8 nM IKKε or TBK1 kinase respectively, and 3% DMSO in kinase assay buffer consisting of 50 mM HEPES (pH 7.5), 10 mM MgCl, 1 mM EGTA, 0.01% Brij-35.Compound dilutions were prepared from 10 mM DMSO stocks by dilution into DMSO. Compound dilution series were further diluted in kinase assay buffer to give a 12% DMSO stock, the final concentration in the assay being 3% DMSO.The kinase phosphorylation assay was initiated by the addition of the kinase and the reaction was allowed to proceed for 1 h or 2.5 h for IKKε and TBK-1 kinase respectively.	B	N#Cc1cc(-c2ccnc(Nc3ccc(NCCN4CCOCC4)nc3)n2)cnc1N1CC[C@H](F)C1		CHEMBL3919184	<	IC50	nM	30.0	CHEMBL5408	Homo sapiens	IC50	nM	30.0
429054	17790722	CHEMBL3889017	Time-Resolved Fluorescence-based Lanthascreen Assay: Kinase inhibition assays (10 μL) were performed at 20° C. in 384-well plate format. Compound IC50 values were determined at the apparent Km for ATP (20 μM) based on a radiometric assay (Invitrogen) using 8 or 10 point curves in duplicate. The final reaction conditions contained 400 nM fluorescein-IkBα substrate (DRHDSGLDSMKDE), 20 μM ATP, 2 nM or 8 nM IKKε or TBK1 kinase respectively, and 3% DMSO in kinase assay buffer consisting of 50 mM HEPES (pH 7.5), 10 mM MgCl, 1 mM EGTA, 0.01% Brij-35.Compound dilutions were prepared from 10 mM DMSO stocks by dilution into DMSO. Compound dilution series were further diluted in kinase assay buffer to give a 12% DMSO stock, the final concentration in the assay being 3% DMSO.The kinase phosphorylation assay was initiated by the addition of the kinase and the reaction was allowed to proceed for 1 h or 2.5 h for IKKε and TBK-1 kinase respectively.	B	N#Cc1cc(-c2ccnc(Nc3ccc(CN4CCOCC4)nc3)n2)cnc1N1CC[C@H](F)C1		CHEMBL3943587	<	IC50	nM	15.0	CHEMBL5408	Homo sapiens	IC50	nM	15.0
429055	17790723	CHEMBL3889017	Time-Resolved Fluorescence-based Lanthascreen Assay: Kinase inhibition assays (10 μL) were performed at 20° C. in 384-well plate format. Compound IC50 values were determined at the apparent Km for ATP (20 μM) based on a radiometric assay (Invitrogen) using 8 or 10 point curves in duplicate. The final reaction conditions contained 400 nM fluorescein-IkBα substrate (DRHDSGLDSMKDE), 20 μM ATP, 2 nM or 8 nM IKKε or TBK1 kinase respectively, and 3% DMSO in kinase assay buffer consisting of 50 mM HEPES (pH 7.5), 10 mM MgCl, 1 mM EGTA, 0.01% Brij-35.Compound dilutions were prepared from 10 mM DMSO stocks by dilution into DMSO. Compound dilution series were further diluted in kinase assay buffer to give a 12% DMSO stock, the final concentration in the assay being 3% DMSO.The kinase phosphorylation assay was initiated by the addition of the kinase and the reaction was allowed to proceed for 1 h or 2.5 h for IKKε and TBK-1 kinase respectively.	B	N#Cc1cc(-c2ccnc(Nc3ccc(NC(=O)CN4CC[C@H](F)C4)nc3)n2)cnc1N1CC[C@H](F)C1		CHEMBL3977169	<	IC50	nM	100.0	CHEMBL5408	Homo sapiens	IC50	nM	100.0
429056	17790724	CHEMBL3889017	Time-Resolved Fluorescence-based Lanthascreen Assay: Kinase inhibition assays (10 μL) were performed at 20° C. in 384-well plate format. Compound IC50 values were determined at the apparent Km for ATP (20 μM) based on a radiometric assay (Invitrogen) using 8 or 10 point curves in duplicate. The final reaction conditions contained 400 nM fluorescein-IkBα substrate (DRHDSGLDSMKDE), 20 μM ATP, 2 nM or 8 nM IKKε or TBK1 kinase respectively, and 3% DMSO in kinase assay buffer consisting of 50 mM HEPES (pH 7.5), 10 mM MgCl, 1 mM EGTA, 0.01% Brij-35.Compound dilutions were prepared from 10 mM DMSO stocks by dilution into DMSO. Compound dilution series were further diluted in kinase assay buffer to give a 12% DMSO stock, the final concentration in the assay being 3% DMSO.The kinase phosphorylation assay was initiated by the addition of the kinase and the reaction was allowed to proceed for 1 h or 2.5 h for IKKε and TBK-1 kinase respectively.	B	N#Cc1cc(-c2ccnc(Nc3ccc(OCCN4CC[C@H](F)C4)nc3)n2)cnc1N1CC[C@H](F)C1		CHEMBL3906502	<	IC50	nM	100.0	CHEMBL5408	Homo sapiens	IC50	nM	100.0
429057	17790725	CHEMBL3889017	Time-Resolved Fluorescence-based Lanthascreen Assay: Kinase inhibition assays (10 μL) were performed at 20° C. in 384-well plate format. Compound IC50 values were determined at the apparent Km for ATP (20 μM) based on a radiometric assay (Invitrogen) using 8 or 10 point curves in duplicate. The final reaction conditions contained 400 nM fluorescein-IkBα substrate (DRHDSGLDSMKDE), 20 μM ATP, 2 nM or 8 nM IKKε or TBK1 kinase respectively, and 3% DMSO in kinase assay buffer consisting of 50 mM HEPES (pH 7.5), 10 mM MgCl, 1 mM EGTA, 0.01% Brij-35.Compound dilutions were prepared from 10 mM DMSO stocks by dilution into DMSO. Compound dilution series were further diluted in kinase assay buffer to give a 12% DMSO stock, the final concentration in the assay being 3% DMSO.The kinase phosphorylation assay was initiated by the addition of the kinase and the reaction was allowed to proceed for 1 h or 2.5 h for IKKε and TBK-1 kinase respectively.	B	N#Cc1cc(-c2ccnc(Nc3ccnc(N4CCOCC4)c3)n2)cnc1N1CC[C@H](O)C1		CHEMBL3968667	<	IC50	nM	30.0	CHEMBL5408	Homo sapiens	IC50	nM	30.0
429058	17790726	CHEMBL3889017	Time-Resolved Fluorescence-based Lanthascreen Assay: Kinase inhibition assays (10 μL) were performed at 20° C. in 384-well plate format. Compound IC50 values were determined at the apparent Km for ATP (20 μM) based on a radiometric assay (Invitrogen) using 8 or 10 point curves in duplicate. The final reaction conditions contained 400 nM fluorescein-IkBα substrate (DRHDSGLDSMKDE), 20 μM ATP, 2 nM or 8 nM IKKε or TBK1 kinase respectively, and 3% DMSO in kinase assay buffer consisting of 50 mM HEPES (pH 7.5), 10 mM MgCl, 1 mM EGTA, 0.01% Brij-35.Compound dilutions were prepared from 10 mM DMSO stocks by dilution into DMSO. Compound dilution series were further diluted in kinase assay buffer to give a 12% DMSO stock, the final concentration in the assay being 3% DMSO.The kinase phosphorylation assay was initiated by the addition of the kinase and the reaction was allowed to proceed for 1 h or 2.5 h for IKKε and TBK-1 kinase respectively.	B	COCCNc1cc(Nc2nccc(-c3cnc(N4CC[C@H](F)C4)c(C#N)c3)n2)ccn1		CHEMBL3901065	<	IC50	nM	15.0	CHEMBL5408	Homo sapiens	IC50	nM	15.0
429059	17790727	CHEMBL3889017	Time-Resolved Fluorescence-based Lanthascreen Assay: Kinase inhibition assays (10 μL) were performed at 20° C. in 384-well plate format. Compound IC50 values were determined at the apparent Km for ATP (20 μM) based on a radiometric assay (Invitrogen) using 8 or 10 point curves in duplicate. The final reaction conditions contained 400 nM fluorescein-IkBα substrate (DRHDSGLDSMKDE), 20 μM ATP, 2 nM or 8 nM IKKε or TBK1 kinase respectively, and 3% DMSO in kinase assay buffer consisting of 50 mM HEPES (pH 7.5), 10 mM MgCl, 1 mM EGTA, 0.01% Brij-35.Compound dilutions were prepared from 10 mM DMSO stocks by dilution into DMSO. Compound dilution series were further diluted in kinase assay buffer to give a 12% DMSO stock, the final concentration in the assay being 3% DMSO.The kinase phosphorylation assay was initiated by the addition of the kinase and the reaction was allowed to proceed for 1 h or 2.5 h for IKKε and TBK-1 kinase respectively.	B	N#Cc1cc(-c2ccnc(Nc3cccc(=O)[nH]3)n2)cnc1N1CC[C@H](F)C1		CHEMBL3961080	<	IC50	nM	1000.0	CHEMBL5408	Homo sapiens	IC50	nM	1000.0
429060	17790728	CHEMBL3889017	Time-Resolved Fluorescence-based Lanthascreen Assay: Kinase inhibition assays (10 μL) were performed at 20° C. in 384-well plate format. Compound IC50 values were determined at the apparent Km for ATP (20 μM) based on a radiometric assay (Invitrogen) using 8 or 10 point curves in duplicate. The final reaction conditions contained 400 nM fluorescein-IkBα substrate (DRHDSGLDSMKDE), 20 μM ATP, 2 nM or 8 nM IKKε or TBK1 kinase respectively, and 3% DMSO in kinase assay buffer consisting of 50 mM HEPES (pH 7.5), 10 mM MgCl, 1 mM EGTA, 0.01% Brij-35.Compound dilutions were prepared from 10 mM DMSO stocks by dilution into DMSO. Compound dilution series were further diluted in kinase assay buffer to give a 12% DMSO stock, the final concentration in the assay being 3% DMSO.The kinase phosphorylation assay was initiated by the addition of the kinase and the reaction was allowed to proceed for 1 h or 2.5 h for IKKε and TBK-1 kinase respectively.	B	CN(C(=O)CN1CCOCC1)c1ccc(Nc2nccc(-c3cnc(N4CC[C@H](F)C4)c(C#N)c3)n2)cn1		CHEMBL3892095	<	IC50	nM	100.0	CHEMBL5408	Homo sapiens	IC50	nM	100.0
429061	17790729	CHEMBL3889017	Time-Resolved Fluorescence-based Lanthascreen Assay: Kinase inhibition assays (10 μL) were performed at 20° C. in 384-well plate format. Compound IC50 values were determined at the apparent Km for ATP (20 μM) based on a radiometric assay (Invitrogen) using 8 or 10 point curves in duplicate. The final reaction conditions contained 400 nM fluorescein-IkBα substrate (DRHDSGLDSMKDE), 20 μM ATP, 2 nM or 8 nM IKKε or TBK1 kinase respectively, and 3% DMSO in kinase assay buffer consisting of 50 mM HEPES (pH 7.5), 10 mM MgCl, 1 mM EGTA, 0.01% Brij-35.Compound dilutions were prepared from 10 mM DMSO stocks by dilution into DMSO. Compound dilution series were further diluted in kinase assay buffer to give a 12% DMSO stock, the final concentration in the assay being 3% DMSO.The kinase phosphorylation assay was initiated by the addition of the kinase and the reaction was allowed to proceed for 1 h or 2.5 h for IKKε and TBK-1 kinase respectively.	B	CN(C(=O)CN1CCOCC1)c1ccc(Nc2nccc(-c3cnc(N4CC[C@H](O)C4)c(C#N)c3)n2)cn1		CHEMBL3954664	<	IC50	nM	1000.0	CHEMBL5408	Homo sapiens	IC50	nM	1000.0
429062	17790730	CHEMBL3889017	Time-Resolved Fluorescence-based Lanthascreen Assay: Kinase inhibition assays (10 μL) were performed at 20° C. in 384-well plate format. Compound IC50 values were determined at the apparent Km for ATP (20 μM) based on a radiometric assay (Invitrogen) using 8 or 10 point curves in duplicate. The final reaction conditions contained 400 nM fluorescein-IkBα substrate (DRHDSGLDSMKDE), 20 μM ATP, 2 nM or 8 nM IKKε or TBK1 kinase respectively, and 3% DMSO in kinase assay buffer consisting of 50 mM HEPES (pH 7.5), 10 mM MgCl, 1 mM EGTA, 0.01% Brij-35.Compound dilutions were prepared from 10 mM DMSO stocks by dilution into DMSO. Compound dilution series were further diluted in kinase assay buffer to give a 12% DMSO stock, the final concentration in the assay being 3% DMSO.The kinase phosphorylation assay was initiated by the addition of the kinase and the reaction was allowed to proceed for 1 h or 2.5 h for IKKε and TBK-1 kinase respectively.	B	CN1Cc2ccc(Nc3nccc(-c4cnc(N5CC[C@H](F)C5)c(C#N)c4)n3)cc2C1		CHEMBL3980158	<	IC50	nM	15.0	CHEMBL5408	Homo sapiens	IC50	nM	15.0
429063	17790731	CHEMBL3889017	Time-Resolved Fluorescence-based Lanthascreen Assay: Kinase inhibition assays (10 μL) were performed at 20° C. in 384-well plate format. Compound IC50 values were determined at the apparent Km for ATP (20 μM) based on a radiometric assay (Invitrogen) using 8 or 10 point curves in duplicate. The final reaction conditions contained 400 nM fluorescein-IkBα substrate (DRHDSGLDSMKDE), 20 μM ATP, 2 nM or 8 nM IKKε or TBK1 kinase respectively, and 3% DMSO in kinase assay buffer consisting of 50 mM HEPES (pH 7.5), 10 mM MgCl, 1 mM EGTA, 0.01% Brij-35.Compound dilutions were prepared from 10 mM DMSO stocks by dilution into DMSO. Compound dilution series were further diluted in kinase assay buffer to give a 12% DMSO stock, the final concentration in the assay being 3% DMSO.The kinase phosphorylation assay was initiated by the addition of the kinase and the reaction was allowed to proceed for 1 h or 2.5 h for IKKε and TBK-1 kinase respectively.	B	COCCNCc1ccc(Nc2nccc(-c3cnc(N4CC[C@H](F)C4)c(C#N)c3)n2)cn1		CHEMBL3935316	<	IC50	nM	100.0	CHEMBL5408	Homo sapiens	IC50	nM	100.0
429064	17790732	CHEMBL3889017	Time-Resolved Fluorescence-based Lanthascreen Assay: Kinase inhibition assays (10 μL) were performed at 20° C. in 384-well plate format. Compound IC50 values were determined at the apparent Km for ATP (20 μM) based on a radiometric assay (Invitrogen) using 8 or 10 point curves in duplicate. The final reaction conditions contained 400 nM fluorescein-IkBα substrate (DRHDSGLDSMKDE), 20 μM ATP, 2 nM or 8 nM IKKε or TBK1 kinase respectively, and 3% DMSO in kinase assay buffer consisting of 50 mM HEPES (pH 7.5), 10 mM MgCl, 1 mM EGTA, 0.01% Brij-35.Compound dilutions were prepared from 10 mM DMSO stocks by dilution into DMSO. Compound dilution series were further diluted in kinase assay buffer to give a 12% DMSO stock, the final concentration in the assay being 3% DMSO.The kinase phosphorylation assay was initiated by the addition of the kinase and the reaction was allowed to proceed for 1 h or 2.5 h for IKKε and TBK-1 kinase respectively.	B	C[C@H]1COCCN1Cc1cc(Nc2nccc(-c3cnc(N4CC[C@H](F)C4)c(C#N)c3)n2)ccn1		CHEMBL3934205	<	IC50	nM	15.0	CHEMBL5408	Homo sapiens	IC50	nM	15.0
429065	17790733	CHEMBL3889017	Time-Resolved Fluorescence-based Lanthascreen Assay: Kinase inhibition assays (10 μL) were performed at 20° C. in 384-well plate format. Compound IC50 values were determined at the apparent Km for ATP (20 μM) based on a radiometric assay (Invitrogen) using 8 or 10 point curves in duplicate. The final reaction conditions contained 400 nM fluorescein-IkBα substrate (DRHDSGLDSMKDE), 20 μM ATP, 2 nM or 8 nM IKKε or TBK1 kinase respectively, and 3% DMSO in kinase assay buffer consisting of 50 mM HEPES (pH 7.5), 10 mM MgCl, 1 mM EGTA, 0.01% Brij-35.Compound dilutions were prepared from 10 mM DMSO stocks by dilution into DMSO. Compound dilution series were further diluted in kinase assay buffer to give a 12% DMSO stock, the final concentration in the assay being 3% DMSO.The kinase phosphorylation assay was initiated by the addition of the kinase and the reaction was allowed to proceed for 1 h or 2.5 h for IKKε and TBK-1 kinase respectively.	B	C[C@H]1COCCN1Cc1ccc(Nc2nccc(-c3cnc(N4CC[C@H](F)C4)c(C#N)c3)n2)cn1		CHEMBL3915896	<	IC50	nM	30.0	CHEMBL5408	Homo sapiens	IC50	nM	30.0
429066	17790734	CHEMBL3889017	Time-Resolved Fluorescence-based Lanthascreen Assay: Kinase inhibition assays (10 μL) were performed at 20° C. in 384-well plate format. Compound IC50 values were determined at the apparent Km for ATP (20 μM) based on a radiometric assay (Invitrogen) using 8 or 10 point curves in duplicate. The final reaction conditions contained 400 nM fluorescein-IkBα substrate (DRHDSGLDSMKDE), 20 μM ATP, 2 nM or 8 nM IKKε or TBK1 kinase respectively, and 3% DMSO in kinase assay buffer consisting of 50 mM HEPES (pH 7.5), 10 mM MgCl, 1 mM EGTA, 0.01% Brij-35.Compound dilutions were prepared from 10 mM DMSO stocks by dilution into DMSO. Compound dilution series were further diluted in kinase assay buffer to give a 12% DMSO stock, the final concentration in the assay being 3% DMSO.The kinase phosphorylation assay was initiated by the addition of the kinase and the reaction was allowed to proceed for 1 h or 2.5 h for IKKε and TBK-1 kinase respectively.	B	N#Cc1cc(-c2ccnc(Nc3ccc(CN4CC[C@H](F)C4)nc3)n2)cnc1N1CC[C@H](F)C1		CHEMBL3898354	<	IC50	nM	30.0	CHEMBL5408	Homo sapiens	IC50	nM	30.0
429067	17790735	CHEMBL3889017	Time-Resolved Fluorescence-based Lanthascreen Assay: Kinase inhibition assays (10 μL) were performed at 20° C. in 384-well plate format. Compound IC50 values were determined at the apparent Km for ATP (20 μM) based on a radiometric assay (Invitrogen) using 8 or 10 point curves in duplicate. The final reaction conditions contained 400 nM fluorescein-IkBα substrate (DRHDSGLDSMKDE), 20 μM ATP, 2 nM or 8 nM IKKε or TBK1 kinase respectively, and 3% DMSO in kinase assay buffer consisting of 50 mM HEPES (pH 7.5), 10 mM MgCl, 1 mM EGTA, 0.01% Brij-35.Compound dilutions were prepared from 10 mM DMSO stocks by dilution into DMSO. Compound dilution series were further diluted in kinase assay buffer to give a 12% DMSO stock, the final concentration in the assay being 3% DMSO.The kinase phosphorylation assay was initiated by the addition of the kinase and the reaction was allowed to proceed for 1 h or 2.5 h for IKKε and TBK-1 kinase respectively.	B	Cc1nccn1Cc1ccc(Nc2nccc(-c3cnc(N4CC[C@H](F)C4)c(C#N)c3)n2)cn1		CHEMBL3949617	<	IC50	nM	30.0	CHEMBL5408	Homo sapiens	IC50	nM	30.0
429068	17790736	CHEMBL3889017	Time-Resolved Fluorescence-based Lanthascreen Assay: Kinase inhibition assays (10 μL) were performed at 20° C. in 384-well plate format. Compound IC50 values were determined at the apparent Km for ATP (20 μM) based on a radiometric assay (Invitrogen) using 8 or 10 point curves in duplicate. The final reaction conditions contained 400 nM fluorescein-IkBα substrate (DRHDSGLDSMKDE), 20 μM ATP, 2 nM or 8 nM IKKε or TBK1 kinase respectively, and 3% DMSO in kinase assay buffer consisting of 50 mM HEPES (pH 7.5), 10 mM MgCl, 1 mM EGTA, 0.01% Brij-35.Compound dilutions were prepared from 10 mM DMSO stocks by dilution into DMSO. Compound dilution series were further diluted in kinase assay buffer to give a 12% DMSO stock, the final concentration in the assay being 3% DMSO.The kinase phosphorylation assay was initiated by the addition of the kinase and the reaction was allowed to proceed for 1 h or 2.5 h for IKKε and TBK-1 kinase respectively.	B	COCCN(C)Cc1ccc(Nc2nccc(-c3cnc(N4CC[C@H](F)C4)c(C#N)c3)n2)cn1		CHEMBL3925343	<	IC50	nM	100.0	CHEMBL5408	Homo sapiens	IC50	nM	100.0
429069	17790737	CHEMBL3889017	Time-Resolved Fluorescence-based Lanthascreen Assay: Kinase inhibition assays (10 μL) were performed at 20° C. in 384-well plate format. Compound IC50 values were determined at the apparent Km for ATP (20 μM) based on a radiometric assay (Invitrogen) using 8 or 10 point curves in duplicate. The final reaction conditions contained 400 nM fluorescein-IkBα substrate (DRHDSGLDSMKDE), 20 μM ATP, 2 nM or 8 nM IKKε or TBK1 kinase respectively, and 3% DMSO in kinase assay buffer consisting of 50 mM HEPES (pH 7.5), 10 mM MgCl, 1 mM EGTA, 0.01% Brij-35.Compound dilutions were prepared from 10 mM DMSO stocks by dilution into DMSO. Compound dilution series were further diluted in kinase assay buffer to give a 12% DMSO stock, the final concentration in the assay being 3% DMSO.The kinase phosphorylation assay was initiated by the addition of the kinase and the reaction was allowed to proceed for 1 h or 2.5 h for IKKε and TBK-1 kinase respectively.	B	COC1CN(Cc2ccc(Nc3nccc(-c4cnc(N5CC[C@H](F)C5)c(C#N)c4)n3)cn2)C1		CHEMBL3940846	<	IC50	nM	30.0	CHEMBL5408	Homo sapiens	IC50	nM	30.0
429070	17790738	CHEMBL3889017	Time-Resolved Fluorescence-based Lanthascreen Assay: Kinase inhibition assays (10 μL) were performed at 20° C. in 384-well plate format. Compound IC50 values were determined at the apparent Km for ATP (20 μM) based on a radiometric assay (Invitrogen) using 8 or 10 point curves in duplicate. The final reaction conditions contained 400 nM fluorescein-IkBα substrate (DRHDSGLDSMKDE), 20 μM ATP, 2 nM or 8 nM IKKε or TBK1 kinase respectively, and 3% DMSO in kinase assay buffer consisting of 50 mM HEPES (pH 7.5), 10 mM MgCl, 1 mM EGTA, 0.01% Brij-35.Compound dilutions were prepared from 10 mM DMSO stocks by dilution into DMSO. Compound dilution series were further diluted in kinase assay buffer to give a 12% DMSO stock, the final concentration in the assay being 3% DMSO.The kinase phosphorylation assay was initiated by the addition of the kinase and the reaction was allowed to proceed for 1 h or 2.5 h for IKKε and TBK-1 kinase respectively.	B	N#Cc1cc(-c2ccnc(Nc3ccc(CN4CCOCC4)nc3)n2)cnc1N1CCCOCC1		CHEMBL3912853	<	IC50	nM	100.0	CHEMBL5408	Homo sapiens	IC50	nM	100.0
429071	17790739	CHEMBL3889017	Time-Resolved Fluorescence-based Lanthascreen Assay: Kinase inhibition assays (10 μL) were performed at 20° C. in 384-well plate format. Compound IC50 values were determined at the apparent Km for ATP (20 μM) based on a radiometric assay (Invitrogen) using 8 or 10 point curves in duplicate. The final reaction conditions contained 400 nM fluorescein-IkBα substrate (DRHDSGLDSMKDE), 20 μM ATP, 2 nM or 8 nM IKKε or TBK1 kinase respectively, and 3% DMSO in kinase assay buffer consisting of 50 mM HEPES (pH 7.5), 10 mM MgCl, 1 mM EGTA, 0.01% Brij-35.Compound dilutions were prepared from 10 mM DMSO stocks by dilution into DMSO. Compound dilution series were further diluted in kinase assay buffer to give a 12% DMSO stock, the final concentration in the assay being 3% DMSO.The kinase phosphorylation assay was initiated by the addition of the kinase and the reaction was allowed to proceed for 1 h or 2.5 h for IKKε and TBK-1 kinase respectively.	B	N#Cc1cc(-c2ccnc(Nc3ccc(NC(=O)CN4CCOCC4)nc3)n2)cnc1N1CCCOCC1		CHEMBL3927596	<	IC50	nM	100.0	CHEMBL5408	Homo sapiens	IC50	nM	100.0
429072	17790740	CHEMBL3889017	Time-Resolved Fluorescence-based Lanthascreen Assay: Kinase inhibition assays (10 μL) were performed at 20° C. in 384-well plate format. Compound IC50 values were determined at the apparent Km for ATP (20 μM) based on a radiometric assay (Invitrogen) using 8 or 10 point curves in duplicate. The final reaction conditions contained 400 nM fluorescein-IkBα substrate (DRHDSGLDSMKDE), 20 μM ATP, 2 nM or 8 nM IKKε or TBK1 kinase respectively, and 3% DMSO in kinase assay buffer consisting of 50 mM HEPES (pH 7.5), 10 mM MgCl, 1 mM EGTA, 0.01% Brij-35.Compound dilutions were prepared from 10 mM DMSO stocks by dilution into DMSO. Compound dilution series were further diluted in kinase assay buffer to give a 12% DMSO stock, the final concentration in the assay being 3% DMSO.The kinase phosphorylation assay was initiated by the addition of the kinase and the reaction was allowed to proceed for 1 h or 2.5 h for IKKε and TBK-1 kinase respectively.	B	N#Cc1cc(-c2nc(Nc3ccc(NC(=O)CN4CCOCC4)nc3)ncc2F)cnc1N1CCCOCC1		CHEMBL3896079	<	IC50	nM	100.0	CHEMBL5408	Homo sapiens	IC50	nM	100.0
429073	17790741	CHEMBL3889017	Time-Resolved Fluorescence-based Lanthascreen Assay: Kinase inhibition assays (10 μL) were performed at 20° C. in 384-well plate format. Compound IC50 values were determined at the apparent Km for ATP (20 μM) based on a radiometric assay (Invitrogen) using 8 or 10 point curves in duplicate. The final reaction conditions contained 400 nM fluorescein-IkBα substrate (DRHDSGLDSMKDE), 20 μM ATP, 2 nM or 8 nM IKKε or TBK1 kinase respectively, and 3% DMSO in kinase assay buffer consisting of 50 mM HEPES (pH 7.5), 10 mM MgCl, 1 mM EGTA, 0.01% Brij-35.Compound dilutions were prepared from 10 mM DMSO stocks by dilution into DMSO. Compound dilution series were further diluted in kinase assay buffer to give a 12% DMSO stock, the final concentration in the assay being 3% DMSO.The kinase phosphorylation assay was initiated by the addition of the kinase and the reaction was allowed to proceed for 1 h or 2.5 h for IKKε and TBK-1 kinase respectively.	B	N#Cc1cc(-c2nc(Nc3ccc(CN4CCOCC4)nc3)ncc2F)cnc1N1CCCOCC1		CHEMBL3895616	<	IC50	nM	100.0	CHEMBL5408	Homo sapiens	IC50	nM	100.0
429074	17790742	CHEMBL3889017	Time-Resolved Fluorescence-based Lanthascreen Assay: Kinase inhibition assays (10 μL) were performed at 20° C. in 384-well plate format. Compound IC50 values were determined at the apparent Km for ATP (20 μM) based on a radiometric assay (Invitrogen) using 8 or 10 point curves in duplicate. The final reaction conditions contained 400 nM fluorescein-IkBα substrate (DRHDSGLDSMKDE), 20 μM ATP, 2 nM or 8 nM IKKε or TBK1 kinase respectively, and 3% DMSO in kinase assay buffer consisting of 50 mM HEPES (pH 7.5), 10 mM MgCl, 1 mM EGTA, 0.01% Brij-35.Compound dilutions were prepared from 10 mM DMSO stocks by dilution into DMSO. Compound dilution series were further diluted in kinase assay buffer to give a 12% DMSO stock, the final concentration in the assay being 3% DMSO.The kinase phosphorylation assay was initiated by the addition of the kinase and the reaction was allowed to proceed for 1 h or 2.5 h for IKKε and TBK-1 kinase respectively.	B	N#Cc1cc(-c2nc(Nc3ccc(NC(=O)CN4CCOCC4)nc3)ncc2F)cnc1N1CC[C@H](F)C1		CHEMBL3923611	<	IC50	nM	100.0	CHEMBL5408	Homo sapiens	IC50	nM	100.0
429075	17790743	CHEMBL3889017	Time-Resolved Fluorescence-based Lanthascreen Assay: Kinase inhibition assays (10 μL) were performed at 20° C. in 384-well plate format. Compound IC50 values were determined at the apparent Km for ATP (20 μM) based on a radiometric assay (Invitrogen) using 8 or 10 point curves in duplicate. The final reaction conditions contained 400 nM fluorescein-IkBα substrate (DRHDSGLDSMKDE), 20 μM ATP, 2 nM or 8 nM IKKε or TBK1 kinase respectively, and 3% DMSO in kinase assay buffer consisting of 50 mM HEPES (pH 7.5), 10 mM MgCl, 1 mM EGTA, 0.01% Brij-35.Compound dilutions were prepared from 10 mM DMSO stocks by dilution into DMSO. Compound dilution series were further diluted in kinase assay buffer to give a 12% DMSO stock, the final concentration in the assay being 3% DMSO.The kinase phosphorylation assay was initiated by the addition of the kinase and the reaction was allowed to proceed for 1 h or 2.5 h for IKKε and TBK-1 kinase respectively.	B	N#Cc1cc(-c2nc(Nc3ccc(CN4CCOCC4)nc3)ncc2F)cnc1N1CC[C@H](F)C1		CHEMBL3978449	<	IC50	nM	15.0	CHEMBL5408	Homo sapiens	IC50	nM	15.0
429077	17790744	CHEMBL3889017	Time-Resolved Fluorescence-based Lanthascreen Assay: Kinase inhibition assays (10 μL) were performed at 20° C. in 384-well plate format. Compound IC50 values were determined at the apparent Km for ATP (20 μM) based on a radiometric assay (Invitrogen) using 8 or 10 point curves in duplicate. The final reaction conditions contained 400 nM fluorescein-IkBα substrate (DRHDSGLDSMKDE), 20 μM ATP, 2 nM or 8 nM IKKε or TBK1 kinase respectively, and 3% DMSO in kinase assay buffer consisting of 50 mM HEPES (pH 7.5), 10 mM MgCl, 1 mM EGTA, 0.01% Brij-35.Compound dilutions were prepared from 10 mM DMSO stocks by dilution into DMSO. Compound dilution series were further diluted in kinase assay buffer to give a 12% DMSO stock, the final concentration in the assay being 3% DMSO.The kinase phosphorylation assay was initiated by the addition of the kinase and the reaction was allowed to proceed for 1 h or 2.5 h for IKKε and TBK-1 kinase respectively.	B	N#Cc1cc(-c2nc(Nc3ccnc(NC(=O)CN4CCOCC4)c3)ncc2F)cnc1N1CC[C@H](F)C1		CHEMBL3979474	<	IC50	nM	30.0	CHEMBL5408	Homo sapiens	IC50	nM	30.0
429078	17790745	CHEMBL3889017	Time-Resolved Fluorescence-based Lanthascreen Assay: Kinase inhibition assays (10 μL) were performed at 20° C. in 384-well plate format. Compound IC50 values were determined at the apparent Km for ATP (20 μM) based on a radiometric assay (Invitrogen) using 8 or 10 point curves in duplicate. The final reaction conditions contained 400 nM fluorescein-IkBα substrate (DRHDSGLDSMKDE), 20 μM ATP, 2 nM or 8 nM IKKε or TBK1 kinase respectively, and 3% DMSO in kinase assay buffer consisting of 50 mM HEPES (pH 7.5), 10 mM MgCl, 1 mM EGTA, 0.01% Brij-35.Compound dilutions were prepared from 10 mM DMSO stocks by dilution into DMSO. Compound dilution series were further diluted in kinase assay buffer to give a 12% DMSO stock, the final concentration in the assay being 3% DMSO.The kinase phosphorylation assay was initiated by the addition of the kinase and the reaction was allowed to proceed for 1 h or 2.5 h for IKKε and TBK-1 kinase respectively.	B	N#Cc1cc(-c2ccnc(Nc3ccc(CN4CCOCC4)nc3)n2)cnc1N1CCC2(COC2)C1		CHEMBL3909236	<	IC50	nM	100.0	CHEMBL5408	Homo sapiens	IC50	nM	100.0
429079	17790746	CHEMBL3889017	Time-Resolved Fluorescence-based Lanthascreen Assay: Kinase inhibition assays (10 μL) were performed at 20° C. in 384-well plate format. Compound IC50 values were determined at the apparent Km for ATP (20 μM) based on a radiometric assay (Invitrogen) using 8 or 10 point curves in duplicate. The final reaction conditions contained 400 nM fluorescein-IkBα substrate (DRHDSGLDSMKDE), 20 μM ATP, 2 nM or 8 nM IKKε or TBK1 kinase respectively, and 3% DMSO in kinase assay buffer consisting of 50 mM HEPES (pH 7.5), 10 mM MgCl, 1 mM EGTA, 0.01% Brij-35.Compound dilutions were prepared from 10 mM DMSO stocks by dilution into DMSO. Compound dilution series were further diluted in kinase assay buffer to give a 12% DMSO stock, the final concentration in the assay being 3% DMSO.The kinase phosphorylation assay was initiated by the addition of the kinase and the reaction was allowed to proceed for 1 h or 2.5 h for IKKε and TBK-1 kinase respectively.	B	N#Cc1cc(-c2ccnc(Nc3ccnc(NC(=O)CN4CCOCC4)c3)n2)cnc1N1CCC2(COC2)C1		CHEMBL3984412	<	IC50	nM	100.0	CHEMBL5408	Homo sapiens	IC50	nM	100.0
429080	17790747	CHEMBL3889017	Time-Resolved Fluorescence-based Lanthascreen Assay: Kinase inhibition assays (10 μL) were performed at 20° C. in 384-well plate format. Compound IC50 values were determined at the apparent Km for ATP (20 μM) based on a radiometric assay (Invitrogen) using 8 or 10 point curves in duplicate. The final reaction conditions contained 400 nM fluorescein-IkBα substrate (DRHDSGLDSMKDE), 20 μM ATP, 2 nM or 8 nM IKKε or TBK1 kinase respectively, and 3% DMSO in kinase assay buffer consisting of 50 mM HEPES (pH 7.5), 10 mM MgCl, 1 mM EGTA, 0.01% Brij-35.Compound dilutions were prepared from 10 mM DMSO stocks by dilution into DMSO. Compound dilution series were further diluted in kinase assay buffer to give a 12% DMSO stock, the final concentration in the assay being 3% DMSO.The kinase phosphorylation assay was initiated by the addition of the kinase and the reaction was allowed to proceed for 1 h or 2.5 h for IKKε and TBK-1 kinase respectively.	B	N#Cc1cc(-c2nc(Nc3ccnc(NC(=O)CN4CCOCC4)c3)ncc2F)cnc1N1CCCOCC1		CHEMBL3968490	<	IC50	nM	100.0	CHEMBL5408	Homo sapiens	IC50	nM	100.0
429081	17790748	CHEMBL3889017	Time-Resolved Fluorescence-based Lanthascreen Assay: Kinase inhibition assays (10 μL) were performed at 20° C. in 384-well plate format. Compound IC50 values were determined at the apparent Km for ATP (20 μM) based on a radiometric assay (Invitrogen) using 8 or 10 point curves in duplicate. The final reaction conditions contained 400 nM fluorescein-IkBα substrate (DRHDSGLDSMKDE), 20 μM ATP, 2 nM or 8 nM IKKε or TBK1 kinase respectively, and 3% DMSO in kinase assay buffer consisting of 50 mM HEPES (pH 7.5), 10 mM MgCl, 1 mM EGTA, 0.01% Brij-35.Compound dilutions were prepared from 10 mM DMSO stocks by dilution into DMSO. Compound dilution series were further diluted in kinase assay buffer to give a 12% DMSO stock, the final concentration in the assay being 3% DMSO.The kinase phosphorylation assay was initiated by the addition of the kinase and the reaction was allowed to proceed for 1 h or 2.5 h for IKKε and TBK-1 kinase respectively.	B	COCCNc1cc(Nc2ncc(F)c(-c3cnc(N4CCCOCC4)c(C#N)c3)n2)ccn1		CHEMBL3903354	<	IC50	nM	100.0	CHEMBL5408	Homo sapiens	IC50	nM	100.0
429082	17790749	CHEMBL3889017	Time-Resolved Fluorescence-based Lanthascreen Assay: Kinase inhibition assays (10 μL) were performed at 20° C. in 384-well plate format. Compound IC50 values were determined at the apparent Km for ATP (20 μM) based on a radiometric assay (Invitrogen) using 8 or 10 point curves in duplicate. The final reaction conditions contained 400 nM fluorescein-IkBα substrate (DRHDSGLDSMKDE), 20 μM ATP, 2 nM or 8 nM IKKε or TBK1 kinase respectively, and 3% DMSO in kinase assay buffer consisting of 50 mM HEPES (pH 7.5), 10 mM MgCl, 1 mM EGTA, 0.01% Brij-35.Compound dilutions were prepared from 10 mM DMSO stocks by dilution into DMSO. Compound dilution series were further diluted in kinase assay buffer to give a 12% DMSO stock, the final concentration in the assay being 3% DMSO.The kinase phosphorylation assay was initiated by the addition of the kinase and the reaction was allowed to proceed for 1 h or 2.5 h for IKKε and TBK-1 kinase respectively.	B	CC(c1ccc(Nc2nccc(-c3cnc(N4CC[C@H](F)C4)c(C#N)c3)n2)cn1)N1CCOCC1		CHEMBL3931338	<	IC50	nM	15.0	CHEMBL5408	Homo sapiens	IC50	nM	15.0
429083	17790750	CHEMBL3889017	Time-Resolved Fluorescence-based Lanthascreen Assay: Kinase inhibition assays (10 μL) were performed at 20° C. in 384-well plate format. Compound IC50 values were determined at the apparent Km for ATP (20 μM) based on a radiometric assay (Invitrogen) using 8 or 10 point curves in duplicate. The final reaction conditions contained 400 nM fluorescein-IkBα substrate (DRHDSGLDSMKDE), 20 μM ATP, 2 nM or 8 nM IKKε or TBK1 kinase respectively, and 3% DMSO in kinase assay buffer consisting of 50 mM HEPES (pH 7.5), 10 mM MgCl, 1 mM EGTA, 0.01% Brij-35.Compound dilutions were prepared from 10 mM DMSO stocks by dilution into DMSO. Compound dilution series were further diluted in kinase assay buffer to give a 12% DMSO stock, the final concentration in the assay being 3% DMSO.The kinase phosphorylation assay was initiated by the addition of the kinase and the reaction was allowed to proceed for 1 h or 2.5 h for IKKε and TBK-1 kinase respectively.	B	CO[C@H]1CCN(Cc2ccc(Nc3nccc(-c4cnc(N5CC[C@H](F)C5)c(C#N)c4)n3)cn2)C1		CHEMBL3984119	<	IC50	nM	30.0	CHEMBL5408	Homo sapiens	IC50	nM	30.0
429084	17790751	CHEMBL3889017	Time-Resolved Fluorescence-based Lanthascreen Assay: Kinase inhibition assays (10 μL) were performed at 20° C. in 384-well plate format. Compound IC50 values were determined at the apparent Km for ATP (20 μM) based on a radiometric assay (Invitrogen) using 8 or 10 point curves in duplicate. The final reaction conditions contained 400 nM fluorescein-IkBα substrate (DRHDSGLDSMKDE), 20 μM ATP, 2 nM or 8 nM IKKε or TBK1 kinase respectively, and 3% DMSO in kinase assay buffer consisting of 50 mM HEPES (pH 7.5), 10 mM MgCl, 1 mM EGTA, 0.01% Brij-35.Compound dilutions were prepared from 10 mM DMSO stocks by dilution into DMSO. Compound dilution series were further diluted in kinase assay buffer to give a 12% DMSO stock, the final concentration in the assay being 3% DMSO.The kinase phosphorylation assay was initiated by the addition of the kinase and the reaction was allowed to proceed for 1 h or 2.5 h for IKKε and TBK-1 kinase respectively.	B	CS(=O)(=O)CCNCc1ccc(Nc2nccc(-c3cnc(N4CC[C@H](F)C4)c(C#N)c3)n2)cn1		CHEMBL3952082	<	IC50	nM	30.0	CHEMBL5408	Homo sapiens	IC50	nM	30.0
429085	17790752	CHEMBL3889017	Time-Resolved Fluorescence-based Lanthascreen Assay: Kinase inhibition assays (10 μL) were performed at 20° C. in 384-well plate format. Compound IC50 values were determined at the apparent Km for ATP (20 μM) based on a radiometric assay (Invitrogen) using 8 or 10 point curves in duplicate. The final reaction conditions contained 400 nM fluorescein-IkBα substrate (DRHDSGLDSMKDE), 20 μM ATP, 2 nM or 8 nM IKKε or TBK1 kinase respectively, and 3% DMSO in kinase assay buffer consisting of 50 mM HEPES (pH 7.5), 10 mM MgCl, 1 mM EGTA, 0.01% Brij-35.Compound dilutions were prepared from 10 mM DMSO stocks by dilution into DMSO. Compound dilution series were further diluted in kinase assay buffer to give a 12% DMSO stock, the final concentration in the assay being 3% DMSO.The kinase phosphorylation assay was initiated by the addition of the kinase and the reaction was allowed to proceed for 1 h or 2.5 h for IKKε and TBK-1 kinase respectively.	B	N#Cc1cc(-c2ccnc(Nc3ccnc(CN4CCOCC4)c3)n2)cnc1N1CC[C@H](F)C1		CHEMBL3976096	<	IC50	nM	15.0	CHEMBL5408	Homo sapiens	IC50	nM	15.0
429086	17790753	CHEMBL3889017	Time-Resolved Fluorescence-based Lanthascreen Assay: Kinase inhibition assays (10 μL) were performed at 20° C. in 384-well plate format. Compound IC50 values were determined at the apparent Km for ATP (20 μM) based on a radiometric assay (Invitrogen) using 8 or 10 point curves in duplicate. The final reaction conditions contained 400 nM fluorescein-IkBα substrate (DRHDSGLDSMKDE), 20 μM ATP, 2 nM or 8 nM IKKε or TBK1 kinase respectively, and 3% DMSO in kinase assay buffer consisting of 50 mM HEPES (pH 7.5), 10 mM MgCl, 1 mM EGTA, 0.01% Brij-35.Compound dilutions were prepared from 10 mM DMSO stocks by dilution into DMSO. Compound dilution series were further diluted in kinase assay buffer to give a 12% DMSO stock, the final concentration in the assay being 3% DMSO.The kinase phosphorylation assay was initiated by the addition of the kinase and the reaction was allowed to proceed for 1 h or 2.5 h for IKKε and TBK-1 kinase respectively.	B	N#Cc1cc(-c2ccnc(Nc3cncc(CN4CCOCC4)c3)n2)cnc1N1CC[C@H](F)C1		CHEMBL3946780	<	IC50	nM	30.0	CHEMBL5408	Homo sapiens	IC50	nM	30.0
429087	17790754	CHEMBL3889017	Time-Resolved Fluorescence-based Lanthascreen Assay: Kinase inhibition assays (10 μL) were performed at 20° C. in 384-well plate format. Compound IC50 values were determined at the apparent Km for ATP (20 μM) based on a radiometric assay (Invitrogen) using 8 or 10 point curves in duplicate. The final reaction conditions contained 400 nM fluorescein-IkBα substrate (DRHDSGLDSMKDE), 20 μM ATP, 2 nM or 8 nM IKKε or TBK1 kinase respectively, and 3% DMSO in kinase assay buffer consisting of 50 mM HEPES (pH 7.5), 10 mM MgCl, 1 mM EGTA, 0.01% Brij-35.Compound dilutions were prepared from 10 mM DMSO stocks by dilution into DMSO. Compound dilution series were further diluted in kinase assay buffer to give a 12% DMSO stock, the final concentration in the assay being 3% DMSO.The kinase phosphorylation assay was initiated by the addition of the kinase and the reaction was allowed to proceed for 1 h or 2.5 h for IKKε and TBK-1 kinase respectively.	B	CN(CCO)c1cc(Nc2nccc(-c3cnc(N4CC[C@H](F)C4)c(C#N)c3)n2)ccn1		CHEMBL3928858	<	IC50	nM	30.0	CHEMBL5408	Homo sapiens	IC50	nM	30.0
429088	17790755	CHEMBL3889017	Time-Resolved Fluorescence-based Lanthascreen Assay: Kinase inhibition assays (10 μL) were performed at 20° C. in 384-well plate format. Compound IC50 values were determined at the apparent Km for ATP (20 μM) based on a radiometric assay (Invitrogen) using 8 or 10 point curves in duplicate. The final reaction conditions contained 400 nM fluorescein-IkBα substrate (DRHDSGLDSMKDE), 20 μM ATP, 2 nM or 8 nM IKKε or TBK1 kinase respectively, and 3% DMSO in kinase assay buffer consisting of 50 mM HEPES (pH 7.5), 10 mM MgCl, 1 mM EGTA, 0.01% Brij-35.Compound dilutions were prepared from 10 mM DMSO stocks by dilution into DMSO. Compound dilution series were further diluted in kinase assay buffer to give a 12% DMSO stock, the final concentration in the assay being 3% DMSO.The kinase phosphorylation assay was initiated by the addition of the kinase and the reaction was allowed to proceed for 1 h or 2.5 h for IKKε and TBK-1 kinase respectively.	B	N#Cc1cc(-c2ccnc(Nc3ccc(CN4CCNC(=O)C4)nc3)n2)cnc1N1CC[C@H](F)C1		CHEMBL3904385	<	IC50	nM	15.0	CHEMBL5408	Homo sapiens	IC50	nM	15.0
429089	17790756	CHEMBL3889017	Time-Resolved Fluorescence-based Lanthascreen Assay: Kinase inhibition assays (10 μL) were performed at 20° C. in 384-well plate format. Compound IC50 values were determined at the apparent Km for ATP (20 μM) based on a radiometric assay (Invitrogen) using 8 or 10 point curves in duplicate. The final reaction conditions contained 400 nM fluorescein-IkBα substrate (DRHDSGLDSMKDE), 20 μM ATP, 2 nM or 8 nM IKKε or TBK1 kinase respectively, and 3% DMSO in kinase assay buffer consisting of 50 mM HEPES (pH 7.5), 10 mM MgCl, 1 mM EGTA, 0.01% Brij-35.Compound dilutions were prepared from 10 mM DMSO stocks by dilution into DMSO. Compound dilution series were further diluted in kinase assay buffer to give a 12% DMSO stock, the final concentration in the assay being 3% DMSO.The kinase phosphorylation assay was initiated by the addition of the kinase and the reaction was allowed to proceed for 1 h or 2.5 h for IKKε and TBK-1 kinase respectively.	B	N#Cc1cc(-c2ccnc(Nc3ccc(CN4CCCOCC4)nc3)n2)cnc1N1CC[C@H](F)C1		CHEMBL3891771	<	IC50	nM	100.0	CHEMBL5408	Homo sapiens	IC50	nM	100.0
429090	17790757	CHEMBL3889017	Time-Resolved Fluorescence-based Lanthascreen Assay: Kinase inhibition assays (10 μL) were performed at 20° C. in 384-well plate format. Compound IC50 values were determined at the apparent Km for ATP (20 μM) based on a radiometric assay (Invitrogen) using 8 or 10 point curves in duplicate. The final reaction conditions contained 400 nM fluorescein-IkBα substrate (DRHDSGLDSMKDE), 20 μM ATP, 2 nM or 8 nM IKKε or TBK1 kinase respectively, and 3% DMSO in kinase assay buffer consisting of 50 mM HEPES (pH 7.5), 10 mM MgCl, 1 mM EGTA, 0.01% Brij-35.Compound dilutions were prepared from 10 mM DMSO stocks by dilution into DMSO. Compound dilution series were further diluted in kinase assay buffer to give a 12% DMSO stock, the final concentration in the assay being 3% DMSO.The kinase phosphorylation assay was initiated by the addition of the kinase and the reaction was allowed to proceed for 1 h or 2.5 h for IKKε and TBK-1 kinase respectively.	B	CN(CCO)Cc1ccc(Nc2nccc(-c3cnc(N4CC[C@H](F)C4)c(C#N)c3)n2)cn1		CHEMBL3960782	<	IC50	nM	100.0	CHEMBL5408	Homo sapiens	IC50	nM	100.0
429092	17790758	CHEMBL3889017	Time-Resolved Fluorescence-based Lanthascreen Assay: Kinase inhibition assays (10 μL) were performed at 20° C. in 384-well plate format. Compound IC50 values were determined at the apparent Km for ATP (20 μM) based on a radiometric assay (Invitrogen) using 8 or 10 point curves in duplicate. The final reaction conditions contained 400 nM fluorescein-IkBα substrate (DRHDSGLDSMKDE), 20 μM ATP, 2 nM or 8 nM IKKε or TBK1 kinase respectively, and 3% DMSO in kinase assay buffer consisting of 50 mM HEPES (pH 7.5), 10 mM MgCl, 1 mM EGTA, 0.01% Brij-35.Compound dilutions were prepared from 10 mM DMSO stocks by dilution into DMSO. Compound dilution series were further diluted in kinase assay buffer to give a 12% DMSO stock, the final concentration in the assay being 3% DMSO.The kinase phosphorylation assay was initiated by the addition of the kinase and the reaction was allowed to proceed for 1 h or 2.5 h for IKKε and TBK-1 kinase respectively.	B	N#Cc1cc(-c2ccnc(Nc3ccc(CN4C(=O)OCC4CO)nc3)n2)cnc1N1CC[C@H](F)C1		CHEMBL3918874	<	IC50	nM	30.0	CHEMBL5408	Homo sapiens	IC50	nM	30.0
429093	17790759	CHEMBL3889017	Time-Resolved Fluorescence-based Lanthascreen Assay: Kinase inhibition assays (10 μL) were performed at 20° C. in 384-well plate format. Compound IC50 values were determined at the apparent Km for ATP (20 μM) based on a radiometric assay (Invitrogen) using 8 or 10 point curves in duplicate. The final reaction conditions contained 400 nM fluorescein-IkBα substrate (DRHDSGLDSMKDE), 20 μM ATP, 2 nM or 8 nM IKKε or TBK1 kinase respectively, and 3% DMSO in kinase assay buffer consisting of 50 mM HEPES (pH 7.5), 10 mM MgCl, 1 mM EGTA, 0.01% Brij-35.Compound dilutions were prepared from 10 mM DMSO stocks by dilution into DMSO. Compound dilution series were further diluted in kinase assay buffer to give a 12% DMSO stock, the final concentration in the assay being 3% DMSO.The kinase phosphorylation assay was initiated by the addition of the kinase and the reaction was allowed to proceed for 1 h or 2.5 h for IKKε and TBK-1 kinase respectively.	B	COCCNCc1cncc(Nc2nccc(-c3cnc(N4CC[C@H](F)C4)c(C#N)c3)n2)c1		CHEMBL3915999	<	IC50	nM	100.0	CHEMBL5408	Homo sapiens	IC50	nM	100.0
429094	17790760	CHEMBL3889017	Time-Resolved Fluorescence-based Lanthascreen Assay: Kinase inhibition assays (10 μL) were performed at 20° C. in 384-well plate format. Compound IC50 values were determined at the apparent Km for ATP (20 μM) based on a radiometric assay (Invitrogen) using 8 or 10 point curves in duplicate. The final reaction conditions contained 400 nM fluorescein-IkBα substrate (DRHDSGLDSMKDE), 20 μM ATP, 2 nM or 8 nM IKKε or TBK1 kinase respectively, and 3% DMSO in kinase assay buffer consisting of 50 mM HEPES (pH 7.5), 10 mM MgCl, 1 mM EGTA, 0.01% Brij-35.Compound dilutions were prepared from 10 mM DMSO stocks by dilution into DMSO. Compound dilution series were further diluted in kinase assay buffer to give a 12% DMSO stock, the final concentration in the assay being 3% DMSO.The kinase phosphorylation assay was initiated by the addition of the kinase and the reaction was allowed to proceed for 1 h or 2.5 h for IKKε and TBK-1 kinase respectively.	B	CC(C)(N)c1ccc(Nc2nccc(-c3cnc(N4CC[C@H](F)C4)c(C#N)c3)n2)cn1		CHEMBL3943961	<	IC50	nM	100.0	CHEMBL5408	Homo sapiens	IC50	nM	100.0
429095	17790761	CHEMBL3889017	Time-Resolved Fluorescence-based Lanthascreen Assay: Kinase inhibition assays (10 μL) were performed at 20° C. in 384-well plate format. Compound IC50 values were determined at the apparent Km for ATP (20 μM) based on a radiometric assay (Invitrogen) using 8 or 10 point curves in duplicate. The final reaction conditions contained 400 nM fluorescein-IkBα substrate (DRHDSGLDSMKDE), 20 μM ATP, 2 nM or 8 nM IKKε or TBK1 kinase respectively, and 3% DMSO in kinase assay buffer consisting of 50 mM HEPES (pH 7.5), 10 mM MgCl, 1 mM EGTA, 0.01% Brij-35.Compound dilutions were prepared from 10 mM DMSO stocks by dilution into DMSO. Compound dilution series were further diluted in kinase assay buffer to give a 12% DMSO stock, the final concentration in the assay being 3% DMSO.The kinase phosphorylation assay was initiated by the addition of the kinase and the reaction was allowed to proceed for 1 h or 2.5 h for IKKε and TBK-1 kinase respectively.	B	N#Cc1cc(-c2ccnc(Nc3cncc(NC(=O)CN4CCOCC4)c3)n2)cnc1N1CC[C@H](F)C1		CHEMBL3928470	<	IC50	nM	30.0	CHEMBL5408	Homo sapiens	IC50	nM	30.0
429096	17790762	CHEMBL3889017	Time-Resolved Fluorescence-based Lanthascreen Assay: Kinase inhibition assays (10 μL) were performed at 20° C. in 384-well plate format. Compound IC50 values were determined at the apparent Km for ATP (20 μM) based on a radiometric assay (Invitrogen) using 8 or 10 point curves in duplicate. The final reaction conditions contained 400 nM fluorescein-IkBα substrate (DRHDSGLDSMKDE), 20 μM ATP, 2 nM or 8 nM IKKε or TBK1 kinase respectively, and 3% DMSO in kinase assay buffer consisting of 50 mM HEPES (pH 7.5), 10 mM MgCl, 1 mM EGTA, 0.01% Brij-35.Compound dilutions were prepared from 10 mM DMSO stocks by dilution into DMSO. Compound dilution series were further diluted in kinase assay buffer to give a 12% DMSO stock, the final concentration in the assay being 3% DMSO.The kinase phosphorylation assay was initiated by the addition of the kinase and the reaction was allowed to proceed for 1 h or 2.5 h for IKKε and TBK-1 kinase respectively.	B	N#Cc1cc(-c2ccnc(Nc3cnc4c(c3)CNC4)n2)cnc1N1CC[C@H](F)C1		CHEMBL3952708	<	IC50	nM	100.0	CHEMBL5408	Homo sapiens	IC50	nM	100.0
429097	17790763	CHEMBL3889017	Time-Resolved Fluorescence-based Lanthascreen Assay: Kinase inhibition assays (10 μL) were performed at 20° C. in 384-well plate format. Compound IC50 values were determined at the apparent Km for ATP (20 μM) based on a radiometric assay (Invitrogen) using 8 or 10 point curves in duplicate. The final reaction conditions contained 400 nM fluorescein-IkBα substrate (DRHDSGLDSMKDE), 20 μM ATP, 2 nM or 8 nM IKKε or TBK1 kinase respectively, and 3% DMSO in kinase assay buffer consisting of 50 mM HEPES (pH 7.5), 10 mM MgCl, 1 mM EGTA, 0.01% Brij-35.Compound dilutions were prepared from 10 mM DMSO stocks by dilution into DMSO. Compound dilution series were further diluted in kinase assay buffer to give a 12% DMSO stock, the final concentration in the assay being 3% DMSO.The kinase phosphorylation assay was initiated by the addition of the kinase and the reaction was allowed to proceed for 1 h or 2.5 h for IKKε and TBK-1 kinase respectively.	B	CC1(O)CN(Cc2ccc(Nc3nccc(-c4cnc(N5CC[C@H](F)C5)c(C#N)c4)n3)cn2)C1		CHEMBL3929670	<	IC50	nM	100.0	CHEMBL5408	Homo sapiens	IC50	nM	100.0
429098	17790764	CHEMBL3889017	Time-Resolved Fluorescence-based Lanthascreen Assay: Kinase inhibition assays (10 μL) were performed at 20° C. in 384-well plate format. Compound IC50 values were determined at the apparent Km for ATP (20 μM) based on a radiometric assay (Invitrogen) using 8 or 10 point curves in duplicate. The final reaction conditions contained 400 nM fluorescein-IkBα substrate (DRHDSGLDSMKDE), 20 μM ATP, 2 nM or 8 nM IKKε or TBK1 kinase respectively, and 3% DMSO in kinase assay buffer consisting of 50 mM HEPES (pH 7.5), 10 mM MgCl, 1 mM EGTA, 0.01% Brij-35.Compound dilutions were prepared from 10 mM DMSO stocks by dilution into DMSO. Compound dilution series were further diluted in kinase assay buffer to give a 12% DMSO stock, the final concentration in the assay being 3% DMSO.The kinase phosphorylation assay was initiated by the addition of the kinase and the reaction was allowed to proceed for 1 h or 2.5 h for IKKε and TBK-1 kinase respectively.	B	N#Cc1cc(-c2ccnc(Nc3ccnc(NC(=O)CN4CCOCC4)c3)n2)cnc1N1CC[C@@H](F)C1		CHEMBL4114133	<	IC50	nM	15.0	CHEMBL5408	Homo sapiens	IC50	nM	15.0
429099	17790765	CHEMBL3889017	Time-Resolved Fluorescence-based Lanthascreen Assay: Kinase inhibition assays (10 μL) were performed at 20° C. in 384-well plate format. Compound IC50 values were determined at the apparent Km for ATP (20 μM) based on a radiometric assay (Invitrogen) using 8 or 10 point curves in duplicate. The final reaction conditions contained 400 nM fluorescein-IkBα substrate (DRHDSGLDSMKDE), 20 μM ATP, 2 nM or 8 nM IKKε or TBK1 kinase respectively, and 3% DMSO in kinase assay buffer consisting of 50 mM HEPES (pH 7.5), 10 mM MgCl, 1 mM EGTA, 0.01% Brij-35.Compound dilutions were prepared from 10 mM DMSO stocks by dilution into DMSO. Compound dilution series were further diluted in kinase assay buffer to give a 12% DMSO stock, the final concentration in the assay being 3% DMSO.The kinase phosphorylation assay was initiated by the addition of the kinase and the reaction was allowed to proceed for 1 h or 2.5 h for IKKε and TBK-1 kinase respectively.	B	N#Cc1cc(-c2ccnc(Nc3ccc(NC(=O)CN4CCOCC4)nc3)n2)cnc1N1CC[C@@H](F)C1		CHEMBL4109686	<	IC50	nM	30.0	CHEMBL5408	Homo sapiens	IC50	nM	30.0
429100	17790766	CHEMBL3889017	Time-Resolved Fluorescence-based Lanthascreen Assay: Kinase inhibition assays (10 μL) were performed at 20° C. in 384-well plate format. Compound IC50 values were determined at the apparent Km for ATP (20 μM) based on a radiometric assay (Invitrogen) using 8 or 10 point curves in duplicate. The final reaction conditions contained 400 nM fluorescein-IkBα substrate (DRHDSGLDSMKDE), 20 μM ATP, 2 nM or 8 nM IKKε or TBK1 kinase respectively, and 3% DMSO in kinase assay buffer consisting of 50 mM HEPES (pH 7.5), 10 mM MgCl, 1 mM EGTA, 0.01% Brij-35.Compound dilutions were prepared from 10 mM DMSO stocks by dilution into DMSO. Compound dilution series were further diluted in kinase assay buffer to give a 12% DMSO stock, the final concentration in the assay being 3% DMSO.The kinase phosphorylation assay was initiated by the addition of the kinase and the reaction was allowed to proceed for 1 h or 2.5 h for IKKε and TBK-1 kinase respectively.	B	CC(=O)Nc1ccc(Nc2nccc(-c3cnc(NC4CCOC4)c(C#N)c3)n2)cn1		CHEMBL3938562	<	IC50	nM	1000.0	CHEMBL5408	Homo sapiens	IC50	nM	1000.0
429101	17790767	CHEMBL3889017	Time-Resolved Fluorescence-based Lanthascreen Assay: Kinase inhibition assays (10 μL) were performed at 20° C. in 384-well plate format. Compound IC50 values were determined at the apparent Km for ATP (20 μM) based on a radiometric assay (Invitrogen) using 8 or 10 point curves in duplicate. The final reaction conditions contained 400 nM fluorescein-IkBα substrate (DRHDSGLDSMKDE), 20 μM ATP, 2 nM or 8 nM IKKε or TBK1 kinase respectively, and 3% DMSO in kinase assay buffer consisting of 50 mM HEPES (pH 7.5), 10 mM MgCl, 1 mM EGTA, 0.01% Brij-35.Compound dilutions were prepared from 10 mM DMSO stocks by dilution into DMSO. Compound dilution series were further diluted in kinase assay buffer to give a 12% DMSO stock, the final concentration in the assay being 3% DMSO.The kinase phosphorylation assay was initiated by the addition of the kinase and the reaction was allowed to proceed for 1 h or 2.5 h for IKKε and TBK-1 kinase respectively.	B	CN1CCC(Nc2ccc(Nc3nccc(-c4cnc(NC5CCOC5)c(C#N)c4)n3)cn2)CC1		CHEMBL3904581	<	IC50	nM	100.0	CHEMBL5408	Homo sapiens	IC50	nM	100.0
429102	17790768	CHEMBL3889017	Time-Resolved Fluorescence-based Lanthascreen Assay: Kinase inhibition assays (10 μL) were performed at 20° C. in 384-well plate format. Compound IC50 values were determined at the apparent Km for ATP (20 μM) based on a radiometric assay (Invitrogen) using 8 or 10 point curves in duplicate. The final reaction conditions contained 400 nM fluorescein-IkBα substrate (DRHDSGLDSMKDE), 20 μM ATP, 2 nM or 8 nM IKKε or TBK1 kinase respectively, and 3% DMSO in kinase assay buffer consisting of 50 mM HEPES (pH 7.5), 10 mM MgCl, 1 mM EGTA, 0.01% Brij-35.Compound dilutions were prepared from 10 mM DMSO stocks by dilution into DMSO. Compound dilution series were further diluted in kinase assay buffer to give a 12% DMSO stock, the final concentration in the assay being 3% DMSO.The kinase phosphorylation assay was initiated by the addition of the kinase and the reaction was allowed to proceed for 1 h or 2.5 h for IKKε and TBK-1 kinase respectively.	B	CN1CCC(NC(=O)c2cccc(Nc3nccc(-c4cnc(NC5CCOC5)c(C#N)c4)n3)c2)CC1		CHEMBL3936211	<	IC50	nM	1000.0	CHEMBL5408	Homo sapiens	IC50	nM	1000.0
429103	17790769	CHEMBL3889017	Time-Resolved Fluorescence-based Lanthascreen Assay: Kinase inhibition assays (10 μL) were performed at 20° C. in 384-well plate format. Compound IC50 values were determined at the apparent Km for ATP (20 μM) based on a radiometric assay (Invitrogen) using 8 or 10 point curves in duplicate. The final reaction conditions contained 400 nM fluorescein-IkBα substrate (DRHDSGLDSMKDE), 20 μM ATP, 2 nM or 8 nM IKKε or TBK1 kinase respectively, and 3% DMSO in kinase assay buffer consisting of 50 mM HEPES (pH 7.5), 10 mM MgCl, 1 mM EGTA, 0.01% Brij-35.Compound dilutions were prepared from 10 mM DMSO stocks by dilution into DMSO. Compound dilution series were further diluted in kinase assay buffer to give a 12% DMSO stock, the final concentration in the assay being 3% DMSO.The kinase phosphorylation assay was initiated by the addition of the kinase and the reaction was allowed to proceed for 1 h or 2.5 h for IKKε and TBK-1 kinase respectively.	B	Cn1cc(Nc2nccc(-c3cnc(NC4CCOC4)c(C#N)c3)n2)cn1		CHEMBL3950198	<	IC50	nM	1000.0	CHEMBL5408	Homo sapiens	IC50	nM	1000.0
429104	17790770	CHEMBL3889017	Time-Resolved Fluorescence-based Lanthascreen Assay: Kinase inhibition assays (10 μL) were performed at 20° C. in 384-well plate format. Compound IC50 values were determined at the apparent Km for ATP (20 μM) based on a radiometric assay (Invitrogen) using 8 or 10 point curves in duplicate. The final reaction conditions contained 400 nM fluorescein-IkBα substrate (DRHDSGLDSMKDE), 20 μM ATP, 2 nM or 8 nM IKKε or TBK1 kinase respectively, and 3% DMSO in kinase assay buffer consisting of 50 mM HEPES (pH 7.5), 10 mM MgCl, 1 mM EGTA, 0.01% Brij-35.Compound dilutions were prepared from 10 mM DMSO stocks by dilution into DMSO. Compound dilution series were further diluted in kinase assay buffer to give a 12% DMSO stock, the final concentration in the assay being 3% DMSO.The kinase phosphorylation assay was initiated by the addition of the kinase and the reaction was allowed to proceed for 1 h or 2.5 h for IKKε and TBK-1 kinase respectively.	B	N#Cc1cc(-c2ccnc(Nc3cccc(C(=O)NC4CCNCC4)c3)n2)cnc1NC1CCOC1		CHEMBL3922477	<	IC50	nM	1000.0	CHEMBL5408	Homo sapiens	IC50	nM	1000.0
429105	17790771	CHEMBL3889017	Time-Resolved Fluorescence-based Lanthascreen Assay: Kinase inhibition assays (10 μL) were performed at 20° C. in 384-well plate format. Compound IC50 values were determined at the apparent Km for ATP (20 μM) based on a radiometric assay (Invitrogen) using 8 or 10 point curves in duplicate. The final reaction conditions contained 400 nM fluorescein-IkBα substrate (DRHDSGLDSMKDE), 20 μM ATP, 2 nM or 8 nM IKKε or TBK1 kinase respectively, and 3% DMSO in kinase assay buffer consisting of 50 mM HEPES (pH 7.5), 10 mM MgCl, 1 mM EGTA, 0.01% Brij-35.Compound dilutions were prepared from 10 mM DMSO stocks by dilution into DMSO. Compound dilution series were further diluted in kinase assay buffer to give a 12% DMSO stock, the final concentration in the assay being 3% DMSO.The kinase phosphorylation assay was initiated by the addition of the kinase and the reaction was allowed to proceed for 1 h or 2.5 h for IKKε and TBK-1 kinase respectively.	B	COCCNc1ncc(-c2ccnc(Nc3ccc(NC4CCN(C)CC4)nc3)n2)cc1C#N		CHEMBL3931256	<	IC50	nM	1000.0	CHEMBL5408	Homo sapiens	IC50	nM	1000.0
429106	17790772	CHEMBL3889017	Time-Resolved Fluorescence-based Lanthascreen Assay: Kinase inhibition assays (10 μL) were performed at 20° C. in 384-well plate format. Compound IC50 values were determined at the apparent Km for ATP (20 μM) based on a radiometric assay (Invitrogen) using 8 or 10 point curves in duplicate. The final reaction conditions contained 400 nM fluorescein-IkBα substrate (DRHDSGLDSMKDE), 20 μM ATP, 2 nM or 8 nM IKKε or TBK1 kinase respectively, and 3% DMSO in kinase assay buffer consisting of 50 mM HEPES (pH 7.5), 10 mM MgCl, 1 mM EGTA, 0.01% Brij-35.Compound dilutions were prepared from 10 mM DMSO stocks by dilution into DMSO. Compound dilution series were further diluted in kinase assay buffer to give a 12% DMSO stock, the final concentration in the assay being 3% DMSO.The kinase phosphorylation assay was initiated by the addition of the kinase and the reaction was allowed to proceed for 1 h or 2.5 h for IKKε and TBK-1 kinase respectively.	B	CNc1ncc(-c2ccnc(Nc3ccc(NC4CCN(C)CC4)nc3)n2)cc1C#N		CHEMBL3927876	<	IC50	nM	100.0	CHEMBL5408	Homo sapiens	IC50	nM	100.0
429107	17790773	CHEMBL3889017	Time-Resolved Fluorescence-based Lanthascreen Assay: Kinase inhibition assays (10 μL) were performed at 20° C. in 384-well plate format. Compound IC50 values were determined at the apparent Km for ATP (20 μM) based on a radiometric assay (Invitrogen) using 8 or 10 point curves in duplicate. The final reaction conditions contained 400 nM fluorescein-IkBα substrate (DRHDSGLDSMKDE), 20 μM ATP, 2 nM or 8 nM IKKε or TBK1 kinase respectively, and 3% DMSO in kinase assay buffer consisting of 50 mM HEPES (pH 7.5), 10 mM MgCl, 1 mM EGTA, 0.01% Brij-35.Compound dilutions were prepared from 10 mM DMSO stocks by dilution into DMSO. Compound dilution series were further diluted in kinase assay buffer to give a 12% DMSO stock, the final concentration in the assay being 3% DMSO.The kinase phosphorylation assay was initiated by the addition of the kinase and the reaction was allowed to proceed for 1 h or 2.5 h for IKKε and TBK-1 kinase respectively.	B	CN1CCC(Nc2ccc(Nc3nccc(-c4cnc(NCCO)c(C#N)c4)n3)cn2)CC1		CHEMBL3985702	<	IC50	nM	100.0	CHEMBL5408	Homo sapiens	IC50	nM	100.0
429108	17790774	CHEMBL3889017	Time-Resolved Fluorescence-based Lanthascreen Assay: Kinase inhibition assays (10 μL) were performed at 20° C. in 384-well plate format. Compound IC50 values were determined at the apparent Km for ATP (20 μM) based on a radiometric assay (Invitrogen) using 8 or 10 point curves in duplicate. The final reaction conditions contained 400 nM fluorescein-IkBα substrate (DRHDSGLDSMKDE), 20 μM ATP, 2 nM or 8 nM IKKε or TBK1 kinase respectively, and 3% DMSO in kinase assay buffer consisting of 50 mM HEPES (pH 7.5), 10 mM MgCl, 1 mM EGTA, 0.01% Brij-35.Compound dilutions were prepared from 10 mM DMSO stocks by dilution into DMSO. Compound dilution series were further diluted in kinase assay buffer to give a 12% DMSO stock, the final concentration in the assay being 3% DMSO.The kinase phosphorylation assay was initiated by the addition of the kinase and the reaction was allowed to proceed for 1 h or 2.5 h for IKKε and TBK-1 kinase respectively.	B	N#Cc1cc(-c2ccnc(Nc3ccc(CN4CCOCC4)nc3)n2)cnc1NC1CC1		CHEMBL3908778	<	IC50	nM	100.0	CHEMBL5408	Homo sapiens	IC50	nM	100.0
429109	17790775	CHEMBL3889017	Time-Resolved Fluorescence-based Lanthascreen Assay: Kinase inhibition assays (10 μL) were performed at 20° C. in 384-well plate format. Compound IC50 values were determined at the apparent Km for ATP (20 μM) based on a radiometric assay (Invitrogen) using 8 or 10 point curves in duplicate. The final reaction conditions contained 400 nM fluorescein-IkBα substrate (DRHDSGLDSMKDE), 20 μM ATP, 2 nM or 8 nM IKKε or TBK1 kinase respectively, and 3% DMSO in kinase assay buffer consisting of 50 mM HEPES (pH 7.5), 10 mM MgCl, 1 mM EGTA, 0.01% Brij-35.Compound dilutions were prepared from 10 mM DMSO stocks by dilution into DMSO. Compound dilution series were further diluted in kinase assay buffer to give a 12% DMSO stock, the final concentration in the assay being 3% DMSO.The kinase phosphorylation assay was initiated by the addition of the kinase and the reaction was allowed to proceed for 1 h or 2.5 h for IKKε and TBK-1 kinase respectively.	B	N#Cc1cc(-c2nc(Nc3ccc(CN4CCOCC4)nc3)ncc2F)cnc1NC1CC1		CHEMBL3945627	<	IC50	nM	100.0	CHEMBL5408	Homo sapiens	IC50	nM	100.0
429110	17790776	CHEMBL3889017	Time-Resolved Fluorescence-based Lanthascreen Assay: Kinase inhibition assays (10 μL) were performed at 20° C. in 384-well plate format. Compound IC50 values were determined at the apparent Km for ATP (20 μM) based on a radiometric assay (Invitrogen) using 8 or 10 point curves in duplicate. The final reaction conditions contained 400 nM fluorescein-IkBα substrate (DRHDSGLDSMKDE), 20 μM ATP, 2 nM or 8 nM IKKε or TBK1 kinase respectively, and 3% DMSO in kinase assay buffer consisting of 50 mM HEPES (pH 7.5), 10 mM MgCl, 1 mM EGTA, 0.01% Brij-35.Compound dilutions were prepared from 10 mM DMSO stocks by dilution into DMSO. Compound dilution series were further diluted in kinase assay buffer to give a 12% DMSO stock, the final concentration in the assay being 3% DMSO.The kinase phosphorylation assay was initiated by the addition of the kinase and the reaction was allowed to proceed for 1 h or 2.5 h for IKKε and TBK-1 kinase respectively.	B	N#Cc1cc(-c2nc(Nc3ccnc(NC(=O)CN4CCOCC4)c3)ncc2F)cnc1NC1CC1		CHEMBL3921247	<	IC50	nM	100.0	CHEMBL5408	Homo sapiens	IC50	nM	100.0
429111	17790777	CHEMBL3889017	Time-Resolved Fluorescence-based Lanthascreen Assay: Kinase inhibition assays (10 μL) were performed at 20° C. in 384-well plate format. Compound IC50 values were determined at the apparent Km for ATP (20 μM) based on a radiometric assay (Invitrogen) using 8 or 10 point curves in duplicate. The final reaction conditions contained 400 nM fluorescein-IkBα substrate (DRHDSGLDSMKDE), 20 μM ATP, 2 nM or 8 nM IKKε or TBK1 kinase respectively, and 3% DMSO in kinase assay buffer consisting of 50 mM HEPES (pH 7.5), 10 mM MgCl, 1 mM EGTA, 0.01% Brij-35.Compound dilutions were prepared from 10 mM DMSO stocks by dilution into DMSO. Compound dilution series were further diluted in kinase assay buffer to give a 12% DMSO stock, the final concentration in the assay being 3% DMSO.The kinase phosphorylation assay was initiated by the addition of the kinase and the reaction was allowed to proceed for 1 h or 2.5 h for IKKε and TBK-1 kinase respectively.	B	COCCNc1cc(Nc2ncc(F)c(-c3cnc(NC4CC4)c(C#N)c3)n2)ccn1		CHEMBL3914507	<	IC50	nM	100.0	CHEMBL5408	Homo sapiens	IC50	nM	100.0
429112	17790778	CHEMBL3889017	Time-Resolved Fluorescence-based Lanthascreen Assay: Kinase inhibition assays (10 μL) were performed at 20° C. in 384-well plate format. Compound IC50 values were determined at the apparent Km for ATP (20 μM) based on a radiometric assay (Invitrogen) using 8 or 10 point curves in duplicate. The final reaction conditions contained 400 nM fluorescein-IkBα substrate (DRHDSGLDSMKDE), 20 μM ATP, 2 nM or 8 nM IKKε or TBK1 kinase respectively, and 3% DMSO in kinase assay buffer consisting of 50 mM HEPES (pH 7.5), 10 mM MgCl, 1 mM EGTA, 0.01% Brij-35.Compound dilutions were prepared from 10 mM DMSO stocks by dilution into DMSO. Compound dilution series were further diluted in kinase assay buffer to give a 12% DMSO stock, the final concentration in the assay being 3% DMSO.The kinase phosphorylation assay was initiated by the addition of the kinase and the reaction was allowed to proceed for 1 h or 2.5 h for IKKε and TBK-1 kinase respectively.	B	N#Cc1cc(-c2ccnc(Nc3ccc4c(c3)CNC4)n2)cnc1N1CC[C@H](F)C1		CHEMBL3984327	<	IC50	nM	15.0	CHEMBL5408	Homo sapiens	IC50	nM	15.0
429113	17790779	CHEMBL3889017	Time-Resolved Fluorescence-based Lanthascreen Assay: Kinase inhibition assays (10 μL) were performed at 20° C. in 384-well plate format. Compound IC50 values were determined at the apparent Km for ATP (20 μM) based on a radiometric assay (Invitrogen) using 8 or 10 point curves in duplicate. The final reaction conditions contained 400 nM fluorescein-IkBα substrate (DRHDSGLDSMKDE), 20 μM ATP, 2 nM or 8 nM IKKε or TBK1 kinase respectively, and 3% DMSO in kinase assay buffer consisting of 50 mM HEPES (pH 7.5), 10 mM MgCl, 1 mM EGTA, 0.01% Brij-35.Compound dilutions were prepared from 10 mM DMSO stocks by dilution into DMSO. Compound dilution series were further diluted in kinase assay buffer to give a 12% DMSO stock, the final concentration in the assay being 3% DMSO.The kinase phosphorylation assay was initiated by the addition of the kinase and the reaction was allowed to proceed for 1 h or 2.5 h for IKKε and TBK-1 kinase respectively.	B	COCCN1Cc2ccc(Nc3nccc(-c4cnc(N5CC[C@H](F)C5)c(C#N)c4)n3)cc2C1		CHEMBL3892171	<	IC50	nM	15.0	CHEMBL5408	Homo sapiens	IC50	nM	15.0
429114	17790780	CHEMBL3889017	Time-Resolved Fluorescence-based Lanthascreen Assay: Kinase inhibition assays (10 μL) were performed at 20° C. in 384-well plate format. Compound IC50 values were determined at the apparent Km for ATP (20 μM) based on a radiometric assay (Invitrogen) using 8 or 10 point curves in duplicate. The final reaction conditions contained 400 nM fluorescein-IkBα substrate (DRHDSGLDSMKDE), 20 μM ATP, 2 nM or 8 nM IKKε or TBK1 kinase respectively, and 3% DMSO in kinase assay buffer consisting of 50 mM HEPES (pH 7.5), 10 mM MgCl, 1 mM EGTA, 0.01% Brij-35.Compound dilutions were prepared from 10 mM DMSO stocks by dilution into DMSO. Compound dilution series were further diluted in kinase assay buffer to give a 12% DMSO stock, the final concentration in the assay being 3% DMSO.The kinase phosphorylation assay was initiated by the addition of the kinase and the reaction was allowed to proceed for 1 h or 2.5 h for IKKε and TBK-1 kinase respectively.	B	N#Cc1cc(-c2ccnc(Nc3cnn(CCO)c3)n2)cnc1N1CCCC1		CHEMBL3934438	<	IC50	nM	30.0	CHEMBL5408	Homo sapiens	IC50	nM	30.0
429115	17790781	CHEMBL3889017	Time-Resolved Fluorescence-based Lanthascreen Assay: Kinase inhibition assays (10 μL) were performed at 20° C. in 384-well plate format. Compound IC50 values were determined at the apparent Km for ATP (20 μM) based on a radiometric assay (Invitrogen) using 8 or 10 point curves in duplicate. The final reaction conditions contained 400 nM fluorescein-IkBα substrate (DRHDSGLDSMKDE), 20 μM ATP, 2 nM or 8 nM IKKε or TBK1 kinase respectively, and 3% DMSO in kinase assay buffer consisting of 50 mM HEPES (pH 7.5), 10 mM MgCl, 1 mM EGTA, 0.01% Brij-35.Compound dilutions were prepared from 10 mM DMSO stocks by dilution into DMSO. Compound dilution series were further diluted in kinase assay buffer to give a 12% DMSO stock, the final concentration in the assay being 3% DMSO.The kinase phosphorylation assay was initiated by the addition of the kinase and the reaction was allowed to proceed for 1 h or 2.5 h for IKKε and TBK-1 kinase respectively.	B	N#Cc1cc(-c2ccnc(Nc3ccc(C(N)=O)cc3)n2)cnc1N1CCCC1		CHEMBL3971959	<	IC50	nM	15.0	CHEMBL5408	Homo sapiens	IC50	nM	15.0
429116	17790782	CHEMBL3889017	Time-Resolved Fluorescence-based Lanthascreen Assay: Kinase inhibition assays (10 μL) were performed at 20° C. in 384-well plate format. Compound IC50 values were determined at the apparent Km for ATP (20 μM) based on a radiometric assay (Invitrogen) using 8 or 10 point curves in duplicate. The final reaction conditions contained 400 nM fluorescein-IkBα substrate (DRHDSGLDSMKDE), 20 μM ATP, 2 nM or 8 nM IKKε or TBK1 kinase respectively, and 3% DMSO in kinase assay buffer consisting of 50 mM HEPES (pH 7.5), 10 mM MgCl, 1 mM EGTA, 0.01% Brij-35.Compound dilutions were prepared from 10 mM DMSO stocks by dilution into DMSO. Compound dilution series were further diluted in kinase assay buffer to give a 12% DMSO stock, the final concentration in the assay being 3% DMSO.The kinase phosphorylation assay was initiated by the addition of the kinase and the reaction was allowed to proceed for 1 h or 2.5 h for IKKε and TBK-1 kinase respectively.	B	N#Cc1cc(-c2ccnc(Nc3cnn(C[C@H](O)CO)c3)n2)cnc1N1CCCC1		CHEMBL3943196	<	IC50	nM	15.0	CHEMBL5408	Homo sapiens	IC50	nM	15.0
429117	17790783	CHEMBL3889017	Time-Resolved Fluorescence-based Lanthascreen Assay: Kinase inhibition assays (10 μL) were performed at 20° C. in 384-well plate format. Compound IC50 values were determined at the apparent Km for ATP (20 μM) based on a radiometric assay (Invitrogen) using 8 or 10 point curves in duplicate. The final reaction conditions contained 400 nM fluorescein-IkBα substrate (DRHDSGLDSMKDE), 20 μM ATP, 2 nM or 8 nM IKKε or TBK1 kinase respectively, and 3% DMSO in kinase assay buffer consisting of 50 mM HEPES (pH 7.5), 10 mM MgCl, 1 mM EGTA, 0.01% Brij-35.Compound dilutions were prepared from 10 mM DMSO stocks by dilution into DMSO. Compound dilution series were further diluted in kinase assay buffer to give a 12% DMSO stock, the final concentration in the assay being 3% DMSO.The kinase phosphorylation assay was initiated by the addition of the kinase and the reaction was allowed to proceed for 1 h or 2.5 h for IKKε and TBK-1 kinase respectively.	B	N#Cc1cc(-c2ccnc(Nc3cnn(C[C@@H](O)CO)c3)n2)cnc1N1CCCC1		CHEMBL4106630	<	IC50	nM	15.0	CHEMBL5408	Homo sapiens	IC50	nM	15.0
429118	17790784	CHEMBL3889017	Time-Resolved Fluorescence-based Lanthascreen Assay: Kinase inhibition assays (10 μL) were performed at 20° C. in 384-well plate format. Compound IC50 values were determined at the apparent Km for ATP (20 μM) based on a radiometric assay (Invitrogen) using 8 or 10 point curves in duplicate. The final reaction conditions contained 400 nM fluorescein-IkBα substrate (DRHDSGLDSMKDE), 20 μM ATP, 2 nM or 8 nM IKKε or TBK1 kinase respectively, and 3% DMSO in kinase assay buffer consisting of 50 mM HEPES (pH 7.5), 10 mM MgCl, 1 mM EGTA, 0.01% Brij-35.Compound dilutions were prepared from 10 mM DMSO stocks by dilution into DMSO. Compound dilution series were further diluted in kinase assay buffer to give a 12% DMSO stock, the final concentration in the assay being 3% DMSO.The kinase phosphorylation assay was initiated by the addition of the kinase and the reaction was allowed to proceed for 1 h or 2.5 h for IKKε and TBK-1 kinase respectively.	B	Cn1cc(Nc2nccc(-c3cnc(N4CCC[C@@H]4C(=O)O)c(C#N)c3)n2)cn1		CHEMBL4109238	<	IC50	nM	1000.0	CHEMBL5408	Homo sapiens	IC50	nM	1000.0
429119	17790785	CHEMBL3889017	Time-Resolved Fluorescence-based Lanthascreen Assay: Kinase inhibition assays (10 μL) were performed at 20° C. in 384-well plate format. Compound IC50 values were determined at the apparent Km for ATP (20 μM) based on a radiometric assay (Invitrogen) using 8 or 10 point curves in duplicate. The final reaction conditions contained 400 nM fluorescein-IkBα substrate (DRHDSGLDSMKDE), 20 μM ATP, 2 nM or 8 nM IKKε or TBK1 kinase respectively, and 3% DMSO in kinase assay buffer consisting of 50 mM HEPES (pH 7.5), 10 mM MgCl, 1 mM EGTA, 0.01% Brij-35.Compound dilutions were prepared from 10 mM DMSO stocks by dilution into DMSO. Compound dilution series were further diluted in kinase assay buffer to give a 12% DMSO stock, the final concentration in the assay being 3% DMSO.The kinase phosphorylation assay was initiated by the addition of the kinase and the reaction was allowed to proceed for 1 h or 2.5 h for IKKε and TBK-1 kinase respectively.	B	Cn1cc(NC(=O)[C@H]2CCCN2c2ncc(-c3ccnc(Nc4cnn(C)c4)n3)cc2C#N)cn1		CHEMBL4112421	<	IC50	nM	100.0	CHEMBL5408	Homo sapiens	IC50	nM	100.0
429120	17790786	CHEMBL3889017	Time-Resolved Fluorescence-based Lanthascreen Assay: Kinase inhibition assays (10 μL) were performed at 20° C. in 384-well plate format. Compound IC50 values were determined at the apparent Km for ATP (20 μM) based on a radiometric assay (Invitrogen) using 8 or 10 point curves in duplicate. The final reaction conditions contained 400 nM fluorescein-IkBα substrate (DRHDSGLDSMKDE), 20 μM ATP, 2 nM or 8 nM IKKε or TBK1 kinase respectively, and 3% DMSO in kinase assay buffer consisting of 50 mM HEPES (pH 7.5), 10 mM MgCl, 1 mM EGTA, 0.01% Brij-35.Compound dilutions were prepared from 10 mM DMSO stocks by dilution into DMSO. Compound dilution series were further diluted in kinase assay buffer to give a 12% DMSO stock, the final concentration in the assay being 3% DMSO.The kinase phosphorylation assay was initiated by the addition of the kinase and the reaction was allowed to proceed for 1 h or 2.5 h for IKKε and TBK-1 kinase respectively.	B	Cn1cc(Nc2nccc(-c3cnc(N4CCC[C@H]4C#N)c(C#N)c3)n2)cn1		CHEMBL3900993	<	IC50	nM	100.0	CHEMBL5408	Homo sapiens	IC50	nM	100.0
429121	17790787	CHEMBL3889017	Time-Resolved Fluorescence-based Lanthascreen Assay: Kinase inhibition assays (10 μL) were performed at 20° C. in 384-well plate format. Compound IC50 values were determined at the apparent Km for ATP (20 μM) based on a radiometric assay (Invitrogen) using 8 or 10 point curves in duplicate. The final reaction conditions contained 400 nM fluorescein-IkBα substrate (DRHDSGLDSMKDE), 20 μM ATP, 2 nM or 8 nM IKKε or TBK1 kinase respectively, and 3% DMSO in kinase assay buffer consisting of 50 mM HEPES (pH 7.5), 10 mM MgCl, 1 mM EGTA, 0.01% Brij-35.Compound dilutions were prepared from 10 mM DMSO stocks by dilution into DMSO. Compound dilution series were further diluted in kinase assay buffer to give a 12% DMSO stock, the final concentration in the assay being 3% DMSO.The kinase phosphorylation assay was initiated by the addition of the kinase and the reaction was allowed to proceed for 1 h or 2.5 h for IKKε and TBK-1 kinase respectively.	B	Cn1cc(Nc2nccc(-c3cnc(N4CCC[C@@H]4C(N)=O)c(C#N)c3)n2)cn1		CHEMBL4115221	<	IC50	nM	100.0	CHEMBL5408	Homo sapiens	IC50	nM	100.0
429122	17790788	CHEMBL3889017	Time-Resolved Fluorescence-based Lanthascreen Assay: Kinase inhibition assays (10 μL) were performed at 20° C. in 384-well plate format. Compound IC50 values were determined at the apparent Km for ATP (20 μM) based on a radiometric assay (Invitrogen) using 8 or 10 point curves in duplicate. The final reaction conditions contained 400 nM fluorescein-IkBα substrate (DRHDSGLDSMKDE), 20 μM ATP, 2 nM or 8 nM IKKε or TBK1 kinase respectively, and 3% DMSO in kinase assay buffer consisting of 50 mM HEPES (pH 7.5), 10 mM MgCl, 1 mM EGTA, 0.01% Brij-35.Compound dilutions were prepared from 10 mM DMSO stocks by dilution into DMSO. Compound dilution series were further diluted in kinase assay buffer to give a 12% DMSO stock, the final concentration in the assay being 3% DMSO.The kinase phosphorylation assay was initiated by the addition of the kinase and the reaction was allowed to proceed for 1 h or 2.5 h for IKKε and TBK-1 kinase respectively.	B	Cn1cc(Nc2nccc(-c3cnc(N4C5CCC4CC(O)C5)c(C#N)c3)n2)cn1		CHEMBL3985522	<	IC50	nM	15.0	CHEMBL5408	Homo sapiens	IC50	nM	15.0
429123	17790789	CHEMBL3889017	Time-Resolved Fluorescence-based Lanthascreen Assay: Kinase inhibition assays (10 μL) were performed at 20° C. in 384-well plate format. Compound IC50 values were determined at the apparent Km for ATP (20 μM) based on a radiometric assay (Invitrogen) using 8 or 10 point curves in duplicate. The final reaction conditions contained 400 nM fluorescein-IkBα substrate (DRHDSGLDSMKDE), 20 μM ATP, 2 nM or 8 nM IKKε or TBK1 kinase respectively, and 3% DMSO in kinase assay buffer consisting of 50 mM HEPES (pH 7.5), 10 mM MgCl, 1 mM EGTA, 0.01% Brij-35.Compound dilutions were prepared from 10 mM DMSO stocks by dilution into DMSO. Compound dilution series were further diluted in kinase assay buffer to give a 12% DMSO stock, the final concentration in the assay being 3% DMSO.The kinase phosphorylation assay was initiated by the addition of the kinase and the reaction was allowed to proceed for 1 h or 2.5 h for IKKε and TBK-1 kinase respectively.	B	Cn1cc(Nc2nccc(-c3cnc(N4C5CCC4COC5)c(C#N)c3)n2)cn1		CHEMBL3896086	<	IC50	nM	100.0	CHEMBL5408	Homo sapiens	IC50	nM	100.0
429124	17790790	CHEMBL3889017	Time-Resolved Fluorescence-based Lanthascreen Assay: Kinase inhibition assays (10 μL) were performed at 20° C. in 384-well plate format. Compound IC50 values were determined at the apparent Km for ATP (20 μM) based on a radiometric assay (Invitrogen) using 8 or 10 point curves in duplicate. The final reaction conditions contained 400 nM fluorescein-IkBα substrate (DRHDSGLDSMKDE), 20 μM ATP, 2 nM or 8 nM IKKε or TBK1 kinase respectively, and 3% DMSO in kinase assay buffer consisting of 50 mM HEPES (pH 7.5), 10 mM MgCl, 1 mM EGTA, 0.01% Brij-35.Compound dilutions were prepared from 10 mM DMSO stocks by dilution into DMSO. Compound dilution series were further diluted in kinase assay buffer to give a 12% DMSO stock, the final concentration in the assay being 3% DMSO.The kinase phosphorylation assay was initiated by the addition of the kinase and the reaction was allowed to proceed for 1 h or 2.5 h for IKKε and TBK-1 kinase respectively.	B	N#Cc1cc(-c2ccnc(Nc3cnn(CCO)c3)n2)cnc1N1C2CCC1COC2		CHEMBL3970737	<	IC50	nM	100.0	CHEMBL5408	Homo sapiens	IC50	nM	100.0
429125	17790791	CHEMBL3889017	Time-Resolved Fluorescence-based Lanthascreen Assay: Kinase inhibition assays (10 μL) were performed at 20° C. in 384-well plate format. Compound IC50 values were determined at the apparent Km for ATP (20 μM) based on a radiometric assay (Invitrogen) using 8 or 10 point curves in duplicate. The final reaction conditions contained 400 nM fluorescein-IkBα substrate (DRHDSGLDSMKDE), 20 μM ATP, 2 nM or 8 nM IKKε or TBK1 kinase respectively, and 3% DMSO in kinase assay buffer consisting of 50 mM HEPES (pH 7.5), 10 mM MgCl, 1 mM EGTA, 0.01% Brij-35.Compound dilutions were prepared from 10 mM DMSO stocks by dilution into DMSO. Compound dilution series were further diluted in kinase assay buffer to give a 12% DMSO stock, the final concentration in the assay being 3% DMSO.The kinase phosphorylation assay was initiated by the addition of the kinase and the reaction was allowed to proceed for 1 h or 2.5 h for IKKε and TBK-1 kinase respectively.	B	N#Cc1cc(-c2ccnc(Nc3ccc(C(N)=O)nc3)n2)cnc1N1CC[C@H](F)C1		CHEMBL3984886	<	IC50	nM	30.0	CHEMBL5408	Homo sapiens	IC50	nM	30.0
429126	17790792	CHEMBL3889017	Time-Resolved Fluorescence-based Lanthascreen Assay: Kinase inhibition assays (10 μL) were performed at 20° C. in 384-well plate format. Compound IC50 values were determined at the apparent Km for ATP (20 μM) based on a radiometric assay (Invitrogen) using 8 or 10 point curves in duplicate. The final reaction conditions contained 400 nM fluorescein-IkBα substrate (DRHDSGLDSMKDE), 20 μM ATP, 2 nM or 8 nM IKKε or TBK1 kinase respectively, and 3% DMSO in kinase assay buffer consisting of 50 mM HEPES (pH 7.5), 10 mM MgCl, 1 mM EGTA, 0.01% Brij-35.Compound dilutions were prepared from 10 mM DMSO stocks by dilution into DMSO. Compound dilution series were further diluted in kinase assay buffer to give a 12% DMSO stock, the final concentration in the assay being 3% DMSO.The kinase phosphorylation assay was initiated by the addition of the kinase and the reaction was allowed to proceed for 1 h or 2.5 h for IKKε and TBK-1 kinase respectively.	B	N#Cc1cc(-c2ccnc(Nc3ccc(C(=O)NCCO)cc3)n2)cnc1N1CC[C@H](F)C1		CHEMBL3956235	<	IC50	nM	15.0	CHEMBL5408	Homo sapiens	IC50	nM	15.0
429127	17790793	CHEMBL3889017	Time-Resolved Fluorescence-based Lanthascreen Assay: Kinase inhibition assays (10 μL) were performed at 20° C. in 384-well plate format. Compound IC50 values were determined at the apparent Km for ATP (20 μM) based on a radiometric assay (Invitrogen) using 8 or 10 point curves in duplicate. The final reaction conditions contained 400 nM fluorescein-IkBα substrate (DRHDSGLDSMKDE), 20 μM ATP, 2 nM or 8 nM IKKε or TBK1 kinase respectively, and 3% DMSO in kinase assay buffer consisting of 50 mM HEPES (pH 7.5), 10 mM MgCl, 1 mM EGTA, 0.01% Brij-35.Compound dilutions were prepared from 10 mM DMSO stocks by dilution into DMSO. Compound dilution series were further diluted in kinase assay buffer to give a 12% DMSO stock, the final concentration in the assay being 3% DMSO.The kinase phosphorylation assay was initiated by the addition of the kinase and the reaction was allowed to proceed for 1 h or 2.5 h for IKKε and TBK-1 kinase respectively.	B	N#Cc1cc(-c2ccnc(Nc3ccc(N4CCOCC4)cc3)n2)cnc1N1CC[C@H](O)C1		CHEMBL3979910	<	IC50	nM	15.0	CHEMBL5408	Homo sapiens	IC50	nM	15.0
429128	17790794	CHEMBL3889017	Time-Resolved Fluorescence-based Lanthascreen Assay: Kinase inhibition assays (10 μL) were performed at 20° C. in 384-well plate format. Compound IC50 values were determined at the apparent Km for ATP (20 μM) based on a radiometric assay (Invitrogen) using 8 or 10 point curves in duplicate. The final reaction conditions contained 400 nM fluorescein-IkBα substrate (DRHDSGLDSMKDE), 20 μM ATP, 2 nM or 8 nM IKKε or TBK1 kinase respectively, and 3% DMSO in kinase assay buffer consisting of 50 mM HEPES (pH 7.5), 10 mM MgCl, 1 mM EGTA, 0.01% Brij-35.Compound dilutions were prepared from 10 mM DMSO stocks by dilution into DMSO. Compound dilution series were further diluted in kinase assay buffer to give a 12% DMSO stock, the final concentration in the assay being 3% DMSO.The kinase phosphorylation assay was initiated by the addition of the kinase and the reaction was allowed to proceed for 1 h or 2.5 h for IKKε and TBK-1 kinase respectively.	B	N#Cc1cc(-c2ccnc(Nc3ccc(N4CCOCC4)nc3)n2)cnc1N1CC[C@H](O)C1		CHEMBL3947539	<	IC50	nM	30.0	CHEMBL5408	Homo sapiens	IC50	nM	30.0
429129	17790795	CHEMBL3889017	Time-Resolved Fluorescence-based Lanthascreen Assay: Kinase inhibition assays (10 μL) were performed at 20° C. in 384-well plate format. Compound IC50 values were determined at the apparent Km for ATP (20 μM) based on a radiometric assay (Invitrogen) using 8 or 10 point curves in duplicate. The final reaction conditions contained 400 nM fluorescein-IkBα substrate (DRHDSGLDSMKDE), 20 μM ATP, 2 nM or 8 nM IKKε or TBK1 kinase respectively, and 3% DMSO in kinase assay buffer consisting of 50 mM HEPES (pH 7.5), 10 mM MgCl, 1 mM EGTA, 0.01% Brij-35.Compound dilutions were prepared from 10 mM DMSO stocks by dilution into DMSO. Compound dilution series were further diluted in kinase assay buffer to give a 12% DMSO stock, the final concentration in the assay being 3% DMSO.The kinase phosphorylation assay was initiated by the addition of the kinase and the reaction was allowed to proceed for 1 h or 2.5 h for IKKε and TBK-1 kinase respectively.	B	N#Cc1cc(-c2ccnc(Nc3cnn(CCO)c3)n2)cnc1N1CC[C@H](F)C1		CHEMBL3971833	<	IC50	nM	30.0	CHEMBL5408	Homo sapiens	IC50	nM	30.0
429130	17790796	CHEMBL3889017	Time-Resolved Fluorescence-based Lanthascreen Assay: Kinase inhibition assays (10 μL) were performed at 20° C. in 384-well plate format. Compound IC50 values were determined at the apparent Km for ATP (20 μM) based on a radiometric assay (Invitrogen) using 8 or 10 point curves in duplicate. The final reaction conditions contained 400 nM fluorescein-IkBα substrate (DRHDSGLDSMKDE), 20 μM ATP, 2 nM or 8 nM IKKε or TBK1 kinase respectively, and 3% DMSO in kinase assay buffer consisting of 50 mM HEPES (pH 7.5), 10 mM MgCl, 1 mM EGTA, 0.01% Brij-35.Compound dilutions were prepared from 10 mM DMSO stocks by dilution into DMSO. Compound dilution series were further diluted in kinase assay buffer to give a 12% DMSO stock, the final concentration in the assay being 3% DMSO.The kinase phosphorylation assay was initiated by the addition of the kinase and the reaction was allowed to proceed for 1 h or 2.5 h for IKKε and TBK-1 kinase respectively.	B	N#Cc1cc(-c2ccnc(Nc3cnn(CCCO)c3)n2)cnc1N1CC[C@H](F)C1		CHEMBL3942227	<	IC50	nM	30.0	CHEMBL5408	Homo sapiens	IC50	nM	30.0
429131	17790797	CHEMBL3889017	Time-Resolved Fluorescence-based Lanthascreen Assay: Kinase inhibition assays (10 μL) were performed at 20° C. in 384-well plate format. Compound IC50 values were determined at the apparent Km for ATP (20 μM) based on a radiometric assay (Invitrogen) using 8 or 10 point curves in duplicate. The final reaction conditions contained 400 nM fluorescein-IkBα substrate (DRHDSGLDSMKDE), 20 μM ATP, 2 nM or 8 nM IKKε or TBK1 kinase respectively, and 3% DMSO in kinase assay buffer consisting of 50 mM HEPES (pH 7.5), 10 mM MgCl, 1 mM EGTA, 0.01% Brij-35.Compound dilutions were prepared from 10 mM DMSO stocks by dilution into DMSO. Compound dilution series were further diluted in kinase assay buffer to give a 12% DMSO stock, the final concentration in the assay being 3% DMSO.The kinase phosphorylation assay was initiated by the addition of the kinase and the reaction was allowed to proceed for 1 h or 2.5 h for IKKε and TBK-1 kinase respectively.	B	N#Cc1cc(-c2ccnc(Nc3cnn(CCN4CCOCC4)c3)n2)cnc1N1CC[C@H](F)C1		CHEMBL3957288	<	IC50	nM	30.0	CHEMBL5408	Homo sapiens	IC50	nM	30.0
429132	17790798	CHEMBL3889017	Time-Resolved Fluorescence-based Lanthascreen Assay: Kinase inhibition assays (10 μL) were performed at 20° C. in 384-well plate format. Compound IC50 values were determined at the apparent Km for ATP (20 μM) based on a radiometric assay (Invitrogen) using 8 or 10 point curves in duplicate. The final reaction conditions contained 400 nM fluorescein-IkBα substrate (DRHDSGLDSMKDE), 20 μM ATP, 2 nM or 8 nM IKKε or TBK1 kinase respectively, and 3% DMSO in kinase assay buffer consisting of 50 mM HEPES (pH 7.5), 10 mM MgCl, 1 mM EGTA, 0.01% Brij-35.Compound dilutions were prepared from 10 mM DMSO stocks by dilution into DMSO. Compound dilution series were further diluted in kinase assay buffer to give a 12% DMSO stock, the final concentration in the assay being 3% DMSO.The kinase phosphorylation assay was initiated by the addition of the kinase and the reaction was allowed to proceed for 1 h or 2.5 h for IKKε and TBK-1 kinase respectively.	B	COCCNCC(=O)Nc1ccc(Nc2nccc(-c3cnc(N4CC[C@H](F)C4)c(C#N)c3)n2)cn1		CHEMBL3933243	<	IC50	nM	100.0	CHEMBL5408	Homo sapiens	IC50	nM	100.0
429133	17790799	CHEMBL3889017	Time-Resolved Fluorescence-based Lanthascreen Assay: Kinase inhibition assays (10 μL) were performed at 20° C. in 384-well plate format. Compound IC50 values were determined at the apparent Km for ATP (20 μM) based on a radiometric assay (Invitrogen) using 8 or 10 point curves in duplicate. The final reaction conditions contained 400 nM fluorescein-IkBα substrate (DRHDSGLDSMKDE), 20 μM ATP, 2 nM or 8 nM IKKε or TBK1 kinase respectively, and 3% DMSO in kinase assay buffer consisting of 50 mM HEPES (pH 7.5), 10 mM MgCl, 1 mM EGTA, 0.01% Brij-35.Compound dilutions were prepared from 10 mM DMSO stocks by dilution into DMSO. Compound dilution series were further diluted in kinase assay buffer to give a 12% DMSO stock, the final concentration in the assay being 3% DMSO.The kinase phosphorylation assay was initiated by the addition of the kinase and the reaction was allowed to proceed for 1 h or 2.5 h for IKKε and TBK-1 kinase respectively.	B	CC(NCc1ccccc1)C(=O)Nc1ccc(Nc2nccc(-c3cnc(N4CC[C@H](F)C4)c(C#N)c3)n2)cn1		CHEMBL3956706	<	IC50	nM	30.0	CHEMBL5408	Homo sapiens	IC50	nM	30.0
429134	17790800	CHEMBL3889017	Time-Resolved Fluorescence-based Lanthascreen Assay: Kinase inhibition assays (10 μL) were performed at 20° C. in 384-well plate format. Compound IC50 values were determined at the apparent Km for ATP (20 μM) based on a radiometric assay (Invitrogen) using 8 or 10 point curves in duplicate. The final reaction conditions contained 400 nM fluorescein-IkBα substrate (DRHDSGLDSMKDE), 20 μM ATP, 2 nM or 8 nM IKKε or TBK1 kinase respectively, and 3% DMSO in kinase assay buffer consisting of 50 mM HEPES (pH 7.5), 10 mM MgCl, 1 mM EGTA, 0.01% Brij-35.Compound dilutions were prepared from 10 mM DMSO stocks by dilution into DMSO. Compound dilution series were further diluted in kinase assay buffer to give a 12% DMSO stock, the final concentration in the assay being 3% DMSO.The kinase phosphorylation assay was initiated by the addition of the kinase and the reaction was allowed to proceed for 1 h or 2.5 h for IKKε and TBK-1 kinase respectively.	B	CC(N)C(=O)Nc1ccc(Nc2nccc(-c3cnc(N4CC[C@H](F)C4)c(C#N)c3)n2)cn1		CHEMBL3985372	<	IC50	nM	100.0	CHEMBL5408	Homo sapiens	IC50	nM	100.0
429135	17790801	CHEMBL3889017	Time-Resolved Fluorescence-based Lanthascreen Assay: Kinase inhibition assays (10 μL) were performed at 20° C. in 384-well plate format. Compound IC50 values were determined at the apparent Km for ATP (20 μM) based on a radiometric assay (Invitrogen) using 8 or 10 point curves in duplicate. The final reaction conditions contained 400 nM fluorescein-IkBα substrate (DRHDSGLDSMKDE), 20 μM ATP, 2 nM or 8 nM IKKε or TBK1 kinase respectively, and 3% DMSO in kinase assay buffer consisting of 50 mM HEPES (pH 7.5), 10 mM MgCl, 1 mM EGTA, 0.01% Brij-35.Compound dilutions were prepared from 10 mM DMSO stocks by dilution into DMSO. Compound dilution series were further diluted in kinase assay buffer to give a 12% DMSO stock, the final concentration in the assay being 3% DMSO.The kinase phosphorylation assay was initiated by the addition of the kinase and the reaction was allowed to proceed for 1 h or 2.5 h for IKKε and TBK-1 kinase respectively.	B	Cc1nccn1CC(=O)Nc1ccc(Nc2nccc(-c3cnc(N4CC[C@H](F)C4)c(C#N)c3)n2)cn1		CHEMBL3962112	<	IC50	nM	30.0	CHEMBL5408	Homo sapiens	IC50	nM	30.0
429136	17790802	CHEMBL3889017	Time-Resolved Fluorescence-based Lanthascreen Assay: Kinase inhibition assays (10 μL) were performed at 20° C. in 384-well plate format. Compound IC50 values were determined at the apparent Km for ATP (20 μM) based on a radiometric assay (Invitrogen) using 8 or 10 point curves in duplicate. The final reaction conditions contained 400 nM fluorescein-IkBα substrate (DRHDSGLDSMKDE), 20 μM ATP, 2 nM or 8 nM IKKε or TBK1 kinase respectively, and 3% DMSO in kinase assay buffer consisting of 50 mM HEPES (pH 7.5), 10 mM MgCl, 1 mM EGTA, 0.01% Brij-35.Compound dilutions were prepared from 10 mM DMSO stocks by dilution into DMSO. Compound dilution series were further diluted in kinase assay buffer to give a 12% DMSO stock, the final concentration in the assay being 3% DMSO.The kinase phosphorylation assay was initiated by the addition of the kinase and the reaction was allowed to proceed for 1 h or 2.5 h for IKKε and TBK-1 kinase respectively.	B	N#Cc1cc(-c2ccnc(Nc3ccc(N)nc3)n2)cnc1N1CC[C@H](F)C1		CHEMBL3982149	<	IC50	nM	30.0	CHEMBL5408	Homo sapiens	IC50	nM	30.0
429137	17790803	CHEMBL3889017	Time-Resolved Fluorescence-based Lanthascreen Assay: Kinase inhibition assays (10 μL) were performed at 20° C. in 384-well plate format. Compound IC50 values were determined at the apparent Km for ATP (20 μM) based on a radiometric assay (Invitrogen) using 8 or 10 point curves in duplicate. The final reaction conditions contained 400 nM fluorescein-IkBα substrate (DRHDSGLDSMKDE), 20 μM ATP, 2 nM or 8 nM IKKε or TBK1 kinase respectively, and 3% DMSO in kinase assay buffer consisting of 50 mM HEPES (pH 7.5), 10 mM MgCl, 1 mM EGTA, 0.01% Brij-35.Compound dilutions were prepared from 10 mM DMSO stocks by dilution into DMSO. Compound dilution series were further diluted in kinase assay buffer to give a 12% DMSO stock, the final concentration in the assay being 3% DMSO.The kinase phosphorylation assay was initiated by the addition of the kinase and the reaction was allowed to proceed for 1 h or 2.5 h for IKKε and TBK-1 kinase respectively.	B	CC(=O)NCC1CCCN1c1ncc(-c2ccnc(Nc3ccc(CN4CCOCC4)nc3)n2)cc1C#N		CHEMBL3973089	<	IC50	nM	1000.0	CHEMBL5408	Homo sapiens	IC50	nM	1000.0
429138	17790804	CHEMBL3889017	Time-Resolved Fluorescence-based Lanthascreen Assay: Kinase inhibition assays (10 μL) were performed at 20° C. in 384-well plate format. Compound IC50 values were determined at the apparent Km for ATP (20 μM) based on a radiometric assay (Invitrogen) using 8 or 10 point curves in duplicate. The final reaction conditions contained 400 nM fluorescein-IkBα substrate (DRHDSGLDSMKDE), 20 μM ATP, 2 nM or 8 nM IKKε or TBK1 kinase respectively, and 3% DMSO in kinase assay buffer consisting of 50 mM HEPES (pH 7.5), 10 mM MgCl, 1 mM EGTA, 0.01% Brij-35.Compound dilutions were prepared from 10 mM DMSO stocks by dilution into DMSO. Compound dilution series were further diluted in kinase assay buffer to give a 12% DMSO stock, the final concentration in the assay being 3% DMSO.The kinase phosphorylation assay was initiated by the addition of the kinase and the reaction was allowed to proceed for 1 h or 2.5 h for IKKε and TBK-1 kinase respectively.	B	N#Cc1cc(-c2ccnc(Nc3ccc(CN4CCOCC4)nc3)n2)cnc1N1CCCC1CC(N)=O		CHEMBL3902062	<	IC50	nM	30.0	CHEMBL5408	Homo sapiens	IC50	nM	30.0
429139	17790805	CHEMBL3889017	Time-Resolved Fluorescence-based Lanthascreen Assay: Kinase inhibition assays (10 μL) were performed at 20° C. in 384-well plate format. Compound IC50 values were determined at the apparent Km for ATP (20 μM) based on a radiometric assay (Invitrogen) using 8 or 10 point curves in duplicate. The final reaction conditions contained 400 nM fluorescein-IkBα substrate (DRHDSGLDSMKDE), 20 μM ATP, 2 nM or 8 nM IKKε or TBK1 kinase respectively, and 3% DMSO in kinase assay buffer consisting of 50 mM HEPES (pH 7.5), 10 mM MgCl, 1 mM EGTA, 0.01% Brij-35.Compound dilutions were prepared from 10 mM DMSO stocks by dilution into DMSO. Compound dilution series were further diluted in kinase assay buffer to give a 12% DMSO stock, the final concentration in the assay being 3% DMSO.The kinase phosphorylation assay was initiated by the addition of the kinase and the reaction was allowed to proceed for 1 h or 2.5 h for IKKε and TBK-1 kinase respectively.	B	N#Cc1cc(-c2ccnc(Nc3ccc(CN4CCOCC4)nc3)n2)cnc1N1CCC(CC(N)=O)C1		CHEMBL3984323	<	IC50	nM	100.0	CHEMBL5408	Homo sapiens	IC50	nM	100.0
429140	17790806	CHEMBL3889017	Time-Resolved Fluorescence-based Lanthascreen Assay: Kinase inhibition assays (10 μL) were performed at 20° C. in 384-well plate format. Compound IC50 values were determined at the apparent Km for ATP (20 μM) based on a radiometric assay (Invitrogen) using 8 or 10 point curves in duplicate. The final reaction conditions contained 400 nM fluorescein-IkBα substrate (DRHDSGLDSMKDE), 20 μM ATP, 2 nM or 8 nM IKKε or TBK1 kinase respectively, and 3% DMSO in kinase assay buffer consisting of 50 mM HEPES (pH 7.5), 10 mM MgCl, 1 mM EGTA, 0.01% Brij-35.Compound dilutions were prepared from 10 mM DMSO stocks by dilution into DMSO. Compound dilution series were further diluted in kinase assay buffer to give a 12% DMSO stock, the final concentration in the assay being 3% DMSO.The kinase phosphorylation assay was initiated by the addition of the kinase and the reaction was allowed to proceed for 1 h or 2.5 h for IKKε and TBK-1 kinase respectively.	B	CC1CN(c2ncc(-c3ccnc(Nc4ccc(CN5CCOCC5)nc4)n3)cc2C#N)CCO1		CHEMBL3921294	<	IC50	nM	1000.0	CHEMBL5408	Homo sapiens	IC50	nM	1000.0
429141	17790807	CHEMBL3889017	Time-Resolved Fluorescence-based Lanthascreen Assay: Kinase inhibition assays (10 μL) were performed at 20° C. in 384-well plate format. Compound IC50 values were determined at the apparent Km for ATP (20 μM) based on a radiometric assay (Invitrogen) using 8 or 10 point curves in duplicate. The final reaction conditions contained 400 nM fluorescein-IkBα substrate (DRHDSGLDSMKDE), 20 μM ATP, 2 nM or 8 nM IKKε or TBK1 kinase respectively, and 3% DMSO in kinase assay buffer consisting of 50 mM HEPES (pH 7.5), 10 mM MgCl, 1 mM EGTA, 0.01% Brij-35.Compound dilutions were prepared from 10 mM DMSO stocks by dilution into DMSO. Compound dilution series were further diluted in kinase assay buffer to give a 12% DMSO stock, the final concentration in the assay being 3% DMSO.The kinase phosphorylation assay was initiated by the addition of the kinase and the reaction was allowed to proceed for 1 h or 2.5 h for IKKε and TBK-1 kinase respectively.	B	CC(=O)NC1CCN(c2ncc(-c3ccnc(Nc4ccc(CN5CCOCC5)nc4)n3)cc2C#N)C1		CHEMBL3911737	<	IC50	nM	1000.0	CHEMBL5408	Homo sapiens	IC50	nM	1000.0
429142	17790808	CHEMBL3889017	Time-Resolved Fluorescence-based Lanthascreen Assay: Kinase inhibition assays (10 μL) were performed at 20° C. in 384-well plate format. Compound IC50 values were determined at the apparent Km for ATP (20 μM) based on a radiometric assay (Invitrogen) using 8 or 10 point curves in duplicate. The final reaction conditions contained 400 nM fluorescein-IkBα substrate (DRHDSGLDSMKDE), 20 μM ATP, 2 nM or 8 nM IKKε or TBK1 kinase respectively, and 3% DMSO in kinase assay buffer consisting of 50 mM HEPES (pH 7.5), 10 mM MgCl, 1 mM EGTA, 0.01% Brij-35.Compound dilutions were prepared from 10 mM DMSO stocks by dilution into DMSO. Compound dilution series were further diluted in kinase assay buffer to give a 12% DMSO stock, the final concentration in the assay being 3% DMSO.The kinase phosphorylation assay was initiated by the addition of the kinase and the reaction was allowed to proceed for 1 h or 2.5 h for IKKε and TBK-1 kinase respectively.	B	COCC1CCN(c2ncc(-c3ccnc(Nc4ccc(CN5CCOCC5)nc4)n3)cc2C#N)C1		CHEMBL3971527	<	IC50	nM	1000.0	CHEMBL5408	Homo sapiens	IC50	nM	1000.0
429143	17790809	CHEMBL3889017	Time-Resolved Fluorescence-based Lanthascreen Assay: Kinase inhibition assays (10 μL) were performed at 20° C. in 384-well plate format. Compound IC50 values were determined at the apparent Km for ATP (20 μM) based on a radiometric assay (Invitrogen) using 8 or 10 point curves in duplicate. The final reaction conditions contained 400 nM fluorescein-IkBα substrate (DRHDSGLDSMKDE), 20 μM ATP, 2 nM or 8 nM IKKε or TBK1 kinase respectively, and 3% DMSO in kinase assay buffer consisting of 50 mM HEPES (pH 7.5), 10 mM MgCl, 1 mM EGTA, 0.01% Brij-35.Compound dilutions were prepared from 10 mM DMSO stocks by dilution into DMSO. Compound dilution series were further diluted in kinase assay buffer to give a 12% DMSO stock, the final concentration in the assay being 3% DMSO.The kinase phosphorylation assay was initiated by the addition of the kinase and the reaction was allowed to proceed for 1 h or 2.5 h for IKKε and TBK-1 kinase respectively.	B	N#Cc1cc(-c2ccnc(Nc3ccc(CN4CCOCC4)nc3)n2)cnc1N1CCC(OC(F)F)C1		CHEMBL3903934	<	IC50	nM	100.0	CHEMBL5408	Homo sapiens	IC50	nM	100.0
429144	17790810	CHEMBL3889017	Time-Resolved Fluorescence-based Lanthascreen Assay: Kinase inhibition assays (10 μL) were performed at 20° C. in 384-well plate format. Compound IC50 values were determined at the apparent Km for ATP (20 μM) based on a radiometric assay (Invitrogen) using 8 or 10 point curves in duplicate. The final reaction conditions contained 400 nM fluorescein-IkBα substrate (DRHDSGLDSMKDE), 20 μM ATP, 2 nM or 8 nM IKKε or TBK1 kinase respectively, and 3% DMSO in kinase assay buffer consisting of 50 mM HEPES (pH 7.5), 10 mM MgCl, 1 mM EGTA, 0.01% Brij-35.Compound dilutions were prepared from 10 mM DMSO stocks by dilution into DMSO. Compound dilution series were further diluted in kinase assay buffer to give a 12% DMSO stock, the final concentration in the assay being 3% DMSO.The kinase phosphorylation assay was initiated by the addition of the kinase and the reaction was allowed to proceed for 1 h or 2.5 h for IKKε and TBK-1 kinase respectively.	B	N#Cc1cc(-c2ccnc(Nc3ccc(CN4CCOCC4)nc3)n2)cnc1N1CCC(CCC(N)=O)C1		CHEMBL3974819	<	IC50	nM	100.0	CHEMBL5408	Homo sapiens	IC50	nM	100.0
429145	17790811	CHEMBL3889017	Time-Resolved Fluorescence-based Lanthascreen Assay: Kinase inhibition assays (10 μL) were performed at 20° C. in 384-well plate format. Compound IC50 values were determined at the apparent Km for ATP (20 μM) based on a radiometric assay (Invitrogen) using 8 or 10 point curves in duplicate. The final reaction conditions contained 400 nM fluorescein-IkBα substrate (DRHDSGLDSMKDE), 20 μM ATP, 2 nM or 8 nM IKKε or TBK1 kinase respectively, and 3% DMSO in kinase assay buffer consisting of 50 mM HEPES (pH 7.5), 10 mM MgCl, 1 mM EGTA, 0.01% Brij-35.Compound dilutions were prepared from 10 mM DMSO stocks by dilution into DMSO. Compound dilution series were further diluted in kinase assay buffer to give a 12% DMSO stock, the final concentration in the assay being 3% DMSO.The kinase phosphorylation assay was initiated by the addition of the kinase and the reaction was allowed to proceed for 1 h or 2.5 h for IKKε and TBK-1 kinase respectively.	B	N#Cc1cc(-c2ccnc(Nc3ccc(CN4CCOCC4)nc3)n2)cnc1N1CCNC(=O)CC1		CHEMBL3941055	<	IC50	nM	1000.0	CHEMBL5408	Homo sapiens	IC50	nM	1000.0
429146	17790812	CHEMBL3889017	Time-Resolved Fluorescence-based Lanthascreen Assay: Kinase inhibition assays (10 μL) were performed at 20° C. in 384-well plate format. Compound IC50 values were determined at the apparent Km for ATP (20 μM) based on a radiometric assay (Invitrogen) using 8 or 10 point curves in duplicate. The final reaction conditions contained 400 nM fluorescein-IkBα substrate (DRHDSGLDSMKDE), 20 μM ATP, 2 nM or 8 nM IKKε or TBK1 kinase respectively, and 3% DMSO in kinase assay buffer consisting of 50 mM HEPES (pH 7.5), 10 mM MgCl, 1 mM EGTA, 0.01% Brij-35.Compound dilutions were prepared from 10 mM DMSO stocks by dilution into DMSO. Compound dilution series were further diluted in kinase assay buffer to give a 12% DMSO stock, the final concentration in the assay being 3% DMSO.The kinase phosphorylation assay was initiated by the addition of the kinase and the reaction was allowed to proceed for 1 h or 2.5 h for IKKε and TBK-1 kinase respectively.	B	CC(Nc1ncc(-c2ccnc(Nc3ccc(CN4CCOCC4)nc3)n2)cc1C#N)C(N)=O		CHEMBL3916574	<	IC50	nM	100.0	CHEMBL5408	Homo sapiens	IC50	nM	100.0
429147	17790813	CHEMBL3889017	Time-Resolved Fluorescence-based Lanthascreen Assay: Kinase inhibition assays (10 μL) were performed at 20° C. in 384-well plate format. Compound IC50 values were determined at the apparent Km for ATP (20 μM) based on a radiometric assay (Invitrogen) using 8 or 10 point curves in duplicate. The final reaction conditions contained 400 nM fluorescein-IkBα substrate (DRHDSGLDSMKDE), 20 μM ATP, 2 nM or 8 nM IKKε or TBK1 kinase respectively, and 3% DMSO in kinase assay buffer consisting of 50 mM HEPES (pH 7.5), 10 mM MgCl, 1 mM EGTA, 0.01% Brij-35.Compound dilutions were prepared from 10 mM DMSO stocks by dilution into DMSO. Compound dilution series were further diluted in kinase assay buffer to give a 12% DMSO stock, the final concentration in the assay being 3% DMSO.The kinase phosphorylation assay was initiated by the addition of the kinase and the reaction was allowed to proceed for 1 h or 2.5 h for IKKε and TBK-1 kinase respectively.	B	CC(C(N)=O)N(C)c1ncc(-c2ccnc(Nc3ccc(CN4CCOCC4)nc3)n2)cc1C#N		CHEMBL3889505	<	IC50	nM	100.0	CHEMBL5408	Homo sapiens	IC50	nM	100.0
429148	17790814	CHEMBL3889017	Time-Resolved Fluorescence-based Lanthascreen Assay: Kinase inhibition assays (10 μL) were performed at 20° C. in 384-well plate format. Compound IC50 values were determined at the apparent Km for ATP (20 μM) based on a radiometric assay (Invitrogen) using 8 or 10 point curves in duplicate. The final reaction conditions contained 400 nM fluorescein-IkBα substrate (DRHDSGLDSMKDE), 20 μM ATP, 2 nM or 8 nM IKKε or TBK1 kinase respectively, and 3% DMSO in kinase assay buffer consisting of 50 mM HEPES (pH 7.5), 10 mM MgCl, 1 mM EGTA, 0.01% Brij-35.Compound dilutions were prepared from 10 mM DMSO stocks by dilution into DMSO. Compound dilution series were further diluted in kinase assay buffer to give a 12% DMSO stock, the final concentration in the assay being 3% DMSO.The kinase phosphorylation assay was initiated by the addition of the kinase and the reaction was allowed to proceed for 1 h or 2.5 h for IKKε and TBK-1 kinase respectively.	B	CC(C)C(Nc1ncc(-c2ccnc(Nc3ccc(CN4CCOCC4)nc3)n2)cc1C#N)C(N)=O		CHEMBL3916897	<	IC50	nM	15.0	CHEMBL5408	Homo sapiens	IC50	nM	15.0
429149	17790815	CHEMBL3889017	Time-Resolved Fluorescence-based Lanthascreen Assay: Kinase inhibition assays (10 μL) were performed at 20° C. in 384-well plate format. Compound IC50 values were determined at the apparent Km for ATP (20 μM) based on a radiometric assay (Invitrogen) using 8 or 10 point curves in duplicate. The final reaction conditions contained 400 nM fluorescein-IkBα substrate (DRHDSGLDSMKDE), 20 μM ATP, 2 nM or 8 nM IKKε or TBK1 kinase respectively, and 3% DMSO in kinase assay buffer consisting of 50 mM HEPES (pH 7.5), 10 mM MgCl, 1 mM EGTA, 0.01% Brij-35.Compound dilutions were prepared from 10 mM DMSO stocks by dilution into DMSO. Compound dilution series were further diluted in kinase assay buffer to give a 12% DMSO stock, the final concentration in the assay being 3% DMSO.The kinase phosphorylation assay was initiated by the addition of the kinase and the reaction was allowed to proceed for 1 h or 2.5 h for IKKε and TBK-1 kinase respectively.	B	CN(CC1CCOC1)c1ncc(-c2ccnc(Nc3ccc(CN4CCOCC4)nc3)n2)cc1C#N		CHEMBL3943539	<	IC50	nM	1000.0	CHEMBL5408	Homo sapiens	IC50	nM	1000.0
429150	17790816	CHEMBL3889017	Time-Resolved Fluorescence-based Lanthascreen Assay: Kinase inhibition assays (10 μL) were performed at 20° C. in 384-well plate format. Compound IC50 values were determined at the apparent Km for ATP (20 μM) based on a radiometric assay (Invitrogen) using 8 or 10 point curves in duplicate. The final reaction conditions contained 400 nM fluorescein-IkBα substrate (DRHDSGLDSMKDE), 20 μM ATP, 2 nM or 8 nM IKKε or TBK1 kinase respectively, and 3% DMSO in kinase assay buffer consisting of 50 mM HEPES (pH 7.5), 10 mM MgCl, 1 mM EGTA, 0.01% Brij-35.Compound dilutions were prepared from 10 mM DMSO stocks by dilution into DMSO. Compound dilution series were further diluted in kinase assay buffer to give a 12% DMSO stock, the final concentration in the assay being 3% DMSO.The kinase phosphorylation assay was initiated by the addition of the kinase and the reaction was allowed to proceed for 1 h or 2.5 h for IKKε and TBK-1 kinase respectively.	B	N#Cc1cc(-c2ccnc(Nc3ccc(CN4CCOCC4)nc3)n2)cnc1NCC1CCOC1		CHEMBL3966321	<	IC50	nM	100.0	CHEMBL5408	Homo sapiens	IC50	nM	100.0
429151	17790817	CHEMBL3889017	Time-Resolved Fluorescence-based Lanthascreen Assay: Kinase inhibition assays (10 μL) were performed at 20° C. in 384-well plate format. Compound IC50 values were determined at the apparent Km for ATP (20 μM) based on a radiometric assay (Invitrogen) using 8 or 10 point curves in duplicate. The final reaction conditions contained 400 nM fluorescein-IkBα substrate (DRHDSGLDSMKDE), 20 μM ATP, 2 nM or 8 nM IKKε or TBK1 kinase respectively, and 3% DMSO in kinase assay buffer consisting of 50 mM HEPES (pH 7.5), 10 mM MgCl, 1 mM EGTA, 0.01% Brij-35.Compound dilutions were prepared from 10 mM DMSO stocks by dilution into DMSO. Compound dilution series were further diluted in kinase assay buffer to give a 12% DMSO stock, the final concentration in the assay being 3% DMSO.The kinase phosphorylation assay was initiated by the addition of the kinase and the reaction was allowed to proceed for 1 h or 2.5 h for IKKε and TBK-1 kinase respectively.	B	N#Cc1cc(-c2ccnc(Nc3ccc(CN4CCOCC4)nc3)n2)cnc1NC1CCCC1		CHEMBL3969564	<	IC50	nM	100.0	CHEMBL5408	Homo sapiens	IC50	nM	100.0
429152	17790818	CHEMBL3889017	Time-Resolved Fluorescence-based Lanthascreen Assay: Kinase inhibition assays (10 μL) were performed at 20° C. in 384-well plate format. Compound IC50 values were determined at the apparent Km for ATP (20 μM) based on a radiometric assay (Invitrogen) using 8 or 10 point curves in duplicate. The final reaction conditions contained 400 nM fluorescein-IkBα substrate (DRHDSGLDSMKDE), 20 μM ATP, 2 nM or 8 nM IKKε or TBK1 kinase respectively, and 3% DMSO in kinase assay buffer consisting of 50 mM HEPES (pH 7.5), 10 mM MgCl, 1 mM EGTA, 0.01% Brij-35.Compound dilutions were prepared from 10 mM DMSO stocks by dilution into DMSO. Compound dilution series were further diluted in kinase assay buffer to give a 12% DMSO stock, the final concentration in the assay being 3% DMSO.The kinase phosphorylation assay was initiated by the addition of the kinase and the reaction was allowed to proceed for 1 h or 2.5 h for IKKε and TBK-1 kinase respectively.	B	COCCN(C)c1ncc(-c2ccnc(Nc3ccc(CN4CCOCC4)nc3)n2)cc1C#N		CHEMBL3939994	<	IC50	nM	1000.0	CHEMBL5408	Homo sapiens	IC50	nM	1000.0
429153	17790819	CHEMBL3889017	Time-Resolved Fluorescence-based Lanthascreen Assay: Kinase inhibition assays (10 μL) were performed at 20° C. in 384-well plate format. Compound IC50 values were determined at the apparent Km for ATP (20 μM) based on a radiometric assay (Invitrogen) using 8 or 10 point curves in duplicate. The final reaction conditions contained 400 nM fluorescein-IkBα substrate (DRHDSGLDSMKDE), 20 μM ATP, 2 nM or 8 nM IKKε or TBK1 kinase respectively, and 3% DMSO in kinase assay buffer consisting of 50 mM HEPES (pH 7.5), 10 mM MgCl, 1 mM EGTA, 0.01% Brij-35.Compound dilutions were prepared from 10 mM DMSO stocks by dilution into DMSO. Compound dilution series were further diluted in kinase assay buffer to give a 12% DMSO stock, the final concentration in the assay being 3% DMSO.The kinase phosphorylation assay was initiated by the addition of the kinase and the reaction was allowed to proceed for 1 h or 2.5 h for IKKε and TBK-1 kinase respectively.	B	CN(c1ncc(-c2ccnc(Nc3ccc(CN4CCOCC4)nc3)n2)cc1C#N)C1CCOC1		CHEMBL3931468	<	IC50	nM	100.0	CHEMBL5408	Homo sapiens	IC50	nM	100.0
429154	17790820	CHEMBL3889017	Time-Resolved Fluorescence-based Lanthascreen Assay: Kinase inhibition assays (10 μL) were performed at 20° C. in 384-well plate format. Compound IC50 values were determined at the apparent Km for ATP (20 μM) based on a radiometric assay (Invitrogen) using 8 or 10 point curves in duplicate. The final reaction conditions contained 400 nM fluorescein-IkBα substrate (DRHDSGLDSMKDE), 20 μM ATP, 2 nM or 8 nM IKKε or TBK1 kinase respectively, and 3% DMSO in kinase assay buffer consisting of 50 mM HEPES (pH 7.5), 10 mM MgCl, 1 mM EGTA, 0.01% Brij-35.Compound dilutions were prepared from 10 mM DMSO stocks by dilution into DMSO. Compound dilution series were further diluted in kinase assay buffer to give a 12% DMSO stock, the final concentration in the assay being 3% DMSO.The kinase phosphorylation assay was initiated by the addition of the kinase and the reaction was allowed to proceed for 1 h or 2.5 h for IKKε and TBK-1 kinase respectively.	B	N#Cc1nc(-c2ccnc(Nc3ccc(N4CCOCC4)cc3)n2)ccc1N1CC[C@H](O)C1		CHEMBL3955566	<	IC50	nM	15.0	CHEMBL5408	Homo sapiens	IC50	nM	15.0
429155	17790821	CHEMBL3889017	Time-Resolved Fluorescence-based Lanthascreen Assay: Kinase inhibition assays (10 μL) were performed at 20° C. in 384-well plate format. Compound IC50 values were determined at the apparent Km for ATP (20 μM) based on a radiometric assay (Invitrogen) using 8 or 10 point curves in duplicate. The final reaction conditions contained 400 nM fluorescein-IkBα substrate (DRHDSGLDSMKDE), 20 μM ATP, 2 nM or 8 nM IKKε or TBK1 kinase respectively, and 3% DMSO in kinase assay buffer consisting of 50 mM HEPES (pH 7.5), 10 mM MgCl, 1 mM EGTA, 0.01% Brij-35.Compound dilutions were prepared from 10 mM DMSO stocks by dilution into DMSO. Compound dilution series were further diluted in kinase assay buffer to give a 12% DMSO stock, the final concentration in the assay being 3% DMSO.The kinase phosphorylation assay was initiated by the addition of the kinase and the reaction was allowed to proceed for 1 h or 2.5 h for IKKε and TBK-1 kinase respectively.	B	N#Cc1nc(-c2ccnc(Nc3ccc(N4CCOCC4)cc3)n2)ccc1N1CCCC1		CHEMBL3890843	<	IC50	nM	15.0	CHEMBL5408	Homo sapiens	IC50	nM	15.0
429156	17790822	CHEMBL3889017	Time-Resolved Fluorescence-based Lanthascreen Assay: Kinase inhibition assays (10 μL) were performed at 20° C. in 384-well plate format. Compound IC50 values were determined at the apparent Km for ATP (20 μM) based on a radiometric assay (Invitrogen) using 8 or 10 point curves in duplicate. The final reaction conditions contained 400 nM fluorescein-IkBα substrate (DRHDSGLDSMKDE), 20 μM ATP, 2 nM or 8 nM IKKε or TBK1 kinase respectively, and 3% DMSO in kinase assay buffer consisting of 50 mM HEPES (pH 7.5), 10 mM MgCl, 1 mM EGTA, 0.01% Brij-35.Compound dilutions were prepared from 10 mM DMSO stocks by dilution into DMSO. Compound dilution series were further diluted in kinase assay buffer to give a 12% DMSO stock, the final concentration in the assay being 3% DMSO.The kinase phosphorylation assay was initiated by the addition of the kinase and the reaction was allowed to proceed for 1 h or 2.5 h for IKKε and TBK-1 kinase respectively.	B	Cn1cc(Nc2nccc(-c3ccc(N4CC[C@H](O)C4)c(C#N)n3)n2)cn1		CHEMBL3918912	<	IC50	nM	100.0	CHEMBL5408	Homo sapiens	IC50	nM	100.0
429157	17790823	CHEMBL3889017	Time-Resolved Fluorescence-based Lanthascreen Assay: Kinase inhibition assays (10 μL) were performed at 20° C. in 384-well plate format. Compound IC50 values were determined at the apparent Km for ATP (20 μM) based on a radiometric assay (Invitrogen) using 8 or 10 point curves in duplicate. The final reaction conditions contained 400 nM fluorescein-IkBα substrate (DRHDSGLDSMKDE), 20 μM ATP, 2 nM or 8 nM IKKε or TBK1 kinase respectively, and 3% DMSO in kinase assay buffer consisting of 50 mM HEPES (pH 7.5), 10 mM MgCl, 1 mM EGTA, 0.01% Brij-35.Compound dilutions were prepared from 10 mM DMSO stocks by dilution into DMSO. Compound dilution series were further diluted in kinase assay buffer to give a 12% DMSO stock, the final concentration in the assay being 3% DMSO.The kinase phosphorylation assay was initiated by the addition of the kinase and the reaction was allowed to proceed for 1 h or 2.5 h for IKKε and TBK-1 kinase respectively.	B	Cn1cc(Nc2nccc(-c3ccc(N4CCC(C(N)=O)CC4)c(C#N)n3)n2)cn1		CHEMBL3980121	<	IC50	nM	100.0	CHEMBL5408	Homo sapiens	IC50	nM	100.0
429158	17790824	CHEMBL3889017	Time-Resolved Fluorescence-based Lanthascreen Assay: Kinase inhibition assays (10 μL) were performed at 20° C. in 384-well plate format. Compound IC50 values were determined at the apparent Km for ATP (20 μM) based on a radiometric assay (Invitrogen) using 8 or 10 point curves in duplicate. The final reaction conditions contained 400 nM fluorescein-IkBα substrate (DRHDSGLDSMKDE), 20 μM ATP, 2 nM or 8 nM IKKε or TBK1 kinase respectively, and 3% DMSO in kinase assay buffer consisting of 50 mM HEPES (pH 7.5), 10 mM MgCl, 1 mM EGTA, 0.01% Brij-35.Compound dilutions were prepared from 10 mM DMSO stocks by dilution into DMSO. Compound dilution series were further diluted in kinase assay buffer to give a 12% DMSO stock, the final concentration in the assay being 3% DMSO.The kinase phosphorylation assay was initiated by the addition of the kinase and the reaction was allowed to proceed for 1 h or 2.5 h for IKKε and TBK-1 kinase respectively.	B	N#Cc1nc(-c2ccnc(Nc3ccc(NC(=O)CN4CCOCC4)nc3)n2)ccc1N1CC[C@H](O)C1		CHEMBL3954923	<	IC50	nM	100.0	CHEMBL5408	Homo sapiens	IC50	nM	100.0
429159	17790825	CHEMBL3889017	Time-Resolved Fluorescence-based Lanthascreen Assay: Kinase inhibition assays (10 μL) were performed at 20° C. in 384-well plate format. Compound IC50 values were determined at the apparent Km for ATP (20 μM) based on a radiometric assay (Invitrogen) using 8 or 10 point curves in duplicate. The final reaction conditions contained 400 nM fluorescein-IkBα substrate (DRHDSGLDSMKDE), 20 μM ATP, 2 nM or 8 nM IKKε or TBK1 kinase respectively, and 3% DMSO in kinase assay buffer consisting of 50 mM HEPES (pH 7.5), 10 mM MgCl, 1 mM EGTA, 0.01% Brij-35.Compound dilutions were prepared from 10 mM DMSO stocks by dilution into DMSO. Compound dilution series were further diluted in kinase assay buffer to give a 12% DMSO stock, the final concentration in the assay being 3% DMSO.The kinase phosphorylation assay was initiated by the addition of the kinase and the reaction was allowed to proceed for 1 h or 2.5 h for IKKε and TBK-1 kinase respectively.	B	N#Cc1nc(-c2ccnc(Nc3ccc(NC(=O)CN4CCOCC4)nc3)n2)ccc1N1CC[C@H](F)C1		CHEMBL3975272	<	IC50	nM	15.0	CHEMBL5408	Homo sapiens	IC50	nM	15.0
429160	17790826	CHEMBL3889017	Time-Resolved Fluorescence-based Lanthascreen Assay: Kinase inhibition assays (10 μL) were performed at 20° C. in 384-well plate format. Compound IC50 values were determined at the apparent Km for ATP (20 μM) based on a radiometric assay (Invitrogen) using 8 or 10 point curves in duplicate. The final reaction conditions contained 400 nM fluorescein-IkBα substrate (DRHDSGLDSMKDE), 20 μM ATP, 2 nM or 8 nM IKKε or TBK1 kinase respectively, and 3% DMSO in kinase assay buffer consisting of 50 mM HEPES (pH 7.5), 10 mM MgCl, 1 mM EGTA, 0.01% Brij-35.Compound dilutions were prepared from 10 mM DMSO stocks by dilution into DMSO. Compound dilution series were further diluted in kinase assay buffer to give a 12% DMSO stock, the final concentration in the assay being 3% DMSO.The kinase phosphorylation assay was initiated by the addition of the kinase and the reaction was allowed to proceed for 1 h or 2.5 h for IKKε and TBK-1 kinase respectively.	B	N#Cc1nc(-c2ccnc(Nc3ccc(CN4CCOCC4)nc3)n2)ccc1N1CC[C@H](F)C1		CHEMBL3904420	<	IC50	nM	15.0	CHEMBL5408	Homo sapiens	IC50	nM	15.0
429161	17790827	CHEMBL3889017	Time-Resolved Fluorescence-based Lanthascreen Assay: Kinase inhibition assays (10 μL) were performed at 20° C. in 384-well plate format. Compound IC50 values were determined at the apparent Km for ATP (20 μM) based on a radiometric assay (Invitrogen) using 8 or 10 point curves in duplicate. The final reaction conditions contained 400 nM fluorescein-IkBα substrate (DRHDSGLDSMKDE), 20 μM ATP, 2 nM or 8 nM IKKε or TBK1 kinase respectively, and 3% DMSO in kinase assay buffer consisting of 50 mM HEPES (pH 7.5), 10 mM MgCl, 1 mM EGTA, 0.01% Brij-35.Compound dilutions were prepared from 10 mM DMSO stocks by dilution into DMSO. Compound dilution series were further diluted in kinase assay buffer to give a 12% DMSO stock, the final concentration in the assay being 3% DMSO.The kinase phosphorylation assay was initiated by the addition of the kinase and the reaction was allowed to proceed for 1 h or 2.5 h for IKKε and TBK-1 kinase respectively.	B	N#Cc1nc(-c2ccnc(Nc3ccc(CN4CCOCC4)nc3)n2)ccc1N1CC[C@H](O)C1		CHEMBL3968958	<	IC50	nM	30.0	CHEMBL5408	Homo sapiens	IC50	nM	30.0
429162	17790828	CHEMBL3889017	Time-Resolved Fluorescence-based Lanthascreen Assay: Kinase inhibition assays (10 μL) were performed at 20° C. in 384-well plate format. Compound IC50 values were determined at the apparent Km for ATP (20 μM) based on a radiometric assay (Invitrogen) using 8 or 10 point curves in duplicate. The final reaction conditions contained 400 nM fluorescein-IkBα substrate (DRHDSGLDSMKDE), 20 μM ATP, 2 nM or 8 nM IKKε or TBK1 kinase respectively, and 3% DMSO in kinase assay buffer consisting of 50 mM HEPES (pH 7.5), 10 mM MgCl, 1 mM EGTA, 0.01% Brij-35.Compound dilutions were prepared from 10 mM DMSO stocks by dilution into DMSO. Compound dilution series were further diluted in kinase assay buffer to give a 12% DMSO stock, the final concentration in the assay being 3% DMSO.The kinase phosphorylation assay was initiated by the addition of the kinase and the reaction was allowed to proceed for 1 h or 2.5 h for IKKε and TBK-1 kinase respectively.	B	N#Cc1nc(-c2ccnc(Nc3ccc(NC(=O)CN4CC[C@H](F)C4)nc3)n2)ccc1N1CC[C@H](F)C1		CHEMBL3894306	<	IC50	nM	30.0	CHEMBL5408	Homo sapiens	IC50	nM	30.0
429163	17790829	CHEMBL3889017	Time-Resolved Fluorescence-based Lanthascreen Assay: Kinase inhibition assays (10 μL) were performed at 20° C. in 384-well plate format. Compound IC50 values were determined at the apparent Km for ATP (20 μM) based on a radiometric assay (Invitrogen) using 8 or 10 point curves in duplicate. The final reaction conditions contained 400 nM fluorescein-IkBα substrate (DRHDSGLDSMKDE), 20 μM ATP, 2 nM or 8 nM IKKε or TBK1 kinase respectively, and 3% DMSO in kinase assay buffer consisting of 50 mM HEPES (pH 7.5), 10 mM MgCl, 1 mM EGTA, 0.01% Brij-35.Compound dilutions were prepared from 10 mM DMSO stocks by dilution into DMSO. Compound dilution series were further diluted in kinase assay buffer to give a 12% DMSO stock, the final concentration in the assay being 3% DMSO.The kinase phosphorylation assay was initiated by the addition of the kinase and the reaction was allowed to proceed for 1 h or 2.5 h for IKKε and TBK-1 kinase respectively.	B	N#Cc1nc(-c2ccnc(Nc3ccc(NC(=O)CN4CC[C@H](F)C4)nc3)n2)ccc1N1CC[C@H](O)C1		CHEMBL3926764	<	IC50	nM	30.0	CHEMBL5408	Homo sapiens	IC50	nM	30.0
429164	17790830	CHEMBL3889017	Time-Resolved Fluorescence-based Lanthascreen Assay: Kinase inhibition assays (10 μL) were performed at 20° C. in 384-well plate format. Compound IC50 values were determined at the apparent Km for ATP (20 μM) based on a radiometric assay (Invitrogen) using 8 or 10 point curves in duplicate. The final reaction conditions contained 400 nM fluorescein-IkBα substrate (DRHDSGLDSMKDE), 20 μM ATP, 2 nM or 8 nM IKKε or TBK1 kinase respectively, and 3% DMSO in kinase assay buffer consisting of 50 mM HEPES (pH 7.5), 10 mM MgCl, 1 mM EGTA, 0.01% Brij-35.Compound dilutions were prepared from 10 mM DMSO stocks by dilution into DMSO. Compound dilution series were further diluted in kinase assay buffer to give a 12% DMSO stock, the final concentration in the assay being 3% DMSO.The kinase phosphorylation assay was initiated by the addition of the kinase and the reaction was allowed to proceed for 1 h or 2.5 h for IKKε and TBK-1 kinase respectively.	B	N#Cc1nc(-c2ccnc(Nc3ccc(OCCN4CC[C@H](F)C4)nc3)n2)ccc1N1CC[C@H](F)C1		CHEMBL3895278	<	IC50	nM	30.0	CHEMBL5408	Homo sapiens	IC50	nM	30.0
429165	17790831	CHEMBL3889017	Time-Resolved Fluorescence-based Lanthascreen Assay: Kinase inhibition assays (10 μL) were performed at 20° C. in 384-well plate format. Compound IC50 values were determined at the apparent Km for ATP (20 μM) based on a radiometric assay (Invitrogen) using 8 or 10 point curves in duplicate. The final reaction conditions contained 400 nM fluorescein-IkBα substrate (DRHDSGLDSMKDE), 20 μM ATP, 2 nM or 8 nM IKKε or TBK1 kinase respectively, and 3% DMSO in kinase assay buffer consisting of 50 mM HEPES (pH 7.5), 10 mM MgCl, 1 mM EGTA, 0.01% Brij-35.Compound dilutions were prepared from 10 mM DMSO stocks by dilution into DMSO. Compound dilution series were further diluted in kinase assay buffer to give a 12% DMSO stock, the final concentration in the assay being 3% DMSO.The kinase phosphorylation assay was initiated by the addition of the kinase and the reaction was allowed to proceed for 1 h or 2.5 h for IKKε and TBK-1 kinase respectively.	B	N#Cc1nc(-c2ccnc(Nc3ccc(OCCN4CC[C@H](F)C4)nc3)n2)ccc1N1CC[C@H](O)C1		CHEMBL3917806	<	IC50	nM	100.0	CHEMBL5408	Homo sapiens	IC50	nM	100.0
429166	17790832	CHEMBL3889017	Time-Resolved Fluorescence-based Lanthascreen Assay: Kinase inhibition assays (10 μL) were performed at 20° C. in 384-well plate format. Compound IC50 values were determined at the apparent Km for ATP (20 μM) based on a radiometric assay (Invitrogen) using 8 or 10 point curves in duplicate. The final reaction conditions contained 400 nM fluorescein-IkBα substrate (DRHDSGLDSMKDE), 20 μM ATP, 2 nM or 8 nM IKKε or TBK1 kinase respectively, and 3% DMSO in kinase assay buffer consisting of 50 mM HEPES (pH 7.5), 10 mM MgCl, 1 mM EGTA, 0.01% Brij-35.Compound dilutions were prepared from 10 mM DMSO stocks by dilution into DMSO. Compound dilution series were further diluted in kinase assay buffer to give a 12% DMSO stock, the final concentration in the assay being 3% DMSO.The kinase phosphorylation assay was initiated by the addition of the kinase and the reaction was allowed to proceed for 1 h or 2.5 h for IKKε and TBK-1 kinase respectively.	B	C[C@H]1COCCN1Cc1ccc(Nc2nccc(-c3cc(C#N)c(N4CC[C@H](F)C4)c(C#N)n3)n2)cn1		CHEMBL3889803	<	IC50	nM	15.0	CHEMBL5408	Homo sapiens	IC50	nM	15.0
429167	17790833	CHEMBL3889017	Time-Resolved Fluorescence-based Lanthascreen Assay: Kinase inhibition assays (10 μL) were performed at 20° C. in 384-well plate format. Compound IC50 values were determined at the apparent Km for ATP (20 μM) based on a radiometric assay (Invitrogen) using 8 or 10 point curves in duplicate. The final reaction conditions contained 400 nM fluorescein-IkBα substrate (DRHDSGLDSMKDE), 20 μM ATP, 2 nM or 8 nM IKKε or TBK1 kinase respectively, and 3% DMSO in kinase assay buffer consisting of 50 mM HEPES (pH 7.5), 10 mM MgCl, 1 mM EGTA, 0.01% Brij-35.Compound dilutions were prepared from 10 mM DMSO stocks by dilution into DMSO. Compound dilution series were further diluted in kinase assay buffer to give a 12% DMSO stock, the final concentration in the assay being 3% DMSO.The kinase phosphorylation assay was initiated by the addition of the kinase and the reaction was allowed to proceed for 1 h or 2.5 h for IKKε and TBK-1 kinase respectively.	B	N#Cc1nc(-c2ccnc(Nc3ccc(CN4CC[C@H](F)C4)nc3)n2)ccc1N1CC[C@H](F)C1		CHEMBL3941194	<	IC50	nM	15.0	CHEMBL5408	Homo sapiens	IC50	nM	15.0
429168	17790834	CHEMBL3889017	Time-Resolved Fluorescence-based Lanthascreen Assay: Kinase inhibition assays (10 μL) were performed at 20° C. in 384-well plate format. Compound IC50 values were determined at the apparent Km for ATP (20 μM) based on a radiometric assay (Invitrogen) using 8 or 10 point curves in duplicate. The final reaction conditions contained 400 nM fluorescein-IkBα substrate (DRHDSGLDSMKDE), 20 μM ATP, 2 nM or 8 nM IKKε or TBK1 kinase respectively, and 3% DMSO in kinase assay buffer consisting of 50 mM HEPES (pH 7.5), 10 mM MgCl, 1 mM EGTA, 0.01% Brij-35.Compound dilutions were prepared from 10 mM DMSO stocks by dilution into DMSO. Compound dilution series were further diluted in kinase assay buffer to give a 12% DMSO stock, the final concentration in the assay being 3% DMSO.The kinase phosphorylation assay was initiated by the addition of the kinase and the reaction was allowed to proceed for 1 h or 2.5 h for IKKε and TBK-1 kinase respectively.	B	Cc1nccn1Cc1ccc(Nc2nccc(-c3ccc(N4CC[C@H](F)C4)c(C#N)n3)n2)cn1		CHEMBL3916744	<	IC50	nM	30.0	CHEMBL5408	Homo sapiens	IC50	nM	30.0
429169	17790835	CHEMBL3889017	Time-Resolved Fluorescence-based Lanthascreen Assay: Kinase inhibition assays (10 μL) were performed at 20° C. in 384-well plate format. Compound IC50 values were determined at the apparent Km for ATP (20 μM) based on a radiometric assay (Invitrogen) using 8 or 10 point curves in duplicate. The final reaction conditions contained 400 nM fluorescein-IkBα substrate (DRHDSGLDSMKDE), 20 μM ATP, 2 nM or 8 nM IKKε or TBK1 kinase respectively, and 3% DMSO in kinase assay buffer consisting of 50 mM HEPES (pH 7.5), 10 mM MgCl, 1 mM EGTA, 0.01% Brij-35.Compound dilutions were prepared from 10 mM DMSO stocks by dilution into DMSO. Compound dilution series were further diluted in kinase assay buffer to give a 12% DMSO stock, the final concentration in the assay being 3% DMSO.The kinase phosphorylation assay was initiated by the addition of the kinase and the reaction was allowed to proceed for 1 h or 2.5 h for IKKε and TBK-1 kinase respectively.	B	COCCN(C)Cc1ccc(Nc2nccc(-c3ccc(N4CC[C@H](F)C4)c(C#N)n3)n2)cn1		CHEMBL3932195	<	IC50	nM	30.0	CHEMBL5408	Homo sapiens	IC50	nM	30.0
429170	17790836	CHEMBL3889017	Time-Resolved Fluorescence-based Lanthascreen Assay: Kinase inhibition assays (10 μL) were performed at 20° C. in 384-well plate format. Compound IC50 values were determined at the apparent Km for ATP (20 μM) based on a radiometric assay (Invitrogen) using 8 or 10 point curves in duplicate. The final reaction conditions contained 400 nM fluorescein-IkBα substrate (DRHDSGLDSMKDE), 20 μM ATP, 2 nM or 8 nM IKKε or TBK1 kinase respectively, and 3% DMSO in kinase assay buffer consisting of 50 mM HEPES (pH 7.5), 10 mM MgCl, 1 mM EGTA, 0.01% Brij-35.Compound dilutions were prepared from 10 mM DMSO stocks by dilution into DMSO. Compound dilution series were further diluted in kinase assay buffer to give a 12% DMSO stock, the final concentration in the assay being 3% DMSO.The kinase phosphorylation assay was initiated by the addition of the kinase and the reaction was allowed to proceed for 1 h or 2.5 h for IKKε and TBK-1 kinase respectively.	B	N#Cc1nc(-c2nc(Nc3ccc(N4CCOCC4)cc3)ncc2F)ccc1N1CC[C@H](F)C1		CHEMBL3904190	<	IC50	nM	15.0	CHEMBL5408	Homo sapiens	IC50	nM	15.0
429171	17790837	CHEMBL3889017	Time-Resolved Fluorescence-based Lanthascreen Assay: Kinase inhibition assays (10 μL) were performed at 20° C. in 384-well plate format. Compound IC50 values were determined at the apparent Km for ATP (20 μM) based on a radiometric assay (Invitrogen) using 8 or 10 point curves in duplicate. The final reaction conditions contained 400 nM fluorescein-IkBα substrate (DRHDSGLDSMKDE), 20 μM ATP, 2 nM or 8 nM IKKε or TBK1 kinase respectively, and 3% DMSO in kinase assay buffer consisting of 50 mM HEPES (pH 7.5), 10 mM MgCl, 1 mM EGTA, 0.01% Brij-35.Compound dilutions were prepared from 10 mM DMSO stocks by dilution into DMSO. Compound dilution series were further diluted in kinase assay buffer to give a 12% DMSO stock, the final concentration in the assay being 3% DMSO.The kinase phosphorylation assay was initiated by the addition of the kinase and the reaction was allowed to proceed for 1 h or 2.5 h for IKKε and TBK-1 kinase respectively.	B	N#Cc1nc(-c2ccnc(Nc3ccc(CN4CCOCC4)nc3)n2)ccc1N1CCCOCC1		CHEMBL3919044	<	IC50	nM	100.0	CHEMBL5408	Homo sapiens	IC50	nM	100.0
429172	17790838	CHEMBL3889017	Time-Resolved Fluorescence-based Lanthascreen Assay: Kinase inhibition assays (10 μL) were performed at 20° C. in 384-well plate format. Compound IC50 values were determined at the apparent Km for ATP (20 μM) based on a radiometric assay (Invitrogen) using 8 or 10 point curves in duplicate. The final reaction conditions contained 400 nM fluorescein-IkBα substrate (DRHDSGLDSMKDE), 20 μM ATP, 2 nM or 8 nM IKKε or TBK1 kinase respectively, and 3% DMSO in kinase assay buffer consisting of 50 mM HEPES (pH 7.5), 10 mM MgCl, 1 mM EGTA, 0.01% Brij-35.Compound dilutions were prepared from 10 mM DMSO stocks by dilution into DMSO. Compound dilution series were further diluted in kinase assay buffer to give a 12% DMSO stock, the final concentration in the assay being 3% DMSO.The kinase phosphorylation assay was initiated by the addition of the kinase and the reaction was allowed to proceed for 1 h or 2.5 h for IKKε and TBK-1 kinase respectively.	B	N#Cc1nc(-c2ccnc(Nc3ccc(CN4CCOCC4)nc3)n2)ccc1N1CCC2(COC2)C1		CHEMBL3985241	<	IC50	nM	30.0	CHEMBL5408	Homo sapiens	IC50	nM	30.0
429173	17790839	CHEMBL3889017	Time-Resolved Fluorescence-based Lanthascreen Assay: Kinase inhibition assays (10 μL) were performed at 20° C. in 384-well plate format. Compound IC50 values were determined at the apparent Km for ATP (20 μM) based on a radiometric assay (Invitrogen) using 8 or 10 point curves in duplicate. The final reaction conditions contained 400 nM fluorescein-IkBα substrate (DRHDSGLDSMKDE), 20 μM ATP, 2 nM or 8 nM IKKε or TBK1 kinase respectively, and 3% DMSO in kinase assay buffer consisting of 50 mM HEPES (pH 7.5), 10 mM MgCl, 1 mM EGTA, 0.01% Brij-35.Compound dilutions were prepared from 10 mM DMSO stocks by dilution into DMSO. Compound dilution series were further diluted in kinase assay buffer to give a 12% DMSO stock, the final concentration in the assay being 3% DMSO.The kinase phosphorylation assay was initiated by the addition of the kinase and the reaction was allowed to proceed for 1 h or 2.5 h for IKKε and TBK-1 kinase respectively.	B	N#Cc1nc(-c2ccnc(Nc3ccc(NC(=O)CN4CCOCC4)nc3)n2)ccc1N1CCCOCC1		CHEMBL3961831	<	IC50	nM	100.0	CHEMBL5408	Homo sapiens	IC50	nM	100.0
429174	17790840	CHEMBL3889017	Time-Resolved Fluorescence-based Lanthascreen Assay: Kinase inhibition assays (10 μL) were performed at 20° C. in 384-well plate format. Compound IC50 values were determined at the apparent Km for ATP (20 μM) based on a radiometric assay (Invitrogen) using 8 or 10 point curves in duplicate. The final reaction conditions contained 400 nM fluorescein-IkBα substrate (DRHDSGLDSMKDE), 20 μM ATP, 2 nM or 8 nM IKKε or TBK1 kinase respectively, and 3% DMSO in kinase assay buffer consisting of 50 mM HEPES (pH 7.5), 10 mM MgCl, 1 mM EGTA, 0.01% Brij-35.Compound dilutions were prepared from 10 mM DMSO stocks by dilution into DMSO. Compound dilution series were further diluted in kinase assay buffer to give a 12% DMSO stock, the final concentration in the assay being 3% DMSO.The kinase phosphorylation assay was initiated by the addition of the kinase and the reaction was allowed to proceed for 1 h or 2.5 h for IKKε and TBK-1 kinase respectively.	B	N#Cc1nc(-c2ccnc(Nc3ccc(NC(=O)CN4CCOCC4)nc3)n2)ccc1N1CCC2(COC2)C1		CHEMBL3892819	<	IC50	nM	100.0	CHEMBL5408	Homo sapiens	IC50	nM	100.0
429175	17790841	CHEMBL3889017	Time-Resolved Fluorescence-based Lanthascreen Assay: Kinase inhibition assays (10 μL) were performed at 20° C. in 384-well plate format. Compound IC50 values were determined at the apparent Km for ATP (20 μM) based on a radiometric assay (Invitrogen) using 8 or 10 point curves in duplicate. The final reaction conditions contained 400 nM fluorescein-IkBα substrate (DRHDSGLDSMKDE), 20 μM ATP, 2 nM or 8 nM IKKε or TBK1 kinase respectively, and 3% DMSO in kinase assay buffer consisting of 50 mM HEPES (pH 7.5), 10 mM MgCl, 1 mM EGTA, 0.01% Brij-35.Compound dilutions were prepared from 10 mM DMSO stocks by dilution into DMSO. Compound dilution series were further diluted in kinase assay buffer to give a 12% DMSO stock, the final concentration in the assay being 3% DMSO.The kinase phosphorylation assay was initiated by the addition of the kinase and the reaction was allowed to proceed for 1 h or 2.5 h for IKKε and TBK-1 kinase respectively.	B	CN(C)c1ccc(-c2ccnc(Nc3ccc(N4CCOCC4)cc3)n2)nc1C#N		CHEMBL3946601	<	IC50	nM	15.0	CHEMBL5408	Homo sapiens	IC50	nM	15.0
429176	17790842	CHEMBL3889017	Time-Resolved Fluorescence-based Lanthascreen Assay: Kinase inhibition assays (10 μL) were performed at 20° C. in 384-well plate format. Compound IC50 values were determined at the apparent Km for ATP (20 μM) based on a radiometric assay (Invitrogen) using 8 or 10 point curves in duplicate. The final reaction conditions contained 400 nM fluorescein-IkBα substrate (DRHDSGLDSMKDE), 20 μM ATP, 2 nM or 8 nM IKKε or TBK1 kinase respectively, and 3% DMSO in kinase assay buffer consisting of 50 mM HEPES (pH 7.5), 10 mM MgCl, 1 mM EGTA, 0.01% Brij-35.Compound dilutions were prepared from 10 mM DMSO stocks by dilution into DMSO. Compound dilution series were further diluted in kinase assay buffer to give a 12% DMSO stock, the final concentration in the assay being 3% DMSO.The kinase phosphorylation assay was initiated by the addition of the kinase and the reaction was allowed to proceed for 1 h or 2.5 h for IKKε and TBK-1 kinase respectively.	B	COCCN(C)c1ccc(-c2ccnc(Nc3cnn(C)c3)n2)nc1C#N		CHEMBL3972720	<	IC50	nM	1000.0	CHEMBL5408	Homo sapiens	IC50	nM	1000.0
429177	17790843	CHEMBL3889017	Time-Resolved Fluorescence-based Lanthascreen Assay: Kinase inhibition assays (10 μL) were performed at 20° C. in 384-well plate format. Compound IC50 values were determined at the apparent Km for ATP (20 μM) based on a radiometric assay (Invitrogen) using 8 or 10 point curves in duplicate. The final reaction conditions contained 400 nM fluorescein-IkBα substrate (DRHDSGLDSMKDE), 20 μM ATP, 2 nM or 8 nM IKKε or TBK1 kinase respectively, and 3% DMSO in kinase assay buffer consisting of 50 mM HEPES (pH 7.5), 10 mM MgCl, 1 mM EGTA, 0.01% Brij-35.Compound dilutions were prepared from 10 mM DMSO stocks by dilution into DMSO. Compound dilution series were further diluted in kinase assay buffer to give a 12% DMSO stock, the final concentration in the assay being 3% DMSO.The kinase phosphorylation assay was initiated by the addition of the kinase and the reaction was allowed to proceed for 1 h or 2.5 h for IKKε and TBK-1 kinase respectively.	B	N#Cc1nc(-c2ccnc(Nc3ccc(CN4CCNC(=O)C4)nc3)n2)ccc1N1CC[C@H](F)C1		CHEMBL3947772	<	IC50	nM	15.0	CHEMBL5408	Homo sapiens	IC50	nM	15.0
429178	17790844	CHEMBL3889017	Time-Resolved Fluorescence-based Lanthascreen Assay: Kinase inhibition assays (10 μL) were performed at 20° C. in 384-well plate format. Compound IC50 values were determined at the apparent Km for ATP (20 μM) based on a radiometric assay (Invitrogen) using 8 or 10 point curves in duplicate. The final reaction conditions contained 400 nM fluorescein-IkBα substrate (DRHDSGLDSMKDE), 20 μM ATP, 2 nM or 8 nM IKKε or TBK1 kinase respectively, and 3% DMSO in kinase assay buffer consisting of 50 mM HEPES (pH 7.5), 10 mM MgCl, 1 mM EGTA, 0.01% Brij-35.Compound dilutions were prepared from 10 mM DMSO stocks by dilution into DMSO. Compound dilution series were further diluted in kinase assay buffer to give a 12% DMSO stock, the final concentration in the assay being 3% DMSO.The kinase phosphorylation assay was initiated by the addition of the kinase and the reaction was allowed to proceed for 1 h or 2.5 h for IKKε and TBK-1 kinase respectively.	B	COCCNCc1ccc(Nc2nccc(-c3ccc(N4CC[C@H](F)C4)c(C#N)n3)n2)cn1		CHEMBL3977034	<	IC50	nM	30.0	CHEMBL5408	Homo sapiens	IC50	nM	30.0
Inactive	17943706	CHEMBL3991905	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	C#Cc1cccc(Nc2ncnc3cc4c(cc23)OCCOCCOCCO4)c1		CHEMBL2087361	>	Kd	nM	30000.0	CHEMBL5408	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17943707	CHEMBL3991905	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	CN1CCN(CCOc2cc(OC3CCOCC3)c3c(Nc4c(Cl)ccc5c4OCO5)ncnc3c2)CC1		CHEMBL217092	>	Kd	nM	30000.0	CHEMBL5408	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17943708	CHEMBL3991905	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	Cc1cc(Nc2ncc(Cl)c(Nc3ccccc3S(=O)(=O)C(C)C)n2)c(OC(C)C)cc1C1CCNCC1		CHEMBL2403108	>	Kd	nM	30000.0	CHEMBL5408	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17943709	CHEMBL3991905	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	COc1cc2c(N3CCN(C(=O)Nc4ccc(OC(C)C)cc4)CC3)ncnc2cc1OCCCN1CCCCC1		CHEMBL124660	>	Kd	nM	30000.0	CHEMBL5408	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17943710	CHEMBL3991905	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3ccc(Cl)c(C(F)(F)F)c3)c(F)c2)ccn1		CHEMBL1946170	>	Kd	nM	30000.0	CHEMBL5408	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17943711	CHEMBL3991905	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	CC[C@@H]1C(=O)N(C)c2cnc(Nc3ccc(C(=O)NC4CCN(C)CC4)cc3OC)nc2N1C1CCCC1		CHEMBL513909	>	Kd	nM	30000.0	CHEMBL5408	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17943712	CHEMBL3991905	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	CC(C)CC(=O)Nc1n[nH]c2c1CN(C(=O)C1CCN(C)CC1)C2(C)C		CHEMBL1230607	>	Kd	nM	30000.0	CHEMBL5408	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17943713	CHEMBL3991905	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	CN1CCC(CNc2ccc3ncc(-c4cccc(OC(F)(F)F)c4)n3n2)CC1		CHEMBL1952329	>	Kd	nM	30000.0	CHEMBL5408	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17943714	CHEMBL3991905	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	Cc1cccc(-c2nn3c(c2-c2ccnc4ccc(C(N)=O)cc24)CCC3)n1		CHEMBL2364611	>	Kd	nM	30000.0	CHEMBL5408	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17943715	CHEMBL3991905	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	CC(=O)Nc1cccc(-n2c(=O)n(C3CC3)c(=O)c3c(Nc4ccc(I)cc4F)n(C)c(=O)c(C)c32)c1		CHEMBL2103875	>	Kd	nM	30000.0	CHEMBL5408	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17943716	CHEMBL3991905	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	CCN1CCN(Cc2ccc(-c3cc4c(N[C@H](C)c5ccccc5)ncnc4[nH]3)cc2)CC1		CHEMBL587723	>	Kd	nM	30000.0	CHEMBL5408	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17943717	CHEMBL3991905	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	COc1cc2nccc(Oc3ccc(NC(=O)Nc4cc(C)on4)c(Cl)c3)c2cc1OC		CHEMBL1289494	>	Kd	nM	30000.0	CHEMBL5408	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17943718	CHEMBL3991905	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	CNC(=O)c1cccc(-c2ccc3c(N4CCOC[C@@H]4C)nc(N4CCOC[C@@H]4C)nc3n2)c1		CHEMBL2336325	>	Kd	nM	30000.0	CHEMBL5408	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17943719	CHEMBL3991905	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	C#Cc1cccc(Nc2ncnc3cc(OC)c(OCCCCCCC(=O)NO)cc23)c1		CHEMBL598797	>	Kd	nM	30000.0	CHEMBL5408	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17943720	CHEMBL3991905	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	CNC(=O)c1ccc(Nc2ncc(C(F)(F)F)c(NCc3nccnc3N(C)S(C)(=O)=O)n2)cc1		CHEMBL3137331	>	Kd	nM	30000.0	CHEMBL5408	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17943721	CHEMBL3991905	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	O=c1[nH]ccc2cc(OC3CCNCC3)ccc12		CHEMBL1667969	>	Kd	nM	30000.0	CHEMBL5408	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17943722	CHEMBL3991905	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	Cn1cnc2c(F)c(Nc3ccc(Br)cc3Cl)c(C(=O)NOCCO)cc21		CHEMBL1614701	>	Kd	nM	30000.0	CHEMBL5408	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17943723	CHEMBL3991905	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	O=C(Cc1ccc(-c2ccc(OCCN3CCOCC3)cc2)cn1)NCc1ccccc1		CHEMBL571546	>	Kd	nM	30000.0	CHEMBL5408	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17943724	CHEMBL3991905	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	CN(C)C[C@@H]1CCn2cc(c3ccccc32)C2=C(C(=O)NC2=O)c2cn(c3ccccc23)CCO1		CHEMBL91829	>	Kd	nM	30000.0	CHEMBL5408	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17943725	CHEMBL3991905	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	O=S(=O)(c1cccc2cnccc12)N1CCCNCC1		CHEMBL38380	>	Kd	nM	30000.0	CHEMBL5408	Homo sapiens	Kd apparent	nM	30000.0
Active	17943726	CHEMBL3991905	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	CCS(=O)(=O)N1CCN(c2ccc(Nc3ncc(C(N)=O)c(NC4CC4)n3)cc2)CC1.Cl		CHEMBL3991929	=	Kd	nM	299.0	CHEMBL5408	Homo sapiens	Kd apparent	nM	299.0
Inactive	17943727	CHEMBL3991905	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	O=S(=O)(c1cccc2c(O)nccc12)N1CCCNCC1		CHEMBL1233300	>	Kd	nM	30000.0	CHEMBL5408	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17943728	CHEMBL3991905	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	CCc1cc2c(cc1N1CCC(N3CCOCC3)CC1)C(C)(C)c1[nH]c3cc(C#N)ccc3c1C2=O		CHEMBL1738797	>	Kd	nM	30000.0	CHEMBL5408	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17943729	CHEMBL3991905	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	Cn1cc(-c2ccc(F)c(C(F)(F)F)c2)nc1C1CCN(c2ncnc3[nH]ncc23)CC1		CHEMBL3545076	>	Kd	nM	30000.0	CHEMBL5408	Homo sapiens	Kd apparent	nM	30000.0
Active	17943730	CHEMBL3991905	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	C[C@]12O[C@H](C[C@]1(O)CO)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)CNC4=O		CHEMBL603469	=	Kd	nM	977.0	CHEMBL5408	Homo sapiens	Kd apparent	nM	977.0
Inactive	17943731	CHEMBL3991905	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	CCn1c(-c2nonc2N)nc2c(C#CC(C)(C)O)ncc(OC[C@H]3CCCNC3)c21		CHEMBL494089	>	Kd	nM	30000.0	CHEMBL5408	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17943732	CHEMBL3991905	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	CN1CCN(C2CCN(C(=O)Nc3cc(Oc4ccc(NC(=O)C5(C(=O)Nc6ccc(F)cc6)CC5)c(F)c4)ccn3)CC2)CC1		CHEMBL3039525	>	Kd	nM	30000.0	CHEMBL5408	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17943733	CHEMBL3991905	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	Cn1cnc(-c2cc3nccc(Oc4ccc(NC(=S)NC(=O)Cc5ccccc5)cc4F)c3s2)c1		CHEMBL254760	>	Kd	nM	30000.0	CHEMBL5408	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17943734	CHEMBL3991905	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	Cc1ccc(NC(=O)c2ccc(CN3CC[C@H](N(C)C)C3)c(C(F)(F)F)c2)cc1Nc1nccc(-c2cncnc2)n1		CHEMBL206834	>	Kd	nM	30000.0	CHEMBL5408	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17943735	CHEMBL3991905	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	Cc1ccc(C(=O)Nc2ccc(CN3CCN(C)CC3)c(C(F)(F)F)c2)cc1C#Cc1cnc2cccnn12		CHEMBL1171837	>	Kd	nM	30000.0	CHEMBL5408	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17943736	CHEMBL3991905	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	COc1cc([C@@H]2c3cc4c(cc3[C@H](O)[C@H]3COC(=O)[C@@H]23)OCO4)cc(OC)c1OC		CHEMBL283120	>	Kd	nM	30000.0	CHEMBL5408	Homo sapiens	Kd apparent	nM	30000.0
Active	17943737	CHEMBL3991905	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	CCNC(=O)C#Cc1ccc2c(c1)NC(=O)/C2=C(\Nc1ccc(CN(C)C)cc1)c1ccccc1		CHEMBL3699142	=	Kd	nM	759.0	CHEMBL5408	Homo sapiens	Kd apparent	nM	759.0
Inactive	17943738	CHEMBL3991905	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	O=C(Nc1cc(C(F)(F)F)cc(C(F)(F)F)c1)c1cc(Cl)ccc1O		CHEMBL536151	>	Kd	nM	30000.0	CHEMBL5408	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17943739	CHEMBL3991905	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	CCc1cnn2c(NCc3ccc[n+]([O-])c3)cc(N3CCCC[C@H]3CCO)nc12		CHEMBL2103840	>	Kd	nM	30000.0	CHEMBL5408	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17943740	CHEMBL3991905	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	C[C@@H]1COC(Nc2ccc3ncnc(Nc4ccc(OCc5nccs5)c(Cl)c4)c3c2)=N1		CHEMBL2103842	>	Kd	nM	30000.0	CHEMBL5408	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17943741	CHEMBL3991905	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	CC1(C)CNc2cc(NC(=O)c3cccnc3NCc3ccncc3)ccc21		CHEMBL572881	>	Kd	nM	30000.0	CHEMBL5408	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17943742	CHEMBL3991905	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	COc1c(OCCCN2CCOCC2)ccc2c1N=C(NC(=O)c1cnc(N)nc1)N1CCN=C21		CHEMBL3218576	>	Kd	nM	30000.0	CHEMBL5408	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17943743	CHEMBL3991905	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	O=C(NC[C@H](O)CO)c1ccncc1Nc1ccc(I)cc1F		CHEMBL2107832	>	Kd	nM	30000.0	CHEMBL5408	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17943744	CHEMBL3991905	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	COc1cc2c(Nc3ccc(Cl)c(Cl)c3F)ncnc2cc1OC[C@@H]1C[C@@H]2CN(C)C[C@@H]2C1		CHEMBL3544983	>	Kd	nM	30000.0	CHEMBL5408	Homo sapiens	Kd apparent	nM	30000.0
Active	17943745	CHEMBL3991905	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	CNC(=O)c1nn(C)c2c1C(C)(C)Cc1cnc(Nc3ccc(N4CCN(C)CC4)cc3)nc1-2		CHEMBL564829	=	Kd	nM	2088.0	CHEMBL5408	Homo sapiens	Kd apparent	nM	2088.0
Active	17943746	CHEMBL3991905	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	CC(C)c1cc(CNc2nc(Nc3cc(C4CC4)[nH]n3)cc(N3CCN(C)CC3)n2)on1		CHEMBL3545085	=	Kd	nM	1118.0	CHEMBL5408	Homo sapiens	Kd apparent	nM	1118.0
Inactive	17943747	CHEMBL3991905	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	C=CC(=O)Nc1cc2c(Nc3ccc(F)c(Cl)c3)ncnc2cc1C#CC(C)(C)N1CCN(C)CC1		CHEMBL2138625	>	Kd	nM	30000.0	CHEMBL5408	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17943748	CHEMBL3991905	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	CN1N=C(N)c2cn([C@@H]3O[C@H](COP(=O)(O)O)[C@@H](O)[C@H]3O)c3ncnc1c23		CHEMBL462018	>	Kd	nM	30000.0	CHEMBL5408	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17943749	CHEMBL3991905	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	COc1ccc(-c2cc3c(C)nc(N)nc3n([C@H]3CC[C@H](OCCO)CC3)c2=O)cn1		CHEMBL1234354	>	Kd	nM	30000.0	CHEMBL5408	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17943750	CHEMBL3991905	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	COc1cccc(Nc2ncnn3ccc(CN4CC[C@@H](N)[C@H](O)C4)c23)c1		CHEMBL3545396	>	Kd	nM	30000.0	CHEMBL5408	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17943751	CHEMBL3991905	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	NC(=O)c1ccc(N(C(N)=O)c2c(F)cccc2F)nc1-c1ccc(F)cc1F		CHEMBL1090090	>	Kd	nM	30000.0	CHEMBL5408	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17943752	CHEMBL3991905	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	CC(=O)c1c(C)c2cnc(Nc3ccc(N4CCNCC4)cn3)nc2n(C2CCCC2)c1=O		CHEMBL189963	>	Kd	nM	30000.0	CHEMBL5408	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17943753	CHEMBL3991905	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	Cc1cc(C(=O)Nc2cc(Oc3ccc4nc(NC(=O)C5CC5)cn4n3)ccc2C)n(C)n1		CHEMBL2180604	>	Kd	nM	30000.0	CHEMBL5408	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17943754	CHEMBL3991905	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	NC(=O)c1c(OCc2c(F)cc(Br)cc2F)nsc1NC(=O)NCCCCN1CCCC1		CHEMBL253969	>	Kd	nM	30000.0	CHEMBL5408	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17943755	CHEMBL3991905	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	COc1ncc(-c2ccc3nccc(-c4ccnnc4)c3c2)cc1NS(=O)(=O)c1ccc(F)cc1F		CHEMBL1236962	>	Kd	nM	30000.0	CHEMBL5408	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17943756	CHEMBL3991905	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	CC(C)(C)c1nc(-c2cccc(NS(=O)(=O)c3c(F)cccc3F)c2F)c(-c2ccnc(N)n2)s1		CHEMBL2028663	>	Kd	nM	30000.0	CHEMBL5408	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17943757	CHEMBL3991905	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	NC1(C(=O)N[C@@H](CCO)c2ccc(Cl)cc2)CCN(c2ncnc3[nH]ccc23)CC1		CHEMBL2325741	>	Kd	nM	30000.0	CHEMBL5408	Homo sapiens	Kd apparent	nM	30000.0
Active	17943758	CHEMBL3991905	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	O=C(Nc1ccc(-c2ccnc(Nc3ccc(N4CCOCC4)cc3)n2)cc1)C1CCCN1		CHEMBL3545328	=	Kd	nM	561.0	CHEMBL5408	Homo sapiens	Kd apparent	nM	561.0
Active	17943759	CHEMBL3991905	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	Cc1cnc(Nc2ccc(OCCN3CCCC3)cc2)nc1Nc1cccc(S(=O)(=O)NC(C)(C)C)c1		CHEMBL1287853	=	Kd	nM	2230.0	CHEMBL5408	Homo sapiens	Kd apparent	nM	2230.0
Inactive	17943760	CHEMBL3991905	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3cc(C(C)(C)C)nn3-c3ccc4ncccc4c3)c(F)c2)ccn1		CHEMBL1738757	>	Kd	nM	30000.0	CHEMBL5408	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17943761	CHEMBL3991905	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	COc1cc2c(Nc3ccc(Br)cc3F)ncnc2cc1OCC1CCN(C)CC1		CHEMBL24828	>	Kd	nM	30000.0	CHEMBL5408	Homo sapiens	Kd apparent	nM	30000.0
Active	17943762	CHEMBL3991905	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	CN1CC[C@H](c2c(O)cc(O)c3c(=O)cc(-c4ccccc4Cl)oc23)[C@H](O)C1		CHEMBL428690	=	Kd	nM	1949.0	CHEMBL5408	Homo sapiens	Kd apparent	nM	1949.0
Inactive	17943763	CHEMBL3991905	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	Cc1ccc(NC(=O)c2ccc(CN3CCN(C)CC3)cc2)cc1Nc1nc(-c2cccnc2)cs1		CHEMBL1908391	>	Kd	nM	30000.0	CHEMBL5408	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17943764	CHEMBL3991905	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	Cn1c(=O)c(F)c(Nc2ccc(I)cc2F)c2c(=O)n(C[C@@H](O)CO)cnc21		CHEMBL1615025	>	Kd	nM	30000.0	CHEMBL5408	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17943765	CHEMBL3991905	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	Cc1csc(-c2nnc(Nc3ccc(Oc4ncccc4-c4ccnc(N)n4)cc3)c3ccccc23)c1		CHEMBL2140408	>	Kd	nM	30000.0	CHEMBL5408	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17943766	CHEMBL3991905	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	COc1cc(F)c(F)c(Nc2ccc(I)cc2F)c1NS(=O)(=O)C1(C[C@H](O)CO)CC1		CHEMBL1236682	>	Kd	nM	30000.0	CHEMBL5408	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17943767	CHEMBL3991905	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	CO[C@@H](C(=O)N1Cc2n[nH]c(NC(=O)c3ccc(N4CCN(C)CC4)cc3)c2C1)c1ccccc1		CHEMBL402548	>	Kd	nM	30000.0	CHEMBL5408	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17943768	CHEMBL3991905	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	CCN(CCCOc1ccc2c(Nc3cc(CC(=O)Nc4cccc(F)c4)[nH]n3)ncnc2c1)CCOP(=O)(O)O		CHEMBL415049	>	Kd	nM	30000.0	CHEMBL5408	Homo sapiens	Kd apparent	nM	30000.0
Active	17943769	CHEMBL3991905	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	COc1cc(Nc2ncc(F)c(Nc3ccc4c(n3)NC(=O)C(C)(C)O4)n2)cc(OC)c1OC		CHEMBL475251	=	Kd	nM	345.0	CHEMBL5408	Homo sapiens	Kd apparent	nM	345.0
Inactive	17943770	CHEMBL3991905	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	CO[C@H]1C[C@@H]2CC[C@@H](C)[C@@](O)(O2)C(=O)C(=O)N2CCCC[C@H]2C(=O)O[C@H]([C@H](C)C[C@@H]2CC[C@@H](OP(C)(C)=O)[C@H](OC)C2)CC(=O)[C@H](C)/C=C(\C)[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)/C=C/C=C/C=C/1C		CHEMBL2103839	>	Kd	nM	30000.0	CHEMBL5408	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17943771	CHEMBL3991905	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	C[C@@H](Oc1cc(C(=O)Nc2ccc(C(=O)N3CCN(C)CC3)cc2)nnc1N)c1c(Cl)ccc(F)c1Cl		CHEMBL2376648	>	Kd	nM	30000.0	CHEMBL5408	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17943772	CHEMBL3991905	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	Cn1cc(C2=Nc3cc(NC(=O)C(N)C4CCCCC4)cc4c3C2=CNNC4=O)cn1		CHEMBL3545137	>	Kd	nM	30000.0	CHEMBL5408	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17943773	CHEMBL3991905	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	Nc1nc(N)c2nc(-c3cccc(O)c3)c(-c3cccc(O)c3)nc2n1		CHEMBL230011	>	Kd	nM	30000.0	CHEMBL5408	Homo sapiens	Kd apparent	nM	30000.0
Active	17943774	CHEMBL3991905	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	CCN(CC)CCNC(=O)c1c(C)[nH]c(/C=C2\C(=O)Nc3ccc(F)cc32)c1C		CHEMBL535	=	Kd	nM	1502.0	CHEMBL5408	Homo sapiens	Kd apparent	nM	1502.0
Inactive	17943775	CHEMBL3991905	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	C#Cc1cccc(Nc2ncnc3cc(OCCOC)c(OCCOC)cc23)c1		CHEMBL553	>	Kd	nM	30000.0	CHEMBL5408	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17943776	CHEMBL3991905	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	Cc1cc(Nc2ncnc3ccc(NC4=NC(C)(C)CO4)cc23)ccc1Oc1ccn2ncnc2c1		CHEMBL3989868	>	Kd	nM	30000.0	CHEMBL5408	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17943777	CHEMBL3991905	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	Cc1ccc(Nc2nccc(N(C)c3ccc4c(C)n(C)nc4c3)n2)cc1S(N)(=O)=O		CHEMBL477772	>	Kd	nM	30000.0	CHEMBL5408	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17943778	CHEMBL3991905	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	COC(=O)N[C@@H](C)CNc1nccc(-c2cn(C(C)C)nc2-c2cc(Cl)cc(NS(C)(=O)=O)c2F)n1		CHEMBL3301612	>	Kd	nM	30000.0	CHEMBL5408	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17943779	CHEMBL3991905	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	O=C(c1ccc(F)c(F)c1Nc1ccc(I)cc1F)N1CC(O)([C@@H]2CCCCN2)C1		CHEMBL2146883	>	Kd	nM	30000.0	CHEMBL5408	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17943780	CHEMBL3991905	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	COc1cc(OC)c(/C=C/S(=O)(=O)Cc2ccc(OC)c(NCC(=O)O)c2)c(OC)c1		CHEMBL1241855	>	Kd	nM	30000.0	CHEMBL5408	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17943781	CHEMBL3991905	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	COc1cc2ncnc(Nc3ccc(F)c(Cl)c3)c2cc1OCCCN1CCOCC1		CHEMBL939	>	Kd	nM	30000.0	CHEMBL5408	Homo sapiens	Kd apparent	nM	30000.0
Active	17943782	CHEMBL3991905	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	CC(=O)NCC(=O)N1C2CCC1c1cc(Nc3ncc(C(F)(F)F)c(NC4CCC4)n3)ccc12		CHEMBL1983111	=	Kd	nM	78.0	CHEMBL5408	Homo sapiens	Kd apparent	nM	78.0
Inactive	17943783	CHEMBL3991905	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	C=CC(=O)N1CCC[C@@H](n2nc(-c3ccc(Oc4ccccc4)cc3)c3c(N)ncnc32)C1		CHEMBL1873475	>	Kd	nM	30000.0	CHEMBL5408	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17943784	CHEMBL3991905	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	CCOc1cc2ncc(C#N)c(Nc3ccc(OCc4ccccn4)c(Cl)c3)c2cc1NC(=O)/C=C/CN(C)C		CHEMBL180022	>	Kd	nM	30000.0	CHEMBL5408	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17943785	CHEMBL3991905	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	O=C(Nc1cccc(Cl)c1)Nc1ncc(CCN=c2[nH]cnc3ccsc23)s1		CHEMBL482767	>	Kd	nM	30000.0	CHEMBL5408	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17943786	CHEMBL3991905	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	COc1ccc2c(OCc3nnc4ccc(-c5ccccc5)nn34)ccnc2c1		CHEMBL496102	>	Kd	nM	30000.0	CHEMBL5408	Homo sapiens	Kd apparent	nM	30000.0
Active	17943787	CHEMBL3991905	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	Cc1nc(Nc2[nH]nc3c2CN(C(=O)N[C@H](CN(C)C)c2ccccc2)C3(C)C)c2sccc2n1		CHEMBL3128043	=	Kd	nM	377.0	CHEMBL5408	Homo sapiens	Kd apparent	nM	377.0
Inactive	17943788	CHEMBL3991905	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	Cc1cn(-c2cc(NC(=O)c3ccc(C)c(Nc4nccc(-c5cccnc5)n4)c3)cc(C(F)(F)F)c2)cn1		CHEMBL255863	>	Kd	nM	30000.0	CHEMBL5408	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17943789	CHEMBL3991905	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	Cn1ncc(Cl)c1-c1cc(C(=O)N[C@H](CN)Cc2cccc(F)c2)sc1Cl		CHEMBL2219422	>	Kd	nM	30000.0	CHEMBL5408	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17943790	CHEMBL3991905	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	COc1cc2ncnc3c2cc1OCCCCCN(C)Cc1ccc(Br)cc1N3		CHEMBL3109738	>	Kd	nM	30000.0	CHEMBL5408	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17943791	CHEMBL3991905	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	CN(C)C(=O)c1cc2cnc(Nc3ccc(N4CCNCC4)cn3)nc2n1C1CCCC1		CHEMBL3545110	>	Kd	nM	30000.0	CHEMBL5408	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17943792	CHEMBL3991905	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	C=CC(=O)Nc1cc2c(Nc3ccc(F)c(Cl)c3)ncnc2cc1OCCCN1CCOCC1		CHEMBL31965	>	Kd	nM	30000.0	CHEMBL5408	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17943793	CHEMBL3991905	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	COc1cc2ncnc(Nc3ccc(F)c(Cl)c3)c2cc1NC(=O)/C=C/CN1CCCCC1		CHEMBL2110732	>	Kd	nM	30000.0	CHEMBL5408	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17943794	CHEMBL3991905	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	C=CC(=O)Nc1cc(Nc2nccc(-c3cn(C)c4ccccc34)n2)c(OC)cc1N(C)CCN(C)C		CHEMBL3353410	>	Kd	nM	30000.0	CHEMBL5408	Homo sapiens	Kd apparent	nM	30000.0
Active	17943795	CHEMBL3991905	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	CC(=O)c1cnc2ccc(-c3cc(Cl)c(O)c(Cl)c3)nc2c1N[C@H]1CC[C@H](CN(C)C)CC1		CHEMBL3688339	=	Kd	nM	452.0	CHEMBL5408	Homo sapiens	Kd apparent	nM	452.0
Inactive	17943796	CHEMBL3991905	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	CC(C)(C)c1cc(NC(=O)Nc2ccc(-c3cn4c(n3)sc3cc(OCCN5CCOCC5)ccc34)cc2)no1		CHEMBL576982	>	Kd	nM	30000.0	CHEMBL5408	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17943797	CHEMBL3991905	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	O=C(NOCCO)c1cc(CN2OCCCC2=O)c(F)c(F)c1Nc1ccc(I)cc1F		CHEMBL1614766	>	Kd	nM	30000.0	CHEMBL5408	Homo sapiens	Kd apparent	nM	30000.0
Active	17943798	CHEMBL3991905	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	CN1CCN(c2ccc3nc(-c4c(N)c5c(F)cccc5[nH]c4=O)[nH]c3c2)CC1		CHEMBL522892	=	Kd	nM	1114.0	CHEMBL5408	Homo sapiens	Kd apparent	nM	1114.0
Uncertain	17943799	CHEMBL3991905	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	Cc1[nH]c(/C=C2\C(=O)Nc3ccc(F)cc32)c(C)c1C(=O)NC[C@H](O)CN1CCOCC1		CHEMBL1721885	=	Kd	nM	1330.0	CHEMBL5408	Homo sapiens	Kd apparent	nM	1330.0
Inactive	17943800	CHEMBL3991905	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	CN1CC[C@@H](c2c(O)cc(O)c3c(=O)cc(-c4ccccc4Cl)oc23)[C@@H]1CO.Cl		CHEMBL3991935	>	Kd	nM	30000.0	CHEMBL5408	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17943801	CHEMBL3991905	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	O=C(O)C1(Cc2cccc(Nc3nccs3)n2)CCC(Oc2cccc(Cl)c2F)CC1		CHEMBL3182444	>	Kd	nM	30000.0	CHEMBL5408	Homo sapiens	Kd apparent	nM	30000.0
Active	17943802	CHEMBL3991905	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	CN[C@@H]1C[C@H]2O[C@@](C)([C@@H]1OC)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)C(=O)N[C@H]4O		CHEMBL574737	=	Kd	nM	393.0	CHEMBL5408	Homo sapiens	Kd apparent	nM	393.0
Inactive	17943803	CHEMBL3991905	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	FC(F)(F)c1ccc(CNc2ccc(Cc3c[nH]c4ncc(Cl)cc34)cn2)cn1		CHEMBL3813873	>	Kd	nM	30000.0	CHEMBL5408	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17943804	CHEMBL3991905	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	CCc1nc(C(N)=O)c(Nc2ccc(N3CCC(N4CCN(C)CC4)CC3)c(OC)c2)nc1NC1CCOCC1		CHEMBL3301622	>	Kd	nM	30000.0	CHEMBL5408	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17943805	CHEMBL3991905	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	Cc1cnc(NC(=O)Nc2cc(Br)c(C)cc2OC[C@@H]2CNCCO2)cn1		CHEMBL3039517	>	Kd	nM	30000.0	CHEMBL5408	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17943806	CHEMBL3991905	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	NC[C@@](O)(c1ccc(Cl)cc1)c1ccc(-c2cn[nH]c2)cc1		CHEMBL3544960	>	Kd	nM	30000.0	CHEMBL5408	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17943807	CHEMBL3991905	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	N#CC[C@H](C1CCCC1)n1cc(-c2ncnc3[nH]ccc23)cn1		CHEMBL1789941	>	Kd	nM	30000.0	CHEMBL5408	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17943808	CHEMBL3991905	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	c1cc(OCCN2CCCCC2)cc(-c2n[nH]c3ccc(-c4nnc[nH]4)cc23)c1		CHEMBL1614713	>	Kd	nM	30000.0	CHEMBL5408	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17943809	CHEMBL3991905	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	O=C(NOC[C@H](O)CO)c1ccc(F)c(F)c1Nc1ccc(I)cc1F		CHEMBL507361	>	Kd	nM	30000.0	CHEMBL5408	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17943810	CHEMBL3991905	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	FC(F)(F)c1ccc(/C=C/c2nc(COc3ccc(CCCCn4ccnn4)cc3)co2)cc1		CHEMBL1614707	>	Kd	nM	30000.0	CHEMBL5408	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17943811	CHEMBL3991905	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	CN(c1ncccc1CNc1nc(Nc2ccc3c(c2)CC(=O)N3)ncc1C(F)(F)F)S(C)(=O)=O		CHEMBL1084546	>	Kd	nM	30000.0	CHEMBL5408	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17943812	CHEMBL3991905	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	COc1ccc(-c2ccc3ncc4c(c3c2)n(-c2ccc(N3CCNCC3)c(C(F)(F)F)c2)c(=O)n4C)cn1		CHEMBL3218578	>	Kd	nM	30000.0	CHEMBL5408	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17943813	CHEMBL3991905	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	CCn1c(C(=O)N(C2CC2)C2CC2)cc2c3c(ncn3C)c(Nc3cc(C)n(C)n3)nc21		CHEMBL3545215	>	Kd	nM	30000.0	CHEMBL5408	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17943814	CHEMBL3991905	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	COc1ccc(-c2ccc3c(N4CCOC[C@@H]4C)nc(N4CCOC[C@@H]4C)nc3n2)cc1CO		CHEMBL1801204	>	Kd	nM	30000.0	CHEMBL5408	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17943815	CHEMBL3991905	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	COc1ccc(F)c(F)c1C(=O)c1cnc(NC2CCN(S(C)(=O)=O)CC2)nc1N		CHEMBL384304	>	Kd	nM	30000.0	CHEMBL5408	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17943816	CHEMBL3991905	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	COc1cc(N2CCC(N3CCN(C)CC3)CC2)ccc1Nc1ncnc(Nc2ccccc2S(=O)(=O)C(C)C)n1		CHEMBL3545360	>	Kd	nM	30000.0	CHEMBL5408	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17943817	CHEMBL3991905	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	CN(C)C/C=C/C(=O)Nc1cc2c(Nc3ccc(F)c(Cl)c3)ncnc2cc1O[C@H]1CCOC1		CHEMBL1173655	>	Kd	nM	30000.0	CHEMBL5408	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17943818	CHEMBL3991905	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	C[C@]1(O)C[C@@H](c2nc(-c3ccc4ccc(-c5ccccc5)nc4c3)c3c(N)nccn32)C1		CHEMBL1091644	>	Kd	nM	30000.0	CHEMBL5408	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17943819	CHEMBL3991905	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	Cc1c(Cn2c(C)nc3c(C(=O)O)cc(N4CCOCC4)cc32)cccc1C(F)(F)F		CHEMBL3188551	>	Kd	nM	30000.0	CHEMBL5408	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17943820	CHEMBL3991905	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	CCCS(=O)(=O)Nc1ccc(F)c(C(=O)c2c[nH]c3ncc(-c4ccc(Cl)cc4)cc23)c1F		CHEMBL1229517	>	Kd	nM	30000.0	CHEMBL5408	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17943821	CHEMBL3991905	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	COCc1c(-c2ccc(NC(=O)Nc3cc(C(F)(F)F)ccc3F)c(F)c2)c2c(N)ncnn2c1CN1CCOCC1		CHEMBL3991934	>	Kd	nM	30000.0	CHEMBL5408	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17943822	CHEMBL3991905	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	C[C@@H](c1ccc2nccn2c1)n1nnc2ncc(-c3cnn(C)c3)nc21		CHEMBL3334567	>	Kd	nM	30000.0	CHEMBL5408	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17943823	CHEMBL3991905	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	CN1CCC(COc2cnc(-c3cccc(Cn4nc(-c5cccc(C#N)c5)ccc4=O)c3)nc2)CC1		CHEMBL3402762	>	Kd	nM	30000.0	CHEMBL5408	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17943824	CHEMBL3991905	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	Cc1cc(C(=O)NOCCO)c(Nc2ccc(I)cc2F)n(C)c1=O		CHEMBL3182621	>	Kd	nM	30000.0	CHEMBL5408	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17943825	CHEMBL3991905	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	COc1cc(Nc2ncc(F)c(Nc3ccc4c(n3)N(COP(=O)(O)O)C(=O)C(C)(C)O4)n2)cc(OC)c1OC		CHEMBL2103830	>	Kd	nM	30000.0	CHEMBL5408	Homo sapiens	Kd apparent	nM	30000.0
Active	17943826	CHEMBL3991905	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	N#CCNC(=O)c1ccc(-c2ccnc(Nc3ccc(N4CCOCC4)cc3)n2)cc1		CHEMBL1078178	=	Kd	nM	562.0	CHEMBL5408	Homo sapiens	Kd apparent	nM	562.0
Inactive	17943827	CHEMBL3991905	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	CN1CCN(c2nc(C3=C(c4c[nH]c5ccccc45)C(=O)NC3=O)c3ccccc3n2)CC1		CHEMBL565612	>	Kd	nM	30000.0	CHEMBL5408	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17943828	CHEMBL3991905	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	Cc1cc2c(F)c(Oc3ncnn4cc(OC[C@@H](C)OC(=O)[C@H](C)N)c(C)c34)ccc2[nH]1		CHEMBL270995	>	Kd	nM	30000.0	CHEMBL5408	Homo sapiens	Kd apparent	nM	30000.0
Active	17943829	CHEMBL3991905	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	CCS(=O)(=O)c1cccc(-c2cc(C(=O)NC3CCN(C)CC3)c(C)c3[nH]c4ncc(C)cc4c23)c1		CHEMBL3544932	=	Kd	nM	2762.0	CHEMBL5408	Homo sapiens	Kd apparent	nM	2762.0
Inactive	17943830	CHEMBL3991905	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	Cc1c(CN2CCN(C(=O)[C@H](C)O)CC2)sc2c(N3CCOCC3)nc(-c3cnc(N)nc3)nc12		CHEMBL1922094	>	Kd	nM	30000.0	CHEMBL5408	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17943831	CHEMBL3991905	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	CO[C@H]1C[C@@H]2CC[C@@H](C)[C@@](O)(O2)C(=O)C(=O)N2CCCC[C@H]2C(=O)O[C@H]([C@H](C)C[C@@H]2CC[C@@H](OC(=O)C(C)(CO)CO)[C@H](OC)C2)CC(=O)[C@H](C)/C=C(\C)[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)/C=C/C=C/C=C/1C		CHEMBL1201182	>	Kd	nM	30000.0	CHEMBL5408	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17943832	CHEMBL3991905	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	COc1cc2nccc(Oc3ccc(NC(=O)NC4CC4)c(Cl)c3)c2cc1C(N)=O		CHEMBL1289601	>	Kd	nM	30000.0	CHEMBL5408	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17943833	CHEMBL3991905	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	CNC(=O)c1ccc(-c2cnc3ncc(Cc4ccc5ncccc5c4)n3n2)cc1F		CHEMBL3188267	>	Kd	nM	30000.0	CHEMBL5408	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17943834	CHEMBL3991905	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	C=CC(=O)N1CCC(Oc2cc3c(Nc4ccc(Cl)c(Cl)c4F)ncnc3cc2OC)CC1		CHEMBL3545154	>	Kd	nM	30000.0	CHEMBL5408	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17943835	CHEMBL3991905	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	Cc1cc([C@@H](C)Nc2ccccc2C(=O)O)c2nc(N3CCOCC3)cc(=O)n2c1		CHEMBL2165191	>	Kd	nM	30000.0	CHEMBL5408	Homo sapiens	Kd apparent	nM	30000.0
Active	17943836	CHEMBL3991905	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	Cc1nc(N)sc1-c1ccnc(Nc2ccc(N3CCOCC3)cc2)n1		CHEMBL482967	=	Kd	nM	1162.0	CHEMBL5408	Homo sapiens	Kd apparent	nM	1162.0
Inactive	17943837	CHEMBL3991905	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	Cn1c(=O)n(-c2ccc(C(C)(C)C#N)cc2)c2c3cc(-c4cnc5ccccc5c4)ccc3ncc21		CHEMBL1879463	>	Kd	nM	30000.0	CHEMBL5408	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17943838	CHEMBL3991905	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	CC[C@H](CO)Nc1nc(NCc2ccccc2)c2ncn(C(C)C)c2n1		CHEMBL14762	>	Kd	nM	30000.0	CHEMBL5408	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17943839	CHEMBL3991905	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	CNS(=O)(=O)Nc1nccc(Cc2c(C)c3ccc(Oc4ncccn4)cc3oc2=O)c1F		CHEMBL3264002	>	Kd	nM	30000.0	CHEMBL5408	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17943840	CHEMBL3991905	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	Cc1cc2c(F)c(Oc3ncnn4cc(OC[C@@H](C)O)c(C)c34)ccc2[nH]1		CHEMBL377300	>	Kd	nM	30000.0	CHEMBL5408	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17943841	CHEMBL3991905	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	Cn1cc(-c2ccc3nnc(Sc4ccc5ncccc5c4)n3n2)cn1		CHEMBL1236107	>	Kd	nM	30000.0	CHEMBL5408	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17943842	CHEMBL3991905	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	CS(=O)(=O)N1CCN(Cc2cc3nc(-c4cccc5[nH]ncc45)nc(N4CCOCC4)c3s2)CC1		CHEMBL521851	>	Kd	nM	30000.0	CHEMBL5408	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17943843	CHEMBL3991905	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	Cc1c(F)cc(C(=O)NC2CC2)cc1-c1ccc(C(=O)NCC(C)(C)C)cn1		CHEMBL1088752	>	Kd	nM	30000.0	CHEMBL5408	Homo sapiens	Kd apparent	nM	30000.0
Active	17943844	CHEMBL3991905	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	COc1cc(Nc2c(C#N)cnc3cc(OCCCN4CCN(C)CC4)c(OC)cc23)c(Cl)cc1Cl		CHEMBL288441	=	Kd	nM	1022.0	CHEMBL5408	Homo sapiens	Kd apparent	nM	1022.0
Inactive	17943845	CHEMBL3991905	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	CCN(CCO)CCCOc1ccc2c(Nc3cc(CC(=O)Nc4cccc(F)c4)[nH]n3)ncnc2c1		CHEMBL215152	>	Kd	nM	30000.0	CHEMBL5408	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17943846	CHEMBL3991905	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	CC[C@@H]1C(=O)N(C)c2cnc(Nc3ccc(C(=O)N[C@H]4CC[C@H](N5CCN(CC6CC6)CC5)CC4)cc3OC)nc2N1C(C)C		CHEMBL1233528	>	Kd	nM	30000.0	CHEMBL5408	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17943847	CHEMBL3991905	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	O=C(NC1CCNCC1)c1n[nH]cc1NC(=O)c1c(Cl)cccc1Cl		CHEMBL445813	>	Kd	nM	30000.0	CHEMBL5408	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17943848	CHEMBL3991905	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	COc1cc(CCc2cc(NC(=O)c3ccc(N4CC(C)NC(C)C4)cc3)n[nH]2)cc(OC)c1		CHEMBL3184679	>	Kd	nM	30000.0	CHEMBL5408	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17943849	CHEMBL3991905	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	CN(C)C1CCN(C(=O)c2ccc(NC(=O)Nc3ccc(-c4nc(N5CCOCC5)nc(N5CCOCC5)n4)cc3)cc2)CC1		CHEMBL592445	>	Kd	nM	30000.0	CHEMBL5408	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17943850	CHEMBL3991905	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	O=C(O)c1ccc(Nc2ncc3c(n2)-c2ccc(Cl)cc2C(c2c(F)cccc2F)=NC3)cc1		CHEMBL259084	>	Kd	nM	30000.0	CHEMBL5408	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17943851	CHEMBL3991905	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	Cc1nc(Nc2ncc(C(=O)Nc3c(C)cccc3Cl)s2)cc(N2CCN(CCO)CC2)n1		CHEMBL1421	>	Kd	nM	30000.0	CHEMBL5408	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17943852	CHEMBL3991905	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	Cn1cc(C2=C(c3cn(C4CCN(Cc5ccccn5)CC4)c4ccccc34)C(=O)NC2=O)c2ccccc21		CHEMBL300138	>	Kd	nM	30000.0	CHEMBL5408	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17943853	CHEMBL3991905	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	CN1CCN(c2ccc(C(=O)Nc3n[nH]c4ccc(Cc5cc(F)cc(F)c5)cc34)c(NC3CCOCC3)c2)CC1		CHEMBL1983268	>	Kd	nM	30000.0	CHEMBL5408	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17943854	CHEMBL3991905	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	COc1cc2c(Oc3ccc(NC(=O)C4(C(=O)Nc5ccc(F)cc5)CC4)cc3F)ccnc2cc1OCCCN1CCOCC1		CHEMBL1230609	>	Kd	nM	30000.0	CHEMBL5408	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17943855	CHEMBL3991905	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	O=C1NC(=O)[C@@H](c2cn3c4c(cccc24)CCC3)[C@@H]1c1c[nH]c2ccccc12		CHEMBL2103882	>	Kd	nM	30000.0	CHEMBL5408	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17943856	CHEMBL3991905	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	Nc1cc(C(F)(F)F)c(-c2cc(N3CCOCC3)nc(N3CCOCC3)n2)cn1		CHEMBL2017974	>	Kd	nM	30000.0	CHEMBL5408	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17943857	CHEMBL3991905	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	O[C@H]1CC[C@H](Nc2ncc3nc(Nc4c(F)cc(F)cc4F)n([C@H]4CCOC4)c3n2)CC1		CHEMBL1950289	>	Kd	nM	30000.0	CHEMBL5408	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17943858	CHEMBL3991905	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	C=CCN(/C=C1/C(=O)O[C@H](COC)[C@@]2(C)C1=C(O)C(=O)C1=C2[C@H](OC(C)=O)C[C@]2(C)C(=O)CC[C@@H]12)CC=C		CHEMBL411907	>	Kd	nM	30000.0	CHEMBL5408	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17943859	CHEMBL3991905	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	Cn1cc(-c2cnn3c(N)c(Br)c([C@@H]4CCCNC4)nc23)cn1		CHEMBL2386889	>	Kd	nM	30000.0	CHEMBL5408	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17943860	CHEMBL3991905	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	C[C@@H](Nc1cc(F)cc(F)c1)c1cc(C(=O)N(C)C)cc2c(=O)cc(N3CCOCC3)oc12		CHEMBL3408248	>	Kd	nM	30000.0	CHEMBL5408	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17943861	CHEMBL3991905	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	C[C@@H](N)c1ccc(C(=O)Nc2ccnc3[nH]ccc23)cc1		CHEMBL571948	>	Kd	nM	30000.0	CHEMBL5408	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17943862	CHEMBL3991905	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	Nc1ncnc2c1c(-c1cccc(OCc3ccccc3)c1)cn2[C@H]1C[C@H](N2CCC2)C1		CHEMBL551064	>	Kd	nM	30000.0	CHEMBL5408	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17943863	CHEMBL3991905	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	C=CC(=O)N1CCC[C@H](n2c(=O)n(-c3ccc(Oc4ccccc4)cc3)c3c(N)ncnc32)C1		CHEMBL3991931	>	Kd	nM	30000.0	CHEMBL5408	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17943864	CHEMBL3991905	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	CC(C)(C)c1cnc(CSc2cnc(NC(=O)C3CCNCC3)s2)o1		CHEMBL296468	>	Kd	nM	30000.0	CHEMBL5408	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17943865	CHEMBL3991905	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	NC1(c2ccc(-c3nc4ccn5c(=O)[nH]nc5c4cc3-c3ccccc3)cc2)CCC1		CHEMBL1079175	>	Kd	nM	30000.0	CHEMBL5408	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17943866	CHEMBL3991905	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	Cc1ccc(C(=O)Nc2ccc(Oc3cc4cnn(C)c4cc3-c3cn[nH]c3)c(F)c2)c(=O)n1-c1ccc(F)cc1		CHEMBL3545307	>	Kd	nM	30000.0	CHEMBL5408	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17943867	CHEMBL3991905	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	O=c1[nH]c(C2CCCN2)nc2c1oc1ccc(Cl)cc12		CHEMBL3544944	>	Kd	nM	30000.0	CHEMBL5408	Homo sapiens	Kd apparent	nM	30000.0
Active	17943868	CHEMBL3991905	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	C1=C/COCc2cc(ccc2OCCN2CCCC2)Nc2nccc(n2)-c2cccc(c2)COC/1		CHEMBL2035187	=	Kd	nM	49601.0	CHEMBL5408	Homo sapiens	Kd apparent	nM	49601.0
Inactive	17943869	CHEMBL3991905	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	CCOc1cc2ncc(C#N)c(Nc3ccc(F)c(Cl)c3)c2cc1NC(=O)/C=C/CN(C)C		CHEMBL607707	>	Kd	nM	30000.0	CHEMBL5408	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17943870	CHEMBL3991905	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	CC[C@@](C)(Nc1ccnc(-c2c[nH]c3ncccc23)n1)C(=O)NCC(F)(F)F		CHEMBL3039513	>	Kd	nM	30000.0	CHEMBL5408	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17943871	CHEMBL3991905	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3ccc(Cl)c(C(F)(F)F)c3)cc2)ccn1		CHEMBL1336	>	Kd	nM	30000.0	CHEMBL5408	Homo sapiens	Kd apparent	nM	30000.0
Active	17943872	CHEMBL3991905	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	Cc1[nH]c(/C=C2\C(=O)Nc3ccccc32)c(C)c1CCC(=O)O		CHEMBL274654	=	Kd	nM	1982.0	CHEMBL5408	Homo sapiens	Kd apparent	nM	1982.0
Inactive	17943873	CHEMBL3991905	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	Cc1cc(Nc2nc(N[C@@H](C)c3ncc(F)cn3)ncc2Cl)[nH]n1		CHEMBL1231124	>	Kd	nM	30000.0	CHEMBL5408	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17943874	CHEMBL3991905	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	CNC(=O)c1cccc2cc(Oc3ccnc4cc(OCC5(N)CC5)c(OC)cc34)ccc12		CHEMBL2220486	>	Kd	nM	30000.0	CHEMBL5408	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17943875	CHEMBL3991905	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	CCS(=O)(=O)N1CC(CC#N)(n2cc(-c3ncnc4[nH]ccc34)cn2)C1		CHEMBL2105759	>	Kd	nM	30000.0	CHEMBL5408	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17943876	CHEMBL3991905	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	N#CC1(c2ccc(NC(=O)c3cccnc3NCc3ccncc3)cc2)CCCC1		CHEMBL3186534	>	Kd	nM	30000.0	CHEMBL5408	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17943877	CHEMBL3991905	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	Cc1ncc(-c2ccnc(Nc3ccc(S(C)(=O)=O)cc3)n2)n1C(C)C		CHEMBL488436	>	Kd	nM	30000.0	CHEMBL5408	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17943878	CHEMBL3991905	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	O=c1sn(-c2cccc3ccccc23)c(=O)n1Cc1ccccc1		CHEMBL3545157	>	Kd	nM	30000.0	CHEMBL5408	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17943879	CHEMBL3991905	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	C=CC(=O)Nc1cccc(Nc2nc(Nc3ccc(N4CCN(C(C)=O)CC4)cc3OC)ncc2C(F)(F)F)c1		CHEMBL3545308	>	Kd	nM	30000.0	CHEMBL5408	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17943880	CHEMBL3991905	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	COc1cc2ncnc(Oc3cccc(NC(=O)Nc4cc(C(C)(C)C(F)(F)F)on4)c3)c2cc1OC		CHEMBL2029988	>	Kd	nM	30000.0	CHEMBL5408	Homo sapiens	Kd apparent	nM	30000.0
Active	17943881	CHEMBL3991905	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	COC(=O)[C@@]1(O)C[C@H]2O[C@]1(C)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)C(=O)NC4		CHEMBL281948	=	Kd	nM	1157.0	CHEMBL5408	Homo sapiens	Kd apparent	nM	1157.0
Inactive	17943882	CHEMBL3991905	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	Cc1ccc(-n2nc(C(C)(C)C)cc2NC(=O)NCc2cc(F)ccc2Oc2ccc3c(cnn3CCO)c2)cc1		CHEMBL3991932	>	Kd	nM	30000.0	CHEMBL5408	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17943883	CHEMBL3991905	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	O=C(O)c1ccc2c(c1)nc(Nc1cccc(Cl)c1)c1ccncc12		CHEMBL1230165	>	Kd	nM	30000.0	CHEMBL5408	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17943884	CHEMBL3991905	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	Cn1cc(-c2ccc3nnc(C(F)(F)c4ccc5ncccc5c4)n3n2)cn1		CHEMBL2133806	>	Kd	nM	30000.0	CHEMBL5408	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17943885	CHEMBL3991905	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	COc1cc2nccc(Oc3ccc(NC(=O)C4(C(=O)Nc5ccc(F)cc5)CC4)cc3)c2cc1OC		CHEMBL2105717	>	Kd	nM	30000.0	CHEMBL5408	Homo sapiens	Kd apparent	nM	30000.0
Active	17943886	CHEMBL3991905	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	COC(=O)c1ccc2c(c1)NC(=O)/C2=C(\Nc1ccc(N(C)C(=O)CN2CCN(C)CC2)cc1)c1ccccc1		CHEMBL502835	=	Kd	nM	5306.0	CHEMBL5408	Homo sapiens	Kd apparent	nM	5306.0
Inactive	17943887	CHEMBL3991905	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	CNC(=O)c1ccccc1Sc1ccc2c(/C=C/c3ccccn3)n[nH]c2c1		CHEMBL1289926	>	Kd	nM	30000.0	CHEMBL5408	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17943888	CHEMBL3991905	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	C[C@@H](Oc1cc(-n2cnc3ccc(CN4CCN(C)CC4)cc32)sc1C(N)=O)c1ccccc1C(F)(F)F		CHEMBL1908394	>	Kd	nM	30000.0	CHEMBL5408	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17943889	CHEMBL3991905	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	C[C@@]1(C(=O)Nc2ccc(F)nc2)CCCN1c1nc(Nc2cc(C3CC3)n[nH]2)c2cccn2n1		CHEMBL575448	>	Kd	nM	30000.0	CHEMBL5408	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17943890	CHEMBL3991905	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	COc1ccc(S(=O)(=O)N(C(C)=O)c2ccccc2/C=C/c2cc[n+]([O-])cc2)cc1		CHEMBL3991927	>	Kd	nM	30000.0	CHEMBL5408	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17943891	CHEMBL3991905	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	N[C@@H]1CCCN(c2c(/C=C3\SC(=O)NC3=O)cccc2-c2ccccc2)C1		CHEMBL2048872	>	Kd	nM	30000.0	CHEMBL5408	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17943892	CHEMBL3991905	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	Cc1ccc(F)c(NC(=O)Nc2ccc(-c3cccc4[nH]nc(N)c34)cc2)c1		CHEMBL223360	>	Kd	nM	30000.0	CHEMBL5408	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17943893	CHEMBL3991905	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	Cn1c(Nc2ccc(C(F)(F)F)cc2)nc2cc(Oc3ccnc(-c4ncc(C(F)(F)F)[nH]4)c3)ccc21		CHEMBL558752	>	Kd	nM	30000.0	CHEMBL5408	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17943894	CHEMBL3991905	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	O=C(Nc1nc2cccc(-c3ccc(CN4CCS(=O)(=O)CC4)cc3)n2n1)C1CC1		CHEMBL3301607	>	Kd	nM	30000.0	CHEMBL5408	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17943895	CHEMBL3991905	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	NC(=O)Nc1cc(-c2cccc(F)c2)sc1C(=O)N[C@H]1CCCNC1		CHEMBL2041933	>	Kd	nM	30000.0	CHEMBL5408	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17943896	CHEMBL3991905	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	Cc1ccc(NC(=O)c2ccc(CN3CCN(C)CC3)cc2)cc1Nc1nccc(-c2cccnc2)n1		CHEMBL941	>	Kd	nM	30000.0	CHEMBL5408	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17943897	CHEMBL3991905	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	CC1(COc2ccc3c(c2)ncn3-c2ccc3cccc(N4CCC(N)CC4)c3n2)COC1		CHEMBL2105728	>	Kd	nM	30000.0	CHEMBL5408	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17943898	CHEMBL3991905	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	C[C@@H](Oc1cc(-c2cnn(C3CCNCC3)c2)cnc1N)c1c(Cl)ccc(F)c1Cl		CHEMBL601719	>	Kd	nM	30000.0	CHEMBL5408	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17943899	CHEMBL3991905	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	C[C@@H]1CCN(C(=O)CC#N)C[C@@H]1N(C)c1ncnc2[nH]ccc12		CHEMBL221959	>	Kd	nM	30000.0	CHEMBL5408	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17943900	CHEMBL3991905	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	COc1cc2c(Oc3ccc4[nH]c(C)cc4c3F)ncnc2cc1OCCCN1CCCC1		CHEMBL491473	>	Kd	nM	30000.0	CHEMBL5408	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17943901	CHEMBL3991905	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	Cn1cc(-c2cnc3ccc4ccc(CS(=O)(=O)NCc5ccccn5)cc4c(=O)c3c2)cn1		CHEMBL2323775	>	Kd	nM	30000.0	CHEMBL5408	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17943902	CHEMBL3991905	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	Cc1nc2cc(-c3nn(C(C)C)c4ncnc(N)c34)ccc2o1		CHEMBL3991933	>	Kd	nM	30000.0	CHEMBL5408	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17943903	CHEMBL3991905	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	OCCn1cc(-c2cnc3nnn(Cc4ccc5ncccc5c4)c3n2)cn1		CHEMBL2001019	>	Kd	nM	30000.0	CHEMBL5408	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17943904	CHEMBL3991905	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	C[C@@H](NC(=O)c1ncnc(N)c1Cl)c1ncc(C(=O)Nc2cc(C(F)(F)F)c(Cl)cn2)s1		CHEMBL3348923	>	Kd	nM	30000.0	CHEMBL5408	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17943905	CHEMBL3991905	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	Cc1c(NC(=O)OC[C@@H]2COCCN2)cn2ncnc(Nc3ccc4c(cnn4Cc4cccc(F)c4)c3)c12		CHEMBL1645462	>	Kd	nM	30000.0	CHEMBL5408	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17943906	CHEMBL3991905	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	COc1cc(Nc2ncc3c(n2)-c2ccc(Cl)cc2C(c2c(F)cccc2OC)=NC3)ccc1C(=O)O		CHEMBL483158	>	Kd	nM	30000.0	CHEMBL5408	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17943907	CHEMBL3991905	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	CC(C)Nc1cc(-c2c[nH]c(C(=O)N[C@H](CO)c3cccc(Cl)c3)c2)c(Cl)cn1		CHEMBL3590106	>	Kd	nM	30000.0	CHEMBL5408	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17943908	CHEMBL3991905	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	CNC(=O)CN1CCC(Oc2cc3c(Nc4cccc(Cl)c4F)ncnc3cc2OC)CC1		CHEMBL2408045	>	Kd	nM	30000.0	CHEMBL5408	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17943909	CHEMBL3991905	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	Cn1ncc(Cl)c1-c1cc(C(=O)N[C@H](CN)Cc2ccc(F)c(F)c2)oc1Cl		CHEMBL3137336	>	Kd	nM	30000.0	CHEMBL5408	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17943910	CHEMBL3991905	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	Cc1cc(-c2cc(O)ccc2Cl)cc2nnc(Nc3ccc(OCCN4CCCC4)cc3)nc12		CHEMBL400402	>	Kd	nM	30000.0	CHEMBL5408	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17943911	CHEMBL3991905	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	COc1ccc(N2CCN(C)CC2)cc1Nc1ncc2c(n1)-c1c(c(C(N)=O)nn1C)CC2		CHEMBL1094408	>	Kd	nM	30000.0	CHEMBL5408	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17943912	CHEMBL3991905	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	CN(C[C@@H]1COCCO1)S(=O)(=O)Nc1ccc2ccc3ncc(-c4cnn(C)c4)cc3c(=O)c2c1		CHEMBL1822792	>	Kd	nM	30000.0	CHEMBL5408	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17943913	CHEMBL3991905	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	Cc1cc(Nc2cc(N3CCN(C)CC3)nc(Sc3ccc(NC(=O)C4CC4)cc3)n2)n[nH]1		CHEMBL572878	>	Kd	nM	30000.0	CHEMBL5408	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17943914	CHEMBL3991905	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	O=C1NC(=O)/C(=C/c2ccc3nccc(-c4ccncc4)c3c2)S1		CHEMBL3544966	>	Kd	nM	30000.0	CHEMBL5408	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17943915	CHEMBL3991905	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	S=C(NCc1ccc2c(c1)OCO2)N1CCN(c2ncnc3c2oc2ccccc23)CC1		CHEMBL2103851	>	Kd	nM	30000.0	CHEMBL5408	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17943916	CHEMBL3991905	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	COc1cccc2cc(-c3nc([C@H]4CC[C@H](C(=O)O)CC4)n4ncnc(N)c34)[nH]c12		CHEMBL3120215	>	Kd	nM	30000.0	CHEMBL5408	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17943917	CHEMBL3991905	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	Cn1nccc1Nc1nccc(-c2ccn([C@H](CO)c3ccc(Cl)c(F)c3)c(=O)c2)n1		CHEMBL3544964	>	Kd	nM	30000.0	CHEMBL5408	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17943918	CHEMBL3991905	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	Cc1ccc(S(=O)(=O)Nc2nc3ccccc3nc2Nc2ccc3nsnc3c2)cc1		CHEMBL3218575	>	Kd	nM	30000.0	CHEMBL5408	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17943919	CHEMBL3991905	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	CNC(=O)c1ccc(C)c(-n2c(C)cc(OCc3ccc(F)cc3F)c(Br)c2=O)c1		CHEMBL1088751	>	Kd	nM	30000.0	CHEMBL5408	Homo sapiens	Kd apparent	nM	30000.0
Active	17943920	CHEMBL3991905	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	C=CCn1c(=O)c2cnc(Nc3ccc(N4CCN(C)CC4)cc3)nc2n1-c1cccc(C(C)(C)O)n1		CHEMBL1976040	=	Kd	nM	1629.0	CHEMBL5408	Homo sapiens	Kd apparent	nM	1629.0
Active	17943921	CHEMBL3991905	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	COCCN1CCN(Cc2ccc(-c3n[nH]c4c3C(=O)c3c(NC(=O)NN5CCOCC5)cccc3-4)cc2)CC1		CHEMBL3545083	=	Kd	nM	2007.0	CHEMBL5408	Homo sapiens	Kd apparent	nM	2007.0
Inactive	17943922	CHEMBL3991905	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	O=C(Nc1ccc(OC(F)(F)F)cc1)c1sccc1NCc1ccnc2ccccc12		CHEMBL1614710	>	Kd	nM	30000.0	CHEMBL5408	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17943923	CHEMBL3991905	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	CCN1CCN(Cc2ccc(Nc3ncc(F)c(-c4cc(F)c5nc(C)n(C(C)C)c5c4)n3)nc2)CC1		CHEMBL3301610	>	Kd	nM	30000.0	CHEMBL5408	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17943924	CHEMBL3991905	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	CO[C@H]1C[C@@H]2CC[C@@H](C)[C@@](O)(O2)C(=O)C(=O)N2CCCC[C@H]2C(=O)O[C@H]([C@H](C)C[C@@H]2CC[C@@H](O)[C@H](OC)C2)CC(=O)[C@H](C)/C=C(\C)[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)/C=C/C=C/C=C/1C		CHEMBL413	>	Kd	nM	30000.0	CHEMBL5408	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17943925	CHEMBL3991905	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	CCn1cc(-c2ccnc3[nH]c(-c4cccc(CN(C)C)c4)cc23)c(-c2ccc(NC(=O)N(C)C)cc2)n1		CHEMBL1090479	>	Kd	nM	30000.0	CHEMBL5408	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17943926	CHEMBL3991905	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	Cc1cc(-c2cc(OC(=O)c3ccccc3)ccc2Cl)cc2nnc(Nc3ccc(OCCN4CCCC4)cc3)nc12		CHEMBL403989	>	Kd	nM	30000.0	CHEMBL5408	Homo sapiens	Kd apparent	nM	30000.0
Active	17943927	CHEMBL3991905	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	O=C(c1ccc(/C=C/c2n[nH]c3ccccc23)cc1)N1CCNCC1		CHEMBL1908397	=	Kd	nM	1966.0	CHEMBL5408	Homo sapiens	Kd apparent	nM	1966.0
Inactive	17943928	CHEMBL3991905	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	COCC(=O)NC/C=C/c1ccc2ncnc(Nc3ccc(Oc4ccc(C)nc4)c(C)c3)c2c1		CHEMBL483321	>	Kd	nM	30000.0	CHEMBL5408	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17943929	CHEMBL3991905	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	CN1C/C=C/CCOc2cccc(c2)-c2ccnc(n2)Nc2cccc(c2)C1		CHEMBL1944698	>	Kd	nM	30000.0	CHEMBL5408	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17943930	CHEMBL3991905	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	CC(C)(O)CC(=O)NCCn1ccc2ncnc(Nc3ccc(Oc4cccc(C(F)(F)F)c4)c(Cl)c3)c21		CHEMBL1614725	>	Kd	nM	30000.0	CHEMBL5408	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17943931	CHEMBL3991905	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	CCCCCCCCCCCCCCCCCCOP(=O)([O-])OC1CC[N+](C)(C)CC1		CHEMBL372764	>	Kd	nM	30000.0	CHEMBL5408	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17943932	CHEMBL3991905	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	COc1cc2ncnc(Nc3ccc(O)cc3)c2cc1OC		CHEMBL405130	>	Kd	nM	30000.0	CHEMBL5408	Homo sapiens	Kd apparent	nM	30000.0
Active	17943933	CHEMBL3991905	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	CO[C@@H]1[C@H](N(C)C(=O)c2ccccc2)C[C@H]2O[C@]1(C)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)C(=O)NC4		CHEMBL608533	=	Kd	nM	188.0	CHEMBL5408	Homo sapiens	Kd apparent	nM	188.0
Inactive	17943934	CHEMBL3991905	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	Cc1cc(Nc2cc(N3CCN(C)CC3)nc(/C=C/c3ccccc3)n2)n[nH]1		CHEMBL482968	>	Kd	nM	30000.0	CHEMBL5408	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17943935	CHEMBL3991905	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	CS(=O)(=O)CCNCc1ccc(-c2ccc3ncnc(Nc4ccc(OCc5cccc(F)c5)c(Cl)c4)c3c2)o1		CHEMBL554	>	Kd	nM	30000.0	CHEMBL5408	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17943936	CHEMBL3991905	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	CC[C@H](Nc1ncnc2[nH]cnc12)c1nc2cccc(F)c2c(=O)n1-c1ccccc1		CHEMBL2216870	>	Kd	nM	30000.0	CHEMBL5408	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17943937	CHEMBL3991905	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	CNC(=O)c1cc(COc2nnc(Nc3ccc(Cl)cc3)c3ccoc23)ccn1		CHEMBL2079588	>	Kd	nM	30000.0	CHEMBL5408	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17943938	CHEMBL3991905	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	Clc1ccc(Nc2nnc(Cc3ccncc3)c3ccccc23)cc1		CHEMBL101253	>	Kd	nM	30000.0	CHEMBL5408	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17943939	CHEMBL3991905	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	Cn1cnc2c(F)c(Nc3ccc(Br)cc3F)c(C(=O)NOCCO)cc21		CHEMBL3187723	>	Kd	nM	30000.0	CHEMBL5408	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17943940	CHEMBL3991905	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	CO[C@H]1C[C@@H]2CC[C@@H](C)[C@@](O)(O2)C(=O)C(=O)N2CCCC[C@H]2C(=O)O[C@H]([C@H](C)C[C@@H]2CC[C@@H](OCCO)[C@H](OC)C2)CC(=O)[C@H](C)/C=C(\C)[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)/C=C/C=C/C=C/1C		CHEMBL1908360	>	Kd	nM	30000.0	CHEMBL5408	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17943941	CHEMBL3991905	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	C[C@H]1CNCCCN1S(=O)(=O)c1cccc2cncc(F)c12		CHEMBL3426621	>	Kd	nM	30000.0	CHEMBL5408	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17943942	CHEMBL3991905	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B			CHEMBL4084193	>	Kd	nM	30000.0	CHEMBL5408	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17943943	CHEMBL3991905	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	Cc1nc(NC(=O)N2CCC[C@H]2C(N)=O)sc1-c1ccnc(C(C)(C)C(F)(F)F)c1		CHEMBL2396661	>	Kd	nM	30000.0	CHEMBL5408	Homo sapiens	Kd apparent	nM	30000.0
Active	17943944	CHEMBL3991905	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	O=C(Nc1c[nH]nc1-c1nc2ccc(CN3CCOCC3)cc2[nH]1)NC1CC1		CHEMBL495727	=	Kd	nM	102.0	CHEMBL5408	Homo sapiens	Kd apparent	nM	102.0
Inactive	17943945	CHEMBL3991905	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	C[C@H]1CN(C(=O)c2cc3c(C(=O)C(=O)N(C)C)cn(C)c3cc2Cl)[C@H](C)CN1Cc1ccc(F)cc1		CHEMBL514201	>	Kd	nM	30000.0	CHEMBL5408	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17943946	CHEMBL3991905	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	CCn1c(=O)c(-c2cc[nH]n2)cc2c(C)nc(N)nc21		CHEMBL3545366	>	Kd	nM	30000.0	CHEMBL5408	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17943947	CHEMBL3991905	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	CCOc1ccn(-c2ccc(F)cc2)c(=O)c1C(=O)Nc1ccc(Oc2ccnc(N)c2Cl)c(F)c1		CHEMBL460702	>	Kd	nM	30000.0	CHEMBL5408	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17943948	CHEMBL3991905	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	Cc1nc2ccc(-n3ncc(C(=O)c4cc5ccccc5[nH]4)c3N)cc2[nH]1		CHEMBL3907479	>	Kd	nM	30000.0	CHEMBL5408	Homo sapiens	Kd apparent	nM	30000.0
	18031880	CHEMBL4007750	Inhibition of TBK1 (unknown origin) after 60 mins by TR-FRET assay	B	CCCNC(=O)c1ccc(Nc2nc(NCC(F)(F)F)c3cc[nH]c3n2)cc1		CHEMBL2006765	=	IC50	nM	1070.0	CHEMBL5408	Homo sapiens	IC50	uM	1.07
	18031881	CHEMBL4007750	Inhibition of TBK1 (unknown origin) after 60 mins by TR-FRET assay	B	FC(F)(F)CNc1nc(Nc2ccc(N3CCOCC3)c(Cl)c2)nc2ccoc12		CHEMBL4078893	>	IC50	nM	10000.0	CHEMBL5408	Homo sapiens	IC50	uM	10.0
	18031882	CHEMBL4007750	Inhibition of TBK1 (unknown origin) after 60 mins by TR-FRET assay	B	FC(F)(F)CNc1nc(Nc2ccc3cn[nH]c3c2)nc2ccoc12		CHEMBL4066664	>	IC50	nM	10000.0	CHEMBL5408	Homo sapiens	IC50	uM	10.0
	18031883	CHEMBL4007750	Inhibition of TBK1 (unknown origin) after 60 mins by TR-FRET assay	B	CC1(C)OCC(=O)Nc2cc(Nc3nc(NCC(F)(F)F)c4occc4n3)ccc21		CHEMBL4069365	=	IC50	nM	7610.0	CHEMBL5408	Homo sapiens	IC50	uM	7.61
	18031884	CHEMBL4007750	Inhibition of TBK1 (unknown origin) after 60 mins by TR-FRET assay	B	Cc1n[nH]c2cc(Nc3nc(NC4CC4)c4occc4n3)ccc12		CHEMBL4062803	>	IC50	nM	10000.0	CHEMBL5408	Homo sapiens	IC50	uM	10.0
	18048608	CHEMBL4011061	Inhibition of TNFalpha-stimulated TBK1 in human U937 cells assessed as residual activity at 10 uM in presence of ATP relative to control	B	S=C(NCc1ccccc1)Nc1ccc2ncnc(Nc3cccc(Br)c3)c2c1		CHEMBL4088718	=	Activity	%	92.0	CHEMBL5408	Homo sapiens	Activity	%	92.0
	18114876	CHEMBL4025406	Inhibition of wild-type human full length TBK1 (M1 to L729 residues) expressed in mammalian expression system assessed as residual activity at 1 uM by Kinomescan method relative to control	B	C=CC(=O)Nc1cc(Nc2cc(-c3cccc(NC(=O)c4ccc(C(C)(C)C)cc4)c3C)cn(C)c2=O)ccc1C(=O)N1CCOCC1		CHEMBL4077123	=	Activity	%	100.0	CHEMBL5408	Homo sapiens	Activity	%	100.0
	18153214	CHEMBL4034506	Inhibition of TBK1 Lysine 1 labelling site (unknown origin) at 10 uM	B	c1cc(-c2c[nH]c3cnccc23)ccn1	Outside typical range	CHEMBL4084955	=	Inhibition	%	-13.6	CHEMBL5408	Homo sapiens	INH	%	-13.6
	18153308	CHEMBL4034340	Inhibition of TBK1 Lysine 2 labelling site (unknown origin) at 10 uM	B	c1cc(-c2c[nH]c3cnccc23)ccn1		CHEMBL4084955	=	Inhibition	%	-0.7	CHEMBL5408	Homo sapiens	INH	%	-0.7
	18203930	CHEMBL4044217	Inhibition of wild-type human full length TBK1 (M1 to L729 residues) expressed in HEK293 cells assessed as residual activity at 1000 nM after 30 mins by Kinomescan method relative to control	B	COc1cc(OC)c(Cl)c(N2Cc3cnc(Nc4ccc(F)cc4)nc3N(C3CCN(C(=O)/C=C/CN(C)C)CC3)C2=O)c1Cl		CHEMBL4092508	=	Activity	%	92.0	CHEMBL5408	Homo sapiens	Activity	%	92.0
	18211563	CHEMBL4045697	Inhibition of TBK1 conserved Lys2 (DIKPGNIMR) in human PBMC at 1 uM	B	CC(C)n1cc(-c2cc(-c3ccc(CN4CCOCC4)cc3)cnc2N)nn1		CHEMBL3971067	=	Inhibition	%	11.0	CHEMBL5408	Homo sapiens	INH	%	11.0
	18211755	CHEMBL4045851	Inhibition of TBK1 conserved Lys1 (TGDLFAIKVFNNISFLRPVDVQMR) in human PBMC at 1 uM	B	CC(C)n1cc(-c2cc(-c3ccc(CN4CCOCC4)cc3)cnc2N)nn1		CHEMBL3971067	=	Inhibition	%	14.5	CHEMBL5408	Homo sapiens	INH	%	14.5
	18211842	CHEMBL4045938	Inhibition of TBK1 conserved Lys2 (DIKPGNIMR) in human PBMC at 0.1 uM	B	CC(C)n1cc(-c2cc(-c3ccc(CN4CCOCC4)cc3)cnc2N)nn1		CHEMBL3971067	=	Inhibition	%	21.7	CHEMBL5408	Homo sapiens	INH	%	21.7
	18211996	CHEMBL4046092	Inhibition of TBK1 conserved Lys1 (TGDLFAIKVFNNISFLRPVDVQMR) in human PBMC at 0.1 uM	B	CC(C)n1cc(-c2cc(-c3ccc(CN4CCOCC4)cc3)cnc2N)nn1	Outside typical range	CHEMBL3971067	=	Inhibition	%	-25.0	CHEMBL5408	Homo sapiens	INH	%	-25.0
	18232204	CHEMBL4050302	Inhibition of human TBK1 assessed as residual activity at 1 uM in presence of 33P-ATP by filter-binding assay relative to control	B	NCCCC[C@H](NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CC(=O)O)NC(=O)CCCCCCCCOc1nc2cc(C(=O)O)ccc2c2cnccc12)C(=O)O		CHEMBL4077554	=	Activity	%	34.0	CHEMBL5408	Homo sapiens	Activity	%	34.0
	18253596	CHEMBL4055082	Inhibition of wild-type human full length TBK1 (M1 to L729 residues) expressed in mammalian expression system assessed as residual activity at 50 nM by Kinomescan method relative to control	B	CC1(C)[C@H](Nc2c(C(N)=O)cnn3cc(-c4ccccc4)cc23)CC[C@]1(C)N		CHEMBL4096145	=	Activity	%	90.0	CHEMBL5408	Homo sapiens	Activity	%	90.0
	18253597	CHEMBL4055082	Inhibition of wild-type human full length TBK1 (M1 to L729 residues) expressed in mammalian expression system assessed as residual activity at 50 nM by Kinomescan method relative to control	B	COc1ccc(-c2cc3c(N[C@@H]4CC[C@](C)(N)C4(C)C)c(C(N)=O)cnn3c2)cn1		CHEMBL4080797	=	Activity	%	97.0	CHEMBL5408	Homo sapiens	Activity	%	97.0
	18274950	CHEMBL4118362	Inhibition of TBK1 in human SKCO1 cells at 1 uM after 4 hrs using biotin labeled DIKPGNIMR probe by mass-spectrometric analysis relative to control	B	C=CC(=O)Nc1ccccc1Nc1nc(Nc2ccc(N3CCN(C)CC3)cc2)ncc1Cl		CHEMBL3883384	=	Inhibition	%	59.3	CHEMBL5408	Homo sapiens	INH	%	59.3
	18274951	CHEMBL4118362	Inhibition of TBK1 in human SKCO1 cells at 1 uM after 4 hrs using biotin labeled DIKPGNIMR probe by mass-spectrometric analysis relative to control	B	C=CC(=O)Nc1ccccc1Oc1nc(Nc2cnn(CCOC)c2)ncc1Cl	Outside typical range	CHEMBL3884839	=	Inhibition	%	-47.6	CHEMBL5408	Homo sapiens	INH	%	-47.6
	18274952	CHEMBL4118362	Inhibition of TBK1 in human SKCO1 cells at 1 uM after 4 hrs using biotin labeled DIKPGNIMR probe by mass-spectrometric analysis relative to control	B	COc1cc(O)c2c(c1)/C=C/C[C@H](O)[C@H](O)C(=O)/C=C\C[C@H](C)OC2=O	Outside typical range	CHEMBL1077979	=	Inhibition	%	-28.7	CHEMBL5408	Homo sapiens	INH	%	-28.7
	18275313	CHEMBL4118483	Inhibition of TBK1 in human SKCO1 cells at 1 uM after 4 hrs using biotin labeled TGDLFAIKVFNNISFLRPVDVQMR probe by mass-spectrometric analysis relative to control	B	C=CC(=O)Nc1ccccc1Nc1nc(Nc2ccc(N3CCN(C)CC3)cc2)ncc1Cl		CHEMBL3883384	=	Inhibition	%	61.0	CHEMBL5408	Homo sapiens	INH	%	61.0
	18275314	CHEMBL4118483	Inhibition of TBK1 in human SKCO1 cells at 1 uM after 4 hrs using biotin labeled TGDLFAIKVFNNISFLRPVDVQMR probe by mass-spectrometric analysis relative to control	B	C=CC(=O)Nc1ccccc1Oc1nc(Nc2cnn(CCOC)c2)ncc1Cl	Outside typical range	CHEMBL3884839	=	Inhibition	%	-31.7	CHEMBL5408	Homo sapiens	INH	%	-31.7
	18275315	CHEMBL4118483	Inhibition of TBK1 in human SKCO1 cells at 1 uM after 4 hrs using biotin labeled TGDLFAIKVFNNISFLRPVDVQMR probe by mass-spectrometric analysis relative to control	B	COc1cc(O)c2c(c1)/C=C/C[C@H](O)[C@H](O)C(=O)/C=C\C[C@H](C)OC2=O	Outside typical range	CHEMBL1077979	=	Inhibition	%	-25.4	CHEMBL5408	Homo sapiens	INH	%	-25.4
	18282184	CHEMBL4120139	Inhibition of recombinant full length GST-tagged human TBK1 expressed in insect cells at 1 uM by FRET assay relative to control	B	CC(C)n1nc(-c2cnc(N)c(OC(F)(F)F)c2)cc1[C@@H]1[C@H]2CN(C3COC3)C[C@H]21		CHEMBL3719135	=	Inhibition	%	9.4	CHEMBL5408	Homo sapiens	INH	%	9.4
	18282503	CHEMBL4120139	Inhibition of recombinant full length GST-tagged human TBK1 expressed in insect cells at 1 uM by FRET assay relative to control	B	Nc1ncc(-c2cc([C@@H]3[C@H]4CN(C5COC5)C[C@H]43)n(CC3CC3)n2)cc1C(F)(F)F		CHEMBL3715238	=	Inhibition	%	5.3	CHEMBL5408	Homo sapiens	INH	%	5.3
	18440472	CHEMBL4157296	Binding affinity to wild-type human full length TBK1 (M1 to L729 residues) expressed in mammalian expression system assessed as residual binding at 1 uM by Kinomescan method relative to control	B	Cc1cccc(S(=O)(=O)Nc2cc(-c3sc(NC(=O)[C@@H](N)C(C)C)nc3C)cnc2Cl)c1		CHEMBL4174988	=	Activity	%	68.0	CHEMBL5408	Homo sapiens	Activity	%	68.0
	18443301	CHEMBL4157915	Inhibition of human TBK1 assessed as enzyme residual activity at 100 nM by radiometric filter binding assay relative to control	B	NCCCC[C@@H](NC(=O)[C@@H](CC(=O)O)NC(=O)[C@@H](CC(=O)O)NC(=O)[C@@H](CC(=O)O)NC(=O)[C@@H](CC(=O)O)NC(=O)[C@@H](CC(=O)O)NC(=O)[C@@H](CC(=O)O)NC(=O)CCCCCNC(=O)CCC(=O)Nc1ncc(-c2ccc(C(=O)O)cc2)s1)C(=O)O		CHEMBL4177303	=	Activity	%	78.0	CHEMBL5408	Homo sapiens	Activity	%	78.0
	18449931	CHEMBL4178165	Inhibition of human TBK1 (1 to 729 residues) assessed as residual activity at 500 nM in presence of 33P-ATP by filter binding assay relative to control	B	Cc1cccc(-c2nc(N)sc2-c2ccc3ncccc3n2)c1		CHEMBL4209540	=	Activity	%	77.0	CHEMBL5408	Homo sapiens	Activity	%	77.0
	18462204	CHEMBL4180891	Inhibition of recombinant human full length His6-tagged TBK1 expressed in Sf21 insect cells assessed as residual activity at 1 uM using AKPKGNKDYHLQTCCGSLAYRRR as substrate after 30 mins in presence of [gamma-33P]ATP relative to control	B	CC(C)=CCC/C(C)=C/Cn1cnc2c(Nc3cccc(Cl)c3)nc(N[C@H]3CC[C@H](N)CC3)nc21		CHEMBL4203120	=	Activity	%	106.0	CHEMBL5408	Homo sapiens	Activity	%	106.0
	18484428	CHEMBL4186075	Binding affinity to wild-type human full length TBK1 (M1 to L729 residues) expressed in HEK293 cells at 1 uM by Kinomescan method relative to control	B	C=CC(=O)Nc1ccc(C(=O)Nc2ccc(Nc3ncc4c(n3)N(C)c3ccc(C)cc3C(=O)N4C)cc2)cc1		CHEMBL3969370	=	Activity	%	94.0	CHEMBL5408	Homo sapiens	Activity	%	94.0
	18484912	CHEMBL4186075	Binding affinity to wild-type human full length TBK1 (M1 to L729 residues) expressed in HEK293 cells at 1 uM by Kinomescan method relative to control	B	CCC(=O)Nc1ccc(C(=O)Nc2ccc(Nc3ncc4c(n3)N(C)c3ccc(C)cc3C(=O)N4C)cc2)cc1		CHEMBL4206831	=	Activity	%	74.0	CHEMBL5408	Homo sapiens	Activity	%	74.0
	18507584	CHEMBL4191207	Inhibition of recombinant full-length human TBK1 at 1 uM using KRRRALS(p)VASLPGL as substrate after 40 mins in presence of [gamma-33P]ATP by scintillation counting method	B	CS(=O)(=O)c1ccc(-n2nc(-c3cnc4[nH]ccc4c3)c3c(N)ncnc32)cc1		CHEMBL4207014	=	Inhibition	%	-4.0	CHEMBL5408	Homo sapiens	INH	%	-4.0
	18566281	CHEMBL4219631	Binding affinity to human full length wild-type TBK1 expressed in mammalian expression system	B	Cc1ncsc1-c1ccc(CNC(=O)[C@@H]2C[C@@H](O)CN2C(=O)[C@@H](NC(=O)COCCCOCCCCOCCCOc2ccc(Nc3ncc(Br)c(NCCCN(C)C(=O)C4CCC4)n3)cc2)C(C)(C)C)cc1		CHEMBL4227907	=	Kd	nM	4.6	CHEMBL5408	Homo sapiens	Kd	nM	4.6
	18566282	CHEMBL4219631	Binding affinity to human full length wild-type TBK1 expressed in mammalian expression system	B	Cc1ncsc1-c1ccc(CNC(=O)[C@@H]2C[C@@H](O)CN2C(=O)[C@@H](NC(=O)COCCCOCCCCOCCCOc2ccc(Nc3nccc(NCCCN(C)C(=O)C4CCC4)n3)cc2)C(C)(C)C)cc1		CHEMBL4228346	=	Kd	nM	725.0	CHEMBL5408	Homo sapiens	Kd	nM	725.0
	18566283	CHEMBL4219631	Binding affinity to human full length wild-type TBK1 expressed in mammalian expression system	B	Cc1ncsc1-c1ccc(CNC(=O)[C@@H]2C[C@@H](O)CN2C(=O)[C@@H](NC(=O)COCCCOCCCCOCCCOc2ccc(Nc3ncc(F)c(NCCCN(C)C(=O)C4CCC4)n3)cc2)C(C)(C)C)cc1		CHEMBL4228790	=	Kd	nM	103.5	CHEMBL5408	Homo sapiens	Kd	nM	103.5
	18566284	CHEMBL4219631	Binding affinity to human full length wild-type TBK1 expressed in mammalian expression system	B	Cc1ncsc1-c1ccc(CNC(=O)[C@@H]2C[C@@H](O)CN2C(=O)[C@@H](NC(=O)COCCCOCCCCOCCCOc2ccc(Nc3ncc(Cl)c(NCCCN(C)C(=O)C4CCC4)n3)cc2)C(C)(C)C)cc1		CHEMBL4226319	=	Kd	nM	10.4	CHEMBL5408	Homo sapiens	Kd	nM	10.4
	18566285	CHEMBL4219631	Binding affinity to human full length wild-type TBK1 expressed in mammalian expression system	B	Cc1ncsc1-c1ccc(CNC(=O)[C@@H]2C[C@@H](O)CN2C(=O)[C@@H](NC(=O)COCCCOCCCCOCCCOc2ccc(Nc3ncc(I)c(NCCCN(C)C(=O)C4CCC4)n3)cc2)C(C)(C)C)cc1		CHEMBL4225766	=	Kd	nM	4.0	CHEMBL5408	Homo sapiens	Kd	nM	4.0
	18566286	CHEMBL4219631	Binding affinity to human full length wild-type TBK1 expressed in mammalian expression system	B	Cc1ncsc1-c1ccc(CNC(=O)[C@@H]2C[C@@H](O)CN2C(=O)[C@@H](NC(=O)COCCCOCCCCOCCCOc2ccc(Nc3ncc(C(F)(F)F)c(NCCCN(C)C(=O)C4CCC4)n3)cc2)C(C)(C)C)cc1		CHEMBL4226591	=	Kd	nM	13.0	CHEMBL5408	Homo sapiens	Kd	nM	13.0
	18566287	CHEMBL4219631	Binding affinity to human full length wild-type TBK1 expressed in mammalian expression system	B	Cc1cnc(Nc2ccc(OCCCOCCCCOCCCOCC(=O)N[C@H](C(=O)N3C[C@H](O)C[C@H]3C(=O)NCc3ccc(-c4scnc4C)cc3)C(C)(C)C)cc2)nc1NCCCN(C)C(=O)C1CCC1		CHEMBL4227342	=	Kd	nM	270.0	CHEMBL5408	Homo sapiens	Kd	nM	270.0
	18566288	CHEMBL4219631	Binding affinity to human full length wild-type TBK1 expressed in mammalian expression system	B	CCc1cnc(Nc2ccc(OCCCOCCCCOCCCOCC(=O)N[C@H](C(=O)N3C[C@H](O)C[C@H]3C(=O)NCc3ccc(-c4scnc4C)cc3)C(C)(C)C)cc2)nc1NCCCN(C)C(=O)C1CCC1		CHEMBL4226837	=	Kd	nM	275.0	CHEMBL5408	Homo sapiens	Kd	nM	275.0
	18566289	CHEMBL4219631	Binding affinity to human full length wild-type TBK1 expressed in mammalian expression system	B	Cc1ncsc1-c1ccc(CNC(=O)[C@@H]2C[C@@H](O)CN2C(=O)[C@@H](NC(=O)COCCCOCCCCOCCCOc2ccc(Nc3ncc(C4CCC4)c(NCCCN(C)C(=O)C4CCC4)n3)cc2)C(C)(C)C)cc1		CHEMBL4225995	=	Kd	nM	1035.0	CHEMBL5408	Homo sapiens	Kd	nM	1035.0
	18566290	CHEMBL4219631	Binding affinity to human full length wild-type TBK1 expressed in mammalian expression system	B	C=Cc1cnc(Nc2ccc(OCCCOCCCCOCCCOCC(=O)N[C@H](C(=O)N3C[C@H](O)C[C@H]3C(=O)NCc3ccc(-c4scnc4C)cc3)C(C)(C)C)cc2)nc1NCCCN(C)C(=O)C1CCC1		CHEMBL4227097	=	Kd	nM	130.0	CHEMBL5408	Homo sapiens	Kd	nM	130.0
	18566291	CHEMBL4219631	Binding affinity to human full length wild-type TBK1 expressed in mammalian expression system	B	Cc1ncsc1-c1ccc(CNC(=O)[C@@H]2C[C@@H](O)CN2C(=O)[C@@H](NC(=O)COCCCOCCCCOCCCOc2ccc(Nc3ncc(C4CC4)c(NCCCN(C)C(=O)C4CCC4)n3)cc2)C(C)(C)C)cc1		CHEMBL4226250	=	Kd	nM	245.0	CHEMBL5408	Homo sapiens	Kd	nM	245.0
Active	18566302	CHEMBL4219637	Antagonist activity at TBK1 in human Panc02.13 cells assessed as decrease in Poly(I:C)-induced IRF3 phosphorylation preincubated for 16 hrs followed by Poly I:C addition measured after 3 hrs by Western blot method	B	Cc1ncsc1-c1ccc(CNC(=O)[C@@H]2C[C@H](O)CN2C(=O)[C@@H](NC(=O)COCCCOCCCCOCCCOc2ccc(Nc3ncc(Br)c(NCCCN(C)C(=O)C4CCC4)n3)cc2)C(C)(C)C)cc1		CHEMBL4226693		Inhibition	%		CHEMBL5408	Homo sapiens	INH		
	18566305	CHEMBL4219640	Inhibition of TBK1 (unknown origin)	B	Cc1ncsc1-c1ccc(CNC(=O)[C@@H]2C[C@@H](O)CN2C(=O)[C@@H](NC(=O)COCCCOCCCCOCCCOc2ccc(Nc3ncc(Br)c(NCCCN(C)C(=O)C4CCC4)n3)cc2)C(C)(C)C)cc1		CHEMBL4227907	=	IC50	nM	1.3	CHEMBL5408	Homo sapiens	IC50	nM	1.3
	18566322	CHEMBL4219631	Binding affinity to human full length wild-type TBK1 expressed in mammalian expression system	B	CCOc1ccc(Nc2ncc(Br)c(NCCCN(C)C(=O)C3CCC3)n2)cc1		CHEMBL4224757	=	Kd	nM	1.3	CHEMBL5408	Homo sapiens	Kd	nM	1.3
	18566323	CHEMBL4219631	Binding affinity to human full length wild-type TBK1 expressed in mammalian expression system	B	Cc1ncsc1-c1ccc(CNC(=O)[C@@H]2C[C@H](O)CN2C(=O)[C@@H](NC(=O)COCCCOCCCCOCCCOc2ccc(Nc3ncc(Br)c(NCCCN(C)C(=O)C4CCC4)n3)cc2)C(C)(C)C)cc1		CHEMBL4226693	=	Kd	nM	5.9	CHEMBL5408	Homo sapiens	Kd	nM	5.9
	18653335	CHEMBL4230238	Inhibition of TBK1 (unknown origin) at 1 uM by mobility shift microfluidics platform based assay relative to control	B	CC(C)n1nc(C#Cc2cccc(NC(=O)c3cccc(C(F)(F)F)c3)c2)c2c(N)ncnc21		CHEMBL3736320	=	Inhibition	%	6.0	CHEMBL5408	Homo sapiens	INH	%	6.0
	18653336	CHEMBL4230238	Inhibition of TBK1 (unknown origin) at 1 uM by mobility shift microfluidics platform based assay relative to control	B	CC(C)n1nc(C#Cc2cccc3cc(-c4cccc(C(F)(F)F)c4)ncc23)c2c(N)ncnc21		CHEMBL4247506	=	Inhibition	%	1.0	CHEMBL5408	Homo sapiens	INH	%	1.0
	18655260	CHEMBL4230975	Binding affinity to wild-type human full length TBK1 (M1 to L729 residues) expressed in mammalian expression system assessed as residual binding level at 1 uM by Kinomescan method relative to control	B	Cc1ccc(NC(=O)c2ccc(CN(CCN(C)C)C(=O)c3cccnc3)cc2)cc1Nc1nccc(-c2cccnc2)n1		CHEMBL4247298	=	Activity	%	86.0	CHEMBL5408	Homo sapiens	Activity	%	86.0
	18665445	CHEMBL4233363	Inhibition of NAK (unknown origin)	B	O=C(Cc1cccc(OCCCN2CCNCC2)c1)Nc1nc(-c2ccncc2)cs1		CHEMBL4245507	>	IC50	nM	10000.0	CHEMBL5408	Homo sapiens	IC50	nM	10000.0
	18665456	CHEMBL4233415	Inhibition of TBK1 (unknown origin)	B	O=C(Cc1cccc(OCCCN2CCNCC2)c1)Nc1nc(-c2ccncc2)cs1		CHEMBL4245507	>	IC50	nM	1000.0	CHEMBL5408	Homo sapiens	IC50	nM	1000.0
	18665475	CHEMBL4233363	Inhibition of NAK (unknown origin)	B	O=C(Cc1cccc(OCCCC2CCNCC2)c1)Nc1nc(-c2ccncc2)cs1		CHEMBL4251324	>	IC50	nM	10000.0	CHEMBL5408	Homo sapiens	IC50	nM	10000.0
	18674778	CHEMBL4235394	Inhibition of NAK (unknown origin)	B	CS(=O)(=O)Nc1cccc(CC(=O)Nc2nc(-c3c[nH]c4ncccc34)cs2)c1		CHEMBL4249925	>	Ki	nM	10000.0	CHEMBL5408	Homo sapiens	Ki	nM	10000.0
	18674779	CHEMBL4235394	Inhibition of NAK (unknown origin)	B	O=C(Cc1cccc(OCCCC2CCNCC2)c1)Nc1nc(-c2c[nH]c3ncccc23)cs1		CHEMBL4245242	>	Ki	nM	10000.0	CHEMBL5408	Homo sapiens	Ki	nM	10000.0
	18674780	CHEMBL4235394	Inhibition of NAK (unknown origin)	B	CN1CCN(CCCOc2cccc(CC(=O)Nc3nc(-c4c[nH]c5ncccc45)cs3)c2)CC1		CHEMBL4248525	>	Ki	nM	10000.0	CHEMBL5408	Homo sapiens	Ki	nM	10000.0
	18674919	CHEMBL4235442	Inhibition of TBK1 (unknown origin)	B	CS(=O)(=O)Nc1cccc(CC(=O)Nc2nc(-c3c[nH]c4ncccc34)cs2)c1		CHEMBL4249925	>	Ki	nM	2000.0	CHEMBL5408	Homo sapiens	Ki	nM	2000.0
	18674920	CHEMBL4235442	Inhibition of TBK1 (unknown origin)	B	O=C(Cc1cccc(OCCCC2CCNCC2)c1)Nc1nc(-c2c[nH]c3ncccc23)cs1		CHEMBL4245242	>	Ki	nM	2000.0	CHEMBL5408	Homo sapiens	Ki	nM	2000.0
Not Determined	18674921	CHEMBL4235442	Inhibition of TBK1 (unknown origin)	B	CN1CCN(CCCOc2cccc(CC(=O)Nc3nc(-c4c[nH]c5ncccc45)cs3)c2)CC1		CHEMBL4248525		Ki			CHEMBL5408	Homo sapiens	Ki		
	18751251	CHEMBL4263960	Inhibition of TBK1 (unknown origin) at 1 uM relative to control	B	NC1(c2ccc(-c3cnc4c(-c5ccc(S(N)(=O)=O)c6ccccc56)cnn4c3)cc2)CCC1		CHEMBL4278763	=	Inhibition	%	5.0	CHEMBL5408	Homo sapiens	INH	%	5.0
	18752227	CHEMBL4264564	Binding affinity to wild-type human full length TBK1 (M1 to L729 residues) expressed in mammalian expression system assessed as remaining unbound target protein level at 1000 nM by Kinomescan method relative to control	B	COCCN[C@H]1CC[C@H](Nc2cc(-c3csc(NCC4(C#N)CCOCC4)n3)c(Cl)cn2)CC1		CHEMBL4281048	=	Activity	%	86.0	CHEMBL5408	Homo sapiens	Activity	%	86.0
	18761586	CHEMBL4266637	Inhibition of recombinant human full length N-terminal His6-tagged TBK1 expressed in baculovirus infected Sf21 insect cells at 1 uM relative to control	B	CN(C)[C@H]1CC[C@H](Nc2ncnc3[nH]cc([C@H]4CC[C@H](C(N)=O)CC4)c23)CC1		CHEMBL4279192	=	Inhibition	%	2.0	CHEMBL5408	Homo sapiens	INH	%	2.0
	18761857	CHEMBL4266637	Inhibition of recombinant human full length N-terminal His6-tagged TBK1 expressed in baculovirus infected Sf21 insect cells at 1 uM relative to control	B	CC(=O)N1CCN([C@H]2CC[C@H](Nc3ncnn4ccc(C(C)C)c34)CC2)CC1		CHEMBL4278882	=	Inhibition	%	6.0	CHEMBL5408	Homo sapiens	INH	%	6.0
	18762020	CHEMBL4266637	Inhibition of recombinant human full length N-terminal His6-tagged TBK1 expressed in baculovirus infected Sf21 insect cells at 1 uM relative to control	B	CC(=O)N1CCN([C@H]2CC[C@H](Nc3ncnn4ccc(C5CCOCC5)c34)CC2)CC1		CHEMBL4290222	=	Inhibition	%	-1.0	CHEMBL5408	Homo sapiens	INH	%	-1.0
	18764620	CHEMBL4267109	Inhibition of human TBK1 at 100 nM	B	CN1CCC(c2nc(-c3ccc(F)cc3)c(-c3ccnc(Nc4ccc(N5CCNCC5)cc4)n3)s2)CC1		CHEMBL4288103	<	Inhibition	%	70.0	CHEMBL5408	Homo sapiens	INH	%	70.0
	18764621	CHEMBL4267109	Inhibition of human TBK1 at 100 nM	B	CN1CCC(c2nc(-c3cccc(S(C)(=O)=O)c3)c(-c3ccnc(Nc4ccc(N5CCNCC5)cc4)n3)s2)CC1		CHEMBL4286880	<	Inhibition	%	70.0	CHEMBL5408	Homo sapiens	INH	%	70.0
	18764622	CHEMBL4267109	Inhibition of human TBK1 at 100 nM	B	CN1CCC(c2nc(-c3ccc(F)c(NS(C)(=O)=O)c3)c(-c3ccnc(NCC4CC4)n3)s2)CC1		CHEMBL4286841	<	Inhibition	%	70.0	CHEMBL5408	Homo sapiens	INH	%	70.0
	18781586	CHEMBL4270225	Inhibition of TBK1 (unknown origin) using fluorescein-labelled DRHDSGLDSMKDE as substrate after 1 hr by TR-FRET assay	B	N#Cc1cc(-c2ccnc(Nc3ccc(CN4CCOCC4)nc3)n2)cnc1N1CC[C@H](F)C1	Non standard unit for type	CHEMBL3943587	<	INH	nM	15.0	CHEMBL5408	Homo sapiens	INH	nM	15.0
	18781587	CHEMBL4270225	Inhibition of TBK1 (unknown origin) using fluorescein-labelled DRHDSGLDSMKDE as substrate after 1 hr by TR-FRET assay	B	CN1CCN(Cc2ccc(Nc3nccc(-c4cnc(N5CC[C@H](F)C5)c(C#N)c4)n3)cn2)CC1	Non standard unit for type	CHEMBL4280039	=	INH	nM	17.0	CHEMBL5408	Homo sapiens	INH	nM	17.0
	18781588	CHEMBL4270225	Inhibition of TBK1 (unknown origin) using fluorescein-labelled DRHDSGLDSMKDE as substrate after 1 hr by TR-FRET assay	B	CCN1CCN(Cc2ccc(Nc3nccc(-c4cnc(N5CC[C@@H](F)C5)c(C#N)c4)n3)cn2)CC1	Non standard unit for type	CHEMBL4287265	=	INH	nM	20.0	CHEMBL5408	Homo sapiens	INH	nM	20.0
	18781589	CHEMBL4270225	Inhibition of TBK1 (unknown origin) using fluorescein-labelled DRHDSGLDSMKDE as substrate after 1 hr by TR-FRET assay	B	CCN1CCN(Cc2ccc(Nc3nccc(-c4cnc(N5CC[C@H](F)C5)c(C#N)c4)n3)cn2)CC1	Non standard unit for type	CHEMBL4295211	=	INH	nM	9.0	CHEMBL5408	Homo sapiens	INH	nM	9.0
	18781596	CHEMBL4270225	Inhibition of TBK1 (unknown origin) using fluorescein-labelled DRHDSGLDSMKDE as substrate after 1 hr by TR-FRET assay	B	N#Cc1cc(-c2ccnc(Nc3ccc(NC(=O)CN4CCOCC4)nc3)n2)cnc1N1CC[C@H](F)C1	Non standard unit for type	CHEMBL3919474	<	INH	nM	30.0	CHEMBL5408	Homo sapiens	INH	nM	30.0
	18781610	CHEMBL4270225	Inhibition of TBK1 (unknown origin) using fluorescein-labelled DRHDSGLDSMKDE as substrate after 1 hr by TR-FRET assay	B	N#Cc1cc(-c2ccnc(Nc3ccc(CN4CCNC(=O)C4)nc3)n2)cnc1N1CC[C@H](F)C1	Non standard unit for type	CHEMBL3904385	<	INH	nM	15.0	CHEMBL5408	Homo sapiens	INH	nM	15.0
	18782866	CHEMBL4270732	Inhibition of TBK1 (unknown origin) assessed as residual enzyme activity at 1 uM relative to untreated control	B	Cc1cccc(-c2nn3c(c2-c2ccc(O)cc2)C(C)C(C)(C)C3)n1		CHEMBL4277021	>	Activity	%	80.0	CHEMBL5408	Homo sapiens	Activity	%	80.0
	18811257	CHEMBL4276006	Inhibition of human TBK1 (1 to 657 residues) expressed in Baculovirus infected SF9 insect cells at 1 uM using myelin basic protein as substrate in presence of [gamma-33P]-ATP by radiometric kinase assay	B	CC(C)c1ccc2oc3nc(N)c(C(=O)O)cc3c(=O)c2c1		CHEMBL1096	=	Inhibition	%	50.0	CHEMBL5408	Homo sapiens	INH	%	50.0
	18811258	CHEMBL4276006	Inhibition of human TBK1 (1 to 657 residues) expressed in Baculovirus infected SF9 insect cells at 1 uM using myelin basic protein as substrate in presence of [gamma-33P]-ATP by radiometric kinase assay	B	CN(C)c1ccc2oc3nc(N)c(C(=O)O)cc3c(=O)c2c1		CHEMBL4279379	=	Inhibition	%	53.0	CHEMBL5408	Homo sapiens	INH	%	53.0
	18811259	CHEMBL4276006	Inhibition of human TBK1 (1 to 657 residues) expressed in Baculovirus infected SF9 insect cells at 1 uM using myelin basic protein as substrate in presence of [gamma-33P]-ATP by radiometric kinase assay	B	CN(C)CCCc1ccc2oc3nc(N)c(C(=O)O)cc3c(=O)c2c1		CHEMBL4287613	=	Inhibition	%	35.0	CHEMBL5408	Homo sapiens	INH	%	35.0
	18811260	CHEMBL4276006	Inhibition of human TBK1 (1 to 657 residues) expressed in Baculovirus infected SF9 insect cells at 1 uM using myelin basic protein as substrate in presence of [gamma-33P]-ATP by radiometric kinase assay	B	CN(C)CC#Cc1ccc2oc3nc(N)c(C(=O)O)cc3c(=O)c2c1		CHEMBL4279893	=	Inhibition	%	20.0	CHEMBL5408	Homo sapiens	INH	%	20.0
	18811261	CHEMBL4276006	Inhibition of human TBK1 (1 to 657 residues) expressed in Baculovirus infected SF9 insect cells at 1 uM using myelin basic protein as substrate in presence of [gamma-33P]-ATP by radiometric kinase assay	B	CC(C)CCc1cc2c(=O)c3cc(C(=O)O)c(N)nc3oc2cc1F		CHEMBL4291630	=	Inhibition	%	32.0	CHEMBL5408	Homo sapiens	INH	%	32.0
	18811262	CHEMBL4276006	Inhibition of human TBK1 (1 to 657 residues) expressed in Baculovirus infected SF9 insect cells at 1 uM using myelin basic protein as substrate in presence of [gamma-33P]-ATP by radiometric kinase assay	B	CC(C)(C)CCc1cc2c(=O)c3cc(C(=O)O)c(N)nc3oc2cc1F		CHEMBL4281895	=	Inhibition	%	14.0	CHEMBL5408	Homo sapiens	INH	%	14.0
	18811263	CHEMBL4276006	Inhibition of human TBK1 (1 to 657 residues) expressed in Baculovirus infected SF9 insect cells at 1 uM using myelin basic protein as substrate in presence of [gamma-33P]-ATP by radiometric kinase assay	B	CC(C)(C)/C=C/c1cc2c(=O)c3cc(C(=O)O)c(N)nc3oc2cc1F		CHEMBL4288219	=	Inhibition	%	8.7	CHEMBL5408	Homo sapiens	INH	%	8.7
	18811264	CHEMBL4276006	Inhibition of human TBK1 (1 to 657 residues) expressed in Baculovirus infected SF9 insect cells at 1 uM using myelin basic protein as substrate in presence of [gamma-33P]-ATP by radiometric kinase assay	B	Nc1nc2oc3ccc(C4CCC4)cc3c(=O)c2cc1C(=O)O		CHEMBL4290720	=	Inhibition	%	44.0	CHEMBL5408	Homo sapiens	INH	%	44.0
	18811265	CHEMBL4276006	Inhibition of human TBK1 (1 to 657 residues) expressed in Baculovirus infected SF9 insect cells at 1 uM using myelin basic protein as substrate in presence of [gamma-33P]-ATP by radiometric kinase assay	B	Nc1nc2oc3ccc(C4CCCC4)cc3c(=O)c2cc1C(=O)O		CHEMBL4280074	=	Inhibition	%	67.0	CHEMBL5408	Homo sapiens	INH	%	67.0
	18811266	CHEMBL4276006	Inhibition of human TBK1 (1 to 657 residues) expressed in Baculovirus infected SF9 insect cells at 1 uM using myelin basic protein as substrate in presence of [gamma-33P]-ATP by radiometric kinase assay	B	Nc1nc2oc3ccc(C4CCCCC4)cc3c(=O)c2cc1C(=O)O		CHEMBL4287304	=	Inhibition	%	34.0	CHEMBL5408	Homo sapiens	INH	%	34.0
	18811267	CHEMBL4276006	Inhibition of human TBK1 (1 to 657 residues) expressed in Baculovirus infected SF9 insect cells at 1 uM using myelin basic protein as substrate in presence of [gamma-33P]-ATP by radiometric kinase assay	B	Nc1nc2oc3ccc(C4=CCCCC4)cc3c(=O)c2cc1C(=O)O		CHEMBL4276661	=	Inhibition	%	44.0	CHEMBL5408	Homo sapiens	INH	%	44.0
	18811268	CHEMBL4276006	Inhibition of human TBK1 (1 to 657 residues) expressed in Baculovirus infected SF9 insect cells at 1 uM using myelin basic protein as substrate in presence of [gamma-33P]-ATP by radiometric kinase assay	B	Nc1nc2oc3ccc(C4CCCCCC4)cc3c(=O)c2cc1C(=O)O		CHEMBL4278971	=	Inhibition	%	32.0	CHEMBL5408	Homo sapiens	INH	%	32.0
	18811269	CHEMBL4276006	Inhibition of human TBK1 (1 to 657 residues) expressed in Baculovirus infected SF9 insect cells at 1 uM using myelin basic protein as substrate in presence of [gamma-33P]-ATP by radiometric kinase assay	B	Nc1nc2oc3cc(C4CCCCC4)ccc3c(=O)c2cc1C(=O)O		CHEMBL4286893	=	Inhibition	%	11.0	CHEMBL5408	Homo sapiens	INH	%	11.0
	18811270	CHEMBL4276006	Inhibition of human TBK1 (1 to 657 residues) expressed in Baculovirus infected SF9 insect cells at 1 uM using myelin basic protein as substrate in presence of [gamma-33P]-ATP by radiometric kinase assay	B	Nc1nc2oc3cc(C4=CCCCC4)ccc3c(=O)c2cc1C(=O)O		CHEMBL4294121	=	Inhibition	%	15.0	CHEMBL5408	Homo sapiens	INH	%	15.0
	18811271	CHEMBL4276006	Inhibition of human TBK1 (1 to 657 residues) expressed in Baculovirus infected SF9 insect cells at 1 uM using myelin basic protein as substrate in presence of [gamma-33P]-ATP by radiometric kinase assay	B	Nc1nc2oc3ccc(-c4ccccc4)cc3c(=O)c2cc1C(=O)O		CHEMBL4283536	=	Inhibition	%	34.0	CHEMBL5408	Homo sapiens	INH	%	34.0
	18811272	CHEMBL4276006	Inhibition of human TBK1 (1 to 657 residues) expressed in Baculovirus infected SF9 insect cells at 1 uM using myelin basic protein as substrate in presence of [gamma-33P]-ATP by radiometric kinase assay	B	Nc1nc2oc3ccc(C4CCC(F)(F)CC4)cc3c(=O)c2cc1C(=O)O		CHEMBL4277066	=	Inhibition	%	14.0	CHEMBL5408	Homo sapiens	INH	%	14.0
	18811273	CHEMBL4276006	Inhibition of human TBK1 (1 to 657 residues) expressed in Baculovirus infected SF9 insect cells at 1 uM using myelin basic protein as substrate in presence of [gamma-33P]-ATP by radiometric kinase assay	B	Nc1nc2oc3ccc(C4=CCC(F)(F)CC4)cc3c(=O)c2cc1C(=O)O		CHEMBL4285013	=	Inhibition	%	27.0	CHEMBL5408	Homo sapiens	INH	%	27.0
	18811274	CHEMBL4276006	Inhibition of human TBK1 (1 to 657 residues) expressed in Baculovirus infected SF9 insect cells at 1 uM using myelin basic protein as substrate in presence of [gamma-33P]-ATP by radiometric kinase assay	B	CC1CCC(c2ccc3oc4nc(N)c(C(=O)O)cc4c(=O)c3c2)CC1		CHEMBL4293209	=	Inhibition	%	19.0	CHEMBL5408	Homo sapiens	INH	%	19.0
	18811275	CHEMBL4276006	Inhibition of human TBK1 (1 to 657 residues) expressed in Baculovirus infected SF9 insect cells at 1 uM using myelin basic protein as substrate in presence of [gamma-33P]-ATP by radiometric kinase assay	B	Nc1nc2oc3ccc(C4CCC(C(F)(F)F)CC4)cc3c(=O)c2cc1C(=O)O		CHEMBL4290078	=	Inhibition	%	33.0	CHEMBL5408	Homo sapiens	INH	%	33.0
	18811276	CHEMBL4276006	Inhibition of human TBK1 (1 to 657 residues) expressed in Baculovirus infected SF9 insect cells at 1 uM using myelin basic protein as substrate in presence of [gamma-33P]-ATP by radiometric kinase assay	B	Nc1nc2oc3ccc(C4=CCC(C(F)(F)F)CC4)cc3c(=O)c2cc1C(=O)O		CHEMBL4282863	=	Inhibition	%	4.0	CHEMBL5408	Homo sapiens	INH	%	4.0
	18811277	CHEMBL4276006	Inhibition of human TBK1 (1 to 657 residues) expressed in Baculovirus infected SF9 insect cells at 1 uM using myelin basic protein as substrate in presence of [gamma-33P]-ATP by radiometric kinase assay	B	CC1(C)CCC(c2ccc3oc4nc(N)c(C(=O)O)cc4c(=O)c3c2)CC1		CHEMBL4293465	=	Inhibition	%	15.0	CHEMBL5408	Homo sapiens	INH	%	15.0
	18811278	CHEMBL4276006	Inhibition of human TBK1 (1 to 657 residues) expressed in Baculovirus infected SF9 insect cells at 1 uM using myelin basic protein as substrate in presence of [gamma-33P]-ATP by radiometric kinase assay	B	CC1(C)CC=C(c2ccc3oc4nc(N)c(C(=O)O)cc4c(=O)c3c2)CC1		CHEMBL4286247	=	Inhibition	%	38.0	CHEMBL5408	Homo sapiens	INH	%	38.0
	18811279	CHEMBL4276006	Inhibition of human TBK1 (1 to 657 residues) expressed in Baculovirus infected SF9 insect cells at 1 uM using myelin basic protein as substrate in presence of [gamma-33P]-ATP by radiometric kinase assay	B	Nc1nc2oc3ccc(C4CCC(O)CC4)cc3c(=O)c2cc1C(=O)O		CHEMBL4278331	=	Inhibition	%	37.0	CHEMBL5408	Homo sapiens	INH	%	37.0
	18811280	CHEMBL4276006	Inhibition of human TBK1 (1 to 657 residues) expressed in Baculovirus infected SF9 insect cells at 1 uM using myelin basic protein as substrate in presence of [gamma-33P]-ATP by radiometric kinase assay	B	Nc1nc2oc3ccc(C4=CCC(O)CC4)cc3c(=O)c2cc1C(=O)O		CHEMBL4289666	=	Inhibition	%	27.0	CHEMBL5408	Homo sapiens	INH	%	27.0
	18811281	CHEMBL4276006	Inhibition of human TBK1 (1 to 657 residues) expressed in Baculovirus infected SF9 insect cells at 1 uM using myelin basic protein as substrate in presence of [gamma-33P]-ATP by radiometric kinase assay	B	Nc1nc2oc3ccc(C4CCC(=O)CC4)cc3c(=O)c2cc1C(=O)O		CHEMBL4281788	=	Inhibition	%	52.0	CHEMBL5408	Homo sapiens	INH	%	52.0
	18811282	CHEMBL4276006	Inhibition of human TBK1 (1 to 657 residues) expressed in Baculovirus infected SF9 insect cells at 1 uM using myelin basic protein as substrate in presence of [gamma-33P]-ATP by radiometric kinase assay	B	Nc1nc2oc3ccc(C4CCC5(CC4)OCCO5)cc3c(=O)c2cc1C(=O)O		CHEMBL4285588	=	Inhibition	%	63.0	CHEMBL5408	Homo sapiens	INH	%	63.0
	18811283	CHEMBL4276006	Inhibition of human TBK1 (1 to 657 residues) expressed in Baculovirus infected SF9 insect cells at 1 uM using myelin basic protein as substrate in presence of [gamma-33P]-ATP by radiometric kinase assay	B	Nc1nc2oc3ccc(C4=CCC5(CC4)OCCO5)cc3c(=O)c2cc1C(=O)O		CHEMBL4278727	=	Inhibition	%	54.0	CHEMBL5408	Homo sapiens	INH	%	54.0
	18811284	CHEMBL4276006	Inhibition of human TBK1 (1 to 657 residues) expressed in Baculovirus infected SF9 insect cells at 1 uM using myelin basic protein as substrate in presence of [gamma-33P]-ATP by radiometric kinase assay	B	Cl.Nc1nc2oc3ccc(C4CCNCC4)cc3c(=O)c2cc1C(=O)O		CHEMBL4278266	=	Inhibition	%	12.0	CHEMBL5408	Homo sapiens	INH	%	12.0
	18811285	CHEMBL4276006	Inhibition of human TBK1 (1 to 657 residues) expressed in Baculovirus infected SF9 insect cells at 1 uM using myelin basic protein as substrate in presence of [gamma-33P]-ATP by radiometric kinase assay	B	Nc1nc2oc3ccc(C4=CCNCC4)cc3c(=O)c2cc1C(=O)O		CHEMBL4286183	=	Inhibition	%	22.0	CHEMBL5408	Homo sapiens	INH	%	22.0
	18811286	CHEMBL4276006	Inhibition of human TBK1 (1 to 657 residues) expressed in Baculovirus infected SF9 insect cells at 1 uM using myelin basic protein as substrate in presence of [gamma-33P]-ATP by radiometric kinase assay	B	Nc1nc2oc3ccc(C4CCN(C=O)CC4)cc3c(=O)c2cc1C(=O)O		CHEMBL4281733	=	Inhibition	%	68.0	CHEMBL5408	Homo sapiens	INH	%	68.0
	18811287	CHEMBL4276006	Inhibition of human TBK1 (1 to 657 residues) expressed in Baculovirus infected SF9 insect cells at 1 uM using myelin basic protein as substrate in presence of [gamma-33P]-ATP by radiometric kinase assay	B	CC(=O)N1CCC(c2ccc3oc4nc(N)c(C(=O)O)cc4c(=O)c3c2)CC1		CHEMBL4289613	=	Inhibition	%	66.0	CHEMBL5408	Homo sapiens	INH	%	66.0
	18811288	CHEMBL4276006	Inhibition of human TBK1 (1 to 657 residues) expressed in Baculovirus infected SF9 insect cells at 1 uM using myelin basic protein as substrate in presence of [gamma-33P]-ATP by radiometric kinase assay	B	Nc1nc2oc3ccc(C4CCOCC4)cc3c(=O)c2cc1C(=O)O		CHEMBL4290024	=	Inhibition	%	46.0	CHEMBL5408	Homo sapiens	INH	%	46.0
	18811289	CHEMBL4276006	Inhibition of human TBK1 (1 to 657 residues) expressed in Baculovirus infected SF9 insect cells at 1 uM using myelin basic protein as substrate in presence of [gamma-33P]-ATP by radiometric kinase assay	B	Nc1nc2oc3ccc(C4=CCOCC4)cc3c(=O)c2cc1C(=O)O		CHEMBL4279336	=	Inhibition	%	46.0	CHEMBL5408	Homo sapiens	INH	%	46.0
	18811290	CHEMBL4276006	Inhibition of human TBK1 (1 to 657 residues) expressed in Baculovirus infected SF9 insect cells at 1 uM using myelin basic protein as substrate in presence of [gamma-33P]-ATP by radiometric kinase assay	B	Nc1nc2oc3ccc(C4CCSCC4)cc3c(=O)c2cc1C(=O)O		CHEMBL4293403	=	Inhibition	%	46.0	CHEMBL5408	Homo sapiens	INH	%	46.0
	18811291	CHEMBL4276006	Inhibition of human TBK1 (1 to 657 residues) expressed in Baculovirus infected SF9 insect cells at 1 uM using myelin basic protein as substrate in presence of [gamma-33P]-ATP by radiometric kinase assay	B	Nc1nc2oc3ccc(C4CCS(=O)(=O)CC4)cc3c(=O)c2cc1C(=O)O		CHEMBL4282790	=	Inhibition	%	57.0	CHEMBL5408	Homo sapiens	INH	%	57.0
	18811292	CHEMBL4276006	Inhibition of human TBK1 (1 to 657 residues) expressed in Baculovirus infected SF9 insect cells at 1 uM using myelin basic protein as substrate in presence of [gamma-33P]-ATP by radiometric kinase assay	B	Nc1nc2oc3ccc(N4CCOCC4)cc3c(=O)c2cc1C(=O)O		CHEMBL4291939	=	Inhibition	%	32.0	CHEMBL5408	Homo sapiens	INH	%	32.0
	18811293	CHEMBL4276006	Inhibition of human TBK1 (1 to 657 residues) expressed in Baculovirus infected SF9 insect cells at 1 uM using myelin basic protein as substrate in presence of [gamma-33P]-ATP by radiometric kinase assay	B	Nc1nc2oc3cc(F)c(C4CCCCC4)cc3c(=O)c2cc1C(=O)O		CHEMBL4281322	=	Inhibition	%	26.0	CHEMBL5408	Homo sapiens	INH	%	26.0
	18811294	CHEMBL4276006	Inhibition of human TBK1 (1 to 657 residues) expressed in Baculovirus infected SF9 insect cells at 1 uM using myelin basic protein as substrate in presence of [gamma-33P]-ATP by radiometric kinase assay	B	Nc1nc2oc3cc(F)c(C4=CCCCC4)cc3c(=O)c2cc1C(=O)O		CHEMBL4285590	=	Inhibition	%	10.0	CHEMBL5408	Homo sapiens	INH	%	10.0
	18811295	CHEMBL4276006	Inhibition of human TBK1 (1 to 657 residues) expressed in Baculovirus infected SF9 insect cells at 1 uM using myelin basic protein as substrate in presence of [gamma-33P]-ATP by radiometric kinase assay	B	Nc1nc2oc3cnc(C4CCCCC4)cc3c(=O)c2cc1C(=O)O		CHEMBL4277647	=	Inhibition	%	14.0	CHEMBL5408	Homo sapiens	INH	%	14.0
	18811296	CHEMBL4276006	Inhibition of human TBK1 (1 to 657 residues) expressed in Baculovirus infected SF9 insect cells at 1 uM using myelin basic protein as substrate in presence of [gamma-33P]-ATP by radiometric kinase assay	B	Nc1nc2oc3cnc(C4=CCCCC4)cc3c(=O)c2cc1C(=O)O		CHEMBL4282158	=	Inhibition	%	-1.2	CHEMBL5408	Homo sapiens	INH	%	-1.2
	18811297	CHEMBL4276006	Inhibition of human TBK1 (1 to 657 residues) expressed in Baculovirus infected SF9 insect cells at 1 uM using myelin basic protein as substrate in presence of [gamma-33P]-ATP by radiometric kinase assay	B	Nc1nc2oc3ccc(CCC4CC4)cc3c(=O)c2cc1C(=O)O		CHEMBL4292770	=	Inhibition	%	31.0	CHEMBL5408	Homo sapiens	INH	%	31.0
	18811298	CHEMBL4276006	Inhibition of human TBK1 (1 to 657 residues) expressed in Baculovirus infected SF9 insect cells at 1 uM using myelin basic protein as substrate in presence of [gamma-33P]-ATP by radiometric kinase assay	B	Nc1nc2oc3ccc(/C=C/C4CC4)cc3c(=O)c2cc1C(=O)O		CHEMBL4292376	=	Inhibition	%	29.0	CHEMBL5408	Homo sapiens	INH	%	29.0
	18811299	CHEMBL4276006	Inhibition of human TBK1 (1 to 657 residues) expressed in Baculovirus infected SF9 insect cells at 1 uM using myelin basic protein as substrate in presence of [gamma-33P]-ATP by radiometric kinase assay	B	Nc1nc2oc3ccc(C#CC4CC4)cc3c(=O)c2cc1C(=O)O		CHEMBL4284481	=	Inhibition	%	11.0	CHEMBL5408	Homo sapiens	INH	%	11.0
	18811300	CHEMBL4276006	Inhibition of human TBK1 (1 to 657 residues) expressed in Baculovirus infected SF9 insect cells at 1 uM using myelin basic protein as substrate in presence of [gamma-33P]-ATP by radiometric kinase assay	B	Nc1nc2oc3ccc(CCC4CCC4)cc3c(=O)c2cc1C(=O)O		CHEMBL4288976	=	Inhibition	%	26.0	CHEMBL5408	Homo sapiens	INH	%	26.0
	18811301	CHEMBL4276006	Inhibition of human TBK1 (1 to 657 residues) expressed in Baculovirus infected SF9 insect cells at 1 uM using myelin basic protein as substrate in presence of [gamma-33P]-ATP by radiometric kinase assay	B	Nc1nc2oc3ccc(CCC4CCCC4)cc3c(=O)c2cc1C(=O)O		CHEMBL4281068	=	Inhibition	%	3.2	CHEMBL5408	Homo sapiens	INH	%	3.2
	18811302	CHEMBL4276006	Inhibition of human TBK1 (1 to 657 residues) expressed in Baculovirus infected SF9 insect cells at 1 uM using myelin basic protein as substrate in presence of [gamma-33P]-ATP by radiometric kinase assay	B	Nc1nc2oc3ccc(/C=C/C4CCCC4)cc3c(=O)c2cc1C(=O)O		CHEMBL4282053	=	Inhibition	%	44.0	CHEMBL5408	Homo sapiens	INH	%	44.0
	18811303	CHEMBL4276006	Inhibition of human TBK1 (1 to 657 residues) expressed in Baculovirus infected SF9 insect cells at 1 uM using myelin basic protein as substrate in presence of [gamma-33P]-ATP by radiometric kinase assay	B	Nc1nc2oc3cc(CCC4CCCC4)ccc3c(=O)c2cc1C(=O)O		CHEMBL4290240	=	Inhibition	%	4.7	CHEMBL5408	Homo sapiens	INH	%	4.7
	18811304	CHEMBL4276006	Inhibition of human TBK1 (1 to 657 residues) expressed in Baculovirus infected SF9 insect cells at 1 uM using myelin basic protein as substrate in presence of [gamma-33P]-ATP by radiometric kinase assay	B	Nc1nc2oc3cc(/C=C/C4CCCC4)ccc3c(=O)c2cc1C(=O)O		CHEMBL4283708	=	Inhibition	%	8.8	CHEMBL5408	Homo sapiens	INH	%	8.8
	18811305	CHEMBL4276006	Inhibition of human TBK1 (1 to 657 residues) expressed in Baculovirus infected SF9 insect cells at 1 uM using myelin basic protein as substrate in presence of [gamma-33P]-ATP by radiometric kinase assay	B	Nc1nc2oc3cc(F)c(CCC4CCCC4)cc3c(=O)c2cc1C(=O)O		CHEMBL4291565	=	Inhibition	%	-4.4	CHEMBL5408	Homo sapiens	INH	%	-4.4
	18811306	CHEMBL4276006	Inhibition of human TBK1 (1 to 657 residues) expressed in Baculovirus infected SF9 insect cells at 1 uM using myelin basic protein as substrate in presence of [gamma-33P]-ATP by radiometric kinase assay	B	Nc1nc2oc3cc(F)c(/C=C/C4CCCC4)cc3c(=O)c2cc1C(=O)O		CHEMBL4280251	=	Inhibition	%	2.9	CHEMBL5408	Homo sapiens	INH	%	2.9
	18811307	CHEMBL4276006	Inhibition of human TBK1 (1 to 657 residues) expressed in Baculovirus infected SF9 insect cells at 1 uM using myelin basic protein as substrate in presence of [gamma-33P]-ATP by radiometric kinase assay	B	Nc1nc2oc3ccc(CCC4CCCCC4)cc3c(=O)c2cc1C(=O)O		CHEMBL4288153	=	Inhibition	%	-1.9	CHEMBL5408	Homo sapiens	INH	%	-1.9
	18811308	CHEMBL4276006	Inhibition of human TBK1 (1 to 657 residues) expressed in Baculovirus infected SF9 insect cells at 1 uM using myelin basic protein as substrate in presence of [gamma-33P]-ATP by radiometric kinase assay	B	Nc1nc2oc3ccc(/C=C/C4CCCCC4)cc3c(=O)c2cc1C(=O)O		CHEMBL4276820	=	Inhibition	%	13.0	CHEMBL5408	Homo sapiens	INH	%	13.0
	18811309	CHEMBL4276006	Inhibition of human TBK1 (1 to 657 residues) expressed in Baculovirus infected SF9 insect cells at 1 uM using myelin basic protein as substrate in presence of [gamma-33P]-ATP by radiometric kinase assay	B	Nc1nc2oc3ccc(C4CCCCC4)cc3c(=O)c2cc1-c1nn[nH]n1		CHEMBL4284757	=	Inhibition	%	64.0	CHEMBL5408	Homo sapiens	INH	%	64.0
	18811310	CHEMBL4276006	Inhibition of human TBK1 (1 to 657 residues) expressed in Baculovirus infected SF9 insect cells at 1 uM using myelin basic protein as substrate in presence of [gamma-33P]-ATP by radiometric kinase assay	B	Nc1nc2oc3ccc(C4=CCCCC4)cc3c(=O)c2cc1-c1nn[nH]n1		CHEMBL4291966	=	Inhibition	%	52.0	CHEMBL5408	Homo sapiens	INH	%	52.0
	18811311	CHEMBL4276006	Inhibition of human TBK1 (1 to 657 residues) expressed in Baculovirus infected SF9 insect cells at 1 uM using myelin basic protein as substrate in presence of [gamma-33P]-ATP by radiometric kinase assay	B	CN(C)c1ccc2oc3nc(N)c(-c4nn[nH]n4)cc3c(=O)c2c1		CHEMBL4281345	=	Inhibition	%	33.0	CHEMBL5408	Homo sapiens	INH	%	33.0
	18811312	CHEMBL4276006	Inhibition of human TBK1 (1 to 657 residues) expressed in Baculovirus infected SF9 insect cells at 1 uM using myelin basic protein as substrate in presence of [gamma-33P]-ATP by radiometric kinase assay	B	Nc1nc2oc3ccc(N4CCOCC4)cc3c(=O)c2cc1-c1nn[nH]n1		CHEMBL4288542	=	Inhibition	%	34.0	CHEMBL5408	Homo sapiens	INH	%	34.0
	18811313	CHEMBL4276006	Inhibition of human TBK1 (1 to 657 residues) expressed in Baculovirus infected SF9 insect cells at 1 uM using myelin basic protein as substrate in presence of [gamma-33P]-ATP by radiometric kinase assay	B	Nc1nc2oc3ccc(N4CCOCC4)cc3c(=O)c2cc1C(=O)Nc1nn[nH]n1		CHEMBL4277887	=	Inhibition	%	49.0	CHEMBL5408	Homo sapiens	INH	%	49.0
	18811314	CHEMBL4276010	Inhibition of human TBK1 (1 to 657 residues) expressed in Baculovirus infected SF9 insect cells using myelin basic protein as substrate in presence of [gamma-33P]-ATP by radiometric kinase assay	B	CC(C)c1ccc2oc3nc(N)c(C(=O)O)cc3c(=O)c2c1		CHEMBL1096	=	IC50	nM	850.0	CHEMBL5408	Homo sapiens	IC50	uM	0.85
	18811315	CHEMBL4276010	Inhibition of human TBK1 (1 to 657 residues) expressed in Baculovirus infected SF9 insect cells using myelin basic protein as substrate in presence of [gamma-33P]-ATP by radiometric kinase assay	B	C=C(C)c1ccc2oc3nc(N)c(C(=O)O)cc3c(=O)c2c1		CHEMBL4277614	=	IC50	nM	1300.0	CHEMBL5408	Homo sapiens	IC50	uM	1.3
	18811316	CHEMBL4276010	Inhibition of human TBK1 (1 to 657 residues) expressed in Baculovirus infected SF9 insect cells using myelin basic protein as substrate in presence of [gamma-33P]-ATP by radiometric kinase assay	B	CC(C)c1ccc2c(=O)c3cc(C(=O)O)c(N)nc3oc2c1		CHEMBL4285560	=	IC50	nM	300.0	CHEMBL5408	Homo sapiens	IC50	uM	0.3
	18811317	CHEMBL4276010	Inhibition of human TBK1 (1 to 657 residues) expressed in Baculovirus infected SF9 insect cells using myelin basic protein as substrate in presence of [gamma-33P]-ATP by radiometric kinase assay	B	C=C(C)c1ccc2c(=O)c3cc(C(=O)O)c(N)nc3oc2c1		CHEMBL4281039	=	IC50	nM	2300.0	CHEMBL5408	Homo sapiens	IC50	uM	2.3
	18811318	CHEMBL4276010	Inhibition of human TBK1 (1 to 657 residues) expressed in Baculovirus infected SF9 insect cells using myelin basic protein as substrate in presence of [gamma-33P]-ATP by radiometric kinase assay	B	CC(C)c1cccc2oc3nc(N)c(C(=O)O)cc3c(=O)c12		CHEMBL4288939	=	IC50	nM	1100.0	CHEMBL5408	Homo sapiens	IC50	uM	1.1
	18811319	CHEMBL4276010	Inhibition of human TBK1 (1 to 657 residues) expressed in Baculovirus infected SF9 insect cells using myelin basic protein as substrate in presence of [gamma-33P]-ATP by radiometric kinase assay	B	CC(C)c1cc2c(=O)c3cc(C(=O)O)c(N)nc3oc2cc1F		CHEMBL4284443	=	IC50	nM	400.0	CHEMBL5408	Homo sapiens	IC50	uM	0.4
	18811320	CHEMBL4276010	Inhibition of human TBK1 (1 to 657 residues) expressed in Baculovirus infected SF9 insect cells using myelin basic protein as substrate in presence of [gamma-33P]-ATP by radiometric kinase assay	B	C=C(C)c1cc2c(=O)c3cc(C(=O)O)c(N)nc3oc2cc1F		CHEMBL4292344	=	IC50	nM	790.0	CHEMBL5408	Homo sapiens	IC50	uM	0.79
	18811321	CHEMBL4276010	Inhibition of human TBK1 (1 to 657 residues) expressed in Baculovirus infected SF9 insect cells using myelin basic protein as substrate in presence of [gamma-33P]-ATP by radiometric kinase assay	B	CC(C)c1cc2c(=O)c3cc(C(=O)O)c(N)nc3oc2cn1		CHEMBL4287847	=	IC50	nM	570.0	CHEMBL5408	Homo sapiens	IC50	uM	0.57
	18811322	CHEMBL4276010	Inhibition of human TBK1 (1 to 657 residues) expressed in Baculovirus infected SF9 insect cells using myelin basic protein as substrate in presence of [gamma-33P]-ATP by radiometric kinase assay	B	C=C(C)c1cc2c(=O)c3cc(C(=O)O)c(N)nc3oc2cn1		CHEMBL4277195	=	IC50	nM	2000.0	CHEMBL5408	Homo sapiens	IC50	uM	2.0
	18811323	CHEMBL4276010	Inhibition of human TBK1 (1 to 657 residues) expressed in Baculovirus infected SF9 insect cells using myelin basic protein as substrate in presence of [gamma-33P]-ATP by radiometric kinase assay	B	CN(C)c1ccc2oc3nc(N)c(C(=O)O)cc3c(=O)c2c1		CHEMBL4279379	=	IC50	nM	400.0	CHEMBL5408	Homo sapiens	IC50	uM	0.4
	18811324	CHEMBL4276010	Inhibition of human TBK1 (1 to 657 residues) expressed in Baculovirus infected SF9 insect cells using myelin basic protein as substrate in presence of [gamma-33P]-ATP by radiometric kinase assay	B	CC(C)Cc1ccc2oc3nc(N)c(C(=O)O)cc3c(=O)c2c1		CHEMBL4290544	=	IC50	nM	550.0	CHEMBL5408	Homo sapiens	IC50	uM	0.55
	18811325	CHEMBL4276010	Inhibition of human TBK1 (1 to 657 residues) expressed in Baculovirus infected SF9 insect cells using myelin basic protein as substrate in presence of [gamma-33P]-ATP by radiometric kinase assay	B	CC(C)CCc1ccc2oc3nc(N)c(C(=O)O)cc3c(=O)c2c1		CHEMBL4295050	=	IC50	nM	830.0	CHEMBL5408	Homo sapiens	IC50	uM	0.83
	18811326	CHEMBL4276010	Inhibition of human TBK1 (1 to 657 residues) expressed in Baculovirus infected SF9 insect cells using myelin basic protein as substrate in presence of [gamma-33P]-ATP by radiometric kinase assay	B	CC(C)C#Cc1ccc2oc3nc(N)c(C(=O)O)cc3c(=O)c2c1		CHEMBL4287123	=	IC50	nM	12000.0	CHEMBL5408	Homo sapiens	IC50	uM	12.0
	18811327	CHEMBL4276010	Inhibition of human TBK1 (1 to 657 residues) expressed in Baculovirus infected SF9 insect cells using myelin basic protein as substrate in presence of [gamma-33P]-ATP by radiometric kinase assay	B	Nc1nc2oc3ccc(C4CC4)cc3c(=O)c2cc1C(=O)O		CHEMBL4278101	=	IC50	nM	2300.0	CHEMBL5408	Homo sapiens	IC50	uM	2.3
	18811328	CHEMBL4276010	Inhibition of human TBK1 (1 to 657 residues) expressed in Baculovirus infected SF9 insect cells using myelin basic protein as substrate in presence of [gamma-33P]-ATP by radiometric kinase assay	B	Nc1nc2oc3ccc(C4CCC4)cc3c(=O)c2cc1C(=O)O		CHEMBL4290720	=	IC50	nM	4600.0	CHEMBL5408	Homo sapiens	IC50	uM	4.6
	18811329	CHEMBL4276010	Inhibition of human TBK1 (1 to 657 residues) expressed in Baculovirus infected SF9 insect cells using myelin basic protein as substrate in presence of [gamma-33P]-ATP by radiometric kinase assay	B	Nc1nc2oc3ccc(C4CCCC4)cc3c(=O)c2cc1C(=O)O		CHEMBL4280074	=	IC50	nM	1800.0	CHEMBL5408	Homo sapiens	IC50	uM	1.8
	18811330	CHEMBL4276010	Inhibition of human TBK1 (1 to 657 residues) expressed in Baculovirus infected SF9 insect cells using myelin basic protein as substrate in presence of [gamma-33P]-ATP by radiometric kinase assay	B	Nc1nc2oc3ccc(C4CCCCC4)cc3c(=O)c2cc1C(=O)O		CHEMBL4287304	=	IC50	nM	1900.0	CHEMBL5408	Homo sapiens	IC50	uM	1.9
	18811331	CHEMBL4276010	Inhibition of human TBK1 (1 to 657 residues) expressed in Baculovirus infected SF9 insect cells using myelin basic protein as substrate in presence of [gamma-33P]-ATP by radiometric kinase assay	B	Nc1nc2oc3ccc(C4=CCCCC4)cc3c(=O)c2cc1C(=O)O		CHEMBL4276661	=	IC50	nM	1700.0	CHEMBL5408	Homo sapiens	IC50	uM	1.7
	18811332	CHEMBL4276010	Inhibition of human TBK1 (1 to 657 residues) expressed in Baculovirus infected SF9 insect cells using myelin basic protein as substrate in presence of [gamma-33P]-ATP by radiometric kinase assay	B	Nc1nc2oc3ccc(C4CCC(=O)CC4)cc3c(=O)c2cc1C(=O)O		CHEMBL4281788	=	IC50	nM	450.0	CHEMBL5408	Homo sapiens	IC50	uM	0.45
	18811333	CHEMBL4276010	Inhibition of human TBK1 (1 to 657 residues) expressed in Baculovirus infected SF9 insect cells using myelin basic protein as substrate in presence of [gamma-33P]-ATP by radiometric kinase assay	B	Nc1nc2oc3ccc(C4CCC5(CC4)OCCO5)cc3c(=O)c2cc1C(=O)O		CHEMBL4285588	=	IC50	nM	440.0	CHEMBL5408	Homo sapiens	IC50	uM	0.44
	18811334	CHEMBL4276010	Inhibition of human TBK1 (1 to 657 residues) expressed in Baculovirus infected SF9 insect cells using myelin basic protein as substrate in presence of [gamma-33P]-ATP by radiometric kinase assay	B	Nc1nc2oc3ccc(C4=CCC5(CC4)OCCO5)cc3c(=O)c2cc1C(=O)O		CHEMBL4278727	=	IC50	nM	750.0	CHEMBL5408	Homo sapiens	IC50	uM	0.75
	18811335	CHEMBL4276010	Inhibition of human TBK1 (1 to 657 residues) expressed in Baculovirus infected SF9 insect cells using myelin basic protein as substrate in presence of [gamma-33P]-ATP by radiometric kinase assay	B	Nc1nc2oc3ccc(C4CCN(C=O)CC4)cc3c(=O)c2cc1C(=O)O		CHEMBL4281733	=	IC50	nM	490.0	CHEMBL5408	Homo sapiens	IC50	uM	0.49
	18811336	CHEMBL4276010	Inhibition of human TBK1 (1 to 657 residues) expressed in Baculovirus infected SF9 insect cells using myelin basic protein as substrate in presence of [gamma-33P]-ATP by radiometric kinase assay	B	CC(=O)N1CCC(c2ccc3oc4nc(N)c(C(=O)O)cc4c(=O)c3c2)CC1		CHEMBL4289613	=	IC50	nM	270.0	CHEMBL5408	Homo sapiens	IC50	uM	0.27
	18811337	CHEMBL4276010	Inhibition of human TBK1 (1 to 657 residues) expressed in Baculovirus infected SF9 insect cells using myelin basic protein as substrate in presence of [gamma-33P]-ATP by radiometric kinase assay	B	Nc1nc2oc3ccc(C4CCOCC4)cc3c(=O)c2cc1C(=O)O		CHEMBL4290024	=	IC50	nM	750.0	CHEMBL5408	Homo sapiens	IC50	uM	0.75
	18811338	CHEMBL4276010	Inhibition of human TBK1 (1 to 657 residues) expressed in Baculovirus infected SF9 insect cells using myelin basic protein as substrate in presence of [gamma-33P]-ATP by radiometric kinase assay	B	Nc1nc2oc3ccc(C4=CCOCC4)cc3c(=O)c2cc1C(=O)O		CHEMBL4279336	=	IC50	nM	860.0	CHEMBL5408	Homo sapiens	IC50	uM	0.86
	18811339	CHEMBL4276010	Inhibition of human TBK1 (1 to 657 residues) expressed in Baculovirus infected SF9 insect cells using myelin basic protein as substrate in presence of [gamma-33P]-ATP by radiometric kinase assay	B	Nc1nc2oc3ccc(C4CCSCC4)cc3c(=O)c2cc1C(=O)O		CHEMBL4293403	=	IC50	nM	290.0	CHEMBL5408	Homo sapiens	IC50	uM	0.29
	18811340	CHEMBL4276010	Inhibition of human TBK1 (1 to 657 residues) expressed in Baculovirus infected SF9 insect cells using myelin basic protein as substrate in presence of [gamma-33P]-ATP by radiometric kinase assay	B	Nc1nc2oc3ccc(C4CCS(=O)(=O)CC4)cc3c(=O)c2cc1C(=O)O		CHEMBL4282790	=	IC50	nM	830.0	CHEMBL5408	Homo sapiens	IC50	uM	0.83
	18811341	CHEMBL4276010	Inhibition of human TBK1 (1 to 657 residues) expressed in Baculovirus infected SF9 insect cells using myelin basic protein as substrate in presence of [gamma-33P]-ATP by radiometric kinase assay	B	Nc1nc2oc3ccc(C4CCCCC4)cc3c(=O)c2cc1-c1nn[nH]n1		CHEMBL4284757	=	IC50	nM	1900.0	CHEMBL5408	Homo sapiens	IC50	uM	1.9
	18811342	CHEMBL4276010	Inhibition of human TBK1 (1 to 657 residues) expressed in Baculovirus infected SF9 insect cells using myelin basic protein as substrate in presence of [gamma-33P]-ATP by radiometric kinase assay	B	Nc1nc2oc3ccc(C4=CCCCC4)cc3c(=O)c2cc1-c1nn[nH]n1		CHEMBL4291966	=	IC50	nM	490.0	CHEMBL5408	Homo sapiens	IC50	uM	0.49
	18811343	CHEMBL4276010	Inhibition of human TBK1 (1 to 657 residues) expressed in Baculovirus infected SF9 insect cells using myelin basic protein as substrate in presence of [gamma-33P]-ATP by radiometric kinase assay	B	CN(C)c1ccc2oc3nc(N)c(-c4nn[nH]n4)cc3c(=O)c2c1		CHEMBL4281345	=	IC50	nM	530.0	CHEMBL5408	Homo sapiens	IC50	uM	0.53
	18811344	CHEMBL4276010	Inhibition of human TBK1 (1 to 657 residues) expressed in Baculovirus infected SF9 insect cells using myelin basic protein as substrate in presence of [gamma-33P]-ATP by radiometric kinase assay	B	Nc1nc2oc3ccc(N4CCOCC4)cc3c(=O)c2cc1-c1nn[nH]n1		CHEMBL4288542	=	IC50	nM	540.0	CHEMBL5408	Homo sapiens	IC50	uM	0.54
	18811345	CHEMBL4276010	Inhibition of human TBK1 (1 to 657 residues) expressed in Baculovirus infected SF9 insect cells using myelin basic protein as substrate in presence of [gamma-33P]-ATP by radiometric kinase assay	B	Nc1nc2oc3ccc(N4CCOCC4)cc3c(=O)c2cc1C(=O)Nc1nn[nH]n1		CHEMBL4277887	=	IC50	nM	760.0	CHEMBL5408	Homo sapiens	IC50	uM	0.76
	18811346	CHEMBL4276010	Inhibition of human TBK1 (1 to 657 residues) expressed in Baculovirus infected SF9 insect cells using myelin basic protein as substrate in presence of [gamma-33P]-ATP by radiometric kinase assay	B	CC(C)c1ccc2oc3nc(N)c(C(=O)O)cc3c(=O)c2c1		CHEMBL1096	=	IC50	nM	851.14	CHEMBL5408	Homo sapiens	pIC50		6.07
	18811347	CHEMBL4276010	Inhibition of human TBK1 (1 to 657 residues) expressed in Baculovirus infected SF9 insect cells using myelin basic protein as substrate in presence of [gamma-33P]-ATP by radiometric kinase assay	B	C=C(C)c1ccc2oc3nc(N)c(C(=O)O)cc3c(=O)c2c1		CHEMBL4277614	=	IC50	nM	1348.96	CHEMBL5408	Homo sapiens	pIC50		5.87
	18811348	CHEMBL4276010	Inhibition of human TBK1 (1 to 657 residues) expressed in Baculovirus infected SF9 insect cells using myelin basic protein as substrate in presence of [gamma-33P]-ATP by radiometric kinase assay	B	CC(C)c1ccc2c(=O)c3cc(C(=O)O)c(N)nc3oc2c1		CHEMBL4285560	=	IC50	nM	302.0	CHEMBL5408	Homo sapiens	pIC50		6.52
	18811349	CHEMBL4276010	Inhibition of human TBK1 (1 to 657 residues) expressed in Baculovirus infected SF9 insect cells using myelin basic protein as substrate in presence of [gamma-33P]-ATP by radiometric kinase assay	B	C=C(C)c1ccc2c(=O)c3cc(C(=O)O)c(N)nc3oc2c1		CHEMBL4281039	=	IC50	nM	2290.87	CHEMBL5408	Homo sapiens	pIC50		5.64
	18811350	CHEMBL4276010	Inhibition of human TBK1 (1 to 657 residues) expressed in Baculovirus infected SF9 insect cells using myelin basic protein as substrate in presence of [gamma-33P]-ATP by radiometric kinase assay	B	CC(C)c1cccc2oc3nc(N)c(C(=O)O)cc3c(=O)c12		CHEMBL4288939	=	IC50	nM	1096.48	CHEMBL5408	Homo sapiens	pIC50		5.96
	18811351	CHEMBL4276010	Inhibition of human TBK1 (1 to 657 residues) expressed in Baculovirus infected SF9 insect cells using myelin basic protein as substrate in presence of [gamma-33P]-ATP by radiometric kinase assay	B	CC(C)c1cc2c(=O)c3cc(C(=O)O)c(N)nc3oc2cc1F		CHEMBL4284443	=	IC50	nM	398.11	CHEMBL5408	Homo sapiens	pIC50		6.4
	18811352	CHEMBL4276010	Inhibition of human TBK1 (1 to 657 residues) expressed in Baculovirus infected SF9 insect cells using myelin basic protein as substrate in presence of [gamma-33P]-ATP by radiometric kinase assay	B	C=C(C)c1cc2c(=O)c3cc(C(=O)O)c(N)nc3oc2cc1F		CHEMBL4292344	=	IC50	nM	794.33	CHEMBL5408	Homo sapiens	pIC50		6.1
	18811353	CHEMBL4276010	Inhibition of human TBK1 (1 to 657 residues) expressed in Baculovirus infected SF9 insect cells using myelin basic protein as substrate in presence of [gamma-33P]-ATP by radiometric kinase assay	B	CC(C)c1cc2c(=O)c3cc(C(=O)O)c(N)nc3oc2cn1		CHEMBL4287847	=	IC50	nM	85113.8	CHEMBL5408	Homo sapiens	pIC50		4.07
	18811354	CHEMBL4276010	Inhibition of human TBK1 (1 to 657 residues) expressed in Baculovirus infected SF9 insect cells using myelin basic protein as substrate in presence of [gamma-33P]-ATP by radiometric kinase assay	B	C=C(C)c1cc2c(=O)c3cc(C(=O)O)c(N)nc3oc2cn1	Outside typical range	CHEMBL4277195	=	IC50	nM	524807.46	CHEMBL5408	Homo sapiens	pIC50		3.28
	18811355	CHEMBL4276010	Inhibition of human TBK1 (1 to 657 residues) expressed in Baculovirus infected SF9 insect cells using myelin basic protein as substrate in presence of [gamma-33P]-ATP by radiometric kinase assay	B	CN(C)c1ccc2oc3nc(N)c(C(=O)O)cc3c(=O)c2c1		CHEMBL4279379	=	IC50	nM	95499.26	CHEMBL5408	Homo sapiens	pIC50		4.02
	18811356	CHEMBL4276010	Inhibition of human TBK1 (1 to 657 residues) expressed in Baculovirus infected SF9 insect cells using myelin basic protein as substrate in presence of [gamma-33P]-ATP by radiometric kinase assay	B	CC(C)Cc1ccc2oc3nc(N)c(C(=O)O)cc3c(=O)c2c1	Outside typical range	CHEMBL4290544	=	IC50	nM	2818382.93	CHEMBL5408	Homo sapiens	pIC50		2.55
	18811357	CHEMBL4276010	Inhibition of human TBK1 (1 to 657 residues) expressed in Baculovirus infected SF9 insect cells using myelin basic protein as substrate in presence of [gamma-33P]-ATP by radiometric kinase assay	B	CC(C)CCc1ccc2oc3nc(N)c(C(=O)O)cc3c(=O)c2c1	Outside typical range	CHEMBL4295050	=	IC50	nM	10715193.05	CHEMBL5408	Homo sapiens	pIC50		1.97
	18811358	CHEMBL4276010	Inhibition of human TBK1 (1 to 657 residues) expressed in Baculovirus infected SF9 insect cells using myelin basic protein as substrate in presence of [gamma-33P]-ATP by radiometric kinase assay	B	CC(C)C#Cc1ccc2oc3nc(N)c(C(=O)O)cc3c(=O)c2c1	Outside typical range	CHEMBL4287123	=	IC50	nM	50118723.36	CHEMBL5408	Homo sapiens	pIC50		1.3
	18811359	CHEMBL4276010	Inhibition of human TBK1 (1 to 657 residues) expressed in Baculovirus infected SF9 insect cells using myelin basic protein as substrate in presence of [gamma-33P]-ATP by radiometric kinase assay	B	Nc1nc2oc3ccc(C4CCCCC4)cc3c(=O)c2cc1C(=O)O	Outside typical range	CHEMBL4287304	=	IC50	nM	19054607.18	CHEMBL5408	Homo sapiens	pIC50		1.72
	18811360	CHEMBL4276010	Inhibition of human TBK1 (1 to 657 residues) expressed in Baculovirus infected SF9 insect cells using myelin basic protein as substrate in presence of [gamma-33P]-ATP by radiometric kinase assay	B	Nc1nc2oc3ccc(C4CCC(=O)CC4)cc3c(=O)c2cc1C(=O)O	Outside typical range	CHEMBL4281788	=	IC50	nM	630957.34	CHEMBL5408	Homo sapiens	pIC50		3.2
	18811361	CHEMBL4276010	Inhibition of human TBK1 (1 to 657 residues) expressed in Baculovirus infected SF9 insect cells using myelin basic protein as substrate in presence of [gamma-33P]-ATP by radiometric kinase assay	B	CC(=O)N1CCC(c2ccc3oc4nc(N)c(C(=O)O)cc4c(=O)c3c2)CC1		CHEMBL4289613	=	IC50	nM	16982.44	CHEMBL5408	Homo sapiens	pIC50		4.77
	18811362	CHEMBL4276010	Inhibition of human TBK1 (1 to 657 residues) expressed in Baculovirus infected SF9 insect cells using myelin basic protein as substrate in presence of [gamma-33P]-ATP by radiometric kinase assay	B	Nc1nc2oc3ccc(C4=CCOCC4)cc3c(=O)c2cc1C(=O)O	Outside typical range	CHEMBL4279336	=	IC50	nM	257039.58	CHEMBL5408	Homo sapiens	pIC50		3.59
	18811363	CHEMBL4276010	Inhibition of human TBK1 (1 to 657 residues) expressed in Baculovirus infected SF9 insect cells using myelin basic protein as substrate in presence of [gamma-33P]-ATP by radiometric kinase assay	B	Nc1nc2oc3ccc(C4CCSCC4)cc3c(=O)c2cc1C(=O)O	Outside typical range	CHEMBL4293403	=	IC50	nM	489778.82	CHEMBL5408	Homo sapiens	pIC50		3.31
	18811364	CHEMBL4276010	Inhibition of human TBK1 (1 to 657 residues) expressed in Baculovirus infected SF9 insect cells using myelin basic protein as substrate in presence of [gamma-33P]-ATP by radiometric kinase assay	B	Nc1nc2oc3ccc(C4CCCCC4)cc3c(=O)c2cc1-c1nn[nH]n1		CHEMBL4284757	=	IC50	nM	1905.46	CHEMBL5408	Homo sapiens	pIC50		5.72
	18811365	CHEMBL4276010	Inhibition of human TBK1 (1 to 657 residues) expressed in Baculovirus infected SF9 insect cells using myelin basic protein as substrate in presence of [gamma-33P]-ATP by radiometric kinase assay	B	Nc1nc2oc3ccc(C4=CCCCC4)cc3c(=O)c2cc1-c1nn[nH]n1		CHEMBL4291966	=	IC50	nM	489.78	CHEMBL5408	Homo sapiens	pIC50		6.31
	18811366	CHEMBL4276010	Inhibition of human TBK1 (1 to 657 residues) expressed in Baculovirus infected SF9 insect cells using myelin basic protein as substrate in presence of [gamma-33P]-ATP by radiometric kinase assay	B	CN(C)c1ccc2oc3nc(N)c(-c4nn[nH]n4)cc3c(=O)c2c1		CHEMBL4281345	=	IC50	nM	524.81	CHEMBL5408	Homo sapiens	pIC50		6.28
	18811367	CHEMBL4276010	Inhibition of human TBK1 (1 to 657 residues) expressed in Baculovirus infected SF9 insect cells using myelin basic protein as substrate in presence of [gamma-33P]-ATP by radiometric kinase assay	B	Nc1nc2oc3ccc(N4CCOCC4)cc3c(=O)c2cc1-c1nn[nH]n1		CHEMBL4288542	=	IC50	nM	537.03	CHEMBL5408	Homo sapiens	pIC50		6.27
	18811368	CHEMBL4276011	Potency index, ratio of amlexanoc IC50 to compound IC50 for inhibition of human TBK1 (1 to 657 residues) expressed in Baculovirus infected SF9 insect cells	B	C=C(C)c1ccc2oc3nc(N)c(C(=O)O)cc3c(=O)c2c1		CHEMBL4277614	=	Ratio IC50		0.7	CHEMBL5408	Homo sapiens	Ratio IC50		0.7
	18811369	CHEMBL4276011	Potency index, ratio of amlexanoc IC50 to compound IC50 for inhibition of human TBK1 (1 to 657 residues) expressed in Baculovirus infected SF9 insect cells	B	CC(C)c1ccc2c(=O)c3cc(C(=O)O)c(N)nc3oc2c1		CHEMBL4285560	=	Ratio IC50		2.8	CHEMBL5408	Homo sapiens	Ratio IC50		2.8
	18811370	CHEMBL4276011	Potency index, ratio of amlexanoc IC50 to compound IC50 for inhibition of human TBK1 (1 to 657 residues) expressed in Baculovirus infected SF9 insect cells	B	C=C(C)c1ccc2c(=O)c3cc(C(=O)O)c(N)nc3oc2c1		CHEMBL4281039	=	Ratio IC50		0.4	CHEMBL5408	Homo sapiens	Ratio IC50		0.4
	18811371	CHEMBL4276011	Potency index, ratio of amlexanoc IC50 to compound IC50 for inhibition of human TBK1 (1 to 657 residues) expressed in Baculovirus infected SF9 insect cells	B	CC(C)c1cccc2oc3nc(N)c(C(=O)O)cc3c(=O)c12		CHEMBL4288939	=	Ratio IC50		0.8	CHEMBL5408	Homo sapiens	Ratio IC50		0.8
	18811372	CHEMBL4276011	Potency index, ratio of amlexanoc IC50 to compound IC50 for inhibition of human TBK1 (1 to 657 residues) expressed in Baculovirus infected SF9 insect cells	B	CC(C)c1cc2c(=O)c3cc(C(=O)O)c(N)nc3oc2cc1F		CHEMBL4284443	=	Ratio IC50		2.1	CHEMBL5408	Homo sapiens	Ratio IC50		2.1
	18811373	CHEMBL4276011	Potency index, ratio of amlexanoc IC50 to compound IC50 for inhibition of human TBK1 (1 to 657 residues) expressed in Baculovirus infected SF9 insect cells	B	C=C(C)c1cc2c(=O)c3cc(C(=O)O)c(N)nc3oc2cc1F		CHEMBL4292344	=	Ratio IC50		1.1	CHEMBL5408	Homo sapiens	Ratio IC50		1.1
	18811374	CHEMBL4276011	Potency index, ratio of amlexanoc IC50 to compound IC50 for inhibition of human TBK1 (1 to 657 residues) expressed in Baculovirus infected SF9 insect cells	B	CC(C)c1cc2c(=O)c3cc(C(=O)O)c(N)nc3oc2cn1		CHEMBL4287847	=	Ratio IC50		1.5	CHEMBL5408	Homo sapiens	Ratio IC50		1.5
	18811375	CHEMBL4276011	Potency index, ratio of amlexanoc IC50 to compound IC50 for inhibition of human TBK1 (1 to 657 residues) expressed in Baculovirus infected SF9 insect cells	B	C=C(C)c1cc2c(=O)c3cc(C(=O)O)c(N)nc3oc2cn1		CHEMBL4277195	=	Ratio IC50		0.4	CHEMBL5408	Homo sapiens	Ratio IC50		0.4
	18811376	CHEMBL4276011	Potency index, ratio of amlexanoc IC50 to compound IC50 for inhibition of human TBK1 (1 to 657 residues) expressed in Baculovirus infected SF9 insect cells	B	CN(C)c1ccc2oc3nc(N)c(C(=O)O)cc3c(=O)c2c1		CHEMBL4279379	=	Ratio IC50		2.1	CHEMBL5408	Homo sapiens	Ratio IC50		2.1
	18811377	CHEMBL4276011	Potency index, ratio of amlexanoc IC50 to compound IC50 for inhibition of human TBK1 (1 to 657 residues) expressed in Baculovirus infected SF9 insect cells	B	CC(C)Cc1ccc2oc3nc(N)c(C(=O)O)cc3c(=O)c2c1		CHEMBL4290544	=	Ratio IC50		1.5	CHEMBL5408	Homo sapiens	Ratio IC50		1.5
	18811378	CHEMBL4276011	Potency index, ratio of amlexanoc IC50 to compound IC50 for inhibition of human TBK1 (1 to 657 residues) expressed in Baculovirus infected SF9 insect cells	B	CC(C)CCc1ccc2oc3nc(N)c(C(=O)O)cc3c(=O)c2c1		CHEMBL4295050	=	Ratio IC50		1.0	CHEMBL5408	Homo sapiens	Ratio IC50		1.0
	18811379	CHEMBL4276011	Potency index, ratio of amlexanoc IC50 to compound IC50 for inhibition of human TBK1 (1 to 657 residues) expressed in Baculovirus infected SF9 insect cells	B	CC(C)C#Cc1ccc2oc3nc(N)c(C(=O)O)cc3c(=O)c2c1		CHEMBL4287123	=	Ratio IC50		0.1	CHEMBL5408	Homo sapiens	Ratio IC50		0.1
	18811380	CHEMBL4276011	Potency index, ratio of amlexanoc IC50 to compound IC50 for inhibition of human TBK1 (1 to 657 residues) expressed in Baculovirus infected SF9 insect cells	B	Nc1nc2oc3ccc(C4CC4)cc3c(=O)c2cc1C(=O)O		CHEMBL4278101	=	Ratio IC50		0.4	CHEMBL5408	Homo sapiens	Ratio IC50		0.4
	18811381	CHEMBL4276011	Potency index, ratio of amlexanoc IC50 to compound IC50 for inhibition of human TBK1 (1 to 657 residues) expressed in Baculovirus infected SF9 insect cells	B	Nc1nc2oc3ccc(C4CCC4)cc3c(=O)c2cc1C(=O)O		CHEMBL4290720	=	Ratio IC50		0.2	CHEMBL5408	Homo sapiens	Ratio IC50		0.2
	18811382	CHEMBL4276011	Potency index, ratio of amlexanoc IC50 to compound IC50 for inhibition of human TBK1 (1 to 657 residues) expressed in Baculovirus infected SF9 insect cells	B	Nc1nc2oc3ccc(C4CCCC4)cc3c(=O)c2cc1C(=O)O		CHEMBL4280074	=	Ratio IC50		0.5	CHEMBL5408	Homo sapiens	Ratio IC50		0.5
	18811383	CHEMBL4276011	Potency index, ratio of amlexanoc IC50 to compound IC50 for inhibition of human TBK1 (1 to 657 residues) expressed in Baculovirus infected SF9 insect cells	B	Nc1nc2oc3ccc(C4CCCCC4)cc3c(=O)c2cc1C(=O)O		CHEMBL4287304	=	Ratio IC50		0.5	CHEMBL5408	Homo sapiens	Ratio IC50		0.5
	18811384	CHEMBL4276011	Potency index, ratio of amlexanoc IC50 to compound IC50 for inhibition of human TBK1 (1 to 657 residues) expressed in Baculovirus infected SF9 insect cells	B	Nc1nc2oc3ccc(C4=CCCCC4)cc3c(=O)c2cc1C(=O)O		CHEMBL4276661	=	Ratio IC50		0.5	CHEMBL5408	Homo sapiens	Ratio IC50		0.5
	18811385	CHEMBL4276011	Potency index, ratio of amlexanoc IC50 to compound IC50 for inhibition of human TBK1 (1 to 657 residues) expressed in Baculovirus infected SF9 insect cells	B	Nc1nc2oc3ccc(C4CCC(=O)CC4)cc3c(=O)c2cc1C(=O)O		CHEMBL4281788	=	Ratio IC50		1.9	CHEMBL5408	Homo sapiens	Ratio IC50		1.9
	18811386	CHEMBL4276011	Potency index, ratio of amlexanoc IC50 to compound IC50 for inhibition of human TBK1 (1 to 657 residues) expressed in Baculovirus infected SF9 insect cells	B	Nc1nc2oc3ccc(C4CCC5(CC4)OCCO5)cc3c(=O)c2cc1C(=O)O		CHEMBL4285588	=	Ratio IC50		1.9	CHEMBL5408	Homo sapiens	Ratio IC50		1.9
	18811387	CHEMBL4276011	Potency index, ratio of amlexanoc IC50 to compound IC50 for inhibition of human TBK1 (1 to 657 residues) expressed in Baculovirus infected SF9 insect cells	B	Nc1nc2oc3ccc(C4=CCC5(CC4)OCCO5)cc3c(=O)c2cc1C(=O)O		CHEMBL4278727	=	Ratio IC50		1.1	CHEMBL5408	Homo sapiens	Ratio IC50		1.1
	18811388	CHEMBL4276011	Potency index, ratio of amlexanoc IC50 to compound IC50 for inhibition of human TBK1 (1 to 657 residues) expressed in Baculovirus infected SF9 insect cells	B	Nc1nc2oc3ccc(C4CCN(C=O)CC4)cc3c(=O)c2cc1C(=O)O		CHEMBL4281733	=	Ratio IC50		1.7	CHEMBL5408	Homo sapiens	Ratio IC50		1.7
	18811389	CHEMBL4276011	Potency index, ratio of amlexanoc IC50 to compound IC50 for inhibition of human TBK1 (1 to 657 residues) expressed in Baculovirus infected SF9 insect cells	B	CC(=O)N1CCC(c2ccc3oc4nc(N)c(C(=O)O)cc4c(=O)c3c2)CC1		CHEMBL4289613	=	Ratio IC50		3.1	CHEMBL5408	Homo sapiens	Ratio IC50		3.1
	18811390	CHEMBL4276011	Potency index, ratio of amlexanoc IC50 to compound IC50 for inhibition of human TBK1 (1 to 657 residues) expressed in Baculovirus infected SF9 insect cells	B	Nc1nc2oc3ccc(C4CCOCC4)cc3c(=O)c2cc1C(=O)O		CHEMBL4290024	=	Ratio IC50		1.1	CHEMBL5408	Homo sapiens	Ratio IC50		1.1
	18811391	CHEMBL4276011	Potency index, ratio of amlexanoc IC50 to compound IC50 for inhibition of human TBK1 (1 to 657 residues) expressed in Baculovirus infected SF9 insect cells	B	Nc1nc2oc3ccc(C4=CCOCC4)cc3c(=O)c2cc1C(=O)O		CHEMBL4279336	=	Ratio IC50		1.0	CHEMBL5408	Homo sapiens	Ratio IC50		1.0
	18811392	CHEMBL4276011	Potency index, ratio of amlexanoc IC50 to compound IC50 for inhibition of human TBK1 (1 to 657 residues) expressed in Baculovirus infected SF9 insect cells	B	Nc1nc2oc3ccc(C4CCSCC4)cc3c(=O)c2cc1C(=O)O		CHEMBL4293403	=	Ratio IC50		2.9	CHEMBL5408	Homo sapiens	Ratio IC50		2.9
	18811393	CHEMBL4276011	Potency index, ratio of amlexanoc IC50 to compound IC50 for inhibition of human TBK1 (1 to 657 residues) expressed in Baculovirus infected SF9 insect cells	B	Nc1nc2oc3ccc(C4CCS(=O)(=O)CC4)cc3c(=O)c2cc1C(=O)O		CHEMBL4282790	=	Ratio IC50		1.0	CHEMBL5408	Homo sapiens	Ratio IC50		1.0
	18811394	CHEMBL4276011	Potency index, ratio of amlexanoc IC50 to compound IC50 for inhibition of human TBK1 (1 to 657 residues) expressed in Baculovirus infected SF9 insect cells	B	Nc1nc2oc3ccc(C4CCCCC4)cc3c(=O)c2cc1-c1nn[nH]n1		CHEMBL4284757	=	Ratio IC50		0.4	CHEMBL5408	Homo sapiens	Ratio IC50		0.4
	18811395	CHEMBL4276011	Potency index, ratio of amlexanoc IC50 to compound IC50 for inhibition of human TBK1 (1 to 657 residues) expressed in Baculovirus infected SF9 insect cells	B	Nc1nc2oc3ccc(C4=CCCCC4)cc3c(=O)c2cc1-c1nn[nH]n1		CHEMBL4291966	=	Ratio IC50		1.7	CHEMBL5408	Homo sapiens	Ratio IC50		1.7
	18811396	CHEMBL4276011	Potency index, ratio of amlexanoc IC50 to compound IC50 for inhibition of human TBK1 (1 to 657 residues) expressed in Baculovirus infected SF9 insect cells	B	CN(C)c1ccc2oc3nc(N)c(-c4nn[nH]n4)cc3c(=O)c2c1		CHEMBL4281345	=	Ratio IC50		1.6	CHEMBL5408	Homo sapiens	Ratio IC50		1.6
	18811397	CHEMBL4276011	Potency index, ratio of amlexanoc IC50 to compound IC50 for inhibition of human TBK1 (1 to 657 residues) expressed in Baculovirus infected SF9 insect cells	B	Nc1nc2oc3ccc(N4CCOCC4)cc3c(=O)c2cc1-c1nn[nH]n1		CHEMBL4288542	=	Ratio IC50		1.6	CHEMBL5408	Homo sapiens	Ratio IC50		1.6
	18811398	CHEMBL4276011	Potency index, ratio of amlexanoc IC50 to compound IC50 for inhibition of human TBK1 (1 to 657 residues) expressed in Baculovirus infected SF9 insect cells	B	Nc1nc2oc3ccc(N4CCOCC4)cc3c(=O)c2cc1C(=O)Nc1nn[nH]n1		CHEMBL4277887	=	Ratio IC50		1.1	CHEMBL5408	Homo sapiens	Ratio IC50		1.1
	18858227	CHEMBL4308073	Binding affinity to wild-type human full length TBK1 (M1 to L729 residues) expressed in mammalian expression system assessed as residual binding level at 10 uM by Kinomescan method relative to control	B	CC(C)N1C(=O)C(NCCCN(C)C)=C(c2cn(C)c3ccccc23)C1=O.Cl		CHEMBL4533018	=	Activity	%	73.0	CHEMBL5408	Homo sapiens	Activity	%	73.0
	18890210	CHEMBL4314015	Inhibition of recombinant full length GST-tagged human TBK1 expressed in insect cells at 0.5 uM using Ser/Thr 05 as substrate in presence of ATP at Km concentration after 1 hr by Z'-LYTE assay relative to control	B	COc1cc(C(=O)NC2CCNCC2)ccc1Nc1nc(Nc2ccccc2P(C)(C)=O)c2cc[nH]c2n1		CHEMBL4448754	=	Inhibition	%	23.0	CHEMBL5408	Homo sapiens	INH	%	23.0
	18892986	CHEMBL4314952	Inhibition of recombinant full-length human TBK1 assessed as residual activity at 10 uM using KRRRALS(p)VASLPGL as substrate measured after 40 mins in presence of [gamma33P]ATP by scintillation counting method	B	Cc1cc(C)c(CNc2nc(Cl)nc3c2ncn3C2CCCC2)c(=O)[nH]1		CHEMBL4557538	=	Activity	%	99.5	CHEMBL5408	Homo sapiens	Activity	%	99.5
	18919550	CHEMBL4322906	Binding affinity to recombinant human full length N-terminal GST-tagged TBK1 expressed in baculovirus expression system using CKtide as substrate incubated for 1 hr by TR-FRET assay	B	CO[C@@H]1[C@H](NCCOCCOCCOCCNC(=O)CCC2=[N+]3C(=Cc4c(C)cc(C)n4[B-]3(F)F)C=C2)C[C@H]2O[C@]1(C)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)C(=O)NC4		CHEMBL4465866	=	Kd	nM	17.0	CHEMBL5408	Homo sapiens	Kd	nM	17.0
	18919738	CHEMBL4322906	Binding affinity to recombinant human full length N-terminal GST-tagged TBK1 expressed in baculovirus expression system using CKtide as substrate incubated for 1 hr by TR-FRET assay	B	CO[C@@H]1[C@H](N(C)CCOCCOCCOCCNC(=O)CCC2=[N+]3C(=Cc4c(C)cc(C)n4[B-]3(F)F)C=C2)C[C@H]2O[C@]1(C)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)C(=O)NC4		CHEMBL4576489	=	Kd	nM	9.0	CHEMBL5408	Homo sapiens	Kd	nM	9.0
	18938347	CHEMBL4327900	Inhibition of human TBK1 assessed as residual activity at 1 uM using KRRRAL[pS]VASLPGL as substrate by [gamma-33P]-ATP assay relative to control	B	ClC/C=C/C[N+]12CN3CN(CN(C3)C1)C2.[Cl-]		CHEMBL4438024	=	Activity	%	104.81	CHEMBL5408	Homo sapiens	Activity	%	104.81
	18938348	CHEMBL4327900	Inhibition of human TBK1 assessed as residual activity at 1 uM using KRRRAL[pS]VASLPGL as substrate by [gamma-33P]-ATP assay relative to control	B	C(=C/c1ccccc1)\C[N+]12CN3CN(CN(C3)C1)C2.[Cl-]		CHEMBL4446405	=	Activity	%	103.34	CHEMBL5408	Homo sapiens	Activity	%	103.34
	18938745	CHEMBL4328264	Inhibition of human TBK1 assessed as residual activity at 100 uM using KRRRAL[pS]VASLPGL as substrate by [gamma-33P]-ATP assay relative to control	B	CN[C@@H]1C[C@H]2O[C@@](C)([C@@H]1OC)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)C(=O)NC4		CHEMBL388978	<	Activity	%	65.0	CHEMBL5408	Homo sapiens	Activity	%	65.0
	18939131	CHEMBL4328628	Inhibition of human TBK1 using KRRRAL[pS]VASLPGL as substrate by [gamma-33P]-ATP assay	B	CN[C@@H]1C[C@H]2O[C@@](C)([C@@H]1OC)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)C(=O)NC4		CHEMBL388978	=	IC50	nM	2.18	CHEMBL5408	Homo sapiens	IC50	10'-9M	2.18
	18958999	CHEMBL4333655	Binding affinity to wild-type human full length TBK1 (M1 to L729 residues) expressed in mammalian expression system assessed as residual binding level at 1 uM by Kinomescan method relative to control	B	CC(C)Nc1sc(C(=O)c2ccc(Cl)s2)c(N)c1C#N		CHEMBL4563315	=	Activity	%	97.0	CHEMBL5408	Homo sapiens	Activity	%	97.0
	18964739	CHEMBL4335311	Inhibition of recombinant full-length human TBK1 at 1 uM assessed as residual activity at 1 uM using KRRRALS(p)VASLPGL as substrate measured after 40 mins in presence of [gamma33P]ATP by scintillation counting method relative to control	B	N=C1NC(=O)/C(=C\c2ccc(-c3cccc([N+](=O)[O-])c3)o2)S1		CHEMBL4455512	=	Activity	%	105.0	CHEMBL5408	Homo sapiens	Activity	%	105.0
	18964740	CHEMBL4335311	Inhibition of recombinant full-length human TBK1 at 1 uM assessed as residual activity at 1 uM using KRRRALS(p)VASLPGL as substrate measured after 40 mins in presence of [gamma33P]ATP by scintillation counting method relative to control	B	C=CCOC(=O)c1cc(-c2ccc(/C=C3/NC(=S)NC3=O)o2)ccc1Cl		CHEMBL4568120	=	Activity	%	98.0	CHEMBL5408	Homo sapiens	Activity	%	98.0
	18972125	CHEMBL4337135	Inhibition of recombinant full length human TBK1 assessed as residual activity at 10 uM using KRRRALS(p)VASLPGL as substrate incubated for 40 mins in presence of [gamma33P]ATP by scintillation counting based radiometry assay relative to control	B	C[C@@H](c1ccccc1)n1nnc2cnc3ccc(-c4cnc5[nH]ccc5c4)cc3c21		CHEMBL4472294	=	Activity	%	85.0	CHEMBL5408	Homo sapiens	Activity	%	85.0
	18972814	CHEMBL4337328	Induction of TBK1 in human PBMC assessed as increase in cGAMP secretion	B	CCn1nc(C)cc1C(=O)/N=c1\[nH]c2cc(C(N)=O)ccc2n1CCCCn1/c(=N/C(=O)c2cc(C)nn2CC)[nH]c2cc(C(N)=O)ccc21		CHEMBL4440744	=	EC50	nM	53900.0	CHEMBL5408	Homo sapiens	EC50(app)	uM	53.9
	19021570	CHEMBL4347793	Inhibition of recombinant human TBK1 at 20 nM using Ulight-FLGFTYVAP as substrate measured after 15 mins by LANCE method relative to control	B	O=C(CCCCCn1cc(Nc2ncc(Cl)c(Nc3ccc(Cl)cc3)n2)cn1)NO		CHEMBL4526274	=	Inhibition	%	0.0	CHEMBL5408	Homo sapiens	INH	%	0.0
	19021571	CHEMBL4347794	Inhibition of recombinant human TBK1 at 200 nM using Ulight-FLGFTYVAP as substrate measured after 15 mins by LANCE method relative to control	B	O=C(CCCCCn1cc(Nc2ncc(Cl)c(Nc3ccc(Cl)cc3)n2)cn1)NO		CHEMBL4526274	=	Inhibition	%	47.0	CHEMBL5408	Homo sapiens	INH	%	47.0
Not Active	19040183	CHEMBL4352084	Inhibition of recombinant full-length human TBK1 at 10 uM using KRRRALS(p)VASLPGL as substrate measured after 40 mins in presence of [gamma33P]ATP by scintillation counting method	B	CN1C[C@H](Nc2nc3cc[nH]c3c(=O)n2C)C[C@H](c2ccc3c(c2)OCCO3)C1		CHEMBL4574669		Inhibition	%		CHEMBL5408	Homo sapiens	INH		
Active	19041302	CHEMBL4352563	Inhibition of human TBK1 at 10 uM using KRRRAL[pS]VASLPGL as substrate in presence of [gamma-33P]-ATP	B	CC(C)(C)C(=O)N1N=CC[C@H]1c1ccccc1		CHEMBL4521353		Inhibition	%		CHEMBL5408	Homo sapiens	INH		
	19059852	CHEMBL4358153	Binding affinity to wild-type human full length TBK1 (M1 to L729 residues) expressed in mammalian expression system assessed as residual binding level at 1 uM by Kinomescan method relative to control	B	C=CC(=O)Nc1ccccc1Nc1nc(Nc2ccc(N3CCN(C)CC3)cc2)ncc1C(=O)Nc1c(C)cccc1Cl		CHEMBL4515441	=	Activity	%	70.0	CHEMBL5408	Homo sapiens	Activity	%	70.0
	19084198	CHEMBL4364389	Binding affinity to TBK1 in human HEK293/K562/placenta/HepG2 cell lysate mixture incubated for 45 mins by kinobeads based assay	B	O=C(NCCCNc1nc(Nc2cccc(NC(=O)N3CCCC3)c2)ncc1I)c1cccs1		CHEMBL577784	=	Kd	nM	19.95	CHEMBL5408	Homo sapiens	pKd		7.7
	19084199	CHEMBL4364389	Binding affinity to TBK1 in human HEK293/K562/placenta/HepG2 cell lysate mixture incubated for 45 mins by kinobeads based assay	B	Cc1nn(CC(F)(F)F)cc1Nc1ncc(Br)c(NCc2ccc(S(N)(=O)=O)cc2)n1		CHEMBL4446892	=	Kd	nM	10.0	CHEMBL5408	Homo sapiens	pKd		8.0
	19084200	CHEMBL4364389	Binding affinity to TBK1 in human HEK293/K562/placenta/HepG2 cell lysate mixture incubated for 45 mins by kinobeads based assay	B	O=C(NCCCNc1nc(Nc2cccc(CN3CCOCC3)c2)ncc1C1CC1)C1CCC1		CHEMBL3605057	=	Kd	nM	79.43	CHEMBL5408	Homo sapiens	pKd		7.1
	19084203	CHEMBL4364391	Binding affinity to phosphorylated TBK1 in calyculin A stimulated human Ramos cell lysate incubated for 45 mins by kinobeads based assay	B	O=C(NCCCNc1nc(Nc2cccc(NC(=O)N3CCCC3)c2)ncc1I)c1cccs1		CHEMBL577784	=	Kd	nM	39.81	CHEMBL5408	Homo sapiens	pKd		7.4
	19084204	CHEMBL4364392	Binding affinity to TBK1 in human Ramos cell lysate incubated for 45 mins by kinobeads based assay	B	O=C(NCCCNc1nc(Nc2cccc(CN3CCOCC3)c2)ncc1C1CC1)C1CCC1		CHEMBL3605057	=	Kd	nM	251.19	CHEMBL5408	Homo sapiens	pKd		6.6
	19084226	CHEMBL4364392	Binding affinity to TBK1 in human Ramos cell lysate incubated for 45 mins by kinobeads based assay	B	Cc1nn(CC(F)(F)F)cc1Nc1ncc(Br)c(NCc2ccc(S(N)(=O)=O)cc2)n1		CHEMBL4446892	=	Kd	nM	19.95	CHEMBL5408	Homo sapiens	pKd		7.7
	19084227	CHEMBL4364412	Inhibition of recombinant human TBK1 using MBP as substrate in presence of gamma-33P]-ATP by Hotspot assay	B	Cc1nn(CC(F)(F)F)cc1Nc1ncc(Br)c(NCc2ccc(S(N)(=O)=O)cc2)n1		CHEMBL4446892	=	IC50	nM	158.49	CHEMBL5408	Homo sapiens	pIC50		6.8
	19084229	CHEMBL4364414	Inhibition of TBK1 in human Ramos cells assessed as decrease in poly(I:C)-stimulated IRF3 phosphorylation at Ser396 residue preincubated for 60 mins followed by poly(I:C) addition and measured after 120 mins by Western blot analysis	B	Cc1nn(CC(F)(F)F)cc1Nc1ncc(Br)c(NCc2ccc(S(N)(=O)=O)cc2)n1		CHEMBL4446892	=	IC50	nM	1000.0	CHEMBL5408	Homo sapiens	pIC50		6.0
	19084230	CHEMBL4364415	Inhibition of TBK1 in TLR3-stimulated human PBMC assessed as decrease in poly(I:C)-induced IFNalpha secretion preincubated for 1 hr followed by poly(I:C) addition and measured after 16 hrs by FACS based cytometric bead array method	B	Cc1nn(CC(F)(F)F)cc1Nc1ncc(Br)c(NCc2ccc(S(N)(=O)=O)cc2)n1		CHEMBL4446892	=	IC50	nM	794.33	CHEMBL5408	Homo sapiens	pIC50		6.1
Active	19084231	CHEMBL4364416	Inhibition of TBK1 in human PBMC assessed as decrease in poly(I:C) stimulated IFNbeta secretion preincubated for 1 hr followed by poly(I:C) addition and measured after 16 hrs by ELISA	B	Cc1nn(CC(F)(F)F)cc1Nc1ncc(Br)c(NCc2ccc(S(N)(=O)=O)cc2)n1		CHEMBL4446892		Inhibition	%		CHEMBL5408	Homo sapiens	INH		
	19084232	CHEMBL4364417	Inhibition of TBK1 in human THP1 cells assessed as decrease in baculovirus-stimulated IFNbeta secretion preincubated for 45 mins followed by virus addition and measured after 20 hrs by electrochemiluminescence method	B	Cc1nn(CC(F)(F)F)cc1Nc1ncc(Br)c(NCc2ccc(S(N)(=O)=O)cc2)n1		CHEMBL4446892	=	IC50	nM	1258.93	CHEMBL5408	Homo sapiens	pIC50		5.9
	19084233	CHEMBL4364418	Inhibition of TBK1 in human THP1 cells assessed as decrease in c-GAMP stimulated IFNbeta secretion preincubated for 45 mins followed by c-GAMP addition and measured after 20 hrs by electrochemiluminescence method	B	Cc1nn(CC(F)(F)F)cc1Nc1ncc(Br)c(NCc2ccc(S(N)(=O)=O)cc2)n1		CHEMBL4446892	=	IC50	nM	501.19	CHEMBL5408	Homo sapiens	pIC50		6.3
Active	19084234	CHEMBL4364419	Inhibition of TBK1 in human PBMC assessed as decrease in poly(I:C) stimulated IFNalpha secretion preincubated for 1 hr followed by poly(I:C) addition and measured after 16 hrs in presence of IFNAR2 antibody by cytometric bead array-based FACS analysis	B	Cc1nn(CC(F)(F)F)cc1Nc1ncc(Br)c(NCc2ccc(S(N)(=O)=O)cc2)n1		CHEMBL4446892		Inhibition	%		CHEMBL5408	Homo sapiens	INH		
	19084239	CHEMBL4364391	Binding affinity to phosphorylated TBK1 in calyculin A stimulated human Ramos cell lysate incubated for 45 mins by kinobeads based assay	B	Cc1nn(CC(F)(F)F)cc1Nc1ncc(Br)c(NCc2ccc(S(N)(=O)=O)cc2)n1		CHEMBL4446892	=	Kd	nM	158.49	CHEMBL5408	Homo sapiens	pKd		6.8
	19084240	CHEMBL4364391	Binding affinity to phosphorylated TBK1 in calyculin A stimulated human Ramos cell lysate incubated for 45 mins by kinobeads based assay	B	O=C(NCCCNc1nc(Nc2cccc(CN3CCOCC3)c2)ncc1C1CC1)C1CCC1		CHEMBL3605057	=	Kd	nM	31.62	CHEMBL5408	Homo sapiens	pKd		7.5
	19084241	CHEMBL4364392	Binding affinity to TBK1 in human Ramos cell lysate incubated for 45 mins by kinobeads based assay	B	O=C(NCCCNc1nc(Nc2cccc(NC(=O)N3CCCC3)c2)ncc1I)c1cccs1		CHEMBL577784	=	Kd	nM	158.49	CHEMBL5408	Homo sapiens	pKd		6.8
	19090416	CHEMBL4365990	Inhibition of wild-type human full length TBK1 (M1 to L729 residues) expressed in mammalian expression system assessed as residual activity at 10 uM by Kinomescan method relative to control	B	O=C(Nc1cccnc1)c1cc(C(=O)c2c(F)cccc2Br)c[nH]1		CHEMBL4436895	=	Activity	%	89.0	CHEMBL5408	Homo sapiens	Activity	%	89.0
	19092139	CHEMBL4366613	Inhibition of human TBK1 at 100 nM using KRRRAL[pS]VASLPGL as substrate by [gamma-33P]-ATP assay	B	COc1ccc(N2C(=O)COc3ccc(-c4cnc(OC)c(NS(=O)(=O)c5ccc(F)cc5)c4)cc32)cc1		CHEMBL4528675	=	Inhibition	%	5.37	CHEMBL5408	Homo sapiens	INH	%	5.37
	19114724	CHEMBL4371457	Binding affinity to TBK1 in SILAC-labeled human MDA-MB-231 cells lysate by mass spectrometry based kinAffinity assay	B	COc1cc2c(Oc3ccc(NS(=O)(=O)c4c(F)cccc4F)cc3F)ccnc2cc1OCCCN1CCN(C)CC1		CHEMBL4462318	=	Kd	nM	3273.0	CHEMBL5408	Homo sapiens	Kd(free)	uM	3.273
	19125344	CHEMBL4373767	Competitive inhibition of TBK1 (unknown origin) by immunoprecipitation method	B	O=C(NCCCNc1nc(Nc2cccc(NC(=O)N3CCCC3)c2)ncc1I)c1cccs1		CHEMBL577784	=	IC50	nM	6.0	CHEMBL5408	Homo sapiens	IC50	nM	6.0
	19125345	CHEMBL4373750	Inhibition of TBK1 (unknown origin) using biotinylated peptide as substrate preincubated for 30 mins by fluorescence activity-based assay	B	Cc1cc(Nc2cc(N3CCN(C)CC3)nc(Sc3ccc(NC(=O)C4CC4)cc3)n2)n[nH]1		CHEMBL572878	=	IC50	nM	6.22	CHEMBL5408	Homo sapiens	IC50	nM	6.22
	19125346	CHEMBL4373750	Inhibition of TBK1 (unknown origin) using biotinylated peptide as substrate preincubated for 30 mins by fluorescence activity-based assay	B	Cc1cc(Nc2cc(N3CCN(C)CC3)nc(Oc3ccc([N+](=O)[O-])cc3)n2)n[nH]1		CHEMBL3604928	=	IC50	nM	0.06	CHEMBL5408	Homo sapiens	IC50	nM	0.06
	19125348	CHEMBL4373768	Competitive inhibition of TBK1 (unknown origin) upto 1 uM in presence of ATP by single point screening assay	B	C#CCNC(=O)c1ccc(-c2ccnc(Nc3ccc(N4CCOCC4)cc3)n2)cc1		CHEMBL4465099	<	IC50	nM	100.0	CHEMBL5408	Homo sapiens	IC50	nM	100.0
	19125349	CHEMBL4373769	Inhibition of TBK1 (unknown origin)	B	N#Cc1cc(-c2ccnc(Nc3ccc4c(c3)CC(=O)N4)n2)ccc1N1CCCC1		CHEMBL3650697	=	IC50	nM	1.0	CHEMBL5408	Homo sapiens	IC50	nM	1.0
	19125350	CHEMBL4373769	Inhibition of TBK1 (unknown origin)	B	O=C(NCCCNc1nc(Nc2cccc(CN3CCOCC3)c2)ncc1C1CC1)C1CCC1		CHEMBL3605057	=	IC50	nM	19.0	CHEMBL5408	Homo sapiens	IC50	nM	19.0
	19125351	CHEMBL4373769	Inhibition of TBK1 (unknown origin)	B	COc1ccc(-c2ccc(-c3nc4c(NNCCCNC(=O)C5CCCCC5)c(C(N)=O)cnc4[nH]3)cc2)cc1		CHEMBL4532014	=	IC50	nM	5.0	CHEMBL5408	Homo sapiens	IC50	nM	5.0
	19125358	CHEMBL4373769	Inhibition of TBK1 (unknown origin)	B	COc1ccc(-n2ncc3cnc(Nc4cc(OC)c(OC)c(OCCCN5CCN(C)CC5)c4)nc32)cc1		CHEMBL4582703	=	IC50	nM	13.0	CHEMBL5408	Homo sapiens	IC50	nM	13.0
	19140839	CHEMBL4376603	Inhibition of recombinant full length human GST-tagged TBK1 expressed in insect cells at 1 uM using biotin as substrate preincubated for 5 mins followed by substrate addition and measured after 30 to 60 mins in presence of ATP by HTRF assay relative to control	B	Cn1cc(-c2ccc(F)cc2)c(=O)c2c(Nc3ccc(Oc4ccnc(NC(=O)C5CC5)c4)c(F)c3)nccc21		CHEMBL4584949	<	Inhibition	%	50.0	CHEMBL5408	Homo sapiens	INH	%	50.0
	19144906	CHEMBL4377922	Inhibition of recombinant full-length human TBK1 at 1 uM using KRRRALS(p)VASLPGL as substrate measured after 40 mins in presence of [gamma33P]ATP by scintillation counting method relative to control	B	CN(C)C(=O)c1cc2cnc(Nc3ccc(NC(=O)CCCCCCCN=C=S)cc3)nc2n1C1CCCC1		CHEMBL4548580	=	Inhibition	%	12.0	CHEMBL5408	Homo sapiens	INH	%	12.0
	19148062	CHEMBL4379458	Inhibition of recombinant full length human TBK1 using KRRRALS(p)VAS as substrate incubated for 40 mins in presence of [gamma33P]ATP by radiometric scintillation counting analysis	B	CN(C)c1ccc(C(=O)Nc2cccc(NC(=O)COc3ccc4c(=O)ccoc4c3)c2)cc1		CHEMBL4438748	>	IC50	nM	10000.0	CHEMBL5408	Homo sapiens	IC50	uM	10.0
	19152883	CHEMBL4380518	Inhibition of recombinant full length human N-terminal His-tagged TBK1 using biotin-labelled Ahx-GDEDFSSFAEPG peptide as substrate preincubated with enzyme for 15 mins followed by substrate addition and further incubated for 30 mins in presence of 1 mM of ATP by TR-FRET assay	B	O=C(NCC1CC1)c1ccc2nc(Nc3cc(CN4CCN(C(=O)CC(F)(F)F)CC4)ccn3)[nH]c2c1		CHEMBL4456062	=	IC50	nM	1390.0	CHEMBL5408	Homo sapiens	IC50	nM	1390.0
	19152884	CHEMBL4380518	Inhibition of recombinant full length human N-terminal His-tagged TBK1 using biotin-labelled Ahx-GDEDFSSFAEPG peptide as substrate preincubated with enzyme for 15 mins followed by substrate addition and further incubated for 30 mins in presence of 1 mM of ATP by TR-FRET assay	B	N#Cc1ccc2nc(Nc3cc(CN4CCN(C(=O)CC(F)(F)F)CC4)ccn3)[nH]c2c1		CHEMBL4459120	=	IC50	nM	618.0	CHEMBL5408	Homo sapiens	IC50	nM	618.0
	19152885	CHEMBL4380518	Inhibition of recombinant full length human N-terminal His-tagged TBK1 using biotin-labelled Ahx-GDEDFSSFAEPG peptide as substrate preincubated with enzyme for 15 mins followed by substrate addition and further incubated for 30 mins in presence of 1 mM of ATP by TR-FRET assay	B	O=C(NCCCNc1nc(Nc2cccc(NC(=O)N3CCCC3)c2)ncc1I)c1cccs1		CHEMBL577784	=	IC50	nM	45.0	CHEMBL5408	Homo sapiens	IC50	nM	45.0
	19152886	CHEMBL4380517	Inhibition of recombinant full length human N-terminal His-tagged TBK1 using biotin-labelled Ahx-GDEDFSSFAEPG peptide as substrate preincubated with enzyme for 15 mins followed by substrate addition and further incubated for 30 mins in presence of 10 uM of ATP by TR-FRET assay	B	CN(C)c1ncnc(-c2ccc3nc(Nc4cc(CN5CCN(C(=O)CC(F)(F)F)CC5)ccn4)[nH]c3c2)c1Cl		CHEMBL4538591	=	IC50	nM	1140.0	CHEMBL5408	Homo sapiens	IC50	nM	1140.0
	19152887	CHEMBL4380517	Inhibition of recombinant full length human N-terminal His-tagged TBK1 using biotin-labelled Ahx-GDEDFSSFAEPG peptide as substrate preincubated with enzyme for 15 mins followed by substrate addition and further incubated for 30 mins in presence of 10 uM of ATP by TR-FRET assay	B	CC(C)Oc1cncnc1-c1ccc2nc(Nc3cc([C@@H](C)N4CCN(C(=O)CC(F)(F)F)CC4)ccn3)[nH]c2c1		CHEMBL4543618	=	IC50	nM	2.0	CHEMBL5408	Homo sapiens	IC50	nM	2.0
	19152888	CHEMBL4380517	Inhibition of recombinant full length human N-terminal His-tagged TBK1 using biotin-labelled Ahx-GDEDFSSFAEPG peptide as substrate preincubated with enzyme for 15 mins followed by substrate addition and further incubated for 30 mins in presence of 10 uM of ATP by TR-FRET assay	B	C[C@H](c1ccnc(Nc2nc3ccc(-c4cc(N(C)C)ncn4)cc3[nH]2)c1)N1CCN(C(=O)CC(F)(F)F)CC1		CHEMBL4537673	=	IC50	nM	2.0	CHEMBL5408	Homo sapiens	IC50	nM	2.0
	19152889	CHEMBL4380517	Inhibition of recombinant full length human N-terminal His-tagged TBK1 using biotin-labelled Ahx-GDEDFSSFAEPG peptide as substrate preincubated with enzyme for 15 mins followed by substrate addition and further incubated for 30 mins in presence of 10 uM of ATP by TR-FRET assay	B	CN(C)c1cc(-c2ccc3nc(Nc4cc(CN5CCN(C(=O)CC(F)(F)F)CC5)ccn4)[nH]c3c2)ncn1		CHEMBL4453292	=	IC50	nM	9.0	CHEMBL5408	Homo sapiens	IC50	nM	9.0
	19152890	CHEMBL4380517	Inhibition of recombinant full length human N-terminal His-tagged TBK1 using biotin-labelled Ahx-GDEDFSSFAEPG peptide as substrate preincubated with enzyme for 15 mins followed by substrate addition and further incubated for 30 mins in presence of 10 uM of ATP by TR-FRET assay	B	CNc1cc(-c2ccc3nc(Nc4cc(CN5CCN(C(=O)CC(F)(F)F)CC5)ccn4)[nH]c3c2)ncn1		CHEMBL4594167	=	IC50	nM	10.0	CHEMBL5408	Homo sapiens	IC50	nM	10.0
	19152891	CHEMBL4380517	Inhibition of recombinant full length human N-terminal His-tagged TBK1 using biotin-labelled Ahx-GDEDFSSFAEPG peptide as substrate preincubated with enzyme for 15 mins followed by substrate addition and further incubated for 30 mins in presence of 10 uM of ATP by TR-FRET assay	B	C[C@H](c1ccnc(Nc2nc3ccc(-c4cc(OCC5CC5)ncn4)cc3[nH]2)c1)N1CCN(C(=O)CC(F)(F)F)CC1		CHEMBL4454902	=	IC50	nM	2.0	CHEMBL5408	Homo sapiens	IC50	nM	2.0
	19152892	CHEMBL4380517	Inhibition of recombinant full length human N-terminal His-tagged TBK1 using biotin-labelled Ahx-GDEDFSSFAEPG peptide as substrate preincubated with enzyme for 15 mins followed by substrate addition and further incubated for 30 mins in presence of 10 uM of ATP by TR-FRET assay	B	COCc1cc(-c2ccc3nc(Nc4cc([C@@H](C)N5CCN(C(=O)CC(F)(F)F)CC5)ccn4)[nH]c3c2)ncn1		CHEMBL4566796	=	IC50	nM	0.7	CHEMBL5408	Homo sapiens	IC50	nM	0.7
	19152893	CHEMBL4380517	Inhibition of recombinant full length human N-terminal His-tagged TBK1 using biotin-labelled Ahx-GDEDFSSFAEPG peptide as substrate preincubated with enzyme for 15 mins followed by substrate addition and further incubated for 30 mins in presence of 10 uM of ATP by TR-FRET assay	B	Cc1cc(-c2ccc3nc(Nc4cc([C@@H](C)N5CCN(C(=O)CC(F)(F)F)CC5)ccn4)[nH]c3c2)ncn1		CHEMBL4538751	=	IC50	nM	2.0	CHEMBL5408	Homo sapiens	IC50	nM	2.0
	19152894	CHEMBL4380517	Inhibition of recombinant full length human N-terminal His-tagged TBK1 using biotin-labelled Ahx-GDEDFSSFAEPG peptide as substrate preincubated with enzyme for 15 mins followed by substrate addition and further incubated for 30 mins in presence of 10 uM of ATP by TR-FRET assay	B	Cc1cc(-c2ccc3nc(Nc4cc(CN5CCN(C(=O)CC(F)(F)F)CC5)ccn4)[nH]c3c2)ncn1		CHEMBL4552254	=	IC50	nM	15.0	CHEMBL5408	Homo sapiens	IC50	nM	15.0
	19152895	CHEMBL4380517	Inhibition of recombinant full length human N-terminal His-tagged TBK1 using biotin-labelled Ahx-GDEDFSSFAEPG peptide as substrate preincubated with enzyme for 15 mins followed by substrate addition and further incubated for 30 mins in presence of 10 uM of ATP by TR-FRET assay	B	CN(C)c1cc(-c2ccc3nc(Nc4cc(CN5CCN(C(=O)CC(F)(F)F)CC5)ccn4)[nH]c3c2)ccn1		CHEMBL4451595	=	IC50	nM	23.0	CHEMBL5408	Homo sapiens	IC50	nM	23.0
	19152896	CHEMBL4380517	Inhibition of recombinant full length human N-terminal His-tagged TBK1 using biotin-labelled Ahx-GDEDFSSFAEPG peptide as substrate preincubated with enzyme for 15 mins followed by substrate addition and further incubated for 30 mins in presence of 10 uM of ATP by TR-FRET assay	B	Cc1cc(-c2ccc3nc(Nc4cc(CN5CCN(C(=O)CC(F)(F)F)CC5)ccn4)[nH]c3c2)ccn1		CHEMBL4515413	=	IC50	nM	54.0	CHEMBL5408	Homo sapiens	IC50	nM	54.0
	19152897	CHEMBL4380517	Inhibition of recombinant full length human N-terminal His-tagged TBK1 using biotin-labelled Ahx-GDEDFSSFAEPG peptide as substrate preincubated with enzyme for 15 mins followed by substrate addition and further incubated for 30 mins in presence of 10 uM of ATP by TR-FRET assay	B	C[C@H](c1ccnc(Nc2nc3ccc(-c4cnn(CC5CCC5)c4)cc3[nH]2)c1)N1CCN(C(=O)CC(F)(F)F)CC1		CHEMBL4436188	=	IC50	nM	2.0	CHEMBL5408	Homo sapiens	IC50	nM	2.0
	19152898	CHEMBL4380517	Inhibition of recombinant full length human N-terminal His-tagged TBK1 using biotin-labelled Ahx-GDEDFSSFAEPG peptide as substrate preincubated with enzyme for 15 mins followed by substrate addition and further incubated for 30 mins in presence of 10 uM of ATP by TR-FRET assay	B	C[C@H](c1ccnc(Nc2nc3ccc(-c4cnn(CC5CC5)c4)cc3[nH]2)c1)N1CCN(C(=O)CC(F)(F)F)CC1		CHEMBL4435393	=	IC50	nM	1.0	CHEMBL5408	Homo sapiens	IC50	nM	1.0
	19152899	CHEMBL4380517	Inhibition of recombinant full length human N-terminal His-tagged TBK1 using biotin-labelled Ahx-GDEDFSSFAEPG peptide as substrate preincubated with enzyme for 15 mins followed by substrate addition and further incubated for 30 mins in presence of 10 uM of ATP by TR-FRET assay	B	O=C(CC(F)(F)F)N1CCN(Cc2ccnc(Nc3nc4ccc(-c5cnn(CC6CC6)c5)cc4[nH]3)c2)CC1		CHEMBL4468020	=	IC50	nM	5.0	CHEMBL5408	Homo sapiens	IC50	nM	5.0
	19152900	CHEMBL4380517	Inhibition of recombinant full length human N-terminal His-tagged TBK1 using biotin-labelled Ahx-GDEDFSSFAEPG peptide as substrate preincubated with enzyme for 15 mins followed by substrate addition and further incubated for 30 mins in presence of 10 uM of ATP by TR-FRET assay	B	CCn1cc(-c2ccc3nc(Nc4cc(CN5CCN(C(=O)CC(F)(F)F)CC5)ccn4)[nH]c3c2)cn1		CHEMBL4453481	=	IC50	nM	50.0	CHEMBL5408	Homo sapiens	IC50	nM	50.0
	19152901	CHEMBL4380517	Inhibition of recombinant full length human N-terminal His-tagged TBK1 using biotin-labelled Ahx-GDEDFSSFAEPG peptide as substrate preincubated with enzyme for 15 mins followed by substrate addition and further incubated for 30 mins in presence of 10 uM of ATP by TR-FRET assay	B	Cn1cc(-c2ccc3nc(Nc4cc(CN5CCN(C(=O)CC(F)(F)F)CC5)ccn4)[nH]c3c2)cn1		CHEMBL4436416	=	IC50	nM	55.0	CHEMBL5408	Homo sapiens	IC50	nM	55.0
	19152902	CHEMBL4380517	Inhibition of recombinant full length human N-terminal His-tagged TBK1 using biotin-labelled Ahx-GDEDFSSFAEPG peptide as substrate preincubated with enzyme for 15 mins followed by substrate addition and further incubated for 30 mins in presence of 10 uM of ATP by TR-FRET assay	B	CC(C)Cc1noc(-c2ccc3nc(Nc4cc(CN5CCN(C(=O)CC(F)(F)F)CC5)ccn4)[nH]c3c2)n1		CHEMBL4547610	=	IC50	nM	72.0	CHEMBL5408	Homo sapiens	IC50	nM	72.0
	19152903	CHEMBL4380517	Inhibition of recombinant full length human N-terminal His-tagged TBK1 using biotin-labelled Ahx-GDEDFSSFAEPG peptide as substrate preincubated with enzyme for 15 mins followed by substrate addition and further incubated for 30 mins in presence of 10 uM of ATP by TR-FRET assay	B	O=C(CC(F)(F)F)N1CCN(Cc2ccnc(Nc3nc4ccc(-c5nc(C6CC6)no5)cc4[nH]3)c2)CC1		CHEMBL4466150	=	IC50	nM	58.0	CHEMBL5408	Homo sapiens	IC50	nM	58.0
	19152904	CHEMBL4380517	Inhibition of recombinant full length human N-terminal His-tagged TBK1 using biotin-labelled Ahx-GDEDFSSFAEPG peptide as substrate preincubated with enzyme for 15 mins followed by substrate addition and further incubated for 30 mins in presence of 10 uM of ATP by TR-FRET assay	B	Cc1noc(-c2ccc3nc(Nc4cc(C(=O)N5CCN(C(=O)CC(F)(F)F)CC5)ccn4)[nH]c3c2)n1		CHEMBL4524534	=	IC50	nM	1210.0	CHEMBL5408	Homo sapiens	IC50	nM	1210.0
	19152905	CHEMBL4380517	Inhibition of recombinant full length human N-terminal His-tagged TBK1 using biotin-labelled Ahx-GDEDFSSFAEPG peptide as substrate preincubated with enzyme for 15 mins followed by substrate addition and further incubated for 30 mins in presence of 10 uM of ATP by TR-FRET assay	B	Cc1noc(-c2ccc3nc(Nc4cc([C@@H](C)N5CCN(C(=O)CC(F)(F)F)CC5)ccn4)[nH]c3c2)n1		CHEMBL4553949	=	IC50	nM	19.0	CHEMBL5408	Homo sapiens	IC50	nM	19.0
	19152906	CHEMBL4380517	Inhibition of recombinant full length human N-terminal His-tagged TBK1 using biotin-labelled Ahx-GDEDFSSFAEPG peptide as substrate preincubated with enzyme for 15 mins followed by substrate addition and further incubated for 30 mins in presence of 10 uM of ATP by TR-FRET assay	B	Cc1noc(-c2ccc3nc(Nc4cc([C@H](C)N5CCN(C(=O)CC(F)(F)F)CC5)ccn4)[nH]c3c2)n1		CHEMBL4577511	=	IC50	nM	106.0	CHEMBL5408	Homo sapiens	IC50	nM	106.0
	19152907	CHEMBL4380517	Inhibition of recombinant full length human N-terminal His-tagged TBK1 using biotin-labelled Ahx-GDEDFSSFAEPG peptide as substrate preincubated with enzyme for 15 mins followed by substrate addition and further incubated for 30 mins in presence of 10 uM of ATP by TR-FRET assay	B	Cc1noc(-c2ccc3nc(Nc4cc(C(C)N5CCN(C(=O)CC(F)(F)F)CC5)ccn4)[nH]c3c2)n1		CHEMBL4455930	=	IC50	nM	34.0	CHEMBL5408	Homo sapiens	IC50	nM	34.0
	19152908	CHEMBL4380517	Inhibition of recombinant full length human N-terminal His-tagged TBK1 using biotin-labelled Ahx-GDEDFSSFAEPG peptide as substrate preincubated with enzyme for 15 mins followed by substrate addition and further incubated for 30 mins in presence of 10 uM of ATP by TR-FRET assay	B	Cc1noc(-c2ccc3nc(Nc4cc(CN5CCN(C(=O)c6ccco6)CC5)ccn4)[nH]c3c2)n1		CHEMBL4462056	=	IC50	nM	429.0	CHEMBL5408	Homo sapiens	IC50	nM	429.0
	19152909	CHEMBL4380517	Inhibition of recombinant full length human N-terminal His-tagged TBK1 using biotin-labelled Ahx-GDEDFSSFAEPG peptide as substrate preincubated with enzyme for 15 mins followed by substrate addition and further incubated for 30 mins in presence of 10 uM of ATP by TR-FRET assay	B	Cc1noc(-c2ccc3nc(Nc4cc(CN5CCN(C(=O)C6CCC6)CC5)ccn4)[nH]c3c2)n1		CHEMBL4573638	=	IC50	nM	146.0	CHEMBL5408	Homo sapiens	IC50	nM	146.0
	19152910	CHEMBL4380517	Inhibition of recombinant full length human N-terminal His-tagged TBK1 using biotin-labelled Ahx-GDEDFSSFAEPG peptide as substrate preincubated with enzyme for 15 mins followed by substrate addition and further incubated for 30 mins in presence of 10 uM of ATP by TR-FRET assay	B	Cc1noc(-c2ccc3nc(Nc4cc(CN5CCN(C(=O)CC6CC6)CC5)ccn4)[nH]c3c2)n1		CHEMBL4483062	=	IC50	nM	115.0	CHEMBL5408	Homo sapiens	IC50	nM	115.0
	19152911	CHEMBL4380517	Inhibition of recombinant full length human N-terminal His-tagged TBK1 using biotin-labelled Ahx-GDEDFSSFAEPG peptide as substrate preincubated with enzyme for 15 mins followed by substrate addition and further incubated for 30 mins in presence of 10 uM of ATP by TR-FRET assay	B	Cc1noc(-c2ccc3nc(Nc4cc(CN5CCN(C(=O)C6CC6)CC5)ccn4)[nH]c3c2)n1		CHEMBL4450510	=	IC50	nM	148.0	CHEMBL5408	Homo sapiens	IC50	nM	148.0
	19152912	CHEMBL4380517	Inhibition of recombinant full length human N-terminal His-tagged TBK1 using biotin-labelled Ahx-GDEDFSSFAEPG peptide as substrate preincubated with enzyme for 15 mins followed by substrate addition and further incubated for 30 mins in presence of 10 uM of ATP by TR-FRET assay	B	Cc1noc(-c2ccc3nc(Nc4cc(CN5CCN(CC(F)(F)F)CC5)ccn4)[nH]c3c2)n1		CHEMBL4438389	=	IC50	nM	188.0	CHEMBL5408	Homo sapiens	IC50	nM	188.0
	19152913	CHEMBL4380517	Inhibition of recombinant full length human N-terminal His-tagged TBK1 using biotin-labelled Ahx-GDEDFSSFAEPG peptide as substrate preincubated with enzyme for 15 mins followed by substrate addition and further incubated for 30 mins in presence of 10 uM of ATP by TR-FRET assay	B	Cc1noc(-c2ccc3nc(Nc4cc(CN5CCN(CC(F)F)CC5)ccn4)[nH]c3c2)n1		CHEMBL4587843	=	IC50	nM	98.0	CHEMBL5408	Homo sapiens	IC50	nM	98.0
	19152914	CHEMBL4380517	Inhibition of recombinant full length human N-terminal His-tagged TBK1 using biotin-labelled Ahx-GDEDFSSFAEPG peptide as substrate preincubated with enzyme for 15 mins followed by substrate addition and further incubated for 30 mins in presence of 10 uM of ATP by TR-FRET assay	B	Cc1noc(-c2ccc3nc(Nc4cc(CN5CCN(CCC(F)(F)F)CC5)ccn4)[nH]c3c2)n1		CHEMBL4566710	=	IC50	nM	281.0	CHEMBL5408	Homo sapiens	IC50	nM	281.0
	19152915	CHEMBL4380517	Inhibition of recombinant full length human N-terminal His-tagged TBK1 using biotin-labelled Ahx-GDEDFSSFAEPG peptide as substrate preincubated with enzyme for 15 mins followed by substrate addition and further incubated for 30 mins in presence of 10 uM of ATP by TR-FRET assay	B	Cc1noc(-c2ccc3nc(Nc4cc(CN5CCN(CCO)CC5)ccn4)[nH]c3c2)n1		CHEMBL4521346	=	IC50	nM	1060.0	CHEMBL5408	Homo sapiens	IC50	nM	1060.0
	19152916	CHEMBL4380517	Inhibition of recombinant full length human N-terminal His-tagged TBK1 using biotin-labelled Ahx-GDEDFSSFAEPG peptide as substrate preincubated with enzyme for 15 mins followed by substrate addition and further incubated for 30 mins in presence of 10 uM of ATP by TR-FRET assay	B	CCCN1CCN(Cc2ccnc(Nc3nc4ccc(-c5nc(C)no5)cc4[nH]3)c2)CC1		CHEMBL4461416	=	IC50	nM	1440.0	CHEMBL5408	Homo sapiens	IC50	nM	1440.0
	19152917	CHEMBL4380517	Inhibition of recombinant full length human N-terminal His-tagged TBK1 using biotin-labelled Ahx-GDEDFSSFAEPG peptide as substrate preincubated with enzyme for 15 mins followed by substrate addition and further incubated for 30 mins in presence of 10 uM of ATP by TR-FRET assay	B	Cc1noc(-c2ccc3nc(Nc4cc(CN5CCNCC5)ccn4)[nH]c3c2)n1		CHEMBL4575832	=	IC50	nM	764.0	CHEMBL5408	Homo sapiens	IC50	nM	764.0
	19152918	CHEMBL4380517	Inhibition of recombinant full length human N-terminal His-tagged TBK1 using biotin-labelled Ahx-GDEDFSSFAEPG peptide as substrate preincubated with enzyme for 15 mins followed by substrate addition and further incubated for 30 mins in presence of 10 uM of ATP by TR-FRET assay	B	Cc1noc(-c2ccc3nc(Nc4cc(CN5CCN(C(=O)OC(C)(C)C)CC5)ccn4)[nH]c3c2)n1		CHEMBL4545291	=	IC50	nM	273.0	CHEMBL5408	Homo sapiens	IC50	nM	273.0
	19152919	CHEMBL4380517	Inhibition of recombinant full length human N-terminal His-tagged TBK1 using biotin-labelled Ahx-GDEDFSSFAEPG peptide as substrate preincubated with enzyme for 15 mins followed by substrate addition and further incubated for 30 mins in presence of 10 uM of ATP by TR-FRET assay	B	Cc1noc(-c2ccc3nc(Nc4cc(CN5CCN(C(=O)CC(F)(F)F)CC5)ccn4)[nH]c3c2)n1		CHEMBL4549459	=	IC50	nM	129.0	CHEMBL5408	Homo sapiens	IC50	nM	129.0
	19152920	CHEMBL4380517	Inhibition of recombinant full length human N-terminal His-tagged TBK1 using biotin-labelled Ahx-GDEDFSSFAEPG peptide as substrate preincubated with enzyme for 15 mins followed by substrate addition and further incubated for 30 mins in presence of 10 uM of ATP by TR-FRET assay	B	O=C(NCC1CC1)c1ccc2nc(Nc3cc(CN4CCN(C(=O)CC(F)(F)F)CC4)ccn3)[nH]c2c1		CHEMBL4456062	=	IC50	nM	93.0	CHEMBL5408	Homo sapiens	IC50	nM	93.0
	19152921	CHEMBL4380517	Inhibition of recombinant full length human N-terminal His-tagged TBK1 using biotin-labelled Ahx-GDEDFSSFAEPG peptide as substrate preincubated with enzyme for 15 mins followed by substrate addition and further incubated for 30 mins in presence of 10 uM of ATP by TR-FRET assay	B	N#Cc1ccc2nc(Nc3cc(CN4CCN(C(=O)CC(F)(F)F)CC4)ccn3)[nH]c2c1		CHEMBL4459120	=	IC50	nM	29.0	CHEMBL5408	Homo sapiens	IC50	nM	29.0
	19152922	CHEMBL4380517	Inhibition of recombinant full length human N-terminal His-tagged TBK1 using biotin-labelled Ahx-GDEDFSSFAEPG peptide as substrate preincubated with enzyme for 15 mins followed by substrate addition and further incubated for 30 mins in presence of 10 uM of ATP by TR-FRET assay	B	O=C(NCCCNc1nc(Nc2cccc(NC(=O)N3CCCC3)c2)ncc1I)c1cccs1		CHEMBL577784	=	IC50	nM	8.0	CHEMBL5408	Homo sapiens	IC50	nM	8.0
	19152923	CHEMBL4380518	Inhibition of recombinant full length human N-terminal His-tagged TBK1 using biotin-labelled Ahx-GDEDFSSFAEPG peptide as substrate preincubated with enzyme for 15 mins followed by substrate addition and further incubated for 30 mins in presence of 1 mM of ATP by TR-FRET assay	B	Cc1noc(-c2ccc3nc(Nc4cc(CN5CCN(C(=O)CC(F)(F)F)CC5)ccn4)[nH]c3c2)n1		CHEMBL4549459	=	IC50	nM	2270.0	CHEMBL5408	Homo sapiens	IC50	nM	2270.0
	19152924	CHEMBL4380518	Inhibition of recombinant full length human N-terminal His-tagged TBK1 using biotin-labelled Ahx-GDEDFSSFAEPG peptide as substrate preincubated with enzyme for 15 mins followed by substrate addition and further incubated for 30 mins in presence of 1 mM of ATP by TR-FRET assay	B	Cc1noc(-c2ccc3nc(Nc4cc(CN5CCN(C(=O)OC(C)(C)C)CC5)ccn4)[nH]c3c2)n1		CHEMBL4545291	>	IC50	nM	20000.0	CHEMBL5408	Homo sapiens	IC50	nM	20000.0
	19152925	CHEMBL4380518	Inhibition of recombinant full length human N-terminal His-tagged TBK1 using biotin-labelled Ahx-GDEDFSSFAEPG peptide as substrate preincubated with enzyme for 15 mins followed by substrate addition and further incubated for 30 mins in presence of 1 mM of ATP by TR-FRET assay	B	Cc1noc(-c2ccc3nc(Nc4cc(CN5CCNCC5)ccn4)[nH]c3c2)n1		CHEMBL4575832	=	IC50	nM	14700.0	CHEMBL5408	Homo sapiens	IC50	nM	14700.0
	19152926	CHEMBL4380518	Inhibition of recombinant full length human N-terminal His-tagged TBK1 using biotin-labelled Ahx-GDEDFSSFAEPG peptide as substrate preincubated with enzyme for 15 mins followed by substrate addition and further incubated for 30 mins in presence of 1 mM of ATP by TR-FRET assay	B	CCCN1CCN(Cc2ccnc(Nc3nc4ccc(-c5nc(C)no5)cc4[nH]3)c2)CC1		CHEMBL4461416	=	IC50	nM	16700.0	CHEMBL5408	Homo sapiens	IC50	nM	16700.0
	19152927	CHEMBL4380518	Inhibition of recombinant full length human N-terminal His-tagged TBK1 using biotin-labelled Ahx-GDEDFSSFAEPG peptide as substrate preincubated with enzyme for 15 mins followed by substrate addition and further incubated for 30 mins in presence of 1 mM of ATP by TR-FRET assay	B	Cc1noc(-c2ccc3nc(Nc4cc(CN5CCN(CCO)CC5)ccn4)[nH]c3c2)n1		CHEMBL4521346	=	IC50	nM	5110.0	CHEMBL5408	Homo sapiens	IC50	nM	5110.0
	19152928	CHEMBL4380518	Inhibition of recombinant full length human N-terminal His-tagged TBK1 using biotin-labelled Ahx-GDEDFSSFAEPG peptide as substrate preincubated with enzyme for 15 mins followed by substrate addition and further incubated for 30 mins in presence of 1 mM of ATP by TR-FRET assay	B	Cc1noc(-c2ccc3nc(Nc4cc(CN5CCN(CCC(F)(F)F)CC5)ccn4)[nH]c3c2)n1		CHEMBL4566710	=	IC50	nM	5290.0	CHEMBL5408	Homo sapiens	IC50	nM	5290.0
	19152929	CHEMBL4380518	Inhibition of recombinant full length human N-terminal His-tagged TBK1 using biotin-labelled Ahx-GDEDFSSFAEPG peptide as substrate preincubated with enzyme for 15 mins followed by substrate addition and further incubated for 30 mins in presence of 1 mM of ATP by TR-FRET assay	B	Cc1noc(-c2ccc3nc(Nc4cc(CN5CCN(CC(F)F)CC5)ccn4)[nH]c3c2)n1		CHEMBL4587843	=	IC50	nM	2040.0	CHEMBL5408	Homo sapiens	IC50	nM	2040.0
	19152930	CHEMBL4380518	Inhibition of recombinant full length human N-terminal His-tagged TBK1 using biotin-labelled Ahx-GDEDFSSFAEPG peptide as substrate preincubated with enzyme for 15 mins followed by substrate addition and further incubated for 30 mins in presence of 1 mM of ATP by TR-FRET assay	B	Cc1noc(-c2ccc3nc(Nc4cc(CN5CCN(CC(F)(F)F)CC5)ccn4)[nH]c3c2)n1		CHEMBL4438389	=	IC50	nM	3740.0	CHEMBL5408	Homo sapiens	IC50	nM	3740.0
	19152931	CHEMBL4380518	Inhibition of recombinant full length human N-terminal His-tagged TBK1 using biotin-labelled Ahx-GDEDFSSFAEPG peptide as substrate preincubated with enzyme for 15 mins followed by substrate addition and further incubated for 30 mins in presence of 1 mM of ATP by TR-FRET assay	B	Cc1noc(-c2ccc3nc(Nc4cc(CN5CCN(C(=O)C6CC6)CC5)ccn4)[nH]c3c2)n1		CHEMBL4450510	=	IC50	nM	1270.0	CHEMBL5408	Homo sapiens	IC50	nM	1270.0
	19152932	CHEMBL4380518	Inhibition of recombinant full length human N-terminal His-tagged TBK1 using biotin-labelled Ahx-GDEDFSSFAEPG peptide as substrate preincubated with enzyme for 15 mins followed by substrate addition and further incubated for 30 mins in presence of 1 mM of ATP by TR-FRET assay	B	Cc1noc(-c2ccc3nc(Nc4cc(CN5CCN(C(=O)CC6CC6)CC5)ccn4)[nH]c3c2)n1		CHEMBL4483062	=	IC50	nM	1920.0	CHEMBL5408	Homo sapiens	IC50	nM	1920.0
	19152933	CHEMBL4380518	Inhibition of recombinant full length human N-terminal His-tagged TBK1 using biotin-labelled Ahx-GDEDFSSFAEPG peptide as substrate preincubated with enzyme for 15 mins followed by substrate addition and further incubated for 30 mins in presence of 1 mM of ATP by TR-FRET assay	B	Cc1noc(-c2ccc3nc(Nc4cc(CN5CCN(C(=O)C6CCC6)CC5)ccn4)[nH]c3c2)n1		CHEMBL4573638	=	IC50	nM	2660.0	CHEMBL5408	Homo sapiens	IC50	nM	2660.0
	19152934	CHEMBL4380518	Inhibition of recombinant full length human N-terminal His-tagged TBK1 using biotin-labelled Ahx-GDEDFSSFAEPG peptide as substrate preincubated with enzyme for 15 mins followed by substrate addition and further incubated for 30 mins in presence of 1 mM of ATP by TR-FRET assay	B	Cc1noc(-c2ccc3nc(Nc4cc(CN5CCN(C(=O)c6ccco6)CC5)ccn4)[nH]c3c2)n1		CHEMBL4462056	=	IC50	nM	5070.0	CHEMBL5408	Homo sapiens	IC50	nM	5070.0
	19152935	CHEMBL4380518	Inhibition of recombinant full length human N-terminal His-tagged TBK1 using biotin-labelled Ahx-GDEDFSSFAEPG peptide as substrate preincubated with enzyme for 15 mins followed by substrate addition and further incubated for 30 mins in presence of 1 mM of ATP by TR-FRET assay	B	Cc1noc(-c2ccc3nc(Nc4cc(C(C)N5CCN(C(=O)CC(F)(F)F)CC5)ccn4)[nH]c3c2)n1		CHEMBL4455930	=	IC50	nM	829.0	CHEMBL5408	Homo sapiens	IC50	nM	829.0
	19152936	CHEMBL4380518	Inhibition of recombinant full length human N-terminal His-tagged TBK1 using biotin-labelled Ahx-GDEDFSSFAEPG peptide as substrate preincubated with enzyme for 15 mins followed by substrate addition and further incubated for 30 mins in presence of 1 mM of ATP by TR-FRET assay	B	Cc1noc(-c2ccc3nc(Nc4cc([C@H](C)N5CCN(C(=O)CC(F)(F)F)CC5)ccn4)[nH]c3c2)n1		CHEMBL4577511	=	IC50	nM	2490.0	CHEMBL5408	Homo sapiens	IC50	nM	2490.0
	19152937	CHEMBL4380518	Inhibition of recombinant full length human N-terminal His-tagged TBK1 using biotin-labelled Ahx-GDEDFSSFAEPG peptide as substrate preincubated with enzyme for 15 mins followed by substrate addition and further incubated for 30 mins in presence of 1 mM of ATP by TR-FRET assay	B	Cc1noc(-c2ccc3nc(Nc4cc([C@@H](C)N5CCN(C(=O)CC(F)(F)F)CC5)ccn4)[nH]c3c2)n1		CHEMBL4553949	=	IC50	nM	372.0	CHEMBL5408	Homo sapiens	IC50	nM	372.0
	19152938	CHEMBL4380518	Inhibition of recombinant full length human N-terminal His-tagged TBK1 using biotin-labelled Ahx-GDEDFSSFAEPG peptide as substrate preincubated with enzyme for 15 mins followed by substrate addition and further incubated for 30 mins in presence of 1 mM of ATP by TR-FRET assay	B	Cc1noc(-c2ccc3nc(Nc4cc(C(=O)N5CCN(C(=O)CC(F)(F)F)CC5)ccn4)[nH]c3c2)n1		CHEMBL4524534	>	IC50	nM	20000.0	CHEMBL5408	Homo sapiens	IC50	nM	20000.0
	19152939	CHEMBL4380518	Inhibition of recombinant full length human N-terminal His-tagged TBK1 using biotin-labelled Ahx-GDEDFSSFAEPG peptide as substrate preincubated with enzyme for 15 mins followed by substrate addition and further incubated for 30 mins in presence of 1 mM of ATP by TR-FRET assay	B	O=C(CC(F)(F)F)N1CCN(Cc2ccnc(Nc3nc4ccc(-c5nc(C6CC6)no5)cc4[nH]3)c2)CC1		CHEMBL4466150	>	IC50	nM	20000.0	CHEMBL5408	Homo sapiens	IC50	nM	20000.0
	19152940	CHEMBL4380518	Inhibition of recombinant full length human N-terminal His-tagged TBK1 using biotin-labelled Ahx-GDEDFSSFAEPG peptide as substrate preincubated with enzyme for 15 mins followed by substrate addition and further incubated for 30 mins in presence of 1 mM of ATP by TR-FRET assay	B	CC(C)Cc1noc(-c2ccc3nc(Nc4cc(CN5CCN(C(=O)CC(F)(F)F)CC5)ccn4)[nH]c3c2)n1		CHEMBL4547610	>	IC50	nM	20000.0	CHEMBL5408	Homo sapiens	IC50	nM	20000.0
	19152941	CHEMBL4380518	Inhibition of recombinant full length human N-terminal His-tagged TBK1 using biotin-labelled Ahx-GDEDFSSFAEPG peptide as substrate preincubated with enzyme for 15 mins followed by substrate addition and further incubated for 30 mins in presence of 1 mM of ATP by TR-FRET assay	B	Cn1cc(-c2ccc3nc(Nc4cc(CN5CCN(C(=O)CC(F)(F)F)CC5)ccn4)[nH]c3c2)cn1		CHEMBL4436416	=	IC50	nM	2100.0	CHEMBL5408	Homo sapiens	IC50	nM	2100.0
	19152942	CHEMBL4380518	Inhibition of recombinant full length human N-terminal His-tagged TBK1 using biotin-labelled Ahx-GDEDFSSFAEPG peptide as substrate preincubated with enzyme for 15 mins followed by substrate addition and further incubated for 30 mins in presence of 1 mM of ATP by TR-FRET assay	B	CCn1cc(-c2ccc3nc(Nc4cc(CN5CCN(C(=O)CC(F)(F)F)CC5)ccn4)[nH]c3c2)cn1		CHEMBL4453481	=	IC50	nM	530.0	CHEMBL5408	Homo sapiens	IC50	nM	530.0
	19152943	CHEMBL4380518	Inhibition of recombinant full length human N-terminal His-tagged TBK1 using biotin-labelled Ahx-GDEDFSSFAEPG peptide as substrate preincubated with enzyme for 15 mins followed by substrate addition and further incubated for 30 mins in presence of 1 mM of ATP by TR-FRET assay	B	O=C(CC(F)(F)F)N1CCN(Cc2ccnc(Nc3nc4ccc(-c5cnn(CC6CC6)c5)cc4[nH]3)c2)CC1		CHEMBL4468020	=	IC50	nM	137.0	CHEMBL5408	Homo sapiens	IC50	nM	137.0
	19152944	CHEMBL4380518	Inhibition of recombinant full length human N-terminal His-tagged TBK1 using biotin-labelled Ahx-GDEDFSSFAEPG peptide as substrate preincubated with enzyme for 15 mins followed by substrate addition and further incubated for 30 mins in presence of 1 mM of ATP by TR-FRET assay	B	C[C@H](c1ccnc(Nc2nc3ccc(-c4cnn(CC5CC5)c4)cc3[nH]2)c1)N1CCN(C(=O)CC(F)(F)F)CC1		CHEMBL4435393	=	IC50	nM	18.0	CHEMBL5408	Homo sapiens	IC50	nM	18.0
	19152945	CHEMBL4380518	Inhibition of recombinant full length human N-terminal His-tagged TBK1 using biotin-labelled Ahx-GDEDFSSFAEPG peptide as substrate preincubated with enzyme for 15 mins followed by substrate addition and further incubated for 30 mins in presence of 1 mM of ATP by TR-FRET assay	B	C[C@H](c1ccnc(Nc2nc3ccc(-c4cnn(CC5CCC5)c4)cc3[nH]2)c1)N1CCN(C(=O)CC(F)(F)F)CC1		CHEMBL4436188	=	IC50	nM	6.0	CHEMBL5408	Homo sapiens	IC50	nM	6.0
	19152946	CHEMBL4380518	Inhibition of recombinant full length human N-terminal His-tagged TBK1 using biotin-labelled Ahx-GDEDFSSFAEPG peptide as substrate preincubated with enzyme for 15 mins followed by substrate addition and further incubated for 30 mins in presence of 1 mM of ATP by TR-FRET assay	B	Cc1cc(-c2ccc3nc(Nc4cc(CN5CCN(C(=O)CC(F)(F)F)CC5)ccn4)[nH]c3c2)ccn1		CHEMBL4515413	=	IC50	nM	391.0	CHEMBL5408	Homo sapiens	IC50	nM	391.0
	19152947	CHEMBL4380518	Inhibition of recombinant full length human N-terminal His-tagged TBK1 using biotin-labelled Ahx-GDEDFSSFAEPG peptide as substrate preincubated with enzyme for 15 mins followed by substrate addition and further incubated for 30 mins in presence of 1 mM of ATP by TR-FRET assay	B	CN(C)c1cc(-c2ccc3nc(Nc4cc(CN5CCN(C(=O)CC(F)(F)F)CC5)ccn4)[nH]c3c2)ccn1		CHEMBL4451595	=	IC50	nM	388.0	CHEMBL5408	Homo sapiens	IC50	nM	388.0
	19152948	CHEMBL4380518	Inhibition of recombinant full length human N-terminal His-tagged TBK1 using biotin-labelled Ahx-GDEDFSSFAEPG peptide as substrate preincubated with enzyme for 15 mins followed by substrate addition and further incubated for 30 mins in presence of 1 mM of ATP by TR-FRET assay	B	Cc1cc(-c2ccc3nc(Nc4cc(CN5CCN(C(=O)CC(F)(F)F)CC5)ccn4)[nH]c3c2)ncn1		CHEMBL4552254	=	IC50	nM	434.0	CHEMBL5408	Homo sapiens	IC50	nM	434.0
	19152949	CHEMBL4380518	Inhibition of recombinant full length human N-terminal His-tagged TBK1 using biotin-labelled Ahx-GDEDFSSFAEPG peptide as substrate preincubated with enzyme for 15 mins followed by substrate addition and further incubated for 30 mins in presence of 1 mM of ATP by TR-FRET assay	B	Cc1cc(-c2ccc3nc(Nc4cc([C@@H](C)N5CCN(C(=O)CC(F)(F)F)CC5)ccn4)[nH]c3c2)ncn1		CHEMBL4538751	=	IC50	nM	17.0	CHEMBL5408	Homo sapiens	IC50	nM	17.0
	19152950	CHEMBL4380518	Inhibition of recombinant full length human N-terminal His-tagged TBK1 using biotin-labelled Ahx-GDEDFSSFAEPG peptide as substrate preincubated with enzyme for 15 mins followed by substrate addition and further incubated for 30 mins in presence of 1 mM of ATP by TR-FRET assay	B	COCc1cc(-c2ccc3nc(Nc4cc([C@@H](C)N5CCN(C(=O)CC(F)(F)F)CC5)ccn4)[nH]c3c2)ncn1		CHEMBL4566796	=	IC50	nM	7.0	CHEMBL5408	Homo sapiens	IC50	nM	7.0
	19152951	CHEMBL4380518	Inhibition of recombinant full length human N-terminal His-tagged TBK1 using biotin-labelled Ahx-GDEDFSSFAEPG peptide as substrate preincubated with enzyme for 15 mins followed by substrate addition and further incubated for 30 mins in presence of 1 mM of ATP by TR-FRET assay	B	C[C@H](c1ccnc(Nc2nc3ccc(-c4cc(OCC5CC5)ncn4)cc3[nH]2)c1)N1CCN(C(=O)CC(F)(F)F)CC1		CHEMBL4454902	=	IC50	nM	5.0	CHEMBL5408	Homo sapiens	IC50	nM	5.0
	19152952	CHEMBL4380518	Inhibition of recombinant full length human N-terminal His-tagged TBK1 using biotin-labelled Ahx-GDEDFSSFAEPG peptide as substrate preincubated with enzyme for 15 mins followed by substrate addition and further incubated for 30 mins in presence of 1 mM of ATP by TR-FRET assay	B	CNc1cc(-c2ccc3nc(Nc4cc(CN5CCN(C(=O)CC(F)(F)F)CC5)ccn4)[nH]c3c2)ncn1		CHEMBL4594167	=	IC50	nM	155.0	CHEMBL5408	Homo sapiens	IC50	nM	155.0
	19152953	CHEMBL4380518	Inhibition of recombinant full length human N-terminal His-tagged TBK1 using biotin-labelled Ahx-GDEDFSSFAEPG peptide as substrate preincubated with enzyme for 15 mins followed by substrate addition and further incubated for 30 mins in presence of 1 mM of ATP by TR-FRET assay	B	CN(C)c1cc(-c2ccc3nc(Nc4cc(CN5CCN(C(=O)CC(F)(F)F)CC5)ccn4)[nH]c3c2)ncn1		CHEMBL4453292	=	IC50	nM	167.0	CHEMBL5408	Homo sapiens	IC50	nM	167.0
	19152954	CHEMBL4380518	Inhibition of recombinant full length human N-terminal His-tagged TBK1 using biotin-labelled Ahx-GDEDFSSFAEPG peptide as substrate preincubated with enzyme for 15 mins followed by substrate addition and further incubated for 30 mins in presence of 1 mM of ATP by TR-FRET assay	B	C[C@H](c1ccnc(Nc2nc3ccc(-c4cc(N(C)C)ncn4)cc3[nH]2)c1)N1CCN(C(=O)CC(F)(F)F)CC1		CHEMBL4537673	=	IC50	nM	30.0	CHEMBL5408	Homo sapiens	IC50	nM	30.0
	19152955	CHEMBL4380518	Inhibition of recombinant full length human N-terminal His-tagged TBK1 using biotin-labelled Ahx-GDEDFSSFAEPG peptide as substrate preincubated with enzyme for 15 mins followed by substrate addition and further incubated for 30 mins in presence of 1 mM of ATP by TR-FRET assay	B	CC(C)Oc1cncnc1-c1ccc2nc(Nc3cc([C@@H](C)N4CCN(C(=O)CC(F)(F)F)CC4)ccn3)[nH]c2c1		CHEMBL4543618	=	IC50	nM	50.0	CHEMBL5408	Homo sapiens	IC50	nM	50.0
	19152956	CHEMBL4380518	Inhibition of recombinant full length human N-terminal His-tagged TBK1 using biotin-labelled Ahx-GDEDFSSFAEPG peptide as substrate preincubated with enzyme for 15 mins followed by substrate addition and further incubated for 30 mins in presence of 1 mM of ATP by TR-FRET assay	B	CN(C)c1ncnc(-c2ccc3nc(Nc4cc(CN5CCN(C(=O)CC(F)(F)F)CC5)ccn4)[nH]c3c2)c1Cl		CHEMBL4538591	>	IC50	nM	20000.0	CHEMBL5408	Homo sapiens	IC50	nM	20000.0
	19159680	CHEMBL4382784	Binding affinity to wild-type human full length TBK1 (M1 to L729 residues) expressed in mammalian expression system assessed as residual binding level at 1 uM by Kinomescan method relative to control	B	C=CC(=O)Nc1cc(Nc2ncc(Cl)c(Nc3ccccc3S(=O)(=O)C(C)C)n2)c(OC)cc1N(C)CCN(C)C		CHEMBL4473365	=	Activity	%	21.0	CHEMBL5408	Homo sapiens	Activity	%	21.0
	19181155	CHEMBL4387366	Inhibition of recombinant full length human GST-tagged TBK1 expressed in insect expression system at 0.1 uM using serine/threonine-5 peptide as substrate incubated for 60 mins by Z'-LYTE assay relative to control	B	CCN1CCN(Cc2ccc(Nc3ncc(F)c(-c4cc(F)c5nc(C)n(C(C)C)c5c4)n3)nc2)CC1		CHEMBL3301610	=	Inhibition	%	43.0	CHEMBL5408	Homo sapiens	INH	%	43.0
	19181380	CHEMBL4387366	Inhibition of recombinant full length human GST-tagged TBK1 expressed in insect expression system at 0.1 uM using serine/threonine-5 peptide as substrate incubated for 60 mins by Z'-LYTE assay relative to control	B	CCN1CC2(C1)CN(c1ccc(Nc3ncc(F)c(-c4cnn5c4[C@H](C)CCCC5)n3)nc1)C2		CHEMBL4545456	=	Inhibition	%	8.0	CHEMBL5408	Homo sapiens	INH	%	8.0
	19191327	CHEMBL4389503	Inhibition of wild-type human full length TBK1 (M1 to L729 residues) expressed in mammalian expression system at 10 uM by Kinomescan method relative to control	B	O=C(Nc1cccc([C@H]2CCCN(c3ncnc4[nH]ccc34)C2)c1)Nc1ccccc1N1CCCC1		CHEMBL4555459	=	Inhibition	%	57.0	CHEMBL5408	Homo sapiens	INH	%	57.0
	19192166	CHEMBL4389980	Inhibition of wild-type human full length TBK1 (M1 to L729 residues) expressed in mammalian expression system at 1 uM by Kinomescan method relative to control	B	O=C(Nc1cccc([C@@H]2CN(c3ncnc4[nH]ccc34)CCN2CCO)c1)Nc1c(F)cccc1N1CCCC1		CHEMBL4564973	=	Inhibition	%	81.0	CHEMBL5408	Homo sapiens	INH	%	81.0
	19200422	CHEMBL4391606	Binding affinity to wild-type human full length TBK1 (M1 to L729 residues) expressed in mammalian expression system assessed as residual binding level at 10 uM by Kinomescan method relative to control	B	O=C(Nc1cc(-c2cn(CCNc3c4c(nc5ccccc35)CCCC4)nn2)ccn1)Nc1cccc2c1C1CCCCN1C2=O		CHEMBL4559936	=	Activity	%	10.0	CHEMBL5408	Homo sapiens	Activity	%	10.0
	19266638	CHEMBL4405588	Inhibition of wild-type human full length TBK1 (M1 to L729 residues) expressed in mammalian expression system at 1 uM by Kinomescan method relative to control	B	CC[C@H](Nc1nc(N)nc(C)c1C#N)c1nc2cccc(NCc3ccc(C(=O)NO)cc3)c2c(=O)n1-c1ccccc1		CHEMBL4455923	<	Inhibition	%	50.0	CHEMBL5408	Homo sapiens	INH	%	50.0
	19276148	CHEMBL4408151	Inhibition of recombinant human full length TBK1 at 1 uM using KRRRALS(p)VASLPGL as substrate incubated for 40 mins in presence of [gamma-33P]-ATP by scintillation counting method relative to control	B	Cc1ccc(NC(=O)C2(C(=O)Nc3ccc(Nc4ncc(F)c(-c5cc(F)c6nc(C)n(C(C)C)c6c5)n4)cc3)CC2)cc1		CHEMBL4445335	=	Inhibition	%	9.0	CHEMBL5408	Homo sapiens	INH	%	9.0
	19303856	CHEMBL4414289	Inhibition of TBK1 (unknown origin) assessed as residual activity at 50 uM relative to control	B	O=C(O)c1ccc(Nc2nc(-c3cccc(Br)c3)cs2)cc1		CHEMBL4458300	=	Activity	%	75.0	CHEMBL5408	Homo sapiens	Activity	%	75.0
	19476637	CHEMBL4479785	Inhibition of full-length recombinant human GST-tagged TBK1 expressed in insect cells by Z'-LYTE assay	B	O=C(NCC(F)(F)F)c1cc(-c2cnn3cc(-c4ccc(OCCN5CCCCC5)cc4)cnc23)cs1		CHEMBL4569508	<	IC50	nM	10.0	CHEMBL5408	Homo sapiens	IC50	nM	10.0
	19476737	CHEMBL4479785	Inhibition of full-length recombinant human GST-tagged TBK1 expressed in insect cells by Z'-LYTE assay	B	Cn1cc(-c2cnc3c(-c4csc(C(=O)NCC(F)(F)F)c4)cnn3c2)cn1		CHEMBL4550702	<	IC50	nM	10.0	CHEMBL5408	Homo sapiens	IC50	nM	10.0
	19476837	CHEMBL4479785	Inhibition of full-length recombinant human GST-tagged TBK1 expressed in insect cells by Z'-LYTE assay	B	Cn1cc(-c2cnc3c(-c4csc(C(=O)N[C@@H]5CCCC[C@@H]5N)c4)cnn3c2)cn1		CHEMBL4568087	<	IC50	nM	1.0	CHEMBL5408	Homo sapiens	IC50	nM	1.0
	19476937	CHEMBL4479785	Inhibition of full-length recombinant human GST-tagged TBK1 expressed in insect cells by Z'-LYTE assay	B	Cc1sc(C(=O)N[C@@H]2[C@H](N)CCCC2(F)F)cc1-c1cnn2cc(Cl)cnc12		CHEMBL4552628	<	IC50	nM	10.0	CHEMBL5408	Homo sapiens	IC50	nM	10.0
	20600687	CHEMBL4603639	Inhibition of recombinant full length human GST-tagged TBK1 expressed in insect expression system using serine/threonine-5 peptide as substrate incubated for 60 mins in presence of ATP by Z'-LYTE assay	B	C[C@@H]1C[C@H]1C(=O)N1CCN(c2cnc(C#N)c(-c3cnn(C)c3)n2)C[C@H]1C		CHEMBL4634634	>	IC50	nM	100000.0	CHEMBL5408	Homo sapiens	IC50	uM	100.0
	22392176	CHEMBL4667271	Inhibition of recombinant human GST-tagged full length TBK1 expressed in insect expression system using Ser/Thr 05 as substrate at 10 uM incubated for 60 mins by Z'-Lyte assay relative to control	B	CN1C(=O)[C@@H](NC(=O)c2n[nH]c3ncc(C(F)(F)C(F)(F)F)cc23)COc2ccccc21		CHEMBL4785812	=	Inhibition	%	1.5	CHEMBL5408	Homo sapiens	INH	%	1.5
	22423195	CHEMBL4674173	Inhibition of human TBK1 using KRRRAL[pS]VASLPGL as substrate assessed as residual activity at 1 uM by [gamma-33P]-ATP assay relative to control	B	Nc1ncc(-c2cnc(C3CCNCC3)s2)cc1OC1CCCCC1		CHEMBL4785602	=	Activity	%	97.9	CHEMBL5408	Homo sapiens	Activity	%	97.9
	22423196	CHEMBL4674173	Inhibition of human TBK1 using KRRRAL[pS]VASLPGL as substrate assessed as residual activity at 1 uM by [gamma-33P]-ATP assay relative to control	B	Nc1ncc(-c2cnc(C3CCNCC3)s2)cc1OCc1ccncc1		CHEMBL4749141	=	Activity	%	16.24	CHEMBL5408	Homo sapiens	Activity	%	16.24
	22752658	CHEMBL4700135	Inhibition of human TBK1 by kinase-profiling analysis	B	C#Cc1nc(Nc2cccc(CC(N)=O)c2)nc2[nH]cnc12		CHEMBL4786783	=	IC50	nM	740.0	CHEMBL5408	Homo sapiens	IC50	uM	0.74
	22793206	CHEMBL4710178	Inhibition of recombinant human TBK1 in presence of ATP at Km concentration by radiometric filter-binding assay	B	O=C(O)c1ccc2c(c1)nc(Nc1cccc(Cl)c1)c1ccncc12		CHEMBL1230165	=	IC50	nM	35.0	CHEMBL5408	Homo sapiens	IC50	nM	35.0
	22820588	CHEMBL4716296	Inhibition of recombinant full length N-terminal His6-tagged human TBK1 expressed in baculovirus infected Sf21 insect cells assessed as residual activity at 1 uM relative to control	B	Cc1cc(Nc2ncc(Cl)c(Nc3ccccc3S(=O)(=O)C(C)C)n2)c(OC(C)C)cc1C1CCNCC1		CHEMBL2403108	=	Activity	%	94.0	CHEMBL5408	Homo sapiens	Activity	%	94.0
	22820589	CHEMBL4716296	Inhibition of recombinant full length N-terminal His6-tagged human TBK1 expressed in baculovirus infected Sf21 insect cells assessed as residual activity at 1 uM relative to control	B	COc1cc2c(cc1Nc1ncc(Cl)c(Nc3ccccc3S(=O)(=O)C(C)C)n1)CCNC2		CHEMBL4782674	=	Activity	%	64.0	CHEMBL5408	Homo sapiens	Activity	%	64.0
	22843545	CHEMBL4720531	Inhibition of human TBK1 using KRRRAL[pS]VASLPGL as substrate by [gamma-33P]-ATP assay	B	CN[C@@H]1C[C@H]2O[C@@](C)([C@@H]1OC)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)C(=O)NC4		CHEMBL388978	=	IC50	nM	3.86	CHEMBL5408	Homo sapiens	IC50	10^-9M	3.86
	22843888	CHEMBL4720874	Inhibition of human TBK1 assessed as residual activity using KRRRAL[pS]VASLPGL as substrate at 1 uM by [gamma-33P]-ATP assay relative to control	B	O=C(Nc1cc2c(Nc3ccc(F)c(Cl)c3)ncnc2cc1OCCCN1CCOCC1)c1cc([N+](=O)[O-])ccc1F		CHEMBL4750196	=	Activity	%	90.02	CHEMBL5408	Homo sapiens	Activity	%	90.02
	22844880	CHEMBL4721555	Inhibition of wild-type human full length TBK1 (M1 to L729 residues) expressed in mammalian expression system assessed as residual activity at 1 uM by Kinomescan method relative to control	B	CCOc1nc(Nc2ccc(C(=O)N3CCOCC3)cc2OC)nc2[nH]ccc12		CHEMBL4794578	=	Activity	%	91.74	CHEMBL5408	Homo sapiens	Activity	%	91.74
	22915617	CHEMBL4735393	Inhibition of wild-type human full length TBK1 (M1 to L729 residues) expressed in mammalian expression system assessed as residual activity at 1 uM by Kinomescan method relative to control	B	Nc1n[nH]c2cc(-c3ccc(=O)n(Cc4ccccc4F)c3)ccc12		CHEMBL4752141	=	Activity	%	35.0	CHEMBL5408	Homo sapiens	Activity	%	35.0
	22949498	CHEMBL4765810	Inhibition of human TBK1 assessed as residual activity at 0.1 uM relative to control	B	CNS(=O)(=O)c1ccc2c(c1)/C(=C/c1cn(C)c3ccc(OC)cc13)C(=O)N2		CHEMBL104519	=	Activity	%	97.0	CHEMBL5408	Homo sapiens	Activity	%	97.0
	22949499	CHEMBL4765810	Inhibition of human TBK1 assessed as residual activity at 0.1 uM relative to control	B	CN(C)S(=O)(=O)c1ccc2c(c1)/C(=C/c1cn(C)c3ccc(O)cc13)C(=O)N2		CHEMBL4798255	=	Activity	%	96.0	CHEMBL5408	Homo sapiens	Activity	%	96.0
	22949500	CHEMBL4765810	Inhibition of human TBK1 assessed as residual activity at 0.1 uM relative to control	B	COc1ccc2c(c1)c(/C=C1\C(=O)Nc3ccc(S(=O)(=O)N(C)C)cc31)cn2C		CHEMBL322153	=	Activity	%	100.0	CHEMBL5408	Homo sapiens	Activity	%	100.0
	22949501	CHEMBL4765810	Inhibition of human TBK1 assessed as residual activity at 0.1 uM relative to control	B	COc1ccc2[nH]cc(/C=C3\C(=O)Nc4ccc(S(N)(=O)=O)cc43)c2c1		CHEMBL106226	=	Activity	%	96.0	CHEMBL5408	Homo sapiens	Activity	%	96.0
	22949502	CHEMBL4765810	Inhibition of human TBK1 assessed as residual activity at 0.1 uM relative to control	B	COc1ccc2c(c1)c(/C=C1\C(=O)Nc3ccc(S(N)(=O)=O)cc31)cn2C		CHEMBL104333	=	Activity	%	79.0	CHEMBL5408	Homo sapiens	Activity	%	79.0
	22949503	CHEMBL4765810	Inhibition of human TBK1 assessed as residual activity at 0.1 uM relative to control	B	Cn1cc(/C=C2\C(=O)Nc3ccc(S(N)(=O)=O)cc32)c2ccccc21		CHEMBL104279	=	Activity	%	75.0	CHEMBL5408	Homo sapiens	Activity	%	75.0
	22949504	CHEMBL4765811	Inhibition of human TBK1 assessed as residual activity at 1 uM relative to control	B	CNS(=O)(=O)c1ccc2c(c1)/C(=C/c1cn(C)c3ccc(OC)cc13)C(=O)N2		CHEMBL104519	=	Activity	%	93.0	CHEMBL5408	Homo sapiens	Activity	%	93.0
	22949505	CHEMBL4765811	Inhibition of human TBK1 assessed as residual activity at 1 uM relative to control	B	CN(C)S(=O)(=O)c1ccc2c(c1)/C(=C/c1cn(C)c3ccc(O)cc13)C(=O)N2		CHEMBL4798255	=	Activity	%	81.0	CHEMBL5408	Homo sapiens	Activity	%	81.0
	22949506	CHEMBL4765811	Inhibition of human TBK1 assessed as residual activity at 1 uM relative to control	B	COc1ccc2c(c1)c(/C=C1\C(=O)Nc3ccc(S(=O)(=O)N(C)C)cc31)cn2C		CHEMBL322153	=	Activity	%	79.0	CHEMBL5408	Homo sapiens	Activity	%	79.0
	22949507	CHEMBL4765811	Inhibition of human TBK1 assessed as residual activity at 1 uM relative to control	B	COc1ccc2[nH]cc(/C=C3\C(=O)Nc4ccc(S(N)(=O)=O)cc43)c2c1		CHEMBL106226	=	Activity	%	62.0	CHEMBL5408	Homo sapiens	Activity	%	62.0
	22949508	CHEMBL4765811	Inhibition of human TBK1 assessed as residual activity at 1 uM relative to control	B	COc1ccc2c(c1)c(/C=C1\C(=O)Nc3ccc(S(N)(=O)=O)cc31)cn2C		CHEMBL104333	=	Activity	%	55.0	CHEMBL5408	Homo sapiens	Activity	%	55.0
	22949509	CHEMBL4765811	Inhibition of human TBK1 assessed as residual activity at 1 uM relative to control	B	Cn1cc(/C=C2\C(=O)Nc3ccc(S(N)(=O)=O)cc32)c2ccccc21		CHEMBL104279	=	Activity	%	58.0	CHEMBL5408	Homo sapiens	Activity	%	58.0
	22953015	CHEMBL4766952	Inhibition of recombinant full length human TBK1 assessed as residual activity at 10 uM using KRRRALS(p)VASLPGL as substrate incubated for 40 mins in presence of [gamma33P]ATP by scintillation counting based radiometry assay relative to control	B	CC(C)(C)c1cc(NC(=O)Nc2ccc(Nc3ncnc4c3OCCCN4)cc2)no1		CHEMBL4793380	=	Activity	%	85.0	CHEMBL5408	Homo sapiens	Activity	%	85.0
	23121109	CHEMBL4804505	Inhibition of TBK1 in human NCI-H929 cells by mass spectroscopic analysis	B	Nc1ncc(-c2cccc3ncsc23)cc1-c1ccc2c(c1)CCNC2=O	Outside typical range	CHEMBL4855542	=	IC50	nM	-23100.0	CHEMBL5408	Homo sapiens	IC50	uM	-23.1
	23121110	CHEMBL4804505	Inhibition of TBK1 in human NCI-H929 cells by mass spectroscopic analysis	B	CN(C1CC1)S(=O)(=O)c1ccc(-c2cnc(N)c(-c3ccc4c(c3)CCNC4=O)c2)c(F)c1		CHEMBL4860979	=	IC50	nM	3400.0	CHEMBL5408	Homo sapiens	IC50	uM	3.4
	23121111	CHEMBL4804505	Inhibition of TBK1 in human NCI-H929 cells by mass spectroscopic analysis	B	COc1cc(NS(=O)(=O)C2CC2)ccc1-c1cnc(N)c(-c2ccc3c(c2)CCNC3=O)c1	Outside typical range	CHEMBL4867931	=	IC50	nM	-7500.0	CHEMBL5408	Homo sapiens	IC50	uM	-7.5
	23121112	CHEMBL4804505	Inhibition of TBK1 in human NCI-H929 cells by mass spectroscopic analysis	B	Nc1ncc(-c2ccc(NS(=O)(=O)C3CC3)cc2F)cc1-c1ccc2c(c1)CCNC2=O		CHEMBL4855730	=	IC50	nM	35800.0	CHEMBL5408	Homo sapiens	IC50	uM	35.8
	23121113	CHEMBL4804505	Inhibition of TBK1 in human NCI-H929 cells by mass spectroscopic analysis	B	Nc1ncc(-c2ccc(NS(=O)(=O)C3CC3)cc2OC2CCCCC2)cc1-c1ccc2c(c1)CCNC2=O		CHEMBL4868141	=	IC50	nM	74600.0	CHEMBL5408	Homo sapiens	IC50	uM	74.6
	23121114	CHEMBL4804505	Inhibition of TBK1 in human NCI-H929 cells by mass spectroscopic analysis	B	Nc1ncc(-c2cccc([N+](=O)[O-])c2F)cc1-c1ccc2c(c1)CCNC2=O		CHEMBL4859660	=	IC50	nM	23700.0	CHEMBL5408	Homo sapiens	IC50	uM	23.7
	23122147	CHEMBL4804687	Inhibition of TBK1 in human NCI-H929 cells at 10 uM by mass spectroscopic analysis relative to control	B	Nc1ncc(-c2cccc3ncsc23)cc1-c1ccc2c(c1)CCNC2=O		CHEMBL4855542	=	Inhibition	%	0.0	CHEMBL5408	Homo sapiens	INH	%	0.0
	23122148	CHEMBL4804687	Inhibition of TBK1 in human NCI-H929 cells at 10 uM by mass spectroscopic analysis relative to control	B	CN(C1CC1)S(=O)(=O)c1ccc(-c2cnc(N)c(-c3ccc4c(c3)CCNC4=O)c2)c(F)c1		CHEMBL4860979	=	Inhibition	%	0.0	CHEMBL5408	Homo sapiens	INH	%	0.0
	23122149	CHEMBL4804687	Inhibition of TBK1 in human NCI-H929 cells at 10 uM by mass spectroscopic analysis relative to control	B	COc1cc(NS(=O)(=O)C2CC2)ccc1-c1cnc(N)c(-c2ccc3c(c2)CCNC3=O)c1		CHEMBL4867931	=	Inhibition	%	0.0	CHEMBL5408	Homo sapiens	INH	%	0.0
	23122150	CHEMBL4804687	Inhibition of TBK1 in human NCI-H929 cells at 10 uM by mass spectroscopic analysis relative to control	B	Nc1ncc(-c2ccc(NS(=O)(=O)C3CC3)cc2F)cc1-c1ccc2c(c1)CCNC2=O		CHEMBL4855730	=	Inhibition	%	35.0	CHEMBL5408	Homo sapiens	INH	%	35.0
	23122151	CHEMBL4804687	Inhibition of TBK1 in human NCI-H929 cells at 10 uM by mass spectroscopic analysis relative to control	B	Nc1ncc(-c2ccc(NS(=O)(=O)C3CC3)cc2OC2CCCCC2)cc1-c1ccc2c(c1)CCNC2=O		CHEMBL4868141	=	Inhibition	%	50.0	CHEMBL5408	Homo sapiens	INH	%	50.0
	23122152	CHEMBL4804687	Inhibition of TBK1 in human NCI-H929 cells at 10 uM by mass spectroscopic analysis relative to control	B	Nc1ncc(-c2cccc([N+](=O)[O-])c2F)cc1-c1ccc2c(c1)CCNC2=O		CHEMBL4859660	=	Inhibition	%	0.0	CHEMBL5408	Homo sapiens	INH	%	0.0
	23122837	CHEMBL4805188	Inhibition of human TBK1 assessed as percent of control at 2000 nM by KINOMEscan assay relative to control	B	CN1CCN(C(=O)c2ccc3cc(CCNc4ccnc5ccc(C#N)cc45)ccc3c2)CC1		CHEMBL4878072	=	Activity	%	88.0	CHEMBL5408	Homo sapiens	Activity	%	88.0
	23123532	CHEMBL4805776	Inhibition of human TBK1 assessed as percent of control at 1000 nM by KINOMEscan assay relative to control	B	COc1cc2nc(NC3CC3)nc(NC3CCN(C(C)C)CC3)c2cc1OC.O=C(O)C(F)(F)F		CHEMBL4870304	=	Activity	%	98.0	CHEMBL5408	Homo sapiens	Activity	%	98.0
	23123984	CHEMBL4806228	Inhibition of DNA-tagged human TBK1 assessed as percent of control at 50000 nM by qPCR analysis relative to control	B	CN1C(=O)/C(=C2/C(=O)Nc3ccccc32)c2ccccc21		CHEMBL607535	=	Activity	%	50.0	CHEMBL5408	Homo sapiens	Activity	%	50.0
	23125154	CHEMBL4806793	Inhibition of human TBK1 assessed as percent of control at 2000 nM by KINOMEscan assay relative to control	B	CN(C)C(=O)c1ccc(N2CCCN(c3ccnc4sc(C(N)=O)c(N)c34)CC2)cc1		CHEMBL2348350	=	Activity	%	99.0	CHEMBL5408	Homo sapiens	Activity	%	99.0
	23125155	CHEMBL4806793	Inhibition of human TBK1 assessed as percent of control at 2000 nM by KINOMEscan assay relative to control	B	CN(C)C(=O)c1ccc(N2CCCN(c3ccnc4sc(C(N)=O)c(N)c34)CC2)cc1		CHEMBL2348350	=	Activity	%	97.0	CHEMBL5408	Homo sapiens	Activity	%	97.0
	23127477	CHEMBL4807627	Inhibition of TBK1 (unknown origin) assessed as residual activity at 1 uM	B	Cc1nc(Nc2ncc(C(=O)Nc3c(C)csc3Cl)s2)cc(N2CCN(CCO)CC2)n1		CHEMBL4867844	=	Activity	%	49.0	CHEMBL5408	Homo sapiens	Activity	%	49.0
	23127478	CHEMBL4807627	Inhibition of TBK1 (unknown origin) assessed as residual activity at 1 uM	B	Cc1nc(Nc2ncc(C(=O)Nc3c(C)cccc3Cl)s2)cc(N2CCN(CCO)CC2)n1		CHEMBL1421	=	Activity	%	86.0	CHEMBL5408	Homo sapiens	Activity	%	86.0
	23128632	CHEMBL4808019	Inhibition of TBK1 (unknown origin) assessed as residual activity measured at 1 uM	B	Cc1nc(Nc2ncc(C(=O)Nc3c(C)csc3Cl)s2)cc(N2CCN(CCO)CC2)n1		CHEMBL4867844	=	Activity	%	25.0	CHEMBL5408	Homo sapiens	Activity	%	25.0
	23128633	CHEMBL4808019	Inhibition of TBK1 (unknown origin) assessed as residual activity measured at 1 uM	B	Cc1nc(Nc2ncc(C(=O)Nc3c(Cl)ccnc3C)s2)cc(NN2CCN(CCO)CC2)n1		CHEMBL4855726	>	Activity	%	75.0	CHEMBL5408	Homo sapiens	Activity	%	75.0
	23128634	CHEMBL4808019	Inhibition of TBK1 (unknown origin) assessed as residual activity measured at 1 uM	B	Cc1nc(Nc2ncc(C(=O)Nc3c(C)cccc3Cl)s2)cc(N2CCN(CCO)CC2)n1		CHEMBL1421	>	Activity	%	75.0	CHEMBL5408	Homo sapiens	Activity	%	75.0
	23248259	CHEMBL4830436	Inhibition of human TBK1 using KRRRAL[pS]VASLPGL as substrate assessed as enzyme activity incubated for 2 hrs by [gamma-33P]-ATP assay relative to control	B	CC(C)c1c2cc(-c3ccnc(Nc4ccc5c(N6CCN(C)CC6)ccnc5c4)n3)ccc2nn1C		CHEMBL4856177	<	Activity	%	20.0	CHEMBL5408	Homo sapiens	Activity	%	20.0
	23295515	CHEMBL4840527	Inhibition of recombinant GST-tagged full length human TBK1 expressed in baculovirus expression system at 1 uM measured by select screen assay relative to control	B	CN1CCN(c2ccc(C(=O)Nc3n[nH]c4c3CN(Cc3cc(F)cc(F)c3)C4(C)C)cc2)CC1		CHEMBL4849505	=	Inhibition	%	7.0	CHEMBL5408	Homo sapiens	INH	%	7.0
	23299266	CHEMBL4841733	Inhibition of TBK1 (unknown origin) at 1000 nM relative to control	B	Nc1c(-c2nc3cc(N4CCN(C(=O)CCCCCNc5cccc6c5C(=O)N(C5CCC(=O)NC5=O)C6=O)CC4)ccc3[nH]2)c(=O)[nH]c2cccc(F)c12		CHEMBL4860038	=	Inhibition	%	22.0	CHEMBL5408	Homo sapiens	INH	%	22.0
	23299267	CHEMBL4841733	Inhibition of TBK1 (unknown origin) at 1000 nM relative to control	B	CN1CCN(c2ccc3nc(-c4c(N)c5c(F)cccc5[nH]c4=O)[nH]c3c2)CC1		CHEMBL522892	=	Inhibition	%	64.0	CHEMBL5408	Homo sapiens	INH	%	64.0
Not Active	23317673	CHEMBL4879979	KinomeScan assay: inhibition of TBK1	B	CCC(=N\O)/C(C)=C/c1ccc(F)cc1		CHEMBL3697701		% Control	%	75.0	CHEMBL5408	Homo sapiens	% Control	%	75.0
Not Active	23318141	CHEMBL4879979	KinomeScan assay: inhibition of TBK1	B	CCC(=N\O)/C(C)=C/c1ccc(F)c(C)c1		CHEMBL3701197		% Control	%	93.0	CHEMBL5408	Homo sapiens	% Control	%	93.0
Not Active	23318807	CHEMBL4879979	KinomeScan assay: inhibition of TBK1	B	Cn1cncc1[C@](O)(COc1ccc(C#N)cc1-c1ccc(OC(F)(F)F)cc1)c1ccc(C#N)cc1		CHEMBL4586794		% Control	%	100.0	CHEMBL5408	Homo sapiens	% Control	%	100.0
Not Active	23319291	CHEMBL4879979	KinomeScan assay: inhibition of TBK1	B	Cn1cncc1[C@@](O)(COc1ccc(C#N)cc1-c1ccc(OC(F)(F)F)cc1)c1ccc(C#N)cc1		CHEMBL4526341		% Control	%	100.0	CHEMBL5408	Homo sapiens	% Control	%	100.0
Not Active	23319927	CHEMBL4879979	KinomeScan assay: inhibition of TBK1	B	CCCCN(CCCC)C(=O)CN1C[C@H](c2cc(OC)c3c(c2)OCO3)[C@@H](C(=O)O)[C@@H]1CC(C)(C)CCC		CHEMBL111612		% Control	%	100.0	CHEMBL5408	Homo sapiens	% Control	%	100.0
Not Active	23320403	CHEMBL4879979	KinomeScan assay: inhibition of TBK1	B	CCCCN(CCCC)C(=O)CN1C[C@@H](c2cc(OC)c3c(c2)OCO3)[C@H](C(=O)O)[C@H]1CC(C)(C)CCC		CHEMBL4513786		% Control	%	100.0	CHEMBL5408	Homo sapiens	% Control	%	100.0
Not Active	23321081	CHEMBL4879979	KinomeScan assay: inhibition of TBK1	B	c1ccc(N2CCN(Cc3nc4ccccc4[nH]3)CC2)nc1		CHEMBL440687		% Control	%	77.0	CHEMBL5408	Homo sapiens	% Control	%	77.0
Not Active	23321549	CHEMBL4879979	KinomeScan assay: inhibition of TBK1	B	CSc1cccnc1N1CCN(Cc2nc3ccccc3[nH]2)CC1		CHEMBL4630641		% Control	%	100.0	CHEMBL5408	Homo sapiens	% Control	%	100.0
Not Active	23322179	CHEMBL4879979	KinomeScan assay: inhibition of TBK1	B	CCCOc1ccc([C@H]2[C@H](C(=O)O)[C@@H](c3ccc4c(c3)OCO4)CN2CC(=O)Nc2c(CC)cccc2CC)cc1		CHEMBL332794		% Control	%	91.0	CHEMBL5408	Homo sapiens	% Control	%	91.0
Not Active	23322647	CHEMBL4879979	KinomeScan assay: inhibition of TBK1	B	CCCOc1ccc([C@@H]2[C@@H](C(=O)O)[C@H](c3ccc4c(c3)OCO4)CN2CC(=O)Nc2c(CC)cccc2CC)cc1		CHEMBL4533479		% Control	%	100.0	CHEMBL5408	Homo sapiens	% Control	%	100.0
Not Active	23323336	CHEMBL4879979	KinomeScan assay: inhibition of TBK1	B	COc1ccc2c(c1)O[C@@H](c1ccc(OC)c(OC)c1)C[C@H]2NC(=O)C1(c2ccc3c(c2)OC(F)(F)O3)CC1		CHEMBL4093612		% Control	%	86.0	CHEMBL5408	Homo sapiens	% Control	%	86.0
Not Active	23323804	CHEMBL4879979	KinomeScan assay: inhibition of TBK1	B	COc1ccc2c(c1)O[C@H](c1ccc(OC)c(OC)c1)C[C@@H]2NC(=O)C1(c2ccc3c(c2)OC(F)(F)O3)CC1		CHEMBL4066040		% Control	%	99.0	CHEMBL5408	Homo sapiens	% Control	%	99.0
Not Active	23324147	CHEMBL4880765	TBK1 (h) Millipore kinase activity assay	B	CC1=C(C#N)C(c2ccc3[nH]nc(C)c3c2)C(C#N)=C(C)N1		CHEMBL4593677		Inhibition	%	-6.0	CHEMBL5408	Homo sapiens	% inhibition	%	-6.0
Not Active	23324658	CHEMBL4879979	KinomeScan assay: inhibition of TBK1	B	CC1=C(C#N)[C@@H](c2ccc3[nH]nc(C)c3c2)C(C#N)=C(c2ccc(Cl)cc2)N1		CHEMBL4522773		% Control	%	58.7	CHEMBL5408	Homo sapiens	% Control	%	58.7
Not Active	23325293	CHEMBL4879979	KinomeScan assay: inhibition of TBK1	B	O=C(c1ccc(OCCC2CCOCC2)cc1)[C@H]1CC[C@@H](Cn2nnc3ccccc3c2=O)[C@@H]1C(=O)O		CHEMBL4585243		% Control	%	94.0	CHEMBL5408	Homo sapiens	% Control	%	94.0
Not Active	23325761	CHEMBL4879979	KinomeScan assay: inhibition of TBK1	B	O=C(c1ccc(OCCC2CCOCC2)cc1)[C@@H]1CC[C@H](Cn2nnc3ccccc3c2=O)[C@H]1C(=O)O		CHEMBL4539943		% Control	%	100.0	CHEMBL5408	Homo sapiens	% Control	%	100.0
Not Active	23326408	CHEMBL4879979	KinomeScan assay: inhibition of TBK1	B	NS(=O)(=O)c1cc(NC(=O)Cc2ccccc2)ccc1Oc1cccc(Cl)c1		CHEMBL4521594		% Control	%	68.0	CHEMBL5408	Homo sapiens	% Control	%	68.0
Not Active	23326876	CHEMBL4879979	KinomeScan assay: inhibition of TBK1	B	NS(=O)(=O)c1cc(NC(=O)C2(c3ccccc3Cl)CC2)ccc1Oc1cccc(Cl)c1		CHEMBL4516843		% Control	%	62.0	CHEMBL5408	Homo sapiens	% Control	%	62.0
Not Active	23327576	CHEMBL4879979	KinomeScan assay: inhibition of TBK1	B	O=C(NCc1ncc(C(F)(F)F)cc1Cl)c1ccc2c(c1)C1(CCS(=O)(=O)CC1)[C@H](C1CC1)N2S(=O)(=O)c1ccc(F)cc1		CHEMBL4537788		% Control	%	80.0	CHEMBL5408	Homo sapiens	% Control	%	80.0
Not Active	23328044	CHEMBL4879979	KinomeScan assay: inhibition of TBK1	B	O=C(NCc1ncc(C(F)(F)F)cc1Cl)c1ccc2c(c1)C1(CCS(=O)(=O)CC1)[C@@H](C1CC1)N2S(=O)(=O)c1ccc(F)cc1		CHEMBL4564312		% Control	%	84.0	CHEMBL5408	Homo sapiens	% Control	%	84.0
Not Active	23328631	CHEMBL4879979	KinomeScan assay: inhibition of TBK1	B	Cc1c(NC(=O)c2cc(C(N)=O)nc3cc(F)ccc23)c(C(F)(F)F)nn1Cc1ccc(C#N)cc1		CHEMBL4448899		% Control	%	70.0	CHEMBL5408	Homo sapiens	% Control	%	70.0
Not Active	23329099	CHEMBL4879979	KinomeScan assay: inhibition of TBK1	B	Cc1c(NC(=O)c2cc(C(N)=O)nc3cc(F)ccc23)c(C(F)(F)F)nn1Cc1ccc(C(C)(C)C)cc1		CHEMBL4552180		% Control	%	95.0	CHEMBL5408	Homo sapiens	% Control	%	95.0
Not Active	23329548	CHEMBL4881255	TBK1(h) Eurofins Kinase panel	B	CN1CCN(c2cnc3c(C4CCN(C(=O)c5ccc(OC(F)(F)F)cc5N)CC4)ncnc3c2)CC1		CHEMBL4445670		% residual kinase activity	%	118.0	CHEMBL5408	Homo sapiens	% residual kinase activity	%	118.0
Not Active	23330045	CHEMBL4879979	KinomeScan assay: inhibition of TBK1	B	CN1CCN(c2cnc3c(C4CCN(C(=O)c5ccc(OC(F)(F)F)cc5N)CC4)ncnc3c2)CC1		CHEMBL4445670		% Control	%	61.0	CHEMBL5408	Homo sapiens	% Control	%	61.0
Not Active	23330513	CHEMBL4879979	KinomeScan assay: inhibition of TBK1	B	Cc1nc(C2CCN(C(=O)c3ccc(OC(F)(F)F)cc3N)CC2)c2ncc(N3CCN(C)CC3)cc2n1		CHEMBL4455582		% Control	%	100.0	CHEMBL5408	Homo sapiens	% Control	%	100.0
Not Active	23331269	CHEMBL4879979	KinomeScan assay: inhibition of TBK1	B	O=C(N1CCS(=O)(=O)CC1)N1C[C@H](c2ccc(OC(F)(F)F)cc2)C[C@H](c2nc(C3CC3)no2)C1		CHEMBL4630644		% Control	%	94.0	CHEMBL5408	Homo sapiens	% Control	%	94.0
Not Active	23331737	CHEMBL4879979	KinomeScan assay: inhibition of TBK1	B	Cc1noc([C@H]2C[C@@H](c3ccc(C(F)(F)F)cc3)CN(C(=O)N3CCS(=O)(=O)C3)C2)n1		CHEMBL4630643		% Control	%	68.0	CHEMBL5408	Homo sapiens	% Control	%	68.0
Not Active	23332324	CHEMBL4879979	KinomeScan assay: inhibition of TBK1	B	Cc1cc(C)c(-n2ccn3nc(-c4cccnc4)cc23)cc1NC(=O)c1cc(C#N)cc(S(F)(F)(F)(F)F)c1		CHEMBL3907057		% Control	%	62.8	CHEMBL5408	Homo sapiens	% Control	%	62.8
Slightly Active	23332790	CHEMBL4879979	KinomeScan assay: inhibition of TBK1	B	Cc1cc(NC(=O)c2cccc(S(F)(F)(F)(F)F)c2)cc(-n2ccn3nc(-c4cccnc4)cc23)c1		CHEMBL4526351		% Control	%	49.7	CHEMBL5408	Homo sapiens	% Control	%	49.7
Not Active	23333508	CHEMBL4879979	KinomeScan assay: inhibition of TBK1	B	CC(=O)C1=C(C)N(c2cccc(C(F)(F)F)c2)C(=O)N[C@@H]1c1ccc(C#N)nc1		CHEMBL3617968		% Control	%	89.5	CHEMBL5408	Homo sapiens	% Control	%	89.5
Not Active	23334147	CHEMBL4879979	KinomeScan assay: inhibition of TBK1	B	CNCc1ccccc1-c1csc([C@@H](C)Nc2nc(C)nc3cc(OC)c(OC)cc23)c1		CHEMBL4535474		% Control	%	100.0	CHEMBL5408	Homo sapiens	% Control	%	100.0
Not Active	23334615	CHEMBL4879979	KinomeScan assay: inhibition of TBK1	B	CNCc1ccccc1-c1csc([C@H](C)Nc2nc(C)nc3cc(OC)c(OC)cc23)c1		CHEMBL4520788		% Control	%	100.0	CHEMBL5408	Homo sapiens	% Control	%	100.0
Not Active	23335594	CHEMBL4879979	KinomeScan assay: inhibition of TBK1	B	Cc1c[nH]c2nccc(Oc3c(F)cc(Nc4cc(Cl)nc(N)n4)cc3F)c12		CHEMBL1971943		% Control	%	96.0	CHEMBL5408	Homo sapiens	% Control	%	96.0
Not Active	23336062	CHEMBL4879979	KinomeScan assay: inhibition of TBK1	B	Cn1cc(Cl)c2c(Oc3c(F)cc(Nc4cc(Cl)nc(N)n4)cc3F)ccnc21		CHEMBL4546802		% Control	%	100.0	CHEMBL5408	Homo sapiens	% Control	%	100.0
Not Active	23336689	CHEMBL4879979	KinomeScan assay: inhibition of TBK1	B	O=C(NC[C@H]1[C@@H]2CN(C(=O)OCc3cc(C(F)(F)F)cc(C(F)(F)F)c3)C[C@H]12)c1ccc2[nH]nnc2c1		CHEMBL4165749		% Control	%	100.0	CHEMBL5408	Homo sapiens	% Control	%	100.0
Not Active	23337157	CHEMBL4879979	KinomeScan assay: inhibition of TBK1	B	Cc1nccc(COC(=O)N2C[C@H]3[C@H](CNC(=O)c4ccc5[nH]nnc5c4)[C@H]3C2)n1		CHEMBL4552354		% Control	%	96.0	CHEMBL5408	Homo sapiens	% Control	%	96.0
Not Active	23337795	CHEMBL4882166	TBK1 Invitrogen selectivity data (BI)	B	CN(C)C(=O)Cn1cc(-c2nc([C@@](C)(c3ccc(-c4cnc(N)nc4)cc3)C3CC3)no2)cn1		CHEMBL3417525		% Ctrl	%	92.0	CHEMBL5408	Homo sapiens	% Ctrl	%	92.0
Not Active	23338238	CHEMBL4879979	KinomeScan assay: inhibition of TBK1	B	CN(C)C(=O)Cn1cc(-c2nc([C@@](C)(c3ccc(-c4cnc(N)nc4)cc3)C3CC3)no2)cn1		CHEMBL3417525		% Control	%	85.0	CHEMBL5408	Homo sapiens	% Control	%	85.0
Not Active	23338706	CHEMBL4879979	KinomeScan assay: inhibition of TBK1	B	CN(C)C(=O)Cn1cc(-c2nc(C3(c4ccc(-c5cnc(N)nc5)cc4)CC3)no2)cn1		CHEMBL4560241		% Control	%	87.0	CHEMBL5408	Homo sapiens	% Control	%	87.0
Not Active	23339318	CHEMBL4879979	KinomeScan assay: inhibition of TBK1	B	CCS(=O)(=O)c1cc2cc(C[C@](O)(CC(C)(C)c3ccc(F)cc3C(N)=O)C(F)(F)F)[nH]c2cn1		CHEMBL3358954		% Control	%	93.0	CHEMBL5408	Homo sapiens	% Control	%	93.0
Not Active	23339786	CHEMBL4879979	KinomeScan assay: inhibition of TBK1	B	CCS(=O)(=O)c1cc2cc(C[C@@](O)(CC(C)(C)c3ccc(F)cc3C(N)=O)C(F)(F)F)[nH]c2cn1		CHEMBL4531220		% Control	%	87.0	CHEMBL5408	Homo sapiens	% Control	%	87.0
Not Active	23340423	CHEMBL4879979	KinomeScan assay: inhibition of TBK1	B	CS(=O)(=O)c1cc(C2(NC(=O)c3cncc4c3cnn4-c3ccc(F)cc3)CC2)ccn1		CHEMBL4456123		% Control	%	94.0	CHEMBL5408	Homo sapiens	% Control	%	94.0
Not Active	23340891	CHEMBL4879979	KinomeScan assay: inhibition of TBK1	B	CS(=O)(=O)NCC[C@H](NC(=O)c1cncc2c1cnn2-c1ccc(F)cc1)c1ccnc(S(C)(=O)=O)c1		CHEMBL4539555		% Control	%	94.0	CHEMBL5408	Homo sapiens	% Control	%	94.0
Not Active	23341548	CHEMBL4879979	KinomeScan assay: inhibition of TBK1	B	CC(=O)N1CCC(c2ccc(C(=O)NC(=N)N)cc2C(F)(F)F)CC1		CHEMBL2170610		% Control	%	100.0	CHEMBL5408	Homo sapiens	% Control	%	100.0
Not Active	23342016	CHEMBL4879979	KinomeScan assay: inhibition of TBK1	B	CC(=O)N1CCC(c2ccc(C(=O)NC3=NCCN3)cc2C(F)(F)F)CC1		CHEMBL4540759		% Control	%	98.0	CHEMBL5408	Homo sapiens	% Control	%	98.0
Not Active	23342632	CHEMBL4879979	KinomeScan assay: inhibition of TBK1	B	CCC(=O)N[C@H]1CC[C@@H](C(=O)N(C)c2ccc(-c3nc4ccccc4o3)cc2)C1		CHEMBL1834184		% Control	%	78.0	CHEMBL5408	Homo sapiens	% Control	%	78.0
Not Active	23343100	CHEMBL4879979	KinomeScan assay: inhibition of TBK1	B	CCC(=O)N[C@@H]1CC[C@H](C(=O)N(C)c2ccc(-c3nc4ccccc4o3)cc2)C1		CHEMBL1834199		% Control	%	65.0	CHEMBL5408	Homo sapiens	% Control	%	65.0
Not Active	23343730	CHEMBL4879979	KinomeScan assay: inhibition of TBK1	B	CCOC(=O)c1cc2cc(-c3cc(C(=O)NCc4ccc(C(=O)O)cc4)nn3C)ccc2[nH]1		CHEMBL1939876		% Control	%	84.0	CHEMBL5408	Homo sapiens	% Control	%	84.0
Not Active	23344198	CHEMBL4879979	KinomeScan assay: inhibition of TBK1	B	Cn1nc(C(=O)NCc2ccc(C(=O)O)cc2)cc1-c1ccc2[nH]ccc2c1		CHEMBL1939880		% Control	%	77.0	CHEMBL5408	Homo sapiens	% Control	%	77.0
Not Active	23344836	CHEMBL4879979	KinomeScan assay: inhibition of TBK1	B	CCOCCn1cc(C(=O)Nc2ccc(-n3nc(-c4cccnc4)cc3C(F)(F)F)cn2)ccc1=O		CHEMBL4516982		% Control	%	76.0	CHEMBL5408	Homo sapiens	% Control	%	76.0
Not Active	23345409	CHEMBL4879979	KinomeScan assay: inhibition of TBK1	B	COc1ccc2c(O[C@@H]3C[C@H]4C(=O)N[C@]5(C(=O)O)CC5/C=C\CCCCC[C@H](NC(=O)OC5CCCC5)C(=O)N4C3)cc(-c3csc(NC(=O)C(C)C)n3)nc2c1C		CHEMBL4588900		% Control	%	86.0	CHEMBL5408	Homo sapiens	% Control	%	86.0
Not Active	23345877	CHEMBL4879979	KinomeScan assay: inhibition of TBK1	B	O=C(N[C@H]1CCCCC/C=C\C2C[C@@]2(C(=O)O)NC(=O)[C@@H]2C[C@@H](Oc3ccncc3)CN2C1=O)OC1CCCC1		CHEMBL4516471		% Control	%	100.0	CHEMBL5408	Homo sapiens	% Control	%	100.0
Not Active	23346453	CHEMBL4879979	KinomeScan assay: inhibition of TBK1	B	Cc1cc(Nc2nccc(C)n2)cc(-c2cnc([C@@]3(O)CC[C@H](C(=O)O)C(C)(C)C3)s2)c1		CHEMBL3685796		% Control	%	55.5	CHEMBL5408	Homo sapiens	% Control	%	55.5
Not Active	23346922	CHEMBL4879979	KinomeScan assay: inhibition of TBK1	B	Cc1ccc(-c2cnc([C@@]3(O)CC[C@H](C(=O)O)C(C)(C)C3)s2)cc1Nc1cccc(C(F)(F)F)n1		CHEMBL4530401		% Control	%	86.4	CHEMBL5408	Homo sapiens	% Control	%	86.4
Not Active	23347083	CHEMBL4882610	Invitrogen kinase screen (TBK1)	B	C[C@@H](NC(=O)Nc1cc2[nH]ncc2c(CO)n1)c1ccccc1	Non standard unit for type	CHEMBL4538174		IC50	µM	0.77	CHEMBL5408	Homo sapiens	IC50	µM	0.77
Not Active	23347522	CHEMBL4879979	KinomeScan assay: inhibition of TBK1	B	C[C@@H](NC(=O)Nc1cc2[nH]ncc2c(CO)n1)c1ccccc1		CHEMBL4538174		% Control	%	84.8	CHEMBL5408	Homo sapiens	% Control	%	84.8
Slightly Active	23348014	CHEMBL4879979	KinomeScan assay: inhibition of TBK1	B	C[C@H](NC(=O)Nc1cc2[nH]ncc2c(CO)n1)c1ccccn1		CHEMBL4557026		% Control	%	48.3	CHEMBL5408	Homo sapiens	% Control	%	48.3
Not Active	23348593	CHEMBL4879979	KinomeScan assay: inhibition of TBK1	B	CC(=O)Nc1c(C(C)=O)c(=O)n(C)c2nc(-c3ccc(Cl)cc3Cl)c(-c3ccc(Cl)cc3)cc12		CHEMBL204232		% Control	%	81.0	CHEMBL5408	Homo sapiens	% Control	%	81.0
Not Active	23349061	CHEMBL4879979	KinomeScan assay: inhibition of TBK1	B	CC(=O)c1c(NS(C)(=O)=O)c2cc(-c3ccc(Cl)cc3)c(-c3ccc(Cl)cc3Cl)nc2n(C)c1=O		CHEMBL4578164		% Control	%	92.0	CHEMBL5408	Homo sapiens	% Control	%	92.0
Not Active	23349648	CHEMBL4879979	KinomeScan assay: inhibition of TBK1	B	O=S(=O)(NC1CCC(c2cc(F)ccc2F)(S(=O)(=O)c2ccc(Cl)cc2)CC1)C(F)(F)F		CHEMBL1091513		% Control	%	100.0	CHEMBL5408	Homo sapiens	% Control	%	100.0
Not Active	23350266	CHEMBL4879979	KinomeScan assay: inhibition of TBK1	B	COc1cc(-c2cn(C3CCc4c(F)cccc4N(CC(F)(F)F)C3=O)nn2)ccc1-n1cnc(C)c1		CHEMBL3609637		% Control	%	100.0	CHEMBL5408	Homo sapiens	% Control	%	100.0
Not Active	23350734	CHEMBL4879979	KinomeScan assay: inhibition of TBK1	B	COc1cc(-c2cn(C3CCc4ccccc4N(CC(F)(F)F)C3=O)nn2)ccc1-n1ccc(C)n1		CHEMBL4534005		% Control	%	88.0	CHEMBL5408	Homo sapiens	% Control	%	88.0
Not Active	23351339	CHEMBL4879979	KinomeScan assay: inhibition of TBK1	B	CN([C@@H]1CCc2c(CC(=O)O)c3ccccc3n2C1)S(=O)(=O)c1ccc(F)cc1		CHEMBL561132		% Control	%	100.0	CHEMBL5408	Homo sapiens	% Control	%	100.0
Not Active	23351807	CHEMBL4879979	KinomeScan assay: inhibition of TBK1	B	CN([C@@H]1CCc2c(CC(=O)O)c3cc(S(C)(=O)=O)ccc3n2C1)S(=O)(=O)c1ccc(F)cc1		CHEMBL1643772		% Control	%	97.0	CHEMBL5408	Homo sapiens	% Control	%	97.0
Not Active	23352246	CHEMBL4882935	TBK1 Kinase screen	B	C[C@H]1CN(c2cc(-c3n[nH]c4ccc(OC5(C)CC5)cc34)ncn2)C[C@@H](C)O1		CHEMBL4098877		Inhibition	%	7.78	CHEMBL5408	Homo sapiens	% Inhibition	%	7.7804
Not Active	23352831	CHEMBL4879979	KinomeScan assay: inhibition of TBK1	B	C[C@H]1CN(c2cc(-c3n[nH]c4ccc(OC5(C)CC5)cc34)ncn2)C[C@@H](C)O1		CHEMBL4098877		% Control	%	68.0	CHEMBL5408	Homo sapiens	% Control	%	68.0
Not Active	23353299	CHEMBL4879979	KinomeScan assay: inhibition of TBK1	B	C[C@H]1CN(c2cc(-c3nn(C)c4ccc(OC5(C)CC5)cc34)ncn2)C[C@@H](C)O1		CHEMBL4560589		% Control	%	75.0	CHEMBL5408	Homo sapiens	% Control	%	75.0
Not Active	23354181	CHEMBL4879979	KinomeScan assay: inhibition of TBK1	B	O=C(O)c1cc(-c2ccc(C3CCNCC3)cc2)c2ccc(-c3ccc(C(F)(F)F)cc3)cc2c1		CHEMBL1800685		% Control	%	80.0	CHEMBL5408	Homo sapiens	% Control	%	80.0
Not Active	23354649	CHEMBL4879979	KinomeScan assay: inhibition of TBK1	B	Cc1c(C(=O)O)cc(-c2ccc(C3CCNCC3)cc2)c2ccc(-c3ccc(C(F)(F)F)cc3)cc12		CHEMBL4566600		% Control	%	73.0	CHEMBL5408	Homo sapiens	% Control	%	73.0
Not Active	23355381	CHEMBL4879979	KinomeScan assay: inhibition of TBK1	B	COCCOc1nc(-c2ccc(Cl)nc2)nc2c1CN(C(=O)c1ncn3ccccc13)CC2		CHEMBL2204538		% Control	%	68.0	CHEMBL5408	Homo sapiens	% Control	%	68.0
Not Active	23355849	CHEMBL4879979	KinomeScan assay: inhibition of TBK1	B	CC(C)CC(=O)N1CCc2nc(-c3ccc(Br)cc3)nc(N(C)Cc3ccccc3)c2C1		CHEMBL4518342		% Control	%	75.0	CHEMBL5408	Homo sapiens	% Control	%	75.0
Not Active	23356485	CHEMBL4879979	KinomeScan assay: inhibition of TBK1	B	CC(C)(O)c1cncc(-c2nc3ccc(F)cc3n2C2CC2)c1		CHEMBL3582478		% Control	%	72.0	CHEMBL5408	Homo sapiens	% Control	%	72.0
Not Active	23356953	CHEMBL4879979	KinomeScan assay: inhibition of TBK1	B	FC(F)(F)c1ccc2c(c1)nc(-c1cccnc1)n2C1CC1		CHEMBL3582461		% Control	%	82.0	CHEMBL5408	Homo sapiens	% Control	%	82.0
Not Active	23357562	CHEMBL4879979	KinomeScan assay: inhibition of TBK1	B	C[C@H](c1ccc(F)cc1)N(Cc1cccc(C(=O)O)c1)C(=O)c1cnc2ccccc2c1		CHEMBL3577885		% Control	%	91.0	CHEMBL5408	Homo sapiens	% Control	%	91.0
Not Active	23358209	CHEMBL4879979	KinomeScan assay: inhibition of TBK1	B	O=C(Nc1cccnn1)N1CCC(=Cc2cccc(Oc3ccc(C(F)(F)F)cn3)c2)CC1		CHEMBL1651534		% Control	%	100.0	CHEMBL5408	Homo sapiens	% Control	%	100.0
Not Active	23358677	CHEMBL4879979	KinomeScan assay: inhibition of TBK1	B	O=C(Nc1cccnn1)N1CC(C/C=C/c2cncc(Oc3ccc(C(F)(F)F)cn3)n2)C1		CHEMBL4780458		% Control	%	72.0	CHEMBL5408	Homo sapiens	% Control	%	72.0
Not Active	23359263	CHEMBL4879979	KinomeScan assay: inhibition of TBK1	B	COc1cccc(CNC(=O)c2nc3scc(COCc4ccc(C(=O)O)cc4)c3c(=O)[nH]2)c1		CHEMBL3337894		% Control	%	94.0	CHEMBL5408	Homo sapiens	% Control	%	94.0
Not Active	23359861	CHEMBL4879979	KinomeScan assay: inhibition of TBK1	B	C[C@H](c1cccc(C#N)c1)n1cc(Cl)cc(C(N)=O)c1=N		CHEMBL3799292		% Control	%	98.0	CHEMBL5408	Homo sapiens	% Control	%	98.0
Not Active	23360329	CHEMBL4879979	KinomeScan assay: inhibition of TBK1	B	C[C@@H](c1cccc(C#N)c1)n1cc(Cl)cc(C(N)=O)c1=N		CHEMBL3797887		% Control	%	89.0	CHEMBL5408	Homo sapiens	% Control	%	89.0
Not Active	23360914	CHEMBL4879979	KinomeScan assay: inhibition of TBK1	B	Cn1nc(C(F)(F)F)cc1-c1cnc(N2CCc3cc(S(=O)(=O)Nc4c(F)cc(Cl)cc4F)cc(N4CCCC4=O)c32)nc1		CHEMBL4455357		% Control	%	95.0	CHEMBL5408	Homo sapiens	% Control	%	95.0
Not Active	23361382	CHEMBL4879979	KinomeScan assay: inhibition of TBK1	B	Nc1cnc(N2CCc3cc(S(=O)(=O)Nc4c(F)cc(Cl)cc4F)cc(N4CCCC4=O)c32)nc1		CHEMBL4585920		% Control	%	85.0	CHEMBL5408	Homo sapiens	% Control	%	85.0
Not Active	23361955	CHEMBL4879979	KinomeScan assay: inhibition of TBK1	B	Cc1nc(N2CC[C@@H](O)C2)ncc1-c1cc(C(F)(F)F)cc2[nH]ncc12		CHEMBL3799512		% Control	%	82.0	CHEMBL5408	Homo sapiens	% Control	%	82.0
Not Active	23362491	CHEMBL4879979	KinomeScan assay: inhibition of TBK1	B	Cc1cc(-n2nc(Cc3cc(F)cc(C(F)(F)F)c3)nc2C)ccc1C(N)=O		CHEMBL4082756		% Control	%	89.0	CHEMBL5408	Homo sapiens	% Control	%	89.0
Not Active	23362959	CHEMBL4879979	KinomeScan assay: inhibition of TBK1	B	Cc1nc(Cc2cccc(C(F)(F)F)c2)sc1-c1ccc(C(N)=O)nc1		CHEMBL4100408		% Control	%	91.0	CHEMBL5408	Homo sapiens	% Control	%	91.0
Not Active	23364601	CHEMBL4879979	KinomeScan assay: inhibition of TBK1	B	CO[C@H]1CC[C@H](CNc2ccc(S(=O)(=O)NC(=O)c3ccc(N4CCN(CC5=C(c6ccc(Cl)cc6)CC(C)(C)CC5)CC4)cc3Oc3cnc4[nH]ccc4c3)cc2[N+](=O)[O-])CC1		CHEMBL4228713		% Control	%	60.0	CHEMBL5408	Homo sapiens	% Control	%	60.0
Not Active	23365069	CHEMBL4879979	KinomeScan assay: inhibition of TBK1	B	O=C(NS(=O)(=O)c1ccc(NCC2CCOCC2)c([N+](=O)[O-])c1)c1ccc(N2CCN(Cc3ccc(C(F)(F)F)cc3-c3ccc(Cl)cc3)CC2)cc1Oc1cnc2[nH]ccc2c1		CHEMBL4551344		% Control	%	74.0	CHEMBL5408	Homo sapiens	% Control	%	74.0
Not Active	23365808	CHEMBL4879979	KinomeScan assay: inhibition of TBK1	B	CN(C)CC#Cc1ccc(OCCCc2sc(N3CCc4cccc(C(=O)Nc5nc6ccccc6s5)c4C3)nc2C(=O)O)c(F)c1		CHEMBL3342332		% Control	%	100.0	CHEMBL5408	Homo sapiens	% Control	%	100.0
Not Active	23366351	CHEMBL4879979	KinomeScan assay: inhibition of TBK1	B	Cc1c(Oc2c(F)cccc2F)c(OC(C)C)nn1-c1ncc(C2CC2)cc1F		CHEMBL3589752		% Control	%	98.0	CHEMBL5408	Homo sapiens	% Control	%	98.0
Not Active	23366941	CHEMBL4879979	KinomeScan assay: inhibition of TBK1	B	Nc1c(C(=O)NCc2ccc(C(=O)NCCCC3CCCCC3)cc2)cnn1-c1ccccc1		CHEMBL4436748		% Control	%	96.0	CHEMBL5408	Homo sapiens	% Control	%	96.0
Not Active	23367409	CHEMBL4879979	KinomeScan assay: inhibition of TBK1	B	O=C(NCCCC1CCCCC1)c1ccc(CNC(=O)c2cnn(-c3ccccc3)c2C(F)(F)F)cc1		CHEMBL4531775		% Control	%	100.0	CHEMBL5408	Homo sapiens	% Control	%	100.0
Not Active	23367761	CHEMBL4884114	TBK1 ProQinase selectivity panel	B	O=C1c2ccc(Nc3ccc(F)cc3F)cc2CCc2ccc(OC[C@H](O)CO)cc21		CHEMBL2152944		% Residual activity with Skepinone-L	%	87.0	CHEMBL5408	Homo sapiens	% Residual activity with Skepinone-L	%	87.0
Not Active	23368287	CHEMBL4879979	KinomeScan assay: inhibition of TBK1	B	O=C(Nc1cnc(Oc2ccc(F)cc2)nc1)N1CCc2ncccc2[C@@H]1c1ccc(F)cc1		CHEMBL4458424		% Control	%	87.0	CHEMBL5408	Homo sapiens	% Control	%	87.0
Not Active	23368755	CHEMBL4879979	KinomeScan assay: inhibition of TBK1	B	O=C(Nc1ccc(Oc2ccc(F)cc2)cc1)N1CCc2ncccc2[C@H]1c1ccc(F)cc1		CHEMBL4592872		% Control	%	81.0	CHEMBL5408	Homo sapiens	% Control	%	81.0
Active	23368907	CHEMBL4884194	Biochemical assay (low ATP) with TBK1	B	C[C@H](c1ccnc(Nc2nc3ccc(-c4cc(N(C)C)ncn4)cc3[nH]2)c1)N1CCN(C(=O)CC(F)(F)F)CC1		CHEMBL4537673		IC50	nM	2.0	CHEMBL5408	Homo sapiens	IC50	nM	2.0
Active	23368908	CHEMBL4884195	Biochemical assay (high ATP) with TBK1	B	C[C@H](c1ccnc(Nc2nc3ccc(-c4cc(N(C)C)ncn4)cc3[nH]2)c1)N1CCN(C(=O)CC(F)(F)F)CC1		CHEMBL4537673		IC50	nM	18.0	CHEMBL5408	Homo sapiens	IC50	nM	18.0
Active	23368910	CHEMBL4884197	NanoBRET with TBK1	B	C[C@H](c1ccnc(Nc2nc3ccc(-c4cc(N(C)C)ncn4)cc3[nH]2)c1)N1CCN(C(=O)CC(F)(F)F)CC1		CHEMBL4537673		IC50	nM	312.0	CHEMBL5408	Homo sapiens	IC50	nM	312.0
Active	23369354	CHEMBL4879979	KinomeScan assay: inhibition of TBK1	B	C[C@H](c1ccnc(Nc2nc3ccc(-c4cc(N(C)C)ncn4)cc3[nH]2)c1)N1CCN(C(=O)CC(F)(F)F)CC1		CHEMBL4537673		% Control	%	2.4	CHEMBL5408	Homo sapiens	% Control	%	2.4
Slightly Active	23369822	CHEMBL4879979	KinomeScan assay: inhibition of TBK1	B	CN(C)c1ncnc(-c2ccc3nc(Nc4cc(CN5CCN(C(=O)CC(F)(F)F)CC5)ccn4)[nH]c3c2)c1Cl		CHEMBL4538591		% Control	%	24.0	CHEMBL5408	Homo sapiens	% Control	%	24.0
Not Active	23370258	CHEMBL4884497	TBK1(h) Eurofins kinase panel	B	CCc1ccccc1C(=O)Nc1n[nH]c2c(C)c(F)c(C3C(C#N)=C(C)N(C)C(C)=C3C#N)cc12		CHEMBL4580220		% residual kinase activity	%	106.0	CHEMBL5408	Homo sapiens	% residual kinase activity	%	106.0
Not Active	23370790	CHEMBL4879979	KinomeScan assay: inhibition of TBK1	B	CCc1ccccc1C(=O)Nc1n[nH]c2c(C)c(F)c(C3C(C#N)=C(C)N(C)C(C)=C3C#N)cc12		CHEMBL4580220		% Control	%	77.0	CHEMBL5408	Homo sapiens	% Control	%	77.0
Not Active	23371258	CHEMBL4879979	KinomeScan assay: inhibition of TBK1	B	CC1=C(C#N)C(c2ccc3c(c2)c(NC(=O)c2ccccc2C)nn3C)C(C#N)=C(C)N1		CHEMBL4630642		% Control	%	69.0	CHEMBL5408	Homo sapiens	% Control	%	69.0
Not Active	23372067	CHEMBL4879979	KinomeScan assay: inhibition of TBK1	B	CS(=O)(=O)N1CCCC(NC(=O)[C@H](CCC2CCCCC2)NC(=O)c2ccc(CNC(=O)c3cnc4ccccn34)cc2)C1		CHEMBL4591082		% Control	%	75.0	CHEMBL5408	Homo sapiens	% Control	%	75.0
Not Active	23372535	CHEMBL4879979	KinomeScan assay: inhibition of TBK1	B	CS(=O)(=O)N1CCCC(NC(=O)[C@H](CCC2CCCCC2)NC(=O)c2ccc(CNc3ncnc4c3nnn4-c3ccccc3)cc2)C1		CHEMBL4568183		% Control	%	88.0	CHEMBL5408	Homo sapiens	% Control	%	88.0
	23372911	CHEMBL4884876	TBK1(TBK1CGF1) Takeda global kinase panel	B	CN1C(=O)[C@@H](N2CCc3cn(Cc4ccccc4)nc3C2=O)COc2ccccc21		CHEMBL4088216		IC50	nM	1000.0	CHEMBL5408	Homo sapiens	pIC50		6.0
	23373320	CHEMBL4885167	TBK1(TBK1CGF1) Takeda global kinase panel	B	CN1C(=O)[C@@H](N2CCc3c(nn(Cc4ccccc4)c3Br)C2=O)COc2ccccc21		CHEMBL4549667		IC50	nM	1000.0	CHEMBL5408	Homo sapiens	pIC50		6.0
	23373674	CHEMBL4885451	TBK1(TBK1CGF1) Takeda global kinase panel	B	CN1C(=O)[C@@H](N2CCc3cn(CC4CCS(=O)(=O)CC4)nc3C2=O)COc2ccccc21		CHEMBL4097778		IC50	nM	1000.0	CHEMBL5408	Homo sapiens	pIC50		6.0
Not Active	23375113	CHEMBL4886100	TBK1 Kinase panel	B	CC(C)(O)[C@H](F)CN1Cc2cc(NC(=O)c3cnn4cccnc34)c(N3CCOCC3)cc2C1=O		CHEMBL4475494		Inhibition	%	5.5	CHEMBL5408	Homo sapiens	% Inhibition	%	5.5
Not Active	23375389	CHEMBL4886371	TANK-binding kinase 1 Millipore kinase panel	B	COCCc1ccc(-c2c(C)nc3c(N4CCOCC4)ccnn23)cn1		CHEMBL2180408		Inhibition	%	-3.0	CHEMBL5408	Homo sapiens	% inhibition	%	-3.0
Not Active	23375962	CHEMBL4879979	KinomeScan assay: inhibition of TBK1	B	O=C1CCc2cc(Nc3cc(OC4CCOCC4)c([N+](=O)[O-])cc3Cl)ccc2N1		CHEMBL4075278		% Control	%	100.0	CHEMBL5408	Homo sapiens	% Control	%	100.0
Not Active	23376430	CHEMBL4879979	KinomeScan assay: inhibition of TBK1	B	N#Cc1ccc(Nc2ccc3[nH]c(=O)[nH]c3c2)c(Cl)c1		CHEMBL4063249		% Control	%	100.0	CHEMBL5408	Homo sapiens	% Control	%	100.0
Not Active	23377007	CHEMBL4879979	KinomeScan assay: inhibition of TBK1	B	O=c1nc(-c2ccccn2)sc2ccccc12		CHEMBL4516611		% Control	%	91.0	CHEMBL5408	Homo sapiens	% Control	%	91.0
Not Active	23377475	CHEMBL4879979	KinomeScan assay: inhibition of TBK1	B	O=C1NC(c2ccccn2)Sc2ccccc21		CHEMBL4561806		% Control	%	87.0	CHEMBL5408	Homo sapiens	% Control	%	87.0
Not Active	23378335	CHEMBL4879979	KinomeScan assay: inhibition of TBK1	B	CNC(=O)Nc1ccc2c(c1)CC[C@@]21OC(=O)N(CC(=O)N(Cc2ccc(F)cc2)[C@@H](C)C(F)(F)F)C1=O		CHEMBL4282264		% Control	%	83.0	CHEMBL5408	Homo sapiens	% Control	%	83.0
Not Active	23378803	CHEMBL4879979	KinomeScan assay: inhibition of TBK1	B	CNC(=O)Nc1ccc2c(c1)[C@@]1(CC2)OC(=O)N(CC(=O)N(Cc2ccc(F)cc2)[C@@H](C)C(F)(F)F)C1=O		CHEMBL4536197		% Control	%	84.0	CHEMBL5408	Homo sapiens	% Control	%	84.0
Not Active	23379970	CHEMBL4879979	KinomeScan assay: inhibition of TBK1	B	N#CC1(c2ccccn2)CCN(Cc2cc(C(=O)O)c(=O)n3ccccc23)CC1		CHEMBL1800285		% Control	%	98.0	CHEMBL5408	Homo sapiens	% Control	%	98.0
Not Active	23380438	CHEMBL4879979	KinomeScan assay: inhibition of TBK1	B	N#CC1(c2ccccn2)CCN(Cc2cc(C(=O)N3CCCC3)c(=O)n3ccccc23)CC1		CHEMBL2204283		% Control	%	99.0	CHEMBL5408	Homo sapiens	% Control	%	99.0
Not Active	23381132	CHEMBL4879979	KinomeScan assay: inhibition of TBK1	B	COc1ccc2cc(OCC3(C(=O)O)CN(C(=O)c4ccc(F)cc4)C3)ccc2c1		CHEMBL3286797		% Control	%	100.0	CHEMBL5408	Homo sapiens	% Control	%	100.0
Not Active	23381780	CHEMBL4879979	KinomeScan assay: inhibition of TBK1	B	C[C@H](NC(=O)c1cnc2n1[C@](C)(Cc1ccc(C#N)cc1)C(=O)N2c1cc(Cl)c(F)c(Cl)c1)C(=O)NC1(c2ccccn2)CC1		CHEMBL4530740		% Control	%	97.0	CHEMBL5408	Homo sapiens	% Control	%	97.0
Not Active	23382248	CHEMBL4879979	KinomeScan assay: inhibition of TBK1	B	C[C@@]1(Cc2ccc(C#N)cc2)C(=O)N(c2cc(Cl)cc(Cl)c2)c2ncc(C(=O)NC3(c4nc(C5CCC5)no4)CC3)n21		CHEMBL4577237		% Control	%	95.0	CHEMBL5408	Homo sapiens	% Control	%	95.0
Not Active	23382872	CHEMBL4879979	KinomeScan assay: inhibition of TBK1	B	CNC(=O)c1ccc(Nc2ncc(C(F)(F)F)c(NCc3nccnc3N(C)S(C)(=O)=O)n2)cc1		CHEMBL3137331		% Control	%	75.0	CHEMBL5408	Homo sapiens	% Control	%	75.0
Slightly Active	23383340	CHEMBL4879979	KinomeScan assay: inhibition of TBK1	B	CN(c1ccnc(CNc2nc(Nc3ccc4c(c3)CC(=O)N4)ncc2C(F)(F)F)n1)S(C)(=O)=O		CHEMBL4518706		% Control	%	21.0	CHEMBL5408	Homo sapiens	% Control	%	21.0
Not Active	23384012	CHEMBL4887611	TBK1 Invitrogen Lab (UK) kinase screen (BI)	B	CCC(F)(F)c1cc(N2CCC(S(C)(=O)=O)CC2)nc2sc(C(N)=O)c(N)c12		CHEMBL4522930		% Ctrl	%	96.0	CHEMBL5408	Homo sapiens	% Ctrl	%	96.0
Not Active	23384486	CHEMBL4888081	TBK1(h) Millipore kinase panel	B	CC[C@@H](Nc1c(C#N)c(-c2ccc(-c3cccc(C)c3F)cc2)nc2cnccc12)C(=O)O		CHEMBL4802045		Inhibition	%	8.44	CHEMBL5408	Homo sapiens	% inhibition	%	8.44
Not Active	23384722	CHEMBL4888248	TBK1 SelectScreen Kinase panel (LifeTechnologies)	B	C=CC(=O)Nc1ccc2[nH]c(=O)n(C3CCN(Cc4ccc(-c5nc6cc[nH]c(=O)c6cc5-c5ccccc5)cc4)CC3)c2c1		CHEMBL4795065		Inhibition	%	6.0	CHEMBL5408	Homo sapiens	% Inhibition	%	6.0
Not Active	23385255	CHEMBL4879979	KinomeScan assay: inhibition of TBK1	B	CO[C@@H](C)c1c(Nc2ccc([C@H](N(C)C(=O)C3CCS(=O)(=O)CC3)C(F)(F)F)cc2)cnc2cc(Cl)nn12		CHEMBL4568735		% Control	%	59.0	CHEMBL5408	Homo sapiens	% Control	%	59.0
Not Active	23385722	CHEMBL4879979	KinomeScan assay: inhibition of TBK1	B	CO[C@@H](C)c1c(Nc2ccc([C@@H](N(C)C(=O)C3CCS(=O)(=O)CC3)C(F)(F)F)cc2)cnc2cc(Cl)nn12		CHEMBL4584981		% Control	%	77.0	CHEMBL5408	Homo sapiens	% Control	%	77.0
